PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Xing, J; Wriggers, W; Jefferson, GM; Stein, R; Cheung, HC; Rosenfeld, SS				Xing, J; Wriggers, W; Jefferson, GM; Stein, R; Cheung, HC; Rosenfeld, SS			Kinesin has three nucleotide-dependent conformations - Implications for strain-dependent release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; MOTOR DOMAIN; KINETIC MECHANISM; ATP HYDROLYSIS; PURIFICATION; FLUORESCENCE; EXPRESSION; SKELETAL; COMPLEX; ENERGY	Although crystallographic information is available on several nucleotide-induced states in myosin, little is known about the corresponding structural changes in kinesin, since a crystallographic model is only available for the kinesin:ADP complex. This makes it difficult to characterize at a molecular level the structural changes that occur in this motor through the course of its ATPase cycle. In this study, we report on the production of a series of single tryptophan mutants of a monomeric human kinesin motor domain, which demonstrate nucleotide-dependent changes in microtubule affinity that are similar to wild type, We have used these mutations to measure intramolecular distances in both strong and weak binding states, using florescence resonance energy transfer. This work provides direct evidence that movement of the switch II loop and helix are essential to mediate communication between the catalytic and microtubule binding sites, evidence that is supported as well by molecular modeling. Kinetic studies of fluorescent nucleotide binding to these mutants are consistent with these distance changes, and demonstrate as well that binding of ADP produces two structural transitions, neither of which are identical to that produced by the binding of ATP. This study provides a basis for understanding current structural models of the kinesin mechanochemical cycle.	Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Grad Program Cell & Mol Biol, Birmingham, AL 35294 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Scripps Research Institute	Rosenfeld, SS (corresponding author), Univ Alabama Birmingham, Dept Neurol, UAB Stn, Birmingham, AL 35294 USA.	srosenfeld@email.neuro.uab.edu		Wriggers, Willy/0000-0001-5326-3152	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034856] Funding Source: NIH RePORTER; NCRR NIH HHS [RR10404] Funding Source: Medline; NINDS NIH HHS [NS34856] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Brendza KM, 1999, J BIOL CHEM, V274, P31506, DOI 10.1074/jbc.274.44.31506; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, XPLOR VERSION 3 SYST; CHEUNG HC, 1991, BIOCHEMISTRY-US, V30, P5238, DOI 10.1021/bi00235a018; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Dong WJ, 1997, BIOCHEMISTRY-US, V36, P6754, DOI 10.1021/bi9622276; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Gulick AM, 1998, BIOCHEMISTRY-US, V37, P1769, DOI 10.1021/bi972504o; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hancock WO, 1999, P NATL ACAD SCI USA, V96, P13147, DOI 10.1073/pnas.96.23.13147; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; Pastor R., 1994, MOL DYNAMICS LIQUID, P85, DOI 10.1007/978-94-011-1168-3_5; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1920; Rosenfeld SS, 1996, J BIOL CHEM, V271, P30212, DOI 10.1074/jbc.271.47.30212; Rosenfeld SS, 1998, J BIOL CHEM, V273, P28682, DOI 10.1074/jbc.273.44.28682; Rosenfeld SS, 1996, J BIOL CHEM, V271, P9473, DOI 10.1074/jbc.271.16.9473; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; She MD, 1997, BIOPHYS J, V73, P1042, DOI 10.1016/S0006-3495(97)78137-2; Straume M, 1991, TOPICS FLUORESCENCE, P177, DOI DOI 10.1007/B112907; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3; Wriggers W, 1998, BIOPHYS J, V75, P646, DOI 10.1016/S0006-3495(98)77555-1	36	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35413	35423		10.1074/jbc.M004232200	http://dx.doi.org/10.1074/jbc.M004232200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	10852922	hybrid, Green Submitted			2022-12-25	WOS:000165422800078
J	Antil-Delbeke, S; Gaillard, C; Tamiya, T; Corringer, PJ; Changeux, JP; Servent, D; Menez, A				Antil-Delbeke, S; Gaillard, C; Tamiya, T; Corringer, PJ; Changeux, JP; Servent, D; Menez, A			Molecular determinants by which a long chain toxin from snake venom interacts with the neuronal alpha 7-nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PROTEIN-PROTEIN INTERACTIONS; DOUBLE MUTANT CYCLES; NICOTINIC RECEPTOR; ALPHA-NEUROTOXIN; K+ CHANNEL; 3-DIMENSIONAL STRUCTURE; CURAREMIMETIC TOXINS; PROTON NMR; IDENTIFICATION	Long chain curarimimetic toxins from snake venom bind with high affinities to both muscular type nicotinic acetylcholine receptors (AChRs) (K-d in the pM range) and neuronal alpha 7-AChRs (K-d in the nM range). To understand the molecular basis of this dual function, we submitted alpha-cobratoxin (alpha-Cbtx), a typical long chain curarimimetic toxin, to an extensive mutational analysis. By exploring 36 toxin mutants, we found that Trp-25, Asp-27, Phe-29, Arg-33, Arg-36, and Phe-65 are involved in binding to both neuronal and Torpedo (Antil, S., Servent, D., and Menez, A. (1999) J. Biol. Chem. 274, 34851-34858) AChRs and that some of them (Trp-25, Asp-27, and Arg-33) have similar binding energy contributions for the two receptors. In contrast, Ala-28, Lys-35, and Cys-26-Cys-30 selectively bind to the alpha 7-AChR, whereas Lys-23 and Lys-49 bind solely to the Torpedo AChR. Therefore, alpha-Cbtx binds to two AChR subtypes using both common and specific residues. Double mutant cycle analyses suggested that Arg-33 in alpha-Cbtx is close to Tyr-187 and Pro-193 in the alpha 7 receptor. Since Arg-33 of another curarimimetic toxin is close to the homologous alpha Tyr-190 of the muscular receptor (Ackermann, E. J., Ang, E. T. H., Kanter, J. R., Tsigelny, I., and Taylor, P. (1998) J. Biol Chem. 273, 10958-10964), toxin binding probably occurs in homologous regions of neuronal and muscular AChRs. However, no coupling was seen between alpha-Cbtx Arg-33 and alpha 7 receptor Trp-54, Leu-118, and Asp-163, in contrast to what was observed in a homologous situation involving another toxin and a muscular receptor (Osaka, H., Malany, S., Molles, B. E., Sine, S. M., and Taylor, P. (2000) J. Biol Chem. 275, 5478-5484). Therefore, although occurring in homologous regions, the detailed modes of toxin binding to alpha 7 and muscular receptors are likely to be different, These data offer a molecular basis for the design of toxins with predetermined specificities for various members of the AChR family.	CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France; Inst Pasteur, Mol Neurobiol Lab, F-75724 Paris 15, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Servent, D (corresponding author), CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France.		Fruchart Gaillard, Carole/GWV-2801-2022	Fruchart Gaillard, Carole/0000-0002-3149-4774; Servent, Denis/0000-0002-0774-1691				Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Ackermann EJ, 1997, BIOCHEMISTRY-US, V36, P12836, DOI 10.1021/bi971513u; Alessandri-Haber N, 1999, J BIOL CHEM, V274, P35653, DOI 10.1074/jbc.274.50.35653; Antil S, 1999, J BIOL CHEM, V274, P34851, DOI 10.1074/jbc.274.49.34851; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BETZEL C, 1991, J BIOL CHEM, V266, P21530; CHANGEUX JP, 1970, P NATL ACAD SCI USA, V67, P1241, DOI 10.1073/pnas.67.3.1241; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; Drevet P, 1997, PROTEIN EXPRES PURIF, V10, P293, DOI 10.1006/prep.1997.0740; Ducancel F, 1996, J BIOL CHEM, V271, P31345, DOI 10.1074/jbc.271.49.31345; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; ENDO T, 1991, SNAKE TOXINS; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Grant GA, 1998, BIOCHEMISTRY-US, V37, P12166, DOI 10.1021/bi981227y; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; LEGOAS R, 1992, BIOCHEMISTRY-US, V31, P4867, DOI 10.1021/bi00135a018; LOW BW, 1986, EUR J BIOCHEM, V161, P579, DOI 10.1111/j.1432-1033.1986.tb10481.x; MENEZ A, 1997, GUIDEBOOK PROTEIN TO, P194; Osaka H, 2000, J BIOL CHEM, V275, P5478, DOI 10.1074/jbc.275.8.5478; Osaka H, 1999, J BIOL CHEM, V274, P9581, DOI 10.1074/jbc.274.14.9581; Otzen DE, 1999, PROTEIN ENG, V12, P41, DOI 10.1093/protein/12.1.41; PILLET L, 1993, J BIOL CHEM, V268, P909; PRASAD L, 1993, J BIOL CHEM, V268, P10705; Rosenthal JA, 1999, BIOCHEMISTRY-US, V38, P7847, DOI 10.1021/bi990045g; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279; Servent D, 1998, J PHYSIOLOGY-PARIS, V92, P107, DOI 10.1016/S0928-4257(98)80146-0; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; TSERNOGLOU D, 1977, P NATL ACAD SCI USA, V74, P971, DOI 10.1073/pnas.74.3.971; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0; WALKINSHAW MD, 1980, P NATL ACAD SCI-BIOL, V77, P2400, DOI 10.1073/pnas.77.5.2400; WEBER M, 1974, MOL PHARMACOL, V10, P15; Wuster W, 1996, TOXICON, V34, P399, DOI 10.1016/0041-0101(95)00139-5; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	35	100	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29594	29601		10.1074/jbc.M909746199	http://dx.doi.org/10.1074/jbc.M909746199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10852927	hybrid			2022-12-25	WOS:000089439800056
J	Chernousov, MA; Rothblum, K; Tyler, WA; Stahl, RC; Carey, DJ				Chernousov, MA; Rothblum, K; Tyler, WA; Stahl, RC; Carey, DJ			Schwann cells synthesize type V collagen that contains a novel alpha 4 chain - Molecular cloning, biochemical characterization, and high affinity heparin binding of alpha 4(V) collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-SYNDECAN; EXPRESSION; ORGANIZATION; DOMAIN	Previously, we reported the isolation of a heparan sulfate-binding collagenous protein, p200, that is expressed by Schwann cells in developing peripheral nerves ((1996) J, Biol, Chem, 271, 13844-13853; (1999) J. Neurosci. Res. 56, 284-294), Here, we report the cloning of p200 cDNA from a Schwann cell cDNA library. The deduced amino acid sequence identifies p200 as a novel member of the collagen type V gene family. This polypeptide, which me have named alpha 4 type V (alpha 4(V)) collagen, contains an uninterrupted GIS-X-X collagen domain of 1011 amino acids that shows 82% sequence identity to human alpha 3(V) collagen and 71% identity to rat alpha 1(V) collagen. alpha 4(V) is secreted by Schwann cells as a collagen heterotrimer that also contains alpha 1(V) chains. alpha 4(V)-containing collagen molecules synthesized by Schmann cells retain their amino-terminal non-collagenous domains. alpha 4(V) mRNA was detected by reverse transcriptase-linked polymerase chain reaction amplification in neonatal and adult brain and neonatal peripheral nerve. alpha 4(V) mRNA and protein were not detected in most other tissues, including the placenta and heart, which are known to contain alpha 3(V). This pattern of alpha 4(V) expression contrasted with that of alpha 1(V) mRNA and protein, which were ubiquitously expressed. The isolated alpha 4(V) chain demonstrated an unusually high affinity for heparin, The restricted expression and unusual properties of alpha 4(V)-containing collagen type V molecules suggest a unique and important role for these molecules in peripheral nerve development.	Geisinger Clin, Sigfried & Janet Weis Ctr Res, Danville, PA 17822 USA		Carey, DJ (corresponding author), Geisinger Clin, Sigfried & Janet Weis Ctr Res, 100 Acad Ave, Danville, PA 17822 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925] Funding Source: NIH RePORTER; NINDS NIH HHS [NS21925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABEDIN MZ, 1982, BIOSCIENCE REP, V2, P493, DOI 10.1007/BF01115247; Asundi VK, 1997, EXP CELL RES, V230, P145, DOI 10.1006/excr.1996.3400; BUNGE MB, 1980, J CELL BIOL, V84, P184, DOI 10.1083/jcb.84.1.184; CARERI G, 1992, NANOBIOLOGY, V1, P117; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; Carey DJ, 1997, J BIOL CHEM, V272, P2873, DOI 10.1074/jbc.272.5.2873; Chernousov MA, 1999, J NEUROSCI RES, V56, P284, DOI 10.1002/(SICI)1097-4547(19990501)56:3<284::AID-JNR8>3.3.CO;2-H; Chernousov MA, 1996, J BIOL CHEM, V271, P13844, DOI 10.1074/jbc.271.23.13844; Chernousov MA, 1998, J CELL SCI, V111, P2763; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; Imamura Y, 2000, J BIOL CHEM, V275, P8749, DOI 10.1074/jbc.275.12.8749; LEE SB, 1995, BIOCHEM J, V310, P15, DOI 10.1042/bj3100015; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MANN K, 1992, BIOL CHEM H-S, V373, P69, DOI 10.1515/bchm3.1992.373.1.69; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MAYNE R, 1993, J BIOL CHEM, V268, P9381; Mizuno K, 1996, J BIOCHEM-TOKYO, V120, P934; MORADIAMELI M, 1994, EUR J BIOCHEM, V221, P987, DOI 10.1111/j.1432-1033.1994.tb18815.x; NIYIBIZI C, 1984, J BIOL CHEM, V259, P4170; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Verrecchio A, 2000, J BIOL CHEM, V275, P7701, DOI 10.1074/jbc.275.11.7701	22	49	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28208	28215						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10852920				2022-12-25	WOS:000089197100090
J	Dong, JF; Schade, AJ; Romo, GM; Andrews, RK; Gao, S; McIntire, LV; Lopez, JA				Dong, JF; Schade, AJ; Romo, GM; Andrews, RK; Gao, S; McIntire, LV; Lopez, JA			Novel gain-of-function mutations of platelet glycoprotein Ib alpha by valine mutagenesis in the Cys(209)-Cys(24)8 disulfide loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; IX-V COMPLEX; VONWILLEBRAND-FACTOR BINDING; MOLECULAR MECHANISMS; ENDOTHELIAL-CELLS; P-SELECTIN; DISEASE; EXPRESSION; IDENTIFICATION; SUBSTITUTION	Platelet-type von Willebrand disease is a bleeding disorder resulting from gain-of-function mutations of glycoprotein (GP) Ib alpha that increase its affinity for von Willebrand factor (vWf). The two known naturally occurring mutations, G233V and M239V, both enrich the valine content of an already valine-rich region within the Cys(209)-Cys(248) disulfide loop. We tested the effect of converting other non-valine residues in this region to valine. Of 10 mutants expressed in CHO cells as components of GP nb-M complexes, four displayed a gain-of-function phenotype (G233V, D235V, K237V, and M239V) based on I-125-vWf binding and adhesion to immobilized vWf. The remainder displayed loss-of-function phenotypes. The gain-of-function mutants bound vWf spontaneously and had a heightened response to low concentrations of ristocetin or botrocetin, whereas the loss-of-function mutants bound vWf more poorly than wild-type GP Ib alpha. No distinct gain- or loss-of-function conformations were identified with conformation-sensitive antibodies. Compared with cells expressing wild-type GP Ib alpha, cells expressing the gain of-function mutants rolled significantly more slowly over immobilized vWf under flow than wild-type cells and were able to adhere to vWf coated at lower densities. In aggregate, these data indicate that the region of GP Ib alpha bounded by Asn(226) and Ala(244) regulates the affinity for vWf.	Baylor Coll Med, Thrombosis Res Sect, Dept Internal Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Vet Affairs Med Ctr, Houston, TX 77030 USA; Rice Univ, Cox Lab Bioengn, Houston, TX 77030 USA; Baker Med Res Inst, Melbourne, Vic, Australia	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Rice University; Baker Heart and Diabetes Institute	Lopez, JA (corresponding author), Baylor Coll Med, Thrombosis Res Sect, Dept Internal Med, BCM 286 N1319,1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002463, R29HL046416] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02463, HL46416, HL18673] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; Andrews RK, 1997, INT J BIOCHEM CELL B, V29, P91, DOI 10.1016/S1357-2725(96)00122-7; BERNDT MC, 1988, BIOCHEMISTRY-US, V27, P633, DOI 10.1021/bi00402a021; CRUZ MA, 1992, J BIOL CHEM, V267, P1303; DONG J, 1996, BLOOD, V88, P51; Dong JF, 1997, BIOCHEMISTRY-US, V36, P12421, DOI 10.1021/bi970636b; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Dong JF, 1998, J BIOL CHEM, V273, P31449, DOI 10.1074/jbc.273.47.31449; FEDERICI AB, 1989, BRIT J HAEMATOL, V73, P93, DOI 10.1111/j.1365-2141.1989.tb00226.x; Fredrickson BJ, 1998, BLOOD, V92, P3684, DOI 10.1182/blood.V92.10.3684.422k39_3684_3693; JONES DA, 1993, BIOPHYS J, V65, P1560, DOI 10.1016/S0006-3495(93)81195-0; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KATAGIRI Y, 1990, THROMB HAEMOSTASIS, V63, P122; KRONER PA, 1992, BLOOD, V79, P2048; Kukreti S, 1997, BLOOD, V89, P4104, DOI 10.1182/blood.V89.11.4104; Kunishima S, 1997, BLOOD COAGUL FIBRIN, V8, P311, DOI 10.1097/00001721-199707000-00009; LI CQ, 1995, J BIOL CHEM, V270, P16302, DOI 10.1074/jbc.270.27.16302; Lopez J A, 1997, Curr Opin Hematol, V4, P323; Lopez JA, 1998, BLOOD, V91, P4397, DOI 10.1182/blood.V91.12.4397.412k42_4397_4418; LOPEZ JA, 1994, J BIOL CHEM, V269, P23716; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; MILLER JL, 1991, P NATL ACAD SCI USA, V88, P4761, DOI 10.1073/pnas.88.11.4761; MILLER JL, 1982, BLOOD, V60, P790; MILLER JL, 1990, BRIT J HAEMATOL, V74, P313, DOI 10.1111/j.1365-2141.1990.tb02589.x; Miller JL, 1996, THROMB HAEMOSTASIS, V75, P865; Moriki T, 1997, BLOOD, V90, P698, DOI 10.1182/blood.V90.2.698.698_698_705; MURATA M, 1993, J CLIN INVEST, V91, P2133, DOI 10.1172/JCI116438; MURATA M, 1991, J BIOL CHEM, V266, P15474; PINCUS MR, 1991, BIOCHIM BIOPHYS ACTA, V1097, P133, DOI 10.1016/0925-4439(91)90097-S; PINCUS MR, 1994, J PROTEIN CHEM, V13, P629, DOI 10.1007/BF01890461; Romo GM, 1999, J EXP MED, V190, P803, DOI 10.1084/jem.190.6.803; RUAN C, 1981, BRIT J HAEMATOL, V49, P511, DOI 10.1111/j.1365-2141.1981.tb07259.x; RUSSELL SD, 1993, BLOOD, V81, P1787; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; Shen Y, 2000, BLOOD, V95, P903, DOI 10.1182/blood.V95.3.903.003k37_903_910; SLACK SM, 1994, THROMB HAEMOSTASIS, V72, P777; TAKAHASHI H, 1985, AM J HEMATOL, V18, P179, DOI 10.1002/ajh.2830180209; TAKAHASHI H, 1995, BLOOD, V85, P727, DOI 10.1182/blood.V85.3.727.bloodjournal853727; Ward CM, 1996, BIOCHEMISTRY-US, V35, P4929, DOI 10.1021/bi952456c; WEISS HJ, 1982, NEW ENGL J MED, V306, P326, DOI 10.1056/NEJM198202113060603	42	51	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27663	27670						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10837490				2022-12-25	WOS:000089197100020
J	George, SR; Fan, T; Xie, ZD; Tse, R; Tam, V; Varghese, G; O'Dowd, BF				George, SR; Fan, T; Xie, ZD; Tse, R; Tam, V; Varghese, G; O'Dowd, BF			Oligomerization of mu- and delta-opioid receptors - Generation of novel functional properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN; AGONISTS; BRAIN; DESENSITIZATION; PHOSPHORYLATION; PALMITOYLATION; HETERODIMERS; MODULATION; EXPRESSION; DIMERS	The existence of dimers and oligomers for many G protein-coupled receptors has been described by us and others. Since many G protein-coupled receptor subtypes are highly homologous to each other, we examined whether closely related receptors may interact with each other directly and thus have the potential to create novel signaling units. Using mu- and delta-opioid receptors, we show that each receptor expressed individually was pharmacologically distinct and could be visualized following electrophoresis as monomers, homodimers, homotetramers, and higher molecular mass oligomers. When mu- and delta-opioid receptors were coexpressed, the highly selective synthetic agonists for each had reduced potency and altered rank order, whereas endomorphin-1 and Leu-enkephalin had enhanced affinity, suggesting the formation of a novel binding pocket. No heterodimers were visualized in the membranes coexpressing mu- and delta-receptors by the methods available. However, heterooligomers were identified by the ability to co-immunoprecipitate mu-receptors with delta-receptors and vice versa using differentially epitope-tagged receptors, In contrast to the individually expressed mu- and delta-receptors, the coexpressed receptors showed insensitivity to pertussis toxin and continued signal transduction, likely due to interaction with a different subtype of G protein. In this study, we provide, for the first time, evidence for the direct interaction of mu- and delta-opioid receptors to form oligomers, with the generation of novel pharmacology and G protein coupling properties.	Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Ctr Addict & Mental Hlth, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada	George, SR (corresponding author), Univ Toronto, Dept Pharmacol, Med Sci Bldg,Rm 4358,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		George, Susan R/P-9669-2018; George, Susan/W-7494-2019	Tam, Vincent/0000-0001-8732-0530				Allouche S, 1999, BIOCHEM J, V342, P71, DOI 10.1042/0264-6021:3420071; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; ELLIOTT J, 1995, BRIT J PHARMACOL, V114, P1064, DOI 10.1111/j.1476-5381.1995.tb13314.x; FRANKLIN TG, 1991, BRIT J PHARMACOL, V102, P718, DOI 10.1111/j.1476-5381.1991.tb12239.x; Garzon J, 1998, EUR J NEUROSCI, V10, P2557, DOI 10.1046/j.1460-9568.1998.t01-1-00267.x; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Marshall FH, 1999, TRENDS PHARMACOL SCI, V20, P396, DOI 10.1016/S0165-6147(99)01383-8; Matthes HWD, 1998, J NEUROSCI, V18, P7285; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; Nimchinsky EA, 1997, J BIOL CHEM, V272, P29229, DOI 10.1074/jbc.272.46.29229; Obadiah J, 1999, CELL MOL NEUROBIOL, V19, P653, DOI 10.1023/A:1006988603199; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; Pak Y, 1996, MOL PHARMACOL, V50, P1214; PORRECA F, 1992, J PHARMACOL EXP THER, V263, P147; ROTHMAN RB, 1988, J PHARMACOL EXP THER, V247, P405; TRAYNOR JR, 1993, TRENDS PHARMACOL SCI, V14, P84, DOI 10.1016/0165-6147(93)90068-U; Xie XD, 1999, FEBS LETT, V456, P63, DOI 10.1016/S0014-5793(99)00918-7; Zawarynski P, 1998, FEBS LETT, V441, P383, DOI 10.1016/S0014-5793(98)01588-9; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z; [No title captured]	23	475	498	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26128	26135		10.1074/jbc.M000345200	http://dx.doi.org/10.1074/jbc.M000345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10842167	hybrid			2022-12-25	WOS:000088999700035
J	Wittpoth, C; Scholich, K; Bilyeu, JD; Patel, TB				Wittpoth, C; Scholich, K; Bilyeu, JD; Patel, TB			Adenylyl cyclase regulates signal onset via the inhibitory GTP-binding protein, G(i)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNITS; ACTIVATING PROTEINS; BETA-GAMMA; IDENTIFICATION; RECEPTOR; DESENSITIZATION; PHOSPHORYLATION; MYRISTOYLATION; STIMULATION; DIVERSITY	Adenylyl cyclase, the enzyme that converts ATP to cAMP, is regulated by its stimulatory and inhibitory GTP-binding proteins, G(s), and G(i), respectively. Recently, we demonstrated that besides catalyzing the synthesis of cAMP, type V adenylyl cyclase (ACV) can act as a GTPase activating protein for G alpha(s) and also enhance the ability of activated receptors to stimulate GTP-GDP exchange on heterotrimeric G(s), (Scholich, K., Mullenix, J. B., Wittpoth, C., Poppleton, H. M., Pierre, S. C., Lindorfer, M. A., Garrison, J. C., and Patel, T. B. (1999) Science 283, 1328-1331). This latter action of ACV would facilitate the rapid onset of signaling via G(s). Because the C1 region of ACV interacts with the inhibitory GTP-binding protein G alpha(i), we investigated whether the receptor-mediated activation of heterotrimeric G(i) was also regulated by ACV and its subdomains. Our data show that ACV and its C1 domain increased the ability of a muscarinic receptor mimetic peptide (MIII-4) to enhance activation of heterotrimeric G(i) such that the amount of peptide required to stimulate G(i) in steady state GTPase activity assays was 3-4 orders of magnitude less than without the C1 domain. Additionally, the MIII-4-mediated binding of guanosine 5'-(gamma-thio)triphosphate (GTP gamma S) to G(i) was also markedly increased in the presence of ACV or its C1 domain. In contrast, the C2 domain of ACV was not able to alter either the GTPase activity or the GTP gamma S binding to G(i) in the presence of MIII-4. Furthermore, in adenylyl cyclase assays employing 549 cyc(-) cell membranes, the C1 (but not the C2) domain of ACV enhanced the ability of peptide MIII-4 as well as endogenous somatostatin receptors to activate endogenous G(i) and to inhibit adenylyl cyclase activity. These data demonstrate that adenylyl cyclase and its C1 domain facilitate receptor-mediated activation of G(i).	Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Patel, TB (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, 115 Crowe Bldg,874 Union Ave, Memphis, TN 38163 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059679] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59679] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAUVE A, 1990, J BACTERIOL, V172, P2614; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; KASSIS S, 1982, J BIOL CHEM, V257, P5312; KATADA T, 1984, J BIOL CHEM, V259, P3586; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1991, J BIOL CHEM, V266, P4654; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; ROY A, 1982, MOL GEN GENET, V188, P465, DOI 10.1007/BF00330050; Scholich K, 1999, SCIENCE, V283, P1328, DOI 10.1126/science.283.5406.1328; SCHOLICH K, 1997, P NATL ACAD SCI USA, V94, P2916; STERNWEIS PC, 1979, J BIOL CHEM, V254, P3333; SUN H, 1995, P NATL ACAD SCI USA, V92, P2229, DOI 10.1073/pnas.92.6.2229; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Wittpoth C, 1999, P NATL ACAD SCI USA, V96, P9551, DOI 10.1073/pnas.96.17.9551	25	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25915	25919		10.1074/jbc.M001687200	http://dx.doi.org/10.1074/jbc.M001687200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852906	hybrid			2022-12-25	WOS:000088999700006
J	Chandel, NS; McClintock, DS; Feliciano, CE; Wood, TM; Melendez, JA; Rodriguez, AM; Schumacker, PT				Chandel, NS; McClintock, DS; Feliciano, CE; Wood, TM; Melendez, JA; Rodriguez, AM; Schumacker, PT			Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1 alpha during hypoxia - A mechanism of O-2 sensing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; FACTOR 1-ALPHA HIF-1-ALPHA; CYTOCHROME-C-OXIDASE; DNA-BINDING ACTIVITY; HYDROGEN-PEROXIDE; FACTOR-I; PARACOCCUS-DENITRIFICANS; CELLULAR RESPIRATION; TRANSCRIPTION FACTOR; SIGNALING PATHWAY	During hypoxia, hypoxia-inducible factor-1 alpha (HIF-1 alpha) is required for induction of a variety of genes including erythropoietin and vascular endothelial growth factor. Hypoxia increases mitochondrial reactive oxygen species (ROS) generation at Complex III, which causes accumulation of HIF-1 alpha protein responsible for initiating expression of a luciferase reporter construct under the control of a hypoxic response element. This response is lost in cells depleted of mitochondrial DNA (rho degrees cells). Overexpression of catalase abolishes hypoxic response element-luciferase expression during hypoxia. Exogenous H2O2 stabilizes HIF-1 alpha protein during normoxia and activates luciferase expression in wild-type and rho degrees cells. Isolated mitochondria increase ROS generation during hypoxia, as does the bacterium Paracoccus denitrificans. These findings reveal that mitochondria-derived ROS are both required and sufficient to initiate HIF-1 alpha stabilization during hypoxia.	Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Chicago	Schumacker, PT (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave,MC6026, Chicago, IL 60637 USA.			Schumacker, Paul T/0000-0001-9591-2034; Melendez, Juan/0000-0001-8021-3097	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035440, R01HL032646, R55HL032646] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32646, HL35440] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; BASS DA, 1983, J IMMUNOL, V130, P1910; Beavis AD, 1996, J BIOENERG BIOMEMBR, V28, P207, DOI 10.1007/BF02110652; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253; CHANDEL N, 1995, AM J PHYSIOL-LUNG C, V268, pL918, DOI 10.1152/ajplung.1995.268.6.L918; Chandel NS, 1996, J BIOL CHEM, V271, P18672, DOI 10.1074/jbc.271.31.18672; Chandel NS, 1997, J BIOL CHEM, V272, P18808, DOI 10.1074/jbc.272.30.18808; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; Duranteau J, 1998, J BIOL CHEM, V273, P11619, DOI 10.1074/jbc.273.19.11619; Ehleben W, 1998, RESP PHYSIOL, V114, P25, DOI 10.1016/S0034-5687(98)00078-4; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; GLEADLE JM, 1995, EUR J BIOCHEM, V234, P92, DOI 10.1111/j.1432-1033.1995.092_c.x; Goldstein BJ, 1998, MOL CELL BIOCHEM, V182, P91, DOI 10.1023/A:1006812218502; Hohler B, 1999, FEBS LETT, V457, P53, DOI 10.1016/S0014-5793(99)00999-0; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; JIANG ZY, 1990, FEBS LETT, V268, P69, DOI 10.1016/0014-5793(90)80974-N; JOHN P, 1975, NATURE, V254, P495, DOI 10.1038/254495a0; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LUDWIG B, 1986, METHOD ENZYMOL, V126, P153; MAJANDER A, 1994, J BIOL CHEM, V269, P21037; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Nakamura K, 1997, J NEUROCHEM, V69, P1850; Pollenz RS, 1996, J BIOL CHEM, V271, P30886, DOI 10.1074/jbc.271.48.30886; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salceda S, 1997, KIDNEY INT, V51, P556, DOI 10.1038/ki.1997.78; SCHUMACKER PT, 1993, AM J PHYSIOL, V265, pL395, DOI 10.1152/ajplung.1993.265.4.L395; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; TAKAHASHI MA, 1983, ARCH BIOCHEM BIOPHYS, V226, P558, DOI 10.1016/0003-9861(83)90325-9; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, BIOCHEM BIOPH RES CO, V212, P550, DOI 10.1006/bbrc.1995.2005; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wood JG, 1999, J APPL PHYSIOL, V87, P1734, DOI 10.1152/jappl.1999.87.5.1734; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	48	1452	1492	3	109	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25130	25138		10.1074/jbc.M001914200	http://dx.doi.org/10.1074/jbc.M001914200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833514	hybrid			2022-12-25	WOS:000088849400014
J	Valentinis, B; Navarro, M; Zanocco-Marani, T; Edmonds, P; McCormick, J; Morrione, A; Sacchi, A; Romano, G; Reiss, K; Baserga, R				Valentinis, B; Navarro, M; Zanocco-Marani, T; Edmonds, P; McCormick, J; Morrione, A; Sacchi, A; Romano, G; Reiss, K; Baserga, R			Insulin receptor substrate-1, p70(S6K), and cell size in transformation and differentiation of hemopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; P70 S6 KINASE; MULTIPLE SIGNALING PATHWAYS; HEMATOPOIETIC-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; PHOSPHORYLATION SITES; OKADAIC ACID; APOPTOSIS; ACTIVATION	After an initial burst of cell proliferation, the type 1 insulin-like growth factor receptor (IGF-IR) induces granulocytic differentiation of 32D IGF-IR cells, an interleukin-3-dependent murine hemopoietic cell line devoid of insulin receptor substrate-1 (IRS-1). The combined expression of the IGF-IR and IRS-1 (32D IGF-IR/IRS-1 cells) inhibits IGF-I-mediated differentiation, and causes malignant transformation of 32D cells. Because of the role of IRS-1 in changing the fate of 32D IGF-IR cells from differentiation land subsequent cell death) to malignant transformation, we have looked for differences in IGF-IR signaling between 32D IGF-IR and 32D IGF-IR/IRS-1 cells. In this report, we have focused on p70(S6K), which is activated by the IRS-l pathway. We find that the ectopic expression of IRS-1 and the inhibition of differentiation correlated with a sustained activation of p70(S6K), and an increase in cell size. Phosphorylation in vivo of threonine 389 and, to a lesser extent, of threonine 421/serine 424 of p70S6K seemed to be a requirement for inhibition of differentiation. A role of IRS-1 and p70(S6K) in the alternative between transformation or differentiation of 32D IGF-IR cells was confirmed by findings that inhibition of p70(S6K) activation or IRS-1 signaling, by rapamycin or okadaic acid, induced differentiation of 32D IGF-IR/IRS-1 cells. We have also found that the expression of myeloperoxidase mRNA (a marker of differentiation, which sharply increases in 32D IGF-IR cells), does not increase in 32D IGF-IRI/IRS-1 cells, suggesting that the expression of IRS-1 in 32D IGF-IR cells causes the extinction of the differentiation program initiated by the IGF-IR, while leaving intact its proliferation program.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; Inst Regina Elena Studio & Cura Tumori, Ctr Ric Sperimentale, Lab Oncogenesi Mol, I-00158 Rome, Italy	Jefferson University; Jefferson University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.	r_baserga@lac.jci.tju.edu	Zanocco Marani, Tommaso/D-5801-2015	Zanocco Marani, Tommaso/0000-0002-9911-7078	NATIONAL CANCER INSTITUTE [P01CA078890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033694] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78890] Funding Source: Medline; NIGMS NIH HHS [GM 33694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKEW DS, 1991, ONCOGENE, V6, P1915; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BASERGA R, 1995, BIOL CELL REPROD; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; DAmbrosio C, 1997, CANCER RES, V57, P3264; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; Feng SH, 1999, MOL CELL BIOL, V19, P7995; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khaleghpour K, 1999, MOL CELL BIOL, V19, P4302; KRUGER A, 1991, ONCOGENE, V6, P245; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; METCALF D, 1985, BLOOD, V65, P357; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; Rose DW, 1998, ONCOGENE, V17, P889, DOI 10.1038/sj.onc.1201997; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Soon L, 1999, MOL CELL BIOL, V19, P3816; SURMACZ E, 1987, MOL CELL BIOL, V7, P657, DOI 10.1128/MCB.7.2.657; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784; Yenush L, 1996, MOL CELL BIOL, V16, P2509; Zamorano J, 1996, J IMMUNOL, V157, P4926	57	98	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25451	25459		10.1074/jbc.M002271200	http://dx.doi.org/10.1074/jbc.M002271200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10846175	Green Published, hybrid			2022-12-25	WOS:000088849400054
J	Zhang, Y; Turkson, J; Carter-Su, C; Smithgall, T; Levitzki, A; Kraker, A; Krolewski, JJ; Medveczky, P; Jove, R				Zhang, Y; Turkson, J; Carter-Su, C; Smithgall, T; Levitzki, A; Kraker, A; Krolewski, JJ; Medveczky, P; Jove, R			Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; DNA-BINDING ACTIVITY; PROTEIN-TYROSINE KINASE; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; CELL-PROLIFERATION; SIGNAL TRANSDUCERS; INTERFERON-GAMMA; GENE-REGULATION	Signal transducers and activators of transcription (STATs) are latent cytoplasmic transcription factors that transduce signals from the cell membrane to the nucleus upon activation by tyrosine phosphorylation. Several protein-tyrosine kinases can induce phosphorylation of STATs in cells, including Janus kinase (JAK) and Src family kinases, One STAT family member, Stat3, is constitutively activated in Src-transformed NIH3T3 cells and is required for cell transformation. However, it is not entirely clear whether Src kinase can phosphorylate Stat3 directly or through another pathway, such as JAK family kinases, To address this question, we investigated the phosphorylation of STATs in baculovirus-infected Sf-9 insect cells in the presence of Src. Our results show that Src can tyrosine-phosphorylate Stat1 and Stat3 but not Stat5 in this system. The phosphorylated Stat1 and Stat3 proteins are functionally activated, as measured by their abilities to specifically bind DNA oligonucleotide probes. In addition, the JAK family member Jak1 efficiently phosphorylates Stat1 but not Stat3 in Sf-9 cells. By contrast, we observe that AG490, a JAK family-selective inhibitor, and dominant negative Jak1 protein can significantly inhibit Stat3-induced DNA binding activity as well as Stat3-mediated gene activation in NIH3T3 cells. Furthermore, wild-type or kinase-inactive platelet-derived growth factor receptor enhances Stat3 activation by v-Src, consistent with the receptor serving a scaffolding function for recruitment and activation of Stat3. Our results demonstrate that Src kinase is capable of activating STATs in Sf-9 insect cells without expression of JAK family members; however, Jak1 and platelet-derived growth factor receptor are required for maximal Stat3 activation by Src kinase in mammalian cells. Based on these findings, we propose a model in which Jak1 serves to recruit Stat3 to a receptor complex with Src kinase, which in turn directly phosphorylates and activates Stat3 in Src-transformed fibroblasts.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Inst Biomol Sci, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA; Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Pittsburgh, Sch Med, Dept Physiol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel; Parke Davis Res Inst, Dept Canc Res, Ann Arbor, MI 48105 USA; Univ Calif Irvine, Dept Pathol, Irvine, CA 92697 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Michigan System; University of Michigan; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Hebrew University of Jerusalem; Pfizer; University of California System; University of California Irvine	Jove, R (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Medveczky, Peter/A-6846-2012	Medveczky, Peter/0000-0002-1798-2595	NCI NIH HHS [CA55652, R01 CA055652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055652] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Campbell GS, 1997, J BIOL CHEM, V272, P2591, DOI 10.1074/jbc.272.5.2591; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Frank DA, 1999, MOL MED, V5, P432; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; GOUILLEUX F, 1995, ENDOCRINOLOGY, V136, P5700, DOI 10.1210/en.136.12.5700; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KOVALENKO M, 1994, CANCER RES, V54, P6106; KRAKER A, 2000, IN PRESS BIOCH PHARM; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lund TC, 1999, CELL SIGNAL, V11, P789, DOI 10.1016/S0898-6568(99)00045-5; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; PARK S, 1992, J BIOL CHEM, V267, P11612; PARK S, 1992, J BIOL CHEM, V267, P17194; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	58	139	158	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24935	24944		10.1074/jbc.M002383200	http://dx.doi.org/10.1074/jbc.M002383200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10823829	hybrid			2022-12-25	WOS:000088683300094
J	Shi, ZD; Xu, WZ; Loechel, F; Wewer, UM; Murphy, LJ				Shi, ZD; Xu, WZ; Loechel, F; Wewer, UM; Murphy, LJ			ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR (IGF)-BINDING PROTEIN-3; BREAST-CANCER CELLS; PROTEASE ACTIVITY; MELTRIN-ALPHA; FACTOR-I; PROTEOLYSIS; CIRCULATION; INDUCTION; CULTURE	Insulin-like growth factor-binding protein (IGFBP)-3 binds the insulin-like growth factors with high affinity and modulates their actions. Proteolytic cleavage of IGFBP-3 may. regulate insulin-like growth factor bioavailability IGFBP-3 is extensively degraded in serum during pregnancy; however, as yet the pregnancy-specific protease, or proteases, have not been identified. We utilized a yeast two-hybrid assay and a human placental cDNA library to investigate IGFBP-3-interacting proteins. A disintegrin and metalloprotease-12 (ADAM 12), a member of a family of metalloprotease disintegrins that is highly expressed in placental tissue, was identified as interacting with IGFBP-3, This interaction involved the cysteine-rich domain of ADAM 12. Unlike other members of this family of disintegrin metalloproteases that are membrane proteins, ADAM 12 exists as an alternatively spliced soluble secreted protein. To verify the interaction between ADAM 12 and IGFBP-3, an expression construct containing an ADAM 12-S c-DNA was transfected into COS-l cells. Go-precipitation was observed when conditioned medium was analyzed by immunoprecipitation with an antibody against either ADAM 12 or IGFBP-3 followed by Western blotting with anti-IGFBP-3 or anti-ADAM 12, Although minimal proteolysis of IGFBP-3 was observed in conditioned medium from control cells, this was increased similar to 4-fold in conditioned medium from ADAM 12-S-transfected cells. Recombinant ADAM 12-S partially purified from conditioned medium on a heparin-Sepharose column also proteolyzed IGFBP-3. The degradation pattern was similar to that seen with pregnancy serum, and the presence of ADAM 12-S in serum during pregnancy was confirmed. The data suggest that ADAM 12-S has IGFBP-3 protease activity, and it may contribute to the IGFBP-3 protease activity present in pregnancy serum.	Univ Manitoba, Dept Physiol, Winnipeg, MB R3E 0W3, Canada; Univ Manitoba, Dept Internal Med, Winnipeg, MB R3E 0W3, Canada; Univ Copenhagen, Inst Mol Pathol, DK-2100 Copenhagen, Denmark	University of Manitoba; University of Manitoba; University of Copenhagen	Murphy, LJ (corresponding author), Univ Manitoba, Dept Physiol, Winnipeg, MB R3E 0W3, Canada.							Alpan RS, 1996, CANCER RES, V56, P4358; Bang P, 1997, ENDOCRINOLOGY, V138, P3912, DOI 10.1210/en.138.9.3912; Baxter R C, 1989, Prog Growth Factor Res, V1, P49, DOI 10.1016/0955-2235(89)90041-0; BEREKET A, 1995, J CLIN ENDOCR METAB, V80, P2282, DOI 10.1210/jc.80.8.2282; DAVIES SC, 1991, J ENDOCRINOL, V130, P469, DOI 10.1677/joe.0.1300469; Elliott T, 1997, ADV IMMUNOL, V65, P47, DOI 10.1016/S0065-2776(08)60741-5; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Globus RK, 1998, J CELL SCI, V111, P1385; GRIMES RW, 1994, ENDOCRINOLOGY, V134, P337, DOI 10.1210/en.134.1.337; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P753, DOI 10.1530/acta.0.1210753; Irwin JC, 2000, ENDOCRINOLOGY, V141, P666, DOI 10.1210/en.141.2.666; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kubler B, 1998, ENDOCRINOLOGY, V139, P1556, DOI 10.1210/en.139.4.1556; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; OH Y, 1993, J BIOL CHEM, V268, P26045; Ooi GT, 1998, MOL ENDOCRINOL, V12, P675, DOI 10.1210/me.12.5.675; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Sakai K, 1997, ENDOCR J, V44, P409, DOI 10.1507/endocrj.44.409; Salahifar H, 1997, ENDOCRINOLOGY, V138, P1683, DOI 10.1210/en.138.4.1683; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Xu S, 1997, J CLIN ENDOCR METAB, V82, P1863, DOI 10.1210/jc.82.6.1863; ZAPF J, 1989, P NATL ACAD SCI USA, V86, P3813, DOI 10.1073/pnas.86.10.3813	23	159	174	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18574	18580		10.1074/jbc.M002172200	http://dx.doi.org/10.1074/jbc.M002172200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849447	hybrid			2022-12-25	WOS:000087659400090
J	Gaulin, JF; Fiset, A; Fortier, S; Faure, RL				Gaulin, JF; Fiset, A; Fortier, S; Faure, RL			Characterization of Cdk2-cyclin E complexes in plasma membrane and endosomes of liver parenchyma - Insulin-dependent regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; VESICLE FUSION INVITRO; CYCLIN-E; CELL-CYCLE; TYROSINE KINASE; S-PHASE; MULTIVESICULAR BODY; ENDOCYTIC VESICLES; GOLGI-APPARATUS; COATED PITS	Rat liver parenchyma Golgi/endosomes fractions harbor a tyrosine-phosphorylated 34-kDa protein. Screening of Golgi, endosomes (ENs), plasmalemma (PM), and cytosolic (Cyt) fractions revealed the presence of the mitotic kinase Cdk2 in ENs, PM and Cyt. The fluid phase endocytic marker horseradish peroxidase gained access to the endosomal Cdk2, confirming its localization, Cdk2 was shown to be associated to cyclin E and was active in ENs and PM fractions. The administration of a single dose of insulin (1.5 mu g/100 g, body weight) induced a time-dependent activation of the insulin receptor kinase in these structures. Insulin receptor-kinase activation was followed by the inhibition of immunoprecipitated Cdk2-cyclin E kinase activity in PM and the progressive disappearance of cyclin E. In marked contrast, no such effect was observed in ENs. The injection of a phosphotyrosyl phosphatase inhibitor (bpV-(phen)) increased the levels of cyclin E in ENs and PM. A massive recruitment of p27(hip1) was observed in the Cdk2-cyclin E complexes isolated from PM and Cyt but not from ENs. In vitro, Cdk2-cyclin E complexes have the capacity to inhibit the formation of hybrid structures containing horseradish peroxidase and radioiodinated epidermal growth factor. Therefore, in the PM and ENs of adult rat liver, an active and regulated pool of the mitotic kinase Cdk2-cyclin E and some yet to be defined effecters are present. Cdk2 may contribute to the modulation of transport events and/or maintenance of the topology of endocytic elements.	Univ Laval, CHUL, Ctr Rech, Lab Biol Cellulaire,Unite Rech Pediat, Quebec City, PQ G1V 4G2, Canada	Laval University	Faure, RL (corresponding author), CHU Laval, Ctr Rech, Unite Rech Pediat, Lab 9800, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	Robert.Faure@crchul.ulaval.ca						AJIOKA RS, 1987, J CELL BIOL, V104, P77, DOI 10.1083/jcb.104.1.77; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; BERGERON JJM, 1986, BIOCHEMISTRY-US, V25, P1756, DOI 10.1021/bi00355a046; BERLIN RD, 1978, CELL, V15, P327, DOI 10.1016/0092-8674(78)90002-8; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; Brule S, 2000, BIOL REPROD, V62, P642, DOI 10.1095/biolreprod62.3.642; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; CLARKE PR, 1995, CURR BIOL, V5, P40, DOI 10.1016/S0960-9822(95)00013-3; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Contreres JO, 1998, J BIOL CHEM, V273, P22007, DOI 10.1074/jbc.273.34.22007; COURTOY PJ, 1984, J CELL BIOL, V98, P870, DOI 10.1083/jcb.98.3.870; Dealy MJ, 1999, NAT GENET, V23, P245, DOI 10.1038/13886; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DOHERTY JJ, 1990, J CELL BIOL, V110, P35, DOI 10.1083/jcb.110.1.35; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; FAURE R, 1992, J BIOL CHEM, V267, P11215; FAURE R, 1995, J CELL BIOCHEM, V59, P389, DOI 10.1002/jcb.240590310; FAURE R, 1999, BIOL REPROD, V1, P132; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; FUTTER CE, 1993, J CELL BIOL, V120, P77, DOI 10.1083/jcb.120.1.77; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Haucke V, 1999, SCIENCE, V285, P1268, DOI 10.1126/science.285.5431.1268; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; KHAN MN, 1986, J BIOL CHEM, V261, P8462; KHAN MN, 1989, J BIOL CHEM, V264, P12931; Komada M, 1999, GENE DEV, V13, P1475, DOI 10.1101/gad.13.11.1475; Komada M, 1997, J BIOL CHEM, V272, P20538, DOI 10.1074/jbc.272.33.20538; LAI WH, 1989, J CELL BIOL, V109, P2741, DOI 10.1083/jcb.109.6.2741; LAI WH, 1989, J CELL BIOL, V109, P2751, DOI 10.1083/jcb.109.6.2751; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; Lohi O, 1998, J BIOL CHEM, V273, P21408, DOI 10.1074/jbc.273.33.21408; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Najjar SM, 1998, J BIOL CHEM, V273, P12923, DOI 10.1074/jbc.273.21.12923; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; POSNER BI, 1994, J BIOL CHEM, V269, P4596; PYPAERT M, 1991, J CELL BIOL, V114, P1159, DOI 10.1083/jcb.114.6.1159; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Schmid JA, 1998, EUR J CELL BIOL, V77, P166, DOI 10.1016/S0171-9335(98)80104-0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Shima DT, 1998, J CELL BIOL, V141, P955, DOI 10.1083/jcb.141.4.955; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Smith E, 1997, J CELL BIOCHEM, V66, P141, DOI 10.1002/(SICI)1097-4644(19970801)66:2<141::AID-JCB2>3.0.CO;2-Q; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; THOMAS L, 1992, J BIOL CHEM, V267, P6183; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; TOBEY RA, 1975, NATURE, V254, P245, DOI 10.1038/254245a0; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; Verges M, 1997, BIOCHEM BIOPH RES CO, V230, P49, DOI 10.1006/bbrc.1996.5851; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; Waga S, 1998, MOL CELL BIOL, V18, P4177, DOI 10.1128/MCB.18.7.4177; Wang YS, 1999, CURR BIOL, V9, P1191, DOI 10.1016/S0960-9822(00)80024-X; WARREN G, 1984, EMBO J, V3, P2217, DOI 10.1002/j.1460-2075.1984.tb02119.x; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; WOODMAN PG, 1993, MOL BIOL CELL, V4, P541, DOI 10.1091/mbc.4.5.541; WOODMAN PG, 1989, METHOD CELL BIOL, V31, P197; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	73	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16658	16665		10.1074/jbc.275.22.16658	http://dx.doi.org/10.1074/jbc.275.22.16658			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828061	hybrid			2022-12-25	WOS:000087392200038
J	Adryan, B; Decker, HJH; Papas, TS; Hsu, T				Adryan, B; Decker, HJH; Papas, TS; Hsu, T			Tracheal development and the von Hippel-Lindau tumor suppressor homolog in Drosophila	ONCOGENE			English	Article						Drosophila; tracheal development; VHL; vascularization	BIOLOGICALLY-ACTIVE PRODUCT; ENDOTHELIAL GROWTH-FACTOR; UBIQUITIN LIGASE COMPLEX; GENETIC INTERFERENCE; RENAL-CARCINOMA; CELL-MIGRATION; PROTEIN; ANGIOGENESIS; TRANSCRIPTION; HYPOXIA	von Hippel-Lindau disease is a hereditary cancer syndrome, Mutations in the VHL tumor suppressor gene predispose individuals to highly vascularized tumors. However, VHL-deficient mice die in utero due to a lack of vascularization in the placenta. To resolve the contradiction, we cloned the Drosophila VHL homologue (d-VHL) and studied its function. It showed an overall 50% similarity to the human counterpart and 76% similarity in the crucial functional domain: the elongin C binding site. The putative d-VHL protein can bind Drosophila elongin C in vitro. During embryogenesis, d-VHL is expressed in the developing tracheal regions where tube outgrowth no longer occurs, Reduced d-VHL activity (using RNA interference methodology) caused breakage of the main vasculature accompanied by excessive looping of smaller branches, whereas overexpression caused a general lack of vasculature. Importantly, human VHL can induce the same gain-of-function phenotypes, VHL is likely involved in halting cell migration at the end of vascular tube outgrowth. Loss of VHL activity can therefore lead to disruption of major vasculature las in the mouse embryo), which requires precise cell movement and tube fusion, or ectopic outgrowth from existing secondary vascular branches las in the adult tumors).	Med Univ S Carolina, Ctr Mol & Struct Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA; Johannes Gutenberg Univ Mainz, Dept Hematol & Oncol, D-55131 Mainz, Germany	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Johannes Gutenberg University of Mainz	Hsu, T (corresponding author), Med Univ S Carolina, Ctr Mol & Struct Biol, HCC 334,86 Jonathan Lucas St, Charleston, SC 29425 USA.			Adryan, Boris/0000-0003-4588-7867; Hsu, Tien/0000-0003-2308-4297	NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057843] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA78582] Funding Source: Medline; NIGMS NIH HHS [GM57843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aso T, 1997, BIOCHEM BIOPH RES CO, V241, P334, DOI 10.1006/bbrc.1997.7819; Beroud C, 1998, NUCLEIC ACIDS RES, V26, P256, DOI 10.1093/nar/26.1.256; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Gnarra JR, 1996, BBA-REV CANCER, V1242, P201, DOI 10.1016/0304-419X(95)00012-5; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; Isaac DD, 1996, GENE DEV, V10, P103, DOI 10.1101/gad.10.1.103; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jarecki J, 1999, CELL, V99, P211, DOI 10.1016/S0092-8674(00)81652-9; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Liu YR, 1999, DEVELOPMENT, V126, P1869; Mantrova EY, 1998, GENE DEV, V12, P1166; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Okuda H, 1999, BIOCHEM BIOPH RES CO, V263, P491, DOI 10.1006/bbrc.1999.1347; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; Pause A, 1999, P NATL ACAD SCI USA, V96, P9533, DOI 10.1073/pnas.96.17.9533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; STROUMBAKIS ND, 1994, GENE, V143, P171, DOI 10.1016/0378-1119(94)90093-0; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; TanakaMatakatsu M, 1996, DEVELOPMENT, V122, P3697; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8	44	45	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2000	19	24					2803	2811		10.1038/sj.onc.1203611	http://dx.doi.org/10.1038/sj.onc.1203611			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851083				2022-12-25	WOS:000087403600001
J	Barycki, JJ; O'Brien, LK; Strauss, AW; Banaszak, LJ				Barycki, JJ; O'Brien, LK; Strauss, AW; Banaszak, LJ			Sequestration of the active site by interdomain shifting - Crystallographic and spectroscopic evidence for distinct conformations of L-3-hydroxyacyl-CoA dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DEHYDROGENASE; FATTY-ACID OXIDATION; ENOYL-COA HYDRATASE; LARGE ALPHA-SUBUNIT; MALATE-DEHYDROGENASE; MULTIENZYME COMPLEX; BIFUNCTIONAL ENZYME; ESCHERICHIA-COLI; BOVINE LIVER; MECHANISM	L-3-Hydroxyacyl-CoA dehydrogenase reversibly catalyzes the conversion of L-3-hydroxyacyl-CoA to 3-ketoacyl-CoA concomitant with the reduction of NAD(+) to NADH as part of the beta-oxidation spiral. In this report, crystal structures have been solved for the apoenzyme, binary complexes of the enzyme with reduced cofactor or 3-hydroxybutyryl-CoA substrate, and an abortive ternary complex of the enzyme with NAD(+) and acetoacetyl-CoA The models illustrate positioning of cofactor and substrate within the active site of the enzyme. Comparison of these structures with the previous model of the enzyme-NAD(+) complex reveals that although significant shifting of the NAD(+)-binding domain relative to the C-terminal domain occurs in the ternary and substrate-bound complexes, there are few differences between the apoenzyme and cofactor-bound complexes. Analysis of these models clarifies the role of key amino acids implicated in catalysis and highlights additional critical residues. Furthermore, a novel charge transfer complex has been identified in the course of abortive ternary complex formation, and its characterization provides additional insight into aspects of the catalytic mechanism of L-3-hydroxyacyl-CoA dehydrogenase.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	University of Minnesota System; University of Minnesota Twin Cities; Washington University (WUSTL)	Banaszak, LJ (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.				NIDDK NIH HHS [1F32-DK09759] Funding Source: Medline; NIGMS NIH HHS [GM13925] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009759] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5327; ADAMS MJ, 1994, STRUCTURE, V2, P651, DOI 10.1016/S0969-2126(00)00066-6; AUER HE, 1980, J BIOL CHEM, V255, P8157; Barycki JJ, 1999, BIOCHEMISTRY-US, V38, P5786, DOI 10.1021/bi9829027; BIRKTOFT JJ, 1987, P NATL ACAD SCI USA, V84, P8262, DOI 10.1073/pnas.84.23.8262; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cunningham MA, 1997, BIOCHEMISTRY-US, V36, P4800, DOI 10.1021/bi962734n; de Launoit Y, 1999, J MOL ENDOCRINOL, V22, P227, DOI 10.1677/jme.0.0220227; DJORDJEVIC S, 1995, BIOCHEMISTRY-US, V34, P2163, DOI 10.1021/bi00007a009; ENGEL PC, 1971, BIOCHEM J, V125, P889, DOI 10.1042/bj1250889; GOWARD CR, 1994, PROTEIN SCI, V3, P1883, DOI 10.1002/pro.5560031027; HARTMANN D, 1991, BIOCHEMISTRY-US, V30, P2782, DOI 10.1021/bi00225a007; He XY, 1996, BIOCHEMISTRY-US, V35, P9625, DOI 10.1021/bi960374y; He XY, 1997, BIOCHEMISTRY-US, V36, P261, DOI 10.1021/bi961841e; He XY, 1998, J BIOL CHEM, V273, P10741, DOI 10.1074/jbc.273.17.10741; HOEFLER G, 1994, GENOMICS, V19, P60, DOI 10.1006/geno.1994.1013; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P437; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ESF CCP4 NEWSLETTER, V31, P9; Kobayashi A, 1996, J BIOCHEM-TOKYO, V119, P775, DOI 10.1093/oxfordjournals.jbchem.a021307; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; MASSEY V, 1974, ANN NY ACAD SCI, V227, P446, DOI 10.1111/j.1749-6632.1974.tb14407.x; NOYES BE, 1973, J BIOL CHEM, V248, P3052; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Rodgers DW, 1997, METHOD ENZYMOL, V276, P183, DOI 10.1016/S0076-6879(97)76059-2; Roe C. R., 1995, METABOLIC MOL BASES, P1501; SAHA SK, 1994, J BIOL CHEM, V269, P29592; Saha SK, 1999, BBA-PROTEIN STRUCT M, V1431, P261, DOI 10.1016/S0167-4838(99)00040-0; Slifkin M. A., 1971, CHARGE TRANSFER INTE; STERN JR, 1956, J BIOL CHEM, V221, P33; Woenckhaus C., 1987, PYRIDINE NUCLEOTID A, P449; YANG SY, 1994, COMP BIOCHEM PHYS B, V109, P557, DOI 10.1016/0305-0491(94)90117-1	33	58	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27186	27196						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10840044				2022-12-25	WOS:000089144800070
J	Taylor, SC; Green, KN; Carpenter, E; Peers, C				Taylor, SC; Green, KN; Carpenter, E; Peers, C			Protein kinase C evokes quantal catecholamine release from PC12 cells via activation of L-type Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMITTER RELEASE; CALCIUM-CHANNEL; PHORBOL ESTERS; N-TYPE; NEUROTRANSMITTER RELEASE; SYNAPTIC TRANSMISSION; CHROMAFFIN CELLS; PHOSPHORYLATION; ENHANCEMENT; EXOCYTOSIS	Application of the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) to PC12 cells under resting conditions evoked quantal catecholamine secretion, as detected amperometrically, This effect was not mimicked by 4 alpha-phorbol-12,13-didecanoate, another phorbol ester, which is inactive with respect to protein kinase C activation, and was prevented by the protein kinase C inhibitor bisindolylmaleimide, TPA also caused a rise of [Ca2+](i) in Fura-2-loaded PC12 cells, and again this was not mimicked by 4 alpha-phorbol-12,13-didecanoate and could be blocked by bisindolylmaleimide, TPA-evoked secretion was entirely dependent on extracellular Ca2+ and was fully abolished by nifedipine, as were TPA-induced rises of [Ca2+](i). Resting membrane potential, monitored using perforated patch recordings, was unaffected by TPA. However, a small (6-8 mV) hyperpolarizing shift in the voltage dependence of Ca2+ channel currents (determined using whole-cell patch clamp recordings) was induced by TPA, and this could be fully prevented by nifedipine. In contrast to results with depolarizing stimuli, which evoke exocytosis because of Ca2+ influx through N-type channels in these cells, the present results indicate that protein kinase C activation leads directly to quantal catecholamine secretion in the absence of depolarizing stimuli via a selective shift in the activation of L-type Ca2+ channels.	Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Peers, C (corresponding author), Univ Leeds, Inst Cardiovasc Res, Leeds LS2 9JT, W Yorkshire, England.	c.s.peers@leeds.ac.uk		Peers, Chris/0000-0002-8354-346X				AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192; Billiard J, 1997, P NATL ACAD SCI USA, V94, P12192, DOI 10.1073/pnas.94.22.12192; Boudier JA, 1996, EUR J NEUROSCI, V8, P545, DOI 10.1111/j.1460-9568.1996.tb01239.x; CAPOGNA M, 1995, J NEUROSCI, V15, P1249; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Chen YA, 1999, J BIOL CHEM, V274, P26469, DOI 10.1074/jbc.274.37.26469; Chow Robert H., 1995, P245; Cousin MA, 1999, EUR J NEUROSCI, V11, P101, DOI 10.1046/j.1460-9568.1999.00412.x; Dickens G, 1997, J NEUROSCI RES, V47, P271, DOI 10.1002/(SICI)1097-4547(19970201)47:3<271::AID-JNR5>3.0.CO;2-F; DOERNER D, 1990, J NEUROSCI, V10, P1699; ELFAR O, 1995, FEBS LETT, V361, P101, DOI 10.1016/0014-5793(95)00156-4; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HELL JW, 1994, J BIOL CHEM, V269, P7390; Hille B, 1999, J PHYSIOL-LONDON, V520, P23, DOI 10.1111/j.1469-7793.1999.00023.x; Hirling H, 1996, P NATL ACAD SCI USA, V93, P11945, DOI 10.1073/pnas.93.21.11945; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; Jia M, 1999, J NEUROPHYSIOL, V82, P2847, DOI 10.1152/jn.1999.82.6.2847; Liu HY, 1996, J NEUROSCI, V16, P7557; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; POZZAN T, 1984, J CELL BIOL, V99, P628, DOI 10.1083/jcb.99.2.628; REEVE HL, 1995, PFLUG ARCH EUR J PHY, V429, P729, DOI 10.1007/BF00373996; SHAPIRA R, 1987, NATURE, V325, P58, DOI 10.1038/325058a0; SHEARMAN MS, 1989, PHARMACOL REV, V41, P211; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; Shistik E, 1998, J BIOL CHEM, V273, P17901, DOI 10.1074/jbc.273.28.17901; TAKASHIMA A, 1985, BIOCHIM BIOPHYS ACTA, V847, P101, DOI 10.1016/0167-4889(85)90159-4; TAKASHIMA A, 1987, BIOCHIM BIOPHYS ACTA, V930, P264, DOI 10.1016/0167-4889(87)90039-5; Taylor SC, 1999, J NEUROCHEM, V73, P874, DOI 10.1046/j.1471-4159.1999.0730874.x; Taylor SC, 1998, BIOCHEM BIOPH RES CO, V248, P13, DOI 10.1006/bbrc.1998.8905; TAYLOR SC, 1999, J PHYSIOL-LONDON, V519, P756; TISCHLER AS, 1983, J NEUROCHEM, V40, P364, DOI 10.1111/j.1471-4159.1983.tb11291.x; Vaughan PFT, 1998, MOL NEUROBIOL, V18, P125, DOI 10.1007/BF02914269; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10754, DOI 10.1073/pnas.88.23.10754; YANG J, 1993, NEURON, V10, P127, DOI 10.1016/0896-6273(93)90305-B; Yawo H, 1999, J PHYSIOL-LONDON, V515, P169, DOI 10.1111/j.1469-7793.1999.169ad.x; Yokoyama CT, 1997, J NEUROSCI, V17, P6929	37	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26786	26791						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10852919				2022-12-25	WOS:000089144800018
J	Kim, S; Jung, Y; Kim, D; Koh, H; Chung, J				Kim, S; Jung, Y; Kim, D; Koh, H; Chung, J			Extracellular zinc activates p70 S6 kinase through the phosphatidylinositol 3-kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MAMMALIAN PROTEIN; EPITHELIAL-CELLS; P70(S6K); INSULIN; AKT; MECHANISM; STRESS; TARGET; PHOSPHORYLATION	We have studied a possible role of extracellular zinc ion in the activation of p70S6k, which plays an important role in the progression of cells from the G(1) to S phase of the cell cycle, Treatment of Swiss 3T3 cells with zinc sulfate led to the activation and phosphorylation of p70S6k in a dose-dependent manner, The activation of p70S6k by zinc treatment was biphasic, the early phase being at 30 min followed by the late phase at 120 min. The zinc-induced activation of p70S6k was partially inhibited by down-regulation of phorbol 12-myristate 13-acetate-responsive protein kinase C (PKC) by chronic treatment with phorbol 12-myristate 13-acetate, but this was not significant. Moreover, Go6976, a specific calcium-dependent PKC inhibitor, did not significantly inhibit the activation of p70S6k by zinc. These results demonstrate that the zinc-induced activation of p70S6k is not related to PKC, Also, extracellular calcium was not involved in the activation of p70S6k by zinc. Further characterization of the zinc-induced activation of p70S6k using specific inhibitors of the p70S6k signaling pathway, namely rapamycin, wortmannin, and LY294002, showed that zinc acted upstream of mTOR/FRAP/RAFT and phosphatidylinositol 3-kinase (PI3K), because these inhibitors caused the inhibition of zinc-induced p70S6k activity, In addition, Akt, the upstream component of p70S6k, was activated by zinc in a biphasic manner, as was p70S6k, Moreover, dominant interfering alleles of Akt and PDK1 blocked the zinc-induced activation of p70S6k, whereas the lipid kinase activity of PI3K was potently activated by zinc, Taken together, our data suggest that zinc activates p70S6k through the PI3K signaling pathway.	Korea Adv Inst Sci & Technol, Dept Sci Biol, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Chung, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Sci Biol, 373-1 Kusong Dong, Taejon 305701, South Korea.	jchung@mail.kaist.ac.kr	Koh, Hyoungjong/C-1615-2012	Koh, Hyongjong/0000-0003-2594-4799				Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Amaldi F, 1997, Prog Mol Subcell Biol, V18, P1; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BUSH AI, 1993, J BIOL CHEM, V268, P16109; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Grammer TC, 1996, CANCER SURV, V27, P271; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; Huang JS, 1999, EUR J BIOCHEM, V266, P943, DOI 10.1046/j.1432-1327.1999.00932.x; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kiss Z, 1997, FEBS LETT, V415, P71, DOI 10.1016/S0014-5793(97)01095-8; KOH JY, 1994, NEUROSCIENCE, V60, P1049, DOI 10.1016/0306-4522(94)90282-8; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MAY JM, 1982, J BIOL CHEM, V257, P4362; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Park JA, 1999, J NEUROCHEM, V73, P450, DOI 10.1046/j.1471-4159.1999.0730450.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Wu WD, 1999, AM J PHYSIOL-LUNG C, V277, pL924, DOI 10.1152/ajplung.1999.277.5.L924	44	88	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25979	25984		10.1074/jbc.M001975200	http://dx.doi.org/10.1074/jbc.M001975200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851233	hybrid			2022-12-25	WOS:000088999700015
J	Peracchia, C; Sotkis, A; Wang, XG; Peracchia, LL; Persechini, A				Peracchia, C; Sotkis, A; Wang, XG; Peracchia, LL; Persechini, A			Calmodulin directly gates gap junction channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRAYFISH SEPTATE AXONS; GATING SENSITIVITY; COMMUNICATING JUNCTIONS; INTRACELLULAR CALCIUM; BINDING SITES; CONDUCTANCE; PH; PERMEABILITY; PROTEINS; CX32	Cytosolic changes control gap junction channel gating via poorly understood mechanisms. In the past two decades calmodulin participation in gating has been suggested, but compelling evidence for it has been lacking. Here we show that calnodulin indeed is associated with gap junctions and plays a direct role in chemical gating. Expression of a calmodulin mutant with the N-terminal EF hand pair replaced by a copy of the C-terminal pair dramatically increases the chemical gating sensitivity of gap junction channels composed of connexin 32 and decreases their sensitivity to transjunctional voltage. The increased chemical gating sensitivity, most likely because of the higher overall Ca2+ binding affinity of this mutant as compared with native calnodulin, and the decreased voltage sensitivity are only observed when the mutant is expressed before connexin 32, This indicates that the mutant, and by extension native calmodulin, must interact with connexin 32 before gap junctions are formed. Immunofluorescence data suggest further that this interaction leads to incorporation of native or mutant calmodulin into the connexon as an integral regulatory subunit.	Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	University of Rochester	Peracchia, C (corresponding author), Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, 601 Elmwood Ave, Rochester, NY 14642 USA.	camillo_peracchia@urmc.rochester.edu		Peracchia, Camillo/0000-0001-7405-1271	NIGMS NIH HHS [GM20113] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020113] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; Bukauskas FF, 1997, BIOPHYS J, V72, P2137, DOI 10.1016/S0006-3495(97)78856-8; Cotrina ML, 1998, J NEUROSCI, V18, P2520; CROW JM, 1994, INVEST OPHTH VIS SCI, V35, P3332; Dermietzel, 1996, GAP JUNCTIONS NERVOU, P135; ENKVIST MOK, 1994, J NEUROCHEM, V62, P489; Fanger CM, 1999, J BIOL CHEM, V274, P5746, DOI 10.1074/jbc.274.9.5746; HERTZBERG EL, 1981, COLD SPRING HARB SYM, V46, P639; Lan L, 1998, BIOCHEM J, V330, P1149, DOI 10.1042/bj3301149; LAZRAK A, 1993, BIOPHYS J, V65, P2002, DOI 10.1016/S0006-3495(93)81242-6; LAZRAK A, 1994, BIOPHYS J, V67, P1052, DOI 10.1016/S0006-3495(94)80570-3; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Levitan IB, 1999, NEURON, V22, P645, DOI 10.1016/S0896-6273(00)80722-9; MEARS D, 1995, J MEMBRANE BIOL, V146, P163; MENEGAZZI P, 1994, BIOCHEMISTRY-US, V33, P9078, DOI 10.1021/bi00197a008; Mori M, 2000, BIOCHEMISTRY-US, V39, P1316, DOI 10.1021/bi9912600; PERACCHIA C, 1984, J MEMBRANE BIOL, V81, P49, DOI 10.1007/BF01868809; Peracchia C, 1999, AM J PHYSIOL-CELL PH, V276, pC1361, DOI 10.1152/ajpcell.1999.276.6.C1361; PERACCHIA C, 1987, PFLUG ARCH EUR J PHY, V408, P379, DOI 10.1007/BF00581132; Peracchia C, 2000, CURR TOP MEMBR, V49, P271; PERACCHIA C, 1981, J CELL BIOL, V91, pA124; PERACCHIA C, 1983, PFLUG ARCH EUR J PHY, V399, P152, DOI 10.1007/BF00663912; Peracchia C, 1996, PFLUG ARCH EUR J PHY, V431, P379, DOI 10.1007/BF02207275; PERACCHIA C, 1990, J MEMBRANE BIOL, V117, P79, DOI 10.1007/BF01871567; PERACCHIA C, 1990, J MEMBRANE BIOL, V113, P75, DOI 10.1007/BF01869608; PERACCHIA C, 1988, MODERN CELL BIOL, V7, P267; PERACCHIA C, 2000, CURRENT TOPICS MEMBR, V49; PERACCHIA C, 1994, HDB MEMBRANE CHANNEL, P361; Persechini A, 1996, BIOCHEMISTRY-US, V35, P224, DOI 10.1021/bi952383x; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; ROSE B, 1975, NATURE, V254, P250, DOI 10.1038/254250a0; SAIMI Y, 1994, HDB MEMBRANE CHANNEL, P435; Skerrett IM, 2000, BIOPHYS J, V78, p22A; SPRAY DC, 1981, SCIENCE, V211, P712, DOI 10.1126/science.6779379; Torok K, 1997, BIOCHEM J, V326, P479; TURIN L, 1980, J PHYSIOL-LONDON, V300, P489, DOI 10.1113/jphysiol.1980.sp013174; TURIN L, 1977, NATURE, V270, P56, DOI 10.1038/270056a0; VANELDIK LJ, 1985, BIOCHEM BIOPH RES CO, V126, P825, DOI 10.1016/0006-291X(85)90259-1; Wang XG, 1997, BIOPHYS J, V73, P798, DOI 10.1016/S0006-3495(97)78112-8; WANG XG, 1998, AM J PHYSIOL, V44, pC1384; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Zhou XW, 1997, BIOPHYS J, V72, P1946, DOI 10.1016/S0006-3495(97)78840-4; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	44	92	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26220	26224		10.1074/jbc.M004007200	http://dx.doi.org/10.1074/jbc.M004007200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852921	hybrid			2022-12-25	WOS:000088999700047
J	Vickers, MF; Yao, SYM; Baldwin, SA; Young, JD; Cass, CE				Vickers, MF; Yao, SYM; Baldwin, SA; Young, JD; Cass, CE			Nucleoside transporter proteins of Saccharomyces cerevisiae - Demonstration of a transporter (FUI1) with high uridine selectivity in plasma membranes and a transporter (FUN26) with broad nucleoside selectivity in intracellular membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIOCARCINOMA BEWO CELLS; XENOPUS-LAEVIS OOCYTES; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; VESICLES; PURINE; RECONSTITUTION; ADENOSINE; SYSTEM; EI	FUI1 and function unknown now 26 (FUN26) are proteins of uncertain function with sequence similarities to members of the uracil/allantoin permease and equilibrative nucleoside transporter families of transporter proteins, respectively, [H-3]Uridine influx was eliminated by disruption of the gene encoding FUI1 (fui1) and restored by expression of FUI1 cDNA, whereas influx in transport-competent and full-negative yeast were unaffected, respectively, by disruption of the FUN26 gene or overexpression of FUN26 cDNA, FUI1 transported uridine with high affinity (K-m, 22 +/- 3 mu M) and was unaffected or inhibited only partially by high concentrations (1 mM) Of a variety of ribo- and deoxyribonucleosides or nucleobases. When FUN26 cDNA was expressed in oocytes of Xenopus laevis, inward fluxes of [H-3]uridine, [H-3]adenosine, and [H-3]cytidine were stimulated, and uridine influx was independent of pH and not inhibited by dilazep, dipyridamole, or nitrobenzylmercaptopurine ribonucleoside. Fractionation of yeast membranes containing immunotagged recombinant FUN26 (shown to be functional in oocytes) demonstrated that the protein was primarily in intracellular membranes. These results indicated that FUI1 has high selectivity for uracil-containing ribonucleosides and imports uridine across cell-surface membranes, whereas FUN26 has broad nucleoside selectivity and most likely functions to transport nucleosides across intracellular membranes.	Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Mol Biol Membranes Grp, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Membrane Transport Res Grp, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Dept Physiol, Edmonton, AB T6G 1Z2, Canada; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Leeds	Cass, CE (corresponding author), Cross Canc Inst, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.							AUSUBEL F, 1997, CURRENT PROTOCOLS MO, V3; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; BARTON AB, 1994, J BACTERIOL, V176, P1872, DOI 10.1128/jb.176.7.1872-1880.1994; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Booth JW, 1997, J BIOL CHEM, V272, P20408, DOI 10.1074/jbc.272.33.20408; BOUMAH CE, 1992, BIOCHEM J, V288, P987, DOI 10.1042/bj2880987; Camins A, 1996, LIFE SCI, V58, P753, DOI 10.1016/0024-3205(95)02353-4; Cass CE, 1998, BIOCHEM CELL BIOL, V76, P761, DOI 10.1139/bcb-76-5-761; CASS CE, 1999, MEMBRANE TRANSPORTER, V12, P313; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CHE MX, 1995, J BIOL CHEM, V270, P13596, DOI 10.1074/jbc.270.23.13596; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; GRENSON M, 1969, EUR J BIOCHEM, V11, P249, DOI 10.1111/j.1432-1033.1969.tb00767.x; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; HARLEY ER, 1982, CANCER RES, V42, P1289; HOGUE DL, 1990, BIOCHEM CELL BIOL, V68, P199, DOI 10.1139/o90-026; HUANG QQ, 1994, J BIOL CHEM, V269, P17757; HUANG QQ, 1993, J BIOL CHEM, V268, P20613; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JUND R, 1970, J BACTERIOL, V102, P607, DOI 10.1128/JB.102.3.607-615.1970; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Mani RS, 1998, J BIOL CHEM, V273, P30818, DOI 10.1074/jbc.273.46.30818; MATILE P, 1969, BIOCHEM J, V111, pP26, DOI 10.1042/bj1110026P; NAGY M, 1979, BIOCHIM BIOPHYS ACTA, V558, P221, DOI 10.1016/0005-2736(79)90062-2; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; Nelissen B, 1995, FEBS LETT, V377, P232, DOI 10.1016/0014-5793(95)01380-6; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; PISONI RL, 1989, J BIOL CHEM, V264, P4850; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Sambrook J., 2002, MOL CLONING LAB MANU; SATO T, 1984, J BIOL CHEM, V259, P1505; SATO T, 1984, J BIOL CHEM, V259, P1509; SEKLER I, 1995, J BIOL CHEM, V270, P21028, DOI 10.1074/jbc.270.36.21028; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Vickers MF, 1999, BIOCHEM J, V339, P21, DOI 10.1042/0264-6021:3390021; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; Wagner R, 1998, FEMS MICROBIOL LETT, V159, P69, DOI 10.1111/j.1574-6968.1998.tb12843.x; WILLIAMS JB, 1995, BIOCHEM BIOPH RES CO, V213, P325, DOI 10.1006/bbrc.1995.2133; Yao SYM, 1996, MOL PHARMACOL, V50, P1529; Yao SYM, 1996, MOL PHARMACOL, V50, P388; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423	47	62	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25931	25938		10.1074/jbc.M000239200	http://dx.doi.org/10.1074/jbc.M000239200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10827169	hybrid			2022-12-25	WOS:000088999700009
J	Kadowaki, T; Tsukuba, T; Bertenshaw, GP; Bond, JS				Kadowaki, T; Tsukuba, T; Bertenshaw, GP; Bond, JS			N-linked oligosaccharides on the meprin A metalloprotease are important for secretion and enzymatic activity, but not for apical targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; BETA-SUBUNIT; CHROMOSOMAL LOCALIZATION; ENDOPLASMIC-RETICULUM; ASTACIN FAMILY; MDCK CELLS; EXPRESSION; GLYCOSYLATION; DOMAIN; ASSOCIATION	The alpha and beta subunits of meprins, mammalian zinc metalloendopeptidases, are extensively glycosylated; similar to 25% of the total molecular mass of the subunits is carbohydrate. The aim of this study was to investigate the roles of the N-linked oligosaccharides on the secreted form of mouse meprin A. Recombinant meprin cu and mutants in which one of the 10 potential Asn glycosylation sites was mutated to Can were all secreted and sorted exclusively into the apical medium of polarized Madin-Darby canine kidney cells, indicating that no specific N-linked oligosaccharide acts as a determinant for apical targeting of meprin rw. Several of the mutant proteins had decreased enzymatic activity using a bradykinin analog as substrate, and deglycosylation of the wildtype protein resulted in loss of 75-100% activity. Some of the mutants were also more sensitive to heat inactivation. In studies with agents that inhibit glycosylation processes in vivo, tunicamycin markedly decreased secretion of meprin, whereas castanospermine and swainsonine had little effect on secretion, sorting, or enzymatic properties of meprin, When all the potential glycosylation sites on a truncated form of meprin cy (alpha-(1-445)) were mutated, the protein was not secreted into the medium, but was retained within the cells even after 10 h. These results indicate that there is no one specific glycosylation site or type of oligosaccharide thigh mannose- or complex-type) that determines apical sorting, but that core N-linked carbohydrates are required for optimal enzymatic activity and for secretion of meprin alpha.	Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Bond, JS (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, H171, Hershey, PA 17033 USA.		Tsukuba, Takayuki/I-9542-2018	Tsukuba, Takayuki/0000-0003-3322-1339; Bertenshaw, Greg/0000-0003-4903-3412	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK019691, R01DK019691, R56DK019691] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 19691] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beynon RJ, 1996, BIOCHEM J, V315, P461, DOI 10.1042/bj3150461; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; Chestukhin A, 1997, J BIOL CHEM, V272, P3153, DOI 10.1074/jbc.272.6.3153; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; JIANG WP, 1993, J BIOL CHEM, V268, P10380; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JOHNSON GD, 1994, J BIOL CHEM, V269, P7682; Johnson GD, 1997, J BIOL CHEM, V272, P28126, DOI 10.1074/jbc.272.44.28126; JOHNSON GD, 1999, HDB PROTEOLYTIC ENZY, P1222; Keller SH, 1998, J BIOL CHEM, V273, P17064, DOI 10.1074/jbc.273.27.17064; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; Lottaz D, 1999, CANCER RES, V59, P1127; Marchand P, 1996, J BIOL CHEM, V271, P24236, DOI 10.1074/jbc.271.39.24236; MARCHAND P, 1994, J BIOL CHEM, V269, P15388; MARCHAND P, 1995, J BIOL CHEM, V270, P5449, DOI 10.1074/jbc.270.10.5449; Martina JA, 1998, J BIOL CHEM, V273, P3725, DOI 10.1074/jbc.273.6.3725; Matters GL, 1999, MOL CARCINOGEN, V25, P169, DOI 10.1002/(SICI)1098-2744(199907)25:3<169::AID-MC3>3.0.CO;2-Y; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SHAKINESHLEMAN SH, 1992, J BIOL CHEM, V267, P10690; STOCKER W, 1993, EUR J BIOCHEM, V214, P215, DOI 10.1111/j.1432-1033.1993.tb17915.x; Tang J, 1998, ARCH BIOCHEM BIOPHYS, V349, P192, DOI 10.1006/abbi.1997.0453; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; Tsukuba T, 1998, J BIOL CHEM, V273, P35260, DOI 10.1074/jbc.273.52.35260; WOLZ RL, 1995, METHOD ENZYMOL, V248, P325; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929	33	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25577	25584		10.1074/jbc.M003521200	http://dx.doi.org/10.1074/jbc.M003521200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837482	hybrid			2022-12-25	WOS:000088849400071
J	Moy, FJ; Desai, SA; Wang, XH; Noronha, EJ; Zhou, QW; Ferrone, S; Powers, R				Moy, FJ; Desai, SA; Wang, XH; Noronha, EJ; Zhou, QW; Ferrone, S; Powers, R			Analysis by NMR spectroscopy of the structural homology between the linear and the cyclic peptide recognized by anti-human leukocyte antigen class I monoclonal antibody TP25.99	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; RESTRAINED MOLECULAR-DYNAMICS; DISTANCE GEOMETRY; 3-DIMENSIONAL STRUCTURE; PROTEIN STRUCTURES; HIGH-RESOLUTION; CONFORMATIONS; INHIBITOR; ASSIGNMENT; COMPLEXES	The anti-human leukocyte antigen (HLA) class I monoclonal antibody (mAb) TP25.99 has a unique specificity since it recognizes both a conformational and a linear determinant expressed on the beta(2)-mu-associated and beta(2)-mu-free HLA class I heavy chains, respectively. Previously, we reported the identification of a cyclic and a linear peptide that inhibits mAb TP25.99 binding to the beta(2)-mu-associated and beta(2)-mu-free HLA class I heavy chains (S. A. Desal, X. Wang, E. J. Noronha, Q. Zhou, V. Rebmann, H. Grosse-Wilde, F. J. Moy, R. Powers, and S. Ferrone, submitted for publication). The linear X-19 and cyclic LX-8 peptides contain sequence homologous to residues 239-242, 245, and 246 and to residues 194-198, respectively, of HLA class I heavy chain alpha(3) domain. Analysis by two-dimensional transfer nuclear Overhauser effect spectroscopy of the induced solution structures of the linear X-19 and cyclic LX-8 peptides in the presence of mAb TP25.99 showed that the two peptides adopt a similar structural motif despite the lack of sequence homology, The backbone fold is suggestive of a short helical segment followed by a tight turn, reminiscent of the determinant loop region (residues 194-198) on beta(2)-mu-associated HLA class I heavy chains. The structural similarity between the linear X-19 and cyclic LX-8 peptides and the lack of sequence homology suggests that mAb TP25.99 predominantly recognizes a structural motif instead of a consensus sequence.	Wyeth Ayerst Res, Dept Biol Chem, Cambridge, MA 02140 USA; Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA	Pfizer; Roswell Park Cancer Institute	Powers, R (corresponding author), Wyeth Ayerst Res, Dept Biol Chem, 85 Bolton St,Rm 222B, Cambridge, MA 02140 USA.		Powers, Robert/AAK-3431-2020	Powers, Robert/0000-0001-9948-6837				BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BOTHNERBY AA, 1988, J MAGN RESON, V77, P524, DOI 10.1016/0022-2364(88)90010-8; BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; BUSHKIN Y, 1986, J EXP MED, V164, P458, DOI 10.1084/jem.164.2.458; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1983, J MAGN RESON, V53, P423, DOI 10.1016/0022-2364(83)90215-9; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DURSO CM, 1991, J CLIN INVEST, V87, P284, DOI 10.1172/JCI114984; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GLAUDEMANS CPJ, 1990, BIOCHEMISTRY-US, V29, P10906, DOI 10.1021/bi00501a007; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JING GZ, 1995, BBA-PROTEIN STRUCT M, V1250, P189, DOI 10.1016/0167-4838(95)00073-4; Kuszewski J, 1997, J MAGN RESON, V125, P171, DOI 10.1006/jmre.1997.1116; Kuszewski J, 1996, PROTEIN SCI, V5, P1067; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; Moy FJ, 1996, BIOCHEMISTRY-US, V35, P13552, DOI 10.1021/bi961260p; NI F, 1994, PROG NUCL MAG RES SP, V26, P517, DOI 10.1016/0079-6565(94)90000-0; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POWERS R, 1993, BIOCHEMISTRY-US, V32, P6744, DOI 10.1021/bi00077a030; QUARANTA V, 1981, IMMUNOGENETICS, V13, P285, DOI 10.1007/BF00364494; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; TANABE M, 1992, J IMMUNOL, V148, P3202; TEMPONI M, 1989, HYBRIDOMA, V8, P85, DOI 10.1089/hyb.1989.8.85; TSOU CL, 1988, BIOCHEMISTRY-US, V27, P1809, DOI 10.1021/bi00406a001; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WILLIAMSON MP, 1985, J MOL BIOL, V182, P295, DOI 10.1016/0022-2836(85)90347-X; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K, 1986, NMR PROTEINS NUCL AC	36	3	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24679	24685		10.1074/jbc.M003647200	http://dx.doi.org/10.1074/jbc.M003647200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10825172	hybrid			2022-12-25	WOS:000088683300061
J	Onley, DJ; Knight, CG; Tuckwell, DS; Barnes, MJ; Farndale, RW				Onley, DJ; Knight, CG; Tuckwell, DS; Barnes, MJ; Farndale, RW			Micromolar Ca2+ concentrations are essential for Mg2+-dependent binding of collagen by the integrin alpha(2)beta(1) in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; BETA-PROPELLER DOMAIN; I-DOMAIN; CRYSTAL-STRUCTURE; A-DOMAIN; DEPENDENT ADHESION; PLASMA-MEMBRANES; DIVALENT-CATIONS; GLYCOPROTEIN-IA; ALPHA-SUBUNITS	Integrin receptor alpha(2)beta(1) requires micromolar Ca2+ to bind to collagen and to the peptide GPC(GPP)(5)GFO-GER(GPP)(5)GPC (denoted GFOGER-GPP, where O represents hydroxyproline), which contains the minimum recognition sequence for the collagen-binding alpha(2) I-domain (Knight, C, G,, Morton, L, F,, Peachey, A. R,, Tuckwell, D. S,, Farndale, R, W,, and Barnes, M. J, (2000) J, Biol. Chem. 275, 35-40), Platelet adhesion to these ligands is completely dependent on alpha(2)beta(1) in the presence of 2 mM Mg2+. However, we show here that this interaction was abolished in the presence of 25 mu M EGTA. Adhesion of Glanzmann's thrombasthenic platelets, which lack the fibrinogen receptor alpha(IIb)beta(3), was also inhibited by micromolar EGTA. Mg2+-dependent adhesion of platelets was restored by the addition of 10 mu M Ca2+, but millimolar Ca2+ was inhibitory. Binding of isolated alpha(2)beta(1) to GFOGER-GPP was 70% inhibited by 50 mu M EGTA but, as with intact platelets, was fully restored by the addition of micromolar Ca2+. 2 mM Ca2+ did not inhibit binding of isolated alpha(2)beta(1) to collagen or to GFOGER-GPP, Binding of recombinant Lu, I-domain was not inhibited by EGTA, nor did millimolar Ca2+ inhibit binding. Our data suggest that high affinity Ca2+ binding to alpha(2)beta(1), outside the I-domain, is essential for adhesion to collagen, This is the first demonstration of a Ca2+ requirement in alpha(2)beta(1) function.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Cambridge; University of Manchester	Onley, DJ (corresponding author), Univ Cambridge, Dept Biochem, Bldg 0, Cambridge CB2 1QW, England.							BELLAVITE P, 1994, ANAL BIOCHEM, V216, P444, DOI 10.1006/abio.1994.1066; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; COLLER BS, 1989, BLOOD, V74, P182; Dickeson SK, 1998, BIOCHEMISTRY-US, V37, P11280, DOI 10.1021/bi9727848; Dickeson SK, 1997, J BIOL CHEM, V272, P7661, DOI 10.1074/jbc.272.12.7661; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; FUJIMURA K, 1983, J BIOL CHEM, V258, P247; HARGREAVES PG, 1994, THROMB HAEMOSTASIS, V72, P634; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; Kehrel B, 1998, BLOOD, V91, P491; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; Knight CG, 1999, CARDIOVASC RES, V41, P450, DOI 10.1016/S0008-6363(98)00306-X; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Messent AJ, 1998, J CELL SCI, V111, P1127; Moroi M, 1997, THROMB HAEMOSTASIS, V78, P439; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; MORTON LF, 1987, BIOCHEM J, V248, P483, DOI 10.1042/bj2480483; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Nolte M, 1999, FEBS LETT, V452, P379, DOI 10.1016/S0014-5793(99)00666-3; Oxvig C, 1998, P NATL ACAD SCI USA, V95, P4870, DOI 10.1073/pnas.95.9.4870; Pelletier AJ, 1996, J BIOL CHEM, V271, P1364, DOI 10.1074/jbc.271.3.1364; PHILLIPS DR, 1983, J BIOL CHEM, V258, P240; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SHATTIL SJ, 1986, BLOOD, V68, P1224; Sixma JJ, 1997, THROMB HAEMOSTASIS, V78, P434; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; Verkleij MW, 1998, BLOOD, V91, P3808	38	64	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24560	24564		10.1074/jbc.M004111200	http://dx.doi.org/10.1074/jbc.M004111200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827198	hybrid			2022-12-25	WOS:000088683300045
J	Shirai, Y; Segawa, S; Kuriyama, M; Goto, K; Sakai, N; Saito, N				Shirai, Y; Segawa, S; Kuriyama, M; Goto, K; Sakai, N; Saito, N			Subtype-specific translocation of diacylglycerol kinase alpha and gamma and its correlation with protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAINS; PLECKSTRIN HOMOLOGY DOMAIN; PHORBOL ESTER BINDING; MOLECULAR-CLONING; INTRACELLULAR CALCIUM; PHOSPHATIDIC-ACID; HUMAN-PLATELETS; CELLS; ACTIVATION; ZETA	We examined the translocation of diacylglycerol kinase (DGH) alpha and gamma fused with green fluorescent protein in Living Chinese hamster ovary K1 cells (CHO-K1) and investigated temporal and spatial correlations between DGK and protein kinase C (PKC) when both kinases are overexpressed. DGK alpha and gamma were present throughout the cytoplasm of CHO-K1 cells. Tetradecanoylphorbol 13-acetate (TPA) induced irreversible translocation of DCR gamma, but not DGR alpha, from the cytoplasm to the plasma membrane. The (TPA)-induced translocation of DGK gamma was inhibited by the mutation of C1A but not C1B domain of DGH gamma and was not inhibited by staurosporine. Arachidonic acid induced reversible translocation of DGK gamma from the cytoplasm to the plasma membrane, whereas DGK alpha showed irreversible translocation to the plasma membrane and the Golgi network. Purinergic stimulation induced reversible translocation of both DGK gamma and alpha to the plasma membrane. The timing of the ATP-indeed translocation of DGK gamma roughly coincided with that of PKC gamma re-translocation from the membrane to the cytoplasm. Furthermore, re-translocation of PRC gamma was obviously hastened by co-expression with DGK gamma and was blocked by an inhibitor of DGK (R59022). These results indicate that DGK shows subtype-specific translocation depending on extracellular signals and suggest that PRC and DGK are orchestrated temporally and spatially in the signal transduction.	Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Nada Ku, Kobe, Hyogo 6578501, Japan; Yamagata Univ, Sch Med, Dept Anat, Yamagata 9909585, Japan	Kobe University; Yamagata University	Saito, N (corresponding author), Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Nada Ku, 1-1 Rokkodai Cho, Kobe, Hyogo 6578501, Japan.		Shirai, Yasuhito/O-3255-2018					BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Ding L, 1998, J BIOL CHEM, V273, P32746, DOI 10.1074/jbc.273.49.32746; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GOTO K, 1993, P NATL ACAD SCI USA, V90, P7598, DOI 10.1073/pnas.90.16.7598; Houssa B, 1997, J BIOL CHEM, V272, P10422; Houssa B, 1998, BIOCHEM J, V331, P677; Hurley JH, 1997, PROTEIN SCI, V6, P477; IREDALE PA, 1993, BRIT J PHARMACOL, V110, P1305, DOI 10.1111/j.1476-5381.1993.tb13960.x; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; ISHII M, 1987, AM J OTOLARYNG, V3, P144; JONES GA, 1993, J BIOL CHEM, V268, P20845; KANOH H, 1989, BIOCHEM J, V258, P455, DOI 10.1042/bj2580455; KANOH H, 1986, FEBS LETT, V201, P97, DOI 10.1016/0014-5793(86)80577-4; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; KOSE A, 1988, J NEUROSCI, V8, P4262; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; MARONEY AC, 1989, J BIOL CHEM, V264, P2537; Moriyama T, 1999, J BIOCHEM, V125, P1077, DOI 10.1093/oxfordjournals.jbchem.a022389; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Nobe K, 1997, BIOCHEM PHARMACOL, V53, P1683, DOI 10.1016/S0006-2952(97)82454-9; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; PREISS J, 1986, J BIOL CHEM, V261, P8597; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; Sakane F, 1996, J BIOL CHEM, V271, P8394, DOI 10.1074/jbc.271.14.8394; Shirai Y, 2000, J CELL SCI, V113, P1335; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; Tang W, 1996, J BIOL CHEM, V271, P10237, DOI 10.1074/jbc.271.17.10237; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; Yamasaki M., 1998, BIOIMAGES, V6, P1	36	78	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24760	24766		10.1074/jbc.M003151200	http://dx.doi.org/10.1074/jbc.M003151200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827086	hybrid			2022-12-25	WOS:000088683300072
J	Abdelouahed, M; Ludlow, A; Brunner, G; Lawler, J				Abdelouahed, M; Ludlow, A; Brunner, G; Lawler, J			Accelerated Publication - Activation of platelet-transforming growth factor beta-1 in the absence of thrombospondin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATENT TGF-BETA; MICE; CELLS; INFLAMMATION; TGF-BETA-1; MECHANISM; DISEASE; PROTEIN; DEFECTS; PALATE	Thrombospondin-1 (TSP-1) has been shown to bind and activate transforming growth factor-beta 1 (TGF-beta 1). This observation raises the possibility that TSP-1 helps to sequester TGF-beta 1 in platelet alpha granules and activates TGF-beta 1 once both proteins are secreted. Herein, we evaluated the level of active and latent TGF-beta 1 in the plasma and in the supernatant of thrombin-treated platelets from TSP-1 null and wild-type mice on two genetic backgrounds (C57BL/6 and 129Sv). The plasminogen activator inhibitor-1/luciferase bioassay and an immunological assay were used to determine active and latent TGF-beta 1, No significant differences were observed in the levels of active and latent TGF-beta 1 in the supernatant of thrombin-treated platelets from TSP-1 null and wildtype mice. Active and latent TGF-beta 1 were significantly increased in the plasma and platelets of C57BL/6 mice as compared with 129Sv mice. In addition, there was an increase of plasma level of latent TGF-beta 1 in TSP-1 null mice as compared with wild-type mice on the C57BL/6 background but not on the 129Sv background. No active TGF-beta 1 was observed in the plasma of either TSP-1 null and wild-type mice. These data indicate that TSP-I does not function as a chaperon for TGF-beta 1 during platelet production and does not activate significant quantities of secreted TGF-beta 1 despite a vast excess in the number of TSP-1 molecules as compared with TGF-beta 1 molecules. Because platelet releasates from TSP-1 null mice contain active TGF-beta 1, we suggest that other important mechanisms of physiological activation of TGF-beta 1 probably exist in platelets.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Munster, Fachklin Hornheide, Dept Canc Res, D-48157 Munster, Germany; Univ Manchester, Sch Biol Sci, Div Cells Immunol & Dev, Manchester M13 9PT, Lancs, England	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Munster; University of Manchester	Lawler, J (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Res N,Rm 270C,99 Brookline Ave, Boston, MA 02215 USA.	lawler@mbcrr.harvard.edu	Lawler, Jack/AAJ-1379-2020		NHLBI NIH HHS [HL28749] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028749] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; BOIVIN GP, 1995, AM J PATHOL, V146, P276; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Diebold RJ, 1995, P NATL ACAD SCI USA, V92, P12215, DOI 10.1073/pnas.92.26.12215; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; GRAINGER DJ, 1995, NAT MED, V1, P932, DOI 10.1038/nm0995-932; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; LAWLER J, 1986, BLOOD, V67, P1197; Lawrence DA, 1996, EUR CYTOKINE NETW, V7, P363; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCCAFFREY TA, 1994, J CELL PHYSIOL, V159, P51, DOI 10.1002/jcp.1041590108; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; PHILLIPS DR, 1980, J BIOL CHEM, V255, P1629; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26775; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587	31	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17933	17936		10.1074/jbc.275.24.17933	http://dx.doi.org/10.1074/jbc.275.24.17933			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849431	hybrid			2022-12-25	WOS:000087659400005
J	Kim, H; Lee, TH; Park, ES; Suh, JM; Park, SJ; Chung, HK; Kwon, OY; Kim, YK; Ro, HK; Shong, M				Kim, H; Lee, TH; Park, ES; Suh, JM; Park, SJ; Chung, HK; Kwon, OY; Kim, YK; Ro, HK; Shong, M			Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced apoptosis in thyroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; FAS-MEDIATED APOPTOSIS; I GENE-EXPRESSION; NF-KAPPA-B; MAMMALIAN PEROXIREDOXIN; THIOREDOXIN PEROXIDASE; STIMULATING HORMONE; PROTEIN IODINATION; FOLLICULAR CELLS; THYROTROPIN	Peroxiredoxins (Prxs) play an important role in regulating cellular differentiation and proliferation in several types of mammalian cells. One mechanism for this action involves modulation of hydrogen peroxide (H2O2)-mediated cellular responses. This report examines the expression of Prx I and Prx II: in thyroid cells and their roles in eliminating H2O2 produced in response to thyrotropin (TSH), Prx I and Prx II are constitutively expressed in FRTL-5 thyroid cells. Prx I expression, but not Prx II expression, is stimulated by exposure to TSH and H2O2. In addition, methimazole induces a high level of Prx I mRNA and protein in these cells, Overexpression of Prx I and Prx II enhances the elimination of H2O2 produced by TSH in FRTL-5 cells. Treatment with 500 mu M H2O2 causes apoptosis in FRTL-5 cells as evidenced big standard assays of apoptosis the. terminal deoxynucleotidyl transferase deoxyuridine triphosphate-biotin nick end labeling, BAX expression, and poly(ADP-ribose) polymerase cleavage. Overexpression of Prx I and Prx II reduces the amount of H2O2-induced apoptosis measured by these assays. These results suggest that Prx I and Prx LI are involved in the removal of H2O2 in thyroid cells and can protect these cells from undergoing apoptosis. These proteins are likely to be involved in the normal physiological response to TSH-induced production of H2O2 in thyroid cells.	Chungnam Natl Univ, Dept Internal Med, Taejon 301721, South Korea; Chungnam Natl Univ, Dept Anat, Taejon 301721, South Korea; Korea Res Inst Biosci & Biotechnol, Yusong Gu, Taejon 305600, South Korea	Chungnam National University; Chungnam National University; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Shong, M (corresponding author), Chungnam Natl Univ, Dept Internal Med, 640 Daesadong Chungku, Taejon 301721, South Korea.	minhos@hanbat.chungnam.ac.kr	/H-7803-2012; Lee, Tae-Hoon/AAR-3708-2021	Lee, Tae-Hoon/0000-0003-0105-1750; shong, minho/0000-0002-0247-7115; Kwon, O-Yu/0000-0002-4236-6276				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; BALAZS C, 1986, CLIN ENDOCRINOL, V25, P7, DOI 10.1111/j.1365-2265.1986.tb03590.x; BJORKMAN U, 1992, ENDOCRINOLOGY, V130, P393, DOI 10.1210/en.130.1.393; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; Bretz JD, 1999, J BIOL CHEM, V274, P25433, DOI 10.1074/jbc.274.36.25433; Cadet J, 1999, MUTAT RES-FUND MOL M, V424, P9, DOI 10.1016/S0027-5107(99)00004-4; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Carvalho DP, 1996, ENDOCRINOLOGY, V137, P1007, DOI 10.1210/en.137.3.1007; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; CHAE HZ, 1994, BIOFACTORS, V4, P177; CHO BY, 1992, CLIN ENDOCRINOL, V36, P585, DOI 10.1111/j.1365-2265.1992.tb02269.x; Clement MV, 1999, FREE RADICAL RES, V30, P247, DOI 10.1080/10715769900300271; CORVILAIN B, 1991, ENDOCRINOLOGY, V128, P779, DOI 10.1210/endo-128-2-779; Ekholm R, 1997, ENDOCRINOLOGY, V138, P2871, DOI 10.1210/en.138.7.2871; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; Feldkamp J, 1999, HORM METAB RES, V31, P355, DOI 10.1055/s-2007-978753; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; HEUFELDER AE, 1992, J CLIN ENDOCR METAB, V74, P737, DOI 10.1210/jc.74.4.737; IMAMURA M, 1986, ACTA ENDOCRINOL-COP, V112, P210, DOI 10.1530/acta.0.1120210; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KIMURA T, 1995, ENDOCRINOLOGY, V136, P116, DOI 10.1210/en.136.1.116; KINGSTON RE, 1993, CURRENT PROTOCOL MOL, V1; Knoops B, 1999, J BIOL CHEM, V274, P30451, DOI 10.1074/jbc.274.43.30451; KOHN LD, 1986, Patent No. 4609622; KUMURA T, 1997, AM J PHYSIOL, V273, pE639; Lee TH, 1999, GENE, V234, P337, DOI 10.1016/S0378-1119(99)00190-0; Leseney AM, 1999, BIOCHIMIE, V81, P373, DOI 10.1016/S0300-9084(99)80084-4; Li X, 1999, ENDOCRINOLOGY, V140, P5962, DOI 10.1210/en.140.12.5962; Lim MJ, 1998, GENE, V216, P197, DOI 10.1016/S0378-1119(98)00290-X; Lyu MS, 1999, MAMM GENOME, V10, P1017, DOI 10.1007/s003359901150; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Matsumoto A, 1999, FEBS LETT, V443, P246, DOI 10.1016/S0014-5793(98)01736-0; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Montani V, 1998, ENDOCRINOLOGY, V139, P280, DOI 10.1210/en.139.1.280; Montani V, 1998, ENDOCRINOLOGY, V139, P290, DOI 10.1210/en.139.1.290; Mozes E, 1998, J CLIN IMMUNOL, V18, P106, DOI 10.1023/A:1023242732212; NAKAMURA Y, 1991, BIOCHEMISTRY-US, V30, P4880, DOI 10.1021/bi00234a007; Netto LES, 1996, J BIOL CHEM, V271, P15315, DOI 10.1074/jbc.271.26.15315; Nishida S, 1997, FEBS LETT, V416, P69, DOI 10.1016/S0014-5793(97)01171-X; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Ohmori M, 1996, MOL ENDOCRINOL, V10, P1407, DOI 10.1210/me.10.11.1407; Park ES, 1999, THYROID, V9, P601, DOI 10.1089/thy.1999.9.601; RASPE E, 1995, ENDOCRINOLOGY, V136, P965, DOI 10.1210/en.136.3.965; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Riou C, 1999, ENDOCRINOLOGY, V140, P1990, DOI 10.1210/en.140.5.1990; Riou C, 1998, J ENDOCRINOL, V156, P315, DOI 10.1677/joe.0.1560315; Saji M, 1997, J BIOL CHEM, V272, P20096, DOI 10.1074/jbc.272.32.20096; Suzuki K, 1999, P NATL ACAD SCI USA, V96, P2285, DOI 10.1073/pnas.96.5.2285; Taniguchi S, 1998, MOL ENDOCRINOL, V12, P19, DOI 10.1210/mend.12.1.0052; Villette S, 1998, FEBS LETT, V438, P81, DOI 10.1016/S0014-5793(98)01280-0; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	57	194	209	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18266	18270		10.1074/jbc.275.24.18266	http://dx.doi.org/10.1074/jbc.275.24.18266			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849441	hybrid			2022-12-25	WOS:000087659400049
J	Feng, X; Becker, KP; Stribling, SD; Peters, KG; Hannun, YA				Feng, X; Becker, KP; Stribling, SD; Peters, KG; Hannun, YA			Regulation of receptor-mediated protein kinase C membrane trafficking by autophosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; PLASMA-MEMBRANE; IN-VIVO; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-D; LIVING CELLS; BETA-II; ACTIVATION; DOMAIN; PHOSPHORYLATION	Signal transduction via protein kinase C (PRC) is closely regulated by its subcellular localization. In response to activation of cell-surface receptors, PKC is directed to the plasma membrane by two membrane-targeting domains, namely the C1 and C2 regions. This is followed by the return of the enzyme to the cytoplasm, a process shown recently to require PHC autophosphorylation (Feng, X., and Hannun, Y. A. (1998) J. Biol. Chem. 273, 26870-26874). In the present study, we examined mechanisms of translocation and reverse translocation and the role of autophosphorylation in these processes. By visualizing the trafficking of wild-type as well as mutant PKC beta II in live cells, we demonstrated that in response to cell-surface receptor activation, the function of the C1 region is required but not sufficient for recruitment of the enzyme to the plasma membrane. The C2 region is also critical in anchoring the enzyme to the plasma membrane. Furthermore, the inability of a kinase-deficient PKC to undergo reverse translocation was restored by the addition of intracellular calcium chelators, suggesting a role for the C2 region in the persistent phase of translocation, On the other hand, the inability of a C2 deletion mutant (C1 region intact) to translocate in response to agonist was reversed in mutants lacking kinase activity or by mutation of the Ser(660) autophosphorylation site to alanine, suggesting that autophosphorylation of this site is required for opposing the action of the C2 region Therefore, the membrane-targeting function of the C1 region is facilitated by the C2 region and appears to be opposed by autophosphorylation. Taken together, these findings provide novel evidence of the functional regulation of reversible PRC membrane localization by autophosphorylation, and they show that the dynamic translocation of PKC in response to agonists is tightly regulated in a collaborative fashion by the C1 and C2 regions in balance with the effects of autophosphorylation.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Medical University of South Carolina; Duke University; Duke University	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 171 Ashley Ave, Charleston, SC 29425 USA.	hannun@musc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43707] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; Blobe GC, 1996, CANCER SURV, V27, P213; BORNER C, 1989, J BIOL CHEM, V264, P13902; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; KATER LA, 1976, J CLIN INVEST, V57, P1173, DOI 10.1172/JCI108385; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LUO JH, 1993, J BIOL CHEM, V268, P23580; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; Mosior M, 1996, BIOCHEMISTRY-US, V35, P1612, DOI 10.1021/bi952031q; Nakhost A, 1999, J BIOL CHEM, V274, P28944, DOI 10.1074/jbc.274.41.28944; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; OLSON SC, 1991, J BIOL CHEM, V266, P17236; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ORR JW, 1994, J BIOL CHEM, V269, P27715; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pepio AM, 1998, J BIOL CHEM, V273, P19040, DOI 10.1074/jbc.273.30.19040; Quest AFG, 1996, ENZYME PROTEIN, V49, P231, DOI 10.1159/000468635; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121	42	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17024	17034		10.1074/jbc.275.22.17024	http://dx.doi.org/10.1074/jbc.275.22.17024			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828076	hybrid			2022-12-25	WOS:000087392200088
J	Fu, X; Inouye, M; Shinde, U				Fu, X; Inouye, M; Shinde, U			Folding pathway mediated by an intramolecular chaperone - The inhibitory and chaperone functions of the subtilisin propeptide are not obligatorily linked	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PRO-SEQUENCE; CARBOXYPEPTIDASE-Y; CRYSTAL-STRUCTURE; COMPLEX; BPN'; REQUIREMENT; CATALYSIS; PROTEINS; REGION	The subtilisin propeptide functions as an intramolecular chaperone (IMC) that facilitates correct folding of the catalytic domain while acting like a competitive inhibitor of proteolytic activity. Upon completion of folding, subtilisin initiates IMC degradation to complete precursor maturation. Existing data suggest that the chaperone and inhibitory functions of the subtilisin IMC domain are interdependent during folding. Based on x-ray structure of the IMC-subtilisin complex, we introduce a point mutation (E112A) to disrupt three hydrogen bonds that stabilize the interface between the protease and its IMC domain. This mutation within subtilisin does not alter the folding kinetics but dramatically slows down autoprocessing of the IMC domain. Inhibition of E112A-subtilisin activity by the IMC added in trans is 35-fold weaker than wild-type subtilisin. Although the IMC domain displays substantial loss of inhibitory function, its ability to chaperone E112A-subtilisin folding remains intact. Our results show that (i) the chaperone activity of the IMC domain is not obligatorily linked with its ability to bind with and inhibit active subtilisin; (ii) degradation and not autoprocessing of the IMC domain is the rate-limiting step in precursor maturation; and (iii) the Glu(112) residue within the IMC-subtilisin interface is not crucial for initiating folding but is important in maintaining the IMC structure capable of binding subtilisin.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Shinde, U (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Ln, Piscataway, NJ 08854 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056419] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-56419-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; BRYAN P, 1995, INTRAMOLECULAR CHAPE; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; EDER J, 1993, BIOCHEMISTRY-US, V32, P18, DOI 10.1021/bi00052a004; EDER J, 1993, J MOL BIOL, V233, P293, DOI 10.1006/jmbi.1993.1507; Ellis RJ, 1998, TRENDS BIOCHEM SCI, V23, P43, DOI 10.1016/S0968-0004(98)01175-X; GALLAGHER T, 1995, STRUCTURE, V3, P907, DOI 10.1016/S0969-2126(01)00225-8; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; Hu ZX, 1996, J BIOL CHEM, V271, P3375; IKEMURA H, 1988, J BIOL CHEM, V263, P12959; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; Jain SC, 1998, J MOL BIOL, V284, P137, DOI 10.1006/jmbi.1998.2161; KWON ST, 1988, EUR J BIOCHEM, V73, P1; LEE YC, 1991, AGR BIOL CHEM TOKYO, V55, P3027, DOI 10.1080/00021369.1991.10857921; LI YY, 1994, J BIOL CHEM, V269, P4169; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; Marie-Claire C, 1999, J MOL BIOL, V285, P1911, DOI 10.1006/jmbi.1998.2449; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Shinde U, 1999, J BIOL CHEM, V274, P15615, DOI 10.1074/jbc.274.22.15615; SHINDE U, 1993, P NATL ACAD SCI USA, V90, P6924, DOI 10.1073/pnas.90.15.6924; SHINDE U, 1994, J BIOCHEM, V115, P629, DOI 10.1093/oxfordjournals.jbchem.a124386; Shinde U, 2000, SEMIN CELL DEV BIOL, V11, P35, DOI 10.1006/scdb.1999.0349; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SHINDE U, 1995, J MOL BIOL, V252, P25, DOI 10.1006/jmbi.1995.0472; SHINDE U, 1995, J MOL BIOL, V247, P390, DOI 10.1006/jmbi.1994.0147; SHINDE U, 1997, MOL CHAPERONES PROTE, P467; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; SILEN JL, 1989, NATURE, V341, P362; SMITH SM, 1989, J BIOL CHEM, V264, P20487; SORENSEN P, 1993, BIOCHEMISTRY-US, V32, P12160; STRAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P8112, DOI 10.1021/bi00083a009; SUTER U, 1992, J NEUROSCI, V12, P306; THORNE BA, 1994, MOL CELL BIOL, V14, P1635, DOI 10.1128/MCB.14.3.1635; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; WONG SL, 1986, J BIOL CHEM, V261, P176; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	38	69	90	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16871	16878		10.1074/jbc.275.22.16871	http://dx.doi.org/10.1074/jbc.275.22.16871			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828069	hybrid			2022-12-25	WOS:000087392200067
J	Baksh, S; DeCaprio, JA; Burakoff, SJ				Baksh, S; DeCaprio, JA; Burakoff, SJ			Calcineurin regulation of the mammalian G(0)/G(1) checkpoint element, cyclin dependent kinase 4	ONCOGENE			English	Article						cell cycle; calcineurin; cdk4; cyclin activating kinase; Jurkat cells	RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; PHOSPHORYLATION; PHOSPHATASE; FAMILY; CELLS; NFAT; CDK4	Cyclin dependent kinase 4 (cdk8) activity is controlled by the binding of regulatory subunits and inhibitory factors, as well as tyrosine and serine/threonine phosphorylation, More recently the influence of calcium levels have been demonstrated. Using transient transfections in Jurkat cells, we observed specific binding between cdk4 and the calcium and calmodulin activated serine/threonine phosphatase, calcineurin. Furthermore, we demonstrated that the inhibition of the phosphatase activity of calcineurin with FK506 and cyclosporin A resulted in an overall increase in cdk4 kinase activity, suggesting that the phosphatase activity of calcineurin was inhibitory to the kinase activity of cdkA In contrast, we were not able to observe a similar effect on the kinase activity of either cdk6 or cdk2, indicating that the phosphatase activity of calcineurin was specific for cdk4, In addition, using an in vitro phosphatase assay for calcineurin, we observed that the exogenous addition of calcineurin resulted in the dephosphorylation of cdk4, an event that downregulated the kinase activity of cdk4 Calcineurin could, therefore, play an opposing role to the action of the cyclin activating kinase complex, an enzyme that upregulates the kinase activity of cdk4, an important G(0)/G(1) checkpoint element in mammalian cells.	Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Burakoff, SJ (corresponding author), Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.		Baksh, Shairaz/GRX-2106-2022					Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; FRUMAN DA, 1992, EUR J IMMUNOL, V22, P2513, DOI 10.1002/eji.1830221008; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Jinno S, 1999, ONCOGENE, V18, P565, DOI 10.1038/sj.onc.1202347; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KREK W, 1995, METHOD ENZYMOL, V254, P114; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mizunuma M, 1998, NATURE, V392, P303, DOI 10.1038/32695; Mondragon A, 1997, BIOCHEMISTRY-US, V36, P4934, DOI 10.1021/bi9631935; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	23	47	49	1	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2000	19	24					2820	2827		10.1038/sj.onc.1203585	http://dx.doi.org/10.1038/sj.onc.1203585			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851085				2022-12-25	WOS:000087403600003
J	Inoue, H; Tanabe, T; Umesono, K				Inoue, H; Tanabe, T; Umesono, K			Feedback control of cyclooxygenase-2 expression through PPAR gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; ACTIVATED RECEPTOR-GAMMA; FACTOR-KAPPA-B; VASCULAR ENDOTHELIAL-CELLS; NUCLEAR FACTOR; FACTOR-ALPHA; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); TRANSCRIPTIONAL REGULATION; DIFFERENTIAL EXPRESSION; RESPONSE ELEMENT	Cyclooxygenase-2 (COX-2), a rate-limiting enzyme for prostaglandins (PG), plays a key role in inflammation, tumorigenesis, development, and circulatory homeostasis. The POD, metabolite 15-deoxy-Delta(12,14) PGJ(2) (15d-PGJ(2)) was identified as a potent natural ligand for the peroxisome proliferator-activated receptor-gamma (PPAR gamma), PPAR gamma expressed in macrophages has been postulated as a negative regulator of inflammation and a positive regulator of differentiation into foam cell associated with atherogenesis. Here, we show that 15d-PGJ(2) suppresses the Lipopolysaccharide (LPS)-induced expression of COX-2 in the macrophage-like differentiated U937 cells but not in vascular endothelial cells. PPAR gamma mRNA abundantly expressed in the U937 cells, not in the endothelial cells, is down-regulated by LPS, In contrast, LPS up-regulates mRNA for the glucocorticoid receptor which ligand anti-inflammatory steroid dexamethasone (DEX) strongly suppresses the LPS-induced expression of COX-2, although both 15d-PGJ(2) and DEX suppressed COX-2 promoter activity by interfering with the NF-kappa B signaling pathway, Transfection of a PPAR gamma expression vector into the endothelial cells acquires this suppressive regulation of COX-2 gene by 15d-PGJ(2) but not by DM. A selective COX-2 inhibitor, NS-398, inhibits production of PGD(2) in the U937 cells. Taking these findings together, we propose that expression of COX-2 is regulated by a negative feedback loop mediated through PPAR gamma, which makes possible a dynamic production of PC, especially in macrophages, and may be attributed to various expression patterns and physiological functions of COX-2.	Natl Cardiovasc Ctr, Res Inst, Dept Pharmacol, Osaka 5658565, Japan; Kyoto Univ, Inst Virus Res, Dept Mol Biol & Genet, Sakyo Ku, Kyoto 068397, Japan	National Cerebral & Cardiovascular Center - Japan; Kyoto University	Inoue, H (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Pharmacol, 5-7-1 Fujishiro Dai, Osaka 5658565, Japan.							BIENKOWSKI MJ, 1989, J BIOL CHEM, V264, P6536; Callejas NA, 1999, J PHARMACOL EXP THER, V288, P1235; Chinery R, 1999, CANCER RES, V59, P2739; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fournier T, 1997, J BIOL CHEM, V272, P31065, DOI 10.1074/jbc.272.49.31065; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Greene M. E., 1995, Gene Expression, V4, P281; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Inoue H, 1999, BIOCHEM BIOPH RES CO, V254, P292, DOI 10.1006/bbrc.1998.9939; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; Katsuyama M, 1998, BIOCHEM BIOPH RES CO, V251, P727, DOI 10.1006/bbrc.1998.9540; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; Kuwamoto S, 1997, FEBS LETT, V409, P242, DOI 10.1016/S0014-5793(97)00516-4; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; Liu JM, 1999, J BIOL CHEM, V274, P35037, DOI 10.1074/jbc.274.49.35037; Ma HW, 1998, J BIOL CHEM, V273, P30131, DOI 10.1074/jbc.273.46.30131; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Newton R, 1998, EUR J BIOCHEM, V254, P81, DOI 10.1046/j.1432-1327.1998.2540081.x; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; SIROIS J, 1993, J BIOL CHEM, V268, P12199; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Sundvold H, 1997, BIOCHEM BIOPH RES CO, V239, P857, DOI 10.1006/bbrc.1997.7564; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; URADE Y, 1989, J IMMUNOL, V143, P2982; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; ZAKAR T, 1995, ENDOCRINOLOGY, V136, P1610, DOI 10.1210/en.136.4.1610	48	259	271	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28028	28032						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10827178				2022-12-25	WOS:000089197100067
J	Jokiranta, TS; Hellwage, J; Koistinen, V; Zipfel, PF; Meri, S				Jokiranta, TS; Hellwage, J; Koistinen, V; Zipfel, PF; Meri, S			Each of the three binding sites on complement factor H interacts with a distinct site on C3b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULONEPHRITIS TYPE-II; SURFACE-PLASMON RESONANCE; ALTERNATIVE PATHWAY; HEPARIN-BINDING; PROTEIN BETA-1H; SIALIC-ACID; FACTOR-B; MONOCLONAL-ANTIBODIES; REGULATORY DOMAINS; TRYPTIC FRAGMENT	Factor H (fH) restricts activation of the alternative pathway of complement at the level of C3, both in the fluid phase and on self-structures, but allows the activation to proceed on foreign structures. To study the interactions between fH and C3b we used surface plasmon resonance analysis (Biacore(R)) and eight recombinantly expressed fH constructs containing fragments of the 20 short consensus repeat domains (SCRs) of fH. We analyzed the binding of these constructs to C3b and its cleavage products C3c and C3d. Three binding sites for C3b were found on fH. Site 1 was localized to the five amino-terminal SCRs (SCR1-5), and its reciprocal binding site on C3b was found to be lost upon the cleavage of C3b to C3c and C3d, Site 2 on fH was localized by exclusion probably within or near SCRs 12-14 (fragment SCR8-20 bound to C3b, C3c, and C3d; SCR8-11 did not bind to C3b at all; and SCR15-20 bound only to the C3d part of C3b). Site 3 on fH for C3b was localized to the carboxyl-terminal SCRs 19-20, and its reciprocal binding site was mapped to the C3d part of C3b. In conclusion, we confirmed and mapped three binding sites on fH for C3b and demonstrated that the three binding sites on fH interact with distinct sites on C3b. Multiple reciprocal interactions between C3b and fH can provide a basis for the different reactivity of the alternative pathway with different target structures.	Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst & HD Diagnost, Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00290 Helsinki, Finland; Bernhard Nocht Inst Trop Med, Res Grp Biomol Med, D-20359 Hamburg, Germany; Hans Knoell Inst Naturstoff Forsch, D-07708 Jena, Germany	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Bernhard Nocht Institut fur Tropenmedizin	Jokiranta, TS (corresponding author), Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst & HD Diagnost, Haartmaninkatu 3, Helsinki, Finland.	sakari.jokiranta@helsinki.fi	Jokiranta, T. Sakari/F-1906-2011					ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389; ALSENZ J, 1990, CURR TOP MICROBIOL, V153, P235; Ault BH, 1997, J BIOL CHEM, V272, P25168, DOI 10.1074/jbc.272.40.25168; BECHERER JD, 1992, BIOCHEMISTRY-US, V31, P1787, DOI 10.1021/bi00121a029; Blackmore TK, 1996, J IMMUNOL, V157, P5422; Blackmore TK, 1998, J IMMUNOL, V160, P3342; CULLEN DC, 1987, BIOSENSORS, V3, P211; EGGERTSEN G, 1985, MOL IMMUNOL, V22, P833, DOI 10.1016/0161-5890(85)90067-7; Fagerstam L G, 1990, J Mol Recognit, V3, P208, DOI 10.1002/jmr.300030507; FEARON DT, 1975, J IMMUNOL, V115, P1357; FEARON DT, 1975, J EXP MED, V142, P856, DOI 10.1084/jem.142.4.856; FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971; GORDON DL, 1995, J IMMUNOL, V155, P348; HOGASEN K, 1995, J CLIN INVEST, V95, P1054, DOI 10.1172/JCI117751; HONG K, 1982, J IMMUNOL, V129, P647; HORSTMANN RD, 1985, J IMMUNOL, V134, P1101; JANSEN JH, 1993, AM J PATHOL, V143, P1356; Jokiranta TS, 1996, FEBS LETT, V393, P297; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; KOISTINEN V, 1989, COMPLEMENT INFLAMMAT, V6, P270, DOI 10.1159/000463102; KUHN S, 1995, GENE, V162, P225, DOI 10.1016/0378-1119(95)00360-I; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; KUHN S, 1995, J IMMUNOL, V155, P5663; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBRIS JD, 1988, J BIOL CHEM, V263, P12147; Lambris JD, 1996, J IMMUNOL, V156, P4821; LEVY M, 1986, KIDNEY INT, V30, P949, DOI 10.1038/ki.1986.278; MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982; MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008; MORGAN BP, 1994, SPRINGER SEMIN IMMUN, V15, P369, DOI 10.1007/BF01837366; Muller-Eberhard H J, 1980, Adv Immunol, V29, P1, DOI 10.1016/S0065-2776(08)60042-5; MULLEREBERHARD HJ, 1986, ANNU REV IMMUNOL, V4, P503, DOI 10.1146/annurev.iy.04.040186.002443; PANGBURN MK, 1980, J EXP MED, V152, P1102, DOI 10.1084/jem.152.4.1102; PANGBURN MK, 1987, J IMMUNOL METHODS, V102, P7, DOI 10.1016/S0022-1759(87)80003-0; PANGBURN MK, 1991, J BIOL CHEM, V266, P16847; PANGBURN MK, 1983, BIOCHEMISTRY-US, V22, P178, DOI 10.1021/bi00270a026; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; PANGBURN MK, 1978, P NATL ACAD SCI USA, V75, P2416, DOI 10.1073/pnas.75.5.2416; Pathak SS, 1997, IMMUNOL TODAY, V18, P464, DOI 10.1016/S0167-5699(97)01124-9; PICHETTE V, 1994, AM J KIDNEY DIS, V24, P936, DOI 10.1016/S0272-6386(12)81065-1; PLATTSMI.TA, 1974, J IMMUNOL, V113, P348; Prodinger WM, 1998, BIOCHEM J, V331, P41, DOI 10.1042/bj3310041; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; RIPOCHE J, 1986, BIOSCIENCE REP, V6, P65, DOI 10.1007/BF01145180; SCHREIBER RD, 1978, P NATL ACAD SCI USA, V75, P3948, DOI 10.1073/pnas.75.8.3948; SCHULZ TF, 1986, EUR J IMMUNOL, V16, P1351, DOI 10.1002/eji.1830161107; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; SIM RB, 1981, BIOCHEM J, V193, P115, DOI 10.1042/bj1930115; SIM RB, 1982, BIOCHEM J, V205, P285, DOI 10.1042/bj2050285; TANIGUCHISIDLE A, 1994, J IMMUNOL, V153, P5285; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOGT BA, 1995, PEDIATR NEPHROL, V9, P11, DOI 10.1007/BF00858956; WEILER JM, 1976, P NATL ACAD SCI USA, V73, P3268, DOI 10.1073/pnas.73.9.3268; WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147	54	174	183	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27657	27662						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10837479				2022-12-25	WOS:000089197100019
J	Keilhack, H; Hellman, U; van Hengel, J; van Roy, F; Godovac-Zimmermann, J; Bohmer, FD				Keilhack, H; Hellman, U; van Hengel, J; van Roy, F; Godovac-Zimmermann, J; Bohmer, FD			The protein-tyrosine phosphatase SHP-1 binds to and dephosphorylates p120 catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; CELL-ADHESION MOLECULE; TUMOR-SUPPRESSOR GENE; E-CADHERIN; BETA-CATENIN; INHIBITORY RECEPTOR; SIGNAL-TRANSDUCTION; COMPLEX-FORMATION; ALPHA-CATENIN; EGF RECEPTOR	A prominent tyrosine-phosphorylated protein of similar to 100 kDa (designated pp100) in epidermal growth factor (EGF)-stimulated A431 cells was found to be a main interaction partner of the protein-tyrosine phosphatase SHP-1 in pull-down experiments with a glutathione S-transferase-SHP-1 fusion protein. Binding was largely mediated by the N-terminal SH2 domain of SHP-1 and apparently direct and independent from the previously described association of SHP-1 with the activated EGF receptor. pp100 was partially purified and identified by mass spectrometric analysis of tryptic fragments, partial amino acid sequencing, and use of authentic antibodies as the 3A isoform of the Armadillo repeat protein superfamily member p120 catenin (p120(ctn)). Different p120(ctn) isoforms expressed in human embryonal kidney 293 cells, exhibited differential binding to SHP-1 that correlated partly with the extent of EGF-dependent p120(ctn) tyrosine phosphorylation. Despite strong phosphorylation, p120(ctn) isoforms 3B and 3AB bound, however, less readily to SHP-1. SHP-1 associated transiently with p120(ctn) in EGF-stimulated A431 cells stably transfected with a tetracycline-responsive SHP-1 expression construct, and p120(ctn) exhibited elevated phosphorylation upon a tetracycline-mediated decrease in the SHP-1 level. Functions of p120(ctn), which are regulated by tyrosine phosphorylation, may be modulated by the described SHP-1-p120(ctn) interaction.	Univ Jena Klinikum, Res Unit Mol Cell Biol, D-07747 Jena, Germany; Ludwig Inst Canc Res, Uppsala Branch, SE-75124 Uppsala, Sweden; State Univ Ghent VIB, Dept Mol Biol, Mol Cell Biol Unit, B-9000 Ghent, Belgium; Inst Mol Biotechnol, D-07745 Jena, Germany	Friedrich Schiller University of Jena; Ludwig Institute for Cancer Research; Flanders Institute for Biotechnology (VIB); Ghent University	Bohmer, FD (corresponding author), Univ Jena Klinikum, Res Unit Mol Cell Biol, Drackendorfer Str 1, D-07747 Jena, Germany.	i5frbo@rz.uni-jena.de	Zimmermann, Jasminka Godovac/E-6863-2010; van Roy, Frans M/C-6123-2009	van Roy, Frans M/0000-0003-4358-1039				Adachi M, 1996, CELL, V85, P15; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; BIRCHMEIER W, 1994, BIOESSAYS, V16, P305, DOI 10.1002/bies.950160503; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Blery M, 1998, P NATL ACAD SCI USA, V95, P2446, DOI 10.1073/pnas.95.5.2446; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; DOWNING JR, 1991, ONCOGENE, V6, P607; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; Finnemann S, 1997, J BIOL CHEM, V272, P11856, DOI 10.1074/jbc.272.18.11856; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hellman U, 1997, SPRING LAB MAN, P97; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Keirsebilck A, 1998, GENOMICS, V50, P129, DOI 10.1006/geno.1998.5325; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KIM L, 1995, MOL CELL BIOL, V15, P4553; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Lehr S, 1999, BIOCHEMISTRY-US, V38, P151, DOI 10.1021/bi9818265; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; Maeda A, 1998, J EXP MED, V187, P1355, DOI 10.1084/jem.187.8.1355; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; Mo YY, 1996, CANCER RES, V56, P2633; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; Perez-Villar JJ, 1999, MOL CELL BIOL, V19, P2903; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Reynolds AB, 1996, EXP CELL RES, V225, P328, DOI 10.1006/excr.1996.0183; Roach TIA, 1998, CURR BIOL, V8, P1035, DOI 10.1016/S0960-9822(07)00426-5; Rosato R, 1998, MOL CELL BIOL, V18, P5762, DOI 10.1128/MCB.18.10.5762; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Shultz LD, 1997, TRENDS BIOTECHNOL, V15, P302, DOI 10.1016/S0167-7799(97)01060-3; Takayama T, 1998, BRIT J CANCER, V77, P605, DOI 10.1038/bjc.1998.97; Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1; Tenev T, 1997, J BIOL CHEM, V272, P5966, DOI 10.1074/jbc.272.9.5966; Thiery JP, 1996, J CELL BIOCHEM, V61, P489; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; Ulyanova T, 1997, IMMUNOL RES, V16, P101, DOI 10.1007/BF02786326; van Hengel J, 1999, P NATL ACAD SCI USA, V96, P7980, DOI 10.1073/pnas.96.14.7980; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779	67	55	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26376	26384		10.1074/jbc.M001315200	http://dx.doi.org/10.1074/jbc.M001315200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10835420	hybrid			2022-12-25	WOS:000088999700068
J	Boudrez, A; Beullens, M; Groenen, P; Van Eynde, A; Vulsteke, V; Jagiello, I; Murray, M; Krainer, AR; Stalmans, W; Bollen, M				Boudrez, A; Beullens, M; Groenen, P; Van Eynde, A; Vulsteke, V; Jagiello, I; Murray, M; Krainer, AR; Stalmans, W; Bollen, M			NIPP1-mediated interaction of protein phosphatase-1 with CDC5L, a regulator of pre-mRNA splicing and mitotic entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; NUCLEAR-ORGANIZATION; TARGETING SUBUNIT; CATALYTIC SUBUNIT; BINDING DOMAIN; RNA-BINDING; FHA DOMAIN; NIPP-1; PHOSPHORYLATION; IDENTIFICATION	NIPP1 is a regulatory subunit of a species of protein phosphatase-1 (PP1) that co-localizes with splicing factors in nuclear speckles. We report that the N-terminal third of NIPP1 largely consists of a Forkhead-associated (FHA) protein interaction domain, a known phosphopeptide interaction module. A yeast two-hybrid screening revealed an interaction between this domain and a human homolog (CDC5L) of the fission yeast protein cdc5, which is required for G(2)/M progression and pre-mRNA splicing, CDC5L and NIPP1 co-localized in nuclear speckles in COS-1 cells. Furthermore, an interaction between CDC5L, NIPP1, and PP1 in rat liver nuclear extracts could be demonstrated by co-immunoprecipitation and/or co-purification experiments, The binding of the FHA domain of NIPP1 to CDC5L was dependent on the phosphorylation of CDC5L, e.g. by cyclin E-Cdk2. When expressed in COS-1 or HeLa cells, the FHA domain of NIPP1 did not affect the number of cells in the G(2)/M transition. However, the FHA domain blocked beta-globin pre-mRNA splicing in nuclear extracts, A mutation in the FHA domain that abolished its interaction with CDC5L also canceled its anti-splicing effects. We suggest that NIPP1 either targets CDC5L or an associated protein for dephosphorylation by PP1 or serves as an anchor for both PP1 and CDC5L.	Katholieke Univ Leuven, Afdeling Biochem, Fac Geneeskunde, B-3000 Louvain, Belgium; Katholieke Univ Leuven VIB, Fac Geneeskunde, Ctr Human Genet, B-3000 Louvain, Belgium; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; Cold Spring Harbor Laboratory	Bollen, M (corresponding author), Katholieke Univ Leuven, Afdeling Biochem, Fac Geneeskunde, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Mathieu.Bollen@med.kuleuven.ac.be		Krainer, Adrian/0000-0001-9024-9501	NIGMS NIH HHS [GM-42699] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042699] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armstrong CG, 1998, BIOCHEM J, V336, P699, DOI 10.1042/bj3360699; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bernstein HS, 1998, J BIOL CHEM, V273, P4666, DOI 10.1074/jbc.273.8.4666; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Burns CG, 1999, P NATL ACAD SCI USA, V96, P13789, DOI 10.1073/pnas.96.24.13789; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; Chen JH, 1998, J BIOL CHEM, V273, P1038, DOI 10.1074/jbc.273.2.1038; ClaverieMartin F, 1997, J BIOL CHEM, V272, P13823, DOI 10.1074/jbc.272.21.13823; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DARZYNKIEWICZ Z, 1990, METHOD CELL BIOL, V33, P1; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Gailly P, 1996, EUR J BIOCHEM, V239, P326, DOI 10.1111/j.1432-1033.1996.0326u.x; Groenen PMA, 1998, GENOMICS, V49, P218, DOI 10.1006/geno.1998.5254; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hirayama T, 1996, P NATL ACAD SCI USA, V93, P13371, DOI 10.1073/pnas.93.23.13371; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; Jagiello I, 1997, J BIOL CHEM, V272, P22067, DOI 10.1074/jbc.272.35.22067; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Jin QM, 1999, BIOCHEM J, V342, P13, DOI 10.1042/0264-6021:3420013; Kim KK, 1996, NAT STRUCT BIOL, V3, P849, DOI 10.1038/nsb1096-849; Li J, 1999, P NATL ACAD SCI USA, V96, P7821, DOI 10.1073/pnas.96.14.7821; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Lipsick JS, 1996, ONCOGENE, V13, P223; Mayeda A, 1999, METH MOL B, V118, P315; Mayeda A, 1999, METH MOL B, V118, P309; McDonald WH, 1999, MOL CELL BIOL, V19, P5352; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; Neubauer G, 1998, NAT GENET, V20, P46, DOI 10.1038/1700; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; Ohi R, 1998, MOL CELL BIOL, V18, P4097, DOI 10.1128/MCB.18.7.4097; Seghezzi W, 1998, MOL CELL BIOL, V18, P4526, DOI 10.1128/MCB.18.8.4526; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Tanaka J, 1998, BIOCHEMISTRY-US, V37, P16697, DOI 10.1021/bi980782x; Trinkle-Mulcahy L, 1999, J CELL SCI, V112, P157; Tsai WY, 1999, J BIOL CHEM, V274, P9455, DOI 10.1074/jbc.274.14.9455; Van Eynde A, 1995, J BIOL CHEM, V270, P28068, DOI 10.1074/jbc.270.47.28068; Vulsteke V, 1997, J BIOL CHEM, V272, P32972, DOI 10.1074/jbc.272.52.32972	43	86	91	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25411	25417		10.1074/jbc.M001676200	http://dx.doi.org/10.1074/jbc.M001676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827081	hybrid			2022-12-25	WOS:000088849400049
J	Escoubas, P; De Weille, JR; Lecoq, A; Diochot, S; Waldmann, R; Champigny, G; Moinier, D; Menez, A; Lazdunski, M				Escoubas, P; De Weille, JR; Lecoq, A; Diochot, S; Waldmann, R; Champigny, G; Moinier, D; Menez, A; Lazdunski, M			Isolation of a tarantula toxin specific for a class of proton-gated Na+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONS CAUSING NEURODEGENERATION; MAMMALIAN DEGENERIN MDEG; ROOT GANGLION NEURONS; SENSORY NEURONS; ION CHANNELS; CAENORHABDITIS-ELEGANS; CATION CHANNEL; POTASSIUM CHANNELS; MOLECULAR-CLONING; CALCIUM-CHANNEL	Acid sensing is associated with nociception, taste transduction, and perception of extracellular pH fluctuations in the brain. Acid sensing is carried out by the simplest class of ligand-gated channels, the family of H+-gated Na+ channels. These channels have recently been cloned and belong to the acid-sensitive ion channel (ASIC) family. Toxins from animal venoms have been essential for studies of voltage-sensitive and ligand-gated ion channels. This paper describes a novel 40-amino acid toxin from tarantula venom, which potently blocks (IC50 = 0.9 nM) a particular subclass of ASIC channels that are highly expressed in both central nervous system neurons and sensory neurons from dorsal root ganglia. This channel type has properties identical to those described for the homomultimeric assembly of ASIC1a. Homomultimeric assemblies of other members of the ASIC family and heteromultimeric assemblies of ASIC1a with other ASIC subunits are insensitive to the toxin. The new toxin is the first high affinity and highly selective pharmacological agent for this novel class of ionic channels. It will be important for future studies of their physiological and physio-pathological roles.	CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France; Univ Paris 06, F-75006 Paris, France; CEA Saclay, Dept Ingn Prot, F-91130 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Sorbonne Universite; CEA; UDICE-French Research Universities; Universite Paris Saclay	Lazdunski, M (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles, F-06560 Valbonne, France.		Diochot, Sylvie/ABG-5495-2020; Waldmann, Rainer/Q-2108-2016; de Weille, Jan R/F-8103-2014	Waldmann, Rainer/0000-0002-4599-2926; de Weille, Jan R/0000-0002-0505-3166				AKAIKE N, 1994, PROG NEUROBIOL, V43, P73, DOI 10.1016/0301-0082(94)90016-7; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Benson CJ, 1999, CIRC RES, V84, P921; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Chen XJ, 1997, INVEST OPHTH VIS SCI, V38, P1944; DAVIES NW, 1988, J PHYSIOL-LONDON, V400, P159, DOI 10.1113/jphysiol.1988.sp017116; de Weille JR, 1998, FEBS LETT, V433, P257, DOI 10.1016/S0014-5793(98)00916-8; Diochot S, 1999, BRIT J PHARMACOL, V126, P251, DOI 10.1038/sj.bjp.0702283; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; Kress M, 1999, TRENDS PHARMACOL SCI, V20, P112, DOI 10.1016/S0165-6147(99)01294-8; KRISHTAL OA, 1981, BRAIN RES, V214, P150, DOI 10.1016/0006-8993(81)90446-7; KRISHTAL OA, 1981, NEUROSCI LETT, V24, P243, DOI 10.1016/0304-3940(81)90164-6; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; LAMPE RA, 1993, MOL PHARMACOL, V44, P451; Lauritzen I, 1997, BRAIN RES, V753, P8, DOI 10.1016/S0006-8993(96)01491-6; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; McCleskey EW, 1999, ANNU REV PHYSIOL, V61, P835, DOI 10.1146/annurev.physiol.61.1.835; NARASIMHAN L, 1994, NAT STRUCT BIOL, V1, P850, DOI 10.1038/nsb1294-850; Newcomb R, 1998, BIOCHEMISTRY-US, V37, P15353, DOI 10.1021/bi981255g; Norton RS, 1998, TOXICON, V36, P1573, DOI 10.1016/S0041-0101(98)00149-4; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; Pan HL, 1999, J PHYSIOL-LONDON, V518, P857, DOI 10.1111/j.1469-7793.1999.0857p.x; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Sanguinetti MC, 1997, MOL PHARMACOL, V51, P491; SWARTZ KJ, 1995, NEURON, V15, P941, DOI 10.1016/0896-6273(95)90184-1; Varming T, 1999, NEUROPHARMACOLOGY, V38, P1875, DOI 10.1016/S0028-3908(99)00079-9; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6	38	372	386	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25116	25121		10.1074/jbc.M003643200	http://dx.doi.org/10.1074/jbc.M003643200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829030	hybrid			2022-12-25	WOS:000088849400012
J	Kaftan, EJ; Xu, T; Abercrombie, RF; Hille, B				Kaftan, EJ; Xu, T; Abercrombie, RF; Hille, B			Mitochondria shape hormonally induced cytoplasmic calcium oscillations and modulate exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; SYMPATHETIC NEURONS; PITUITARY GONADOTROPES; FREE CA2+; MECHANISMS; PARTICIPATION; ACCUMULATION; HOMEOSTASIS; INDICATORS; CLEARANCE	Pituitary gonadotropes transduce hormonal input into cytoplasmic calcium ([Ca2+](cyt)) oscillations that drive rhythmic exocytosis of gonadotropins, Using Calcium Green-1 and rhod-2 as optical measures of cytoplasmic and mitochondrial free Ca2+, we show that mitochondria sequester Ca2+ and tune the frequency of [Ca2+](cyt) oscillations in rat gonadotropes. Mitochondria accumulated Ca2+ rapidly and in phase with elevations of [Ca2+](cyt) after GnRH stimulation or membrane depolarization. Inhibiting mitochondrial Ca2+ uptake by the protonophore CCCP reduced the frequency of GnRH-induced [Ca2+](cyt) oscillations or, occasionally, stopped them. Much of the Ca2+ that entered mitochondria is bound by intramitochondrial Ca2+ buffering systems. The mitochondrial Ca2+ binding ratio may be dynamic because [Ca2+](mit), appeared to reach a plateau as mitochondrial Ca2+ accumulation continued. Entry of Ca2+ into mitochondria was associated with a small drop in the mitochondrial membrane potential. Ca2+ was extruded from mitochondria more slowly than it entered, and much of this efflux could be blocked by CGP-37157, a selective inhibitor of mitochondrial Na+-Ca2+ exchange. Plasma membrane capacitance changes in response to depolarizing voltage trains were increased when CCCP was added, showing that mitochondria lower the local [Ca2+](cyt) near sites that trigger exocytosis. Thus, we demonstrate a central role for mitochondria in a significant physiological response.	Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Emory Univ, Dept Physiol, Atlanta, GA 30322 USA	University of Washington; University of Washington Seattle; Emory University	Kaftan, EJ (corresponding author), Univ Washington, Dept Physiol & Biophys, G-424 Hlth Sci Bldg, Seattle, WA 98195 USA.		Xu, Tao/G-5474-2010		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD012629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR017803, R01AR017803] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR17803] Funding Source: Medline; NICHD NIH HHS [U54 HD12629] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABERCROMBIE RF, 1986, AM J PHYSIOL, V250, pC391, DOI 10.1152/ajpcell.1986.250.3.C391; Babcock DF, 1998, CURR OPIN NEUROBIOL, V8, P398, DOI 10.1016/S0959-4388(98)80067-6; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; COX DA, 1993, TRENDS PHARMACOL SCI, V14, P408, DOI 10.1016/0165-6147(93)90063-P; David G, 1999, J NEUROSCI, V19, P7495, DOI 10.1523/JNEUROSCI.19-17-07495.1999; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; FRIEL DD, 1994, J NEUROSCI, V14, P4007; Gillis Kevin D., 1995, P155; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hehl S, 1996, CELL CALCIUM, V20, P515, DOI 10.1016/S0143-4160(96)90094-9; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; HILLE B, 1995, RECENT PROG HORM RES, V50, P75; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; KAFTAN EJ, 1997, J GEN PHYSIOL, V110, P6529; Kaiser UB, 1997, ENDOCR REV, V18, P46, DOI 10.1210/er.18.1.46; LI YX, 1994, P NATL ACAD SCI USA, V91, P58, DOI 10.1073/pnas.91.1.58; MINTA A, 1989, J BIOL CHEM, V264, P8171; Monteith GR, 1999, AM J PHYSIOL-CELL PH, V276, pC1193, DOI 10.1152/ajpcell.1999.276.5.C1193; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Peng TI, 1998, MOL PHARMACOL, V53, P974; Peng TI, 1998, EXP NEUROL, V149, P1, DOI 10.1006/exnr.1997.6599; PENNISTON JT, 1973, BIOCHEMISTRY-US, V12, P650, DOI 10.1021/bi00728a013; Pivovarova NB, 1999, J NEUROSCI, V19, P6372; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; SCARPA A, 1973, J GEN PHYSIOL, V62, P756, DOI 10.1085/jgp.62.6.756; SCARPA A, 1979, MEMBRANE TRANSPORT B, V2, P263; SHAPIRO MS, 1993, NEURON, V10, P11, DOI 10.1016/0896-6273(93)90237-L; SOMLYO AP, 1989, FASEB J, V3, P2266, DOI 10.1096/fasebj.3.11.2506092; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; THAYER SA, 1990, J PHYSIOL-LONDON, V425, P85, DOI 10.1113/jphysiol.1990.sp018094; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; TSE A, 1994, J PHYSIOL-LONDON, V477, P511, DOI 10.1113/jphysiol.1994.sp020212; Tse A, 1994, METHODS NEUROSCIENCE, P85; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; Tse FW, 1997, NEURON, V18, P121, DOI 10.1016/S0896-6273(01)80051-9; Voets T, 1999, NEURON, V23, P607, DOI 10.1016/S0896-6273(00)80812-0; WHITE RJ, 1995, J NEUROSCI, V15, P1318; Xu T, 1999, EMBO J, V18, P3293, DOI 10.1093/emboj/18.12.3293; [No title captured]	42	97	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25465	25470		10.1074/jbc.M000903200	http://dx.doi.org/10.1074/jbc.M000903200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10835418	hybrid			2022-12-25	WOS:000088849400056
J	Matthias, A; Ohlson, KBE; Fredriksson, JM; Jacobsson, A; Nedergaard, J; Cannon, B				Matthias, A; Ohlson, KBE; Fredriksson, JM; Jacobsson, A; Nedergaard, J; Cannon, B			Thermogenic responses in brown fat cells are fully UCP1-dependent - UCP2 or UCP3 do not substitute for UCP1 in adrenergically or fatty acid-induced thermogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL UNCOUPLING PROTEIN; HETEROLOGOUS EXPRESSION SYSTEM; ADIPOSE-TISSUE MITOCHONDRIA; PROTON TRANSPORT; SKELETAL-MUSCLE; GUINEA-PIG; ADIPOCYTES; BINDING; MECHANISM; MICE	To examine the thermogenic significance of the classical uncoupling protein-1 (UCP1), the thermogenic potential of brown adipocytes isolated from UCP1-ablated mice was investigated. Ucp1(-/-) cells had a basal metabolic rate identical to wild-type; the mitochondria within them were coupled to the same degree. The response to norepinephrine in wild-type cells was robust (approximate to 10-fold increase in thermogenesis); Ucp1(-/-) cells only responded approximate to 3% of this, Ucp1(-/-) cells were as potent as wild-type in norepinephrine-induced cAMP accumulation and lipolysis and had a similar mitochondrial respiratory complement. In wild-type cells, fatty acids induced a thermogenic response similar to norepinephrine, but fatty acids (and retinoate) were practically without effect in Ucp1(-/-) cells. It is concluded that no other adrenergically induced thermogenic mechanism exists in brown adipocytes except that mediated by UCP1 and that entopic expression of UCP1 does not Lead to overt innate uncoupling, and it is suggested that fatty acids are transformed to an intracellular physiological activator of UCP1, High expression of UCP2 and UCP3 in the tissue was not associated with an overt innate highly uncoupled state of mitochondria within the cells, nor with an ability of norepinephrine or endo- or exogenous fatty acids to induce uncoupled respiration in the cells, Thus, UCP1 remains the only physiologically potent thermogenic uncoupling protein in these cells.	Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden	Stockholm University	Nedergaard, J (corresponding author), Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden.	barbara.cannon@wgi.su.se	Nedergaard, Jan/Q-8286-2019; Nedergaard, Jan/A-1706-2010; Cannon, Barbara/B-3089-2016	Nedergaard, Jan/0000-0003-2070-1587; Cannon, Barbara/0000-0001-6594-2363				BATHGATE B, 1992, MOL MICROBIOL, V6, P363, DOI 10.1111/j.1365-2958.1992.tb01479.x; BERNSON VSM, 1979, BIOCHIM BIOPHYS ACTA, V587, P353; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; BOUILLAUD F, 1994, EMBO J, V13, P1990, DOI 10.1002/j.1460-2075.1994.tb06468.x; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; BUKOWIECKI L, 1980, AM J PHYSIOL, V238, pE552, DOI 10.1152/ajpendo.1980.238.6.E552; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; Cannon B, 1999, PROG OBES R, P13; CANNON B, 1977, FEBS LETT, V74, P43, DOI 10.1016/0014-5793(77)80748-5; CHAPPELL JB, 1965, BIOCHEM J, V95, P378, DOI 10.1042/bj0950378; CUNNINGHAM SA, 1986, EUR J BIOCHEM, V157, P415, DOI 10.1111/j.1432-1033.1986.tb09683.x; Daikoku T, 1997, FEBS LETT, V410, P383, DOI 10.1016/S0014-5793(97)00619-4; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Garlid KD, 1998, FEBS LETT, V438, P10, DOI 10.1016/S0014-5793(98)01246-0; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Gonzalez-Barroso MM, 1998, J BIOL CHEM, V273, P15528, DOI 10.1074/jbc.273.25.15528; GonzalezBarroso MM, 1996, EUR J BIOCHEM, V239, P445, DOI 10.1111/j.1432-1033.1996.0445u.x; Hagen T, 1999, FEBS LETT, V454, P201, DOI 10.1016/S0014-5793(99)00811-X; Hinz W, 1999, FEBS LETT, V448, P57, DOI 10.1016/S0014-5793(99)00331-2; HOLM C, 1987, BIOSCIENCE REP, V7, P897, DOI 10.1007/BF01119481; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; Jezek P, 1999, FEBS LETT, V455, P79, DOI 10.1016/S0014-5793(99)00853-4; KATIYAR SS, 1991, BIOCHEM BIOPH RES CO, V175, P1104, DOI 10.1016/0006-291X(91)91679-7; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Li B, 1999, J BIOL CHEM, V274, P17534, DOI 10.1074/jbc.274.25.17534; Liu QY, 1998, GENE, V207, P1, DOI 10.1016/S0378-1119(97)00596-9; LOCKE RM, 1982, EUR J BIOCHEM, V129, P381, DOI 10.1111/j.1432-1033.1982.tb07061.x; Matthias A, 1999, J BIOL CHEM, V274, P28150, DOI 10.1074/jbc.274.40.28150; MOHELL N, 1983, EUR J PHARMACOL, V93, P183, DOI 10.1016/0014-2999(83)90136-X; Monemdjou S, 1999, AM J PHYSIOL-ENDOC M, V276, pE1073, DOI 10.1152/ajpendo.1999.276.6.E1073; NEDERGAARD J, 1979, EUR J BIOCHEM, V95, P139, DOI 10.1111/j.1432-1033.1979.tb12948.x; NEDERGAARD J, 1982, INT REV CYTOL, V74, P187, DOI 10.1016/S0074-7696(08)61173-0; NEDERGAARD J, 1977, NATURE, V267, P518, DOI 10.1038/267518a0; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; OHLSON KBE, 1994, ANESTHESIOLOGY, V81, P176, DOI 10.1097/00000542-199407000-00024; Paulik MA, 1998, PHARM RES-DORDR, V15, P944, DOI 10.1023/A:1011993019385; PRUSINER SB, 1968, EUR J BIOCHEM, V6, P15, DOI 10.1111/j.1432-1033.1968.tb00413.x; PRUSINER SB, 1968, EUR J BIOCHEM, V7, P51, DOI 10.1111/j.1432-1033.1968.tb19572.x; RAFAEL J, 1994, EUR J BIOCHEM, V223, P971, DOI 10.1111/j.1432-1033.1994.tb19075.x; RAFAEL J, 1986, AM J PHYSIOL, V250, pC228, DOI 10.1152/ajpcell.1986.250.2.C228; REED N, 1968, J BIOL CHEM, V243, P2843; REED N, 1968, J BIOL CHEM, V243, P6077; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; SHULACHEV VP, 1998, BIOCHIM BIOPHYS ACTA, V1363, P100; Smith R., 1961, PHYSIOLOGIST, V4, P113; SOBOLL S, 1985, BIOCHIM BIOPHYS ACTA, V807, P245, DOI 10.1016/0005-2728(85)90255-5; Stuart JA, 1999, BBA-BIOENERGETICS, V1413, P50, DOI 10.1016/S0005-2728(99)00081-X; SUNDIN U, 1980, COMP BIOCHEM PHYS B, V65, P463, DOI 10.1016/0305-0491(80)90298-9; SUNDIN U, 1987, AM J PHYSIOL, V252, pR822, DOI 10.1152/ajpregu.1987.252.5.R822; UNELIUS L, 1993, AM J PHYSIOL, V265, pC1340, DOI 10.1152/ajpcell.1993.265.5.C1340; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WOITCZAK L, 1993, BIOCHIM BIOPHYS ACTA, V1183, P41, DOI 10.1016/0005-2728(93)90004-Y; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X; Zhao J, 1998, CAN J PHYSIOL PHARM, V76, P428, DOI 10.1139/cjpp-76-4-428; Zhao J, 1998, AM J PHYSIOL-REG I, V275, pR2002, DOI 10.1152/ajpregu.1998.275.6.R2002; Zhao J, 1997, J BIOL CHEM, V272, P32847, DOI 10.1074/jbc.272.52.32847	62	260	268	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25073	25081		10.1074/jbc.M000547200	http://dx.doi.org/10.1074/jbc.M000547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10825155	hybrid			2022-12-25	WOS:000088849400006
J	Okumoto, K; Abe, I; Fujiki, Y				Okumoto, K; Abe, I; Fujiki, Y			Molecular anatomy of the peroxin Pex12p - Ring finger domain is essential for Pex12p function and interacts with the peroxisome-targeting signal type 1-receptor Pex5p and a ring peroxin, Pex10p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARY CELL MUTANTS; INTEGRAL MEMBRANE-PROTEIN; ZELLWEGER-SYNDROME; PTS1 RECEPTOR; 3-KETOACYL-COA THIOLASE; CDNA CLONING; BIOGENESIS DISORDERS; MUTATION ANALYSIS; REVERSE 2-HYBRID; AMINO-TERMINUS	The three peroxin genes, PEX12, PEX2, and PEX10, encode peroxisomal integral membrane proteins with RING finger at the C-terminal part and are responsible for human peroxisome biogenesis disorders. Mutation analysis in PEX12 of Chinese hamster ovary cell mutants revealed a homozygous nonsense mutation at residue Trp263Ter in ZP104 cells and a pair of heterozygous nonsense mutations, Trp170Ter and Trp114Ter, in ZP109. This result and domain mapping of Pex12p showed that RING finger is essential for peroxisome-restoring activity of Pex12p but not necessary for targeting to peroxisomes. The N-terminal region of Pex12p, including amino acid residues at positions 17-76, was required for localization to peroxisomes, while the sequence 17-76 was not sufficient for peroxisomal targeting. Peroxins interacting with RING finger of Pex2p, Pex10p, and Pex12p were investigated by yeast two-hybrid as well as in vitro binding assays. The RING finger of Pex12p bound to Pex10p and the PTS1-receptor Pex5p. Pex10p also interacted with Pex2p and Pex5p in vitro. Moreover, Pex12p was co-immunoprecipitated with Pex10p from CHO-K1 cells, where Pex5p was not associated with the Pex12p-Pex10p complex. This observation suggested that Pex5p does not bind to, or only transiently interacts with, Pex10p and Pex12p when Pex10p and Pex12p are in the oligomeric complex in peroxisome membranes. Hence, the RING finger peroxins are most likely to be involved in Pex5p-mediated matrix protein import into peroxisomes.	Kyushu Univ, Grad Sch Sci, Dept Biol, Higashi Ku, Fukuoka 8128581, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1700013, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Fujiki, Y (corresponding author), Kyushu Univ, Grad Sch Sci, Dept Biol, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.							Baerends RJS, 1996, J BIOL CHEM, V271, P8887, DOI 10.1074/jbc.271.15.8887; Brzovic PS, 1998, J BIOL CHEM, V273, P7795, DOI 10.1074/jbc.273.14.7795; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; Chang CC, 1997, NAT GENET, V15, P385, DOI 10.1038/ng0497-385; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Dyer JM, 1996, J CELL BIOL, V133, P269, DOI 10.1083/jcb.133.2.269; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; Fujiki Y, 1997, BBA-MOL BASIS DIS, V1361, P235, DOI 10.1016/S0925-4439(97)00051-3; Ghaedi K, 2000, MOL BIOL CELL, V11, P2085, DOI 10.1091/mbc.11.6.2085; Ghaedi K, 1999, EXP CELL RES, V248, P489, DOI 10.1006/excr.1999.4413; Gould SJ, 1996, J CELL BIOL, V135, P85, DOI 10.1083/jcb.135.1.85; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Harano T, 1999, J BIOCHEM-TOKYO, V125, P1168, DOI 10.1093/oxfordjournals.jbchem.a022400; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Kammerer S, 1998, FEBS LETT, V429, P53, DOI 10.1016/S0014-5793(98)00557-2; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Matsumura T, 2000, J BIOL CHEM, V275, P21715, DOI 10.1074/jbc.M000721200; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; MIURA S, 1992, J BIOL CHEM, V267, P14405; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; Okumoto K, 1997, EXP CELL RES, V233, P11, DOI 10.1006/excr.1997.3552; Okumoto K, 1997, NAT GENET, V17, P265, DOI 10.1038/ng1197-265; Okumoto K, 1998, HUM MOL GENET, V7, P1399, DOI 10.1093/hmg/7.9.1399; Okumoto K, 1998, MOL CELL BIOL, V18, P4324, DOI 10.1128/MCB.18.7.4324; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; Otera H, 2000, J BIOL CHEM, V275, P21703, DOI 10.1074/jbc.M000720200; Otera H, 1998, MOL CELL BIOL, V18, P388, DOI 10.1128/MCB.18.1.388; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; SHIMOZAWA N, 1992, J CLIN INVEST, V90, P1864, DOI 10.1172/JCI116063; SHIMOZAWA N, 1992, SCIENCE, V255, P1132, DOI 10.1126/science.1546315; Soukupova M, 1999, EUR J CELL BIOL, V78, P357, DOI 10.1016/S0171-9335(99)80078-8; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; Toyama R, 1999, HUM MOL GENET, V8, P1673, DOI 10.1093/hmg/8.9.1673; TSUKAMOTO T, 1994, J BIOL CHEM, V269, P6001; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V230, P402, DOI 10.1006/bbrc.1996.5971; TSUKAMOTO T, 1994, MOL CELL BIOL, V14, P5458, DOI 10.1128/MCB.14.8.5458; TSUKAMOTO T, 1990, J CELL BIOL, V110, P651, DOI 10.1083/jcb.110.3.651; TSUKAMOTO T, 1995, NAT GENET, V11, P395, DOI 10.1038/ng1295-395; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Warren DS, 1998, AM J HUM GENET, V63, P347, DOI 10.1086/301963; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973; Will GK, 1999, MOL CELL BIOL, V19, P2265	50	90	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25700	25710		10.1074/jbc.M003303200	http://dx.doi.org/10.1074/jbc.M003303200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837480	hybrid			2022-12-25	WOS:000088849400085
J	Hew, Y; Lau, C; Grzelczak, Z; Keeley, FW				Hew, Y; Lau, C; Grzelczak, Z; Keeley, FW			Identification of a GA-rich sequence as a protein-binding site in the 3 '-untranslated region of chicken elastin mRNA with a potential role in the developmental regulation of elastin mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; AORTIC ORGAN; TROPOELASTIN; ELEMENTS; GENE; CULTURES; ACID	Synthesis of aortic elastin peaks in the perinatal period and then is strongly down-regulated with postnatal development and growth. Decreased stability of elastin mRNA contributes to this developmental decrease in chick aortic elastin production. We have previously shown that destabilization of elastin mRNA is correlated with decreased binding of cytosolic protein(s) to a large, GC-rich region of secondary structure in the 3'-untranslated region (3'-UTR) of elastin mRNk In this study, using gel migration shift assays, deletion constructs, and antisense competition assays, we identify a major protein-binding site in the 3'-UTR of elastin as a GA-rich sequence (UGGGGGGAGGGAGGGAGGGA), which we have designated the G3A motif. This motif is present in the 3'-UTR of elastin from several species, Binding proteins are present in both nuclear and cytoplasmic extracts, and their abundance is associated with tissues producing elastin and correlated with circumstances in which elastin mRNA is stable. These results suggest that the conserved GA-rich sequence of the elastin 3'-UTR is an important element in the regulation of stability of the elastin mRNA.	Hosp Sick Children, Res Inst, Cardiovasc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Keeley, FW (corresponding author), Hosp Sick Children, Div Cardiovasc Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	fwk@sickkids.on.ca						Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Bagga PS, 1998, NUCLEIC ACIDS RES, V26, P5343, DOI 10.1093/nar/26.23.5343; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; DAVIS EC, 1993, HISTOCHEMISTRY, V100, P17, DOI 10.1007/BF00268874; Dibbens JA, 1999, MOL BIOL CELL, V10, P907, DOI 10.1091/mbc.10.4.907; DODSON RE, 1994, MOL CELL BIOL, V14, P3130, DOI 10.1128/MCB.14.5.3130; Einstein RS, 1998, J NUTR, V128, P2295, DOI 10.1093/jn/128.12.2295; Fraboulet S, 1998, ENDOCRINOLOGY, V139, P894, DOI 10.1210/en.139.3.894; Hew Y, 1999, J BIOL CHEM, V274, P14415, DOI 10.1074/jbc.274.20.14415; INDIK Z, 1987, P NATL ACAD SCI USA, V84, P5680, DOI 10.1073/pnas.84.16.5680; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; JOHNSON DJ, 1990, CONNECT TISSUE RES, V24, P277, DOI 10.3109/03008209009152155; JOHNSON DJ, 1995, CIRC RES, V77, P1107, DOI 10.1161/01.RES.77.6.1107; KEELEY FW, 1990, ARCH BIOCHEM BIOPHYS, V282, P226, DOI 10.1016/0003-9861(90)90109-C; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; LEFEVRE M, 1980, BIOCHIM BIOPHYS ACTA, V630, P519, DOI 10.1016/0304-4165(80)90006-9; MATUNIS MJ, 1994, NUCLEIC ACIDS RES, V22, P1059, DOI 10.1093/nar/22.6.1059; PIERCE RA, 1992, GENOMICS, V12, P651, DOI 10.1016/0888-7543(92)90289-5; QIAN ZW, 1994, NUCLEIC ACIDS RES, V22, P2334, DOI 10.1093/nar/22.12.2334; RAJU K, 1987, J BIOL CHEM, V262, P5755; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; STOECKLE MY, 1992, NUCLEIC ACIDS RES, V20, P1123, DOI 10.1093/nar/20.5.1123; SWEE MH, 1995, J BIOL CHEM, V270, P14899, DOI 10.1074/jbc.270.25.14899; Tu GC, 1998, J BIOL CHEM, V273, P25125, DOI 10.1074/jbc.273.39.25125; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WEISS IM, 1995, MOL CELL BIOL, V15, P2457; YOON K, 1985, ARCH BIOCHEM BIOPHYS, V241, P684, DOI 10.1016/0003-9861(85)90595-8; Zhang MC, 1999, MOL CELL BIOL, V19, P7314; Zhang MC, 1999, J BIOL CHEM, V274, P981, DOI 10.1074/jbc.274.2.981	29	27	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24857	24864		10.1074/jbc.M002776200	http://dx.doi.org/10.1074/jbc.M002776200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10829024	hybrid			2022-12-25	WOS:000088683300083
J	Chen, ZM; Guo, K; Toh, SY; Zhou, ZH; Li, P				Chen, ZM; Guo, K; Toh, SY; Zhou, ZH; Li, P			Mitochondria localization and dimerization are required for CIDE-B to induce apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA FRAGMENTATION; PROTEIN; TRANSLOCATION; INHIBITOR; HOMOLOGY; DOMAINS; FAMILY; DFF45; BAX	Cell death-inducing DFF45-like effector (CIDE)-B is a member of the novel family of apoptosis-inducing factors that share homology with the N-terminal region of DFF, the DNA fragmentation factor. The molecular mechanism of CIDE-B-induced apoptosis is unclear. We have shown here that CIDE-B protein is localized in mitochondria and forms homodimers and heterodimers with other family members. Serial deletion analyses suggest that the mitochondria localization signal and dimerization interface are overlapped and localized to the 30 amino acid residues at the C-terminal region of CIDE-B. Mitochondria localization and dimerization are both required for CIDE-B-induced apoptosis. Our study has thus revealed a mechanism for CIDE-B-induced apoptosis by localization to mitochondria and the formation of a high affinity homo- or heterodimeric complex.	Inst Cell & Mol Biol, Lab Apoptosis Regulat, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Li, P (corresponding author), Inst Cell & Mol Biol, Lab Apoptosis Regulat, 30 Med Dr, Singapore 117609, Singapore.			Toh, Shen Yon/0000-0002-6421-0862				Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Inohara N, 1999, CELL DEATH DIFFER, V6, P823, DOI 10.1038/sj.cdd.4400570; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lugovskoy AA, 1999, CELL, V99, P747, DOI 10.1016/S0092-8674(00)81672-4; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P181, DOI 10.1006/bbrc.1999.1498; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P176, DOI 10.1006/bbrc.1999.1497; Porter AG, 1999, TRENDS CELL BIOL, V9, P394, DOI 10.1016/S0962-8924(99)01624-4; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415	18	67	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22619	22622		10.1074/jbc.C000207200	http://dx.doi.org/10.1074/jbc.C000207200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10837461	hybrid			2022-12-25	WOS:000088419400004
J	Razzini, G; Berrie, CP; Vignati, S; Broggini, M; Mascetta, G; Brancaccio, A; Falasca, M				Razzini, G; Berrie, CP; Vignati, S; Broggini, M; Mascetta, G; Brancaccio, A; Falasca, M			Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines	FASEB JOURNAL			English	Article						antitumor agents; inositol polyphosphates; PH domain-binding antagonists; phosphatidylinositols	PROTEIN-KINASE-B; PLECKSTRIN-HOMOLOGY DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; SIGNALING MOLECULES; AKT PROTOONCOGENE; TRANSFORMATION; ACTIVATION; PATHWAY; BINDING	New efforts in cancer therapy are being focused at various levels of signaling pathways. With phosphoinositide 3-kinase (PI3-K) potentially being necessary for a range of cancer-related functions, we have investigated the influence of selected inositol tristo hexakisphosphates on cell growth and tumorigenicity. We show that micromolar concentrations of inositol 1,3,4,5,6-pentakisphosphate and inositol 1,4,5,6-tetrakisphosphate [Ins(1,4,5,6)P-4] inhibit IGF-1-induced [H-3]-thymidine incorporation in human breast cancer (MCF-7) cells and the ability to grow in liquid medium and form colonies in agarose semisolid medium by small cell lung cancer (SCLC) cells, a human cancer cell line containing a constitutively active PI3-K. In an ovarian cancer cell line that also contains a constitutively active PI3-K (SKOV-3 cells), Ins(1,4,5,6)P-4 again inhibited liquid medium growth. Furthermore, when applied extracellularly, inositol 1,3,4,5-tetrakisphosphate was shown indeed to enter SCLC cells. These effects appeared specifically related to PH domains known to bind to phosphatidylinositol 3,4-bisphosphate [PtdIns(3,4)P-2] and phosphatidylinositol 3,4-bisphosphate [PtdIns(3,4,5)P-3], indicating involvement of the PI3-K downstream target protein kinase B (PKB/Akt). This was further supported by inhibition of PKB/Akt PH domain membrane targeting in COS-7 cells by Ins(1,4,5,6)P-4. Thus, we propose that specific inositol polyphosphates inhibit PI3-K by competing with PtdIns(3,4,5)P-3-binding PH domains and that this occurs mainly at: the level of the downstream PI3-K target, PKB/Akt.-Razzini, G., Berrie, C. P., Vignati, S., Broggini, M., Mascetta, G., Brancaccio, A., Falasca, M. Novel functional PI3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Unit Physiopathol Cell Signalling, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Italy; Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Lab Cell & Mol Endocrinol, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Italy; Mario Negri Inst Pharmacol Res, Mol Pharmacol Unit, I-20157 Milan, Italy; Fdn CARIPE, Oncol Mol Lab, Pescara, Italy	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Falasca, M (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Unit Physiopathol Cell Signalling, Dept Cell Biol & Oncol, Via Nazl, I-66030 Santa Maria Imbaro, Italy.	falasca@cmns.mnegri.it	broggini, massimo/AAA-6460-2020; Falasca, Marco/S-4020-2016	BROGGINI, MASSIMO/0000-0002-8138-9358; Falasca, Marco/0000-0002-9801-7235	Telethon [E.0841] Funding Source: Medline	Telethon(Fondazione Telethon)		Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Eckmann L, 1997, P NATL ACAD SCI USA, V94, P14456, DOI 10.1073/pnas.94.26.14456; Falasca M, 1998, ONCOGENE, V16, P2357, DOI 10.1038/sj.onc.1201758; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Huang CS, 1997, CANCER RES, V57, P2873; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kitchen E, 1996, BRIT J PHARMACOL, V117, P979, DOI 10.1111/j.1476-5381.1996.tb15291.x; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MACHAMA T, 1999, TRENDS CELL BIOL, V9, P125; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Moore SM, 1998, CANCER RES, V58, P5239; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RUSCHKOWSKI S, 1992, FEMS MICROBIOL LETT, V95, P121; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Takeuchi H, 1997, BBA-MOL CELL RES, V1359, P275, DOI 10.1016/S0167-4889(97)00109-2; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X	35	67	73	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1179	1187		10.1096/fasebj.14.9.1179	http://dx.doi.org/10.1096/fasebj.14.9.1179			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834940				2022-12-25	WOS:000087427300015
J	Lin, YC; Peng, JM; Wang, WB				Lin, YC; Peng, JM; Wang, WB			The N-terminal common domain of simian virus 40 large T and small t antigens acts as a transformation suppressor of the HER-2/neu oncogene	ONCOGENE			English	Article						simian virus 40 (SV40); small t antigen; T/t-common; HER-2/neu; tumor suppressor	E1A GENE-PRODUCTS; SV40 SMALL-T; OVARIAN-CANCER CELLS; SMALL TUMOR-ANTIGEN; RNA-POLYMERASE-II; NEU ONCOGENE; TRANSCRIPTIONAL REPRESSION; PROTEIN PHOSPHATASE-2A; MOLECULAR-CLONING; BREAST-CANCER	Overexpression of HER-2/neu (also known as c-erbB-2) proto-oncogene frequently occurs in many different types of human cancers, including ovarian carcinoma, and is known to enhance tumor metastasis and chemoresistance. Previous studies showed that inhibition of HER-2/neu expression by various agents, such as adenovirus E1A and simian virus 40 large T, can lead to suppression of tumorigenicity of HER-2/neu-overexpressing cancer cells. Here we report that T/t-common, which contains the N-terminal common domain of simian, virus 40 large T and small t antigens, could specifically repress the HER-2/neu promoter. When the coding sequence of T/t-common was stably transfected into the HER-2/neu-overexpressing human ovarian carcinoma SK-OV-3 cells, the expression of HER-2/neu was dramatically reduced by the expression of Tit-common. Accordingly the tumorigenic potential of these T/t-common-expressing clones, including the ability to grow anchorage-independently and the ability to induce tumor in nu/nu mice, was also drastically suppressed. Furthermore, when T/t-common was transiently cotransfected with the activated genomic neu into NIH3T3 cells, the transforming activity of the latter was suppressed by Tit-common in soft-agarose microcolony formation assays. Taken together, these data suggest that Tit-common may act as a transformation suppressor of the HER-2/neu oncogene.	Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei, Taiwan	National Taiwan University	Wang, WB (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, No 1,Jen Ai Rd,1st Sect, Taipei, Taiwan.							Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BERCHUCK A, 1990, CANCER RES, V50, P4087; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Chang JY, 1996, ONCOGENE, V13, P1405; Chang JY, 1997, ONCOGENE, V14, P561, DOI 10.1038/sj.onc.1200861; Chen H, 1997, ONCOGENE, V14, P1965, DOI 10.1038/sj.onc.1201030; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HARLOW E, 1988, ANTIBODES LAB MANUAL; Hong KL, 1997, FEBS LETT, V400, P233, DOI 10.1016/S0014-5793(96)01397-X; Hung MC, 1999, SEMIN ONCOL, V26, P51; HUNG MC, 1992, CANCER LETT, V61, P95, DOI 10.1016/0304-3835(92)90166-S; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kao MC, 1998, ONCOGENE, V16, P547, DOI 10.1038/sj.onc.1201513; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOEKEN M, 1988, CELL, V55, P1171, DOI 10.1016/0092-8674(88)90261-9; MATIN A, 1993, CELL GROWTH DIFFER, V4, P1051; MONTANO X, 1990, P NATL ACAD SCI USA, V87, P7448, DOI 10.1073/pnas.87.19.7448; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Porras A, 1996, J VIROL, V70, P6902; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; RUBIN H, 1982, CELL, V30, P469, DOI 10.1016/0092-8674(82)90244-6; Rushton JJ, 1997, J VIROL, V71, P5620, DOI 10.1128/JVI.71.7.5620-5623.1997; Sambrook J., 2002, MOL CLONING LAB MANU; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; STOKER M, 1968, NATURE, V218, P234, DOI 10.1038/218234a0; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; Tevethia MJ, 1997, J VIROL, V71, P8157, DOI 10.1128/JVI.71.11.8157-8166.1997; Tooze J, 1981, MOL BIOL TUMOR VIRUS; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WANG WB, 1994, J VIROL, V68, P6180, DOI 10.1128/JVI.68.10.6180-6187.1994; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1995, ONCOGENE, V11, P1383; ZHANG YJ, 1995, ONCOGENE, V10, P1947	59	13	13	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2704	2713		10.1038/sj.onc.1203582	http://dx.doi.org/10.1038/sj.onc.1203582			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851070				2022-12-25	WOS:000087193000006
J	Lou, JR; Cao, WS; Bernardin, F; Ayyanathan, K; Rauscher, FJ; Friedman, AD				Lou, JR; Cao, WS; Bernardin, F; Ayyanathan, K; Rauscher, FJ; Friedman, AD			Exogenous cdk4 overcomes reduced cdk4 RNA and inhibition of G1 progression in hematopoietic cells expressing a dominant-negative CBF - a model for overcoming inhibition of proliferation by CBF oncoproteins	ONCOGENE			English	Article						CBF; CBF beta-SMMHC; AML1-ETO; cdk4; leukemia	ACUTE MYELOID-LEUKEMIA; MYOSIN HEAVY-CHAIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; BINDING-FACTOR-BETA; TRANSCRIPTION FACTOR; DNA-BINDING; AML1 GENE; MURINE MYELOPEROXIDASE; FUSION TRANSCRIPT	Core Binding Factor (CBF) is required for the development of definitive hematopoiesis, and the CBF oncoproteins AML1-ETO, TEL-AML1, and CBF beta-SMMHC are commonly expressed in subsets of acute leukemia. CBF beta-SMMHC slows the G1 to S cell cycle transition in hematopoietic cells, but the mechanism of this effect is uncertain, We have sought to determine whether inhibition of CBF-mediated trans-activation is sufficient to stow proliferation. We demonstrate that activation of KRAB-AML1-ER, a protein containing the AML1 DNA-binding domain, the KRAB repression domain, and the Estrogen receptor ligand binding domain, also slows G1, if its DNA-binding domain is intact, Also, exogenous AML1 overcame CBF beta-SMMHC-induced inhibition of proliferation, Representational difference analysis (RDA) identified cdk4 RNA expression as an early target of KRAB-AML1 activation. Inhibition of CBF activities by KRAB-AML1-ER or CBF beta-SMMHC rapidly reduced endogenous cdk4 mRNA levels, even in cells proliferating at or near control rates as a result of exogenous cdk4 expression, Over-expression of cdk4, especially a variant which cannot bind p16(INK4a) overcame cell cycle inhibition resulting from activation of KRAB-AML1-ER, although cdk4 did not accelerate proliferation when expressed alone. These findings indicate that mutations which alter the expression of G1 regulatory proteins can overcome inhibition of proliferation by CBF oncoproteins.	Johns Hopkins Univ, Johns Hopkins Oncol Ctr, Div Pediat Oncol, Baltimore, MD 21231 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	Johns Hopkins University; Johns Hopkins Medicine; The Wistar Institute	Friedman, AD (corresponding author), Johns Hopkins Univ, Johns Hopkins Oncol Ctr, Div Pediat Oncol, Canc Res Bldg,Room 255,1650 Orleans St, Baltimore, MD 21231 USA.				NHLBI NIH HHS [HL51388] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051388] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; BAE SC, 1993, ONCOGENE, V8, P809; Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; BritosBray M, 1997, MOL CELL BIOL, V17, P5127, DOI 10.1128/MCB.17.9.5127; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Friedman AD, 1999, LEUKEMIA, V13, P1932, DOI 10.1038/sj.leu.2401590; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Herman JG, 1996, CANCER RES, V56, P722; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; LENNY N, 1995, ONCOGENE, V11, P1761; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V88, P5167; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rossman TG, 1999, CARCINOGENESIS, V20, P311, DOI 10.1093/carcin/20.2.311; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Segade F, 1995, LIFE SCI, V58, P277, DOI 10.1016/0024-3205(95)02288-0; Sepehri S, 1997, GENOME RES, V7, P1006, DOI 10.1101/gr.7.10.1006; SMITH IM, 1993, ENERG FUEL, V7, P7, DOI 10.1021/ef00037a003; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; Tanaka Y, 1997, ONCOGENE, V15, P677, DOI 10.1038/sj.onc.1201235; Tanaka Y, 1998, ONCOGENE, V17, P699, DOI 10.1038/sj.onc.1201985; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zent CS, 1996, P NATL ACAD SCI USA, V93, P1044, DOI 10.1073/pnas.93.3.1044; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	57	50	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2000	19	22					2695	2703		10.1038/sj.onc.1203588	http://dx.doi.org/10.1038/sj.onc.1203588			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851069				2022-12-25	WOS:000087193000005
J	Meng, TC; Lee, MS; Lin, MF				Meng, TC; Lee, MS; Lin, MF			Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells	ONCOGENE			English	Article						androgen responsiveness; human prostate cancer; ErbB-2; prostatic acid phosphatase; tyrosine phosphorylation	NEGATIVE BREAST-CANCER; ACID-PHOSPHATASE; FACTOR RECEPTOR; CARCINOMA-CELLS; HORMONAL-THERAPY; MAMMARY-CARCINOMA; ESTROGEN-RECEPTOR; STEROID-HORMONES; ERBB RECEPTORS; POOR-PROGNOSIS	Steroid hormones play key roles in regulating cell proliferation and differentiation in targeting tissues. However, in advanced cancers, the steroid hormone regulation is frequently attenuated through a Set unknown mechanism even in the presence of functional steroid hormone receptors, We investigate the functional role of tyrosine phosphorylation signaling in the hormone-refractory growth of human prostate tumors. Initial studies demonstrate that the androgen-responsive phenotype of human prostate cancer cells associates,vith a low phosphotyrosine (p-Tyr) level of ErbB-2, which is regulated by cellular prostatic acid phosphatase (PAcP), a protein tyrosine phosphatase. In prostate cancer cells, the p-Tyr le,el, but not the protein level, of ErbB-2 inversely correlates with the androgen-responsiveness of cell proliferation. Androgen-stimulated cell growth concurs with a down-regulation of cellular PAcP, an elevated p-Tyr level of ErbB-2, and the activation of mitogen-activated protein kinases, Furthermore, only the ErbB-2 inhibitor AG 879, but not the EGFR inhibitor AG 1478, abolishes androgen-induced cell proliferation. Forced expression of ErbB-2 can also attenuate androgen promotion of cell growth. Data taken collectively conclude that in human prostate cancer cells, the tyrosine phosphorylation of ErbB-2 regulated by cellular PAcP plays a key role in regulating androgen-mediated proliferation signaling.	Univ Nebraska, Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Coll Med, Sect Urol Surg, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Canc Inst, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska, Med Ctr, Coll Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.		Meng, Tzu-Ching/G-5426-2019	Meng, Tzu-Ching/0000-0001-7693-2021; LEE, MING-SHYUE/0000-0002-5884-4535	NCI NIH HHS [CA72274] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072274] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arai Y, 1997, PROSTATE, V30, P195, DOI 10.1002/(SICI)1097-0045(19970215)30:3<195::AID-PROS8>3.0.CO;2-L; Bacus SS, 1996, AM J PATHOL, V148, P549; BAGCHI MK, 1992, ENDOCR REV, V13, P525, DOI 10.1210/er.13.3.525; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BRASS AL, 1995, CANCER RES, V55, P3197; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DEWINTER JAR, 1990, J PATHOL, V160, P329, DOI 10.1002/path.1711600409; DIAMOND DA, 1984, J UROLOGY, V132, P821, DOI 10.1016/S0022-5347(17)49881-8; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FANGER BO, 1984, ARCH BIOCHEM BIOPHYS, V235, P141, DOI 10.1016/0003-9861(84)90262-5; FOTI AG, 1977, CANCER RES, V37, P4120; Gioeli D, 1999, CANCER RES, V59, P279; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; GLAUBER JG, 1992, SEMIN ONCOL, V19, P308; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAYHACK JT, 1987, CANCER, V60, P589, DOI 10.1002/1097-0142(19870801)60:3+<589::AID-CNCR2820601526>3.0.CO;2-R; Gu KF, 1996, CANCER LETT, V99, P185, DOI 10.1016/0304-3835(95)04061-7; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HORWITZ KB, 1992, ENDOCR REV, V13, P146, DOI 10.1210/er.13.2.146; Hua WH, 1995, J STEROID BIOCHEM, V55, P279, DOI 10.1016/0960-0760(95)00187-5; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; ISAACS JT, 1982, CANCER RES, V42, P5010; JANES PW, 1994, ONCOGENE, V9, P3601; Jensen E V, 1991, Curr Top Pathol, V83, P365; KALLIO PJ, 1994, ENDOCRINOLOGY, V134, P998, DOI 10.1210/en.134.2.998; KUHN EJ, 1993, J UROLOGY, V150, P1427, DOI 10.1016/S0022-5347(17)35799-3; LATIL A, 1994, INT J CANCER, V59, P637, DOI 10.1002/ijc.2910590510; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LI HC, 1984, EUR J BIOCHEM, V138, P45, DOI 10.1111/j.1432-1033.1984.tb07879.x; Lin MF, 1996, BIOCHEM BIOPH RES CO, V226, P206, DOI 10.1006/bbrc.1996.1334; LIN MF, 1988, MOL CELL BIOL, V8, P5477, DOI 10.1128/MCB.8.12.5477; LIN MF, 1986, MOL CELL BIOL, V6, P4753, DOI 10.1128/MCB.6.12.4753; LIN MF, 1993, ARCH BIOCHEM BIOPHYS, V300, P384, DOI 10.1006/abbi.1993.1052; LIN MF, 1986, BIOCHEM J, V235, P351, DOI 10.1042/bj2350351; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; LIN MF, 1992, CANCER RES, V52, P4600; LIN MF, 2000, IN PRESS CELL BIOL I; LIN MF, 1987, ADV PROT PHOSPHATASE, V4, P199; LIU XH, 1993, J CLIN ENDOCR METAB, V77, P1472, DOI 10.1210/jc.77.6.1472; LOOR R, 1981, CANCER LETT, V14, P63, DOI 10.1016/0304-3835(81)90010-0; Lu S, 1997, CANCER RES, V57, P4511; MACOSKA JA, 1992, J UROLOGY, V147, P1142, DOI 10.1016/S0022-5347(17)37504-3; Marengo SR, 1997, MOL CARCINOGEN, V19, P165; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; MILLER JI, 1992, J UROLOGY, V147, P956, DOI 10.1016/S0022-5347(17)37432-3; MURPHY LJ, 1986, CANCER RES, V46, P728; NICHOLSON S, 1990, J STEROID BIOCHEM, V37, P811, DOI 10.1016/0960-0760(90)90424-J; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRESS MF, 1993, CANCER RES, V53, P4960; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; QUARMBY VE, 1990, CANCER RES, V50, P735; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; REIF AE, 1973, CANCER-AM CANCER SOC, V31, P689, DOI 10.1002/1097-0142(197303)31:3<689::AID-CNCR2820310331>3.0.CO;2-F; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; SADASIVAN R, 1993, J UROLOGY, V150, P126, DOI 10.1016/S0022-5347(17)35413-7; SADI MV, 1993, CANCER, V71, P2574, DOI 10.1002/1097-0142(19930415)71:8<2574::AID-CNCR2820710823>3.0.CO;2-1; Sandberg A A, 1980, Prog Clin Biol Res, V37, P9; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; SCHUURMANS ALG, 1991, J STEROID BIOCHEM, V40, P193, DOI 10.1016/0960-0760(91)90182-5; SCOTT WW, 1980, CANCER-AM CANCER SOC, V45, P1929, DOI 10.1002/cncr.1980.45.s7.1929; Sherwood ER, 1998, BRIT J CANCER, V77, P855, DOI 10.1038/bjc.1998.142; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STAMEY TA, 1989, J UROLOGY, V141, P1088, DOI 10.1016/S0022-5347(17)41177-3; STROHMEYER TG, 1994, J UROLOGY, V151, P1479, DOI 10.1016/S0022-5347(17)35284-9; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; TENNISWOOD M, 1986, PROSTATE, V9, P375, DOI 10.1002/pros.2990090407; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; WEISS C, 1990, LEUKEMIA RES, V14, P327, DOI 10.1016/0145-2126(90)90159-7; WRIGHT C, 1992, J CLIN PATHOL, V45, P459, DOI 10.1136/jcp.45.5.459-b; YAM LT, 1974, AM J MED, V56, P604, DOI 10.1016/0002-9343(74)90630-5; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; YUAN SX, 1993, CANCER RES, V53, P1304; Zelivianski S, 1998, BIOCHEM BIOPH RES CO, V245, P108, DOI 10.1006/bbrc.1998.8386	90	57	58	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2664	2677		10.1038/sj.onc.1203576	http://dx.doi.org/10.1038/sj.onc.1203576			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851066				2022-12-25	WOS:000087193000002
J	Ait-Si-Ali, S; Polesskaya, A; Filleur, S; Ferreira, R; Duquet, A; Robin, P; Vervish, A; Trouche, D; Cabon, F; Harel-Bellan, A				Ait-Si-Ali, S; Polesskaya, A; Filleur, S; Ferreira, R; Duquet, A; Robin, P; Vervish, A; Trouche, D; Cabon, F; Harel-Bellan, A			CBP/p300 histone acetyl-transferase activity is important for the G1/S transition	ONCOGENE			English	Article						CBP/p300; histone acetyl-transferase; proliferation; E2F; G1/S transition; microinjection	CREB-BINDING PROTEIN; ADENOVIRAL ONCOPROTEIN E1A; SERUM RESPONSE FACTOR; B-MYB TRANSCRIPTION; ACETYLTRANSFERASE ACTIVITY; P300/CBP-ASSOCIATED FACTOR; FUNCTIONAL COLLABORATION; REPRESS TRANSCRIPTION; CELL-DIFFERENTIATION; CHROMATIN DISRUPTION	Transforming viral proteins such as E1A which force quiescent cells into S phase have two essential cellular target proteins, Rb and CBP/p300, Rb regulates the G1/S transition by controlling the transcription factor E2F, CBP/p300 is a transcriptional co-activator with intrinsic histone acetyl-transferase activity. This activity is regulated in a cell cycle dependent manner and shows a peak at the G1/S transition, suggesting a function for CBP/p300 in this crucial step of the cell cycle. Here, we have artificially modulated CBP/p300 levels in individual cells through microinjection of specific antibodies and expression vectors. We show that CBP/p300 is required for cell proliferation and has an essential function during the G1/S transition. Using the same microinjection system and GFP-reporter vectors, we demonstrate that CBP/p300 is essential for the activity of E2F, a transcription factor that controls the G1/S transition. In addition, our results suggest that CBP HAT activity is required both for the G1/S transition and for E2F activity. Thus CBP/p300 seems to be a versatile protein involved in opposing cellular processes, which raises the question of how its multiple activities are regulated.	CNRS, IFC 01, Lab Oncogenese Differenciat & Transduct Signal, F-94801 Villejuif, France; CNRS, IFC 01, Lab Cytoretrie, F-94801 Villejuif, France; CNRS, UPR 9006, LBME, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Harel-Bellan, A (corresponding author), CNRS, IFC 01, Lab Oncogenese Differenciat & Transduct Signal, 7 Rue Guys Moquet, F-94801 Villejuif, France.		Trouche, Didier/B-2854-2008; Cabon, Florence/B-3284-2013; Harel-Bellan, Annick/M-9795-2015	Cabon, Florence/0000-0002-6149-082X; Harel-Bellan, Annick/0000-0002-2339-153X; Filleur, Stephanie/0000-0002-3420-5536; Trouche, Didier/0000-0003-1398-6481				Ait-Si-Ali S, 1998, NUCLEIC ACIDS RES, V26, P3869, DOI 10.1093/nar/26.16.3869; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bennett JD, 1996, ONCOGENE, V13, P1073; BERNARDS R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P33; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chiarugi V, 1998, ONCOL RES, V10, P55; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dyson N, 1989, Princess Takamatsu Symp, V20, P191; Eckner R, 1996, BIOL CHEM, V377, P685; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Fry CJ, 1999, J BIOL CHEM, V274, P15883, DOI 10.1074/jbc.274.22.15883; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Groisman R, 1996, J BIOL CHEM, V271, P5258; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Li Q, 1999, EMBO J, V18, P5634, DOI 10.1093/emboj/18.20.5634; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1999, SEMIN CELL DEV BIOL, V10, P197, DOI 10.1006/scdb.1999.0301; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Muraoka M, 1996, ONCOGENE, V12, P1565; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Scolnick DM, 1997, CANCER RES, V57, P3693; Shi Y, 1998, GENE DEV, V12, P943, DOI 10.1101/gad.12.7.943; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Smits PHM, 1996, ONCOGENE, V12, P1529; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; WEINBERG RA, 1992, CANCER SURV, V12, P43; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	67	110	112	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2000	19	20					2430	2437		10.1038/sj.onc.1203562	http://dx.doi.org/10.1038/sj.onc.1203562			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828885				2022-12-25	WOS:000087018400008
J	Kim, YS; Ryu, JH; Han, SJ; Choi, KH; Nam, KB; Jang, IH; Lemaitre, B; Brey, PT; Lee, WJ				Kim, YS; Ryu, JH; Han, SJ; Choi, KH; Nam, KB; Jang, IH; Lemaitre, B; Brey, PT; Lee, WJ			Gram-negative bacteria-binding protein, a pattern recognition receptor for lipopolysaccharide and beta-1,3-glucan that mediates the signaling for the induction of innate immune genes in drosophila melanogaster cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; HOST-DEFENSE; ANOPHELES-GAMBIAE; GLUCAN-BINDING; BOMBYX-MORI; ACTIVATION; SYSTEM; PEPTIDOGLYCAN; CLONING; INSECTS	Pattern recognition receptors, non-clonal immune proteins recognizing common microbial components, are critical for non-self recognition and the subsequent induction of Rel/NF-kappaB-controlled innate immune genes. However, the molecular identities of such receptors are still obscure. Here, we present data showing that Drosophila possesses at least three cDNAs encoding members of the Gram-negative bacteria-binding protein (DGNBP) family, one of which, DGNBP-1, has been characterized, Western blot, flow cytometric, and confocal laser microscopic analyses demonstrate that DGNSP-1 exists in both a soluble and a glycosylphosphatidylinositol-anchored membrane form in culture medium supernatant and on Drosophila immunocompetent cells, respectively. DGNBP-1 has a high affinity to microbial immune elicitors such as lipopolysaccharide (LPS) and beta -1,3-glucan whereas no binding affinity is detected with peptidoglycan, beta -1,4-glucan, or chitin, Importantly, the overexpression of DGNBP-1 in Drosophila immunocompetent cells enhances LPS- and beta -1,5-glucan-induced innate immune gene (NF-kappaB-dependent antimicrobial peptide gene) expression, which can be specifically blocked by pretreatment with anti-DGNBP-1 antibody, These results suggest that DGNBP-1 functions as a pattern recognition receptor for LPS from Gram-negative bacteria and beta -1,3-glucan from fungi and plays an important role in non-self recognition and the subsequent immune signal transmission for the induction of antimicrobial peptide genes in the Drosophila innate immune system.	Yonsei Univ, Coll Med, Ctr Med Sci BK21, Immunol Lab, Seoul, South Korea; Yonsei Univ, Coll Med, Med Res Ctr, Seoul, South Korea; Inst Pasteur, Lab Biochim & Biol Mol Insectes, F-75724 Paris, France; CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Lee, WJ (corresponding author), Yonsei Univ, Coll Med, Ctr Med Sci BK21, Immunol Lab, 134 Shinchon Dong,CPO Box 8044, Seoul, South Korea.	wjlee1@yumc.yonsei.ac.kr	Han, Sung-Jun/B-9547-2012; Lemaitre, Bruno/T-8146-2019	Lemaitre, Bruno/0000-0001-7970-1667				ASLING B, 1995, INSECT BIOCHEM MOLEC, V25, P511, DOI 10.1016/0965-1748(94)00091-C; Beschin A, 1998, J BIOL CHEM, V273, P24948, DOI 10.1074/jbc.273.38.24948; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Cario E, 2000, J IMMUNOL, V164, P966, DOI 10.4049/jimmunol.164.2.966; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; Engstrom Ylva, 1998, P211; FEHLBAUM P, 1994, J BIOL CHEM, V269, P33159; FYRBERG EA, 1981, CELL, V24, P107, DOI 10.1016/0092-8674(81)90506-7; Harlow E., 1988, ANTIBODIES LAB MANUA; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Janeway CA, 1999, CURR BIOL, V9, pR879, DOI 10.1016/S0960-9822(00)80073-1; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kim YS, 2000, J BIOL CHEM, V275, P2071, DOI 10.1074/jbc.275.3.2071; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; Lee SY, 2000, J BIOL CHEM, V275, P1337, DOI 10.1074/jbc.275.2.1337; Lee WJ, 1996, P NATL ACAD SCI USA, V93, P7888, DOI 10.1073/pnas.93.15.7888; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; MA C, 1998, J BIOL CHEM, V273, P369; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Richman AM, 1997, EMBO J, V16, P6114, DOI 10.1093/emboj/16.20.6114; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; SEKI N, 1994, J BIOL CHEM, V269, P1370; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Wu LP, 1998, NATURE, V392, P93, DOI 10.1038/32195; YAHATA N, 1990, GENE, V86, P113, DOI 10.1016/0378-1119(90)90122-8; Yoshimura A, 1999, J IMMUNOL, V163, P1	41	239	266	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32721	32727		10.1074/jbc.M003934200	http://dx.doi.org/10.1074/jbc.M003934200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10827089	Green Submitted, hybrid			2022-12-25	WOS:000090003800049
J	Biederer, CH; Ries, SJ; Moser, M; Florio, M; Israel, MA; McCormick, F; Buettner, R				Biederer, CH; Ries, SJ; Moser, M; Florio, M; Israel, MA; McCormick, F; Buettner, R			The basic helix-loop-helix transcription factors myogenin and Id2 mediate specific induction of caveolin-3 gene expression during embryonic development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC TRANSCRIPTION; MOLECULAR-CLONING; E-BOX; PROTEINS; ACTIVATION; FAMILY; MYOD; DIFFERENTIATION; MEMBRANE; IDENTIFICATION	Caveolin-3 protein is the only member of the caveolin family that shows a unique muscle-specific expression pattern, and loss of its functional activity causes muscular dystrophy. Caveolin-3 mRNA levels are dramatically increased during the formation of myotubes in the C2C12 cell line. In this study, we characterized the human caveolin-3 5'-flanking region. Promoter analyses demonstrate that the proximal E box element serves as a myogenin binding site and is both necessary and sufficient to control caveolin-3 gene transcription. Transient transfection assays indicated that overexpression of myogenin activates caveolin-3 reporter gene expression, whereas Id2 overexpression inhibited caveolin-3 promoter activation by myogenin. A mutant Id2 protein lacking the HLH domain was not capable of suppressing myogenin-mediated activation. Determination of caveolin-3 transcript distribution patterns in vivo revealed that mRNA was first detectable at day 10 of gestation in the developing somites and heart. Caveolin-3 protein in myoblasts and myotubes was expressed in both the plasma membrane and vesicular structures. During skeletal myogenesis the level of Id2, an inhibitor of differentiation, decreases, allowing the induced basic helix-loop-helix transcription factor myogenin to form transcriptionally active heterodimers that bind to the caveolin-3 promoter and thereby mediate its transcription.	Univ Hosp, Rhein Westfal TH Aachen, Inst Pathol, D-52074 Aachen, Germany; Univ Calif San Francisco, Sch Med, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol Surg, Preuss Lab Mol Neurooncol, Brain Tumor Res Ctr, San Francisco, CA 94143 USA	RWTH Aachen University; RWTH Aachen University Hospital; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Buettner, R (corresponding author), Univ Hosp, Rhein Westfal TH Aachen, Inst Pathol, Pauwelsstr 30, D-52074 Aachen, Germany.							Biederer C, 1998, BBA-MOL BASIS DIS, V1406, P5, DOI 10.1016/S0925-4439(97)00095-1; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Ikezu T, 1998, BRAIN RES, V804, P177, DOI 10.1016/S0006-8993(98)00498-3; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; RAWLS A, 1995, DEV BIOL, V172, P37, DOI 10.1006/dbio.1995.0004; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; TAKEDA S, 1995, J BIOL CHEM, V270, P15664, DOI 10.1074/jbc.270.26.15664; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3	31	43	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26245	26251		10.1074/jbc.M001430200	http://dx.doi.org/10.1074/jbc.M001430200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10835421	hybrid			2022-12-25	WOS:000088999700051
J	Friesen, MJ; Dreyfuss, G				Friesen, MJ; Dreyfuss, G			Specific sequences of the Sm and Sm-like (Lsm) proteins mediate their interaction with the spinal muscular atrophy disease gene product (SMN)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR-NEURON GENE; WERDNIG-HOFFMANN DISEASE; RNA-BINDING PROTEINS; SMALL NUCLEAR-RNA; SNRNP PROTEINS; IN-VITRO; NUCLEOCYTOPLASMIC TRANSPORT; MOLECULAR ANALYSIS; U6 SNRNA; M3G CAP	The spinal muscular atrophy disease gene product (SMN) is crucial for small nuclear ribonuclear protein (snRNP) biogenesis in the cytoplasm and plays a role in pre-mRNA splicing in the nucleus. SMN oligomers interact avidly with the snRNP core proteins SmB, -D1, and -D3. We have delineated the specific sequences in the Sm proteins that mediate their interaction with SMN. We show that unique carboxyl-terminal arginine- and glycine-rich domains comprising the last 29 amino acids of SmD1 and the last 32 amino acids of SmD3 are necessary and sufficient for SMN binding. Interestingly, SMN also interacts with at least two of the U6-associated Sm-like (Lsm) proteins, Lsm4 and Lsm6. Furthermore, the carboxyl-terminal arginine- and glycine-rich domain of Lsm4 directly interacts with SMN. This suggests that SMN also functions in the assembly of the U6 snRNP in the nucleus and in the assembly of other Lsm-containing complexes. These findings demonstrate that arginine- and glycine-rich domains are necessary and sufficient for SMN interaction, and they expand further the range of targets of the SMN protein.	Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Dreyfuss, G (corresponding author), Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA.		Dreyfuss, Gideon/D-1218-2013	Dreyfuss, Gideon/0000-0001-8129-8774				Achsel T, 1999, EMBO J, V18, P5789, DOI 10.1093/emboj/18.20.5789; BEYER AL, 1977, CELL, V11, P127, DOI 10.1016/0092-8674(77)90323-3; BOELENS WC, 1995, RNA, V1, P273; BOFFA LC, 1977, BIOCHEM BIOPH RES CO, V74, P969, DOI 10.1016/0006-291X(77)91613-8; BRZUSTOWICZ LM, 1990, NATURE, V344, P540, DOI 10.1038/344540a0; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913; BUSSAGLIA E, 1995, NAT GENET, V11, P335, DOI 10.1038/ng1195-335; Camasses A, 1998, MOL CELL BIOL, V18, P1956, DOI 10.1128/MCB.18.4.1956; CHANG JG, 1995, AM J HUM GENET, V57, P1503; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; COBBEN JM, 1995, AM J HUM GENET, V57, P805; CZEIZEL A, 1989, J MED GENET, V26, P761, DOI 10.1136/jmg.26.12.761; DAHLBERG JE, 1991, SCIENCE, V254, P1462, DOI 10.1126/science.1962205; DEROBERTIS EM, 1983, CELL, V32, P1021, DOI 10.1016/0092-8674(83)90285-4; DEVEGVAR HEN, 1990, MOL CELL BIOL, V10, P3365, DOI 10.1128/MCB.10.7.3365; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; Fury MG, 1997, EXP CELL RES, V237, P63, DOI 10.1006/excr.1997.3750; Gavrilov DK, 1998, NAT GENET, V20, P230, DOI 10.1038/3030; GENNARELLI M, 1995, BIOCHEM BIOPH RES CO, V213, P342, DOI 10.1006/bbrc.1995.2135; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Hahnen ET, 1996, HUM GENET, V98, P122, DOI 10.1007/s004390050172; Hannus S, 2000, HUM MOL GENET, V9, P663, DOI 10.1093/hmg/9.5.663; Henry MF, 1996, MOL CELL BIOL, V16, P3668; HERMANN H, 1995, EMBO J, V14, P2076, DOI 10.1002/j.1460-2075.1995.tb07199.x; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; KASTNER B, 1990, P NATL ACAD SCI USA, V87, P1710, DOI 10.1073/pnas.87.5.1710; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LEHMEIER T, 1994, P NATL ACAD SCI USA, V91, P12317, DOI 10.1073/pnas.91.25.12317; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; Mayes AE, 1999, EMBO J, V18, P4321, DOI 10.1093/emboj/18.15.4321; MELKI J, 1990, LANCET, V336, P271, DOI 10.1016/0140-6736(90)91803-I; Miguel-Aliaga I, 1999, HUM MOL GENET, V8, P2133, DOI 10.1093/hmg/8.12.2133; Owen N, 2000, HUM MOL GENET, V9, P675, DOI 10.1093/hmg/9.5.675; PEARN J, 1978, J MED GENET, V15, P409, DOI 10.1136/jmg.15.6.409; PEARN JH, 1973, J MED GENET, V10, P260, DOI 10.1136/jmg.10.3.260; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Raker VA, 1996, EMBO J, V15, P2256, DOI 10.1002/j.1460-2075.1996.tb00579.x; ROBERTS DF, 1970, ARCH DIS CHILD, V45, P33, DOI 10.1136/adc.45.239.33; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; Schrank B, 1997, P NATL ACAD SCI USA, V94, P9920, DOI 10.1073/pnas.94.18.9920; SERAPHIN B, 1995, EMBO J, V14, P2089, DOI 10.1002/j.1460-2075.1995.tb07200.x; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Talbot K, 1997, HUM MOL GENET, V6, P497, DOI 10.1093/hmg/6.3.497; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; Velasco E, 1996, HUM MOL GENET, V5, P257, DOI 10.1093/hmg/5.2.257	60	117	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26370	26375		10.1074/jbc.M003299200	http://dx.doi.org/10.1074/jbc.M003299200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851237	hybrid			2022-12-25	WOS:000088999700067
J	Ohmori, S; Sakai, N; Shirai, Y; Yamamoto, H; Miyamoto, E; Shimizu, N; Saito, N				Ohmori, S; Sakai, N; Shirai, Y; Yamamoto, H; Miyamoto, E; Shimizu, N; Saito, N			Importance of protein kinase C targeting for the phosphorylation of its substrate, myristoylated alanine-rich C-kinase substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; GAMMA-MUTANT MICE; MEMBRANE ASSOCIATION; MOLECULAR-CLONING; PHORBOL ESTER; CELLULAR SUBSTRATE; MAJOR SUBSTRATE; PLASMA-MEMBRANE; PHOSPHOLIPASE-C; 87-KDA PROTEIN	We visualized the translocation of myristoylated alanine-rich protein kinase C substrate (MARCKS) in living Chinese hamster ovary-K1 cells using MARCKS tagged to green fluorescent protein (MARCKS-GFP). MARCKS-GFP was rapidly translocated from the plasma membrane to the cytoplasm after the treatment with phorbol ester, which translocates protein kinase C (PKC) to the plasma membrane. In contrast, PKC activation by hydrogen peroxide, which was not accompanied by PKC translocation, did not alter the intracellular localization of MARCKS-GFP. Non-myristoylated mutant of MARCKS-GFP was distributed throughout the cytoplasm, including the nucleoplasm, and was not translocated by phorbol ester or by hydrogen peroxide. Phosphorylation of wild-type MARCKS-GFP was observed in cells treated with phorbol ester but not with hydrogen peroxide, whereas non-myristoylated mutant of MARCKS-GFP was phosphorylated in cells treated with hydrogen peroxide but not with phorbol ester. Phosphorylation of both MARCKS-GFPs reduced the amount of F-actin. These findings revealed that PKC targeting to the plasma membrane is required for the phosphorylation of membrane-associated MARCKS and that a mutant MARCKS existing in the cytoplasm can be phosphorylated by PKC activated in the cytoplasm without translocation but not by PHC targeted to the membrane.	Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Nada Ku, Kobe, Hyogo 6578501, Japan; Kumamoto Univ, Sch Med, Dept Pharmacol, Kumamoto 8600811, Japan; Keio Univ, Sch Med, Dept Mol Biol, Shinjuku Ku, Tokyo 1608582, Japan	Kobe University; Kumamoto University; Keio University	Saito, N (corresponding author), Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Nada Ku, Rokkodai Cho 1-1, Kobe, Hyogo 6578501, Japan.		Shirai, Yasuhito/O-3255-2018					ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; GRAFF JM, 1989, J BIOL CHEM, V264, P21818; GREGORIO CC, 1994, J CELL BIOL, V125, P345, DOI 10.1083/jcb.125.2.345; HARLAN DM, 1991, J BIOL CHEM, V266, P14399; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Huang XP, 1997, J CELL SCI, V110, P1625; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KLIGMAN D, 1986, J NEUROCHEM, V47, P298; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; LEACH KL, 1989, J CELL BIOL, V109, P685, DOI 10.1083/jcb.109.2.685; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; SAKAI K, 1992, GENOMICS, V14, P175, DOI 10.1016/S0888-7543(05)80301-5; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; Seki K, 1996, ARCH BIOCHEM BIOPHYS, V326, P193, DOI 10.1006/abbi.1996.0065; SEYKORA JT, 1991, P NATL ACAD SCI USA, V88, P2505, DOI 10.1073/pnas.88.6.2505; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; SIMEK SL, 1989, P NATL ACAD SCI USA, V86, P7410, DOI 10.1073/pnas.86.19.7410; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; THELEN M, 1990, P NATL ACAD SCI USA, V87, P5603, DOI 10.1073/pnas.87.15.5603; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; Wang YC, 1999, BIOCHEM MOL BIOL INT, V47, P673; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; WU WCS, 1982, P NATL ACAD SCI-BIOL, V79, P5249, DOI 10.1073/pnas.79.17.5249; Yamamoto H, 1998, ARCH BIOCHEM BIOPHYS, V359, P151, DOI 10.1006/abbi.1998.0920	57	92	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26449	26457		10.1074/jbc.M003588200	http://dx.doi.org/10.1074/jbc.M003588200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10840037	hybrid			2022-12-25	WOS:000088999700079
J	Trepakova, ES; Csutora, P; Hunton, DL; Marchase, RB; Cohen, RA; Bolotina, VM				Trepakova, ES; Csutora, P; Hunton, DL; Marchase, RB; Cohen, RA; Bolotina, VM			Calcium influx factor directly activates store-operated cation channels in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+; XENOPUS OOCYTES; DIFFUSIBLE MESSENGER; HUMAN PLATELETS; HTRP3 CHANNELS; ENTRY; RECEPTOR; RELEASE; TRP; RETICULUM	Recently, we described a novel 3-pS Ca2+-conducting channel that is activated by BAPTA and thapsigargin-induced passive depletion of intracellular Ca2+ stores and likely to be a native store-operated channel in vascular smooth muscle cells (SMC). Neither Ca2+ nor inositol 1,4,5-trisphosphate or other second messengers tested activated this channel in membrane patches excised from resting SMC. Here we report that these 3-pS channels are activated in inside-out membrane patches from SMC immediately upon application of Ca2+ influx factor (CIF) extracted from mutant yeast, which has been previously shown to activate Ca2+ influx in Xenopus oocytes and Ca2+ release-activated Ca2+ current in Jurkat cells. In bioassay experiments depletion of Ca2+ stores in permeabilized human platelets resulted in the release of endogenous factor, which activated 3-pS channels in isolated inside-out membrane patches excised from SMC and exposed to permeabilized platelets. The same 3-pS channels in excised membrane patches were also activated by acid extracts of CIF derived from human platelets with depleted Ca2+ stores, which also stimulated Ca2+ influx upon injection into Xenopus oocytes, Specific high pressure liquid chromatography fractions of platelet extracts were found to have CIF activity when injected into oocytes and activate 3-pS channels in excised membrane patches. These data show for the first time that CIF produced by mammalian cells and yeast with depleted Ca2+ stores directly activates native 3-pS cation channels, which in intact SMC are activated by Ca2+ store depletion.	Boston Univ, Sch Med, Vasc Biol Unit, Dept Med, Boston, MA 02118 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	Boston University; University of Alabama System; University of Alabama Birmingham	Bolotina, VM (corresponding author), Boston Univ, Sch Med, Vasc Biol Unit, Dept Med, 650 Albany St,X-704, Boston, MA 02118 USA.			Bolotina, Victoria/0000-0001-5862-181X; /0000-0002-1070-6408	NHLBI NIH HHS [HL55993, HL07224, HL54150] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054150, P50HL055993] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; Friel DD, 1996, CELL, V85, P617, DOI 10.1016/S0092-8674(00)81021-1; Hirakawa Y, 1999, AM J PHYSIOL-HEART C, V277, pH1732, DOI 10.1152/ajpheart.1999.277.5.H1732; HOTH M, 1993, ANN NY ACAD SCI, V707, P198, DOI 10.1111/j.1749-6632.1993.tb38053.x; Jaconi M, 1997, CURR BIOL, V7, P599, DOI 10.1016/S0960-9822(06)00259-4; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; KIM HY, 1995, J BIOL CHEM, V270, P9706, DOI 10.1074/jbc.270.17.9706; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; Oliver AE, 1999, BBA-BIOMEMBRANES, V1416, P349, DOI 10.1016/S0005-2736(98)00239-9; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Petersen CCH, 1996, PFLUG ARCH EUR J PHY, V432, P286, DOI 10.1007/s004240050135; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SOMASUNDARAM B, 1995, BIOCHEM J, V309, P725, DOI 10.1042/bj3090725; Trepakova ES, 1999, CIRC RES, V84, P201, DOI 10.1161/01.RES.84.2.201; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhu X, 1998, NEWS PHYSIOL SCI, V13, P211	27	94	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26158	26163		10.1074/jbc.M004666200	http://dx.doi.org/10.1074/jbc.M004666200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851243	hybrid			2022-12-25	WOS:000088999700039
J	Clish, CB; Levy, BD; Chiang, N; Tai, HH; Serhan, CN				Clish, CB; Levy, BD; Chiang, N; Tai, HH; Serhan, CN			Oxidoreductases in lipoxin A(4) metabolic inactivation - A novel role for 15-oxoprostaglandin 13-reductase/leukotriene B-4 12-hydroxydehydrogenase in inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOTRIENE B-4; STABLE ANALOGS; CDNA CLONING; IDENTIFICATION; PURIFICATION; EXPRESSION; CONVERSION; RECEPTOR; ENZYMES; CELLS	The lipoxins (LX) are autacoids that act within a local inflammatory milieu to dampen neutrophil recruitment and promote resolution. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) and 15-oxoprostaglandin 13-reductase, also termed leukotriene B-4 12-hydroxydehydrogenase (PGR/LTB4DH), are two enzymatic activities appreciated for their roles in the metabolism of prostaglandins and LTB4. Here, we determined whether these oxidoreductases also catalyze the conversion of lipoxin A(4) (LXA(4)) and assessed the activities of these LXA(4) metabolites. 15-Oxo-LXA(4) was generated by incubating LXA(4) with 15-PGDH and NAD(+) for studies of its further conversion. PGR/LTB4DH catalyzed the NADH-dependent reduction of 15-oxo-LXA(4) to yield 13,14-dihydro-15-loxo-LXA(4). With NADH as a cofactor, 15-PGDH acted as a 15-carbonyl reductase and catalyzed the conversion of 13,14-dihydro-15-oxo-LXA(4) to 13,14-dihydro-LXA(4). Human polymorphonuclear leukocytes (PMN) exposed to native LXA(4), 15-oxo-LXA(4), or 13,14-dihydro-LXA(4) did not produce superoxide anions. At concentrations where LXA(4) and a metabolically stable LXA(4) analog potently inhibited leukotriene B-4-induced superoxide anion generation, the further metabolites were devoid of activity. Neither 15-oxo-LXA(4) nor 13,14-dihydro-LXA(4) effectively competed with H-3-labeled LXA(4) for specific binding to recombinant LXA(4) receptor (ALXR). In addition, introducing recombinant PGR/LTB4DH into a murine exudative model of inflammation increased PMN number by similar to 2-fold, suggesting that this enzyme participates in the regulation of PMN trafficking. These results establish the structures of LXA(4) further metabolites and indicate that conversion of LXA(4) to oxo- and dihydro- products represents a mode of LXA(4) inactivation in inflammation. Moreover, they suggest that these eicosanoid oxidoreductases have multifaceted roles controlling the levels of specific eicosanoids involved in the regulation of inflammation.	Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Kentucky	Serhan, CN (corresponding author), Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, 75 Francis St, Boston, MA 02115 USA.		Clish, Clary/AAB-7124-2019; Chiang, Nan/ABA-4924-2021; Clish, Clary B/ABB-9374-2021	Chiang, Nan/0000-0003-1963-1585; Clish, Clary B/0000-0001-8259-9245	NHLBI NIH HHS [HL-46296, K08-HL03788] Funding Source: Medline; NIDDK NIH HHS [DK-50305] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046296, K08HL003788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bandeira-Melo C, 2000, J IMMUNOL, V164, P1029, DOI 10.4049/jimmunol.164.2.1029; Chiang N, 2000, J EXP MED, V191, P1197, DOI 10.1084/jem.191.7.1197; Chiang N, 1998, J PHARMACOL EXP THER, V287, P779; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; Ensor CM, 1998, BIOCHEM J, V330, P103, DOI 10.1042/bj3300103; ENSOR CM, 1991, PROSTAGLANDINS LEUKO, P39; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923; LEVY BD, 1999, HDB METHODS SIGNAL T, P83; Maddox JE, 1996, J EXP MED, V183, P137, DOI 10.1084/jem.183.1.137; MURPHY RC, 1989, PROSTAGLANDINS CLIN, P1; Okita RT, 1996, CRIT REV BIOCHEM MOL, V31, P101, DOI 10.3109/10409239609106581; Powell WS, 1996, J PHARMACOL EXP THER, V276, P728; Primiano T, 1998, CARCINOGENESIS, V19, P999, DOI 10.1093/carcin/19.6.999; SERHAN CN, 1995, BIOCHEMISTRY-US, V34, P14609, DOI 10.1021/bi00044a041; SERHAN CN, 1993, BIOCHEMISTRY-US, V32, P6313, DOI 10.1021/bi00076a002; SERHAN CN, 1999, INFLAMMATION BASIC P, P373; SHIMIZU T, 1988, INT J BIOCHEM, V20, P661, DOI 10.1016/0020-711X(88)90160-7; SIN YM, 1986, ANN RHEUM DIS, V45, P873, DOI 10.1136/ard.45.10.873; Sinzinger H, 1998, PROSTAG OTH LIPID M, V55, P265, DOI 10.1016/S0090-6980(98)00025-2; Sobal G, 1998, PROSTAG OTH LIPID M, V55, P67, DOI 10.1016/S0090-6980(98)00005-7; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Tong M, 2000, BBA-MOL CELL RES, V1497, P61, DOI 10.1016/S0167-4889(00)00039-2; WAINWRIGHT SL, 1991, J BIOL CHEM, V266, P20899; WETTERHOLM A, 1992, BIOCHIM BIOPHYS ACTA, V1123, P275, DOI 10.1016/0005-2760(92)90007-I; YOKOMIZO T, 1993, J BIOL CHEM, V268, P18128; Yokomizo T, 1996, J BIOL CHEM, V271, P2844, DOI 10.1074/jbc.271.5.2844; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	28	154	161	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25372	25380		10.1074/jbc.M002863200	http://dx.doi.org/10.1074/jbc.M002863200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837478	hybrid, Green Published			2022-12-25	WOS:000088849400045
J	Kobayashi, T; Ushikubi, F; Narumiya, S				Kobayashi, T; Ushikubi, F; Narumiya, S			Amino acid residues conferring ligand binding properties of prostaglandin I and prostaglandin D receptors - Identification by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORTHERN BLOT ANALYSIS; THROMBOXANE-A2 RECEPTOR; PROSTACYCLIN RECEPTOR; EP(2) SUBTYPE; CDNA CLONING; EXPRESSION; SELECTIVITY; PROTEIN	Using chimeras of the mouse prostaglandin (PG) I receptor (mIP) and the mouse PGD receptor (mDP), we previously revealed that the cyclopentane ring recognition by these receptors is specified by a region from the first to third transmembrane domain of each receptor; recognition by this region of mIP is broad, accommodating the D, E, and I types of cyclopentane rings, whereas that of mDP binds the D type of PGs alone (Kobayashi, T., Kiriyama, M., Hirata, T., Hirata, M, Ushikubi, F., and Narumiya, S. (1997) J. Biol. Chem. 272, 15154-15160). In the present study, we performed a more detailed chimera analysis, and narrowed the domain for the ring recognition to a region from the first transmembrane domain to the first extracellular loop. One chimera with the replacement of the second transmembrane domain and the first extracellular loop of mDP with that of mIP bound only iloprost. The amino acid substitutions in this chimera suggest that Ser(50) in the first transmembrane domain of mIP confers the broad ligand recognition of mIP and that Lys(75) and Leu(83) in the second transmembrane domain of mDP confer the high affinity to PGD(2) and the strict specificity of ligand binding of mDP, respectively.	Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068501, Japan; Asahikawa Med Coll, Dept Pharmacol, Asahikawa, Hokkaido 0788307, Japan	Kyoto University; Asahikawa Medical College	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 606, Japan.							Audoly L, 1997, J BIOL CHEM, V272, P13475, DOI 10.1074/jbc.272.21.13475; BOIE Y, 1995, J BIOL CHEM, V270, P18910, DOI 10.1074/jbc.270.32.18910; FEIGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI DOI 10.1073/PNAS.84.21.7413; GETHER U, 1993, P NATL ACAD SCI USA, V90, P6194, DOI 10.1073/pnas.90.13.6194; HIRATA M, 1994, P NATL ACAD SCI USA, V91, P11192, DOI 10.1073/pnas.91.23.11192; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HONDA A, 1993, J BIOL CHEM, V268, P7759; KATSUYAMA M, 1995, FEBS LETT, V372, P151, DOI 10.1016/0014-5793(95)00966-D; Kedzie KM, 1998, MOL PHARMACOL, V54, P584, DOI 10.1124/mol.54.3.584; Kobayashi T, 1997, J BIOL CHEM, V272, P15154, DOI 10.1074/jbc.272.24.15154; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEIGH PJ, 1984, J BIOL CHEM, V259, P2431; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; NAMBA T, 1994, J BIOL CHEM, V269, P9986; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; REGAN JW, 1994, MOL PHARMACOL, V46, P213; Rehwald M, 1999, FEBS LETT, V443, P357, DOI 10.1016/S0014-5793(99)00007-1; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; TOH H, 1995, FEBS LETT, V361, P17, DOI 10.1016/0014-5793(95)00129-W; TOWN MH, 1983, PROSTAGLANDINS, V25, P13; TSAI AL, 1989, J BIOL CHEM, V264, P61; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WATABE A, 1993, J BIOL CHEM, V268, P20175; WISE H, 2000, PROSTACYCLIN ITS REC	27	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24294	24303		10.1074/jbc.M002437200	http://dx.doi.org/10.1074/jbc.M002437200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827082	hybrid			2022-12-25	WOS:000088683300010
J	Potapova, O; Gorospe, M; Bost, F; Dean, NM; Gaarde, WA; Mercola, D; Holbrook, NJ				Potapova, O; Gorospe, M; Bost, F; Dean, NM; Gaarde, WA; Mercola, D; Holbrook, NJ			c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; LUNG-CARCINOMA CELLS; PROTEIN-KINASE; HA-RAS; ACTIVATION DOMAIN; DNA-SYNTHESIS; G(1) ARREST; MAP KINASES; INDUCTION; JNK	The c-Jun N-terminal kinase/stress-activated protein kinase (JNR/SAPK) pathway is activated by numerous cellular stresses. Although it has been implicated in me diating apoptosis and growth factor signaling, its role in regulating cell growth is not yet clear. Here, the influence of JNK on basal (unstimulated) growth of human tumor glioblastoma T98G cells was investigated using highly specific JNK antisense oligonucleotides to inhibit JNK expression. Transient depletion of either JNK1 or JNK2 suppressed cell growth associated with an inhibition of DNA synthesis and cell cycle arrest in S phase. The growth-inhibitory potency of JNK2 antisense ((JNK)2 IC50 = 0.14 mu M) was greater than that of JNK1 antisense ((JNK)1 IC50 = 0.37 mu M), suggesting that JNK2 plays a dominant role in regulating growth of T98G cells. Indeed, JNK2 antisense-treated populations exhibited greater inhibition of DNA synthesis and accumulation of S-phase cells than did the JNK1 antisense-treated cultures, with a significant proportion of these cells detaching from the tissue culture plate. JNK2 (but not JNK1) antisense-treated cultures exhibited marked elevation in the expression of the cyclin-dependent kinase inhibitor p21(cip1/waf1) accompanied by inhibition of Cdk2/Cdc2 kinase activities. Taken together, these results indicate that JNK is required for growth of T98G cells in nonstress conditions and that p21(cip1/waf1) may contribute to the sustained growth arrest of JNK2-depleted T98G cultures.	NIA, Ctr Gerontol Res, Biol Chem Lab, Cell Stress & Aging Sect,NIH, Baltimore, MD 21224 USA; Sidney Kimmel Canc Ctr, San Diego, CA 91212 USA; ISIS Pharmaceut Inc, Carlsbad, CA 92008 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Isis Pharmaceuticals Inc	Holbrook, NJ (corresponding author), NIA, Ctr Gerontol Res, Biol Chem Lab, Cell Stress & Aging Sect,NIH, 5600 Nathan Shock Dr,Box 12, Baltimore, MD 21224 USA.	nikki_holbrook@nih.gov	BOST, Frederic/AAN-4691-2020; mercola, dan/L-4182-2013	BOST, Frederic/0000-0003-4509-4701; mercola, dan/0000-0002-0281-9840	NATIONAL CANCER INSTITUTE [R01CA076173, R01CA063783] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000511, Z01AG000511] Funding Source: NIH RePORTER; NCI NIH HHS [CA76173, CA63783] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Auer KL, 1998, MOL BIOL CELL, V9, P561, DOI 10.1091/mbc.9.3.561; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bost F, 1999, MOL CELL BIOL, V19, P1938; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Bost F, 1998, CANCER GENE THER, V5, pS27; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HOLBROOK NJ, 1996, STRESS INDUCIBLE CEL, P273; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Shenberger JS, 1999, AM J RESP CELL MOL, V21, P395, DOI 10.1165/ajrcmb.21.3.3604; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Toms SA, 1998, ANTICANCER RES, V18, P289; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WALDMAN T, 1995, CANCER RES, V55, P5187; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu XXS, 1998, J BIOL CHEM, V273, P33230, DOI 10.1074/jbc.273.50.33230; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yao RJ, 1997, J BIOL CHEM, V272, P18261, DOI 10.1074/jbc.272.29.18261; Zhang YX, 2000, CANCER RES, V60, P2025	53	98	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24767	24775		10.1074/jbc.M904591199	http://dx.doi.org/10.1074/jbc.M904591199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10825181	hybrid			2022-12-25	WOS:000088683300073
J	Royo, J; Gomez, E; Hueros, G				Royo, J; Gomez, E; Hueros, G			A maize homologue of the bacterial CMP-3-deoxy-D-manno-2-octulosonate (KDO) synthetases - Similar pathways operate in plants and bacteria for the activation of KDO prior to its incorporation into outer cellular envelopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; RHAMNOGALACTURONAN-II; TRANSPOSABLE ELEMENT; MOLECULAR-STRUCTURE; ACID SYNTHETASE; CODON USAGE; POLYSACCHARIDE; WALL; CMP; CYTIDYLYLTRANSFERASE	The eight-carbon acid sugar 3-deoxy-D-manno-2-octulosonate (KDO) is an essential component of Gram-negative bacterial cell walls and capsular polysaccharides. KDO is incorporated into these polymers as CMP-KDO, which is produced in an unusual activation step catalyzed by the enzyme CMP-KDO synthetase. CMP-KDO synthetase activity has traditionally been considered exclusive to Gram-negative bacteria. CMP-KDO synthetase inhibitors attract great interest owing to their potential as selective bactericides. The sugar KDO is also a component of the rhamnogalacturonan II pectin fraction of the primary cell walls of most higher plants and of the cell wall polysaccharides of some green algae. However, the metabolic pathway leading to its incorporation into the plant cell mall is unknown. This paper describes the isolation and characterization of a maize gene, which codes for a protein very similar in sequence and activity to prokaryotic CMP-KDO synthetases. Remarkably, the maize gene can complement a CMP-KDO synthetase (kdsB) Salmonella typhimurium mutant defective in cell wall synthesis, ZmCKS activity is novel in eukaryotes, The evolutionary origin of ZmCKS is discussed in relation to the high degree of conservation between the plant and bacterial genes and its atypical codon usage in maize.	Univ Alcala de Henares, Dept Biol Celular & Genet, ES-28871 Alcala De Henares, Spain	Universidad de Alcala	Hueros, G (corresponding author), Univ Alcala de Henares, Dept Biol Celular & Genet, ES-28871 Alcala De Henares, Spain.	gregorio.hueros@alcala.es	Gomez, Elisa E/A-8122-2013; Hueros, Gregorio/L-3513-2017; Royo, Joaquin/L-4855-2015	Hueros, Gregorio/0000-0003-1172-5405; Royo, Joaquin/0000-0002-8245-5791				ALBERSHEIM P, 1994, BIOCHEM SOC T, V22, P374, DOI 10.1042/bst0220374; BECKER B, 1995, CARBOHYD RES, V267, P313, DOI 10.1016/0008-6215(94)00300-5; Becker B, 1998, J PHYCOL, V34, P779, DOI 10.1046/j.1529-8817.1998.340779.x; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; Chou IT, 1997, PLANT MOL BIOL, V35, P873, DOI 10.1023/A:1005930024796; Clark JB, 1997, P NATL ACAD SCI USA, V94, P11428, DOI 10.1073/pnas.94.21.11428; Cosgrove DJ, 1997, ANNU REV CELL DEV BI, V13, P171, DOI 10.1146/annurev.cellbio.13.1.171; DELMER DP, 1988, BIOCH PLANTS, V14, P373; Delwiche CF, 1996, MOL BIOL EVOL, V13, P873, DOI 10.1093/oxfordjournals.molbev.a025647; Edashige Y, 1998, PHYTOCHEMISTRY, V49, P681, DOI 10.1016/S0031-9422(98)00238-6; EDWARDS U, 1992, FEMS MICROBIOL LETT, V96, P161; Feingold D. S., 1990, METHODS PLANT BIOCH, V2, P39; FINKE A, 1989, J BACTERIOL, V171, P3074, DOI 10.1128/jb.171.6.3074-3079.1989; Fowler JE, 1997, ANNU REV CELL DEV BI, V13, P697, DOI 10.1146/annurev.cellbio.13.1.697; FRY SC, 1993, PLANT PHYSIOL, V103, P1, DOI 10.1104/pp.103.1.1; GOLDMAN RC, 1985, J BACTERIOL, V163, P256, DOI 10.1128/JB.163.1.256-261.1985; GOTTESMAN S, 1981, J BACTERIOL, V148, P265, DOI 10.1128/JB.148.1.265-273.1981; GOUY M, 1982, NUCLEIC ACIDS RES, V10, P7055, DOI 10.1093/nar/10.22.7055; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HUEROS G, 1995, PLANT CELL, V7, P747, DOI 10.1105/tpc.7.6.747; Jelakovic S, 1996, FEBS LETT, V391, P157, DOI 10.1016/0014-5793(96)00724-7; John M, 1997, TRENDS PLANT SCI, V2, P111, DOI 10.1016/S1360-1385(97)01005-4; Joshi CP, 1997, PLANT MOL BIOL, V35, P993, DOI 10.1023/A:1005816823636; Lawrence JG, 1998, P NATL ACAD SCI USA, V95, P9413, DOI 10.1073/pnas.95.16.9413; LENTER M, 1990, CARBOHYD RES, V197, P197, DOI 10.1016/0008-6215(90)84142-H; Nakamura Y, 1999, NUCLEIC ACIDS RES, V27, P292, DOI 10.1093/nar/27.1.292; Nimtz M, 1997, EUR J BIOCHEM, V250, P608, DOI 10.1111/j.1432-1033.1997.0608a.x; O'Neill M., 1990, METHODS PLANT BIOCH, V2, P415, DOI DOI 10.1016/B978-0-12-461012-5.50018-5; OBRIEN WE, 1976, ANAL BIOCHEM, V76, P423, DOI 10.1016/0003-2697(76)90337-7; Osborn MJ., 1979, BACTERIAL OUTER MEMB, P15; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAY PH, 1982, METHOD ENZYMOL, V83, P535; RICK PD, 1982, J BACTERIOL, V150, P456, DOI 10.1128/JB.150.2.456-464.1982; ROBERTSON HM, 1993, NATURE, V362, P241, DOI 10.1038/362241a0; ROSENOW C, 1995, FEMS MICROBIOL LETT, V125, P159, DOI 10.1016/0378-1097(94)00492-A; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHARP PM, 1994, CURR OPIN GENET DEV, V4, P851, DOI 10.1016/0959-437X(94)90070-1; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Shin KS, 1997, CARBOHYD RES, V300, P239, DOI 10.1016/S0008-6215(97)00055-4; YORK WS, 1985, CARBOHYD RES, V138, P109, DOI 10.1016/0008-6215(85)85228-9; ZAHRINGER U, 1994, ADV CARBOHYD CHEM BI, V50, P211, DOI 10.1016/S0065-2318(08)60152-3	42	36	38	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24993	24999		10.1074/jbc.M905750199	http://dx.doi.org/10.1074/jbc.M905750199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10829033	hybrid			2022-12-25	WOS:000088683300101
J	Urbatsch, IL; Gimi, K; Wilke-Mounts, S; Senior, AE				Urbatsch, IL; Gimi, K; Wilke-Mounts, S; Senior, AE			Conserved Walker A Ser residues in the catalytic sites of P-glycoprotein are critical for catalysis and involved primarily at the transition state step	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; NUCLEOTIDE-BINDING DOMAINS; STIMULATED ATPASE ACTIVITY; DRUG-BINDING; ABC TRANSPORTER; INHIBITION; MDR1; IDENTIFICATION; MODULATION; F1-ATPASE	P-glycoprotein mutants S430A/T and S1073A/T, affecting conserved Walker A Ser residues, were characterized to elucidate molecular roles of the Ser and functioning of the two P-glycoprotein catalytic sites, Results showed the Ser-OH is critical for MgATPase activity and formation of the normal transition state, although not for initial MgATP binding. Mutation to Ala in either catalytic site abolished MgATPase and transition state formation in both sites, whereas Thr mutants had similar MgATPase to wild-type. Trapping of 1 mol of MgADP/mol of P-glycoprotein by vanadate, shown here with pure protein, yielded full inhibition of ATPase, Thus, congruent with previous work, both sites must be intact and must interact for catalysis, Equivalent mutations (Ala or Thr) in the two catalytic sites had identical effects on a wide range of activities, emphasizing that the two catalytic sites function symmetrically. The role of the Ser-OH is to coordinate Mg2+ in MgATP, but only at the stage of the transition state are its effects tangible. Initial substrate binding is apparently to an "open" catalytic site conformation, where the Ser-OH is dispensable. This changes to a "closed" conformation required to attain the transition state, in which the Ser-OH is a critical ligand, Formation of the latter conformation requires both sites; both sites may provide direct ligands to the transition state.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.	alan_senior@urmc.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050156] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50156] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; Demeule M, 1998, BIOCHEMISTRY-US, V37, P18110, DOI 10.1021/bi981992c; Demmer A, 1999, EUR J BIOCHEM, V264, P800, DOI 10.1046/j.1432-1327.1999.00702.x; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GEORGES E, 1991, J CELL PHYSIOL, V148, P479, DOI 10.1002/jcp.1041480321; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; JOHN J, 1993, J BIOL CHEM, V268, P923; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7750; Muller M, 1996, J BIOL CHEM, V271, P1877; Nikaido K, 1997, J BIOL CHEM, V272, P27745, DOI 10.1074/jbc.272.44.27745; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Rosen BP, 1999, BBA-BIOMEMBRANES, V1461, P207, DOI 10.1016/S0005-2736(99)00159-5; Sankaran B, 1997, FEBS LETT, V417, P119, DOI 10.1016/S0014-5793(97)01268-4; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Sankaran B, 1997, ARCH BIOCHEM BIOPHYS, V341, P160, DOI 10.1006/abbi.1997.9944; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; Stein WD, 1997, PHYSIOL REV, V77, P545, DOI 10.1152/physrev.1997.77.2.545; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; Weber J, 1998, BIOCHEMISTRY-US, V37, P608, DOI 10.1021/bi972370e; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	48	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					25031	25038		10.1074/jbc.M003962200	http://dx.doi.org/10.1074/jbc.M003962200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10831598	hybrid			2022-12-25	WOS:000088683300106
J	Duriez, PJ; Wong, F; Dorovini-Zis, K; Shahidi, R; Karsan, A				Duriez, PJ; Wong, F; Dorovini-Zis, K; Shahidi, R; Karsan, A			A1 functions at the mitochondria to delay endothelial apoptosis in response to tumor necrosis factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ALPHA-INDUCED APOPTOSIS; FACTOR-MEDIATED CYTOTOXICITY; BCL-2 FAMILY MEMBER; INDUCED CELL-DEATH; SIGNALING COMPLEX; CYTOCHROME-C; INTERLEUKIN-1-CONVERTING ENZYME; CD95 FAS/APO-1; PROTEIN	Tumor necrosis factor (TNF) does not cause endothelial apoptosis unless the expression of cytoprotective genes is blocked. We have previously demonstrated that one of the TNF-inducible cytoprotective genes is the Bcl-2 family member, Al. Al is induced by the action of the transcription factor, NF kappa B, in response to inflammatory mediators. In this report we demonstrate that, as with other cell types, inhibition of NF kappa B initiates microvascular endothelial apoptosis in response to TNF. Al is able to inhibit this apoptosis over 24 h, We demonstrate that Al is localized to and functions at the mitochondria. Whereas Al is able to inhibit mitochondrial depolarization, loss of cytochrome c, cleavage of caspase 9, BID, and poly(ADP-ribose) polymerase, it does not block caspase 8 or caspase 3 cleavage. In contrast, Al is not able to prevent endothelial apoptosis by TNF over 72 h, when NF kappa B signaling is blocked. On the other hand, the caspase inhibitor, benzyloxycarbonyl-VAD-formylmethyl ketone, completely blocks TNF-induced endothelial apoptosis over 72 h. Our findings indicate that Al is able to maintain temporary survival of endothelial cells in response to TNF by maintaining mitochondrial viability and function. However, a mitochondria-independent caspase pathway eventually results in endothelial death despite mitochondrial protection by A1.	St Pauls Hosp, UBC McDonald Res Labs, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6Z 1Y6, Canada	St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of British Columbia	Karsan, A (corresponding author), St Pauls Hosp, UBC McDonald Res Labs, Rm B292,1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	akarsan@mrl.ubc.ca	Karsan, Aly/K-2067-2015	Shahidi, Reza/0000-0001-9452-2595; Duriez, Patrick/0000-0003-1814-2552				ABELLO PA, 1994, ARCH SURG-CHICAGO, V129, P134; ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Beyaert R, 1997, J BIOL CHEM, V272, P11694, DOI 10.1074/jbc.272.18.11694; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Choi KB, 1998, J BIOL CHEM, V273, P20185, DOI 10.1074/jbc.273.32.20185; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; D'Sa-Eipper C, 1998, ONCOGENE, V16, P3105, DOI 10.1038/sj.onc.1201851; DSaEipper C, 1996, CANCER RES, V56, P3879; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Han ZY, 1999, MOL CELL BIOL, V19, P1381; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HENNET T, 1993, CANCER RES, V53, P1456; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; Karsan A, 1998, TRENDS CARDIOVAS MED, V8, P19, DOI 10.1016/S1050-1738(97)00126-6; Karsan A, 1997, AM J PATHOL, V151, P1775; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Magnusson C, 1999, IMMUNOL CELL BIOL, V77, P41, DOI 10.1046/j.1440-1711.1999.00800.x; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; PALEOLOG EM, 1994, BLOOD, V84, P2578; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schumann RR, 1998, BLOOD, V91, P577, DOI 10.1182/blood.V91.2.577.577_577_584; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slowik MR, 1997, LAB INVEST, V77, P257; Smith DJ, 1997, J IMMUNOL, V158, P163; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Stehlik C, 1998, BIOCHEM BIOPH RES CO, V243, P827, DOI 10.1006/bbrc.1998.8185; Sugiyama H, 1999, J BIOL CHEM, V274, P19532, DOI 10.1074/jbc.274.28.19532; SUZUKI H, 1991, INT REV EXP PATHOL, V32, P95; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Watanabe N, 1998, CYTOKINE, V10, P645, DOI 10.1006/cyto.1998.0341; Wong WW, 1998, AGENT ACTION SUPPL, V49, P5; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zen K, 1999, J BIOL CHEM, V274, P28808, DOI 10.1074/jbc.274.40.28808; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	63	85	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18099	18107		10.1074/jbc.M908925199	http://dx.doi.org/10.1074/jbc.M908925199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849436	hybrid			2022-12-25	WOS:000087659400028
J	Ricciardi, A; le Du, MH; Khayati, M; Dajas, F; Boulain, JC; Menez, A; Ducancel, F				Ricciardi, A; le Du, MH; Khayati, M; Dajas, F; Boulain, JC; Menez, A; Ducancel, F			Do structural deviations between toxins adopting the same fold reflect functional differences?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NUCLEAR-MAGNETIC-RESONANCE; 3-DIMENSIONAL SOLUTION STRUCTURE; MAMBA SNAKE-VENOM; CRYSTAL-STRUCTURE; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; DENDROASPIS-ANGUSTICEPS; ACETYLCHOLINE-RECEPTOR; CURAREMIMETIC TOXIN	Three-finger proteins form a structurally related family of compounds that exhibit a great variety of biological properties. To address the question of the prediction of functional. areas on their surfaces, we tentatively conferred the acetylcholinesterase inhibitory activity of fasciculins on a short-chain curaremimetic toxin. For this purpose, we assimilated the three-dimensional structure of fasciculin 2 with the one of toxin a. This comparison revealed that the tips of the first and second loops, together with the C terminus residue, deviated most. A first recombinant fasciculin/toxin a chimera was designed by transferring loop 1 in its entirety together with the tip of loop 2 of fasciculin 2 into the toxin a scaffold. A second chimera (rChII) was obtained by adding the point Asn-61 --> Tyr substitution. Comparison of functional and structural properties of both chimeras show that rChII can accommodate the imposed modifications and displays nearly all the acetylcholinesterase-blocking activities of fasciculins. The three-dimensional structure of rChII demonstrates that rChII adopts a typical three-fingered fold with structural features of both parent toxins. Taken together, these results emphasize the great structural flexibility and functional adaptability of that fold and confirm that structural deviations between fasciculins and short-chain neurotoxins do indeed reflect functional diversity.	Clemente Estable, Inst Invest Biol, Montevideo 11600, Uruguay; CE Saclay, Commissariat Energie Atom, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France	Instituto de Investigaciones Biologicas Clemente Estable Uruguay; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay	Ricciardi, A (corresponding author), Clemente Estable, Inst Invest Biol, Montevideo 11600, Uruguay.							ALBRAND JP, 1995, BIOCHEMISTRY-US, V34, P5923, DOI 10.1021/bi00017a022; BETZEL C, 1991, J BIOL CHEM, V266, P21530; BouhaoualaZahar B, 1996, EUR J BIOCHEM, V238, P653, DOI 10.1111/j.1432-1033.1996.0653w.x; BOULAIN JC, 1982, SCIENCE, V217, P732, DOI 10.1126/science.7100919; BOULAIN JC, 1982, BIOCHEMISTRY-US, V21, P2910, DOI 10.1021/bi00541a016; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; BOYOT P, 1990, FEBS LETT, V266, P87, DOI 10.1016/0014-5793(90)81513-N; BROWN LR, 1992, J MOL BIOL, V227, P1118, DOI 10.1016/0022-2836(92)90525-O; CERVENANSKY C, 1991, SNAKE TOXINS, P302; Chang C.C., 1979, SNAKE VENOMS, P309; CORNISHB.A, 1974, BIOCHEM J, V137, P143, DOI 10.1042/bj1370143; DANSE JM, 1994, FEBS LETT, V356, P153, DOI 10.1016/0014-5793(94)01235-0; DEWAN JC, 1994, BIOCHEMISTRY-US, V33, P13147, DOI 10.1021/bi00248a026; DIXON M, 1972, BIOCHEM J, V129, P197, DOI 10.1042/bj1290197; Drakopoulou E, 1996, J BIOL CHEM, V271, P11979, DOI 10.1074/jbc.271.20.11979; Drevet P, 1997, PROTEIN EXPRES PURIF, V10, P293, DOI 10.1006/prep.1997.0740; Ducancel F., 1991, P385; Ducancel F, 1996, J BIOL CHEM, V271, P31345, DOI 10.1074/jbc.271.49.31345; DUCANCEL F, 1989, PROTEIN ENG, V3, P139, DOI 10.1093/protein/3.2.139; DUFTON MJ, 1984, J MOL EVOL, V20, P128, DOI 10.1007/BF02257373; DURAN R, 1994, BBA-GEN SUBJECTS, V1201, P381, DOI 10.1016/0304-4165(94)90066-3; EAKER DL, 1967, JPN J MICROBIOL, V11, P353, DOI 10.1111/j.1348-0421.1967.tb00356.x; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Endo T., 1991, P165; FIORDALISI JJ, 1994, BIOCHEMISTRY-US, V33, P3872, DOI 10.1021/bi00179a011; Guenneugues M, 1997, BIOCHEMISTRY-US, V36, P16097, DOI 10.1021/bi971293k; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HATANAKA H, 1994, J MOL BIOL, V240, P155, DOI 10.1006/jmbi.1994.1429; HODGSON D, 1993, EUR J BIOCHEM, V212, P441, DOI 10.1111/j.1432-1033.1993.tb17680.x; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; Le Du MH, 2000, J MOL BIOL, V296, P1017; LeDu MH, 1996, ACTA CRYSTALLOGR D, V52, P87, DOI 10.1107/S0907444995007517; LEDU MH, 1992, J BIOL CHEM, V267, P22122; Lobeck K, 1998, INFECT IMMUN, V66, P418, DOI 10.1128/IAI.66.2.418-423.1998; Masson P, 1996, EUR J BIOCHEM, V235, P36, DOI 10.1111/j.1432-1033.1996.00036.x; MENEZ A, 1993, POUR SCI, V190, P34; MENEZ A, 1992, ADV DRUG DISCOVERY, P83; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; Ohno M, 1998, PROG NUCLEIC ACID RE, V59, P307; OSWALD RE, 1991, BIOCHEMISTRY-US, V30, P4901, DOI 10.1021/bi00234a010; PILLET L, 1993, J BIOL CHEM, V268, P909; RODRIGUEZITHURRALDE D, 1983, NEUROCHEM INT, V5, P267, DOI 10.1016/0197-0186(83)90028-1; Ruoppolo M, 1998, BIOCHEMISTRY-US, V37, P16060, DOI 10.1021/bi981492j; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SEGALAS I, 1995, BIOCHEMISTRY-US, V34, P1248, DOI 10.1021/bi00004a019; Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279; Servent D, 1998, TOXICOL LETT, V103, P199, DOI 10.1016/S0378-4274(98)00307-5; STRYDOM DJ, 1979, SNAKE VENOMS HDB EXP, V52, P159; TREMEAU O, 1986, FEBS LETT, V208, P236, DOI 10.1016/0014-5793(86)81024-9; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; Vita C, 1997, CURR OPIN BIOTECH, V8, P429, DOI 10.1016/S0958-1669(97)80064-X; Vozza LA, 1996, BIO-TECHNOL, V14, P77, DOI 10.1038/nbt0196-77; WALKINSHAW MD, 1980, P NATL ACAD SCI-BIOL, V77, P2400, DOI 10.1073/pnas.77.5.2400; WEBER M, 1974, MOL PHARMACOL, V10, P1; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011; ZINNJUSTIN S, 1994, PROTEIN ENG, V7, P917, DOI 10.1093/protein/7.7.917	58	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18302	18310		10.1074/jbc.275.24.18302	http://dx.doi.org/10.1074/jbc.275.24.18302			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849442	hybrid			2022-12-25	WOS:000087659400055
J	Gornikiewicz, A; Sautner, T; Brostjan, C; Schmierer, B; Fugger, R; Roth, E; Muhlbacher, F; Bergmann, M				Gornikiewicz, A; Sautner, T; Brostjan, C; Schmierer, B; Fugger, R; Roth, E; Muhlbacher, F; Bergmann, M			Catecholamines up-regulate lipopolysaccharide-induced IL-6 production in human microvascular endothelial cells	FASEB JOURNAL			English	Article						immunomodulation; transcription; adrenoreceptors	TUMOR-NECROSIS-FACTOR; ANTIINFLAMMATORY CYTOKINE; INTERLEUKIN-10 PRODUCTION; MONONUCLEAR-CELLS; GROWTH-FACTOR; WHOLE-BLOOD; CYCLIC-AMP; SEPSIS; ENDOTOXEMIA; EXPRESSION	The catecholamine-mediated modulation of the cytokine network has primarily been demonstrated for leukocytes, Whereas catecholamines decrease the LPS-induced production of IL-6 by leukocytes, serum levels of IL-6 are dramatically increased by the catecholamine epinephrine in animal endotoxemia models. We now demonstrate that epinephrine as well as norepinephrine can induce IL-6 in an endothelial cell line (HMEC-1). Furthermore, these catecholamines could even potentiate the LPS-induced IL-5 protein production. The synergistic effect of catecholamines and LPS could be reproduced in primary human skin microvascular endothelial cells. The catecholamine-induced IL-6 stimulation is based on increased IL-6 mRNA levels. RNA stability assays revealed that this regulation is not a result of enhanced RNA stability and therefore is most likely due to an increased transcription. Treatment with cycloheximide indicated that new protein synthesis is not necessary for this transcriptional up-regulation of IL-6 mRNA Preincubation with alpha and beta receptor antagonists showed that the effect is mediated by beta(1)- and beta(2)-adrenergic receptors. Thus, endothelial cells might be a possible source of increased IL-6 production observed in situations such as stress or septic shock, in which catecholamines are elevated due to endogenous production or exogenous application.-Gonlikiewicz, A., Sautner, T., Brostjan, C., Schmierer, B., Fugger, R., Roth, E., Muhlbacher, F., Bergmann, M. Catecholamines up-regulate lipopolysaccharide-induced IL-6 production in human microvascular endothelial cells.	Univ Vienna, Dept Surg, A-1090 Vienna, Austria	University of Vienna	Bergmann, M (corresponding author), Univ Vienna, Dept Surg, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	Michael.Bergmann@akh-wien.ac.at	Schmierer, Bernhard/C-1416-2009; Schmierer, Bernhard/P-4208-2019; Sautner, Thomas/AAQ-8899-2021; Bergmann, Michael/GZK-7700-2022	Schmierer, Bernhard/0000-0002-9082-7022; Schmierer, Bernhard/0000-0002-9082-7022; Sautner, Thomas/0000-0003-0033-3414; Bergmann, Michael/0000-0001-8529-1166; Brostjan, Christine/0000-0003-1462-5397				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Bergmann M, 1999, SHOCK, V12, P421, DOI 10.1097/00024382-199912000-00002; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; DERIJK RH, 1994, PSYCHONEUROENDOCRINO, V19, P155, DOI 10.1016/0306-4530(94)90005-1; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; ERTEL W, 1995, BLOOD, V85, P1341, DOI 10.1182/blood.V85.5.1341.bloodjournal8551341; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HACK CE, 1989, BLOOD, V74, P1704; JIRIK FR, 1989, J IMMUNOL, V142, P144; LeTulzo Y, 1997, J CLIN INVEST, V99, P1516, DOI 10.1172/JCI119314; LIAO JF, 1995, AM J PHYSIOL-REG I, V268, pR896, DOI 10.1152/ajpregu.1995.268.4.R896; MALEFYT RD, 1991, J EXP MED, V174, P1209; MARCHANT A, 1994, LANCET, V343, P707, DOI 10.1016/S0140-6736(94)91584-9; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; NehlsenCannarella SL, 1997, J APPL PHYSIOL, V82, P1662, DOI 10.1152/jappl.1997.82.5.1662; Papanicolaou DA, 1996, AM J PHYSIOL-ENDOC M, V271, pE601; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; SCHINDLER R, 1990, BLOOD, V75, P40; SEVERN A, 1992, J IMMUNOL, V148, P3441; STEININGER R, 1994, TRANSPLANTATION, V58, P179, DOI 10.1097/00007890-199407270-00008; Szabo C, 1997, IMMUNOLOGY, V90, P95, DOI 10.1046/j.1365-2567.1997.00137.x; THIJS LG, 1995, INTENS CARE MED, V21, pS258, DOI 10.1007/BF01740764; TILG H, 1994, BLOOD, V83, P113; Tilg H, 1997, IMMUNOL TODAY, V18, P428, DOI 10.1016/S0167-5699(97)01103-1; vanderPoll T, 1997, J INFECT DIS, V175, P118, DOI 10.1093/infdis/175.1.118; VANDERPOLL T, 1994, INFECT IMMUN, V62, P2046, DOI 10.1128/IAI.62.5.2046-2050.1994; vanderPoll T, 1996, J CLIN INVEST, V97, P713, DOI 10.1172/JCI118469; Volk HD, 1996, INTENS CARE MED, V22, pS474, DOI 10.1007/BF01743727; Zeni F, 1997, CRIT CARE MED, V25, P1095, DOI 10.1097/00003246-199707000-00001	32	60	68	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1093	1100		10.1096/fasebj.14.9.1093	http://dx.doi.org/10.1096/fasebj.14.9.1093			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834930				2022-12-25	WOS:000087427300005
J	Lassus, P; Roux, P; Zugasti, O; Philips, A; Fort, P; Hibner, U				Lassus, P; Roux, P; Zugasti, O; Philips, A; Fort, P; Hibner, U			Extinction of Rac1 and Cdc42Hs signalling defines a novel p53-dependent apoptotic pathway	ONCOGENE			English	Article						Rac1; Cdc42Hs; adhesion; apoptosis; p53; MAPK	NF-KAPPA-B; WISKOTT-ALDRICH SYNDROME; CELL-DEATH; SIGNALING PATHWAY; ACTIN-CYTOSKELETON; GTPASE CDC42HS; ONCOGENIC RAS; P53; PROTEIN; KINASE	Apoptosis is a normal physiological process which eliminates cells that do not receive adequate extracellular signals. One of the pathways signalling apoptosis is controlled by the small GTPases of the Rho family, also involved in cell proliferation, differentiation and motility, Another major apoptosis signalling pathway involves the p53 tumour suppressor which is activated by a variety of stress and mediates growth arrest or apoptosis in normal cells. We show here that upon detachment from the extracellular matrix, fibroblasts undergo rapid apoptosis that can be rescued by constitutive activation of Rad and Cdc42Hs GTPases, Conversely, inhibition of Rad and Cdc42Hs efficiently triggers apoptosis in adherent cells. Interestingly, apoptosis is not observed in p53(-/-) cells either cultured in suspension or inhibited for Rad and Cdc42Hs activity. Moreover, Rad and Cdc42Hs extinction in normal cells activates endogenous p53, Using specific inhibitors of MAPK pathways, we demonstrate that, in our experimental system, p38 signals survival, while ERK activity is required for apoptosis, Our data constitute the first demonstration that Rad and Cdc42Hs control pathways that require simultaneous signalling through MAPK ERK and p53 to induce apoptosis.	Inst Genet Mol, CNRS, UMR5535, IFR 24, F-34293 Montpellier 5, France; Ctr Rech Biochim Macromol, CNRS, UPR1086, IFR 24, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Hibner, U (corresponding author), Inst Genet Mol, CNRS, UMR5535, IFR 24, 1919 Route Mende, F-34293 Montpellier 5, France.		PHILIPS, Alexandre/AAB-6047-2020; Zugasti, Olivier/P-1352-2017; Roux, Pierre/D-8833-2017; Fort, Philippe/M-9498-2015	Fort, Philippe/0000-0001-5997-8722; Zugasti, Olivier/0000-0002-5616-734X; Lassus, Patrice/0000-0002-2785-7843; Hibner, Urszula/0000-0002-5520-7311				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Donovan FM, 1997, J NEUROSCI, V17, P5316; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dutartre H, 1996, J CELL SCI, V109, P367; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Fort P, 1999, Prog Mol Subcell Biol, V22, P159; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Jimenez LA, 1997, AM J PHYSIOL-LUNG C, V273, pL1029, DOI 10.1152/ajplung.1997.273.5.L1029; Joneson T, 1999, MOL CELL BIOL, V19, P5892; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lassus P, 1998, NUCLEIC ACIDS RES, V26, P5233, DOI 10.1093/nar/26.22.5233; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moorman JP, 1996, J IMMUNOL, V156, P4146; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Ozes ON, 1999, NATURE, V401, P82; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	54	35	37	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2377	2385		10.1038/sj.onc.1203553	http://dx.doi.org/10.1038/sj.onc.1203553			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828879				2022-12-25	WOS:000087018400002
J	Gunnewijk, MGW; Poolman, B				Gunnewijk, MGW; Poolman, B			HPr(His similar to P)-mediated phosphorylation differently affects counterflow and proton motive force-driven uptake via the lactose transport protein of Streptococcus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; ATP-DEPENDENT PHOSPHORYLATION; PHOSPHOCARRIER PROTEIN; ESCHERICHIA-COLI; CATABOLITE REPRESSION; LACTOBACILLUS-BREVIS; SERYL RESIDUE; HPR; PHOSPHOENOLPYRUVATE; RECONSTITUTION	The lactose transport protein (LacS) of Streptococcus thermophilus has a G-terminal hydrophilic domain that is homologous to IIA protein and protein domains of the phosphoenolpyruvate:carbohydrate phosphotransferase system (PTS). The IIA domain of LacS is phosphorylated on His-552 by the general energy coupling proteins of the PTS, which are Enzyme I and HPr. To study the effect of phosphorylation on transport, the LacS protein was purified and incorporated into liposomes with the IIA domain facing outwards. This allowed the phosphorylation of the membrane-reconstituted protein by purified HPr(His similar toP) of S. thermophilus. Phosphorylation of LacS increased the V-max of counterflow transport, whereas the V-max of the proton motive force (Deltap)-driven lactose uptake was not affected. In line with a range of kinetic studies, we propose that phosphorylation affects the rate constants for the reorientation of the ternary complex (LacS with bound lactose plus proton), which is rate-determining for counterflow but not for Deltap-driven transport.	Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen	Poolman, B (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Poolman, Bert/D-1882-2012					DASHPER SG, 1994, BIOCHEM BIOPH RES CO, V199, P1297, DOI 10.1006/bbrc.1994.1372; DEUTSCHER J, 1983, P NATL ACAD SCI-BIOL, V80, P6790, DOI 10.1073/pnas.80.22.6790; DEUTSCHER J, 1985, J BACTERIOL, V163, P1203, DOI 10.1128/JB.163.3.1203-1209.1985; FOUCAUD C, 1992, J BIOL CHEM, V267, P22087; Galinier A, 1998, P NATL ACAD SCI USA, V95, P1823, DOI 10.1073/pnas.95.4.1823; Galinier A, 1997, P NATL ACAD SCI USA, V94, P8439, DOI 10.1073/pnas.94.16.8439; Gunnewijk MGW, 2000, J BIOL CHEM, V275, P34073, DOI 10.1074/jbc.M003512200; Gunnewijk MGW, 1999, J BACTERIOL, V181, P632, DOI 10.1128/JB.181.2.632-641.1999; Hoischen C, 1996, J BACTERIOL, V178, P6082, DOI 10.1128/jb.178.20.6082-6086.1996; Knol J, 1998, BIOCHEMISTRY-US, V37, P16410, DOI 10.1021/bi981596u; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; NELSON SO, 1983, EMBO J, V2, P715, DOI 10.1002/j.1460-2075.1983.tb01490.x; OSUMI T, 1982, P NATL ACAD SCI-BIOL, V79, P1457, DOI 10.1073/pnas.79.5.1457; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; POOLMAN B, 1995, P NATL ACAD SCI USA, V92, P778, DOI 10.1073/pnas.92.3.778; POOLMAN B, 1995, J BIOL CHEM, V270, P12995, DOI 10.1074/jbc.270.22.12995; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; ROBILLARD GT, 1987, BIOCHEMISTRY-US, V26, P5796, DOI 10.1021/bi00392a032; Sambrook J., 2002, MOL CLONING LAB MANU; VADEBONCOEUR C, 1991, BIOCHIMIE, V73, P1427, DOI 10.1016/0300-9084(91)90174-Y; VADEBONCOEUR C, 1995, RES MICROBIOL, V146, P525, DOI 10.1016/0923-2508(96)80558-4; Veenhoff LM, 1999, J BIOL CHEM, V274, P33244, DOI 10.1074/jbc.274.47.33244; WEIGEL N, 1982, J BIOL CHEM, V257, P4499; YE JJ, 1994, P NATL ACAD SCI USA, V91, P3102, DOI 10.1073/pnas.91.8.3102; YE JJ, 1994, J BACTERIOL, V176, P3484, DOI 10.1128/JB.176.12.3484-3492.1994	25	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34080	34085		10.1074/jbc.M003513200	http://dx.doi.org/10.1074/jbc.M003513200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10842178	Green Published, hybrid			2022-12-25	WOS:000165095300014
J	Dunphy, JL; Balic, A; Barcham, GJ; Horvath, AJ; Nash, AD; Meeusen, ENT				Dunphy, JL; Balic, A; Barcham, GJ; Horvath, AJ; Nash, AD; Meeusen, ENT			Isolation and characterization of a novel inducible mammalian galectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEYDEN CRYSTAL PROTEIN; ENDOGENOUS LECTIN; BINDING PROTEIN; ANIMAL LECTIN; ACTIVATION; FAMILY; CELLS; GENE; RNA; LYSOPHOSPHOLIPASE	A novel mammalian galectin cDNA (ovgal11) was isolated by representational difference analysis from sheep stomach (abomasal) tissue infected with the nematode parasite, Haemonchus contortus. The mRNA is greatly up-regulated in helminth larval infected gastrointestinal tissue subject to inflammation and eosinophil infiltration. Immunohistological analysis indicates that the protein is localized in the cytoplasm and nucleus of upper epithelial cells of the gastrointestinal tract. The protein is also detected in mucus samples collected from infected abomasum but not from uninfected tissue. The restricted and inducible expression of ovgal11 mRNA and limited secretion of the protein support the hypothesis that OVGAL11 may be involved in gastrointestinal immune/inflammatory responses and possibly protection against infection.	Univ Melbourne, Sch Vet Sci, Ctr Anim Biotechnol, Parkville, Vic 3010, Australia; AMRAD Operat Propietary Ltd, Burnley, Vic 3121, Australia	University of Melbourne	Meeusen, ENT (corresponding author), Univ Melbourne, Sch Vet Sci, Ctr Anim Biotechnol, Parkville, Vic 3010, Australia.		Balic, Adam/C-7718-2013	Meeusen, Els/0000-0003-1239-6287				ACKERMAN SJ, 1993, J IMMUNOL, V150, P456; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Balic A, 2000, VET IMMUNOL IMMUNOP, V75, P109, DOI 10.1016/S0165-2427(00)00189-6; Balic A, 2000, ADV PARASIT, V45, P181, DOI 10.1016/S0065-308X(00)45005-0; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; Bresalier RS, 1996, CANCER RES, V56, P4354; CHO MJ, 1995, J BIOL CHEM, V270, P5207, DOI 10.1074/jbc.270.10.5207; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colnot C, 1998, IMMUNOLOGY, V94, P290, DOI 10.1046/j.1365-2567.1998.00517.x; Danielsen EM, 1997, MOL BIOL CELL, V8, P2241, DOI 10.1091/mbc.8.11.2241; Dyer KD, 1997, GENOMICS, V40, P217, DOI 10.1006/geno.1996.4590; Dyer KD, 1996, LIFE SCI, V58, P2073, DOI 10.1016/0024-3205(96)00201-9; Fourney R.M., 1988, FOCUS, V10, P5; Gitt MA, 1998, J BIOL CHEM, V273, P2961, DOI 10.1074/jbc.273.5.2961; Greenhalgh CJ, 1996, IMMUNOL CELL BIOL, V74, P497, DOI 10.1038/icb.1996.82; Harrison GBL, 1999, INT J PARASITOL, V29, P459, DOI 10.1016/S0020-7519(98)00221-5; HSU DK, 1992, J BIOL CHEM, V267, P14167; HU L, 1994, J BIOL CHEM, V269, P183; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; JENG KCG, 1994, IMMUNOL LETT, V42, P113, DOI 10.1016/0165-2478(94)90072-8; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; Leonidas DD, 1995, STRUCTURE, V3, P1379, DOI 10.1016/S0969-2126(01)00275-1; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Matsumoto R, 1998, J BIOL CHEM, V273, P16976, DOI 10.1074/jbc.273.27.16976; Mehul B, 1997, J CELL SCI, V110, P1169; NAWA Y, 1994, PARASITE IMMUNOL, V16, P333, DOI 10.1111/j.1365-3024.1994.tb00358.x; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; Pfeffer A, 1996, INT J PARASITOL, V26, P765, DOI 10.1016/0020-7519(96)00052-5; RAIMOND J, 1995, FEBS LETT, V363, P165, DOI 10.1016/0014-5793(95)00310-6; Rainbird MA, 1998, PARASITE IMMUNOL, V20, P93, DOI 10.1046/j.1365-3024.1998.00132.x; Salamov AA, 1998, BIOINFORMATICS, V14, P384, DOI 10.1093/bioinformatics/14.5.384; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; Stylianou E, 1998, INT J BIOCHEM CELL B, V30, P1075, DOI 10.1016/S1357-2725(98)00081-8; Tate WP, 1995, BIOCHEM CELL BIOL, V73, P1095, DOI 10.1139/o95-118; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUONG MJ, 1993, J EXP MED, V177, P243, DOI 10.1084/jem.177.1.243; Vasta GR, 1999, DEV COMP IMMUNOL, V23, P401, DOI 10.1016/S0145-305X(99)00020-8; Vyakarnam A, 1998, EXP CELL RES, V242, P419, DOI 10.1006/excr.1998.4111; Vyakarnam A, 1997, MOL CELL BIOL, V17, P4730, DOI 10.1128/MCB.17.8.4730; WANG L, 1995, BIOCHEM BIOPH RES CO, V217, P292, DOI 10.1006/bbrc.1995.2777; Wasano K, 1997, J HISTOCHEM CYTOCHEM, V45, P275, DOI 10.1177/002215549704500212; YAMAOKA A, 1995, J IMMUNOL, V154, P3479	42	83	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					32106	32113		10.1074/jbc.M003739200	http://dx.doi.org/10.1074/jbc.M003739200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10851241	hybrid			2022-12-25	WOS:000089858900076
J	Eriksson, P; Alipour, H; Adler, L; Blomberg, A				Eriksson, P; Alipour, H; Adler, L; Blomberg, A			Rap1p-binding sites in the Saccharomyces cerevisiae GPD1 promoter are involved in its response to NaCl	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-EFFICIENCY TRANSFORMATION; DNA-BINDING DOMAIN; MAP KINASE CASCADE; 0.7 M NACL; OSMOTIC-STRESS; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; CHLORAMPHENICOL ACETYLTRANSFERASE; PROTEIN EXPRESSION; SHUTTLE VECTORS; GENE-EXPRESSION	Mechanisms involved in transcriptional regulation of the osmotically controlled GPD1 gene in Saccharomyces cerevisiae were investigated by promoter analysis. The GPD1 gene encodes NAD(+)-dependent glycerol-3-phosphate dehydrogenase, a key enzyme in the production of the compatible solute glycerol. By analysis of promoter deletions, we identified a region at nucleotides -478 to -324, in relation to start of translation, to be of great importance for both basal activity and osmotic induction of GPD1. Electrophoretic mobility shift and DNase I footprint analyses demonstrated protein binding to parts of this region that contain three consensus sequences for Rap1p (repressor activator protein 1)-binding sites. Actual binding of Rap1p to this region was confirmed by demonstrating enhanced electrophoretic mobility of the protein-DNA complex with extracts containing an N-terminally truncated version of Rap1p. The detected Rap1p-DNA interactions were not affected by changes in the osmolarity of the growth medium. Specific inactivation of the Rap1p-binding sites by a C-to-A point mutation in the core of the consensus showed that this factor is a major determinant of GPD1 expression since mutations in all three putative binding sites for Rap1p strongly hampered osmotic induction and drastically lowered basal activity. We also show that the Rap1p-binding sites appear functionally distinct; the most distal site (core of the consensus at position -386) exhibited the highest affinity for Rap1p and was strictly required for low salt induction (less than or equal to 0.6 M NaCl), but not for the response at higher salinities (greater than or equal to 0.8 M NaCl). This indicates that different molecular mechanisms might be operational for low and high salt responses of the GPD1 promoter.	Gothenburg Univ, Lundberg Lab, Dept Cell & Mol Biol Microbiol, S-41390 Gothenburg, Sweden	University of Gothenburg	Blomberg, A (corresponding author), Gothenburg Univ, Lundberg Lab, Dept Cell & Mol Biol Microbiol, Medicinaregat 9C, S-41390 Gothenburg, Sweden.	anders.blomberg@gmm.gu.se						Akhtar N, 1997, FEBS LETT, V403, P173, DOI 10.1016/S0014-5793(97)00048-3; ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Alipour H, 1999, ANAL BIOCHEM, V270, P153, DOI 10.1006/abio.1999.4069; ANDRE L, 1991, FEBS LETT, V286, P13, DOI 10.1016/0014-5793(91)80930-2; AUSUBEL FM, 1996, CURRENT PROTOCOLS MO, V1; BAKER HV, 1991, P NATL ACAD SCI USA, V88, P9443, DOI 10.1073/pnas.88.21.9443; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BLOMBERG A, 1989, J BACTERIOL, V171, P1087, DOI 10.1128/jb.171.2.1087-1092.1989; BLOMBERG A, 1995, J BACTERIOL, V177, P3563, DOI 10.1128/jb.177.12.3563-3572.1995; Blomberg A., 1993, STRESS TOLERANCE FUN, P209; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; EDGLEY M, 1983, J GEN MICROBIOL, V129, P3453; ERIKSSON P, 1995, MOL MICROBIOL, V17, P95, DOI 10.1111/j.1365-2958.1995.mmi_17010095.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; GRAHAM IR, 1994, NUCLEIC ACIDS RES, V22, P124, DOI 10.1093/nar/22.2.124; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; HIRAYAMA T, 1995, MOL GEN GENET, V249, P127, DOI 10.1007/BF00290358; Hohmann S., 1997, YEAST STRESS RESPONS, P101; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MANNHAUPT G, 1988, GENE, V67, P287, DOI 10.1016/0378-1119(88)90405-2; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; Marquez JA, 1998, EMBO J, V17, P2543, DOI 10.1093/emboj/17.9.2543; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MIRALLES VJ, 1995, MOL MICROBIOL, V17, P653, DOI 10.1111/j.1365-2958.1995.mmi_17040653.x; Norbeck J, 1996, FEMS MICROBIOL LETT, V137, P1; Norbeck J, 2000, YEAST, V16, P121, DOI 10.1002/(SICI)1097-0061(20000130)16:2<121::AID-YEA511>3.0.CO;2-A; Norbeck J, 1997, J BIOL CHEM, V272, P5544, DOI 10.1074/jbc.272.9.5544; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; Proft M, 1999, MOL CELL BIOL, V19, P537; Rep M, 1999, MICROBIOL-UK, V145, P715, DOI 10.1099/13500872-145-3-715; Rep M, 1999, MOL CELL BIOL, V19, P5474; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; SCHULLER HJ, 1994, EUR J BIOCHEM, V225, P213, DOI 10.1111/j.1432-1033.1994.00213.x; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SIKORSKI RS, 1989, GENETICS, V122, P19; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TORNOW J, 1993, EMBO J, V12, P2431, DOI 10.1002/j.1460-2075.1993.tb05897.x; TROLLMO C, 1988, FEMS MICROBIOL LETT, V56, P321, DOI 10.1016/0378-1097(88)90082-1; Uemura H, 1997, GENETICS, V147, P521; VARELA JCS, 1995, MOL CELL BIOL, V15, P6232; Yu LN, 1999, MOL CELL BIOL, V19, P5279	49	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29368	29376		10.1074/jbc.M001663200	http://dx.doi.org/10.1074/jbc.M001663200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10842169	hybrid			2022-12-25	WOS:000089439800027
J	Oka, T; Futai, M				Oka, T; Futai, M			Requirement of V-ATPase for ovulation and embryogenesis in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; MOLECULAR-CLONING; GENE; CELL; EXPRESSION; OOCYTE; ACIDIFICATION; PROTEOLIPIDS; MUTATIONS; SUBUNIT	Immunofluorescence analysis indicated that VHA-11, the C subunit of Caenorhabditis elegans V-ATPase, was localized in dot-like structures around the nuclei of early embryonic cells and was also detected in embryonic intestinal cells after comma stage. Vital staining with acridine orange showed that the intestinal cells had acidic compartments generated by V-ATPase, consistent with the intracellular localization of VHA-11. RNA interference could efficiently silence vha-ll gene expression: introduction of vha-ll double strand RNA led to embryonic lethality. Worms injected with the vha-11 double strand RNA produced embryos that became lethal. The development of embryos was arrested at various stages. However, their numbers gradually decreased, and the worms eventually became sterile due to the failure of ovulation. Similar results were obtained for RNA interference of the V-ATPase proteolipid genes. These results suggest that V-ATPases, and thus inside-acidic organelles, are required for ovulation and embryogenesis.	Osaka Univ, Japan Sci & TEchnol Corp, CREST, Inst Sci & Ind Res,Div Biol Sci, Osaka 5670047, Japan	Japan Science & Technology Agency (JST); Osaka University	Futai, M (corresponding author), Osaka Univ, Japan Sci & TEchnol Corp, CREST, Inst Sci & Ind Res,Div Biol Sci, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp						BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; Breton S, 1996, NAT MED, V2, P470, DOI 10.1038/nm0496-470; Brown D, 2000, J EXP BIOL, V203, P137; CLOKEY GV, 1986, MECH AGEING DEV, V35, P79, DOI 10.1016/0047-6374(86)90068-0; FAGOTTO F, 1994, J CELL BIOL, V125, P1047, DOI 10.1083/jcb.125.5.1047; FINBOW ME, 1994, J CELL SCI, V107, P1817; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Forgac M, 2000, J EXP BIOL, V203, P71; Futai M, 2000, J EXP BIOL, V203, P107; Graham LA, 2000, J EXP BIOL, V203, P61; Grant B, 1999, MOL BIOL CELL, V10, P4311, DOI 10.1091/mbc.10.12.4311; GREENSTEIN D, 1994, GENE DEV, V8, P1935, DOI 10.1101/gad.8.16.1935; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; HASEBE M, 1992, BIOCHEM BIOPH RES CO, V183, P856, DOI 10.1016/0006-291X(92)90562-Y; Iwasaki K, 1996, J CELL BIOL, V134, P699, DOI 10.1083/jcb.134.3.699; KEMPHUES KJ, 1997, C ELEGANS, V0002, P00335; MELLMAN I, 1992, J EXP BIOL, V172, P39; Moriyama Y, 2000, J EXP BIOL, V203, P117; Myers CD, 1996, J CELL BIOL, V132, P1061, DOI 10.1083/jcb.132.6.1061; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; Oka T, 1998, J BIOL CHEM, V273, P22570, DOI 10.1074/jbc.273.35.22570; Oka T, 1997, J BIOL CHEM, V272, P24387, DOI 10.1074/jbc.272.39.24387; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; SCHEDL T, 1997, C ELEGANS, V2, P241; Sulston J., 1988, NEMATODE CAENORHABDI, P587; TOYAMA R, 1991, YEAST, V7, P989, DOI 10.1002/yea.320070911; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; Wallace R A, 1985, Dev Biol (N Y 1985), V1, P127; WHITE J, 1998, NEMATODE CAENORHABDI, P81; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	33	56	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29556	29561		10.1074/jbc.M002756200	http://dx.doi.org/10.1074/jbc.M002756200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10846178	hybrid			2022-12-25	WOS:000089439800051
J	Swaminathan, CP; Gupta, A; Surolia, N; Surolia, A				Swaminathan, CP; Gupta, A; Surolia, N; Surolia, A			Plasticity in the primary binding site of galactose/N-acetylgalactosamine-specific lectins - Implication of the C-H center dot center dot center dot O hydrogen bond at the specificity-determining C-4 locus of the saccharide in 4-methoxygalactose recognition by jacalin and winged bean (basic) agglutinin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSOPHOCARPUS-TETRAGONOLOBUS; CRYSTALLOGRAPHIC EVIDENCE; CARBOHYDRATE-RECOGNITION; PROTEINS; DYNAMICS; DESIGN; H...O; DNA	It is currently believed that an unsubstituted axial hydroxyl at the specificity-determining C-4 locus of galactose is indispensable for recognition by galactose/N-acetylgalactosamine-specific lectins. Titration calorimetry demonstrates that 4-methoxygalactose retains binding allegiance to the Moraceae lectin jacalin and the Leguminosae lectin, winged bean (basic) agglutinin (WBA I). The binding reactions were driven by dominant favorable enthalpic contributions and exhibited significant enthalpy-entropy compensation. Proton NMR titration of C-methoxygalactose with jacalin and WBA I resulted in broadening of the sugar resonances without any change in chemical shift. The alpha-and beta-anomers of 4-methoxygalactose were found to be in slow exchange with free and lectin-bound states. Both the anomers experience magnetically equivalent environments at the respective binding sites. The binding constants derived from the dependence of NMR line widths on 4-methoxygalactose concentration agreed well with those obtained from titration calorimetry. The results unequivocally demonstrate that the loci corresponding to the axially oriented C-4 hydroxyl group of galactose within the primary binding site of these lectins exhibit plasticity. These analyses suggest, for the first time, the existence of C-H ... O-type hydrogen-bond(s) in protein-carbohydrate interactions in general and between the C-4 locus of galactose derivative and the lectins jacalin and WBA I in particular.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.	surolia@mbu.iisc.ernet.in	SUROLIA, AVADESHA/C-5442-2009					Bella J, 1996, J MOL BIOL, V264, P734, DOI 10.1006/jmbi.1996.0673; Berger I, 1996, P NATL ACAD SCI USA, V93, P12116, DOI 10.1073/pnas.93.22.12116; Bond CS, 1999, STRUCTURE, V7, P81, DOI 10.1016/S0969-2126(99)80011-2; CASU B, 1968, TETRAHEDRON, V24, P803, DOI 10.1016/0040-4020(68)88030-5; Chakrabarti P, 1998, J MOL BIOL, V284, P867, DOI 10.1006/jmbi.1998.2199; Cooper A, 1999, CURR OPIN CHEM BIOL, V3, P557, DOI 10.1016/S1367-5931(99)00008-3; DEREWENDA ZS, 1995, J MOL BIOL, V252, P248, DOI 10.1006/jmbi.1995.0492; DEREWENDA ZS, 1994, J MOL BIOL, V241, P83, DOI 10.1006/jmbi.1994.1475; DESIRAJU GR, 1993, ACTA CRYSTALLOGR B, V49, P880, DOI 10.1107/S0108768193001703; Desiraju GR, 1996, ACCOUNTS CHEM RES, V29, P441, DOI 10.1021/ar950135n; Elgavish S, 1997, TRENDS BIOCHEM SCI, V22, P462, DOI 10.1016/S0968-0004(97)01146-8; Engh RA, 1996, STRUCTURE, V4, P1353, DOI 10.1016/S0969-2126(96)00142-6; Ghosh A, 1999, J MOL BIOL, V294, P1149, DOI 10.1006/jmbi.1999.3323; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; KHAN MI, 1986, J BIOL CHEM, V261, P3013; Kuduva SS, 1999, J AM CHEM SOC, V121, P1936, DOI 10.1021/ja981967u; Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g; Mandel-Gutfreund Y, 1998, J MOL BIOL, V277, P1129, DOI 10.1006/jmbi.1998.1660; Prabu MM, 1998, J MOL BIOL, V276, P787, DOI 10.1006/jmbi.1997.1568; RATHBONE EB, 1971, CARBOHYD RES, V20, P357, DOI 10.1016/S0008-6215(00)81390-7; Sankaranarayanan R, 1996, NAT STRUCT BIOL, V3, P596, DOI 10.1038/nsb0796-596; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; SASTRY MVK, 1988, J BIOL CHEM, V263, P14826; Sharma V, 1997, J MOL BIOL, V267, P433, DOI 10.1006/jmbi.1996.0863; SRINIVAS VR, 1998, CARBOHYDR LETT, V3, P129; Steiner T, 1998, CHEM COMMUN, P891, DOI 10.1039/a708099i; Swaminathan CP, 1998, J AM CHEM SOC, V120, P5153, DOI 10.1021/ja9733696; Swaminathan CP, 1997, BIOCHEMISTRY-US, V36, P13428, DOI 10.1021/bi970550i; SWIFT TJ, 1962, J CHEM PHYS, V37, P307, DOI 10.1063/1.1701321; TAYLOR R, 1982, J AM CHEM SOC, V104, P5063, DOI 10.1021/ja00383a012; Vijayan M, 1999, CURR OPIN STRUC BIOL, V9, P707, DOI 10.1016/S0959-440X(99)00034-2; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	33	13	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28483	28487		10.1074/jbc.M004685200	http://dx.doi.org/10.1074/jbc.M004685200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10837488	hybrid			2022-12-25	WOS:000089330700020
J	Ouzzine, M; Gulberti, S; Netter, P; Magdalou, J; Fournel-Gigleux, S				Ouzzine, M; Gulberti, S; Netter, P; Magdalou, J; Fournel-Gigleux, S			Structure/function of the human Gal beta 1,3-glucuronosyltransferase - Dimerization and functional activity are mediated by two crucial cysteine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; GLUCURONOSYLTRANSFERASE-I; MOLECULAR-CLONING; CARBOHYDRATE EPITOPE; GOLGI RETENTION; BIOSYNTHESIS; PROTEOGLYCANS; EXPRESSION; SULFATE; ENZYME	Gal beta 1,3-glucuronosyltransferase (GlcAT-I) that catalyzes the transfer of a glucuronic acid residue onto the trisaccharide primer of the glycosaminoglycan-protein Linkage region plays an essential role in the early steps of the biosynthesis of glycosaminoglycans. In order to gain insight into the structure/function of the enzyme, the human recombinant GlcAT-I was successfully expressed in the yeast Pichia pastoris, with an apparent molecular mass of 43 kDa, Analysis of the electrophoretic mobility of the membrane-bound protein in nonreducing and reducing conditions, together with cross-linking studies, indicated that the membrane-bound GlcAT-I formed active disulfide-linked dimers, GlcAT-I expressed without the predicted N-terminal cytoplasmic tail or secreted as a polypeptide lacking the cytoplasmic tail and transmembrane domain was similarly organized as dimers, suggesting that the structural determinants for the dimerization state are localized in the luminal domain of the protein. In addition, the role of Cys(33) and Cys(301) in that process was investigated by site-directed mutagenesis combined with chemical modification of GlcAT-I by N-phenylmaleimide. Replacement of Cys(33) with alanine abolished the formation of dimers with a concomitant decrease in the catalytic efficiency mainly due to a decrease in apparent maximal velocity and in affinity for UDP-glucuronic acid. On the other hand, N-phenylmaleimide treatment or alanine substitution of the Cys(301) residue inactivated the enzyme, Our study demonstrates that GlcAT-I is organized as a homodimer as a result of disulfide bond formation mediated by Cys(33) localized in the stem region, whereas the residue Cys(301) localized in a conserved C-terminal domain is strictly required for the functional integrity of the enzyme.	Univ Nancy 1, Fac Med, CNRS, UMR 7561, F-54505 Vandoeuvre Nancy, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine	Ouzzine, M (corresponding author), Univ Nancy 1, Fac Med, CNRS, UMR 7561, BP 184, F-54505 Vandoeuvre Nancy, France.		Ouzzine, Mohamed/G-4368-2013	OUZZINE, Mohamed/0000-0003-0058-4950; GULBERTI, Sandrine/0000-0002-9378-4697				Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; Glavas S, 1999, BIOCHEMISTRY-US, V38, P4106, DOI 10.1021/bi982663n; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; HELTING T, 1969, J BIOL CHEM, V244, P2799; HENION TR, 1994, GLYCOBIOLOGY, V4, P193, DOI 10.1093/glycob/4.2.193; Ikushiro S, 1997, BIOCHEMISTRY-US, V36, P7154, DOI 10.1021/bi9702344; Jaskiewicz E, 1996, GLYCOCONJUGATE J, V13, P213, DOI 10.1007/BF00731496; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; Ouzzine M, 1999, J BIOL CHEM, V274, P31401, DOI 10.1074/jbc.274.44.31401; PILLOT T, 1993, J BIOL CHEM, V268, P25636; Pless D, 1999, DRUG METAB DISPOS, V27, P588; POOLE AR, 1986, BIOCHEM J, V236, P1; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SALIMATH PV, 1995, J BIOL CHEM, V270, P9164, DOI 10.1074/jbc.270.16.9164; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Seiki T, 1999, BIOCHEM BIOPH RES CO, V255, P182, DOI 10.1006/bbrc.1999.0151; Sugumaran G, 1997, J BIOL CHEM, V272, P14399, DOI 10.1074/jbc.272.22.14399; Sugumaran G, 1998, BIOCHEM J, V329, P203, DOI 10.1042/bj3290203; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; TOLOV AA, 1990, NUCLEIC ACIDS RES, V18, P3983; Tone Y, 1999, FEBS LETT, V459, P415, DOI 10.1016/S0014-5793(99)01287-9; WANG WT, 1984, ANAL BIOCHEM, V141, P366, DOI 10.1016/0003-2697(84)90057-5; Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170	33	36	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28254	28260						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10842173				2022-12-25	WOS:000089197100096
J	Hatai, T; Matsuzawa, A; Inoshita, S; Mochida, Y; Kuroda, T; Sakamaki, K; Kuida, K; Yonehara, S; Ichijo, H; Takeda, K				Hatai, T; Matsuzawa, A; Inoshita, S; Mochida, Y; Kuroda, T; Sakamaki, K; Kuida, K; Yonehara, S; Ichijo, H; Takeda, K			Execution of apoptosis signal-regulating kinase 1 (ASK1)-induced apoptosis by the mitochondria-dependent caspase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C; PROTEIN-KINASE; TRANSDUCTION PATHWAYS; MICE LACKING; MAP KINASES; SURVIVAL; FAMILY; BCL-2; CASCADE	ASK1 activates JNK and p38 mitogen-activated protein kinases and constitutes a pivotal signaling pathway in cytokine- and stress-induced apoptosis. However, little is known about the mechanism of how ASK1 executes apoptosis. Here we investigated the roles of caspases and mitochondria in ASK1-induced apoptosis. We found that benzyloxycarbonyl-vaI-Ala-Asp-fluoromethyl ketone (zVAD-fmk), a broad-spectrum caspase inhibitor, mostly inhibited ASK1-induced cell death, suggesting that caspases are required for ASK1-induced apoptosis. Overexpression of ASK1 Delta N, a constitutively active mutant of ASK1, induced cytochrome c release from mitochondria and activation of caspase-9 and caspase-3 but not of caspase 8-like proteases. Consistently, caspase-8-deficient (Casp8 (-/-)) cells were sensitive to ASK1-induced caspase-3 activation and apoptosis, suggesting that caspase-8 is dispensable for ASK1-induced apoptosis, whereas ASK1 failed to activate caspase-3 in caspase-9-dificient (Casp9 (-/-)) cells. Moreover, mitochondrial cytochrome c release, which was not inhibited by zVAD-fmk, preceded the onset of caspase-3 activation and cell death induced by ASK1. ASK1 thus appears to execute apoptosis mainly by the mitochondria-dependent caspase activation.	Tokyo Med & Dent Univ, Dept Hard Tissue Engn, Div Biomatrix, Grad Sch,Lab Cell Signaling,Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Maxillofacial Reconstruct & Funct, Div Maxillofacial & Neck Reconstruct,Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Regulat Internal Environm & Reprod, Div System Organ Regulat,Bunkyo Ku, Tokyo 1138549, Japan; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Vertex Pharmaceut, Cambridge, MA 02139 USA; Kissei Pharmaceut Co Ltd, Cent Res Labs, Nagano 3998304, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Kyoto University; Vertex Pharmaceuticals; Kissei Pharmaceutical Co Ltd	Ichijo, H (corresponding author), Tokyo Med & Dent Univ, Dept Hard Tissue Engn, Div Biomatrix, Grad Sch,Lab Cell Signaling,Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.		Matsuzawa, Atsushi/GLU-1387-2022	Ichijo, Hidenori/0000-0002-5005-6438; Mochida, Yoshiyuki/0000-0002-2115-4303; Matsuzawa, Atsushi/0000-0001-8303-3905; Takeda, Kohsuke/0000-0002-8359-8399; Sakamaki, Kazuhiro/0000-0002-7072-9628				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bergmann A, 1998, ONCOGENE, V17, P3215, DOI 10.1038/sj.onc.1202586; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; CHRISTINE TR, 1999, NAT CELL BIOL, V1, P69; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Faris M, 1998, J IMMUNOL, V160, P134; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sakamaki K, 1998, EUR J BIOCHEM, V253, P399, DOI 10.1046/j.1432-1327.1998.2530399.x; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Takeda K, 2000, J BIOL CHEM, V275, P9805, DOI 10.1074/jbc.275.13.9805; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; ZHENG TS, 2000, IN PRESS NAT MED; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	45	282	299	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26576	26581		10.1074/jbc.M003412200	http://dx.doi.org/10.1074/jbc.M003412200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10849426	hybrid			2022-12-25	WOS:000088999700095
J	Klemperer, N; Zhang, D; Skangalis, M; O'Donnell, M				Klemperer, N; Zhang, D; Skangalis, M; O'Donnell, M			Cross-utilization of the beta sliding clamp by replicative polymerases of evolutionary divergent organisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III ACCESSORY PROTEINS; DNA-POLYMERASE; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; STAPHYLOCOCCUS-AUREUS; STRUCTURAL GENE; LAGGING-STRAND; HOLOENZYME; SUBUNIT; PURIFICATION	Chromosomal replicases are multiprotein machines comprised of a DNA polymerase, a sliding clamp, and a clamp loader. This study examines replicase components for their ability to be switched between Grampositive and Gram-negative organisms. These two cell types diverged over 1 billion years ago, and their sequences have diverged widely. Yet the Escherichia coli beta clamp binds directly to Staphylococcus aureus PolC and makes it highly processive, confirming and extending earlier results (Low, R, L,, Rashbaum, S, A., and Cozzarelli, N, R, (1976) J, Biol, Chem, 251, 1311-1325), We have also examined the S. aureus beta clamp. The results show that it functions with S, aureus PolC, but not with E, coli polymerase III core, PolC is a rather potent polymerase by itself and can extend a primer with an intrinsic speed of 80-120 nucleotides per s, Both E, coli beta and S, aureus beta converted PolC to a highly processive polymerase, but surprisingly, beta also increased the intrinsic rate of DNA synthesis to 240-580 nucleotides per s, This finding expands the scope of beta function beyond a simple mechanical tether for processivity to include that of an effector that increases the intrinsic rate of nucleotide incorporation by the polymerase.	Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute	O'Donnell, M (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.			O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO JC, 1995, MOL GEN GENET, V246, P680, DOI 10.1007/BF00290713; BARNES MH, 1979, NUCLEIC ACIDS RES, V6, P1203, DOI 10.1093/nar/6.3.1203; BARNES MH, 1994, MOL MICROBIOL, V13, P843, DOI 10.1111/j.1365-2958.1994.tb00476.x; BONNER CA, 1992, J BIOL CHEM, V267, P11431; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1474; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; COZZARELLI NR, 1973, BIOCHEM BIOPH RES CO, V51, P151, DOI 10.1016/0006-291X(73)90521-4; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; GASS KB, 1973, P NATL ACAD SCI USA, V70, P103, DOI 10.1073/pnas.70.1.103; GASS KB, 1973, J BIOL CHEM, V248, P7688; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION, P165; KREISWIRTH BN, 1983, NATURE, V305, P709, DOI 10.1038/305709a0; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; LEE SH, 1991, J BIOL CHEM, V266, P594; LOW RL, 1974, P NATL ACAD SCI USA, V71, P2973, DOI 10.1073/pnas.71.8.2973; LOW RL, 1976, J BIOL CHEM, V251, P1311; MACKENZIE JM, 1973, P NATL ACAD SCI USA, V70, P512, DOI 10.1073/pnas.70.2.512; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; PACITTI DF, 1995, GENE, V165, P51, DOI 10.1016/0378-1119(95)00377-I; ROWEN L, 1978, J BIOL CHEM, V253, P758; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Turner J, 1995, METHOD ENZYMOL, V262, P442; XIAO H, 1993, J BIOL CHEM, V268, P11773; Yao N, 2000, J BIOL CHEM, V275, P1421, DOI 10.1074/jbc.275.2.1421	42	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26136	26143		10.1074/jbc.M002566200	http://dx.doi.org/10.1074/jbc.M002566200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851235	hybrid			2022-12-25	WOS:000088999700036
J	Lukyanov, KA; Fradkov, AF; Gurskaya, NG; Matz, MV; Labas, YA; Savitsky, AP; Markelov, ML; Zaraisky, AG; Zhao, XN; Fang, Y; Tan, WY; Lukyanov, SA				Lukyanov, KA; Fradkov, AF; Gurskaya, NG; Matz, MV; Labas, YA; Savitsky, AP; Markelov, ML; Zaraisky, AG; Zhao, XN; Fang, Y; Tan, WY; Lukyanov, SA			Natural animal coloration can be determined by a nonfluorescent green fluorescent protein homolog	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								It is generally accepted that the colors displayed by living organisms are determined by low molecular weight pigments or chromoproteins that require a prosthetic group. The exception to this rule is green fluorescent protein (GFP) from Aequorea victoria that forms a fluorophore by self-catalyzed protein backbone modification. Here we found a naturally nonfluorescent homolog of GFP to determine strong purple coloration of tentacles in the sea anemone Anemonia sulcata, Under certain conditions, this novel chromoprotein produces a trace amount of red fluorescence (emission lambda(max) = 595 nm), The fluorescence demonstrates unique behavior: its intensity increases in the presence of green light but is inhibited by blue light. The quantum yield of fluorescence can be enhanced dramatically by single amino acid replacement, which probably restores the ancestral fluorescent state of the protein. Other fluorescent Variants of the novel protein have emission peaks that are red-shifted up to 610 nm, They demonstrate that long wavelength fluorescence is attainable in GFP-like fluorescent proteins.	Russian Acad Sci, Shemiakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117871, Russia; Russian Acad Sci, Inst Biochem, Moscow 117071, Russia; Russian Acad Sci, Inst Ecol & Evolut, Moscow 117071, Russia; Clontech Labs Inc, Palo Alto, CA 94303 USA	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Research Center of Biotechnology RAS; Russian Academy of Sciences; Russian Academy of Sciences	Lukyanov, SA (corresponding author), Russian Acad Sci, Shemiakin & Ovchinnikov Inst Bioorgan Chem, Miklukho Maklaya 16-10, Moscow 117871, Russia.		Lukyanov, Konstantin A/D-4030-2013; Gurskaya, Nadya G/Q-1750-2016; Savitsky, Alexander P/O-9799-2015; Lukyanov, Sergey/F-9140-2014; Matz, Mikhail V/K-4392-2017; Zaraisky, Andrey G/Q-2323-2016	Lukyanov, Konstantin A/0000-0001-9845-2088; Gurskaya, Nadya G/0000-0002-8028-8176; Savitsky, Alexander P/0000-0002-6820-2341; Matz, Mikhail V/0000-0001-5453-9819; Zaraisky, Andrey G/0000-0003-4681-8169				BLANQUET RS, 1987, MAR BIOL, V94, P423, DOI 10.1007/BF00428249; CHAFLIE M, 1994, SCIENCE, V263, P802; Cheesman D. F., 1967, Biological Reviews, V42, P132; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; Dove SG, 1995, BIOL BULL, V189, P288, DOI 10.2307/1542146; Fox DL, 1944, BIOL REV CAMB PHILOS, V19, P121, DOI 10.1111/j.1469-185X.1944.tb00307.x; HERRING PJ, 1972, NATURE, V205, P103; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHNSON FH, 1962, J CELL COMPAR PHYSL, V60, P85, DOI 10.1002/jcp.1030600111; Kendall JM, 1998, TRENDS BIOTECHNOL, V16, P216, DOI 10.1016/S0167-7799(98)01184-6; LEBOEUF RD, 1981, COMP BIOCHEM PHYS B, V68, P25, DOI 10.1016/0305-0491(81)90175-9; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; WEST HH, 1979, COMP BIOCHEM PHYS B, V64, P195, DOI 10.1016/0305-0491(79)90160-3; WICKSTEN MK, 1989, B MAR SCI, V45, P519; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246	18	259	292	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25879	25882		10.1074/jbc.C000338200	http://dx.doi.org/10.1074/jbc.C000338200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852900	hybrid			2022-12-25	WOS:000088999700001
J	Lyngso, C; Bouteiller, G; Damgaard, CK; Ryom, D; Sanchez-Munoz, S; Norby, PL; Bonven, BJ; Jorgensen, P				Lyngso, C; Bouteiller, G; Damgaard, CK; Ryom, D; Sanchez-Munoz, S; Norby, PL; Bonven, BJ; Jorgensen, P			Interaction between the transcription factor SPBP and the positive cofactor RNF4 - An interplay between protein binding zinc fingers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-II; RING-FINGER; AP-1 TRANSCRIPTION; GENE-TRANSCRIPTION; REPRESSOR DOMAIN; CELL-CYCLE; YEAST; EXPRESSION; IDENTIFICATION; CLONING	The activator of stromelysin 1 gene transcription, SPBP, interacts with the RING finger protein RNF4. Both proteins are ubiquitously expressed and localized in the nucleus. RNF4 facilitates accumulation of specific SPBP-DNA complexes in vitro and acts as a positive cofactor in SPBP-mediated transactivation. SPBP harbors an internal zinc finger of the PHD/LAP type. This domain can form intra-chain protein-protein contacts in SPBP resulting in negative modulation of SPBP-RNF4 interaction.	Aarhus Univ, Dept Biol Mol & Struct, DK-8000 Aarhus C, Denmark	Aarhus University	Bonven, BJ (corresponding author), Aarhus Univ, Dept Biol Mol & Struct, CF Mollers Alle 130, DK-8000 Aarhus C, Denmark.	bjb@mbio.aau.dk	Damgaard, Christian/AAR-4075-2020; Damgaard, Christian K/G-7360-2015	Damgaard, Christian/0000-0003-4940-0868				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BENDIXEN C, 1994, NUCLEIC ACIDS RES, V22, P1778, DOI 10.1093/nar/22.9.1778; BORDEN KLB, 1995, EMBO J, V14, P5947, DOI 10.1002/j.1460-2075.1995.tb00283.x; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Chiariotti L, 1998, GENOMICS, V47, P258, DOI 10.1006/geno.1997.5105; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; DELTITO BJD, 1995, J BACTERIOL, V177, P7086, DOI 10.1128/jb.177.24.7086-7091.1995; Fedele M, 2000, J BIOL CHEM, V275, P7894, DOI 10.1074/jbc.275.11.7894; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Gstaiger M, 1996, TRENDS GENET, V12, P393, DOI 10.1016/S0168-9525(96)90096-7; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; IMAI Y, 1995, MOL BRAIN RES, V31, P1, DOI 10.1016/0169-328X(95)00020-S; James P, 1996, GENETICS, V144, P1425; JENSEN TH, 1995, GENE, V162, P235, DOI 10.1016/0378-1119(95)00328-4; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; LI FQ, 1994, MOL CELL BIOL, V14, P3013, DOI 10.1128/MCB.14.5.3013; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; Lium EK, 1997, J VIROL, V71, P8602, DOI 10.1128/JVI.71.11.8602-8614.1997; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; NIELSEN AL, 1992, MOL CELL BIOL, V12, P3449, DOI 10.1128/MCB.12.8.3449; O'Rourke D, 1998, J GEN VIROL, V79, P537, DOI 10.1099/0022-1317-79-3-537; PALLISGAARD N, 1994, GENE, V138, P115, DOI 10.1016/0378-1119(94)90791-9; PALLISGAARD N, 1990, ADV AP BIOT, V7, P87; Poukka H, 2000, J BIOL CHEM, V275, P571, DOI 10.1074/jbc.275.1.571; Prikhodko EA, 1998, J VIROL, V72, P684; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SANZ L, 1995, MOL CELL BIOL, V15, P3164; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Vallian S, 1998, ONCOGENE, V16, P2843, DOI 10.1038/sj.onc.1201837; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VONBAUR E, 1996, EMBO J, V15, P110; WASSERMAN RA, 1993, CANCER RES, V53, P3591	47	42	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26144	26149		10.1074/jbc.M003405200	http://dx.doi.org/10.1074/jbc.M003405200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10849425	hybrid			2022-12-25	WOS:000088999700037
J	Takeuchi, T; Harris, JL; Huang, W; Yan, KW; Coughlin, SR; Craik, CS				Takeuchi, T; Harris, JL; Huang, W; Yan, KW; Coughlin, SR; Craik, CS			Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX-DEGRADING PROTEASE; BREAST-CANCER CELLS; MOLECULAR-CLONING; THROMBIN RECEPTOR; COMBINATORIAL APPROACH; PHAGE DISPLAY; GRANZYME-B; PRO-UPA; SPECIFICITIES; TRYPSIN	Membrane-type serine protease 1 (MT-SP1) was recently cloned, and we now report its biochemical characterization. MT-SP1 is predicted to be a type II trans membrane protein with an extracellular protease domain. This localization was experimentally verified using immunofluorescent microscopy and a cell-surface biotinylation technique. The substrate specificity of MT-SP1 was determined using a positional scanning-synthetic combinatorial library and substrate phage techniques. The preferred cleavage sequences were found to be (P4-(Arg/Lys)P3-(X)P2-(Ser)P1-(Arg)P1'-(Ala)) and (P4-(X)P3-(Arg/Lys)P2-(Ser)P1(Arg)P1'(Ala)), where X is a non-basic amino acid, Protease-activated receptor 2 (PAR2) and single chain urokinase-type plasminogen activator are proteins that are localized to the extracellular surface and contain the preferred MT-SP1 cleavage sequence. The ability of MT-SP1 to activate PARs was assessed by exposing PAR-expressing Xenopus oocytes to the soluble MT-SP1 protease domain. The latter triggered calcium signaling in PAR2-expressing oocytes at 10 nM but failed to trigger calcium signaling in oocytes expressing PAR1, PAR3, or PAR4 at 100 nM. Single-chain urokinase-type plasminogen activator was activated using catalytic amounts of MT-SP1 (1 nM), but plasminogen was not cleaved under similar conditions. The membrane localization of MT-SP1 and its affinity for these key extracellular substrates suggests a role of the proteolytic activity in regulatory events.	Univ Calif San Francisco, Dept Pharmaceut Chem & Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; San Francisco State Univ, Ctr Biomed Lab Sci, San Francisco, CA 94132 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; California State University System; San Francisco State University	Craik, CS (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem & Biochem & Biophys, San Francisco, CA 94143 USA.				NATIONAL CANCER INSTITUTE [F32CA071097, P01CA072006] Funding Source: NIH RePORTER; NCI NIH HHS [CA71097, CA72006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTIN JG, 1995, ANAL BIOCHEM, V224, P382, DOI 10.1006/abio.1995.1054; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; Backes BJ, 1999, J ORG CHEM, V64, P2322, DOI 10.1021/jo981990y; Bohm SK, 1996, BIOCHEM J, V314, P1009; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; GORETZKI L, 1992, FEBS LETT, V297, P112, DOI 10.1016/0014-5793(92)80339-I; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1993, J BIOL CHEM, V268, P9780; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; KAZAMA Y, 1995, J BIOL CHEM, V270, P66, DOI 10.1074/jbc.270.1.66; Ke SH, 1997, J BIOL CHEM, V272, P16603, DOI 10.1074/jbc.272.26.16603; Kim MG, 1999, IMMUNOGENETICS, V49, P420, DOI 10.1007/s002510050515; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Kong WY, 1997, P NATL ACAD SCI USA, V94, P8884, DOI 10.1073/pnas.94.16.8884; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MATTHEWS DJ, 1994, PROTEIN SCI, V3, P1197, DOI 10.1002/pro.5560030805; MCGRATH ME, 1994, EMBO J, V13, P1503; Miyata S, 2000, J BIOL CHEM, V275, P4592, DOI 10.1074/jbc.275.7.4592; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; OSTRESH JM, 1994, BIOPOLYMERS, V34, P1681, DOI 10.1002/bip.360341212; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; POLONIGIACOBINO A, 1997, GENOMICS, V44, P309; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schuberth HJ, 1996, J IMMUNOL METHODS, V189, P89, DOI 10.1016/0022-1759(95)00238-3; SHI YE, 1993, CANCER RES, V53, P1409; STACK MS, 1994, J BIOL CHEM, V269, P9416; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Unal A, 1997, J VIROL, V71, P7030, DOI 10.1128/JVI.71.9.7030-7038.1997; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Yamaoka K, 1998, J BIOL CHEM, V273, P11895, DOI 10.1074/jbc.273.19.11895; Yan W, 1999, J BIOL CHEM, V274, P14926, DOI 10.1074/jbc.274.21.14926; YOSHIDA E, 1994, CANCER RES, V54, P3300; Yoshida E, 1995, INT J CANCER, V63, P863, DOI 10.1002/ijc.2910630618	52	369	413	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26333	26342		10.1074/jbc.M002941200	http://dx.doi.org/10.1074/jbc.M002941200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10831593	hybrid			2022-12-25	WOS:000088999700063
J	Tchurikov, NA; Chistyakova, LG; Zavilgelsky, GB; Manukhov, IV; Chernov, BK; Golova, YB				Tchurikov, NA; Chistyakova, LG; Zavilgelsky, GB; Manukhov, IV; Chernov, BK; Golova, YB			Gene-specific silencing by expression of parallel complementary RNA in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; INTERFERENCE; DEGRADATION; COLI; DNA; COSUPPRESSION; MUTAGENESIS; DROSOPHILA; TRANSGENES; SEQUENCES	Gene-specific silencing refers to a phenomenon in which expression of an individual gene can be specifically repressed by different mechanisms on the levels of transcription, RNA splicing, transport, degradation in nuclei or cytoplasm, or blocking of translation. In different species gene-specific silencing was observed by expression or injections of antiparallel double-stranded RNA formed by a fragment of mRNA and antisense RNA. Here we show a potent and specific gene silencing in bacteria by expression of RNA, that is complementary in a parallel orientation to Escherichia coli ion mRNA Moreover, the expression of parallel RNA is more effective at producing interference than expression of antisense RNA corresponding to the same mRNA region. Both effects of interference mediated either by parallel RNA or antiparallel RNA gradually decrease up to the 40th generation. Together with in vitro nuclease protection studies these results indicate that a parallel RNA duplex might be formed in vivo and both types of duplexes, antiparallel or parallel, can induce gene specific silencing by similar mechanisms.	Russian Acad Sci, Dept Genome Org, Moscow 117984, Russia; Russian Acad Sci, Engelhardt Inst Mol Biol, Grp Genes Chem Synth, Moscow 117984, Russia; State Sci Ctr Russian Federat GNIIGENETICA, Lab Bacterial Genet, Moscow 113545, Russia	Russian Academy of Sciences; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Tchurikov, NA (corresponding author), Russian Acad Sci, Dept Genome Org, Vavilov Str 32, Moscow 117984, Russia.	tchur@imb.ac.ru	Zavilgelsky, Gennadii/AAE-8051-2021; Manukhov, Ilya V/L-1375-2014; Tchurikov, Nickolai A./R-4850-2016	Manukhov, Ilya V/0000-0001-8646-7207; 				Alvarado AS, 1999, P NATL ACAD SCI USA, V96, P5049, DOI 10.1073/pnas.96.9.5049; Bosher JM, 2000, NAT CELL BIOL, V2, pE31, DOI 10.1038/35000102; CECH TR, 1993, GENE, V135, P33, DOI 10.1016/0378-1119(93)90046-6; Chistyakova L G, 1990, Biomed Sci, V1, P359; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GOLDBERG AL, 1972, P NATL ACAD SCI USA, V69, P422, DOI 10.1073/pnas.69.2.422; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; KUNG HJ, 1976, CELL, V7, P609, DOI 10.1016/0092-8674(76)90211-7; MAURIZI MR, 1985, J BACTERIOL, V164, P1124, DOI 10.1128/JB.164.3.1124-1135.1985; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Pal-Bhadra M, 1999, CELL, V99, P35, DOI 10.1016/S0092-8674(00)80060-4; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; Rauhut R, 1999, FEMS MICROBIOL REV, V23, P353, DOI 10.1016/S0168-6445(99)00012-1; RICH A, 1961, J MOL BIOL, V3, P71, DOI 10.1016/S0022-2836(61)80009-0; RIPPE K, 1990, J BIOMOL STRUCT DYN, V7, P1199, DOI 10.1080/07391102.1990.10508559; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; TCHURIKOV NA, 1992, GENETICA, V87, P113, DOI 10.1007/BF00121001; Tchurikov NA, 1995, J BIOMOL STRUCT DYN, V13, P507, DOI 10.1080/07391102.1995.10508860; TEHURIKOV NA, 1988, P RUSSIAN ACAD SCI, V303, P1254; VANDESANDE JH, 1988, SCIENCE, V241, P551, DOI 10.1126/science.3399890; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WAGNER EG, 1994, ANNU REV MICROBIOL, V48, P714; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; Wianny F, 2000, NAT CELL BIOL, V2, P70, DOI 10.1038/35000016; ZAVILGELSKII GB, 1994, GENETIKA+, V30, P337	31	28	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26523	26529		10.1074/jbc.M002833200	http://dx.doi.org/10.1074/jbc.M002833200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10849423	hybrid			2022-12-25	WOS:000088999700088
J	Ireton, GC; Stewart, L; Parker, LH; Champoux, JJ				Ireton, GC; Stewart, L; Parker, LH; Champoux, JJ			Expression of human topoisomerase I with a partial deletion of the linker region yields monomeric and dimeric enzymes that respond differently to camptothecin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA CLEAVABLE COMPLEXES; CATALYTIC ACTIVITY; REPLICATION FORKS; EUKARYOTIC TOPOISOMERASE; DRUG CAMPTOTHECIN; MAMMALIAN-CELLS; NUCLEIC-ACID; PROTEIN; IDENTIFICATION; YEAST	Human topoisomerase I is a 765-residue protein composed of four major domains as follows: the unconserved and highly charged NH2-terminal domain, a conserved core domain, the positively charged linker region, and the highly conserved COOH-terminal domain containing the active site tyrosine, Previous studies of the domain structure revealed that near full topoisomerase I activity can be reconstituted in vitro by fragment complementation between recombinant polypeptides approximating the core and COOH-terminal domains. Here we demonstrate that deletion of linker residues Asp(660) to Lys(688) yields an active enzyme (topo70 Delta L) that purifies as both a monomer and a dimer, The dimer is shown to result from domain swapping involving the COOH-terminal and core domains of the two subunits, The monomeric form is insensitive to the anti-tumor agent camptothecin and distributive during in vitro plasmid relaxation assays, whereas the dimeric form is camptothecin-sensitive and processive. However, the addition of camptothecin to enzyme/DNA mixtures causes enhancement of SDS-induced breakage by both monomeric and dimeric forms of the mutant enzyme. The similarity of the dimeric form to the wild type enzyme suggests that some structural feature of the dimer is providing a surrogate linker. Yeast cells expressing topo70 Delta L were found to be insensitive to camptothecin.	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.	champoux@u.washington.edu			NIGMS NIH HHS [T32-GM07207, GM49156] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELSON HT, 1973, BIOCHEM BIOPH RES CO, V50, P1048; ALSNER J, 1992, J BIOL CHEM, V267, P12408; ANDOH T, 1987, P NATL ACAD SCI USA, V84, P5565, DOI 10.1073/pnas.84.16.5565; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BENEDETTI P, 1993, CANCER RES, V53, P4343; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; Caron P R, 1994, Adv Pharmacol, V29B, P271; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; COVEY JM, 1989, CANCER RES, V49, P5016; DARPA P, 1990, CANCER RES, V50, P6919; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; ENG WK, 1988, MOL PHARMACOL, V34, P755; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GREEN SM, 1995, NAT STRUCT BIOL, V2, P746, DOI 10.1038/nsb0995-746; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HERTZBERG RP, 1990, J BIOL CHEM, V265, P19287; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; HORWITZ SB, 1971, MOL PHARMACOL, V7, P632; HORWITZ SB, 1973, CANCER RES, V33, P2834; HSIANG YH, 1988, CANCER RES, V48, P1722; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; HSIANG YH, 1989, CANCER RES, V49, P4385; JAZWINSKI SM, 1990, METHOD ENZYMOL, V182, P154; KIKUCHI A, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P121; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KUBOTA N, 1992, BIOCHEM BIOPH RES CO, V188, P571, DOI 10.1016/0006-291X(92)91094-7; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI LH, 1972, CANCER RES, V32, P2643; Li XG, 1997, BIOCHEM PHARMACOL, V53, P1019, DOI 10.1016/S0006-2952(96)00899-4; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LIU LF, 1994, DNA TOPOISOMERASES A, V29; MADDEN KR, 1992, CANCER RES, V52, P525; MATTERN MR, 1987, CANCER RES, V47, P1793; MCCONAUGHY BL, 1981, BIOCHIM BIOPHYS ACTA, V655, P1, DOI 10.1016/0005-2787(81)90059-9; MCLELLAN T, 1982, ANAL BIOCHEM, V126, P94, DOI 10.1016/0003-2697(82)90113-0; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; RAAG R, 1995, FASEB J, V9, P73, DOI 10.1096/fasebj.9.1.7821762; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; RUBIN E, 1994, J BIOL CHEM, V269, P2433; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; SHIN CG, 1990, BIOCHEMISTRY-US, V29, P10934, DOI 10.1021/bi00501a011; SHIN CG, 1990, BIOCHEM BIOPH RES CO, V168, P135, DOI 10.1016/0006-291X(90)91684-K; Stewart L, 1999, J BIOL CHEM, V274, P32950, DOI 10.1074/jbc.274.46.32950; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TAMURA H, 1991, NUCLEIC ACIDS RES, V19, P69, DOI 10.1093/nar/19.1.69; THRASH C, 1984, J BIOL CHEM, V259, P1375; TSAO YP, 1993, CANCER RES, V53, P5908; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223	60	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25820	25830		10.1074/jbc.M002144200	http://dx.doi.org/10.1074/jbc.M002144200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827183	hybrid			2022-12-25	WOS:000088849400100
J	Schroeder, F; Frolov, A; Starodub, O; Atshaves, BB; Russell, W; Petrescu, A; Huang, H; Gallegos, AM; McIntosh, A; Tahotna, D; Russell, DH; Billheimer, JT; Baum, CL; Kier, AB				Schroeder, F; Frolov, A; Starodub, O; Atshaves, BB; Russell, W; Petrescu, A; Huang, H; Gallegos, AM; McIntosh, A; Tahotna, D; Russell, DH; Billheimer, JT; Baum, CL; Kier, AB			Pro-sterol carrier protein-2 - Role of the N-terminal presequence in structure, function, and peroxisomal targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING PROTEIN; L-CELL FIBROBLASTS; ACYL-COENZYME-A; FATTY-ACID; RAT-LIVER; INTRACELLULAR TRAFFICKING; MEMBRANE INTERACTION; MAMMALIAN-CELLS; BOVINE LIVER; CHOLESTEROL	Although the 20-amino acid presequence present in 15-kDa pro-sterol carrier protein-2 (pro-SCP-2, the precursor of the mature 13-kDa SCP-2) alters the function of SCP-2 in lipid metabolism, the molecular basis for this effect is unresolved. The presequence dramatically altered SCP-2 structure as determined by circular dichroism, mass spectroscopy, and antibody accessibility such that pro-SCP-2 had 3-fold less alpha-helix, 7-fold more p-structure, 6-fold more reactive C terminus to carboxypeptidase A, 2-fold less binding of anti-SCP-2, and did not enhance sterol transfer from plasma membranes. These differences were not due to protein stability since (i) the same concentration of guanidine hydrochloride was required for 50% unfolding, and (ii) the ligand binding sites displayed the same high affinity (nanomolar K-d values) in the order: cholesterol much greater than straight chain fatty acid > kinked chain fatty acid. Laser scanning confocal microscopy and double immunofluorescence demonstrated that pro-SCP-2 was more efficiently targeted to peroxisomes. Transfection of L-cells or McAR7777 hepatoma cells with cDNA encoding pro-SCP-2 resulted in 45% and 59% of SCP-2, respectively, colocalizing with the peroxisomal marker PMP70. In contrast, L-cells transfected with cDNA encoding SCP-2 exhibited 3-fold lower colocalization of SCP-2 with PMP70. In summary, the data suggest for the first time that the 20-amino acid presequence of pro-SCP-2 alters SCP-2 structure to facilitate peroxisomal targeting mediated by the C-terminal SKL peroxisomal targeting sequence.	Texas A&M Univ, Dept Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Pathobiol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Dupont Merck Pharmaceut Co, Cardiovasc Dept, Wilmington, DE 19898 USA; Univ Chicago, Dept Med, Clin Nutr Res Unit, Chicago, IL 60637 USA; Univ Chicago, Gastroenterol Sect, Chicago, IL 60637 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; DuPont; University of Chicago; University of Chicago	Schroeder, F (corresponding author), Texas A&M Univ, Dept Physiol & Pharmacol, College Stn, TX 77843 USA.	fschroeder@cvm.tamu.edu	Russell, David H/C-3618-2015	Russell, David H/0000-0003-0830-3914	NIDDK NIH HHS [DK41402] Funding Source: Medline; NIEHS NIH HHS [P30-ES0916] Funding Source: Medline; NIGMS NIH HHS [GM 31561] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041402] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Atshaves BP, 1999, J LIPID RES, V40, P610; Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chanderbhan RF, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P197; COMPTON LA, 1986, ANAL BIOCHEM, V155, P155, DOI 10.1016/0003-2697(86)90241-1; Ferdinandusse S, 2000, J LIPID RES, V41, P336; FISCHER RT, 1985, BIOCHEMISTRY-US, V24, P3322, DOI 10.1021/bi00334a037; Frolov A, 1996, J LIPID RES, V37, P1862; Frolov A, 1996, J BIOL CHEM, V271, P16075, DOI 10.1074/jbc.271.27.16075; Frolov A, 1997, BIOCHEMISTRY-US, V36, P6545, DOI 10.1021/bi970205t; Frolov A, 1996, J BIOL CHEM, V271, P31878, DOI 10.1074/jbc.271.50.31878; Gallegos AM, 2000, CHEM PHYS LIPIDS, V105, P9, DOI 10.1016/S0009-3084(99)00128-0; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; Harlow E., 1988, ANTIBODIES LAB MANUA; Huang H, 1999, BIOCHEMISTRY-US, V38, P13231, DOI 10.1021/bi990870x; Huang H, 1999, BIOCHEM J, V344, P593, DOI 10.1042/0264-6021:3440593; Jatzke C, 1999, BBA-PROTEIN STRUCT M, V1432, P265, DOI 10.1016/S0167-4838(99)00114-4; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; JOHNSON WJ, 1994, J LIPID RES, V35, P563; Kannenberg F, 1999, J BIOL CHEM, V274, P35455, DOI 10.1074/jbc.274.50.35455; KELLER GA, 1987, P NATL ACAD SCI USA, V84, P3264, DOI 10.1073/pnas.84.10.3264; KELLER GA, 1991, J CELL BIOL, V114, P893, DOI 10.1083/jcb.114.5.893; King SM, 1999, PROTEINS, V35, P313, DOI 10.1002/(SICI)1097-0134(19990515)35:3<313::AID-PROT5>3.3.CO;2-T; MATSUURA JE, 1993, BIOCHEMISTRY-US, V32, P567, DOI 10.1021/bi00053a023; McArthur MJ, 1999, J LIPID RES, V40, P1371; Moncecchi D, 1996, BBA-LIPID LIPID MET, V1302, P110, DOI 10.1016/0005-2760(96)00044-6; Murphy EJ, 1998, AM J PHYSIOL-GASTR L, V275, pG237, DOI 10.1152/ajpgi.1998.275.2.G237; Murphy EJ, 2000, J LIPID RES, V41, P788; Murphy EJ, 1997, BBA-LIPID LIPID MET, V1345, P283, DOI 10.1016/S0005-2760(97)00003-9; NOLAND BJ, 1980, J BIOL CHEM, V255, P4282; Ossendorp BC, 1996, ARCH BIOCHEM BIOPHYS, V334, P251, DOI 10.1006/abbi.1996.0453; PASTUSZYN A, 1987, J BIOL CHEM, V262, P13219; Pu LX, 1998, PROTEIN EXPRES PURIF, V13, P337, DOI 10.1006/prep.1998.0908; Schoer JK, 2000, BIOCHEMISTRY-US, V39, P7662, DOI 10.1021/bi992686h; Schroeder F, 1998, INTRACELLULAR CHOLESTEROL TRAFFICKING, P213; SCHROEDER F, 1995, BIOCHEMISTRY-US, V34, P11919, DOI 10.1021/bi00037a033; SCHROEDER F, 1976, J BIOL CHEM, V251, P5015; SCHULENBERGSCHELL H, 1988, EUR J BIOCHEM, V170, P565, DOI 10.1111/j.1432-1033.1988.tb13735.x; SEEDORF U, 1994, J BIOL CHEM, V269, P21277; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; STARODUB O, 2000, IN PRESS AM J PHYSL; Stolowich N, 1999, J BIOL CHEM, V274, P35425, DOI 10.1074/jbc.274.50.35425; VANDERKRIFT TP, 1985, BIOCHIM BIOPHYS ACTA, V812, P387, DOI 10.1016/0005-2736(85)90313-X; VANHEUSDEN GPH, 1990, BIOCHIM BIOPHYS ACTA, V1046, P315, DOI 10.1016/0005-2760(90)90247-U; WALTON PA, 1992, MOL CELL BIOL, V12, P531, DOI 10.1128/MCB.12.2.531; WESTERMAN J, 1985, BIOCHEM BIOPH RES CO, V127, P333, DOI 10.1016/S0006-291X(85)80163-7; WOODFORD JK, 1995, CHEM PHYS LIPIDS, V76, P73, DOI 10.1016/0009-3084(95)02436-M; Wouters FS, 1998, EMBO J, V17, P7179, DOI 10.1093/emboj/17.24.7179; YAMAMOTO R, 1991, P NATL ACAD SCI USA, V88, P463, DOI 10.1073/pnas.88.2.463	49	50	53	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25547	25555		10.1074/jbc.M000431200	http://dx.doi.org/10.1074/jbc.M000431200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833510	hybrid			2022-12-25	WOS:000088849400067
J	Scott, SV; Nice, DC; Nau, JJ; Weisman, LS; Kamada, Y; Keizer-Gunnink, I; Funakoshi, T; Veenhuis, M; Ohsumi, Y; Klionsky, DJ				Scott, SV; Nice, DC; Nau, JJ; Weisman, LS; Kamada, Y; Keizer-Gunnink, I; Funakoshi, T; Veenhuis, M; Ohsumi, Y; Klionsky, DJ			Apg13p and Vac8p are part of a complex of phosphoproteins that are required for cytoplasm to vacuole targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; AMINOPEPTIDASE-I; DEFICIENT MUTANTS; YEAST VACUOLE; PROTEIN; AUTOPHAGY; TRANSPORT; PATHWAY; MEMBRANE; GENE	We have been studying protein components that function in the cytoplasm to vacuole targeting (Cvt) pathway and the overlapping process of macroautophagy. The Vac8 and Apg13 proteins are required for the import of aminopeptidase I (API) through the Cvt pathway. We have identified a protein-protein interaction between Vac8p and Apg13p by both two-hybrid and co-immunoprecipitation analysis. Subcellular fractionation of API indicates that Vac8p and Apg13p are involved in the vesicle formation step of the Cvt pathway. Kinetic analysis of the Cvt pathway and autophagy indicates that, although Vac8p is essential for Cvt transport, it is less important for autophagy, In vivo phosphorylation experiments demonstrate that both Vac8p and Apg13p are phosphorylated proteins, and Apg13p phosphorylation is regulated by changing nutrient conditions. Although Apg13p interacts with the serine/threonine kinase Apg1p, this protein is not required for phosphorylation of either Vac8p or Apg13p, Subcellular fractionation experiments indicate that Apg13p and a fraction of Apg1p are membrane-associated, Vac8p and Apg13p may be part of a larger protein complex that includes Apg1p and additional interacting proteins. Together, these components may form a protein complex that regulates the conversion between Cvt transport and autophagy in response to changing nutrient conditions.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Groningen, Dept Microbiol, NL-9751 NN Haren, Netherlands; Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan	University of California System; University of California Davis; University of Iowa; University of Groningen; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Klionsky, DJ (corresponding author), Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA.	djklionsky@ucdavis.edu	Ohsumi, Yoshinori/C-6449-2009	Ohsumi, Yoshinori/0000-0003-2384-2166; Kamada, Yoshiaki/0000-0001-7395-660X	NIGMS NIH HHS [GM53396, GM50403] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396, R01GM050403] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 1999, EMBO J, V18, P6005, DOI 10.1093/emboj/18.21.6005; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Bai C, 1997, METHOD ENZYMOL, V283, P141; BAUM P, 1978, P NATL ACAD SCI USA, V75, P4962, DOI 10.1073/pnas.75.10.4962; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; Fleckenstein D, 1998, J CELL SCI, V111, P3109; Funakoshi T, 1997, GENE, V192, P207, DOI 10.1016/S0378-1119(97)00031-0; George MD, 2000, MOL BIOL CELL, V11, P969, DOI 10.1091/mbc.11.3.969; Gerhardt B, 1998, J BIOL CHEM, V273, P15818, DOI 10.1074/jbc.273.25.15818; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; HARPER JW, 1993, CELL, V75, P805; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; James P, 1996, GENETICS, V144, P1425; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 1997, J CELL BIOL, V137, P609, DOI 10.1083/jcb.137.3.609; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1990, J BIOL CHEM, V265, P5349; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; Oda MN, 1996, J CELL BIOL, V132, P999, DOI 10.1083/jcb.132.6.999; Pan XZ, 1998, J CELL SCI, V111, P2137; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Scott SV, 1995, J CELL BIOL, V131, P1727, DOI 10.1083/jcb.131.6.1727; Scott SV, 1998, CURR OPIN CELL BIOL, V10, P523, DOI 10.1016/S0955-0674(98)80068-9; Straub M, 1997, J BACTERIOL, V179, P3875, DOI 10.1128/jb.179.12.3875-3883.1997; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Wang YX, 1996, MOL BIOL CELL, V7, P1375, DOI 10.1091/mbc.7.9.1375; Wang YX, 1998, J CELL BIOL, V140, P1063, DOI 10.1083/jcb.140.5.1063	42	184	191	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25840	25849		10.1074/jbc.M002813200	http://dx.doi.org/10.1074/jbc.M002813200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837477	Green Published, hybrid			2022-12-25	WOS:000088849400102
J	Bann, JG; Bachinger, HP				Bann, JG; Bachinger, HP			Glycosylation/hydroxylation-induced stabilization of the collagen triple helix - 4-trans-hydroxyproline in the Xaa position can stabilize the triple helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FMOC AMINO-ACIDS; THERMAL-STABILITY; CUTICLE COLLAGEN; SEQUENCE; PEPTIDE; GLYCOPEPTIDES; WATER	We have shown recently that glycosylation of threonine in the peptide Ac-(Gly-Pro-Thr)(10)-NH2 with beta-D-galactose induces the formation of a collagen triple helix, whereas the nonglycosylated peptide does not. In this report, we present evidence that a collagen triple helix can also be formed in the Ac-(Gly-Pro-Thr)(10)-NH2 peptide, if the proline (Pro) in the Xaa position is replaced with 4-transhydroxyproline (Hyp). Furthermore, replacement of Pro with Hyp in the sequence Ac-(Gly-Pro-Thr(beta-D-Gal))(10)-NH2 increases the T-m of the triple helix by 15.7 degrees C, It is generally believed that Hyp in the Xaa position destabilizes the triple helix because (Pro-Pro-Gly)(10) and (Pro-Hyp-Gly)(10) farm stable triple helices but the peptide (Hyp-Pro-Gly)(10) does not. Our data suggest that the destabilizing effect of Hyp relative to Pro in the Xaa position is only true in the case of (Hyp-Pro-Gly)(10), Increasing concentrations of galactose in the solvent stabilize the triple helix of Ac-(Gly-Hyp-Thr)(10)-NH2 but to a much lesser extent than that achieved by covalently linked galactose. The data explain some of the forces governing the stability of the annelid/vestimentiferan cuticle collagens.	Shriners Hosp Crippled Childrens, Dept Res, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Bachinger, HP (corresponding author), Shriners Hosp Crippled Childrens, Dept Res, 3101 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	hpb@shcc.org						ADAMS E, 1977, J BIOL CHEM, V252, P7591; Bann JG, 2000, FEBS LETT, V473, P237, DOI 10.1016/S0014-5793(00)01493-9; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BROWN FR, 1972, J MOL BIOL, V63, P101, DOI 10.1016/0022-2836(72)90524-4; BROWN FR, 1972, J MOL BIOL, V63, P85, DOI 10.1016/0022-2836(72)90523-2; BURJANADZE TV, 1979, BIOPOLYMERS, V18, P931, DOI 10.1002/bip.1979.360180413; Eberhardt ES, 1996, J AM CHEM SOC, V118, P12261, DOI 10.1021/ja9623119; ELOFSSON M, 1991, TETRAHEDRON LETT, V32, P7613, DOI 10.1016/0040-4039(91)80548-K; ENGEL J, 1977, BIOPOLYMERS, V16, P601, DOI 10.1002/bip.1977.360160310; ENGEL J, 2000, IN PRESS MATRIX BIOL; GAILL F, 1995, J MOL BIOL, V246, P284, DOI 10.1006/jmbi.1994.0084; GEKKO K, 1983, J BIOCHEM-TOKYO, V94, P199, DOI 10.1093/oxfordjournals.jbchem.a134330; GOLDSTEIN A, 1970, J BIOL CHEM, V245, P5478; HARRINGTON WILLIAM G., 1967, P513; INOUYE K, 1982, ARCH BIOCHEM BIOPHYS, V219, P198, DOI 10.1016/0003-9861(82)90149-7; Kihlberg J, 1997, METHOD ENZYMOL, V289, P221; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; Kramer RZ, 1999, NAT STRUCT BIOL, V6, P454; Kramer RZ, 1998, J MOL BIOL, V280, P623, DOI 10.1006/jmbi.1998.1881; Mann K, 1996, J MOL BIOL, V261, P255, DOI 10.1006/jmbi.1996.0457; Nagarajan V, 1999, J BIOCHEM-TOKYO, V125, P310, DOI 10.1093/oxfordjournals.jbchem.a022288; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; SHARMA YD, 1984, ANAL BIOCHEM, V141, P205, DOI 10.1016/0003-2697(84)90447-0	23	81	82	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24466	24469		10.1074/jbc.M003336200	http://dx.doi.org/10.1074/jbc.M003336200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827193	hybrid			2022-12-25	WOS:000088683300031
J	Liu, C; Gelius, E; Liu, G; Steiner, H; Dziarski, R				Liu, C; Gelius, E; Liu, G; Steiner, H; Dziarski, R			Mammalian peptidoglycan recognition protein binds peptidoglycan with high affinity, is expressed in neutrophils, and inhibits bacterial growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL COMPONENTS; BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN; TOLL-LIKE RECEPTOR-2; SOLUBLE PEPTIDOGLYCAN; STAPHYLOCOCCAL PEPTIDOGLYCAN; INNATE IMMUNITY; HOST-DEFENSE; BOMBYX-MORI; CD14; LYMPHOCYTES	Peptidoglycan recognition protein (PGRP) is conserved from insects to mammals. In insects, PGRP recognizes bacterial cell wall peptidoglycan (PGN) and activates prophenoloxidase cascade, a part of the insect antimicrobial defense system. Because mammals do not have the prophenoloxidase cascade, its function in mammals is unknown. However, it was suggested that an identical protein (Tag7) was a tumor necrosis factor-like cytokine. Therefore, the aim of this study was to identify the function of PGRP in mammals. Mouse PGRP bound to PGN with fast kinetics and nanomolar affinity (K-d = 13 nM). The binding was specific for polymeric PGN or Gram-positive bacteria with unmodified PGN, and PGRP did not bind to other cell wall components or Gram-negative bacteria. PGRP mRNA and protein were expressed in neutrophils and bone marrow cells, but not in spleen cells, mononuclear cells, T or B lymphocytes, NK cells, thymocytes, monocytes, and macrophages. PGRP was not a PGN-lytic or a bacteriolytic enzyme, but it inhibited the growth of Gram-positive but not Gramnegative bacteria. PGRP inhibited phagocytosis of Gram-positive bacteria by macrophages, induction of oxidative burst by Gram-positive bacteria in neutrophils, and induction of cytokine production by PGN in macrophages. PGRP had no tumor necrosis factor-like cytotoxicity for mammalian cells, and it was not chemotactic on its own or in combination with PGN. Therefore, mammalian PGRP binds to PGN and Gram-positive bacteria with nanomolar affinity, is expressed in neutrophils, and inhibits growth of bacteria.	Indiana Univ, Sch Med, NW Ctr Med Educ, Gary, IN 46408 USA; Univ Stockholm, Dept Microbiol, S-10691 Stockholm, Sweden	Indiana University System; Indiana University Northwest; Stockholm University	Dziarski, R (corresponding author), Indiana Univ, Sch Med, NW Ctr Med Educ, 3400 Broadway, Gary, IN 46408 USA.				NIAID NIH HHS [AI2879] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashida M., 1997, MOL MECH IMMUNE RESP, P135; CAMPBELL PA, 1995, CURRENT PROTOCOLS IM; CHENG XD, 1994, P NATL ACAD SCI USA, V91, P4034, DOI 10.1073/pnas.91.9.4034; CHIPMAN DM, 1967, J BIOL CHEM, V242, P4388; COLLAWAN JF, 1995, CURRENT PROTOCOLS IM; COOPER HM, 1995, CURRENT PROTOCOLS IM; DZIARSKI R, 1991, J BIOL CHEM, V266, P4713; DZIARSKI R, 1980, J IMMUNOL, V125, P2478; DZIARSKI R, 1994, J BIOL CHEM, V269, P2100; Dziarski R, 2000, CHEM IMMUNOL, V74, P83; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Dziarski R. A., 2000, GLYCOMICROBIOLOGY, P145; Elsbach P, 1998, J LEUKOCYTE BIOL, V64, P14, DOI 10.1002/jlb.64.1.14; Elsbach P, 1998, CURR OPIN IMMUNOL, V10, P45, DOI 10.1016/S0952-7915(98)80030-7; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FORTIER AH, 1995, CURRENT PROTOCOLS IM; GUPTA D, 1995, J IMMUNOL, V155, P2620; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; Heymer B., 1985, IMMUNOLOGY BACTERIAL, P11; Jin YP, 1998, J INFECT DIS, V177, P1629, DOI 10.1086/515318; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Kiselev SL, 1998, J BIOL CHEM, V273, P18633, DOI 10.1074/jbc.273.29.18633; LEONARD EJ, 1995, CURRENT PROTOCOLS IM; LEVINSON AI, 1983, INFECT IMMUN, V39, P290, DOI 10.1128/IAI.39.1.290-296.1983; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; OKEN MM, 1981, INFECT IMMUN, V31, P208, DOI 10.1128/IAI.31.1.208-213.1981; PARK BH, 1968, LANCET, V2, P532; RIEDY MC, 1995, CURRENT PROTOCOLS IM; ROSENTHAL RS, 1994, METHOD ENZYMOL, V235, P253; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; STROMINGER JL, 1967, SCIENCE, V156, P213, DOI 10.1126/science.156.3772.213; Stryer L., 1995, BIOCHEMISTRY-US, P207; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199; WEIDEMANN B, 1994, INFECT IMMUN, V62, P4709, DOI 10.1128/IAI.62.11.4709-4715.1994; Weidemann B, 1997, INFECT IMMUN, V65, P858, DOI 10.1128/IAI.65.3.858-864.1997; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wullner U, 1998, DEV BRAIN RES, V110, P1, DOI 10.1016/S0165-3806(98)00079-0; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; Yoshimura A, 1999, J IMMUNOL, V163, P1	42	158	172	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24490	24499		10.1074/jbc.M001239200	http://dx.doi.org/10.1074/jbc.M001239200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827080	hybrid			2022-12-25	WOS:000088683300035
J	Raney, A; Baron, AC; Mize, GJ; Law, GL; Morris, DR				Raney, A; Baron, AC; Mize, GJ; Law, GL; Morris, DR			In vitro translation of the upstream open reading frame in the mammalian mRNA encoding S-adenosylmethionine decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM SYSTEM; MESSENGER-RNA; NASCENT-PEPTIDE; NEUROSPORA-CRASSA; RAT-LIVER; POLYAMINES; TERMINATION; RIBOSOME; LEADER; INITIATION	The upstream open reading frame (uORF) in the mRNA encoding S-adenosylmethionine decarboxylase is a polyamine-responsive element that suppresses translation of the associated downstream cistron in vivo. In this paper, we provide the first direct evidence of peptide sysnthesis from the S-adenosylmethionine decarboxylase uORF using an in vitro translation system. We examine both the influence of cation concentration on peptide synthesis and the effect of altering the uORF sequence on peptide synthesis. Synthesis of wild type and altered peptides was similar at all concentrations of magnesium tested. In contrast, synthesis of the wild type peptide was more sensitive than that of altered peptides to elevated concentrations of the naturally occurring polyamines, spermidine and spermine, as well as several polyamine analogs. The sensitivity of in vitro synthesis to spermidine was influenced by both the amino acid sequence and the length of the peptide product of the uORF. Findings from the present study correlate with the effects of the uORF and polyamines on translation of a downstream cistron in vivo and support the hypothesis that polyamines and the structure of the nascent peptide create a rate-limiting step in uORF translation, perhaps through a ribosome stalling mechanism.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Morris, DR (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.		Morris, David/G-4503-2011		NCI NIH HHS [CA39053] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON CW, 1983, METHOD ENZYMOL, V101, P635; Cao JH, 1996, MOL CELL BIOL, V16, P603; Cao JH, 1996, MOL CELL BIOL, V16, P7109; Cao JH, 1998, RNA, V4, P181; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GOERTZ B, 1979, BRAIN RES, V173, P125, DOI 10.1016/0006-8993(79)91100-4; GRILLO MA, 1994, BIOCHEM SOC T, V22, P894, DOI 10.1042/bst0220894; HACKETT PB, 1986, J MOL BIOL, V190, P45, DOI 10.1016/0022-2836(86)90074-4; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; Hershey JWB, 1996, TRANSLATIONAL CONTRO; HILL JR, 1993, J BIOL CHEM, V268, P726; HILL JR, 1992, J BIOL CHEM, V267, P21886; HUNTER AR, 1977, EUR J BIOCHEM, V75, P149, DOI 10.1111/j.1432-1033.1977.tb11512.x; IGARASHI K, 1974, EUR J BIOCHEM, V48, P495, DOI 10.1111/j.1432-1033.1974.tb03790.x; KNAPP D, 1979, HDB ANAL DERIVATIZAT, P253; LARGE PJ, 1992, FEMS MICROBIOL LETT, V88, P249, DOI 10.1111/j.1574-6968.1992.tb04991.x; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; Marton LJ, 1987, INHIB POLYAM METABOL, P79; Mize GJ, 1998, J BIOL CHEM, V273, P32500, DOI 10.1074/jbc.273.49.32500; MORCH MD, 1986, METHOD ENZYMOL, V118, P154; MORRIS DR, 1991, J CELL BIOCHEM, V46, P102, DOI 10.1002/jcb.240460203; PAJUNEN A, 1988, J BIOL CHEM, V263, P17040; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1982, AM J PHYSIOL, V243, P212; ROGERS EJ, 1994, MOL MICROBIOL, V12, P181, DOI 10.1111/j.1365-2958.1994.tb01007.x; Ruan HJ, 1996, J BIOL CHEM, V271, P29576, DOI 10.1074/jbc.271.47.29576; SEILER N, 1983, METHOD ENZYMOL, V94, P10; SHIRAHATA A, 1985, J BIOL CHEM, V260, P9583; SHIRAHATA A, 1986, J BIOL CHEM, V261, P3833; SPERRAZZA JM, 1981, BIOCHEMISTRY-US, V20, P5073, DOI 10.1021/bi00520a038; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1976, ANNU REV BIOCHEM, V45, P285, DOI 10.1146/annurev.bi.45.070176.001441; TABOR H, 1964, PHARMACOL REV, V16, P245; TAKEDA Y, 1969, BIOCHEM BIOPH RES CO, V37, P917, DOI 10.1016/0006-291X(69)90218-6; Wang Z, 1997, J BIOL CHEM, V272, P255; Wang Z, 1997, MOL CELL BIOL, V17, P4904, DOI 10.1128/MCB.17.9.4904; WHITE MW, 1990, BIOCHEM J, V268, P657, DOI 10.1042/bj2680657	39	38	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24444	24450		10.1074/jbc.M003364200	http://dx.doi.org/10.1074/jbc.M003364200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10829027	hybrid			2022-12-25	WOS:000088683300028
J	Saiardi, A; Caffrey, JJ; Snyder, SH; Shears, SB				Saiardi, A; Caffrey, JJ; Snyder, SH; Shears, SB			The inositol hexakisphosphate kinase family - Catalytic flexibility and function in yeast vacuole biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHOINOSITOL POLYPHOSPHATE PHOSPHOHYDROLASE; SACCHAROMYCES-CEREVISIAE; PROTEIN; TETRAKISPHOSPHATE; PENTAKISPHOSPHATE; CELLS; METABOLISM; TURNOVER; 1,3,4,5,6-PENTAKISPHOSPHATE; 1,3,4,6-TETRAKISPHOSPHATE	Saiardi et al. (Saiardi, A., Erdjument-Bromage, H., Snowman, A., Tempst, P., and Snyder, S. H. (1999) Curr. Biol. 9, 1323-1326) previously described the cloning of a kinase from yeast and two kinases from mammals (types 1 and 2), which phosphorylate inositol hexakisphosphate (InsP(6)) to diphosphoinositol pentakisphosphate, a "high energy" candidate regulator of cellular trafficking. We have now studied the significance of InsP(6) kinase activity in Saccharomyces cerevisiae by disrupting the kinase gene. These ip6k Delta cells grew more slowly their levels of diphosphoinositol polyphosphates were 60-80% lower than wild-type cells, and the cells contained abnormally small and fragmented vacuoles. Novel activities of the mammalian and yeast InsP(6) kinases mere identified; inositol pentakisphosphate (InsP(5)) was phosphorylated to diphosphoinositol tetrakisphosphate (PP-InsP(4)), which was further metabolized to a novel compound, tentatively identified as bis-diphosphoinositol trisphosphate, The latter is a new substrate for human diphosphoinositol polyphosphate phosphohydrolase. Kinetic parameters for the mammalian type 1 kinase indicate that InsP(5) (K-m = 1.2 mu M) and InsP(6) (K-m = 6.7 mu M) compete for phosphorylation in vivo. This is the first time a PP-InsP(4) synthase has been identified. The mammalian type 2 kinase and the yeast kinase are more specialized for the phosphorylation of InsP(6). Synthesis of the diphosphorylated inositol phosphates is thus revealed to be more complex and interdependent than previously envisaged.	NIEHS, Inositide Signaling Grp, Inositide Signaling Sect, Lab Signal Transduct,NIH, Res Triangle Pk, NC 27709 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Shears, SB (corresponding author), NIEHS, Inositide Signaling Grp, Inositide Signaling Sect, Lab Signal Transduct,NIH, 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	Shears@niehs.nih.gov	Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NIDA NIH HHS [DA00074] Funding Source: Medline; NIMH NIH HHS [MH18501] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albert C, 1997, BIOCHEM J, V327, P553, DOI 10.1042/bj3270553; ALI N, 1995, BIOCHEM J, V310, P279, DOI 10.1042/bj3100279; BALLA T, 1994, MOL BIOL CELL, V5, P17, DOI 10.1091/mbc.5.1.17; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Caffrey JJ, 2000, J BIOL CHEM, V275, P12730, DOI 10.1074/jbc.275.17.12730; CONIBEAR E, 1995, CELL, V83, P513, DOI 10.1016/0092-8674(95)90088-8; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; GLENNON MC, 1993, BIOCHEM J, V293, P583, DOI 10.1042/bj2930583; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; GUSE AH, 1993, J BIOL CHEM, V268, P7129; HESLOP JP, 1985, J EXP BIOL, V119, P395; Hinchliffe KA, 1998, BBA-MOL CELL BIOL L, V1436, P87, DOI 10.1016/S0005-2760(98)00140-4; Ho MWY, 1997, AM J PHYSIOL-CELL PH, V272, pC1160, DOI 10.1152/ajpcell.1997.272.4.C1160; Huang CF, 1998, BIOCHEMISTRY-US, V37, P14998, DOI 10.1021/bi981920l; HUANG KN, 1995, GENETICS, V141, P1275; HUGHES PJ, 1989, J BIOL CHEM, V264, P19871; IRVINE RF, 1988, PHILOS T ROY SOC B, V320, P281, DOI 10.1098/rstb.1988.0077; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Safrany ST, 1999, BIOL CHEM, V380, P945, DOI 10.1515/BC.1999.117; Safrany ST, 1999, J BIOL CHEM, V274, P21735, DOI 10.1074/jbc.274.31.21735; Safrany ST, 1998, EMBO J, V17, P1710, DOI 10.1093/emboj/17.6.1710; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Saiardi A, 2000, FEBS LETT, V468, P28, DOI 10.1016/S0014-5793(00)01194-7; Schell MJ, 1999, FEBS LETT, V461, P169, DOI 10.1016/S0014-5793(99)01462-3; SHEARS SB, 1995, J BIOL CHEM, V270, P10489, DOI 10.1074/jbc.270.18.10489; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; SHEARS SB, 1997, SIGNALLING INOSITIDE, P33; Srivastava A, 1998, GENETICS, V148, P85; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; Voglmaier SM, 1996, P NATL ACAD SCI USA, V93, P4305, DOI 10.1073/pnas.93.9.4305; Xie WW, 1996, J BIOL CHEM, V271, P14092, DOI 10.1074/jbc.271.24.14092; Yamaguchi Y, 1996, J BIOL CHEM, V271, P27838, DOI 10.1074/jbc.271.44.27838; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96	37	141	146	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24686	24692		10.1074/jbc.M002750200	http://dx.doi.org/10.1074/jbc.M002750200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827188	hybrid			2022-12-25	WOS:000088683300062
J	Waldegger, S; Jentsch, TJ				Waldegger, S; Jentsch, TJ			Functional and structural analysis of ClC-K chloride channels involved in renal disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THICK ASCENDING LIMB; BARTTERS-SYNDROME; RAT-KIDNEY; CA2+-SENSING RECEPTOR; PLASMA-MEMBRANE; DENTS-DISEASE; MUTATIONS; MYOTONIA; DOMINANT; LOCALIZATION	CIC-K channels belong to the CLC family of chloride channels and are predominantly expressed in the kidney. Genetic evidence suggests their involvement in transepithelial transport of chloride in distal nephron segments; ClC-K1 gene deletion leads to nephrogenic diabetes insipidus in mice, and mutations of the hClC-Kb gene cause Bartter's syndrome type III in humans. Expression of rClC-K1 in Xenopus oocytes yielded voltage-independent currents that were pH-sensitive, had a Br- > NO3- = Cl- > I- conductance sequence, and were activated by extracellular calcium. A glutamate for valine exchange at amino acid position 166 induced strong voltage dependence and altered the conductance sequence of ClC-K1. This demonstrates that rClC-K1 indeed functions as an anion channel. By contrast, we did not detect currents upon hClC-Kb expression in Xenopus oocytes. Using a chimeric approach, we defined a protein domain that, when replaced by that of rClC-K1, allowed the functional expression of a chimera consisting predominantly of hClC-Kb. Its currents were linear and were inhibited by extracellular acidification. Contrasting with rClC-K1, they displayed a Cl- > Br- > I- > NO3- conductance sequence and mere not augmented by extracellular calcium, Insertion of point mutations associated with Bartter's syndrome type III destroyed channel activity. We conclude that ClC-K proteins form constitutively open chloride channels with distinct physiological characteristics.	Univ Hamburg, ZMNH, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Waldegger, S (corresponding author), Univ Hamburg, ZMNH, Zentrum Mol Neurobiol, Martinistr 85, D-20246 Hamburg, Germany.	siegfried.waldegger@zmnh.uni-hamburg.de		Jentsch, Thomas/0000-0002-3509-2553				ADACHI S, 1994, J BIOL CHEM, V269, P17677; Asplin JR, 1996, AM J PHYSIOL-RENAL, V270, pF604, DOI 10.1152/ajprenal.1996.270.4.F604; Brown EM, 1995, J AM SOC NEPHROL, V6, P1530; Buyse G, 1997, J BIOL CHEM, V272, P3615, DOI 10.1074/jbc.272.6.3615; Devuyst O, 1999, HUM MOL GENET, V8, P247, DOI 10.1093/hmg/8.2.247; Fahlke C, 1997, P NATL ACAD SCI USA, V94, P2729, DOI 10.1073/pnas.94.6.2729; Fahlke C, 1997, NATURE, V390, P529, DOI 10.1038/37391; Fahlke C, 1998, NATURE, V394, P687, DOI 10.1038/29319; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; GUINAMARD R, 1995, J PHYSIOL-LONDON, V485, P97, DOI 10.1113/jphysiol.1995.sp020715; Gunther W, 1998, P NATL ACAD SCI USA, V95, P8075, DOI 10.1073/pnas.95.14.8075; Hebert SC, 1997, J EXP BIOL, V200, P295; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; KONDO Y, 1988, AM J PHYSIOL, V254, pF232, DOI 10.1152/ajprenal.1988.254.2.F232; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Ludewig U, 1997, J PHYSIOL-LONDON, V498, P691, DOI 10.1113/jphysiol.1997.sp021893; Ludewig U, 1997, J GEN PHYSIOL, V110, P165, DOI 10.1085/jgp.110.2.165; Ludewig U, 1996, NATURE, V383, P340, DOI 10.1038/383340a0; Matsumura Y, 1999, NAT GENET, V21, P95, DOI 10.1038/5036; Maulet Y, 1999, BIOCHEM J, V340, P737, DOI 10.1042/bj3400737; Middleton RE, 1996, NATURE, V383, P337, DOI 10.1038/383337a0; PAULAIS M, 1990, J MEMBRANE BIOL, V113, P253, DOI 10.1007/BF01870076; Ponting CP, 1997, J MOL MED-JMM, V75, P160; PUSCH M, 1995, NATURE, V373, P527, DOI 10.1038/373527a0; Pusch M, 1995, NEURON, V15, P1455, DOI 10.1016/0896-6273(95)90023-3; Sands JM, 1997, J CLIN INVEST, V99, P1399, DOI 10.1172/JCI119299; Saviane C, 1999, J GEN PHYSIOL, V113, P457, DOI 10.1085/jgp.113.3.457; SchmidtRose T, 1997, P NATL ACAD SCI USA, V94, P7633, DOI 10.1073/pnas.94.14.7633; SchmidtRose T, 1997, J BIOL CHEM, V272, P20515, DOI 10.1074/jbc.272.33.20515; Schwappach B, 1998, J BIOL CHEM, V273, P15110, DOI 10.1074/jbc.273.24.15110; Simon DB, 1996, NAT GENET, V14, P152, DOI 10.1038/ng1096-152; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; Simon DB, 1997, NAT GENET, V17, P171, DOI 10.1038/ng1097-171; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; UCHIDA S, 1995, J CLIN INVEST, V95, P104, DOI 10.1172/JCI117626; UCHIDA S, 1993, J BIOL CHEM, V268, P3821; Vandewalle A, 1997, AM J PHYSIOL-RENAL, V272, pF678, DOI 10.1152/ajprenal.1997.272.5.F678; Winters CJ, 1999, KIDNEY INT, V55, P1444, DOI 10.1046/j.1523-1755.1999.00401.x; Winters CJ, 1997, AM J PHYSIOL-RENAL, V273, pF1030, DOI 10.1152/ajprenal.1997.273.6.F1030; Zhang J, 2000, J BIOL CHEM, V275, P2999, DOI 10.1074/jbc.275.4.2999; ZIMNIAK L, 1995, KIDNEY INT, V48, P1828, DOI 10.1038/ki.1995.481	42	86	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24527	24533		10.1074/jbc.M001987200	http://dx.doi.org/10.1074/jbc.M001987200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10831588	hybrid			2022-12-25	WOS:000088683300040
J	Xie, Z; Ho, WT; Exton, JH				Xie, Z; Ho, WT; Exton, JH			Association of the N- and C-terminal domains of phospholipase D - Contribution of the conserved HKD motifs to the interaction and the requirement of the association for Ser/Thr phosphorylation of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADP-RIBOSYLATION FACTOR; RAT-BRAIN; TYROSINE PHOSPHORYLATION; AGONIST STIMULATION; D DEFINES; D ISOZYME; FAMILY; SUPERFAMILY; EXPRESSION	Rat brain phospholipase D1 (rPLD1) belongs to a superfamily defined by the highly conserved catalytic motif (H(X)K(X)(4)D, denoted HKD.rPLD1 contains two HKD domains, located in the N- and C-terminal regions. The integrity of the two HKD domains is essential for enzymatic activity, Our previous studies showed that the N-terminal half of rPLD1 containing one HKD motif can associate with the C-terminal half containing the other HKD domain to reconstruct wild type PLD activity (Xie, Z., Ho, W.-T. and Exton, J. H. (1998) J. Biol. Chem. 273, 34679-34682), In the present study, we have shown by mutagenesis that conserved amino acids in the HKD domains are important for both the catalytic activity and the association between the two halves of rPLD1, Furthermore, we found that rPLD1 could be modified by Ser/Thr phosphorylation, The modification occurred at the N-terminal half of the enzyme, however, the association of the N-terminal domain with the C-terminal domain was required for the modification The phosphorylation of the enzyme was not required for its catalytic activity or response to PKC alpha and small G proteins in vitro, although the phosphorylated form of rPLD1 was localized exclusively in the crude membrane fraction. In addition, me found that the individually expressed Nand C-terminal fragments did not interact when mixed in vitro and were unable to reconstruct PLD activity under these conditions. It is concluded that the association of the N- and C-terminal halves of rPLD1 requires their co-expression in vivo and depends on conserved residues in the HRD domains. The association is also required for Ser/Thr phosphorylation of the enzyme.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, 221 Kirkland Hall, Nashville, TN 37232 USA.							Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Czarny M, 1999, J BIOL CHEM, V274, P2717, DOI 10.1074/jbc.274.5.2717; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; Gottlin EB, 1998, P NATL ACAD SCI USA, V95, P9202, DOI 10.1073/pnas.95.16.9202; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Horstman DA, 1996, P NATL ACAD SCI USA, V93, P7518, DOI 10.1073/pnas.93.15.7518; Houle MG, 1999, BBA-MOL CELL BIOL L, V1439, P135, DOI 10.1016/S1388-1981(99)00090-6; KATO I, 1969, J BIOL CHEM, V244, P1004; Kim JH, 1999, BIOCHEMISTRY-US, V38, P3763, DOI 10.1021/bi982478+; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; MACKINTOSH C, 1990, FEBS LETT, V264, P187, DOI 10.1016/0014-5793(90)80245-E; MacMillan LB, 1999, J BIOL CHEM, V274, P35845, DOI 10.1074/jbc.274.50.35845; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; Marcil J, 1997, J BIOL CHEM, V272, P20660, DOI 10.1074/jbc.272.33.20660; Min DS, 1998, J BIOL CHEM, V273, P7044, DOI 10.1074/jbc.273.12.7044; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Niu TQ, 1999, J CELL BIOCHEM, V72, P145, DOI 10.1002/(SICI)1097-4644(19990101)72:1<145::AID-JCB15>3.0.CO;2-G; Park SK, 1998, BIOCHEM BIOPH RES CO, V244, P364, DOI 10.1006/bbrc.1998.8275; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Ponting CP, 1996, PROTEIN SCI, V5, P914; Rudge SA, 1998, J CELL BIOL, V140, P81, DOI 10.1083/jcb.140.1.81; Rudolph AE, 1999, J BIOL CHEM, V274, P11824, DOI 10.1074/jbc.274.17.11824; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; Stuckey JA, 1999, NAT STRUCT BIOL, V6, P278; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; ULLMANN A, 1967, J MOL BIOL, V24, P339, DOI 10.1016/0022-2836(67)90341-5; Watanabe H, 2000, BBA-MOL CELL RES, V1495, P121, DOI 10.1016/S0167-4889(99)00165-2; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Xie Z, 1998, J BIOL CHEM, V273, P34679, DOI 10.1074/jbc.273.52.34679; Yamazaki M, 1999, J BIOL CHEM, V274, P6035, DOI 10.1074/jbc.274.10.6035	39	48	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24962	24969		10.1074/jbc.M909745199	http://dx.doi.org/10.1074/jbc.M909745199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10825182	hybrid			2022-12-25	WOS:000088683300097
J	Brelot, A; Heveker, N; Montes, M; Alizon, M				Brelot, A; Heveker, N; Montes, M; Alizon, M			Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; CELL-DERIVED FACTOR-1; HIV-1 ENTRY; TROPIC HIV; LYMPHOCYTE CHEMOATTRACTANT; ENVELOPE GLYCOPROTEIN; MOLECULAR-CLONING; C5A RECEPTOR; TYPE-1 ENTRY; FACTOR-I	CXCR4 is a G-coupled receptor for the stromal cell-derived factor (SDF-1) chemokine, and a CD4-associated human immunodeficiency virus type 1 (HIV-1) coreceptor. These functions were studied in a panel of CXCR4 mutants bearing deletions in the NH2-terminal extracellular domain (NT) or substitutions in the NT, the extracellular loops (ECL), or the transmembrane domains (TMs). The coreceptor activity of CXCR4 was markedly impaired by mutations of two Tyr residues in NT (Y7A/ Y12A) or at a single Asp residue in ECL2 (D193A), ECL3 (D262A), or TMII (D97N). These acidic residues could engage electrostatical interactions with basic residues of the HIV-1 envelope protein gp120, known to contribute to the selectivity for CXCR4. The ability of CXCR4 mutants to bind SDF-1 and mediate cell signal was consistent with the two-site model of chemokine-receptor interaction. Site I involved in SDF-1 binding but not signaling was located in NT with particular importance of Glu(14) and/or Glu(15) and Tyr(21). Residues required for both SDF-1 binding and signaling, and thus probably part of site II, were identified in ECL2 (Asp(187)), TMII (Asp(97)), and TMVII (Glu(288)). The first residues (2-9) of NT also seem required for SDF-1 binding and signaling. A deletion in the third intracellular loop abolished signaling, probably by disrupting the coupling with G proteins. The identification of CXCR4 residues involved in the interaction with both SDF-1 and HIV-1 may account for the signaling activity of gp120 and has implications for the development of antiviral compounds.	Inst Cochin Genet Mol, INSERM, U332, F-75014 Paris, France; CHU Pitie Salpetriere, CNRS, URA 7627, F-75013 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS)	Alizon, M (corresponding author), Inst Cochin Genet Mol, INSERM, U332, 22 Rue Mechain, F-75014 Paris, France.		Heveker, Nikolaus/G-5306-2012; Brelot, Anne/P-4129-2017	Brelot, Anne/0000-0002-8095-4909				Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Baggiolini M, 1997, J EXP MED, V186, P1189, DOI 10.1084/jem.186.8.1189; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Brelot A, 1999, J VIROL, V73, P2576, DOI 10.1128/JVI.73.4.2576-2586.1999; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; Chabot DJ, 1999, J VIROL, V73, P6598, DOI 10.1128/JVI.73.8.6598-6609.1999; Chen ZG, 1998, J BIOL CHEM, V273, P10411, DOI 10.1074/jbc.273.17.10411; Cho MW, 1998, J VIROL, V72, P2509, DOI 10.1128/JVI.72.3.2509-2515.1998; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; DRAGIC T, 1995, METH MOL G, V7, P218; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Gupta SK, 1999, J IMMUNOL, V163, P2368; HARRINGTON RD, 1993, J VIROL, V67, P5939, DOI 10.1128/JVI.67.10.5939-5947.1993; Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1; Hoffman T L, 1998, AIDS, V12 Suppl A, pS17; Iyengar S, 1999, J IMMUNOL, V162, P6263; Labrosse B, 1998, J VIROL, V72, P6381, DOI 10.1128/JVI.72.8.6381-6388.1998; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Loetscher P, 1998, J BIOL CHEM, V273, P22279, DOI 10.1074/jbc.273.35.22279; Lu ZH, 1997, P NATL ACAD SCI USA, V94, P6426, DOI 10.1073/pnas.94.12.6426; McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405; Mondor I, 1998, VIROLOGY, V248, P394, DOI 10.1006/viro.1998.9282; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; PEDEN K, 1991, VIROLOGY, V185, P661, DOI 10.1016/0042-6822(91)90537-L; Pelchen-Matthews A, 1999, IMMUNOL REV, V168, P33, DOI 10.1111/j.1600-065X.1999.tb01281.x; Pleskoff O, 1998, J VIROL, V72, P6389, DOI 10.1128/JVI.72.8.6389-6397.1998; Pleskoff O, 1997, J VIROL, V71, P3259, DOI 10.1128/JVI.71.4.3259-3262.1997; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; Rabut GEE, 1998, J VIROL, V72, P3464, DOI 10.1128/JVI.72.4.3464-3468.1998; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259; Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Speck RF, 1997, J VIROL, V71, P7136, DOI 10.1128/JVI.71.9.7136-7139.1997; SPIRE B, 1989, GENE, V81, P275, DOI 10.1016/0378-1119(89)90188-1; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Wang ZX, 1998, J BIOL CHEM, V273, P15007, DOI 10.1074/jbc.273.24.15007; Weissman D, 1997, NATURE, V389, P981, DOI 10.1038/40173; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Zhang LQ, 1998, J VIROL, V72, P5035, DOI 10.1128/JVI.72.6.5035-5045.1998; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	61	202	210	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23736	23744		10.1074/jbc.M000776200	http://dx.doi.org/10.1074/jbc.M000776200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10825158	hybrid			2022-12-25	WOS:000088564200047
J	Fei, YJ; Sugawara, M; Nakanishi, T; Huang, W; Wang, HP; Prasad, PD; Leibach, FH; Ganapathy, V				Fei, YJ; Sugawara, M; Nakanishi, T; Huang, W; Wang, HP; Prasad, PD; Leibach, FH; Ganapathy, V			Primary structure, genomic organization, and functional and electrogenic characteristics of human system N 1, a Na+- and H+-coupled glutamine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-TRANSPORT; SKELETAL-MUSCLE; MOLECULAR-BIOLOGY; RAT-LIVER; METABOLISM; IDENTIFICATION; CLONING; CELL; COTRANSPORTER; EXPRESSION	We have cloned the human Na+- and H+-coupled amino acid transport system N (hSN1) from HepG2 liver cells and investigated its functional characteristics. Human SN1 protein consists of 504 amino acids and shows high homology to rat SN1 and rat brain glutamine transporter (GlnT). When expressed in mammalian cells, the transport function of human SN1 could be demonstrated with glutamine as the substrate in the presence of LiCl (instead of NaCl) and cysteine. The transport activity was saturable, pH-sensitive, and specific for glutamine, histidine, asparagine, and alanine. Analysis of Li+ activation kinetics showed a Li+:glutamine stoichiometry of 2:1. When expressed in Xenopus laevis oocytes, the transport of glutamine or asparagine via human SN1 was associated with inward currents under voltage-clamped conditions. The transport function, monitored as glutamine- or asparagine-induced currents, was saturable, Na+-dependent, Li+-tolerant, and pH-sensitive. The transport cycle was associated with the involvement of more than one Na+ ion. Uptake of asparagine was directly demonstrable in these oocytes by using radiolabeled substrate, and this uptake was inhibited by membrane depolarization. In addition, simultaneous measurement of asparagine influx and charge influx in the same oocyte yielded an asparagine:charge ratio of 1. These data suggest that SN1 mediates the influx of two Na+ and one amino acid substrate per transport cycle coupled to the efflux of one H+, rendering the transport process electrogenic.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Ganapathy, V (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.	vganapat@mail.mcg.edu	Sugawara, Mitsuru/A-5274-2012; Nakanishi, Takeo/C-3891-2015	Sugawara, Mitsuru/0000-0001-5350-2950; Nakanishi, Takeo/0000-0002-6561-7138	NICHD NIH HHS [HD33347] Funding Source: Medline; NIDA NIH HHS [DA10045] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010045] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ABUMRAD NN, 1989, DIABETES METAB REV, V5, P213, DOI 10.1002/dmr.5610050302; AHMED A, 1993, AM J PHYSIOL, V264, pE993, DOI 10.1152/ajpendo.1993.264.6.E993; BRANDSCH M, 1994, BBA-BIOMEMBRANES, V1192, P177, DOI 10.1016/0005-2736(94)90116-3; CAHILL GF, 1976, CLIN ENDOCRINOL META, V5, P397, DOI 10.1016/S0300-595X(76)80028-X; Chaudhry FA, 1999, CELL, V99, P769, DOI 10.1016/S0092-8674(00)81674-8; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; FEI YJ, 1995, BIOCHEMISTRY-US, V34, P8744, DOI 10.1021/bi00027a025; Fei YJ, 1999, BBA-BIOMEMBRANES, V1418, P344, DOI 10.1016/S0005-2736(99)00046-2; HAUSSINGER D, 1989, EUR J BIOCHEM, V185, P189, DOI 10.1111/j.1432-1033.1989.tb15101.x; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; Kekuda R, 1997, AM J PHYSIOL-GASTR L, V272, pG1463, DOI 10.1152/ajpgi.1997.272.6.G1463; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Kekuda R, 1996, J BIOL CHEM, V271, P18657, DOI 10.1074/jbc.271.31.18657; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; Mackenzie B, 1996, BBA-BIOMEMBRANES, V1284, P125, DOI 10.1016/S0005-2736(96)00170-8; McIntire SL, 1997, NATURE, V389, P870, DOI 10.1038/39908; MITSUMOTO Y, 1986, J BIOL CHEM, V261, P4549; OLIVER J, 1977, EUR J CLIN INVEST, V7, P445, DOI 10.1111/j.1365-2362.1977.tb01632.x; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PENG L, 1993, DEV NEUROSCI-BASEL, V15, P367, DOI 10.1159/000111357; Pouyssegur J, 1987, Methods Enzymol, V151, P131, DOI 10.1016/S0076-6879(87)51014-X; Prasad PD, 2000, BIOCHEM BIOPH RES CO, V270, P836, DOI 10.1006/bbrc.2000.2498; Rajan DP, 1999, J BIOL CHEM, V274, P29005, DOI 10.1074/jbc.274.41.29005; Rajan DP, 2000, BBA-BIOMEMBRANES, V1463, P6, DOI 10.1016/S0005-2736(99)00224-2; Rennie MJ, 1996, BIOCHEM SOC T, V24, P869, DOI 10.1042/bst0240869; RENNIE MJ, 1989, METABOLISM, V38, P47, DOI 10.1016/0026-0495(89)90140-6; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; SHOTWELL MA, 1981, J BIOL CHEM, V256, P5422; Sibson NR, 1997, P NATL ACAD SCI USA, V94, P2699, DOI 10.1073/pnas.94.6.2699; Sugawara M, 2000, J BIOL CHEM, V275, P16473, DOI 10.1074/jbc.C000205200; Tamarappoo BK, 1997, J NEUROCHEM, V68, P954; Taylor P, 1999, BIOMEMBRANE TRANSPOR, P295, DOI [DOI 10.1016/B978-012714510-5/50011-8, 10.1016/B978-012714510-5/50011-8]; Torres-Zamorano V, 1998, BIOCHEM BIOPH RES CO, V245, P824, DOI 10.1006/bbrc.1998.8434; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; VAUGHN PR, 1995, AM J PHYSIOL-ENDOC M, V268, pE705, DOI 10.1152/ajpendo.1995.268.4.E705; Wang HP, 1999, BBA-BIOMEMBRANES, V1461, P1, DOI 10.1016/S0005-2736(99)00182-0; Wang HP, 2000, AM J PHYSIOL-CELL PH, V278, pC1019, DOI 10.1152/ajpcell.2000.278.5.C1019; Windmueller HG., 1984, GLUTAMINE METABOLISM; Wu X, 1998, J BIOL CHEM, V273, P32776, DOI 10.1074/jbc.273.49.32776; Zalkin H, 1998, ADV ENZYMOL RAMB, V72, P87	45	86	91	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23707	23717		10.1074/jbc.M002282200	http://dx.doi.org/10.1074/jbc.M002282200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10823827	hybrid			2022-12-25	WOS:000088564200043
J	Oshel, KM; Knight, JB; Cao, KT; Thai, MV; Olson, AL				Oshel, KM; Knight, JB; Cao, KT; Thai, MV; Olson, AL			Identification of a 30-base pair regulatory element and novel DNA binding protein that regulates the human GLUT4 promoter in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE-TRANSPORTER; TRANSCRIPTIONAL REGULATION; INSULIN-RESISTANCE; SKELETAL-MUSCLE; GENE-EXPRESSION; ADIPOSE-TISSUE; MESSENGER-RNA; PRETRANSLATIONAL SUPPRESSION; OVEREXPRESSING GLUT4; METABOLIC-REGULATION	We have previously demonstrated that the important cis-acting elements regulating transcription of the human GLUT4 gene reside within 895 base pairs (bp) upstream of the transcription initiation site (Thai, M. V., Guruswamy, S., Cao, K. T., Pessin, J. E., and Olson, A. L. (1998) J. Biol. Chem. 273, 14285-14292). Our studies demonstrated that an MEF2 binding site within this region was necessary, but not sufficient, for GLUT4 promoter function in transgenic mice. We have identified a second regulatory element (Domain I) that functions cooperatively with the MEF2 domain in regulating GLUT4 transcription. Using a yeast-one hybrid screen, we obtained a partial cDNA and generated an antibody directed against a protein binding specifically to Domain I. Sequence analysis of the partial cDNA indicates that the protein binding to Domain I is a novel protein. The antibody specifically labels two proteins of approximately 70 and 50 kDa in Western blot analysis. These molecular masses correspond to Domain I binding proteins identified by UV-cross-linking nuclear extracts to a Domain I probe. The antibody raised against the Domain I binding protein inhibited formation of a Domain I-protein complex in electrophoretic mobility shift assays. We conclude that we have identified an authentic, novel, Domain I binding protein required for transcriptional regulation of the human GLUT4 promoter.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Olson, AL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, POB 26901,Rm 853-BMSB, Oklahoma City, OK 73190 USA.				NIDDK NIH HHS [DK47894] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK047894, R01DK047894] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGER J, 1989, NATURE, V340, P70, DOI 10.1038/340070a0; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BOUREY RE, 1990, J CLIN INVEST, V86, P542, DOI 10.1172/JCI114742; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; CHARRON MJ, 1990, J BIOL CHEM, V265, P7994; Charron MJ, 1999, J BIOL CHEM, V274, P3253, DOI 10.1074/jbc.274.6.3253; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cooke DW, 1999, J BIOL CHEM, V274, P12917, DOI 10.1074/jbc.274.18.12917; Cooke DW, 1998, J BIOL CHEM, V273, P6210, DOI 10.1074/jbc.273.11.6210; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; GARVEY WT, 1991, J CLIN INVEST, V87, P1072, DOI 10.1172/JCI115068; GARVEY WT, 1989, SCIENCE, V245, P60, DOI 10.1126/science.2662408; GERRITS PM, 1993, J BIOL CHEM, V268, P640; GIBBS EM, 1995, J CLIN INVEST, V95, P1512, DOI 10.1172/JCI117823; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; LEMARCHANDBRUSTEL Y, 1990, ENDOCRINOLOGY, V127, P2687; Leturque A, 1996, DIABETES, V45, P23, DOI 10.2337/diabetes.45.1.23; LIU ML, 1992, J BIOL CHEM, V267, P11673; LIU ML, 1993, P NATL ACAD SCI USA, V90, P11346, DOI 10.1073/pnas.90.23.11346; NEUFER PD, 1993, J BIOL CHEM, V268, P13824; Olson AL, 1996, SEMIN CELL DEV BIOL, V7, P287, DOI 10.1006/scdb.1996.0037; OLSON AL, 1990, PEDIATR RES, V28, P183, DOI 10.1203/00006450-199009000-00001; OLSON AL, 1993, J BIOL CHEM, V268, P9839; OLSON AL, 1995, J BIOL CHEM, V270, P23491, DOI 10.1074/jbc.270.40.23491; Olson AL, 1996, ANNU REV NUTR, V16, P235, DOI 10.1146/annurev.nu.16.070196.001315; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SIVITZ WI, 1990, MOL ENDOCRINOL, V4, P583, DOI 10.1210/mend-4-4-583; SIVITZ WI, 1989, NATURE, V340, P72, DOI 10.1038/340072a0; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; Tozzo E, 1997, ENDOCRINOLOGY, V138, P1604, DOI 10.1210/en.138.4.1604; TREADWAY JL, 1994, J BIOL CHEM, V269, P29956; TSUSHUEN T, 1996, DIABETES, V45, P28	37	79	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23666	23673		10.1074/jbc.M001452200	http://dx.doi.org/10.1074/jbc.M001452200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10825161	hybrid			2022-12-25	WOS:000088564200038
J	Hagemann, D; Kuschel, M; Kuramochi, T; Zhu, WZ; Cheng, HP; Xiao, RP				Hagemann, D; Kuschel, M; Kuramochi, T; Zhu, WZ; Cheng, HP; Xiao, RP			Frequency-encoding Thr(17) phospholamban phosphorylation is independent of Ser(16) phosphorylation in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC STIMULATION; PROTEIN-KINASE; HEART-CELLS; INTACT HEART; MECHANISMS; SITES; CONTRACTILITY; RELAXATION; VENTRICLES; CANINE	Both Ser(16) and Thr(17) Of phospholamban (PLB) are phosphorylated, respectively, by cAMP-dependent protein kinase (PKA) and Ca2+/calmodulin-dependent protein kinase II (CaMKII), PLB phosphorylation relieves cardiac sarcoplasmic reticulum Ca2+ pump from inhibition by PLB. Previous studies have suggested that phosphorylation of Ser(16) by PKA is a prerequisite for Thr(17) phosphorylation by CaMKII and is essential to the relaxant effect of beta-adrenergic stimulation. To determine the role of Thr(17) PLB phosphorylation, we investigated the dual-site phosphorylation of PLB in isolated adult rat cardiac myocytes in response to beta(1)-adrenergic stimulation or electrical field stimulation (0.1-3 Hz) or both. A beta(1)-adrenergic agonist, norepinephrine (10(-9)-10(-6) M), in the presence of an alpha(1)-adrenergic antagonist, prazosin (10(-6) hr), selectively increases the PKA-dependent phos- phorylation of PLB at Ser(16) in quiescent myocytes, In contrast, electrical pacing induces an opposite phosphorylation pattern, selectively enhancing the CaMKII-mediated Thr(17) PLB phosphorylation in a frequency-dependent manner. When combined, electric stimulation (2 Hz) and beta(1)-adrenergic stimulation lead to dual phosphorylation of PLB and exert a synergistic effect on phosphorylation of Thr(17) but not Ser(16) Frequency-dependent Thr(17) phosphorylation is closely correlated with a decrease in 50% relaxation time (t(50)) of cell contraction, which is independent of, but additive to, the relaxant effect of Ser(16) phosphorylation, resulting in hastened contractile relaxation at high stimulation frequencies. Thus, we conclude that in intact cardiac myocytes, phosphorylation of PLB at Thr(17) occurs in the absence of prior Ser(16) phosphorylation, and that frequencydependent Thr(17) PLB phosphorylation may provide an intrinsic mechanism for cardiac myocytes to adapt to a sudden change of heart rate.	NIA, Gerontol Res Ctr, Cardiovasc Sci Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Xiao, RP (corresponding author), NIA, Gerontol Res Ctr, Cardiovasc Sci Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Xiao, Rui-Ping/AAE-2629-2019; Heping, Cheng/AAE-2680-2019; Yimei, Wang/AAE-4083-2019	Heping, Cheng/0000-0002-9604-6702; 				ALTSCHULD RA, 1995, CIRCULATION, V92, P1612, DOI 10.1161/01.CIR.92.6.1612; BEAN BP, 1984, NATURE, V307, P371, DOI 10.1038/307371a0; BILEZIKJIAN LM, 1981, CIRC RES, V49, P1356, DOI 10.1161/01.RES.49.6.1356; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DEWEILENMANN CM, 1987, BASIC RES CARDIOL, V82, P507; DRAGO GA, 1994, J BIOL CHEM, V269, P25073; Gupta RC, 1996, AM J PHYSIOL-HEART C, V270, pH1159, DOI 10.1152/ajpheart.1996.270.4.H1159; INUI M, 1986, J BIOL CHEM, V261, P1794; KARCZEWSKI P, 1990, BIOCHEM J, V266, P115, DOI 10.1042/bj2660115; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Kuschel M, 1999, AM J PHYSIOL-HEART C, V276, pH1625, DOI 10.1152/ajpheart.1999.276.5.H1625; Kuschel M, 1999, J BIOL CHEM, V274, P22048, DOI 10.1074/jbc.274.31.22048; Kuschel M, 1999, CIRCULATION, V99, P2458, DOI 10.1161/01.CIR.99.18.2458; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; LINDEMANN JP, 1985, J BIOL CHEM, V260, P4516; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luo WS, 1998, J BIOL CHEM, V273, P4734, DOI 10.1074/jbc.273.8.4734; MACDOUGALL LK, 1991, EUR J BIOCHEM, V196, P725, DOI 10.1111/j.1432-1033.1991.tb15871.x; Mayer EJ, 2000, BIOCHEM BIOPH RES CO, V267, P40, DOI 10.1006/bbrc.1999.1920; MundinaWeilenmann C, 1996, J BIOL CHEM, V271, P33561, DOI 10.1074/jbc.271.52.33561; NAPOLITANO R, 1992, J MOL CELL CARDIOL, V24, P387, DOI 10.1016/0022-2828(92)93193-N; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; SPURGEON HA, 1990, AM J PHYSIOL, V258, P574; TALOSI L, 1993, AM J PHYSIOL, V264, pH791; VITTONE L, 1990, AM J PHYSIOL, V258, pH318, DOI 10.1152/ajpheart.1990.258.2.H318; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; XIAO RP, 1994, J BIOL CHEM, V269, P19151; XIAO RP, 1993, CIRC RES, V73, P286, DOI 10.1161/01.RES.73.2.286; Xu A, 1997, J MOL CELL CARDIOL, V29, P405, DOI 10.1006/jmcc.1996.0284	31	116	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22532	22536		10.1074/jbc.C000253200	http://dx.doi.org/10.1074/jbc.C000253200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10825152	hybrid			2022-12-25	WOS:000088363800104
J	Holopainen, JM; Medina, OP; Metso, AJ; Kinnunen, PKJ				Holopainen, JM; Medina, OP; Metso, AJ; Kinnunen, PKJ			Sphingomyelinase activity associated with human plasma low density lipoprotein - Possible functional implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATHEROGENIC LIPOPROTEINS; SECRETORY SPHINGOMYELINASE; HUMAN ATHEROSCLEROSIS; ARTERIAL-WALL; CERAMIDE; APOPTOSIS; AGGREGATION; PATHWAY; CELLS; PHOSPHATIDYLCHOLINE	Isolated human plasma low density lipoprotein (LDL) was observed to possess sphingomyelinase activity. Accordingly, the formation of ceramide was catalyzed by LDL at 37 degrees C using tertiary Liposomes composed of sphingomyelin (mole fraction (x) = 0.2), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (x = 0.7), 1,2-dimyristoyl-sn-glycero-3-phospho-rac-glycerol (x = 0.1), and either the fluorescent sphingomyelin analog Bodipy-sphingomyelin or [C-14]sphingomyelin as substrates. However, this activity was not present in either very low density lipoprotein or the high density lipoprotein subfractions HDL2 and HDL3. Oxidation of LDL abrogated its sphingomyelinase activity. Aggregation of the liposomes upon incubation with LDL was evident from the light scattering measurements. Microinjection of LDL to the surface of giant liposomes composed of 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC), N-palmitoyl-D-sphingomyelin (C16:0-sphingomyelin), and Bodipy-sphingomyelin as a fluorescent tracer (0.75:-0.20:0.05, respectively) revealed the induction of vectorial budding of vesicles, resembling endocytosis.	Univ Helsinki, Dept Med Chem, Inst Biomed, Helsinki Biophys & Biomembrane Grp, FIN-00014 Helsinki, Finland	University of Helsinki	Kinnunen, PKJ (corresponding author), Univ Helsinki, Dept Med Chem, Inst Biomed, Helsinki Biophys & Biomembrane Grp, POB 8,Siltavuorenpenger 10A, FIN-00014 Helsinki, Finland.		medina, oula penate/G-5136-2012; Penate-Medina, oula/ABB-8198-2021	medina, oula penate/0000-0001-9878-5309; Penate-Medina, oula/0000-0001-9878-5309				ANGELOVA MI, 1986, FARADAY DISCUSS, V81, P303; Auge N, 1996, J BIOL CHEM, V271, P19251, DOI 10.1074/jbc.271.32.19251; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; CAMEJO G, 1980, ATHEROSCLEROSIS, V35, P307, DOI 10.1016/0021-9150(80)90129-X; CATAPANO AL, 1979, J BIOL CHEM, V254, P1007; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; Fanani ML, 1997, MOL MEMBR BIOL, V14, P25, DOI 10.3109/09687689709048166; FONG LG, 1987, J LIPID RES, V28, P1466; GENG YJ, 1995, AM J PATHOL, V147, P251; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; GUYTON JR, 1996, THROMB VASC BIOL, V16, P4; HAN DKM, 1995, AM J PATHOL, V147, P267; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Heinecke JW, 1997, CURR OPIN LIPIDOL, V8, P268, DOI 10.1097/00041433-199710000-00005; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; Holopainen JM, 2000, BIOPHYS J, V78, P830, DOI 10.1016/S0006-3495(00)76640-9; Holopainen JM, 1997, CHEM PHYS LIPIDS, V88, P1, DOI 10.1016/S0009-3084(97)00040-6; HOLOPAINEN JM, 2000, IN PRESS BIOPHYS J; HUANG XQ, 1991, ADV APPL MATH, V12, P337, DOI 10.1016/0196-8858(91)90017-D; HurtCamejo E, 1997, ARTERIOSCL THROM VAS, V17, P1011, DOI 10.1161/01.ATV.17.6.1011; Jarvis WD, 1996, CLIN CANCER RES, V2, P1; Jeong TS, 1998, J CLIN INVEST, V101, P905, DOI 10.1172/JCI870; KHOO JC, 1988, ARTERIOSCLEROSIS, V8, P348, DOI 10.1161/01.ATV.8.4.348; Kinscherf R, 1997, FEBS LETT, V405, P55, DOI 10.1016/S0014-5793(97)00157-9; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; Kruth HS, 1997, CURR OPIN LIPIDOL, V8, P246, DOI 10.1097/00041433-199710000-00002; Lauraeus S, 1998, BBA-BIOMEMBRANES, V1373, P147, DOI 10.1016/S0005-2736(98)00102-3; Marathe S, 1998, J BIOL CHEM, V273, P4081, DOI 10.1074/jbc.273.7.4081; Matsuo Y, 1996, PROTEIN SCI, V5, P2459, DOI 10.1002/pro.5560051208; Murphy HC, 1997, BIOCHEM BIOPH RES CO, V234, P733, DOI 10.1006/bbrc.1997.6634; PARTHASARATHY S, 1990, P NATL ACAD SCI USA, V87, P9741, DOI 10.1073/pnas.87.24.9741; Parthasarathy S, 1999, J LIPID RES, V40, P2143; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P300; REAVEN E, 1986, J CLIN INVEST, V77, P1971, DOI 10.1172/JCI112526; REISFELD N, 1993, FEBS LETT, V315, P267, DOI 10.1016/0014-5793(93)81176-Z; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schissel SL, 1996, J CLIN INVEST, V98, P1455, DOI 10.1172/JCI118934; Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738; SCHNORF M, 1994, EXP CELL RES, V210, P260, DOI 10.1006/excr.1994.1038; SOMMER A, 1992, J BIOL CHEM, V267, P24217; SRINIVAS.SR, 1972, ATHEROSCLEROSIS, V16, P95, DOI 10.1016/0021-9150(72)90012-3; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; TABAS I, 1993, J BIOL CHEM, V268, P20419; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V; XU XX, 1991, J BIOL CHEM, V266, P24849; Zhang WY, 1997, J BIOL CHEM, V272, P31700, DOI 10.1074/jbc.272.50.31700	53	48	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16484	16489		10.1074/jbc.275.22.16484	http://dx.doi.org/10.1074/jbc.275.22.16484			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828058	hybrid			2022-12-25	WOS:000087392200014
J	Lankiewicz, S; Luetjens, CM; Bui, NT; Krohn, AJ; Poppe, M; Cole, GM; Saido, TC; Prehn, JHM				Lankiewicz, S; Luetjens, CM; Bui, NT; Krohn, AJ; Poppe, M; Cole, GM; Saido, TC; Prehn, JHM			Activation of calpain I converts excitotoxic neuron death into a caspase-independent cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL-D-ASPARTATE; RAT HIPPOCAMPAL-NEURONS; CYTOCHROME-C; GLUTAMATE EXCITOTOXICITY; PROTEOLYTIC CLEAVAGE; INDUCED APOPTOSIS; CORTICAL-NEURONS; NUCLEAR-CHANGES; NITRIC-OXIDE; MITOCHONDRIAL	Glutamate receptor overactivation contributes to neuron death after stroke, trauma, and epileptic seizures. Exposure of cultured rat hippocampal neurons to the selective glutamate receptor agonist N-methyl-D-aspartate (300 mu M, 5 min) or to the apoptosis-inducing protein kinase inhibitor staurosporine (300 nM) induced a delayed neuron death. In both cases, neuron death was preceded by the mitochondrial release of the pro-apoptotic factor cytochrome c. Unlike staurosporine, the N-methyl-D-aspartate-induced release of cytochrome c did not lead to significant activation of caspase-3, the main caspase involved in the execution of neuronal apoptosis. In contrast, activation of the Ca2+-activated neutral protease calpain I was readily detectable after the exposure to N-methyl-D-aspartate. In a neuronal cell-free apoptosis system, calpain I prevented the ability of cytochrome c to activate the caspase cascade by inhibiting the processing of procaspase-3 and -9 into their active subunits. In the hippocampal neuron cultures, the inhibition of calpain activity restored caspase-3-like protease activity after an exposure to N-methyl-D-aspartate. Our data demonstrate the existence of signal transduction pathways that prevent the entry of cells into a caspase-dependent cell death program after the mitochondrial release of cytochrome c.	Univ Munster, Fac Med, Res Grp Apoptosis & Cell Death, Interdisciplinary Ctr Clin Res IZKF, D-48149 Munster, Germany; Univ Calif Los Angeles, Sepulvda Vet Affairs Med Ctr, GRECC, Sepulveda, CA 91343 USA; RIKEN, Brain Sci Inst, Wako, Saitama 3510198, Japan	University of Munster; Geriatric Research Education & Clinical Center; University of California System; University of California Los Angeles; RIKEN	Prehn, JHM (corresponding author), Univ Munster, Fac Med, Res Grp Apoptosis & Cell Death, Interdisciplinary Ctr Clin Res IZKF, Rontgenstr 21, D-48149 Munster, Germany.	prehn@uni-muenster.de	Sado, Takaomi/AAN-2759-2021; Prehn, Jochen HM/A-3928-2010; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Prehn, Jochen HM/0000-0003-3479-7794; Saido, Takaomi C/0000-0003-1970-6903				Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Armstrong RC, 1997, J NEUROSCI, V17, P553; BINDOKAS VP, 1995, J NEUROSCI, V15, P6999; Black SC, 1998, J MOL CELL CARDIOL, V30, P733, DOI 10.1006/jmcc.1998.0660; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; CAMPAGNE MV, 1995, EUR J NEUROSCI, V7, P1627; Castilho RF, 1998, J NEUROSCI, V18, P10277; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Didier M, 1996, J NEUROSCI, V16, P2238; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; DUGAN LL, 1995, J NEUROSCI, V15, P6377; DYKENS JA, 1994, J NEUROCHEM, V63, P584; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faddis BT, 1997, J NEUROSCI, V17, P951; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Johnson MD, 1999, J NEUROSCI, V19, P2996; Jordan J, 1997, J NEUROCHEM, V68, P1612; Krohn AJ, 1999, J NEUROSCI, V19, P7394, DOI 10.1523/JNEUROSCI.19-17-07394.1999; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Llado J, 1999, J NEUROSCI, V19, P10803, DOI 10.1523/JNEUROSCI.19-24-10803.1999; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nicotera P, 1997, CELL DEATH DIFFER, V4, P435, DOI 10.1038/sj.cdd.4400265; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; PREHN JHM, 1994, P NATL ACAD SCI USA, V91, P12599, DOI 10.1073/pnas.91.26.12599; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SIMAN R, 1989, J NEUROSCI, V9, P1579; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Takadera T, 1999, J NEUROCHEM, V73, P548, DOI 10.1046/j.1471-4159.1999.0730548.x; Tenneti L, 1998, J NEUROCHEM, V71, P946; Wadia JS, 1998, J NEUROSCI, V18, P932; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; WHITE RJ, 1995, J NEUROSCI, V15, P1318; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Yang FS, 1998, AM J PATHOL, V152, P379; Yu SP, 1999, SCIENCE, V284, P336, DOI 10.1126/science.284.5412.336; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	56	227	231	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17064	17071		10.1074/jbc.275.22.17064	http://dx.doi.org/10.1074/jbc.275.22.17064			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828077	hybrid			2022-12-25	WOS:000087392200093
J	Legros, C; Pollmann, V; Knaus, HG; Farrell, AM; Darbon, H; Bougis, PE; Martin-Eauclaire, MF; Pongs, O				Legros, C; Pollmann, V; Knaus, HG; Farrell, AM; Darbon, H; Bougis, PE; Martin-Eauclaire, MF; Pongs, O			Grenerating a high affinity scorpion toxin receptor in KcsA-Kv1.3 chimeric potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER K+ CHANNEL; STREPTOMYCES-LIVIDANS; CHARYBDOTOXIN BLOCK; SELECTIVITY; MECHANISM; SEQUENCE; PEPTIDES; CELLS; BRAIN; PORE	The crystal structure of the bacterial K+ channel, KcsA (Doyle, D. A., Morais, C. J., Pfuetzner, R. A., Kuo, A., Gulbis, J. M., Cohen, S. L., Chait, B. T., and MacKinnon, R. (1998) Science 280, 69-77), and subsequent mutagenesis have revealed a high structural conservation from bacteria to human (MacKinnon, R., Cohen, S, L., Kuo, A., Lee, A., and Chait, B. T. (1998) Science 280, 106-109). me have explored this conservation by swapping subregions of the M1-M2 linker of KcsA with those of the S5-S6 linker of the human Kv-channel Kv1.3. The chimeric K+ channel constructs were expressed in Escherichia coli, and their multimeric state was analyzed after purification. We used two scorpion toxins, kaliotoxin and hongotoxin 1, which bind specifically to Kv1.3, to analyze the pharmacological properties of the KcsA-Kv1.3 chimeras. The results demonstrate that the high affinity scorpion toxin receptor of Kv1.3 could be transferred to KcsA. Our biochemical studies with purified KcsA-Kv1.3 chimeras provide direct chemical evidence that a tetrameric channel structure is necessary for forming a functional scorpion toxin receptor. We have obtained KcsA-Kv1.3 chimeras with kaliotoxin affinities (IC50 values of similar to 4 pM) like native Kv1.3 channels. Furthermore, we show that a subregion of the S5-S6 linker may be an important determinant of the pharmacological profile of K+ channels. Using available structural information on KcsA and kaliotoxin, we have developed a structural model for the complex between KcsA-1.3 chimeras and kaliotoxin to aid future pharmacological studies of K+ channels.	Univ Hamburg, ZMNH, Inst Neurale Signalverarbeitung, D-20246 Hamburg, Germany; Univ Innsbruck, Inst Biochem Pharmakol, A-6020 Innsbruck, Austria; Inst Biol Struct & Microbiol, CNRS, UPR 9039, F-13402 Marseille 20, France; Univ Aix Marseille 2, Fac Med Secteur Nord, Inst Federat Rech Jean Roche, Lab Biochim,CNRS,UMR 6560, F-13916 Marseille 20, France	University of Hamburg; University of Innsbruck; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Pongs, O (corresponding author), Univ Hamburg, ZMNH, Inst Neurale Signalverarbeitung, Martinistr 52, D-20246 Hamburg, Germany.	pointuri@uke.uni-hamburg.de	Legros, Christian/K-1346-2015; BOUGIS, Pierre E/I-2111-2013	LEGROS, Christian/0000-0002-3346-7059				AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; Aiyar J, 1996, J BIOL CHEM, V271, P31013, DOI 10.1074/jbc.271.49.31013; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; Cahalan MD, 1997, CURR OPIN BIOTECH, V8, P749, DOI 10.1016/S0958-1669(97)80130-9; CORNET B, 1995, STRUCTURE, V3, P435, DOI 10.1016/S0969-2126(01)00177-0; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; GOLDSTEIN SAN, 1992, BIOPHYS J, V62, P5, DOI 10.1016/S0006-3495(92)81760-5; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GROSS A, 1994, NEURON, V13, P961, DOI 10.1016/0896-6273(94)90261-5; Helms LMH, 1997, BIOCHEMISTRY-US, V36, P3737, DOI 10.1021/bi962351p; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Koschak A, 1998, J BIOL CHEM, V273, P2639, DOI 10.1074/jbc.273.5.2639; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARA B, 1995, BIOCHEM PHARMACOL, V49, P1459, DOI 10.1016/0006-2952(94)00524-P; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Naini AA, 1996, BIOCHEMISTRY-US, V35, P6181, DOI 10.1021/bi960067s; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; ROMI R, 1993, J BIOL CHEM, V268, P26302; SABATIER JM, 1993, BIOCHEMISTRY-US, V32, P2763, DOI 10.1021/bi00062a005; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT TGM, 1993, PROTEIN ENG, V6, P109, DOI 10.1093/protein/6.1.109; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X	31	59	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16918	16924		10.1074/jbc.275.22.16918	http://dx.doi.org/10.1074/jbc.275.22.16918			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828071	hybrid			2022-12-25	WOS:000087392200074
J	Bhatia, R; Lin, H; Lal, R				Bhatia, R; Lin, H; Lal, R			Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for A beta P channel-mediated cellular toxicity	FASEB JOURNAL			English	Article						AFM; scanning probe microscopy; real-time cellular imaging; endothelial cells; amyloid beta protein; neurotoxicity; Alzheimer's disease; calcium imaging; cytoskeletal reorganization	ALZHEIMERS-DISEASE; IN-VITRO; ZN2+-SENSITIVE CHANNEL; PRECURSOR PROTEIN; CORTICAL-NEURONS; PC12 CELLS; PEPTIDE; NEUROTOXICITY; APOPTOSIS; VASOACTIVITY	Amyloid beta peptides (A beta P) deposit as plaques in vascular and parenchymal areas of Alzheimer's disease (AD) tissues and Down's syndrome patients. Although neuronal toxicity is a feature of late stages of AD, vascular pathology appears to be a feature of all stages of AD. Globular and nonfibrillar A beta Ps are continuously released during normal cellular metabolism, form calcium-permeable channels, and alter cellular calcium level. We used atomic force microscopy, laser confocal microscopy, and calcium imaging to examine the real-time and acute effects of fresh and globular A beta P1-42, A beta P1-40, and A beta P25-35 on cultured endothelial cells. A beta Ps induced morphological changes that were observed within minutes after A beta P treatment and led to eventual cellular degeneration. Cellular morphological changes were most sensitive to A beta P1-42. APP(1-42)-induced morphological changes were observed at nanomolar concentrations and were accompanied by an elevated cellular calcium level. Morphological changes were prevented by anti-A beta P antibody, A beta P-channel antagonist zinc, and the removal of extracellular calcium, but not by tachykinin neuropeptide, voltage-sensitive calcium channel blocker cadmium, or antioxidants DTT and Trolox. Thus, nanomolar fresh and globular A beta P1-42 induces rapid cellular degeneration by elevating intracellular calcium, most likely via calcium-permeable A beta P channels and not by its interaction with membrane receptors or by activating oxidative pathways. Such rapid degeneration also suggests that the plaques, and especially fibrillar A beta Ps, may not have a direct causative role in AD pathogenic cascades.-Bhatia, R., Lin H., Lal, R. Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for APE channel-mediated cellular toxicity.	Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Bhatia, R (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.	bhatia@lifesci.ucsb.edu						Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Arispe N, 1996, P NATL ACAD SCI USA, V93, P1710, DOI 10.1073/pnas.93.4.1710; BARBEE KA, 1995, AM J PHYSIOL-HEART C, V268, pH1765, DOI 10.1152/ajpheart.1995.268.4.H1765; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; Blanc EM, 1997, J NEUROCHEM, V68, P1870; BUEE L, 1994, ACTA NEUROPATHOL, V87, P469; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Crawford F, 1998, EXP NEUROL, V150, P159, DOI 10.1006/exnr.1997.6743; Dikalov SI, 1999, J BIOL CHEM, V274, P9392, DOI 10.1074/jbc.274.14.9392; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; Good TA, 1996, BIOPHYS J, V70, P296, DOI 10.1016/S0006-3495(96)79570-X; GRAMMAS P, 1995, DEMENTIA, V6, P126, DOI 10.1159/000106934; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Hirakura Y, 1999, J NEUROSCI RES, V57, P458, DOI 10.1002/(SICI)1097-4547(19990815)57:4<458::AID-JNR5>3.0.CO;2-4; Hirakura Y, 1999, BIOPHYS J, V76, pA443; ITO E, 1994, P NATL ACAD SCI USA, V91, P534, DOI 10.1073/pnas.91.2.534; Ivins KJ, 1999, J BIOL CHEM, V274, P2107, DOI 10.1074/jbc.274.4.2107; Janson J, 1999, DIABETES, V48, P491, DOI 10.2337/diabetes.48.3.491; Kawahara M, 1997, BIOPHYS J, V73, P67, DOI 10.1016/S0006-3495(97)78048-2; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOSIK K, 1992, NEUROBIOL AGING, V13, P535, DOI 10.1016/0197-4580(92)90052-Y; LAL R, 1994, AM J PHYSIOL, V266, pC1, DOI 10.1152/ajpcell.1994.266.1.C1; LAL R, 1995, AM J PHYSIOL-CELL PH, V269, pC275, DOI 10.1152/ajpcell.1995.269.1.C275; Lane NJ, 1998, J NEUROCYTOL, V27, P707, DOI 10.1023/A:1006976400227; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Lin H, 1999, BIOCHEMISTRY-US, V38, P11189, DOI 10.1021/bi982997c; Lin MX, 1997, J BIOL CHEM, V272, P44; Liu YB, 1998, J NEUROCHEM, V71, P2322; LOCKHART BP, 1994, J NEUROSCI RES, V39, P494, DOI 10.1002/jnr.490390416; MAESTRE GE, 1993, BRAIN RES, V621, P145, DOI 10.1016/0006-8993(93)90311-A; MATTILA KM, 1994, ACTA NEUROL SCAND, V89, P192; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; MECOCCI P, 1995, J NEUROIMMUNOL, V57, P165, DOI 10.1016/0165-5728(94)00180-V; Mirzabekov TA, 1996, J BIOL CHEM, V271, P1988, DOI 10.1074/jbc.271.4.1988; NASLUND J, 1995, NEURON, V15, P219, DOI 10.1016/0896-6273(95)90079-9; Pallitto MM, 1999, BIOCHEMISTRY-US, V38, P3570, DOI 10.1021/bi982119e; PERLMUTTER LS, 1994, MOL NEUROBIOL, V9, P33, DOI 10.1007/BF02816103; Perry G, 1998, BRAIN RES, V791, P63, DOI 10.1016/S0006-8993(98)00006-7; Rhee SK, 1998, J BIOL CHEM, V273, P13379, DOI 10.1074/jbc.273.22.13379; Sanderson KL, 1997, BRAIN RES, V744, P7, DOI 10.1016/S0006-8993(96)01060-8; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; Suo ZM, 1997, BRAIN RES, V762, P144, DOI 10.1016/S0006-8993(97)00383-1; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; White AR, 1998, J NEUROSCI, V18, P6207; WHITSON JS, 1995, NEUROBIOL AGING, V16, P5, DOI 10.1016/0197-4580(95)80002-9; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; Zhu YJ, 2000, FASEB J, V14, P1244, DOI 10.1096/fasebj.14.9.1244	56	207	217	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1233	1243		10.1096/fasebj.14.9.1233	http://dx.doi.org/10.1096/fasebj.14.9.1233			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834945				2022-12-25	WOS:000087427300020
J	Dutertre, S; Ababou, M; Onclercq, R; Delic, J; Chatton, B; Jaulin, C; Amor-Gueret, M				Dutertre, S; Ababou, M; Onclercq, R; Delic, J; Chatton, B; Jaulin, C; Amor-Gueret, M			Cell cycle regulation of the endogenous wild type Bloom's syndrome DNA helicase	ONCOGENE			English	Article						Bloom's syndrome; RecQ 3 '-5 ' DNA helicase; cell cycle; post-translational modifications; cancer predisposition	UBIQUITIN-PROTEASOME PATHWAY; ESCHERICHIA-COLI RECQ; SYNDROME GENE-PRODUCT; BETA-CATENIN; REPLICATION; HOMOLOG; PROTEIN; CLONING; PHOSPHORYLATION; DEGRADATION	Bloom's syndrome (BS) is a rare human autosomal recessive disorder characterized by an increased risk to develop cancer of all types, BS cells are characterized by a generalized genetic instability including a high level of sister chromatid exchanges, BS arises through mutations in both alleles of the BLM gene which encodes a 3'-5' DNA helicase identified as a member of the RecQ family. We developed polyclonal antibodies specific for the NH2- and COOH-terminal region of BLM, Using these antibodies, we analysed BLM expression during the cell cycle and showed that the BLM protein accumulates to high levels in S phase, persists in G2/M and sharply declines in G1, strongly suggestive of degradation during mitosis, The BLM protein is subject to post-translational modifications in mitosis, as revealed by slow migrating forms of BLM found in both demecolcine-treated cells and in mitotic cells isolated from non-treated asynchronous populations. Phosphatase treatment indicated that phosphorylation events were solely responsible for the appearance of the retarded moieties, a possible signal for subsequent degradation. Together, these results are consistent with a role of BLM in a replicative (S phase) and/or post-replicative (G2 phase) process.	Inst Gustave Roussy, CNRS, UMR 1598, F-94805 Villejuif, France; Inst Curie, Lab Radiopathol, CEA, Lab Rech Correspondant,DSV,DRR, F-75005 Paris, France; ULP, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, CU De Strasbour, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; CEA; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Amor-Gueret, M (corresponding author), Inst Gustave Roussy, CNRS, UMR 1598, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		CHATTON, Bruno/R-3813-2019; Jaulin, Christian/L-9126-2018	CHATTON, Bruno/0000-0003-4515-7119; ababou, mouna/0000-0003-4276-3754				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bahr A, 1998, ONCOGENE, V17, P2565, DOI 10.1038/sj.onc.1202389; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Chester N, 1998, GENE DEV, V12, P3382, DOI 10.1101/gad.12.21.3382; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; COUX O, 1996, ANNU REV BIOCHEM, V65, P80; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Frei C, 2000, GENE DEV, V14, P81; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; German J, 1997, CANCER GENET CYTOGEN, V93, P100, DOI 10.1016/S0165-4608(96)00336-6; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Gharibyan V, 1999, MOL CARCINOGEN, V26, P261, DOI 10.1002/(SICI)1098-2744(199912)26:4<261::AID-MC5>3.0.CO;2-A; GIANNELLI F, 1977, NATURE, V265, P466, DOI 10.1038/265466a0; HAND R, 1975, P NATL ACAD SCI USA, V72, P758, DOI 10.1073/pnas.72.2.758; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kusano K, 1999, GENETICS, V151, P1027; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; LEVENSON V, 1993, NUCLEIC ACIDS RES, V21, P3997, DOI 10.1093/nar/21.17.3997; LONN U, 1990, CANCER RES, V50, P3141; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; MULLER H, 1992, MUTAT RES, V284, P15, DOI 10.1016/0027-5107(92)90021-S; Murray JM, 1997, MOL CELL BIOL, V17, P6868, DOI 10.1128/MCB.17.12.6868; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RODMAN TC, 1980, CYTOGENET CELL GENET, V27, P98, DOI 10.1159/000131471; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; SKOOG L, 1971, EUR J BIOCHEM, V19, P81, DOI 10.1111/j.1432-1033.1971.tb01290.x; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; Walpita D, 1999, P NATL ACAD SCI USA, V96, P5622, DOI 10.1073/pnas.96.10.5622; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; ZHUO S, 1993, J BIOL CHEM, V268, P17754	41	97	100	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 25	2000	19	23					2731	2738		10.1038/sj.onc.1203595	http://dx.doi.org/10.1038/sj.onc.1203595			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851073				2022-12-25	WOS:000087318500001
J	Jiang, JG; Gao, B; Zarnegar, R				Jiang, JG; Gao, B; Zarnegar, R			The concerted regulatory functions of the transcription factors nuclear factor-1 and upstream stimulatory factor on a composite element in the promoter of the hepatocyte growth factor gene	ONCOGENE			English	Article						hepatocyte growth factor; NF1; USF; promoter; partial hepatectomy; transcription	FACTOR SCATTER-FACTOR; MAJOR LATE PROMOTER; USF FAMILY; EXPRESSION; PROTEINS; REGION; RECEPTOR; LIVER; DNA; BINDS	Hepatocyte growth factor (HGF) is an important multifunctional cytokine whose gene expression is regulated mainly at the transcriptional level, Previous studies using transgenic mice as well as in vitro analyses showed that a potential regulatory element(s) exists between -260 to -230 bp in the upstream region of the HGF gene promoter. In the present study, me have discovered that this region is a composite site through which members of the nuclear factor 1 (NF1) and upstream stimulatory factor (USF) families bind to and regulate HGF gene transcription. Gel mobility shift and supershift assays revealed that USF and NF1 have high binding affinity for this region and that the binding sites of the two different transcription factor families overlap. Functional studies showed that NF1 suppresses HGF gene promoter activity and that USF has an activating function, We found that the NF1/X and NF1/Red1 isoforms strongly suppressed HGF promoter activity while the NF1/L variant had no obvious effects. USF1, but not USF2, of the USF family stimulated HGF gene promoter activity, More interestingly, during liver regeneration after partial hepatectomy, a process which activates the HGF gene, we noted that the binding activity of USF to the HGF promoter element increased while that of NF1 decreased. These data provide insight into the molecular mechanisms that govern HGF gene transcription.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Virginia Commonwealth University	Zarnegar, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA.		Jiang, Jie-Gen/K-3845-2019		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006109] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01ES 06109] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARAVAMUDAN B, 1993, BIOCHEM BIOPH RES CO, V195, P346, DOI 10.1006/bbrc.1993.2050; Bell AW, 1998, J BIOL CHEM, V273, P6900, DOI 10.1074/jbc.273.12.6900; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; Gao B, 1998, J BIOL CHEM, V273, P31784, DOI 10.1074/jbc.273.48.31784; Gao B, 1996, MOL CELL BIOL, V16, P5997; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; Jiang JG, 1997, J BIOL CHEM, V272, P3928, DOI 10.1074/jbc.272.7.3928; Jiang JG, 1997, ONCOGENE, V14, P3039, DOI 10.1038/sj.onc.1201152; Jiang JG, 1997, MOL CELL BIOL, V17, P5758, DOI 10.1128/MCB.17.10.5758; KONO S, 1992, BIOCHEM BIOPH RES CO, V186, P991, DOI 10.1016/0006-291X(92)90844-B; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; LIU YH, 1994, J BIOL CHEM, V269, P4152; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; OKAJIMA A, 1993, EUR J BIOCHEM, V213, P113, DOI 10.1111/j.1432-1033.1993.tb17740.x; PLASCHKESCHLUTTER A, 1995, J BIOL CHEM, V270, P830, DOI 10.1074/jbc.270.2.830; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Sirito Mario, 1992, Gene Expression, V2, P231; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	26	13	14	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 25	2000	19	23					2786	2790		10.1038/sj.onc.1203581	http://dx.doi.org/10.1038/sj.onc.1203581			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851080				2022-12-25	WOS:000087318500008
J	Ma, YY; Wei, SJ; Lin, YC; Lung, JC; Chang, TC; Whang-Peng, J; Liu, JM; Yang, DM; Yang, WK; Shen, CY				Ma, YY; Wei, SJ; Lin, YC; Lung, JC; Chang, TC; Whang-Peng, J; Liu, JM; Yang, DM; Yang, WK; Shen, CY			PIK3CA as an oncogene in cervical cancer	ONCOGENE			English	Article						PIK3CA; p110 alpha; cervical cancer; AKT; PI 3-kinase; 3q26.3	SYNTHASE KINASE 3-BETA; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; INTRAEPITHELIAL NEOPLASIA; CYCLIN-E; PATHWAY; CELLS; AKT; D1; TRANSFORMATION	Amplification of chromosome arm 3q is the most consistent aberration in cervical cancer, and is implicated in the progression of dysplastic uterine cervical cells into invasive cancer. The present study employed the 'positional candidate gene' strategy to determine the contribution of PIK3CA, which is located in 3q26.3, in cervical tumorigenesis, PIK3CA is known to be involved in the PI 3-kinase/AKT signaling pathway, which plays an important role in regulating cell growth and apoptosis, The results of comparative genomic hybridization show that the 3q26.3 amplification was the most consistent chromosomal aberration in primary tissues of cervical carcinoma, and a positive correlation between an increased copy number of PIK3CA (detected by competitive PCR) and 3q26.3 amplification was found in tumor tissues and in cervical cancer cell lines. In cervical cancer cell lines harboring amplified PIK3CA, the expression of gene product (p110 alpha) of PIK3CA was increased, and was subsequently associated with high kinase activity. In addition, transformation phenotypes in these lines, including increased cell growth and decreased apoptosis, were found to be significantly affected by the treatment of specific PI 3-kinase inhibitor, suggesting that increased expression of PIK3CA in cervical cancer may result in promoting cell proliferation and reducing apoptosis, These evidences support that PIK3CA is an oncogene in cervical cancer and PIK3CA amplification may be linked to cervical tumorigenesis.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Natl Hlth Res Inst, Canc Res Div, Taipei 115, Taiwan; Natl Def Med Univ, Taipei 100, Taiwan; Chang Gung Mem Hosp, Tao Yuan, Taiwan	Academia Sinica - Taiwan; National Health Research Institutes - Taiwan; National Defense Medical Center; Chang Gung Memorial Hospital	Shen, CY (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.		Shen, CY/F-6271-2010	Wei, Sung Jen/0000-0002-9810-9041				Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chu TY, 1999, GENE CHROMOSOME CANC, V24, P127, DOI 10.1002/(SICI)1098-2264(199902)24:2<127::AID-GCC5>3.0.CO;2-8; Clerici M, 1997, J NATL CANCER I, V89, P245, DOI 10.1093/jnci/89.3.245; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; Ebert AD, 1999, CANCER RES, V59, P4502; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Imani F, 1997, J BIOL CHEM, V272, P7927, DOI 10.1074/jbc.272.12.7927; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Ku WH, 1997, INT J CANCER, V72, P270, DOI 10.1002/(SICI)1097-0215(19970717)72:2<270::AID-IJC12>3.0.CO;2-K; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Pao CC, 1997, J CLIN ONCOL, V15, P1932, DOI 10.1200/JCO.1997.15.5.1932; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Ried T, 1999, GENE CHROMOSOME CANC, V25, P195, DOI 10.1002/(SICI)1098-2264(199907)25:3<195::AID-GCC1>3.0.CO;2-8; Rooney PH, 1999, BRIT J CANCER, V80, P862, DOI 10.1038/sj.bjc.6690433; Shah K. V., 1996, FIELDS VIROLOGY; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; Tlsty TD, 1999, NAT GENET, V21, P64, DOI 10.1038/4998; VOLINIA S, 1994, GENOMICS, V24, P472, DOI 10.1006/geno.1994.1655	27	363	408	1	14	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 25	2000	19	23					2739	2744		10.1038/sj.onc.1203597	http://dx.doi.org/10.1038/sj.onc.1203597			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851074				2022-12-25	WOS:000087318500002
J	Firon, M; Shaharabany, M; Altstock, RT; Horev, J; Abramovici, A; Resau, JH; Vande Woude, GF; Tsarfaty, I				Firon, M; Shaharabany, M; Altstock, RT; Horev, J; Abramovici, A; Resau, JH; Vande Woude, GF; Tsarfaty, I			Dominant negative Met reduces tumorigenicity-metastasis and increases tubule formation in mammary cells	ONCOGENE			English	Article						Met; HGF/SF; dominant negative; tubulogenesis; breast cancer cells	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; HUMAN BREAST-CANCER; C-MET; TYROSINE KINASE; EPITHELIAL-CELLS; FACTOR-RECEPTOR; FACTOR/SCATTER FACTOR; TUMOR PROGRESSION; MET/HGF RECEPTOR	Activation of the Met tyrosine kinase growth factor receptor by its ligand HGF/SF has been shown to increase in vitro invasiveness in epithelial cell lines. To study the effect of Met-HGF/SF signaling in breast cancer cells, we transfected met, hgf/sf and dominant negative (DN) forms of met into the poorly differentiated metastatic murine mammary adenocarcinoma cell line DA3, These cells express moderate levels of endogenous Met, which is rapidly phosphorylated in response to HGF/SF treatment. Met+hgf/sf transfection results in significantly increased tumorigenic and metastatic activity in vivo accompanied by reduced tubule formation. DA3 cells transfected with DN forms of Met (DN-DA3) exhibit reduced Met phosphorylation following exposure to HGF/SF, Furthermore, as compared to the parental cells, the DN-DA3 cells exhibit diminished in vitro scattering and invasiveness, while in vitro they display greatly reduced tumorigenicity and spontaneous metastasis, Tumors emanating from DN-DA3 cells injected to BALB/C mice are highly differentiated and display extensive tubule formation. These results suggest that Met-HGF/SF signaling is a determining factor in the delicate balance between differentiation/tubule formation and tumorigenicity-metastasis.	Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Pathol, IL-69978 Tel Aviv, Israel; NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Ft Detrick, MD 21702 USA	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Tsarfaty, I (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel.			Tsarfaty, Ilan/0000-0002-5230-7093				ALBINI A, 1987, CANCER RES, V47, P3239; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BENZ CC, 1995, GENE, V159, P3, DOI 10.1016/0378-1119(95)00147-X; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; Beviglia L, 1997, INT J CANCER, V74, P301, DOI 10.1002/(SICI)1097-0215(19970620)74:3<301::AID-IJC12>3.0.CO;2-E; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Clark GM, 1996, DIS BREAST, P461; Cortner J., 1995, V74, P89; CUNHA GR, 1994, CANCER, V74, P1030, DOI 10.1002/1097-0142(19940801)74:3+<1030::AID-CNCR2820741510>3.0.CO;2-Q; DENG G, 1994, CANCER RES, V54, P499; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; ETHIER SP, 1995, J NATL CANCER I, V87, P964, DOI 10.1093/jnci/87.13.964; FU YX, 1990, CANCER RES, V50, P227; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, ONCOGENE, V13, P853; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lamszus K, 1997, LAB INVEST, V76, P339; Liang TJ, 1996, J CLIN INVEST, V97, P2872, DOI 10.1172/JCI118744; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; NAGY J, 1995, J SURG ONCOL, V60, P95, DOI 10.1002/jso.2930600206; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; PEPPER MS, 1995, EXP CELL RES, V219, P204, DOI 10.1006/excr.1995.1220; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; QIAN XL, 1994, ONCOGENE, V9, P1507; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; Robinson ML, 1995, DEVELOPMENT, V121, P3959; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1995, CANCER RES, V55, P1963; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1989, IN VITRO CELL DEV B, V25, P163; ROSEN EM, 1993, SYM SOC EXP BIOL, V47, P227; ROSEN EM, 1994, INT J CANCER, V57, P706, DOI 10.1002/ijc.2910570517; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SORIANO JV, 1995, J CELL SCI, V108, P413; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tsarfaty I, 1999, ANAL QUANT CYTOL, V21, P397; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; YAMASHITA J, 1994, CANCER RES, V54, P1630; YAMASHITA J, 1993, RES COMMUN CHEM PATH, V82, P249; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Yao Y, 1996, AM J PATHOL, V149, P1707; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	62	48	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2000	19	20					2386	2397		10.1038/sj.onc.1203557	http://dx.doi.org/10.1038/sj.onc.1203557			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828880				2022-12-25	WOS:000087018400003
J	Cheng, HL; Steinway, ML; Russell, JW; Feldman, EL				Cheng, HL; Steinway, ML; Russell, JW; Feldman, EL			GTPases and phosphatidylinositol 3-kinase are critical for insulin-like growth factor-I-mediated Schwann cell motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SMOOTH-MUSCLE CELLS; GTP-BINDING PROTEIN; STIMULATES TYROSINE PHOSPHORYLATION; NERVOUS-SYSTEM FUNCTION; HUMAN-MELANOMA CELLS; ACTIN CYTOSKELETON; FACTOR-BB; MOLECULAR-BIOLOGY; FACTOR RECEPTOR	Previously, we reported insulin-like growth factor-I (IGF-I) promotes motility and focal adhesion kinase (FAK) activation in neuronal cells. In the current study, we examined the role of IGF-I in Schwann cell (SC) motility. IGF-I increases SC process extension and motility. In parallel, IG;F-I activates IG;F-I receptor, insulin receptor substrate-1 (IRS-1), phosphatidylinositol 3 (PI-3)-kinase, and FAK. LY294002, a PI-3 kinase inhibitor, blocks IGF-I-induced motility and FAK phosphorylation. The Rho family of GTPases is important in the regulation of the cytoskeleton. Overexpression of constitutively active Leu-61 Cdc42 and Val-12 Rad enhances SC motility which is unaffected by LY294002. In parallel, stable transfection of SC with dominant negative Asn-17 Rad blocks IGF-I-mediated SC motility and FAK phosphorylation, implying Pac is an upstream regulator of FAK. Collectively our results suggest that IGF-I regulates SC motility by reorganization of the actin cytoskeleton via the downstream activation of a PI-3 kinase, small GTPase, and FAK pathway.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Feldman, EL (corresponding author), Univ Michigan, Dept Neurol, 200 Zina Pitcher Pl,4414 Kresge 3, Ann Arbor, MI 48109 USA.	efeldman@umich.edu		Feldman, Eva/0000-0002-9162-2694	NINDS NIH HHS [NS38849, NS01938, NS36778] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001938, R01NS036778, R01NS038849] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Allen WE, 1997, J CELL SCI, V110, P707; AltunGultekin ZF, 1996, J NEUROSCI RES, V44, P308, DOI 10.1002/(SICI)1097-4547(19960515)44:4<308::AID-JNR2>3.0.CO;2-G; BARKER FG, 1995, NEUROL CLIN, V13, P701, DOI 10.1016/S0733-8619(18)30014-8; Berfield AK, 1997, J HISTOCHEM CYTOCHEM, V45, P583, DOI 10.1177/002215549704500410; BONDY CA, 1993, ANN NY ACAD SCI, V692, P33; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Cheng HL, 1999, ANN NY ACAD SCI, V883, P124, DOI 10.1111/j.1749-6632.1999.tb08575.x; Cheng HL, 1996, J NEUROCHEM, V66, P525; Cheng HL, 1998, J BIOL CHEM, V273, P14560, DOI 10.1074/jbc.273.23.14560; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; GAVRILOVIC J, 1995, EUR J NEUROSCI, V7, P77, DOI 10.1111/j.1460-9568.1995.tb01022.x; GOLD MR, 1992, J IMMUNOL, V148, P2012; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HEPLER JE, 1990, MOL NEUROBIOL, V4, P93, DOI 10.1007/BF02935586; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Ilic D, 1996, EXP CELL RES, V222, P298, DOI 10.1006/excr.1996.0038; ILLC D, 1995, NATURE, V377, P539; Jessen KR, 1999, TRENDS NEUROSCI, V22, P402, DOI 10.1016/S0166-2236(98)01391-5; KANAIAZUMA M, 1993, BIOL REPROD, V48, P252, DOI 10.1095/biolreprod48.2.252; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kim BS, 1998, J NEUROCHEM, V71, P1333; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LEROITH D, 1993, ANN NY ACAD SCI, V692, P22; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; Leventhal PS, 1996, J BIOL CHEM, V271, P5957, DOI 10.1074/jbc.271.11.5957; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; MARTIN DM, 1993, J CELL PHYSIOL, V155, P290, DOI 10.1002/jcp.1041550210; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; Meier C, 1999, J NEUROSCI, V19, P3847; NAKAOHAYASHI J, 1992, ATHEROSCLEROSIS, V92, P141, DOI 10.1016/0021-9150(92)90273-J; Nishida T, 1996, J CELL PHYSIOL, V169, P159, DOI 10.1002/(SICI)1097-4652(199610)169:1<159::AID-JCP16>3.0.CO;2-8; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nolte C, 1996, NEUROSCIENCE, V73, P1091, DOI 10.1016/0306-4522(96)00106-6; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Royal I, 1997, J CELL PHYSIOL, V173, P196, DOI 10.1002/(SICI)1097-4652(199711)173:2<196::AID-JCP20>3.0.CO;2-D; RUSSELL JW, 1994, ANN NEUROL, V36, P221, DOI 10.1002/ana.410360215; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; SILLETTI S, 1991, CANCER RES, V51, P3507; Singleton JR, 1996, CANCER RES, V56, P4522; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; STRACKE ML, 1988, BIOCHEM BIOPH RES CO, V153, P1076, DOI 10.1016/S0006-291X(88)81338-X; Tapia JA, 1999, BBA-MOL CELL RES, V1448, P486, DOI 10.1016/S0167-4889(98)00157-8; Taylor JM, 1998, J BIOL CHEM, V273, P8063, DOI 10.1074/jbc.273.14.8063; Theodorescu D, 1998, CELL GROWTH DIFFER, V9, P919; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Wang MH, 1996, ONCOGENE, V13, P2167; WINDEBANK AJ, 1986, J NEUROPATH EXP NEUR, V45, P683, DOI 10.1097/00005072-198611000-00006; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	60	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27197	27204						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10829021				2022-12-25	WOS:000089144800071
J	del Peso, L; Gonzalez, VM; Inohara, N; Ellis, RE; Nunez, G				del Peso, L; Gonzalez, VM; Inohara, N; Ellis, RE; Nunez, G			Disruption of the CED-9 center dot CED-4 complex by EGL-1 is a critical step for programmed cell death in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 PROTEIN FAMILY; C-ELEGANS; CYTOCHROME-C; CED-3 ACTIVATION; X-L; APOPTOSIS; APAF-1; MITOCHONDRIA; BCL-X(L); ENCODES	In the nematode Caenorhabditis elegans, the apoptotic machinery is composed of four basic elements: the caspase CED-3, the Apaf-1 homologue CED-4, and the Bcl-2 family members CED-9 and EGL-1. The ced-9(n1950) gain-of-function mutation prevents most, if not all, somatic cell deaths in C. elegans. It encodes a CED-9 protein with a glycine-to-glutamate substitution at position 169, which is located within the highly conserved Bcl-2 homology 1 domain, We performed biochemical analyses with the CED-9G169E protein to gain insight into the mechanism of programmed cell death, We find that CED-9G169E retains the ability to bind both EGL-1 and CED-4, although its affinity for EGL-1 is reduced. In contrast to the behavior of wild-type CED-9, the interaction between CED-9G169E and CED-4 is not disrupted by expression of EGL-1. Furthermore, CED-4 and CED-9G169E co-localizes with EGL-1 to the mitochondria in mammalian cells, and expression of EGL-1 does not induce translocation of CED-4 to the cytosol, Finally, the ability of EGL-1 to promote apoptosis is impaired by the replacement of wild-type CED-9 with CED-9G169E, and this effect is correlated with the inability of EGL-1 to induce the displacement of CED-4 from the CED-9 CED-4 complex. These studies suggest that the release of CED-4 from the CED-9.CED-4 complex is a necessary step for induction of programmed cell death in C. elegans.	Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nunez, G (corresponding author), Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.		Gonzalez, Victor M/F-7396-2010; del Peso, Luis/K-9391-2014	Gonzalez, Victor M/0000-0001-7538-0552; del Peso, Luis/0000-0003-4014-5688	NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; CHINNAIYAN A, 1997, NATURE, V388, P6644; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Irmler M, 1997, FEBS LETT, V406, P189, DOI 10.1016/S0014-5793(97)00271-8; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ottilie S, 1997, J BIOL CHEM, V272, P16955, DOI 10.1074/jbc.272.27.16955; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Seshagiri S, 1997, CURR BIOL, V7, P455, DOI 10.1016/S0960-9822(06)00216-8; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	38	53	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27205	27211						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10846174				2022-12-25	WOS:000089144800072
J	Eder, M; Stolz, M; Wallimann, T; Schlattner, U				Eder, M; Stolz, M; Wallimann, T; Schlattner, U			A conserved negatively charged cluster in the active site of creatine kinase is critical for enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-METABOLISM; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; MUSCLE; ISOENZYMES; RESIDUES; BINDING; RESOLUTION; EXPRESSION; INHIBITION	Creatine kinase catalyzes the reversible transphosphorylation of creatine by MgATP. From the sequence homology and the molecular structure of creatine kinase isoenzymes, we have identified several highly conserved residues with a potential function in the active site: a negatively charged cluster (Glu(226), Glu(227), Asp(228)) and a serine (Ser(280)), Mutant proteins E226Q, E226L, E227Q, E227L, D228N, and S280A/S280D of human sarcomeric mitochondrial creatine kinase were generated by in vitro mutagenesis, expressed in Escherichia coli, and purified to homogeneity, Their overall structural integrity was confirmed by CD spectroscopy and gel filtration chromatography. The enzymatic activity of all proteins mutated in the negatively charged cluster was extremely low (0.002-0.4% of wild type) and showed apparent Michaelis constants (K-m) similar to wild type, suggesting that most of the residual activity may be attributed to wild-type revertants, Mutations of Ser280 led to higher residual activities and altered K-m values; S280A showed an increase of K-m for phosphocreatine (65-fold), creatine (6-fold), and ATP (6-fold); S280D showed a decrease of K-m for creatine (g-fold). These results, together with the transition state structure of the homologous arginine kinase (Zhou, G., Somasundaram, T., Blanc, E., Parthasarathy G., Ellington, W. R., and Chapman, M. S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8449-8454), strongly suggest a critical role of Glu(226), Glu(227), and Asp(228) in substrate binding and catalysis and point to Glu(227) as a catalytic base.	Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Schlattner, U (corresponding author), Swiss Fed Inst Technol, Inst Cell Biol, Honggerberg, CH-8093 Zurich, Switzerland.	schlattn@cell.biol.ethz.ch	Schlattner, Uwe/D-1267-2009; Wallimann, Theo/C-6047-2008	Schlattner, Uwe/0000-0003-1159-5911; Wallimann, Theo/0000-0003-4957-5836				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen LH, 1996, BIOCHEMISTRY-US, V35, P7895, DOI 10.1021/bi952798i; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1204, DOI 10.1021/bi00508a023; Eder M, 1999, PROTEIN SCI, V8, P2258; Eder M, 2000, PROTEINS, V39, P216, DOI 10.1002/(SICI)1097-0134(20000515)39:3<216::AID-PROT40>3.0.CO;2-#; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Forstner M, 1997, PROTEIN SCI, V6, P331; Forstner M, 1998, BIOPHYS J, V75, P1016, DOI 10.1016/S0006-3495(98)77590-3; FritzWolf K, 1996, NATURE, V381, P341, DOI 10.1038/381341a0; FURTER R, 1992, BIOCHEM J, V288, P771, DOI 10.1042/bj2880771; FURTER R, 1993, BIOCHEMISTRY-US, V32, P7022, DOI 10.1021/bi00078a030; GROSS M, 1994, PROTEIN SCI, V3, P1058, DOI 10.1002/pro.5560030708; GROSS M, 1993, BIOCHEMISTRY-US, V32, P13933, DOI 10.1021/bi00213a024; HANSEN DE, 1981, J BIOL CHEM, V256, P5967; Kenyon GL, 1996, NATURE, V381, P281, DOI 10.1038/381281a0; KENYON GL, 1983, ADV ENZYMOL RAMB, V54, P367; MARCILLAT O, 1987, BIOCHIM BIOPHYS ACTA, V890, P233, DOI 10.1016/0005-2728(87)90024-7; MCLAUGHLIN AC, 1972, J BIOL CHEM, V247, P4382; MILNERWH.EJ, 1971, BIOCHEM J, V122, P727, DOI 10.1042/bj1220727; MORRISON JF, 1966, J BIOL CHEM, V241, P673; MUHLEBACH SM, 1994, MOL CELL BIOCHEM, V133, P245, DOI 10.1007/BF01267958; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Rao JK, 1998, FEBS LETT, V439, P133; ROSENBERGER RF, 1994, DEV BIOL STAND, V83, P21; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIMERLIK MI, 1973, J BIOL CHEM, V248, P8418; Schlattner U, 1998, MOL CELL BIOCHEM, V184, P125, DOI 10.1023/A:1006851330913; Schlattner U, 2000, J BIOL CHEM, V275, P17314, DOI 10.1074/jbc.M001919200; SCORER CA, 1991, NUCLEIC ACIDS RES, V19, P3511, DOI 10.1093/nar/19.13.3511; SEIDMAN CG, 1997, CURRENT PROTOCOLS MO, V1; STORM DR, 1970, P NATL ACAD SCI USA, V66, P445, DOI 10.1073/pnas.66.2.445; Stroud RM, 1996, NAT STRUCT BIOL, V3, P567, DOI 10.1038/nsb0796-567; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; Wood TD, 1998, P NATL ACAD SCI USA, V95, P3362, DOI 10.1073/pnas.95.7.3362; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; Zhou GF, 1998, P NATL ACAD SCI USA, V95, P8449, DOI 10.1073/pnas.95.15.8449	37	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27094	27099						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10829032				2022-12-25	WOS:000089144800058
J	Bellido, T; Huening, M; Raval-Pandya, M; Manolagas, SC; Christakos, S				Bellido, T; Huening, M; Raval-Pandya, M; Manolagas, SC; Christakos, S			Calbindin-D-28k is expressed in osteoblastic cells and suppresses their apoptosis by inhibiting caspase-3 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; GROWTH-FACTOR; CULTURED HIPPOCAMPAL; BONE-MARROW; CYTOKINES; NEURONS; ALPHA; LINES; DIFFERENTIATION; IDENTIFICATION	The rate of osteoblast apoptosis is a critical determinant of the rate of bone formation. Because the calcium-binding protein calbindin-D-28k has anti-apoptotic properties in neuronal cells and lymphocytes, we searched for the presence of this protein in osteoblastic cells and investigated whether it can modify their response to proapoptotic signals. Calbindin-D-28k was expressed at low levels in several osteoblastic cell lines and at high levels in primary cultures of murine osteoblastic cells. Transient transfection of rat calbindin-D-28k cDNA blocked tumor necrosis factor alpha (TNF alpha)-induced apoptosis in osteoblastic MC3T3-E1 cells, as determined by cell viability and nuclear morphology of cells cotransfected with the green fluorescent protein targeted to the nucleus, whereas transfection of the empty vector had no effect. Calbindin-D-28k levels in several stably transfected MC3T3-E1 lines were directly related to protection from TNF alpha-induced apoptosis, Purified rat calbindin-D-28k markedly reduced the activity of caspase-3, a critical molecule for the degradation phase of apoptosis, in a cell-free assay. In addition, cell extracts from MC3T3-E1 cells expressing high levels of calbindin-D-28k decreased caspase-3 activity, compared with extracts from vector-transfected cells. This effect was apparently unrelated to the calcium binding properties of calbindin, as chelation of calcium by EGTA or addition of other calcium-binding proteins such as calbindin-D-9k, S100, calmodulin, and osteocalcin, did not affect caspase-3 activity. Last, calbindin-D-28k interacts with the active form of caspase-3 as demonstrated by a GST pull-down assay. These results demonstrate that calbindin-D-28k is a biosynthetic product of osteoblasts with a role in the regulation of apoptosis. They also reveal that the antiapoptotic properties of calbindin-D-28k may result not only from calcium buffering but also from the ability of the protein to interact with and to inhibit caspase-3 activity, a property that is independent of its calcium binding capability.	Univ Arkansas Med Sci, Div Endocrinol & Metab, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Ctr Osteoporosis & Metab Bone Dis, Little Rock, AR 72205 USA; Cent Arkansas Vet Hlth Care Syst, Little Rock, AR 72205 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; Rutgers State University New Brunswick; Rutgers State University Medical Center	Bellido, T (corresponding author), Univ Arkansas Med Sci, Div Endocrinol & Metab, 4301 W Markham,Mail Slot 587, Little Rock, AR 72205 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038961] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG013918] Funding Source: NIH RePORTER; NIAMS NIH HHS [R29AR43453] Funding Source: Medline; NIA NIH HHS [P01AG/AMS13918] Funding Source: Medline; NIDDK NIH HHS [DK38961] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; Bellido T, 1998, J BIOL CHEM, V273, P21137, DOI 10.1074/jbc.273.33.21137; Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666; BERDAL A, 1993, DEV BIOL, V155, P172, DOI 10.1006/dbio.1993.1016; Berdal A, 1996, J BONE MINER RES, V11, P768; BOSWELL HS, 1990, EXP HEMATOL, V18, P794; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CENTRELLA M, 1988, ENDOCRINOLOGY, V123, P1442, DOI 10.1210/endo-123-3-1442; CHENG B, 1992, J NEUROSCI, V12, P1558; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; DOWD DR, 1992, MOL ENDOCRINOL, V6, P1843, DOI 10.1210/me.6.11.1843; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Guo Q, 1998, P NATL ACAD SCI USA, V95, P3227, DOI 10.1073/pnas.95.6.3227; HEREMANS H, 1978, ONCOLOGY, V35, P246, DOI 10.1159/000225298; Hill PA, 1997, ENDOCRINOLOGY, V138, P3849, DOI 10.1210/en.138.9.3849; Hughes DE, 1997, J CLIN PATHOL-MOL PA, V50, P132, DOI 10.1136/mp.50.3.132; HUNZIKER W, 1988, MOL ENDOCRINOL, V2, P465, DOI 10.1210/mend-2-5-465; IACOPINO A, 1992, MOL BRAIN RES, V13, P251, DOI 10.1016/0169-328X(92)90033-8; IACOPINO AM, 1990, P NATL ACAD SCI USA, V87, P4078, DOI 10.1073/pnas.87.11.4078; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; KAISER N, 1977, P NATL ACAD SCI USA, V74, P638, DOI 10.1073/pnas.74.2.638; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014; Kitajima I, 1996, J BONE MINER RES, V11, P200; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Macho A, 1997, J IMMUNOL, V158, P4612; Manolagas SC, 1999, ENDOCRINOLOGY, V140, P4377, DOI 10.1210/en.140.10.4377; MANOLAGAS SC, 1980, J BIOL CHEM, V255, P4414; MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506; MATTSON MP, 1995, J NEUROSCI RES, V42, P357, DOI 10.1002/jnr.490420310; MATTSON MP, 1991, NEURON, V6, P41, DOI 10.1016/0896-6273(91)90120-O; MATTSON MP, 1989, J NEUROSCI, V9, P3728; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; Motulsky H., 1995, INTUITIVE BIOSTATIST; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NIETOBONA MP, 1995, J NEUROSCI RES, V42, P371, DOI 10.1002/jnr.490420311; PANSINI AR, 1984, J BIOL CHEM, V259, P9735; Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SONNENBERG J, 1984, ENDOCRINOLOGY, V115, P640, DOI 10.1210/endo-115-2-640; STASHENKO P, 1989, IMMUNOL INVEST, V18, P239, DOI 10.3109/08820138909112240; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; Wernyj RP, 1999, MOL BRAIN RES, V64, P69, DOI 10.1016/S0169-328X(98)00307-6; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; ZIPORI D, 1985, BLOOD, V66, P447	54	114	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26328	26332		10.1074/jbc.M003600200	http://dx.doi.org/10.1074/jbc.M003600200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10835428	hybrid			2022-12-25	WOS:000088999700062
J	Tanaka, K; Hiramoto, T; Fukuda, T; Miyagawa, K				Tanaka, K; Hiramoto, T; Fukuda, T; Miyagawa, K			A novel human Rad54 homologue, Rad54B, associates with Rad51	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN BREAKAGE SYNDROME; RECOMBINATION PROTEINS; DNA-REPAIR; YEAST RAD51; GENE; SACCHAROMYCES; CONFORMATION; RESISTANCE; MUTATIONS; COMPLEX	Members of the SNF2/SWI2 family, characterized with sequence motifs similar to those found in DNA and RNA helicases, play roles in various aspects of cellular fundamental processes such as transcriptional regulation, chromosome stability, nucleotide excision repair, and recombination. We have isolated a novel member of the human SNF2/SWI2 family, RAD54B, which is highly homologous to mammalian RAD54. The RAD54 gene is a member of the RAD52 epistasis group which is involved in the recombinational repair of DNA damage, Here we demonstrate that human Rad54B (hRad54B), like human Rad54 (hRad54), associates with human Rad51 (hRad51). Both hRad54B and hRad54 associate with hRad51 through their NH2-terminal domains, but there are differences in their ways of association with hRad51. In contrast to Rad54, whose association with Rad51 is induced by ionizing radiation, Rad54B associates with Rad51 constitutively in immunoprecipitation experiments, Also, the failure to detect the interaction between hRad54B and hRad51 in the yeast two-hybrid assay suggests that their interaction, unlike that between hRad54 and hRad51, may be indirect. Immunofluorescence microscopy revealed that hRad54B formed nuclear foci that colocalized with hRad51, hRad54, and BRCA1. These findings suggest that Rad54B may be functionally distinct from Rad54, although it may play an active role in recombination processes in concert with other members of the RAD52 epistasis group.	Hiroshima Univ, Dept Mol Pathol, Res Inst Radiat Biol & Med, Minami Ku, Hiroshima 7348553, Japan	Hiroshima University	Miyagawa, K (corresponding author), Hiroshima Univ, Dept Mol Pathol, Res Inst Radiat Biol & Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.		Tanaka, Kozo/Y-6566-2018	Tanaka, Kozo/0000-0001-6086-2858				Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Golub EI, 1997, NUCLEIC ACIDS RES, V25, P4106, DOI 10.1093/nar/25.20.4106; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; Hiramoto T, 1999, ONCOGENE, V18, P3422, DOI 10.1038/sj.onc.1202691; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Matsuda M, 1999, ONCOGENE, V18, P3427, DOI 10.1038/sj.onc.1202692; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Schoenmakers EFPM, 1999, CANCER RES, V59, P19; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Tanaka K, 1998, BLOOD, V91, P1688, DOI 10.1182/blood.V91.5.1688.1688_1688_1699; Tashiro S, 1996, ONCOGENE, V12, P2165; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5	30	49	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26316	26321		10.1074/jbc.M910306199	http://dx.doi.org/10.1074/jbc.M910306199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851248	hybrid			2022-12-25	WOS:000088999700060
J	Wang, ZP; Juttermann, R; Soloway, PD				Wang, ZP; Juttermann, R; Soloway, PD			TIMP-2 is required for efficient activation of proMMP-2 in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASE-3 STROMELYSIN; HUMAN GELATINASE-A; TISSUE INHIBITOR; PROGELATINASE-A; BRANCHING MORPHOGENESIS; IV COLLAGENASE; INTRACELLULAR ACTIVATION; ENZYMATIC-PROPERTIES; BASEMENT-MEMBRANE; HUMAN-FIBROBLASTS	Matrix metalloproteinases (MMPs) are synthesized as latent proenzymes. A proteolytic cleavage event involving processing of the cysteine-rich N-terminal propeptide is required for their full activation. Previous in vitro studies indicated that activation of proMMP-2 can occur through formation of a trimolecular complex between MMP-14, TIMP-2, and proMMP-2 at the cell surface. Using TIMP-2-deficient mice and cells derived from them, TIMP-2 was shown to be required for efficient proMMP-2 activation both in vivo and in vitro. The requirement for TIMP-2 was not cell-autonomous as exogenously added TIMP-2 could restore activation of proMMP-2 to TIMP-2-deficient cells. Mutant mice were overtly normal, viable, and fertile on the C57BL/6 background, indicating that both TIMP-2 and activated proMMP-2 are dispensable for normal development.	Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Soloway, PD (corresponding author), Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Elm & Carlton Sts, Buffalo, NY 14263 USA.	psoloway@mcbio.med.buffalo.edu	Soloway, Paul/T-8243-2019	Soloway, Paul/0000-0003-1967-0437	NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011279] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA016056, CA 16056] Funding Source: Medline; NEI NIH HHS [R01 EY011279, EY 11279, R01 EY011279-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABE S, 1973, J BIOCHEM-TOKYO, V73, P897, DOI 10.1093/oxfordjournals.jbchem.a130153; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Baramova EN, 1997, FEBS LETT, V405, P157, DOI 10.1016/S0014-5793(97)00175-0; Barasch J, 1999, J CLIN INVEST, V103, P1299, DOI 10.1172/JCI4586; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; Butler GS, 1999, J BIOL CHEM, V274, P20391, DOI 10.1074/jbc.274.29.20391; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Caterina JJ, 2000, J BIOL CHEM, V275, P26416, DOI 10.1074/jbc.M001271200; DARMIENTO J, 1992, CELL, V71, P955, DOI 10.1016/0092-8674(92)90391-O; Fata JE, 1999, DEV BIOL, V211, P238, DOI 10.1006/dbio.1999.9313; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hogan B, 1994, MANIPULATING MOUSE E; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; Itoh T, 1998, CANCER RES, V58, P1048; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; JUBB RW, 1980, J PATHOL, V130, P159, DOI 10.1002/path.1711300304; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Lee AY, 1997, P NATL ACAD SCI USA, V94, P4424, DOI 10.1073/pnas.94.9.4424; Lelongt B, 1997, J CELL BIOL, V136, P1363, DOI 10.1083/jcb.136.6.1363; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MOSES MA, 1991, J CELL BIOCHEM, V47, P230, DOI 10.1002/jcb.240470308; MURPHY G, 1981, CLIN SCI, V61, P711, DOI 10.1042/cs0610711; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; Okumura Y, 1997, FEBS LETT, V402, P181, DOI 10.1016/S0014-5793(96)01523-2; Osiewicz K, 1999, ANN NY ACAD SCI, V878, P494, DOI 10.1111/j.1749-6632.1999.tb07706.x; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Shofuda K, 1998, J BIOCHEM-TOKYO, V124, P462, DOI 10.1093/oxfordjournals.jbchem.a022136; Stanton H, 1998, J CELL SCI, V111, P2789; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Wang ZP, 1999, ANN NY ACAD SCI, V878, P519, DOI 10.1111/j.1749-6632.1999.tb07714.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113	55	299	308	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26411	26415		10.1074/jbc.M001270200	http://dx.doi.org/10.1074/jbc.M001270200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10827175	Green Accepted, hybrid			2022-12-25	WOS:000088999700073
J	Bae, J; Leo, CP; Hsu, SY; Hsueh, AJW				Bae, J; Leo, CP; Hsu, SY; Hsueh, AJW			MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; SURVIVAL-PROMOTING PROTEINS; HUMAN FOLLICULAR LYMPHOMA; CYTOCHROME-C RELEASE; INTERACTING PROTEIN; SIGNALING PATHWAY; RAT OVARY; B-CELLS; X-L; GENE	MCL-1 (myeloid cell leukemia-1) is an antiapoptotic BCL-2 family protein discovered as an early induction gene during myeloblastic leukemia cell differentiation. This survival protein has the BCL-2 homology (BH) domains 1, a, and 3 and a C-terminal transmembrane region. We identified a short splicing variant of the MCL-1 mRNA in the human placenta encoding a protein, termed MCL-1 short (MCL-1S), with an altered C terminus as compared with the full-length MCL-1 long (MCL-1L), leading to the loss of BH1, BH2, and the transmembrane domains. Analysis of the human MCL-1 gene indicated that MCL-1S results from the splicing out of exon 2 during mRNA processing. MCL-1S, unlike MCL-1L, does not interact with diverse proapoptotic BCL-2-related proteins in the yeast two-hybrid system. In contrast, MCL-1S dimerizes with MCL-1L in the yeast assay and coprecipitates with MCL-1L in transfected mammalian cells. Overexpression of MCL-1S induces apoptosis in transfected Chinese hamster ovary cells, and the MCL-1S action was antagonized by the antiapoptotic MCL-1L. Thus, the naturally occurring MCL-1S variant represents a new proapoptotic BH3 domain-only protein capable of dimerizing with the antiapoptotic MCL-1L. The fate of MCL-1-expressing cells could be regulated through alternative splicing mechanisms and interactions of the resulting anti- and proapoptotic gene products.	Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA	Stanford University	Hsueh, AJW (corresponding author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA.			Leo, Chandra/0000-0002-4463-3614	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031566] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-31566] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; APTE SS, 1995, GENOMICS, V26, P592, DOI 10.1016/0888-7543(95)80180-T; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1995, ONCOGENE, V11, P1921; Chang BS, 1999, MOL CELL BIOL, V19, P6673; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; CLARKE MF, 1995, P NATL ACAD SCI USA, V92, P11024, DOI 10.1073/pnas.92.24.11024; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; FANG W, 1994, J IMMUNOL, V153, P4388; Gibson L, 1996, ONCOGENE, V13, P665; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu SY, 1998, J BIOL CHEM, V273, P30139, DOI 10.1074/jbc.273.46.30139; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kaipia A, 1997, ENDOCRINOLOGY, V138, P5497, DOI 10.1210/en.138.12.5497; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Leo CP, 1999, ENDOCRINOLOGY, V140, P5469, DOI 10.1210/en.140.12.5469; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Moore M., 1993, RNA WORLD, P303; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; TANAKA S, 1993, J BIOL CHEM, V268, P10920; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Yang XF, 1997, IMMUNITY, V7, P629, DOI 10.1016/S1074-7613(00)80384-2; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101; Zhou M, 1998, J BIOL CHEM, V273, P11930, DOI 10.1074/jbc.273.19.11930; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	54	227	245	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25255	25261		10.1074/jbc.M909826199	http://dx.doi.org/10.1074/jbc.M909826199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837489	hybrid			2022-12-25	WOS:000088849400030
J	Bernal-Mizrachi, E; Wice, B; Inoue, H; Permutt, MA				Bernal-Mizrachi, E; Wice, B; Inoue, H; Permutt, MA			Activation of serum response factor in the depolarization induction of Egr-1 transcription in pancreatic islet beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; TERNARY COMPLEX FACTORS; GROWTH FACTOR-I; C-FOS PROMOTER; PROTEIN-KINASE; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; REGULATORY FACTOR; RAT ISLETS; HORMONE	The results of the current studies define the major elements whereby glucose metabolism in islet beta-cells leads to transcriptional activation of an early response gene in insulinoma cell lines and in rat islets, Glucose stimulation (2-20 mM) resulted in a 4-fold increase in Egr-1 mRNA at 30 min, as did the depolarizing agents KCl and tolbutamide. This response was inhibited by diazoxide and EGTA, indicating that beta-cell depolarization and Ca2+ influx, respectively, are essential. Pharmacological inhibition of the Egr-1 induction by H89 (48%) and calmidazolium (35%), but not by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1 and 2 or phosphatidylinositol 3-kinase inhibitors, implied that protein kinase A and Ca2+/calmodulin pathways are involved. Deletion mapping of the Egr-1 promoter revealed that the proximal -198 base pairs containing two serum response elements (SREs) and one cAMP-response element retained the depolarization response. Depolarization resulted in phosphorylation of cAMP-response element-binding protein, yet partial inhibition by a dominant negative cAMP-response element-binding protein, along with a robust response of a cAMP-response element-mutated Egr-1 promoter suggested the presence of a second Ca2+-responsive element, Depolarization activation of 5XSRE-LUC and serum response factor (SRF)-GAL4 constructs, along with activation of SRF-GAL4 by co-transfection with constitutively active calmodulin kinase IV and protein kinase A, and binding of Ser(103)-phosphorylated SRF in nuclear extracts, indicated that the SRE.SRF complexes contribute to the Ca2+-mediated transcriptional regulation of Egr-1, The results of the current experiments demonstrate for the first time SRE-dependent transcription and the role of SRF, a transcription factor known to be a major component of growth responses, in glucose-mediated transcriptional regulation in insulinoma cells.	Washington Univ, Sch Med, Div Endocrinol Diabet & Metab, St Louis, MO 63110 USA	Washington University (WUSTL)	Bernal-Mizrachi, E (corresponding author), Washington Univ, Sch Med, Div Endocrinol Diabet & Metab, Campus Box 8127,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK088126, R37DK016746, R01DK016746] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK16746, R01 DK088126] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AUSBEL FM, 1989, CURRENT PROTOCOLS MO; Beattie GM, 1996, DIABETES, V45, P1223, DOI 10.2337/diabetes.45.9.1223; BILLESTRUP N, 1991, ENDOCRINOLOGY, V129, P883, DOI 10.1210/endo-129-2-883; BRELJE TC, 1991, ENDOCRINOLOGY, V128, P45, DOI 10.1210/endo-128-1-45; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cohen DM, 1996, J BIOL CHEM, V271, P12903, DOI 10.1074/jbc.271.22.12903; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRODIN M, 1995, J BIOL CHEM, V270, P7882, DOI 10.1074/jbc.270.14.7882; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Harada S, 1996, J BIOL CHEM, V271, P30222, DOI 10.1074/jbc.271.47.30222; Hardingham GE, 1998, CELL CALCIUM, V23, P131, DOI 10.1016/S0143-4160(98)90111-7; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; JHUN BH, 1995, BIOCHEMISTRY-US, V34, P7996, DOI 10.1021/bi00025a005; Josefsen K, 1999, DIABETOLOGIA, V42, P195, DOI 10.1007/s001250051139; Khoo S, 1997, P NATL ACAD SCI USA, V94, P5599, DOI 10.1073/pnas.94.11.5599; KNEPEL W, 1990, MOL CELL BIOL, V10, P6799, DOI 10.1128/MCB.10.12.6799; KUWADA M, 1994, MOL PHARMACOL, V46, P587; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; MACK KJ, 1995, MOL BRAIN RES, V29, P140, DOI 10.1016/0169-328X(94)00243-8; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MISRA RP, 1994, J BIOL CHEM, V269, P25483; NIELSEN JH, 1989, MOL ENDOCRINOL, V3, P165, DOI 10.1210/mend-3-1-165; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; Persaud SJ, 1996, BIOCHEM J, V313, P119, DOI 10.1042/bj3130119; POLAK M, 1993, P NATL ACAD SCI USA, V90, P5781, DOI 10.1073/pnas.90.12.5781; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Shao H, 1997, J EXP MED, V185, P731, DOI 10.1084/jem.185.4.731; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Susini S, 2000, FASEB J, V14, P128, DOI 10.1096/fasebj.14.1.128; Susini S, 1998, FASEB J, V12, P1173, DOI 10.1096/fasebj.12.12.1173; SWENNE I, 1987, DIABETES, V36, P288, DOI 10.2337/diabetes.36.3.288; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; Taupenot L, 1998, J CLIN INVEST, V101, P863, DOI 10.1172/JCI1129; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WELSH M, 1993, DIABETES METAB REV, V9, P25, DOI 10.1002/dmr.5610090104	52	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25681	25689		10.1074/jbc.M003424200	http://dx.doi.org/10.1074/jbc.M003424200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829028	hybrid			2022-12-25	WOS:000088849400083
J	Fasshauer, M; Klein, J; Ueki, K; Kriauciunas, KM; Benito, M; White, MF; Kahn, CR				Fasshauer, M; Klein, J; Ueki, K; Kriauciunas, KM; Benito, M; White, MF; Kahn, CR			Essential role of insulin receptor substrate-2 in insulin stimulation of Glut4 translocation and glucose uptake in brown adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; RAT ADIPOSE-CELLS; 3T3-L1 ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; POTENTIAL ROLE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; GLUT4-CONTAINING VESICLES; PHOSPHOINOSITIDE 3-KINASE; GLYCOGEN-SYNTHESIS; GENE-TRANSFER	Insulin and insulin-like growth factor I signals are mediated via phosphorylation of a family of insulin receptor substrate (IRS) proteins, which may serve both complementary and overlapping functions in the cell. To study the metabolic effects of these proteins in more detail, we established brown adipocyte cell lines from wild type and various IRS knockout (KO) animals and characterized insulin action in these cells in vitro. Preadipocytes derived from both wild type and TRS-S KO mice could be fully differentiated into mature brown adipocytes, In differentiated IRS-2 KO adipocytes, insulin-induced glucose uptake was decreased by 50% compared with their wild type counterparts. This was the result of a decrease in insulin-stimulated Glut4 translocation to the plasma membrane. This decrease in insulin-induced glucose uptake could be partially reconstituted in these cells by retrovirus-mediated reexpression of IRS-2, but not overexpression of IRS-1, Insulin signaling studies revealed a total loss of IRS-2-associated phosphatidylinositol (PI) 3-kinase activity and a reduction in phosphotyrosine-associated PI 3-kinase by 30% (p < 0.05) in the RO cells. The phosphorylation and activity of Akt, a major downstream effector of PI 3-kinase, as well as Akt-dependent phosphorylation of glycogen synthase kinase-3 and p70S6 kinase were not affected by the lack of IRS-2; however, there was a decrease in insulin stimulation of Akt associated with the plasma membrane. These results provide evidence for a critical role of IRS-2 as a mediator of insulin-stimulated Glut4 translocation and glucose uptake in adipocytes, This occurs without effects in differentiation, total activation of Akt and its downstream effecters, but may be caused by alterations in compartmentalization of these downstream signals.	Joslin Diabet Ctr, Dept Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Med Univ Lubeck, Dept Internal Med 1, D-23538 Lubeck, Germany; Univ Complutense Madrid, Fac Farm, E-28040 Madrid, Spain	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; University of Lubeck; Complutense University of Madrid	Kahn, CR (corresponding author), Joslin Diabet Ctr, Dept Res, 1 Joslin Pl, Boston, MA 02215 USA.		Kahn, Ronald/AAY-2435-2021; Benito, Manuel/J-5637-2014	Kahn, Ronald/0000-0002-7583-9228; Benito, Manuel/0000-0002-7218-406X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033201, P30DK036836] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 36836, DK 33201, DK 5545] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brooks CC, 2000, J BIOL CHEM, V275, P2029, DOI 10.1074/jbc.275.3.2029; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; Force WR, 1997, J BIOL CHEM, V272, P30835, DOI 10.1074/jbc.272.49.30835; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Higaki Y, 1999, J BIOL CHEM, V274, P20791, DOI 10.1074/jbc.274.30.20791; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Hunter SJ, 1998, AM J MED, V105, P331, DOI 10.1016/S0002-9343(98)00300-3; Inoue G, 1998, J BIOL CHEM, V273, P11548, DOI 10.1074/jbc.273.19.11548; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; Kaburagi Y, 1997, J BIOL CHEM, V272, P25839, DOI 10.1074/jbc.272.41.25839; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klein J, 1999, J BIOL CHEM, V274, P34795, DOI 10.1074/jbc.274.49.34795; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kupriyanova TA, 1999, J BIOL CHEM, V274, P1458, DOI 10.1074/jbc.274.3.1458; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moyers JS, 1996, J BIOL CHEM, V271, P23111, DOI 10.1074/jbc.271.38.23111; OKADA T, 1994, J BIOL CHEM, V269, P3568; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; QUON MJ, 1994, J BIOL CHEM, V269, P27920; RICE KM, 1994, BIOCHEM BIOPH RES CO, V198, P523, DOI 10.1006/bbrc.1994.1077; SawkaVerhelle D, 1996, J BIOL CHEM, V271, P5980, DOI 10.1074/jbc.271.11.5980; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Valverde AM, 1999, DIABETES, V48, P2122, DOI 10.2337/diabetes.48.11.2122; Wang QH, 1999, MOL CELL BIOL, V19, P4008; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Zhou LX, 1997, J BIOL CHEM, V272, P29829, DOI 10.1074/jbc.272.47.29829	45	144	151	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25494	25501		10.1074/jbc.M004046200	http://dx.doi.org/10.1074/jbc.M004046200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829031	hybrid			2022-12-25	WOS:000088849400060
J	Gohara, DW; Crotty, S; Arnold, JJ; Yoder, JD; Andino, R; Cameron, CE				Gohara, DW; Crotty, S; Arnold, JJ; Yoder, JD; Andino, R; Cameron, CE			Poliovirus RNA-dependent RNA polymerase (3D(pol)) - Structural, biochemical, and biological analysis of conserved structural motifs A and B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; HEPATITIS-C VIRUS; PHI-29 DNA-POLYMERASE; I KLENOW FRAGMENT; ESCHERICHIA-COLI; KINETIC-ANALYSIS; CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; BINDING POCKET; HELIX CLAMP	We have constructed a structural model for poliovirus RNA-dependent RNA polymerase (3D(pol)) in complex with a primer-template (sym/sub) and ATP. Residues found in conserved structural motifs A (Asp-238) and B (Asn-297) are involved in nucleotide selection. Asp-238 appears to couple binding of nucleotides with the correct sugar configuration to catalytic efficiency at the active site of the enzyme. Asn-297 is involved in selection of ribonucleoside triphosphates over 2'-dNTPs, a role mediated most likely via a hydrogen bond between the side chain of this residue and the 2'-OH of the ribonucleoside triphosphate. Substitutions at position 238 or 297 of 3D(pol) produced derivatives exhibiting a range of catalytic efficiencies when assayed in vitro for poly(rU) polymerase activity or sym/sub elongation activity. A direct correlation existed between activity on sym/sub and biological phenotypes; a 2.5-fold reduction in polymerase elongation rate produced virus with a temperature-sensitive growth phenotype. These data permit us to propose a detailed, structural model for nucleotide selection by 3D(pol), confirm the biological relevance of the sym/sub system, and provide additional evidence for kinetic coupling between RNA synthesis and subsequent steps in the virus life cycle.	Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of California System; University of California San Francisco	Cameron, CE (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.	cec9@psu.edu	Crotty, Shane/AAC-6703-2019; Crotty, Shane/AAE-8446-2019	Crotty, Shane/0000-0002-6484-6262; Gohara, David/0000-0001-8799-9125	NATIONAL CANCER INSTITUTE [K01CA075118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040085, R21AI040085, R01AI045818] Funding Source: NIH RePORTER; NCI NIH HHS [CA75118] Funding Source: Medline; NIAID NIH HHS [AI45818, AI40085] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Aiyar A, 1996, Methods Mol Biol, V57, P177; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; Arnaud-Barbe N, 1998, NUCLEIC ACIDS RES, V26, P3550, DOI 10.1093/nar/26.15.3550; Arnold JJ, 2000, J BIOL CHEM, V275, P5329, DOI 10.1074/jbc.275.8.5329; Arnold JJ, 1999, J BIOL CHEM, V274, P37060, DOI 10.1074/jbc.274.52.37060; ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Astatke M, 1998, J MOL BIOL, V278, P147, DOI 10.1006/jmbi.1998.1672; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beard WA, 1996, J BIOL CHEM, V271, P12213, DOI 10.1074/jbc.271.21.12213; Benkovic SJ, 1995, METHOD ENZYMOL, V262, P257; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Bonnin A, 1999, J MOL BIOL, V290, P241, DOI 10.1006/jmbi.1999.2900; BOYER PL, 1994, J MOL BIOL, V243, P472, DOI 10.1006/jmbi.1994.1673; Boyer PL, 2000, P NATL ACAD SCI USA, V97, P3056, DOI 10.1073/pnas.97.7.3056; Brandis JW, 1996, BIOCHEMISTRY-US, V35, P2189, DOI 10.1021/bi951682j; Brieba LG, 2000, BIOCHEMISTRY-US, V39, P919, DOI 10.1021/bi992324+; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; Crotty S, 1999, J VIROL, V73, P9485, DOI 10.1128/JVI.73.11.9485-9495.1999; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; EICK D, 1994, TRENDS GENET, V10, P292, DOI 10.1016/0168-9525(90)90013-V; ESTEBAN JA, 1993, J BIOL CHEM, V268, P2719; FERSHT A, 1999, STRUCTURE MECH PROTE, P30; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gohara DW, 1999, PROTEIN EXPRES PURIF, V17, P128, DOI 10.1006/prep.1999.1100; Gutierrez-Rivas M, 1999, J MOL BIOL, V290, P615, DOI 10.1006/jmbi.1999.2880; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Harris D, 1998, J BIOL CHEM, V273, P33624, DOI 10.1074/jbc.273.50.33624; HERMANN T, 1994, NUCLEIC ACIDS RES, V22, P4625, DOI 10.1093/nar/22.22.4625; Herold J, 2000, J VIROL, V74, P6394, DOI 10.1128/JVI.74.14.6394-6400.2000; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Huang Y, 1997, BIOCHEMISTRY-US, V36, P8231, DOI 10.1021/bi962674l; Jia YP, 1997, J BIOL CHEM, V272, P30147, DOI 10.1074/jbc.272.48.30147; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joyce CM, 1997, P NATL ACAD SCI USA, V94, P1619, DOI 10.1073/pnas.94.5.1619; Kaushik N, 1997, BIOCHEMISTRY-US, V36, P14430, DOI 10.1021/bi970645k; Kaushik N, 1999, BIOCHEMISTRY-US, V38, P2617, DOI 10.1021/bi9824285; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197; Kornberg A., 1991, DNA REPLICATION; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lewis DA, 1999, J BIOL CHEM, V274, P32924, DOI 10.1074/jbc.274.46.32924; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; Nugent CI, 1999, J VIROL, V73, P427, DOI 10.1128/JVI.73.1.427-435.1999; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; REARDON JE, 1993, J BIOL CHEM, V268, P8743; RECHINSKY VO, 1992, FEBS LETT, V306, P129, DOI 10.1016/0014-5793(92)80983-N; RICCHETTI M, 1993, EMBO J, V12, P387, DOI 10.1002/j.1460-2075.1993.tb05670.x; Richards OC, 1997, J BIOL CHEM, V272, P23261, DOI 10.1074/jbc.272.37.23261; RIENITZ A, 1985, NUCLEIC ACIDS RES, V13, P5685, DOI 10.1093/nar/13.15.5685; SANKAR S, 1992, J BIOL CHEM, V267, P10168; SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; ZINNEN S, 1994, J BIOL CHEM, V269, P24195	63	96	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25523	25532		10.1074/jbc.M002671200	http://dx.doi.org/10.1074/jbc.M002671200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827187	hybrid			2022-12-25	WOS:000088849400064
J	Higgins, JMG; Cernadas, M; Tan, K; Irie, A; Wang, JH; Takada, Y; Brenner, MB				Higgins, JMG; Cernadas, M; Tan, K; Irie, A; Wang, JH; Takada, Y; Brenner, MB			The role of alpha and beta chains in ligand recognition by beta(7) integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; FUNCTION-ASSOCIATED ANTIGEN-1; I-DOMAIN; BINDING-SITE; CRYSTAL-STRUCTURE; E-CADHERIN; A-DOMAIN; MONOCLONAL-ANTIBODY; T-CELLS; ALPHA(E)BETA(7) INTEGRIN	Integrins alpha(E)beta(7) and alpha(4)beta(7) are involved in localization of leukocytes at mucosal sites. Although both alpha(E)beta(7) and alpha(4)beta(7) utilize the beta(7) chain, they have distinct binding specificities for E-cadherin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1), respectively. We found that mutation of the metal ion-dependent adhesion site (MIDAS) in the alpha(E) A-domain (D190A) abolished E-cadherin binding, as did mutation F298A on the A-domain surface near the MIDAS cleft. A docking model of the A-domain with E-cadherin domain 1 indicates that coordination of the alpha(E) MIDAS metal ion by E-cadherin Glu(31) and a novel projection of Phe(298) into a hydrophobic pocket on E-cadherin provide the basis for the interaction. The location of the binding site on the alpha(E) A-domain resembles that on other integrins, but its structure appears distinctive and particularly adapted to recognize the tip of E-cadherin, a unique integrin ligand. Additionally, mutation of the beta(7) MIDAS motif (D140A) abolished alpha(E)beta(7) binding to E-cadherin and alpha(4)beta(7)-mediated adhesion to MAdCAM-1, and alpha(4) chain mutations that abrogated binding of alpha(4)beta(1) to vascular cell adhesion molecule-1 and fibronectin similarly reduced alpha(4)beta(7) interaction with MAdCAM-1. Thus, although specificity can be determined by the integrin alpha or beta chain, common structural features of both subunits are required for recognition of dissimilar ligands.	Harvard Univ, Sch Med, Brigham & Womens Hosp,Lymphocyte Biol Sect, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Pulm & Crit Care Div, Boston, MA 02115 USA; Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Scripps Research Institute	Higgins, JMG (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp,Lymphocyte Biol Sect, Div Rheumatol Immunol & Allergy, Smith Bldg,Rm 538D,1 Jimmy Fund Way, Boston, MA 02115 USA.	jhiggins@rics.bwh.harvard.edu		takada, yoshikazu/0000-0001-5481-9589; Higgins, Jonathan/0000-0001-6622-8268				ANDREW DP, 1994, J IMMUNOL, V153, P3847; AOTA S, 1994, J BIOL CHEM, V269, P24756; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BAJT ML, 1994, J BIOL CHEM, V269, P20913; Baneres JL, 1998, J BIOL CHEM, V273, P24744, DOI 10.1074/jbc.273.38.24744; Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Brenan M, 1997, EUR J IMMUNOL, V27, P3070, DOI 10.1002/eji.1830271145; Briskin MJ, 1996, J IMMUNOL, V156, P719; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; Coligan JE., 1994, CURRENT PROTOCOLS IM; Dickeson SK, 1999, J BIOL CHEM, V274, P32182, DOI 10.1074/jbc.274.45.32182; EDWARDS CP, 1995, J BIOL CHEM, V270, P12635, DOI 10.1074/jbc.270.21.12635; Edwards CP, 1998, J BIOL CHEM, V273, P28937, DOI 10.1074/jbc.273.44.28937; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; ERLE DJ, 1994, J IMMUNOL, V153, P517; FLENGHI L, 1990, BRIT J HAEMATOL, V76, P451, DOI 10.1111/j.1365-2141.1990.tb07900.x; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; Green N, 1999, CELL ADHES COMMUN, V7, P167, DOI 10.3109/15419069909010800; Hadley GA, 1997, J IMMUNOL, V159, P3748; HEMLER ME, 1987, J BIOL CHEM, V262, P11478; Hesterberg PE, 1996, GASTROENTEROLOGY, V111, P1373, DOI 10.1053/gast.1996.v111.pm8898653; Higgins JMG, 1998, J CELL BIOL, V140, P197, DOI 10.1083/jcb.140.1.197; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; HUANG XZ, 1995, AM J RESP CELL MOL, V13, P245, DOI 10.1165/ajrcmb.13.2.7626292; Irie A, 1997, P NATL ACAD SCI USA, V94, P7198, DOI 10.1073/pnas.94.14.7198; IRIE A, 1995, EMBO J, V14, P5550, DOI 10.1002/j.1460-2075.1995.tb00242.x; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; Kamata T, 1999, J BIOL CHEM, V274, P32108, DOI 10.1074/jbc.274.45.32108; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; Karecla PI, 1996, J BIOL CHEM, V271, P30909, DOI 10.1074/jbc.271.48.30909; KARECLA PI, 1995, EUR J IMMUNOL, V25, P852, DOI 10.1002/eji.1830250333; KERN A, 1994, J BIOL CHEM, V269, P22811; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; KRUSCHWITZ M, 1991, J CLIN PATHOL, V44, P636, DOI 10.1136/jcp.44.8.636; LAZAROVITS AI, 1984, J IMMUNOL, V133, P1857; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; Lin ECK, 1997, J BIOL CHEM, V272, P14236, DOI 10.1074/jbc.272.22.14236; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; Ludviksson BR, 1999, J IMMUNOL, V162, P4975; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MICKLEM KJ, 1991, AM J PATHOL, V139, P1297; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Newham P, 1997, J BIOL CHEM, V272, P19429, DOI 10.1074/jbc.272.31.19429; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Picarella D, 1997, J IMMUNOL, V158, P2099; PULIDO R, 1991, J BIOL CHEM, V266, P10241; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RANDI AM, 1994, J BIOL CHEM, V269, P12395; REILLY PL, 1995, J IMMUNOL, V155, P529; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; Ruiz-Velasco N, 2000, J BIOL CHEM, V275, P7052, DOI 10.1074/jbc.275.10.7052; RUSSELL GJ, 1994, EUR J IMMUNOL, V24, P2832, DOI 10.1002/eji.1830241138; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; Schon MP, 1999, J IMMUNOL, V162, P6641; SCHWEIGHOFFER T, 1993, J IMMUNOL, V151, P717; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SMITH TJ, 1994, IMMUNITY, V1, P393, DOI 10.1016/1074-7613(94)90070-1; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STRAUCH UG, 1994, INT IMMUNOL, V6, P263, DOI 10.1093/intimm/6.2.263; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; Tan K, 1998, STRUCTURE, V6, P793, DOI 10.1016/S0969-2126(98)00080-X; TANAKA T, 1995, INT IMMUNOL, V7, P1183, DOI 10.1093/intimm/7.8.1183; TANIGUCHISIDLE A, 1994, J IMMUNOL, V153, P5285; Taraszka KS, 2000, J EXP MED, V191, P1555, DOI 10.1084/jem.191.9.1555; Tidswell M, 1997, J IMMUNOL, V159, P1497; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; Van der Vieren M, 1999, J IMMUNOL, V163, P1984; WANG JH, 1995, P NATL ACAD SCI USA, V92, P5714, DOI 10.1073/pnas.92.12.5714; WONG WW, 1991, J IMMUNOL, V146, P656; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211	89	29	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25652	25664		10.1074/jbc.M001228200	http://dx.doi.org/10.1074/jbc.M001228200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837471	hybrid			2022-12-25	WOS:000088849400080
J	Shih, WL; Kuo, ML; Chuang, SE; Cheng, AL; Doong, SL				Shih, WL; Kuo, ML; Chuang, SE; Cheng, AL; Doong, SL			Hepatitis B virus X protein inhibits transforming growth factor-beta-induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIDDLE T-ANTIGEN; NF-KAPPA-B; HBX PROTEIN; GENE-PRODUCT; BINDING PROTEIN; HEPATOMA-CELLS; RECEPTOR GENE; I RECEPTOR; TRANSCRIPTION; KINASE	Transforming growth factor-beta (TGF-beta) is a potent inducer of apoptosis in Hep 3B cells. This work investigated how hepatitis B virus X protein (HBx) affects TGF-beta-induced apoptosis. Trypan blue exclusion and colony formation assays revealed that HBx increased the ID50 toward TGF-beta. In the presence of HBx, TGF-beta-induced DNA laddering was decreased, indicating that HBx had the ability to block TGF-beta-induced apoptosis. Furthermore, HBx did not alter the expression levels of type I and type II TGF-beta receptors. HBx did not affect TGF-beta-induced activation of promoter activities of the plasminogen activator inhibitor-1 (PAI-I) gene. These results indicate that HBx interferes with only a subset of TGF-beta activity. In the presence of phosphatidylinositol (PI) 3-kinase inhibitors, wortmannin or LY294002, the HBx-mediated inhibitory effect on TGF-beta-induced apoptosis was alleviated. In addition, the tyrosine phosphorylation levels of the regulatory subunit p85 of phosphatidylinositol 3-kinase (PI 3-kinase) and PI 3-kinase activity were elevated in stable clones with HBx expression. Transactivation-deficient mutants of HBx lost their ability to inhibit TGF-beta-induced apoptosis. Phosphorylation of the p85 subunit of PI 3-kinase and Akt, a downstream target of PI 3-kinase, was not observed in stable clones with transactivation-deficient HBx mutant's expression. Thus, the anti-apoptotic effect of HBx against TGF-beta can be mediated through the activation of the PI 3-kinase signaling pathway, and the transactivation function of HBx is required for its anti-apoptosis activity.	Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 10019, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei 10019, Taiwan; Natl Taiwan Univ, Coll Med, Canc Res Ctr, Taipei 10019, Taiwan; Natl Hlth Res Inst, Taipei 11529, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10019, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University; National Health Research Institutes - Taiwan; National Taiwan University; National Taiwan University Hospital	Doong, SL (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, 1,Sect 1,Jen Ai Rd, Taipei 10019, Taiwan.		Chuang, Shuang-En/D-2080-2010; Kuo, Min-Liang/C-4872-2009	KUO, MIN-LIANG/0000-0002-7139-0144; DOONG, SHIN-LIAN/0000-0002-0936-3858; Cheng, Ann-Lii/0000-0002-9152-6512				Al-Shami A, 1999, J BIOL CHEM, V274, P5333, DOI 10.1074/jbc.274.9.5333; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; Dahl J, 1998, J VIROL, V72, P3221, DOI 10.1128/JVI.72.4.3221-3226.1998; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Fan GS, 1996, ONCOGENE, V12, P1909; Gottlob K, 1998, CANCER RES, V58, P3566; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kim SO, 1996, CANCER RES, V56, P3831; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; KOIKE K, 1994, J CLIN INVEST, V94, P44, DOI 10.1172/JCI117343; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lee Y, 1998, CLIN CANCER RES, V4, P1711; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Lee YI, 1998, ONCOGENE, V16, P2367, DOI 10.1038/sj.onc.1201760; LIN JK, 1992, CANCER RES, V52, P385; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; MENZO S, 1993, VIROLOGY, V196, P878, DOI 10.1006/viro.1993.1550; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; NATOLI G, 1994, ONCOGENE, V9, P2837; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Oshikawa O, 1996, BIOCHEM BIOPH RES CO, V222, P770, DOI 10.1006/bbrc.1996.0819; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SHARFE N, 1995, BLOOD, V86, P2077, DOI 10.1182/blood.V86.6.2077.bloodjournal8662077; Shintani Y, 1999, J GEN VIROL, V80, P3257, DOI 10.1099/0022-1317-80-12-3257; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; TANAKA S, 1996, CANCER RES, V56, P391; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; WANG XW, 1995, CANCER RES, V55, P6012; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	55	163	186	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25858	25864		10.1074/jbc.M003578200	http://dx.doi.org/10.1074/jbc.M003578200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10835427	hybrid			2022-12-25	WOS:000088849400104
J	Nunomura, W; Takakuwa, Y; Parra, M; Conboy, J; Mohandas, N				Nunomura, W; Takakuwa, Y; Parra, M; Conboy, J; Mohandas, N			Regulation of protein 4.1R, p55, and glycophorin C ternary complex in human erythrocyte membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING INTERFACE; SKELETAL PROTEIN-4.1; OPTICAL BIOSENSOR; RESONANT MIRROR; CALMODULIN; IDENTIFICATION; PURIFICATION; MODULATION; HOMOLOG; MEMBER	Three binary protein-protein interactions, glycophorin C (GPC)-4.1R, GPC-p55, and p55-4.1R, constitute the GPC-4.1R-p55 ternary complex in the erythrocyte membrane. Little is known regarding the molecular basis for the interaction of 4.1R with either GPC or p55 and regarding the role of 4.1R in regulating the various protein-protein interactions that constitute the GPC-4.1R-p55 ternary complex. In the present study, we present evidence that sequences in the 30-kDa domain encoded by exon 8 and exon 10 of 4,1R constitute the binding interfaces for GPC and p55, respectively. We further show that 4.1R increases the affinity of p55 binding to GPC by an order of magnitude, implying that 4,1R modulates the interaction between p55 and GPC. Finally, we document that binding of calmodulin to 4.1R decreases the affinity of 4.1R interactions with both p55 and GPC in a Ca2+-dependent manner, implying that the GPC-4.1R-p55 ternary protein complex can undergo dynamic regulation in the erythrocyte membrane. Taken together, these findings have enabled us to identify an important role for 4.1R in regulating the GPC-4.1R-p55 ternary complex in the erythrocyte membrane.	Tokyo Womens Med Univ, Sch Med, Dept Biochem, Shinju Ku, Tokyo 1628666, Japan; Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	Tokyo Women's Medical University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Mohandas, N (corresponding author), Univ Calif Berkeley, Berkeley Natl Lab, Mail Stop 74-157,1 Cyclotron Rd, Berkeley, CA 94720 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094, R01DK026263, R37DK026263] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL31579] Funding Source: Medline; NIDDK NIH HHS [DK 32094, DK 26263] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLOISIO N, 1993, BLOOD, V82, P1323, DOI 10.1182/blood.V82.4.1323.bloodjournal8241323; An XL, 1996, J BIOL CHEM, V271, P33187, DOI 10.1074/jbc.271.52.33187; Baklouti F, 1997, GENOMICS, V39, P289, DOI 10.1006/geno.1996.4512; CHANG CD, 1978, INT J PEPT PROT RES, V11, P246; Chishti A H, 1998, Curr Opin Hematol, V5, P116; CHISHTI AH, 1989, J BIOL CHEM, V264, P8985; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; CONBOY JG, 1991, J BIOL CHEM, V266, P8273; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GEORGE AJT, 1995, J IMMUNOL METHODS, V183, P51, DOI 10.1016/0022-1759(95)00031-5; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HEMMING NJ, 1995, J BIOL CHEM, V270, P5360, DOI 10.1074/jbc.270.10.5360; HEMMING NJ, 1994, BIOCHEM J, V299, P191, DOI 10.1042/bj2990191; HUSAIN A, 1985, BIOCHEM INT, V10, P1; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KARAS M, 1987, INT J MASS SPECTRUM, V78, P58; Kim AC, 1996, GENOMICS, V31, P223, DOI 10.1006/geno.1996.0035; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LETO TL, 1984, J BIOL CHEM, V259, P4603; LOMBARDO CR, 1994, BBA-BIOMEMBRANES, V1196, P139, DOI 10.1016/0005-2736(94)00233-9; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; MARFATIA SM, 1994, J BIOL CHEM, V269, P8631; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Nunomura W, 2000, J BIOL CHEM, V275, P6360, DOI 10.1074/jbc.275.9.6360; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; Parra M, 1998, GENOMICS, V49, P298, DOI 10.1006/geno.1998.5265; REID ME, 1990, BLOOD, V75, P2229; SOBUE K, 1981, BIOCHEM BIOPH RES CO, V100, P1063, DOI 10.1016/0006-291X(81)91931-8; TAKAKUWA Y, 1988, J CLIN INVEST, V82, P394, DOI 10.1172/JCI113611; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; Tanaka K, 1988, RAPID COMMUN MASS SP, V2, P151, DOI [10.1002/RCM.1290020802, DOI 10.1002/RCM.1290020802, 10.1002/rcm.1290020802]; TANAKA T, 1991, J BIOL CHEM, V266, P1134; TCHERNIA G, 1981, J CLIN INVEST, V68, P454, DOI 10.1172/JCI110275; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; Walensky LD, 1998, J CELL BIOL, V141, P143, DOI 10.1083/jcb.141.1.143; Walensky LD, 1999, J NEUROSCI, V19, P6457; WATTS HJ, 1994, ANAL CHEM, V66, P2465, DOI 10.1021/ac00087a010	46	84	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24540	24546		10.1074/jbc.M002492200	http://dx.doi.org/10.1074/jbc.M002492200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10831591	hybrid			2022-12-25	WOS:000088683300042
J	Tran, K; Wang, YW; DeLong, CJ; Cui, Z; Yao, ZM				Tran, K; Wang, YW; DeLong, CJ; Cui, Z; Yao, ZM			The assembly of very low density lipoproteins in rat hepatoma McA-RH7777 cells is inhibited by phospholipase A(2) antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; B-CONTAINING LIPOPROTEINS; HUMAN PANCREATIC-ISLETS; N-3 FATTY-ACIDS; HEP G2 CELLS; APOLIPOPROTEIN-B; ENDOPLASMIC-RETICULUM; P388D(1) MACROPHAGES; GOLGI-COMPLEX; PHOSPHATIDYLETHANOLAMINE METHYLATION	In McA-RH7777 cells, the oleate-stimulated assembly and secretion of very low density lipoproteins (VLDL) was associated with enhanced deacylation of phospholipids, which was markedly decreased by inactivation of the cellular phospholipase A(2). Treatment of the cells with antagonists or antisense oligonucleotide of the Ca2+-independent phospholipase A(2) (iPLA(2)) significantly inhibited secretion of apoB100-VLDL and triglyceride, Similar inhibitory effect of the iPLA(2) antagonists was observed on apoB48-VLDL secretion, but secretion of high density lipoprotein particles (such as apoAI- and apoB48-high density lipoprotein) or proteins in general was unaffected. The iPLA(2) antagonist did not affect the synthesis of apoB100 or triglyceride, nor did it affect the activities of phospholipase D, phosphatidate phosphohydrolase, or microsomal triglyceride transfer protein. Inactivation of iPLA(2) resulted in impaired apoB100-VLDL assembly as shown by decreased apoB100-VLDL and triglyceride within the microsomal lumen, with concomitant increase in apoB100 association with the microsomal membranes. The inhibitory effect of iPLA(2) antagonists on apoB100-VLDL assembly/secretion could be abated by pretreatment of cells with oleate. Analysis of molecular species of microsomal phosphatidylcholine and phosphatidylethanolamine by electron spray tandem mass spectrometry revealed that the enrichment of oleoyl moieties was altered by the treatment of iPLA(2) antagonist. These results suggest that the oleate-induced VLDL assembly/secretion may depend upon the establishment of membrane glycerolipids enriched in oleoyl chain, a process mediated by the iPLA(2) activity.	Univ Ottawa, Inst Heart, Dept Pathol & Lab Med, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Dept Biochem, Ottawa, ON K1Y 4W7, Canada; Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; Wake Forest University	Yao, ZM (corresponding author), Univ Ottawa, Inst Heart, Dept Pathol & Lab Med, Lipoprot & Atherosclerosis Grp, Ottawa, ON K1Y 4W7, Canada.			DeLong, Cynthia/0000-0002-6823-8619	NATIONAL CANCER INSTITUTE [T32CA009422] Funding Source: NIH RePORTER; NCI NIH HHS [CA09422, CA85757] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Adeli K, 1997, J BIOL CHEM, V272, P5031, DOI 10.1074/jbc.272.8.5031; ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; BARON H, 1971, BIOCHIM BIOPHYS ACTA, V248, P1, DOI 10.1016/0005-2760(71)90068-3; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; Brindley DN, 1998, J BIOL CHEM, V273, P24281, DOI 10.1074/jbc.273.38.24281; CARTWRIGHT IJ, 1995, BIOCHEM J, V310, P897, DOI 10.1042/bj3100897; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; de Figueiredo P, 1998, P NATL ACAD SCI USA, V95, P8642, DOI 10.1073/pnas.95.15.8642; de Figueiredo P, 1999, MOL BIOL CELL, V10, P1763, DOI 10.1091/mbc.10.6.1763; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; FUJII T, 1979, J BIOCHEM-TOKYO, V86, P1345, DOI 10.1093/oxfordjournals.jbchem.a132651; GIBBONS GF, 1994, J LIPID RES, V35, P1801; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; JAMAL Z, 1991, J BIOL CHEM, V266, P2988; LANG CA, 1990, J LIPID RES, V31, P2079; LINTON MF, 1993, J LIPID RES, V34, P521; Ma ZM, 1999, J BIOL CHEM, V274, P9607, DOI 10.1074/jbc.274.14.9607; Ma ZM, 1997, J BIOL CHEM, V272, P11118; MAYORGA LS, 1993, P NATL ACAD SCI USA, V90, P10255, DOI 10.1073/pnas.90.21.10255; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NishimakiMogami T, 1996, BBA-LIPID LIPID MET, V1304, P21, DOI 10.1016/S0005-2760(96)00100-2; Pecheur EI, 2000, J BIOL CHEM, V275, P3936, DOI 10.1074/jbc.275.6.3936; Pettitt TR, 1997, J BIOL CHEM, V272, P17354, DOI 10.1074/jbc.272.28.17354; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P13499, DOI 10.1021/bi00212a015; REDGRAVE TG, 1979, J LIPID RES, V20, P217; Roth MG, 1999, TRENDS CELL BIOL, V9, P174, DOI 10.1016/S0962-8924(99)01535-4; RUSINOL AE, 1995, J BIOL CHEM, V270, P13318, DOI 10.1074/jbc.270.22.13318; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; Scales SJ, 1999, NATURE, V401, P123, DOI 10.1038/43582; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Sjoberg A, 1996, J LIPID RES, V37, P275; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; SPARKS CE, 1986, METABOLISM, V35, P1128, DOI 10.1016/0026-0495(86)90026-0; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; SWIFT LL, 1995, J LIPID RES, V36, P395; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; WANG HX, 1993, J CLIN INVEST, V91, P1380, DOI 10.1172/JCI116340; WANG HX, 1994, J BIOL CHEM, V269, P18514; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; WETTERAU JR, 1992, SCIENCE, V258, P999; Wiggins D, 1996, BIOCHEM J, V320, P673, DOI 10.1042/bj3200673; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6	62	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					25023	25030		10.1074/jbc.M908971199	http://dx.doi.org/10.1074/jbc.M908971199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827200	hybrid			2022-12-25	WOS:000088683300105
J	Xiao, Z; Liu, XD; Lodish, HF				Xiao, Z; Liu, XD; Lodish, HF			Importin beta mediates nuclear translocation of Smad 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCALIZATION SIGNAL; PROTEIN IMPORT; BINDING; IDENTIFICATION; ALPHA; REV	Smad proteins are intracellular mediators of transforming growth factor-beta (TGF-beta) and related cytokines, Although ligand-induced nuclear translocation of Smad proteins is clearly established, the pathway mediating this import is yet to be determined. We previously identified a nuclear localization signal (NLS) in the N-terminal region of Smad 3, the major Smad protein involved in TGF-beta signal transduction. This basic motif (Lys(40)-Lys-Leu-Lys-Lys(44)), conserved among all the pathway-specific Smad proteins, is required for Smad 3 nuclear import in response to ligand, Here we studied the nuclear import pathway of Smad 3 mediated by this NLS, We demonstrate that the isolated Smad 3 MH1 domain displays significant specific binding to importin beta, which is diminished or eliminated by mutations in the NLS, Full-size Smad 3 exhibits weak but specific binding to importin beta, which is enhanced after phosphorylation by the type I TGF-beta receptor. In contrast, no interaction was observed between importin alpha and Smad 3 or its MH1 domain, indicating that nuclear translocation of Smad proteins may occur through direct binding to importin beta, We propose that activation of all of the pathway-specific Smad proteins (Smads 1, 2, 3, 5, 8, and 9) exposes the conserved NLS motif, which then binds directly to importin beta and triggers nuclear translocation.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.			LIU, XUEDONG/0000-0001-7209-4964	NCI NIH HHS [CA63260] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063260] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Henderson BR, 1997, J MOL BIOL, V274, P693, DOI 10.1006/jmbi.1997.1420; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Sekimoto T, 1997, EMBO J, V16, P7067, DOI 10.1093/emboj/16.23.7067; Takizawa CG, 1999, P NATL ACAD SCI USA, V96, P7938, DOI 10.1073/pnas.96.14.7938; Tiganis T, 1997, J BIOL CHEM, V272, P21548, DOI 10.1074/jbc.272.34.21548; Truant R, 1998, MOL CELL BIOL, V18, P1449, DOI 10.1128/MCB.18.3.1449; Truant R, 1999, MOL CELL BIOL, V19, P1210; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Xiao Z, 2000, P NATL ACAD SCI USA, V97, P7853, DOI 10.1073/pnas.97.14.7853	20	134	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23425	23428		10.1074/jbc.C000345200	http://dx.doi.org/10.1074/jbc.C000345200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10846168	hybrid			2022-12-25	WOS:000088564200005
J	Yue, LL; Lu, SJ; Garces, J; Jin, TQ; Li, JX				Yue, LL; Lu, SJ; Garces, J; Jin, TQ; Li, JX			Protein kinase C-regulated dynamitin-macrophage-enriched myristoylated alanine-rice C kinase substrate interaction is involved in macrophage cell spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-RELATED PROTEIN; CYTOPLASMIC DYNEIN; DYNACTIN COMPLEX; SIGNAL-TRANSDUCTION; FOCAL ADHESIONS; MOTOR PROTEINS; PHOSPHORYLATION; MARCKS; MACMARCKS; INTEGRINS	Macrophage spreading requires the microtubule cytoskeleton and protein kinase C (PKC). The mechanism of involvement of the microtubules and PKC in this event is not fully understood. Dynamitin is a subunit of dynactin, which is important for linking the microtubule-dependent motor protein dynein to vesicle membranes. We report that dynamitin is a Ca2+/calmodulin-binding protein and that dynamitin binds directly to macrophage-enriched myristoylated alanine-rice C kinase substrate (MacMARCKS), a membrane-associated PKC substrate involved in macrophage spreading and integrin activation. Dynamitin was found to copurify with MacMARCKS both during MacMARCKS purification with conventional chromatography and during the immunoabsorption of MacMARCKS using anti-MacMARCKS antibody. Vice verse, MacMARCKS was also found to cosediment with the 20 S dynactin complex. We determined that the effector domain of MacMARCKS is required to interact with the N-terminal domain of dynamitin. MacMARCKS and dynamitin also partially colocalized at peripheral regions of macrophages and in the cell-cell border of 293 epithelial cells. Treatment with phorbol esters abolished this colocalization. Disrupting the interaction with a short peptide derived from the MacMARCKS-binding domain of dynamitin caused macrophages to spread and flatten. These data suggest that the dynamitin-MacMARCKS interaction is involved in cell spreading. Furthermore, the regulation of this interaction by PKC and Ca2+/calmodulin provides a possible regulatory mechanism for cell adhesion and spreading.	Univ Illinois, Coll Dent, Dept Oral Biol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Pediat, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Ctr Canc, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Massachusetts System; University of Massachusetts Worcester	Li, JX (corresponding author), Univ Illinois, Coll Dent, Dept Oral Biol, 801 S Paulina St, Chicago, IL 60612 USA.	jxli@uic.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054715] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54715] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allan V, 1996, CURR BIOL, V6, P630, DOI 10.1016/S0960-9822(09)00434-5; BECK KA, 1994, J CELL BIOL, V127, P707, DOI 10.1083/jcb.127.3.707; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Chang S, 1996, J BIOL CHEM, V271, P1174, DOI 10.1074/jbc.271.2.1174; CHEUNG HT, 1980, CELL BIOL INT REP, V4, P1125, DOI 10.1016/0309-1651(80)90050-8; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DEBRABANDER M, 1977, CELL BIOL INT REP, P453; DILLMAN JF, 1995, BIOPHYS J, V68, pS226; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Eckley DM, 1999, J CELL BIOL, V147, P307, DOI 10.1083/jcb.147.2.307; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Garces JA, 1999, CURR BIOL, V9, P1497, DOI 10.1016/S0960-9822(00)80122-0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Holleran EA, 1998, INT REV CYTOL, V182, P69, DOI 10.1016/S0074-7696(08)62168-3; HOLZBAUR ELF, 1991, NATURE, V351, P579, DOI 10.1038/351579a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IVANOVA OY, 1976, EXP CELL RES, V101, P207, DOI 10.1016/0014-4827(76)90431-6; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; Kucik DF, 1996, J CLIN INVEST, V97, P2139, DOI 10.1172/JCI118651; Li JX, 1996, J BIOL CHEM, V271, P12985, DOI 10.1074/jbc.271.22.12985; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; LIN SXH, 1994, J CELL BIOL, V127, P1009, DOI 10.1083/jcb.127.4.1009; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; MCILVAIN JM, 1994, J BIOL CHEM, V269, P19176; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; PASCHAL BM, 1993, J BIOL CHEM, V268, P15318; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PETTY HR, 1989, BIOCHIM BIOPHYS ACTA, V1012, P284, DOI 10.1016/0167-4889(89)90110-9; PHAIREWASHINGTON L, 1980, J CELL BIOL, V86, P634, DOI 10.1083/jcb.86.2.634; RODIONOV VI, 1993, J CELL BIOL, V123, P1811, DOI 10.1083/jcb.123.6.1811; Roghi C, 1999, J CELL SCI, V112, P4673; ROSALES C, 1995, J LEUKOCYTE BIOL, V57, P189, DOI 10.1002/jlb.57.2.189; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; Schroer TA, 1996, TRENDS CELL BIOL, V6, P212, DOI 10.1016/0962-8924(96)20014-5; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; STEWART M, 1995, CURR OPIN CELL BIOL, V7, P690, DOI 10.1016/0955-0674(95)80111-1; Swierczynski SL, 1996, J BIOL CHEM, V271, P23424, DOI 10.1074/jbc.271.38.23424; Thompson LJ, 1996, J BIOL CHEM, V271, P15045, DOI 10.1074/jbc.271.25.15045; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2; Valetti C, 1999, MOL BIOL CELL, V10, P4107, DOI 10.1091/mbc.10.12.4107; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; Vallee RB, 1995, COLD SPRING HARB SYM, V60, P803, DOI 10.1101/SQB.1995.060.01.086; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALLIS WJ, 1985, J IMMUNOL, V135, P2323; WATERMANSTORER CM, 1995, P NATL ACAD SCI USA, V92, P1634, DOI 10.1073/pnas.92.5.1634; Weber C, 1996, J CELL BIOL, V134, P1063, DOI 10.1083/jcb.134.4.1063; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yue LL, 1999, J CELL PHYSIOL, V181, P355, DOI 10.1002/(SICI)1097-4652(199911)181:2<355::AID-JCP17>3.0.CO;2-B; Yue LL, 2000, CELL ADHES COMMUN, V7, P359, DOI 10.3109/15419060009109018; Zhou XM, 2000, J BIOL CHEM, V275, P20217, DOI 10.1074/jbc.M909129199; ZHU ZX, 1995, J BIOL CHEM, V270, P17652, DOI 10.1074/jbc.270.30.17652; [No title captured]	68	41	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23948	23956		10.1074/jbc.M001845200	http://dx.doi.org/10.1074/jbc.M001845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10827182	hybrid			2022-12-25	WOS:000088564200075
J	Renard, CA; Fourel, G; Bralet, MP; Degott, C; De la Coste, A; Perret, C; Tiollais, P; Buendia, MA				Renard, CA; Fourel, G; Bralet, MP; Degott, C; De la Coste, A; Perret, C; Tiollais, P; Buendia, MA			Hepatocellular carcinoma in WHV/N-myc2 transgenic mice: oncogenic mutations of beta-catenin and synergistic effect of p53 null alleles	ONCOGENE			English	Article						woodchuck; hepatocellular carcinoma; hepatitis B virus; N-myc; p53; beta-catenin	WOODCHUCK HEPATITIS-VIRUS; GROWTH-FACTOR-II; C-MYC TRANSGENE; WILD-TYPE P53; LIVER-TUMORS; HEPADNAVIRUS INSERTION; INDUCED CARCINOGENESIS; NUCLEOTIDE-SEQUENCE; CELL-PROLIFERATION; N-MYC2 RETROPOSON	The intronless N-myc2 gene was originally identified as the major target of hepatitis virus insertion in woodchuck liver tumors. Here we report that transgenic mice carrying the N-myc2 gene controlled by woodchuck hepatitis virus (WHV) regulatory sequences are highly predisposed to fiver cancer. In a WHV/N-myc2 transgenic line, hepatocellular carcinomas or adenomas arose in over 70% of mice, despite barely detectable expression of the methylated transgene in liver cells, Furthermore, a transgenic founder carrying unmethylated transgene sequences succumbed to a large liver tumor by the age of two months, demonstrating the high oncogenicity of the woodchuck N-myc2 retroposon, Stabilizing mutations or deletions of beta-catenin were found in 25% of liver tumors and correlated with reduced tumor latency (P<0.05), confirming the important role of beta-catenin activation in MSc-induced tnmorigenesis, The ability of the tumor suppressor gene p53 to cooperate with N-myc2 in liver cell transformation was tested by introducing a p53-null allele into WHV/N-myc2 transgenic mice. The loss of one p53 allele in transgenic animals markedly accelerated the onset of liver cancer (P=0.0001), and most tumors of WHV/N-myc2 p53+/Delta mice harbored either a deletion of the wt p53 allele or a beta-catenin mutation. These findings provide direct evidence that activation of N-myc2 and reduction of p53 levels act synergistically during multistage carcinogenesis in vivo and suggest that different genetic pathways may underlie liver carcinogenesis initiated by a myc transgene.	Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, F-75015 Paris, France; Hop Beaujon, Lab Anatomopathol, Clichy, France; Univ Paris 05, ICGM, INSERM, U129, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	Buendia, MA (corresponding author), Inst Pasteur, INSERM, U163, Unite Recombinaison & Express Genet, 28 Rue Dr Roux, F-75015 Paris, France.		Perret-Mayeux, Christine/L-3297-2017	perret, christine/0000-0003-4710-7051				BLYTH K, 1995, ONCOGENE, V10, P1717; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Bruni R, 1999, VIROLOGY, V257, P483, DOI 10.1006/viro.1999.9678; BUENDIA MA, 1998, VIRAL HEPATITIS, P179; CARTIER N, 1992, ONCOGENE, V7, P1413; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; de la Coste A, 1999, CANCER RES, V59, P5017; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Devereux TR, 1999, ONCOGENE, V18, P4726, DOI 10.1038/sj.onc.1202858; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELSON A, 1995, ONCOGENE, V11, P181; ETIEMBLE J, 1994, ONCOGENE, V9, P727; Factor VM, 1997, HEPATOLOGY, V26, P1434; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GALIBERT F, 1982, J VIROL, V41, P51, DOI 10.1128/JVI.41.1.51-65.1982; Ghebranious N, 1998, HEPATOLOGY, V27, P967, DOI 10.1002/hep.510270411; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANSEN LJ, 1993, MOL CELL BIOL, V13, P659, DOI 10.1128/MCB.13.1.659; HSU B, 1995, ONCOGENE, V11, P175; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Liu P, 1997, HEPATOLOGY, V25, P874, DOI 10.1002/hep.510250415; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MURAKAMI H, 1993, CANCER RES, V53, P1719; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Nagai H, 1998, HEPATITIS B VIRUS, P182; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; Quignon F, 1996, ONCOGENE, V12, P2011; Renard CA, 1998, RES VIROLOGY, V149, P133, DOI 10.1016/S0923-2516(98)80031-9; SANDGREN EP, 1989, ONCOGENE, V4, P715; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; Schafer DF, 1999, LANCET, V353, P1253, DOI 10.1016/S0140-6736(98)09148-X; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Tsujiuchi T, 1999, CANCER RES, V59, P3904; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992; Yang DY, 1996, J VIROL, V70, P6260, DOI 10.1128/JVI.70.9.6260-6268.1996	56	33	40	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2678	2686		10.1038/sj.onc.1203617	http://dx.doi.org/10.1038/sj.onc.1203617			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851067				2022-12-25	WOS:000087193000003
J	Hamada, M; Sakulich, AL; Koduru, SB; Maraia, RJ				Hamada, M; Sakulich, AL; Koduru, SB; Maraia, RJ			Transcription termination by RNA polymerase III in fission yeast - A genetic and biochemically tractable model system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LA ANTIGEN; SCHIZOSACCHAROMYCES-POMBE; DNA-BINDING; INITIATION-FACTOR; ALPHA-AMANITIN; BETA' SUBUNIT; S-CEREVISIAE; PROTEIN; SEQUENCES; CLEAVAGE	In order for RNA polymerase (pol) III to produce a sufficient quantity of RNAs of appropriate structure, initiation, termination, and reinitiation must be accurate and efficient. Termination-associated factors have been shown to facilitate reinitiation and regulate transcription in some species. Suppressor tRNA genes that differ in the dT(n) termination signal were examined for function in Schizosaccharomyces pombe, We also developed an S. pombe extract that is active for tRNA transcription that is described here for the first time. The ability of this tRNA gene to be transcribed in extracts from different species allowed us to compare termination in three model systems. Although human pol III terminates efficiently at 4 dTs and S. pombe at 5 dTs, Saccharomyces cerevisiae pol III requires 6 dTs to direct comparable but lower termination efficiency and also appears qualitatively distinct. Interestingly, this pattern of sensitivity to a minimal dT(n) termination signal was found to correlate with the sensitivity to alpha-amanitin, as S. pombe was intermediate between human and S. cerevisiae pols III. The results establish that the pols III of S. cerevisiae, S. pombe, and human exhibit distinctive properties and that termination occurs in S. pombe in a manner that is functionally more similar to human than is S. cerevisiae.	NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Maraia, RJ (corresponding author), 6 Ctr Dr,Rm 416, Bethesda, MD 20892 USA.		Maraia, Richard/ABC-1442-2020	Maraia, Richard/0000-0002-5209-0066	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000412] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000412] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADENIYIJONES S, 1984, NUCLEIC ACIDS RES, V12, P1101, DOI 10.1093/nar/12.2.1101; ALLISON DS, 1985, EMBO J, V4, P2657, DOI 10.1002/j.1460-2075.1985.tb03984.x; Arrebola R, 1998, MOL CELL BIOL, V18, P1; Baserga S., 1993, RNA WORLD, P359; Bobkova EV, 1997, J BIOL CHEM, V272, P22832, DOI 10.1074/jbc.272.36.22832; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; CAMPBELL FE, 1992, MOL CELL BIOL, V12, P2260, DOI 10.1128/MCB.12.5.2260; CASTANO JG, 1985, J BIOL CHEM, V260, P9002; CHAFIN DR, 1995, J BIOL CHEM, V270, P19114, DOI 10.1074/jbc.270.32.19114; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; Chu WM, 1997, NUCLEIC ACIDS RES, V25, P2077, DOI 10.1093/nar/25.11.2077; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; CONNOLLY T, 1994, MOL CELL BIOL, V14, P768, DOI 10.1128/MCB.14.1.768; Dieci G, 1996, CELL, V84, P245, DOI 10.1016/S0092-8674(00)80979-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fan H, 1997, CELL, V88, P707, DOI 10.1016/S0092-8674(00)81913-3; Fan H, 1998, MOL CELL BIOL, V18, P3201, DOI 10.1128/MCB.18.6.3201; FURTER R, 1992, BIOCHEMISTRY-US, V31, P10817, DOI 10.1021/bi00159a024; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; Goodier JL, 1998, J BIOL CHEM, V273, P26110, DOI 10.1074/jbc.273.40.26110; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; Gunnery S, 1999, J MOL BIOL, V286, P745, DOI 10.1006/jmbi.1998.2518; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; HOFSTETTER H, 1981, CELL, V24, P573, DOI 10.1016/0092-8674(81)90348-2; HOTTINGER H, 1982, MOL GEN GENET, V188, P219, DOI 10.1007/BF00332678; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; INTINE RVA, 2000, IN PRESS MOL CELL; JAOZEIRO CAP, 1996, GENE DEV, V10, P725; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1994, TRANSCRIPTION MECHAN, P107; KEENEY JB, 1994, GENETICS, V136, P849; Kohli J, 1989, MOL BIOL FISSION YEA, P75; LAGNA G, 1994, MOL CELL BIOL, V14, P3053, DOI 10.1128/MCB.14.5.3053; LEVINGER L, 1995, J BIOL CHEM, V270, P18903, DOI 10.1074/jbc.270.32.18903; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MAO JI, 1980, CELL, V21, P509, DOI 10.1016/0092-8674(80)90488-2; MARAIA RJ, 1992, MOL CELL BIOL, V12, P1500, DOI 10.1128/MCB.12.4.1500; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; MARAIA RJ, 1991, NUCLEIC ACIDS RES, V19, P5695, DOI 10.1093/nar/19.20.5695; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; McBryant SJ, 1999, J MOL BIOL, V286, P973, DOI 10.1006/jmbi.1999.2539; MURPHY MH, 1983, NUCLEIC ACIDS RES, V11, P7695, DOI 10.1093/nar/11.22.7695; NICHOLS M, 1990, METHOD ENZYMOL, V181, P377; Rodicker F, 1999, GENE EXPRESSION, V8, P165; SEVERINOV K, 1995, J BIOL CHEM, V270, P23926, DOI 10.1074/jbc.270.41.23926; Shaaban SA, 1996, MOL CELL BIOL, V16, P6468; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; Thuillier V, 1996, EMBO J, V15, P618, DOI 10.1002/j.1460-2075.1996.tb00394.x; VALENZUELA P, 1976, P NATL ACAD SCI USA, V73, P1024, DOI 10.1073/pnas.73.4.1024; Van Horn DJ, 1997, RNA, V3, P1434; VNENCAKJONES CL, 1987, MOL CELL BIOL, V7, P4134, DOI 10.1128/MCB.7.11.4134; Wang ZX, 1998, MOL CELL, V1, P749, DOI 10.1016/S1097-2765(00)80074-X; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; Wang ZX, 1997, GENE DEV, V11, P1315, DOI 10.1101/gad.11.10.1315; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; WILIS I, 1986, P NATL ACAD SCI USA, V83, P7860; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; YANG XF, 1995, J BIOL CHEM, V270, P23930, DOI 10.1074/jbc.270.41.23930	63	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29076	29081		10.1074/jbc.M003980200	http://dx.doi.org/10.1074/jbc.M003980200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10843998	hybrid			2022-12-25	WOS:000089330700095
J	Corbett, EF; Michalak, KM; Oikawa, K; Johnson, S; Campbell, ID; Eggleton, P; Kay, C; Michalak, M				Corbett, EF; Michalak, KM; Oikawa, K; Johnson, S; Campbell, ID; Eggleton, P; Kay, C; Michalak, M			The conformation of calreticulin is influenced by the endoplasmic reticulum luminal environment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; GLUCOSE-REGULATED PROTEIN; MUSCLE SARCOPLASMIC-RETICULUM; CHAIN-BINDING-PROTEIN; MOLECULAR CHAPERONE; ATP-BINDING; IN-VITRO; NUCLEOTIDE SULFATE; SECRETORY PROTEINS; GOLGI-APPARATUS	In order to understand the dynamics of the endoplasmic reticulum (ER) luminal environment, we investigated the role of Ca2+, Zn2+, and ATP on conformational changes of calreticulin. Purified calreticulin was digested with trypsin in the presence or absence of Ca2+, Zn2+, and ATP, At low Ca2+ concentration (<100 mu M), calreticulin is rapidly and fully degraded by trypsin, indicating that under these conditions the protein is in a highly trypsin-susceptible conformation, Increasing Ca2+ concentration up to 500 mu M or 1 mM resulted in protection of the full-length calreticulin and in generation of the 27-kDa fragment highly resistant to trypsin digestion, The 27-kDa protease-resistant core of the protein represented the NH2-terminal half of calreticulin and was identified by its reactivity with specific antibodies and by NH2-terminal amino acid sequence analysis. Ca2+ dependent changes in calreticulin's sensitivity to proteolysis indicate that agonist-induced fluctuation in the free ER luminal Ca2+ concentration may affect the protein conformation and function. Trypsin digestion of calreticulin in the presence of Zn2+ resulted in the formation of a 17-kDa central protease-resistant core in the protein corresponding to the central region of the protein, indicating that under these conditions the N- and C-domains of the protein are in an extended conformation. Here we also show that calreticulin is an ATP-binding protein but that it does not contain detectable ATPase activity, Digestion of the protein with trypsin in the presence of Mg2+-ATP protects the full-length protein. These results indicate that calreticulin may undergo frequent, ion-induced conformation changes, which may affect its function and its ability to interact with other proteins in the lumen of the ER.	Univ Alberta, Dept Biochem, CIHR Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Prot Engn Network Ctr Excellence, Canadian Inst Hlth Res Grp Prot Struct & Funct, Edmonton, AB T6G 2H7, Canada; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England	University of Alberta; University of Alberta; University of Oxford	Michalak, M (corresponding author), Univ Alberta, Dept Biochem, CIHR Grp Mol Biol Membranes, Edmonton, AB T6G 2H7, Canada.		; Johnson, Steven/F-9182-2016	Eggleton, Paul/0000-0001-8244-2125; Johnson, Steven/0000-0002-7877-3543				Baksh S, 1995, J BIOL CHEM, V270, P31338, DOI 10.1074/jbc.270.52.31338; BAKSH S, 1995, FEBS LETT, V376, P53, DOI 10.1016/0014-5793(95)01246-4; BAKSH S, 1991, J BIOL CHEM, V266, P21458; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BERGMEYER HU, 1965, METHOD ENZYMAT AN, P999; Berninsone P, 1998, ANN NY ACAD SCI, V842, P91, DOI 10.1111/j.1749-6632.1998.tb09636.x; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burrell, 1993, ENZYMES MOL BIOL; Cala SE, 1999, BIOCHEM BIOPH RES CO, V259, P233, DOI 10.1006/bbrc.1999.0760; CALA SE, 1994, J BIOL CHEM, V269, P5926; Chen NQ, 1996, BIOCHEMISTRY-US, V35, P8299, DOI 10.1021/bi960296e; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; Dierks T, 1996, EMBO J, V15, P6931, DOI 10.1002/j.1460-2075.1996.tb01085.x; DORNER AJ, 1994, BIOLOGICALS, V22, P103, DOI 10.1006/biol.1994.1016; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; Eggleton P, 2000, CLIN EXP IMMUNOL, V120, P384, DOI 10.1046/j.1365-2249.2000.01214.x; Eggleton P, 1997, LUPUS, V6, P564, DOI 10.1177/096120339700600703; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FREDERICKSON CJ, 1987, J HISTOCHEM CYTOCHEM, V35, P579, DOI 10.1177/35.5.2435783; FURUKAWA T, 1993, J PHYSIOL-LONDON, V466, P707; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Guthapfel R, 1996, J BIOL CHEM, V271, P2663, DOI 10.1074/jbc.271.5.2663; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; HOLM IE, 1988, HISTOCHEMISTRY, V89, P289, DOI 10.1007/BF00493154; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; KHANNA NC, 1986, J BIOL CHEM, V261, P8883; KIRCHGESSNER M, 1980, Z TIERPHYSIOL TIERER, V43, P130; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUSTEK T, 1991, ARCH BIOCHEM BIOPHYS, V289, P256, DOI 10.1016/0003-9861(91)90469-Y; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Meldolesi J, 1998, NATURE, V392, P863, DOI 10.1038/31804; Meldolesi J, 1998, J CELL BIOL, V142, P1395, DOI 10.1083/jcb.142.6.1395; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; MILNER RE, 1991, J BIOL CHEM, V266, P7155; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; PICELLO E, 1992, BIOCHEM BIOPH RES CO, V186, P659, DOI 10.1016/0006-291X(92)90797-O; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; Poch E, 1998, AM J PHYSIOL-CELL PH, V275, pC1449, DOI 10.1152/ajpcell.1998.275.6.C1449; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; QUEMENEUR E, 1994, J BIOL CHEM, V269, P5485; REDDY AG, 1989, CYTOBIOS, V60, P21; RINDRESS D, 1993, J BIOL CHEM, V268, P5139; Saito Y, 1999, EMBO J, V18, P6718, DOI 10.1093/emboj/18.23.6718; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; STENDAHL O, 1994, SCIENCE, V265, P1439, DOI 10.1126/science.8073285; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; URADE R, 1993, J BIOL CHEM, V268, P22004; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; VANDELDEN C, 1992, BIOCHEM J, V281, P651, DOI 10.1042/bj2810651; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670; WILLIAMS DB, 1995, BIOCHEM CELL BIOL, V73, P123, DOI 10.1139/o95-015	69	106	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27177	27185						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842171				2022-12-25	WOS:000089144800069
J	Moyer, BD; Duhaime, M; Shaw, C; Denton, J; Reynolds, D; Karlson, KH; Pfeiffer, J; Wang, SS; Mickle, JE; Milewski, M; Cutting, GR; Guggino, WB; Li, M; Stanton, BA				Moyer, BD; Duhaime, M; Shaw, C; Denton, J; Reynolds, D; Karlson, KH; Pfeiffer, J; Wang, SS; Mickle, JE; Milewski, M; Cutting, GR; Guggino, WB; Li, M; Stanton, BA			The PDZ-interacting domain of cystic fibrosis transmembrane conductance regulator is required for functional expression in the apical plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; BETA(2)-ADRENERGIC RECEPTOR; BASOLATERAL MEMBRANE; MOLECULAR-BASIS; GENE-PRODUCT; MDCK CELLS; PROTEIN; LOCALIZATION; CFTR; IDENTIFICATION	Polarization of cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-activated chloride channel to the apical plasma membrane in epithelial cells is critical for vectorial chloride transport. Previously, we reported that the C terminus of CFTR constitutes a PDZ-interacting domain that is required for CFTR polarization to the apical plasma membrane and interaction with the PDZ domain-containing protein EBP50 (NHERF). PDZ interacting domains are typically composed of the C-terminal three to five amino acids, which in CFTR are QDTRL. Our goal was to Identify the key amino acid(s) in the PDZ-interacting domain of CFTR with regard to its apical polarization, interaction with EBP50, and ability to mediate transepithelial chloride secretion. Point substitution of the C-terminal leucine (Leu at position 0) with alanine abrogated apical polarization of CFTR, interaction between CFTR and EBP50, efficient expression of CFTR in the apical membrane, and chloride secretion. Point substitution of the threonine (Thr at position -2) with alanine or valine had no effect on the apical polarization of CFTR, but reduced interaction between CFTR and EBP50, efficient expression of CFTR in the apical membrane as well as chloride secretion. By contrast, individual point substitution of the other C-terminal amino acids (Gln at position -4, Asp at position -3 and Arg at position -1) with alanine had no effect on measured parameters. We conclude that the PDZ-interacting domain, in particular the leucine (position 0) and threonine (position -2) residues, are required for the efficient, polarized expression of CFTR in the apical plasma membrane, interaction of CFTR with EBP50, and for the ability of CFTR to mediate chloride secretion, Mutations that delete the C terminus of CFTR may cause cystic fibrosis because CFTR is not polarized, complexed with EBP50, or efficiently expressed in the apical membrane of epithelial cells.	Dartmouth Med Sch, Dept Physiol, Hanover, NH 03755 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Ctr Med Genet, Johns Hopkins Hosp, CMSC 104, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Dartmouth College; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Stanton, BA (corresponding author), Dartmouth Med Sch, Dept Physiol, Hanover, NH 03755 USA.	bruce.a.stanton@dartmouth.edu	Milewski, Michal/C-7144-2012	Milewski, Michal/0000-0001-7982-2565	NHLBI NIH HHS [HL 47122] Funding Source: Medline; NIDDK NIH HHS [DK 32753, DK 48977] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032753, P50DK048977, R37DK032753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Caplan MJ, 1997, AM J PHYSIOL-RENAL, V272, pF425, DOI 10.1152/ajprenal.1997.272.4.F425; CHENG J, 1999, PEDIATR PULM, V19, P168; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; Ciruela F, 1999, FEBS LETT, V448, P91, DOI 10.1016/S0014-5793(99)00341-5; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Corbeil D, 1999, J CELL SCI, V112, P1023; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; Li DQ, 2000, J BIOL CHEM, V275, P11597, DOI 10.1074/jbc.275.16.11597; Mickle JE, 1998, HUM MOL GENET, V7, P729, DOI 10.1093/hmg/7.4.729; Mickle JE, 1998, CLIN CHEST MED, V19, P443, DOI 10.1016/S0272-5231(05)70092-7; Mohamed A, 1997, BIOCHEM J, V322, P259, DOI 10.1042/bj3220259; MORRIS AP, 1993, AM J PHYSIOL, V265, pC688, DOI 10.1152/ajpcell.1993.265.3.C688; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 1999, AM J PHYSIOL-RENAL, V277, pF271, DOI 10.1152/ajprenal.1999.277.2.F271; Muth TR, 1998, J BIOL CHEM, V273, P25616, DOI 10.1074/jbc.273.40.25616; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Ponce A, 1997, J MEMBRANE BIOL, V159, P149, DOI 10.1007/s002329900278; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; RICH DP, 1993, RECEPTOR CHANNEL, V1, P221; RIORDAN JR, 1989, SCIENCE, V245, P1066; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stanton BA, 1997, WIEN KLIN WOCHENSCHR, V109, P457; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang XB, 1999, CHINESE J ORG CHEM, V19, P249; Weimbs T, 1997, TRENDS CELL BIOL, V7, P393, DOI 10.1016/S0962-8924(97)01130-6; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087; Zhang L, 1998, P NATL ACAD SCI USA, V95, P10158, DOI 10.1073/pnas.95.17.10158	52	149	150	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27069	27074						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10852925				2022-12-25	WOS:000089144800055
J	Yang, Y; Janota, K; Tabei, K; Huang, N; Siegel, MM; Lin, YI; Rasmussen, BA; Shlaes, DM				Yang, Y; Janota, K; Tabei, K; Huang, N; Siegel, MM; Lin, YI; Rasmussen, BA; Shlaes, DM			Mechanism of inhibition of the class A beta-lactamases PC1 and TEM-1 by tazobactam - Observation of reaction products by electrospray ionization mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLAVULANIC ACID; ESCHERICHIA-COLI; SULBACTAM; SEQUENCE	The reactions of class A beta-lactamases PC1 and TEM-1 with tazobactam (TZB), a potent penicillanic sulfone inhibitor for class A beta-lactamases, were studied using electrospray ionization mass spectrometry (ESI/MS). Following inactivation of the beta-lactamases by TZB, new abundant high mass components were observed including three with molecular masses of 52, 70, and 88 Da greater than PC1 and TEM-1, respectively, and a component with a molecular mass of 300 Da greater than PC1. In addition, three TZB reaction products with molecular masses of 248, 264, and 280 Da were observed, High performance liquid chromatography (HPLC)/ESI/MS analysis of the TZB-PC1 adduct digested with Glu-C revealed three new components with masses 52, 70, and 88 Da greater than that of the peptide composed of amino acid residues 58-82 and one new component with a mass 70 Da greater than that of the peptide composed of amino acid residues 125-141, HPLC/ESI/MS/MS analysis of the two digested peptides whose masses increased by 70 Da indicated that Ser-70 and Ser-130 were the most likely TZB-modified amino acid residues. Based on these data, a mechanism for the inactivation of the class A beta-lactamases by TZB is proposed. In this scheme, initial acylation of Ser-70 by TZB and opening of the lactam ring are followed by one of several different events: (1) the rapid decomposition of TZB with loss of the enamine moiety to form the propiolylated enzyme, (2) an intramolecular nucleophilic displacement of the imine or enamine moiety by Ser-130 to form a cross-linked vinyl ether, and (3) hydrolysis of the imine or enamines to form a Ser-70-linked aldehyde.	Wyeth Ayerst Res, Infect Dis Res Div, Pearl River, NY 10965 USA	Pfizer	Yang, Y (corresponding author), Wyeth Ayerst Res, Infect Dis Res Div, 401 N Middletown Rd,Bldg 205,Rm 227, Pearl River, NY 10965 USA.							AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; AMBLER RP, 1975, BIOCHEM J, V151, P197, DOI 10.1042/bj1510197; APLIN RT, 1993, J CHEM SOC CHEM COMM, P121, DOI 10.1039/c39930000121; Bonomo RA, 1997, FEMS MICROBIOL LETT, V148, P59, DOI 10.1016/S0378-1097(97)00013-X; Brown RPA, 1996, BIOCHEMISTRY-US, V35, P12421, DOI 10.1021/bi961044g; BUSH K, 1993, ANTIMICROB AGENTS CH, V37, P851, DOI 10.1128/AAC.37.4.851; CHEN CCH, 1992, J MOL BIOL, V224, P1103, DOI 10.1016/0022-2836(92)90472-V; IMTIAZ U, 1994, BIOCHEMISTRY-US, V33, P5728, DOI 10.1021/bi00185a009; IMTIAZ U, 1993, J AM CHEM SOC, V115, P4435, DOI 10.1021/ja00064a003; KUCK NA, 1989, ANTIMICROB AGENTS CH, V33, P1964, DOI 10.1128/AAC.33.11.1964; McLaughlin J R, 1981, J Biol Chem, V256, P11272; Mirgorodskaya E, 1999, ANAL CHEM, V71, P4431, DOI 10.1021/ac990578v; MURRAY PR, 1994, DIAGN MICR INFEC DIS, V19, P111, DOI 10.1016/0732-8893(94)90121-X; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; PAYNE DJ, 1994, ANTIMICROB AGENTS CH, V38, P767, DOI 10.1128/AAC.38.4.767; Payne DJ, 1997, ANTIMICROB AGENTS CH, V41, P135, DOI 10.1128/AAC.41.1.135; RASMUSSEN BA, 1991, MOL MICROBIOL, V5, P1211, DOI 10.1111/j.1365-2958.1991.tb01895.x; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SAVES I, 1995, BIOCHEMISTRY-US, V34, P11660, DOI 10.1021/bi00037a003; SUTCLIFFE JG, 1978, P NATL ACAD SCI USA, V75, P3731; TABEI K, 1998, P AM SOC MASS SPECTR, P186; YANG Y, 1997, 37 INT C ANT AG CHEM, P82	22	50	53	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26674	26682						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10837472				2022-12-25	WOS:000089144800003
J	Kariya, Y; Kyogashima, M; Suzuki, K; Isomura, T; Sakamoto, T; Horie, K; Ishihara, M; Takano, R; Kamei, K; Hara, S				Kariya, Y; Kyogashima, M; Suzuki, K; Isomura, T; Sakamoto, T; Horie, K; Ishihara, M; Takano, R; Kamei, K; Hara, S			Preparation of completely 6-O-desulfated heparin and its ability to enhance activity of basic fibroblast growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR COMPLEX; BINDING SEQUENCE; CELL-SURFACE; SULFATE PROTEOGLYCANS; BIOLOGICAL-ACTIVITY; LIPOPROTEIN-LIPASE; 6-O-SULFATE GROUPS; ENDOTHELIAL-CELLS; SELF-ASSOCIATION; FGF RECEPTOR	Although regioselective removal of 6-O-sulfate groups of heparin has been undertaken by several researchers, complete 6-O-desulfation with little side reaction has not been attained successfully. In this work, a modified method with a certain silylating reagent, N-methyl-N-(trimethylsilyl)trifluoroacetamide, has been established to produce completely 6-O-desulfated heparin with few other chemical changes. The degrees of 6-O-desulfation were estimated by means of chemical disaccharide analyses and/or C-13 NMR spectra. Although the completely 6-O-desulfated heparin lost about 20% of 2-O-sulfate groups, any other chemical changes and depolymerization were not detected. The completely 6-O-desulfated heparin displayed strong inhibition of COS-1 cell adhesion to basic fibroblast growth factor (bFGF)-coated well in a dose-dependent manner, as was clarified by the competitive cell-adhesion assay. Furthermore, the completely 6-O-desulfated heparin was shown to promote in vitro A31 fibroblast proliferation in a dose-dependent manner in the presence of bFGF. These results suggest that signal transduction through bFGF/bFGF receptor in A31 cells occurs in the absence of 6-O-sulfate groups in heparin. The involvement of 6-O-sulfate group(s) of heparin/heparan sulfate in the promotion of bFGF mitogenic activity was reported by several groups. This discrepancy between our results and those of other groups would be due to the differences in molecular size of heparin/heparan sulfate derivatives and/or cell species used for the assay.	Seikagaku Corp, Tokyo Res Inst, Tokyo 2070021, Japan; Natl Def Med Coll, Inst Res, Div Biomed Engn, Tokorozawa, Saitama 3598513, Japan; Kyoto Inst Technol, Sakyo Ku, Kyoto 6068585, Japan	Seikagaku Corporation; National Defense Medical College - Japan; Kyoto Institute of Technology	Kariya, Y (corresponding author), Seikagaku Corp, Tokyo Res Inst, 3-1253 Tateno, Tokyo 2070021, Japan.	kariya@to.seikagaku.co.jp						AVIEZER D, 1994, J BIOL CHEM, V269, P114; AYOTTE L, 1986, CARBOHYD RES, V145, P267, DOI 10.1016/S0008-6215(00)90434-8; Baumann H, 1998, CARBOHYD RES, V308, P381, DOI 10.1016/S0008-6215(98)00097-4; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; CHENG CF, 1981, J BIOL CHEM, V256, P2893; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; GUO YC, 1988, ANAL BIOCHEM, V168, P54, DOI 10.1016/0003-2697(88)90009-7; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; ISHIHARA M, 1992, ANAL BIOCHEM, V206, P400, DOI 10.1016/0003-2697(92)90385-K; ISHIHARA M, 1992, ANAL BIOCHEM, V202, P310, DOI 10.1016/0003-2697(92)90111-J; Ishihara M, 1997, J BIOCHEM-TOKYO, V121, P345; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P451, DOI 10.1093/glycob/4.4.451; ISHIHARA M, 1995, J BIOCHEM-TOKYO, V118, P1255, DOI 10.1093/oxfordjournals.jbchem.a125015; Ishihara M, 1993, TRENDS GLYCOSCI GLYC, V5, P343, DOI 10.4052/tigg.5.343; Kan M, 1996, J BIOL CHEM, V271, P26143, DOI 10.1074/jbc.271.42.26143; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kariya Y, 1998, J BIOCHEM-TOKYO, V123, P240; KARIYA Y, 1992, COMP BIOCHEM PHYS B, V103, P473, DOI 10.1016/0305-0491(92)90323-J; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; Lam K, 1998, J BIOMOL STRUCT DYN, V15, P1009, DOI 10.1080/07391102.1998.10508997; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MARCUM JA, 1984, BIOCHEMISTRY-US, V23, P1730, DOI 10.1021/bi00303a023; MATSUO M, 1993, CARBOHYD RES, V241, P209, DOI 10.1016/0008-6215(93)80107-P; MCKEEHAN WL, 1994, MOL REPROD DEV, V39, P69, DOI 10.1002/mrd.1080390112; Moy FJ, 1997, BIOCHEMISTRY-US, V36, P4782, DOI 10.1021/bi9625455; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; NAGASAWA K, 1980, METHODS CARBOHYDR CH, V8, P287; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PIANI S, 1993, J CARBOHYD CHEM, V12, P507, DOI 10.1080/07328309308019404; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RICHARD C, 1995, J BIOL CHEM, V270, P24188, DOI 10.1074/jbc.270.41.24188; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUSNATI M, 1994, BIOCHEM BIOPH RES CO, V203, P450, DOI 10.1006/bbrc.1994.2203; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; TAKANO R, 1995, J CARBOHYD CHEM, V14, P885, DOI 10.1080/07328309508005382; TAKANO R, 1998, CARBOHYDR LETT, V3, P71; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Van den Berghe L, 1998, BIOCHEM BIOPH RES CO, V252, P420, DOI 10.1006/bbrc.1998.9668; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P3658, DOI 10.1073/pnas.96.7.3658; Venkataraman G, 1996, P NATL ACAD SCI USA, V93, P845, DOI 10.1073/pnas.93.2.845; Wang HM, 1997, BIOCHEM BIOPH RES CO, V235, P369, DOI 10.1006/bbrc.1997.6789; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	54	58	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25949	25958		10.1074/jbc.M004140200	http://dx.doi.org/10.1074/jbc.M004140200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10837484	hybrid			2022-12-25	WOS:000088999700011
J	Matias, PM; Donner, P; Coelho, R; Thomaz, M; Peixoto, C; Macedo, S; Otto, N; Joschko, S; Scholz, P; Wegg, A; Basler, S; Schafer, M; Egner, U; Carrondo, MA				Matias, PM; Donner, P; Coelho, R; Thomaz, M; Peixoto, C; Macedo, S; Otto, N; Joschko, S; Scholz, P; Wegg, A; Basler, S; Schafer, M; Egner, U; Carrondo, MA			Structural evidence for ligand specificity in the binding domain of the human androgen receptor - Implications for pathogenic gene mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; INSENSITIVITY SYNDROME; CRYSTAL-STRUCTURE; MACROMOLECULAR STRUCTURES; RAR-GAMMA; ACID; REFINEMENT; RECOGNITION; ANTAGONISM; RESISTANCE	The crystal structures of the human androgen receptor (hAR) and human progesterone receptor ligand-binding domains in complex with the same ligand metribolone (R1881) have been determined. Both three-dimensional structures show the typical nuclear receptor fold. The change of two residues in the ligand-binding pocket between the human progesterone receptor and hAR is most likely the source for the specificity of R1881 to the hAR. The structural implications of the 14 known mutations in the ligand-binding pocket of the hAR ligand-binding domains associated with either prostate cancer or the partial or complete androgen receptor insensitivity syndrome were analyzed. The effects of most of these mutants could be explained on the basis of the crystal structure.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780 Oeiras, Portugal; Schering AG, Res Labs, D-13342 Berlin, Germany; Inst Biol Expt & Tecnol, P-2780 Oeiras, Portugal	Universidade Nova de Lisboa; Schering AG	Carrondo, MA (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Apartado 127, P-2780 Oeiras, Portugal.	carrondo@itqb.unl.pt	Matias, Pedro M/B-7180-2008; Peixoto, Cristina/K-8945-2014	Matias, Pedro M/0000-0001-6170-451X; Thomaz, Monica/0000-0002-3133-0278; Peixoto, Cristina/0000-0002-0995-6637; Carrondo, Maria Armenia/0000-0002-1261-1162				Albers N, 1997, J PEDIATR-US, V131, P386, DOI 10.1016/S0022-3476(97)80063-7; ALLEN FH, 1979, ACTA CRYSTALLOGR B, V35, P2331, DOI 10.1107/S0567740879009249; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BELLIS AD, 1992, MOL ENDOCRINOL, V6, P1909; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bevan CL, 1996, HUM MOL GENET, V5, P265, DOI 10.1093/hmg/5.2.265; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Cabral DF, 1998, BRAZ J MED BIOL RES, V31, P775, DOI 10.1590/S0100-879X1998000600008; Gottlieb B, 1998, NUCLEIC ACIDS RES, V26, P234, DOI 10.1093/nar/26.1.234; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; JAKUBICZKA S, 1992, HUM GENET, V90, P311; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Klaholz BP, 1998, NAT STRUCT BIOL, V5, P199, DOI 10.1038/nsb0398-199; Kleywegt G. J., 1995, CCP4 ESF EACBM NEWSL, V31, P45; Komori S, 1998, ARCH GYNECOL OBSTET, V261, P95, DOI 10.1007/s004040050206; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Letz M, 1999, BBA-PROTEIN STRUCT M, V1429, P391, DOI 10.1016/S0167-4838(98)00249-0; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; Lumbroso S, 1996, J CLIN ENDOCR METAB, V81, P1984, DOI 10.1210/jc.81.5.1984; MARCELLI M, 1994, J CLIN INVEST, V94, P1642, DOI 10.1172/JCI117507; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAKAO R, 1992, J CLIN ENDOCR METAB, V74, P1152, DOI 10.1210/jc.74.5.1152; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; PINSKY L, 1992, CLIN INVEST MED, V15, P456; PRECIGOUX G, 1981, ACTA CRYSTALLOGR B, V37, P291, DOI 10.1107/S0567740881002835; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Ribeiro RCJ, 1998, J STEROID BIOCHEM, V65, P133, DOI 10.1016/S0960-0760(98)00029-6; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; ROUSSEL A, 1990, 15 IUCR C BORD FRANC, P66; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; TEUTSCH G, 1994, J STEROID BIOCHEM, V48, P111, DOI 10.1016/0960-0760(94)90257-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tickle IJ, 1998, ACTA CRYSTALLOGR D, V54, P547, DOI 10.1107/S0907444997013875; Uppenberg J, 1998, J BIOL CHEM, V273, P31108, DOI 10.1074/jbc.273.47.31108; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Yong EL, 1998, MOL CELL ENDOCRINOL, V137, P41, DOI 10.1016/S0303-7207(97)00229-3; [No title captured]	54	477	526	1	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26164	26171		10.1074/jbc.M004571200	http://dx.doi.org/10.1074/jbc.M004571200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10840043	hybrid			2022-12-25	WOS:000088999700040
J	Mizobata, T; Kawagoe, M; Hongo, K; Nagai, J; Kawata, Y				Mizobata, T; Kawagoe, M; Hongo, K; Nagai, J; Kawata, Y			Refolding of target proteins from a "rigid" mutant chaperonin demonstrates a minimal mechanism of chaperonin binding and release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DODECAMERIC GLUTAMINE-SYNTHETASE; INDUCED CONFORMATIONAL-CHANGES; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS; FOLDING REACTION; ATPASE CYCLE; GROEL; POLYPEPTIDE; INTERMEDIATE	One of the most interesting facets of GroEL-facilitated protein folding lies in the fact that the requirement for a successful folding reaction of a given protein target depends upon the refolding conditions used. In this report, we utilize a mutant of GroEL (GroEL T89W) whose domain movements have been drastically restricted, producing a chaperonin that is incapable of utilizing the conventional cyclic mechanism of chaperonin action. This mutant was, however, still capable of improving the refolding yield of lactate dehydrogenase in the absence of both GroES and ATP hydrolysis. A very rapid interconversion of conformations was detected in the mutant immediately after ATP binding, and this interconversion was inferred to form part of the target release mechanism in this mutant. The possibility exists that some target proteins, although dependent on GroEL for improved refolding yields, are capable of refolding successfully by utilizing only portions of the entire mechanism provided by the chaperonins.	Tottori Univ, Fac Engn, Dept Biotechnol, Tottori 6800945, Japan	Tottori University	Kawata, Y (corresponding author), Tottori Univ, Fac Engn, Dept Biotechnol, Tottori 6800945, Japan.		Mizobata, Tomohiro/V-6672-2019; Kawata, Yasushi/ABA-9608-2021	Mizobata, Tomohiro/0000-0002-7808-2099; Kawata, Yasushi/0000-0002-2744-1506				BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BETCHERLANGE SL, 1978, J BIOL CHEM, V253, P3757; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; Cliff MJ, 1999, J MOL BIOL, V293, P667, DOI 10.1006/jmbi.1999.3138; Coyle JE, 1999, NAT STRUCT BIOL, V6, P683; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Fenton WA, 1997, PROTEIN SCI, V6, P743; FISHER MT, 1994, J BIOL CHEM, V269, P13629; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; Kad NM, 1998, J MOL BIOL, V278, P267, DOI 10.1006/jmbi.1998.1704; Katsumata K, 1996, J MOL BIOL, V258, P827, DOI 10.1006/jmbi.1996.0290; KAWATA Y, 1994, FEBS LETT, V345, P229, DOI 10.1016/0014-5793(94)00456-0; Kawata Y, 1999, BIOCHEMISTRY-US, V38, P15731, DOI 10.1021/bi9909750; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUBO T, 1993, J BIOL CHEM, V268, P19346; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MIZOBATA T, 1994, BBA-PROTEIN STRUCT M, V1209, P83, DOI 10.1016/0167-4838(94)90140-6; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; Rye HS, 1999, CELL, V97, P325, DOI 10.1016/S0092-8674(00)80742-4; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; Walter S, 1996, P NATL ACAD SCI USA, V93, P9425, DOI 10.1073/pnas.93.18.9425; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Yifrach O, 1998, BIOCHEMISTRY-US, V37, P7083, DOI 10.1021/bi980370o; Zahn R, 1996, SCIENCE, V271, P642, DOI 10.1126/science.271.5249.642	40	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25600	25607		10.1074/jbc.M000795200	http://dx.doi.org/10.1074/jbc.M000795200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837467	hybrid			2022-12-25	WOS:000088849400074
J	O'Hare, MJ; Hou, ST; Morris, EJ; Cregan, SP; Xu, Q; Slack, RS; Park, DS				O'Hare, MJ; Hou, ST; Morris, EJ; Cregan, SP; Xu, Q; Slack, RS; Park, DS			Induction and modulation of cerebellar granule neuron death by E2F-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; TRANSCRIPTION-INDEPENDENT MECHANISMS; ALZHEIMERS-DISEASE BRAIN; S-PHASE ENTRY; CELL-CYCLE; CEREBRAL-ISCHEMIA; PC12 CELLS; RETINOBLASTOMA PROTEIN; INDUCED APOPTOSIS; DNA-SYNTHESIS	Growing evidence suggests that certain cell cycle regulators also mediate neuronal death. Of relevance, cyclin D1-associated kinase activity is increased and the retinoblastoma protein (Rb), a substrate of the cyclin D1-Cdk4/6 complex, is phosphorylated during K+ deprivation-evoked death of cerebellar granule neurons (CGNs), Cyclin-dependent kinase (CDK) inhibitors block this death, suggesting a requirement for the cyclin D1/Cdk4/6-Rb pathway. However, the downstream target(s) of this pathway are not well defined. The transcription factor E2F-1 is regulated by Rb and is reported to evoke death in proliferating cells when overexpressed. Accordingly, we examined whether E2F-1 was sufficient to evoke death of CGNs and whether it was required for death evoked by low K+. We show that adenovirus-mediated expression of E2F-1 in CGNs results in apoptotic death, which is independent of p53, dependent upon Bax, and associated with caspase 3-like activity. In addition, we demonstrate that levels of E2F-1 mRNA and protein increase during K+ deprivation-evoked death. The increase in E2F-1 protein is blocked by the CDK inhibitor flavopiridol, Finally, E2F-1-deficient neurons are modestly resistant to death induced by low K+. These results indicate that E2F-1 expression is sufficient to promote neuronal apoptosis and that endogenous E2F-1 modulates the death of CGNs evoked by low K+.	Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; Massachusetts Gen Hosp, Ctr Canc, Oncol Mol Lab, Charlestown, MA 02129 USA	University of Ottawa; National Research Council Canada; Harvard University; Massachusetts General Hospital	Park, DS (corresponding author), Univ Ottawa, Neurosci Res Inst, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.		Hou, Sheng Tao/AAM-7756-2020; Hou, Sheng Tao/O-3202-2018; Cregan, Sean/M-3205-2013	Park, David/0000-0002-4490-3784; Slack, Ruth/0000-0002-1552-2835; Hou, Sheng Tao/0000-0001-9736-342X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Busser J, 1998, J NEUROSCI, V18, P2801; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Cregan SP, 1999, J NEUROSCI, V19, P7860; Deckwerth TL, 1998, EXP NEUROL, V152, P150, DOI 10.1006/exnr.1998.6846; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; GALLO V, 1987, J NEUROSCI, V7, P2203; GAO CY, 1995, EXP CELL RES, V219, P612, DOI 10.1006/excr.1995.1271; Gill JS, 1998, J CLIN INVEST, V101, P2842, DOI 10.1172/JCI1130; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Giovanni A, 1999, J BIOL CHEM, V274, P19011, DOI 10.1074/jbc.274.27.19011; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hou ST, 1997, BIOCHEM CELL BIOL, V75, P383, DOI 10.1139/bcb-75-4-383; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Lavia P, 1999, BIOESSAYS, V21, P221; Li Y, 1997, J CEREBR BLOOD F MET, V17, P846, DOI 10.1097/00004647-199708000-00003; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MacManus JP, 1999, NEUROREPORT, V10, P2711, DOI 10.1097/00001756-199909090-00004; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; Marks N, 1998, J NEUROSCI RES, V52, P334, DOI 10.1002/(SICI)1097-4547(19980501)52:3<334::AID-JNR9>3.0.CO;2-E; McGinnis KM, 1999, J NEUROCHEM, V72, P1899, DOI 10.1046/j.1471-4159.1999.0721899.x; McShea A, 1997, AM J PATHOL, V150, P1933; MELLO D, 1993, P NATL ACAD SCI USA, V90, P10989; Miller TM, 1997, J BIOL CHEM, V272, P9847; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Namura S, 1998, J NEUROSCI, V18, P3659; NEVINS JR, 1992, SCIENCE, V258, P424; NITATORI T, 1995, J NEUROSCI, V15, P1001; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Schulz JB, 1996, J NEUROSCI, V16, P4696; Slack RS, 1996, DEV GENET, V18, P81, DOI 10.1002/(SICI)1520-6408(1996)18:1<81::AID-DVG9>3.0.CO;2-Y; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; Stefanis L, 1999, J NEUROSCI, V19, P6235; Timsit S, 1999, EUR J NEUROSCI, V11, P263, DOI 10.1046/j.1460-9568.1999.00434.x; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Vincent I, 1997, J NEUROSCI, V17, P3588; Watson A, 1998, J NEUROSCI, V18, P751; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu CL, 1996, MOL CELL BIOL, V16, P3698; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; YAN GZ, 1995, J NEUROSCI, V15, P6200	64	131	134	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25358	25364		10.1074/jbc.M001725200	http://dx.doi.org/10.1074/jbc.M001725200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10851232	hybrid			2022-12-25	WOS:000088849400043
J	Stockando, JD; Bao, HF; Schenck, J; Malik, B; Middleton, P; Schlanger, LE; Eaton, DC				Stockando, JD; Bao, HF; Schenck, J; Malik, B; Middleton, P; Schlanger, LE; Eaton, DC			Differential effects of protein kinase C on the levels of epithelial Na+ channel subunit proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL; ALPHA-SUBUNIT; ALDOSTERONE; CELLS; TRANSPORT	Regulation of epithelial Na+ channel (ENaC) subunit levels by protein kinase C (PKC) was investigated in A6 cells. PKC activation altered ENaC subunit levels, differentially decreasing the levels of both beta and gamma, but not alpha ENaC. Temporal regulation of beta and gamma ENaC by PKC differed; gamma ENaC decreased with a time constant of 3.7 +/- 1.0 h, whereas beta ENaC decreased in 13.9 +/- 3.0 h. Activation of PRC also resulted in a decrease in trans-epithelial Na+ reabsorption for up to 48 h. PIMA activation of PRC resulted in negative feedback inhibition of PKC protein levels beginning within 4 h, Both beta and gamma ENaC levels, as well as transport tended toward pretreatment values after 48 h of PMA treatment. PKC inhibitors attenuated the effects of PMA on ENaC subunit levels and Na+ transport. These results directly show for the first time that PRC differentially regulates ENaC subunit levels by decreasing the levels of beta and gamma but not alpha ENaC protein. These results imply a PKC-dependent, long term decrease in Na+ reabsorption.	Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA; Emory Univ, Dept Physiol, Ctr Cell & Mol Signaling, Atlanta, GA 30322 USA	University of Texas System; University of Texas Health San Antonio; Emory University	Stockando, JD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Physiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.			Stockand, James/0000-0002-3817-4319; Eaton, Douglas/0000-0002-2686-6692	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009729, R37DK037963, R01DK037963] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09729, DK37963] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Awayda MS, 1996, J GEN PHYSIOL, V108, P49, DOI 10.1085/jgp.108.1.49; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; DUCHATELLE P, 1992, MOL CELL BIOCHEM, V114, P27; EATON DC, 1995, KIDNEY INT, V48, P941, DOI 10.1038/ki.1995.375; Els WJ, 1998, AM J PHYSIOL-CELL PH, V275, pC120; Frindt G, 1996, AM J PHYSIOL-RENAL, V270, pF371, DOI 10.1152/ajprenal.1996.270.2.F371; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; LING BN, 1990, MOL CELL BIOCHEM, V99, P141, DOI 10.1007/BF00230344; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; May A, 1997, J AM SOC NEPHROL, V8, P1813; MIDDLETON P, 2000, IN PRESS AM J PHYSL; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; Rokaw MD, 1996, J BIOL CHEM, V271, P32468, DOI 10.1074/jbc.271.50.32468; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Stockand JD, 1999, J BIOL CHEM, V274, P35449, DOI 10.1074/jbc.274.50.35449; Verrey F, 1998, EXP NEPHROL, V6, P294; VERREY F, 1995, J MEMBRANE BIOL, V144, P93; Verrey F, 1999, AM J PHYSIOL-RENAL, V277, pF319, DOI 10.1152/ajprenal.1999.277.3.F319; Zentner MD, 1998, J BIOL CHEM, V273, P30770, DOI 10.1074/jbc.273.46.30770	22	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25760	25765		10.1074/jbc.M003615200	http://dx.doi.org/10.1074/jbc.M003615200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829029	hybrid			2022-12-25	WOS:000088849400092
J	Dapic, V; Oliver, D				Dapic, V; Oliver, D			Distinct membrane binding properties of N- and C-terminal domains of Escherichia coli SecA ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TRANSLOCATION ATPASE; PREPROTEIN TRANSLOCASE; PLASMA-MEMBRANE; INNER MEMBRANE; IN-VIVO; ACIDIC PHOSPHOLIPIDS; PRECURSOR PROTEINS; SECRETORY PROTEIN; CATALYTIC CYCLE; REGION	SecA is a motor protein that drives protein translocation at the Escherichia coli translocon. SecA membrane binding has been shown to occur with high affinity at SecYE and low affinity at anionic phospholipids. To dissect SecA-membrane interaction with reference to SecA structure, the membrane binding properties of N- and C-terminal SecA domains, denoted SecA-N664 and SecA-619C, respectively, were characterized. Remarkably, only SecA-N664 bound to the membrane with high affinity, whereas SecA-619C bound with low affinity in a nonsaturable manner through partitioning with phospholipids. Moreover, SecA-N664 and SecA-619C associated with each other to reconstitute wild type binding affinity. Corroborative results were also obtained from membrane binding competition and subcellular fractionation studies along with binding studies to membranes prepared from strains overproducing SecYE protein. Together, these findings indicate that the specific interaction of SecA with SecYE occurs through its N-terminal domain and that the C-terminal domain, although important in SecA membrane cycling at a later stage of translocation, appears to initially assist SecA membrane binding by interaction with phospholipids. These results provide the first evidence for distinct membrane binding characteristics of the two SecA primary domains and their importance for optimal binding activity, and they are significant for understanding SecA dynamics at the translocon.	Wesleyan Univ, Dept Mol Biol & Biochem, Middletown, CT 06459 USA	Wesleyan University	Oliver, D (corresponding author), Wesleyan Univ, Dept Mol Biol & Biochem, Middletown, CT 06459 USA.	doliver@wesleyan.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042033] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42033] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Behrmann M, 1998, J BIOL CHEM, V273, P13898, DOI 10.1074/jbc.273.22.13898; BREUKINK E, 1995, J BIOL CHEM, V270, P7902, DOI 10.1074/jbc.270.14.7902; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; Cabelli RJ, 1991, THESIS STATE U NEW Y; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Chen XC, 1996, J BIOL CHEM, V271, P29698, DOI 10.1074/jbc.271.47.29698; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHUN SY, 1994, J BACTERIOL, V176, P4197, DOI 10.1128/jb.176.14.4197-4203.1994; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; Danese PN, 1998, ANNU REV GENET, V32, P59, DOI 10.1146/annurev.genet.32.1.59; DOUVILLE K, 1995, J BIOL CHEM, V270, P20106, DOI 10.1074/jbc.270.34.20106; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Duong F, 1999, EMBO J, V18, P3263, DOI 10.1093/emboj/18.12.3263; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1998, J BIOL CHEM, V273, P21675, DOI 10.1074/jbc.273.34.21675; Eichler J, 1997, EMBO J, V16, P2188, DOI 10.1093/emboj/16.9.2188; Fekkes P, 1997, EMBO J, V16, P6105, DOI 10.1093/emboj/16.20.6105; Harris CR, 1999, J BACTERIOL, V181, P3438, DOI 10.1128/JB.181.11.3438-3444.1999; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; Hirano M, 1996, BIOCHEM BIOPH RES CO, V229, P90, DOI 10.1006/bbrc.1996.1762; ITO K, 1992, MOL MICROBIOL, V6, P2423; Karamanou S, 1999, MOL MICROBIOL, V34, P1133, DOI 10.1046/j.1365-2958.1999.01686.x; KIM YJ, 1994, CELL, V78, P845; KIMURA E, 1991, J BIOL CHEM, V266, P6600; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; KUSTERS R, 1992, FEBS LETT, V308, P97, DOI 10.1016/0014-5793(92)81060-Y; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Manting EH, 1999, J BIOL CHEM, V274, P23868, DOI 10.1074/jbc.274.34.23868; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; Matsumoto G, 1998, P NATL ACAD SCI USA, V95, P13567, DOI 10.1073/pnas.95.23.13567; MATSUYAMA S, 1990, J BIOL CHEM, V265, P8760; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; Miller J. H., 1972, EXPT MOL GENETICS, P431; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Mori H, 1998, J BIOCHEM, V124, P122, DOI 10.1093/oxfordjournals.jbchem.a022070; Nishiyama K, 1999, EMBO J, V18, P1049, DOI 10.1093/emboj/18.4.1049; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; Pohlschroder M, 1996, J BIOL CHEM, V271, P19908, DOI 10.1074/jbc.271.33.19908; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; Price A, 1996, J BIOL CHEM, V271, P31580, DOI 10.1074/jbc.271.49.31580; Rajapandi T, 1996, MOL MICROBIOL, V20, P43, DOI 10.1111/j.1365-2958.1996.tb02487.x; RAJAPANDI T, 1991, J BACTERIOL, V173, P7092, DOI 10.1128/jb.173.22.7092-7097.1991; Ramamurthy V, 1998, J BACTERIOL, V180, P6419; Ramamurthy V, 1997, J BIOL CHEM, V272, P23239, DOI 10.1074/jbc.272.37.23239; RHOADS DB, 1984, J BACTERIOL, V159, P63, DOI 10.1128/JB.159.1.63-70.1984; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Scotti PA, 1999, J BIOL CHEM, V274, P29883, DOI 10.1074/jbc.274.42.29883; Snyders S, 1997, J BIOL CHEM, V272, P11302; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; van Voorst F, 1998, BIOCHEMISTRY-US, V37, P12261, DOI 10.1021/bi9809021; vanderDoes C, 1996, MOL MICROBIOL, V22, P619, DOI 10.1046/j.1365-2958.1996.d01-1712.x; WINZOR DJ, 1995, QUANTITATIVE CHARACT	62	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					25000	25007		10.1074/jbc.M001100200	http://dx.doi.org/10.1074/jbc.M001100200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10835419	hybrid			2022-12-25	WOS:000088683300102
J	Stasiolek, M; Gavrilyuk, V; Sharp, A; Horvath, P; Selmaj, K; Feinstein, DL				Stasiolek, M; Gavrilyuk, V; Sharp, A; Horvath, P; Selmaj, K; Feinstein, DL			Inhibitory and stimulatory effects of lactacystin on expression of nitric oxide synthase type 2 in brain glial cells - The role of I kappa B-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK RESPONSE; UBIQUITIN-PROTEASOME PATHWAY; INTERFERON-GAMMA; NUCLEAR TRANSLOCATION; REACTIVE ASTROCYTES; MULTIPLE-SCLEROSIS; GENE-TRANSCRIPTION; INDUCIBLE FORM; ACTIVATION; INDUCTION	Expression of inflammatory nitric oxide synthase (NOS2) is mediated by transcription factor NF kappa B. By using the specific proteasome inhibitor lactacystin to examine I kappa B degradation, we observed a paradoxical increase in lipopolysaccharide- and cytokine-dependent NOS2 expression at low concentrations or when lactacystin was added subsequent to cytokines. Lactacystin reduced the initial accumulation of NOS2 mRNA but reduced its subsequent decrease. Lactacystin increased NOS2 promoter activation after 24 h, but not after 4 h, and similarly prevented initial NF kappa B activation and at later times caused NF kappa B reactivation. Lactacystin reduced initial degradation of I kappa B-alpha and I kappa B-beta, however, at later times selectively increased I kappa B-beta, which was predominantly non-phosphorylated. Expression of full-length rat I kappa B-beta, but not a carboxyl-terminal truncated form, inhibited NOS2 induction and potentiation by lactacystin, Lactacystin increased I kappa B-beta expression in the absence of NOS2 inducers, as well as expression of heat shock protein 70, and the heat shock response due to hyperthermia increased I kappa B-beta expression. These results suggest that I kappa B-beta contributes to persistent NF kappa B activation and NOS2 expression in glial cells, that I kappa B-beta is a stress protein inducible by hyperthermia or proteasome inhibitors, and that delayed addition of proteasome inhibitors can have stimulatory rather than inhibitory actions.	Univ Illinois, Dept Anesthesiol, Chicago, IL 60607 USA; Med Univ Lodz, Dept Neurol, PL-90153 Lodz, Poland	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Medical University Lodz	Feinstein, DL (corresponding author), Univ Illinois, Dept Anesthesiol, 900 S Ashland Ave,MC513, Chicago, IL 60607 USA.	dlfeins@uic.edu	feinstein, doug/M-9414-2019; Stasiołek, Mariusz/M-3732-2014; Stasiolek, Mariusz Pawel/S-9546-2016	Stasiolek, Mariusz Pawel/0000-0002-2582-1708; Selmaj, Krzysztof/0000-0003-1213-7218				Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Attar RM, 1998, MOL CELL BIOL, V18, P477, DOI 10.1128/MCB.18.1.477; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; Bush KT, 1997, J BIOL CHEM, V272, P9086; Chao CC, 1997, NEUROREPORT, V8, P3163, DOI 10.1097/00001756-199709290-00031; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; CROSS AH, 1994, J CLIN INVEST, V93, P2684, DOI 10.1172/JCI117282; DeGroot CJA, 1997, J NEUROPATH EXP NEUR, V56, P10, DOI 10.1097/00005072-199701000-00002; DeLuca C, 1999, J BIOL CHEM, V274, P13010, DOI 10.1074/jbc.274.19.13010; DeMeester SL, 1997, ARCH SURG-CHICAGO, V132, P1283; deVera ME, 1996, SURGERY, V120, P144, DOI 10.1016/S0039-6060(96)80281-9; ENDOH M, 1994, BRAIN RES, V651, P92, DOI 10.1016/0006-8993(94)90683-1; Feinstein DL, 1998, J NEUROCHEM, V70, P1484; Feinstein DL, 1997, NITRIC OXIDE-BIOL CH, V1, P167, DOI 10.1006/niox.1997.0117; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Fiebich BL, 1999, NEUROPHARMACOLOGY, V38, P1325, DOI 10.1016/S0028-3908(99)00055-6; FUJISAWA H, 1995, J NEUROCHEM, V64, P85; GALEA E, 1994, J NEUROSCI RES, V37, P406, DOI 10.1002/jnr.490370313; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Hao W, 1999, AUTOIMMUNITY, V29, P93, DOI 10.3109/08916939908995378; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HEWETT SJ, 1993, NEUROSCI LETT, V164, P229, DOI 10.1016/0304-3940(93)90898-U; Hori K, 1999, BLOOD, V93, P1843, DOI 10.1182/blood.V93.6.1843.406k40_1843_1850; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; Ju WK, 1998, J NEUROVIROL, V4, P445; Kemler I, 1999, GLIA, V26, P212, DOI 10.1002/(SICI)1098-1136(199905)26:3<212::AID-GLIA3>3.0.CO;2-F; Kim D, 1999, BIOCHEM BIOPH RES CO, V254, P264, DOI 10.1006/bbrc.1998.9840; Kloetzel PM, 1998, GENE THER, V5, P1297, DOI 10.1038/sj.gt.3300724; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R; Licinio J, 1999, MOL MED TODAY, V5, P225, DOI 10.1016/S1357-4310(99)01453-7; Lin KI, 1998, CELL DEATH DIFFER, V5, P577, DOI 10.1038/sj.cdd.4400384; Mathew A, 1998, MOL CELL BIOL, V18, P5091, DOI 10.1128/MCB.18.9.5091; Mellgren RL, 1997, J BIOL CHEM, V272, P29899, DOI 10.1074/jbc.272.47.29899; Meng XZ, 1996, AM J PHYSIOL-CELL PH, V271, pC1316, DOI 10.1152/ajpcell.1996.271.4.C1316; Murphy WJ, 1996, J ENDOTOXIN RES, V3, P381, DOI 10.1177/096805199600300502; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Rossi A, 1998, J BIOL CHEM, V273, P16446, DOI 10.1074/jbc.273.26.16446; Scarim AL, 1998, ENDOCRINOLOGY, V139, P5050, DOI 10.1210/en.139.12.5050; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; SIMMONS ML, 1993, EUR J NEUROSCI, V5, P825, DOI 10.1111/j.1460-9568.1993.tb00934.x; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; Suyang H, 1996, MOL CELL BIOL, V16, P5444; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Velasco M, 1997, J BIOL CHEM, V272, P23025, DOI 10.1074/jbc.272.37.23025; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wallace MN, 1997, EXP NEUROL, V144, P266, DOI 10.1006/exnr.1996.6373; WALLACE MN, 1994, NEUROSCIENCE, V59, P905, DOI 10.1016/0306-4522(94)90294-1; Wong HR, 1997, BIOCHEM BIOPH RES CO, V231, P257, DOI 10.1006/bbrc.1997.6076; Wong HR, 1999, CELL STRESS CHAPERON, V4, P1; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Zhang HF, 1998, BIOCHEM PHARMACOL, V55, P1873, DOI 10.1016/S0006-2952(98)00078-1; Zhou MY, 1996, J BIOL CHEM, V271, P24769, DOI 10.1074/jbc.271.40.24769	64	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24847	24856		10.1074/jbc.M910284199	http://dx.doi.org/10.1074/jbc.M910284199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827092	hybrid			2022-12-25	WOS:000088683300082
J	Yoshida, K; Yamashita, Y; Miyazato, A; Ohya, K; Kitanaka, A; Ikeda, U; Shimada, K; Yamanaka, T; Ozawa, K; Mano, H				Yoshida, K; Yamashita, Y; Miyazato, A; Ohya, K; Kitanaka, A; Ikeda, U; Shimada, K; Yamanaka, T; Ozawa, K; Mano, H			Mediation by the protein-tyrosine kinase Tec of signaling between the B cell antigen receptor and Dok-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; GAP-ASSOCIATED PROTEIN; HEMATOPOIETIC-CELLS; BINDING-PROTEINS; MOLECULAR-CLONING; DOCKING PROTEIN; PH DOMAIN; GENE; ACTIVATION; EXPRESSION	A variety of growth factor receptors induce the tyrosine phosphorylation of a nonreceptor protein-tyrosine kinase Tec as well as that of a Tee-binding protein of 62 kDa. Given the similarity in properties between this 62-kDa protein and p62(DOk-1), th, possibility that these two proteins are identical was investigated. Overexpression of a constitutively active form of Tec in a pro-B cell Line induced the hyperphosphorylation of endogenous Dok-1. Tec also associated with Dok-1 in a phosphorylation-dependent manner in 293 cells. Tec mediated marked phosphorylation of Dok-1 both in vivo and in vitro, and this effect required both the Tec homology and Src homology 2 domains of Tec in addition to its kinase activity. Expression of Dok-1 in 293 cells induced inhibition of Res activity, suggesting that Dok-1 is a negative regulator of Ras. In the immature B cell line Ramos, cross linking of the B cell antigen receptor (BCR) resulted in tyrosine phosphorylation of Dok-1, and this effect was markedly inhibited by expression of dominant negative mutants of Tee. Furthermore, overexpression of Dok-1 inhibited activation of the c-fos promoter induced by stimulation of the BCR. These results suggest that Tec is an important mediator of signaling from the BCR to Dok-1.	Jichi Med Sch, Div Functional Genom, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Hematol, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Cardiol, Minami Kawachi, Tochigi 3290498, Japan; Omiya Med Ctr, Omiya, Saitama 3308503, Japan; Kagawa Med Univ, Dept Internal Med 1, Kagawa 7610793, Japan	Jichi Medical University; Jichi Medical University; Jichi Medical University; Jichi Medical University; Kagawa University	Mano, H (corresponding author), Jichi Med Sch, Div Functional Genom, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.							Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; Baba Y, 1999, BLOOD, V93, P2003, DOI 10.1182/blood.V93.6.2003.406k13_2003_2012; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; HAIRE RN, 1995, MAMM GENOME, V6, P476, DOI 10.1007/BF00360659; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; HU Q, 1995, J BIOL CHEM, V270, P1928, DOI 10.1074/jbc.270.4.1928; Ito K, 1997, BLOOD, V90, P3884, DOI 10.1182/blood.V90.10.3884; IZUMI M, 1991, EXP CELL RES, V197, P229, DOI 10.1016/0014-4827(91)90427-V; Kitanaka A, 1998, BLOOD, V91, P940, DOI 10.1182/blood.V91.3.940.940_940_948; MANO H, 1990, ONCOGENE, V5, P1781; Mano H, 1998, GENES CELLS, V3, P431, DOI 10.1046/j.1365-2443.1998.00201.x; MANO H, 1995, BLOOD, V85, P343; Mano H, 1999, INT J HEMATOL, V69, P6; MANO H, 1993, ONCOGENE, V8, P417; Mano H, 1996, FASEB J, V10, P637, DOI 10.1096/fasebj.10.5.8621063; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Miyazato A, 1996, CELL GROWTH DIFFER, V7, P1135; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Ohya K, 1999, P NATL ACAD SCI USA, V96, P11976, DOI 10.1073/pnas.96.21.11976; Paez-Espinosa V, 1998, ENDOCRINE, V8, P193, DOI 10.1385/ENDO:8:2:193; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SANCHEZMARGALET V, 1995, ENDOCRINOLOGY, V136, P316, DOI 10.1210/en.136.1.316; Shirai T, 1998, BBA-MOL CELL RES, V1402, P292, DOI 10.1016/S0167-4889(98)00014-7; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; Takata M, 1996, J EXP MED, V184, P31, DOI 10.1084/jem.184.1.31; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yamashita Y, 1998, BLOOD, V91, P1496, DOI 10.1182/blood.V91.5.1496.1496_1496_1507; Yang WC, 1999, J BIOL CHEM, V274, P607, DOI 10.1074/jbc.274.2.607; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604	45	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24945	24952		10.1074/jbc.M909012199	http://dx.doi.org/10.1074/jbc.M909012199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10823839	hybrid			2022-12-25	WOS:000088683300095
J	Zhang, R; Tan, ZJ; Liang, P				Zhang, R; Tan, ZJ; Liang, P			Identification of a novel ligand-receptor pair constitutively activated by ras oncogenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-ASSOCIATED GENE; HUMAN-MELANOMA DIFFERENTIATION; EPIDERMAL GROWTH-FACTOR; EPSTEIN-BARR-VIRUS; MESSENGER-RNA; EXPRESSION CLONING; CELL-GROWTH; 3T3 CELLS; DISPLAY; TRANSFORMATION	The Ras signaling pathway is thought to control the expression of a subset of yet to be defined genes that are crucial for cell growth and differentiation. Here we have identified by differential display a novel oncogenic Ras target, mob-5, encoding a 23-kDa cytokine-like secreted protein. Mob-5 expression could be induced by oncogenic Ha-ras and Ki-ras, but not by normal ras activation. Inhibitors of both Ha-Ras and mitogen-activated protein kinase kinase completely abolished the mob-5 expression in ras transformed cells, with concomitant loss of the transformation phenotype. Using an alkaline phosphatase-tagged Mob-5 as ligand, a putative Mob-5 receptor was identified on the cell surface of oncogenic ras transformed cells. Thus, the Mob-5/Mob-5 receptor may represent a novel putative autocrine loop coordinately activated by ras oncogenes.	Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA	Vanderbilt University	Liang, P (corresponding author), Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Dept Cell Biol, 649 MRB II, Nashville, TN 37232 USA.				NCI NIH HHS [CA76960, CA74067] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074067, R01CA076960] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; COHEN RL, 1989, J BIOL CHEM, V264, P8375; CRAIG AM, 1988, BIOCHEM BIOPH RES CO, V157, P166, DOI 10.1016/S0006-291X(88)80028-7; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; DURKIN JP, 1986, MOL CELL BIOL, V6, P1386, DOI 10.1128/MCB.6.5.1386; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; GODWIN AK, 1990, ONCOGENE, V5, P1231; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Jo H, 1998, METHODS, V16, P365, DOI 10.1006/meth.1998.0691; KIARIS H, 1995, INT J ONCOL, V7, P413; KO TC, 1995, ONCOGENE, V10, P177; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; Liang P, 1998, METHODS, V16, P361, DOI 10.1006/meth.1998.0690; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, METHOD ENZYMOL, V254, P304; LIANG P, 1994, P NATL ACAD SCI USA, V91, P12515, DOI 10.1073/pnas.91.26.12515; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; LIU Y, 1994, J IMMUNOL, V152, P1821; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MIYAZAKI I, 1993, J EXP MED, V178, P439, DOI 10.1084/jem.178.2.439; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Sheng HM, 1998, J BIOL CHEM, V273, P22120, DOI 10.1074/jbc.273.34.22120; Soo C, 1999, J CELL BIOCHEM, V74, P1; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Zhang R, 1997, ONCOGENE, V14, P1607, DOI 10.1038/sj.onc.1200957; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131	37	53	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24436	24443		10.1074/jbc.M001958200	http://dx.doi.org/10.1074/jbc.M001958200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10825166	hybrid			2022-12-25	WOS:000088683300027
J	Nishio, K; Nakai, M				Nishio, K; Nakai, M			Transfer of iron-sulfur cluster from NifU to apoferredoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-CLUSTER; AZOTOBACTER-VINELANDII; ESCHERICHIA-COLI; PROTEINS; IDENTIFICATION; MITOCHONDRIA; METABOLISM; BIOGENESIS; NFS1P	Iron-sulfur proteins are present in a wide variety of organisms and are known to play important physiological roles, not only in electron transfer and metabolic reactions, but also in transcriptional regulation. However, little is known about how iron-sulfur clusters themselves are synthesized and assembled within polypeptides. Here we show that a [2Fe-2S] cluster-containing NifU of cyanobacterium Synechocystis PCC6803, SyNifU, possesses the ability to deliver its [2Fe-2S] cluster to an apoferredoxin without the aid of other proteinaceous or nonproteinaceous factor(s), Upon delivery the reconstituted holoferredoxin regained electron transfer ability. The [2Fe-2S] cluster contained within SyNifU was labile upon exposure to the iron-chelating reagent EDTA, suggesting that the iron-sulfur cluster is abnormally exposed to solvent. We propose that NifU serves as a scaffold for iron-sulfur cluster assembly and functions as a mediator for iron-sulfur cluster delivery.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Osaka University	Nakai, M (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	nakai@protein.osaka-u.ac.jp						Agar JN, 2000, J BIOL INORG CHEM, V5, P167, DOI 10.1007/s007750050361; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; Craig EA, 1999, BIOL CHEM, V380, P1167, DOI 10.1515/BC.1999.148; FU WG, 1994, BIOCHEMISTRY-US, V33, P13455, DOI 10.1021/bi00249a034; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Johnson MK, 1998, CURR OPIN CHEM BIOL, V2, P173, DOI 10.1016/S1367-5931(98)80058-6; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; KUO CF, 1988, ANAL BIOCHEM, V170, P183, DOI 10.1016/0003-2697(88)90106-6; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; Nakai Y, 1998, FEBS LETT, V433, P143, DOI 10.1016/S0014-5793(98)00897-7; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; Nakamura Y, 1998, NUCLEIC ACIDS RES, V26, P63, DOI 10.1093/nar/26.1.63; Nishio K, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P3155; OUZOUNIS C, 1994, TRENDS BIOCHEM SCI, V19, P199, DOI 10.1016/0968-0004(94)90021-3; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264	25	102	104	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22615	22618		10.1074/jbc.C000279200	http://dx.doi.org/10.1074/jbc.C000279200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10837463	hybrid			2022-12-25	WOS:000088419400003
J	Okada, Y; Sawa, H; Tanaka, S; Takada, A; Suzuki, S; Hasegawa, H; Umemura, T; Fujisawa, J; Tanaka, Y; Hall, WW; Nagashima, K				Okada, Y; Sawa, H; Tanaka, S; Takada, A; Suzuki, S; Hasegawa, H; Umemura, T; Fujisawa, J; Tanaka, Y; Hall, WW; Nagashima, K			Transcriptional activation of JC virus by human T-lymphotropic virus type I tax protein in human neuronal cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; NF-KAPPA-B; HUMAN POLYOMAVIRUS JC; HTLV-I; ENHANCER; DNA; SEQUENCE; ELEMENT; P40TAX; KINASE	Polyomavirus JC (JCV) causes the human demyelinating disease, progressive multifocal leukoencephalopathy (PML). The recent demonstration of cases of PML in association with human T-lymphotropic virus type I (HTLV-I) infection prompted us to examine whether the HTLV-I-encoded regulatory protein Tax activates JCV transcription. By employing a dual luciferase assay, we initially found that the expression of Tax activated the transcriptional potential of both early and late promoters of JCV in human neuronal but not in non-neuronal cells. We subsequently analyzed the mechanism of Tax-induced activation of the JCV promoter in neuronal cells with the following results: 1) the JCV promoter that lacks the NF-kappa B-binding motif could not be activated by Tax; 2) the overexpression of I kappa B alpha abolished Tax-induced transcriptional activation of the JCV promoter; 3) a Tax mutant M22) lacking the potential for activation via the NF-kappa B pathway did not activate the JCV promoter. Furthermore, Tax enhances the gene expression of JCV T antigen and VP1. We examined mechanisms of the cell-specific activation of the JCV promoter by Tax. Electrophoretic mobility shift assay demonstrated the presence of Tax-bound protein(s) that were specifically present in non-neuronal cells. This study is the first demonstration of the activation of JCV promoter by HTLV-I Tax in an NF-kappa B-dependent manner.	Hokkaido Univ, Sch Med, Lab Mol & Cellular Pathol, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Hokkaido Univ, Grad Sch Vet Med, Lab Comparat Pathol, Kita Ku, Sapporo, Hokkaido 0608638, Japan; Sapporo Municipal Hosp, Dept Pathol, Chuo Ku, Sapporo, Hokkaido 0608604, Japan; Sapporo Municipal Hosp, Japan Sci & Technol, CREST, Chuo Ku, Sapporo, Hokkaido 0608604, Japan; Natl Inst Infect Dis, Dept Infect Pathol, Shinjuku Ku, Tokyo 1620052, Japan; Kansai Med Univ, Dept Microbiol, Osaka 5708506, Japan; Univ Ryukyu, Dept Immunol & Infect Dis, Nishihara, Okinawa 9030125, Japan; Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dept Med Microbiol, Dublin 2, Ireland	Hokkaido University; Hokkaido University; Japan Science & Technology Agency (JST); National Institute of Infectious Diseases (NIID); Kansai Medical University; University of the Ryukyus; University College Dublin	Sawa, H (corresponding author), Hokkaido Univ, Sch Med, Lab Mol & Cellular Pathol, Kita Ku, N15,W7, Sapporo, Hokkaido 0608638, Japan.		Sawa, Hirofumi/AAW-8816-2021; Umemura, Takashi/A-6938-2012; Tanaka, Shinya/D-3586-2011; Hasegawa, Hideki/C-7978-2014; Sawa, Hirofumi/F-6954-2012	Sawa, Hirofumi/0000-0003-2569-2755				DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Krachmarov CP, 1996, P NATL ACAD SCI USA, V93, P14112, DOI 10.1073/pnas.93.24.14112; MOCH H, 1992, J VIROL, V66, P7346, DOI 10.1128/JVI.66.12.7346-7354.1992; NAKAMURA M, 1989, J BIOL CHEM, V264, P20189; Raj GV, 1996, J VIROL, V70, P5944, DOI 10.1128/JVI.70.9.5944-5953.1996; RAJ GV, 1995, VIROLOGY, V213, P283, DOI 10.1006/viro.1995.0001; Shimizu N, 1999, INTERNAL MED, V38, P932, DOI 10.2169/internalmedicine.38.932; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sock E, 1996, J VIROL, V70, P1512, DOI 10.1128/JVI.70.3.1512-1520.1996; SUZUKI T, 1993, ONCOGENE, V8, P2391; TAKAHASHI H, 1992, ACTA NEUROPATHOL, V83, P105, DOI 10.1007/BF00308469; TANAKA Y, 1991, INT J CANCER, V48, P623, DOI 10.1002/ijc.2910480423; Tokui M, 1997, BIOCHEM BIOPH RES CO, V233, P527, DOI 10.1006/bbrc.1997.6485; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Wakutani Y, 1998, NEUROPATHOLOGY, V18, P347, DOI 10.1111/j.1440-1789.1998.tb00126.x; Weber T, 1997, INTERVIROLOGY, V40, P98, DOI 10.1159/000150537; WEGNER M, 1993, P NATL ACAD SCI USA, V90, P4743, DOI 10.1073/pnas.90.10.4743; WHITE FA, 1992, J VIROL, V66, P5726, DOI 10.1128/JVI.66.10.5726-5734.1992; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; YOGO Y, 1990, J VIROL, V64, P3139, DOI 10.1128/JVI.64.6.3139-3143.1990	24	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17016	17023		10.1074/jbc.275.22.17016	http://dx.doi.org/10.1074/jbc.275.22.17016			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828075	hybrid			2022-12-25	WOS:000087392200087
J	Sawada, H; Ibi, M; Kihara, T; Urushitani, M; Honda, K; Nakanishi, M; Akaike, A; Shimohama, S				Sawada, H; Ibi, M; Kihara, T; Urushitani, M; Honda, K; Nakanishi, M; Akaike, A; Shimohama, S			Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons	FASEB JOURNAL			English	Article						estrogen receptor beta; AP-1 element; Parkinson's disease; neuroprotection	PROGRAMMED CELL-DEATH; ACTIVATED PROTEIN-KINASE; PRIMARY CORTICAL-NEURONS; NF-KAPPA-B; PARKINSONS-DISEASE; OXIDATIVE STRESS; INDUCED APOPTOSIS; NEUROBLASTOMA-CELLS; MEDIATED APOPTOSIS; ALZHEIMERS-DISEASE	Parkinson's disease is characterized by the mesencephalic dopaminergic neuronal loss, possibly by apoptosis, and the prevalence is higher in males than in females. The estrogen receptor (ER) subtype in the mesencephalon is exclusively ER beta, a recently cloned novel subtype. Bound with estradiol, it enhances gene transcription through the estrogen response element (ERE) or inhibits it through the activator protein-1 (AP-1) site. We demonstrated that 17 beta-estradiol provided protection against nigral neuronal apoptosis caused by exposure to either bleomycin sulfate (BLM) or buthionine sulfoximine (BSO). BLM and BSO-induced nigral apoptosis was blocked by inhibitors for caspase-3 or c-Jun/AP-1. The antiapoptotic effect by estradiol was blocked by ICI 182,780, an antagonist for ER, but not by a synthesized peptide that inhibits binding of the ER to the ERE. Estradiol had no effects on caspase-3 activation and c-Jun NH2-terminal kinase (JNK), which were activated by BLM. It also suppressed apoptosis by serum deprivation, which was independent of caspase-3 activation. Therefore, the antiapoptotic neuroprotection by estradiol is mediated by transcription through AP-1 site downstream from JNK and caspase-3 activation. Furthermore, 17 alpha-estradiol, a stereoisomer without female hormone activity, also provided an antiapoptotic effect. Therefore, the antiapoptotic effect is independent of female hormone activity.-Sawada, H., Ibi, M., Kihara, T., Urushitani, M., Honda, K, Nakanishi, M., Akaike, A., Shimohama, S. Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons.	Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Shimohama, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Neurol, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.			Urushitani, Makoto/0000-0003-2773-9836; Sawada, Hideyuki/0000-0002-5909-3366; Ibi, Masakazu/0000-0003-1414-100X				Amato SF, 1998, CANCER RES, V58, P241; AMBANI LM, 1975, ARCH NEUROL-CHICAGO, V32, P114, DOI 10.1001/archneur.1975.00490440064010; [Anonymous], 1996, PHYSIOLOGIST; ARNOLD SF, 1995, P NATL ACAD SCI USA, V92, P7475, DOI 10.1073/pnas.92.16.7475; Barkhem T, 1998, MOL PHARMACOL, V54, P105, DOI 10.1124/mol.54.1.105; BAUER RB, 1982, J AM GERIATR SOC, V30, P322, DOI 10.1111/j.1532-5415.1982.tb05621.x; Bayne K, 1996, Physiologist, V39, P208; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; Birge SJ, 1996, J AM GERIATR SOC, V44, P865, DOI 10.1111/j.1532-5415.1996.tb03749.x; Birge SJ, 1997, NEUROLOGY, V48, pS36, DOI 10.1212/WNL.48.5_Suppl_7.36S; CASPARY WJ, 1982, BIOCHEMISTRY-US, V21, P334, DOI 10.1021/bi00531a021; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512290-00014; Clark J. H., 1992, TXB ENDOCRINOLOGY, P35; DMELLO SR, IN PRESS J NEUROSCI; Dubal DB, 1999, J NEUROSCI, V19, P6385; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; Garcia-Segura LM, 1998, NEUROREPORT, V9, P593, DOI 10.1097/00001756-199803090-00006; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Green PS, 1998, NEUROSCIENCE, V84, P7, DOI 10.1016/S0306-4522(97)00595-2; Green PS, 1997, J NEUROSCI, V17, P511; Green PS, 1996, NEUROSCI LETT, V218, P165, DOI 10.1016/S0304-3940(96)13148-7; Gridley KE, 1998, MOL PHARMACOL, V54, P874, DOI 10.1124/mol.54.5.874; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P5606, DOI 10.1073/pnas.76.11.5606; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; HAMILTON RF, 1995, AM J PHYSIOL-LUNG C, V269, pL318, DOI 10.1152/ajplung.1995.269.3.L318; Henderson Victor W., 1997, American Journal of Medicine, V103, p11S, DOI 10.1016/S0002-9343(97)00261-1; Higuchi Y, 1997, FREE RADICAL BIO MED, V23, P90, DOI 10.1016/S0891-5849(96)00589-8; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Ishikawa Y, 1997, BIOCHEM BIOPH RES CO, V240, P496, DOI 10.1006/bbrc.1997.7665; Jacobs-Helber SM, 1998, MOL CELL BIOL, V18, P3699, DOI 10.1128/MCB.18.7.3699; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KISH SJ, 1985, NEUROSCI LETT, V58, P343, DOI 10.1016/0304-3940(85)90078-3; KUIPER GG, 1996, P NATL ACAD SCI USA, V39, P5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; KYPRIANOU N, 1991, CANCER RES, V51, P162; LI SC, 1985, ARCH NEUROL-CHICAGO, V42, P655, DOI 10.1001/archneur.1985.04060070045013; Li YH, 1997, J CELL BIOL, V139, P1317, DOI 10.1083/jcb.139.5.1317; Liebermann DA, 1998, INT J ONCOL, V12, P685; Marini M, 1996, BIOCHEM BIOPH RES CO, V229, P910, DOI 10.1006/bbrc.1996.1901; Matsura T, 1999, FREE RADICAL RES, V30, P73, DOI 10.1080/10715769900300081; MAYEUX R, 1995, AM J EPIDEMIOL, V142, P820, DOI 10.1093/oxfordjournals.aje.a117721; Mochizuki H, 1996, J NEUROL SCI, V137, P120, DOI 10.1016/0022-510X(95)00336-Z; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.0.CO;2-G; POLLARD JW, 1987, CELL TISSUE RES, V249, P533; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; RATAN RR, 1994, J NEUROCHEM, V62, P376; RINK A, 1995, AM J PATHOL, V147, P1575; Saraste A, 1999, HERZ, V24, P189, DOI 10.1007/BF03044961; Sawada H, 1996, J NEUROSCI RES, V46, P509, DOI 10.1002/(SICI)1097-4547(19961115)46:4<509::AID-JNR13>3.0.CO;2-T; Sawada H, 1998, ANN NEUROL, V44, P110, DOI 10.1002/ana.410440117; Sawada H, 2000, J NEUROCHEM, V74, P1175; Sawada H, 1996, J NEUROSCI RES, V43, P503, DOI 10.1002/(SICI)1097-4547(19960215)43:4<503::AID-JNR12>3.0.CO;2-2; Sawada H, 1998, J NEUROSCI RES, V54, P707, DOI 10.1002/(SICI)1097-4547(19981201)54:5<707::AID-JNR16>3.0.CO;2-T; Sawada H, 2000, NEUROSCI BIOBEHAV R, V24, P143, DOI 10.1016/S0149-7634(99)00059-7; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; Sengpiel B, 1998, EUR J NEUROSCI, V10, P1903, DOI 10.1046/j.1460-9568.1998.00202.x; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Singer CA, 1999, J NEUROSCI, V19, P2455; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; Singer CA, 1996, NEUROSCI LETT, V212, P13, DOI 10.1016/0304-3940(96)12760-9; Singh M, 1999, J NEUROSCI, V19, P1179; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Tan SL, 1998, J NEUROCHEM, V71, P95; Tan SL, 1998, J CELL BIOL, V141, P1423, DOI 10.1083/jcb.141.6.1423; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Watabe M, 1998, ONCOGENE, V16, P779, DOI 10.1038/sj.onc.1201592; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6	73	131	139	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1202	1214		10.1096/fasebj.14.9.1202	http://dx.doi.org/10.1096/fasebj.14.9.1202			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834942				2022-12-25	WOS:000087427300017
J	Shoemaker, AR; Haigis, KM; Baker, SM; Dudley, S; Liskay, RM; Dove, WF				Shoemaker, AR; Haigis, KM; Baker, SM; Dudley, S; Liskay, RM; Dove, WF			Mlh1 deficiency enhances several phenotypes of Apc(Min/+) mice	ONCOGENE			English	Article						Apc; Mlh1; Min; mutation; tumor	DNA MISMATCH REPAIR; NONPOLYPOSIS COLON-CANCER; INTESTINAL TUMORIGENESIS; MIN MICE; CHROMOSOME SYNAPSIS; MUTANT MICE; MOUSE; GENE; NEOPLASIA; MSH2	Defects in APC and DNA mismatch repair genes are associated with a strong predisposition to colon cancer in humans, and numerous mouse strains with mutations in these genes have been generated. In this report we describe the phenotype of Min/+ Mlh1(-/-) mice. We find that these doubly mutant mice develop more than three times the number of intestinal adenomas compared to Min/+ Mlh1(+/+) or (+/-) mice but that these tumors do not show advanced progression in terms of tumor size or histological appearance. Full length Apc protein was not detected in the tumor cells from Min/+ Mlh1(-/-) mice. Molecular analyses indicated that in many tumors from Min/+ Mlh1(-/-) mice, Apc was inactivated by intragenic mutation. Mlh1 deficiency in Min/+ mice also led to an increase in cystic intestinal crypt multiplicity as well as enhancing desmoid tumorigenesis and epidermoid cyst development. Thus, Mlh1 deficiency influences the somatic events involved in the development of most of the phenotypes associated with the Min mutation.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Genet Lab, Madison, WI 53706 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Oregon Health & Science University	Dove, WF (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA.		Dudley, Samuel C/A-7085-2009		NATIONAL CANCER INSTITUTE [R01CA063677, R37CA063677] Funding Source: NIH RePORTER; NCI NIH HHS [CA07075, CA63677, CA58085] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; Baker SM, 1998, CANCER RES, V58, P1087; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CLARKE AR, 1995, ONCOGENE, V11, P1913; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; de Vries SS, 1999, GENE DEV, V13, P523, DOI 10.1101/gad.13.5.523; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 1999, CANCER RES, V59, P1301; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Flores-Rozas H, 1998, P NATL ACAD SCI USA, V95, P12404, DOI 10.1073/pnas.95.21.12404; Gong JG, 1999, NATURE, V399, P806; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Halberg RB, 2000, P NATL ACAD SCI USA, V97, P3461, DOI 10.1073/pnas.050585597; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEVY DB, 1994, CANCER RES, V54, P5953; Luongo C, 1996, GENE CHROMOSOME CANC, V17, P194, DOI 10.1002/1098-2264(199611)17:3<194::AID-GCC2870170302>3.0.CO;2-E; LUONGO C, 1994, CANCER RES, V54, P5947; Peckham M., 1995, OXFORD TXB ONCOLOGY; Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5; POTTEN CS, 1988, J CELL SCI, P45; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Reitmair AH, 1996, CANCER RES, V56, P2922; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; SHOEMAKER AR, 1995, CANCER RES, V55, P4479; Shoemaker AR, 1997, CANCER RES, V57, P1999; Shoemaker AR, 1998, P NATL ACAD SCI USA, V95, P10826, DOI 10.1073/pnas.95.18.10826; Shoemaker AR, 1997, BBA-REV CANCER, V1332, pF25, DOI 10.1016/S0304-419X(96)00041-8; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850; Zhang H, 1999, CANCER RES, V59, P3021	42	45	47	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2000	19	23					2774	2779		10.1038/sj.onc.1203574	http://dx.doi.org/10.1038/sj.onc.1203574			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851078				2022-12-25	WOS:000087318500006
J	Chotani, MA; Touhalisky, K; Chiu, IM				Chotani, MA; Touhalisky, K; Chiu, IM			The small GTPases Ras, Rac, and Cdc42 transcriptionally regulate expression of human fibroblast growth factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE ACTIVATION; RHO-GTPASES; CELLS; PROMOTER; BINDING; PHOSPHORYLATION; GENE; PHENOTYPE; FAMILY	Four distinct promoters (1A, 1B, 1C, and 1D) of fibroblast growth factor 1 (FGF1), spaced up to 70 kilobase pairs apart, direct the expression of alternatively spliced transcript variants (FGF1.A, -1.B, -1.C, and -1.D) that encode FGF1. These FGF1 transcripts can be detected in cultured cells as well as in normal and diseased tissues. These transcripts are differentially regulated in a cell-specific manner. To further delineate the biological function of multiple promoter usage by a single gene, we investigated the transcriptional regulation of these promoters by defined signaling pathways associated with cell proliferation and cell survival. Here we show a specific association of two of the FGF1 promoters, 1C and 1D, with signaling cascades of the Ras superfamily of GTPases. A serum-response element, comprised of the Ets and CArG motifs, present in promoter 1D was shown to be the target of distinct signaling cascades; the Ets motif target of Ras, Rac1, and Cdc42 regulation; and the CArG motif target of de novo protein synthesis-independent cascade. Ras and Rac1 also activated the FGF2 promoter. Further, the transcription factor Ets2 synergistically activated FGF1 gene, but not FGF2, in a Ras- and Rac1-dependent signaling pathway. In support of these conclusions high levels of intracellular FGF1 were detected in cells undergoing cytokinesis. Altogether, our results suggest that FGF1 may play a fundamental role in cell division, spreading, and migration, in addition to cell proliferation.	Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA	Ohio State University	Chiu, IM (corresponding author), Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA.		Chotani, Maqsood/E-2891-2011; Chiu, Ing-Ming/B-1534-2008		NATIONAL CANCER INSTITUTE [R01CA045611] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA45611] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BUNNAG P, 1991, IN VITRO CELL DEV B, V27, P89; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; Chotani MA, 1996, GENET ANAL-BIOMOL E, V12, P133, DOI 10.1016/1050-3862(95)00124-7; Chotani MA, 1997, CELL GROWTH DIFFER, V8, P999; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Liu Y, 1998, J BIOL CHEM, V273, P19269, DOI 10.1074/jbc.273.30.19269; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MYERS RL, 1995, ONCOGENE, V11, P785; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; MYERS RL, 1993, ONCOGENE, V8, P341; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Payson RA, 1998, J STEROID BIOCHEM, V66, P93, DOI 10.1016/S0960-0760(98)00051-X; Ray SK, 1997, J BIOL CHEM, V272, P7546, DOI 10.1074/jbc.272.11.7546; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SEGER R, 1994, J BIOL CHEM, V269, P25699; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; Treisman R, 1990, Semin Cancer Biol, V1, P47; Trinh T, 1994, FOCUS, V16, P78; Yang BS, 1996, MOL CELL BIOL, V16, P538	32	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30432	30438		10.1074/jbc.M003545200	http://dx.doi.org/10.1074/jbc.M003545200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10849427	hybrid			2022-12-25	WOS:000089577900070
J	Kathofer, S; Zhang, W; Karle, C; Thomas, D; Schoels, W; Kiehn, J				Kathofer, S; Zhang, W; Karle, C; Thomas, D; Schoels, W; Kiehn, J			Functional coupling of human beta(3)-adrenoreceptors to the KvLQT1/MinK potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; III ANTIARRHYTHMIC AGENT; RECTIFIER K+-CURRENT; LONG-QT SYNDROME; XENOPUS-OOCYTES; MODULATION; ARRHYTHMIAS; RECEPTOR; CAMP; HERG	The slow component of the delayed rectifier potassium current (IKs) plays an important role during repolarization in the human heart. Life-threatening arrhythmias can be triggered by sympathetic stimulation, presumably acting on IKs. The ion channel responsible for the IKs current is made of two proteins, the KvLQT1 protein and the MinK protein, In this study, we investigated the effects of adrenergic stimulation on the KvLQT1/MinK channel by coexpressing KvLQT1/MinK channels with the human beta(3)-adrenoreceptor subunit heterologously in Xenopus oocytes, Western blot experiments revealed that beta(3)-adrenoreceptor proteins appear in the cell membrane of Xenopus oocytes, when the corresponding cRNA was injected. In electrophysiological measurements we found that stimulation with the beta-adrenergic agonist isoproterenol increased the current amplitude of the beta(3)/KvLQT1/MinK complex up to 237% with an ED50 of 8 nM, a value similar to that found on IKs in guinea pig cardiomyocytes. When oocytes with beta(3)/KvLQT1/MinK were preincubated with cholera toxin (2 mu g/ml), an activator of G(S) proteins, the basal current amplitude of the beta(3)/KvLQT1/MinK complex was increased 3.1-fold, and the current amplitude increase by isoproterenol was drastically reduced, indicating that the signal transduction cascade was mediated via G(s) proteins. The knowledge about functional coupling of the human beta(3)-adrenoreceptor to KvLQT1/MinK channels reveals interesting aspects about the genesis and therapy of arrhythmias.	Med Univ Hosp Heidelberg, Dept Cardiol, D-69115 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Kiehn, J (corresponding author), Med Univ Hosp Heidelberg, Dept Cardiol, Bergheimer Str 58, D-69115 Heidelberg, Germany.	johann_kiehn@ukl.uni-heidelberg.de	Thomas, Dierk/V-3940-2017; Thomas, Dierk/ABA-4706-2021	Thomas, Dierk/0000-0002-5687-7843				Arellano RO, 1998, AM J PHYSIOL-CELL PH, V274, pC333, DOI 10.1152/ajpcell.1998.274.2.C333; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Barry DM, 1996, ANNU REV PHYSIOL, V58, P363, DOI 10.1146/annurev.ph.58.030196.002051; Carmeliet E, 1999, PHYSIOL REV, V79, P917, DOI 10.1152/physrev.1999.79.3.917; DUCHATELLEGOURDON I, 1989, J PHYSIOL-LONDON, V415, P251, DOI 10.1113/jphysiol.1989.sp017721; ESCHENHAGEN T, 1993, CELL BIOL INT, V17, P723, DOI 10.1006/cbir.1993.1135; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Gauthier C, 1996, J CLIN INVEST, V98, P556, DOI 10.1172/JCI118823; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; JURKIEWICZ NK, 1993, CIRC RES, V72, P75, DOI 10.1161/01.RES.72.1.75; Kaczmarek LK, 1997, PHYSIOL REV, V77, P627, DOI 10.1152/physrev.1997.77.3.627; Kaumann AJ, 1997, N-S ARCH PHARMACOL, V355, P667, DOI 10.1007/PL00004999; KAUMANN AJ, 1993, N-S ARCH PHARMACOL, V348, P536; Kiehn J, 1998, J BIOL CHEM, V273, P25285, DOI 10.1074/jbc.273.39.25285; Kiehn J, 1996, CIRCULATION, V94, P2572, DOI 10.1161/01.CIR.94.10.2572; Lo CF, 1998, CIRC RES, V83, P995, DOI 10.1161/01.RES.83.10.995; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; Lowe MD, 1998, BRIT J PHARMACOL, V124, P1341, DOI 10.1038/sj.bjp.0702013; MURPHY PM, 1992, J BIOL CHEM, V267, P883; Nara M, 1998, J BIOL CHEM, V273, P14920, DOI 10.1074/jbc.273.24.14920; Roden DM, 1996, CIRCULATION, V94, P1996, DOI 10.1161/01.CIR.94.8.1996; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SANGUINETTI MC, 1991, CIRC RES, V68, P77, DOI 10.1161/01.RES.68.1.77; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; STROSBERG AD, 1993, PROTEIN SCI, V2, P1198, DOI 10.1002/pro.5560020802; Tristani-Firouzi M, 1998, J PHYSIOL-LONDON, V510, P37, DOI 10.1111/j.1469-7793.1998.037bz.x; UEZONO Y, 1993, RECEPTOR CHANNEL, V1, P233; VARNUM MD, 1993, P NATL ACAD SCI USA, V90, P11528, DOI 10.1073/pnas.90.24.11528; Wilde AAM, 1999, J AM COLL CARDIOL, V33, P327, DOI 10.1016/S0735-1097(98)00578-6; Wollnik B, 1997, HUM MOL GENET, V6, P1943, DOI 10.1093/hmg/6.11.1943; ZENG JL, 1995, CIRC RES, V77, P140, DOI 10.1161/01.RES.77.1.140	31	34	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26743	26747						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10823835				2022-12-25	WOS:000089144800012
J	Bi, RF; Rong, YQ; Bernard, A; Khrestchatisky, M; Baudry, M				Bi, RF; Rong, YQ; Bernard, A; Khrestchatisky, M; Baudry, M			Src-mediated tyrosine phosphorylation of NR2 subunits of N-methyl-D-aspartate receptors protects from calpain-mediated truncation of their C-terminal domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA-RECEPTOR; KINASE-C; BRAIN SPECTRIN; RAT-BRAIN; IN-VIVO; 2B; POTENTIATION; PROTEOLYSIS; NEURONS; PSD-95	Src-mediated tyrosine phosphorylation of N-methyl-D-aspartate receptor subunits has been shown to modify the functional properties of N-methyl-D-aspartate receptors. Moreover, calpain-mediated truncation of N-methyl-D-aspartate receptor subunits has been found to alter the structure of the receptors. In the present study, we first used immunoprecipitation with a variety of antibodies against N-methyl-D-aspartate receptor subunits and anti-phosphotyrosine antibodies to show that tyrosine-phosphorylated subunits of N-methyl-D-aspartate receptor are protected against calpain-mediated truncation of their C-terminal domains. A GST fusion protein containing the C-terminal domain of NR2A was used to identify the calpain cutting sites in the C-terminal domain. One site was identified at residues 1278-1279, corresponding to one of the preferred calpain truncation sites. This site is adjacent to a consensus sequence for Src-mediated tyrosine phosphorylation, and Src mediated tyrosine phosphorylation of the GST-NR2A C-terminal fusion protein also inhibited calpain-mediated truncation of the fusion protein. We propose that phosphorylation of NR2 subunits and the resulting inhibition of calpain-mediated truncation of their C-terminal domains provide for the stabilization of the N-methyl-D-aspartate receptors in postsynaptic structures.	Univ So Calif, Program Neurosci, Los Angeles, CA 90089 USA; INSERM, U 29, INMED, F-13273 Marseille, France	University of Southern California; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Baudry, M (corresponding author), Univ So Calif, Program Neurosci, Los Angeles, CA 90089 USA.				NIA NIH HHS [AG-14751] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG014751] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bi RF, 1998, BRAIN RES, V797, P154, DOI 10.1016/S0006-8993(98)00433-8; Bi XN, 1997, J NEUROCHEM, V68, P1484; Bi XN, 1998, BRAIN RES, V790, P245, DOI 10.1016/S0006-8993(98)00067-5; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; FERHAT L, 1994, NEUROCHEM INT, V25, P327, DOI 10.1016/0197-0186(94)90139-2; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; ISHII T, 1993, J BIOL CHEM, V268, P2836; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LIBERMAN DN, 1994, NATURE, V369, P235; LYNCH G, 1987, BRAIN RES BULL, V18, P809, DOI 10.1016/0361-9230(87)90220-6; Lynch G, 1998, NEUROBIOL LEARN MEM, V70, P82, DOI 10.1006/nlme.1998.3840; MASSICOTTE G, 1990, MOL PHARMACOL, V32, P278; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; Menegoz M, 1995, NEUROREPORT, V7, P125, DOI 10.1097/00001756-199512290-00030; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Niethammer M, 1996, J NEUROSCI, V16, P2157; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; SAIDO TC, 1993, J BIOL CHEM, V268, P25239; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Sheng M, 1997, BIOESSAYS, V19, P847, DOI 10.1002/bies.950191004; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Takagi N, 1997, J NEUROCHEM, V69, P1060; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDERKLISH P, 1995, MOL BRAIN RES, V32, P25, DOI 10.1016/0169-328X(95)00057-Y; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Wang YT, 1996, P NATL ACAD SCI USA, V93, P1721, DOI 10.1073/pnas.93.4.1721; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zheng F, 1998, NAT NEUROSCI, V1, P185, DOI 10.1038/634	46	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26477	26483		10.1074/jbc.M003763200	http://dx.doi.org/10.1074/jbc.M003763200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10846184	hybrid			2022-12-25	WOS:000088999700082
J	Cabezon, E; Butler, PJG; Runswick, MJ; Walker, JE				Cabezon, E; Butler, PJG; Runswick, MJ; Walker, JE			Modulation of the oligomerization state of the bovine F-1-ATPase inhibitor protein, IF1, by pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; HEART-MITOCHONDRIA; ATP SYNTHASE; IDENTIFICATION; PURIFICATION	Bovine IF1, a basic protein of 84 amino acids, is involved in the regulation of the catalytic activity of the F-1 domain of ATP synthase, At pH 6.5, but not at basic pH values, it inhibits the ATP hydrolase activity of the enzyme. The oligomeric state of bovine LF, has been investigated at various pH values by sedimentation equilibrium analytical ultracentrifugation and by covalent cross-linking. Both techniques confirm that the protein forms a tetramer at pH 8, and below pH 6.5, the protein is predominantly dimeric, By covalent cross-linking, it has been found that at pH 8.0 the fragment of IF, consisting of residues 44-84 forms a dimer, whereas the fragment from residues 32-84 is tetrameric. Therefore, some or all of the residues between positions 32 and 43 are necessary for tetramer formation and are involved in the pH-sensitive interconversion between dimer and tetramer, One important residue in the interconversion is histidine 49, Mutation of this residue to lysine abolishes the pH-dependent activation-inactivation, and the mutant protein is active and dimeric at all pH values investigated. It is likely from MMR studies that the inhibitor protein dimerizes by forming an antiparallel alpha-helical coiled-coil over its C-terminal region and that at high pH values, where the protein is tetrameric, the inhibitory regions are masked. The mutation of histidine 49 to lysine is predicted to abolish coiled-coil formation over residues 32-43 preventing interaction between two dimers, forcing the equilibrium toward the dimeric state, thereby freeing the N-terminal inhibitory regions and allowing them to interact with F-1.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; MRC Laboratory Molecular Biology	Walker, JE (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.		Cabezon, Elena/K-5874-2014	Walker, John/0000-0001-7929-2162; Cabezon, Elena/0000-0002-6177-5016				Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; CASASSA EF, 1964, ADV PROTEIN CHEM, V19, P287, DOI 10.1016/S0065-3233(08)60191-6; CINTRON NM, 1979, J BIOL CHEM, V254, P3439; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; Eisenberg H, 1976, BIOL MACROMOLECULES; HASHIMOTO T, 1981, J BIOCHEM-TOKYO, V90, P1151, DOI 10.1093/oxfordjournals.jbchem.a133567; Johnson M.L., 1994, MODERN ANAL ULTRACEN, P37; KLEIN G, 1980, BIOCHEMISTRY-US, V19, P2919, DOI 10.1021/bi00554a016; Kratky O, 1973, Methods Enzymol, V27, P98; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZMEDIAVILLA C, 1993, EUR J BIOCH, V215; LUTTER R, 1993, J MOL BIOL, V229, P787, DOI 10.1006/jmbi.1993.1081; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; NORLING B, 1990, EUR J BIOCHEM, V188, P247, DOI 10.1111/j.1432-1033.1990.tb15396.x; PANCHENKO MV, 1985, FEBS LETT, V184, P226, DOI 10.1016/0014-5793(85)80611-6; Papa S, 1996, EUR J BIOCHEM, V240, P461, DOI 10.1111/j.1432-1033.1996.0461h.x; PEDERSEN PL, 1981, CURR TOP BIOENERG, V11, P149; PENIN F, 1988, BIOCHEMISTRY-US, V27, P8969, DOI 10.1021/bi00425a014; PULLMAN ME, 1963, J BIOL CHEM, V238, P3762; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schnizer R, 1996, BBA-PROTEIN STRUCT M, V1292, P241, DOI 10.1016/0167-4838(95)00208-1; VANHOLDE KE, 1958, J PHYS CHEM-US, V62, P734, DOI 10.1021/j150564a025; vanRaaij MJ, 1996, BIOCHEMISTRY-US, V35, P15618, DOI 10.1021/bi960628f; WALKER JE, 1994, CURR OPIN STRUC BIOL, V4, P912, DOI 10.1016/0959-440X(94)90274-7; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606	25	150	154	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25460	25464		10.1074/jbc.M003859200	http://dx.doi.org/10.1074/jbc.M003859200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10831597	hybrid			2022-12-25	WOS:000088849400055
J	Tortorella, M; Pratta, M; Liu, RQ; Abbaszade, I; Ross, H; Burn, T; Arner, E				Tortorella, M; Pratta, M; Liu, RQ; Abbaszade, I; Ross, H; Burn, T; Arner, E			The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SYNOVIAL-FLUID; INTERGLOBULAR DOMAIN; CARTILAGE AGGRECAN; ARTICULAR-CARTILAGE; CELL-ADHESION; FAMILY; BINDING; PROTEIN; MATRIX; OSTEOARTHRITIS	Aggrecanase-1 (ADAMTS-4) is a member of the a disintegrin and metalloprotease with thrombospondin motifs (ADAMTS) protein family that was recently identified. Aggrecanase-1 is one of two ADAMTS cartilage-degrading enzymes purified from interleukin-1-stimulated bovine nasal cartilage (Tortorella, M. D., Burn, T. C., Pratta, M. A., Abbaszade, I., Hollis, J. Ri., Liu, R., Rosenfeld, S. A,, Copeland, R. A., Decicco, C. P., Wynn, R., Rockwell, A, Yang, F., Duke, J. L., Solomon, K., George, R, Bruckner, R., Nagase, H., Itoh, Y., Ellis, D. M., Boss, H., Wiswall, B. H., Murphy, K., Hillman, M. C., Jr., Hollis, G. F., and Arner, E.C. (1999) Science 284, 1664-1666; 2 Abbaszade, I., Liu, R. Q., Yang, F., Rosenfeld, S. A., Boss, O. H., Link, J. R., Ellis, D. M., Tortorella, M. D., Pratta, M. A., Hollis, J. M., Wynn, R., Duke, J. L., George, H. J., Hillman, M. C., Jr., Murphy, K., Wiswall, B. H., Copeland, R. A., Decicco, C. P., Bruckner, R., Nagase, H., Itoh, Y., Newton, R. C., Magolda, R. L., Trzaskos, J. M., and Burn, T. C. (1999) J. Biol. Chem. 274, 23443-23450). The aggrecan products generated by this enzyme are found in cartilage cultures stimulated with cytokines and in synovial fluid from patients with arthritis, suggesting that aggrecanase-1 may be important in diseases involving cartilage destruction. Here we demonstrate that the thrombospondin type-1 (TSP-1) motif located within the C terminus of aggrecanase-1 binds to the glycosaminoglycans of aggrecan. Data from several studies indicate that this binding of aggrecanase-1 to aggrecan through the TSP-1 motif is necessary for enzymatic cleavage of aggrecan. 1) A truncated form of aggrecanase-1 lacking the TSP-I motif was not effective in cleaving aggrecan. 2) Several peptides representing different regions of the TSP-1 motif effectively blocked aggrecanase-1 cleavage of aggrecan by preventing the enzyme from binding to the substrate. 3) Aggrecanase-1 was not effective in cleaving glycosaminoglycan-free aggrecan. Taken together, these data suggest that the TSP-1 motif of aggrecanase-1 is critical for substrate recognition and cleavage.	Dupont Merck Pharmaceut Co, Dept Inflammatory Dis Res, Wilmington, DE 19880 USA; Dupont Merck Pharmaceut Co, Dept Appl Biotechnol, Wilmington, DE 19880 USA	DuPont; DuPont	Tortorella, M (corresponding author), Kennedy Inst Rheumatol, 1 Aspenlea Rd, London W6 8LH, England.			Burn, Timothy/0000-0001-6648-4333				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Arner EC, 1997, J BIOL CHEM, V272, P9294; Arner EC, 1998, OSTEOARTHR CARTILAGE, V6, P214, DOI 10.1053/joca.1998.0114; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; FLANNERY CR, 1992, J BIOL CHEM, V267, P1008; FLANNERY CR, 1993, ORTHOP T, V17, P677; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Gantt SM, 1997, J BIOL CHEM, V272, P19205, DOI 10.1074/jbc.272.31.19205; Ghosh P, 1996, OSTEOARTHR CARTILAGE, V4, P43, DOI 10.1016/S1063-4584(96)80006-9; GUO NH, 1992, J BIOL CHEM, V267, P19349; HARDINGHAM TE, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P5; HASCALL VC, 1969, J BIOL CHEM, V244, P2384; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; ILIC MZ, 1992, ARCH BIOCHEM BIOPHYS, V294, P115, DOI 10.1016/0003-9861(92)90144-L; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1997, GENOMICS, V46, P466, DOI 10.1006/geno.1997.5064; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LEULAKIS P, 1992, BIOCHEM J, V264, P589; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; Magnetto S, 1998, CELL BIOCHEM FUNCT, V16, P211, DOI 10.1002/(SICI)1099-0844(199809)16:3<211::AID-CBF788>3.3.CO;2-Q; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; PRATTA MA, 1997, T ORTHOP RES SOC, V22, P453; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; Sugimoto K, 1999, J BIOCHEM, V126, P449, DOI 10.1093/oxfordjournals.jbchem.a022471; Tang BL, 1999, FEBS LETT, V445, P223, DOI 10.1016/S0014-5793(99)00119-2; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; TORTORELLA MD, 2000, IN PRESS J BIOL CHEM, V275; TORTORELLA MD, 1999, T ORTHOP RES SOC, V24, P84; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; WILLIAMS JW, 1979, BIOCHEMISTRY-US, V18, P2567, DOI 10.1021/bi00579a021; WOLSBERG TG, 1996, DEV BIOL, V180, P389	38	155	164	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25791	25797		10.1074/jbc.M001065200	http://dx.doi.org/10.1074/jbc.M001065200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827174	hybrid			2022-12-25	WOS:000088849400096
J	Stotz, SC; Hamid, J; Spaetgens, RL; Jarvis, SE; Zamponi, GW				Stotz, SC; Hamid, J; Spaetgens, RL; Jarvis, SE; Zamponi, GW			Fast inactivation of voltage-dependent calcium channels - A hinged-lid mechanism?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNELS; MOLECULAR DETERMINANTS; FUNCTIONAL EXPRESSION; BETA-SUBUNIT; BLOCK; FAMILY; ALPHA(1)-SUBUNIT; MUTATIONS; CLONING; MEMBER	We recently described domains II and III as important determinants of fast, voltage-dependent inactivation of R-type calcium channels (Spaetgens, R, L., and Zamponi, G. W. (1999) J. Biol. Chem. 274, 22428-22438). Here we examine in greater detail the structural determinants of inactivation using a series of chimeras comprising various regions of wild type alpha(1C) and alpha(1E) calcium channels. Substitution of the II S6 and/or III S6 segments of alpha(1E) into the alpha(1C) backbone resulted in rapid inactivation rates that closely approximated those of wild type alpha(1E) channels. However, neither individual or combined substitution of the II S6 and III S6 segments could account for the 60 mV more negative half-inactivation potential seen with wild type alpha(1E) channels, indicating that the S6 regions contribute only partially to the voltage dependence of inactivation. Interestingly, the converse replacement of alpha(1E) S6 segments of domains II, III, or II + III with those of cu,, was insufficient to significantly slow inactivation rates. Only when the I-II linker region and the domain II and III S6 regions of alpha(1E) were concomitantly replaced with alpha(1C) sequence could inactivation be abolished. Conversely, introduction of the cu,, domain I-II linker sequence into alpha(1C) conferred alpha(1E)-like inactivation rates, indicating that the domain I-II linker is a key contributor to calcium channel inactivation. Overall, our data are consistent with a mechanism in which inactivation of voltage-dependent calcium channels may occur via docking of the I-II linker region to a site comprising, at least in part, the domain II and III S6 segments.	Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB T2N 4N1, Canada; Univ Calgary, Neurosci Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Zamponi, GW (corresponding author), Univ Calgary, Dept Pharmacol & Therapeut, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Zamponi, Gerald W./0000-0002-0644-9066				ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P447; Bech-Hansen NT, 1998, NAT GENET, V19, P264, DOI 10.1038/947; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Cens T, 1999, J BIOL CHEM, V274, P5483, DOI 10.1074/jbc.274.9.5483; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; EAHOLTZ G, 1994, NEURON, V12, P1041, DOI 10.1016/0896-6273(94)90312-3; FUTITA Y, 1993, NEURON, V10, P465; HAWTHORN MH, 1992, EUR J PHARMACOL, V229, P143, DOI 10.1016/0014-2999(92)90548-I; Hering S, 1997, P NATL ACAD SCI USA, V94, P13323, DOI 10.1073/pnas.94.24.13323; Hering S, 1996, J BIOL CHEM, V271, P24471, DOI 10.1074/jbc.271.40.24471; Hering S, 1998, TRENDS PHARMACOL SCI, V19, P439, DOI 10.1016/S0165-6147(98)01258-9; HERLITZE S, 1997, P NATL ACAD SCI USA, V94, P1402; HOSHI T, 1991, NEURON, V7, P454; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; Kraus RL, 1998, J BIOL CHEM, V273, P5586, DOI 10.1074/jbc.273.10.5586; KUKULJAN M, 1995, AM J PHYSIOL, V268, pC425; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; McCleskey Edwin W., 1994, Current Opinion in Neurobiology, V4, P304, DOI 10.1016/0959-4388(94)90090-6; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Olcese R, 1996, J PHYSIOL-LONDON, V497, P675, DOI 10.1113/jphysiol.1996.sp021799; ORRENIUS S, 1994, J NEURAL TRANSM-SUPP, P1; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 1998, P NATL ACAD SCI USA, V95, P4690, DOI 10.1073/pnas.95.8.4690; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; Spaetgens RL, 1999, J BIOL CHEM, V274, P22428, DOI 10.1074/jbc.274.32.22428; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; STEA A, 1995, HDB RECEPTORS CHANNE, P113; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; TOTTENE A, 1997, J NEUROSCI, V16, P6342; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; ZAGOTTA WN, 1990, SCIENCE, V250, P506; Zamponi GW, 1996, J NEUROSCI, V16, P2430; ZAMPONI GW, 1993, BIOPHYS J, V65, P2335, DOI 10.1016/S0006-3495(93)81292-X; ZAMPONI GW, 1993, BIOPHYS J, V65, P2324, DOI 10.1016/S0006-3495(93)81291-8; ZHANG JF, 1994, NATURE, V372, P97, DOI 10.1038/372097a0	47	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24575	24582		10.1074/jbc.M000399200	http://dx.doi.org/10.1074/jbc.M000399200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10823819	hybrid			2022-12-25	WOS:000088683300047
J	Trask, TM; Trask, BC; Ritty, TM; Abrams, WR; Rosenbloom, J; Mecham, RP				Trask, TM; Trask, BC; Ritty, TM; Abrams, WR; Rosenbloom, J; Mecham, RP			Interaction of tropoelastin with the amino-terminal domains of fibrillin-1 and fibrillin-2 suggests a role for the fibrillins in elastic fiber assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE SULFATION; EXTRACELLULAR-MATRIX; CROSS-LINKING; LIGAMENTUM NUCHAE; MARFAN-SYNDROME; VITREOUS-HUMOR; LYSYL OXIDASE; MICROFIBRILS; COMPONENT; FIBROBLASTS	Alignment of tropoelastin molecules during the process of elastogenesis is thought to require fibrillin-containing microfibrils. In this study, we have demonstrated that amino-terminal domains of two microfibrillar proteins, fibrilIin-1 and fibrillin-2, interact with tropoelastin in solid phase binding assays. The tropoelastin-binding site was localized to a region beginning at the glycine-rich and proline-rich regions of fibrillin-2 and fibrillin-1, respectively, and continuing through the second 8-cysteine domain. Characterization of the binding requirements using the fibrillin-2 construct found that a folded, secondary structure was necessary for binding. Furthermore, binding between tropoelastin and fibrillin was mediated by ionic interactions involving the lysine side chains of tropoelastin. The importance of the lysine side chains was corroborated by the finding that the fibrillin-2 construct did not bind to mature elastin, whose lysine side chains have been modified to form cross-links. Interestingly, there was no interaction between the fibrillin constructs and tropoelastin in solution phase, suggesting that binding of tropoelastin to a solid substrate exposes a cryptic binding site. These results suggest that fibrillin plays an important role in elastic fiber assembly by binding tropoelastin and perhaps facilitating side chain alignment for efficient cross-linking.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ Penn, Sch Dent Med, Dept Anat & Histol, Philadelphia, PA 19104 USA	Washington University (WUSTL); University of Pennsylvania	Mecham, RP (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.		Abrams, William R/A-5782-2008		NHLBI NIH HHS [HL/HD62295, HL53325, HL61006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL053325, R01HL062295, R01HL053325, P50HL061006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ausubel FM, 1992, CURRENT PROTOCOLS MO; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; BROWNAUGSBURGER P, 1995, J BIOL CHEM, V270, P17778, DOI 10.1074/jbc.270.30.17778; CHRISTIANO AM, 1994, J INVEST DERMATOL, V103, P53; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; INDIK Z, 1990, ARCH BIOCHEM BIOPHYS, V280, P80, DOI 10.1016/0003-9861(90)90521-Y; Ingham KC, 1997, J BIOL CHEM, V272, P1718, DOI 10.1074/jbc.272.3.1718; KAGAN HM, 1991, AM J RESP CELL MOL, V5, P206, DOI 10.1165/ajrcmb/5.3.206; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; Kielty CM, 1996, FEBS LETT, V386, P169, DOI 10.1016/0014-5793(96)00423-1; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; MECHAM RP, 1984, J CELL BIOL, V98, P1804, DOI 10.1083/jcb.98.5.1804; MECHAM RP, 1981, J CELL BIOL, V90, P332, DOI 10.1083/jcb.90.2.332; PARTRIDGE SM, 1955, BIOCHEM J, V61, P11, DOI 10.1042/bj0610011; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; Pereira L, 1997, NAT GENET, V17, P218, DOI 10.1038/ng1097-218; PROSSER IW, 1991, CONNECT TISSUE RES, V25, P265, DOI 10.3109/03008209109029162; REBERMULLER S, 1995, DEV BIOL, V169, P662, DOI 10.1006/dbio.1995.1177; REISER K, 1992, FASEB J, V6, P2439, DOI 10.1096/fasebj.6.7.1348714; REN ZX, 1991, J STRUCT BIOL, V106, P57, DOI 10.1016/1047-8477(91)90062-2; Ritty TM, 1999, J BIOL CHEM, V274, P8933, DOI 10.1074/jbc.274.13.8933; ROSENQUIST GL, 1993, PROTEIN SCI, V2, P215; ROSS R, 1976, ADV EXP MED BIOL, V79, P7; SAGE H, 1979, COMP BIOCHEM PHYS B, V64, P313, DOI 10.1016/0305-0491(79)90277-3; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; Trask BC, 2000, MOL BIOL CELL, V11, P1499, DOI 10.1091/mbc.11.5.1499; Trask TM, 1999, BIOCHEM J, V340, P693, DOI 10.1042/0264-6021:3400693; WALLACE RN, 1991, CURR EYE RES, V10, P99, DOI 10.3109/02713689109007614; WRIGHT DW, 1988, J ULTRA MOL STRUCT R, V100, P224, DOI 10.1016/0889-1605(88)90039-0; ZHANG H, 1995, J CELL BIOL, V129, P1165, DOI 10.1083/jcb.129.4.1165; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	36	103	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24400	24406		10.1074/jbc.M003665200	http://dx.doi.org/10.1074/jbc.M003665200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10825173	hybrid, Green Submitted			2022-12-25	WOS:000088683300022
J	Weisz, OA; Gibson, GA; Leung, SM; Roder, J; Jeromin, A				Weisz, OA; Gibson, GA; Leung, SM; Roder, J; Jeromin, A			Overexpression of frequenin, a modulator of phosphatidylinositol 4-kinase, inhibits biosynthetic delivery of an apical protein in polarized Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; GOLGI-COMPLEX; SECRETION; TRANSPORT; KINASE; ACTIN; PHOSPHOINOSITIDES; CHROMAFFIN; HOMOLOG; CLONING	Polyphosphoinositides regulate numerous steps in membrane transport. The levels of individual phosphatidylinositols are controlled by specific lipid kinases, whose activities and localization are in turn regulated by a variety of effecters. Here we have examined the effect of overexpression of frequenin, a modulator of phosphatidylinositol 4-kinase activity, on biosynthetic and postendocytic traffic in polarized Madin-Darby canine kidney cells. Endogenous frequenin was identified in these cells by polymerase chain reaction, Western blotting, and indirect immunofluorescence. Adenoviral-mediated overexpression of frequenin had no effect on early Golgi transport of membrane proteins, as assessed by acquisition of resistance to endoglycosidase H. However, delivery of newly synthesized influenza hemagglutinin from the trans-Golgi network to the apical cell surface was severely inhibited in cells overexpressing frequenin, whereas basolateral delivery of the polymeric immunoglobulin receptor was unaffected. Overexpression of frequenin did not affect postendocytic trafficking steps including apical and basolateral recycling and basal-to-apical transcytosis. We conclude that frequenin, and by inference, phosphatidylinositol 4-kinase, plays an important and selective role in apical delivery in polarized cells.	Univ Pittsburgh, Renal Electrolyte Div, Lab Epithelial Cell Biol, Pittsburgh, PA 15261 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Weisz, OA (corresponding author), Univ Pittsburgh, Renal Electrolyte Div, Lab Epithelial Cell Biol, 3550 Terrace St, Pittsburgh, PA 15261 USA.	weisz@msx.dept-med.pitt.edu	Roder, John/G-6468-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054407] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK54407] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chernomordik L, 1996, CHEM PHYS LIPIDS, V81, P203, DOI 10.1016/0009-3084(96)02583-2; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Fang M, 1998, BBA-MOL CELL RES, V1404, P85, DOI 10.1016/S0167-4889(98)00049-4; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Henkel JR, 1998, MOL BIOL CELL, V9, P2477, DOI 10.1091/mbc.9.9.2477; Henkel JR, 2000, J CELL BIOL, V148, P495, DOI 10.1083/jcb.148.3.495; Henkel JR, 1998, J BIOL CHEM, V273, P6518, DOI 10.1074/jbc.273.11.6518; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; Lorra C, 1999, NAT CELL BIOL, V1, pE113, DOI 10.1038/12939; Ma L, 1998, J CELL BIOL, V140, P1125; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; Sorensen SD, 1998, MOL PHARMACOL, V53, P827; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Werle MJ, 2000, NEUROSCI LETT, V284, P33, DOI 10.1016/S0304-3940(00)01004-1; Wiedemann C, 1998, J NEUROSCI, V18, P5594; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236	31	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24341	24347		10.1074/jbc.M000671200	http://dx.doi.org/10.1074/jbc.M000671200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10825156	hybrid			2022-12-25	WOS:000088683300015
J	Guerre-Millo, M; Gervois, P; Raspe, E; Madsen, L; Poulain, P; Derudas, B; Herbert, JM; Winegar, DA; Willson, TM; Fruchart, JC; Berge, RK; Staels, B				Guerre-Millo, M; Gervois, P; Raspe, E; Madsen, L; Poulain, P; Derudas, B; Herbert, JM; Winegar, DA; Willson, TM; Fruchart, JC; Berge, RK; Staels, B			Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PPAR-GAMMA ACTIVATORS; IMPAIRED GLUCOSE-TOLERANCE; HIGH-FAT DIET; IN-VIVO; LIPOPROTEIN METABOLISM; RESISTANCE SYNDROME; LIPID AVAILABILITY; INDUCED INHIBITION; ZUCKER RATS	Fibrates and glitazones are two classes of drugs currently used in the treatment of dyslipidemia and insulin resistance (IR), respectively. Whereas glitazones are insulin sensitizers acting via activation of the peroxisome proliferator-activated receptor (PPAR) gamma subtype, fibrates exert their lipid-lowering activity via PPAR alpha. To determine whether PPAR alpha activators also improve insulin sensitivity, we measured the capacity of three PPAR alpha-selective agonists, fenofibrate, ciprofibrate, and the new compound GW9578, in two rodent models of high fat diet-induced (C57BL/6 mice) or genetic (obese Zucker rats) IR. At doses yielding serum concentrations shown to activate selectively PPAR alpha, these compounds markedly lowered hyperinsulinemia and, when present, hyperglycemia in both animal models. This effect relied on the improvement of insulin action on glucose utilization, as indicated by a lower insulin peak in response to intraperitoneal glucose in ciprofibrate-treated IR obese Zucker rats. In addition, fenofibrate treatment prevented high fat diet-induced increase of body weight and adipose tissue mass without influencing caloric intake. The specificity for PPAR alpha activation in vivo was demonstrated by marked alterations in the expression of PPAR alpha target genes, whereas PPAR gamma target gene mRNA levels did not change in treated animals. These results indicate that compounds with a selective PPAR alpha activation profile reduce insulin resistance without having adverse effects on body weight and adipose tissue mass in animal models of IR.	Inst Biomed Cordeliers, INSERM, U465, F-75006 Paris, France; Inst Pasteur, Dept Atherosclerose, INSERM, U325, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59006 Lille, France; Univ Bergen, Haukeland Hosp, Dept Biol Clin, Div Biochem, N-5021 Bergen, Norway; Sanofi Rech, F-31036 Toulouse, France; Glaxo Wellcome Res & Dev, Res Triangle Pk, NC 27709 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; University of Bergen; Haukeland University Hospital; Sanofi-Aventis; Sanofi France; GlaxoSmithKline	Staels, B (corresponding author), Inst Pasteur, Dept Atherosclerose, INSERM, U325, 1 Rue Calmette, F-59019 Lille, France.	bart.staels@pasteur-lille.fr	feinstein, doug/M-9414-2019; Staels, Bart/N-9497-2016; Madsen, Lise/C-6246-2012; Guerre-Millo, Michele/G-7253-2017	Staels, Bart/0000-0002-3784-1503; Madsen, Lise/0000-0003-4468-1947; 				ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; BAZIN R, 1982, J LIPID RES, V23, P839; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; Brown PJ, 1999, J MED CHEM, V42, P3785, DOI 10.1021/jm9903601; DESOUZA CJ, 1995, DIABETES, V44, P984, DOI 10.2337/diabetes.44.8.984; Despres Jean-Pierre, 1994, Current Opinion in Lipidology, V5, P274, DOI 10.1097/00041433-199408000-00006; DESPRES JP, 1993, NUTRITION, V9, P452; DeVos P, 1996, J CLIN INVEST, V98, P1004, DOI 10.1172/JCI118860; Goodpaster BH, 1998, CURR OPIN LIPIDOL, V9, P231, DOI 10.1097/00041433-199806000-00008; Hallakou S, 1997, DIABETES, V46, P1393, DOI 10.2337/diabetes.46.9.1393; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; Houseknecht KL, 1998, BIOCHEM BIOPH RES CO, V244, P678, DOI 10.1006/bbrc.1998.8303; HUTTUNEN JK, 1991, ANN MED, V23, P155, DOI 10.3109/07853899109148041; Inoue I, 1995, METABOLISM, V44, P1626, DOI 10.1016/0026-0495(95)90085-3; INOUE I, 1994, DIABETES RES CLIN PR, V25, P199, DOI 10.1016/0168-8227(94)90009-4; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; JONES IR, 1990, DIABETES CARE, V13, P855, DOI 10.2337/diacare.13.8.855; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Madej A, 1998, INT J CLIN PHARM TH, V36, P345; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Matsui HR, 1997, DIABETES, V46, P348, DOI 10.2337/diabetes.46.3.348; Mayorek N, 1997, DIABETES, V46, P1958, DOI 10.2337/diabetes.46.12.1958; MIKHAILIDIS DP, 1990, J CARDIOVASC PHARM, V16, pS26, DOI 10.1097/00005344-199006169-00006; Miles PDG, 1997, DIABETES, V46, P1678, DOI 10.2337/diabetes.46.11.1678; Morin CL, 1997, ENDOCRINOLOGY, V138, P4665, DOI 10.1210/en.138.11.4665; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Murakami K, 1998, DIABETES, V47, P1841, DOI 10.2337/diabetes.47.12.1841; OAKES ND, 1994, DIABETES, V43, P1203, DOI 10.2337/diabetes.43.10.1203; Oakes ND, 1997, METABOLISM, V46, P935, DOI 10.1016/S0026-0495(97)90083-4; Peraldi P, 1997, J CLIN INVEST, V100, P1863, DOI 10.1172/JCI119715; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; RANDLE PJ, 1963, LANCET, V1, P785; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Schoonjans K, 1997, CURR OPIN LIPIDOL, V8, P159, DOI 10.1097/00041433-199706000-00006; Schwartz S, 1998, NEW ENGL J MED, V338, P861, DOI 10.1056/NEJM199803263381302; Souza SC, 1998, DIABETES, V47, P691, DOI 10.2337/diabetes.47.4.691; Staels B, 1998, CIRCULATION, V98, P2088, DOI 10.1161/01.CIR.98.19.2088; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Willson TM, 1997, CURR OPIN CHEM BIOL, V1, P235, DOI 10.1016/S1367-5931(97)80015-4; Zhang B, 1996, J BIOL CHEM, V271, P9455, DOI 10.1074/jbc.271.16.9455	46	517	547	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16638	16642		10.1074/jbc.275.22.16638	http://dx.doi.org/10.1074/jbc.275.22.16638			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828060	hybrid			2022-12-25	WOS:000087392200035
J	Bell, R; Stevens, WK; Jia, ZC; Samis, J; Cote, HCF; MacGillivray, RTA; Nesheim, ME				Bell, R; Stevens, WK; Jia, ZC; Samis, J; Cote, HCF; MacGillivray, RTA; Nesheim, ME			Fluorescence properties and functional roles of tryptophan residues 60d, 96, 148, 207, and 215 of thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ALPHA-THROMBIN; PRO-TRP INSERTION; PROTEIN-C; FACTOR-V; FIBRINOLYSIS INHIBITOR; CRYSTAL-STRUCTURE; ANTITHROMBIN-III; EXTINCTION COEFFICIENTS; CATALYZED ACTIVATION; KUNITZ INHIBITORS	Conservative Trp-to-Phe mutations were individually created in human thrombin at positions 60d, 96, 148, 207, and 215. Fluorescence intensities for these residues varied by a factor of 6. Residues 60d, 96, 148, and 215 transferred energy to the thrombin inhibitor 5-dimethylaminonaphthalene-1-sulfonylarginine-N- (3-ethyl-1,5-pentanediyl)amide efficiently, but residue 207 did not. Intensities correlated inversely with exposure to solvent, and measured and theoretical energy transfer efficiencies agreed well. Function was measured with respect to fibrinogen clotting, platelet and factor V activation, inhibition by antithrombin, and the thrombomodulin-dependent activation of protein C and thrombin-activable fibrinolysis inhibitor (TAFI). All activities of W96F and W207F ranged from 74 to 154% of the wild-type activity. This was also true for W148F, except for inhibition by antithrombin, where it showed 60% activity. W60dF was deficient by 30, 57, and 43% with fibrinogen clotting, platelet activation, and factor V cleavage (Arg(1006)), respectively. W215F was deficient by 90, 55, and 56% with fibrinogen clotting, platelet activation, and factor V cleavage (Arg(1536)). With protein C and TAFI, W96F, W148F, and W207F were normal. W60dF, however, was 76 and 23% of normal levels with protein C and TAFI, respectively. In contrast, W215F was 25 and 124% of normal levels in these reactions. Thus, many activities of thrombin are retained upon substitution of Trp with Phe at positions 96, 148, and 207. Trp(60d), however, appears to be very important for TAFI activation, and Trp(215) appears to very important for clotting and protein C activation.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Univ British Columbia, Dept Biochem, Vancouver, BC V6T 1Z3, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada; University of British Columbia	Nesheim, ME (corresponding author), Queens Univ, Dept Biochem, Botterell Hall,Rm A212,Stuart St, Kingston, ON K7L 3N6, Canada.		Cote, Helene/K-7896-2012					Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BANFIELD DK, 1992, P NATL ACAD SCI USA, V89, P2779, DOI 10.1073/pnas.89.7.2779; BLOMBACK B, 1967, NATURE, V215, P1445, DOI 10.1038/2151445a0; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BOUTON MC, 1995, EUR J BIOCHEM, V229, P526, DOI 10.1111/j.1432-1033.1995.0526k.x; Callis PR, 1997, METHOD ENZYMOL, V278, P113; COTE HCF, 1994, J BIOL CHEM, V269, P11374; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DiBella EE, 1996, BIOCHEMISTRY-US, V35, P4427, DOI 10.1021/bi952617c; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; ESMON CT, 1991, ANN NY ACAD SCI, V614, P30, DOI 10.1111/j.1749-6632.1991.tb43689.x; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG CS, 1987, BLOOD, V69, P867; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; Kokame K, 1998, J BIOL CHEM, V273, P12135, DOI 10.1074/jbc.273.20.12135; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P303; LEBONNIEC BF, 1994, BIOCHEMISTRY-US, V33, P3959, DOI 10.1021/bi00179a023; LEBONNIEC BF, 1993, J BIOL CHEM, V268, P19055; LEBONNIEC BF, 1992, J BIOL CHEM, V267, P19341; LORD ST, 1990, J BIOL CHEM, V265, P838; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; LUNDBLAD RL, 1984, J BIOL CHEM, V259, P6991; Malkowski MG, 1997, PROTEIN SCI, V6, P1438, DOI 10.1002/pro.5560060708; Malkowski MG, 1997, BIOCHEM J, V326, P815, DOI 10.1042/bj3260815; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Meagher JL, 1998, J BIOL CHEM, V273, P23283, DOI 10.1074/jbc.273.36.23283; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; NESHEIM M, 1986, J BIOL CHEM, V261, P3214; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1984, J BIOL CHEM, V259, P3187; NOWAK W, 1993, J MOL STRUCT THEOCHE, V283, P1; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PARKINSON JF, 1992, BIOCHEM BIOPH RES CO, V185, P567, DOI 10.1016/0006-291X(92)91662-A; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; RICHMOND TJ, 1984, J MOL BIOL, V178, P63, DOI 10.1016/0022-2836(84)90231-6; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; SILVERBERG SA, 1980, J BIOL CHEM, V255, P8550; STEINBERG IZ, 1971, ANNU REV BIOCHEM, V40, P83, DOI 10.1146/annurev.bi.40.070171.000503; STEVENS WK, 1993, BIOCHEMISTRY-US, V32, P2787, DOI 10.1021/bi00062a008; Stevens WK, 1996, J BIOL CHEM, V271, P8062, DOI 10.1074/jbc.271.14.8062; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; THOMPSON EA, 1988, THROMB HAEMOSTASIS, V59, P415; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; UHTEG LC, 1977, BIOCHIM BIOPHYS ACTA, V491, P551, DOI 10.1016/0005-2795(77)90300-2; Wang W, 2000, J BIOL CHEM, V275, P22942, DOI 10.1074/jbc.M001760200	58	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29513	29520		10.1074/jbc.M001759200	http://dx.doi.org/10.1074/jbc.M001759200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10831587	hybrid			2022-12-25	WOS:000089439800045
J	de Vocht, ML; Reviakine, I; Wosten, HAB; Brisson, A; Wessels, JGH; Robillard, GT				de Vocht, ML; Reviakine, I; Wosten, HAB; Brisson, A; Wessels, JGH; Robillard, GT			Structural and functional role of the disulfide bridges in the hydrophobin SC3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNGAL HYDROPHOBIN; AERIAL HYPHAE; SCHIZOPHYLLUM-COMMUNE; RODLET LAYER; PROTEINS; SURFACE; DISEASE	Hydrophobins function in fungal development by self-assembly at hydrophobic-hydrophilic interfaces such as the interface between the fungal cell wall and the air or a hydrophobic solid. These proteins contain eight conserved cysteine residues that form four disulfide bonds. To study the effect of the disulfide bridges on the self-assembly, the disulfides of the SC3 hydrophobin were reduced with 1,4-dithiothreitol, The free thiols were then blocked with either iodoacetic acid (IAA) or iodoacetamide (WM), introducing eight or zero negative charges, respectively. Circular dichroism and infrared spectroscopy showed that after opening of the disulfide bridges SC3 is initially unfolded. IAA-SC3 did not self-assemble at the air-water interface upon shaking an aqueous solution. Remarkably, after drying down IAA-SC3 or after exposing it to Teflon, it refolded into a structure similar to that observed for native SC3 at these interfaces. Iodoacetamide-SC3 on the other hand, which does not contain extra charges, spontaneously refolded in water in the amyloid-like beta-sheet conformation, characteristic for SC3 assembled at the water-air interface. From this we conclude that the disulfide bridges of SC3 are not directly involved in self-assembly but keep hydrophobin monomers soluble in the fungal cell or its aqueous environment, preventing premature self-assembly.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands	University of Groningen	Robillard, GT (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Reviakine, Ilya/B-2631-2013; Wösten, Han AB/K-2769-2016	Reviakine, Ilya/0000-0002-3448-5072; Wösten, Han AB/0000-0002-0399-3648				BETZ SF, 1993, PROTEIN SCI, V2, P1551, DOI 10.1002/pro.5560021002; BRASH JL, 1995, ACS SYM SER, V602, P1; de Vocht ML, 1998, BIOPHYS J, V74, P2059, DOI 10.1016/S0006-3495(98)77912-3; DEVRIES OMH, 1993, ARCH MICROBIOL, V159, P330, DOI 10.1007/BF00290915; Dufrene YF, 1999, J BACTERIOL, V181, P5350; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; HAYNES CA, 1995, J COLLOID INTERF SCI, V169, P313, DOI 10.1006/jcis.1995.1039; HOLLECKER M, 1989, PROTEIN STRUCTURE PR, P145; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Lugones LG, 1998, MICROBIOL-UK, V144, P2345, DOI 10.1099/00221287-144-8-2345; Talbot NJ, 1996, PLANT CELL, V8, P985, DOI 10.1105/tpc.8.6.985; Taubes G, 1996, SCIENCE, V271, P1493, DOI 10.1126/science.271.5255.1493; Wessels JGH, 1997, ADV MICROB PHYSIOL, V38, P1; WESSELS JGH, 1991, PLANT CELL, V3, P793; WESSELS JGH, 1991, J GEN MICROBIOL, V137, P2439, DOI 10.1099/00221287-137-10-2439; Wosten HAB, 1999, CURR BIOL, V9, P85, DOI 10.1016/S0960-9822(99)80019-0; WOSTEN HAB, 1993, PLANT CELL, V5, P1567; WOSTEN HAB, 1994, EMBO J, V13, P5848, DOI 10.1002/j.1460-2075.1994.tb06929.x; WOSTEN HAB, 1994, EUR J CELL BIOL, V63, P122; YAGUCHI M, 1993, DUTCH ELM DISEASE RESEARCH, P152	21	87	97	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28428	28432		10.1074/jbc.M000691200	http://dx.doi.org/10.1074/jbc.M000691200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10829014	hybrid, Green Published			2022-12-25	WOS:000089330700014
J	Richard, DE; Berra, E; Pouyssegur, J				Richard, DE; Berra, E; Pouyssegur, J			Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1 alpha in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; UBIQUITIN-PROTEASOME PATHWAY; FACTOR GENE-EXPRESSION; ANGIOTENSIN-II; TRANSCRIPTIONAL ACTIVATION; CRITICAL COMPONENT; OXIDASE; HIF-1-ALPHA; PROTEIN; TRANSACTIVATION	Hypoxia-inducible factor-1 (HIF-1) controls the expression of a number of genes such as vascular endothelial growth factor (VEGF) and Erythropoietin in low oxygen conditions (hypoxia), VEGF is strongly induced at both the mRNA and protein expression level by a number of hormones and growth factors in vascular smooth muscle cells (VSMC) independently of the oxygen environment. However, the role of HIF-1 alpha in this induction has not been studied. We report here that HIF-1 alpha protein levels are strongly increased by fetal calf serum in quiescent VSMC, More interestingly, Angiotensin II (Ang II), thrombin, platelet-derived growth factor, and other hormones can also increase HIF-1 alpha in VSMC to levels that are substantially more elevated than the hypoxic treatment. HIF-1 alpha induced by Ang II is located in the nucleus, binds to the hypoxic response element, and is transcriptionally active. The induction of HIF-1 alpha by hormones is mediated through the production of reactive oxygen species (ROS), since it can be blocked by the ROS inhibitors, diphenyleneiodonium and catalase. Finally, strong induction of VEGF mRNA by Ang II can also be inhibited by these ROS inhibitors. These results implicate HIF-1 alpha and HIF-1-dependent transcriptional activity in the induction of VEGF expression after agonist stimulation and define novel hypoxia-independent mechanisms that should play a major role in vascular remodeling.	Ctr Antoine Lacassagne, UMR CNRS 6543, Inst Signaling Dev Biol & Canc Res, F-06189 Nice, France	UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Richard, DE (corresponding author), Ctr Antoine Lacassagne, UMR CNRS 6543, Inst Signaling Dev Biol & Canc Res, 33 Ave Valombrose, F-06189 Nice, France.		Berra, Edurne/F-9692-2011; Richard, Darren E./K-6760-2019	Berra, Edurne/0000-0002-3820-5744; Richard, Darren/0000-0003-2690-0480				Agani F, 1998, MOL PHARMACOL, V54, P749, DOI 10.1124/mol.54.5.749; Brar SS, 1999, J BIOL CHEM, V274, P20017, DOI 10.1074/jbc.274.28.20017; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Feldser D, 1999, CANCER RES, V59, P3915; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; LI H, 1994, J BIOL CHEM, V269, P28098; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wenger RH, 1996, BLOOD, V87, P756, DOI 10.1182/blood.V87.2.756.bloodjournal872756; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WILLIAMS B, 1995, HYPERTENSION, V25, P913, DOI 10.1161/01.HYP.25.5.913; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	44	538	572	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26765	26771						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10837481				2022-12-25	WOS:000089144800015
J	Castagliuolo, I; Valenick, L; Liu, J; Pothoulakis, C				Castagliuolo, I; Valenick, L; Liu, J; Pothoulakis, C			Epidermal growth factor receptor transactivation mediates substance P-induced mitogenic responses in U-373 MG cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; INFLAMMATORY BOWEL-DISEASE; SMOOTH-MUSCLE CELLS; EGF RECEPTOR; FACTOR-I; SIGNALING CASCADES; ASTROCYTOMA-CELLS; HORMONE RECEPTORS; EPITHELIAL-CELLS; ANGIOTENSIN-II	Ligand-induced activation of G protein-coupled receptors is emerging as an important pathway leading to the activation of certain receptors with intrinsic tyrosine kinase activity, such as the epidermal growth factor receptor (EGFR). Substance P (SP) exerts many effects via activation of its G protein-coupled receptor (neurokinin-l, NIF-l). SP participates in acute inflammation and activates hey proteins involved in mitogenic pathways, such mitogen-activated protein kinases (MAPKs), stimulating DNA synthesis. We tested the hypothesis that SP-induced MAPK activation and DNA synthesis require activation of the EGFR. In U-373 MG cells, which express functional NK-1, SP induced tyrosine phosphorylation of several proteins including EGFR. SP induced formation of an activated EGFR complex containing the adapter proteins SHC and Grb2, but not c-Src. SP activated the MAPK pathway as shown by increased Erk2 kinase activity. SP induced Erk2 activation, and DNA synthesis was inhibited in cells transfected with a dominant negative EGFR plasmid lacking kinase activity, as well as in cells treated with a specific EGFR inhibitor. In addition, pertussis toxin, an inhibitor of G alpha(i) protein subunits, prevented SP-induced EGFR transactivation and subsequent DNA synthesis. Our results implicate EGFR as an essential regulator in SP/NK-1-induced activation of the MAPK pathway and cell proliferation in U-373 MG cells, and these events are mediated by a pertussis toxin-sensitive G alpha protein. We suggest that this mechanism by which SP controls cell proliferation is an important pathway in tissue restoration and healing.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Castagliuolo, I (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Gastroenterol, Dana 501,330 Brookline Ave, Boston, MA 02215 USA.		CASTAGLIUOLO, IGNAZIO/K-9963-2016	CASTAGLIUOLO, IGNAZIO/0000-0001-9888-7030				BARSHAVIT Z, 1980, BIOCHEM BIOPH RES CO, V94, P1445, DOI 10.1016/0006-291X(80)90581-1; BENRATH J, 1995, NEUROSCI LETT, V200, P17, DOI 10.1016/0304-3940(95)12062-9; Bhatia M, 1998, P NATL ACAD SCI USA, V95, P4760, DOI 10.1073/pnas.95.8.4760; Binion DG, 1997, GASTROENTEROLOGY, V112, P1895, DOI 10.1053/gast.1997.v112.pm9178682; BOSIC CR, 1996, SCIENCE, V273, P1722; Brain SD, 1997, IMMUNOPHARMACOLOGY, V37, P133, DOI 10.1016/S0162-3109(97)00055-6; Castagliuolo I, 1998, J CLIN INVEST, V101, P1547, DOI 10.1172/JCI2039; Castagliuolo I, 1997, P NATL ACAD SCI USA, V94, P4788, DOI 10.1073/pnas.94.9.4788; Chiarugi V, 1998, INT J MOL MED, V2, P715; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DiversePierluissi M, 1997, P NATL ACAD SCI USA, V94, P5417, DOI 10.1073/pnas.94.10.5417; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EISTETTER HR, 1992, GLIA, V6, P89, DOI 10.1002/glia.440060203; GALANDIUK S, 1993, ARCH SURG-CHICAGO, V128, P637; GARCIA M, 1994, BIOCHEM PHARMACOL, V48, P1735, DOI 10.1016/0006-2952(94)90459-6; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAUCK W, 1995, J BIOL CHEM, V270, P3602, DOI 10.1074/jbc.270.8.3602; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; KAHLER CM, 1993, J CELL PHYSIOL, V156, P579, DOI 10.1002/jcp.1041560318; Kahler CM, 1996, J CELL PHYSIOL, V166, P601; KJARTANSSON J, 1987, PLAST RECONSTR SURG, V79, P218, DOI 10.1097/00006534-198702000-00012; LEE CM, 1989, BRAIN RES, V488, P328, DOI 10.1016/0006-8993(89)90724-5; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; LOTZ M, 1987, SCIENCE, V235, P893, DOI 10.1126/science.2433770; Luo WH, 1996, CANCER RES, V56, P4983; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; MANTYH CR, 1988, P NATL ACAD SCI USA, V85, P3235, DOI 10.1073/pnas.85.9.3235; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; Nakamura M, 1998, BIOCHEM BIOPH RES CO, V246, P777, DOI 10.1006/bbrc.1998.8704; Nakamura M, 1997, EXP EYE RES, V65, P321, DOI 10.1006/exer.1997.0345; Nakamura M, 1999, BRIT J PHARMACOL, V127, P489, DOI 10.1038/sj.bjp.0702550; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; Nishimura K, 1998, J RECEPT SIGNAL TR R, V18, P51, DOI 10.3109/10799899809039164; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; PALMA C, 1995, J NEUROIMMUNOL, V59, P155, DOI 10.1016/0165-5728(95)00040-9; PAYAN DG, 1983, J IMMUNOL, V131, P1613; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PERNOW B, 1983, PHARMACOL REV, V35, P85; Pothoulakis C, 1998, AM J PHYSIOL-GASTR L, V275, pG68, DOI 10.1152/ajpgi.1998.275.1.G68; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Reubi JC, 1996, GASTROENTEROLOGY, V110, P1719, DOI 10.1053/gast.1996.v110.pm8964396; Roush ED, 1998, FEBS LETT, V428, P291, DOI 10.1016/S0014-5793(98)00553-5; RUFF MR, 1985, PEPTIDES S, V2, P107; SHARIF M, 1994, MOL CELL ENDOCRINOL, V100, P115, DOI 10.1016/0303-7207(94)90289-5; SHARKEY KA, 1992, ANN NY ACAD SCI, V664, P425; Solomon MJ, 1998, WORLD J SURG, V22, P352, DOI 10.1007/s002689900396; VAN BT, 1995, NATURE, V376, P781; WEIDERMANN CJ, 1989, N-S ARCH PHARMACOL, V340, P185; Wiedermann CJ, 1996, EUR J PHARMACOL, V298, P335, DOI 10.1016/0014-2999(95)00818-7	55	100	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26545	26550		10.1074/jbc.M003990200	http://dx.doi.org/10.1074/jbc.M003990200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10846186	hybrid			2022-12-25	WOS:000088999700091
J	Feinberg, MW; Jain, MK; Werner, F; Sibinga, NES; Wiesel, P; Wang, H; Topper, JN; Perrella, MA; Lee, ME				Feinberg, MW; Jain, MK; Werner, F; Sibinga, NES; Wiesel, P; Wang, H; Topper, JN; Perrella, MA; Lee, ME			Transforming growth factor-ss 1 inhibits cytokine-mediated induction of human metalloelastase in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MATRIX-DEGRADING METALLOPROTEINASES; TGF-BETA; ATHEROSCLEROTIC PLAQUES; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; INCREASED EXPRESSION; STROMELYSIN GENE; SMAD PROTEINS; COLLAGENASE	Matrix metalloproteinases (MMP) have been identified in vulnerable areas of atherosclerotic plaques and may contribute to plaque instability through extracellular matrix degradation. Human metalloelastase (MMP-12) is a macrophage-specific MMP with broad substrate specificity and is capable of degrading proteins found in the extracellular matrix of atheromas, Despite its potential importance, little is known about the regulation of MMP-12 expression in the context of atherosclerosis. In this study, we report that in human peripheral blood-derived macrophages, MMP-12 mRNA was markedly upregulated by several pro-atherosclerotic cytokines and growth factors including interleukin-1 beta, tumor necrosis factor-alpha, macrophage colony-stimulating factor, vascular endothelial growth factor, and platelet-derived growth factor-BB. In contrast, the pleiotropic anti-inflammatory growth factor transforming growth factor-beta 1 (TGF-beta 1) inhibited cytokine-mediated induction of MMP-12 mRNA, protein, and enzymatic activity. Analyses of MMP-12 promoter through transient transfections and electrophoretic mobility shift assays indicated that both its induction by cytokines and its inhibition by TGF-beta 1 depended on signaling through an AP-1 site at -81 base pairs. Moreover, the inhibitory effect of TGF-beta 1 on MMP-12 was dependent on Smad3. Taken together, MMP-12 is induced by several factors implicated in atherosclerosis. The inhibition of MMP-12 expression by TGF-beta 1 suggests that TGF-beta 1, acting via Smad3, may promote plaque stability.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Program Dev Cardiovasc Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Stanford Univ, Sch Med, Dept Med, Div Cardiovasc, Stanford, CA 94305 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Stanford University	Feinberg, MW (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, 75 Francis St,Thorn 11, Boston, MA 02115 USA.		Sibinga, Nicholas/GOJ-8544-2022	Feinberg, Mark/0000-0001-9523-3859; Sibinga, Nicholas/0000-0003-4838-910X	NHLBI NIH HHS [HL03914, HL03747, HL03274] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUSUBEL FM, 1993, SHORT PROTOCOLS MOL; BANDA MJ, 1981, BIOCHEM J, V193, P589, DOI 10.1042/bj1930589; BELAAOUAJ A, 1995, J BIOL CHEM, V270, P14568, DOI 10.1074/jbc.270.24.14568; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOTTALICO LA, 1991, J BIOL CHEM, V266, P22866; BROWN DL, 1995, CIRCULATION, V91, P2125, DOI 10.1161/01.CIR.91.8.2125; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; CHAMBERLAIN SH, 1993, J CELL BIOCHEM, V52, P337, DOI 10.1002/jcb.240520310; Chandler S, 1996, BIOCHEM BIOPH RES CO, V228, P421, DOI 10.1006/bbrc.1996.1677; Coligan JE., 1994, CURRENT PROTOCOLS IM; DAVID TJ, 1992, J ROY SOC MED, V85, P1; Ernofsson M, 1996, BRIT J HAEMATOL, V95, P249, DOI 10.1046/j.1365-2141.1996.d01-1893.x; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GAMBLE JR, 1995, ARTERIOSCL THROM VAS, V15, P949, DOI 10.1161/01.ATV.15.7.949; GRAINGER DJ, 1995, NAT MED, V1, P74, DOI 10.1038/nm0195-74; Gronski TJ, 1997, J BIOL CHEM, V272, P12189, DOI 10.1074/jbc.272.18.12189; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HENNEY AM, 1991, P NATL ACAD SCI USA, V88, P8154, DOI 10.1073/pnas.88.18.8154; HERRON GS, 1986, J BIOL CHEM, V261, P2814; HOFMANN M, 1993, CANCER RES, V53, P1516; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Johnson LL, 1998, CURR OPIN CHEM BIOL, V2, P466, DOI 10.1016/S1367-5931(98)80122-1; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li ZH, 1996, AM J PATHOL, V148, P121; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Matsumoto S, 1998, AM J PATHOL, V153, P109, DOI 10.1016/S0002-9440(10)65551-4; NIKKARI ST, 1995, CIRCULATION, V92, P1393, DOI 10.1161/01.CIR.92.6.1393; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J., 2002, MOL CLONING LAB MANU; Schulick AH, 1998, P NATL ACAD SCI USA, V95, P6983, DOI 10.1073/pnas.95.12.6983; SHAH PK, 1995, CIRCULATION, V92, P1565; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; Takami S, 1998, CIRCULATION, V97, P721, DOI 10.1161/01.CIR.97.8.721; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36; White LA, 1995, MATRIX BIOL, V14, P715, DOI 10.1016/S0945-053X(05)80014-9; WIGHT TN, 1995, CURR OPIN LIPIDOL, V6, P326, DOI 10.1097/00041433-199510000-00013; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	58	135	141	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25766	25773		10.1074/jbc.M002664200	http://dx.doi.org/10.1074/jbc.M002664200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10825169	hybrid			2022-12-25	WOS:000088849400093
J	Leonard, DM; Stachelek, SJ; Safran, M; Farwell, AP; Kowalik, TF; Leonard, JL				Leonard, DM; Stachelek, SJ; Safran, M; Farwell, AP; Kowalik, TF; Leonard, JL			Cloning, expression, and functional characterization of the substrate binding subunit of rat type II iodothyronine 5 '-deiodinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE METABOLISM; STIMULATED GLIAL-CELLS; CEREBRAL-CORTEX; ACTIN POLYMERIZATION; INTRACELLULAR 3,5,3'-TRIIODOTHYRONINE; REVERSE TRIIODOTHYRONINE; 3'-UNTRANSLATED REGION; SELENIUM DEFICIENCY; ENZYME INACTIVATION; DIFFERENT PATHWAYS	Type II iodothyronine 5'-deiodinase catalyzes the bioactivation of thyroid hormone in the brain. In astrocytes, this similar to 200-kDa, membrane-bound enzyme is composed of at least one p29 subunit, an similar to 60-kDa, cAMP-induced activation protein, and one or more unidentified catalytic subunit(s), Recently, an artificial type II-like selenodeiodinase was engineered by fusing two independent cDNAs together; however, no native type II selenodeiodinase polypeptide is translated in the brain or brown adipose tissue of rats. These data suggest that the native type II 5'-deiodinase in rat brain is unrelated to this artificial selenoprotein. In this report, we describe the cloning of the 29-kDa subunit (p29) of type II 5'-deiodinase from a lambda zapII cDNA library prepared from cAMP-induced astrocytes, The 3.3-kilobase (kb) cDNA encodes an similar to 30-kDa, 277-amino acid long, hydrophobic protein lacking selenocysteine, Northern blot analysis showed that a 3.5-kb p29 mRNA was present in tissues showing type II 5'-deiodinase activity such as brain and cAMP-stimulated astrocytes, Domain-specific, anti-p29 antibodies specifically immunoprecipitated enzyme activity. Overexpression of exogenous p29 or a green fluorescence protein (GFP)-tagged p29 fusion protein led to a > 100-fold increase in deiodinating activity in cAMP-stimulated astrocytes, and the increased activity was specifically immunoprecipitated by anti-GFP antibodies. Steady-state reaction kinetics of the enzyme in GFP-tagged p29-expressing astrocytes are identical to those of the native enzyme in brain. Direct injection of replication-deficient Ad5-p29(GFP) virus particles into the cerebral cortex of neonatal rats leads to a similar to 2-fold increase in brain type II 5'-deiodinating activity. These data show 1) that the 3.3-kb p29 cDNA encodes an essential subunit of rat type II iodothyronine 5'-deiodinase and 2) identify the first non-selenocysteine containing subunit of the deiodinase family of enzymes.	Univ Massachusetts, Med Ctr,Sch Med, Dept Cellular & Mol Physiol, Mol Endocrinol Labs, Worcester, MA 01655 USA; Univ Massachusetts, Med Ctr,Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Leonard, JL (corresponding author), Univ Massachusetts, Med Ctr,Sch Med, Dept Cellular & Mol Physiol, Mol Endocrinol Labs, 55 Lake Ave N, Worcester, MA 01655 USA.			Farwell, Alan/0000-0001-7716-2719				ABEND SL, 1991, J CLIN INVEST, V88, P898, DOI 10.1172/JCI115392; ARTHUR JR, 1991, CAN J PHYSIOL PHARM, V69, P1648, DOI 10.1139/y91-243; BEHNE D, 1990, BIOCHEM BIOPH RES CO, V173, P1143, DOI 10.1016/S0006-291X(05)80905-2; BERRY MJ, 1991, ENDOCRINOLOGY, V129, P550, DOI 10.1210/endo-129-1-550; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; Buettner C, 1998, J BIOL CHEM, V273, P33374, DOI 10.1074/jbc.273.50.33374; CHANOINE JP, 1992, ENDOCRINOLOGY, V131, P1787, DOI 10.1210/en.131.4.1787; CHANOINE JP, 1992, ENDOCRINOLOGY, V131, P479, DOI 10.1210/en.131.1.479; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRANTZ FR, 1980, J CLIN INVEST, V65, P935, DOI 10.1172/JCI109749; CRANTZ FR, 1982, ENDOCRINOLOGY, V110, P367, DOI 10.1210/endo-110-2-367; Croteau W, 1996, J CLIN INVEST, V98, P405, DOI 10.1172/JCI118806; DAVEY JC, 1995, J BIOL CHEM, V270, P26786, DOI 10.1074/jbc.270.45.26786; Davey JC, 1999, ENDOCRINOLOGY, V140, P1022, DOI 10.1210/endo.140.2.6678; FARWELL AP, 1989, J BIOL CHEM, V264, P20561; FARWELL AP, 1992, ENDOCRINOLOGY, V131, P721, DOI 10.1210/en.131.2.721; Farwell AP, 1996, J BIOL CHEM, V271, P16369, DOI 10.1074/jbc.271.27.16369; FARWELL AP, 1993, J BIOL CHEM, V268, P5055; FARWELL AP, 1990, J BIOL CHEM, V265, P18546; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Gondou A, 1998, THYROID, V8, P615, DOI 10.1089/thy.1998.8.615; Guadano-Ferraz A, 1999, J NEUROSCI, V19, P3430; GuadanoFerraz A, 1997, P NATL ACAD SCI USA, V94, P10391, DOI 10.1073/pnas.94.19.10391; KAISER CA, 1986, ENDOCRINOLOGY, V119, P762, DOI 10.1210/endo-119-2-762; KOZAK M, 1990, NUCLEIC ACIDS RES, V18, P2828, DOI 10.1093/nar/18.9.2828; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEONARD JL, 1981, BIOCHIM BIOPHYS ACTA, V659, P205, DOI 10.1016/0005-2744(81)90285-0; LEONARD JL, 1985, BRAIN RES, V327, P1, DOI 10.1016/0006-8993(85)91493-3; Leonard JL, 1999, ENDOCRINOLOGY, V140, P2206, DOI 10.1210/en.140.5.2206; LEONARD JL, 1984, ENDOCRINOLOGY, V114, P998, DOI 10.1210/endo-114-3-998; LEONARD JL, 1990, J BIOL CHEM, V265, P940; Leonard JL, 1996, J CELL BIOCHEM, V61, P410, DOI 10.1002/(SICI)1097-4644(19960601)61:3<410::AID-JCB8>3.0.CO;2-W; LEONARD JL, 1988, BIOCHEM BIOPH RES CO, V151, P1164, DOI 10.1016/S0006-291X(88)80488-1; MEINHOLD H, 1992, ACTA MED AUST, V19, P8; MEINHOLD H, 1993, EXP CLIN ENDOCRINOL, V101, P87, DOI 10.1055/s-0029-1211212; Pallud S, 1997, J BIOL CHEM, V272, P18104, DOI 10.1074/jbc.272.29.18104; Ramauge M, 1996, ENDOCRINOLOGY, V137, P3021, DOI 10.1210/en.137.7.3021; Safran M, 1996, J BIOL CHEM, V271, P16363, DOI 10.1074/jbc.271.27.16363; SAFRAN M, 1993, J BIOL CHEM, V268, P14224; SAFRAN M, 1991, J BIOL CHEM, V266, P13477; SAFRAN M, 1991, J BIOL CHEM, V266, P3233; Salvatore D, 1999, BIOCHIMIE, V81, P535, DOI 10.1016/S0300-9084(99)80106-0; SALVATORE D, 1995, J CLIN INVEST, V96, P2421, DOI 10.1172/JCI118299; Salvatore D, 1996, ENDOCRINOLOGY, V137, P3308, DOI 10.1210/en.137.8.3308; Salvatore D, 1996, J CLIN INVEST, V98, P962, DOI 10.1172/JCI118880; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN QC, 1995, RNA, V1, P519; SHEN QC, 1993, J BIOL CHEM, V268, P11463; SIEGRISTKAISER CA, 1990, J BIOL CHEM, V265, P5296; SILVA JE, 1984, J CLIN INVEST, V73, P898, DOI 10.1172/JCI111313; SILVA JE, 1982, J CLIN INVEST, V69, P1176, DOI 10.1172/JCI110554; SILVA JE, 1985, ENDOCRINOLOGY, V116, P1627, DOI 10.1210/endo-116-4-1627; Steinsapir J, 1998, J CLIN INVEST, V102, P1895, DOI 10.1172/JCI4672; StGermain DL, 1997, THYROID, V7, P655; STGERMAIN DL, 1994, P NATL ACAD SCI USA, V91, P11282; Tu HM, 1997, ENDOCRINOLOGY, V138, P3359, DOI 10.1210/en.138.8.3359; VANDOORN J, 1982, ACTA ENDOCRINOL-COP, V101, P386, DOI 10.1530/acta.0.1010386; VANDOORN J, 1986, ACTA ENDOCRINOL-COP, V113, P59, DOI 10.1530/acta.0.1130059; VANDOORN J, 1983, J CLIN INVEST, V72, P1778, DOI 10.1172/JCI111138; VANDOORN J, 1984, ENDOCRINOLOGY, V115, P174, DOI 10.1210/endo-115-1-174; VISSER TJ, 1981, BIOCHEM BIOPH RES CO, V101, P1297, DOI 10.1016/0006-291X(81)91588-6; VISSER TJ, 1983, MOL CELL ENDOCRINOL, V33, P321, DOI 10.1016/0303-7207(83)90177-6; VISSER TJ, 1983, J CLIN INVEST, V71, P992, DOI 10.1172/JCI110854; VISSER TJ, 1982, P NATL ACAD SCI-BIOL, V79, P5080, DOI 10.1073/pnas.79.16.5080	65	30	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25194	25201		10.1074/jbc.M002036200	http://dx.doi.org/10.1074/jbc.M002036200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829019	hybrid			2022-12-25	WOS:000088849400022
J	Nogami, K; Shima, M; Hosokawa, K; Nagata, M; Koide, T; Saenko, EL; Tanaka, I; Shibata, M; Yoshioka, A				Nogami, K; Shima, M; Hosokawa, K; Nagata, M; Koide, T; Saenko, EL; Tanaka, I; Shibata, M; Yoshioka, A			Factor VIIIC2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg(1689)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; ABNORMAL FACTOR-VIII; ACTIVATED PROTEIN-C; PORCINE FACTOR-VIII; MILD HEMOPHILIA-A; FACTOR-XA; VONWILLEBRAND-FACTOR; LIGHT-CHAIN; PROCOAGULANT ACTIVITY; COMPLEX	Thrombin-catalyzed factor WI activation is an essential positive feedback mechanism regulating intrinsic blood coagulation. A factor VIII human. antibody, A-FF, with C2 epitope, exclusively inhibited factor VIII activation and cleavage at Arg(1689) by thrombin. The results suggested that A-FF prevented the interaction of thrombin with factor Vm and that the C2 domain was involved in the interaction with thrombin. We performed direct binding assays using anhydro-thrombin, a catalytically inactive derivative of thrombin in which the active-site serine is converted to dehydroalanine. Intact factor VIII, 80-kDa light chain, 72-kDa light chain, and heavy chain fragments bound dose-dependently to anhydro-thrombin, and the K-d values were 48, 150, 106, and 180 nM, respectively. The C2 and A2 domains also dose-dependently bound to anhydro-thrombin, and the K-d values were 440 and 488 nM, respectively. The Al domain did not bind to anhydro-thrombin. A-FF completely inhibited C2 domain binding to anhydro-thrombin (IC50, 18 nM), whereas it did not inhibit A2 domain binding. Furthermore, CS-specific affinity purified F(ab)'(2) of A-FF, and the recombinant Ca domain inhibited thrombin cleavage at Arg(1689). Our results indicate that the C2 domain contains the thrombin-binding site responsible for the cleavage at Arg(1689).	Nara Med Univ, Dept Pediat, Kashihara, Nara 6348522, Japan; Fujimori Kogyo Co, Nakahara Ku, Kawasaki, Kanagawa 2110067, Japan; Himeji Inst Technol, Fac Sci, Dept Life Sci, Harima, Hyogo 6781297, Japan; Amer Red Cross, Holland Lab, Rockville, MD 20855 USA	Nara Medical University; University of Hyogo; American Red Cross	Shima, M (corresponding author), Nara Med Univ, Dept Pediat, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.	mshima@nmu-gw.cc.naramed-u.ac.jp						EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J CLIN INVEST, V82, P123, DOI 10.1172/JCI113559; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HAMER RJ, 1987, EUR J BIOCHEM, V167, P253, DOI 10.1111/j.1432-1033.1987.tb13331.x; HOYER LW, 1981, BLOOD, V58, P1; KAMISUE S, 1994, BRIT J HAEMATOL, V86, P106, DOI 10.1111/j.1365-2141.1994.tb03259.x; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; KOEDAM JA, 1990, EUR J BIOCHEM, V189, P229, DOI 10.1111/j.1432-1033.1990.tb15481.x; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; NEUENSCHWANDER P, 1988, BLOOD, V72, P1761; Nogami K, 1999, J BIOL CHEM, V274, P31000, DOI 10.1074/jbc.274.43.31000; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; Parker ET, 1997, BIOCHEMISTRY-US, V36, P9365, DOI 10.1021/bi970599o; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; Prescott R, 1997, BLOOD, V89, P3663, DOI 10.1182/blood.V89.10.3663.3663_3663_3671; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; Saenko EL, 1997, J BIOL CHEM, V272, P18007, DOI 10.1074/jbc.272.29.18007; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; SCANDELLA D, 1995, BLOOD, V86, P1811, DOI 10.1182/blood.V86.5.1811.bloodjournal8651811; SHIMA M, 1995, BRIT J HAEMATOL, V91, P714, DOI 10.1111/j.1365-2141.1995.tb05374.x; SHIMA M, 1989, BLOOD, V74, P1612; SHIMA M, 1991, INT J HEMATOL, V54, P515; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; Suzuki H, 1997, THROMB HAEMOSTASIS, V77, P862; Thompson AR, 1997, BLOOD, V90, P1902, DOI 10.1182/blood.V90.5.1902; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TUDDENHAM EGD, 1994, NUCLEIC ACIDS RES, V22, P3511, DOI 10.1093/nar/22.17.3511; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	37	54	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25774	25780		10.1074/jbc.M002007200	http://dx.doi.org/10.1074/jbc.M002007200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10831589	hybrid			2022-12-25	WOS:000088849400094
J	Tjalsma, H; Stover, AG; Driks, A; Venema, G; Bron, S; van Dijl, JM				Tjalsma, H; Stover, AG; Driks, A; Venema, G; Bron, S; van Dijl, JM			Conserved serine and histidine residues are critical for activity of the ER-type signal peptidase SipW of Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; ENDOPLASMIC-RETICULUM MEMBRANE; PROTEIN TRANSLOCATION; ESCHERICHIA-COLI; PREPROTEIN TRANSLOCASE; CATALYTIC MECHANISM; FUNCTIONAL-ANALYSIS; SECRETORY PROTEINS; LEADER PEPTIDASE; IDENTIFICATION	Type I signal peptidases (SPases) are required for the removal of signal peptides from translocated proteins and, subsequently, release of the mature protein from the trans side of the membrane. Interestingly, prokaryotic (P-type) and endoplasmic reticular (ER-type) SPases are functionally equivalent, but structurally quite different, forming two distinct SPase families that share only few conserved residues. P-type SPases were, so far, exclusively identified in eubacteria and organelles, whereas ER-type SPases were found in the three kingdoms of life. Strikingly, the presence of ER-type SPases appears to be limited to sporulating Grampositive eubacteria. The present studies were aimed at the identification of potential active site residues of the ER-type SPase SipW of Bacillus subtilis, which is required for processing of the spore-associated protein Task Conserved serine, histidine, and aspartic acid residues are critical for SipW activity, suggesting that the ER-ty-pe SPases employ a Ser-His-Asp catalytic tried or, alternatively, a Ser-His catalytic dyad. In contrast, the P-type SPases employ a Ser-Lys catalytic dyed (Paetzel, M., Dalbey, R. E., and Strynadka, N. C. J. (1998) Nature 396, 186-190). Notably, catalytic activity of SipW was not only essential for pre-Task processing, but also for the incorporation of mature Task into spores.	Groningen Biomol Sci & Biotechnol Inst, Dept Genet, NL-9751 NN Haren, Netherlands; Loyola Univ, Med Ctr, Dept Microbiol & Immunol, Maywood, IL 60153 USA	University of Groningen; Loyola University Chicago	van Dijl, JM (corresponding author), Univ Groningen, Dept Pharmaceut Biol, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	j.m.van.dijl@farm.rug.nl	Tjalsma, Harold/I-7146-2012; van Dijl, Jan Maarten/G-1205-2013		NIGMS NIH HHS [GM539898] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BLACK MT, 1993, J BACTERIOL, V175, P4957, DOI 10.1128/JB.175.16.4957-4961.1993; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; Bolhuis A, 1999, J BIOL CHEM, V274, P15865, DOI 10.1074/jbc.274.22.15865; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; DenBlaauwen T, 1996, ARCH MICROBIOL, V165, P1, DOI 10.1007/s002030050289; Economou A, 1998, MOL MICROBIOL, V27, P511, DOI 10.1046/j.1365-2958.1998.00713.x; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; Kawarabayasi Y, 1998, DNA Res, V5, P147, DOI 10.1093/dnares/5.2.147; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Klenotic PA, 2000, J BIOL CHEM, V275, P6490, DOI 10.1074/jbc.275.9.6490; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LIN LL, 1989, J MOL BIOL, V210, P439, DOI 10.1016/0022-2836(89)90121-6; LITTLE JW, 1993, J BACTERIOL, V175, P4943, DOI 10.1128/JB.175.16.4943-4950.1993; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MASON JM, 1988, J BACTERIOL, V170, P239, DOI 10.1128/jb.170.1.239-244.1988; MEIJER WJJ, 1995, MOL MICROBIOL, V17, P621, DOI 10.1111/j.1365-2958.1995.mmi_17040621.x; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Pohlschroder M, 1997, CELL, V91, P563, DOI 10.1016/S0092-8674(00)80443-2; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Riezman H, 1997, SCIENCE, V278, P1728, DOI 10.1126/science.278.5344.1728; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Serrano M, 1999, J BACTERIOL, V181, P3632, DOI 10.1128/JB.181.12.3632-3643.1999; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; SIGNS SA, 1994, MOL CELL BIOCHEM, V139, P21, DOI 10.1007/BF00944199; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Stover AG, 1999, J BACTERIOL, V181, P7065; Stover AG, 1999, J BACTERIOL, V181, P1664; Stover AG, 1999, J BACTERIOL, V181, P5476; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; TALARICO TL, 1991, BIOCHEM BIOPH RES CO, V181, P650, DOI 10.1016/0006-291X(91)91240-D; Tjalsma H, 1999, J BACTERIOL, V181, P2448, DOI 10.1128/JB.181.8.2448-2454.1999; Tjalsma H, 1997, J BIOL CHEM, V272, P25983, DOI 10.1074/jbc.272.41.25983; Tjalsma H, 1998, GENE DEV, V12, P2318, DOI 10.1101/gad.12.15.2318; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; VANDIJL JM, 1991, MOL GEN GENET, V227, P40, DOI 10.1007/BF00260704; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANDIJL JM, 1995, J BIOL CHEM, V270, P3611, DOI 10.1074/jbc.270.8.3611; VanValkenburgh C, 1999, J BIOL CHEM, V274, P11519, DOI 10.1074/jbc.274.17.11519; von Heijne G, 1990, CURR OPIN CELL BIOL, V2, P604, DOI 10.1016/0955-0674(90)90100-S; von Heijne G, 1998, NATURE, V396, P111, DOI 10.1038/24036; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; Wickner W, 1996, J BIOL CHEM, V271, P29514, DOI 10.1074/jbc.271.47.29514	53	50	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25102	25108		10.1074/jbc.M002676200	http://dx.doi.org/10.1074/jbc.M002676200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827084	hybrid			2022-12-25	WOS:000088849400010
J	MacKenzie, SJ; Baillie, GS; McPhee, I; Bolger, GB; Houslay, MD				MacKenzie, SJ; Baillie, GS; McPhee, I; Bolger, GB; Houslay, MD			ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases - The involvement of COOH-terminal docking sites and NH2-terminal UCR regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-SPECIFIC PHOSPHODIESTERASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; MAP KINASE; TYROSINE-PHOSPHATASE; ROLIPRAM INHIBITION; INTERACTION MOTIF; PTP-SL; FAMILY; PATHWAY; CELLS	The cAMP-specific phosphodiesterase family 4, sub- family D, isoform 3 (PDE4D3) is shown to have FQF and RIM docking sites for extracellular signal-regulated kinase 2 (ERK2) (p42(MAPK)). These straddle the target residue, Ser(579), for ERK2 phosphorylation of PDE4D3. Mutation of either or both of these docking sites prevented ERK2 from being co-immunoprecipitated with PDE4D3, ablated the ability of epidermal growth factor to inhibit PDE4D3 through ERK2 action in transfected COS cells, and attenuated the ability of ERK2 to phosphorylate PDE4D3 in vitro. The two conserved NH2-terminal blocks of sequence, called upstream conserved regions 1 and 2 (UCR1 and UCR2), that characterize PDE4 long isoforms, are proposed to amplify the small, inherent inhibitory effect that ERK2 phosphorylation exerts on the PDE4D catalytic unit, In contrast to this, the lone intact UCR2 region found in PDE4D1 directs COOH-terminal ERK2 phosphorylation to cause the activation of this short isoform. From the analysis of PDE4D3 truncates, it is suggested that UCR1 and UCR2 provide a regulatory signal integration module that serves to orchestrate the functional consequences of ERK2 phosphorylation. The PDE4D gene thus encodes a series of isoenzymes that are either inhibited or activated by ERK2 phosphorylation and thereby offers the potential for ERK2 activation either to increase or decrease cAMP levels in cellular compartments.	Univ Glasgow, Div Biochem & Mol Biol, Mol Pharmacol Grp, IBLS, Glasgow G12 8QQ, Lanark, Scotland; Univ Utah, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84132 USA; Vet Affairs Med Ctr, Huntsman Canc Inst, Salt Lake City, UT 84132 USA	University of Glasgow; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Houslay, MD (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Mol Pharmacol Grp, IBLS, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	M.Houslay@bio.gla.ac.uk	Houslay, Miles/AAM-5281-2020; Houslay, Miles D/A-6825-2011	Houslay, Miles/0000-0002-3826-8091	NIGMS NIH HHS [R01-GM58553] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058553] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad F, 1999, J IMMUNOL, V162, P4864; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; Bolger GB, 1997, BIOCHEM J, V328, P539; BOLGER GB, 1994, CELL SIGNAL, V6, P851, DOI 10.1016/0898-6568(94)90018-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Granovsky AE, 1998, J BIOL CHEM, V273, P24485, DOI 10.1074/jbc.273.38.24485; HEYWORTH CM, 1983, BIOCHEM J, V214, P93, DOI 10.1042/bj2140093; Hoffmann R, 1998, BIOCHEM J, V333, P139, DOI 10.1042/bj3330139; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kolch W, 1996, ONCOGENE, V13, P1305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lenhard JM, 1996, BIOCHEM J, V316, P751, DOI 10.1042/bj3160751; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; MacKenzie SJ, 1998, P NATL ACAD SCI USA, V95, P3549, DOI 10.1073/pnas.95.7.3549; MANGANIELLO VC, 1995, ARCH BIOCHEM BIOPHYS, V322, P1, DOI 10.1006/abbi.1995.1429; MARCHMONT RJ, 1980, BIOCHEM J, V187, P381, DOI 10.1042/bj1870381; McPhee I, 1999, J BIOL CHEM, V274, P11796, DOI 10.1074/jbc.274.17.11796; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Murphy BJ, 1998, TRENDS CARDIOVAS MED, V8, P89, DOI 10.1016/S1050-1738(97)00131-X; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; Rogers DF, 1998, TRENDS PHARMACOL SCI, V19, P160, DOI 10.1016/S0165-6147(98)01198-5; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Souness JE, 1997, CELL SIGNAL, V9, P227, DOI 10.1016/S0898-6568(96)00173-8; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Turko IV, 1998, BIOCHEM J, V329, P505; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	44	193	197	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16609	16617		10.1074/jbc.275.22.16609	http://dx.doi.org/10.1074/jbc.275.22.16609			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828059	hybrid			2022-12-25	WOS:000087392200031
J	Varea, J; Saiz, JL; Lopez-Zumel, C; Monterroso, B; Medrano, FJ; Arrondo, JLR; Iloro, I; Laynez, J; Garcia, JL; Menendez, M				Varea, J; Saiz, JL; Lopez-Zumel, C; Monterroso, B; Medrano, FJ; Arrondo, JLR; Iloro, I; Laynez, J; Garcia, JL; Menendez, M			Do sequence repeats play an equivalent role in the choline-binding module of pneumococcal LytA amidase?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM SPECTRA; STREPTOCOCCUS-PNEUMONIAE; MOLECULAR CHARACTERIZATION; ULTRAVIOLET-ABSORPTION; THERMAL-DENATURATION; SCANNING CALORIMETRY; AQUEOUS-SOLUTIONS; AUTOLYSIN	LytA amidase breaks down the N-acetylmuramoyl-L-alanine bonds in the peptidoglycan backbone of Streptococcus pneumoniae, Its polypeptide chain has two modules: the NH2-terminal module, responsible for the catalytic activity, and the COOH-terminal module, constructed by six tandem repeats of 20 or 21 amino acids (p1-p6) and a short COOH-terminal tail. The polypeptide chain must contain at least four repeats to efficiently anchor the autolysin to the choline residues of the cell wall. Nevertheless, the catalytic efficiency decreases by 90% upon deletion of the final tail. The structural implications of deleting step by step the two last (p5 and p6) repeats and the final COOH-tail and their effects on choline-amidase interactions have been examined by comparing four truncated mutants with LytA amidase by means of different techniques. Removal of this region has minor effects on secondary structure content but significantly affects the stability of native conformations. The last 11 amino acids and the p5 repeat stabilize the COOH-terminal module; each increases the module transition temperature by about 6 degrees C, Moreover, the p5 motif also seems to participate, in a choline-dependent way, in the stabilization of the NH2-terminal module. The effects of choline binding on the thermal stability profile of the mutant lacking the p5 repeat might reflect a cooperative pathway providing molecular communication between the choline-binding module and the NH2-terminal region, The three sequence motives favor the choline-amidase interaction, but the tail is an essential factor in the monomer <----> dimer self-association equilibrium of LytA and its regulation by choline, The final tail is required for preferential interaction of choline with LytA dimers and for the existence of different sets of choline-binding sites. The p6 repeat scarcely affects the amidase stability but could provide the proper three dimensional orientation of the final tail.	CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain; CSIC, Ctr Invest Biol, E-28006 Madrid, Spain; Univ Basque Country, Dept Bioquim, Unidad Asociada CSIC, Grp Biomembranes, E-48080 Bilbao, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country	Menendez, M (corresponding author), CSIC, Inst Quim Fis Rocasolano, Serrano 119, E-28006 Madrid, Spain.	mmenendez@iqfr.csic.es	Monterroso, Begoña/J-9748-2014; Menendez, Margarita/M-1795-2014; Iloro, Ibon/L-6022-2014; Medrano, Francisco Javier/ABF-9860-2020; Garcia Lopez, Jose Luis/G-9139-2015	Monterroso, Begoña/0000-0003-2538-084X; Menendez, Margarita/0000-0002-3267-4443; Iloro, Ibon/0000-0002-9537-1714; Garcia Lopez, Jose Luis/0000-0002-9238-2485; Medrano, Francisco/0000-0002-8185-9751				ARRONDO JLR, 1989, FEBS LETT, V252, P118, DOI 10.1016/0014-5793(89)80901-9; ARRONDO JLR, 1994, BIOCHEMISTRY-US, V33, P11650, DOI 10.1021/bi00204a029; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; AUER HE, 1973, J AM CHEM SOC, V95, P3003, DOI 10.1021/ja00790a046; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; BERRY AM, 1989, INFECT IMMUN, V57, P2324, DOI 10.1128/IAI.57.8.2324-2330.1989; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; BRANDTS JF, 1989, BIOCHEMISTRY-US, V28, P8588, DOI 10.1021/bi00447a048; Brooks-Walter A, 1999, INFECT IMMUN, V67, P6533; CAMPOSOLIVAS R, 1995, BIOCHEMISTRY-US, V34, P3009, DOI 10.1021/bi00009a032; CASTRESANA J, 1988, BIOCHEM BIOPH RES CO, V152, P69, DOI 10.1016/S0006-291X(88)80681-8; DAY LA, 1973, BIOCHEMISTRY-US, V12, P5329, DOI 10.1021/bi00750a017; Echabe I, 1998, PROTEIN SCI, V7, P1172, DOI 10.1002/pro.5560070511; Freire E, 1999, P NATL ACAD SCI USA, V96, P10118, DOI 10.1073/pnas.96.18.10118; FREIRE E, 1990, ANNU REV BIOPHYS BIO, V19, P159; Garcia JL, 1998, MICROB DRUG RESIST, V4, P25, DOI 10.1089/mdr.1998.4.25; GARCIA JL, 1987, ARCH MICROBIOL, V149, P52, DOI 10.1007/BF00423136; GARCIA JL, 1994, J BACTERIOL, V176, P4066, DOI 10.1128/JB.176.13.4066-4072.1994; Garcia P, 1999, MOL MICROBIOL, V33, P128, DOI 10.1046/j.1365-2958.1999.01455.x; Garcia P, 1999, MOL MICROBIOL, V31, P1275, DOI 10.1046/j.1365-2958.1999.01238.x; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GRISHINA IB, 1994, FARADAY DISCUSS, V99, P245, DOI 10.1039/fd9949900245; HILL C, 1983, TRENDS BIOCHEM SCI, V8, P364, DOI 10.1016/0968-0004(83)90363-8; HOLTJE JV, 1975, J BIOL CHEM, V250, P6072; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lipsitch M, 1999, EMERG INFECT DIS, V5, P336, DOI 10.3201/eid0503.990304; Luque I, 1998, BIOCHEMISTRY-US, V37, P5791, DOI 10.1021/bi9802521; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; Martinez A, 1996, J BIOL CHEM, V271, P19737, DOI 10.1074/jbc.271.33.19737; Medrano FJ, 1996, J BIOL CHEM, V271, P29152, DOI 10.1074/jbc.271.46.29152; Menendez M, 1995, EUR J BIOCHEM, V234, P887, DOI 10.1111/j.1432-1033.1995.887_a.x; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PERCZEL A, 1992, PROTEINS, V13, P57, DOI 10.1002/prot.340130106; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; Romero A, 1996, EUR J BIOCHEM, V241, P453, DOI 10.1111/j.1432-1033.1996.00453.x; Sanchez-Beato AR, 1998, FEMS MICROBIOL LETT, V164, P207, DOI 10.1016/S0378-1097(98)00206-7; Sanchez-Ruiz J M, 1995, Subcell Biochem, V24, P133; SanchezBeato AR, 1996, GENE, V180, P13, DOI 10.1016/S0378-1119(96)00390-3; SANCHEZPUELLES JM, 1990, GENE, V89, P69, DOI 10.1016/0378-1119(90)90207-8; SANCHEZPUELLES JM, 1987, GENE, V61, P13, DOI 10.1016/0378-1119(87)90360-X; SANZ JM, 1988, FEBS LETT, V232, P308, DOI 10.1016/0014-5793(88)80759-2; SANZ JM, 1992, MOL MICROBIOL, V6, P921, DOI 10.1111/j.1365-2958.1992.tb01542.x; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; SUSI H, 1986, METHOD ENZYMOL, V130, P290; Susi H., 1969, STRUCTURE STABILITY, P575; TODD M, 1993, BIOPHYS J, V64, P166; TUOMANEN E, 1986, EUR J CLIN MICROBIOL, V5, P682, DOI 10.1007/BF02013304; Usobiaga P, 1996, J BIOL CHEM, V271, P6832, DOI 10.1074/jbc.271.12.6832; Varela PF, 1997, J MOL BIOL, V274, P635, DOI 10.1006/jmbi.1997.1424; Woody RW, 1974, PEPTIDES POLYPEPTIDE, P338; WYMAN J, 1990, BINDING LINKAGE FUNC, P33; YANG JT, 1986, METHOD ENZYMOL, V130, P208	55	37	38	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26842	26855						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10849429				2022-12-25	WOS:000089144800026
J	Wang, H; Liu, CJ; Lu, YB; Chatterjee, G; Ma, XY; Eisenman, RN; Lengyel, P				Wang, H; Liu, CJ; Lu, YB; Chatterjee, G; Ma, XY; Eisenman, RN; Lengyel, P			The interferon- and differentiation-inducible p202a protein inhibits the transcriptional activity of c-Myc by blocking its association with Max	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; GENE 200 CLUSTER; MURINE CHROMOSOME-1; ACTIVATABLE GENES; INDUCED APOPTOSIS; HIN-200 FAMILY; GROWTH-FACTOR; TARGET GENES; PEF-BOS; EXPRESSION	p202a is a murine protein that is induced during the fusion of myoblasts to myotubes and can also be induced by interferon. Even 23-fold overexpression of p202a in cells retards proliferation. p202a was shown to modulate transcription by binding, and inhibiting the activity of several transcription factors including c-Fos, c-Jun, AP-2, E2F1, E2F4, NF-kappa B, MyoD, and myogenin, Here we report that p202a also bound the c-Myc protein in vitro and in vivo; the C-terminal p202a b segment bound the C-terminal basic region helix-loop-helix-leucine zipper (bHLHLZ) region of c-Myc. The transfection of a p202a expression plasmid inhibited the c-Myc-dependent expression of reporter plasmids in transient assays; moreover, overexpression of p202a in stable cell lines decreased the endogenous levels of mRNAs whose expression is driven by c-Myc, These effects of p202a are consistent with our finding that the binding of p202a to c-Myc inhibited the binding of c-Myc to Max in vitro and in vivo. p202a also inhibited the e-Myc-induced anchorage-independent growth and apoptosis of Rat-1 cells. The inhibition of c-Myc-dependent transcription, proliferation, and apoptosis by p202a is in line with the involvement of p202a in differentiation.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA	Yale University; Fred Hutchinson Cancer Center	Lengyel, P (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 333 Cedar St, New Haven, CT 06520 USA.	peter.lengyel@yale.edu		liu, chuanju/0000-0002-7181-8032; Wang, Hong/0000-0003-4130-8741	NCI NIH HHS [CA20525] Funding Source: Medline; NIAID NIH HHS [R37-AI12320] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020525, R37CA020525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012320] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bouck N, 1979, Methods Enzymol, V58, P296; BRIGGS JA, 1992, J CELL BIOCHEM, V49, P82, DOI 10.1002/jcb.240490114; BRIGGS RC, 1994, J CELL BIOCHEM, V56, P559, DOI 10.1002/jcb.240560417; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; Choubey D, 1997, ONCOGENE, V15, P291, DOI 10.1038/sj.onc.1201184; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Dang CV, 1999, MOL CELL BIOL, V19, P1; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; DAWSON MJ, 1995, IMMUNOGENETICS, V41, P40, DOI 10.1007/BF00188431; Dawson MJ, 1996, J LEUKOCYTE BIOL, V60, P310, DOI 10.1002/jlb.60.3.310; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Foley KP, 1999, BBA-REV CANCER, V1423, pM37, DOI 10.1016/S0304-419X(99)00012-8; Gariglio M, 1998, J LEUKOCYTE BIOL, V64, P608, DOI 10.1002/jlb.64.5.608; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Gribaudo G, 1997, EUR J BIOCHEM, V249, P258, DOI 10.1111/j.1432-1033.1997.t01-1-00258.x; Gutterman JU, 1999, CELL GROWTH DIFFER, V10, P93; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hertel L, 1999, VIROLOGY, V262, P1, DOI 10.1006/viro.1999.9885; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KARN J, 1989, ONCOGENE, V4, P773; Koul D, 1998, BIOCHEM BIOPH RES CO, V247, P379, DOI 10.1006/bbrc.1998.8804; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Landolfo S, 1998, BIOCHIMIE, V80, P721, DOI 10.1016/S0300-9084(99)80025-X; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; MAREU KB, 1992, ANNU REV BIOCHEM, V61, P809; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; Min W, 1996, MOL CELL BIOL, V16, P359; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; OPDENAKKER G, 1989, VIROLOGY, V171, P568, DOI 10.1016/0042-6822(89)90626-0; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; RYSECK RP, 1991, ONCOGENE, V6, P533; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; SEN GC, 1998, TRANSCRIPTIONAL REGU; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; TANNENBAUM CS, 1993, J LEUKOCYTE BIOL, V53, P563, DOI 10.1002/jlb.53.5.563; TRAPANI JA, 1994, IMMUNOGENETICS, V40, P415; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang H, 1999, GENOMICS, V60, P281, DOI 10.1006/geno.1999.5923; Yan DH, 1999, ONCOGENE, V18, P807, DOI 10.1038/sj.onc.1202369; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	86	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27377	27385						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10835425				2022-12-25	WOS:000089144800095
J	Asp, L; Claesson, C; Boren, J; Olofsson, SO				Asp, L; Claesson, C; Boren, J; Olofsson, SO			ADP-ribosylation factor 1 and its activation of phospholipase D are important for the assembly of very low density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; ENDOPLASMIC-RETICULUM; BREFELDIN-A; GUANINE-NUCLEOTIDE; MCA-RH7777 CELLS; APOLIPOPROTEIN-B; COATED VESICLES; GOLGI MEMBRANES; PULSE-CHASE; FACTOR ARF	The role of ADP-ribosylation factor 1 (ARF-1) in the assembly of very low density lipoproteins (VLDL) was investigated by expressing dominant-negative mutants in McA-RH7777 cells, Transient expression of ARF-1(T31N), a GDP-restrictive mutant, significantly inhibited apolipoprotein B-100 (apoB-100) VLDL production without influencing the biosynthesis of apoB-100 low density lipoproteins or total apoB production (indicating that it inhibited the second step of VLDL assembly) and without altering total protein production or biosynthesis of transferrin, phosphatidylcholine, or triglycerides, These effects were confirmed in stable inducible transfectants. In contrast, expression of an ARF-1 mutant lacking the N-terminal 17 amino acids, which has no myristoylation site and cannot interact with the microsomal membrane, did not affect VLDL assembly, Thus, active ARF-1 is needed for the second step of the process. To further explore these observations, we developed a cell-free system based on the postnuclear supernatant isolated from McA-RH7777 cells. In this system, 10-15% of the apoB-100 pool was converted to VLDL in a time- and temperature-dependent way. The assembly process was highly dependent on a heat-stable factor in the d > 1.21 g/ml infranatant of fetal calf serum; this factor was not present in low density lipoproteins or VLDL, Brefeldin A inhibited VLDL assembly in this system, as did a synthetic peptide (corresponding to N-terminal amino acids 2-17 of ARF-1) that displaces ARF-1 from the membrane, Thus, active ARF-1 is also needed for cell-free assembly of VLDL, Guanosine 5'-3-O-(thio)triphosphate also inhibited VLDL assembly in this system, indicating that the process requires ongoing hydrolysis of GTP. 1-Butanol, which inhibits the formation of phosphatidic acid (PA) and instead gives rise to phosphatidylbutanol, inhibited VLDL assembly, whereas a-butanol, which does not inhibit PA formation, failed to do so. Thus, phospholipase D (PLD)-catalyzed formation of PA from phosphatidylcholine is essential for VLDL assembly. In support of this conclusion, exogenous PLD prevented brefeldin A from inhibiting the assembly process. Our results indicate that ARF-1 participates in the second step of VLDL assembly through a process that involves activation of PLD and production of PA.	Univ Gothenburg, Dept Med Biochem, SE-40530 Gothenburg, Sweden; Univ Gothenburg, Wallenberg Lab Cardiovasc Res, SE-40530 Gothenburg, Sweden	University of Gothenburg; University of Gothenburg	Olofsson, SO (corresponding author), Univ Gothenburg, Dept Med Biochem, Box 440, SE-40530 Gothenburg, Sweden.		Adiels, Martin/C-9278-2011					ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; ANDERSSON M, 1994, J LIPID RES, V35, P535; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; BALCH WE, 1992, J BIOL CHEM, V267, P13053; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1994, J BIOL CHEM, V269, P25879; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; Bremser M, 1999, CELL, V96, P495, DOI 10.1016/S0092-8674(00)80654-6; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Faundez V, 1997, J CELL BIOL, V138, P505, DOI 10.1083/jcb.138.3.505; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KERNS BG, 1997, NATURE, V387, P101; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Martin TFJ, 1997, NATURE, V387, P21, DOI 10.1038/387021a0; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; OLEGARD R, 1970, ACTA PAEDIATR SCAND, V59, P637, DOI 10.1111/j.1651-2227.1970.tb17698.x; Olofsson SO, 1999, CURR OPIN LIPIDOL, V10, P341, DOI 10.1097/00041433-199908000-00008; ORCI L, 1991, CELL, V64, P1183; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Pavel J, 1998, P NATL ACAD SCI USA, V95, P2140, DOI 10.1073/pnas.95.5.2140; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; SCHEKMAN R, 1996, SCIENCE, V271, P1525; Shome K, 1997, CURR BIOL, V7, P387, DOI 10.1016/S0960-9822(06)00186-2; Stamnes M, 1998, P NATL ACAD SCI USA, V95, P13676, DOI 10.1073/pnas.95.23.13676; Stillemark P, 2000, J BIOL CHEM, V275, P10506, DOI 10.1074/jbc.275.14.10506; Vasudevan C, 1998, J CELL SCI, V111, P1277; WETTESTEN M, 1985, EUR J BIOCHEM, V149, P461, DOI 10.1111/j.1432-1033.1985.tb08947.x; Wieland F, 1999, CURR OPIN CELL BIOL, V11, P440, DOI 10.1016/S0955-0674(99)80063-5; Wiggins D, 1996, BIOCHEM J, V320, P673, DOI 10.1042/bj3200673; ZHAO L, 1997, P NATL ACAD SCI USA, V94, P4417	46	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26285	26292		10.1074/jbc.M003520200	http://dx.doi.org/10.1074/jbc.M003520200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10843997	hybrid			2022-12-25	WOS:000088999700056
J	Guillemot, L; Levy, A; Zhao, ZJ; Bereziat, G; Rothhut, B				Guillemot, L; Levy, A; Zhao, ZJ; Bereziat, G; Rothhut, B			The protein-tyrosine phosphatase SHP-2 is required during angiotensin II-mediated activation of cyclin D1 promoter in CHO-AT(1A) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; GROWTH-FACTOR RECEPTOR; KINASE-C ACTIVATION; SIGNAL-TRANSDUCTION; PHOSPHOTYROSINE PHOSPHATASE; PHOSPHATIDYLINOSITOL 3'-KINASE; EGF-RECEPTOR; SH2 DOMAIN; COUPLED RECEPTORS; G(1) PROGRESSION	Angiotensin II (Ang II) binds to specific G protein-coupled receptors and is mitogenic in Chinese hamster ovary (CHO) cells stably expressing a rat vascular angiotensin II type LA receptor (CHO-AT(1A)). Cyclin D1 protein expression is regulated by mitogens, and its assembly with the cyclin-dependent kinases induces phosphorylation of the retinoblastoma protein pRb, a critical step in G(1) to S phase cell cycle progression contributing to the proliferative responses. In the present study, we found that in CHO-AT(1A) cells, Ang II induced a rapid and reversible tyrosine phosphorylation of various intracellular proteins including the protein-tyrosine phosphatase SHP-2. Ang II also induced cyclin D1 protein expression in a phosphatidylinositol 3-kinase and mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK)-dependent manner. Using a pharmacological and a co-transfection approach, we found that p21(ras), Raf-1, phosphatidylinositol 3-kinase and also the catalytic activity of SHP-2 and its Src homology 2 domains are required for cyclin D1 promoter/reporter gene activation by Ang II through the regulation of MAPK/ERK activity. Our findings suggest for the first time that SHP-2 could play an important role in the regulation of a gene involved in the control of cell cycle progression resulting from stimulation of a G protein-coupled receptor independently of epidermal growth factor receptor transactivation.	Univ Paris 06, Lab Signalisat Cellulaire Mediateurs Lipid & Cont, CNRS, UPRESA 7079, F-75005 Paris, France; Vanderbilt Univ, Sch Med, Div Hematol Oncol, Nashville, TN 37232 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Vanderbilt University	Rothhut, B (corresponding author), Univ Paris 06, Lab Signalisat Cellulaire Mediateurs Lipid & Cont, CNRS, UPRESA 7079, 7 Quai St Bernard,Batiment A,5eme Etage, F-75005 Paris, France.	rothhut@ccr.jussieu.fr		Rothhut, Bernard/0000-0001-6467-8134	NATIONAL CANCER INSTITUTE [R01CA075218] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057393] Funding Source: NIH RePORTER; NCI NIH HHS [CA75218] Funding Source: Medline; NHLBI NIH HHS [HL-57393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Ali MS, 1997, J BIOL CHEM, V272, P12373, DOI 10.1074/jbc.272.19.12373; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Berk BC, 1997, CIRC RES, V80, P607, DOI 10.1161/01.RES.80.5.607; BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BOOZ GW, 1994, AM J PHYSIOL-CELL PH, V267, pC1308, DOI 10.1152/ajpcell.1994.267.5.C1308; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; Eder AM, 1998, J BIOL CHEM, V273, P28025, DOI 10.1074/jbc.273.43.28025; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FILMUS J, 1994, ONCOGENE, V9, P3627; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GERLACH MS, 1995, J BIOL CHEM, V270, P24635, DOI 10.1074/jbc.270.42.24635; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GRIENDLING KK, 1993, SEMIN NEPHROL, V13, P558; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HERBER B, 1994, ONCOGENE, V9, P1295; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Huckle William R., 1994, Progress in Growth Factor Research, V5, P177, DOI 10.1016/0955-2235(94)90004-3; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; INAGAMI T, 1994, J HYPERTENS, V12, pS83; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KATO J, 1993, GENE DEV, V7, P331; KAWAHARA Y, 1988, BIOCHEM BIOPH RES CO, V150, P52, DOI 10.1016/0006-291X(88)90485-8; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; MARRERO MB, 1995, CARDIOVASC RES, V30, P530, DOI 10.1016/0008-6363(95)00094-1; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NEVINS JR, 1992, SCIENCE, V258, P424; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Sagawa K, 1997, J BIOL CHEM, V272, P31086, DOI 10.1074/jbc.272.49.31086; Saward L, 1997, CIRC RES, V81, P249, DOI 10.1161/01.RES.81.2.249; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TEUTSCH B, 1992, BIOCHEM BIOPH RES CO, V187, P1381, DOI 10.1016/0006-291X(92)90455-T; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; TURNER CE, 1995, J CELL SCI, V108, P333; Ugi S, 1996, J BIOL CHEM, V271, P12595, DOI 10.1074/jbc.271.21.12595; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Wen YS, 1996, AM J PHYSIOL-CELL PH, V271, pC1212, DOI 10.1152/ajpcell.1996.271.4.C1212; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Yu ZB, 1997, J BIOL CHEM, V272, P7519, DOI 10.1074/jbc.272.11.7519; Zhao RX, 2000, J BIOL CHEM, V275, P5453, DOI 10.1074/jbc.275.8.5453; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	87	26	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26349	26358		10.1074/jbc.M001614200	http://dx.doi.org/10.1074/jbc.M001614200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10843991	hybrid			2022-12-25	WOS:000088999700065
J	Hashiguchi, M; Sobue, K; Paudel, HK				Hashiguchi, M; Sobue, K; Paudel, HK			14-3-3 zeta is an effector of tau protein phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; PSEUDOMONAS-AERUGINOSA; BINDING-SITE; EXOENZYME-S; KINASE-C; T-CELLS; 14-3-3-PROTEINS; BRAIN; ACTIVATION	Neurofibrillary tangles associated with Alzheimer's disease are composed mainly of paired helical filaments that are formed by the aggregation of abnormally phosphorylated microtubule-associated protein tau. 14-3-3, a highly conserved protein family that exists as seven isoforms and regulates diverse cellular processes is present in neurofibrillary tangles (Layfield, R., Fergusson, J., Aitken, k, Lowe, J., Landon, NI., Mayer, R. J. (1996) Neurosci. Lett. 209, 57-60). The role of 14-3-3 in Alzheimer's disease pathogenesis is not known. In this study, we found that the 14-3-3 zeta isoform is associated with tau in brain extract and profoundly stimulates cAMP-dependent protein kinase catalyzed in vitro phosphorylation on Ser(262)/Ser(356) located within the microtubule-binding region of tan. 14-3-3 zeta binds to both phosphorylated and nonphosphorylated tau, and the binding site is located within the microtubule-binding region of tan. From brain extract, 14-3-3 zeta co-purifies with microtubules, and tubulin blocks 14-3-3 zeta-tau binding. Among four 14-3-3 isoforms tested, beta and zeta but not gamma and epsilon associate with tau. Our data suggest that 14-3-3(zeta) is a tau protein effector and may be involved in the abnormal tau phosphorylation occurring during Alzheimer's disease ontogeny.	Sir Mortimer B Davis Jewish Hosp, Bloomfield Ctr Res Aging, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University	Paudel, HK (corresponding author), Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.	mdhp@musica.mcgill.ca						Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRANDT R, 1994, J BIOL CHEM, V269, P11776; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; CORREAS I, 1992, J BIOL CHEM, V267, P15721; Craparo A, 1997, J BIOL CHEM, V272, P11663; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GREENWOOD JA, 1994, J BIOL CHEM, V269, P4373; Gu MY, 1998, J BIOL CHEM, V273, P33465, DOI 10.1074/jbc.273.50.33465; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Jicha GA, 1999, J NEUROSCI, V19, P7486, DOI 10.1523/JNEUROSCI.19-17-07486.1999; KOPKE E, 1993, J BIOL CHEM, V268, P24374; Layfield R, 1996, NEUROSCI LETT, V209, P57, DOI 10.1016/0304-3940(96)12598-2; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Liao H, 1998, J BIOL CHEM, V273, P21901, DOI 10.1074/jbc.273.34.21901; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; PADILLA R, 1990, MOL CELL BIOCHEM, V97, P35; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PATEL Y, 1994, BBA-MOL CELL RES, V1222, P405, DOI 10.1016/0167-4889(94)90048-5; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Paudel HK, 1999, J BIOL CHEM, V274, P8029, DOI 10.1074/jbc.274.12.8029; Paudel HK, 1997, J BIOL CHEM, V272, P1777; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Reuther GW, 1996, VITAM HORM, V52, P149, DOI 10.1016/S0083-6729(08)60410-0; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SINGH TJ, 1995, J NEUROCHEM, V64, P1420; Sobue K, 2000, J BIOL CHEM, V275, P16673, DOI 10.1074/jbc.M000784200; Sontag E, 1999, J BIOL CHEM, V274, P25490, DOI 10.1074/jbc.274.36.25490; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; WATANABE A, 1993, J BIOL CHEM, V268, P25712; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1999, BIOCHEMISTRY-US, V38, P12159, DOI 10.1021/bi991019l	59	173	185	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25247	25254		10.1074/jbc.M003738200	http://dx.doi.org/10.1074/jbc.M003738200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10840038	hybrid			2022-12-25	WOS:000088849400029
J	Hiraga, K; Suzuki, T; Oda, K				Hiraga, K; Suzuki, T; Oda, K			A novel double-headed proteinaceous inhibitor for metalloproteinase and serine proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES SUBTILISIN INHIBITOR; STREPTOVERTICILLIUM ANTICOAGULANT SAC; ALPHA-AMYLASE/TRYPSIN INHIBITOR; CINNAMONEUM SUBSP CINNAMONEUM; AMINO-ACID-SEQUENCE; NIGRESCENS TK-23; REACTIVE-SITE; ERWINIA-CHRYSANTHEMI; TEMPORARY INHIBITION; CRYSTAL-STRUCTURE	A novel proteinaceous inhibitor for the metalloproteinase of Streptomyces caespitosus has been isolated from the culture supernatant of Streptomyces sp. I-355. It was named ScNPI (Streptomyces caespitosus neutral proteinase inhibitor). ScNPI exhibited strong inhibitory activity toward ScNP with a K-i value of 1.6 nM. In addition, ScNPI was capable of inhibiting subtilisin BPN' (K-i = 1.4 nM) (EC 3.4.21.62). The scnpi gene consists of two regions, a signal peptide (28 amino acid residues) and a mature region (113 amino acid residues, M-r= 11,857). The deduced amino acid sequence of scnpi showed high similarity to those of Streptomyces subtilisin inhibitor (SSI) and its homologues. The reactive site of ScNPI for inhibition of subtilisin BPN' was identified to be Met(71)-Tyr(72) bond by specific cleavage. To identify the reactive site for ScNP, Tyr(33) and Tyr(72), which are not conserved among other SSI family inhibitors but are preferable amino acid residues for ScNP, were replaced separately by Ala. The Y33A mutant retained inhibitory activity toward subtilisin BPN' but did not show any inhibitory activity toward ScNP. Moreover, a dimer of ternary complexes among ScNPI, ScNP, and subtilisin BPN' was formed to give the 2:2:2 stoichiometry. These results strongly indicate that ScNPI is a double-headed inhibitor that has individual reactive sites for ScNP and subtilisin BPN'.	Kyoto Inst Technol, Fac Text Sci, Dept Appl Biol, Sakyo Ku, Kyoto 6068585, Japan	Kyoto Institute of Technology	Oda, K (corresponding author), Kyoto Inst Technol, Fac Text Sci, Dept Appl Biol, Sakyo Ku, Kyoto 6068585, Japan.							APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; BAUMANN U, 1995, J MOL BIOL, V248, P653, DOI 10.1006/jmbi.1995.0249; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; HARADA S, 1995, EUR J BIOCHEM, V233, P683, DOI 10.1111/j.1432-1033.1995.683_2.x; Hiromi K, 1985, PROTEIN PROTEASE INH, P1; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; IKENAKA T, 1974, J BIOCHEM-TOKYO, V76, P1191, DOI 10.1093/oxfordjournals.jbchem.a130672; INOUYE K, 1978, J BIOCHEM-TOKYO, V84, P843, DOI 10.1093/oxfordjournals.jbchem.a132196; JIANG WP, 1992, FEBS LETT, V312, P110, DOI 10.1016/0014-5793(92)80916-5; Kurisu G, 1997, J FERMENT BIOENG, V83, P590, DOI 10.1016/S0922-338X(97)81142-7; Kurisu G, 1997, J BIOCHEM, V121, P304; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Leco KJ, 1997, FEBS LETT, V401, P213, DOI 10.1016/S0014-5793(96)01474-3; LETOFFE S, 1989, MOL MICROBIOL, V3, P79, DOI 10.1111/j.1365-2958.1989.tb00106.x; Maskos K, 1996, FEBS LETT, V397, P11, DOI 10.1016/S0014-5793(96)01131-3; MITSUI Y, 1979, J MOL BIOL, V131, P697, DOI 10.1016/0022-2836(79)90198-0; MORIHARA K, 1965, J BIOL CHEM, V240, P3295; ODA K, 1979, BIOCHIM BIOPHYS ACTA, V571, P147, DOI 10.1016/0005-2744(79)90235-3; Oda K, 1996, BIOSCI BIOTECH BIOCH, V60, P463, DOI 10.1271/bbb.60.463; Ohno A, 1998, J MOL BIOL, V282, P421, DOI 10.1006/jmbi.1998.2022; OSTHUES A, 1992, FEBS LETT, V296, P16, DOI 10.1016/0014-5793(92)80393-U; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seeram SS, 1997, J BIOCHEM-TOKYO, V122, P788; Seeram SS, 1997, J BIOCHEM-TOKYO, V121, P1088; Shibata M, 1997, BIOSCI BIOTECH BIOCH, V61, P710, DOI 10.1271/bbb.61.710; SHIVARAJ B, 1981, BIOCHEM J, V193, P29, DOI 10.1042/bj1930029; STROBL S, 1995, BIOCHEMISTRY-US, V34, P8281, DOI 10.1021/bi00026a009; TAGUCHI S, 1993, APPL MICROBIOL BIOT, V39, P732, DOI 10.1007/BF00164458; TAKAHASHI S, 1981, J BIOCHEM, V90, P1677, DOI 10.1093/oxfordjournals.jbchem.a133643; TAMURA A, 1991, BIOCHEMISTRY-US, V30, P5275, DOI 10.1021/bi00235a022; TANABE M, 1994, J BIOCHEM-TOKYO, V115, P743, DOI 10.1093/oxfordjournals.jbchem.a124405; TANABE M, 1994, J BIOCHEM, V115, P752, DOI 10.1093/oxfordjournals.jbchem.a124406; TANAKA T, 1977, J BACTERIOL, V129, P1487, DOI 10.1128/JB.129.3.1487-1494.1977; TERABE M, 1994, EUR J BIOCHEM, V226, P627, DOI 10.1111/j.1432-1033.1994.tb20089.x; UEDA Y, 1992, J BIOCHEM, V112, P204, DOI 10.1093/oxfordjournals.jbchem.a123878; YOKOTE Y, 1969, Nippon Nogeikagaku Kaishi, V43, P125; YOKOTE Y, 1969, Nippon Nogeikagaku Kaishi, V43, P132	39	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25173	25179		10.1074/jbc.M002623200	http://dx.doi.org/10.1074/jbc.M002623200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827083	hybrid			2022-12-25	WOS:000088849400019
J	Iwasaki, T; Watanabe, E; Ohmori, D; Imai, T; Urushiyama, A; Akiyama, M; Hayashi-Iwasaki, Y; Cosper, NJ; Scott, RA				Iwasaki, T; Watanabe, E; Ohmori, D; Imai, T; Urushiyama, A; Akiyama, M; Hayashi-Iwasaki, Y; Cosper, NJ; Scott, RA			Spectroscopic investigation of selective cluster conversion of archaeal zinc-containing ferredoxin from Sulfolobus sp strain 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; PROTON MAGNETIC-RESONANCE; RAY-ABSORPTION SPECTROSCOPY; PUTIDA 7-IRON FERREDOXINS; AZOTOBACTER-VINELANDII; PYROCOCCUS-FURIOSUS; THERMOACIDOPHILIC ARCHAEON; 4FE-4S CLUSTER; EVOLUTIONARY IMPLICATIONS; 3FE-4S CLUSTERS	Archaeal zinc-containing ferredoxin from Sulfolobus sp. strain 7 contains one [3Fe-4S] cluster (cluster I), one [4Fe-4S] cluster (cluster II), and one isolated zinc center. Oxidative degradation of this ferredoxin led to the formation of a stable intermediate with 1 zinc and similar to 6 iron atoms. The metal centers of this intermediate were analyzed by electron paramagnetic resonance (EPR), low temperature resonance Raman, x-ray absorption, and H-1 NMR spectroscopies. The spectroscopic data suggest that (i) cluster II was selectively converted to a cubane [3Fe-4S](1+) cluster in the intermediate, without forming a stable radical species, and that (ii) the local metric environments of cluster I and the isolated zinc site did not change significantly in the intermediate. It is concluded that the initial step of oxidative degradation of the archaeal zinc-containing ferredoxin is selective conversion of cluster II, generating a novel intermediate containing two [3Fe-4S] clusters and an isolated zinc center, At this stage, significant structural rearrangement of the protein does not occur. We propose a new scheme for oxidative degradation of dicluster ferredoxins in which each cluster converts in a stepwise manner, prior to apoprotein formation, and discuss its structural and evolutionary implications.	Nippon Med Sch, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan; Rikkyo St Pauls Univ, Dept Chem, Tokyo 1718501, Japan; Juntendo Univ, Dept Chem, Chiba 2701695, Japan; Tokyo Univ Pharm & Life Sci, Dept Mol Biol, Hachioji, Tokyo 1920392, Japan; Univ Georgia, Ctr Metalloenzyme Studies, Athens, GA 30602 USA; Univ Georgia, Dept Chem, Athens, GA 30602 USA	Nippon Medical School; Rikkyo University; Juntendo University; Tokyo University of Pharmacy & Life Sciences; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Iwasaki, T (corresponding author), Nippon Med Sch, Dept Biochem & Mol Biol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138602, Japan.			Iwasaki, Toshio/0000-0001-9562-4649; Scott, Robert/0000-0003-2236-1336	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042025] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42025] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MWW, 1994, FEMS MICROBIOL REV, V15, P261, DOI 10.1111/j.1574-6976.1994.tb00139.x; Aono S, 1998, BIOCHEMISTRY-US, V37, P9812, DOI 10.1021/bi972818b; ARMSTRONG FA, 1989, FEBS LETT, V259, P15, DOI 10.1016/0014-5793(89)81483-8; ARMSTRONG FA, 1992, ADV INORG CHEM, V38, P117, DOI 10.1016/S0898-8838(08)60063-X; BEAR CA, 1975, ACTA CRYSTALLOGR B, V31, P2713, DOI 10.1107/S056774087500859X; BEINERT H, 1989, EUR J BIOCHEM, V186, P5, DOI 10.1111/j.1432-1033.1989.tb15170.x; BEINERT H, 1983, P NATL ACAD SCI-BIOL, V80, P393, DOI 10.1073/pnas.80.2.393; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Bentrop D, 1996, EUR J BIOCHEM, V236, P92, DOI 10.1111/j.1432-1033.1996.00092.x; Bentrop D, 1999, BIOCHEMISTRY-US, V38, P4669, DOI 10.1021/bi982647q; Bertini I, 1999, CURR OPIN CHEM BIOL, V3, P145, DOI 10.1016/S1367-5931(99)80026-X; BERTINI I, 1993, FEBS LETT, V332, P268, DOI 10.1016/0014-5793(93)80647-D; Bertini I, 1997, BIOCHEMISTRY-US, V36, P3570, DOI 10.1021/bi962799q; BRETON JL, 1995, EUR J BIOCHEM, V233, P937, DOI 10.1111/j.1432-1033.1995.937_3.x; BUSSE SC, 1992, BIOCHEMISTRY-US, V31, P11952, DOI 10.1021/bi00162a038; BUTT JN, 1991, J AM CHEM SOC, V113, P6663, DOI 10.1021/ja00017a045; Butt JN, 1997, J AM CHEM SOC, V119, P9729, DOI 10.1021/ja971403a; CALZOLAI L, 1995, BIOCHEMISTRY-US, V34, P11373, DOI 10.1021/bi00036a010; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CHENG H, 1990, J BIOL CHEM, V265, P12388; CHENG H, 1992, J BIOL CHEM, V267, P8073; Clark-Baldwin K, 1998, J AM CHEM SOC, V120, P8401, DOI 10.1021/ja980580o; CONOVER RC, 1990, J BIOL CHEM, V265, P8533; Cosper NJ, 1999, J BIOL CHEM, V274, P23160, DOI 10.1074/jbc.274.33.23160; Cosper NJ, 1999, J BIOL INORG CHEM, V4, P122, DOI 10.1007/s007750050295; CZERNUSZEWICZ RS, 1987, J AM CHEM SOC, V109, P7178, DOI 10.1021/ja00257a045; Fujii T, 1996, NAT STRUCT BIOL, V3, P834, DOI 10.1038/nsb1096-834; Fujii T, 1997, BIOCHEMISTRY-US, V36, P1505, DOI 10.1021/bi961966j; FUKUYAMA K, 1988, J MOL BIOL, V199, P183, DOI 10.1016/0022-2836(88)90388-9; GEORGE SJ, 1989, BIOCHEM J, V264, P275, DOI 10.1042/bj2640275; Gomes CM, 1998, J BIOL INORG CHEM, V3, P499, DOI 10.1007/s007750050260; GORST CM, 1995, BIOCHEMISTRY-US, V34, P600, DOI 10.1021/bi00002a027; HARROCKS WD, 1980, J INORG BIOCHEM, V12, P131; Hederstedt L, 1999, SCIENCE, V284, P1941, DOI 10.1126/science.284.5422.1941; HU ZG, 1994, BIOCHEMISTRY-US, V33, P14475, DOI 10.1021/bi00252a014; IISMAA SE, 1991, J BIOL CHEM, V266, P21563; IMAI T, 1995, FEBS LETT, V368, P23, DOI 10.1016/0014-5793(95)00601-5; IMAI T, 1995, B CHEM SOC JPN, V68, P2923, DOI 10.1246/bcsj.68.2923; INUBUSHI T, 1983, J MAGN RESON, V51, P128, DOI 10.1016/0022-2364(83)90109-9; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Iwasaki T, 1997, FEBS LETT, V417, P223, DOI 10.1016/S0014-5793(97)01286-6; Iwasaki T, 1997, J BIOL CHEM, V272, P3453, DOI 10.1074/jbc.272.6.3453; IWASAKI T, 1994, J BIOL CHEM, V269, P29444; Jacquamet L, 1998, BIOCHEMISTRY-US, V37, P2564, DOI 10.1021/bi9721344; JOHNSON MK, 1987, BIOCHIM BIOPHYS ACTA, V911, P81, DOI 10.1016/0167-4838(87)90273-1; JOHNSON MK, 1983, J AM CHEM SOC, V105, P6671, DOI 10.1021/ja00360a022; KENNEDY MC, 1992, ADV INORG CHEM RAD, V38, P323, DOI 10.1016/S0898-8838(08)60067-7; KERSCHER L, 1982, EUR J BIOCHEM, V128, P223; KERSCHER L, 1982, TRENDS BIOCHEM SCI, V7, P371, DOI 10.1016/0968-0004(82)90118-9; KERSCHER L, 1977, FEBS LETT, V83, P197, DOI 10.1016/0014-5793(77)81004-1; KISSINGER CR, 1991, J MOL BIOL, V219, P693, DOI 10.1016/0022-2836(91)90665-S; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; LAUBLE H, 1994, J MOL BIOL, V237, P437, DOI 10.1006/jmbi.1994.1246; MacedoRibeiro S, 1996, STRUCTURE, V4, P1291, DOI 10.1016/S0969-2126(96)00137-2; MORGAN TV, 1985, FEBS LETT, V183, P206, DOI 10.1016/0014-5793(85)80777-8; MORGAN TV, 1984, P NATL ACAD SCI-BIOL, V81, P1931, DOI 10.1073/pnas.81.7.1931; MOURA JJG, 1994, METHOD ENZYMOL, V243, P165; MOURA JJG, 1982, J BIOL CHEM, V257, P6259; NAGAYAMA K, 1983, FEBS LETT, V158, P208, DOI 10.1016/0014-5793(83)80579-1; NAGAYAMA K, 1984, FEBS LETT, V173, P15, DOI 10.1016/0014-5793(84)81007-8; NAGAYAMA K, 1984, FEBS LETT, V169, P79, DOI 10.1016/0014-5793(84)80293-8; Nakajima Y, 1998, J BIOCHEM-TOKYO, V123, P521; PARK JB, 1991, J BIOL CHEM, V266, P19351; Pascher T, 1996, SCIENCE, V271, P1558, DOI 10.1126/science.271.5255.1558; SCOTT RA, 1983, INORG CHIM A-BIOINOR, V79, P142, DOI 10.1016/S0020-1693(00)95178-8; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; SCOTT RA, 1984, EXAFS NEAR EDGE STRU, V3, P105; SPIRO TG, 1995, METHODS ENZYMOL, V246, P416; STEPHENS PJ, 1985, P NATL ACAD SCI USA, V82, P5661, DOI 10.1073/pnas.82.17.5661; TEIXEIRA M, 1995, EUR J BIOCHEM, V227, P322, DOI 10.1111/j.1432-1033.1995.tb20392.x; TENG Q, 1994, BIOCHEMISTRY-US, V33, P6316, DOI 10.1021/bi00186a035; Wakagi T, 1996, BIOCHEM BIOPH RES CO, V225, P489, DOI 10.1006/bbrc.1996.1200; ZABINSKY SI, 1995, PHYS REV B, V52, P2995, DOI 10.1103/PhysRevB.52.2995; Zhang Q, 1996, J BIOCHEM-TOKYO, V120, P587	74	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25391	25401		10.1074/jbc.M909243199	http://dx.doi.org/10.1074/jbc.M909243199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827091	hybrid			2022-12-25	WOS:000088849400047
J	Jafferji, A; Allen, JWA; Ferguson, SJ; Fulop, V				Jafferji, A; Allen, JWA; Ferguson, SJ; Fulop, V			X-ray crystallographic study of cyanide binding provides insights into the structure-function relationship for cytochrome cd(1) nitrite reductase from Paracoccus pantotrophus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOSPHAERA-PANTOTROPHA; PSEUDOMONAS-STUTZERI; ESCHERICHIA-COLI; HEME; PURIFICATION; PROTEIN; ENZYME; COMPLEX; PRODUCTS; MODELS	We present a 1.59-Angstrom resolution crystal structure of reduced Paracoccus pantotrophus cytochrome ed, with cyanide bound to the d(1) heme and His/Met coordination of the c heme. Fe-C-N bond angles are 146 degrees for the A subunit and 164 degrees for the B subunit of the dimer, The nitrogen atom of bound cyanide is within hydrogen bonding distance of His(345) and His(388) and either a water molecule in subunit A or Tyr(25), subunit B. The ferrous heme-cyanide complex is unusually stable (K-d similar to 10-(6) M); we propose that this reflects both the design of the specialized d(1) heme ring and a general feature of anion reductases with active site heme, Oxidation of crystals of reduced, cyanide-bound, cytochrome cd(1) results in loss of cyanide and return to the native structure with Tyr(25) as a ligand to the d(1) heme iron and switching to His/His coordination at the c-type heme, No reason for unusually weak binding of cyanide to the ferric state can be identified; rather it is argued that the protein is designed such that a chelate-based effect drives displacement by tyrosine of cyanide or a weaker ligand, like reaction product nitric oxide, from the ferric d(1) heme.	Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; Univ Oxford, Oxford Ctr Mol Sci, Oxford OX1 3QU, England; Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Oxford; University of Oxford; University of Warwick	Fulop, V (corresponding author), Univ Oxford, Dept Biochem, Lab Mol Biophys, S Pk Rd, Oxford OX1 3QU, England.	vilmos@globin.bio.warwick.ac.uk	Fulop, Vilmos/AAZ-7720-2021					Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker SC, 1997, J MOL BIOL, V269, P440, DOI 10.1006/jmbi.1997.1070; BARKIGIA KM, 1992, J AM CHEM SOC, V114, P1701, DOI 10.1021/ja00031a025; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BESSON S, 1995, ANAEROBE, V1, P219, DOI 10.1006/anae.1995.1021; BLACKMORE RS, 1990, BIOCHEM J, V271, P253, DOI 10.1042/bj2710253; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; BRUNORI M, 1992, J BIOL CHEM, V267, P2258; Cheesman MR, 1997, BIOCHEMISTRY-US, V36, P16267, DOI 10.1021/bi971677a; Crane BR, 1997, BIOCHEMISTRY-US, V36, P12120, DOI 10.1021/bi971066i; Cutruzzola F, 1999, BBA-BIOENERGETICS, V1411, P231, DOI 10.1016/S0005-2728(99)00017-1; Eaves DJ, 1998, MOL MICROBIOL, V28, P205, DOI 10.1046/j.1365-2958.1998.00792.x; Einsle O, 1999, NATURE, V400, P476, DOI 10.1038/22802; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FULOP V, 1993, J MOL BIOL, V232, P1211, DOI 10.1006/jmbi.1993.1473; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; Henriksen A, 1999, J BIOL CHEM, V274, P35005, DOI 10.1074/jbc.274.49.35005; HILLIARD NP, 1991, ARCH BIOCHEM BIOPHYS, V291, P195, DOI 10.1016/0003-9861(91)90123-Z; JONES CW, 1982, ASPECTS MICROBIOLOGY, V5, P41; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEILIN D, 1955, BIOCHEM J, V61, P153, DOI 10.1042/bj0610153; Kobayashi K, 1997, BIOCHEMISTRY-US, V36, P13611, DOI 10.1021/bi971045o; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4028, DOI 10.1021/bi991912k; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MOIR JWB, 1993, EUR J BIOCHEM, V212, P377, DOI 10.1111/j.1432-1033.1993.tb17672.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rainey FA, 1999, INT J SYST BACTERIOL, V49, P645, DOI 10.1099/00207713-49-2-645; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SILVESTRINI MC, 1990, J BIOL CHEM, V265, P11783; SINGH J, 1974, BIOCHIM BIOPHYS ACTA, V333, P28, DOI 10.1016/0005-2728(74)90159-5; STEUP MB, 1989, J INORG BIOCHEM, V37, P233, DOI 10.1016/0162-0134(89)80045-5; VANBUUREN KJ, 1972, BIOCHIM BIOPHYS ACTA, V256, P258, DOI 10.1016/0005-2728(72)90057-6; VEGA JM, 1977, J BIOL CHEM, V252, P896; Viola F, 1996, J INORG BIOCHEM, V62, P213, DOI 10.1016/0162-0134(95)00155-7; VOGEL AI, 1989, VOGELS TXB QUANTITAT, P309; WEEGAERSSENS E, 1991, J BIOL CHEM, V266, P7496; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; WU WS, 1987, J AM CHEM SOC, V109, P3149, DOI 10.1021/ja00244a050; YAMANAKA T, 1963, BIOCHEM Z, V338, P62; YU NT, 1986, METHOD ENZYMOL, V130, P350; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	43	42	44	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25089	25094		10.1074/jbc.M001377200	http://dx.doi.org/10.1074/jbc.M001377200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827177	hybrid			2022-12-25	WOS:000088849400008
J	Knapp, LT; Klann, E				Knapp, LT; Klann, E			Superoxide-induced stimulation of protein kinase C via thiol modification and modulation of zinc content	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CYSTEINE-RICH REGIONS; DNA-BINDING ACTIVITY; GLUCOCORTICOID RECEPTOR; PHOSPHOTRANSFERASE ACTIVITY; SIGNAL-TRANSDUCTION; SULFHYDRYL-GROUPS; OXIDATIVE STRESS; STEROID-BINDING; PHORBOL ESTERS	We investigated the effects of mild oxidation on protein kinase C (PKC) using the xanthine/xanthine oxidase system of generating superoxide. Exposure of various PRC preparations to superoxide stimulated the autonomous activity of PKC, Similarly, thiol oxidation increased autonomous PKC activity, consistent with the notion that superoxide stimulates PKC via thiol oxidation, The superoxide-induced stimulation of PKC activity was partially reversed by reducing agents, suggesting that disulfide bond formation contributed to the oxidative stimulation of PRC, In addition, superoxide increased the autonomous activity of the alpha, beta(II), epsilon, and zeta PKC isoforms, all of which contain at least one cysteine-rich region. Taken together, our observations suggested that superoxide interacts with PKC at the cysteine-rich region, zinc finger motif of the enzyme. Therefore, we examined the effects of superoxide on this region by testing the hypothesis that superoxide stimulates PKC by promoting the release of zinc from PKC. We found that a zinc chelator stimulated the autonomous activity of PRC and that superoxide induced zinc release from an PRC-enriched enzyme preparation. In addition, oxidized PKC contained significantly less zinc than reduced PKC. Finally, we have isolated a persistent, autonomously active PKC by DEAE-cellulose column chromatography from hippocampal slices incubated with superoxide, Taken together, these data suggest that superoxide stimulates autonomous PKC activity via thiol oxidation and release of zinc from cysteine-rich region of PKC.	Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Klann, E (corresponding author), Univ Pittsburgh, Dept Neurosci, 446 Crawford Hall, Pittsburgh, PA 15260 USA.				NIMH NIH HHS [MH18273] Funding Source: Medline; NINDS NIH HHS [NS08950, NS34007] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034007, R29NS034007] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; BENZI G, 1995, FREE RADICAL BIO MED, V19, P77, DOI 10.1016/0891-5849(94)00244-E; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BOWLING A, 1995, LIFE SCI, V14, P1151; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAWN MK, 1995, FREE RADICAL RES, V22, P23, DOI 10.3109/10715769509147525; CanoGauci DF, 1996, FEBS LETT, V386, P1, DOI 10.1016/0014-5793(96)00356-0; Casadevall M, 1998, J INORG BIOCHEM, V71, P147, DOI 10.1016/S0162-0134(98)10046-6; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; CROW JP, 1995, BIOCHEMISTRY-US, V34, P3544, DOI 10.1021/bi00011a008; Gahtan E, 1998, EUR J NEUROSCI, V10, P538, DOI 10.1046/j.1460-9568.1998.00058.x; GONZALEZ A, 1993, ANAL BIOCHEM, V215, P184, DOI 10.1006/abio.1993.1574; Gopalakrishna R, 1999, ARCH BIOCHEM BIOPHYS, V363, P246, DOI 10.1006/abbi.1999.1100; GOPALAKRISHNA R, 1995, METHOD ENZYMOL, V252, P132; GOPALAKRISHNA R, 1987, FEBS LETT, V225, P233, DOI 10.1016/0014-5793(87)81164-X; Gopalakrishna R, 1997, ARCH BIOCHEM BIOPHYS, V348, P25, DOI 10.1006/abbi.1997.0334; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; Gorman AM, 1996, J NEUROL SCI, V139, P45, DOI 10.1016/0022-510X(96)00097-4; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HUNT JB, 1985, ANAL BIOCHEM, V146, P150, DOI 10.1016/0003-2697(85)90409-9; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505; HYSLOP PA, 1984, ANAL BIOCHEM, V141, P280, DOI 10.1016/0003-2697(84)90457-3; INOUE M, 1977, J BIOL CHEM, V252, P7610; JOCELYN PC, 1972, BIOCH SH GROUP; Johnson JE, 1997, J BIOL CHEM, V272, P30787, DOI 10.1074/jbc.272.49.30787; KASS GEN, 1989, BIOCHEM J, V260, P499, DOI 10.1042/bj2600499; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; Klann E, 1998, J BIOL CHEM, V273, P4516, DOI 10.1074/jbc.273.8.4516; Klann E, 1998, J NEUROPHYSIOL, V80, P452, DOI 10.1152/jn.1998.80.1.452; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KRAFT AS, 1982, J BIOL CHEM, V257, P13193; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; Krieger C, 1996, TRENDS PHARMACOL SCI, V17, P114, DOI 10.1016/0165-6147(96)10004-3; KRONCKE KD, 1994, BIOCHEM BIOPH RES CO, V200, P1105, DOI 10.1006/bbrc.1994.1564; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LARSSON R, 1989, CANCER RES, V49, P5627; Levin ED, 1998, BEHAV GENET, V28, P381, DOI 10.1023/A:1021673703129; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; MCFADDEN PN, 1989, J BIOL CHEM, V264, P12765; MESHINCHI S, 1990, J BIOL CHEM, V265, P11643; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBRIAN CA, 1988, BIOCHEM BIOPH RES CO, V155, P1374, DOI 10.1016/S0006-291X(88)81293-2; PALUMBO EJ, 1992, BIOCHEM BIOPH RES CO, V187, P1439, DOI 10.1016/0006-291X(92)90463-U; Park JS, 1999, J BIOL CHEM, V274, P29075, DOI 10.1074/jbc.274.41.29075; Quesada AR, 1996, ARCH BIOCHEM BIOPHYS, V334, P241, DOI 10.1006/abbi.1996.0452; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Takekoshi S, 1995, BIOCHEM BIOPH RES CO, V217, P654, DOI 10.1006/bbrc.1995.2824; Telford WG, 1997, BIOCHEM BIOPH RES CO, V238, P86, DOI 10.1006/bbrc.1997.7245; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263; WOLF M, 1985, NATURE, V317, P546, DOI 10.1038/317546a0	55	166	169	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24136	24145		10.1074/jbc.M002043200	http://dx.doi.org/10.1074/jbc.M002043200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10823825	hybrid			2022-12-25	WOS:000088564200099
J	Morgan, H; Smith, M; Burke, Z; Carter, D				Morgan, H; Smith, M; Burke, Z; Carter, D			The transactivation-competent carboxyl-terminal domain of AF-9 is expressed within a sexually dimorphic transcript in rat pituitary	FASEB JOURNAL			English	Article						leukemia; estrogen; oncogene	POLYMERASE CHAIN-REACTION; HORMONE-RELEASING FACTOR; SACCHAROMYCES-CEREVISIAE; ACUTE-LEUKEMIA; NUCLEAR-PROTEIN; GROWTH; GENE; CHROMATIN; RECEPTOR; ENL	We have investigated the biological role of the cellular counterpart of the leukemogenic AF-9 gene by cloning the rat AF-9 (rAF-9) cDNA and defining the regulation of an anterior pituitary-specific rAF-9 transcript that is expressed in a sexually dimorphic manner. Expression of this transcript is down-regulated after puberty in females and can be subsequently up-regulated in adults by ovariectomy. Hormone replacement studies have provided direct evidence that rAF-9 mRNA expression is suppressed by estrogen, Mapping the 1.9 kb anterior pituitary transcript has shown that it corresponds in size to the rAF-9 cDNA clone, which contains an open reading frame (ORF) that is truncated compared with the human AF-9 ORF, but encodes a previously defined transcriptional activation domain. Thus, the cellular AF-9 gene is alternatively expressed in a manner that reflects the presence of translocated, functionally active (oncogenic) AF-9 sequences in leukemias. Using a novel antisera raised against a rAF-9 peptide, we have also demonstrated tissue- and sex-specific expression of a nuclear 41 kDa anterior pituitary protein and have localized this protein to a major population of growth hormone synthesizing cells. By localizing the expression and defining the physiological regulation of rAF-9, our studies have provided novel insights into the AF-9 gene that will facilitate an understanding of both oncogenic and endocrine roles.-Morgan, H., Smith, M., Burke, Z., Carter, D. The transactivation-competent carboxyl-terminal domain of AF-9 is expressed within a sexually dimorphic transcript in rat pituitary.	Cardiff Univ, Sch Biosci, Cardiff CF1 3US, S Glam, Wales	Cardiff University	Carter, D (corresponding author), Cardiff Univ, Sch Biosci, Biomed Bldg,Museum Ave, Cardiff CF1 3US, S Glam, Wales.		Carter, David/A-4479-2010	Carter, David/0000-0002-8419-3975; Morgan, Helen E/0000-0003-2470-9746				Aizawa A, 1996, J BIOCHEM-TOKYO, V119, P296, DOI 10.1093/oxfordjournals.jbchem.a021238; Allen DL, 1997, ENDOCRINOLOGY, V138, P2128, DOI 10.1210/en.138.5.2128; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; BERCHTOLD MW, 1989, NUCLEIC ACIDS RES, V17, P453, DOI 10.1093/nar/17.1.453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; CARTER DA, 1994, NEUROSCIENCE, V62, P1267, DOI 10.1016/0306-4522(94)90358-1; CARTER DA, 1989, J BIOL CHEM, V264, P6601; CHARLTON HM, 1988, J ENDOCRINOL, V119, P51, DOI 10.1677/joe.0.1190051; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CLARK RG, 1987, J ENDOCRINOL, V114, P399, DOI 10.1677/joe.0.1140399; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DUKAS K, 1993, ANAL BIOCHEM, V215, P66, DOI 10.1006/abio.1993.1555; FISHMAN A, 1993, NEUROENDOCRINOLOGY, V57, P782, DOI 10.1159/000126437; IIDA S, 1993, ONCOGENE, V8, P3085; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; JOH T, 1996, ONCOGENE, V13, P1845; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; ONO M, 1995, BIOCHEM BIOPH RES CO, V216, P1060, DOI 10.1006/bbrc.1995.2728; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; RUBNITZ JE, 1994, BLOOD, V84, P1747; Sambrook J., 2002, MOL CLONING LAB MANU; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WEHRENBERG WB, 1986, ENDOCRINOLOGY, V118, P489, DOI 10.1210/endo-118-2-489; WELCH MD, 1994, MOL BIOL CELL, V5, P617, DOI 10.1091/mbc.5.6.617; ZENG Q, 1994, J NEUROENDOCRINOL, V6, P469, DOI 10.1111/j.1365-2826.1994.tb00610.x; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	32	5	5	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1109	1116		10.1096/fasebj.14.9.1109	http://dx.doi.org/10.1096/fasebj.14.9.1109			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834932				2022-12-25	WOS:000087427300007
J	Swaroop, M; Wang, YX; Miller, P; Duan, HJ; Jatkoe, T; Madore, SJ; Sun, Y				Swaroop, M; Wang, YX; Miller, P; Duan, HJ; Jatkoe, T; Madore, SJ; Sun, Y			Yeast homolog of human SAG/ROC2/Rbx2/Hrt2 is essential for cell growth, but not for germination: chip profiling implicates its role in cell cycle regulation	ONCOGENE			English	Article						RING finger; ubiquitin ligase; growth essential; cell cycle; SCF complex; apoptosis	NF-KAPPA-B; UBIQUITIN-LIGASE COMPLEX; SACCHAROMYCES-CEREVISIAE; INDUCED APOPTOSIS; S-PHASE; BCL-2 FAMILY; DEATH; PROTEIN; KINASE; PATHWAY	In an attempt to understand the signaling pathway mediating redox-induced apoptosis, we cloned SAG, an evolutionarily conserved zinc RING finger gene that, when overexpressed, protects cells from apoptosis induced by redox agents. Here we report functional characterization of SAG by the use of yeast genetics approach. Targeted disruption of ySAG, yeast homolog of human SAG, and subsequent tetrad analysis revealed that ySAG is required for yeast viability. Complementation experiment showed that the lethal phenotype induced by the ySAG deletion is fully rescued by wildtype SAG, but not by several hSAG mutants, Complementation experiment has also confirmed that ySAG is essential for normal vegetative growth, rather than being required for sporulation. Furthermore, cell death induced by SAG deletion was accompanied by cell enlargement and abnormal cell cycle profiling with an increased DNA content. Importantly, SAG was found to be the second family member of Rbx (RING box protein) or ROC (Regulator of cullins) or Hrt that is a component of SCF E3 ubiquitin ligase, Indeed, like ROC1/Rbx1/Hrt1, SAG binds to Cull and SAG-Cull complex has ubiquitin ligase activity to promote poly-ubiquitination of E2/ Cdc34. This ligase activity is required for complementation of death phenotype induced by ySAG disruption. Finally, chip profiling of the entire yeast genome revealed induction of several G1/S as well as G2/M checkpoint control genes upon SAG withdrawal. Thus, SAG appears to control cell cycle progression in yeast by promoting ubiquitination and degradation of cell cycle regulatory proteins.	Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA; Parke Davis Pharmaceut Res, Dept Infect Dis, Ann Arbor, MI USA	Pfizer; Pfizer	Sun, Y (corresponding author), Parke Davis Pharmaceut Res, Dept Mol Biol, Ann Arbor, MI 48105 USA.			Swaroop, Manju/0000-0002-0576-1664				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Boger-Nadjar E, 1998, MOL GEN GENET, V260, P232, DOI 10.1007/s004380050891; Chen A, 2000, J BIOL CHEM, V275, P15432, DOI 10.1074/jbc.M907300199; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Duan HJ, 1999, MOL CELL BIOL, V19, P3145; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Farr KA, 1998, MOL CELL BIOL, V18, P2738, DOI 10.1128/MCB.18.5.2738; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Goh PY, 1999, MOL CELL BIOL, V19, P5512; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; IIDA H, 1984, J CELL BIOL, V99, P199, DOI 10.1083/jcb.99.1.199; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KASSIR Y, 1991, METHOD ENZYMOL, V194, P94; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Levine K, 1995, Prog Cell Cycle Res, V1, P101; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; MATSUMOTO Y, 1993, YEAST, V9, P929, DOI 10.1002/yea.320090813; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; Michael WM, 1998, SCIENCE, V282, P1886, DOI 10.1126/science.282.5395.1886; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peter ME, 1997, P NATL ACAD SCI USA, V94, P12736, DOI 10.1073/pnas.94.24.12736; PRINTEN JA, 1994, GENETICS, V138, P609; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; ROBINSON LC, 1991, MOL GEN GENET, V230, P241, DOI 10.1007/BF00290674; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SAZER S, 1990, J CELL SCI, V97, P509; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Sun Y, 1997, FEBS LETT, V408, P16, DOI 10.1016/S0014-5793(97)00380-3; Sun Y, 1997, ONCOGENE, V14, P385, DOI 10.1038/sj.onc.1200834; SUN Y, 1990, FREE RADICAL BIO MED, V8, P583, DOI 10.1016/0891-5849(90)90156-D; Swaroop M, 1999, FREE RADICAL BIO MED, V27, P193, DOI 10.1016/S0891-5849(99)00078-7; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; THIELE DJ, 1986, SCIENCE, V231, P854, DOI 10.1126/science.3080806; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Verma R, 1997, MOL BIOL CELL, V8, P1427, DOI 10.1091/mbc.8.8.1427; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang YX, 1999, FEBS LETT, V445, P269, DOI 10.1016/S0014-5793(99)00136-2; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wu K, 2000, MOL CELL BIOL, V20, P1382, DOI 10.1128/MCB.20.4.1382-1393.2000; Wyllie A H, 1980, Int Rev Cytol, V68, P251	80	48	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2000	19	24					2855	2866		10.1038/sj.onc.1203635	http://dx.doi.org/10.1038/sj.onc.1203635			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851089				2022-12-25	WOS:000087403600007
J	Conforti, G; Nardo, T; D'Incalci, H; Stefanini, M				Conforti, G; Nardo, T; D'Incalci, H; Stefanini, M			Proneness to UV-induced apoptosis in human fibroblasts defective in transcription coupled repair is associated with the lack of Mdm2 transactivation	ONCOGENE			English	Article						UV-sensitivity DNA repair; xeroderma pigmentosum; Cockayne syndrome; p53	NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; COCKAYNE-SYNDROME CELLS; DNA-REPAIR; P53 RESPONSE; PROTEIN STABILITY; ITALIAN PATIENTS; RNA-POLYMERASE; GENE; TRICHOTHIODYSTROPHY	The apoptotic response and the level of expression of p53 and of three genes transcriptionally activated by p53 (Mdm2, p21 and bar) were investigated in UV-sensitive cells from patients with xeroderma pigmentosum (XP) or Cockayne syndome (CS), These disorders are due to different genetic defects affecting transcription-coupled repair (TCR) and/or global genome repair (GGR), the nucleotide excision repair subpathways which remove UV-induced lesions from the transcribed strand of active genes or from the rest of the genome, respectively. After 20 J/m(2) UV light, normal and GGR-defective XP-C fibroblasts showed rapid increase in p53, late induction of Mdm2 and no evidence of apoptosis even 96 h after irradiation. In contrast, in XP-A (defective in GGR and TCR), CS-A and CS-B (defective only in TCR) fibroblasts, the p53 increase was not followed by Mdm2 induction and the persistence of high levels of p53, due to the lack of its degradation by Mdm2, was associated with the appearance of apoptosis, Besides indicating that the persistence of DNA damage in the transcribed strand of active genes leads to apoptosis, these findings provide the first evidence that the lack of activation of Mdm2 plays a key role in the cascade of events leading to apoptosis.	CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy; Ist Ric Farmacol Mario Negri, Dipartimento Oncol, I-20157 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Stefanini, M (corresponding author), CNR, Ist Genet Biochim & Evoluzionist, Via Abbiategrasso 207, I-27100 Pavia, Italy.		D'Incalci, Maurizio/AAA-9021-2020	D'Incalci, Maurizio/0000-0001-8784-1360				BARRETT SF, 1991, MUTAT RES, V255, P281, DOI 10.1016/0921-8777(91)90032-K; Blattner C, 1998, ONCOGENE, V16, P2827, DOI 10.1038/sj.onc.1201827; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; CLAVANNE F, 2000, CANCER RES, V60, P1974; Colella S, 1999, HUM MOL GENET, V8, P935, DOI 10.1093/hmg/8.5.935; CONFORTI G, 1989, BLOOD, V73, P1576; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Dumaz N, 1998, CARCINOGENESIS, V19, P1701, DOI 10.1093/carcin/19.9.1701; Dumaz N, 1997, MOL CARCINOGEN, V20, P340, DOI 10.1002/(SICI)1098-2744(199712)20:4<340::AID-MC3>3.0.CO;2-N; EVANS MK, 1994, MUTAT RES, V314, P221, DOI 10.1016/0921-8777(94)90067-1; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leadon SA, 1999, AM J HUM GENET, V64, P1259, DOI 10.1086/302390; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; Ljungman M, 1996, ONCOGENE, V13, P823; Ljungman M, 1999, ONCOGENE, V18, P583, DOI 10.1038/sj.onc.1202356; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PARRIS CN, 1993, P NATL ACAD SCI USA, V90, P7260, DOI 10.1073/pnas.90.15.7260; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEFANINI M, 1986, HUM GENET, V74, P107, DOI 10.1007/BF00282072; STEFANINI M, 1992, MUTAT RES, V273, P119, DOI 10.1016/0921-8777(92)90073-C; STEFANINI M, 1993, CARCINOGENESIS, V14, P1101, DOI 10.1093/carcin/14.6.1101; Stefanini M, 1996, HUM GENET, V97, P418; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775	42	45	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2000	19	22					2714	2720		10.1038/sj.onc.1203583	http://dx.doi.org/10.1038/sj.onc.1203583			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851071				2022-12-25	WOS:000087193000007
J	Legesse-Miller, A; Sagiv, Y; Glozman, R; Elazar, Z				Legesse-Miller, A; Sagiv, Y; Glozman, R; Elazar, Z			Aut7p, a soluble autophagic factor, participates in multiple membrane trafficking processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CONJUGATION SYSTEM; SYNAPTIC VESICLE DOCKING; ENDOPLASMIC-RETICULUM; GOLGI TRANSPORT; SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; VACUOLE INHERITANCE; BINDING-PROTEIN; V-SNARE; T-SNARE	Aut7p, a protein recently implicated in autophagic events in the yeast Saccharomyces cerevisiae, exhibits significant homology to a mammalian protein, p16, herein termed GATE-16 (Golgi-associated ATPase Enhancer of 16 kDa), a novel intra-Golgi transport factor. Here we provide evidence for the involvement of Aut7p in different membrane trafficking processes. Aut7p largely substitutes for the activity of GATE-16 in mammalian intra-Golgi transport in vitro. In vivo, AUT7 interacts genetically with endoplasmic reticulum to Golgi SNAREs, specifically with BET1 and SEC22. Aut7p interacts physically with the following two v-SNAREs: Bet1p, which is involved in endoplasmic reticulum to Golgi vesicular transport, and Nyv1p, implicated in vacuolar inheritance. We suggest that, in addition to its role in autophagocytosis, Aut7p has pleiotropic effects and participates in at least two membrane traffic events.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Elazar, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							Aalto MK, 1997, P NATL ACAD SCI USA, V94, P7331, DOI 10.1073/pnas.94.14.7331; AALTO MK, 1991, YEAST, V7, P643, DOI 10.1002/yea.320070613; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; Abeliovich H, 1999, EMBO J, V18, P6005, DOI 10.1093/emboj/18.21.6005; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Baba M, 1995, CELL STRUCT FUNCT, V20, P465, DOI 10.1247/csf.20.465; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Barlowe C, 1997, J CELL BIOL, V139, P1097, DOI 10.1083/jcb.139.5.1097; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; COUVE A, 1995, P NATL ACAD SCI USA, V92, P5987, DOI 10.1073/pnas.92.13.5987; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GENGYOANDO K, 1993, NEURON, V11, P703, DOI 10.1016/0896-6273(93)90080-B; Guthrie C., 1991, GUIDE YEAST GENETICS, P194; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Legesse-Miller A, 1998, J BIOL CHEM, V273, P3105, DOI 10.1074/jbc.273.5.3105; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; Lustgarten V, 1999, MOL CELL BIOL, V19, P4480; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SCHONBACHLER M, 1995, EMBO J, V14, P1637, DOI 10.1002/j.1460-2075.1995.tb07152.x; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; Shaywitz DA, 1997, J BIOL CHEM, V272, P25413, DOI 10.1074/jbc.272.41.25413; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Soussan L, 1999, J CELL BIOL, V146, P301, DOI 10.1083/jcb.146.2.301; Spang A, 1998, J CELL BIOL, V143, P589, DOI 10.1083/jcb.143.3.589; Ungermann C, 1999, P NATL ACAD SCI USA, V96, P11194, DOI 10.1073/pnas.96.20.11194; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; von Mollard GF, 1999, MOL BIOL CELL, V10, P1719, DOI 10.1091/mbc.10.6.1719; Xu ZY, 1996, J CELL BIOL, V132, P787, DOI 10.1083/jcb.132.5.787; Xu ZY, 1998, CELL, V93, P1125, DOI 10.1016/S0092-8674(00)81457-9; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299	65	59	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32966	32973		10.1074/jbc.M000917200	http://dx.doi.org/10.1074/jbc.M000917200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10837468	hybrid			2022-12-25	WOS:000090003800081
J	Fuh, G; Garcia, KC; de Vos, AM				Fuh, G; Garcia, KC; de Vos, AM			The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor Flt-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE DOMAIN RECEPTOR; EXON 7-ENCODED DOMAIN; CRYSTAL-STRUCTURE; TYROSINE KINASE; SEMAPHORIN-III; BINDING SITE; TUMOR-CELLS; IN-VITRO; ANGIOGENESIS; MICE	Neuropilin-1 (NP-1) was first identified as a semaphorin receptor involved in neuron guidance. Subsequent studies demonstrated that NP-1 also binds an isoform of vascular endothelial growth factor (VEGF) as well as several VEGF homologs, suggesting that NP-1 may also function in angiogenesis. Here we report in vitro binding experiments that shed light on the interaction between VEGF165 and NP-1, as well as a previously unknown interaction between NP-1 and one of the VEGF receptor tyrosine kinases, VEGFR1 or Flt-1. BIA-core analysis demonstrated that, with the extracellular domain (ECD) of NP-1 immobilized at low density, VEGF165 bound with low affinity (K-d = 2 mu M) and fast kinetics. The interaction was dependent on the heparin-binding domain of VEGF165 and increased the affinity of VEGF165 for its signaling receptor VEGFR2 or kinase insert domain-containing receptor. The affinity of VEGF165 for the NP-1 ECD was greatly enhanced either by increasing the density of immobilized NP-1 (K-d = 113 aw) or by the addition of heparin (K-d = 25 nM). We attribute these affinity enhancements to avidity effects mediated by the bivalent VEGF165 homodimer or multivalent heparin. We also show that the NP-1 ECD binds with high affinity (K-d = 1.8 nM) to domains 3 and 4 of Flt-1 and that this interaction inhibits the binding of NP-1 to VEGF165. Based on these results, we propose that NP-1 acts as a coreceptor for various ligands and that these functions are dependent on the density of NP-1 on the cell membrane. Furthermore, Flt-1 may function as a negative regulator of angiogenesis by competing for NP-1.	Genentech Inc, Dept Prot Engn, S San Francisco, CA 94080 USA; Stanford Univ, Sch Med, Dept Biol Struct, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Roche Holding; Genentech; Stanford University	Fuh, G (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, S San Francisco, CA 94080 USA.							Banerjee SK, 2000, INT J ONCOL, V16, P253; Cai HB, 1999, J NEUROSCI, V19, P6519; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; PARK JE, 1994, J BIOL CHEM, V269, P25646; Park M, 1999, BIOCHEM BIOPH RES CO, V264, P730, DOI 10.1006/bbrc.1999.1580; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071	37	239	250	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26690	26695						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842181				2022-12-25	WOS:000089144800005
J	Jin, L; Briggs, SL; Chandrasekhar, S; Chirgadze, NY; Clawson, DK; Schevitz, RW; Smiley, DL; Tashjian, AH; Zhang, FM				Jin, L; Briggs, SL; Chandrasekhar, S; Chirgadze, NY; Clawson, DK; Schevitz, RW; Smiley, DL; Tashjian, AH; Zhang, FM			Cry stal structure of human parathyroid hormone 1-34 at 0.9-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-1-NMR SPECTROSCOPY; BONE MASS; TERMINAL FRAGMENTS; RECEPTOR; PROTEIN; REGION; ANALOG; CONFORMATION; OSTEOPOROSIS; ANTAGONISTS	The N-terminal fragment 1-34 of parathyroid hormone (PTH), administered intermittently, results in increased bone formation in patients with osteoporosis. PTH and a related molecule, parathyroid hormone-related peptide (PTHrP), act on cells via a common PTH/PTHrP receptor. To define more precisely the ligand-receptor interactions, we have crystallized human PTH (hPTH)-(1-34) and determined the structure to 0.9-Angstrom resolution. hPTH-(1-34) crystallizes as a slightly bent, long helical dimer, Analysis reveals that the extended helical conformation of hPTH-(1-34) is the likely bioactive conformation. We have developed molecular models for the interaction of hPTH-(1-34) and hPTHrP-(1-34) with the PTH/PTHrP receptor. A receptor binding pocket for the N terminus of hPTH-(1-34) and a hydrophobic interface with the receptor for the C terminus of hPTH-(1-34) are proposed.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Lab, Indianapolis, IN 46285 USA	Eli Lilly	Zhang, FM (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Lab, Drop Code 0403, Indianapolis, IN 46285 USA.		ID, IMCACAT/D-5867-2014					Adams AE, 1998, MOL ENDOCRINOL, V12, P1673, DOI 10.1210/me.12.11.1673; BARDEN JA, 1993, BIOCHEMISTRY-US, V32, P7126, DOI 10.1021/bi00079a008; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; Bisello A, 1998, J BIOL CHEM, V273, P22498, DOI 10.1074/jbc.273.35.22498; BLIND E, 1993, EXP CLIN ENDOCRINOL, V101, P150, DOI 10.1055/s-0029-1211222; Brommage R, 1999, J CLIN ENDOCR METAB, V84, P3757, DOI 10.1210/jc.84.10.3757; BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; Canalis Ernesto, 1994, P65; CHASE LR, 1970, J BIOL CHEM, V245, P1520; CHOREV M, 1990, BIOCHEMISTRY-US, V29, P1580, DOI 10.1021/bi00458a032; CHOREV M, 1995, BIOPOLYMERS, V36, P485, DOI 10.1002/bip.360360411; Chorev Michael, 1996, P305; CIVITELLI R, 1988, AM J PHYSIOL, V255, P660; Condon SM, 2000, J AM CHEM SOC, V122, P3007, DOI 10.1021/ja994033u; FISKIN AM, 1997, J BIOL CHEM, V252, P8261; GARDELLA TJ, 1993, ENDOCRINOLOGY, V132, P2024, DOI 10.1210/en.132.5.2024; GARDELLA TJ, 1991, J BIOL CHEM, V266, P13141; Gronwald W, 1997, BIOL CHEM, V378, P1501, DOI 10.1515/bchm.1997.378.12.1501; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KLAUS W, 1991, BIOCHEMISTRY-US, V30, P6936, DOI 10.1021/bi00242a018; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; MARX UC, 1995, J BIOL CHEM, V270, P15194, DOI 10.1074/jbc.270.25.15194; Marx UC, 2000, BIOCHEM BIOPH RES CO, V267, P213, DOI 10.1006/bbrc.1999.1958; Mierke DF, 1997, BIOCHEMISTRY-US, V36, P10372, DOI 10.1021/bi970771o; MOSEKILDE L, 1991, ENDOCRINOLOGY, V129, P421, DOI 10.1210/endo-129-1-421; MOSELEY JM, 1995, CRIT REV CL LAB SCI, V32, P299, DOI 10.3109/10408369509084687; NEUGEBAUER W, 1992, BIOCHEMISTRY-US, V31, P2056, DOI 10.1021/bi00122a023; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellegrini M, 1998, BIOCHEMISTRY-US, V37, P12737, DOI 10.1021/bi981265h; Pellegrini M, 1997, J MED CHEM, V40, P3025, DOI 10.1021/jm970181o; Pellegrini M, 1998, J BIOL CHEM, V273, P10420, DOI 10.1074/jbc.273.17.10420; POTTS JT, 1995, ENDOCRINOLOGY, V2, P920; Rolz C, 1999, BIOCHEMISTRY-US, V38, P6397, DOI 10.1021/bi9829276; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SONE T, 1995, MINER ELECTROL METAB, V21, P232; STRICKLAND LA, 1993, BIOCHEMISTRY-US, V32, P6050, DOI 10.1021/bi00074a016; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; TREGEAR GW, 1973, ENDOCRINOLOGY, V93, P1349, DOI 10.1210/endo-93-6-1349; Vickery BH, 1996, J BONE MINER RES, V11, P1943; Weidler M, 1999, FEBS LETT, V444, P239, DOI 10.1016/S0014-5793(98)01658-5; WRAY V, 1994, BIOCHEMISTRY-US, V33, P1684, DOI 10.1021/bi00173a010	42	108	131	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27238	27244						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10837469				2022-12-25	WOS:000089144800076
J	Zhu, CY; Johansson, M; Karlsson, A				Zhu, CY; Johansson, M; Karlsson, A			Incorporation of nucleoside analogs into nuclear or mitochondrial DNA is determined by the intracellular phosphorylation site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE-EXTRACTS; DEOXYGUANOSINE KINASE; DEOXYCYTIDINE KINASE; CYTOCHROME-C; SUBSTRATE-SPECIFICITY; THYMIDINE KINASE-1; APOPTOTIC PROGRAM; ARA-C; TOXICITY; 2-CHLORODEOXYADENOSINE	Nucleoside analogs used in cancer chemotherapy and in treatment of virus infections are phosphorylated in cells by nucleoside and nucleotide kinases to their pharmacologically active form. The phosphorylated nucleoside analogs are incorporated into DNA and cause cell death or inhibit viral replication. Cellular DNA is replicated both in the nucleus and in the mitochondria, and nucleoside analogs may interfere with DNA replication in both these subcellular locations, In the present study we created a cell model system where nucleoside analogs were phosphorylated, and thereby pharmacologically activated, in either the nucleus, cytosol, or mitochondria of cancer cells. The system was based on the reconstitution of deoxycytidine kinase (dCK)-deficient Chinese hamster ovary cells with genetically engineered dCK targeted to the different subcellular compartments. The nucleoside analogs phosphorylated by dCK in the mitochondria were predominantly incorporated into mitochondrial DNA, whereas the nucleoside analogs phosphorylated in the nucleus or cytosol were incorporated into nuclear DNA, We further show that the nucleoside analogs phosphorylated in the mitochondria induced cell death by an apoptotic program. These data showed that the subcellular site of nucleoside analog phosphorylation is an important determinant for incorporation of nucleoside analogs into nuclear or mitochondrial DNA.	Huddinge Univ Hosp, Karolinska Inst, Div Clin Virol, S-14186 Huddinge, Sweden	Karolinska Institutet	Karlsson, A (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Div Clin Virol, S-14186 Huddinge, Sweden.		Karlsson, Anna/E-7945-2018	Karlsson, Anna/0000-0001-6843-6685				ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6; BALZARINI J, 1994, PHARM WORLD SCI, V16, P113, DOI 10.1007/BF01880662; BERK AJ, 1973, J BIOL CHEM, V248, P2722; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; BEUTLER E, 1992, LANCET, V340, P952, DOI 10.1016/0140-6736(92)92826-2; BOGENHAGEN D, 1977, CELL, V11, P719, DOI 10.1016/0092-8674(77)90286-0; Bogenhagen DF, 1999, AM J HUM GENET, V64, P1276, DOI 10.1086/302392; Bridges EG, 1999, J BIOL CHEM, V274, P4620, DOI 10.1074/jbc.274.8.4620; CHEN CH, 1992, J BIOL CHEM, V267, P2856; CHEN CH, 1991, MOL PHARMACOL, V39, P625; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883; GOWER WR, 1979, J BIOL CHEM, V254, P2180; HARRIS BA, 1981, MOL PHARMACOL, V20, P200; Hatzis P, 1998, J BIOL CHEM, V273, P30239, DOI 10.1074/jbc.273.46.30239; Hui YF, 1997, AM J HEALTH-SYST PH, V54, P162, DOI 10.1093/ajhp/54.2.162; Iwasaki H, 1997, BLOOD, V90, P270; Kim CN, 1997, CANCER RES, V57, P3115; KUFE D, 1984, BLOOD, V64, P54; Leoni LM, 1998, P NATL ACAD SCI USA, V95, P9567, DOI 10.1073/pnas.95.16.9567; Lewis W, 1996, P NATL ACAD SCI USA, V93, P3592, DOI 10.1073/pnas.93.8.3592; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; SODERLUND JCF, 1995, ADV EXP MED BIOL, V370, P201; Wang JH, 1996, ANTIMICROB AGENTS CH, V40, P1555, DOI 10.1128/AAC.40.6.1555; WANG LY, 1993, J BIOL CHEM, V268, P22847; Wettin K, 1999, FEBS LETT, V460, P103, DOI 10.1016/S0014-5793(99)01325-3; WYLIE AH, 1980, NATURE, V284, P555; Zhu CY, 1998, J BIOL CHEM, V273, P14707, DOI 10.1074/jbc.273.24.14707; Zhu CY, 1998, BIOCHEM PHARMACOL, V56, P1035, DOI 10.1016/S0006-2952(98)00150-6	33	33	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26727	26731						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10827186				2022-12-25	WOS:000089144800010
J	Ringvall, M; Ledin, J; Holmborn, K; van Kuppevelt, T; Ellin, F; Eriksson, I; Olofsson, AM; Kjellen, L; Forsberg, E				Ringvall, M; Ledin, J; Holmborn, K; van Kuppevelt, T; Ellin, F; Eriksson, I; Olofsson, AM; Kjellen, L; Forsberg, E			Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking N-deacetylase/N-sulfotransferase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-DEACETYLASE/N-SULFOTRANSFERASE; MOLECULAR-CLONING; MAST-CELLS; EXPRESSION; DROSOPHILA; PROTEOGLYCANS; MOUSE; GENE; ENZYME; IDENTIFICATION	Heparan sulfate is a sulfated polysaccharide present on most cell surfaces and in the extracellular matrix. In vivo functions of heparan sulfate can be studied in mouse strains lacking enzymes involved in the biosynthesis of heparan sulfate. Glucosaminyl N-deacetylase/N-suLfotransferase (NDST) catalyzes the first modifying step in the biosynthesis of the polysaccharide. This bifunctional enzyme occurs in several isoforms. We here report that targeted gene disruption of NDST-1 in the mouse results in a structural alteration of heparan sulfate in most basement membranes as revealed by immunohistochemical staining of fetal tissue sections using antibodies raised against heparan sulfate. Biochemical analysis of heparan sulfate purified from fibroblast cultures, lung, and liver of NDST-1-deficient embryos demonstrated a dramatic reduction in N-sulfate content. Most NDST-1-deficient embryos survive until birth; however, they turn out to be cyanotic and die neonatally in a condition resembling respiratory distress syndrome. In addition, a minor proportion of NDST-1 deficient embryos die during the embryonic period. The cause of the embryonic lethality is still obscure, but incompletely penetrant defects of the skull and the eyes have been observed.	Univ Uppsala, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Swedish Univ Agr Sci, Dept Vet Med Chem, S-75123 Uppsala, Sweden; Catholic Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Univ Uppsala, Dept Cell & Mol Biol, S-75123 Uppsala, Sweden	Uppsala University; Swedish University of Agricultural Sciences; Radboud University Nijmegen; Uppsala University	Forsberg, E (corresponding author), Univ Uppsala, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden.		van Kuppevelt, A.H.M.S.M./L-4463-2015; Kjellen, Lena/F-1362-2011	Ellin, Fredrik/0000-0001-9034-5966; Ledin, Johan/0000-0002-7319-7735				ABBONDANZO SJ, 1993, METHOD ENZYMOL, V225, P803; Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; Arikawa-Hirasawa E, 1999, NAT GENET, V23, P354, DOI 10.1038/15537; AVERY ME, 1959, AM J DIS CHILD, V97, P17; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Cano-Gauci DF, 1999, J CELL BIOL, V146, P255; Cheung WF, 1996, BIOCHEMISTRY-US, V35, P5250, DOI 10.1021/bi952325b; Costell M, 1999, J CELL BIOL, V147, P1109, DOI 10.1083/jcb.147.5.1109; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Jenniskens GJ, 2000, J NEUROSCI, V20, P4099; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kusche-Gullberg M, 1998, J BIOL CHEM, V273, P11902, DOI 10.1074/jbc.273.19.11902; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Sannes PL, 1998, AM J PHYSIOL-LUNG C, V275, pL701, DOI 10.1152/ajplung.1998.275.4.L701; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; Toma L, 1998, J BIOL CHEM, V273, P22458, DOI 10.1074/jbc.273.35.22458; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; Wong CJ, 1996, PEDIATR RES, V39, P930, DOI 10.1203/00006450-199606000-00002	42	200	204	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25926	25930		10.1074/jbc.C000359200	http://dx.doi.org/10.1074/jbc.C000359200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852901	hybrid			2022-12-25	WOS:000088999700008
J	Bai, JH; Earles, CA; Lewis, JL; Chapman, ER				Bai, JH; Earles, CA; Lewis, JL; Chapman, ER			Membrane-embedded synaptotagmin penetrates cis or trans target membranes and clusters via a novel mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C2 DOMAIN; CALCIUM-DEPENDENCE; C(2)A DOMAIN; BINDING; FUSION; CA2+; DEPTH; DROSOPHILA; EXOCYTOSIS; BILAYERS	The synaptic vesicle protein synaptotagmin I has been proposed to serve as a Ca2+ sensor for rapid exocytosis, Synaptotagmin spans the vesicle membrane once and possesses a cytoplasmic domain largely comprised of two C2 domains designated C2A and C2B. We have determined how deep the Ca2+-binding loops of Ca2+ C2A penetrate into the lipid bilayer and report mutations in synaptotagmin that can uncouple membrane penetration from Ca2+-triggered interactions with the SNARE complex. To determine whether C2A penetrates into the vesicle ("cis") or plasma ("trans") membrane, we reconstituted a fragment of synaptotagmin that includes the membrane-spanning and C2A domain (C2A-TMR) into proteoliposomes. Kinetics experiments revealed that cis interactions are rapid (less than or equal to 500 mu s). Binding in the trans mode was distinguished by the slow diffusion of trans target vesicles, Both modes of binding were observed, indicating that the linker between the membrane anchor and C2A domain functions as a flexible tether. C2A-TMR assembled into oligomers via a novel N-terminal oligomerization domain suggesting that synaptotagmin may form clusters on the surface of synaptic vesicles. This novel mode of clustering may allow for rapid Ca2+- triggered oligomerization of the protein via the membrane distal C2B domain.	Univ Wisconsin, Dept Physiol, Sch Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Chapman, ER (corresponding author), Univ Wisconsin, Dept Physiol, Sch Med, 1300 Univ Ave,SMI 129, Madison, WI 53706 USA.			Chapman, Edwin/0000-0001-9787-8140	NIGMS NIH HHS [GM 56827-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056827] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5312, DOI 10.1021/bi00138a010; Birks J., 1970, PHOTOPHYSICS AROMATI, DOI DOI 10.1002/BBPC.19700741223; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Chae YK, 1998, J BIOL CHEM, V273, P25659, DOI 10.1074/jbc.273.40.25659; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; Chapman ER, 1996, J BIOL CHEM, V271, P5844, DOI 10.1074/jbc.271.10.5844; Chapman ER, 1996, BIOCHEM BIOPH RES CO, V225, P326, DOI 10.1006/bbrc.1996.1174; Chapman ER, 1998, J BIOL CHEM, V273, P13995, DOI 10.1074/jbc.273.22.13995; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HELLER H, 1993, J PHYS CHEM-US, V97, P8343, DOI 10.1021/j100133a034; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MCINTOSH TJ, 1987, BIOCHEMISTRY-US, V26, P1783, DOI 10.1021/bi00380a042; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Ren JH, 1997, BIOCHEMISTRY-US, V36, P10213, DOI 10.1021/bi9709295; Sabatini BL, 1996, NATURE, V384, P170, DOI 10.1038/384170a0; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; Shao XG, 1998, BIOCHEMISTRY-US, V37, P16106, DOI 10.1021/bi981789h; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TUGAL HB, 1991, BIOCHEM J, V279, P699, DOI 10.1042/bj2790699; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zhang XY, 1998, BIOCHEMISTRY-US, V37, P12395, DOI 10.1021/bi9807512	45	69	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25427	25435		10.1074/jbc.M906729199	http://dx.doi.org/10.1074/jbc.M906729199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10840045	hybrid			2022-12-25	WOS:000088849400051
J	Knoop, LL; Baker, SJ				Knoop, LL; Baker, SJ			The splicing factor U1C represses EWS/FLI-mediated transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; EXTRASKELETAL MYXOID CHONDROSARCOMA; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEINS; EWINGS-SARCOMA TRANSLOCATION; PRO-ONCOPROTEIN TLS/FUS; BINDING PROTEIN; DNA-BINDING; TRANSCRIPTION FACTOR; CHROMOSOME-TRANSLOCATION; MYELOID-LEUKEMIA	EWS is an RNA-binding protein involved in human tumor-specific chromosomal translocations, In approximately 85% of Ewing's sarcomas, such translocations give rise to the chimeric gene EWS/FLI. In the resulting fusion protein, the RNA binding domains from the C terminus of EWS are replaced by the DNA-binding domain of the ETS protein FLI-1, EWS/FLI can function as a transcription factor with the same DNA binding specificity as FLI-1. EWS and EWS/FLI can associate with the RNA polymerase II holoenzyme as well as with SF1, an essential splicing factor, Here we report that U1C, one of three human U1 small nuclear ribonucleoprotein-specific proteins, interacts in vitro and in vivo with both EWS and EWS/FLI. U1C interacts with other splicing factors and is important in the early stages of spliceosome formation. Importantly, co-expression of U1C represses EWS/FLI-mediated transactivation, demonstrating that this interaction can have functional ramifications. Our findings demonstrate that U1C, a well characterized splicing protein, can also function in transcriptional regulation. Furthermore, they suggest that EWS and EWS/FLI may function both in transcriptional and post-transcriptional processes.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; Univ Tennessee, Dept Pathol, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Baker, SJ (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.	Suzanne.baker@stjude.org			NCI NIH HHS [P30 CA21765, P01-CA-71907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA071907, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arning S, 1996, RNA, V2, P794; Attwooll C, 1999, ONCOGENE, V18, P7599, DOI 10.1038/sj.onc.1203156; Baechtold H, 1999, J BIOL CHEM, V274, P34337, DOI 10.1074/jbc.274.48.34337; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1999, ONCOGENE, V18, P8000, DOI 10.1038/sj.onc.1203207; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bertrand P, 1999, ONCOGENE, V18, P4515, DOI 10.1038/sj.onc.1203048; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; Brody RI, 1997, AM J PATHOL, V150, P1049; BROWN AD, 1995, ONCOGENE, V10, P1749; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Dalton S, 1997, MOL CELL BIOL, V17, P5867, DOI 10.1128/MCB.17.10.5867; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Galjaard H., 1980, GENETIC METABOLIC DI; Ghigna C, 1998, CANCER RES, V58, P5818; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; Hicks GG, 2000, NAT GENET, V24, P175, DOI 10.1038/72842; Hosokawa Y, 1997, CANCER LETT, V113, P123, DOI 10.1016/S0304-3835(97)04605-3; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Kuroda M, 2000, EMBO J, V19, P453, DOI 10.1093/emboj/19.3.453; LADANYI M, 1994, CANCER RES, V54, P2837; LESSNICK SL, 1995, ONCOGENE, V10, P423; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; NELISSEN RLH, 1994, EMBO J, V13, P4113, DOI 10.1002/j.1460-2075.1994.tb06729.x; Panagopoulos I, 1999, ONCOGENE, V18, P7594, DOI 10.1038/sj.onc.1203155; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; QUERY CC, 1989, MOL CELL BIOL, V9, P4872, DOI 10.1128/MCB.9.11.4872; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; Sjogren H, 1999, CANCER RES, V59, P5064; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; Zhang D, 1998, J BIOL CHEM, V273, P18086, DOI 10.1074/jbc.273.29.18086; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	56	99	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24865	24871		10.1074/jbc.M001661200	http://dx.doi.org/10.1074/jbc.M001661200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827180	hybrid			2022-12-25	WOS:000088683300084
J	Phelps, CB; Sengchanthalangsy, LL; Malek, S; Ghosh, G				Phelps, CB; Sengchanthalangsy, LL; Malek, S; Ghosh, G			Mechanism of kappa B DNA binding by Rel/NF-kappa B dimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; P50 HOMODIMER; P50/P65 HETERODIMER; ACTIVATION; DIMERIZATION; PROTEINS; COMPLEX; SUBUNIT; SITE	The DNA binding of three different NF-KB dimers, the p50 and p65 homodimers and the p50/p65 heterodimer, has been examined using a combination of gel mobility shift and fluorescence anisotropy assays. The NF-KB p50/p65 heterodimer is shown here to bind the KB DNA target site of the immunoglobulin kappa enhancer (Ig-KB) with an affinity of approximately 10 nM. The p50 and p65 homodimers bind to the same site with roughly 5- and 15-fold lower affinity, respectively. The nature of the binding isotherms indicates a cooperative mode of binding for all three dimers to the DNA targets. We have further characterized the role of pH, salt, and temperature on the formation of the p50/p65 heterodimer-Ig-KB complex. The heterodimer binds to the Ig-KB DNA target in a pH-dependent manner, with the highest affinity between pH 7.0 and 7.5. A strong salt-dependent interaction between Ig-KB and the p50/p65 heterodimer is observed, with optimum binding occurring at monovalent salt concentrations below 75 mM, with binding becoming virtually nonspecific at a salt concentration of 200 mM. Binding of the heterodimer to DNA was unchanged across a temperature range between 4 degrees C and 42 degrees C. The sensitivity to ionic environment and insensitivity to temperature indicate that NF-KB p50/p65 heterodimers form complexes with specific DNA in an entropically driven manner.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.			Malek, Shiva/0000-0002-9526-7968	NCI NIH HHS [CA-71871] Funding Source: Medline; NIGMS NIH HHS [2-T32-GM07240-24] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Chen FE, 1999, PROTEIN ENG, V12, P423, DOI 10.1093/protein/12.5.423; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HA JH, 1992, J MOL BIOL, V228, P252, DOI 10.1016/0022-2836(92)90504-D; Huang DB, 1997, STRUCTURE, V5, P1427, DOI 10.1016/S0969-2126(97)00293-1; LOHMAN TM, 1980, BIOCHEMISTRY-US, V19, P3522, DOI 10.1021/bi00556a017; Lundback T, 1996, P NATL ACAD SCI USA, V93, P4754, DOI 10.1073/pnas.93.10.4754; MATTHEWS JR, 1995, NUCLEIC ACIDS RES, V23, P3393, DOI 10.1093/nar/23.17.3393; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; O'Brien R, 1998, J MOL BIOL, V279, P117, DOI 10.1006/jmbi.1998.1743; Sengchanthalangsy LL, 1999, J MOL BIOL, V289, P1029, DOI 10.1006/jmbi.1999.2823; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Tisne C, 1999, J MOL BIOL, V293, P139, DOI 10.1006/jmbi.1999.3157; Tisne C, 1998, J MOL BIOL, V279, P127, DOI 10.1006/jmbi.1998.1757; Tisne C, 1999, BIOCHEMISTRY-US, V38, P3883, DOI 10.1021/bi982402d; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; Zhou P, 1998, CELL, V92, P687, DOI 10.1016/S0092-8674(00)81136-8	25	116	117	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24392	24399		10.1074/jbc.M003784200	http://dx.doi.org/10.1074/jbc.M003784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10825175	hybrid			2022-12-25	WOS:000088683300021
J	Wiesel, P; Foster, LC; Pellacani, A; Layne, MD; Hsieh, CM; Huggins, GS; Strauss, P; Yet, SF; Perrella, MA				Wiesel, P; Foster, LC; Pellacani, A; Layne, MD; Hsieh, CM; Huggins, GS; Strauss, P; Yet, SF; Perrella, MA			Thioredoxin facilitates the induction of heme oxygenase-1 in response to inflammatory mediators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; SMOOTH-MUSCLE CELLS; NF-KAPPA-B; REDOX REGULATION; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSCRIPTION FACTORS; DIRECT ASSOCIATION; CARBON-MONOXIDE; STRESS PROTEIN; AP-1	Heme oxygenase (HO)-1 is a stress response protein that is regulated by oxidative stress. HO-1 catalyzes the generation of biliverdin, carbon monoxide, and iron from heme. Lipopolysaccharide (LPS) and interleukin (IL)-1 beta induce HO-1 through the binding of nuclear proteins to AP-1 motifs in enhancer regions upstream from the transcription start site. The DNA binding activity of AP-1 proteins depends on the reduction of cysteines in their DNA-binding domains. We found that agents that disrupt free sulfhydryl groups abolish AP-1 binding activity in nuclear proteins obtained from rat aortic smooth muscle cells and macrophages stimulated with IL-1 beta or LPS. Thioredoxin (TRX) may regulate the redox status of nuclear transcription factors in response to oxidative stimuli, thus we determined the role of TRX in the physiologic regulation of HO-1. TRX underwent nuclear translocation in cells stimulated with IL-1 beta and LPS, We transfected macrophages with a heterologous promoter construct containing two AP-1 sites from an upstream enhancer region in the HO-1 promoter. Recombinant TRX induced promoter activity to a level analogous to that induced by LPS, and this TRX response was abolished by mutation of the AP-1 sites. An inhibitor of TRX reductase, used to prevent TRS translocation in the reduced state, decreased HO-1 induction by IL-1 beta and LPS. These data provide the first evidence that TRX contributes to the induction of HO-1 by inflammatory mediators.	Brigham & Womens Hosp, Div Cardiovasc, Program Dev Cardiovasc Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Massachusetts Gen Hosp, Cardiac Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Northeastern Univ, Dept Biol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Northeastern University	Perrella, MA (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, Program Dev Cardiovasc Biol, 75 Francis St, Boston, MA 02115 USA.		Yet, Shaw-Fang/B-1067-2010; Yet, Shaw-Fang/O-8583-2019	Yet, Shaw-Fang/0000-0001-9097-3962; Layne, Matthew/0000-0003-0007-4870	NHLBI NIH HHS [HL10113, HL60788, HL03194] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060788, F32HL010113] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ALAM J, 1992, J BIOL CHEM, V267, P21894; ARNER ESJ, 1995, J BIOL CHEM, V270, P3479, DOI 10.1074/jbc.270.8.3479; BIGUET C, 1994, J BIOL CHEM, V269, P28865; CAMHI SL, 1995, AM J RESP CELL MOL, V13, P387, DOI 10.1165/ajrcmb.13.4.7546768; Camhi SL, 1998, AM J RESP CELL MOL, V18, P226, DOI 10.1165/ajrcmb.18.2.2910; CHRISTODOULIDES N, 1995, CIRCULATION, V91, P2306, DOI 10.1161/01.CIR.91.9.2306; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Friedrichs B, 1998, ARTERIOSCL THROM VAS, V18, P1829, DOI 10.1161/01.ATV.18.12.1829; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1978, BIOCHEMISTRY-US, V17, P4071, DOI 10.1021/bi00612a031; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KARIN M, 1997, NEW ENGL J MED, V336, P1066; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; Masutani H, 1996, IMMUNOL LETT, V54, P67, DOI 10.1016/S0165-2478(96)02651-X; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; Nikitovic D, 1998, BIOCHEM BIOPH RES CO, V242, P109, DOI 10.1006/bbrc.1997.7930; Pellacani A, 1998, CIRC RES, V83, P396, DOI 10.1161/01.RES.83.4.396; Perrella MA, 1996, J BIOL CHEM, V271, P13776, DOI 10.1074/jbc.271.23.13776; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; Schenk H, 1996, J IMMUNOL, V156, P765; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; STOCKER R, 1987, SCIENCE, V235, P1042; Tanaka T, 1997, LAB INVEST, V77, P145; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163; Yet SF, 1997, J BIOL CHEM, V272, P4295, DOI 10.1074/jbc.272.7.4295	38	106	109	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24840	24846		10.1074/jbc.M000835200	http://dx.doi.org/10.1074/jbc.M000835200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10823822	hybrid			2022-12-25	WOS:000088683300081
J	Bouche, M; Canipari, R; Melchionna, R; Willems, D; Senni, MI; Molinaro, M				Bouche, M; Canipari, R; Melchionna, R; Willems, D; Senni, MI; Molinaro, M			TGF-beta autocrine loop regulates cell growth and myogenic differentiation in human rhabdomyosarcoma cells	FASEB JOURNAL			English	Article						TPA; serine-protease system; muscle regulatory factors; RD cells	UROKINASE PLASMINOGEN-ACTIVATOR; SOFT-TISSUE TUMORS; MESSENGER-RNA; 12-O-TETRADECANOYLPHORBOL-13-ACETATE-INDUCED DIFFERENTIATION; FACTOR RECEPTOR; DNA-BINDING; EXPRESSION; PROTEIN; LOCALIZATION; INHIBITION	Transforming growth factor beta (TGF) is a well-known inhibitor of myogenic differentiation as well as an autocrine product of rhabdomyosarcoma cells. We studied the role of the TGF-beta autocrine loop in regulating growth and myogenic differentiation in the human rhabdomyosarcoma cell, line, RD. We previously reported that the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) induces growth arrest and myogenic differentiation in these cells, which constitutively express muscle regulatory factors. We show that TPA inhibits the activation of secreted latent TGF-beta, thus decreasing the concentration of active TGF-beta to which the cells are exposed. This event is mediated by the TPA-induced alteration of the uPA/ PAI serine-protease system. Complete removal of TGF-beta, mediated by the ectopic expression of a soluble type II TGF-beta receptor dominant negative cDNA, induces growth arrest, but does not trigger differentiation. In contrast, a reduction in the TGF-beta concentration, to a range of 0.14-0.20 x 10(-2) ng/ml (which is similar to that measured in TPA-treated cells), mimics TPA-induced differentiation. Taken together, these data demonstrate that cell growth and suppression of differentiation in rhabdomyosarcoma cells require overproduction of active TGF-beta; furthermore, they show that a 'critical' concentration of TGF-beta is necessary for myogenic differentiation to occur, whereas myogenesis is abolished below and above this concentration. By impairing the TGF-beta autocrine loop, TPA stabilizes the factor concentration within the range compatible for differentiation to occur. In contrast, in human primary muscle cells a much higher concentration of exogenous TGF-beta is required for the differentiation inhibitory effect and TPA inhibits differentiation in these cells probably through a TGF-beta independent mechanism. These data thus clarify the mechanism underlying the multiple roles of TGF-beta in the regulation of both the transformed and differentiated phenotype.-Bouche, M., Canipari, R., Melchionna, R., Willems, D., Senni, M. I., Molinaro, M. TGF-beta autocrine loop regulates cell growth and myogenic differentiation in human rhabdomyosarcoma cells.	Univ Roma La Sapienza, Dept Histol & Med Embryol, I-00161 Rome, Italy	Sapienza University Rome	Bouche, M (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, Via A Scarpa 14, I-00161 Rome, Italy.	bouche@uniroma1.it	melchionna, Roberta/G-2479-2011; SENNI, MICHELE/J-9380-2018	Melchionna, Roberta/0000-0002-8410-9681; SENNI, MICHELE/0000-0001-5502-7882; Bouche, Marina/0000-0002-0938-5360; CANIPARI, Rita/0000-0003-3481-6908	Telethon [859] Funding Source: Medline	Telethon(Fondazione Telethon)		ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; AGUANNO S, 1990, CANCER RES, V50, P3377; ANDREASEN PA, 1990, MOL CELL ENDOCRINOL, V68, P1, DOI 10.1016/0303-7207(90)90164-4; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; BELIN D, 1984, EMBO J, V3, P1901, DOI 10.1002/j.1460-2075.1984.tb02065.x; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BOUCHE M, 1995, CELL GROWTH DIFFER, V6, P845; BOUCHE M, 1993, EXP CELL RES, V208, P209, DOI 10.1006/excr.1993.1239; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DeGiovanni C, 1996, CANCER RES, V56, P3898; DEGIOVANNI C, 1995, BRIT J CANCER, V72, P1224, DOI 10.1038/bjc.1995.490; DERYNCK R, 1987, CANCER RES, V47, P707; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; FILVAROFF EH, 1994, DEVELOPMENT, V120, P1085; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MALONE M, 1994, HISTOPATHOLOGY, V24, P197, DOI 10.1111/j.1365-2559.1994.tb01309.x; MALONE M, 1993, HISTOPATHOLOGY, V23, P203, DOI 10.1111/j.1365-2559.1993.tb01192.x; MARTIN JF, 1992, J BIOL CHEM, V267, P10956; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MAYER M, 1988, J BIOL CHEM, V263, P15688; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MunozCanoves P, 1997, THROMB HAEMOSTASIS, V77, P526; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PLOUG M, 1991, J BIOL CHEM, V266, P1926; QUAX PHA, 1992, DEV BIOL, V151, P166, DOI 10.1016/0012-1606(92)90224-5; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86; VERDE P, 1984, P NATL ACAD SCI-BIOL, V81, P4727, DOI 10.1073/pnas.81.15.4727; WELLS JM, 1994, DEVELOPMENT, V120, P3639; Wells JM, 1997, J CELL PHYSIOL, V171, P217, DOI 10.1002/(SICI)1097-4652(199705)171:2<217::AID-JCP13>3.0.CO;2-A; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	42	42	48	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1147	1158		10.1096/fasebj.14.9.1147	http://dx.doi.org/10.1096/fasebj.14.9.1147			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834937				2022-12-25	WOS:000087427300012
J	Zheng, XL; Matsubara, S; Diao, C; Hollenberg, MD; Wong, NCW				Zheng, XL; Matsubara, S; Diao, C; Hollenberg, MD; Wong, NCW			Activation of apolipoprotein AI gene expression by protein kinase A and kinase C through transcription factor, Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; REVERSE CHOLESTEROL TRANSPORT; HIGH-DENSITY-LIPOPROTEIN; MOLECULAR MECHANISMS; MESSENGER-RNA; DNA-BINDING; FACTOR AP-2; PHOSPHORYLATION; INHIBITOR; PROMOTER	Our previous finding that insulin induces apolipoprotein AI (apoAI) transcription points to the participation of intracellular signaling. This finding prompted us to ask whether two classical G-protein-coupled signaling pathways requiring activated protein kinase A (PKA) or kinase C (PKC) may also regulate apoAI. Therefore, human hepatoma, Rep G2 cells stably transfected with pAI.474-CAT, a reporter construct spanning -474 to -7 of apoAI DNA fused to chloramphenicol acetyltransferase (CAT) were treated with 10 mu M forskolin (FSK) or 50 nM phorbol dibutyrate (PDBu) to activate PKA and PKC, respectively, Results showed that the apoAI promoter activity increased 4-5-fold following 24 h of treatment with either FSK or PDBu. Induction by either agent was blocked with actinomycin D but not the protein synthesis inhibitor, cycloheximide. The PKA inhibitor, PKI 14-22 amide, abrogated induction by FSK, 100 mu M 8-bromo-cAMP, or 100 ng/ml cholera toxin, but it had no effect on activation via PKC. Similarly, PDBu induction was attenuated by 2 mu M Of the PKC inhibitor, GF109203X, but it did not affect FSK activity. Next we used deletional constructs to show that the actions of FSK and PDBu required the insulin-responsive core element (IRCE). This motif matched the consensus binding site for the transcription factor, Spl. The binding of Spl to the IRCE was confirmed by gel-retardation and supershift analysis. Site-directed mutagenesis of the IRCE eliminated Spl action and induction by FSK or PDBu. Whereas overexpression of Spl enhanced basal and FSK or PDBu induced promoter activity, transfection of an antisense oligomer against Spl mRNA attenuated both parameters. In summary, activation of PKA or PKC increases apoAI promoter activity. The activity of both signaling pathways is mediated by the IRCE, a motif that binds the transcription factor, Spl.	Univ Calgary, Fac Med, Hlth Sci Ctr, Dept Med,Endocrine Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Pharmacol & Therapeut, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Calgary	Wong, NCW (corresponding author), Univ Calgary, Fac Med, Hlth Sci Ctr, Dept Med,Endocrine Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Hollenberg, Morley/AFV-6966-2022	Zheng, Xi-Long/0000-0002-0889-1827				Andersson LO, 1997, CURR OPIN LIPIDOL, V8, P225, DOI 10.1097/00041433-199708000-00006; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Barter PJ, 1996, ATHEROSCLEROSIS, V121, P1, DOI 10.1016/0021-9150(95)05675-0; Barter PJ, 1996, CURR OPIN LIPIDOL, V7, P82, DOI 10.1097/00041433-199604000-00006; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; Cook T, 1999, ANN NY ACAD SCI, V880, P94, DOI 10.1111/j.1749-6632.1999.tb09513.x; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; de Backer G, 1998, ATHEROSCLEROSIS, V137, pS1, DOI 10.1016/S0021-9150(97)00310-9; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; GLASS DB, 1989, J BIOL CHEM, V264, P8802; Hargrove GM, 1999, J MOL ENDOCRINOL, V22, P103, DOI 10.1677/jme.0.0220103; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KILBOURNE EJ, 1995, J BIOL CHEM, V270, P7004, DOI 10.1074/jbc.270.12.7004; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; Luoma PV, 1997, PHARMACOL TOXICOL, V81, P57, DOI 10.1111/j.1600-0773.1997.tb00032.x; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; Murao K, 1998, J BIOL CHEM, V273, P18959, DOI 10.1074/jbc.273.30.18959; Ness GC, 1998, BIOCHEM PHARMACOL, V56, P121, DOI 10.1016/S0006-2952(98)00119-1; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Ries S, 1998, J LIPID RES, V39, P2125; Rohlff C, 1998, INT J ONCOL, V12, P383; ROMNEY JS, 1992, MOL ENDOCRINOL, V6, P943, DOI 10.1210/me.6.6.943; Sakai T, 2000, ATHEROSCLEROSIS, V149, P43, DOI 10.1016/S0021-9150(99)00292-0; SOYAL SM, 1995, J BIOL CHEM, V270, P3996, DOI 10.1074/jbc.270.8.3996; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Ungefroren H, 1998, J BIOL CHEM, V273, P29230, DOI 10.1074/jbc.273.44.29230; Wu JYJ, 1999, AM J PHYSIOL-CELL PH, V277, pC537, DOI 10.1152/ajpcell.1999.277.3.C537; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; Zheng XL, 1999, J PHARMACOL EXP THER, V289, P632	36	51	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 13	2000	275	41					31747	31754		10.1074/jbc.M000621200	http://dx.doi.org/10.1074/jbc.M000621200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	363VT	10829013	hybrid			2022-12-25	WOS:000089858900030
J	Masai, H; Matsui, E; You, ZY; Ishimi, Y; Tamai, K; Arai, K				Masai, H; Matsui, E; You, ZY; Ishimi, Y; Tamai, K; Arai, K			Human Cdc7-related kinase complex - In vitro phosphorylation of MCM by concerted actions of Cdks and Cdc7 and that of a critical threonine residue of Cdc7 by Cdks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE CDC7; DNA HELICASE ACTIVITY; CELL-CYCLE REGULATION; LARGE TUMOR-ANTIGEN; PROTEIN-KINASE; S-PHASE; REPLICATION ORIGINS; G(1)/S TRANSITION; MAMMALIAN-CELLS; FISSION YEAST	huCdc7 encodes a catalytic subunit for Saccharomyces cerevisae Cdc7-related kinase complex of human. ASK, whose expression is cell cycle-regulated, binds and activates huCdc7 kinase in a cell cycle-dependent manner (Kumagai, H., Sato, N., Yamada, M., Mahony, D., Seghezzi, W., Lees, E., Arai, K., and Masai, H. (1999) Mel. Cell. Biol. 19, 5083-5095). We have expressed huCdc7 complexed with ASK regulatory subunit using the insect cell expression system. To facilitate purification of the kinase complex, glutathione S-transferase (GST) was fused to huCdc7 and GST-huCdc7-ASK complex was purified. GST-huCdc7 protein is inert as a kinase on its own, and phosphorylation absolutely depends on the presence of the ASK subunit, It autophosphorylates both subunits in vitro and phosphorylates a number of replication proteins to different extents. Among them, MCM2 protein, either in a free form or in a MCM2-4-6-7 complex, serves as an excellent substrate for huCdc7-ASK kinase complex in vitro. MCM4 and MCM6 are also phosphorylated by huCdc7 albeit to less extent. MCM2 and -4 in the MCM2-4-6-7 complex are phosphorylated by Cdks as well, and prior phosphorylation of the MCM2-4-6-7 complex by Cdks facilitates phosphorylation of MCM2 by huCdc7, suggesting collaboration between Cdks and Cdc7 in phosphorylation of MCM for initiation of S phase. huCdc7 and ASK proteins can also be phosphorylated by Cdks in vitro. Among four possible Cdk phosphorylation sites of huCdc7, replacement of Thr-376, corresponding to the activating threonine of Cdk, with alanine (T376A mutant) dramatically reduces kinase activity, indicative of kinase activation by phosphorylation of this residue. In vitro, Cdk2-Cyclin E, Cdk2-Cyclin A, and Cdc2-Cyclin B, but not Cdk4-Cyclin D1, phosphorylates the Thr-376 residue of huCdc7, suggesting possible regulation of huCdc7 by Cdks.	Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Tokyo 1088639, Japan; CREST, Japan Sci & Technol Corp, JST, Machida, Tokyo 1940031, Japan; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 1940031, Japan; Med & Biol Labs Co Ltd, Nagano 1063103, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Masai, H (corresponding author), Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.		Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911				Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Brown GW, 1998, J BIOL CHEM, V273, P22083, DOI 10.1074/jbc.273.34.22083; BUCK V, 1991, MOL GEN GENET, V227, P452, DOI 10.1007/BF00273937; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; DOWELL SJ, 1994, SCIENCE, V265, P1243, DOI 10.1126/science.8066465; Draetta G.F., 1997, CURR BIOL, V7, P50; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FUJITA M, 1999, FRONT BIOSCI, V4, P816; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTWELL LH, 1971, J MOL BIOL, V59, P183, DOI 10.1016/0022-2836(71)90420-7; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Jiang W, 1997, P NATL ACAD SCI USA, V94, P14320, DOI 10.1073/pnas.94.26.14320; JOHNSTON LH, 1982, MOL GEN GENET, V186, P439, DOI 10.1007/BF00729466; Johnston LH, 1999, TRENDS CELL BIOL, V9, P249, DOI 10.1016/S0962-8924(99)01586-X; Kim JM, 1998, J BIOL CHEM, V273, P23248, DOI 10.1074/jbc.273.36.23248; KITADA K, 1992, GENETICS, V131, P21; Kumagai H, 1999, MOL CELL BIOL, V19, P5083; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; MASAI H, 1995, EMBO J, V14, P3094, DOI 10.1002/j.1460-2075.1995.tb07312.x; Masai H., 1999, FRONT BIOSCI, V4, pD834; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Ohtoshi A, 1997, MOL GEN GENET, V254, P562, DOI 10.1007/s004380050452; Pasero P, 1999, GENE DEV, V13, P2159, DOI 10.1101/gad.13.16.2159; Quintana DG, 1997, J BIOL CHEM, V272, P28247, DOI 10.1074/jbc.272.45.28247; QUINTANA DG, 1999, FRONT BIOSCI, V4, P802; Roberts BT, 1999, P NATL ACAD SCI USA, V96, P2800, DOI 10.1073/pnas.96.6.2800; Sato N, 1997, EMBO J, V16, P4340, DOI 10.1093/emboj/16.14.4340; SCLAFANI RA, 1994, MOL MICROBIOL, V11, P805, DOI 10.1111/j.1365-2958.1994.tb00358.x; SEO YS, 1993, P NATL ACAD SCI USA, V90, P702, DOI 10.1073/pnas.90.2.702; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; Takeda T, 1999, MOL CELL BIOL, V19, P5535; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; YOON HJ, 1991, P NATL ACAD SCI USA, V88, P3574, DOI 10.1073/pnas.88.9.3574; You ZY, 1999, MOL CELL BIOL, V19, P8003	44	132	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29042	29052		10.1074/jbc.M002713200	http://dx.doi.org/10.1074/jbc.M002713200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10846177	hybrid			2022-12-25	WOS:000089330700091
J	Wing, HJ; Green, J; Guest, JR; Busby, SJW				Wing, HJ; Green, J; Guest, JR; Busby, SJW			Role of activating region 1 of Escherichia coli FNR protein in transcription activation at class II promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE ALPHA-SUBUNIT; C-TERMINAL DOMAIN; CAP-DNA COMPLEX; RNA-POLYMERASE; RECEPTOR PROTEIN; SPACING REQUIREMENTS; GENE-EXPRESSION; CONTACT SITE; OXYGEN; CAMP	FNR is an Escherichia coli transcription factor that activates gene expression in response to anaerobiosis at a large number of promoters by making direct contacts with RNA polymerase, At class II FNR-dependent promoters, where the DNA site for FNR overlaps the -35 element, activating region 1 of FNR is proposed to interact with the C-terminal domain of the RNA polymerase alpha-subunit. Using a model class II FNR-dependent promoter, FF(-41.5), we have performed in vivo and in vitro experiments to investigate the role of this interaction. Our results show that FNR, carrying substitutions in activating region 1, is compromised in its ability to promote open complex formation and thus to activate transcription. Abortive initiation assays were used to assess the contribution of activating region 1 of FNR to open complex formation. A new method for the purification of the FNR protein is also described.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ Sheffield, Dept Mol Biol & Biotechnol, Western Bank, Sheffield S10 2TN, S Yorkshire, England	University of Birmingham; University of Sheffield	Wing, HJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept IID, 665 Huntington Ave,Bldg 1,Rm 902, Boston, MA 02115 USA.	hwing@hsph.harvard.edu	Busby, Stephen/C-2712-2015	Busby, Stephen/0000-0003-2148-1758; Wing, Helen J./0000-0003-0123-5568				ATTEY A, 1994, NUCLEIC ACIDS RES, V22, P4375, DOI 10.1093/nar/22.21.4375; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; Busby Stephen, 1994, V30, P397; CECH CL, 1980, BIOCHEMISTRY-US, V19, P2440, DOI 10.1021/bi00552a023; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; Guest John R., 1996, P317; Jordan PA, 1997, FEBS LETT, V416, P349, DOI 10.1016/S0014-5793(97)01219-2; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; KILEY PJ, 1991, J BACTERIOL, V173, P16, DOI 10.1128/jb.173.1.16-22.1991; KOLB A, 1995, NUCLEIC ACIDS RES, V23, P819, DOI 10.1093/nar/23.5.819; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; LAZAZZERA BA, 1993, GENE DEV, V7, P1993, DOI 10.1101/gad.7.10.1993; Lloyd GS, 1998, BIOCHEM J, V330, P413; LODGE J, 1992, FEMS MICROBIOL LETT, V95, P271; Lonetto MA, 1998, J MOL BIOL, V284, P1353, DOI 10.1006/jmbi.1998.2268; Miller JH., 1972, EXPT MOL GENETICS; Parkinson G, 1996, J MOL BIOL, V260, P395, DOI 10.1006/jmbi.1996.0409; Savery N. J., 1996, ESSENTIAL TECHNIQUES, P1; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHAW DJ, 1983, J MOL BIOL, V166, P241, DOI 10.1016/S0022-2836(83)80011-4; SPIRO S, 1988, MOL MICROBIOL, V2, P701, DOI 10.1111/j.1365-2958.1988.tb00080.x; SPIRO S, 1990, FEMS MICROBIOL LETT, V75, P399, DOI 10.1016/0378-1097(90)90690-R; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; Williams SM, 1997, NUCLEIC ACIDS RES, V25, P4028, DOI 10.1093/nar/25.20.4028; WING HJ, 1995, J BACTERIOL, V177, P6704, DOI 10.1128/jb.177.23.6704-6710.1995	28	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29061	29065		10.1074/jbc.M000390200	http://dx.doi.org/10.1074/jbc.M000390200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10846171	hybrid			2022-12-25	WOS:000089330700093
J	Cik, M; Masure, S; Lesage, ASJ; Van der Linden, I; Van Gompel, P; Pangalos, MN; Gordon, RD; Leysen, JE				Cik, M; Masure, S; Lesage, ASJ; Van der Linden, I; Van Gompel, P; Pangalos, MN; Gordon, RD; Leysen, JE			Binding of GDNF and neurturin to human GDNF family receptor alpha 1 and 2 - Influence of cRET and cooperative interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTROPHIC FACTOR; TYROSINE KINASE; NEGATIVE COOPERATIVITY; INSULIN-RECEPTOR; LIGAND FAMILY; GROWTH-FACTOR; RET; GFR-ALPHA-3; ACTIVATION; KINETICS	The members of the glial cell line-derived neurotrophic factor (GDNF) family signal via binding to the glycosyl phosphatidylinositol-anchored membrane proteins, the GDNF family receptors alpha (GFR alpha), and activation of cRET. We performed a detailed analysis of the binding of GDNF and neurturin to their receptors and investigated the influence of cRET on the binding affinities. We show that the rate of dissociation of I-125-GDNF from GFR alpha 1 is increased in the presence of 50 nM GDNF, an effect that can be explained by the occurrence of negative cooperativity. Scatchard plots of the ligand concentration binding isotherms reveal a pronounced downward curvature at low I-125-GDNF concentrations suggesting the presence of positive cooperativity. This effect is observed in the range of GDNF concentrations responsible for biological activity (1-20 pM) and may have an important role in cRET-independent signaling, A high affinity site with a K-D of 11 pM for I-125-GDMF is detected only when GFR alpha 1 is co-expressed with cRET at a DNA ratio of 1:3, These results suggest an interaction of GFR alpha 1 and cRET in the absence of GDNF and demonstrate that the high affinity binding can be measured only when cRET is present.	Janssen Res Fdn, Dept Biochem Pharmacol, B-2340 Beerse, Belgium; Janssen Res Fdn, Dept Biotechnol & High Throughput Screening, B-2340 Beerse, Belgium	Johnson & Johnson; Johnson & Johnson	Cik, M (corresponding author), Janssen Res Fdn, Dept Biochem Pharmacol, Turnhoutseweg 30, B-2340 Beerse, Belgium.							Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Baloh RH, 1998, P NATL ACAD SCI USA, V95, P5801, DOI 10.1073/pnas.95.10.5801; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; BALOH RH, 1997, J NEURON, V18, P793; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; CREDOON DJ, 1997, P NATL ACAD SCI USA, V89, P9509; Davies AM, 1997, NEURON, V19, P485; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; Enokido Y, 1998, CURR BIOL, V8, P1019, DOI 10.1016/S0960-9822(07)00422-8; GAMMELTOFT S, 1984, PHYSIOL REV, V64, P1321, DOI 10.1152/physrev.1984.64.4.1321; GU JL, 1988, BIOCHEM BIOPH RES CO, V150, P694, DOI 10.1016/0006-291X(88)90447-0; Ibanez CF, 1998, TRENDS NEUROSCI, V21, P438, DOI 10.1016/S0166-2236(98)01266-1; Jing SQ, 1997, J BIOL CHEM, V272, P33111, DOI 10.1074/jbc.272.52.33111; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Koshland DE, 1996, CURR OPIN STRUC BIOL, V6, P757, DOI 10.1016/S0959-440X(96)80004-2; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MARSH JW, 1984, J BIOL CHEM, V259, P6641; Masure S, 1998, EUR J BIOCHEM, V251, P622, DOI 10.1046/j.1432-1327.1998.2510622.x; MEYTS PD, 1976, J BIOL CHEM, V251, P1877; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Naveilhan P, 1998, P NATL ACAD SCI USA, V95, P1295, DOI 10.1073/pnas.95.3.1295; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; TAIT JF, 1981, J BIOL CHEM, V256, P1086; Thompson J, 1998, MOL CELL NEUROSCI, V11, P117, DOI 10.1006/mcne.1998.0682; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Widenfalk J, 1998, EUR J NEUROSCI, V10, P1508, DOI 10.1046/j.1460-9568.1998.00192.x; WOODRUFF NR, 1986, BIOCHEMISTRY-US, V25, P7956, DOI 10.1021/bi00372a026; Worby CA, 1998, J BIOL CHEM, V273, P3502, DOI 10.1074/jbc.273.6.3502	34	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27505	27512						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10829012				2022-12-25	WOS:000089197100002
J	Oliveira, DM; Nakaie, CR; Sousa, AD; Farah, CS; Reinach, FC				Oliveira, DM; Nakaie, CR; Sousa, AD; Farah, CS; Reinach, FC			Mapping the domain of troponin T responsible for the activation of actomyosin ATPase activity - Identification of residues involved in binding to actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE TROPONIN; THIN FILAMENT; ALPHA-TROPOMYOSIN; ESCHERICHIA-COLI; REGULATORY PROPERTIES; INTEGRAL-EQUATIONS; CA2+ REGULATION; CONTRACTION; FRAGMENTS; SENSITIVITY	The in vitro Ca2+ regulation of the actomyosin Mg2+-ATPase at physiological ratios of actin, tropomyosin, and troponin occurs only in the presence of troponin T. We have previously demonstrated that a polypeptide corresponding to the first 191 amino acids of troponin T (TnT-(1-191)) activates the actomyosin Mg2+-ATPase in the presence of tropomyosin. In order to further characterize this activation domain, we constructed troponin T fragments corresponding to residues 1-157 (Tn-T(1-157)), 1-76 (TnT-(1-76)), 77-157 (TnT-(77-157)), 77-191 (TnT-(77-191)), and 158-191 (TnT-(158-191)). Assays using these fragments demonstrated the following: (a) residues 1-76 do not bind to tropomyosin or actin; (b) residues 158-191 bind to actin cooperatively but not to tropomyosin; (c) the sequence 77-157 is necessary for troponin interaction with residue 263 of tropomyosin; (d) TnT-(77-191) on its own activates the actomyosin ATPase activity as described previously for TnT-(1-191). TnT-(1-157), TnT-(1-76), TnT-(77-157), TnT-(158-191), and combinations of TnT-(158-191) with TnT-(1-157) or TnT-(77-157) showed no effect on the ATPase activity. We conclude that the activation of actomyosin ATPase activity is mediated by a direct interaction between amino acids 77 and 191 of troponin T, tropomyosin, and actin.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05599970 Sao Paulo, Brazil; Univ Fed Sao Paulo, Dept Biofis, BR-04044020 Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP)	Reinach, FC (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, CP 26 077, BR-05599970 Sao Paulo, Brazil.	fdcreina@quim.iq.usp.br	Nakaie, Clovis R./B-3444-2014; Farah, Chuck Shaker/G-5565-2012; Oliveira, Daniela/G-6540-2014	Farah, Chuck Shaker/0000-0003-3110-6302; Sousa, Aurea/0000-0002-9153-7414; Oliveira, Daniela/0000-0002-2832-5726				BRISSON JR, 1986, BIOCHEMISTRY-US, V25, P4548, DOI 10.1021/bi00364a014; Cilli EM, 1996, J ORG CHEM, V61, P8992, DOI 10.1021/jo9611632; Farah CS, 1999, BIOCHEMISTRY-US, V38, P10543, DOI 10.1021/bi982813u; FARAH CS, 1994, J BIOL CHEM, V269, P5230; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; FISHER D, 1995, J BIOL CHEM, V270, P25455, DOI 10.1074/jbc.270.43.25455; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; GREASER ML, 1971, J BIOL CHEM, V246, P4226; Hammell RL, 1996, J BIOL CHEM, V271, P4236; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HASELGROVE JC, 1973, COLD SPRING HARB SYM, V37, P341, DOI 10.1101/SQB.1973.037.01.044; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; Higuchi R., 1990, PCR PROTOCOLS GUIDE; HILL LE, 1992, J BIOL CHEM, V267, P16106; Hinkle A, 1999, J BIOL CHEM, V274, P7157, DOI 10.1074/jbc.274.11.7157; HITCHCOCK SE, 1975, EUR J BIOCHEM, V52, P255, DOI 10.1111/j.1432-1033.1975.tb03993.x; HUXLEY HE, 1973, COLD SPRING HARB SYM, V37, P361, DOI 10.1101/SQB.1973.037.01.046; JACKSON P, 1975, BIOCHEM J, V151, P85, DOI 10.1042/bj1510085; Korman VL, 1999, J BIOL CHEM, V274, P22191, DOI 10.1074/jbc.274.32.22191; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; MALNIC B, 1994, EUR J BIOCHEM, V222, P49, DOI 10.1111/j.1432-1033.1994.tb18840.x; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; OHTSUKI I, 1979, J BIOCHEM, V86, P491, DOI 10.1093/oxfordjournals.jbchem.a132549; PAN BS, 1991, J BIOL CHEM, V266, P12432; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PATO MD, 1981, J BIOL CHEM, V256, P602; PEARLSTONE JR, 1977, CAN J BIOCHEM CELL B, V55, P1032, DOI 10.1139/o77-154; PEARLSTONE JR, 1976, P NATL ACAD SCI USA, V73, P1902, DOI 10.1073/pnas.73.6.1902; PEARLSTONE JR, 1978, CAN J BIOCHEM CELL B, V56, P521, DOI 10.1139/o78-080; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; PEARLSTONE JR, 1985, CAN J BIOCHEM CELL B, V63, P212, DOI 10.1139/o85-030; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P229, DOI 10.1016/0010-4655(82)90174-6; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; QUAGGIO RB, 1993, PROTEIN SCI, V2, P1053, DOI 10.1002/pro.5560020618; REINACH FC, 1982, J CELL BIOL, V95, P78, DOI 10.1083/jcb.95.1.78; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMILLIE LB, 1988, J BIOL CHEM, V263, P18816; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; Squire JM, 1998, FASEB J, V12, P761, DOI 10.1096/fasebj.12.10.761; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANOKURA M, 1984, J BIOCHEM, V95, P1417, DOI 10.1093/oxfordjournals.jbchem.a134749; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; WALSH TP, 1985, J MOL BIOL, V182, P265, DOI 10.1016/0022-2836(85)90344-4; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	55	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27513	27519						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10852909				2022-12-25	WOS:000089197100003
J	Zuk, PA; Elferink, LA				Zuk, PA; Elferink, LA			Rab15 differentially regulates early endocytic trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; SMALL GTPASE RAB5; MEMBRANE-FUSION; AUTOANTIGEN EEA1; WILD-TYPE; ENDOSOMES; TRANSFERRIN; PATHWAY; MUTANT; BIOGENESIS	Rab GTPases play an important regulatory role in early endocytosis. We recently demonstrated that epitope-tagged Rab15 (HArab15) co-localizes with Rab4, -5, and -11 on early endosomal membranes in CHO cells (Zuk, P, A, and Elferink, L, A. (1999) J, Biol. Chem. 274, 22303-22312). To characterize the role of Rab15 in endocytosis, we prepared functional mutants of HArab15 and examined their effects on early endocytic trafficking, Wild-type HArab15 and its constitutively active, GTP-bound mutant (Q67L) reduce fluid phase and receptor-mediated endocytosis without affecting the rate of recycling from early endosomal compartments, Inhibition of early endocytosis appears to be due to a reduction in the rate of homotypic early endosome fusion, Conversely, mutations that constitutively inactivate HArab15 stimulate early endocytosis and the homotypic fusion of early endosomes in vitro. Unlike active forms of HArab15, constitutively inactive HArab15 mutants also affect recycling from early endosomal compartments. Moreover, the two constitutively inactive mutants, GDP-bound HArab15-T22N and the non-nucleotide binding mutant RArab15-N121I, differentially regulate the transit of fluid phase and receptor-mediated endocytic tracers through early/sorting endosomes, Together, these data suggest that HArab15 may counteract the reported stimulatory effect of Rab5 on early endocytosis. Consistent with this, overexpression of constitutively active HArab15-Q67L attenuates Rab5-stimulated endocytosis, whereas Rab5-stimulated endocytosis is augmented in cells overexpressing a constitutively inactive HArab15 mutant defective in guanine nucleotide binding (N121I), Our data indicate that HArab15 differentially regulates distinct steps in membrane trafficking through early/sorting and pericentriolar recycling endosomes.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Elferink, LA (corresponding author), Wayne State Univ, Dept Biol Sci, 5047 Gullen Mall, Detroit, MI 48202 USA.							Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; ESCOLA JM, 1995, J CELL SCI, V108, P2337; GHOSH RN, 1994, J CELL SCI, V107, P2177; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Gournier H, 1998, EMBO J, V17, P1930, DOI 10.1093/emboj/17.7.1930; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LI GP, 1993, J BIOL CHEM, V268, P24475; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MAYOR S, 1993, NATO ASI SERIES H, V74, P269; MCGRAW TE, 1993, J CELL PHYSIOL, V155, P579, DOI 10.1002/jcp.1041550316; MCGRAW TE, 1987, J CELL BIOL, V105, P207, DOI 10.1083/jcb.105.1.207; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; Nagelkerken B, 1997, ELECTROPHORESIS, V18, P2694, DOI 10.1002/elps.1150181427; Olkkonen VM, 1997, INT REV CYTOL, V176, P1, DOI 10.1016/S0074-7696(08)61608-3; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Prekeris R, 1999, MOL BIOL CELL, V10, P3891, DOI 10.1091/mbc.10.11.3891; Ren MD, 1998, P NATL ACAD SCI USA, V95, P6187, DOI 10.1073/pnas.95.11.6187; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Tisdale EJ, 1998, J BIOL CHEM, V273, P17269, DOI 10.1074/jbc.273.27.17269; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; WANG RH, 1990, J BIOL CHEM, V265, P20179; YAMASHIRO DJ, 1987, J CELL BIOL, V105, P2723, DOI 10.1083/jcb.105.6.2723; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; Zuk PA, 1999, J BIOL CHEM, V274, P22303, DOI 10.1074/jbc.274.32.22303	42	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26754	26764						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10837464				2022-12-25	WOS:000089144800014
J	Ogut, O; Jin, JP				Ogut, O; Jin, JP			Cooperative interaction between developmentally regulated troponin T and tropomyosin isoforms in the absence of F-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NH2-TERMINAL VARIABLE REGION; SKELETAL-MUSCLE; THIN FILAMENT; ALPHA-TROPOMYOSIN; MOLECULAR-BASIS; BINDING; GENE; CONTRACTION; EXPRESSION; FRAGMENTS	Troponin T (TnT) is the tropomyosin (Tm) binding subunit of the troponin complex that mediates the Ca2+ regulation of actomyosin interaction in striated muscles. Troponin T isoform diversity is marked by a developmentally regulated acidic to basic switch that may modulate muscle contractility. We previously reported that transgenic expression of fast skeletal muscle TnT altered the cooperativity of cardiac muscle. In the present study, we have demonstrated that the binding of acidic TnT to troponin I is weaker than that of basic TnT. However, affinity chromatography experiments showed that Tm bound to acidic TnT with a greater affinity than to basic TnT, consistent with the significantly higher maximal binding of acidic TnT to Tm in solid phase binding assays. Competition and co-immunoprecipitation experiments demonstrated that the binding of TnT to Tm was cooperative in the absence of F-actin. The cooperativity between TnT molecules for Tm binding can be initiated by the conserved COOH-terminal T2 fragment of TnT. This indicates that the interaction of TnT with Tm induces a conformational change in Tm, promoting interaction of TnT with adjacent Tm dimers. This finding suggests a role for TnT and its acidic and basic isoforms in the cooperative release of the inhibition of striated muscle actomyosin interaction.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Jin, JP (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.			Jin, JP/0000-0001-9932-1063				AKELLA AB, 1995, CIRC RES, V76, P600, DOI 10.1161/01.RES.76.4.600; ANDERSON PAW, 1995, CIRC RES, V76, P681, DOI 10.1161/01.RES.76.4.681; BREITBART RE, 1986, J MOL BIOL, V188, P313, DOI 10.1016/0022-2836(86)90157-9; BRIGGS MM, 1993, DEV BIOL, V158, P503, DOI 10.1006/dbio.1993.1208; BRISSON JR, 1986, BIOCHEMISTRY-US, V25, P4548, DOI 10.1021/bi00364a014; Bucher EA, 1999, J BIOL CHEM, V274, P17661, DOI 10.1074/jbc.274.25.17661; Cooke R, 1997, PHYSIOL REV, V77, P671, DOI 10.1152/physrev.1997.77.3.671; EBASHI S, 1963, NATURE, V200, P1010, DOI 10.1038/2001010a0; GREASER ML, 1971, J BIOL CHEM, V246, P4226; HEELEY DH, 1988, BIOCHEMISTRY-US, V27, P8227, DOI 10.1021/bi00421a036; Hinkle A, 1999, J BIOL CHEM, V274, P7157, DOI 10.1074/jbc.274.11.7157; Huang QQ, 1999, J PHYSIOL-LONDON, V520, P231, DOI 10.1111/j.1469-7793.1999.00231.x; Huang QQ, 1999, GENE, V229, P1, DOI 10.1016/S0378-1119(99)00051-7; Jin JP, 1998, GENE, V214, P121, DOI 10.1016/S0378-1119(98)00214-5; JIN JP, 1988, J BIOL CHEM, V263, P7309; KOPPE RI, 1989, J BIOL CHEM, V264, P14327; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; Miyazaki JI, 1999, J MUSCLE RES CELL M, V20, P655, DOI 10.1023/A:1005504018059; Ogut O, 1999, AM J PHYSIOL-CELL PH, V276, pC1162, DOI 10.1152/ajpcell.1999.276.5.C1162; Ogut O, 1996, BIOCHEMISTRY-US, V35, P16581, DOI 10.1021/bi961712y; Ogut O, 1998, J BIOL CHEM, V273, P27858, DOI 10.1074/jbc.273.43.27858; PAN BS, 1991, J BIOL CHEM, V266, P12432; PEARLSTONE JR, 1981, FEBS LETT, V128, P119, DOI 10.1016/0014-5793(81)81095-2; PEARLSTONE JR, 1978, CAN J BIOCHEM CELL B, V56, P521, DOI 10.1139/o78-080; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; PEARLSTONE JR, 1985, CAN J BIOCHEM CELL B, V63, P212, DOI 10.1139/o85-030; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; REISER PJ, 1992, J PHYSIOL-LONDON, V449, P573, DOI 10.1113/jphysiol.1992.sp019102; SAGGIN L, 1989, J BIOL CHEM, V264, P16299; SCHACHAT F, 1995, DEV BIOL, V171, P233, DOI 10.1006/dbio.1995.1274; SMILLIE LB, 1988, J BIOL CHEM, V263, P18816; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SOLARO RJ, 1988, CIRC RES, V63, P779, DOI 10.1161/01.RES.63.4.779; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Wang J, 1998, BIOCHEMISTRY-US, V37, P14519, DOI 10.1021/bi9812322; Wang J, 1997, GENE, V193, P105, DOI 10.1016/S0378-1119(97)00100-5	42	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26089	26095		10.1074/jbc.M910360199	http://dx.doi.org/10.1074/jbc.M910360199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10844003	hybrid			2022-12-25	WOS:000088999700029
J	Pages, G; Berra, E; Milanini, J; Levy, AP; Pouyssegur, J				Pages, G; Berra, E; Milanini, J; Levy, AP; Pouyssegur, J			Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; INDUCED TRANSCRIPTIONAL ACTIVATION; INTERNAL RIBOSOME ENTRY; FACTOR GENE; FACTOR EXPRESSION; MAMMALIAN-CELLS; HYPOXIA; STABILIZATION; ANGIOGENESIS; MITOGEN	Stability of the vascular endothelial growth factor (VEGF) mRNA is tightly regulated through its 3'-untranslated region (3'-UTR). Here, we demonstrate that VEGF mRNA levels are increased by anisomycin, a strong activator of stress-activated protein kinases. Hence, VEGF mRNA induction is inhibited by SB202190, an inhibitor of JNK and p38/HOG kinase, Furthermore, VEGF mRNA expression is increased in cells that overexpress JNK and p38/HOG; by an increase in its stability. We show by two different approaches that anisomycin exerts its effect on the VEGF mRNA 3'-UTR. First, by using an in vitro mRNA degradation assay, the half-life of the VEGF mRNA 3'-UTR region transcript was found to be increased when incubated with extracts from anisomycin-treated cells; and second, the 3'-UTR was also sufficient to confer mRNA instability to the Nhe3 (Na+/H+ exchanger 3) heterologous reporter gene, and anisomycin treatment stabilized the chimeric mRNA (Nhe3 fused to the VEGF mRNA 3'-UTR). This chimeric mRNA is also more stable in cells overexpressing p38/HOG and JNK that have been stimulated by anisomycin. We show that such regulation is mediated through an AU-rich region of the 3'-UTR contained within a stable hairpin structure. By RNA electrophoretic mobility shift assays, we show that this region binds proteins specifically induced by anisomycin treatment. These findings clearly demonstrate a major role of stress-activated protein kinases in the post-transcriptional regulation of VEGF.	CNRS, UMR 6543, Inst Signaling Dev Biol & Canc Res, F-06189 Nice, France; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Pages, G (corresponding author), CNRS, UMR 6543, Inst Signaling Dev Biol & Canc Res, 33 Ave Valombrose, F-06189 Nice, France.		Berra, Edurne/F-9692-2011; Pages, Gilles/N-7135-2017	Berra, Edurne/0000-0002-3820-5744; Milanini, Julie/0000-0002-5861-2830				AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Breier G, 1996, TRENDS CELL BIOL, V6, P454, DOI 10.1016/0962-8924(96)84935-X; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DETMAR M, 1995, J INVEST DERMATOL, V105, P44, DOI 10.1111/1523-1747.ep12312542; Dibbens JA, 1999, MOL BIOL CELL, V10, P907, DOI 10.1091/mbc.10.4.907; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; NAKAMAKI T, 1995, J CELL PHYSL, V165, P482; Noel J, 1996, J CELL SCI, V109, P929; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; STEIN I, 1995, MOL CELL BIOL, V15, P5363; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; TSE CM, 1992, J BIOL CHEM, V267, P9340; White FC, 1997, GROWTH FACTORS, V14, P199, DOI 10.3109/08977199709021520; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; ZUCKER M, 1989, SCIENCE, V244, P48	51	158	163	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26484	26491		10.1074/jbc.M002104200	http://dx.doi.org/10.1074/jbc.M002104200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10849421	hybrid			2022-12-25	WOS:000088999700083
J	Pronin, AN; Morris, AJ; Surguchov, A; Benovic, JL				Pronin, AN; Morris, AJ; Surguchov, A; Benovic, JL			Synucleins are a novel class of substrates for G protein-coupled receptor kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; PHOSPHOLIPASE-D; PHOSPHORYLATES TUBULIN; BINDING; INHIBITION; DOMAIN; FAMILY; GENE; IDENTIFICATION	G protein-coupled receptor kinases (GRKs) specifically recognize and phosphorylate the agonist-occupied form of numerous G protein-coupled receptors (GPCRs), ultimately resulting in desensitization of receptor signaling. Until recently, GPCRs were considered to be the only natural substrates for GRKs, However, the recent discovery that GRKs also phosphorylate tubulin raised the possibility that additional GRK substrates exist and that the cellular role of GRKs may be much broader than just GPCR regulation. Here we report that synucleins are a novel class of GRK substrates, Synucleins (alpha, beta, gamma, and synoretin) are 14-kDa proteins that are highly expressed in brain but also found in numerous other tissues, alpha-Synuclein has been linked to the development of Alzheimer's and Parkinson's diseases. We found that all synucleins are GRK substrates, with GRK2 preferentially phosphorylating the alpha and beta isoforms, whereas GRK5 prefers alpha-synuclein as a substrate. GRK-mediated phosphorylation of synuclein is activated by factors that stimulate receptor phosphorylation, such as lipids (all GRKs) and G beta gamma subunits (GRK2/3), suggesting that GPCR activation may regulate synuclein phosphorylation, GRKs phosphorylate synucleins at a single serine residue within the C-terminal domain. Although the function of synucleins remains largely unknown, recent studies have demonstrated that these proteins can interact with phospholipids and are potent inhibitors of phospholipase D2 (PLDS) in vitro, PLDS regulates the breakdown of phosphatidylcholine and has been implicated in vesicular trafficking. We found that GRK-mediated phosphorylation inhibits synuclein's interaction with both phospholipids and PLD2, These findings suggest that GPCRs may be able to indirectly stimulate PLD2 activity via their ability to regulate GRK-promoted phosphorylation of synuclein.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; SUNY Stony Brook, Hlth Sci Ctr, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; SUNY Stony Brook, Hlth Sci Ctr, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; Washington Univ, Sch Med, Dept Ophthalmol, St Louis, MO 63110 USA	Jefferson University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Washington University (WUSTL)	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.		Morris, Andrew/B-7869-2010		NIGMS NIH HHS [GM44944] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Carman CV, 1998, J BIOL CHEM, V273, P20308, DOI 10.1074/jbc.273.32.20308; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Chuang TT, 1996, J BIOL CHEM, V271, P28691, DOI 10.1074/jbc.271.45.28691; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Haga K, 1997, BIOCHEMISTRY-US, V36, P1315, DOI 10.1021/bi961613k; Haga K, 1998, EUR J BIOCHEM, V255, P363, DOI 10.1046/j.1432-1327.1998.2550363.x; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Ji HJ, 1997, CANCER RES, V57, P759; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; KIM CM, 1993, RECEPTOR, V3, P39; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; NAKAJO S, 1993, EUR J BIOCHEM, V217, P1057, DOI 10.1111/j.1432-1033.1993.tb18337.x; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pronin AN, 1998, J BIOL CHEM, V273, P31510, DOI 10.1074/jbc.273.47.31510; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Siderovski DP, 1996, CURR BIOL, V6, P211, DOI 10.1016/S0960-9822(02)00454-2; SMITH BJ, 1997, PROTEIN SEQUENCING P, P64; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Surguchov A, 1999, MOL CELL NEUROSCI, V13, P95, DOI 10.1006/mcne.1999.0735	34	324	336	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26515	26522		10.1074/jbc.M003542200	http://dx.doi.org/10.1074/jbc.M003542200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852916	hybrid			2022-12-25	WOS:000088999700087
J	Hidaka, Y; Shimono, C; Ohno, M; Okumura, N; Adermann, K; Forssmann, WG; Shimonishi, Y				Hidaka, Y; Shimono, C; Ohno, M; Okumura, N; Adermann, K; Forssmann, WG; Shimonishi, Y			Dual function of the propeptide of prouroguanylin in the folding of the mature peptide - Disulfide-coupled folding and dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-ACTIVATING PEPTIDE; MESSENGER-RNA EXPRESSION; GROWTH-FACTOR-I; GUANYLATE-CYCLASE; ESCHERICHIA-COLI; GCAP-II; PROTEIN; UROGUANYLIN; SUBTILISIN; INTESTINE	Guanylyl cyclase activating peptide II (GCAP-II), an endogenous ligand of guanylyl cyclase C, is produced via the processing of the precursor protein (prepro-GCAP-II), We have previously shown that the propeptide in pro-GCAP-II functions as an intramolecular chaperone in the proper folding of the mature peptide, GCAP-II (Hidaka, Y., Ohno, M., Hemmasi, B,, Hill, O., Forssmann, W.-G., and Shimonishi, Y. (1998) Biochemistry 37, 8498-8507). Here, we report an essential region in pro-GCAP-II for the correct disulfide pairing of the mature peptide, GCAP-II. Five mutant proteins, in which amino acid residues were sequentially deleted from the N terminus, and three mutant proteins of pro-GCAP-II, in which N-terminal 6, 11, or 17 amino acid residues were deleted, were overproduced using Escherichia coli or human kidney 293T cells respectively, Detailed analysis of in vivo or in vitro folding of these mutant proteins revealed that one or two amino acid residues at the N terminus of pro-GCAP-II are critical, not only for the chaperone function in the folding but also for the net stabilization of pro-GCAP-II. In addition, size exclusion chromatography revealed that pro-GCAP-II exists as a dimer in solution. These data indicate that the propeptide has two roles in proper folding: the disulfide-coupled folding of the mature region and the dimerization of pro-GCAP-II.	Osaka Univ, Inst Prot Res, Div Organ Chem, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Prot Res, Div Prot Metab, Suita, Osaka 5650871, Japan; Lower Saxony Inst Peptide Res, D-30625 Hannover, Germany	Osaka University; Osaka University	Hidaka, Y (corresponding author), Osaka Univ, Inst Prot Res, Div Organ Chem, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yuji@protein.osaka-u.ac.jp		HIDAKA, YUJI/0000-0002-3131-2619				BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CUURIE MG, 1992, P NATL ACAD SCI USA, V89, P947; DESAUVAGE FJ, 1992, P NATL ACAD SCI USA, V89, P9089, DOI 10.1073/pnas.89.19.9089; Fan XH, 1996, BIOCHEM BIOPH RES CO, V219, P457, DOI 10.1006/bbrc.1996.0255; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; FORTE LR, 1995, FASEB J, V9, P643, DOI 10.1096/fasebj.9.8.7768356; GIVOL D, 1965, P NATL ACAD SCI USA, V53, P676, DOI 10.1073/pnas.53.3.676; Hamra FK, 1996, ENDOCRINOLOGY, V137, P257, DOI 10.1210/en.137.1.257; HAMRA FK, 1993, P NATL ACAD SCI USA, V90, P10464, DOI 10.1073/pnas.90.22.10464; HESS R, 1995, FEBS LETT, V374, P34, DOI 10.1016/0014-5793(95)01075-P; Hidaka Y, 1998, BIOCHEMISTRY-US, V37, P8498, DOI 10.1021/bi9731246; HILL O, 1995, BBA-PROTEIN STRUCT M, V1253, P146, DOI 10.1016/0167-4838(95)00204-4; HOBER S, 1994, BIOCHEMISTRY-US, V33, P6758, DOI 10.1021/bi00188a003; Hober S, 1997, BIOCHEMISTRY-US, V36, P4616, DOI 10.1021/bi9611265; Hu ZX, 1996, J BIOL CHEM, V271, P3375; HU ZX, 1994, BIOCHEMISTRY-US, V33, P562, DOI 10.1021/bi00168a022; KATO I, 1969, J BIOL CHEM, V244, P1004; LABHARDT AM, 1979, J MOL BIOL, V135, P245, DOI 10.1016/0022-2836(79)90350-4; LABHARDT AM, 1979, J MOL BIOL, V135, P231, DOI 10.1016/0022-2836(79)90349-8; LAZURE C, 1983, CAN J BIOCHEM CELL B, V61, P501, DOI 10.1139/o83-066; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; Ruoppolo M, 1997, BIOCHEMISTRY-US, V36, P12259, DOI 10.1021/bi970851s; Schulz A, 1999, PROTEIN SCI, V8, P1850, DOI 10.1110/ps.8.9.1850; SHINDE U, 1993, TRENDS BIOCHEM SCI, V18, P442, DOI 10.1016/0968-0004(93)90146-E; SHULTZ S, 1992, J BIOL CHEM, V267, P16019; SHULTZ S, 1990, CELL, V63, P941; Sohl JL, 1998, NATURE, V395, P817, DOI 10.1038/27470; STEINER DF, 1968, P NATL ACAD SCI USA, V60, P622, DOI 10.1073/pnas.60.2.622; Wada A, 1996, INFECT IMMUN, V64, P5144, DOI 10.1128/IAI.64.12.5144-5150.1996; Whitaker TL, 1997, GASTROENTEROLOGY, V113, P1000, DOI 10.1016/S0016-5085(97)70197-5; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637; WULFING C, 1994, MOL MICROBIOL, V12, P685, DOI 10.1111/j.1365-2958.1994.tb01056.x; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	34	31	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25155	25162		10.1074/jbc.M000543200	http://dx.doi.org/10.1074/jbc.M000543200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827170	hybrid			2022-12-25	WOS:000088849400017
J	Rossig, L; Haendeler, J; Hermann, C; Malchow, P; Urbich, C; Zeiher, AM; Dimmeler, S				Rossig, L; Haendeler, J; Hermann, C; Malchow, P; Urbich, C; Zeiher, AM; Dimmeler, S			Nitric oxide down-regulates MKP-3 mRNA levels - Involvement in endothelial cell protection from apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FLUID SHEAR-STRESS; CYTOCHROME-C RELEASE; INHIBITS APOPTOSIS; TYROSINE-PHOSPHATASE; S-NITROSYLATION; BCL-2; PHOSPHORYLATION; MITOCHONDRIA; SYNTHASE	MAP kinase-dependent phosphorylation processes have been shown to interfere with the degradation of the antiapoptotic protein Bcl-2. The cytosolic MAP kinase phosphatase MAP kinase phosphatase-3 (MKP-3) induces apoptosis of endothelial cells in response to tumor necrosis factor cu (TNF alpha) via dephosphorylation of the MAP kinase ERK1/2, Leading to Bcl-2 proteolysis. Here we report that the endothelial cell survival factor nitric oxide (NO) down-regulated MKP-3 by destabilization of MKP-3 mRNA. This effect of NO was paralleled by a decrease in MKP-3 protein levels. Moreover, ERK1/2 was found to be protected against TNF alpha-induced dephosphorylation by coincubation of endothelial cells with the NO donor. Subsequently, both the decrease in Bcl-2 protein levels and the mitochondrial release of cytochrome c in response to TNF alpha were largely prevented by exogenous NO. In cells overexpressing MKP-3, no differences in phosphatase activity in the presence or absence of NO were found, excluding potential posttranslational modifications of MKP-3 protein by NO. These data demonstrate that upstream of the S-nitrosylation of caspase-3, NO exerts additional antiapoptotic effects in endothelial cells, which rely on the down-regulation of MKP-3 mRNA.	Univ Frankfurt, Div Cardiol, Dept Internal Med 4, D-60590 Frankfurt, Germany	Goethe University Frankfurt	Dimmeler, S (corresponding author), Univ Frankfurt, Div Cardiol, Dept Internal Med 4, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.			Haendeler, Judith/0000-0001-8507-4540; Dimmeler, Stefanie/0000-0002-1045-2436				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Batt DB, 1998, METH MOL B, V86, P15; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; Dimmeler S, 1999, CELL DEATH DIFFER, V6, P964, DOI 10.1038/sj.cdd.4400581; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1999, J EXP MED, V189, P1815, DOI 10.1084/jem.189.11.1815; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Filippov G, 1997, J CLIN INVEST, V100, P942, DOI 10.1172/JCI119610; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; Fleming I, 1999, J MOL CELL CARDIOL, V31, P5, DOI 10.1006/jmcc.1998.0839; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Horiuchi M, 1997, J BIOL CHEM, V272, P19022, DOI 10.1074/jbc.272.30.19022; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Muda M, 1996, J BIOL CHEM, V271, P4319; Phelan MW, 1996, J CELL PHYSIOL, V167, P469, DOI 10.1002/(SICI)1097-4652(199606)167:3<469::AID-JCP11>3.3.CO;2-C; Rossig L, 1999, J BIOL CHEM, V274, P6823, DOI 10.1074/jbc.274.11.6823; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Suschek CV, 1999, J BIOL CHEM, V274, P6130, DOI 10.1074/jbc.274.10.6130; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Walter DH, 1998, CIRCULATION, V98, P1153, DOI 10.1161/01.CIR.98.12.1153; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	41	110	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25502	25507		10.1074/jbc.M002283200	http://dx.doi.org/10.1074/jbc.M002283200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10846176	hybrid			2022-12-25	WOS:000088849400061
J	Christendat, D; Saridakis, V; Dharamsi, A; Bochkarev, A; Pai, EF; Arrowsmith, CH; Edwards, AM				Christendat, D; Saridakis, V; Dharamsi, A; Bochkarev, A; Pai, EF; Arrowsmith, CH; Edwards, AM			Crystal structure of dTDP-4-keto-6-deoxy-D-hexulose 3,5-epimerase from Methanobacterium thermoautotrophicum complexed with dTDP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DIFFRACTION DATA; ALIGNMENT; MECHANISM; PROGRAM	Deoxythymidine diphosphate (dTDP)-4-keto-6-deoxy-D-hexulose 3,5-epimerase (RmlC) is involved in the biosynthesis of dTDP-L-rhamnose, which is an essential component of the bacterial cell wall. The crystal structure of RmlC from Methanobacterium thermoautotrophicum was determined in the presence and absence of dTDP, a substrate analogue. RmlC is a homodimer comprising a central jelly roll motif, which extends in two directions into longer beta-sheets, Binding of dTDP is stabilized by ionic interactions to the phosphate group and by a combination of ionic and hydrophobic interactions with the base, The active site, which is located in the center of the jelly roll, is formed by residues that are conserved in all known RmlC sequence homologues, The conservation of the active site residues suggests that the mechanism of action is also conserved and that the RmlC structure may be useful in guiding the design of antibacterial drugs.	Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5W 1L6, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5W 1L6, Canada; Integrated Proteom Inc, Toronto, ON M5G 2M9, Canada; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Oklahoma System; University of Oklahoma Health Sciences Center	Edwards, AM (corresponding author), Ontario Canc Inst, Div Mol & Struct Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.		Pai, Emil/R-8908-2019; Pai, Emil F/D-2526-2013	Pai, Emil/0000-0002-1162-7242; Edwards, Aled/0000-0002-4782-6016; Arrowsmith, Cheryl/0000-0002-4971-3250	NCRR NIH HHS [RR07707] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Giraud MF, 2000, NAT STRUCT BIOL, V7, P398; Graninger M, 1999, J BIOL CHEM, V274, P25069, DOI 10.1074/jbc.274.35.25069; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kopp J, 1999, J MOL BIOL, V287, P761, DOI 10.1006/jmbi.1999.2643; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MERRIT EA, 1991, ACTA CRYSTALLOGR D, V50, P869; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Schafer SL, 1996, BIOCHEMISTRY-US, V35, P5662, DOI 10.1021/bi960174m; Stern RJ, 1999, MICROBIOL-UK, V145, P663, DOI 10.1099/13500872-145-3-663; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6294, DOI 10.1021/bi970025j; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	16	50	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24608	24612		10.1074/jbc.C000238200	http://dx.doi.org/10.1074/jbc.C000238200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827167	hybrid			2022-12-25	WOS:000088683300052
J	Liu, X; Brzeska, H; Korn, ED				Liu, X; Brzeska, H; Korn, ED			Functional analysis of tail domains of Acanthamoeba myosin IC by characterization of truncation and deletion mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN KINASE; ACTIN-BINDING SITE; ACTIVATED ATPASE ACTIVITY; SH3 DOMAIN; IN-VIVO; PHOSPHORYLATION SITE; 3RD ISOFORM; LIGHT-CHAIN; AMINO-ACID; TEDS RULE	Acanthamoeba myosin IC has a single 129-kDa heavy chain and a single l7-kDa light chain. The heavy chain comprises a 75-kDa catalytic head domain with an ATP-sensitive F-actin-binding site, a 3-kDa neck domain, which binds a single 17-kDa light chain, and a 50-kDa tail domain, which binds F-actin in the presence or absence of ATP. The actin-activated MgATPase activity of myosin IC exhibits triphasic actin dependence, apparently as a consequence of the two actin-binding sites, and is regulated by phosphorylation of Ser-329 in the head. The 50-kDa tail consists of a basic domain, a glycine/proline/alanine-rich (GPA) domain, and a Src homology 3 (SH3) domain, often referred to as tail homology (TH)-1, -2, and -3 domains, respectively. The SH3 domain divides the TH-3 domain into GPA-1 and GPA-2. To define the functions of the tail domains more precisely, we determined the properties of expressed wild type and six mutant myosins, an SH3 deletion mutant and five mutants truncated at the C terminus of the SH3, GPA-2, TH-1, neck and head domains, respectively. We found that both the TH-1 and GPA-2 domains bind F-actin in the presence of ATP, Only the mutants that retained an actin-binding site in the tail exhibited triphasic actin-dependent MgATPase activity, in agreement with the F-actin-cross-linking model, but truncation reduced the MgATPase activity at both low and high actin concentrations. Deletion of the SH3 domain had no effect. Also, none of the tail domains, including the SH3 domain, affected either the K-m or V-max for the phosphorylation of Ser-329 by myosin I heavy chain kinase.	NHLBI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Korn, ED (corresponding author), NHLBI, Cell Biol Lab, NIH, Bldg 3,Rm B1-22, Bethesda, MD 20892 USA.		Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000506, ZIAHL000506] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS RJ, 1989, NATURE, V340, P505; ALBANESI JP, 1985, J BIOL CHEM, V260, P3276; ALBANESI JP, 1985, J BIOL CHEM, V260, P1174; Anderson BL, 1998, J CELL BIOL, V141, P1357, DOI 10.1083/jcb.141.6.1357; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAINES IC, 1995, J CELL BIOL, V130, P591, DOI 10.1083/jcb.130.3.591; BAINES IC, 1992, J CELL BIOL, V119, P1193, DOI 10.1083/jcb.119.5.1193; Barylko B, 2000, BBA-MOL CELL RES, V1496, P23, DOI 10.1016/S0167-4889(00)00006-9; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; Brzeska H, 1999, P NATL ACAD SCI USA, V96, P394, DOI 10.1073/pnas.96.2.394; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; BRZESKA H, 1988, J BIOL CHEM, V263, P427; Brzeska HZ, 1999, MOL BIOL CELL, V10, p161A; COTE GP, 1985, J BIOL CHEM, V260, P4543; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; DOBERSTEIN SK, 1993, NATURE, V365, P841, DOI 10.1038/365841a0; Evangelista M, 2000, J CELL BIOL, V148, P353, DOI 10.1083/jcb.148.2.353; FUJISAKI H, 1985, J BIOL CHEM, V260, P11182; GORDON DJ, 1976, J BIOL CHEM, V251, P7474; HAMMER JA, 1983, J BIOL CHEM, V258, P168; JUNG G, 1989, GENE, V82, P269, DOI 10.1016/0378-1119(89)90052-8; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; JUNG G, 1994, FEBS LETT, V342, P197, DOI 10.1016/0014-5793(94)80500-8; Jung G, 1999, MOL BIOL CELL, V10, p6A; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lechler T, 2000, J CELL BIOL, V148, P363, DOI 10.1083/jcb.148.2.363; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; LEE SF, 1993, J BIOL CHEM, V268, P20923; Lee WL, 1999, J BIOL CHEM, V274, P35159, DOI 10.1074/jbc.274.49.35159; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; LYNCH TJ, 1986, J BIOL CHEM, V261, P7156; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; Novak KD, 1998, MOL BIOL CELL, V9, P75, DOI 10.1091/mbc.9.1.75; Osherov N, 1998, J BIOL CHEM, V273, P27017, DOI 10.1074/jbc.273.41.27017; PANTALONI D, 1985, J BIOL CHEM, V260, P1180; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROSENFELD SS, 1994, BIOCHEMISTRY-US, V33, P2322, DOI 10.1021/bi00174a045; Sellers J. R., 1999, MYOSINS; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Stoffler HE, 1998, J BIOL CHEM, V273, P14605, DOI 10.1074/jbc.273.23.14605; SZEZEPANOWSKA JR, 1998, P NATL ACAD SCI USA, V95, P4146; Wang ZY, 1998, P NATL ACAD SCI USA, V95, P15200, DOI 10.1073/pnas.95.26.15200; Wang ZY, 1997, J MUSCLE RES CELL M, V18, P395, DOI 10.1023/A:1018686428955; XU P, 1995, J BIOL CHEM, V270, P25316, DOI 10.1074/jbc.270.43.25316; Xu P, 1997, P NATL ACAD SCI USA, V94, P3685, DOI 10.1073/pnas.94.8.3685	52	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24886	24892		10.1074/jbc.M004287200	http://dx.doi.org/10.1074/jbc.M004287200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10840041	hybrid			2022-12-25	WOS:000088683300087
J	Lacourciere, GM; Mihara, H; Kurihara, T; Esaki, N; Stadtman, TC				Lacourciere, GM; Mihara, H; Kurihara, T; Esaki, N; Stadtman, TC			Escherichia coli NifS-like proteins provide selenium in the pathway for the biosynthesis of selenophosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE LYASE; HAEMOPHILUS-INFLUENZAE; NUCLEOTIDE-SEQUENCE; GENE-PRODUCT; PURIFICATION; ENZYME; SYNTHETASE; CLONING; MECHANISM; CLUSTER	Selenophosphate synthetase (SPS), the selD gene product from Escherichia coli, catalyzes the biosynthesis of monoselenophosphate, AMP, and orthophosphate in a 1:1:1 ratio from selenide and ATP. Kinetic characterization revealed the K-m value for selenide approached levels that; are toxic to the cell, Our previous demonstration that a Se-0-generating system consisting of L-selenocysteine and the Azotobacter vinelandii NifS protein can replace selenide for selenophosphate biosynthesis in vitro suggested a mechanism whereby cells can overcome selenide toxicity. Recently, three E. coli NifS-like proteins, CsdB, CSD, and IscS, have been overexpressed and characterized. All three enzymes act on selenocysteine and cysteine to produce Se-0 and S-0, respectively. In the present study, we demonstrate the ability of each E. coli NifS-like protein to function as a selenium delivery protein for the in vitro biosynthesis of selenophosphate by E. coli wild-type SPS. Significantly, the SPS (C17S) mutant, which is inactive in the standard in vitro assay with selenide as substrate, was found to exhibit detectable activity in the presence of CsdB, CSD, or IscS and L-selenocysteine. Taken together the ability of the NifS-like proteins to generate a selenium substrate for SPS and the activation of the SPS (C17S) mutant suggest a selenium delivery function for the proteins in vivo.	NHLBI, Biochem Lab, NIH, Bethesda, MD 20892 USA; Kyoto Univ, Chem Res Inst, Kyoto 6110011, Japan	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Kyoto University	Lacourciere, GM (corresponding author), NHLBI, Biochem Lab, NIH, Bldg 3 Rm 103,9000 Rockville Pike, Bethesda, MD 20892 USA.	lacourcg@nhlbi.nih.gov	Mihara, Hisaaki/F-2172-2010	Mihara, Hisaaki/0000-0002-5153-4403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000319, Z01HL000205] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiba H, 1996, DNA Res, V3, P363, DOI 10.1093/dnares/3.6.363; Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; CHOCAT P, 1985, J BACTERIOL, V163, P669, DOI 10.1128/JB.163.2.669-676.1985; ESAKI N, 1982, J BIOL CHEM, V257, P4386; ESAKI N, 1988, J BACTERIOL, V170, P751, DOI 10.1128/jb.170.2.751-756.1988; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Flint DH, 1996, J BIOL CHEM, V271, P16068; FORCHHAMMER K, 1991, J BIOL CHEM, V266, P6318; Fujii T, 2000, BIOCHEMISTRY-US, V39, P1263, DOI 10.1021/bi991732a; Green J, 1996, BIOCHEM J, V316, P887, DOI 10.1042/bj3160887; HADDOCK BA, 1982, BIOCHEM SOC T, V10, P478, DOI 10.1042/bst0100478; HIDALGO E, 1996, J BIOL CHEM, V271, P16068; Jacob C, 1999, P NATL ACAD SCI USA, V96, P1910, DOI 10.1073/pnas.96.5.1910; Kambampati R, 2000, J BIOL CHEM, V275, P10727, DOI 10.1074/jbc.275.15.10727; Kambampati R, 1999, BIOCHEMISTRY-US, V38, P16561, DOI 10.1021/bi991119r; Kaneko T, 1996, DNA Res, V3, P109; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; KIM IY, 1992, J BIOL CHEM, V267, P19650; KIM IY, 1993, J BIOL CHEM, V268, P27020; KOLMAN C, 1993, J BACTERIOL, V175, P1433, DOI 10.1128/JB.175.5.1433-1442.1993; Lacourciere GM, 1999, P NATL ACAD SCI USA, V96, P44, DOI 10.1073/pnas.96.1.44; Lacourciere GM, 1998, J BIOL CHEM, V273, P30921, DOI 10.1074/jbc.273.47.30921; LEINFELDER W, 1988, J BACTERIOL, V170, P540, DOI 10.1128/jb.170.2.540-546.1988; LEINFELDER W, 1990, P NATL ACAD SCI USA, V87, P543, DOI 10.1073/pnas.87.2.543; MANDRANDBERTHELOT MA, 1978, FEMS MICROBIOL LETT, V4, P37; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Mihara H, 1997, J BIOL CHEM, V272, P22417, DOI 10.1074/jbc.272.36.22417; Mihara H, 1999, J BIOL CHEM, V274, P14768, DOI 10.1074/jbc.274.21.14768; Muller S, 1997, ARCH MICROBIOL, V168, P421, DOI 10.1007/s002030050517; PECK HD, 1957, J BACTERIOL, V73, P706, DOI 10.1128/JB.73.6.706-721.1957; STADTMAN T C, 1989, Biofactors, V2, P35; SUN DX, 1993, J BACTERIOL, V175, P1423, DOI 10.1128/JB.175.5.1423-1432.1993; TANAKA H, 1987, METHOD ENZYMOL, V143, P240; VERES Z, 1994, J BIOL CHEM, V269, P10597; VERES Z, 1992, P NATL ACAD SCI USA, V89, P2975, DOI 10.1073/pnas.89.7.2975; Walker H, 1998, P NATL ACAD SCI USA, V95, P2180, DOI 10.1073/pnas.95.5.2180; Yamamoto Y, 1997, DNA Res, V4, P91, DOI 10.1093/dnares/4.2.91; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	39	59	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23769	23773		10.1074/jbc.M000926200	http://dx.doi.org/10.1074/jbc.M000926200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10829016	hybrid			2022-12-25	WOS:000088564200051
J	Shen, EC; Stage-Zimmermann, T; Chui, P; Silver, PA				Shen, EC; Stage-Zimmermann, T; Chui, P; Silver, PA			The yeast mRNA-binding protein Npl3p interacts with the cap-binding complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; CARBOXY-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; NUCLEAR EXPORT; HNRNP PROTEINS; POLYMERASE-II; SPLICING FACTORS; CYTOPLASM; METHYLTRANSFERASE; RECOGNITION	A number of RNA-binding proteins are associated with mRNAs in both the nucleus and the cytoplasm. One of these, Np13p, is a heterogeneous nuclear ribonucleoprotein-like protein with some similarity to SR proteins and is essential for growth in the yeast S. cerevisiae. Temperature-sensitive alleles have defects in the export of mRNA out of the nucleus (1). In this report, we define a genetic relationship between NPL3 and the nonessential genes encoding the subunits of the cap-binding complex (CBP80 and CBP20). Deletion of CBP80 or CBP20 in combination with certain temperature-sensitive np13 mutant alleles fail to grow and thus display a synthetic lethal relationship. Further evidence of an interaction between Np13p and the cap-binding complex was revealed by co-immunoprecipitation experiments; Cbp80p and Cbp20p specifically co-precipitate with Np13p. However, the interaction of Np13p with Cbp80p depends on both the presence of Cbp20p and RNA. In addition, we show that Cbp80p is capable of shuttling between the nucleus and the cytoplasm in a manner dependent on the ongoing synthesis of RNA. Taken together, these data support a model whereby mRNAs are co-transcriptionally packaged by proteins including Np13p and cap-binding complex for export out of the nucleus.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Silver, PA (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NIGMS NIH HHS [GM19487, GM57476] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019487, R01GM057476] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BOSSIE MA, 1992, MOL BIOL CELL, V3, P875, DOI 10.1091/mbc.3.8.875; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Colot HV, 1996, GENE DEV, V10, P1699, DOI 10.1101/gad.10.13.1699; DOYE V, 1994, EMBO J, V13, P6062, DOI 10.1002/j.1460-2075.1994.tb06953.x; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FLACH J, 1994, MOL CELL BIOL, V14, P8399, DOI 10.1128/MCB.14.12.8399; Fortes P, 1999, MOL CELL BIOL, V19, P6543; Fortes P, 1999, GENE DEV, V13, P2425, DOI 10.1101/gad.13.18.2425; FU XD, 1995, RNA, V1, P663; Garnepudi VR, 1997, YEAST, V13, P299; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gottschalk A, 1998, RNA, V4, P374; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; Henry M, 1996, GENETICS, V142, P103; Henry MF, 1996, MOL CELL BIOL, V16, P3668; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; IZAURRALDE E, 1994, CELL, V78, P657, DOI 10.1016/0092-8674(94)90530-4; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KOLEDJIAN M, 1994, RNA PROTEIN INTERACT, P127; Krebber H, 1999, GENE DEV, V13, P1994, DOI 10.1101/gad.13.15.1994; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lee MS, 1996, GENE DEV, V10, P1233, DOI 10.1101/gad.10.10.1233; MASISON DC, 1995, MOL CELL BIOL, V15, P2763; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; OHNO M, 1990, NUCLEIC ACIDS RES, V18, P6989, DOI 10.1093/nar/18.23.6989; PinolRoma S, 1997, SEMIN CELL DEV BIOL, V8, P57, DOI 10.1006/scdb.1996.0122; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; RUSSELL ID, 1992, J CELL BIOL, V119, P737, DOI 10.1083/jcb.119.4.737; SALDITTGEORGIEFF M, 1980, CELL, V19, P69, DOI 10.1016/0092-8674(80)90389-X; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGLETON DR, 1995, J CELL SCI, V108, P265; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; UEMURA H, 1992, J BACTERIOL, V174, P5526, DOI 10.1128/JB.174.17.5526-5532.1992; Visa N, 1996, J CELL BIOL, V133, P5, DOI 10.1083/jcb.133.1.5; WILSON SM, 1994, J CELL BIOL, V127, P1173, DOI 10.1083/jcb.127.5.1173; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	44	57	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23718	23724		10.1074/jbc.M002312200	http://dx.doi.org/10.1074/jbc.M002312200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10823828	hybrid			2022-12-25	WOS:000088564200044
J	Seharaseyon, J; Sasaki, N; Ohler, A; Sato, T; Fraser, H; Johns, DC; O'Rourke, B; Marban, E				Seharaseyon, J; Sasaki, N; Ohler, A; Sato, T; Fraser, H; Johns, DC; O'Rourke, B; Marban, E			Evidence against functional heteromultimerization of the K-ATP channel subunits Kir6.1 and Kir6.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFONYLUREA RECEPTOR; POTASSIUM CHANNELS; PANCREATIC-ISLETS; GENE-TRANSFER; SUPPRESSION; MEMBRANE; MUSCLE; HEART; CARDIOPROTECTION; MITOCHONDRIA	K-ATP channels consist of pore-forming potassium inward rectifier (Kir6.x) subunits and sulfonylurea receptors (SURs), Although Kir6.1 or Kir6.2 coassemble with different SUR isoforms to form heteromultimeric functional K-ATP, channels, it is not known whether Kir6.1 and Kir6.2 coassemble with each other. To define the molecular identity of K-ATP channels, we used adenoviral gene transfer to express wild-type and dominant-negative coustructs of Kir6.1 and Kir6.2 in a heterologous expression system (A549 cells) and in native cells (rabbit ventricular myocytes), Dominant-negative (DN) Kir6.2 gene transfer suppressed current through heterologously expressed SUR2A + Kir6.2 channels. Conversely, DN Kir6.1 suppressed SUR2B + Kir6.1 current but had no effect on coexpressed SUR2A + Kir6.2, We next probed the ability of Kir6.1 and Kir6.2 to affect endogenous K-ATP channels in adult rabbit ventricular myocytes, using adenoviral vectors to achieve efficient gene transfer. Infection with the DN Kir6.2 virus for 72 h suppressed pinacidil-inducible K-ATP current density measured by whole-cell patch clamp. However, there was no effect of infection with the DN Kir6.1 on the K-ATP current. Based on these functional assays, we conclude that Kir6.1 and Kir6.2 do not heteromultimerize with each other and that Kir6.2 is the sole K-ATP pore-forming subunit in the surface membrane of heart cells.	Johns Hopkins Univ, Dept Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA	Johns Hopkins University	Marban, E (corresponding author), Johns Hopkins Univ, Dept Med, Inst Mol Cardiobiol, Ross 844,720 Rutland Ave, Baltimore, MD 21205 USA.		Ohler, Annemarie/AAB-7721-2019; Marban, Eduardo/GWC-8514-2022	Ohler, Annemarie/0000-0001-6531-464X; O'Rourke, Brian/0000-0002-5548-4853	NHLBI NIH HHS [R37HL36957, F32HL09586] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036957, F32HL009586] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Akao M, 1997, J CLIN INVEST, V100, P3053, DOI 10.1172/JCI119860; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; Babenko AP, 1998, CIRC RES, V83, P1132, DOI 10.1161/01.RES.83.11.1132; Baron A, 1999, CIRC RES, V85, P707, DOI 10.1161/01.RES.85.8.707; Garlid KD, 1997, CIRC RES, V81, P1072; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hu H, 1999, MOL PHARMACOL, V55, P1000, DOI 10.1124/mol.55.6.1000; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Johns DC, 1999, J NEUROSCI, V19, P1691; Johns DC, 1997, J BIOL CHEM, V272, P31598, DOI 10.1074/jbc.272.50.31598; Jovanovic A, 1998, CIRCULATION, V98, P1548, DOI 10.1161/01.CIR.98.15.1548; Lalli MJ, 1998, PFLUG ARCH EUR J PHY, V436, P957, DOI 10.1007/s004240050729; Liu Y, 1996, BASIC RES CARDIOL, V91, P450, DOI 10.1007/BF00788726; Liu YG, 1998, CIRCULATION, V97, P2463, DOI 10.1161/01.CIR.97.24.2463; Miki T, 1997, P NATL ACAD SCI USA, V94, P11969, DOI 10.1073/pnas.94.22.11969; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; PAUCEK P, 1992, J BIOL CHEM, V267, P26062; Sato T, 1998, CIRC RES, V83, P110, DOI 10.1161/01.RES.83.1.110; SATO T, 2000, IN PRESS CIRCULATION; Suzuki M, 1997, BIOCHEM BIOPH RES CO, V241, P693, DOI 10.1006/bbrc.1997.7891; TRUBE G, 1984, PFLUG ARCH EUR J PHY, V401, P178, DOI 10.1007/BF00583879; Yamada M, 1997, J PHYSIOL-LONDON, V499, P715, DOI 10.1113/jphysiol.1997.sp021963	27	41	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17561	17565		10.1074/jbc.275.23.17561	http://dx.doi.org/10.1074/jbc.275.23.17561			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837494	hybrid			2022-12-25	WOS:000087485000050
J	Wada, H; Yeh, ETH; Kamitani, T				Wada, H; Yeh, ETH; Kamitani, T			A dominant-negative UBC12 mutant sequesters NEDD8 and inhibits NEDD8 conjugation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; KAPPA-B-ALPHA; F-BOX PROTEIN; BETA-CATENIN; COMPLEX; IDENTIFICATION; DEGRADATION; CULLIN-2; SYSTEM; PATHWAY	NEDD8, a novel ubiquitin-like protein, has been shown to conjugate to proteins in a manner analogous to ubiquitination and sentrinization. Recently, human UBC12 was identified as a putative NEDD8 conjugation enzyme (E2). While investigating the in vivo function of UBC12, we found that the point mutant, UBC12(C111S), showed a dominant-negative effect on NEDD8 conjugation. This mutant,with a single Cys-to-Ser substitution at the conserved Cys residue in the E2 family, could specifically inhibit NEDD8 conjugation. We observed the dominant-negative effect on NEDD8 conjugation to substrates, including the C-terminal fragment of cullin-2 (Cul-2-Delta N), full-length cullin-1, and also other uncharacterized target proteins, interestingly, UBC12(C111S) formed a heterodimeric conjugate with NEDD8. This conjugate was stable under stringent conditions, including 6 M guanidine HCl, 8 M urea, 2% SDS, or 5% beta-mercaptoethanol. Our results are consistent with the hypothesis that UBC12(C111S) sequesters the NEDD8 monomer by forming a UBC12(C111S)-NEDD8 conjugate and, in turn, inhibits the subsequent transfer of NEDD8 to its targets. To examine the biological role of NEDD8 conjugation, this dominant-negative form of UBC12 was applied to a cell growth assay. Overexpression of UBC12(C111S) led to inhibition of growth in U2OS and HEK293 cells. Thus, this dominant-negative form of UBC12 could be useful in defining the role of NEDD8 modification in other biological systems.	Univ Texas, Houston Hlth Sci Ctr, Dept Internal Med, Div Mol Med, Houston, TX 77030 USA; Univ Texas, Houston Hlth Sci Ctr, Inst Mol Med Prevent Human Dis, Res Ctr Cardiovasc Dis, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Kamitani, T (corresponding author), Univ Texas, Houston Hlth Sci Ctr, Dept Internal Med, Div Mol Med, 6431 Fannin,Suite 4-200, Houston, TX 77030 USA.	tetsuk@heart.med.uth.tmc.edu	Kamitani, Tetsu/GSI-7613-2022	Kamitani, Tetsu/0000-0002-3257-9630	NIDDK NIH HHS [1 RO1 DK56298-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056298] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Feng H, 1999, NAT CELL BIOL, V1, P486, DOI 10.1038/70272; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Haas AL, 1997, FASEB J, V11, P1257; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kamitani T, 1998, J BIOL CHEM, V273, P11349, DOI 10.1074/jbc.273.18.11349; Kamitani T, 1997, J BIOL CHEM, V272, P22307, DOI 10.1074/jbc.272.35.22307; Kamitani T, 1997, J BIOL CHEM, V272, P14001, DOI 10.1074/jbc.272.22.14001; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; KUMAR S, 1993, BIOCHEM BIOPH RES CO, V195, P393, DOI 10.1006/bbrc.1993.2056; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Liakopoulos D, 1999, P NATL ACAD SCI USA, V96, P5510, DOI 10.1073/pnas.96.10.5510; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Okura T, 1996, J IMMUNOL, V157, P4277; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Wada H, 1998, BIOCHEM BIOPH RES CO, V251, P688, DOI 10.1006/bbrc.1998.9532; Wada H, 1999, BIOCHEM BIOPH RES CO, V257, P100, DOI 10.1006/bbrc.1999.0339; Wada H, 1999, J BIOL CHEM, V274, P36025, DOI 10.1074/jbc.274.50.36025; YEH ETH, 2000, IN PRESS GENE AMST; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324	31	67	69	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17008	17015		10.1074/jbc.275.22.17008	http://dx.doi.org/10.1074/jbc.275.22.17008			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828074	hybrid			2022-12-25	WOS:000087392200086
J	Xu, BE; English, JM; Wilsbacher, JL; Stippec, S; Goldsmith, EJ; Cobb, MH				Xu, BE; English, JM; Wilsbacher, JL; Stippec, S; Goldsmith, EJ; Cobb, MH			WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION; BINDING SITE; IDENTIFICATION; ADENOSINE; PURIFICATION; ACTIVATION; SUBUNIT; CLONING; CASCADE	We have cloned and characterized a novel mammalian serine/threonine protein kinase WNK1 ((w) under bar ith (n) under bar o lysine (K) under bar)) from a rat brain cDNA library. WNK1 has 2126 amino acids and can be detected as a protein of similar to 230 kDa in various cell lines and rat tissues. WNK1 contains a small N-terminal domain followed by the kinase domain and a long C-terminal tail. The WNK1 kinase domain has the greatest similarity to the MEKK protein kinase family. However, overexpression of WNK1 in HEK293 cells exerts no detectable effect on the activity of known, co transfected mitogen-activated protein kinases, suggesting that it belongs to a distinct pathway. WNK1 phosphorylates the exogenous substrate myelin basic protein as well as itself mostly on serine residues, confirming that it is a serine/threonine protein kinase. The demonstration of activity was striking because WNK1, and its homologs in other organisms lack the invariant catalytic lysine in subdomain II of protein kinases that is crucial for binding to ATP. A model of WNK1 using the structure of cAMP-dependent protein kinase suggests that lysine 233 in kinase subdomain I may provide this function. Mutation of this lysine residue to methionine eliminates WNK1 activity, consistent with the conclusion that it is required for catalysis. This distinct organization of catalytic residues indicates that WNK1 belongs to a novel family of serine/threonine protein kinases.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK34128] Funding Source: Medline; NIGMS NIH HHS [GM53032] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARKER WC, 1982, P NATL ACAD SCI-BIOL, V79, P2836, DOI 10.1073/pnas.79.9.2836; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hemmer W, 1997, J BIOL CHEM, V272, P16946, DOI 10.1074/jbc.272.27.16946; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; SEGER R, 1992, J BIOL CHEM, V267, P25628; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TAYLOR SS, 1983, METHOD ENZYMOL, V99, P140; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	31	391	408	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16795	16801		10.1074/jbc.275.22.16795	http://dx.doi.org/10.1074/jbc.275.22.16795			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828064	hybrid			2022-12-25	WOS:000087392200057
J	Wang, HL; Kurtz, A				Wang, HL; Kurtz, A			Breast cancer growth inhibition by delivery of the MDGI-derived peptide P108	ONCOGENE			English	Article						growth inhibitor; peptide delivery; differentiation; experimental therapy	ACID-BINDING PROTEIN; BOVINE HEART; MAMMARY; CELLS; GENE; CLONING; TISSUE	Mammary derived growth inhibitor (MDGI) is a member of the family of cytoplasmic fatty acid binding proteins (FABPs), which bind hydrophobic ligands such as fatty acids, retinoids, eicosanoids and prostaglandines. MDGI and an 11 amino acid MDGI-derived conserved C-terminal peptide (P108) inhibits growth of normal mammary epithelial cells in tissue and organ culture, but fails to inhibit proliferation of many breast cancer cell Lines in vitro, Here, the effects of peptide P108 on tumor growth of MCF-7, MDA-MB468 and MDA-MB231 human breast cancer cell lines in nude mice were tested. To deliver P108 into tumors, a novel peptide production system was applied for expression and secretion of small bioactive peptides in mammalian cells. Functional differentiation was observed in MCF-7 and MDA-MB468 cells upon P108 expression, In addition, EGF-dependent colony formation in soft agar by MDA-MB468 cells was inhibited by secreted P108, Tumor growth in athymic nude mice was suppressed in all three cell lines tested, Furthermore, P108 expressed by MCF-7/P108 cells caused paracrine tumor growth inhibition of MDA-MB231 cells. These results indicate that breast cancer inhibition by P108 is independent of binding to hydrophobic ligands and is perhaps mediated by interference with EGF-dependent signaling pathways.	Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University	Kurtz, A (corresponding author), Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Pharmacol, TRB W208,3970 Reservoir Rd NW, Washington, DC 20007 USA.			Kurtz, Andreas/0000-0003-3301-6546				BILLICH S, 1988, EUR J BIOCHEM, V175, P549, DOI 10.1111/j.1432-1033.1988.tb14227.x; BOEHMER F-D, 1988, Journal of Cellular Biochemistry, V38, P199; BOEHMER FD, 1987, J BIOL CHEM, V262, P15137; BRAKCH N, 1995, FEBS LETT, V362, P143, DOI 10.1016/0014-5793(95)00229-3; BRANDT R, 1992, BIOCHEM BIOPH RES CO, V189, P406, DOI 10.1016/0006-291X(92)91573-9; Brandt R, 1998, Prog Mol Subcell Biol, V20, P197; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; ERVIN PR, 1989, SCIENCE, V244, P1585, DOI 10.1126/science.2662405; Glatz JFC, 1997, PROSTAG LEUKOTR ESS, V57, P373, DOI 10.1016/S0952-3278(97)90413-0; Grosse R, 1992, Cancer Treat Res, V61, P69; Huynh H, 1996, CANCER RES, V56, P4865; HUYNH HT, 1995, CANCER RES, V55, P2225; KURTZ A, 1990, J CELL BIOL, V110, P1779, DOI 10.1083/jcb.110.5.1779; KURTZ A, 1997, BIOCH SOC S, V69, P51; LASSEN D, 1995, EUR J BIOCHEM, V230, P266, DOI 10.1111/j.1432-1033.1995.tb20560.x; LEHMANN W, 1989, BIOMED BIOCHIM ACTA, V48, P143; Liu XH, 1996, CLIN EXP METASTAS, V14, P145, DOI 10.1007/BF00121211; NATARAJAN R, 1998, FRONT BIOSCI, V3, P81; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Phelan CM, 1996, GENOMICS, V34, P63, DOI 10.1006/geno.1996.0241; Phelan CM, 1996, GENOMICS, V36, P377, DOI 10.1006/geno.1996.0481; RYTOMAA T, 1979, MECH AGEING DEV, V9, P471, DOI 10.1016/0047-6374(79)90087-3; SILBERSTEIN G, 1987, SCIENCE, V37, P291; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TREUNER M, 1994, GENE, V147, P237, DOI 10.1016/0378-1119(94)90073-6; VEERKAMP JH, 1995, J CELL BIOL, V127, P1097; VERKAMP J, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1; WALLUKAT G, 1991, MOL CELL BIOCHEM, V102, P49; YANG Y, 1995, J CELL BIOL, V127, P1097; ZSCHIESCHE W, 1995, HISTOCHEM CELL BIOL, V103, P147, DOI 10.1007/BF01454012	30	18	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2455	2460		10.1038/sj.onc.1203575	http://dx.doi.org/10.1038/sj.onc.1203575			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828888				2022-12-25	WOS:000087018400011
J	Hashimoto, T; Cook, WS; Qi, C; Yeldandi, AV; Reddy, JK; Rao, MS				Hashimoto, T; Cook, WS; Qi, C; Yeldandi, AV; Reddy, JK; Rao, MS			Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL BETA-OXIDATION; COA SYNTHASE GENE; ACYL-COA; PPAR-ALPHA; OMEGA-HYDROXYLATION; ADAPTIVE RESPONSE; GAMMA ACTIVATORS; MICE LACKING; RAT-LIVER; EXPRESSION	Fasting causes lipolysis in adipose tissue leading to the release of large quantities of free fatty acids into circulation that reach the liver where they are metabolized to generate ketone bodies to serve as fuels for other tissues. Since fatty acid-metabolizing enzymes in the liver are transcriptionally regulated by peroxisome proliferator-activated receptor alpha (PPAR alpha), we investigated the role of PPAR alpha in the induction of these enzymes in response to fasting and their relationship to the development of hepatic steatosis in mice deficient in PPAR alpha (PPAR alpha(-/-)), peroxisomal fatty acyl-CoA oxidase (AOX(-/-)), and in both PPAR alpha and AOX (double knockout (DKO)), Fasting for 48-72 h caused profound impairment of fatty acid oxidation in both PPAR alpha(-/-) and DKO mice, and DKO mice revealed a greater degree of hepatic steatosis when compared with PPAR alpha(-/-) mice. The absence of PPAR alpha in both PPAR alpha(-/-) and DKO mice impairs the induction of mitochondrial beta-oxidation in liver following fasting which contributes to hypoketonemia and hepatic steatosis, Pronounced steatosis in DRO mouse livers is due to the added deficiency of peroxisomal beta-oxidation system in these animals due to the absence of AOX. In mice deficient in AOX alone, the sustained hyperactivation of PPAR alpha and up-regulation of mitochondrial beta-oxidation and microsomal omega-oxidation systems as well as the regenerative nature of a majority of hepatocytes containing numerous spontaneously proliferated peroxisomes, which appear refractory to store triglycerides, blunt the steatotic response to fasting. Starvation for 48-72 h caused a decrease in PPAR alpha hepatic mRNA levels in wild type mice, with no perceptible compensatory increases in PPAR gamma and PPAR delta mRNA levels. PPAR gamma and PPAR delta hepatic mRNA levels were lower in fed PPAR alpha(-/-) and DKO mice when compared with wild type mice, and fasting caused a slight increase only in PPAR gamma levels and a decrease in PPAR delta levels. Fasting did not change the PPAR isoform levels in AOX(-/-) mouse liver. These observations point to the critical importance of PPAR alpha in the transcriptional regulatory responses to fasting and in determining the severity of hepatic steatosis.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA	Northwestern University	Reddy, JK (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.				NIGMS NIH HHS [GM 23750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750, R01GM023750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; AOYAMA T, 1990, J LIPID RES, V31, P1477; Bergmeyer H, 1974, METHODS ENZYMATIC AN, P1205; Berk PD, 1999, HEPATOLOGY, V29, P1607, DOI 10.1002/hep.510290538; Boukaftane Y, 1997, GENE, V195, P121, DOI 10.1016/S0378-1119(97)00067-X; DRYER C, 1992, CELL, V68, P879; Eaton S, 1996, BIOCHEM J, V320, P345, DOI 10.1042/bj3200345; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Gervois P, 1999, MOL ENDOCRINOL, V13, P1535, DOI 10.1210/me.13.9.1535; GUTMANN I, 1974, METHOD ENZYMAT AN, V2, P1464; Hashimoto T, 1999, J BIOL CHEM, V274, P19228, DOI 10.1074/jbc.274.27.19228; Hashimoto T, 1999, NEUROCHEM RES, V24, P551, DOI 10.1023/A:1022540030918; HILLGARTNER FB, 1995, PHYSIOL REV, V75, P583; Huang MT, 1997, LIFE SCI, V60, P1915, DOI 10.1016/S0024-3205(97)00153-7; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Kerner J, 1998, ANNU REV NUTR, V18, P179, DOI 10.1146/annurev.nutr.18.1.179; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; LANDS WEM, 1995, ALCOHOL CLIN EXP RES, V19, P928, DOI 10.1111/j.1530-0277.1995.tb00969.x; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; LOWE DM, 1985, BIOCHEM J, V232, P37, DOI 10.1042/bj2320037; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; NAGAO M, 1993, J BIOL CHEM, V268, P24114; Palmer CNA, 1998, MOL PHARMACOL, V53, P14, DOI 10.1124/mol.53.1.14; PEARSON DJ, 1974, METHOD ENZYMAT AN, P1758; Qi C, 1999, P NATL ACAD SCI USA, V96, P1585, DOI 10.1073/pnas.96.4.1585; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; Roe C. R., 1995, METABOLIC MOL BASES, P1501; ROEHRIG KL, 1974, ANAL BIOCHEM, V58, P414, DOI 10.1016/0003-2697(74)90210-3; ROMAN LJ, 1993, ARCH BIOCHEM BIOPHYS, V307, P57, DOI 10.1006/abbi.1993.1560; SEITZ HJ, 1977, ARCH BIOCHEM BIOPHYS, V183, P647, DOI 10.1016/0003-9861(77)90399-X; SERRA D, 1993, ARCH BIOCHEM BIOPHYS, V307, P40, DOI 10.1006/abbi.1993.1557; SOLERARGILAGA C, 1976, J LIPID RES, V17, P605; Song XQ, 1997, BBA-MOL BASIS DIS, V1360, P151; SORRENTINO D, 1994, GASTROENTEROLOGY, V107, P1415, DOI 10.1016/0016-5085(94)90544-4; Taroni F, 1996, CURR OPIN NEUROL, V9, P477, DOI 10.1097/00019052-199612000-00015; WILLIAMS.DH, 1971, BIOCHEM J, V121, P41, DOI 10.1042/bj1210041; WILLIAMSON DH, 1974, METHOD ENZYMAT AN, P1837; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	44	340	356	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28918	28928		10.1074/jbc.M910350199	http://dx.doi.org/10.1074/jbc.M910350199			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10844002	hybrid			2022-12-25	WOS:000089330700077
J	Chang, CCY; Sakashita, N; Ornvold, K; Lee, O; Chang, ET; Dong, R; Lin, S; Lee, CYG; Strom, SC; Kashyap, R; Fung, JJ; Farese, RV; Patoiseau, JF; Delhon, A; Chang, TY				Chang, CCY; Sakashita, N; Ornvold, K; Lee, O; Chang, ET; Dong, R; Lin, S; Lee, CYG; Strom, SC; Kashyap, R; Fung, JJ; Farese, RV; Patoiseau, JF; Delhon, A; Chang, TY			Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COENZYME-A; COA-CHOLESTEROL ACYLTRANSFERASE; AFRICAN-GREEN MONKEYS; APOLIPOPROTEIN-B; MESSENGER-RNA; LIPOPROTEIN PARTICLES; MOLECULAR-CLONING; SECRETION; CELLS; EXPRESSION	By using specific anti-ACAT-1 antibodies in immunodepletion studies, we previously found that ACAT-1, a 50-kDa protein, plays a major catalytic role in the adult human liver, adrenal glands, macrophages, and kidneys but not in the intestine. Acyl-coenzyme A:cholesterol acyltransferase (ACAT) activity in the intestine may be largely derived from a different ACAT protein. To test this hypothesis, we produced specific polyclonal anti-ACAT-2 antibodies that quantitatively immunodepleted human ACAT-2, a 46-kDa protein expressed in Chinese hamster ovary cells. In hepatocyte-like HepG2 cells, ACAT-1 comprises 85-90% of the total ACAT activity, with the remainder attributed to ACAT-2. In adult intestines, most of the ACAT activity can be immunodepleted by anti-ACAT-2. ACAT-1 and ACAT-2 do not form heterooligomeric complexes. In differentiating intestinal enterocyte-like Caco-2 cells, ACAT-2 protein content increases by 5-10-fold in 6 days, whereas ACAT-1 protein content remains relatively constant. In the small intestine, ACAT-2 is concentrated at the apices of the villi, whereas ACAT-1 is uniformly distributed along the villus-crypt axis. In the human liver, ACAT-1 is present in both fetal and adult hepatocytes. In contrast, ACAT-2 is evident in fetal but not adult hepatocytes. Our results collectively suggest that in humans, ACAT-2 performs significant catalytic roles in the fetal liver and in intestinal enterocytes.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; Kumamoto Univ, Sch Med, Dept Pathol 2, Kumamoto 8600811, Japan; Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03766 USA; Univ British Columbia, Androl Lab, Vancouver, BC V6T 2B5, Canada; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Med Ctr, TE Starzl Transplantat Inst, Pittsburgh, PA 15261 USA; Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, San Francisco, CA 94141 USA; Ctr Rech Pierre Fabre, F-81106 Castres, France	Dartmouth College; Kumamoto University; Dartmouth College; University of British Columbia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco	Chang, TY (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA.	Ta.yuan.Chang@dartmouth.edu	Chang, Ellen/E-3168-2010; Chang, Ellen/G-5700-2010; FUNG, John Julian/A-2679-2012	FUNG, John Julian/0000-0002-3038-0441	NHLBI NIH HHS [HL 36709, HL 60306] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060306, R01HL036709, R37HL036709] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Accad M, 2000, J CLIN INVEST, V105, P711, DOI 10.1172/JCI9021; Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; BEAULIEU JF, 1989, J BIOL CHEM, V264, P20000; BEAULIEU JF, 1991, BIOCHEM J, V280, P599, DOI 10.1042/bj2800599; Brewer HB, 2000, J CLIN INVEST, V105, P703, DOI 10.1172/JCI9664; BROWN MS, 1980, J BIOL CHEM, V255, P9344; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; CARR TP, 1995, J LIPID RES, V36, P25; CARR TP, 1992, ARTERIOSCLER THROMB, V12, P1274, DOI 10.1161/01.ATV.12.11.1274; Cases S, 1998, J BIOL CHEM, V273, P26755, DOI 10.1074/jbc.273.41.26755; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; Chang CCY, 1998, J BIOL CHEM, V273, P35132, DOI 10.1074/jbc.273.52.35132; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG TY, 1981, ANAL BIOCHEM, V116, P298, DOI 10.1016/0003-2697(81)90360-2; Chang TY, 1997, ANNU REV BIOCHEM, V66, P613, DOI 10.1146/annurev.biochem.66.1.613; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; Davidson Nicholas O., 1995, Current Opinion in Lipidology, V6, P70, DOI 10.1097/00041433-199504000-00002; FIELD FJ, 1995, PROG LIPID RES, V34, P185, DOI 10.1016/0163-7827(95)00005-K; GINSBERG HN, 1995, CURR OPIN LIPIDOL, V6, P275, DOI 10.1097/00041433-199510000-00006; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUFF MW, 1994, ARTERIOSCLER THROMB, V14, P1498, DOI 10.1161/01.ATV.14.9.1498; Joyce C, 1999, CURR OPIN LIPIDOL, V10, P89, DOI 10.1097/00041433-199904000-00002; KRAUSE BR, 1993, J LIPID RES, V34, P279; KRAUSE BR, 1995, ACAT INHIBITORS PHYS, P173; Lee O, 1998, J LIPID RES, V39, P1722; LEVIN MS, 1989, BIOCHIM BIOPHYS ACTA, V1003, P293, DOI 10.1016/0005-2760(89)90235-X; Levy E, 2000, J LIPID RES, V41, P12; LEVY E, 1995, FASEB J, V9, P626, DOI 10.1096/fasebj.9.8.7768354; Li BL, 1999, J BIOL CHEM, V274, P11060, DOI 10.1074/jbc.274.16.11060; Lin S, 1999, J BIOL CHEM, V274, P23276, DOI 10.1074/jbc.274.33.23276; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; Oelkers P, 1998, J BIOL CHEM, V273, P26765, DOI 10.1074/jbc.273.41.26765; PAPE ME, 1995, J LIPID RES, V36, P823; Pease RJ, 1996, CURR OPIN LIPIDOL, V7, P132, DOI 10.1097/00041433-199606000-00004; Sakashita N, 2000, AM J PATHOL, V156, P227, DOI 10.1016/S0002-9440(10)64723-2; STANGE EF, 1983, J BIOL CHEM, V258, P2868; SYLVEN C, 1970, SCAND J GASTROENTERO, V5, P57; TABAS I, 1995, CURR OPIN LIPIDOL, V6, P260, DOI 10.1097/00041433-199510000-00004; TALL A, 1995, ANNU REV BIOCHEM, V64, P235; TANAKA M, 1993, J BIOL CHEM, V268, P12713; Thompson GR, 1996, J LIPID RES, V37, P439; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; Young SG, 1998, CURR OPIN LIPIDOL, V9, P81; Yu CJ, 1999, J BIOL CHEM, V274, P36139, DOI 10.1074/jbc.274.51.36139; Zhang ZJ, 1999, ARTERIOSCL THROM VAS, V19, P743, DOI 10.1161/01.ATV.19.3.743	46	174	180	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28083	28092						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10846185				2022-12-25	WOS:000089197100074
J	Barneche, F; Steinmetz, F; Echeverria, M				Barneche, F; Steinmetz, F; Echeverria, M			Fibrillarin genes encode both a conserved nucleolar protein and a novel small nucleolar RNA involved in ribosomal RNA methylation in Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PREMESSENGER RNA; MAMMALIAN GENE; GUIDE SNORNAS; BOX-C/D; YEAST; COMMON; INTRONS; COMPONENT; BIOGENESIS	Fibrillarin is a key nucleolar protein in eukaryotes which associates with box C/D small nucleolar RNAs (snoRNAs) directing 2'-O-ribose methylation of the rRNA. In this study we describe two genes in Arabidopsis thaliana, AtFib1 and AtFib2, encoding nearly identical proteins conserved with eukaryotic fibrillarins, We demonstrate that AtFib1 and AtFib2 proteins are functional homologs of the yeast Nop1p (fibrillarin) and can rescue a yeast NOP1-null mutant strain. Surprisingly, for the first time in plants, we identified two isoforms of a novel box C/D snoRNA, U60.1f and U60.2f, nested in the fifth intron of AtFib1 and AtFib2, Interestingly after gene duplication the host intronic sequences completely diverged, but the snoRNA was conserved, even in other crucifer fibrillarin genes. We show that the U60f snoRNAs accumulate in seedlings and that their targeted residue on the 25 S rRNA is methylated. Our data reveal that the three modes of expression of snoRNAs, single, polycistronic, and intronic, exist in plants and suggest that the mechanisms directing rRNA methylation, dependent on fibrillarin and box C/D snoRNAs, are evolutionarily conserved in plants.	Univ Perpignan, Lab Genome & Dev Plantes, URM CNRS 5096, F-66860 Perpignan, France	Centre National de la Recherche Scientifique (CNRS); Universite Perpignan Via Domitia	Echeverria, M (corresponding author), Univ Perpignan, Lab Genome & Dev Plantes, URM CNRS 5096, 52 Ave Villeneuve, F-66860 Perpignan, France.		Barneche, Fredy/M-4228-2015; BARNECHE, Fredy/AAB-5054-2019	Barneche, Fredy/0000-0002-7014-7097; BARNECHE, Fredy/0000-0002-7014-7097				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARIS JP, 1991, P NATL ACAD SCI USA, V88, P931, DOI 10.1073/pnas.88.3.931; Bachellerie J. P., 1998, MODIFICATION EDITING, P255; Beven AF, 1996, J CELL SCI, V109, P1241; BLANC G, IN PRESS PLANT CELL; BOORSTEIN WJ, 1990, METHOD ENZYMOL, V180, P347; Brown JWS, 1998, PLANT CELL, V10, P649, DOI 10.1105/tpc.10.5.649; Cavaille J, 1996, BIOCHIMIE, V78, P443, DOI 10.1016/0300-9084(96)84751-1; CECCHINI JP, 1979, EUR J BIOCHEM, V98, P203, DOI 10.1111/j.1432-1033.1979.tb13178.x; CERDIDO A, 1995, CHROMOSOMA, V103, P625; Chanfreau G, 1998, J MOL BIOL, V284, P975, DOI 10.1006/jmbi.1998.2237; Chanfreau G, 1998, EMBO J, V17, P3726, DOI 10.1093/emboj/17.13.3726; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; Cooke R, 1996, PLANT J, V9, P101, DOI 10.1046/j.1365-313X.1996.09010101.x; CREANCIER L, 1993, MOL BIOL CELL, V4, P1239, DOI 10.1091/mbc.4.12.1239; David E, 1997, MOL BIOL CELL, V8, P1051, DOI 10.1091/mbc.8.6.1051; de Carcer G, 1999, J STRUCT BIOL, V128, P139, DOI 10.1006/jsbi.1999.4187; Doyle JJ, 1989, FOCUS, V12, P13; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; FRAGAPANE P, 1993, EMBO J, V12, P2921, DOI 10.1002/j.1460-2075.1993.tb05954.x; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANSEN RP, 1991, J CELL BIOL, V113, P715, DOI 10.1083/jcb.113.4.715; JOHNSTON JR, 1994, MOL GENETICS YEAST; KISS T, 1991, CELL, V65, P517, DOI 10.1016/0092-8674(91)90469-F; KISS T, 1995, GENE DEV, V9, P1411, DOI 10.1101/gad.9.11.1411; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Lafontaine DLJ, 1998, TRENDS BIOCHEM SCI, V23, P383, DOI 10.1016/S0968-0004(98)01260-2; Lafontaine DLJ, 1999, RNA, V5, P455, DOI 10.1017/S135583829998192X; LAPEYRE B, 1990, MOL CELL BIOL, V10, P430, DOI 10.1128/MCB.10.1.430; Leader DJ, 1997, EMBO J, V16, P5742, DOI 10.1093/emboj/16.18.5742; Leader DJ, 1999, PLANT MOL BIOL, V39, P1091, DOI 10.1023/A:1006157022319; Lowe TM, 1999, SCIENCE, V283, P1168, DOI 10.1126/science.283.5405.1168; Lyman SK, 1999, RNA, V5, P1597, DOI 10.1017/S1355838299991288; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MADEN BEH, 1995, BIOCHIMIE, V77, P22, DOI 10.1016/0300-9084(96)88100-4; MAXWELL ES, 1995, ANNU REV BIOCHEM, V35, P897; NICOLOSO M, 1994, MOL CELL BIOL, V14, P5766, DOI 10.1128/MCB.14.9.5766; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; Pelczar P, 1998, MOL CELL BIOL, V18, P4509, DOI 10.1128/MCB.18.8.4509; Petfalski E, 1998, MOL CELL BIOL, V18, P1181, DOI 10.1128/MCB.18.3.1181; PRISLEI S, 1993, NUCLEIC ACIDS RES, V21, P5824, DOI 10.1093/nar/21.25.5824; QU LH, 1994, NUCLEIC ACIDS RES, V22, P4073, DOI 10.1093/nar/22.20.4073; Qu LH, 1999, MOL CELL BIOL, V19, P1144; Saez-Vasquez J, 2000, PLANT SCI, V156, P35, DOI 10.1016/S0168-9452(00)00229-6; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIMMANG T, 1989, EMBO J, V8, P4015, DOI 10.1002/j.1460-2075.1989.tb08584.x; Sicard H, 1998, MOL BIOL CELL, V9, P2011, DOI 10.1091/mbc.9.8.2011; SONNHAMMER ELL, 1995, GENE-COMBIS, V167, P1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; Tycowski KT, 1996, NATURE, V379, P464, DOI 10.1038/379464a0; TYCOWSKI KT, 1993, GENE DEV, V6, P1120; Wang HM, 2000, EMBO J, V19, P317, DOI 10.1093/emboj/19.3.317; Wu P, 1998, J BIOL CHEM, V273, P16453, DOI 10.1074/jbc.273.26.16453	60	108	117	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27212	27220						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10829025				2022-12-25	WOS:000089144800073
J	Miwa, N; Uebi, T; Kawamura, S				Miwa, N; Uebi, T; Kawamura, S			Characterization of p26olf, a novel calcium-binding protein in the frog olfactory epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR NEURONS; TRANSDUCTION; LOCALIZATION; SUBTYPES; CLONING; CYCLASE	We have previously shown that p26olf is a novel S100-like Ca2+-binding protein in the frog olfactory epithelium, In this paper, we characterized the Ca2+ binding property of p26olf, examined the precise localization in the frog olfactory epithelium, and searched for the possible target proteins of p26olf. By flow dialysis experiments using Ca-45, p26olf was suggested to bind similar to 4 Ca2+ Circular dichroism measurement showed that binding of Ca2+ to p26olf induces an increase in the apparent content of both alpha-helix and beta-sheet with an apparent K-d value of 2.4 mu M. Electron microscopic observation disclosed p26olf immunoreactivity in the cilia, dendritic knob, and dendrite of olfactory receptor cells. Blot overlay analysis and affinity purification of p26olf-binding proteins showed that p26olf binds to a frog beta-adrenergic receptor kinase-like protein in a Ca2+-dependent manner. These results suggested that p26olf has some roles in the olfactory transduction or adaptation.	Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600043, Japan	Osaka University	Miwa, N (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Machikane Yama 1-1, Toyonaka, Osaka 5600043, Japan.							ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BORISY FF, 1992, J NEUROSCI, V12, P915; Breer H, 1992, Curr Opin Neurobiol, V2, P439, DOI 10.1016/0959-4388(92)90177-M; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; Firestein S, 1992, Curr Opin Neurobiol, V2, P444, DOI 10.1016/0959-4388(92)90178-N; HARLOW E, 1988, ANTIBODIES LABORATOR, P340; Iacovelli L, 1999, FASEB J, V13, P1; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; Kretsinger RH, 1997, NAT STRUCT BIOL, V4, P514, DOI 10.1038/nsb0797-514; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MATTES T, 1998, J IMMUNOL, V141, P3135; MCCUBBIN WD, 1986, FEBS LETT, V195, P17, DOI 10.1016/0014-5793(86)80121-1; MENCO BPM, 1992, NEURON, V8, P441, DOI 10.1016/0896-6273(92)90272-F; Miwa N, 1998, BIOCHEM BIOPH RES CO, V251, P860, DOI 10.1006/bbrc.1998.9571; REED RR, 1992, COLD SPRING HARB SYM, V57, P501, DOI 10.1101/SQB.1992.057.01.055; SCHLEICHER S, 1993, P NATL ACAD SCI USA, V90, P1420, DOI 10.1073/pnas.90.4.1420; Seemann J, 1996, BIOCHEM J, V319, P123, DOI 10.1042/bj3190123; SKELTON NJ, 1994, NAT STRUCT BIOL, V1, P239, DOI 10.1038/nsb0494-239; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; Tanaka T, 1999, PROTEIN ENG, V12, P395, DOI 10.1093/protein/12.5.395; TSUGA H, 1994, J BIOL CHEM, V269, P32522	26	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27245	27249						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10852910				2022-12-25	WOS:000089144800077
J	Silverman, GL; Qin, KF; Moore, RC; Yang, Y; Mastrangelo, P; Tremblay, P; Prusiner, SB; Cohen, FE; Westaway, D				Silverman, GL; Qin, KF; Moore, RC; Yang, Y; Mastrangelo, P; Tremblay, P; Prusiner, SB; Cohen, FE; Westaway, D			Doppel is an N-glycosylated, glycosylphosphatidylinositol-anchored protein - Expression in testis and ectopic production in the brains of Prnp(o/o) mice predisposed to Purkinje cell loss	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PRION PROTEIN; CLEAVAGE ATTACHMENT SITE; MEMBRANE-PROTEINS; SCRAPIE ISOFORM; PRP GENE; PHOSPHATIDYLINOSITOL; DEFICIENT; SEQUENCE; REGION; ATAXIA	The Prnd gene encodes a homolog of the cellular prion protein (PrPC) called doppel (Dpl), Up-regulation of Prnd mRNA in two distinct lines of PrP gene ablated (Prnp(0/0)) mice, designated Rcm0 and Ngsk, is associated with death of Purkinje cells. Using recombinant Dpl expressed in Escherichia coli and mouse neuroblastoma cells we demonstrate that wild type (wt) Dpl, like PrPC, adopts a predominantly alpha-helical conformation, forms intramolecular disulfide bonds, has two N-linked oligosaccharides, and is presented on the cell surface via a glycosylphosphatidylinositol anchor. Dpl protein was detected in testis of wt mice. Using Triton X-114 phase partitioning to enrich for glycosylphosphatidylinositol-anchored proteins, Dpl was detected in brain samples from Rcm0 Prnp(0/0) mice but was absent in equivalent samples from wt mice and ZrchI Prnp(0/0) mice, indicating that ectopic expression of this protein may cause cerebellar pathology in Rcm0 mice. Biochemical and structural similarities between PrPC and Dpl documented here parallel the observation that ataxic Ngsk Prnp(0/0) mice can be rescued by overexpression of wild-type PrP transgenes, and suggest that cell surface PrPC can antagonize the toxic effect of Dpl expressed in the central nervous system.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Mol Med Res Ctr, Mass Spectrometry Lab, Toronto, ON M5S 3H2, Canada; Univ Calif San Francisco, Inst Neurodegenerat Dis, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cell & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of Toronto; University of Toronto; University of Toronto; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Westaway, D (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Tanz Neurosci Bldg,6 Queens Pk Cres W, Toronto, ON M5S 3H2, Canada.							BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CONZELMANN A, 1986, EMBO J, V5, P3291, DOI 10.1002/j.1460-2075.1986.tb04642.x; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Furukawa Y, 1997, BBA-BIOMEMBRANES, V1328, P185, DOI 10.1016/S0005-2736(97)00084-9; Hornemann S, 1996, J MOL BIOL, V261, P614, DOI 10.1006/jmbi.1996.0487; Hornemann S, 1997, FEBS LETT, V413, P277, DOI 10.1016/S0014-5793(97)00921-6; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Lee IY, 1998, GENOME RES, V8, P1022, DOI 10.1101/gr.8.10.1022; Loftus B, 1997, GENE, V184, P215, DOI 10.1016/S0378-1119(96)00598-7; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; Mehlhorn I, 1996, BIOCHEMISTRY-US, V35, P5528, DOI 10.1021/bi952965e; MICANOVIC R, 1990, P NATL ACAD SCI USA, V87, P157, DOI 10.1073/pnas.87.1.157; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; MORAN P, 1991, J BIOL CHEM, V266, P1250; Nishida N, 1999, LAB INVEST, V79, P689; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STROBL S, 1995, BIOCHEMISTRY-US, V34, P8281, DOI 10.1021/bi00026a009; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Weissmann C, 1999, SCIENCE, V286, P914, DOI 10.1126/science.286.5441.914; WESTAWAY D, 1991, NEURON, V7, P59, DOI 10.1016/0896-6273(91)90074-A	28	139	155	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26834	26841						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842180				2022-12-25	WOS:000089144800025
J	Steet, RA; Melancon, P; Kuchta, RD				Steet, RA; Melancon, P; Kuchta, RD			3 '-azidothymidine potently inhibits the biosynthesis of highly branched N-linked oligosaccharides and poly-N-acetyllactosamine chains in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANEMIA TYPE-II; HEMATOPOIETIC PROGENITOR CELLS; ALTERS GLYCOSPHINGOLIPID SYNTHESIS; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; ALPHA-MANNOSIDASE-II; PROTEIN GLYCOSYLATION; PHASEOLUS-VULGARIS; DOLICHYL PHOSPHATE; HEPARAN-SULFATE; MOLECULAR-BASIS	Previous studies in our laboratory have characterized 3'-azido-3'-deoxythymidine (AZT) as a potent inhibitor of glycosphingolipid biosynthesis in cultured cells (Steet, R,, Alizadeh, M,, Melancon, P,, and Kuchta, R, D, (1999) Glycoconj. J. 16, 237-245; Yan, J.-P,, Ilsley, D, D,, Frohlick, C,, Steet, R,, Hall, E, T,, Kuchta, R, D,, and Melancon, P, (1995) J, Biol, Chem, 270, 22836-22841), Here, we report that AZT treatment of K562 cells results in significant alterations in the profile of N-linked oligosaccharides, Fractionation of [H-3]mannose-labeled oligosaccharides from AZT-treated K562 cells using lectin affinity chromatography revealed striking changes in the branching and processing of N-linked glycoconjugates, AZT treatment resulted in the production of fewer highly branched complex glycans (60% of control at 20 mu M AZT) and a significant accumulation of core-fucosylated biantennary oligosaccharides, In addition, extension of branched oligosaccharides with multiple poly-N-acetyllactosamine repeats is nearly abolished by AZT concentrations as low as 2 mu M, A Shift from multiantennary to moderately branched oligosaccharides was also apparent in the melanoma cell line SK-MEL-30 upon AZT treatment. N-Linked glycans from both cell lines exhibited increased affinity for the beta-galactoside-binding lectin RCA-I in the presence of AZT, suggesting that the addition of terminal sialic acid is sensitive to the drug. These results demonstrate the ability of AZT to modulate strongly the processing of asparagine-linked glycoconjugates in whole cells and reveal a novel mechanism by which AZT treatment may cause anemia.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Alberta, Dept Cell Biol & Anat, Edmonton, AB T6G 2H7, Canada	University of Colorado System; University of Colorado Boulder; University of Alberta	Kuchta, RD (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.		Melancon, Paul/P-1304-2018	Melancon, Paul/0000-0002-8085-3032	NIGMS NIH HHS [GM55709] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asada M, 1997, CANCER RES, V57, P1073; BRESALIER RS, 1990, CANCER RES, V50, P1299; Chui D, 1997, CELL, V90, P157, DOI 10.1016/S0092-8674(00)80322-0; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1235; CUMMINGS RD, 1982, J BIOL CHEM, V257, P13421; CUMMINGS RD, 1984, J BIOL CHEM, V259, P6253; CUMMINGS RD, 1994, METHOD ENZYMOL, V230, P66; DAINIAK N, 1988, BRIT J HAEMATOL, V69, P299, DOI 10.1111/j.1365-2141.1988.tb02366.x; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; Dennis JW, 1992, CELL SURFACE CARBOHY, P161; DO KY, 1993, J BIOL CHEM, V268, P22028; Drzeniek Z, 1999, BLOOD, V93, P2884; DU DL, 1992, BRIT J HAEMATOL, V80, P437, DOI 10.1111/j.1365-2141.1992.tb04555.x; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; FUJIMOTO K, 1991, J BIOL CHEM, V266, P3571; FUKUDA M, 1984, BIOL GLYCOPROTEINS, P183; FUKUDA MN, 1986, BLOOD, V68, P521; FUKUDA MN, 1984, BRIT J HAEMATOL, V56, P55, DOI 10.1111/j.1365-2141.1984.tb01271.x; FUKUDA MN, 1990, P NATL ACAD SCI USA, V87, P7443, DOI 10.1073/pnas.87.19.7443; FUKUDA MN, 1993, BAILLIERE CLIN HAEM, V6, P493, DOI 10.1016/S0950-3536(05)80156-8; FUKUDA MN, 1987, J BIOL CHEM, V262, P7195; GAHMBERG CG, 1984, P NATL ACAD SCI-BIOL, V81, P6752, DOI 10.1073/pnas.81.21.6752; GAHMBERG CG, 1988, J CELL BIOCHEM, V37, P91, DOI 10.1002/jcb.240370109; GANSER A, 1989, EXP HEMATOL, V17, P321; Hakomori S, 1996, CANCER RES, V56, P5309; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HALL ET, 1994, J BIOL CHEM, V269, P14355; HUMPHRIES MJ, 1986, CANCER RES, V46, P5215; HUMPHRIES MJ, 1986, P NATL ACAD SCI USA, V83, P1752, DOI 10.1073/pnas.83.6.1752; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEE N, 1990, J BIOL CHEM, V265, P20476; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; NARASIMHAN S, 1986, CARBOHYD RES, V149, P65, DOI 10.1016/S0008-6215(00)90370-7; PAN YT, 1990, BIOCHEMISTRY-US, V29, P8077, DOI 10.1021/bi00487a013; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; ROSENWALD AG, 1990, J BIOL CHEM, V265, P14544; ROUX L, 1988, J BIOL CHEM, V263, P8879; RUSH JS, 1995, ANAL BIOCHEM, V224, P494, DOI 10.1006/abio.1995.1078; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SAMPATH D, 1992, J BIOL CHEM, V267, P4440; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Steet R, 1999, GLYCOCONJUGATE J, V16, P237, DOI 10.1023/A:1007032522001; Suzuki T, 2000, GLYCOBIOLOGY, V10, P51, DOI 10.1093/glycob/10.1.51; TAKANO R, 1994, GLYCOBIOLOGY, V4, P665, DOI 10.1093/glycob/4.5.665; Toma L, 1996, J BIOL CHEM, V271, P3897; TREVELYAN WE, 1950, NATURE, V166, P444, DOI 10.1038/166444b0; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; VARKI A, 1994, METHOD ENZYMOL, V230, P16; WEST CM, 1986, MOL CELL BIOCHEM, V72, P3; Wickramasinghe SN, 1998, BLOOD REV, V12, P178, DOI 10.1016/S0268-960X(98)90016-9; YAN JP, 1995, J BIOL CHEM, V270, P22836, DOI 10.1074/jbc.270.39.22836; YOGEESWARAN G, 1981, SCIENCE, V212, P1514, DOI 10.1126/science.7233237	53	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26812	26820						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842182				2022-12-25	WOS:000089144800022
J	Herreros, L; Rodriguez-Fernandez, JL; Brown, MC; Alonso-Lebrero, JL; Cabanas, C; Sanchez-Madrid, F; Longo, N; Turner, CE; Sanchez-Mateos, P				Herreros, L; Rodriguez-Fernandez, JL; Brown, MC; Alonso-Lebrero, JL; Cabanas, C; Sanchez-Madrid, F; Longo, N; Turner, CE; Sanchez-Mateos, P			Paxillin localizes to the lymphocyte microtubule organizing center and associates with the microtubule cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; FOCAL ADHESION LOCALIZATION; GAMMA-TUBULIN; T-CELL; TYROSINE PHOSPHORYLATION; CROSS-LINKING; LIM DOMAINS; BINDING; PROTEIN; ACTIVATION	Paxillin is a focal adhesion-associated protein that functions as a multi-domain adapter protein, binding several structural and signaling molecules. alpha-Tubulin was identified as an interacting protein in a two-hybrid screen using the paxillin C-terminal LIM domain as a bait. In vitro binding assays with glutathione S-transferase-paxillin demonstrated an interaction of cy-tubulin with the C terminus of paxillin. Another member of the tubulin family, gamma-tubulin, bound to both the N and the C terminus of paxillin. The interaction between paxillin and both alpha- and gamma-tubulin in vivo was confirmed by immunoprecipitation from human T lymphoblasts. Immunofluorescence studies revealed that, in adherent T cells, paxillin localized to sites of cell-matrix interaction as well as to a large perinuclear region. Confocal microscopy revealed that this region corresponds to the lymphocyte microtubule organizing center, where paxillin colocalizes with alpha- and gamma-tubulin. The localization of paxillin to this area was observed in cells in suspension as well as during adhesion to integrin ligands. These data constitute the first characterization of the interaction of paxillin with the microtubule cytoskeleton, and suggest that paxillin, in addition to its well established role at focal adhesions, could also be associated with the lymphocyte microtubule network.	Hosp Gen Univ Gregorio Maranon, Sern Inmunol, Madrid 28007, Spain; Univ Complutense Madrid, Fac Med, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain; Hosp Princesa, Serv Inmunol, Madrid 28006, Spain; SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	General University Gregorio Maranon Hospital; Complutense University of Madrid; Hospital de La Princesa; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sanchez-Mateos, P (corresponding author), Hosp Gen Univ Gregorio Maranon, Sern Inmunol, C Dr Esquerdo 46, Madrid 28007, Spain.		Sanchez-Madrid, Francisco/M-7889-2016; Rodriguez-Fernandez, Jose Luis/Q-5021-2019; CABAÑAS, CARLOS/J-4595-2012; Sanchez-Mateos, Paloma/E-8931-2013	Sanchez-Madrid, Francisco/0000-0001-5303-0762; Rodriguez-Fernandez, Jose Luis/0000-0001-8874-1425; CABAÑAS, CARLOS/0000-0002-8767-060X; Sanchez-Mateos, Paloma/0000-0001-6589-4445	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047607, R01GM047607] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM047607, GM47607] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERENDT AR, 1992, CELL, V14, P9; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CAMPANERO MR, 1994, J CELL BIOL, V127, P867, DOI 10.1083/jcb.127.3.867; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; Fava F, 1999, J CELL BIOL, V147, P857, DOI 10.1083/jcb.147.4.857; Fuchs E, 1999, CELL, V98, P547, DOI 10.1016/S0092-8674(00)80041-0; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; Gavin RH, 1997, INT REV CYTOL, V173, P207; Gismondi A, 1997, J IMMUNOL, V159, P4729; Goode BL, 2000, CURR OPIN CELL BIOL, V12, P63, DOI 10.1016/S0955-0674(99)00058-7; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; KUPFER A, 1989, J EXP MED, V170, P1697, DOI 10.1084/jem.170.5.1697; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Lowin-Kropf B, 1998, J CELL BIOL, V140, P861, DOI 10.1083/jcb.140.4.861; Moudjou M, 1996, J CELL SCI, V109, P875; Oegema K, 1999, J CELL BIOL, V144, P721, DOI 10.1083/jcb.144.4.721; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Rodriguez-Fernandez JL, 1999, MOL BIOL CELL, V10, P1891, DOI 10.1091/mbc.10.6.1891; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; SANCHEZMATEOS P, 1993, EUR J IMMUNOL, V23, P2642, DOI 10.1002/eji.1830231038; Sancho D, 2000, J CELL BIOL, V149, P1249, DOI 10.1083/jcb.149.6.1249; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Sedwick CE, 1999, J IMMUNOL, V162, P1367; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; TURNER CE, 1994, J CELL SCI, V107, P1583; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; TURNER CE, 1990, J CELL BIOL, V111, P1058; Volkov Y, 1998, J IMMUNOL, V161, P6487; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Wiese C, 1999, CURR OPIN STRUC BIOL, V9, P250, DOI 10.1016/S0959-440X(99)80035-9; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	40	88	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26436	26440		10.1074/jbc.M003970200	http://dx.doi.org/10.1074/jbc.M003970200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10840040	Green Published, hybrid			2022-12-25	WOS:000088999700077
J	Phan, UT; Arunachalam, B; Cresswell, P				Phan, UT; Arunachalam, B; Cresswell, P			Gamma-interferon-inducible lysosomal thiol reductase (GILT) - Maturation, activity, and mechanism of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; PROTEIN DISULFIDE-ISOMERASE; BETA-GALACTOSIDASE; ENDOPLASMIC-RETICULUM; CYSTEINE; ANTIGEN; EXPRESSION; MOLECULES; TRANSPORT; DEFECT	We recently identified a gamma-interferon-inducible lysosomal thiol reductase (GILT), constitutively expressed in antigen-presenting cells, that catalyzes disulfide bond reduction both in vitro and in vivo and is optimally active at acidic pH. GILT is synthesized as a 35-kDa precursor, and following delivery to major histocompatibility complex (MHC) class II-containing compartments (MIICs), is processed to the mature 30-kDa form via cleavage of N- and C-terminal propeptides. The generation of MHC class II epitopes requires both protein denaturation and reduction of intra- and interchain disulfide bonds prior to proteolysis. GILT may be important in disulfide bond reduction of proteins delivered to MIICs and consequently in antigen processing. In this report we show that, like its mature form, precursor GILT reduces disulfide bonds with an acidic pH optimum, suggesting that it may also be involved in disulfide bond reduction in the endocytic pathway. We also show that processing of precursor GILT can be mediated by multiple lysosomal proteases and provide evidence that the mechanism of action of GILT resembles that of other thiol oxidoreductases.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University	Cresswell, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 310 Cedar St, New Haven, CT 06510 USA.			Arunachalam, Arun/0000-0001-6486-5722	NIAID NIH HHS [AI23081] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI023081, R01AI023081] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON KS, 1994, EMBO J, V13, P675, DOI 10.1002/j.1460-2075.1994.tb06306.x; Arunachalam B, 2000, P NATL ACAD SCI USA, V97, P745, DOI 10.1073/pnas.97.2.745; Arunachalam B, 1998, J IMMUNOL, V160, P5797; Chivers PT, 1998, PROLYL HYDROXYLASE P, P487; COLLINS DS, 1991, J IMMUNOL, V147, P4054; DAVIS JE, 1990, J IMMUNOL, V144, P990; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; DENZIN LK, 1994, IMMUNITY, V1, P595, DOI 10.1016/1074-7613(94)90049-3; Frand AR, 1999, MOL CELL, V4, P469, DOI 10.1016/S1097-2765(00)80198-7; Gainey D, 1996, J CELL PHYSIOL, V168, P248, DOI 10.1002/(SICI)1097-4652(199608)168:2<248::AID-JCP3>3.0.CO;2-P; GILBERT HF, 1998, PROLYL HYDROXYLASE P, P341; Gingras R, 1999, J BIOL CHEM, V274, P11742, DOI 10.1074/jbc.274.17.11742; GUY K, 1982, EUR J IMMUNOL, V12, P942, DOI 10.1002/eji.1830121109; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOOGEVEEN AT, 1983, J BIOL CHEM, V258, P2143; HUNTER WM, 1964, BIOCHEM J, V91, P43, DOI 10.1042/bj0910043; IKONEN E, 1993, EMBO J, V12, P295, DOI 10.1002/j.1460-2075.1993.tb05656.x; JENSEN PE, 1991, J EXP MED, V174, P1121, DOI 10.1084/jem.174.5.1121; Krepela E, 1999, BIOL CHEM, V380, P541, DOI 10.1515/BC.1999.069; LUSTER AD, 1988, J BIOL CHEM, V263, P12036; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; McGrath ME, 1999, ANNU REV BIOPH BIOM, V28, P181, DOI 10.1146/annurev.biophys.28.1.181; MEGO JL, 1985, BIOCHIM BIOPHYS ACTA, V841, P139, DOI 10.1016/0304-4165(85)90014-5; MERKEL BJ, 1995, J IMMUNOL, V154, P128; MOBBS CV, 1998, PROLYL HYDROXYLASE P, P237; Mustacich D, 2000, BIOCHEM J, V346, P1, DOI 10.1042/0264-6021:3460001; PALMER JT, 1995, J MED CHEM, V38, P3193, DOI 10.1021/jm00017a002; PISONI RL, 1990, J CELL BIOL, V110, P327, DOI 10.1083/jcb.110.2.327; Riese RJ, 1996, IMMUNITY, V4, P357, DOI 10.1016/S1074-7613(00)80249-6; ROCHE PA, 1990, J IMMUNOL, V144, P1849; TRANCHEMONTAGNE J, 1990, BIOCHEM BIOPH RES CO, V168, P22, DOI 10.1016/0006-291X(90)91669-J; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; Walker KW, 1996, BIOCHEMISTRY-US, V35, P1972, DOI 10.1021/bi952157n; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821; Woo JT, 1996, EUR J PHARMACOL, V300, P131, DOI 10.1016/0014-2999(95)00858-6; YAMAMOTO Y, 1990, DNA CELL BIOL, V9, P119, DOI 10.1089/dna.1990.9.119; ZHANG SQ, 1994, BIOCHEM J, V304, P281, DOI 10.1042/bj3040281	37	156	160	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25907	25914		10.1074/jbc.M003459200	http://dx.doi.org/10.1074/jbc.M003459200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852914	hybrid			2022-12-25	WOS:000088999700005
J	Solorzano, A; Rodriguez-Cousino, N; Esteban, R; Fujimura, T				Solorzano, A; Rodriguez-Cousino, N; Esteban, R; Fujimura, T			Persistent yeast single-stranded RNA viruses exist in vivo as genomic RNA center dot RNA polymerase complexes in 1 : 1 stoichiometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPHIOSTOMA-NOVO-ULMI; ELM DISEASE FUNGUS; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; MITOCHONDRIAL GENOME; HYPOVIRULENT STRAIN; MOLECULAR-CLONING; GENE-EXPRESSION; CELL-GROWTH; T-DSRNA	Yeast narnavirus 20 S and 23 S RNAs encode RNA-dependent RNA polymerases p91 and p104, respectively, but do not encode coat proteins. Both RNAs form ribonucleoprotein complexes with their cognate polymerases. Here we show that these complexes are not localized in mitochondria, unlike the closely related mitoviruses, which reside in these organelles. Cytoplasmic localization of these polymerases was demonstrated by immunofluorescence and by fluorescence emitted from green fluorescent protein-fused polymerases. These fusion proteins were able to form ribonucleoprotein complexes as did the wild-type polymerases. Fluorescent observations and cell fractionation experiments suggested that the polymerases were stabilized by complex formation with their viral RNA genomes. Immunoprecipitation experiments with anti-green fluorescent protein antibodies demonstrated that a single polymerase molecule binds to a single viral RNA genome in the complex. Moreover, the majority (if not all) of 20 S and 23 S RNA molecules were found to form complexes with their cognate RNA polymerases. Since these viral RNAs were not encapsidated, ribonucleoprotein complex formation with their cognate RNA polymerases appears to be their strategy to survive in the host as persistent viruses.	Univ Salamanca, CSIC, Inst Microbiol Bioquim, Dept Genet & Microbiol, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Fujimura, T (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim, Dept Genet & Microbiol, Avda Campo Ccharro S-N, Salamanca 37007, Spain.		Esteban, Rosa/K-4356-2014; Fujimura, Tsutomu/K-5807-2014; Rodríguez-Cousiño, Nieves/K-6465-2014	Esteban, Rosa/0000-0001-6804-7209; Fujimura, Tsutomu/0000-0002-9457-6769; Rodríguez-Cousiño, Nieves/0000-0002-6458-3677; Solorzano, Alicia/0000-0003-0072-3463				Ahmed Rafi, 1996, P207; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Bahler J, 1998, GENE DEV, V12, P1356, DOI 10.1101/gad.12.9.1356; BEALL JA, 1986, J IMMUNOL METHODS, V86, P217, DOI 10.1016/0022-1759(86)90456-4; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CHAN WKY, 1988, GENE, V73, P295, DOI 10.1016/0378-1119(88)90494-5; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; DAUM G, 1982, J BIOL CHEM, V257, P3028; ESTEBAN LM, 1992, J BIOL CHEM, V267, P10874; ESTEBAN LM, 1994, J BIOL CHEM, V269, P29771; ESTEBAN R, 1993, PROG NUCLEIC ACID RE, V46, P155, DOI 10.1016/S0079-6603(08)61021-1; Fernandez-Abalos JM, 1998, MOL MICROBIOL, V27, P121, DOI 10.1046/j.1365-2958.1998.00664.x; FUJIMURA T, 1992, NATURE, V359, P746, DOI 10.1038/359746a0; FUJIMURA T, 1988, CELL, V55, P663, DOI 10.1016/0092-8674(88)90225-5; FUJIMURA T, 1990, CELL, V62, P819, DOI 10.1016/0092-8674(90)90125-X; FUJIMURA T, 1986, P NATL ACAD SCI USA, V83, P4433, DOI 10.1073/pnas.83.12.4433; GARCIACUELLAR MP, 1995, J BIOL CHEM, V270, P20084, DOI 10.1074/jbc.270.34.20084; GarciaCuellar MP, 1997, RNA, V3, P27; GRIFFITHS AJF, 1995, MICROBIOL REV, V59, P673, DOI 10.1128/MMBR.59.4.673-685.1995; HARLAND R, 1988, DEVELOPMENT, V102, P837; Hong YG, 1999, VIROLOGY, V258, P118, DOI 10.1006/viro.1999.9691; Hong YG, 1998, VIROLOGY, V246, P158, DOI 10.1006/viro.1998.9178; ICHO T, 1988, J BIOL CHEM, V263, P1467; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JOHNSON AW, 1995, MOL CELL BIOL, V15, P2719; Koonin EV, 1992, SEMIN VIROL, V3, P327; Lakshman DK, 1998, P NATL ACAD SCI USA, V95, P6425, DOI 10.1073/pnas.95.11.6425; LARIMER FW, 1990, GENE, V95, P85, DOI 10.1016/0378-1119(90)90417-P; MATSUMOTO Y, 1990, P NATL ACAD SCI USA, V87, P7628, DOI 10.1073/pnas.87.19.7628; MIHARA K, 1985, EMBO J, V4, P769, DOI 10.1002/j.1460-2075.1985.tb03695.x; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Paquin B, 1997, CURR GENET, V31, P380, DOI 10.1007/s002940050220; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; POLASHOCK JJ, 1994, P NATL ACAD SCI USA, V91, P8680, DOI 10.1073/pnas.91.18.8680; RIDLEY SP, 1984, MOL CELL BIOL, V4, P761, DOI 10.1128/MCB.4.4.761; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P20363, DOI 10.1074/jbc.273.32.20363; RODRIGUEZCOUSINO N, 1992, NUCLEIC ACIDS RES, V20, P2761, DOI 10.1093/nar/20.11.2761; RODRIGUEZCOUSINO N, 1991, J BIOL CHEM, V266, P12772; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOHE A, 1978, J BACTERIOL, V136, P1002, DOI 10.1128/JB.136.3.1002-1007.1978; Trilla JA, 1999, J CELL BIOL, V145, P1153, DOI 10.1083/jcb.145.6.1153; WESOLOWSKI M, 1984, MOL CELL BIOL, V4, P181, DOI 10.1128/MCB.4.1.181; WICKNER RB, 1991, J VIROL, V65, P155, DOI 10.1128/JVI.65.1.155-161.1991; Wickner RB, 1996, MICROBIOL REV, V60, P250, DOI 10.1128/MMBR.60.1.250-265.1996; WICKNER RB, 1999, VIRUS TAXONOMY, P651	46	19	22	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26428	26435		10.1074/jbc.M002281200	http://dx.doi.org/10.1074/jbc.M002281200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10833519	hybrid			2022-12-25	WOS:000088999700076
J	Takemoto, L; Boyle, D				Takemoto, L; Boyle, D			Specific glutamine and asparagine residues of gamma-S crystallin are resistant to in vivo deamidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-A CRYSTALLIN; HUMAN LENS	It has been hypothesized that resistance to nonenzymatic deamidation of asparagine and glutamine residues may be an important determinant of protein stability in vivo, As a test of this hypothesis, we analyzed the central region of old human lenses, which contain proteins such as gamma-S crystallin that were synthesized during the fetal-embryonic periods of development. Total protein from the fetal embryonic region of old human lenses was digested with trypsin, followed by resolution of tryptic fragments containing amidated and deamidated forms using high pressure liquid chromatography-reverse phase chromatography together with synthetic peptide standards and mass spectral analysis. The results demonstrate no detectable deamidation of glutamine 92, glutamine 96, asparagine 143, and glutamine 170 from gamma-S crystallin from old human lenses, consistent with the hypothesis that very long-lived pro proteins can contain asparagine and glutamine residues that are extremely resistant to in vivo deamidation.	Kansas State Univ, Div Biol, Manhattan, KS 66506 USA	Kansas State University	Takemoto, L (corresponding author), Kansas State Univ, Div Biol, Ackert Hall, Manhattan, KS 66506 USA.				NEI NIH HHS [2 RO1 EY02932-19] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY002932] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; GUO D, 1987, J CHROMATOGR, V386, P205; Hanson SRA, 1998, EXP EYE RES, V67, P301, DOI 10.1006/exer.1998.0530; Robinson A.B., 1974, CURR TOP CELL REGUL, V8, P248; Shestopalov VI, 2000, J CELL SCI, V113, P1913; Takemoto L, 1998, EXP EYE RES, V67, P119, DOI 10.1006/exer.1998.0529; Takemoto L, 1998, BIOCHEMISTRY-US, V37, P13681, DOI 10.1021/bi981542k; TYLERCROSS R, 1991, J BIOL CHEM, V266, P22549; Xie ML, 1999, J PHARM SCI, V88, P8, DOI 10.1021/js9802493; ZARINA S, 1994, PROTEIN SCI, V3, P1840, DOI 10.1002/pro.5560031023	11	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26109	26112		10.1074/jbc.M002809200	http://dx.doi.org/10.1074/jbc.M002809200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10843993	hybrid			2022-12-25	WOS:000088999700032
J	Hughes, E; Burke, RM; Doig, AJ				Hughes, E; Burke, RM; Doig, AJ			Inhibition of toxicity in the beta-amyloid peptide fragment beta-(25-35) using N-methylated derivatives - A general strategy to prevent amyloid formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; FIBRIL FORMATION; IN-VITRO; SHEET CONFORMATION; MISSENSE MUTATIONS; CONGO RED; AGGREGATION; MODEL; NEUROTOXICITY	beta-(25-35) is a synthetic derivative of beta-amyloid, the peptide that is believed to cause Alzheimer's disease. As it is highly toxic and forms fibrillar aggregates typical of P-amyloid, it is suitable as a model for testing inhibitors of aggregation and toxicity. We demonstrate that N-methylated derivatives of beta-(25-35), which in isolation are soluble and non-toxic, can prevent the aggregation and inhibit the resulting toxicity of the wild type peptide. N-Methylation can block hydrogen bonding on the outer edge of the assembling amyloid, The peptides are assayed by Congo red and thioflavin T binding, electron microscopy, and a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) toxicity assay on PC12 cells. One peptide (Gly(25) N-methylated) has properties similar to the wild type, whereas five have varying effects on prefolded fibrils and fibril assembly. In particular, beta-(25-35) with Gly(33) N-methylated is able to completely prevent fibril assembly and to reduce the toxicity of prefolded amyloid. With Leu(34) N-methylated, the fibril morphology is altered and the toxicity reduced. We suggest that the use of N-methylated derivatives of amyloidogenic peptides and proteins could provide a general solution to the problem of amyloid deposition and toxicity.	UMIST, Dept Biomol Sci, Manchester M60 1QD, Lancs, England	University of Manchester	Doig, AJ (corresponding author), UMIST, Dept Biomol Sci, POB 88, Manchester M60 1QD, Lancs, England.		Doig, Andrew/AAD-7456-2019	Doig, Andrew/0000-0003-0346-2270				ASHALL F, 1994, TRENDS BIOCHEM SCI, V19, P42, DOI 10.1016/0968-0004(94)90173-2; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; Benzinger TLS, 2000, BIOCHEMISTRY-US, V39, P3491, DOI 10.1021/bi991527v; Carrell RW, 1998, CURR OPIN STRUC BIOL, V8, P799, DOI 10.1016/S0959-440X(98)80101-2; Chabry J, 1998, J BIOL CHEM, V273, P13203, DOI 10.1074/jbc.273.21.13203; Cribbs DH, 1997, J BIOL CHEM, V272, P7431, DOI 10.1074/jbc.272.11.7431; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Doig AJ, 1997, CHEM COMMUN, P2153, DOI 10.1039/a706167f; Findeis MA, 1999, BIOCHEMISTRY-US, V38, P6791, DOI 10.1021/bi982824n; Ghanta J, 1996, J BIOL CHEM, V271, P29525, DOI 10.1074/jbc.271.47.29525; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Hendriks L, 1996, EUR J BIOCHEM, V237, P6, DOI 10.1111/j.1432-1033.1996.0006n.x; Hughes SR, 1996, P NATL ACAD SCI USA, V93, P2065, DOI 10.1073/pnas.93.5.2065; IVERSEN LL, 1995, BIOCHEM J, V311, P1; Kaytor MD, 1999, J BIOL CHEM, V274, P37507, DOI 10.1074/jbc.274.53.37507; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lansbury PT, 1997, CURR OPIN CHEM BIOL, V1, P260, DOI 10.1016/S1367-5931(97)80018-X; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MANAVALAN P, 1980, BIOPOLYMERS, V19, P1943, DOI 10.1002/bip.1980.360191103; MATTSON MP, 1995, NAT STRUCT BIOL, V2, P926, DOI 10.1038/nsb1195-926; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PIKE CJ, 1993, J NEUROSCI, V13, P1676; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; SHEARMAN MS, 1995, J NEUROCHEM, V65, P218, DOI 10.1046/j.1471-4159.1995.65010218.x; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; TERZI E, 1994, BIOCHEMISTRY-US, V33, P1345, DOI 10.1021/bi00172a009; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; Tjernberg LO, 1997, J BIOL CHEM, V272, P12601, DOI 10.1074/jbc.272.19.12601; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133	42	214	223	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25109	25115		10.1074/jbc.M003554200	http://dx.doi.org/10.1074/jbc.M003554200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10825171	hybrid			2022-12-25	WOS:000088849400011
J	Powell, B; Graham, LA; Stevens, TH				Powell, B; Graham, LA; Stevens, TH			Molecular characterization of the yeast vacuolar H+-ATPase proton pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							16-KDA PROTEOLIPID SUBUNIT; V-TYPE ATPASE; SACCHAROMYCES-CEREVISIAE; ELECTRON-MICROSCOPY; CHROMAFFIN GRANULES; NEUROSPORA-CRASSA; CROSS-LINKING; GENE; SYNTHASE; ROTATION	The Saccharomyces cerevisiae vacuolar ATPase (V-ATPase) is composed of at least 13 polypeptides organized into two distinct domains, V-1 and V-0, that are structurally and mechanistically similar to the F-1-F-0 domains of the F-type ATP synthases. The peripheral V-1 domain is responsible for ATP hydrolysis and is coupled to the mechanism of proton translocation. The integral V-0 domain is responsible for the translocation of protons across the membrane and is composed of five different polypeptides. Unlike the F-0 domain of the F-type ATP synthase, which contains 12 copies of a single 8-kDa proteolipid, the V-ATPase V-0 domain contains three proteolipid species, Vma3p, Vma11p, and Vma16p, with each proteolipid contributing to the mechanism of proton translocation (Hirata, R., Graham, L. A. Takatsuki, A., Stevens, T. H., and Anraku, Y. (1997) J. Biol. Chem. 272, 4795-4803). Experiments with hemagglutinin- and c-Myc epitope-tagged copies of the proteolipids revealed that each V-0 complex contains all three species of proteolipid with only one copy each of Vma11p and Vma16p but multiple copies of Vma3p. Since the proteolipids of the V-0 complex are predicted to possess four membrane-spanning alpha-helices, twice as many as a single F-ATPase proteolipid subunit, only six V-ATPase proteolipids would be required to form a hexameric ring-like structure similar to the F-0 domain. Therefore, each V-0 complex will likely be composed of four copies of the Vma3p proteolipid in addition to Vma11p and Vma16p. Structural differences within the membrane-spanning domains of both V-0 and F-0 may account for the unique properties of the ATP-hydrolyzing V-ATPase compared with the ATP-generating F-type ATP synthase.	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA	University of Oregon	Stevens, TH (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.			Stevens, Tom/0000-0001-6427-6848	NIGMS NIH HHS [GM38006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038006] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANRAKU Y, 1992, J EXP BIOL, V172, P67; ARAI H, 1988, J BIOL CHEM, V263, P8796; Boekema EJ, 1999, NATURE, V401, P37, DOI 10.1038/43369; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; DOW JAT, 1992, GENE, V122, P355, DOI 10.1016/0378-1119(92)90226-F; DSCHIDA WJ, 1992, J BIOL CHEM, V267, P18783; FINBOW ME, 1994, J CELL SCI, V107, P1817; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Futai M, 2000, J EXP BIOL, V203, P107; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Graham LA, 2000, J EXP BIOL, V203, P61; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; HARRISON MA, 1994, EUR J BIOCHEM, V221, P111, DOI 10.1111/j.1432-1033.1994.tb18719.x; HASEBE M, 1992, BIOCHEM BIOPH RES CO, V183, P856, DOI 10.1016/0006-291X(92)90562-Y; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HOLZENBURG A, 1993, EUR J BIOCHEM, V213, P21, DOI 10.1111/j.1432-1033.1993.tb17730.x; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Kaiser C., 1994, METHODS YEAST GENETI; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; Margolles-Clark E, 1999, J BIOENERG BIOMEMBR, V31, P29, DOI 10.1023/A:1005440412633; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; Nishigori H, 1998, GENOMICS, V50, P222, DOI 10.1006/geno.1998.5310; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NOUMI T, 1991, BIOCHEMISTRY, V88; Oka T, 1997, J BIOL CHEM, V272, P24387, DOI 10.1074/jbc.272.39.24387; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SIKORSKI RS, 1989, GENETICS, V122, P19; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SUPEK F, 1994, J BIOL CHEM, V269, P24102; TOYAMA R, 1991, YEAST, V7, P989, DOI 10.1002/yea.320070911; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909	44	90	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23654	23660		10.1074/jbc.M004440200	http://dx.doi.org/10.1074/jbc.M004440200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10825180	hybrid			2022-12-25	WOS:000088564200036
J	Schaefer, M; Plant, TD; Obukhov, AG; Hofmann, T; Gudermann, T; Schultz, G				Schaefer, M; Plant, TD; Obukhov, AG; Hofmann, T; Gudermann, T; Schultz, G			Receptor-mediated regulation of the nonselective cation channels TRPC4 and TRPC5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; LIGHT-SENSITIVE CHANNELS; CURRENT I-CRAC; STORE DEPLETION; CA2+ ENTRY; G-PROTEIN; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; PHOSPHOLIPASE-C; HEK293 CELLS	Mammalian transient receptor potential channels (TRPCs) form a family of Ca2+-permeable cation channels currently consisting of seven members, TRPC1-TRPC7. These channels have been proposed to be molecular correlates for capacitative Ca2+ entry channels. There are only a few studies on the regulation and properties of the subfamily consisting of TRPC4 and TRPC5, and there are contradictory reports concerning the possible role of intracellular Ca2+ store depletion in channel activation. We therefore investigated the regulatory and biophysical properties of murine TRPC4 and TRPC5 (mTRPC4/5) heterologously expressed in human embryonic kidney cells. Activation of G(q/11)-coupled receptors or receptor tyrosine kinases induced Mn2+ entry in fura-2-loaded mTRPC4/5-expressing cells. Accordingly, in whole-cell recordings, stimulation of G(q/11)-coupled receptors evoked large, nonselective cation currents, an effect mimicked by infusion of guanosine 5'-3-O-(thio)triphosphate (GTP gamma S). However, depletion of intracellular Ca2+ stores failed to activate mTRPC4/5, In inside-out patches, single channels with conductances of 42 and 66 picosiemens at -60 mV for mTRPC4 and mTRPC5, respectively, were stimulated by GTP gamma S in a membrane-confined manner. Thus, mTRPC4 and mTRPC5 form nonselective cation channels that integrate signaling pathways from G-protein-coupled receptors and receptor tyrosine kinases independently of store depletion. Furthermore, the biophysical properties of mTRPC4/5 are inconsistent with those of I-crac the most extensively characterized store-operated current.	Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin	Schultz, G (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.	gschultz@zedat.fu-berlin.de	Obukhov, Alexander G/C-7246-2008	Obukhov, Alexander G/0000-0002-3862-6004				Acharya JK, 1997, NEURON, V18, P881, DOI 10.1016/S0896-6273(00)80328-1; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Fasolato C, 1998, PFLUG ARCH EUR J PHY, V436, P69, DOI 10.1007/s004240050605; FATT P, 1958, J PHYSIOL-LONDON, V142, P516, DOI 10.1113/jphysiol.1958.sp006034; Gao TY, 1999, J BIOL CHEM, V274, P2137, DOI 10.1074/jbc.274.4.2137; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Hurst RS, 1998, FEBS LETT, V422, P333, DOI 10.1016/S0014-5793(98)00035-0; INOUE R, 1990, AM J PHYSIOL, V258, pC1173, DOI 10.1152/ajpcell.1990.258.6.C1173; Inoue Ryuji, 1998, Journal of Smooth Muscle Research, V34, P69; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; Mathes C, 1998, J BIOL CHEM, V273, P25020, DOI 10.1074/jbc.273.39.25020; Mizuno N, 1999, MOL BRAIN RES, V64, P41, DOI 10.1016/S0169-328X(98)00296-4; NEHER E, 1977, ANNU REV BIOPHYS BIO, V6, P345, DOI 10.1146/annurev.bb.06.060177.002021; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Otsuka Y, 1998, TOHOKU J EXP MED, V185, P139, DOI 10.1620/tjem.185.139; PAK WL, 1976, SCIENCE, V194, P956, DOI 10.1126/science.824732; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PERETZ A, 1994, NEURON, V12, P1257, DOI 10.1016/0896-6273(94)90442-1; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Reuss H, 1997, NEURON, V19, P1249, DOI 10.1016/S0896-6273(00)80416-X; Shuttleworth TJ, 1998, J BIOL CHEM, V273, P32636, DOI 10.1074/jbc.273.49.32636; Tomita Y, 1998, NEUROSCI LETT, V248, P195, DOI 10.1016/S0304-3940(98)00362-0; Warnat J, 1999, J PHYSIOL-LONDON, V518, P631, DOI 10.1111/j.1469-7793.1999.0631p.x; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	39	330	344	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17517	17526		10.1074/jbc.275.23.17517	http://dx.doi.org/10.1074/jbc.275.23.17517			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837492	hybrid			2022-12-25	WOS:000087485000044
J	Zaffran, Y; Meyer, SC; Negrescu, E; Reddy, KB; Fox, JEB				Zaffran, Y; Meyer, SC; Negrescu, E; Reddy, KB; Fox, JEB			Signaling across the platelet adhesion receptor glycoprotein Ib-IX induces alpha(IIb)beta(3) activation both in platelets and a transfected Chinese hamster ovary cell system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; ACTIN-BINDING PROTEIN; VONWILLEBRAND-FACTOR BINDING; GP-IIB-IIIA; MEMBRANE SKELETON; CYTOPLASMIC DOMAIN; SHEAR-STRESS; THROMBUS FORMATION; TYROSINE KINASE; COMPLEX	In platelets, alpha(IIb)beta(3) exists in a form that cannot bind adhesive proteins in the plasma; although it can interact with immobilized fibrinogen it cannot interact with immobilized von Willebrand factor in the vessel wall. Soluble agonists such as thrombin convert alpha(IIb)beta(3) to a form that recognizes soluble and immobilized ligands. Attempts to reconstitute alpha(IIb)beta(3) activation in a non-hematopoietic, nucleated cell system have been unsuccessful. In the present study, we have developed a transfected Chinese hamster ovary cell model in which alpha(IIb)beta(3) activation is induced by signaling across glycoprotein (GP) Ib-IX by its ligand, von Willebrand factor. GPIb-IX activates not only the transfected alpha(IIb)beta(3) but also endogenous alpha(V)beta(3). Activation of the pathways leading to integrin activation occurred even in cells transfected with GPIb-IX lacking the domain on GPIb alpha that binds 14-3-3 or that which binds actin-binding protein. These studies demonstrate that signals induced by interaction of GPIb-IX with von Willebrand factor lead to alpha(IIb)beta(3) activation and suggest that the signaling pathways by which GPIb-IX induces alpha(IIb)beta(3) activation are different to those used by thrombin. Elucidation of these differences may provide insights into therapeutic ways in which to inhibit integrin activation in selective clinical settings.	Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol NB 50, Dept Mol Cardiol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Fox, JEB (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Joseph J Jacobs Ctr Thrombosis & Vasc Biol NB 50, Dept Mol Cardiol, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL030657, R01HL030657, R01HL056264, R37HL030657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30657, HL56264] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; Andrews RK, 1998, BIOCHEMISTRY-US, V37, P638, DOI 10.1021/bi970893g; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; Blanks JE, 1998, EUR J IMMUNOL, V28, P433, DOI 10.1002/(SICI)1521-4141(199802)28:02<433::AID-IMMU433>3.0.CO;2-U; Calverley DC, 1998, BLOOD, V91, P1295, DOI 10.1182/blood.V91.4.1295; CHOW TW, 1992, BLOOD, V80, P113; Cranmer SL, 1999, J BIOL CHEM, V274, P6097, DOI 10.1074/jbc.274.10.6097; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1988, J BIOL CHEM, V263, P4882; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1987, THROMB DIATH HAEMO, P170; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; Giblin PA, 1997, J IMMUNOL, V159, P3498; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; GULLBERG D, 1990, EXP CELL RES, V186, P264, DOI 10.1016/0014-4827(90)90305-T; HOWARD MA, 1971, THROMB DIATH HAEMOST, V26, P362; Hughes PE, 1998, TRENDS CELL BIOL, V8, P359, DOI 10.1016/S0962-8924(98)01339-7; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; KINASHI T, 1995, BLOOD, V86, P2086, DOI 10.1182/blood.V86.6.2086.bloodjournal8662086; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KOUNS WC, 1991, J BIOL CHEM, V266, P13891; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; Kroll MH, 1996, BLOOD, V88, P1525; LANZA F, 1993, J BIOL CHEM, V268, P20801; LOH E, 1995, J BIOL CHEM, V270, P18631, DOI 10.1074/jbc.270.31.18631; MEYER SC, 1995, J BIOL CHEM, V270, P14693, DOI 10.1074/jbc.270.24.14693; MOAKE JL, 1986, J CLIN INVEST, V78, P1456, DOI 10.1172/JCI112736; MODDERMAN PW, 1992, J BIOL CHEM, V267, P364; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PETERSON DM, 1987, BLOOD, V69, P625; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; Qi WW, 1998, J BIOL CHEM, V273, P15271, DOI 10.1074/jbc.273.24.15271; READ MS, 1989, BLOOD, V74, P1031; ROTH GJ, 1990, BIOCHEM BIOPH RES CO, V170, P153, DOI 10.1016/0006-291X(90)91253-O; RUGGERI ZM, 1982, P NATL ACAD SCI-BIOL, V79, P6038, DOI 10.1073/pnas.79.19.6038; RUGGERI ZM, 1993, THROMB HAEMOSTASIS, V70, P119; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; WEISS HJ, 1986, BLOOD, V67, P322	52	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16779	16787		10.1074/jbc.275.22.16779	http://dx.doi.org/10.1074/jbc.275.22.16779			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828063	hybrid			2022-12-25	WOS:000087392200055
J	Mei, JM; Hord, NG; Winterstein, DF; Donald, SP; Phang, JM				Mei, JM; Hord, NG; Winterstein, DF; Donald, SP; Phang, JM			Expression of prostaglandin endoperoxide H synthase-2 induced by nitric oxide in conditionally immortalized murine colonic epithelial cells	FASEB JOURNAL			English	Article						PGHS-2; NOSII; nitric oxide; colonic epithelial cells	INFLAMMATORY BOWEL-DISEASE; FAMILIAL ADENOMATOUS POLYPOSIS; TRANSCRIPTION FACTOR LEF-1; TUMOR-SUPPRESSOR PROTEIN; BETA-CATENIN; CYCLOOXYGENASE-2 LEVELS; SMALL-INTESTINE; APC GENE; CANCER; ACTIVATION	Increased expression of prostaglandin endoperoxide H synthase-2 (PGHS-2) has been implicated in pathological conditions such as inflammatory bowel diseases and colon cancer. Recently, it has been demonstrated that inducible nitric oxide synthase (NOS II) expression and nitric oxide (NO) production are up-regulated in these diseases as well. However, the apparent link between PGHS-2 and NOS II has not been thoroughly investigated in nontransformed and nontumorigenic colonic epithelial cells. In the present study, we examined the concomitant expression of PGHS-2 and NOS II as well as the production of prostaglandin E2 (PGE2) and NO in conditionally immortalized mouse colonic epithelial cells, namely YAMC (Apc(+/+)). We found that the induction of PGHS-2 and generation of PGE2 in these cells by IFN-gamma and lipopolysaccharide (LPS) were greatly reduced by two selective NOS II inhibitors, L-NIL and SMT. To ascertain the effect of NO on PGHS-2 overexpression, we tested NO-releasing compounds, NOR-1 and SNAP, and found that they caused PGHS-2 expression and PGE2 production. This effect was abolished by hemoglobin, a NO scavenger. Using electrophoretic mobility shift assays, we found that both NOR-1 and SNAP caused beta-catenin/LEF-1 DNA complex formation. Supershift by anti-beta-catenin antibody confirmed the presence of beta-catenin in the complex. Cell fractionation studies indicated that NO donors caused an increase in free soluble cytoplasmic beta-catenin. This is further corroborated by the immunocytochemistry data showing the redistribution of beta-catenin from the predominantly membrane localization into the cytoplasm and nucleus after treatment with NO donors. To further explore the possible connection between PGHS-2 expression and beta-catenin/LEF-1 DNA complex formation, we studied IMCE (Apc(Min/+)) cells, a sister cell line of YAMC with similar genetic background but differing in Ape genotype and, consequently, their beta-catenin levels. We found that IMCE cells, in comparison with YAMC cells, had markedly higher beta-catenin/LEF-1 DNA complex formation under both resting conditions as well as after induction with NO. In parallel fashion, IMCE cells ex pressed significantly higher levels of PGHS-2 mRNA and protein, and generated more PGE2. Overall, this study suggests that NO may be involved in PGHS-2 overexpression in conditionally immortalized mouse colonic epithelial cells. Although the molecular mechanism of the link is still under investigation, this effect of NO appears directly or indirectly to be a result of the increase in free soluble beta-catenin and the formation of nuclear beta-catenin/LEF-1 DNA complex.-Mei, J. M., Hord, N. G., Winterstein, D. F., Donald, S. P., and Phang, J. M. Expression of prostaglandin endoperoxide H synthase-2 induced by nitric oxide in conditionally immortalized murine colonic epithelial cells.	NCI, Metab & Canc Susceptibil Sect, Basic Res Lab, Div Basic Sci, Frederick, MD 21702 USA; NCI, Intramural Res Support Program, SAIC Frederick, FCRDC, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Mei, JM (corresponding author), NCI, Metab & Canc Susceptibil Sect, Basic Res Lab, Div Basic Sci, Rm 12-90,Bldg 560, Frederick, MD 21702 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC010005] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Ambs S, 1998, CANCER RES, V58, P334; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Boolbol SK, 1996, CANCER RES, V56, P2556; BROUET I, 1995, BIOCHEM BIOPH RES CO, V206, P533, DOI 10.1006/bbrc.1995.1076; Dabadie A, 1996, ARCH PEDIATRIE, V3, P884, DOI 10.1016/0929-693X(96)87579-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DuBois RN, 1996, GASTROENTEROLOGY, V110, P1259, DOI 10.1053/gast.1996.v110.pm8613017; DuBois RN, 1996, CANCER RES, V56, P733; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hendel J, 1997, AM J GASTROENTEROL, V92, P1170; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Howe LR, 1999, CANCER RES, V59, P1572; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; JACOBY RF, 1995, GASTROENTEROLOGY, V109, P73, DOI 10.1016/0016-5085(95)90270-8; Jacoby RF, 1996, CANCER RES, V56, P710; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; LIU RH, 1995, MUTAT RES-REV GENET, V339, P73, DOI 10.1016/0165-1110(95)90004-7; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mei JM, 1999, CARCINOGENESIS, V20, P737, DOI 10.1093/carcin/20.4.737; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; Rao CV, 1999, CARCINOGENESIS, V20, P641, DOI 10.1093/carcin/20.4.641; RAO CV, 1995, CANCER RES, V55, P259; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1997, CANCER RES, V57, P4624; Ryuto M, 1997, JPN J CANCER RES, V88, P982, DOI 10.1111/j.1349-7006.1997.tb00319.x; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; Salvemini D, 1997, CELL MOL LIFE SCI, V53, P576, DOI 10.1007/s000180050074; Schmitz FJ, 1997, INT J ANTIMICROB AG, V9, P1, DOI 10.1016/S0924-8579(97)00027-7; Sheng HM, 1998, CANCER RES, V58, P362; Shoemaker AR, 1997, CANCER RES, V57, P1999; Shoemaker AR, 1997, BBA-REV CANCER, V1332, pF25, DOI 10.1016/S0304-419X(96)00041-8; Singer II, 1996, GASTROENTEROLOGY, V111, P871, DOI 10.1016/S0016-5085(96)70055-0; Singer II, 1998, GASTROENTEROLOGY, V115, P297, DOI 10.1016/S0016-5085(98)70196-9; Subbaramaiah K, 1997, P SOC EXP BIOL MED, V216, P201; terSteege J, 1997, LAB INVEST, V77, P29; Thomsen LL, 1997, CANCER RES, V57, P3300; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; VonKnethen A, 1997, FASEB J, V11, P887; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; WHITEHEAD RH, 1994, EPITHELIAL CELL BIOL, V3, P119; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5	62	42	42	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1188	1201		10.1096/fasebj.14.9.1188	http://dx.doi.org/10.1096/fasebj.14.9.1188			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834941				2022-12-25	WOS:000087427300016
J	Nunez, F; Chipchase, MD; Clarke, AR; Melton, DW				Nunez, F; Chipchase, MD; Clarke, AR; Melton, DW			Nucleotide excision repair gene (ERCC1) deficiency causes G(2) arrest in hepatocytes and a reduction in liver binucleation: the role of p53 and p21	FASEB JOURNAL			English	Article						DNA repair; cancer; knockout mice; cell cycle arrest	CELL-CYCLE ARREST; DNA-REPAIR; MICE LACKING; MAMMALIAN-CELLS; S-PHASE; NUCLEAR ABNORMALITIES; GROWTH FAILURE; ULTRAVIOLET-B; GROUP-A; EXPRESSION	A wide range of DNA lesions, both UV and chemically induced, are dealt with by the nucleotide excision repair (NER) pathway. Defects in NER result in human syndromes such as xeroderma pigmentosum (XP) where there is a 1000-fold increased incidence of skin cancer. The ERCC1 protein is essential for NER, but ERCC1 knockout mice are not a model for XP, In the absence of exogenous DNA-damaging agents, these mice are runted and die before weaning, with dramatically accelerated liver polyploidy and elevated levels of p53, Here we present a morphological, immunological, and molecular study to understand the mechanism for the unusual liver pathology in ERCC1-deficient mice. We show that the enlarged ERCC1-deficient hepatocytes are arrested in G(2) and that DNA replication and the normal process of binucleation are both reduced. This is associated with a p53-independent increase in expression of the cyclin-dependent kinase inhibitor p21, The most dramatic feature of the ERCC1-deficient liver phenotype, the accelerated polyploidy, is not rescued by p53 deficiency, but we show that p53 is responsible for the reduced DNA replication and binucleation. We consider that the liver phenotype is a response to unrepaired endogenous DNA damage, which may reflect an additional non-NER-related function for the ERCC1 protein.-Nunez, F,, Chipchase, M. D., Clarke, A. R., Melton, D. W. Nucleotide excision repair gene (ERCC1) deficiency causes G(2) arrest in hepatocytes and a reduction in liver binucleation: the role of p53 and p21.	Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; Univ Edinburgh, Dept Pathol, Edinburgh EH9 3JR, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Melton, DW (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Darwin Bldg,Kings Bldg,Mayfield Rd, Edinburgh EH9 3JR, Midlothian, Scotland.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Clarke, Alan/0000-0002-4281-426X				ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BASI G, 1995, CELL CYCLE CONTROL, P106; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAL G, 1992, CYTOMETRY, V13, P109, DOI 10.1002/cyto.990130202; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cox LS, 1997, J PATHOL, V183, P134, DOI 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EPSTEIN CJ, 1967, P NATL ACAD SCI USA, V57, P327, DOI 10.1073/pnas.57.2.327; Fisher PB, 1996, MOL CELL DIFFER, V4, pU7; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENSI; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; Harada YN, 1999, MOL CELL BIOL, V19, P2366, DOI 10.1128/mcb.19.3.2366; Jacks T, 1996, NATURE, V381, P643, DOI 10.1038/381643a0; JIANG HP, 1994, ONCOGENE, V9, P3397; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MEDVEDEV ZA, 1986, EXP GERONTOL, V21, P277, DOI 10.1016/0531-5565(86)90037-9; Melton DW, 1998, J CELL SCI, V111, P395; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RODEL C, 1992, NUCLEIC ACIDS RES, V20, P6347, DOI 10.1093/nar/20.23.6347; Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513; SANCHEZ Y, 1995, BIOESSAYS, V17, P545, DOI 10.1002/bies.950170611; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Sargent RG, 1997, P NATL ACAD SCI USA, V94, P13122, DOI 10.1073/pnas.94.24.13122; Savio M, 1996, ONCOGENE, V13, P1591; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SOAMES AR, 1994, J HISTOCHEM CYTOCHEM, V42, P939, DOI 10.1177/42.7.8014477; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; VANDUIN M, 1988, MUTAT RES, V193, P123, DOI 10.1016/0167-8817(88)90042-9; VANDUIN M, 1989, MUTAT RES, V217, P83, DOI 10.1016/0921-8777(89)90059-1; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Weeda G, 1997, CURR BIOL, V7, P427, DOI 10.1016/S0960-9822(06)00190-4; WESTERVELD A, 1984, NATURE, V310, P425, DOI 10.1038/310425a0; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245	49	47	49	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1073	1082		10.1096/fasebj.14.9.1073	http://dx.doi.org/10.1096/fasebj.14.9.1073			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834928				2022-12-25	WOS:000087427300003
J	Huber, MD; Dworet, JH; Shire, K; Frappier, L; McAlear, MA				Huber, MD; Dworet, JH; Shire, K; Frappier, L; McAlear, MA			The budding yeast homolog of the human EBNA1-binding protein 2 (Ebp2p) is an essential nucleolar protein required for pre-rRNA processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; SACCHAROMYCES-CEREVISIAE; RIBOSOMAL-RNA; CELLS; DNA; RIBONUCLEOPROTEIN; IDENTIFICATION; LOCALIZATION; REPLICATION; BIOGENESIS	The human EBP2 protein was found by two-hybrid analysis to interact with the Epstein-Barr virus nuclear antigen 1 (EBNA1), Homologs of human EBP2 can be found in Caenorhabditis elegans, Schizosaccharomyces pombe, and in Saccharomyces cerevisiae, and they all share a conserved 200-300-amino acid block of residues at their C termini, To understand the cellular function of EBP2, we have begun to study the protein in S. cerevisiae, The yeast Ebp2 protein contains N-terminal, nucleolar-associated KKE motifs, and deletion analysis reveals that the C-terminal conserved region is required for the activity of the protein. The EBP2 gene codes for an essential protein that localizes to the nucleolus. Temperature-sensitive ebp2-1 mutants become depleted of ribosomes and cease to divide after several generations at the restrictive temperature of 36 degrees C. This decline in ribosome levels is accompanied by a diminution in the levels of the 35 S-derived recombinant RNAs (rRNAs) (in particular the 25 S and 5.8 S rRNAs), Pulse-chase, Northern, and primer extension analysis of the rRNA biosynthetic pathway indicates that ebp2-1 mutants are defective in processing the 27 SA precursor into the 27 SE pre-rRNA.	Wesleyan Univ, Mol Biol & Biochem Dept, Middletown, CT 06459 USA; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	Wesleyan University; University of Toronto	McAlear, MA (corresponding author), Wesleyan Univ, Mol Biol & Biochem Dept, Middletown, CT 06459 USA.	mmcalear@wesleyan.edu	Huber, Michael/C-4176-2008					ADAMS A, 1987, J VIROL, V61, P1743, DOI 10.1128/JVI.61.5.1743-1746.1987; Allmang C, 2000, NUCLEIC ACIDS RES, V28, P1684, DOI 10.1093/nar/28.8.1684; BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; BELTRAME M, 1992, EMBO J, V11, P1531, DOI 10.1002/j.1460-2075.1992.tb05198.x; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CHATTERJEE A, 1987, CANCER RES, V47, P1123; Clarke EM, 1996, J BIOL CHEM, V271, P22189, DOI 10.1074/jbc.271.36.22189; DELECLUSE HJ, 1993, J VIROL, V67, P1292, DOI 10.1128/JVI.67.3.1292-1299.1993; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; Dunbar DA, 1997, MOL CELL BIOL, V17, P5803, DOI 10.1128/MCB.17.10.5803; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P565; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Lee SJ, 1999, MOL CELL BIOL, V19, P5441; MIZUTA K, 1994, MOL CELL BIOL, V14, P2493, DOI 10.1128/MCB.14.4.2493; Moore DD, 1995, GLOB MOB SURV; NOGI Y, 1991, P NATL ACAD SCI USA, V88, P7026, DOI 10.1073/pnas.88.16.7026; Oakes M, 1998, J CELL BIOL, V143, P23, DOI 10.1083/jcb.143.1.23; PETTI L, 1990, VIROLOGY, V176, P563, DOI 10.1016/0042-6822(90)90027-O; Sherman F., 1986, METHODS YEAST GENETI; Shire K, 1999, J VIROL, V73, P2587, DOI 10.1128/JVI.73.4.2587-2595.1999; SIKORSKI RS, 1989, GENETICS, V122, P19; STEVENS A, 1995, J BIOL CHEM, V270, P16063, DOI 10.1074/jbc.270.27.16063; Stolc V, 1998, P NATL ACAD SCI USA, V95, P6716, DOI 10.1073/pnas.95.12.6716; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; Venema J, 1996, EMBO J, V15, P5701, DOI 10.1002/j.1460-2075.1996.tb00954.x; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Weaver PL, 1997, MOL CELL BIOL, V17, P1354, DOI 10.1128/MCB.17.3.1354; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YATES JL, 1991, J VIROL, V65, P483, DOI 10.1128/JVI.65.1.483-488.1991	33	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28764	28773		10.1074/jbc.M000594200	http://dx.doi.org/10.1074/jbc.M000594200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10849420	hybrid			2022-12-25	WOS:000089330700058
J	Oda, Y; Nakayama, K; Abdul-Rahman, B; Kinoshita, M; Hashimoto, O; Kawasaki, N; Hayakawa, T; Kakehi, K; Tomiya, N; Lee, YC				Oda, Y; Nakayama, K; Abdul-Rahman, B; Kinoshita, M; Hashimoto, O; Kawasaki, N; Hayakawa, T; Kakehi, K; Tomiya, N; Lee, YC			Crocus sativus lectin recognizes Man(3)GlcNAc in the N-glycan core structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-BINDING SPECIFICITY; CONCANAVALIN-A; LINKED OLIGOSACCHARIDES; TRIMANNOSIDE; CELLS; THERMODYNAMICS; EUROPIUM; BULBS	Crocus sativus lectin (CSL) is one of the truly mannose-specific plant lectins that has a unique binding specificity that sets it apart from others. We studied sugar-binding specificity of CSL in detail by a solution phase method (fluorescence polarization) and three solid phase methods (flow injection, surface plasmon resonance, and microtiter plate), using a number of different glycopeptides and oligosaccharides. CSL binds the branched mannotriose structure in the N-glycan core. Substitution of the terminal Man in the Man alpha(1-3)Man branch with GlcNAc drastically decreases binding affinity much more than masking of the terminal Man in the Man alpha(l-G)Man branch, Most interestingly, the beta-Man-linked GlcNAc in N-glycan core structure contributes greatly to the binding. The effect of this GlcNAc is so strong that it can substantially offset the negative effect of substitution on the nonreducing terminal Man residues. On the other hand, the GlcNAc that is usually attached to Asn in N-glycans and the L-FUC linked at the 6-position of the GlcNAc are irrelevant to the binding. A bisecting GlcNAc neither contributes to nor interferes with the binding. This unique binding specificity of CSL offers many possibilities of its use in analytical and preparative applications.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Kinki Univ, Fac Pharmaceut Sci, Higashiosaka, Osaka 2778502, Japan; Natl Inst Hlth Sci, Div Biol Chem & Biol, Setagaya Ku, Tokyo 1588501, Japan	Johns Hopkins University; Kindai University (Kinki University); National Institute of Health Sciences - Japan	Lee, YC (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.							ALONSO JM, 1988, EUR J BIOCHEM, V177, P187, DOI 10.1111/j.1432-1033.1988.tb14361.x; ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; CAMILLERI P, 1995, ANAL BIOCHEM, V230, P115, DOI 10.1006/abio.1995.1445; CHANG KJ, 1975, BIOCHIM BIOPHYS ACTA, V406, P294, DOI 10.1016/0005-2736(75)90011-5; Dam TK, 1998, J BIOL CHEM, V273, P32812, DOI 10.1074/jbc.273.49.32812; DUBOIS M, 1956, ANAL CHEM, V28, P356; FAN JQ, 1994, ANAL BIOCHEM, V219, P375, DOI 10.1006/abio.1994.1280; FREDERICQ E, 1949, J BIOL CHEM, V181, P499; HEMMILA I, 1984, ANAL BIOCHEM, V137, P335, DOI 10.1016/0003-2697(84)90095-2; KAKU H, 1990, ARCH BIOCHEM BIOPHYS, V279, P298, DOI 10.1016/0003-9861(90)90495-K; Kato I, 1976, PROTIDES BIOL FLUIDS, V23, P235; Kawasaki N, 1997, ANAL BIOCHEM, V250, P260, DOI 10.1006/abio.1997.2233; LEE YC, 1969, ANAL BIOCHEM, V27, P559, DOI 10.1016/0003-2697(69)90070-0; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1149, DOI 10.1021/bi00171a014; MINOBE S, 1979, J BIOCHEM-TOKYO, V86, P1851, DOI 10.1093/oxfordjournals.jbchem.a132707; Misaki A, 1997, J BIOL CHEM, V272, P25455, DOI 10.1074/jbc.272.41.25455; MISQUITH S, 1994, J BIOL CHEM, V269, P30393; Moothoo DN, 1998, GLYCOBIOLOGY, V8, P173, DOI 10.1093/glycob/8.2.173; Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972; Oda Y, 1997, ANAL BIOCHEM, V254, P41, DOI 10.1006/abio.1997.2396; Oda Y, 1999, ANAL BIOCHEM, V269, P230, DOI 10.1006/abio.1999.4020; Oda Y, 1998, BIOL PHARM BULL, V21, P1215; ODA Y, 1993, BIOL PHARM BULL, V16, P978; ODA Y, 1997, B PHARM RES TECHNOL, V6, P45; PARENTE JP, 1982, J CHROMATOGR, V249, P199, DOI 10.1016/S0021-9673(00)80250-2; PARENTE JP, 1982, J BIOL CHEM, V275, P13173; QI XY, 1988, ANAL BIOCHEM, V175, P139, DOI 10.1016/0003-2697(88)90371-5; Rozwarski DA, 1998, J BIOL CHEM, V273, P32818, DOI 10.1074/jbc.273.49.32818; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1	30	24	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26772	26779						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10837483				2022-12-25	WOS:000089144800016
J	Liu, HG; Palmer, D; Jimmo, SL; Tilley, DG; Dunkerley, HA; Pang, SC; Maurice, DH				Liu, HG; Palmer, D; Jimmo, SL; Tilley, DG; Dunkerley, HA; Pang, SC; Maurice, DH			Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways - A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMP-SPECIFIC PHOSPHODIESTERASE; VASCULAR SMOOTH-MUSCLE; JURKAT T-CELLS; NUCLEOTIDE PHOSPHODIESTERASE; SELECTIVE-INHIBITION; ADENOSINE-MONOPHOSPHATE; RECEPTOR AGONISTS; MESSENGER-RNA; RAT AORTA; PHOSPHORYLATION	Multiple families of cyclic nucleotide phosphodiesterases (PDE) have been described, and the regulated expression of these genes in cells is complex. Although cAMP is known to control the expression of certain PDE in cells, presumably reflecting a system of feedback on cAMP signaling, relatively little is known about the influence of non-cAMP signaling systems on PDE expression. In this study, we describe a novel mechanism by which activators of the protein kinase C (PKC)-Raf-MEK-ERK cascade regulate phosphodiesterase 4D (PDE4D) expression in vascular smooth muscle cells (VSMC) and assess the functional consequences of this effect. Whereas a prolonged elevation of cAMP in VSMC resulted in a protein kinase A (PHA)-dependent induction of expression of two PDE4D variants (PDE4D1 and PDE4D2), simultaneous activation of both the cAMP/-PKA and PRC-Raf-MER-ERK signaling cascades blunted this cAMP-mediated increase in PDE4D expression. By using biochemical, molecular biological, and pharmacological approaches, we demonstrate that this PDE4D-selective effect of activators of the PKC-Raf-MEK-ERK cascade was mediated through a mechanism involving altered PDE4D mRNA stability and markedly attenuated the cAMP-mediated desensitization that results from prolonged activation of the cAMP signaling system in cells. The data are presented in the context of activators of the PKC-Raf-MEK-ERK cascade having both short and long term effects on PDE4D activity and expression in cells that may influence cAMP signaling.	Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada	Maurice, DH (corresponding author), Queens Univ, Dept Pathol, Botterell Hall,A221, Kingston, ON K7L 3N6, Canada.	Mauriced@post.queensu.ca	Palmer, Daniel/J-2967-2014; Palmer, Daniel/Q-7595-2016; Maurice, Donald/AAE-9332-2019	Palmer, Daniel/0000-0002-7954-9332; Palmer, Daniel/0000-0002-7954-9332; Tilley, Douglas/0000-0002-9681-3377				ALVAREZ R, 1995, MOL PHARMACOL, V48, P616; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; Erdogan S, 1997, BIOCHEM J, V321, P165, DOI 10.1042/bj3210165; Fisher DA, 1998, BIOCHEM BIOPH RES CO, V246, P570, DOI 10.1006/bbrc.1998.8684; HARTZELMANN A, 1996, HDB IMMUNOPHARMACOLO, P147; Hoffmann R, 1998, BIOCHEM J, V333, P139, DOI 10.1042/bj3330139; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Johnson-Mills K, 1998, BIOCHEM PHARMACOL, V56, P1065, DOI 10.1016/S0006-2952(98)00239-1; Juilfs D M, 1999, Rev Physiol Biochem Pharmacol, V135, P67, DOI 10.1007/BFb0033670; KOMAS N, 1991, BRIT J PHARMACOL, V104, P495, DOI 10.1111/j.1476-5381.1991.tb12457.x; Kostic MM, 1997, J MOL CELL CARDIOL, V29, P3135, DOI 10.1006/jmcc.1997.0544; Lenhard JM, 1996, BIOCHEM J, V316, P751, DOI 10.1042/bj3160751; Liu H, 1998, BRIT J PHARMACOL, V125, P1501, DOI 10.1038/sj.bjp.0702227; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; LUGNIER C, 1986, BIOCHEM PHARMACOL, V35, P1743, DOI 10.1016/0006-2952(86)90333-3; Manning CD, 1996, J PHARMACOL EXP THER, V276, P810; MAURICE DH, 1990, EUR J PHARMACOL, V191, P471, DOI 10.1016/0014-2999(90)94182-W; MAURICE DH, 1991, EUR J PHARMACOL, V192, P235, DOI 10.1016/0014-2999(91)90048-U; MAURICE DH, 1993, ANAL BIOCHEM, V215, P110, DOI 10.1006/abio.1993.1562; Mehats C, 2000, J PHARMACOL EXP THER, V292, P817; Mehats C, 1999, ENDOCRINOLOGY, V140, P3228, DOI 10.1210/en.140.7.3228; Movsesian MA, 1999, J AM COLL CARDIOL, V34, P318, DOI 10.1016/S0735-1097(99)00220-X; MOVSESIAN MA, 1991, J CLIN INVEST, V88, P15, DOI 10.1172/JCI115272; Palmer D, 1998, CIRC RES, V82, P852; Polson JB, 1996, ANNU REV PHARMACOL, V36, P403, DOI 10.1146/annurev.pa.36.040196.002155; RASCON A, 1992, BIOCHIM BIOPHYS ACTA, V1134, P149, DOI 10.1016/0167-4889(92)90038-D; Rose RJ, 1997, BRIT J PHARMACOL, V122, P233, DOI 10.1038/sj.bjp.0701376; Rybalkin SD, 1997, J CLIN INVEST, V100, P2611, DOI 10.1172/JCI119805; SCHOEFFTER P, 1987, BIOCHEM PHARMACOL, V36, P3965, DOI 10.1016/0006-2952(87)90465-5; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; SETTE C, 1994, J BIOL CHEM, V269, P9245; Seybold J, 1998, J BIOL CHEM, V273, P20575, DOI 10.1074/jbc.273.32.20575; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V190, P516, DOI 10.1006/bbrc.1993.1078; Soderling SH, 1999, P NATL ACAD SCI USA, V96, P7071, DOI 10.1073/pnas.96.12.7071; Soderling SH, 1998, J BIOL CHEM, V273, P15553, DOI 10.1074/jbc.273.25.15553; SOUNESS JE, 1992, BIOCHEM PHARMACOL, V44, P857, DOI 10.1016/0006-2952(92)90116-Z; Spence S, 1997, BIOCHEM J, V321, P157, DOI 10.1042/bj3210157; SPENCE S, 1995, BIOCHEM J, V310, P975, DOI 10.1042/bj3100975; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P8197, DOI 10.1073/pnas.86.21.8197; TORPHY TJ, 1992, J PHARMACOL EXP THER, V263, P1195; TORPHY TJ, 1995, J BIOL CHEM, V270, P23598, DOI 10.1074/jbc.270.40.23598; VERGHESE MW, 1995, MOL PHARMACOL, V47, P1164; Vicini E, 1997, MOL ENDOCRINOL, V11, P839, DOI 10.1210/me.11.7.839; WEISHAAR RE, 1986, BIOCHEM PHARMACOL, V35, P787, DOI 10.1016/0006-2952(86)90247-9	48	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26615	26624		10.1074/jbc.M001634200	http://dx.doi.org/10.1074/jbc.M001634200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851231	hybrid			2022-12-25	WOS:000088999700100
J	Zhuang, SG; Demirs, JT; Kochevar, IE				Zhuang, SG; Demirs, JT; Kochevar, IE			p38 mitogen-activated protein kinase mediates bid cleavage, mitochondrial dysfunction, and caspase-3 activation during apoptosis induced by singlet oxygen but not by hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; OXIDATIVE STRESS; HL-60 CELLS; SUBSTRATE-SPECIFICITY; SIGNAL-TRANSDUCTION; CELLULAR STRESSES; ENDOTHELIAL-CELLS; DEATH RECEPTORS; PATHWAY; FAS	p38 mitogen-activated protein kinase is activated and involved in cleavage of caspase-3 during apoptosis induced by a number of stimuli. However, the signaling events triggered by p38 that result in caspase-3 activation are still unknown. In human leukemia cells, two reactive oxygen species, singlet oxygen and hydrogen peroxide (H2O2), selectively stimulated the phosphorylation of p38, Preincubation of cells with SB203580, a specific inhibitor of p38, dose dependently inhibited DNA fragmentation induced by singlet oxygen but not by H2O2. Protection from apoptosis by SB203580 correlated with inhibition of caspase-3, and several events that are associated with caspase-3 activation, including Bid cleavage, decrease in mitochondrial transmembrane potential and release of cytochrome c from mitochondria, whereas caspase-8 cleavage was not affected by this inhibitor. In contrast, blockade of caspase-8 with Ile-Glu-Thr-Asp-fluoromethyl ketone is sufficient to prevent formation of DNA fragments and to inhibit all the above signaling events, with exception of p38 phosphorylation, in both singlet oxygen- and H2O2-treated cells. These data suggest that caspase-3 activation is regulated through redundant signaling pathways that involve p38 and caspase-8 acting upstream of Bid during singlet oxygen-induced apoptosis, whereas the activation of caspase-3 by H2O2 is only governed by a caspase-8-mediated apoptotic pathway.	Harvard Univ, Wellman Labs Photomed, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital	Kochevar, IE (corresponding author), Harvard Univ, Wellman Labs Photomed, Sch Med, Massachusetts Gen Hosp, WEL-224,55 Fruit St, Boston, MA 02114 USA.				NIGMS NIH HHS [GM 30955] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Chen ZH, 1999, ONCOGENE, V18, P173, DOI 10.1038/sj.onc.1202276; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cook SA, 1999, CIRC RES, V85, P940; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Haimovitz-Friedman A, 1997, BRIT MED BULL, V53, P539; Hale KK, 1999, J IMMUNOL, V162, P4246; Harada J, 1999, JPN J PHARMACOL, V79, P369, DOI 10.1254/jjp.79.369; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; Herrmann JL, 1996, BIOCHEM SOC T, V24, P1059, DOI 10.1042/bst0241059; Hsu SC, 1999, J BIOL CHEM, V274, P25769, DOI 10.1074/jbc.274.36.25769; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Jun CD, 1999, CELL IMMUNOL, V194, P36, DOI 10.1006/cimm.1999.1480; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KANOFSKY JR, 1991, PHOTOCHEM PHOTOBIOL, V53, P93, DOI 10.1111/j.1751-1097.1991.tb08472.x; Kasahara Y, 1997, BLOOD, V89, P1748, DOI 10.1182/blood.V89.5.1748.1748_1748_1753; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Kyriakis JM, 1999, GENE EXPRESSION, V7, P217; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee JC, 1999, PHARMACOL THERAPEUT, V82, P389, DOI 10.1016/S0163-7258(99)00008-X; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsura T, 1999, FREE RADICAL RES, V30, P73, DOI 10.1080/10715769900300081; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; Morita A, 1997, J EXP MED, V186, P1763, DOI 10.1084/jem.186.10.1763; Palmer HJ, 1997, NUTR REV, V55, P353, DOI 10.1111/j.1753-4887.1997.tb01561.x; Poynter ME, 1999, FREE RADICAL BIO MED, V27, P1164, DOI 10.1016/S0891-5849(99)00202-6; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shimizu H, 1999, J INVEST DERMATOL, V112, P769, DOI 10.1046/j.1523-1747.1999.00582.x; Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900; Stadheim TA, 2000, BIOCHEM PHARMACOL, V59, P407, DOI 10.1016/S0006-2952(99)00330-5; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Suhara T, 1998, J IMMUNOL, V160, P4042; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743; Umansky V, 2000, INT J ONCOL, V16, P109; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhuang SG, 1998, FEBS LETT, V437, P158, DOI 10.1016/S0014-5793(98)01222-8; Zhuang SG, 1999, EXP CELL RES, V250, P203, DOI 10.1006/excr.1999.4501	56	241	251	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25939	25948		10.1074/jbc.M001185200	http://dx.doi.org/10.1074/jbc.M001185200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10837470	hybrid			2022-12-25	WOS:000088999700010
J	Thirunavukkarasu, K; Halladay, DL; Miles, RR; Yang, XH; Galvin, RJS; Chandrasekhar, S; Martin, TJ; Onyia, JE				Thirunavukkarasu, K; Halladay, DL; Miles, RR; Yang, XH; Galvin, RJS; Chandrasekhar, S; Martin, TJ; Onyia, JE			The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; RUNT HOMOLOGY DOMAIN; CLEIDOCRANIAL DYSPLASIA; OSTEOCALCIN GENE; PARATHYROID-HORMONE; FACTOR OSF2/CBFA1; BONE-RESORPTION; DNA-BINDING; IN-VITRO; T-CELLS	Bone formation and resorption are tightly coupled under normal conditions, and the interaction of osteoclast precursors with cells of the osteoblast lineage is a prerequisite for osteoclast formation. Cbfa1 is an osteoblast-specific transcription factor that is essential for osteoblast differentiation and bone formation. At present, it is not known whether Cbfa1 regulates any of the osteoblast-derived factors involved in the bone resorption pathway. Osteoprotegerin (OPG) is an osteoblast-secreted glycoprotein that functions as a potent inhibitor of osteoclast differentiation and bone resorption, Cloning and computer analysis of a 5,9-kilobase human OPG promoter sequence revealed the presence of 12 putative Cbfa1 binding elements (osteoblast-specific element 2 (OSE2)), suggesting a possible regulation of OPG by Cbfa1, We cloned the promoter upstream of the beta-galactosidase reporter gene (pOPGEi.Bpgal) and evaluated whether Cbfa1 could regulate its expression in transient transfection assays. The 5,9-kilobase promoter directed increased levels of reporter gene expression, reminiscent of OPG protein levels in osteoblastic cell lines (BALC and U2OS) as compared with the nonosteoblastic cell line COS1, Cotransfection of a Cbfa1 expression construct along with pOPG5.9 beta gal reporter construct led to 39-, 7-, and 16-fold increases in beta-galactosidase activity in COS1, BALC, and U2OS cells, respectively. Removal of all the putative OSE2 elements led to an almost complete loss of transactivation, Mutational analysis demonstrated that the proximal OSE, element contributes to a majority of the effects of Cbfa1, and Cbfa1 bound to the proximal element in a sequence-specific manner. Further, overexpression of Cbfa1 led to a 54% increase in OPG protein levels in U2OS cells. These results indicate that Cbfa1 regulates the expression of OPG, thereby further contributing to a molecular link between bone formation and resorption.	Eli Lilly & Co, Lilly Res Labs, Div Endocrine, Indianapolis, IN 46285 USA; St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	Eli Lilly; St. Vincent's Institute of Medical Research	Onyia, JE (corresponding author), Eli Lilly & Co, Lilly Res Labs, Div Endocrine, Drop Code 0403, Indianapolis, IN 46285 USA.	JEO@lilly.com						Akatsu T, 1998, BONE, V23, P495, DOI 10.1016/S8756-3282(98)00141-0; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; Galvin RJS, 1998, BONE, V23, P233, DOI 10.1016/S8756-3282(98)00096-9; Gao YH, 1998, BIOCHEM BIOPH RES CO, V252, P697, DOI 10.1006/bbrc.1998.9643; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Hakeda Y, 1998, BIOCHEM BIOPH RES CO, V251, P796, DOI 10.1006/bbrc.1998.9523; Jimenez MJG, 1999, MOL CELL BIOL, V19, P4431; John V, 1996, ENDOCRINOLOGY, V137, P2457, DOI 10.1210/en.137.6.2457; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kurokawa M, 1996, J BIOL CHEM, V271, P16870, DOI 10.1074/jbc.271.28.16870; Kwon BS, 1998, FASEB J, V12, P845, DOI 10.1096/fasebj.12.10.845; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; MAJESKA RJ, 1982, CALCIFIED TISSUE INT, V34, P59, DOI 10.1007/BF02411210; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Mizuno A, 1998, BIOCHEM BIOPH RES CO, V247, P610, DOI 10.1006/bbrc.1998.8697; Morinaga T, 1998, EUR J BIOCHEM, V254, P685, DOI 10.1046/j.1432-1327.1998.2540685.x; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nagai M, 1999, BIOCHEM BIOPH RES CO, V257, P719, DOI 10.1006/bbrc.1999.0524; Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788; OBRIEN CA, 1998, BONE, V23, pS149; Onyia JE, 2000, J BONE MINER RES, V15, P863, DOI 10.1359/jbmr.2000.15.5.863; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Porte D, 1999, ONCOGENE, V18, P667, DOI 10.1038/sj.onc.1202333; Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SELBY PB, 1978, MUTAT RES, V51, P199, DOI 10.1016/S0027-5107(78)80019-0; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; SILLENCE DO, 1987, AM J MED GENET, V27, P75, DOI 10.1002/ajmg.1320270109; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Thirunavukkarasu K, 2000, BIOTECHNIQUES, V28, P506, DOI 10.2144/00283st09; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	47	158	179	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25163	25172		10.1074/jbc.M000322200	http://dx.doi.org/10.1074/jbc.M000322200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833509	hybrid			2022-12-25	WOS:000088849400018
J	Zhang, BL; Zhang, YQ; Wang, ZX; Zheng, Y				Zhang, BL; Zhang, YQ; Wang, ZX; Zheng, Y			The role of Mg2+ cofactor in the guanine nucleotide exchange and GTP hydrolysis reactions of Rho family GTP-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ACTIVATING PROTEINS; GTPASES CDC42; CELL-ADHESION; RAS; DBL; FINGER; ANALOG; RAC1; CYTOSKELETON	The biological activities of Rho family GTPases are controlled by their guanine nucleotide binding states in cells. Here we have investigated the role of Mg2+ cofactor in the guanine nucleotide binding and hydrolysis processes of the Rho family members, Cdc42, Rad, and RhoA. Differing from Ras and Rab proteins, which require Mg2+ for GDP and GTP binding, the Rho GTPases bind the nucleotides in the presence or absence of Mg2+ similarly, with dissociation constants in the submicromolar concentration. The presence of Mg2+, however, resulted in a marked decrease in the intrinsic dissociation rates of the nucleotides. The catalytic activity of the guanine nucleotide exchange factors (GEFs) appeared to be negatively regulated by free Mg2+, and GEF binding to Rho GTPase resulted in a 10-fold decrease in affinity for Mg2+, suggesting that one role of GEF is to displace bound Mg2+ from the Rho proteins. The GDP dissociation rates of the GTPases could be further stimulated by GEF upon removal of bound Mg2+, indicating that the GEF-catalyzed nucleotide exchange involves a Mg2+-independent as well as a Mg2+-dependent mechanism. Although Mg2+ is not absolutely required for GTP hydrolysis by the Rho GTPases, the divalent ion apparently participates in the GTPase reaction, since the intrinsic GTP hydrolysis rates were enhanced 4-10-fold upon binding to Mg2+, and k(cat) values of the Rho GTPase-activating protein (RhoGAP)-catalyzed reactions were significantly increased when Mg2+ was present. Furthermore, the p50RhoGAP specificity for Cdc42 was lost in the absence of Mg2+ cofactor. These studies directly demonstrate a role of Mg2+ in regulating the kinetics of nucleotide binding and hydrolysis and in the GEF- and GAP-catalyzed reactions of Rho family GTPases, The results suggest that GEF facilitates nucleotide exchange by destabilizing both bound nucleotide and Mg2+, whereas RhoGAP utilizes the Mg2+ cofactor to achieve high catalytic efficiency and specificity.	Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA; Acad Sinica, Inst Biophys, Beijing 100101, Peoples R China	University of Tennessee System; University of Tennessee Health Science Center; Chinese Academy of Sciences; Institute of Biophysics, CAS	Zheng, Y (corresponding author), Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA.		Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NIGMS NIH HHS [GM 60523] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060523] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bourne HR, 1997, NATURE, V389, P673, DOI 10.1038/39470; BURSTEIN ES, 1992, BIOCHEM J, V282, P387, DOI 10.1042/bj2820387; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; Feltham JL, 1997, BIOCHEMISTRY-US, V36, P8755, DOI 10.1021/bi970694x; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; FRECH M, 1990, J BIOL CHEM, V265, P6353; Geyer M, 1996, BIOCHEMISTRY-US, V35, P10308, DOI 10.1021/bi952858k; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Hirshberg M, 1997, NAT STRUCT BIOL, V4, P147, DOI 10.1038/nsb0297-147; Ihara K, 1998, J BIOL CHEM, V273, P9656, DOI 10.1074/jbc.273.16.9656; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1993, J BIOL CHEM, V268, P923; KABCENELL AK, 1990, J BIOL CHEM, V265, P9366; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; PAN JY, 1996, J BIOL CHEM, V271, P13322; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rudolph MG, 1998, J BIOL CHEM, V273, P18067, DOI 10.1074/jbc.273.29.18067; Shimizu T, 2000, J BIOL CHEM, V275, P18311, DOI 10.1074/jbc.M910274199; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Wei YY, 1997, NAT STRUCT BIOL, V4, P699, DOI 10.1038/nsb0997-699; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Zhang BL, 1997, J BIOL CHEM, V272, P21999, DOI 10.1074/jbc.272.35.21999; Zhang BL, 1998, J BIOL CHEM, V273, P25728, DOI 10.1074/jbc.273.40.25728; Zhang BL, 1998, BIOCHEMISTRY-US, V37, P5249, DOI 10.1021/bi9718447; Zhang BL, 1998, J BIOL CHEM, V273, P8776, DOI 10.1074/jbc.273.15.8776; Zhang BL, 1999, J BIOL CHEM, V274, P2609, DOI 10.1074/jbc.274.5.2609; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77	47	128	130	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25299	25307		10.1074/jbc.M001027200	http://dx.doi.org/10.1074/jbc.M001027200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10843989	hybrid			2022-12-25	WOS:000088849400035
J	Zhang, Y; Neo, SY; Han, JH; Lin, SC				Zhang, Y; Neo, SY; Han, JH; Lin, SC			Dimerization choices control the ability of axin and dishevelled to activate c-jun N-terminal kinase/stress-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; GLYCOGEN-SYNTHASE KINASE-3-BETA; BETA-CATENIN; NEGATIVE REGULATOR; DOMAINS; TRANSCRIPTION; JNK; POLARITY; PHOSPHORYLATION; IDENTIFICATION	Axin and Dishevelled are two downstream components of the Wnt signaling pathway. Dishevelled is a positive regulator and is placed genetically between Frizzled and glycogen synthase kinase-3 beta, whereas Axin is a negative regulator that acts downstream of glycogen synthase kinase-3 beta. It is intriguing that they each can activate the c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) when expressed in the cell. We set out to address if Axin and Dishevelled are functionally cooperative, antagonistic, or entirely independent, in terms of the JNK activation event. We found that in contrast to Axin, Dv12 activation of JNK does not require MEKK1, and complex formation between Dv12 and Axin is independent of Axin-MEKK1 binding. Furthermore, Dv12-DIX and Dv12-Delta DEP proteins deficient for JNK activation can attenuate Axin-activated JNK activity by disrupting Axin dimerization. However, Axin-Delta MID, and Axin-Delta T proteins deficient for JNK activation cannot interfere with Dv12-activated JMK activity. These results indicate that unlike the strict requirement of homodimerization for Axin function, Dv12 can activate JNK either as a monomer or homodimer/heterodimer. We suggest that there may be a switch mechanism based on dimerization combinations, that commands cells to activate Wnt signaling or JNK activation, and to turn on specific activators of JNK in response to various environmental cues.	Natl Univ Singapore, Inst Mol & Cell Biol, Regulatory Biol Lab, Singapore 117609, Singapore; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Scripps Research Institute	Lin, SC (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Regulatory Biol Lab, 30 Med Dr, Singapore 117609, Singapore.		Han, J/G-4671-2010; Lin, SC/G-4666-2010	Zhang, Yi/0000-0003-2785-1780	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041637] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41637] Funding Source: Medline; NIGMS NIH HHS [GM51417] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi-Yamada T, 1999, NATURE, V400, P166, DOI 10.1038/22112; Arias AM, 1999, CURR OPIN GENET DEV, V9, P447, DOI 10.1016/S0959-437X(99)80068-9; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Boutros M, 1999, MECH DEVELOP, V83, P27, DOI 10.1016/S0925-4773(99)00046-5; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Dale TC, 1998, BIOCHEM J, V329, P209; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hedgepeth CM, 1999, MOL CELL BIOL, V19, P7147; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Itoh K, 2000, MOL CELL BIOL, V20, P2228, DOI 10.1128/MCB.20.6.2228-2238.2000; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Sakanaka C, 1999, J BIOL CHEM, V274, P14090, DOI 10.1074/jbc.274.20.14090; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247	38	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					25008	25014		10.1074/jbc.M002491200	http://dx.doi.org/10.1074/jbc.M002491200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10829020	hybrid			2022-12-25	WOS:000088683300103
J	Knox, JD; Araujo, FD; Bigey, P; Slack, AD; Price, GB; Zannis-Hadjopoulos, M; Szyf, M				Knox, JD; Araujo, FD; Bigey, P; Slack, AD; Price, GB; Zannis-Hadjopoulos, M; Szyf, M			Inhibition of DNA methyltransferase inhibits DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CPG ISLAND METHYLATION; SIGNALING PATHWAY; HUMAN CANCERS; CELL LINES; ORIGINS; TUMORIGENESIS; EXPRESSION; NEOPLASIA; ANTISENSE; GROWTH	Ectopic expression of DNA methyltransferase transforms vertebrate cells, and inhibition of DNA methyltransferase reverses the transformed phenotype by an unknown mechanism. me tested the hypothesis that the presence of an active DNA methyltransferase is required for DNA replication in human non-small cell lung carcinoma A549 cells. We show that the inhibition of DNA methyltransferase by two novel mechanisms negatively affects DNA synthesis and progression through the cell cycle, Competitive polymerase chain reaction of newly synthesized DNA shows decreased origin activity at three previously characterized origins of replication following DNA methyltransferase inhibition. We suggest that the requirement of an active DNA methyltransferase for the functioning of the replication machinery has evolved to coordinate DNA replication and inheritance of the DNA methylation pattern.	McGill Univ, Ctr Canc, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Szyf, M (corresponding author), McGill Univ, Ctr Canc, Dept Pharmacol & Therapeut, 3655 Sir William Osler Promenade, Montreal, PQ H3G 1Y6, Canada.	mszyf@pharma.mcgill.ca		bigey, pascal/0000-0002-6795-8569				Ahuja N, 1997, CANCER RES, V57, P3370; Araujo FD, 1999, J BIOL CHEM, V274, P9335, DOI 10.1074/jbc.274.14.9335; Araujo FD, 1998, MOL CELL BIOL, V18, P3475, DOI 10.1128/MCB.18.6.3475; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; Bender CM, 1998, CANCER RES, V58, P95; Bigey P, 1999, J BIOL CHEM, V274, P4594, DOI 10.1074/jbc.274.8.4594; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; CONTREAS G, 1992, BIOTECHNIQUES, V12, P824; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Gerbi SA, 1997, METHODS, V13, P271, DOI 10.1006/meth.1997.0526; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hung MS, 1999, P NATL ACAD SCI USA, V96, P11940, DOI 10.1073/pnas.96.21.11940; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LUI Y, 1998, NUCLEIC ACIDS RES, V26, P1038; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; Rein T, 1999, J BIOL CHEM, V274, P25792, DOI 10.1074/jbc.274.36.25792; Rein T, 1997, MOL CELL BIOL, V17, P416, DOI 10.1128/MCB.17.1.416; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; SZYF M, 1985, J BIOL CHEM, V260, P8653; Szyf M, 1998, CANCER METAST REV, V17, P219, DOI 10.1023/A:1006023023787; SZYF M, 1991, J BIOL CHEM, V266, P10027; SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4; SZYF M, 1998, CURR RES MOL THER, V1, P93; Tao L, 1997, J MOL BIOL, V273, P509, DOI 10.1006/jmbi.1997.1352; Tsvetkov LM, 1997, CANCER RES, V57, P2252; YOSHIURA K, 1994, P NATL ACAD SCI USA, V91, P9700	34	65	67	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17986	17990		10.1074/jbc.C900894199	http://dx.doi.org/10.1074/jbc.C900894199			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849434	hybrid			2022-12-25	WOS:000087659400013
J	Li, M; Pritchard, PH				Li, M; Pritchard, PH			Characterization of the effects of mutations in the putative branchpoint sequence of intron 4 on the splicing within the human lecithin : cholesterol acyltransferase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; U2 SNRNA; LCAT DEFICIENCY; TACTAAC BOX; SITE; POINT; EXPRESSION; INVITRO; YEAST; CONSEQUENCES	We have previously identified a point mutation (intervening sequence (TVS) 4: T --> C) in the branchpoint consensus sequence of intron 4 of the lecithin:cholesterol acyltransferase (LCAT) gene in patients with fish-eye disease. To investigate the possible mechanisms responsible for the defective splicing, we made a series of mutations in the branchpoint sequence and expressed these mutants in HEK-293 cells followed by the analysis of pre-mRNA splicing using reverse transcriptase-polymerase chain reaction as well as LCAT activity assay. The results reveal that 1) the mutation of the branchpoint adenosine to any other nucleotide completely abolishes splicing; 2) the insertion of a normal branch site into the intronic sequence of the natural (IVS4-22c) or the branchpoint (IVS4-20t) mutant completely restores splicing; 3) the natural mutation can be partially rescued by making a single nucleotide change (G --> A) within the branchpoint consensus sequence; and 4) other single base changes, particularly around the branchpoint adenosine residue, significantly decrease the efficiency of splicing and thus enzyme activity. Surprisingly, the nucleotide transversion at the last position of the branchpoint sequence (i.e. IVS4-25a or -25g) results in a 2.7-fold increase in splicing efficiency. Therefore, these observations clearly establish the functional significance of the branchpoint sequence of intron 4 for the splicing of the human LCAT mRNA precursors.	St Pauls Hosp, Healthy Heart Program, Atherosclerosis Specialty Lab, Dept Pathol & Lab Med, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Vancouver, BC V6Z 1Y6, Canada	St. Paul's Hospital; University of Saskatchewan; University of British Columbia	Pritchard, PH (corresponding author), St Pauls Hosp, Healthy Heart Program, Atherosclerosis Specialty Lab, Dept Pathol & Lab Med, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.							Brand K, 1996, J LIPID RES, V37, P1213; Burrows NP, 1998, AM J HUM GENET, V63, P390, DOI 10.1086/301948; GREEN MR, 1986, ANNU REV GENET, V20, P671, DOI 10.1146/annurev.ge.20.120186.003323; HIXSON JE, 1993, GENE, V128, P295, DOI 10.1016/0378-1119(93)90578-Q; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KADOLITSCH YV, 1999, CIRCULATION, V100, P693; KRAWCZAK M, 1992, HUM GENET, V90, P41; Kuivenhoven JA, 1997, J LIPID RES, V38, P191; Kuivenhoven JA, 1996, J CLIN INVEST, V98, P358, DOI 10.1172/JCI118800; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; Li M, 1998, BBA-LIPID LIPID MET, V1391, P256, DOI 10.1016/S0005-2760(97)00198-7; MADHANI HD, 1994, ANNU REV GENET, V28, P1; MCLEAN J, 1986, NUCLEIC ACIDS RES, V14, P9397, DOI 10.1093/nar/14.23.9397; MCLEAN J, 1986, P NATL ACAD SCI USA, V83, P2335, DOI 10.1073/pnas.83.8.2335; Moore M., 1993, RNA WORLD, P303; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; PADGETT RA, 1985, P NATL ACAD SCI USA, V82, P8349, DOI 10.1073/pnas.82.24.8349; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; Pascolo E, 1997, MOL CELL BIOL, V17, P3469, DOI 10.1128/MCB.17.7.3469; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; RISSTALPERS C, 1994, AM J HUM GENET, V54, P609; ROSENTHAL A, 1992, NAT GENET, V2, P107, DOI 10.1038/ng1092-107; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUSKIN B, 1985, CELL, V41, P833, DOI 10.1016/S0092-8674(85)80064-7; Sambrook J., 2002, MOL CLONING LAB MANU; TEISBERG P, 1975, ANN HUM GENET, V38, P327, DOI 10.1111/j.1469-1809.1975.tb00617.x; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; Webb JC, 1996, HUM MOL GENET, V5, P1325, DOI 10.1093/hmg/5.9.1325; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; ZHUANG Y, 1989, Proceedings of the National Academy of Sciences of the United States of America, V86, P2752, DOI 10.1073/pnas.86.8.2752; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	35	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18079	18084		10.1074/jbc.M910197199	http://dx.doi.org/10.1074/jbc.M910197199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849435	hybrid			2022-12-25	WOS:000087659400025
J	Li, J; Houseknecht, KL; Stenbit, AE; Katz, EB; Charron, MJ				Li, J; Houseknecht, KL; Stenbit, AE; Katz, EB; Charron, MJ			Reduced glucose uptake precedes insulin signaling defects in adipocytes from heterozygous GLUT4 knockout mice	FASEB JOURNAL			English	Article						adipocyte glucose transport; NIDDM; hyperglycemia; PI3 kinase	PHOSPHATIDYLINOSITOL 3-KINASE ACTIVITY; 60-KDA PHOSPHOTYROSINE PROTEIN; RECEPTOR SUBSTRATE-1; DIABETES-MELLITUS; ADIPOSE-TISSUE; ANIMAL-MODELS; MUSCLE; OBESE; TRANSPORTER; RESISTANCE	Decreased GLUT4 expression, impaired insulin receptor (IR), TRS-l, and pp60/IRS-3 tyrosine phosphorylation are characteristics of adipocytes from insulin-resistant animal models and obese NIDDM humans. However, the sequence of events leading to the development of insulin signaling defects and the significance of decreased GLUT4 expression in causing adipocyte insulin resistance are unknown. The present study used male heterozygous GLUT4 knockout mice (GLUT4(+/-)) as a novel model of diabetes to study the development of insulin signaling defects in adipocytes with the progression of whole body insulin resistance and diabetes. Male GLUT4(+/-) mice with normal fed glycemia and insulinemia (N/N), normal fed glycemia and hyperinsulinemia (N/H), and fed hyperglycemia with hyperinsulinemia (H/H) exist at all ages. The expression of GLUT4 protein and the maximal insulin-stimulated glucose transport was 50% decreased in adipocytes from all three groups. Insulin signaling was normal in N/N adipose cells. From 35 to 70% reductions in insulin-stimulated tyrosine phosphorylation of IR, IRS-1, and pp60/IRS-3 were noted with no changes in the cellular content of IR, IRS-1, and p85 in N/H adipocytes. Insulin-stimulated protein tyrosine phosphorylation was further decreased to 12-23% in H/H adipose cells accompanied by 42% decreased IR and 80% increased p85 expression. Insulin-stimulated, IRS-1-associated PI3 kinase activity was decreased by 20% in N/H and 68% reduced in H/H GLUT4(+/-) adipocytes. However, total insulin-stimulated PI3 kinase activity was normal in H/H GLUT4(+/-) adipocytes. Taken together, these results strongly suggest that hyperinsulinemia triggers a reduction of IR tyrosine kinase activity that is further exacerbated by the appearance of hyperglycemia. However, the insulin signaling cascade has sufficient plasticity to accommodate significant changes in specific components without further reducing glucose uptake. Furthermore, the data indicate that the cellular content of GLUT4 is the rate-limiting factor in mediating maximal insulin-stimulated glucose uptake in GLUT4(+/-) adipocytes.-Li, J., Houseknecht, K. L., Stenbit, A. E., Katz, E. B., Charron, M. J. Reduced glucose uptake precedes insulin signaling defects in adipocytes from heterozygous GLUT4: knockout mice.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Purdue Univ, Dept Anim Sci, W Lafayette, IN 47907 USA	Yeshiva University; Albert Einstein College of Medicine; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Charron, MJ (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	charron@aecom.yu.edu			NHLBI NIH HHS [HL 58119] Funding Source: Medline; NIDDK NIH HHS [DK 47425] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047425] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; CUSHMAN SW, 1978, J LIPID RES, V19, P269; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; FREIDENBERG GR, 1987, J CLIN INVEST, V79, P240, DOI 10.1172/JCI112789; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HEYDRICK SJ, 1995, AM J PHYSIOL-ENDOC M, V268, pE604, DOI 10.1152/ajpendo.1995.268.4.E604; HIRSCH J, 1968, J LIPID RES, V9, P110; Houseknecht KL, 1996, J BIOL CHEM, V271, P11347, DOI 10.1074/jbc.271.19.11347; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; KORANYI L, 1990, J CLIN INVEST, V85, P962, DOI 10.1172/JCI114526; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; Lavan BE, 1997, J BIOL CHEM, V272, P11439; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; OLEFSKY JM, 1995, AM J CLIN NUTR, V61, p980S, DOI 10.1093/ajcn/61.4.980S; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; Rossetti L, 1997, J CLIN INVEST, V100, P1831, DOI 10.1172/JCI119711; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Shepherd PR, 1996, J MOL ENDOCRINOL, V17, P175, DOI 10.1677/jme.0.0170175; Shepherd PR, 1997, BIOCHEM SOC T, V25, P978, DOI 10.1042/bst0250978; SmithHall J, 1997, BIOCHEMISTRY-US, V36, P8304, DOI 10.1021/bi9630974; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; WHITE MF, 1994, J BIOL CHEM, V269, P1; Yamauchi T, 1996, MOL CELL BIOL, V16, P3074; Zierath JR, 1996, SEMIN CELL DEV BIOL, V7, P295, DOI 10.1006/scdb.1996.0038	38	45	51	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1117	1125		10.1096/fasebj.14.9.1117	http://dx.doi.org/10.1096/fasebj.14.9.1117			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834933				2022-12-25	WOS:000087427300008
J	Saitou, M; Sugimoto, J; Hatakeyama, T; Russo, G; Isobe, M				Saitou, M; Sugimoto, J; Hatakeyama, T; Russo, G; Isobe, M			Identification of the TCL6 genes within the breakpoint cluster region on chromosome 14q32 in T-cell leukemia	ONCOGENE			English	Article						chromosome 14q32; T-cell leukemia; TML1; TCL1; MTCP-1; translocation	ATAXIA-TELANGIECTASIA; LOCUS; TRANSLOCATIONS; RECEPTOR; NEOPLASIA; PATIENT; REVEALS; SUBUNIT; GROWTH; 14Q11	A region on chromosome 14q32.1 is often involved in chromosomal translocations and inversions with one of the T-cell receptor loci in T-cell lymphoproliferative diseases. The breakpoints of the different rearrangements segregate into two clusters; a cluster due to inversion on the centromeric side and a cluster due to simple balanced translocations on the telomeric side. If the target gene activated by these different types of chromosomal rearrangements is the same, the gene must be localized between the two clusters of breakpoints in a region of around 160 kb, Within this breakpoint cluster region, we isolated two genes; namely, TCL1 and TML1/TCL1b genes. In the course of characterizing the TML1 gene, we further identified a third novel gene, which we named TCL6 (T-cell leukemia/lymphoma 6), from a region 7 kb upstream of the TML1 locus. The TCL6 gene expressed at least 11 isoforms through very complex alternative-splicing, including splicing with the TML1 gene. Those isoforms encode at least five open reading frames (ORFs) with no homology to known sequences. The localization of the proteins corresponding to these ORF was determined by fusing green fluorescence protein at the carboxyl terminal of each ORF. ORF141 and ORF72 were observed in the cytoplasmic region, while ORF105, ORF119, and ORF163 were predominantly localized in the nuclear region. Since the TCL6 gene was expressed in T-cell leukemia carrying a t(14;14) (q11;q32.1) chromosome translocation and was not expressed in normal T-cells (just like the TML1 and TCL1 genes), it is also a candidate gene potentially involved in leukemogenesis.	Toyama Univ, Fac Engn, Dept Mat & Biosyst Engn, Toyama 9308555, Japan; IDI IRCCS, Res Labs, I-00167 Rome, Italy	University of Toyama; IRCCS Istituto Dermopatico dell'Immacolata (IDI)	Isobe, M (corresponding author), Toyama Univ, Fac Engn, Dept Mat & Biosyst Engn, Toyama 9308555, Japan.		Russo, Giandomenico/K-9566-2016	Russo, Giandomenico/0000-0002-7718-9687				BRITOBABAPULLE V, 1991, CANCER GENET CYTOGEN, V55, P1, DOI 10.1016/0165-4608(91)90228-M; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; DAVEY MP, 1988, P NATL ACAD SCI USA, V85, P9287, DOI 10.1073/pnas.85.23.9287; Goswami S, 1998, J NEUROCHEM, V71, P1837; Hallas C, 1999, P NATL ACAD SCI USA, V96, P14418, DOI 10.1073/pnas.96.25.14418; ISOBE M, 1985, SCIENCE, V228, P580, DOI 10.1126/science.3983641; ISOBE M, 1988, P NATL ACAD SCI USA, V85, P3933, DOI 10.1073/pnas.85.11.3933; KANZAKI T, 1992, CANCER, V69, P1034, DOI 10.1002/1097-0142(19920215)69:4<1034::AID-CNCR2820690434>3.0.CO;2-E; KUBONISHI I, 1991, AM J HEMATOL, V37, P179, DOI 10.1002/ajh.2830370309; MENGLEGAW L, 1988, P NATL ACAD SCI USA, V85, P9171, DOI 10.1073/pnas.85.23.9171; MENGLEGAW L, 1987, EMBO J, V6, P2273, DOI 10.1002/j.1460-2075.1987.tb02501.x; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURRE C, 1985, NATURE, V316, P549, DOI 10.1038/316549a0; NARDUCCI MG, 1995, BLOOD, V86, P2358, DOI 10.1182/blood.V86.6.2358.bloodjournal8662358; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; SMITH SD, 1989, BLOOD, V73, P2182; STEM MH, 1996, PATHOL BIOL PARIS, V44, P689; Sugimoto J, 1999, CANCER RES, V59, P2313; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; VIRGILIO L, 1993, P NATL ACAD SCI USA, V90, P9275, DOI 10.1073/pnas.90.20.9275	20	37	38	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 25	2000	19	23					2796	2802		10.1038/sj.onc.1203604	http://dx.doi.org/10.1038/sj.onc.1203604			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851082				2022-12-25	WOS:000087318500010
J	Jean, D; Tellez, C; Huang, SY; Davis, DW; Bruns, CJ; McConkey, DJ; Hinrichs, SH; Bar-Eli, M				Jean, D; Tellez, C; Huang, SY; Davis, DW; Bruns, CJ; McConkey, DJ; Hinrichs, SH; Bar-Eli, M			Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment	ONCOGENE			English	Article						melanoma; metastasis; apoptosis; transcriptional regulation	ELEMENT-BINDING PROTEIN; TRANSCRIPTION FACTOR-I; WILD-TYPE P53; HUMAN MELANOCYTES; RESPONSIVE ELEMENT; SOMATOSTATIN GENE; INDUCED APOPTOSIS; DOWN-REGULATION; C-KIT; CELLS	Activating transcription factor-1 (ATF-1) and cAMP-responsive element (CRE)-binding protein (CREB) have been implicated in cAMP and Ca2+-induced transcriptional activation. The expression of the transcription factors CREB and ATF-1 is upregulated in metastatic melanoma cells. However, how overexpression of ATF-1/CREB contributes to the acquisition of the metastatic phenotype remains unclear. Here, the effect of disrupting ATF-1 activity was investigated using intracellular expression of an inhibitory anti-ATF-1 single chain antibody fragment (ScFv), Intracellular expression of ScFv anti-ATF-1 in MeWo melanoma cells caused significant reduction in CRE-dependent promoter activation. In addition, expression of ScFv anti-ATF-1 in melanoma cells suppressed their tumorigenicity and metastatic potential in nude mice. ScFv anti-ATF-1 rendered the melanoma cells susceptible to thapsigargin-induced apoptosis in vitro and caused massive apoptosis in tumors transplanted subcutaneously into nude mice, suggesting that ATF-1 and its associated proteins act as survival factor for human melanoma cells. This is the first report to demonstrate the potential of ScFv anti-ATF-1 as an inhibitor of tumor growth and metastasis of solid tumor in vivo.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Texas System; UTMD Anderson Cancer Center; University of Nebraska System; University of Nebraska Medical Center	Bar-Eli, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.		Jean, Didier/A-1615-2009	Jean, Didier/0000-0001-5823-7404	NATIONAL CANCER INSTITUTE [R01CA076098] Funding Source: NIH RePORTER; NCI NIH HHS [CA76098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO;2-C; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; Bosilevac JM, 1998, J BIOL CHEM, V273, P16874, DOI 10.1074/jbc.273.27.16874; Bosilevac JM, 1999, J BIOL CHEM, V274, P34811, DOI 10.1074/jbc.274.49.34811; Bussfeld D, 1997, IMMUNOBIOLOGY, V198, P291, DOI 10.1016/S0171-2985(97)80049-6; de Fromentel CC, 1999, ONCOGENE, V18, P551, DOI 10.1038/sj.onc.1202338; FIDLER IJ, 1990, CANCER RES, V50, P6130; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; Grim J, 1996, AM J RESP CELL MOL, V15, P348, DOI 10.1165/ajrcmb.15.3.8810638; HALABAN R, 1993, SEMIN CANCER BIOL, V4, P171; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1984, ARCH BIOCHEM BIOPHYS, V230, P383, DOI 10.1016/0003-9861(84)90121-8; HALABAN R, 1983, J CELL BIOL, V97, P480, DOI 10.1083/jcb.97.2.480; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang SY, 1996, ONCOGENE, V13, P2339; HUDSON JM, 1995, DNA CELL BIOL, V14, P759, DOI 10.1089/dna.1995.14.759; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; ISHIKAWA M, 1988, CANCER RES, V48, P665; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; KOPF AW, 1995, CANCER-AM CANCER SOC, V75, P684, DOI 10.1002/1097-0142(19950115)75:2+<684::AID-CNCR2820751411>3.0.CO;2-B; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEMAIGRE FP, 1993, NUCLEIC ACIDS RES, V21, P2907, DOI 10.1093/nar/21.12.2907; LIU F, 1993, J BIOL CHEM, V268, P6714; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; Luca M, 1997, AM J PATHOL, V151, P1105; LUCA M, 1995, ONCOGENE, V11, P1399; MARASCO WA, 1995, IMMUNOTECHNOLOGY, V1, P1, DOI 10.1016/1380-2933(95)00001-1; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; ORTEN DJ, 1994, J BIOL CHEM, V269, P32254; RAAG R, 1995, FASEB J, V9, P73, DOI 10.1096/fasebj.9.1.7821762; RADINSKY R, 1994, ONCOGENE, V9, P1877; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; RICHARDSON JH, 1995, P NATL ACAD SCI USA, V92, P3137, DOI 10.1073/pnas.92.8.3137; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SINGH RK, 1995, CANCER RES, V55, P3669; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VILE RG, 1994, CANCER RES, V54, P6228; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; Xie SH, 1997, CANCER RES, V57, P2295; Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358	53	57	60	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2721	2730		10.1038/sj.onc.1203569	http://dx.doi.org/10.1038/sj.onc.1203569			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851072				2022-12-25	WOS:000087193000008
J	Lelievre, E; Mattot, V; Huber, P; Vandenbunder, B; Soncin, F				Lelievre, E; Mattot, V; Huber, P; Vandenbunder, B; Soncin, F			ETS1 lowers capillary endothelial cell density at confluence and induces the expression of VE-cadherin	ONCOGENE			English	Article						angiogenesis; endothelium; adhesion; transcription	BINDING-SITES; PLASMINOGEN-ACTIVATOR; TRANSGENIC MICE; GENE PROMOTER; CHICK-EMBRYO; DNA-BINDING; TRANSCRIPTION; C-ETS-1; GROWTH; PROTEIN	Ets1 is a transcription factor expressed in endothelial cells during angiogenesis but its target genes and function in blood vessel formation are still unknown. We have over-expressed Ets1 as a tagged protein in brain capillary endothelial cells and in 3T3 fibroblasts using a retroviral vector. Over-expression of Ets1 reduced by nearly half cell density at confluence of endothelials but not of fibroblasts, As density at confluence is controlled in part by cadherins, this growth arrest could be due to the up-regulation of these cell contact molecules. Indeed, Ets1 increased the expression of the endothelial-specific VE-cadherin without affecting N-cadherin expression levels. In parallel, both dominant negative mutant of Ets members and an Ets1 anti-sense oligonucleotide inhibited VE-cadherin expression in endothelial cells, Ets1 bound to two Ets-binding sites located in the proximal region of the VE-cadherin promoter. Mutation of these sites abolished Ets1-induced transactivation of the promoter. The present work is the first demonstration of a function of Ets1 in the regulation of a specific endothelial marker based on its endogenous gene and protein expression.	Inst Pasteur Lille, Inst Biol Lille, CNRS, EP560, F-59021 Lille, France; CEA, Lab Transgenese & Differenciat Cellulaire, Grenoble, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; CEA	Soncin, F (corresponding author), Inst Pasteur Lille, Inst Biol Lille, CNRS, EP560, 1 Rue Calmette, F-59021 Lille, France.		SONCIN, Fabrice/A-1475-2009; Huber, Philippe/C-7971-2019	SONCIN, Fabrice/0000-0001-6312-0673; Huber, Philippe/0000-0002-4153-7694; Lelievre, Etienne/0000-0003-0452-1578				AUERBACH R, 1991, INT J RADIAT BIOL, V60, P1, DOI 10.1080/09553009114551401; Bach TL, 1998, EXP CELL RES, V238, P324, DOI 10.1006/excr.1997.3844; Breier G, 1996, BLOOD, V87, P630, DOI 10.1182/blood.V87.2.630.bloodjournal872630; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; COFFER P, 1994, ONCOGENE, V9, P911; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FISHER RJ, 1991, ONCOGENE, V6, P2249; GARLANDA C, 1994, P NATL ACAD SCI USA, V91, P7291, DOI 10.1073/pnas.91.15.7291; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; Gory S, 1999, BLOOD, V93, P184, DOI 10.1182/blood.V93.1.184.401a20_184_192; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; GREVIN D, 1993, INT J DEV BIOL, V37, P519; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; Huber P, 1996, GENOMICS, V32, P21, DOI 10.1006/geno.1996.0072; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Macias D, 1998, ANAT EMBRYOL, V198, P307, DOI 10.1007/s004290050186; Mager AM, 1998, INT J DEV BIOL, V42, P561; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Mattot V, 2000, ONCOGENE, V19, P762, DOI 10.1038/sj.onc.1203248; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; OKA T, 1991, ONCOGENE, V6, P2077; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; QUEVA C, 1993, ONCOGENE, V8, P2511; Rahimi N, 1999, MOL BIOL CELL, V10, P3401, DOI 10.1091/mbc.10.10.3401; Robinson L, 1997, P NATL ACAD SCI USA, V94, P7170, DOI 10.1073/pnas.94.14.7170; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1990, ONCOGENE, V5, P1761; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; Tanaka K, 1998, J CELL PHYSIOL, V176, P235, DOI 10.1002/(SICI)1097-4652(199808)176:2<235::AID-JCP2>3.0.CO;2-P; Telo P, 1998, J BIOL CHEM, V273, P17565, DOI 10.1074/jbc.273.28.17565; VANDENBUNDER B, 1994, INVAS METAST, V14, P198; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699	51	69	71	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2438	2446		10.1038/sj.onc.1203563	http://dx.doi.org/10.1038/sj.onc.1203563			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828886				2022-12-25	WOS:000087018400009
J	Choi, KH; Kremer, L; Besra, GS; Rock, CO				Choi, KH; Kremer, L; Besra, GS; Rock, CO			Identification and substrate specificity of beta-ketoacyl (Acyl carrier protein) synthase III (mtFabH) from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; ESCHERICHIA-COLI K-12; ISONIAZID TARGET; THIOLACTOMYCIN; INHIBITION; COMPLEX; INHA; FABH; BCG	The long-chain alpha-alkyl-beta-hydroxy fatty acids, termed mycolic acids, which are characteristic components of the mycobacterial cell wall are produced by successive rounds of elongation catalyzed by a multifunctional (type I) fatty acid synthase complex followed by a dissociated (type II) fatty acid synthase, In bacterial type II systems, the first initiation step in elongation is the condensation of acetyl-CoA with malonyl-acyl carrier protein (ACP) catalyzed by beta-ketoacyl-ACP III (FabH), An open reading frame in the Mycobacterium tuberculosis genome (Rv0533c), now termed mtfabH, was 37.3% identical to Escherichia coli ecFabH and contained the Cys-His-Asn catalytic triad signature. However, the purified recombinant mtFabH clearly preferred long-chain acyl-CoA substrates rather than acyl-ACP primers and did not utilize acetyl-CoA as a primer in comparison to ecFabH, In addition, purified mtFabH was sensitive to thiolactomycin and resistant to cerulenin in an in vitro assay, However, mtFabH overexpression in Mycobacterium bovis BCG did not confer thiolactomycin resistance, suggesting that mtFabH may not be the primary target of thiolactomycin inhibition in vivo and led to several changes in the lipid composition of the bacilli. The data presented is consistent with a role for mtFabH as the pivotal link between the type I and type II fatty acid elongation systems in M. tuberculosis. This study opens up new avenues for the development of selective and novel anti-mycobacterial agents targeted against mtFabH.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Newcastle Upon Tyne, Dept Microbiol & Immunol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; Newcastle University - UK; University of Tennessee System; University of Tennessee Health Science Center	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.		Kremer, Laurent/M-4935-2017	Kremer, Laurent/0000-0002-6604-4458; Besra, Gurdyal/0000-0002-5605-0395	NCI NIH HHS [CA 21765] Funding Source: Medline; NIAID NIH HHS [AI-38087] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI038087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BAULARD A, 1992, NUCLEIC ACIDS RES, V20, P4105, DOI 10.1093/nar/20.15.4105; Baulard A.R., 1999, MYCOBACTERIA MOL BIO, P240; BELISLE JT, 1994, RES MICROBIOL, V145, P237, DOI 10.1016/0923-2508(94)90024-8; BELISLE JT, 1989, J BACTERIOL, V171, P3465, DOI 10.1128/jb.171.6.3465-3470.1989; Besra GS, 1998, METH MOL B, V101, P91, DOI 10.1385/0-89603-471-2:91; Bloch K, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P1; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V65, P215; Choi KH, 2000, J BACTERIOL, V182, P365, DOI 10.1128/JB.182.2.365-370.2000; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; Dobson G., 1985, CHEM METHODS BACTERI, P237; GLOBE M, 1993, NEW ENGL J MED, V328, P527; Han L, 1998, J BACTERIOL, V180, P4481, DOI 10.1128/JB.180.17.4481-4486.1998; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; JACKOWSKI S, 1989, J BIOL CHEM, V264, P7624; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; JACKOWSKI S, 1991, EMERGING TARGETS ANT, P151; KIKUCHI S, 1992, ARCH BIOCHEM BIOPHYS, V295, P318, DOI 10.1016/0003-9861(92)90524-Z; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200; KREMER L, 1995, J BACTERIOL, V177, P642, DOI 10.1128/jb.177.3.642-653.1995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee RE, 1996, CURR TOP MICROBIOL, V215, P1; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; Moche M, 1999, J BIOL CHEM, V274, P6031, DOI 10.1074/jbc.274.10.6031; Phetsuksiri B, 1999, ANTIMICROB AGENTS CH, V43, P1042, DOI 10.1128/AAC.43.5.1042; Qiu XY, 1999, J BIOL CHEM, V274, P36465, DOI 10.1074/jbc.274.51.36465; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; ROCK CO, 1979, J BIOL CHEM, V254, P7123; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; Sauton B, 1912, CR HEBD ACAD SCI, V155, P860; Slayden RA, 1996, ANTIMICROB AGENTS CH, V40, P2813, DOI 10.1128/AAC.40.12.2813; Snider Dixie E. Jr., 1994, P3; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; TSAY JT, 1992, J BIOL CHEM, V267, P6807; vanSoolingen D, 1997, INT J SYST BACTERIOL, V47, P1236, DOI 10.1099/00207713-47-4-1236; *WHO, 1997, ANTITUBERCULOSIS DRU; WOOD WI, 1977, J BIOL CHEM, V252, P5745	47	159	169	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28201	28207						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10840036				2022-12-25	WOS:000089197100089
J	Huston, E; Beard, M; McCallum, F; Pyne, NJ; Vandenabeele, P; Scotland, G; Houslay, MD				Huston, E; Beard, M; McCallum, F; Pyne, NJ; Vandenabeele, P; Scotland, G; Houslay, MD			The cAMP-specific phosphodiesterase PDE4A5 is cleaved downstream of its SH3 interaction domain by caspase-3 - Consequences for altered intracellular distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-SPECIFIC PHOSPHODIESTERASE; CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; DEPENDENT PROTEIN-KINASE; N-TERMINAL DOMAIN; MONOPHOSPHATE PHOSPHODIESTERASE; MEMBRANE ASSOCIATION; RPDE-6 RNPDE4A5; SPLICE VARIANT; PC12 CELLS; APOPTOSIS	The unique N-terminal region of the cAMP-specific phosphodiesterase PDE4A5, which confers an ability to bind to certain protein SH3 domains, is cleaved during apoptosis in both Rat-1 fibroblasts and PC12 cells. Cleavage was abolished by the caspase-3-selective inhibitor, z-DEVD-CHO but not the caspase-1 selective inhibitor, z-YVAD-CHO, Caspase-3 treatment of PDE4A5, expressed either transiently in COS cells or generated in vitro by coupled transcription translation, generated a similar cleavage product of 100 kDa compared with the native 110-kDa PDE4A5. This product could be detected immunochemically with an antibody raised to a C-terminal PDE4A5 peptide but not an antibody raised to the N terminus of PDE4A5, indicating that caspase-3 caused N-terminal cleavage of PDE4A5. Deletion of the putative caspase-3 cleavage site, (69)DAVD(72), in PDE4A5, or generation of either the D72A or the D69A mutants, ablated the ability of caspase-3 to cause cleavage. The N-terminal truncate PDE4A5-Delta P3 was engineered to mimic the caspase-cleaved product of PDE4A5. This showed altered catalytic activity and, unlike PDE4A5, was unable to interact with the SH3 domain of the tyrosyl kinase, LYN, Although both PDE4A5 and PDE4A5-Delta P3 mere localized at cell cortical regions (ruffles), the distinct perinuclear association noted for both PDE4A5 and LYN mas not seen for PDE4A5-Delta P3. Staurosporine-induced apoptosis caused a marked redistribution of PDE4A5 but not PDE4A8 in stably transfected Rat-1 cells. The PDE4-selective inhibitor, rolipram together with the adenylyl cyclase activator forskolin, caused a synergistic increase in the apoptosis of Rat-1 cells. Overexpression of PDE4A5 in Rat-1 cells protected against staurosporine-induced apoptosis in contrast to overexpression of PDE4A8, which potentiated apoptosis, PDE4A5 may be the sole PDE4 family member to provide a substrate for caspase-3 cleavage and this action serves to remove the SH3 binding domain that is unique to this isoform within the PDE4A family and to alter its intracellular targeting.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland; Univ Strathclyde, Strathclyde Inst Biomed Sci, Dept Physiol & Pharmacol, Glasgow G4 0NR, Lanark, Scotland; State Univ Ghent VIB, Dept Mol Biol, Mol Signalling Lab, B-9000 Ghent, Belgium	University of Glasgow; University of Strathclyde; Flanders Institute for Biotechnology (VIB); Ghent University	Houslay, MD (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	m.houslay@bio.gla.ac.uk	Houslay, Miles D/A-6825-2011; Vandenabeele, Peter/AAD-5793-2022; Houslay, Miles/AAM-5281-2020; Vandenabeele, Peter/C-8597-2009	Vandenabeele, Peter/0000-0002-6669-8822; Pyne, Nigel/0000-0002-5657-4578; Houslay, Miles/0000-0002-3826-8091				BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BERRIDGE MV, 1993, EXP HEMATOL, V21, P269; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CONTI M, 1995, BIOCHEMISTRY-US, V34, P7979, DOI 10.1021/bi00025a003; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; Hale AJ, 1996, EUR J BIOCHEM, V236, P1, DOI 10.1111/j.1432-1033.1996.00001.x; Houslay MD, 1997, BIOCHEM SOC T, V25, P374, DOI 10.1042/bst0250374; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Huston E, 1996, J BIOL CHEM, V271, P31334, DOI 10.1074/jbc.271.49.31334; Ivins KJ, 1999, J BIOL CHEM, V274, P2107, DOI 10.1074/jbc.274.4.2107; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; Kim DH, 1998, BLOOD, V92, P2484, DOI 10.1182/blood.V92.7.2484.2484_2484_2494; Kim JE, 1999, J NEUROCHEM, V72, P2456, DOI 10.1046/j.1471-4159.1999.0722456.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LOBBAN M, 1994, BIOCHEM J, V304, P399, DOI 10.1042/bj3040399; LOMO J, 1995, J IMMUNOL, V154, P1634; MacKenzie SJ, 1998, P NATL ACAD SCI USA, V95, P3549, DOI 10.1073/pnas.95.7.3549; MANGANIELLO VC, 1995, CELL SIGNAL, V7, P445, DOI 10.1016/0898-6568(95)00017-J; MARCHMONT RJ, 1980, BIOCHEM J, V187, P381, DOI 10.1042/bj1870381; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; McPhee I, 1999, J BIOL CHEM, V274, P11796, DOI 10.1074/jbc.274.17.11796; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; Murphy BJ, 1998, TRENDS CARDIOVAS MED, V8, P89, DOI 10.1016/S1050-1738(97)00131-X; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OConnell JC, 1996, BIOCHEM J, V318, P255, DOI 10.1042/bj3180255; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; POOLEY L, 1997, BIOCHEM J, V271, P177; Rogers DF, 1998, TRENDS PHARMACOL SCI, V19, P160, DOI 10.1016/S0165-6147(98)01198-5; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCOTLAND G, 1995, BIOCHEM J, V308, P673, DOI 10.1042/bj3080673; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; Souness JE, 1997, CELL SIGNAL, V9, P227, DOI 10.1016/S0898-6568(96)00173-8; Srinivasula SM, 1998, J BIOL CHEM, V273, P10107, DOI 10.1074/jbc.273.17.10107; Talanian RV, 1997, J BIOL CHEM, V272, P9677; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; Yao RJ, 1997, J BIOL CHEM, V272, P18261, DOI 10.1074/jbc.272.29.18261; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zhu WH, 1998, LIFE SCI, V63, P265, DOI 10.1016/S0024-3205(98)00270-7	48	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28063	28074						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10829034				2022-12-25	WOS:000089197100072
J	Stad, R; Ramos, YFM; Little, N; Grivell, S; Attema, J; van der Eb, AJ; Jochemsen, AG				Stad, R; Ramos, YFM; Little, N; Grivell, S; Attema, J; van der Eb, AJ; Jochemsen, AG			Hdmx stabilizes Mdm2 and p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERM-CELL TUMORS; P53-BINDING PROTEIN; DEGRADATION; EXPRESSION; APOPTOSIS; DOMAINS; PRODUCT; GROWTH; GENES	The Mdma protein is a key regulator of p53 activity and stability. Upon binding, Mdma inhibits the transcription regulatory activity of p53 and promotes its rapid degradation. In this study we investigated the effect of the human Mdm2 homologue Hdmx on p53 stability. We found that Hdmx does not target p53 for degradation, although, like Mdm2, it inhibits p53-mediated transcription activation. On the contrary, Hdmx was found to counteract the degradation of p53 by Mdma, and to stabilize both p53 and Mdma, The RING finger of Hdmx was found to be necessary and sufficient for this stabilization, and it probably involves hetero-oligomerization with the RING finger of Mdm2, which may lead to inhibition of Mdma's ubiquitin ligase activity. However, Hdmx does not relieve the inhibition by Mdm2 of transcription activation by p53, probably due to the formation of a trimeric complex consisting of Hdmx, Mdm2, and p53, We propose a model in which Hdmx secures a pool of largely inactive p53, which, upon the induction of stress, can be quickly activated.	Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Jochemsen, AG (corresponding author), Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, POB 9503, NL-2300 RA Leiden, Netherlands.		Ramos, Yolande F. M./C-3774-2018	Ramos, Yolande F. M./0000-0003-1459-413X				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; EL DW, 1993, CELL, V75, P817; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Guillou L, 1996, AM J PATHOL, V149, P1221; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; STEEGENGA WT, 1995, ONCOGENE, V11, P49; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; van der Eb A J, 1980, Methods Enzymol, V65, P826	28	122	131	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28039	28044						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10827196				2022-12-25	WOS:000089197100069
J	Kim, Y; Shin, J; Li, RB; Cheong, C; Kim, K; Kim, S				Kim, Y; Shin, J; Li, RB; Cheong, C; Kim, K; Kim, S			A novel anti-tumor cytokine contains an RNA binding motif present in aminoacyl-tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING POLYPEPTIDE-II; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PROTEIN; RESOLUTION; MOLSCRIPT; PRECURSOR; SEQUENCE; COMPLEX	Endothelial monocyte-activating polypeptide II (EMAP II) is a novel pro apoptotic cytokine that shares sequence homology with the C-terminal regions of several tRNA synthetases, Pro-EMAP II, the precursor of EMAP II, is associated with the multi-tRNA synthetase complex and facilitates aminoacylation activity. The structure of human EMAP II, solved at 1.8 Angstrom resolution, revealed the oligomer-binding fold for binding different tRNAs and a domain that is structurally homologous to other chemokines. The similar structures to the RNA binding motif of EMAP II was previously observed in the anticodon binding domain of yeast Asp-tRNA synthetase (AspRSSC) and the B2 domain of Thermus thermophilus Phe tRNA synthetase. The RNA binding pattern of EMAP II is likely to be nonspecific, in contrast to the AspRSSC, The peptide sequence that is responsible for cytokine activity is located, for the most part, in the pi strand. It is divided into two regions by a neighboring loop.	Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; Yeungnam Univ, Sch Chem Engn, Kyongsan 712749, South Korea; Korea Basic Sci Inst, Magnet Resonance Team, Eon Dong Daejon 305333, South Korea; Sungkyunkwan Univ, Natl Creat Res Initiat Ctr ARS Network, Suwon 440746, South Korea	University of Washington; University of Washington Seattle; Yeungnam University; Korea Basic Science Institute (KBSI); Sungkyunkwan University (SKKU)	Kim, Y (corresponding author), Univ Washington, Dept Biol Struct, Hlth Sci Bldg,K-428,Box 357742, Seattle, WA 98195 USA.	ykim1@u.washington.edu	Cheong, Chaejoon/GWC-3135-2022; Kim, Sunghoon/AAE-8314-2020; Kim, Youngsoo/D-6046-2012					Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Behrensdorf HA, 2000, FEBS LETT, V466, P143, DOI 10.1016/S0014-5793(99)01777-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; Cusack S, 1996, EMBO J, V15, P6321, DOI 10.1002/j.1460-2075.1996.tb01022.x; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Goldgur Y, 1997, STRUCTURE, V5, P59, DOI 10.1016/S0969-2126(97)00166-4; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HYNES TR, 1991, PROTEINS, V10, P92, DOI 10.1002/prot.340100203; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAO J, 1994, J BIOL CHEM, V269, P9774; KIM S, 1993, BIOCHEMISTRY-US, V32, P13026, DOI 10.1021/bi00211a011; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; MALKOWSKI MG, 1995, J BIOL CHEM, V270, P7077, DOI 10.1074/jbc.270.13.7077; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morales AJ, 1999, EMBO J, V18, P3475, DOI 10.1093/emboj/18.12.3475; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCMINNEL P, 1995, J MOL EVOL, V40, P531; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; STEIN PE, 1992, NATURE, V355, P748, DOI 10.1038/355748a0; Tas MPR, 1996, INT J BIOCHEM CELL B, V28, P837, DOI 10.1016/1357-2725(96)00038-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Wakasugi K, 1999, J BIOL CHEM, V274, P23155, DOI 10.1074/jbc.274.33.23155; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Whelihan EF, 1997, EMBO J, V16, P2968, DOI 10.1093/emboj/16.10.2968; Wilken J, 1999, CHEM BIOL, V6, P43, DOI 10.1016/S1074-5521(99)80019-2	37	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27062	27068						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10852899				2022-12-25	WOS:000089144800054
J	Dube, P; DeCostanzo, A; Konopka, JB				Dube, P; DeCostanzo, A; Konopka, JB			Interaction between transmembrane domains five and six of the alpha-factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; FACTOR PHEROMONE RECEPTOR; DOMINANT-NEGATIVE MUTATIONS; MEMBRANE-SPANNING SEGMENT; DOPAMINE D2 RECEPTOR; BINDING-SITE CREVICE; SACCHAROMYCES-CEREVISIAE; SCANNING MUTAGENESIS; LIGAND SPECIFICITY; PLASMA-MEMBRANE	The a-factor pheromone receptor (STE2) activates a G protein signal pathway that induces conjugation of the yeast Saccharomyces cerevisiae, Previous studies implicated the third intracellular loop of this receptor in G; protein activation. Therefore, the roles of transmembrane domains five and six (TMD5 and -6) that bracket the third intracellular loop were analyzed by scanning mutagenesis in which each residue was substituted with cysteine. Out of 42 mutants examined, four constitutive mutants and two strong loss-of-function mutants were identified, Double mutants combining Cys substitutions in TMD5 and TMD6 gave a broader range of phenotypes, Interestingly, a V223C mutation in TMD5 caused constitutive activity when combined with the L247C, L248C, or S251C mutations in TMD6, Also, the L226C mutation in TMD5 caused constitutive activity when combined with either the M250C or S251C mutations in TMD6. The residues affected by these mutations are predicted to fall on one side of their respective helices, suggesting that they may interact. In support of this, cysteines substituted at position 223 in TMD5 and position 247 in TMD6 formed a disulfide bond, providing the first direct evidence of an interaction between these transmembrane domains in the ct-factor receptor. Altogether, these results identify an important region of interaction between conserved hydrophobic regions at the base of TMD5 and TMD6 that is required for the proper regulation of receptor signaling.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Mol & Cellular Biol Program, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Konopka, JB (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.	james.konopka@sunysb.edu		Konopka, James/0000-0001-5989-4086	NCI NIH HHS [T32CAO9176] Funding Source: Medline; NIGMS NIH HHS [R01 GM055107, GM55107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055107] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abel MG, 1998, BBA-MOL CELL RES, V1448, P12, DOI 10.1016/S0167-4889(98)00109-8; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Bukusoglu G, 1996, MOL CELL BIOL, V16, P4818; BURKHOLDER AC, 1985, NUCLEIC ACIDS RES, V13, P8463, DOI 10.1093/nar/13.23.8463; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; Chen QJ, 1996, MOL CELL BIOL, V16, P247; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; CLARK CD, 1994, J BIOL CHEM, V269, P8831; Colson AO, 1998, MOL PHARMACOL, V54, P968, DOI 10.1124/mol.54.6.968; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Dosil M, 1998, MOL CELL BIOL, V18, P5981, DOI 10.1128/MCB.18.10.5981; Dube P, 1998, MOL CELL BIOL, V18, P7205, DOI 10.1128/MCB.18.12.7205; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Frillingos S, 1997, BIOCHEMISTRY-US, V36, P14284, DOI 10.1021/bi972314d; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; Fu DY, 1996, BIOCHEMISTRY-US, V35, P11278, DOI 10.1021/bi960928x; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Javitch JA, 1998, BIOCHEMISTRY-US, V37, P998, DOI 10.1021/bi972241y; Konopka JB, 1996, P NATL ACAD SCI USA, V93, P6764, DOI 10.1073/pnas.93.13.6764; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; Leavitt LM, 1999, MOL GEN GENET, V261, P917, DOI 10.1007/s004380051039; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Lin ZL, 1997, PROTEIN ENG, V10, P501, DOI 10.1093/protein/10.5.501; Mahanty SK, 1999, CELL, V98, P501, DOI 10.1016/S0092-8674(00)81978-9; MARSH L, 1988, P NATL ACAD SCI USA, V85, P3855, DOI 10.1073/pnas.85.11.3855; MARSH L, 1992, MOL CELL BIOL, V12, P3959, DOI 10.1128/MCB.12.9.3959; Martin NP, 1999, BIOCHEMISTRY-US, V38, P682, DOI 10.1021/bi982062w; MILLER JH, 1972, EXPT MOL GENETICS, P325; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; Pryciak PM, 1998, GENE DEV, V12, P2684, DOI 10.1101/gad.12.17.2684; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; SCHANDEL KA, 1994, MOL CELL BIOL, V14, P7245, DOI 10.1128/MCB.14.11.7245; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SEN M, 1994, J BIOL CHEM, V269, P968; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; STEFAN CJ, 1994, MOL CELL BIOL, V14, P3339, DOI 10.1128/MCB.14.5.3339; Stefan CJ, 1998, MOL BIOL CELL, V9, P885, DOI 10.1091/mbc.9.4.885; Struthers M, 1999, BIOCHEMISTRY-US, V38, P6597, DOI 10.1021/bi9902384; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002; Zeng FY, 1999, J BIOL CHEM, V274, P16629, DOI 10.1074/jbc.274.23.16629	46	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26492	26499		10.1074/jbc.M002767200	http://dx.doi.org/10.1074/jbc.M002767200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10846179	hybrid			2022-12-25	WOS:000088999700084
J	Hurne, AM; Chai, CLL; Waring, P				Hurne, AM; Chai, CLL; Waring, P			Inactivation of rabbit muscle creatine kinase by reversible formation of an internal disulfide bond induced by the fungal toxin gliotoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE; ACTIVE-SITE; THIOL; MITOCHONDRIA; APOPTOSIS; EPIPOLYTHIODIOXOPIPERAZINES; DENATURATION; SUBUNIT	The biological activity of gliotoxin is dependent on the presence of a strained disulfide bond that can react with accessible cysteine residues on proteins. Rabbit muscle creatine kinase contains 4 cysteines per 42-kDa subunit and is active in solution as a dimer. Only Cys-282 has been identified as essential for activity. Modification of this residue results in loss of activity of the enzyme. Treatment of creatine kinase with gliotoxin resulted in a time-dependent loss of activity abrogated in the presence of reducing agents. Activity was restored when the inactivated enzyme was treated with reducing agents. Inactivation of creatine kinase by gliotoxin was accompanied by the formation of a 37-kDa form of the enzyme. This oxidized form of creatine kinase was rapidly reconverted to the 42-kDa species by the addition of reducing agents concomitant with restoration of activity. A 1:1 mixture of the oxidized and reduced monomer forms of creatine kinase as shown on polyacrylamide gel electrophoresis was equivalent to the activity of the fully reduced form of the enzyme consistent with only one reduced monomer of the dimer necessary for complete activity. Conversion of the second monomeric species of the dimer to the oxidized form by gliotoxin correlated with loss of activity. Our data are consistent with gliotoxin inducing the formation of an internal disulfide bond in creatine kinase by initially binding and possibly activating a cysteine residue on the protein, followed by reaction with a second neighboring thiol. The recently published crystal structure of creatine kinase suggests the disulfide is formed between Cys-282 and Cys-73.	Australian Natl Univ, John Curtin Sch Med Res, Div Cell Biol & Immunol, Canberra, ACT 2601, Australia; Australian Natl Univ, The Faculities, Dept Chem, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research; Australian National University	Waring, P (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Cell Biol & Immunol, Mills Rd, Canberra, ACT 2601, Australia.		Chai, Christina L/A-3133-2014	Chai, Christina/0000-0002-9199-851X				BEAVER JP, 1994, IMMUNOL CELL BIOL, V72, P489, DOI 10.1038/icb.1994.73; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; BODEY G, 1992, EUR J CLIN MICROBIOL, V11, P99, DOI 10.1007/BF01967060; BUECHTER DD, 1992, J BIOL CHEM, V267, P2173; CLOTTES E, 1994, BBA-PROTEIN STRUCT M, V1209, P171, DOI 10.1016/0167-4838(94)90181-3; DAWSON DM, 1965, BIOCHEM BIOPH RES CO, V21, P346, DOI 10.1016/0006-291X(65)90200-7; DECLERCQ E, 1978, BIOCHEM PHARMACOL, V27, P635, DOI 10.1016/0006-2952(78)90497-5; DEGANI Y, 1979, BIOCHEMISTRY-US, V18, P5917, DOI 10.1021/bi00593a024; FURTER R, 1993, BIOCHEMISTRY-US, V32, P7022, DOI 10.1021/bi00078a030; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GROSSMAN SH, 1986, ARCH BIOCHEM BIOPHYS, V248, P234, DOI 10.1016/0003-9861(86)90421-2; HAMES BD, GEL ELECTROPHORESIS, P1; HARA M, 1995, P NATL ACAD SCI USA, V92, P3333, DOI 10.1073/pnas.92.8.3333; Hou LX, 1996, BIOCHIMIE, V78, P219, DOI 10.1016/0300-9084(96)82184-5; HOU LX, 1994, BBA-PROTEIN STRUCT M, V1205, P83, DOI 10.1016/0167-4838(94)90095-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLIE JW, 1993, CANCER RES, V53, P3172; MULLBACHER A, 1986, MOL IMMUNOL, V23, P231, DOI 10.1016/0161-5890(86)90047-7; MUNDAY R, 1987, J APPL TOXICOL, V7, P17, DOI 10.1002/jat.2550070105; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; PRICE NC, 1976, BIOCHIM BIOPHYS ACTA, V445, P364, DOI 10.1016/0005-2744(76)90090-5; Rao JK, 1998, FEBS LETT, V439, P133; ROSSI AM, 1990, J BIOL CHEM, V265, P5258; SCHWEIZER M, 1994, BIOCHEMISTRY-US, V33, P13401, DOI 10.1021/bi00249a028; Silva JP, 1997, REDOX REP, V3, P331, DOI 10.1080/13510002.1997.11747131; SUTTON P, 1994, INFECT IMMUN, V62, P1192, DOI 10.1128/IAI.62.4.1192-1198.1994; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; Tanaka N, 1997, BBA-PROTEIN STRUCT M, V1339, P226, DOI 10.1016/S0167-4838(97)00003-4; TANZER ML, 1959, J BIOL CHEM, V234, P3201; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1984, J BIOL CHEM, V259, P5238; WANG XC, 1990, BIOCHIM BIOPHYS ACTA, V1039, P313, DOI 10.1016/0167-4838(90)90264-G; WANG XC, 1994, SCI CHINA SER B, V37, P964; WANG ZX, 1988, BIOCHEMISTRY-US, V27, P5095, DOI 10.1021/bi00414a022; WARING P, 1994, TOXICON, V32, P491, DOI 10.1016/0041-0101(94)90301-8; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; WARING P, 1995, BIOCHEM PHARMACOL, V49, P1195, DOI 10.1016/0006-2952(95)00039-3; WARING P, 1988, MED RES REV, V8, P499, DOI 10.1002/med.2610080404; Watts D. C., 1973, ENZYMES, V8, P384; YAO QZ, 1984, BIOCHEMISTRY-US, V23, P2740, DOI 10.1021/bi00307a032	40	55	58	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25202	25206		10.1074/jbc.M002278200	http://dx.doi.org/10.1074/jbc.M002278200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827185	hybrid			2022-12-25	WOS:000088849400023
J	Krise, JP; Sincock, PM; Orsel, JG; Pfeffer, SR				Krise, JP; Sincock, PM; Orsel, JG; Pfeffer, SR			Quantitative analysis of TIP47-receptor cytoplasmic domain interactions - Implications for endosome-to-trans Golgi network trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; CELL-SURFACE; INTRACELLULAR TRAFFICKING; PROPROTEIN CONVERTASE; ADAPTER COMPLEXES; LOCALIZATION; TGN38; FURIN; PROTEIN; NEF	TIP47 (tail-interacting protein of 47 kDa) binds to the cytoplasmic domains of the cation-independent and cation-dependent mannose 6-phosphate receptors and is required for their transport from late endosomes to the trans Golgi network in vitro and in vivo. We report here a quantitative analysis of the interaction of recombinant TIP47 with mannose 6-phosphate receptor cytoplasmic domains. Recombinant TIP47 binds more tightly to the cation-independent mannose 6-phosphate receptor (K-D = 1 mu M) than to the cation-dependent mannose 6-phosphate receptor (K-D = 3 mu M) In addition, TIP47 fails to interact with the cytoplasmic domains of the hormone-processing enzymes, furin, phosphorylated furin, and metallocarboxypeptidase D, as well as the cytoplasmic domain of TGN38, proteins that are also transported from endosomes to the trans Golgi network. Although these proteins failed to bind TIP47, furin and TGN38 were readily recognized by the clathrin adaptor, AP-2. These data suggest that TIP47 recognizes a very select set of cargo molecules. Moreover, our data suggest unexpectedly that furin, TGN38, and carboxypeptidase D may use a distinct vesicular carrier and perhaps a distinct route for transport between endosomes and the trans Golgi network.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Stanford University	Pfeffer, SR (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.			Orsel, Joke/0000-0003-0303-4735	NIDDK NIH HHS [DK37336] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; Diaz E, 1997, J CELL BIOL, V138, P283, DOI 10.1083/jcb.138.2.283; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; GODA Y, 1988, CELL, V55, P309, DOI 10.1016/0092-8674(88)90054-2; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; Itin C, 1997, J BIOL CHEM, V272, P27737, DOI 10.1074/jbc.272.44.27737; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Le Gall S, 1998, IMMUNITY, V8, P483, DOI 10.1016/S1074-7613(00)80553-1; Liu GP, 1997, J CELL BIOL, V139, P1719, DOI 10.1083/jcb.139.7.1719; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Mallard F, 1998, J CELL BIOL, V143, P973, DOI 10.1083/jcb.143.4.973; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; Oldridge J, 1998, TRENDS CELL BIOL, V8, P302, DOI 10.1016/S0962-8924(98)01318-X; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Piguet V, 1999, CELL, V97, P63, DOI 10.1016/S0092-8674(00)80715-1; Piguet V, 1998, EMBO J, V17, P2472, DOI 10.1093/emboj/17.9.2472; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Varlamov O, 1998, J CELL SCI, V111, P877; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WONG SH, 1993, J BIOL CHEM, V268, P22853	40	49	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25188	25193		10.1074/jbc.M001138200	http://dx.doi.org/10.1074/jbc.M001138200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829017	hybrid			2022-12-25	WOS:000088849400021
J	Strack, S; Robison, AJ; Bass, MA; Colbran, RJ				Strack, S; Robison, AJ; Bass, MA; Colbran, RJ			Association of calcium/calmodulin-dependent kinase II with developmentally regulated splice variants of the postsynaptic density protein densin-180	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE RECEPTORS; PHOSPHORYLATION; TRANSLOCATION; LOCALIZATION; FAMILY; BRAIN	In a continuing search for proteins that target calcium/calmodulin-dependent protein kinase II (CaMKII) to postsynaptic density (PSD) substrates important in synaptic plasticity, we showed that the PSD protein densin-180 binds CaMKII, Four putative splice variants (A-D) of the cytosolic tail of densin-180 are shown to be differentially expressed during brain development. Densin-180 splicing affects CaMKII phosphorylation of specific serine residues. Variants A, B, and D, but not C, bind CaMKII stoichiometrically and with high affinity, mediated by a differentially spliced domain. Densin-180 differs from the previously identified CaMKII-binding protein NR2B in that binding does not strictly require CaMKII autophosphorylation. Binding of densin-180 and NR2B to CaMKII is noncompetitive, indicating different interaction sites on CaMKII. Expression of the membrane-targeted CaMKII-binding domain of densin-180 confers membrane localization to coexpressed CaMKII without requiring calcium mobilization, suggesting that densin-180 plays a role in the constitutive association of CaMKII with PSDs.	Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Colbran, RJ (corresponding author), Vanderbilt Univ, Dept Mol Physiol & Biophys, Rm 762,MRB-1, Nashville, TN 37232 USA.	Roger.Colbran@mcmail.vanderbilt.edu	Colbran, Roger/AAU-7708-2021; Robison, Alfred J/P-8521-2018	Colbran, Roger/0000-0001-7401-8244; Robison, Alfred J/0000-0002-4150-9570; Strack, Stefan/0000-0002-6175-7280	NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NINDS NIH HHS [NS37508] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037508] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Apperson ML, 1996, J NEUROSCI, V16, P6839; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Elgersma Y, 1999, CURR OPIN NEUROBIOL, V9, P209, DOI 10.1016/S0959-4388(99)80029-4; ERONDU NE, 1985, J NEUROSCI, V5, P3270; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; Strack S, 2000, J BIOL CHEM, V275, P23798, DOI 10.1074/jbc.M001471200; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; Strack S, 1998, J BIOL CHEM, V273, P20689, DOI 10.1074/jbc.273.33.20689; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2; Zlatkine P, 1997, J CELL SCI, V110, P673	16	74	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25061	25064		10.1074/jbc.C000319200	http://dx.doi.org/10.1074/jbc.C000319200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827168	hybrid			2022-12-25	WOS:000088849400003
J	Ma, WP; Kaiser, MW; Lyamicheva, N; Schaefer, JJ; Allawi, HT; Takova, T; Neri, BP; Lyamichev, VI				Ma, WP; Kaiser, MW; Lyamicheva, N; Schaefer, JJ; Allawi, HT; Takova, T; Neri, BP; Lyamichev, VI			RNA template-dependent 5 ' nuclease activity of Thermus aquaticus and Thermus thermophilus DNA polymerases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LARGE FRAGMENT; CRYSTAL-STRUCTURE; KLENOW FRAGMENT; GENOMIC DNA; I KLENOW; REPLICATION; CLEAVAGE; IDENTIFICATION; EUBACTERIAL	DNA replication and repair require a specific mechanism to join the 3'- and 5'-ends of two strands to maintain DNA continuity. In order to understand the details of this process, we studied the activity of the 5' nucleases with substrates containing an RNA template strand. By comparing the eubacterial and archaeal 5' nucleases, we show that the polymerase domain of the eubacterial enzymes is critical for the activity of the 5' nuclease domain on RNA containing substrates. Analysis of the activity of chimeric enzymes between the DNA polymerases from Thermus aquaticus (TaqPol) and Thermus thermophilus (TthPol) reveals two regions, in the "thumb" and in the "palm" subdomains, critical for RNA-dependent 5' nuclease activity. There are two critical amino acids in those regions that are responsible for the high activity of TthPol on RNA containing substrates. Mutating glycine 418 and glutamic acid 507 of TaqPol to lysine and glutamine, respectively, increases its RNA-dependent 5' nuclease activity 4-10-fold, Furthermore, the RNA-dependent DNA polymerase activity is controlled by a completely different region of TaqPol and TthPol, and mutations in this region do not affect the 5' nuclease activity. The results presented here suggest a novel substrate binding mode of the eubacterial DNA polymerase enzymes, called a 5' nuclease mode, that is distinct from the polymerizing and editing modes described previously. The application of the enzymes with improved RNA-dependent 5' nuclease activity for RNA detection using the invasive signal amplification assay is discussed.	Third Wave Technol Inc, Madison, WI 53719 USA		Ma, WP (corresponding author), Third Wave Technol Inc, 502 S Rosa Rd, Madison, WI 53719 USA.							BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; Griffin TJ, 1999, P NATL ACAD SCI USA, V96, P6301, DOI 10.1073/pnas.96.11.6301; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Kaiser MW, 1999, J BIOL CHEM, V274, P21387, DOI 10.1074/jbc.274.30.21387; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; Kwiatkowski RW, 1999, MOL DIAGN, V4, P353, DOI 10.1016/S1084-8592(99)80012-5; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; LUNDQUIST RC, 1982, CELL, V31, P53, DOI 10.1016/0092-8674(82)90404-4; Lyamichev V, 1999, NAT BIOTECHNOL, V17, P292, DOI 10.1038/7044; Lyamichev V, 1999, P NATL ACAD SCI USA, V96, P6143, DOI 10.1073/pnas.96.11.6143; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MAY LT, 1986, P NATL ACAD SCI USA, V83, P8957, DOI 10.1073/pnas.83.23.8957; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PANDEY VN, 1993, EUR J BIOCHEM, V214, P59, DOI 10.1111/j.1432-1033.1993.tb17896.x; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; Ryan D, 1999, MOL DIAGN, V4, P135, DOI 10.1016/S1084-8592(99)80037-X; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; WAGA S, 1994, J BIOL CHEM, V269, P10923	31	15	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24693	24700		10.1074/jbc.M002268200	http://dx.doi.org/10.1074/jbc.M002268200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827184	hybrid			2022-12-25	WOS:000088683300063
J	Meininghaus, M; Chapman, RD; Horndasch, M; Eick, D				Meininghaus, M; Chapman, RD; Horndasch, M; Eick, D			Conditional expression of RNA polymerase II in mammalian cells - Deletion of the carboxyl-terminal domain of the large subunit affects early steps in transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; C-MYC GENE; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; ELONGATION-FACTOR; SPLICING FACTORS; LYMPHOMA CELLS; HIV-1 TAT; IN-VITRO; P-TEFB	The carboxyl-terminal domain (CTD) of the large subunit of mammalian RNA polymerase II contains 52 repeats of a heptapeptide that is the target of a variety of kinases, The hyperphosphorylated CTD recruits important factors for mRNA capping, splicing, and 3'-processing. The role of the CTD for the transcription process in vivo, however, is not yet clear. We have conditionally expressed an alpha-amanitin-resistant large subunit with an almost entirely deleted CTD (LS*Delta 5) in B-cells, These cells have a defect in global transcription of cellular genes in the presence of a-amanitin. Moreover, pol II harboring LS*Delta 5 failed to transcribe up to the promoter-proximal pause sites in the hsp70A and c-fos gene promoters. The results indicate that the CTD is already required for steps that occur before promoter-proximal pausing and maturation of mRNA.	GSF, Res Ctr Environm & Hlth, Inst Clin Mol Biol & Tumor Genet, D-81377 Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Eick, D (corresponding author), GSF, Res Ctr Environm & Hlth, Inst Clin Mol Biol & Tumor Genet, Marchioninistr 25, D-81377 Munich, Germany.							ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Bourquin JP, 1997, NUCLEIC ACIDS RES, V25, P2055, DOI 10.1093/nar/25.11.2055; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; COPPOLA JA, 1983, P NATL ACAD SCI-BIOL, V80, P1251, DOI 10.1073/pnas.80.5.1251; Corden JL, 1997, TRENDS BIOCHEM SCI, V22, P413, DOI 10.1016/S0968-0004(97)01125-0; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hirose Y, 1998, NATURE, V395, P93, DOI 10.1038/25786; Hirose Y, 1999, GENE DEV, V13, P1234, DOI 10.1101/gad.13.10.1234; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Kim E, 1997, J CELL BIOL, V136, P19, DOI 10.1083/jcb.136.1.19; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KUO MT, 1995, J CELL PHYSIOL, V164, P132, DOI 10.1002/jcp.1041640117; Li BY, 1996, MOL CELL BIOL, V16, P5433; Litingtung Y, 1999, MOL GEN GENET, V261, P100, DOI 10.1007/s004380050946; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; McNeil JB, 1998, GENE DEV, V12, P2510, DOI 10.1101/gad.12.16.2510; Meininghaus M, 1999, FEBS LETT, V446, P173, DOI 10.1016/S0014-5793(99)00184-2; MILNER CM, 1990, IMMUNOGENETICS, V32, P242; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; Otero G, 1999, MOL CELL, V3, P109, DOI 10.1016/S1097-2765(00)80179-3; Patturajan M, 1998, MOL CELL BIOL, V18, P2406, DOI 10.1128/MCB.18.4.2406; Pinaud S, 1998, J MOL BIOL, V280, P785, DOI 10.1006/jmbi.1998.1905; PLET A, 1995, ONCOGENE, V10, P319; Raschke EE, 1999, J IMMUNOL, V163, P4375; Reines D, 1999, CURR OPIN CELL BIOL, V11, P342, DOI 10.1016/S0955-0674(99)80047-7; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; Sambrook J., 2002, MOL CLONING LAB MANU; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCHEER U, 1978, CELL, V13, P535, DOI 10.1016/0092-8674(78)90327-6; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; SEISER C, 1995, J BIOL CHEM, V270, P29400, DOI 10.1074/jbc.270.49.29400; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; WOLF DA, 1995, NUCLEIC ACIDS RES, V23, P3373, DOI 10.1093/nar/23.17.3373; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yamaguchi Y, 1998, GENES CELLS, V3, P9, DOI 10.1046/j.1365-2443.1998.00162.x; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	55	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24375	24382		10.1074/jbc.M001883200	http://dx.doi.org/10.1074/jbc.M001883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10825165	hybrid			2022-12-25	WOS:000088683300019
J	Russell-Harde, D; Wagner, TC; Rani, MRS; Vogel, D; Colamonici, O; Ransohoff, RM; Majchrzak, B; Fish, E; Perez, HD; Croze, E				Russell-Harde, D; Wagner, TC; Rani, MRS; Vogel, D; Colamonici, O; Ransohoff, RM; Majchrzak, B; Fish, E; Perez, HD; Croze, E			Role of the intracellular domain of the human type I interferon receptor 2 chain (IFNAR2c) in interferon signaling - Expression of IFNAR2c truncation mutants in U5A cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BETA RECEPTOR; JAK-STAT PATHWAY; TYROSINE PHOSPHORYLATION; IFN RECEPTOR; SUBUNIT; GENE; IDENTIFICATION; KINASE; ACTIVATION; CLONING	A human cell line (USA) lacking the type I interferon (IFN) receptor chain 2 (IFNAR2c) was used to determine the role of the IFNAR2c cytoplasmic domain in regulating IFN-dependent STAT activation, interferon-stimulated gene factor 3 (ISGF3) and c-sis-inducible factor (SIF) complex formation, gene expression, and antiproliferative effects, A panel of U5A cells expressing truncation mutants of IFNAR2c on their cell surface were generated for study. Janus kinase (JAK) activation was detected in all mutant cell lines; however, STAT1 and STATE activation was observed only in U5A cells expressing full-length IFNAR2c and IFNAR2c truncated at residue 462 (R2.462). IFNAR2c mutants truncated at residues 417 (R2.417) and 346 (R2.346) or IFNAR2c mutant lacking tyrosine residues in its cytoplasmic domain (R2.Y-F) render the receptor inactive. A similar pattern was observed for IFN-inducible STAT activation, STAT complex formation, and STAT-DNA binding. Consistent with these data, IFN-inducihle gene expression was ablated in U5A, R2.Y-F, R2.417, and R2.346 cell lines, The implications are that tyrosine phosphorylation and the 462-417 region of IFNAR2c are independently obligatory for receptor activation. In addition, the distal 53 amino acids of the intracellular domain of IFNAR2c are not required for IFN-receptor mediated STAT activation, ISFG3 or SIF complex formation, induction of gene expression, and inhibition of thymidine incorporation. These data demonstrate for the first time that both tyrosine phosphorylation and a specific domain of IFNAR2c are required in human cells for IFN-dependent coupling of JAK activation to STAT phosphorylation, gene induction, and antiproliferative effects. In addition, human and murine cells appear to require different regions of the cytoplasmic domain of IFNAR2c for regulation of IFN responses.	Berlex Biosci, Dept Immunol, Richmond, CA 94804 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Univ Illinois, Chicago, IL 60605 USA; Univ Hlth Network, Toronto, ON M5S 3E2, Canada; Univ Toronto, Toronto, ON M5S 3E2, Canada	Cleveland Clinic Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Croze, E (corresponding author), Berlex Biosci, Dept Immunol, 15049 San Pablo Abe, Richmond, CA 94804 USA.	ec_croze@berlex.com			NATIONAL CANCER INSTITUTE [R01CA055079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054709] Funding Source: NIH RePORTER; NCI NIH HHS [CA55079] Funding Source: Medline; NIGMS NIH HHS [GM54709] Funding Source: Medline; PHS HHS [2PO1 62220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*APL BIOS PERK, 1997, TAQM GOLD RT PCR PRO; COHEN B, 1995, MOL CELL BIOL, V15, P4208; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; Croze E, 1996, J BIOL CHEM, V271, P33165, DOI 10.1074/jbc.271.52.33165; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Domanski P, 1997, J BIOL CHEM, V272, P26388, DOI 10.1074/jbc.272.42.26388; Domanski P, 1998, J BIOL CHEM, V273, P3144, DOI 10.1074/jbc.273.6.3144; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Ghislain JJ, 1996, J BIOL CHEM, V271, P12408, DOI 10.1074/jbc.271.21.12408; Krishnan K, 1998, J BIOL CHEM, V273, P19495, DOI 10.1074/jbc.273.31.19495; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; Mogensen KE, 1999, J INTERF CYTOK RES, V19, P1069, DOI 10.1089/107999099313019; Nadeau OW, 1999, J BIOL CHEM, V274, P4045, DOI 10.1074/jbc.274.7.4045; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PLANTANIAS LC, 1996, J BIOL CHEM, V271, P23630; Platanias LC, 1998, J BIOL CHEM, V273, P5577, DOI 10.1074/jbc.273.10.5577; Rani MRS, 1996, J BIOL CHEM, V271, P22878, DOI 10.1074/jbc.271.37.22878; Russell-Harde D, 1999, BIOCHEM BIOPH RES CO, V255, P539, DOI 10.1006/bbrc.1998.0105; RUSSELLHARDE D, 1995, J BIOL CHEM, V270, P26033, DOI 10.1074/jbc.270.44.26033; RUSSELLHARDE D, 1995, J INTERF CYTOK RES, V15, P31, DOI 10.1089/jir.1995.15.31; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tang MX, 1996, BIOCONJUGATE CHEM, V7, P703, DOI 10.1021/bc9600630; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UZE G, 1996, J INTERFERON CYTOKIN, V15, P3; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; XIAOXIA L, 1997, MOL CELL BIOL, V17, P2048; Yan H, 1998, J BIOL CHEM, V273, P4046, DOI 10.1074/jbc.273.7.4046	31	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23981	23985		10.1074/jbc.M002518200	http://dx.doi.org/10.1074/jbc.M002518200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10825167	hybrid			2022-12-25	WOS:000088564200079
J	Steiniger-White, M; Reznikoff, WS				Steiniger-White, M; Reznikoff, WS			The C-terminal alpha helix of Tn5 transposase is required for synaptic complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; INHIBITION; MECHANISM; PROTEIN; MUTANTS	An important step in Tn5 transposition requires transposase-transposase homodimerization to form a synaptic complex competent for cleavage of transposon DNA free from the flanking sequence. We demonstrate that the C-terminal helix of Tn5 transposase (residues 458-468 of 476 total amino acids) is required for synaptic complex formation during Tn5 transposition. Specifically, deletion of eight amino acids or more from the C terminus greatly reduces or abolishes synaptic complex formation in vitro. Due to this impaired synaptic complex formation, transposases lacking eight amino acids are also defective in the cleavage step of transposition. Interactions within the synaptic complex dimer interface were investigated by site-directed mutagenesis, and residues required for synaptic complex formation include amino acids comprising the dimer interface in the Tn5 inhibitor x-ray crystal structure dimer. Because the crystal structure dimer was hypothesized to be the inhibitory complex and not a synaptic complex, this result was surprising. Based on these data, models for both in vivo and in vitro synaptic complex formation are presented.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Reznikoff, WS (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.				NIGMS NIH HHS [GM50692] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG DE, 1989, MOBILE DNA, P185; Bhasin A, 1999, J BIOL CHEM, V274, P37021, DOI 10.1074/jbc.274.52.37021; BHASIN A, 2000, IN PRESS J MOL BOL; Braam LAM, 1998, J BIOL CHEM, V273, P10908, DOI 10.1074/jbc.273.18.10908; Braam LAM, 1999, J BIOL CHEM, V274, P86, DOI 10.1074/jbc.274.1.86; Davies DR, 1999, J BIOL CHEM, V274, P11904, DOI 10.1074/jbc.274.17.11904; DELACRUZ NB, 1993, J BACTERIOL, V175, P6932, DOI 10.1128/jb.175.21.6932-6938.1993; Goryshin IY, 1998, J BIOL CHEM, V273, P7367, DOI 10.1074/jbc.273.13.7367; Goryshin IY, 2000, NAT BIOTECHNOL, V18, P97, DOI 10.1038/72017; GORYSHIN IY, 1994, P NATL ACAD SCI USA, V91, P10834, DOI 10.1073/pnas.91.23.10834; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Haren L, 1998, J MOL BIOL, V283, P29, DOI 10.1006/jmbi.1998.2053; Haren L, 2000, J MOL BIOL, V296, P757, DOI 10.1006/jmbi.1999.3485; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JOHNSON RC, 1982, CELL, V30, P873, DOI 10.1016/0092-8674(82)90292-6; JOHNSON RC, 1983, NATURE, V204, P280; KREBS MP, 1988, GENE, V63, P277, DOI 10.1016/0378-1119(88)90531-8; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; Reznikoff WS, 1999, BIOCHEM BIOPH RES CO, V266, P729, DOI 10.1006/bbrc.1999.1891; Sambrook J., 2002, MOL CLONING LAB MANU; WEINREICH MD, 1994, J MOL BIOL, V241, P166, DOI 10.1006/jmbi.1994.1486; WEINREICH MD, 1994, GENE DEV, V8, P2363, DOI 10.1101/gad.8.19.2363; WIATER LA, 1990, J BACTERIOL, V172, P4951, DOI 10.1128/jb.172.9.4951-4958.1990; WIEGAND TW, 1994, J MOL BIOL, V235, P486, DOI 10.1006/jmbi.1994.1008; WIEGAND TW, 1992, J BACTERIOL, V174, P1229, DOI 10.1128/jb.174.4.1229-1239.1992; York D, 1998, NUCLEIC ACIDS RES, V26, P1927, DOI 10.1093/nar/26.8.1927; Zhou M, 1998, J MOL BIOL, V276, P913, DOI 10.1006/jmbi.1997.1579; Zhou M, 1997, J MOL BIOL, V271, P362, DOI 10.1006/jmbi.1997.1188	28	21	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23127	23133		10.1074/jbc.M003411200	http://dx.doi.org/10.1074/jbc.M003411200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10825170	hybrid			2022-12-25	WOS:000088419400071
J	Hehner, SP; Hofmann, TG; Dienz, O; Droge, W; Schmitz, ML				Hehner, SP; Hofmann, TG; Dienz, O; Droge, W; Schmitz, ML			Tyrosine-phosphorylated Vav1 as a point of integration for T-cell receptor- and CD28-mediated activation of JNK, p38, and interleukin-2 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JNK/SAPK SIGNALING PATHWAY; EXCHANGE FACTOR VAV; PROTOONCOGENE PRODUCT; IL-2 PROMOTER; RHO-FAMILY; CYTOSKELETAL REORGANIZATION; PROTEIN; KINASE; LYMPHOCYTES; CD28	In this study Re identified tyrosine-phosphorylated Vav1 as an early point of integration between the signaling routes triggered by the T-cell receptor and CD28 in human T-cell leukemia cells. Costimulation resulted in a prolonged and sustained phosphorylation and membrane localization of Vav1 in comparison to T-cell receptor activation alone. T-cell stimulation induced the recruitment of Vav1 to an inducible multiprotein T-cell activation signaling complex at the plasma membrane. Vav1 activated the mitogen-activated protein kinases JNK and p38. The Vav1-mediated activation of JNK employed a pathway involving Rac, HPK1, MLK3, and MKK7. The costimulation-induced activation of p38 was inhibited by dominant negative forms of Vav1, Pac, and MKK6. Here we show that Vav1 also induces transcription factors that bind to the CD28RE/AP element contained in the interleukin-2 promoter. A detailed mutational analysis of Vav1 revealed a series of constitutively active and nonfunctional forms of Vav1. Almost all inactive versions were mutated in their Dbl homology domain and behaved as dominant negative mutants that impaired costimulation-induced activation of JNK, p38, and CD28RE/AP-dependent transcription. In contrast to NF-AT-dependent transcription, Vav1-mediated transcriptional induction of the CD28RE/AP element in the interleukin-a promoter could only partially be inhibited by cyclosporin A, suggesting a dual role of Vav1 for controlling Ca2+-dependent and -independent events.	Deutsch Krebsforschungszentrum, Dept Immunochem, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schmitz, ML (corresponding author), Deutsch Krebsforschungszentrum, Dept Immunochem, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				Arudchandran R, 2000, J EXP MED, V191, P47, DOI 10.1084/jem.191.1.47; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; Cantrell D, 1998, CURR BIOL, V8, pR535, DOI 10.1016/S0960-9822(07)00341-7; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Germani A, 1999, MOL CELL BIOL, V19, P3798; Gomez J, 1998, CRIT REV IMMUNOL, V18, P185, DOI 10.1615/CritRevImmunol.v18.i3.20; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Harhaj EW, 1998, J BIOL CHEM, V273, P25185, DOI 10.1074/jbc.273.39.25185; Hobert O, 1996, ONCOGENE, V12, P1577; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; McGuire KL, 1997, J IMMUNOL, V159, P1319; Michel F, 1998, J BIOL CHEM, V273, P31932, DOI 10.1074/jbc.273.48.31932; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Musci MA, 1997, J IMMUNOL, V159, P1639; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; O'Rourke LM, 1998, IMMUNITY, V8, P635, DOI 10.1016/S1074-7613(00)80568-3; Romero F, 1996, CELL SIGNAL, V8, P545, DOI 10.1016/S0898-6568(96)00118-0; Schraven B, 1999, IMMUNOL TODAY, V20, P431, DOI 10.1016/S0167-5699(99)01519-4; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; Shapiro VS, 1997, MOL CELL BIOL, V17, P4051, DOI 10.1128/MCB.17.7.4051; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Song JS, 1999, J IMMUNOL, V163, P802; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Turner M, 1997, IMMUNITY, V7, P451, DOI 10.1016/S1074-7613(00)80367-2; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; WU J, 1995, MOL CELL BIOL, V15, P4337; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	62	77	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18160	18171		10.1074/jbc.275.24.18160	http://dx.doi.org/10.1074/jbc.275.24.18160			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849438	hybrid			2022-12-25	WOS:000087659400036
J	Sehgal, A; Briggs, J; Rinehart-Kim, J; Basso, J; Bos, TJ				Sehgal, A; Briggs, J; Rinehart-Kim, J; Basso, J; Bos, TJ			The chicken c-Jun 5 ' untranslated region directs translation by internal initiation	ONCOGENE			English	Article						c-Jun; translation; internal initiation; 5 ' UTR	RIBOSOME ENTRY SITE; CAP-DEPENDENT TRANSLATION; EUKARYOTIC MESSENGER-RNAS; NF-KAPPA-B; BINDING-PROTEIN; DNA-BINDING; GLUCOCORTICOID RECEPTOR; 5'-UNTRANSLATED REGION; TRANSCRIPTION FACTORS; SECONDARY STRUCTURE	The 5' untranslated region (UTR) of the chicken c-jun message is exceptionally GC rich and has the potential to form a complex and extremely stable secondary structure. Because stable RNA secondary structures can serve as obstacles to scanning ribosomes, their presence suggests inefficient translation or initiation through alternate mechanisms. We have examined the role of the c-jun 5' UTR with respect to its ability to influence translation both in vitro and in vivo. We find, using rabbit reticulocyte lysates, that the presence of the c-jun 5' UTR severely inhibits translation of both homologous and heterologous genes in vitro. Furthermore, translational inhibition correlates with the degree of secondary structure exhibited by the 5' UTR, Thus, in the rabbit reticulocyte lysate system, the c-jun 5' UTR likely impedes ribosome scanning resulting in inefficient translation. In contrast to our results in vitro, the c-jun 5' UTR does not inhibit translation in a variety of different cell lines suggesting that it may direct an alternate mechanism of translational initiation in vivo, To distinguish among the alternate mechanisms, we generated a series of bicistronic expression plasmids, Our results demonstrate that the downstream cistron, in the bicistronic gene, is expressed to a much higher level when directly preceded by the c-jun 5' UTR, In addition, inhibition of ribosome scanning on the bicistronic message, through insertion of a synthetic stable hairpin, inhibits translation of the first cistron but does not inhibit translation of the cistron downstream of the c-jun 5' UTR, These results are consistent with a model by which the c-jun message is translated through cap independent internal initiation.	Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA	Eastern Virginia Medical School	Bos, TJ (corresponding author), Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, POB 1980, Norfolk, VA 23501 USA.				NCI NIH HHS [R01 CA51982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; AHARON T, 1993, MOL CELL BIOL, V13, P1971, DOI 10.1128/MCB.13.3.1971; Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; Belsham GJ, 1995, CURR TOP MICROBIOL, V203, P85; Belsham GJ, 1996, MICROBIOL REV, V60, P499, DOI 10.1128/MMBR.60.3.499-511.1996; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BORMAN AM, 1995, NUCLEIC ACIDS RES, V23, P3656, DOI 10.1093/nar/23.18.3656; Borman AM, 1997, NUCLEIC ACIDS RES, V25, P925, DOI 10.1093/nar/25.5.925; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BUKH A, 1990, J IMMUNOL, V144, P4835; Chihab R, 1998, MOL BRAIN RES, V63, P105, DOI 10.1016/S0169-328X(98)00266-6; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; CURATOLA AM, 1995, MOL CELL BIOL, V15, P6331; deQuinto SL, 1997, J VIROL, V71, P4171; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; Diamond DA, 1999, J BIOL CHEM, V274, P16959, DOI 10.1074/jbc.274.24.16959; DUTTON CM, 1993, NUCLEIC ACIDS RES, V21, P2953, DOI 10.1093/nar/21.12.2953; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; Gilby KL, 1997, MOL BRAIN RES, V48, P87, DOI 10.1016/S0169-328X(97)00085-5; Gingras AC, 1997, VIROLOGY, V237, P182, DOI 10.1006/viro.1997.8757; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Hadman M, 1996, ONCOGENE, V12, P135; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Jackson RJ, 1995, RNA, V1, P985; Kim YK, 1999, J GEN VIROL, V80, P3159, DOI 10.1099/0022-1317-80-12-3159; Kolupaeva VG, 1998, J BIOL CHEM, V273, P18599, DOI 10.1074/jbc.273.29.18599; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Latorre P, 1998, MOL CELL BIOL, V18, P5021, DOI 10.1128/MCB.18.9.5021; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Martinez-Salas E, 1999, CURR OPIN BIOTECH, V10, P458, DOI 10.1016/S0958-1669(99)00010-5; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; NISHIMURA T, 1988, ONCOGENE, V3, P659; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Sella O, 1999, MOL CELL BIOL, V19, P5429; Sickinger S, 1999, BIOL CHEM, V380, P1217, DOI 10.1515/BC.1999.154; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; TOURAY M, 1991, ONCOGENE, V6, P1227; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Yueh A, 1996, GENE DEV, V10, P1557, DOI 10.1101/gad.10.12.1557; Zuker M., 1999, V70, P11	69	25	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2000	19	24					2836	2845		10.1038/sj.onc.1203601	http://dx.doi.org/10.1038/sj.onc.1203601			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851087				2022-12-25	WOS:000087403600005
J	Zhu, YJ; Lin, H; Lal, R				Zhu, YJ; Lin, H; Lal, R			Fresh and nonfibrillar amyloid beta protein(1-40) induces rapid cellular degeneration in aged human fibroblasts: evidence for A beta P-channel-mediated cellular toxicity	FASEB JOURNAL			English	Article						atomic force microscope; scanning probe microscopy; amyloid beta protein; ion channels; Alzheimer's disease	ATOMIC-FORCE MICROSCOPY; FAMILIAL ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; ZN2+-SENSITIVE CHANNEL; ENDOTHELIAL-CELLS; CORTICAL-NEURONS; PEPTIDE; NEUROTOXICITY; BRAIN; AGGREGATION	Alzheimer's disease (AD) is primarily nonfamilial or sporadic (SAD) in origin, although several genetic linkages are reported. Tissues from AD patients contain fibrillar plaques made of 39 to 43 amino acid-long amyloid beta peptide (A beta P), although the mechanisms of A beta P toxicity are poorly understood. A beta P1-40 is the most prevalent A beta P present in the neuronal and non-neuronal tissues from SAD patients. A beta P1-40 toxicity has been examined mainly after prolonged incubation and correlates with the age and fibrillar morphology of A beta P1-40. Globular and nonfibrillar A beta Ps are released continually during normal cellular metabolism; they elevate cellular Ca2+ and form cation-permeable channels. However, their role in cellular toxicity is poorly understood. We have used an integrated atomic force and light fluorescence microscopy (AFM-LFM), laser confocal microscopy, and calcium imaging to examine real-time and acute effect of fresh and globular A beta P1-40 on cultured, aged human, AD-free fibroblasts. AFM images show that freshly prepared A beta P1-40 in phosphate-buffered saline (PBS) are globular and do not form fiber for an extended time period. A beta P1-40 induced rapid structural modifications, including cytoskeletal reorganization, retraction of cellular processes, and loss of cell-cell contacts, within minutes of incubation. This led to eventual cellular degeneration A beta P1-40-induced degeneration was prevented by anti-A beta P antibody, zinc, and Tris, but not by tachykinin neuropeptides. In Ca2+-free extracellular medium, A beta P1-40, did not induce cellular degeneration. In the presence of extracellular Ca2+, A beta P1-40 induced a sustained increase in the cellular Ca2+. Thus, short-term and acute A beta P1-40 toxicity is mediated by Ca2+ uptake, most likely via calcium-permeable A beta P pores. Such rapid degeneration does not require fibrillar plaques, suggesting that the plaques may not have any causative role.-Zhu, Y. J., Lin, H., Lal, R. Fresh and nonfibrillar amyloid beta protein(1-40) induces rapid cellular degeneration in aged human fibroblasts: evidence for A beta P-channel-mediated cellular toxicity.	Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Lal, R (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA.	rlal@physics.ucsb.edu						ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; Arispe N, 1996, P NATL ACAD SCI USA, V93, P1710, DOI 10.1073/pnas.93.4.1710; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; Bhatia R, 2000, FASEB J, V14, P1233, DOI 10.1096/fasebj.14.9.1233; Blanc EM, 1997, J NEUROCHEM, V68, P1870; CALINGASAN NY, 1995, BRAIN RES, V677, P50, DOI 10.1016/0006-8993(95)00136-E; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; DICKSON DW, 1992, NEUROBIOL AGING, V13, P179, DOI 10.1016/0197-4580(92)90027-U; DURELL SR, 1994, BIOPHYS J, V67, P2137, DOI 10.1016/S0006-3495(94)80717-9; ETCHEBERRIGARAY R, 1994, SCIENCE, V264, P276, DOI 10.1126/science.8146663; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Gasparini L, 1998, FASEB J, V12, P17, DOI 10.1096/fasebj.12.1.17; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; Good TA, 1996, BIOPHYS J, V70, P296, DOI 10.1016/S0006-3495(96)79570-X; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; Hirakura Y, 1999, J NEUROSCI RES, V57, P458, DOI 10.1002/(SICI)1097-4547(19990815)57:4<458::AID-JNR5>3.0.CO;2-4; ITO E, 1994, P NATL ACAD SCI USA, V91, P534, DOI 10.1073/pnas.91.2.534; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; Kawahara M, 1997, BIOPHYS J, V73, P67, DOI 10.1016/S0006-3495(97)78048-2; Kawahara M, 1999, BIOPHYS J, V76, pA396; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOSIK K, 1992, NEUROBIOL AGING, V13, P535, DOI 10.1016/0197-4580(92)90052-Y; LAL R, 1994, AM J PHYSIOL, V266, pC1, DOI 10.1152/ajpcell.1994.266.1.C1; Lal R, 1997, INT J IMAG SYST TECH, V8, P293, DOI 10.1002/(SICI)1098-1098(1997)8:3<293::AID-IMA7>3.0.CO;2-5; LAL R, 1995, AM J PHYSIOL-CELL PH, V269, pC275, DOI 10.1152/ajpcell.1995.269.1.C275; Lane NJ, 1998, J NEUROCYTOL, V27, P707, DOI 10.1023/A:1006976400227; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Lin H, 1999, BIOCHEMISTRY-US, V38, P11189, DOI 10.1021/bi982997c; Lin H, 2000, BIOPHYS J, V78, p177A; Liu YB, 1998, J NEUROCHEM, V71, P2322; MAESTRE GE, 1992, BRAIN RES, V599, P64, DOI 10.1016/0006-8993(92)90853-2; MAESTRE GE, 1993, BRAIN RES, V621, P145, DOI 10.1016/0006-8993(93)90311-A; MARTINS RN, 1995, NEUROREPORT, V6, P1513, DOI 10.1097/00001756-199507310-00012; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; MIRZABEKOV T, 1994, BIOCHEM BIOPH RES CO, V202, P1142, DOI 10.1006/bbrc.1994.2047; NASLUND J, 1995, NEURON, V15, P219, DOI 10.1016/0896-6273(95)90079-9; Pallitto MM, 1999, BIOCHEMISTRY-US, V38, P3570, DOI 10.1021/bi982119e; Rhee SK, 1998, J BIOL CHEM, V273, P13379, DOI 10.1074/jbc.273.22.13379; Salinero O, 1997, J NEUROSCI RES, V47, P216; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; Shao ZF, 1996, ADV PHYS, V45, P1, DOI 10.1080/00018739600101467; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; STGEORGEHYSLOP PH, 1990, NATURE, V347, P194, DOI 10.1038/347194a0; Suo ZM, 1997, BRAIN RES, V762, P144, DOI 10.1016/S0006-8993(97)00383-1; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; Waiter MF, 1997, BIOCHEM BIOPH RES CO, V233, P760, DOI 10.1006/bbrc.1997.6547; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; ZHAO B, 1995, J NEUROSCI RES, V40, P261, DOI 10.1002/jnr.490400215	55	133	139	1	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1244	1254		10.1096/fasebj.14.9.1244	http://dx.doi.org/10.1096/fasebj.14.9.1244			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834946				2022-12-25	WOS:000087427300021
J	Carayol, G; Giron-Michel, J; Azzarone, B; Castagna, L; Cambier, N; Mishal, Z; Bourhis, JH; Chouaib, S; Caignard, A				Carayol, G; Giron-Michel, J; Azzarone, B; Castagna, L; Cambier, N; Mishal, Z; Bourhis, JH; Chouaib, S; Caignard, A			Altered natural killer cell differentiation in CD34(+) progenitors from chronic myeloid leukemia patients	ONCOGENE			English	Article						IL-15; IL-15R; chronic myeloid leukemia; NK cell differentiation	CHRONIC MYELOGENOUS LEUKEMIA; PHILADELPHIA-CHROMOSOME; INTERLEUKIN-2 RECEPTOR; INTERFERON-GAMMA; HUMAN MONOCYTES; IL-2 RECEPTOR; EXPRESSION; ACTIVATION; IDENTIFICATION; TRANSFORMATION	IL-15 and SCF fail to induce NK differentiation and proliferation of CD34(+) hematopoietic progenitors from chronic myeloid leukemia patients in contrast to normal stem cells although, both normal and leukemic CD34(+) cells display comparable expression of c-kit or IL-15 receptor subunits, Interestingly, confocal microscopy analysis revealed that leukemic and most normal CD34(+) cells produce and secrete IL-15, as shown by its trafficking through the Golgi apparatus and early endosomes, However, only leukemic progenitors express the membrane bound IL-15, Colocalization and internalization of IL-15R beta/gamma c and IL-15R alpha/gamma c complexes indicated that IL-15 was specifically uptaken by leukemic progenitors. We also demonstrated that in both normal and leukemic progenitors, the signaling kinase Jak3 is constitutively pre-associated with the gamma c chain. Anti-IL-15 neutralizing mAb treatment resulted in downregulation of gamma c chain and disruption of gamma c/Jak3 interaction in normal but had no effect in leukemic progenitors. Our results suggest the existence in both normal and leukemic CD34(+) cells of a constitutive production of a bioactive IL-15 that does not lead to NK differentiation and further indicate that membrane bound IL-15 and constitutive activation of gamma c are hallmarks of leukemic progenitors.	Inst Gustave Roussy, INSERM, U487, F-94805 Villejuif, France; Inst Gustave Roussy, Serv Hematol, F-94805 Villejuif, France; Hop Paul Brousse, INSERM 506, F-94807 Villejuif, France; CHU Lille, Serv Hematol, F-59037 Lille, France; Lab Cytometrie, CNRS, UPS 47, F-94807 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Centre National de la Recherche Scientifique (CNRS)	Caignard, A (corresponding author), Inst Gustave Roussy, INSERM, U487, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		Chouaib, Salem/F-7939-2016; Castagna, L/ABC-7613-2021; Azzarone, Bruno/AAH-9251-2019; Caignard, Anne/F-8159-2013; Giron-Michel, Julien/Q-4503-2018	Azzarone, Bruno/0000-0002-5962-3849; Caignard, Anne/0000-0001-9923-6045; Giron-Michel, Julien/0000-0001-6613-6099; Castagna, Luca/0000-0002-6239-7387				Alleva DG, 1997, J IMMUNOL, V159, P2941; Barzegar C, 1998, ONCOGENE, V16, P2503, DOI 10.1038/sj.onc.1201775; BOSCO MC, 1994, BLOOD, V83, P2995, DOI 10.1182/blood.V83.10.2995.2995; CALIGIURI MA, 1990, J EXP MED, V171, P1509, DOI 10.1084/jem.171.5.1509; Carayol G, 1998, EUR J IMMUNOL, V28, P1991, DOI 10.1002/(SICI)1521-4141(199806)28:06<1991::AID-IMMU1991>3.0.CO;2-7; Carella AM, 1999, BLOOD, V93, P1534, DOI 10.1182/blood.V93.5.1534.405a05_1534_1539; Carson WE, 1997, J CLIN INVEST, V99, P937, DOI 10.1172/JCI119258; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; Cervantes F, 1996, BLOOD, V87, P2476, DOI 10.1182/blood.V87.6.2476.bloodjournal8762476; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Frassoni F, 1999, BRIT J HAEMATOL, V104, P538, DOI 10.1046/j.1365-2141.1999.01201.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; JOHNSTON JA, 1995, P NATL ACAD SCI USA, V92, P8705, DOI 10.1073/pnas.92.19.8705; KANTARJIAN HM, 1993, BLOOD, V82, P691; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Meazza R, 1996, ONCOGENE, V12, P2187; Mingari MC, 1997, EUR J IMMUNOL, V27, P1374, DOI 10.1002/eji.1830270612; Mrozek E, 1996, BLOOD, V87, P2632, DOI 10.1182/blood.V87.7.2632.bloodjournal8772632; Musso T, 1999, BLOOD, V93, P3531; NOWELL PC, 1960, SCIENCE, V132, P1497; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Tagaya Y, 1997, P NATL ACAD SCI USA, V94, P14444, DOI 10.1073/pnas.94.26.14444; Takahashi N, 1998, BLOOD, V92, P4758, DOI 10.1182/blood.V92.12.4758; VERFAILLIE C, 1990, BLOOD, V76, P401; Washizu J, 1998, IMMUNOGENETICS, V48, P1, DOI 10.1007/s002510050393; WETZLER M, 1995, AM J MED, V99, P402, DOI 10.1016/S0002-9343(99)80189-2	29	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2000	19	23					2758	2766		10.1038/sj.onc.1203584	http://dx.doi.org/10.1038/sj.onc.1203584			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851076				2022-12-25	WOS:000087318500004
J	Bruckheimer, EM; Cho, S; Brisbay, S; Johnson, DJ; Gingrich, JR; Greenberg, N; McDonnell, TJ				Bruckheimer, EM; Cho, S; Brisbay, S; Johnson, DJ; Gingrich, JR; Greenberg, N; McDonnell, TJ			The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo	ONCOGENE			English	Article						prostate; bcl-2; bax; apoptosis; androgen	PROGRAMMED CELL-DEATH; TRANSGENIC MICE; IN-VIVO; IMMUNOHISTOCHEMICAL ANALYSIS; REGULATED EXPRESSION; ANDROGEN-ABLATION; CANCER; APOPTOSIS; ANTIGEN; GENE	Prostatic glandular epithelial cells undergo apoptosis in response to androgen-deprivation. The molecular determinants of androgen-responsiveness in these cells are incompletely understood. Recent evidence suggests that bcl-2 gene family members mag be important in this context, We used the probasin promoter to target a human bcl-2 transgene specifically to the prostate in order to assess its impart on conferring resistance to androgen withdrawal in, otherwise sensitive, prostatic glandular epithelial cells in vivo, We examined the contribution of bax to mediating androgen-responsiveness in prostatic glandular epithelial cells using hair knockout mice, The histologic appearance of the prostates from probasin-bcl-2 transgenic mice or bax(-/-) mice did not differ from those of control littermates. There was no evidence of hyperplastic or neoplastic growth, There was no difference between probasin bcl-2 transgenic mice, bax(-/-) mice, and control littermates in steady-state levels of apoptosis, Following castration our findings suggest that both bax and bcl-2 may each contribute to the androgen-responsiveness of prostatic glandular epithelial cells. It is apparent from these results, however, that bax is not required to mediate cell death in prostatic glandular epithelial cells following castration. A comparison between the apoptotic indices in the ventral prostate from the probasin-hcl-2 and bax(-/-) mice following castration suggests that the presence of bcl-2 may be a more important indicator of androgen-sensitivity than a deficiency of bax.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	McDonnell, TJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.			Gingrich, Jeffrey/0000-0002-4516-2893	NCI NIH HHS [T32CA67759-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA067759] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANERJEE PP, 1995, ENDOCRINOLOGY, V136, P4368, DOI 10.1210/en.136.10.4368; Beham AW, 1998, INT J MOL MED, V1, P953; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; Bruckheimer EM, 1999, SEMIN ONCOL, V26, P382; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; COLOMBEL M, 1993, AM J PATHOL, V143, P390; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gingrich JR, 1996, CANCER RES, V56, P4096; Gingrich JR, 1997, CANCER RES, V57, P4687; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Krajewska M, 1996, AM J PATHOL, V148, P1567; Lakins J, 1998, J BIOL CHEM, V273, P27887, DOI 10.1074/jbc.273.43.27887; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pang S, 1997, CANCER RES, V57, P495; Perlman H, 1999, CELL DEATH DIFFER, V6, P48, DOI 10.1038/sj.cdd.4400453; RAFFO AJ, 1995, CANCER RES, V55, P4438; Schorr K, 1999, CANCER RES, V59, P2541; TUNN S, 1989, PROSTATE, V15, P263, DOI 10.1002/pros.2990150307; Westin P, 1997, INT J ONCOL, V10, P113; Zhang XJ, 1997, PROSTATE, V32, P16, DOI 10.1002/(SICI)1097-0045(19970615)32:1<16::AID-PROS3>3.0.CO;2-A	31	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2404	2412		10.1038/sj.onc.1203571	http://dx.doi.org/10.1038/sj.onc.1203571			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828882				2022-12-25	WOS:000087018400005
J	Brodin, G; Ahgren, A; ten Dijke, P; Heldin, CH; Heuchel, R				Brodin, G; Ahgren, A; ten Dijke, P; Heldin, CH; Heuchel, R			Efficient TGF-beta induction of the Smad7 gene requires cooperation between AP-1, Sp1, and Smad proteins on the mouse Smad7 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR; DNA METHYLATION; TRANSCRIPTION FACTOR; FAMILY MEMBERS; BINDING; ACTIVATION; IDENTIFICATION; SEQUENCES; CELLS	Sma- and Mad-related protein 7 (Smad7) is an antagonist of transforming growth factor-beta (TGF-beta) signaling, which has been shown to be induced by TGF-beta itself and also by other stimuli. In an effort to understand the molecular mechanisms underlying the transcriptional regulation of the Smad7 gene by TGF-beta, we cloned and functionally characterized a mouse genomic DNA fragment encompassing the mouse Smad7 proximal promoter. This region was found to contain a CpG island and to be devoid of a classical TATA box. Cloned upstream of a promoter-lacking luciferase reporter gene, this region conferred robust TGF-beta-induced transcription. Point mutations in a palindromic Smad binding element, abolished TGF-beta inducibility completely. Through the use of electrophoretic mobility shift assays, we showed the presence of Smad2, Smad3, and Smad4 in complexes binding to the Smad binding element. Interestingly, we also found that point mutation and/or deletion of binding sites for the transcription factors activator protein-1 and Spl led to an attenuation of the basal promoter activity, as well as of the TGF-beta-mediated induction of Smad7. Taken together, our data imply that Smads, together with activator protein-1 and Spl transcription factors, are essential for efficient Smad7 promoter activity.	Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Ludwig Institute for Cancer Research; Netherlands Cancer Institute	Heuchel, R (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Box 595, S-75124 Uppsala, Sweden.		Dijke, Peter ten/AAG-4660-2021; Heuchel, Rainer/P-7875-2019	Dijke, Peter ten/0000-0002-7234-342X; Heuchel, Rainer/0000-0002-2782-585X				Afrakhte M, 1998, BIOCHEM BIOPH RES CO, V249, P505, DOI 10.1006/bbrc.1998.9170; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bitzer M, 2000, GENE DEV, V14, P187; Brodin G, 1999, CANCER RES, V59, P2731; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Potchinsky MB, 1997, EXP CELL RES, V231, P96, DOI 10.1006/excr.1996.3422; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; SINGERSAM J, 1990, MOL CELL BIOL, V10, P4987, DOI 10.1128/MCB.10.9.4987; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	41	135	139	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29023	29030		10.1074/jbc.M002815200	http://dx.doi.org/10.1074/jbc.M002815200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10843994	hybrid			2022-12-25	WOS:000089330700089
J	Jha, N; Jurma, O; Lalli, G; Liu, Y; Pettus, EH; Greenamyre, JT; Liu, RM; Forman, HJ; Andersen, JK				Jha, N; Jurma, O; Lalli, G; Liu, Y; Pettus, EH; Greenamyre, JT; Liu, RM; Forman, HJ; Andersen, JK			Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity - Implications for Parkinson's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; BRAIN MITOCHONDRIA; ELECTRON-TRANSPORT; OXIDATIVE STRESS; SUBSTANTIA-NIGRA; THIOL OXIDATION; RAT-KIDNEY; METABOLISM; REDUCTION; NEURONS	Oxidative stress appears to play an important role in degeneration of dopaminergic neurons of the substantia nigra (SN) associated with Parkinson's disease (PD), The SN of early PD patients have dramatically decreased levels of the thiol tripeptide glutathione (GSH), GSH plays multiple roles in the nervous system both as an antioxidant and a redox modulator. We have generated dopaminergic PC12 cell lines in which levels of GSH can be inducibly down-regulated via doxycycline induction of antisense messages against both the heavy and light subunits of gamma-glutamyl-cysteine synthetase, the rate-limiting enzyme in glutathione synthesis. Down-regulation of glutamyl-cysteine synthetase results in reduction in mitochondrial GSH levels, increased oxidative stress, and decreased mitochondrial function. Interestingly, decreases in mitochondrial activities in GSH-depleted PC12 cells appears to be because of a selective inhibition of complex I activity as a result of thiol oxidation. These results suggest that the early observed GSH losses in the SN may be directly responsible for the noted decreases in complex I activity and the subsequent mitochondrial dysfunction, which ultimately leads to dopaminergic cell death associated with PD.	Univ So Calif, Dept Biol Sci, Program Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biol Sci, Program Neurobiol, Los Angeles, CA 90089 USA; Univ So Calif, Andrus Gerontol Ctr, Div Neurogerontol, Los Angeles, CA 90089 USA; Emory Univ, Dept Neurol, Atlanta, GA 30322 USA; Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA; Univ Alabama Birmingham, Sch Publ Hlth, Dept Environm Hlth Sci, Birmingham, AL 35294 USA	University of Southern California; University of Southern California; University of Southern California; Emory University; Emory University; University of Alabama System; University of Alabama Birmingham	Andersen, JK (corresponding author), Univ So Calif, Dept Biol Sci, Program Mol Biol, 3715 McClintock Ave, Los Angeles, CA 90089 USA.	andersen@almaak.usc.edu	Greenamyre, J. Timothy/B-4049-2011	Andersen, Julie/0000-0003-1324-4875; Forman, Henry Jay/0000-0001-5838-2791; Greenamyre, J. Timothy/0000-0003-3468-7878	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R56ES005511, R01ES005511] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009793, R01AG012141, R29AG012141] Funding Source: NIH RePORTER; NIA NIH HHS [AG09793, AG12141] Funding Source: Medline; NIEHS NIH HHS [ES05511] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andersen JK, 1996, J NEUROCHEM, V67, P2164; Balijepalli S, 1999, NEUROPHARMACOLOGY, V38, P567, DOI 10.1016/S0028-3908(98)00215-9; BANNON MJ, 1984, BIOCHEM PHARMACOL, V33, P2697, DOI 10.1016/0006-2952(84)90682-8; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Cohen G, 1997, P NATL ACAD SCI USA, V94, P4890, DOI 10.1073/pnas.94.10.4890; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; DELCORSO A, 1994, INT J BIOCHEM, V26, P745, DOI 10.1016/0020-711X(94)90103-1; DEXTER DT, 1994, MOVEMENT DISORD, V9, P92, DOI 10.1002/mds.870090115; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HAAS RH, 1995, ANN NEUROL, V37, P714, DOI 10.1002/ana.410370604; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HALLMAN H, 1985, J NEUROCHEM, V44, P117, DOI 10.1111/j.1471-4159.1985.tb07120.x; HILLERED L, 1988, J NEUROSCI RES, V19, P94, DOI 10.1002/jnr.490190113; HUANG CS, 1993, J BIOL CHEM, V268, P19675; Hung HC, 1998, FREE RADICAL BIO MED, V24, P76, DOI 10.1016/S0891-5849(97)00206-2; JAIN A, 1991, P NATL ACAD SCI USA, V88, P1913, DOI 10.1073/pnas.88.5.1913; JENNER P, 1993, ACTA NEUROL SCAND, V87, P6; JHA N, 1999, RRD NEUROCHEMISTRY 1, V2, P99; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; KU HH, 1993, MECH AGEING DEV, V72, P67, DOI 10.1016/0047-6374(93)90132-B; Lenaz G, 1997, MOL CELL BIOCHEM, V174, P329, DOI 10.1023/A:1006854619336; Liu RM, 1998, AM J PHYSIOL-LUNG C, V275, pL861, DOI 10.1152/ajplung.1998.275.5.L861; MATTSON MP, 1993, EXP NEUROL, V121, P1, DOI 10.1006/exnr.1993.1066; MEISTER A, 1988, J BIOL CHEM, V263, P17205; Pearce RKB, 1997, J NEURAL TRANSM, V104, P661, DOI 10.1007/BF01291884; PERRY TL, 1986, NEUROSCI LETT, V67, P269, DOI 10.1016/0304-3940(86)90320-4; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; Pettus E. H., 1997, Society for Neuroscience Abstracts, V23, P1640; RAVINDRANATH V, 1990, BIOCHEM BIOPH RES CO, V169, P1075, DOI 10.1016/0006-291X(90)92004-J; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; Sechi G, 1996, PROG NEURO-PSYCHOPH, V20, P1159, DOI 10.1016/S0278-5846(96)00103-0; SEELIG GF, 1985, METHOD ENZYMOL, V113, P379; SHIVAKUMAR BR, 1995, J PHARMACOL EXP THER, V274, P1167; SIAN J, 1994, ANN NEUROL, V36, P356, DOI 10.1002/ana.410360306; SIAN J, 1994, ANN NEUROL, V36, P348, DOI 10.1002/ana.410360305; Sriram K, 1998, J NEUROSCI, V18, P10287; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Wullner U, 1996, NEUROREPORT, V7, P921; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696; ZHANG Y, 1990, J BIOL CHEM, V265, P16330; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	42	222	227	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26096	26101		10.1074/jbc.M000120200	http://dx.doi.org/10.1074/jbc.M000120200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10846169	hybrid			2022-12-25	WOS:000088999700030
J	Zolle, O; Lawrie, AM; Simpson, AWM				Zolle, O; Lawrie, AM; Simpson, AWM			Activation of the particulate and not the soluble guanylate cyclase leads to the inhibition of Ca2+ extrusion through localized elevation of cGMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; ATRIAL-NATRIURETIC-PEPTIDE; VASCULAR SMOOTH-MUSCLE; CYCLIC-GMP; PLASMA-MEMBRANE; SARCOPLASMIC-RETICULUM; ENDOTHELIAL-CELLS; CALCIUM CHANNELS; STORES; ENTRY	We examined whether localized increases in cytosolic cGMP have distinct regulatory effects on the concentration of cytosolic free Ca2+ in ECV304 cells. Stimulation of the particulate guanylate cyclase by brain-type natriuretic peptide in fura-a-loaded cells caused a profound potentiation of the ATP-stimulated and thapsigargin-stimulated rise in cytosolic free Ca2+. This effect is mediated by the inhibition of Ca2+ extrusion via the plasma membrane Ca2+-ATPase pump. Furthermore, the addition of brain-type natriuretic peptide caused the partial inhibition of cation influx in ATP-stimulated cells. In contrast, elevation of cytosolic cGMP by activation of the soluble guanylate cyclase induced by the addition of sodium nitroprusside causes an increased reuptake of Ca2+ into the intracellular stores without affecting cation influx or Ca2+ efflux, Thus, localized pools of cGMP play distinct regulatory roles in the regulation of Ca2+ homeostasis within individual cells. We define a new role for natriuretic peptides in the inhibition of Ca2+ efflux that leads to the potentiation of agonist-evoked increases in cytosolic free Ca2+.	Univ Liverpool, Dept Human Anat & Cell Biol, New Med Sch, Liverpool, Merseyside, England; Univ Aberdeen, IMS, Aberdeen AB25 2DZ, Scotland	University of Liverpool; University of Aberdeen	Simpson, AWM (corresponding author), Univ Liverpool, Dept Human Anat & Cell Biol, New Med Sch, Ashton St, Liverpool, Merseyside, England.	awms@liv.ac.uk						Andrew PJ, 1999, CARDIOVASC RES, V43, P521, DOI 10.1016/S0008-6363(99)00115-7; Barritt GJ, 1998, CELL CALCIUM, V23, P65, DOI 10.1016/S0143-4160(98)90075-6; BEAVO JA, 1988, ADV SEC MESS PHOSPH, V22, P1; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BURNS F, 1996, INTRACELLULAR SIGNAL, P29; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; Etter EF, 1996, P NATL ACAD SCI USA, V93, P5368, DOI 10.1073/pnas.93.11.5368; Fang Y, 1999, CELL CALCIUM, V26, P15, DOI 10.1054/ceca.1999.0046; FERESENKO EE, 1985, NATURE, V313, P310; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; GOLD GH, 1987, TRENDS PHARMACOL SCI, V8, P312, DOI 10.1016/0165-6147(87)90126-X; Graier WF, 1998, J PHYSIOL-LONDON, V506, P109, DOI 10.1111/j.1469-7793.1998.109bx.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOBAI IA, 1998, J PHYSIOL-LONDON, V511, P80; Holschermann H, 1997, AM J PHYSIOL-HEART C, V272, pH91, DOI 10.1152/ajpheart.1997.272.1.H91; HOPEGILL HF, 1979, HORM METAB RES, V11, P698, DOI 10.1055/s-0028-1095813; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HSU YT, 1994, J BIOL CHEM, V269, P29765; IGNARRO LJ, 1986, J PHARMACOL EXP THER, V237, P893; JAFFE LF, 1993, CELL CALCIUM, V14, P736, DOI 10.1016/0143-4160(93)90099-R; Jin XH, 1999, J CLIN INVEST, V103, P167, DOI 10.1172/JCI4327; Klishin A, 1998, AM J PHYSIOL-CELL PH, V274, pC1117, DOI 10.1152/ajpcell.1998.274.4.C1117; Madge L, 1997, J PHYSIOL-LONDON, V498, P351, DOI 10.1113/jphysiol.1997.sp021863; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; MISSIAEN L, 1991, PHARMACOL THERAPEUT, V50, P191, DOI 10.1016/0163-7258(91)90014-D; MITTAL CK, 1985, EUR J PHARMACOL, V115, P127, DOI 10.1016/0014-2999(85)90596-5; Murthy KS, 1998, AM J PHYSIOL-CELL PH, V274, pC1199, DOI 10.1152/ajpcell.1998.274.5.C1199; RAEYMAEKERS L, 1988, BIOCHEM J, V252, P269, DOI 10.1042/bj2520269; RIZZUTO R, 1993, METHOD CELL BIOL, V40, P339; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; SABINE B, 1995, BIOCHEM BIOPH RES CO, V214, P75, DOI 10.1006/bbrc.1995.2258; Sedova M, 1999, CELL CALCIUM, V25, P333, DOI 10.1054/ceca.1999.0036; SIMPSON AWM, 1990, BIOCHEM J, V267, P277, DOI 10.1042/bj2670277; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TWORT CHC, 1988, CIRC RES, V62, P961, DOI 10.1161/01.RES.62.5.961; Uneyama C, 1998, EUR J PHARMACOL, V347, P355, DOI 10.1016/S0014-2999(98)00123-X; VANBREEMEN C, 1995, TRENDS PHARMACOL SCI, V16, P98, DOI 10.1016/S0165-6147(00)88990-7; VROLIX M, 1988, BIOCHEM J, V255, P855, DOI 10.1042/bj2550855; WALDMAN SA, 1984, J BIOL CHEM, V259, P4332; Willmott NJ, 1996, FEBS LETT, V386, P39, DOI 10.1016/0014-5793(96)00413-9; YOSHIDA Y, 1991, J BIOL CHEM, V266, P19819; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	49	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25892	25899		10.1074/jbc.M000786200	http://dx.doi.org/10.1074/jbc.M000786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851228	hybrid			2022-12-25	WOS:000088999700003
J	Mohamed, MR; Niles, EG				Mohamed, MR; Niles, EG			Interaction between nucleoside triphosphate phosphohydrolase I and the H4L subunit of the viral RNA polymerase is required for vaccinia virus early gene transcript release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE-SENSITIVE MUTANTS; NUCLEOTIDE-SEQUENCE; TERMINATION FACTOR; TERNARY COMPLEXES; EXPRESSION SYSTEM; CELLULAR PROTEIN; STAGE GENES; NASCENT RNA; VIRIONS; PURIFICATION	Signal-dependent termination is restricted to early poxvirus genes whose transcription is catalyzed by the virion form of RNA polymerase. Two termination factors have been identified. Vaccinia termination factor/capping enzyme is a multifunctional heterodimer that also catalyzes the first three steps of mRNA cap formation and is an essential intermediate gene transcription initiation factor. Nucleoside triphosphate phosphohydrolase I (NPH I) is a single-stranded DNA-dependent ATPase. COOH-terminal deletion mutations of NPH I retain both ATPase and DNA binding activities but are unable either to terminate transcription or to act as dominant negative mutants in vitro, One appealing model posits that the COOH-terminal region of NPH I binds to one or more components in the termination complex. In an attempt to identify NPH I-related protein/protein interactions involved in transcription termination, a series of pull-down experiments were done. Among several vaccinia virus proteins tested, the H4L subunit, unique to the virion form of RNA polymerase, was shown. to bind glutathione S-transferase (GST)-NPH I. To further confirm this interaction in virus-infected cells, we constructed recombinant vaccinia virus, vNPHINGST, that expresses GST-tagged NPH I. The H4L subunit of virion RNA polymerase specifically co-purified with GST-NPH I, consistent with a physical interaction. Through the analysis of a series of NH2- and COOH-terminal truncation mutations of H4L, the NPH I interaction site was localized to the NH2-terminal 195 amino acids of the H4L protein. The H4L binding site on NPH I was mapped to the COOH-terminal region between 457 and 631, Furthermore, COOH-terminal deletion mutations of NPH I failed to bind the NH2-terminal region of H4L, explaining their inability to support transcription termination. The COOH-terminal end of NPH I was also shown to be required for transcript release activity and for dominant negative inhibition of release. The requirement for an essential interaction between NPH I and H4L provides an explanation for the observed restriction of transcription termination to early viral genes.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Niles, EG (corresponding author), SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, 138 Farber Hall, Buffalo, NY 14214 USA.		Mohamed, Mohamed Ragaa/V-9143-2019	Mohamed, Mohamed Ragaa/0000-0002-9269-3128	NIAID NIH HHS [AI43933] Funding Source: Medline; NIGMS NIH HHS [GM54816] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054816] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1992, P NATL ACAD SCI USA, V89, P3536, DOI 10.1073/pnas.89.8.3536; AHN BY, 1994, J BIOL CHEM, V269, P7552; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; BROYLES SS, 1987, MOL CELL BIOL, V7, P7, DOI 10.1128/MCB.7.1.7; Christen LA, 1999, BIOCHEMISTRY-US, V38, P8072, DOI 10.1021/bi9903749; Christen LM, 1998, VIROLOGY, V245, P360, DOI 10.1006/viro.1998.9177; CONDIT RC, 1983, VIROLOGY, V128, P429, DOI 10.1016/0042-6822(83)90268-4; CONDIT RC, 1981, VIROLOGY, V113, P224, DOI 10.1016/0042-6822(81)90150-1; Condit RC, 1996, VIROLOGY, V218, P169, DOI 10.1006/viro.1996.0177; Deng L, 1996, J BIOL CHEM, V271, P29386, DOI 10.1074/jbc.271.46.29386; DENG L, 1994, J BIOL CHEM, V269, P14323; Deng L, 1998, GENE DEV, V12, P538, DOI 10.1101/gad.12.4.538; Deng L, 1996, J BIOL CHEM, V271, P19556, DOI 10.1074/jbc.271.32.19556; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FALKNER FG, 1988, J VIROL, V62, P1849, DOI 10.1128/JVI.62.6.1849-1854.1988; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GERSHON PD, 1991, CELL, V66, P1269, DOI 10.1016/0092-8674(91)90048-4; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; Gunasinghe SK, 1998, J BIOL CHEM, V273, P27524, DOI 10.1074/jbc.273.42.27524; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HIGMAN MA, 1992, J BIOL CHEM, V267, P16430; KANE EM, 1992, J VIROL, V66, P5752, DOI 10.1128/JVI.66.10.5752-5762.1992; MOSS B, 1975, J BIOL CHEM, V250, P4722; MOSS B, 1996, POXVIRIDAE VIRUSES T, V2, P2637; PAOLETTI E, 1974, J BIOL CHEM, V249, P3273; PAOLETTI E, 1974, J BIOL CHEM, V249, P3281; ROHRMANN G, 1986, CELL, V46, P1029, DOI 10.1016/0092-8674(86)90702-6; ROSALES R, 1994, P NATL ACAD SCI USA, V91, P3794, DOI 10.1073/pnas.91.9.3794; ROSEL J, 1985, J VIROL, V56, P830, DOI 10.1128/JVI.56.3.830-838.1985; ROSEL JL, 1986, J VIROL, V60, P436, DOI 10.1128/JVI.60.2.436-449.1986; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1989, J BIOL CHEM, V264, P21356; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEIR JP, 1983, J VIROL, V46, P530, DOI 10.1128/JVI.46.2.530-537.1983; WITTEK R, 1984, J VIROL, V49, P371, DOI 10.1128/JVI.49.2.371-378.1984; YUEH L, 1986, J VIROL, V60, P3020; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417; ZHANG YF, 1994, J VIROL, V68, P1360, DOI 10.1128/JVI.68.3.1360-1370.1994; Zhu M, 1998, J VIROL, V72, P3893, DOI 10.1128/JVI.72.5.3893-3899.1998	40	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25798	25804		10.1074/jbc.M002250200	http://dx.doi.org/10.1074/jbc.M002250200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833518	hybrid			2022-12-25	WOS:000088849400097
J	Rivera-Walsh, I; Cvijic, ME; Xiao, G; Sun, SC				Rivera-Walsh, I; Cvijic, ME; Xiao, G; Sun, SC			The NF-kappa B signaling pathway is not required for Fas ligand gene induction but mediates protection from activation-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-LOCALIZATION SEQUENCE; T-CELL; INDUCED APOPTOSIS; CD28 COSTIMULATION; KINASE-ALPHA; RESPONSE ELEMENT; ANTIGEN RECEPTOR; BINDING-PROTEINS; DEFICIENT MICE; DNA-BINDING	Stimulation of T cells by antigens or mitogens triggers multiple signaling pathways leading to activation of genes encoding interleukin-2 and other growth-regulatory cytokines. The same stimuli also activate the gene encoding an apoptosis-inducing molecule, Fas ligand (FasL), which contributes to activation-induced cell death. It has been proposed that the signaling pathways involved in cytokine gene induction also contribute to activation-induced Fast expression; however, genetic evidence for this proposal is lacking. In the present study, the role of the NF-kappa B signaling pathway in Fast gene expression was examined using a mutant T cell line deficient in an essential NF-kappa B signaling component, I kappa B kinase gamma, These mutant cells have a blockade in signal-induced activation of NF-kappa B but remained normal in the activation of NF-AT and AP-1 transcription factors. Interestingly, the NF-kappa B signaling defect has no effect on mitogen-stimulated Fast gene expression, although it completely blocks the interleukin-2 gene induction. We further demonstrate that NF-kappa B activation is required for protecting T cells from apoptosis induction by mitogens and an agonistic anti-Fas antibody. These genetic results suggest that the NF-kappa B signaling pathway is not required for activation-induced Fast expression but rather mediates cell growth and protection from activation-induced cell death.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, POB 850, Hershey, PA 17033 USA.	sxs70@psu.edu			NATIONAL CANCER INSTITUTE [R01CA068471, F32CA083280] Funding Source: NIH RePORTER; NCI NIH HHS [1F32CA83280-1, CA68471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bellas RE, 1997, AM J PATHOL, V151, P891; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Brunner T, 1996, Behring Inst Mitt, P161; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Collette Y, 1997, EUR J IMMUNOL, V27, P3283, DOI 10.1002/eji.1830271227; COPELAND KFT, 1994, AIDS RES HUM RETROV, V10, P1259, DOI 10.1089/aid.1994.10.1259; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Desai SH, 1997, J BIOL CHEM, V272, P12809, DOI 10.1074/jbc.272.19.12809; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; FRASER JD, 1993, IMMUNOL TODAY, V14, P357, DOI 10.1016/0167-5699(93)90236-E; FRASER JD, 1992, J EXP MED, V175, P1131, DOI 10.1084/jem.175.4.1131; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; Hetts SW, 1998, JAMA-J AM MED ASSOC, V279, P300, DOI 10.1001/jama.279.4.300; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; Hsu SC, 1999, EUR J IMMUNOL, V29, P2948, DOI 10.1002/(SICI)1521-4141(199909)29:09<2948::AID-IMMU2948>3.0.CO;2-0; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; KASSIM OO, 1978, EXP PARASITOL, V46, P218, DOI 10.1016/0014-4894(78)90134-0; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; LAI JH, 1994, J BIOL CHEM, V269, P30077; Latinis KM, 1997, J IMMUNOL, V158, P4602; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; Maggirwar SB, 1997, MOL CELL BIOL, V17, P2605, DOI 10.1128/MCB.17.5.2605; Matsui K, 1998, J IMMUNOL, V161, P3469; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Noel PJ, 1996, J IMMUNOL, V157, P636; Parra E, 1998, J IMMUNOL, V160, P5374; Radvanyi LG, 1996, J IMMUNOL, V156, P1788; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rivera I, 1998, J BIOL CHEM, V273, P22382, DOI 10.1074/jbc.273.35.22382; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; RUSSELL JH, 1995, CURR OPIN IMMUNOL, V7, P382, DOI 10.1016/0952-7915(95)80114-6; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Torgerson TR, 1998, J IMMUNOL, V161, P6084; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; VERWEIJ CL, 1991, J BIOL CHEM, V266, P14179; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEISS A, 1993, FUND IMMUNOL, V13, P467; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1	94	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25222	25230		10.1074/jbc.M000444200	http://dx.doi.org/10.1074/jbc.M000444200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837465	hybrid			2022-12-25	WOS:000088849400026
J	Sayer, MS; Tilbrook, PA; Spadaccini, A; Ingley, E; Sarna, MK; Williams, JH; Andrews, NC; Klinken, SP				Sayer, MS; Tilbrook, PA; Spadaccini, A; Ingley, E; Sarna, MK; Williams, JH; Andrews, NC; Klinken, SP			Ectopic expression of transcription factor NF-E2 alters the phenotype of erythroid and monoblastoid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORPHOBILINOGEN DEAMINASE GENE; HEMATOPOIETIC LINEAGE SWITCH; LEUCINE ZIPPER PROTEIN; DNA-BINDING PROTEIN; GLOBIN GENE; MESSENGER-RNA; MICE LACKING; J2E CELLS; MACROPHAGE DIFFERENTIATION; MAMMALIAN-CELLS	In this study, regulation of transcription factor NF-EP was examined in differentiating erythroid and myeloid cells, and the impact of raising NF-EB concentrations within these cell types was assessed. NF-EB was expressed in the J2E erythroid cell line, but the levels increased only marginally during erythropoietin-induced differentiation. In contrast, rare myeloid variants of J2E cells did not express NF-E2, Although NF-EB was present in M1 monoblastoid cells, it was undetectable as these cells matured into macrophages. Compared with erythroid cells, transcription of the NF-ES gene was reduced, and the half-life of the mRNA was significantly shorter in monocytoid cells. Ectopic expression of NF-EB had a profound impact upon the J2E cells; morphologically mature erythroid cells spontaneously emerged in culture, but the cells failed to synthesize hemoglobin, even in the presence of erythropoietin, Although proliferation and viability increased in the NF-EB-transfected J2E cells, their responsiveness to erythropoietin was severely diminished. Strikingly, increasing the expression of NF-EB in M1 cells produced sublines that contained erythroid or immature megakaryocytic cells. Finally, overexpression of NF-E2 in primary hemopoietic progenitors from fetal liver increased erythroid colony formation in the absence of erythropoietin. These data demonstrate that elevated NF-E2 (i) had a dominant effect on the phenotype and maturation of J2E erythroid cells, (ii) was able to reprogram the M1 monocytoid line, and (iii) promoted the development of erythroid colonies by normal progenitors.	Royal Perth Hosp, Western Australian Inst Med Res, Lab Canc Med, Perth, WA 6000, Australia; Univ Western Australia, Dept Biochem, Nedlands, WA 6907, Australia; Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Royal Perth Hospital; University of Western Australia; University of Western Australia; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Klinken, SP (corresponding author), Western Australian Inst Med Res, Level 6,MRF Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.		Sarna, Mohinder/Q-7834-2016; Sarna, Mohinder/AAO-9343-2020; Ingley, Evan/C-2401-2013; Sarna, Mohinder/GYR-3271-2022	Sarna, Mohinder/0000-0002-2448-1588; Sarna, Mohinder/0000-0002-2448-1588; Ingley, Evan/0000-0002-8112-9134; Williams, James/0000-0002-0950-1958; Andrews, Nancy/0000-0003-0243-4462				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Andrews NC, 1998, INT J BIOCHEM CELL B, V30, P429, DOI 10.1016/S1357-2725(97)00135-0; BUSFIELD SJ, 1992, BLOOD, V80, P412; BUSFIELD SJ, 1995, EUR J BIOCHEM, V230, P475; BUSFIELD SJ, 1995, CELL GROWTH DIFFER, V6, P429; CALLUS BA, 1995, HEMOGLOBIN, V19, P7; CHAPPELL D, 1997, CELL DEATH DIFFER, V4, P103; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; Chenais B, 1997, LEUKEMIA, V11, P1575, DOI 10.1038/sj.leu.2400755; Cheng XB, 1997, MOL CELL BIOL, V17, P1407, DOI 10.1128/MCB.17.3.1407; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER MC, 1974, P NATL ACAD SCI USA, V71, P1677, DOI 10.1073/pnas.71.5.1677; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; Deveaux S, 1997, EMBO J, V16, P5654, DOI 10.1093/emboj/16.18.5654; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; KEIL U, 1995, CELL GROWTH DIFFER, V6, P439; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; Levin J, 1999, BLOOD, V94, P3037, DOI 10.1182/blood.V94.9.3037.421k42_3037_3047; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LOTEM J, 1989, LEUKEMIA, V3, P804; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Nagai T, 1998, J BIOL CHEM, V273, P5358, DOI 10.1074/jbc.273.9.5358; NEUZ B, 1995, NATURE, V375, P316; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PERKINS AC, 1995, NATURE, V375, P318; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; RAYNER JR, 1994, MOL CELL BIOL, V14, P880, DOI 10.1128/MCB.14.2.880; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; Shivdasani R A, 1996, Stem Cells, V14 Suppl 1, P112; Shivdasani RA, 1997, BLOOD, V90, P1821, DOI 10.1182/blood.V90.5.1821; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; Spadaccini A, 1998, J BIOL CHEM, V273, P23793, DOI 10.1074/jbc.273.37.23793; SPRINGER T, 1979, EUR J IMMUNOL, V9, P301, DOI 10.1002/eji.1830090410; TAKETANI S, 1992, EUR J BIOCHEM, V205, P217, DOI 10.1111/j.1432-1033.1992.tb16771.x; TANIGAWA T, 1995, BLOOD, V85, P379; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Whyatt David J., 1997, Genes and Function, V1, P11; Williams JH, 1999, EMBO J, V18, P5559, DOI 10.1093/emboj/18.20.5559; Yamaguchi Y, 1998, BLOOD, V91, P450, DOI 10.1182/blood.V91.2.450.450_450_457; YonedaKato N, 1996, ONCOGENE, V12, P265	56	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25292	25298		10.1074/jbc.M908695199	http://dx.doi.org/10.1074/jbc.M908695199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10842186	hybrid			2022-12-25	WOS:000088849400034
J	Walter, HJ; McMahon, T; Dadgar, J; Wang, D; Messing, RO				Walter, HJ; McMahon, T; Dadgar, J; Wang, D; Messing, RO			Ethanol regulates calcium channel subunits by protein kinase C delta-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATIONARY NIGHT BLINDNESS; BETA-SUBUNIT; CA2+ CHANNEL; NEUROHYPOPHYSEAL TERMINALS; FUNCTIONAL EXPRESSION; ALCOHOL-CONSUMPTION; PREFERRING RATS; NEURAL CELLS; PC12 CELLS; PKC-DELTA	Chronic exposure to ethanol increases the number of functional L-type voltage-gated calcium channels in neural cells. In PC12 cells, this adaptive response is mediated by protein kinase C delta (PKC delta), but the mechanisms by which this occurs are not known. Since expression of several different calcium channel subunits can increase the abundance of functional L-type channels, we sought to identify which subunits are regulated by ethanol. Incubation of PC12 cells with 120-150 mM ethanol for 6 days increased levels of alpha(1C), alpha(2), and beta(1b) subunit immunoreactivity in cell membranes and selectively increased the abundance of mRNA encoding the alpha(1C-1) splice variant of alpha(1C). In cells expressing a fragment of PKC delta (delta V1) that selectively inhibits PKC delta, there was no increase in membrane-associated alpha(1C), alpha(2), and beta(1b) immunoreactivity following chronic ethanol exposure. However, ethanol still increased levels of alpha(1C-1) mRNA in these cells. These results indicate that ethanol increases the abundance of L-type channels by at least two mechanisms; one involves increases in mRNA encoding a splice variant of alpha(1C) and the other is post-transcriptional, rate-limiting, and requires PKC delta.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Grad Programs Neurosci & Biomed Sci, San Francisco, CA 94143 USA; Ernest Gallo Clin & Res Ctr, Emeryville, CA 94608 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center	Messing, RO (corresponding author), 5858 Horton St,Suite 200, Emeryville, CA 94608 USA.		Messing, Robert/D-3642-2015	Messing, Robert/0000-0002-5345-4431; Walter, Helen/0000-0003-2274-6172	NIAAA NIH HHS [AA08117] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008117] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bech-Hansen NT, 1998, NAT GENET, V19, P264, DOI 10.1038/947; BONE GHA, 1989, PSYCHOPHARMACOLOGY, V99, P386, DOI 10.1007/BF00445563; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Bouron A, 1995, FEBS LETT, V377, P159, DOI 10.1016/0014-5793(95)01327-X; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; COLOMBO G, 1994, EUR J PHARMACOL, V265, P167, DOI 10.1016/0014-2999(94)90427-8; COLOMBO G, 1995, ALCOHOL ALCOHOLISM, V30, P125; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FADDA F, 1992, ALCOHOL CLIN EXP RES, V16, P449, DOI 10.1111/j.1530-0277.1992.tb01398.x; GAYER GG, 1991, J BIOL CHEM, V266, P22279; Gerstin EH, 1998, J BIOL CHEM, V273, P16409, DOI 10.1074/jbc.273.26.16409; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GRANT AJ, 1993, BRAIN RES, V600, P280, DOI 10.1016/0006-8993(93)91384-5; GUPPY LJ, 1995, ALCOHOL ALCOHOLISM, V30, P607; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; Hogan K, 1996, GENOMICS, V31, P392, DOI 10.1006/geno.1996.0066; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Li WQ, 1996, ONCOGENE, V13, P731; LITTLE HJ, 1986, LIFE SCI, V39, P2059, DOI 10.1016/0024-3205(86)90356-5; LITTLETON JM, 1990, PSYCHOPHARMACOLOGY, V100, P387, DOI 10.1007/BF02244612; Liu HY, 1996, J NEUROSCI, V16, P7557; MASSA E, 1995, MOL PHARMACOL, V47, P707; MESSING RO, 1986, P NATL ACAD SCI USA, V83, P6213, DOI 10.1073/pnas.83.16.6213; MILES MF, 1991, J BIOL CHEM, V266, P2409; MILES MF, 1994, MOL PHARMACOL, V46, P873; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PEREZGARCIA MT, 1995, J GEN PHYSIOL, V105, P289, DOI 10.1085/jgp.105.2.289; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; Puri TS, 1997, BIOCHEMISTRY-US, V36, P9605, DOI 10.1021/bi970500d; REZVANI AH, 1991, ALCOHOL ALCOHOLISM, V26, P161, DOI 10.1093/oxfordjournals.alcalc.a045097; REZVANI AH, 1990, PROG NEURO-PSYCHOPH, V14, P623, DOI 10.1016/0278-5846(90)90013-7; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SKATTEBOL A, 1987, BIOCHEM PHARMACOL, V36, P2227, DOI 10.1016/0006-2952(87)90156-0; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; Strom TM, 1998, NAT GENET, V19, P260, DOI 10.1038/940; Walter HJ, 1999, ENDOCRINOLOGY, V140, P520, DOI 10.1210/en.140.1.520; WANG XM, 1991, J PHARMACOL EXP THER, V259, P705; WANG XM, 1994, J NEUROSCI, V14, P5453; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q	53	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25717	25722		10.1074/jbc.M910282199	http://dx.doi.org/10.1074/jbc.M910282199			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10835432	hybrid			2022-12-25	WOS:000088849400087
J	Zheng, DQ; Woodard, AS; Tallini, G; Languino, LR				Zheng, DQ; Woodard, AS; Tallini, G; Languino, LR			Substrate specificity of alpha(nu)beta(3) integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROSTATE CARCINOMA-CELLS; PROTEIN-KINASE; GROWTH-FACTOR; ALPHA(V)BETA(3) INTEGRIN; ALPHA-V-BETA-3 INTEGRIN; SURVIVAL PATHWAY; HUMAN-MELANOMA; PHOSPHOINOSITIDE 3-KINASE; EPITHELIAL-CELLS	The alpha(v)beta(3) integrin has been shown to bind several ligands, including osteopontin and vitronectin. Its role in modulating cell migration and downstream signaling pathways in response to specific extracellular matrix Ligands has been investigated in this study. Highly invasive prostate cancer PC3 cells that constitutively express alpha(v)beta(3) adhere and migrate on osteopontin and vitronectin in an alpha(v)beta(3)-dependent manner. However, exogenous expression of alpha(v)beta(3) in noninvasive prostate cancer LNCaP (beta(3)-LNCaP) cells mediates adhesion and migration on vitronectin but not on osteopontin. Activation of alpha(v)beta(3) by epidermal growth factor stimulation is required to mediate adhesion to osteopontin but is not sufficient to support migration on this substrate, We show that alpha(v)beta(3)-mediated cell migration requires activation of the phosphatidylinositol 3-kinase (PI 3-kinase)/protein kinase B (PKB/AKT) pathway since wortmannin, a PI 3-kinase inhibitor, prevents PC3 cell migration on both osteopontin and vitronectin; furthermore, alpha(v)beta(3) engagement by osteopontin and vitronectin activates the PI 3-kinase/AKT pathway. Migration of beta(3)-LNCaP cells on vitronectin also occurs through activation of the PI 3-kinase pathway; however, AKT phosphorylation is not increased upon engagement by osteopontin. Furthermore, phosphorylation of focal adhesion kinase (FAK), known to support cell migration in beta(3)-LNCaP cells, is detected on both substrates. Thus, in PC3 cells, alpha(v)beta(3) mediates cell migration and PI 3-kinase/AKT pathway activation on vitronectin and osteopontin; in beta(3)-LNCaP cells, alpha(v)beta(3) mediates cell migration and PI 3-kinase/AKT pathway activation on vitronectin, whereas adhesion to osteopontin does not support alpha(v)beta(3)-mediated cell migration and PI 3-kinase/AKT pathway activation. We conclude therefore that alpha(v)beta(3) exists in multiple functional states that can bind either selectively vitronectin or both vitronectin and osteopontin and that can differentially activate cell migration and intracellular signaling pathways in a ligand-specific manner.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Yale University	Languino, LR (corresponding author), Yale Univ, Sch Med, Dept Pathol, POB 208023,310 Cedar St, New Haven, CT 06520 USA.	lucia.languino@yale.edu	Tallini, Giovanni/F-7850-2013	Tallini, Giovanni/0000-0003-0113-6682; Languino, Lucia/0000-0001-9011-7031	NCI NIH HHS [CA-71870] Funding Source: Medline; NIDDK NIH HHS [DK-52670] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA071870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052670] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bayless KJ, 1998, J CELL SCI, V111, P1165; Bennett JS, 1997, J BIOL CHEM, V272, P8137, DOI 10.1074/jbc.272.13.8137; BROWN LF, 1994, AM J PATHOL, V145, P610; BUCKLEY AR, 1988, P NATL ACAD SCI USA, V85, P8649, DOI 10.1073/pnas.85.22.8649; Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765; Byzova TV, 1998, J CELL BIOL, V143, P2081, DOI 10.1083/jcb.143.7.2081; Cairns P, 1997, CANCER RES, V57, P4997; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Crawford HC, 1998, CANCER RES, V58, P5206; Davies MA, 1999, CANCER RES, V59, P2551; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Denda S, 1998, MOL BIOL CELL, V9, P1425, DOI 10.1091/mbc.9.6.1425; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Elgavish A, 1998, PROSTATE, V35, P83; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Faccio R, 1998, BIOCHEM BIOPH RES CO, V249, P522, DOI 10.1006/bbrc.1998.9180; FeldingHabermann B, 1996, J BIOL CHEM, V271, P5892, DOI 10.1074/jbc.271.10.5892; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Fornaro M, 1999, J CLIN INVEST, V103, P321, DOI 10.1172/JCI4585; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; HAAPASALMI K, 1995, AM J PATHOL, V147, P193; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; HRUSKA KA, 1995, ENDOCRINOLOGY, V136, P2984, DOI 10.1210/en.136.7.2984; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; Juliano Rudy, 1996, Bioessays, V18, P911, DOI 10.1002/bies.950181110; Katagiri YU, 1999, CANCER RES, V59, P219; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; Lin JQ, 1999, CANCER RES, V59, P2891; Lindberg FP, 1996, J CELL BIOL, V134, P1313, DOI 10.1083/jcb.134.5.1313; MIYATA Y, 1989, J BIOL CHEM, V264, P15565; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Oates AJ, 1996, ONCOGENE, V13, P97; Otey CA, 1996, INT REV CYTOL, V167, P161, DOI 10.1016/S0074-7696(08)61347-9; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; PELLETIER AJ, 1995, J BIOL CHEM, V270, P18133, DOI 10.1074/jbc.270.30.18133; Pelletier AJ, 1996, J BIOL CHEM, V271, P1364, DOI 10.1074/jbc.271.3.1364; Petitclerc E, 1999, CANCER RES, V59, P2724; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Rittling SR, 1999, EXP NEPHROL, V7, P103; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SAEGUSA Y, 1990, J CELL PHYSIOL, V142, P488, DOI 10.1002/jcp.1041420307; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SENGER DR, 1983, NATURE, V302, P714, DOI 10.1038/302714a0; Senger DR, 1996, BBA-MOL CELL RES, V1314, P13, DOI 10.1016/S0167-4889(96)00067-5; SENGER DR, 1989, BIOCHIM BIOPHYS ACTA, V996, P43, DOI 10.1016/0167-4838(89)90092-7; Senger DR, 1996, AM J PATHOL, V149, P293; Shattil SJ, 1997, J CLIN INVEST, V100, P1, DOI 10.1172/JCI119500; Smith LL, 1998, EXP CELL RES, V242, P351, DOI 10.1006/excr.1998.4108; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Thalmann GN, 1999, CLIN CANCER RES, V5, P2271; Trusolino L, 1998, J CELL BIOL, V142, P1145, DOI 10.1083/jcb.142.4.1145; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; Wei JY, 1998, J BIOL CHEM, V273, P5903, DOI 10.1074/jbc.273.10.5903; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Woodard AS, 1998, J CELL SCI, V111, P469; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Zheng DQ, 1999, CANCER RES, V59, P1655	79	122	128	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24565	24574		10.1074/jbc.M002646200	http://dx.doi.org/10.1074/jbc.M002646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10835423	hybrid			2022-12-25	WOS:000088683300046
J	Verdier, F; Walrafen, P; Hubert, N; Chretien, S; Gisselbrecht, S; Lacombe, C; Mayeux, P				Verdier, F; Walrafen, P; Hubert, N; Chretien, S; Gisselbrecht, S; Lacombe, C; Mayeux, P			Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; INDUCED ERYTHROID-DIFFERENTIATION; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ERYTHROLEUKEMIA-CELLS; STAT5 ACTIVATION; GROWTH-HORMONE; MEDIATED ENDOCYTOSIS; PATHWAY	The binding of erythropoietin (Epo) to its receptor leads to the transient phosphorylation of the Epo receptor (EpoR) and the activation of intracellular signaling pathways. Inactivation mechanisms are simultaneously turned on, and Epo-induced signaling pathways return to nearly basal levels after 30-60 min of stimulation. me show that proteasomes control these inactivation mechanisms. In cells treated with the proteasome inhibitors N-Ac-Leu-Leu-norleucinal (LLnL) or lactacystin, EpoR tyrosine phosphorylation and activation of intracellular signaling pathways (Jak2, STAT5, phosphatidylinositol S-kinase) were sustained for at least 2 h, We show that this effect was due to the continuous replenishment of the cell surface pool of EpoRs in cells treated with proteasome inhibitors. Proteasome inhibitors did not modify the internalization and degradation of Epo EpoR complexes, but they allowed the continuous replacement of the internalized receptors by newly synthesized receptors, Proteasome inhibitors did not modify the synthesis of EpoRs, but they allowed their transport to the cell surface. N-Ac-Leu-Leu-norleucinal, but not lactacystin, also inhibited the degradation of internalized Epo EpoR complexes, most probably through cathepsin inhibition. The internalized EpoRs were not tyrosinephosphorylated, and they did not activate intracellular signaling pathways. Our results show that the proteasome controls the down-regulation of EpoRs in Epo-stimulated cells by inhibiting the cell surface replacement of internalized EpoRs.	Univ Paris 05, Hop Cochin, INSERM U363, Inst Cochin Genet Mol, F-75014 Paris, France; Univ Paris 05, Hop Cochin, Serv Hematol, F-75014 Paris, France; Inst Natl Transfus Sanguine, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Mayeux, P (corresponding author), Univ Paris 05, Hop Cochin, INSERM U363, Inst Cochin Genet Mol, 27 Rue Fraubourg St Jacques, F-75014 Paris, France.		Chretien, Stany/M-5166-2018					Callus BA, 1998, BLOOD, V91, P3182, DOI 10.1182/blood.V91.9.3182.3182_3182_3192; CHRETIEN S, 1994, BLOOD, V83, P1813; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; DAMEN JE, 1993, BLOOD, V81, P3204; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Fontenay-Roupie M, 1999, BRIT J HAEMATOL, V106, P464, DOI 10.1046/j.1365-2141.1999.01539.x; FUKAMACHI H, 1987, INT J CELL CLONING, V5, P209, DOI 10.1002/stem.5530050305; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Gebert CA, 1999, MOL ENDOCRINOL, V13, P38, DOI 10.1210/me.13.1.38; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; GOBERT S, 1995, EUR J BIOCHEM, V234, P75, DOI 10.1111/j.1432-1033.1995.075_c.x; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HE TC, 1993, BLOOD, V82, P3530; HEMAR A, 1995, J CELL BIOL, V129, P55, DOI 10.1083/jcb.129.1.55; Hermine O, 1996, BLOOD, V87, P1746; Hunter MG, 1999, BLOOD, V93, P440, DOI 10.1182/blood.V93.2.440.402k23_440_446; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Komatsu N, 1997, BLOOD, V89, P1182, DOI 10.1182/blood.V89.4.1182; KOMATSU N, 1992, BLOOD, V80, P53; KOMATSU N, 1991, CANCER RES, V51, P341; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Levin I, 1998, FEBS LETT, V427, P164, DOI 10.1016/S0014-5793(98)00414-1; Malek RL, 1999, CYTOKINE, V11, P192, DOI 10.1006/cyto.1998.0421; MAYEUX P, 1987, J BIOL CHEM, V262, P13985; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MAYEUX P, 1990, EUR J BIOCHEM, V194, P271, DOI 10.1111/j.1432-1033.1990.tb19453.x; MIURA O, 1994, J BIOL CHEM, V269, P614; MIURA Y, 1994, J BIOL CHEM, V269, P29962; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; MUFSON RA, 1987, BLOOD, V69, P1485; Neumann D, 1996, BIOCHEM J, V313, P391, DOI 10.1042/bj3130391; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SAWYER ST, 1987, J BIOL CHEM, V262, P5554; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; Strous GJ, 1997, J BIOL CHEM, V272, P40; Verdier F, 1997, J BIOL CHEM, V272, P26173, DOI 10.1074/jbc.272.42.26173; Verdier F, 1998, J BIOL CHEM, V273, P28185, DOI 10.1074/jbc.273.43.28185; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; Ward AC, 1999, BLOOD, V93, P447, DOI 10.1182/blood.V93.2.447; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017	49	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18375	18381		10.1074/jbc.275.24.18375	http://dx.doi.org/10.1074/jbc.275.24.18375			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849444	hybrid			2022-12-25	WOS:000087659400064
J	Bies, J; Feikova, S; Bottaro, DP; Wolff, L				Bies, J; Feikova, S; Bottaro, DP; Wolff, L			Hyperphosphorylation and increased proteolytic breakdown of c-Myb induced by the inhibition of Ser/Thr protein phosphatases	ONCOGENE			English	Article						c-Myb; proteolysis; phosphorylation; 26S proteasome; Ser/Thr phosphatases	NEGATIVE REGULATORY DOMAIN; INDUCED TRANSCRIPTION ACTIVATION; DNA-BINDING DOMAIN; KAPPA-B-ALPHA; V-MYB; PHOSPHORYLATION SITE; PROTEASOME PATHWAY; ONCOGENIC ACTIVATION; TRANS-ACTIVATION; TERMINAL REGION	The c-myb proto-oncogene encodes a nuclear phosphoprotein that plays a crucial role in normal hematopoiesis. It is a short-lived transcription factor rapidly degraded by the 26S proteasome, Although it has been shown that instability determinants reside in its carboxyl terminus, the molecular mechanism of c-Myb degradation is unknown, Here, we report the first evidence that phosphorylation plays a role in targeting the protein to the proteasome, Inhibition of cellular serine/threonine protein phosphatase activity by okadaic acid resulted in hyperphosphorylation of c-Myb and extremely rapid turnover, The hyperphosphorylation resulted in a protein with altered properties that was indicative of conformational changes. Its mobility on gel electrophoresis was altered as well as its recognition by specific monoclonal antibody, The altered hyperphosphorylated protein still bound to DNA with an affinity similar to that of the hypophosphorylated form, Phosphorylation of three previously identified sites, serines 11, 12, and 528, does not appear to be involved in the proposed changes in conformation or stability, However, phosphoamino acid analyses of the hyperphosphorylated form of c-Myb revealed increased c-Myb phosphorylation mainly on threonine residues that correlated with other okadaic acid-induced alterations of c-Myb, These findings indicate that Ser/Thr phosphatases prevent conformational changes that may play an important role in controlled degradation of c-Myb.	NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA; Slovak Acad Sci, Canc Res Inst, Mol Virol Lab, Bratislava 83392, Slovakia; NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Slovak Academy of Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wolff, L (corresponding author), NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA.		Bottaro, Donald P/F-8550-2010; Bottaro, Donald P/AAF-3853-2020	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334	NATIONAL CANCER INSTITUTE [Z01BC008952] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZIZ N, 1993, ONCOGENE, V8, P2259; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BADING H, 1989, ONCOGENE, V4, P33; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bies J, 1996, ONCOGENE, V12, P355; Bies J, 1999, J VIROL, V73, P2038, DOI 10.1128/JVI.73.3.2038-2044.1999; Bies J, 1997, ONCOGENE, V14, P203, DOI 10.1038/sj.onc.1200828; Biesova Z, 1997, ONCOGENE, V14, P233, DOI 10.1038/sj.onc.1200822; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Calkhoven CF, 1996, BIOCHEM J, V317, P329, DOI 10.1042/bj3170329; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DAI P, 1996, GENE DEV, V10, P28; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Dubendorff JW, 1999, ONCOGENE, V18, P3452, DOI 10.1038/sj.onc.1202679; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; KRIEG J, 1995, ONCOGENE, V10, P2221; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; OELGESCHLAGER M, 1995, MOL CELL BIOL, V15, P5966; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Ogata K, 1996, NAT STRUCT BIOL, V3, P178, DOI 10.1038/nsb0296-178; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60; WON KA, 1996, EMBO J, V15, P182	44	26	26	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2000	19	24					2846	2854		10.1038/sj.onc.1203613	http://dx.doi.org/10.1038/sj.onc.1203613			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851088				2022-12-25	WOS:000087403600006
J	Hernandez-Munoz, I; Malumbres, M; Leonardi, P; Pellicer, A				Hernandez-Munoz, I; Malumbres, M; Leonardi, P; Pellicer, A			The Rgr oncogene (homologous to RalGDS) induces transformation and gene expression by activating Ras, Ral and Rho mediated pathways	ONCOGENE			English	Article						Rgr; oncogene; exchange factor; Ral; signal transduction	NUCLEOTIDE EXCHANGE FACTORS; TERNARY COMPLEX FACTORS; C-FOS PROMOTER; NIH 3T3 CELLS; DISSOCIATION STIMULATOR; INCREASING COMPLEXITY; SIGNAL-TRANSDUCTION; BINDING PROTEIN-1; MAMMALIAN-CELL; GTPASES	The effects of the 5'-truncated Rgr oncogene, previously shown specific guanine exchange factor for Ral in vitro, in stimulating proliferation, cell transformation and gene expression were investigated. We have established TetRgr cell lines in which expression of Rgr can be inhibited by the presence of tetracycline in the medium. Using this system, we show that Rgr overexpressing cells are morphologically transformed and grow in a disorganized manner. At the transcriptional level, Rgr enhances the activity of the serum response element and c-Jun. Rgr induces phosphorylation of ERKs, p38 and JNK kinases, and increases the levels of the GTP-bound forms of Ral and Ras. I:as activation could account for the broad spectra of effects displayed by Rgr. The important role of these pathways is confirmed by experiments in which the transcriptional activation events can be blocked by dominant negative versions of Ras, Ral and Rho. Among all the Rgr-induced pathways, the Ras-Raf-MEK-ERK cascade is essential for the transforming properties of Rgr. Additional analysis has shown that the activation of this pathway by Rgr is not due to a feed back mechanism mediated by the Grb2 adaptor protein.	NYU Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU Med Ctr, Kaplan Canc Ctr, New York, NY 10016 USA	New York University; New York University	Pellicer, A (corresponding author), NYU Med Ctr, Dept Pathol, New York, NY 10016 USA.		Malumbres, Marcos/E-8834-2011; MARTINEZ, ANTONIO PELLICER/C-4832-2015; Holt, Janet E/B-2415-2013	Malumbres, Marcos/0000-0002-0829-6315; Pellicer, Angel/0000-0002-5062-0692	NATIONAL CANCER INSTITUTE [R37CA036327, R01CA050434, R01CA036327] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36327, CA 50434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Bos JL, 1997, BBA-REV CANCER, V1333, pM19, DOI 10.1016/S0304-419X(97)00015-2; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; Day GJ, 1998, MOL CELL BIOL, V18, P7444, DOI 10.1128/MCB.18.12.7444; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Goi T, 1999, MOL CELL BIOL, V19, P1731; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Mangues R, 1998, CANCER RES, V58, P1253; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Murai H, 1997, J BIOL CHEM, V272, P10483; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sawamoto K, 1999, J CELL BIOL, V146, P361, DOI 10.1083/jcb.146.2.361; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Verheijen MHG, 1999, ONCOGENE, V18, P4435, DOI 10.1038/sj.onc.1202834; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	53	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2000	19	23					2745	2757		10.1038/sj.onc.1203586	http://dx.doi.org/10.1038/sj.onc.1203586			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851075	Bronze			2022-12-25	WOS:000087318500003
J	Schmidt, M; Lu, Y; Liu, BL; Fang, M; Mendelsohn, J; Fan, Z				Schmidt, M; Lu, Y; Liu, BL; Fang, M; Mendelsohn, J; Fan, Z			Differential modulation of paclitaxel-mediated apoptosis by p21(Waf1) and p27(Kip1)	ONCOGENE			English	Article						paclitaxel; chemoresistance; cell cycle; p21(Waf1); p27(Kip1)	TAXOL-INDUCED APOPTOSIS; CELL-CYCLE ARREST; P34(CDC2) KINASE; DNA-REPLICATION; CARCINOMA-CELLS; PROTEIN-KINASE; G(2)-M ARREST; CANCER CELLS; M-PHASE; PHOSPHORYLATION	The impact of the cyclin dependent kinase (CDK) inhibitors p21(Waf1) and p27(Kip1) on paclitaxel-mediated cytotoxicity was investigated in RKO human colon adenocarcinoma cells with the ecdysone-inducible expression of p21(Waf1) or p27(Kip1). Ectopic expression of p27(Kip1) arrested cells at G1 phase, whereas p21(Waf1) expression arrested cells at G1 and G2, Expression of p21(Waf1) after paclitaxel treatment produced much greater resistance to paclitaxel than did expression of p27(Kip1). We attributed this difference to the additional block at G2 induced by p21(Waf1), which prevented cells from entering M phase and becoming paclitaxel susceptible. Expression of p21(Waf1) inhibited p34cdc2 activity and markedly reduced paclitaxel-mediated mitotic arrest, from 87.5 to 23%, In contrast, p27(Kip1) expression also inhibited p34cdc2 but reduced mitotic arrest only slightly, from 87.4 to 74.5%, We concluded that the G2 block produced by p21(Waf1), but not by p27(Kip1), contributed to their unequal modulation of sensitivity to paclitaxel-mediated apoptosis in RKO cells, and there is no causal relationship between paclitaxel-mediated cytotoxicity and elevation of p34cdc2 activity.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Div Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Div Med, 1515 Holcombe Blvd, Houston, TX 77030 USA.			Liu, Bolin/0000-0003-0150-8650	NCI NIH HHS [CA16672, CA68425] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA068425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amato SF, 1998, CANCER RES, V58, P241; Blagosklonny MV, 1997, CANCER RES, V57, P130; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; Frankel A, 1997, CANCER RES, V57, P2388; Haldar S, 1996, CANCER RES, V56, P1253; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Ibrado AM, 1997, CANCER RES, V57, P1109; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; LARSEN JK, 1986, CYTOMETRY, V7, P54, DOI 10.1002/cyto.990070108; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Li WW, 1999, MOL PHARMACOL, V55, P1088, DOI 10.1124/mol.55.6.1088; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rakovitch E, 1999, INT J RADIAT ONCOL, V44, P1119, DOI 10.1016/S0360-3016(99)00109-1; ROWINSKY EK, 1997, SEMIN ONCOL S19, V24, P1; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Shen SC, 1998, CELL GROWTH DIFFER, V9, P23; Sorger PK, 1997, CURR OPIN CELL BIOL, V9, P807, DOI 10.1016/S0955-0674(97)80081-6; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Uren A, 1997, J BIOL CHEM, V272, P21669, DOI 10.1074/jbc.272.35.21669; van Bree C, 1999, J CANCER RES CLIN, V125, P549, DOI 10.1007/s004320050315; VERLHAC MH, 1993, DEV BIOL, V158, P330, DOI 10.1006/dbio.1993.1192; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wu XP, 1996, ONCOGENE, V12, P1397; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4	33	59	62	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2423	2429		10.1038/sj.onc.1203546	http://dx.doi.org/10.1038/sj.onc.1203546			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828884				2022-12-25	WOS:000087018400007
J	Ashar, HR; James, L; Gray, K; Carr, D; Black, S; Armstrong, L; Bishop, WR; Kirschmeier, P				Ashar, HR; James, L; Gray, K; Carr, D; Black, S; Armstrong, L; Bishop, WR; Kirschmeier, P			Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE SOMATIC-CELLS; PROTEIN TRANSFERASE; IN-VITRO; CHROMOSOME ALIGNMENT; RAS FARNESYLATION; KI-RAS; N-RAS; ANAPHASE; KINETOCHORES; MITOSIS	Human tumor cell lines that are sensitive to the effects of farnesyl transferase inhibitors accumulate in G(2) --> M (except for cells with an activated Ha-ras that accumulate in G(1)). A search for CAAX box proteins from Swiss-Prot revealed more than 300 peptides. Of these, the centromeric proteins CENP-E and CENP-F are preferentially expressed during mitosis and are implicated as mediators of the G(2) --> M checkpoint. Experiments performed here show that peptides from the COOH-terminal CAAX box of CENP-E and CENP-F are substrates for farnesyl transferase but not geranylgeranyl transferase-I. Although both proteins are prenylated in the human tumor cell line DLD-1, their prenylation is completely inhibited by the farnesyl transferase inhibitor, SCH 66336. Immunohistochemical data with the lung carcinoma cell line, A549, showed that preventing the farnesylation of CENP-E and CENP-F by treatment with the farnesyl transferase inhibitor SCH 66336 does not affect their localization to the kinetochores. However, the presence of farnesyl transferase inhibitors alters the association between CENP-E and the microtubules. Our results imply that the inhibition of CENP-E farnesylation results in the alteration of the microtubule-centromere interaction during mitosis and results in the accumulation of cells prior to metaphase.	Schering Plough Corp, Res Inst, Dept Tumor Biol, Kenilworth, NJ 07033 USA	Merck & Company; Schering Plough Corporation	Kirschmeier, P (corresponding author), Schering Plough Corp, Res Inst, Dept Tumor Biol, Mail Stop 4950,2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.	Paul.kirschmeier@spcorp.com						Adjei AA, 2000, CANCER RES, V60, P1871; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; Brown KD, 1996, J CELL SCI, V109, P961; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Cooke CA, 1997, CHROMOSOMA, V106, P446, DOI 10.1007/s004120050266; COX AD, 1994, J BIOL CHEM, V269, P19203; Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; DER J, 1991, CANCER CELL, V3, P331; End DW, 1999, INVEST NEW DRUG, V17, P241, DOI 10.1023/A:1006380320290; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Hill BT, 2000, CRIT REV ONCOL HEMAT, V33, P7, DOI 10.1016/S1040-8428(99)00053-0; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KEATES RAB, 1984, CAN J BIOCHEM CELL B, V62, P803, DOI 10.1139/o84-102; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LIAO H, 1994, SCIENCE, V265, P394, DOI 10.1126/science.8023161; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Liu M, 1998, CANCER RES, V58, P4947; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; LUYKX P, 1965, EXP CELL RES, V39, P643, DOI 10.1016/0014-4827(65)90068-6; Miquel K, 1997, CANCER RES, V57, P1846; Moasser MM, 1998, P NATL ACAD SCI USA, V95, P1369, DOI 10.1073/pnas.95.4.1369; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; NAGASU T, 1995, CANCER RES, V55, P5310; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Njoroge FG, 1997, J MED CHEM, V40, P4290, DOI 10.1021/jm970464g; Pennisi E, 1998, SCIENCE, V279, P477, DOI 10.1126/science.279.5350.477; RATTNER JB, 1993, CELL MOTIL CYTOSKEL, V26, P214, DOI 10.1002/cm.970260305; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Rieder CL, 1998, J CELL BIOL, V142, P1013, DOI 10.1083/jcb.142.4.1013; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Schaar BT, 1997, J CELL BIOL, V139, P1373, DOI 10.1083/jcb.139.6.1373; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; THROWER DA, 1995, EMBO J, V14, P918, DOI 10.1002/j.1460-2075.1995.tb07073.x; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Wood KW, 1997, CELL, V91, P357, DOI 10.1016/S0092-8674(00)80419-5; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95; Wright J, 1999, Oncology (Williston Park), V13, P1533; WRIGHT J, 1999, ONCOLOGY, V13, P1530; WRIGHT J, 1999, ONCOLOGY, V13, P1533; Yao XB, 1997, J CELL BIOL, V139, P435, DOI 10.1083/jcb.139.2.435; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; Zhang FL, 1997, J BIOL CHEM, V272, P10232; ZHU XL, 1995, MOL CELL BIOL, V15, P5017; Zhu XL, 1999, MOL CELL BIOL, V19, P1016; Zhu XL, 1997, J CELL BIOCHEM, V66, P441, DOI 10.1002/(SICI)1097-4644(19970915)66:4<441::AID-JCB3>3.0.CO;2-L; Zujewski J, 2000, J CLIN ONCOL, V18, P927, DOI 10.1200/JCO.2000.18.4.927	55	285	295	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30451	30457		10.1074/jbc.M003469200	http://dx.doi.org/10.1074/jbc.M003469200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10852915	hybrid			2022-12-25	WOS:000089577900073
J	Ogden, SK; Lee, KC; Barton, MC				Ogden, SK; Lee, KC; Barton, MC			Hepatitis B viral transactivator HBx alleviates p53-mediated repression of alpha-fetoprotein gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-X-PROTEIN; TATA-BINDING PROTEIN; P53 RESPONSE ELEMENT; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTOR; LIVER-CANCER; DNA-BINDING; REGULATORY ELEMENTS; SYNTHETIC NUCLEI; WILD-TYPE	Chronic infection with hepatitis B virus (HBV) is associated with development of hepatocellular carcinoma (HCC). The exact mechanism by which chronic infection with HBV contributes to onset of HCC is unknown, However, previous studies have implicated the HBV transactivator protein, HBx, in progression of HCC through its ability to bind the human tumor suppressor protein, p53. In this study, we have examined the ability of HBx to modify p53 regulation of the HCC tumor marker gene, alpha-fetoprotein (AFP). By utilizing in vitro chromatin assembly of DNA templates prior to transcription analysis, we hare demonstrated that HBx functionally disrupts p53-mediated repression of AFP transcription through protein-protein interaction. HBx modification of p53 gene regulation is both tissue-specific and dependent upon the p53 binding element. Our data suggest that the mechanism by which HBx alleviates p53 repression of AFP transcription is through an association with DNA-bound p53, resulting in a loss of p53 interaction with liver-specific transcriptional co-repressors.	Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Barton, MC (corresponding author), Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, POB 670524, Cincinnati, OH 45267 USA.	Michelle.Barton@UC.edu	Ogden, Stacey K/N-2528-2018; Ogden, Stacey K/P-9585-2019	Ogden, Stacey K/0000-0001-8991-3065; Barton, Michelle/0000-0002-4042-1374	NATIONAL CANCER INSTITUTE [T32CA059268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053683] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 59268] Funding Source: Medline; NIGMS NIH HHS [GM53683] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrisani OM, 1999, INT J ONCOL, V15, P373; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Barton MC, 1996, METHOD ENZYMOL, V274, P299; BELAYEW A, 1982, MOL CELL BIOL, V2, P1427, DOI 10.1128/MCB.2.11.1427; Buendia M A, 1992, Semin Cancer Biol, V3, P309; CAMPAGNA JC, 1991, LEGIS STUD QUART, V16, P81, DOI 10.2307/439968; CAMPER SA, 1989, PROG NUCLEIC ACID RE, V36, P131; CAMPER SA, 1989, GENE DEV, V3, P537, DOI 10.1101/gad.3.4.537; CRANDALL BF, 1981, CRC CR REV CL LAB SC, V15, P127, DOI 10.3109/10408368109105870; Crowe AJ, 1999, J BIOL CHEM, V274, P25113, DOI 10.1074/jbc.274.35.25113; CROWE AJ, 1993, ONCOGENE, V8, P181; Crowe AJ, 1999, METHODS, V17, P173, DOI 10.1006/meth.1998.0728; Crowe AJ, 1999, METHOD ENZYMOL, V304, P63; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; EMERSON BM, 1989, CELL, V57, P1189, DOI 10.1016/0092-8674(89)90056-1; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Feitelson MA, 1997, AM J PATHOL, V150, P1141; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; GODBOUT R, 1986, MOL CELL BIOL, V6, P477, DOI 10.1128/MCB.6.2.477; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Hildt E, 1998, RECENT RES CANCER, V154, P315; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSIA CC, 1992, J NATL CANCER I, V84, P1638, DOI 10.1093/jnci/84.21.1638; HSIA CC, 1992, HEPATOLOGY, V16, P1327, DOI 10.1002/hep.1840160604; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jin DK, 1998, P NATL ACAD SCI USA, V95, P8767, DOI 10.1073/pnas.95.15.8767; Kew MC, 1996, CLIN LAB MED, V16, P395, DOI 10.1016/S0272-2712(18)30276-2; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; Lee H, 1995, J BIOL CHEM, V270, P31405, DOI 10.1074/jbc.270.52.31405; Lee H, 1998, J BIOL CHEM, V273, P19786, DOI 10.1074/jbc.273.31.19786; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAMESH TM, 1995, MOL CELL BIOL, V15, P4947; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SPEAR BT, 1994, MOL CELL BIOL, V14, P6497, DOI 10.1128/MCB.14.10.6497; SPEAR BT, 1995, DNA CELL BIOL, V14, P635, DOI 10.1089/dna.1995.14.635; Stuver SO, 1998, SEMIN CANCER BIOL, V8, P299, DOI 10.1006/scbi.1998.0079; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Tilghman S M, 1985, Oxf Surv Eukaryot Genes, V2, P160; TILGHMAN SM, 1982, P NATL ACAD SCI-BIOL, V79, P5254, DOI 10.1073/pnas.79.17.5254; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; VACHER J, 1990, SCIENCE, V250, P1732, DOI 10.1126/science.1702902; Wang XW, 1998, LIFE SCI, V64, P17, DOI 10.1016/S0024-3205(98)00529-3; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEN P, 1993, NUCLEIC ACIDS RES, V21, P1911, DOI 10.1093/nar/21.8.1911; WEN P, 1994, MOL CELL BIOL, V14, P6616, DOI 10.1128/MCB.14.10.6616; WEN P, 1991, DNA CELL BIOL, V10, P525, DOI 10.1089/dna.1991.10.525; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; Zaret KS, 1995, PROTEIN EXPRES PURIF, V6, P821, DOI 10.1006/prep.1995.0014; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929	68	45	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27806	27814						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10842185				2022-12-25	WOS:000089197100040
J	Gadina, M; Sudarshan, C; Visconti, R; Zhou, YJ; Gu, HH; Neel, BG; O'Shea, JJ				Gadina, M; Sudarshan, C; Visconti, R; Zhou, YJ; Gu, HH; Neel, BG; O'Shea, JJ			The docking molecule Gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common gamma chain-using cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL PROLIFERATION; RECEPTOR-BETA-CHAIN; COLONY-STIMULATING FACTOR; TYROSINE PHOSPHORYLATION; IL-2 RECEPTOR; TRANSDUCTION PATHWAYS; KINASE ACTIVATION; JANUS KINASE; PROTEIN; SHC	Interleukin (IL)-2, a critical cytokine with indispensable functions in regulating lymphoid homeostasis, induces the activation of several biochemical pathways. Precisely how these pathways are linked and how they relate to the biological action of IL-2 is incompletely understood. We previously identified SHP-2 (Src homology 2 domain containing phosphatase 2) as an important intermediate in IL-S-dependent MAPK activation and showed its association with a 98-kDa phosphoprotein in response to IL-2. Were, we demonstrate that Gaba, a recently identified adapter molecule, is the major SHP-2 and phosphatidylinositol 31-kinase-associated 98 kDa protein in normal, IL-a-activated lymphocytes. We further demonstrate that phosphorylation of both Gab2 and SHP-2 is largely dependent upon tyrosine 338 of the IL-2 receptor beta chain. Gaba can be a substrate of all the three major classes of non-receptor tyrosine kinases associated with the IL-SR, but in terms of IL-2 signaling, JAK3 but not Lck or Syk is essential for Gabs phosphorylation, We also demonstrate that only IL-2 and IL-15, but not other gamma c cytokines induce Gabs phosphorylation; the ability to phosphorylate Gaba correlates with Shc phosphorylation and ERK1/ERK2 activation. Finally, we also show that Gaba levels are regulated by T cell activation, and resting T cells express little Gaba. Therefore, up-regulation and activation of Gaba may be important in linking the IL-2 receptor to activation of MAPK and may be an important means of achieving specificity in cytokine signaling.	NIAMS, Lymphocyte Cell Biol Sect, Arthrit & Rheumatism Branch, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol,Dept Med, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Gadina, M (corresponding author), Bldg 10,Rm 9N228,10 Ctr Dr,MSC 1820, Bethesda, MD 20892 USA.		Visconti, Roberta/C-5299-2009; Gadina, Massimo/R-4195-2019		NCI NIH HHS [CA72144] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA072144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041106, ZIAAR041106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adachi M, 1997, ONCOGENE, V14, P1629, DOI 10.1038/sj.onc.1200981; BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; Barber DL, 1997, BLOOD, V89, P55, DOI 10.1182/blood.V89.1.55.55_55_64; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BURNS LA, 1993, J BIOL CHEM, V268, P17659; Cho SS, 1996, J IMMUNOL, V157, P4781; Crawley JB, 1996, EUR J IMMUNOL, V26, P2717, DOI 10.1002/eji.1830261125; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Gadina M, 1999, J IMMUNOL, V162, P2081; Gadina M, 1998, J IMMUNOL, V160, P4657; Gesbert F, 1998, J BIOL CHEM, V273, P18273, DOI 10.1074/jbc.273.29.18273; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MERIDA I, 1991, J IMMUNOL, V147, P2202; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Nelson BH, 1997, P NATL ACAD SCI USA, V94, P1878, DOI 10.1073/pnas.94.5.1878; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; Ravichandran KS, 1996, P NATL ACAD SCI USA, V93, P5275, DOI 10.1073/pnas.93.11.5275; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Taniguchi T, 1995, ANN NY ACAD SCI, V766, P235, DOI 10.1111/j.1749-6632.1995.tb26671.x; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; Zhou YJ, 2000, MOL CELL BIOL, V20, P4371, DOI 10.1128/MCB.20.12.4371-4380.2000	40	84	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26959	26966						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10849428				2022-12-25	WOS:000089144800040
J	Kim, YG; Lowenhaupt, K; Maas, S; Herbert, A; Schwartz, T; Rich, A				Kim, YG; Lowenhaupt, K; Maas, S; Herbert, A; Schwartz, T; Rich, A			The Zab domain of the human RNA editing enzyme ADAR1 recognizes Z-DNA when surrounded by B-DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HANDED Z-DNA; Z-ALPHA DOMAIN; Z JUNCTION FORMATION; ADENOSINE-DEAMINASE; BINDING DOMAIN; RESTRICTION-ENDONUCLEASE; PHYSIOLOGICAL CONDITIONS; ANTIBODY-BINDING; ENERGETICS; TRANSITION	The Zab domain of the editing enzyme ADAR1 binds tightly and specifically to Z-DNA stabilized by bromination or supercoiling. A stoichiometric amount of protein has been shown to convert a substrate of suitable sequence to the Z form, as demonstrated by a characteristic change in the CD spectrum of the DNA. Now we show that Zab can bind not only to isolated Z-forming d(CG)(n) sequences but also to d(CG;), embedded in B-DNA, The binding of Zab to such sequences results in a complex including Z-DNA B-DNA, and two B-Z junctions. In this complex, the d(CG), sequence, but not the flanking region, is in the Z conformation. The presence of Z-DNA was detected by cleavage with a Z-DNA specific nuclease, by undermethylation using Z-DNA sensitive SssI methylase, and by circular dichroism. It is possible that Zab binds to B-DNA with low affinity and flips any favorable sequence into Z-DNA, resulting in a high affinity complex. Alternatively, Zab may capture Z-DNA that exists transiently in solution. The binding of Zab to potential as well as established Z-DNA segments suggests that the range of biological substrates might be wider than previously thought.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Rich, A (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Schwartz, Thomas/K-9029-2017; Schwartz, Thomas/ABA-1770-2021; Herbert, Alan/AAY-4286-2020	Schwartz, Thomas/0000-0001-8012-1512; Schwartz, Thomas/0000-0001-8012-1512; /0000-0002-8187-6498; Herbert, Alan/0000-0002-0093-1572				Berger I, 1998, BIOCHEMISTRY-US, V37, P13313, DOI 10.1021/bi9813126; DOKTYCZ MJ, 1990, J MOL BIOL, V212, P3, DOI 10.1016/0022-2836(90)90297-Y; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; HANIFORD DB, 1983, NATURE, V302, P632, DOI 10.1038/302632a0; Herbert A, 1998, NUCLEIC ACIDS RES, V26, P3486, DOI 10.1093/nar/26.15.3486; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; Kim YG, 1999, J BIOL CHEM, V274, P19081, DOI 10.1074/jbc.274.27.19081; Kim YG, 1997, P NATL ACAD SCI USA, V94, P12875, DOI 10.1073/pnas.94.24.12875; LAFER EM, 1985, EMBO J, V4, P3655, DOI 10.1002/j.1460-2075.1985.tb04131.x; Maas S, 1997, CURR OPIN CELL BIOL, V9, P343, DOI 10.1016/S0955-0674(97)80006-3; NORDHEIM A, 1982, CELL, V31, P309, DOI 10.1016/0092-8674(82)90124-6; PECK LJ, 1982, P NATL ACAD SCI-BIOL, V79, P4560, DOI 10.1073/pnas.79.15.4560; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; Schade M, 1999, FEBS LETT, V458, P27, DOI 10.1016/S0014-5793(99)01119-9; Schade M, 1999, P NATL ACAD SCI USA, V96, P12465, DOI 10.1073/pnas.96.22.12465; Schwartz T, 1999, J BIOL CHEM, V274, P2899, DOI 10.1074/jbc.274.5.2899; Schwartz T, 1999, ACTA CRYSTALLOGR D, V55, P1362, DOI 10.1107/S090744499900582X; Schwartz T, 1999, SCIENCE, V284, P1841, DOI 10.1126/science.284.5421.1841; SHEARDY RD, 1993, J MOL BIOL, V231, P475, DOI 10.1006/jmbi.1993.1295; SINGLETON CK, 1982, NATURE, V299, P312, DOI 10.1038/299312a0; Vardimon L, 1985, Prog Clin Biol Res, V198, P23; VARDIMON L, 1984, P NATL ACAD SCI-BIOL, V81, P3268, DOI 10.1073/pnas.81.11.3268; Wah DA, 1998, P NATL ACAD SCI USA, V95, P10564, DOI 10.1073/pnas.95.18.10564	25	48	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26828	26833						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10843996				2022-12-25	WOS:000089144800024
J	Nakamura, K; Yano, H; Uchida, H; Hashimoto, S; Schaefer, E; Sabe, H				Nakamura, K; Yano, H; Uchida, H; Hashimoto, S; Schaefer, E; Sabe, H			Tyrosine phosphorylation of paxillin alpha is involved in temporospatial regulation of paxillin-containing focal adhesion formation and F-actin organization in motile cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARP2/3 COMPLEX; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; STRESS FIBERS; RHO-GTPASES; BINDING; MIGRATION; PROTEIN; KINASE; CYTOSKELETON	Temporal and spatial regulation of actin-based cytoskeletal organization and focal adhesion formation play an essential role in cell migration. Here, we show that tyrosine phosphorylation of a focal adhesion protein, paxillin, crucially participates in these regulations. We found that tyrosine phosphorylation of paxillin was a prominent event upon integrin activation during epithelial-mesenchymal trans differentiation and cell migration. Four major tyrosine phosphorylation sites were identified, and two of them were highly inducible upon integrin activation. Paxillin exhibits three distinct subcellular localizations as follows: localization along the cell periphery colocalized with circumferential actin meshworks, macroaggregation at focal adhesions connected to actin stress fibers, and diffuse cytoplasmic distribution. Tyrosine phosphorylation of paxillin localized at the cell periphery and focal adhesions was shown using phosphorylation site-specific antibodies. Mutations in the phosphorylation sites affected the peripheral localization of paxlllin and paxillin-containing focal adhesion formation during cell migration and cell-cell collision, accompanied by altered actin organizations. Our analysis indicates that phosphorylation of multiple tyrosines in paxillin cu is necessary for the proper function of paxillin and is involved in the temporospatial regulation of focal adhesion formation and actin cytoskeletal organization in motile cells.	Osaka Biosci Inst, Dept Biol Mol, Suita, Osaka 5650874, Japan; Kyoto Univ, Grad Sch Biosci, Sakyo Ku, Kyoto 6068502, Japan; Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Kyoto 6190237, Japan; BioSource Int, Hopkinton, MA 01748 USA	Kyoto University; Japan Science & Technology Agency (JST)	Sabe, H (corresponding author), Osaka Biosci Inst, Dept Biol Mol, 6-2-4 Furuedai, Suita, Osaka 5650874, Japan.	sabe@obi.or.jp	Sabe, Hisataka/GPF-4385-2022; Sabe, Hisataka/A-4066-2012					Bailly M, 1999, J CELL BIOL, V145, P331, DOI 10.1083/jcb.145.2.331; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Butler AA, 1997, J BIOL CHEM, V272, P27660, DOI 10.1074/jbc.272.44.27660; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chicurel ME, 1998, CURR OPIN CELL BIOL, V10, P232, DOI 10.1016/S0955-0674(98)80145-2; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hay ED, 1995, ACTA ANAT, V154, P8; HAY ED, 1995, AM J KIDNEY DIS, V26, P678, DOI 10.1016/0272-6386(95)90610-X; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ILLC D, 1995, NATURE, V377, P539; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAUFFENBURGER DA, 1994, APPL MECH REV, V47, P287; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; Mazaki Y, 1998, J BIOL CHEM, V273, P22435, DOI 10.1074/jbc.273.35.22435; Mazaki Y, 1997, J BIOL CHEM, V272, P7437, DOI 10.1074/jbc.272.11.7437; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mullins RD, 1998, P NATL ACAD SCI USA, V95, P6181, DOI 10.1073/pnas.95.11.6181; Nakashima N, 1999, J BIOL CHEM, V274, P3001, DOI 10.1074/jbc.274.5.3001; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Ostergaard HL, 1998, J BIOL CHEM, V273, P5692, DOI 10.1074/jbc.273.10.5692; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; Radhakrishna H, 1999, J CELL SCI, V112, P855; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sheetz MP, 1998, TRENDS CELL BIOL, V8, P51, DOI 10.1016/S0962-8924(98)80005-6; Small JV, 1999, CURR OPIN CELL BIOL, V11, P54, DOI 10.1016/S0955-0674(99)80007-6; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Tobe K, 1996, MOL CELL BIOL, V16, P4765; Tong X, 1997, J BIOL CHEM, V272, P33373, DOI 10.1074/jbc.272.52.33373; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; TURNER CE, 1994, J CELL SCI, V107, P1583; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; VAN AL, 1997, GENE DEV, V11, P2295; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8	57	110	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27155	27164						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10823820				2022-12-25	WOS:000089144800066
J	Shahs, FS; Curr, KA; Hamburgh, ME; Parniak, M; Mitsuya, H; Arnez, JG; Prasad, VR				Shahs, FS; Curr, KA; Hamburgh, ME; Parniak, M; Mitsuya, H; Arnez, JG; Prasad, VR			Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-I; MISPAIR EXTENSION; DRUG-RESISTANT; WILD-TYPE; HIV-1; FIDELITY; PROCESSIVITY; BINDING; MUTANTS; M184V	Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) variants with the K65R or L74V substitution display resistance to several nucleoside analogs. An in vitro dNTP exclusion assay revealed an increased fidelity for K65R RT compared with wild-type RT, but little change for L74V RT. When the forward mutation rates were measured via a gap-filling assay, the K65R variant displayed an 8-fold decrease in the overall mutation rate (1.0 x 10(-8) versus 8.6 x 10(-5) for wild-type HIV-1 RT), whereas the rate for the L74V variant was closer to that for wild-type RT (5.0 x 10(-3)). The increase in overall fidelity observed for K65R RT is the largest reported for any drug-resistant HIV-1 RT variant. Nucleotide sequence analysis of locZ alpha mutants generated by variant RTs indicated that K65R RT displays uniform reduction in most types of errors, whereas L74V RT does not. Modeling the substitutions into the x-ray structure of the ternary complex revealed that the major influence of Leu(74) in stabilizing the templating base is unaffected by Val substitution, whereas the K65R substitution appears to increase the stringency of dNTP binding. It is speculated that the increased fidelity of K65R RT is due to an altered interaction with the dNTP substrate.	Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Childrens Hosp Montefiore, Div Pediat Infect Dis, Bronx, NY 10467 USA; McGill Univ, AIDS Ctr, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; NCI, Expt Retrovirol Sect, NIH, Bethesda, MD 20892 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Childrens Hospital at Montefiore; Lady Davis Institute; McGill University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Prasad, VR (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Prasad, Vinayaka R./A-1029-2011	Prasad, Vinayaka/0000-0002-9461-0189	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007501, R01AI040375] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40375, T32-AI07501] Funding Source: Medline; NIGMS NIH HHS [T32-GM07491] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arion D, 1996, J BIOL CHEM, V271, P19860, DOI 10.1074/jbc.271.33.19860; ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Balzarini J, 1996, P NATL ACAD SCI USA, V93, P13152, DOI 10.1073/pnas.93.23.13152; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; Drosopoulos WC, 1998, J VIROL, V72, P4224, DOI 10.1128/JVI.72.5.4224-4230.1998; Drosopoulos WC, 1996, J VIROL, V70, P4834, DOI 10.1128/JVI.70.7.4834-4838.1996; Essink BBO, 1997, NUCLEIC ACIDS RES, V25, P3212, DOI 10.1093/nar/25.16.3212; Fletcher RS, 1996, PROTEIN EXPRES PURIF, V7, P27, DOI 10.1006/prep.1996.0004; GU ZX, 1995, ANTIMICROB AGENTS CH, V39, P1888, DOI 10.1128/AAC.39.8.1888; GU ZX, 1994, J BIOL CHEM, V269, P28118; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; Hamburgh ME, 1998, NUCLEIC ACIDS RES, V26, P4389, DOI 10.1093/nar/26.19.4389; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hsu ML, 1997, NUCLEIC ACIDS RES, V25, P4532, DOI 10.1093/nar/25.22.4532; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JI JP, 1994, VIROLOGY, V199, P323, DOI 10.1006/viro.1994.1130; Jonckheere H, 2000, EUR J BIOCHEM, V267, P2658, DOI 10.1046/j.1432-1327.2000.01272.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim B, 1998, BIOCHEMISTRY-US, V37, P5831, DOI 10.1021/bi972672g; Kim B, 1999, J BIOL CHEM, V274, P27666, DOI 10.1074/jbc.274.39.27666; KIM B, 1995, P NATL ACAD SCI USA, V92, P684, DOI 10.1073/pnas.92.3.684; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; Kosalaraksa P, 1999, J VIROL, V73, P5356, DOI 10.1128/JVI.73.7.5356-5363.1999; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LARDER BA, 1993, REVERSE TRANSCRIPTAS, P205; Pandey VN, 1996, BIOCHEMISTRY-US, V35, P2168, DOI 10.1021/bi9516642; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Rezende LF, 1998, NUCLEIC ACIDS RES, V26, P3066, DOI 10.1093/nar/26.12.3066; RICHMAN DD, 1992, AIDS RES HUM RETROV, V8, P1065, DOI 10.1089/aid.1992.8.1065; Rubinek T, 1997, EUR J BIOCHEM, V247, P238, DOI 10.1111/j.1432-1033.1997.00238.x; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; Srinivas RV, 1998, ANTIMICROB AGENTS CH, V42, P1484, DOI 10.1128/AAC.42.6.1484; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; Ueno T, 1997, BIOCHEMISTRY-US, V36, P1092, DOI 10.1021/bi962393d; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Winters MA, 1997, ANTIMICROB AGENTS CH, V41, P757, DOI 10.1128/AAC.41.4.757	41	66	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27037	27044						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10833521				2022-12-25	WOS:000089144800051
J	Arozarena, I; Aaronson, DS; Matallanas, D; Sanz, V; Ajenjo, N; Tenbaum, SP; Teramoto, H; Ighishi, T; Zabala, JC; Gutkind, JS; Crespo, P				Arozarena, I; Aaronson, DS; Matallanas, D; Sanz, V; Ajenjo, N; Tenbaum, SP; Teramoto, H; Ighishi, T; Zabala, JC; Gutkind, JS; Crespo, P			The Rho family GTPase Cdc42 regulates the activation of Ras/MAP kinase by the exchange factor Ras-GRF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-MEDIATED SIGNALS; DBL HOMOLOGY DOMAIN; SACCHAROMYCES-CEREVISIAE; DEPENDENT ACTIVATION; BINDING PROTEINS; PH DOMAIN; CALCIUM; VAV; TRANSFORMATION; PATHWAYS	The Ras guanine-nucleotide exchange factor Ras-GRF/Cdc25(Mn) harbors a complex array of structural motifs that include a Dbl-homology (DH) domain, usually found in proteins that interact functionally with the Rho family GTPases, and the role of which is not yet fully understood. Here, we present evidence that Ras-GRF requires its DH domain to translocate to the membrane, to stimulate exchange on Ras, and to activate mitogen-activated protein kinase (MAPK), In an unprecedented fashion, we have found that these processes are regulated by the Rho family GTPase Cdc42. We show that GDP- but not GTP-bound Cdc42 prevents Ras-GRF recruitment to the membrane and activation of Ras/MAPK, although no direct association of Ras-GrRF with Cdc42 was detected, We also demonstrate that catalyzing GDP/GTP exchange on Cdc42 facilitates Ras-GRF-induced MAPK activation. Moreover, we show that the potentiating effect of ionomycin on Ras-GRF-mediated MAPK stimulation is also regulated by Cdc42. These results provide the first evidence for the involvement of a Rho family G protein in the control of the activity of a Ras exchange factor.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Cantabria, Dept Mol Biol, Santander 39011, Spain; NIDR, Cell Growth Regulat Sect, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Universidad de Cantabria; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Crespo, P (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	pcrespo@iib.uam.es	Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Zabala, Juan Carlos/K-5163-2014; gomez, david/U-9465-2019; Crespo, Piero/M-3273-2014; Arozarena, Imanol/A-5981-2017	Gutkind, J. Silvio/0000-0002-5150-4482; Zabala, Juan Carlos/0000-0003-2679-5473; gomez, david/0000-0002-2360-3141; Crespo, Piero/0000-0003-2825-7783; Arozarena, Imanol/0000-0001-6349-2442; Ajenjo Diez, Nuria/0000-0002-9435-6467	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ajenjo N, 2000, J BIOL CHEM, V275, P7189, DOI 10.1074/jbc.275.10.7189; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; Byrne JL, 1996, ONCOGENE, V13, P2055; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Cheney R. E., 1994, Molecular Biology of the Cell, V5, p21A; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; deMora JF, 1996, J BIOL CHEM, V271, P18272, DOI 10.1074/jbc.271.30.18272; Fan WT, 1998, CURR BIOL, V8, P935, DOI 10.1016/S0960-9822(07)00376-4; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Freshney NW, 1997, FEBS LETT, V407, P111, DOI 10.1016/S0014-5793(97)00309-8; Guerrero C, 1996, ONCOGENE, V12, P1097; HART MJ, 1994, J BIOL CHEM, V269, P62; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MARTTINGLY RR, 1996, NATURE, V382, P268; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; VAN AL, 1997, GENE DEV, V11, P2295; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zippel R, 1996, ONCOGENE, V12, P2697	47	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26441	26448		10.1074/jbc.M002992200	http://dx.doi.org/10.1074/jbc.M002992200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10840034	hybrid			2022-12-25	WOS:000088999700078
J	Belisle, B; Abo, A				Belisle, B; Abo, A			N-formyl peptide receptor ligation induces Rac-dependent actin reorganization through G beta gamma subunits and class Ia phosphoinositide 3-kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ACTIVATED HUMAN NEUTROPHILS; ALDRICH-SYNDROME PROTEIN; BINDING PROTEIN; ARP2/3 COMPLEX; CYTOSKELETON; KINASE; EXCHANGE; GTPASES; FAMILY	The N-formyl peptide receptor is a G protein-coupled transmembrane receptor involved in stimulating a variety of differential responses in neutrophils including chemotaxis, degranulation, superoxide production, transcriptional activation, and actin reorganization. Although it is known that N-formyl-Met-Leu-Phe induces actin reorganization, the sequence of events from the receptor to the actin cytoskeleton is not well characterized. To study the signaling pathway from the N-formyl peptide receptor to the actin cytoskeleton, we developed a model system utilizing microinjection techniques with a nonhematopoietic cell line. An expression vector coding for the N-formyl peptide receptor was microinjected into porcine aortic endothelial cells and stimulated with N-formyl-Met-Leu-Phe to induce actin reorganization and membrane ruffling. The receptor-mediated signal was blocked by pertussis toxin and by a dominant negative Rac-N17, indicating the involvement of G(1)alpha subunit and the small guanosine triphosphatase Rac, respectively. Moreover, G beta gamma subunits and membrane targeted forms of phosphatidylinositol (PI) 3-kinase alpha were sufficient to induce similar actin reorganization, and coexpression of various mutants of PI 3-kinase with the N-formyl peptide receptor identified a link to class Ia PI-3 kinase-mediated actin reorganization.	Onyx Pharmaceut, Richmond, CA 94806 USA		Abo, A (corresponding author), Onyx Pharmaceut, 3031 Res Dr, Richmond, CA 94806 USA.							Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Dekker LV, 2000, SCIENCE, V287, P982, DOI 10.1126/science.287.5455.982; Dharmawardhane S, 1999, J LEUKOCYTE BIOL, V66, P521, DOI 10.1002/jlb.66.3.521; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Huang RY, 1998, MOL CELL BIOL, V18, P7130, DOI 10.1128/MCB.18.12.7130; Katada T, 1999, CHEM PHYS LIPIDS, V98, P79, DOI 10.1016/S0009-3084(99)00020-1; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Klinker JF, 1996, GEN PHARMACOL, V27, P33, DOI 10.1016/0306-3623(95)00107-7; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Panaro MA, 1999, IMMUNOPHARM IMMUNOT, V21, P397, DOI 10.3109/08923979909007117; ROLLET E, 1994, J IMMUNOL, V153, P353; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Suzuki T, 1996, BBA-MOL CELL RES, V1313, P72, DOI 10.1016/0167-4889(96)00048-1; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Weiner OD, 1999, NAT CELL BIOL, V1, P75, DOI 10.1038/10042; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	36	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26225	26232		10.1074/jbc.M002743200	http://dx.doi.org/10.1074/jbc.M002743200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10843992	hybrid			2022-12-25	WOS:000088999700048
J	Eggleston, AK; West, SC				Eggleston, AK; West, SC			Cleavage of holliday junctions by the Escherichia coli RuvABC complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RAD51 PROTEIN; BRANCH MIGRATION; RECA PROTEIN; IN-VITRO; CRYSTAL-STRUCTURE; STRAND EXCHANGE; RUVB PROTEINS; SUBSTRATE-SPECIFICITY; GENETIC-RECOMBINATION; HEXAMERIC RINGS	The Escherichia coli RuvABC proteins process recombination intermediates during genetic recombination and recombinational repair. Although early biochemical studies indicated distinct RuvAB-mediated branch migration and RuvC-mediated Holliday junction resolution reactions, more recent studies have shown that the three proteins act together as a "resolvasome" complex. In this work we have used recombination intermediates made by Reck to determine whether the RuvAB proteins affect the sequence specificity of the RuvC resolvase. We find that RuvAB proteins do not alter significantly the site specificity of RuvC-dependent cleavage, although under certain conditions, they do affect the efficiency of cleavage at particular sites. The presence of RecA also influences cleavage at some sites. We also show that the RuvAB proteins act upon transient strand exchange intermediates made using substrates that have the opposite polarity of those preferred by Reck Together, our results allow us to develop further a model for the recombinational repair of DNA lesions that lead to the formation of post-replication gaps during DNA replication. The novel features of this model are as follows: (i) the RuvABC resolvasome recognizes joints made by Reck (ii) resolution by RuvABC occurs at specific sites containing the RuvC consensus cleavage sequence 5'-(A/T)TT down arrow (G/C)-3'; and (iii) Holliday junction resolution often occurs close to the initiating gap without significant heteroduplex DNA formation.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England		West, SC (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.			Eggleston, Angela/0000-0001-8682-397X; West, Stephen/0000-0001-8848-9418				ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENSON FE, 1994, J BIOL CHEM, V269, P5195; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; Davies AA, 1998, CURR BIOL, V8, P725, DOI 10.1016/S0960-9822(98)70282-9; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; Eggleston AK, 1997, CELL, V89, P607, DOI 10.1016/S0092-8674(00)80242-1; Fogg JM, 1999, BIOCHEMISTRY-US, V38, P11349, DOI 10.1021/bi990926n; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Hagan NFP, 1998, J MOL BIOL, V281, P17, DOI 10.1006/jmbi.1998.1934; Hargreaves D, 1998, NAT STRUCT BIOL, V5, P441, DOI 10.1038/nsb0698-441; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; Mahdi AA, 1996, J MOL BIOL, V257, P561, DOI 10.1006/jmbi.1996.0185; Masson JY, 1999, EMBO J, V18, P6552, DOI 10.1093/emboj/18.22.6552; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; MULLER B, 1993, J BIOL CHEM, V268, P17179; Nishino T, 1998, STRUCTURE, V6, P11, DOI 10.1016/S0969-2126(98)00003-3; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; Rafferty JB, 1998, J MOL BIOL, V278, P105, DOI 10.1006/jmbi.1998.1697; Rafferty JB, 1996, SCIENCE, V274, P415, DOI 10.1126/science.274.5286.415; Roe SM, 1998, MOL CELL, V2, P361, DOI 10.1016/S1097-2765(00)80280-4; ROSS P, 1977, J MOL BIOL, V117, P137, DOI 10.1016/0022-2836(77)90028-6; ROSS P, 1977, J MOL BIOL, V117, P159, DOI 10.1016/0022-2836(77)90029-8; Seigneur M, 1998, CELL, V95, P419, DOI 10.1016/S0092-8674(00)81772-9; SHAH R, 1994, NUCLEIC ACIDS RES, V22, P2490, DOI 10.1093/nar/22.13.2490; Shah R, 1997, EMBO J, V16, P1464, DOI 10.1093/emboj/16.6.1464; SHARPLES GJ, 1994, EMBO J, V13, P6133, DOI 10.1002/j.1460-2075.1994.tb06960.x; Shida T, 1996, J BIOL CHEM, V271, P26105, DOI 10.1074/jbc.271.42.26105; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; van Gool AJ, 1998, EMBO J, V17, P1838, DOI 10.1093/emboj/17.6.1838; van Gool AJ, 1999, GENE DEV, V13, P1861, DOI 10.1101/gad.13.14.1861; West SC, 1998, CELL, V94, P699, DOI 10.1016/S0092-8674(00)81729-8; WEST SC, 1982, MOL GEN GENET, V187, P209, DOI 10.1007/BF00331119; WEST SC, 1981, NATURE, V294, P659, DOI 10.1038/294659a0; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149; West SC, 1997, ANNU REV GENET, V31, P213, DOI 10.1146/annurev.genet.31.1.213; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; Whitby MC, 1996, J MOL BIOL, V264, P878, DOI 10.1006/jmbi.1996.0684; Yu X, 1997, J MOL BIOL, V266, P217, DOI 10.1006/jmbi.1996.0799; Zerbib D, 1998, J MOL BIOL, V281, P621, DOI 10.1006/jmbi.1998.1959	54	37	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26467	26476		10.1074/jbc.M001496200	http://dx.doi.org/10.1074/jbc.M001496200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851230	hybrid			2022-12-25	WOS:000088999700081
J	Smith, CC; Yu, YX; Kulka, M; Aurelian, L				Smith, CC; Yu, YX; Kulka, M; Aurelian, L			A novel human gene similar to the protein kinase (PK) coding domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) codes for a serine-threonine PK and is expressed in melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; EARLY MESSENGER RNA-4; NEOPLASTIC TRANSFORMATION; MEDIATED ACTIVATION; R1 SUBUNIT; ONCOGENE; HSV-2; FAMILY; ATP; TRANSCRIPTION	The large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is a multifunctional protein that contains a serine-threonine protein kinase (PK) activity (Nelson, J. W,, Zhu, J,, Smith, C. C,, Kulka, M., and Aurelian, L. (1996) J, Biol. Chem. 271, 17021-17027). Phylogenetic analyses indicated that ICP10 PK belongs to a distinct subfamily of growth factor receptor serine-threonine PKs that are characterized by their ability to function with a limited number of conserved catalytic motifs (Hunter, J. C. R., Smith, C. C., and Aurelian, L. (1995) Int. J. One. 7, 515-522). Here, we report the isolation and characterization of a novel gene, designated H11, that contains an open reading frame of 588 nucleotides, which encodes a protein similar to ICP10 ph, The H11 protein has Mn2+-dependent serine-threonine-specific PK activity as determined with a GST-H11 fusion protein and by immunocomplex PK immunoblotting assays of 293 cells transfected with a H11 eukaryotic expression vector. PK activity is ablated by mutation of Lys(113) within the presumtive catalytic motif II (invariant Lys), 293 cells stably transfected with H11 acquire anchorage-independent growth. Endogenous H11 RNA and the H11 phosphoprotein are expressed in melanoma cell lines and primary melanoma tissues at levels higher than in normal melanocytes and in benign nevi. Melanoma cell proliferation is inhibited by treatment with antisense oligonucleotides that inhibit H11 translation, suggesting that H11 expression is associated with cell growth.	Univ Maryland, Sch Med, Virol Immunol Labs, Dept Pharmacol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Expt Therapeut, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Aurelian, L (corresponding author), Univ Maryland, Sch Med, Virol Immunol Labs, Dept Pharmacol, 10 S Pine St, Baltimore, MD 21201 USA.				NATIONAL CANCER INSTITUTE [R01CA075453] Funding Source: NIH RePORTER; NCI NIH HHS [CA75453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal S, 1998, CURR OPIN CHEM BIOL, V2, P519, DOI 10.1016/S1367-5931(98)80129-4; Alahari SK, 1998, J PHARMACOL EXP THER, V286, P419; Aurelian L, 1999, VACCINE, V17, P1951, DOI 10.1016/S0264-410X(98)00470-8; AURELIAN L, 1989, CANCER CEL, V7, P187; Aurelian L, 1998, FRONT BIOSCI, V3, P237, DOI 10.2741/A238; Bartkova J, 1996, CANCER RES, V56, P5475; BASOLO F, 1994, INT J CANCER, V56, P736, DOI 10.1002/ijc.2910560521; BAUER SR, 1989, ONCOGENE, V4, P615; Care A, 1996, MOL CELL BIOL, V16, P4842; Child SJ, 1999, J BIOL CHEM, V274, P24335, DOI 10.1074/jbc.274.34.24335; CHUNG TD, 1990, VIROLOGY, V179, P168, DOI 10.1016/0042-6822(90)90286-Z; CHUNG TD, 1989, J VIROL, V63, P3389, DOI 10.1128/JVI.63.8.3389-3398.1989; Citro G, 1998, CANCER RES, V58, P283; CONNER J, 1995, VIROLOGY, V213, P615, DOI 10.1006/viro.1995.0033; COOPER J, 1995, J VIROL, V69, P4979, DOI 10.1128/JVI.69.8.4979-4985.1995; Feng CP, 1996, ANTISENSE NUCLEIC A, V6, P25, DOI 10.1089/oli.1.1996.6.25; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Halaban R, 1998, ONCOGENE, V16, P2489, DOI 10.1038/sj.onc.1201773; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HONNEGER AM, 1987, CELL, V51, P199; Hosokawa Y, 1998, INT J CANCER, V76, P791, DOI 10.1002/(SICI)1097-0215(19980610)76:6<791::AID-IJC4>3.3.CO;2-M; HUNTER JCR, 1995, INT J ONCOL, V7, P515; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; Keller-Melchior R, 1998, J INVEST DERMATOL, V110, P932, DOI 10.1046/j.1523-1747.1998.00211.x; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Kokuba H, 1998, BRIT J DERMATOL, V138, P952; KULKA M, 1993, ANTIVIR RES, V20, P115, DOI 10.1016/0166-3542(93)90002-Z; KULKA M, 1989, P NATL ACAD SCI USA, V86, P6868, DOI 10.1073/pnas.86.18.6868; Langelier Y, 1998, J BIOL CHEM, V273, P1435, DOI 10.1074/jbc.273.3.1435; LAPORTE DC, 1985, J BIOL CHEM, V260, P563; LEADER DP, 1985, GENE, V36, P369, DOI 10.1016/0378-1119(85)90193-3; LEE MS, 1993, ONCOGENE, V8, P387; LIVINGSTONE A, 1994, EUR J CANCER, V30A, P382, DOI 10.1016/0959-8049(94)90260-7; LUO JH, 1992, J BIOL CHEM, V267, P9645; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; Nelson JW, 1996, J BIOL CHEM, V271, P17021, DOI 10.1074/jbc.271.29.17021; NIKAS I, 1986, Proteins Structure Function and Genetics, V1, P376, DOI 10.1002/prot.340010411; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Peng T, 1996, VIROLOGY, V216, P184, DOI 10.1006/viro.1996.0045; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SMITH CC, 1994, VIROLOGY, V200, P598, DOI 10.1006/viro.1994.1223; Smith CC, 1996, VIROLOGY, V217, P425, DOI 10.1006/viro.1996.0136; Smith CC, 1998, J VIROL, V72, P9131, DOI 10.1128/JVI.72.11.9131-9141.1998; SMITH CC, 1992, J GEN VIROL, V73, P1417, DOI 10.1099/0022-1317-73-6-1417; Smith JB, 2000, METHOD ENZYMOL, V314, P537; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TIAN QS, 1995, J EXP MED, V182, P865, DOI 10.1084/jem.182.3.865; WACHSMAN M, 1989, J INFECT DIS, V159, P625, DOI 10.1093/infdis/159.4.625; YANG DJ, 1994, CARCINOGENESIS, V15, P2167, DOI 10.1093/carcin/15.10.2167; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; Zachos G, 1998, ONCOGENE, V16, P3013, DOI 10.1038/sj.onc.1201836; Zachos G, 1999, J BIOL CHEM, V274, P5097, DOI 10.1074/jbc.274.8.5097; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	54	89	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25690	25699		10.1074/jbc.M002140200	http://dx.doi.org/10.1074/jbc.M002140200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833516	hybrid			2022-12-25	WOS:000088849400084
J	Lin, Y; Lee, H; Berg, AH; Lisanti, MP; Shapiro, L; Scherer, PE				Lin, Y; Lee, H; Berg, AH; Lisanti, MP; Shapiro, L; Scherer, PE			The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; INDUCED INSULIN-RESISTANCE; CELL WALL COMPONENTS; ADIPOSE-TISSUE; GENE-PRODUCT; CUTTING EDGE; IMMUNE-RESPONSES; NUCLEAR FACTOR; LYMPH-NODES; IN-VIVO	The central regulatory role of the adipocyte in whole body energy homeostasis is well established, However, recent findings suggest that preadipocytes and adipocytes may play an important physiological role in the regulation of both the innate and adaptive immune response. To systematically characterize the molecular machinery of the adipocyte that mediates the recognition of pathogens, we have focused our analysis on the recently identified Toll-like receptors (TLRs). These receptors have been implicated as mediators of the cellular response to bacterial lipopolysacharides (LPSs), Here, we report the cloning and functional characterization of mouse TLR-2 from 3T3-L1 adipocytes, TLR-2 synthesis is strongly induced in the adipocyte by LPS, TNF alpha, and the yeast cell wall extract zymosan, TLR-2 undergoes a lengthy intracellular maturation process with a half-life of exit from the ER of approximately 3 h, Furthermore, LPS treatment of adipocytes results in dramatic changes at the level of gene expression, including the synthesis of a distinct set of secretory proteins such as interleukin-6, Our studies demonstrate the presence of a fully intact pathway of innate immunity in the adipocyte that can be activated by LPS binding to the cell surface and results in the secretion of immunomodulatory molecules.	Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Scherer, PE (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Scherer, Philipp E/K-7819-2012; Eckhardt, Erik/G-1567-2010; Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Scherer, Philipp E/0000-0003-0680-3392; Lisanti, Michael/0000-0003-2034-1382; 	NCI NIH HHS [R01-CA-80250] Funding Source: Medline; NIDDK NIH HHS [1RO1-DK55758] Funding Source: Medline; NIGMS NIH HHS [T32-GM07491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; CHOY LN, 1992, J BIOL CHEM, V267, P12736; CIANFLONE K, 1994, BIOCHEMISTRY-US, V33, P9489, DOI 10.1021/bi00198a014; Cianflone K, 1999, SEMIN CELL DEV BIOL, V10, P31, DOI 10.1006/scdb.1998.0272; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; Heine H, 1999, J IMMUNOL, V162, P6971; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; Kapur S, 1999, AM J PHYSIOL-ENDOC M, V276, pE635, DOI 10.1152/ajpendo.1999.276.4.E635; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; LORD KA, 1990, ONCOGENE, V5, P1095; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; Mattacks CA, 1999, CYTOKINE, V11, P334, DOI 10.1006/cyto.1998.0442; Means TK, 1999, J IMMUNOL, V163, P3920; Means TK, 1999, J IMMUNOL, V163, P6748; Meister M, 1997, BIOESSAYS, V19, P1019, DOI 10.1002/bies.950191112; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pond CM, 1998, IMMUNOL LETT, V63, P159, DOI 10.1016/S0165-2478(98)00074-1; RENSINGEHL A, 1995, J INFLAMM, V45, P161; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; RODBELL M, 1964, J BIOL CHEM, V239, P375; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Sarraf P, 1997, J EXP MED, V185, P171, DOI 10.1084/jem.185.1.171; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Scherer PE, 1998, NAT BIOTECHNOL, V16, P581, DOI 10.1038/nbt0698-581; Scherer PE, 1996, J CELL BIOL, V133, P257, DOI 10.1083/jcb.133.2.257; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1992, P NATL ACAD SCI USA, V89, P11930, DOI 10.1073/pnas.89.24.11930; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; TAKUMI T, 1994, BIOTECHNIQUES, V17, P443; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; WHITE RT, 1992, J BIOL CHEM, V267, P9210; Yoshimura A, 1999, J IMMUNOL, V163, P1; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	48	263	273	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24255	24263		10.1074/jbc.M002137200	http://dx.doi.org/10.1074/jbc.M002137200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10823826	hybrid			2022-12-25	WOS:000088683300005
J	Storz, P; Hausser, A; Link, G; Dedio, J; Ghebrehiwet, B; Pfizenmaier, K; Johannes, FJ				Storz, P; Hausser, A; Link, G; Dedio, J; Ghebrehiwet, B; Pfizenmaier, K; Johannes, FJ			Protein kinase C mu is regulated by the multifunctional chaperon protein p32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; SIGNAL-TRANSDUCTION; CELLULAR PROTEIN; MITOCHONDRIAL MATRIX; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; DOWN-REGULATION; GLOBULAR HEADS; IN-VITRO; ACTIVATION	We identified the multifunctional chaperon protein p32 as a protein kinase C (PKC)-binding protein interacting with PKC alpha, PKC zeta, PKC delta, and PKC mu. We have analyzed the interaction of PKC mu with p32 in detail, and we show here in vivo association of PKC mu, as revealed from yeast two-hybrid analysis, precipitation assays using glutathione S-transferase fusion proteins, and reciprocal coimmunoprecipitation. In SKW 6.4 cells, PKC mu is constitutively associated with p32 at mitochondrial membranes, evident from colocalization with cytochrome c, p32 interacts with PKC mu in a compartment-specific manner, as it can be coimmunoprecipitated mainly from the particulate and not from the soluble fraction, despite the presence of p32 in both fractions. Although p32 binds to the kinase domain of PKC mu, it does not serve as a substrate. Interestingly, PKC mu-p32 immunocomplexes precipitated from the particulate fraction of two distinct cell lines, SKW 6.4 and 293T, show no detectable substrate phosphorylation, In support of a kinase regulatory function of p32, addition of p32 to in vitro kinase assays blocked, in a dose-dependent manner, aldolase but not autophosphorylation of PKC mu, suggesting a steric hindrance of substrate within the kinase domain. Together, these findings identify p32 as a novel, compartment-specific regulator of PKC mu kinase activity.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Fraunhofer Inst Interfacial Engn, D-70569 Stuttgart, Germany; Univ Mainz, Inst Physiol Chem & Pathobiochem, D-55099 Mainz, Germany; SUNY Stony Brook, Dept Med & Pathol, Stony Brook, NY 11794 USA	University of Stuttgart; Fraunhofer Gesellschaft; Johannes Gutenberg University of Mainz; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Johannes, FJ (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.		Hausser, Angelika/AAC-4531-2021					AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; Dedio J, 1996, FEBS LETT, V399, P255, DOI 10.1016/S0014-5793(96)01339-7; Dedio J, 1998, J IMMUNOL, V160, P3534; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; Ghebrehiwet B, 1996, HYBRIDOMA, V15, P333, DOI 10.1089/hyb.1996.15.333; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; Gommel D, 1999, FEBS LETT, V447, P179, DOI 10.1016/S0014-5793(99)00246-X; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; Hausser A, 1999, J BIOL CHEM, V274, P9258, DOI 10.1074/jbc.274.14.9258; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LUO Y, 1994, J VIROL, V68, P3850, DOI 10.1128/JVI.68.6.3850-3856.1994; Matthews DA, 1998, J GEN VIROL, V79, P1677, DOI 10.1099/0022-1317-79-7-1677; Matthews S, 1999, FEBS LETT, V457, P515, DOI 10.1016/S0014-5793(99)01090-X; Mochly-Rosen D, 1998, FASEB J, V12, P35; Muta T, 1997, J BIOL CHEM, V272, P24363, DOI 10.1074/jbc.272.39.24363; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Peerschke EIB, 1998, BLOOD COAGUL FIBRIN, V9, P29, DOI 10.1097/00001721-199801000-00004; Peterson KL, 1997, CLIN IMMUNOL IMMUNOP, V84, P17, DOI 10.1006/clin.1997.4374; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Puls A, 1997, P NATL ACAD SCI USA, V94, P6191, DOI 10.1073/pnas.94.12.6191; Rennecke J, 1996, EUR J BIOCHEM, V242, P428, DOI 10.1111/j.1432-1033.1996.0428r.x; Seytter T, 1998, YEAST, V14, P303, DOI 10.1002/(SICI)1097-0061(19980315)14:4<303::AID-YEA217>3.0.CO;2-N; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Storz P, 1998, FEBS LETT, V440, P41, DOI 10.1016/S0014-5793(98)01421-5; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; vandenBerg RH, 1997, J IMMUNOL, V158, P3909; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Vertommen D, 2000, J BIOL CHEM, V275, P19567, DOI 10.1074/jbc.M001357200; Wang YL, 1997, VIROLOGY, V236, P18, DOI 10.1006/viro.1997.8739; YU L, 1995, J VIROL, V69, P3007, DOI 10.1128/JVI.69.5.3007-3016.1995	47	77	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24601	24607		10.1074/jbc.M002964200	http://dx.doi.org/10.1074/jbc.M002964200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10831594	hybrid			2022-12-25	WOS:000088683300051
J	Jakubowski, H				Jakubowski, H			Accelerated publication - Translational incorporation of S-nitrosohomocysteine into protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; AMINO-ACIDS; ESCHERICHIA-COLI; PROOFREADING INVIVO; IN-VIVO; HOMOCYSTEINE; FLAVOHEMOGLOBIN; MECHANISM; SELECTION; SITE	The non-protein amino acid homocysteine (Hcy), owing to its structural similarity to the protein amino acids methionine, isoleucine, and leucine, enters first steps of protein synthesis and is activated by methionyl-, isoleucyl-, and leucyl-tRNA synthetases in vivo. However, translational incorporation of Hcy into protein is prevented by editing mechanisms of these synthetases, which convert misactivated Hey into thiolactone. The lack of efficient interactions of the side chain of Hcy with the specificity subsite of the synthetic/editing active site is a prerequisite for editing of Hcy. Thus, if the side chain thiol of Hcy were reversibly modified with a small molecule that would enhance its binding to the specificity subsite and prevent editing, such modified Hcy is predicted to he transferred to tRNA and incorporated translationally into protein. Here I show that S-nitroso-Hcy is in fact transferred to tRNA by methionyl-tRNA synthetase and incorporated into protein by the bacterium Escherichia coli. S-Nitroso-Hcy-tRNA also supports translation of mRNAs in a rabbit reticulocyte system. Removal of the nitroso group yields Hcy-tRNA and protein containing Hcy in peptide bonds. S-Nitrosylation-mediated translational incorporation of Hey into protein may occur under natural conditions in cells and contribute to Hey-induced pathogenesis in atherosclerosis.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Jakubowski, H (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA.	jakubows@umdnj.edu	Jakubowski, Hieronim/AAA-6834-2019; Jakubowski, Hieronim/A-2510-2017	Jakubowski, Hieronim/0000-0001-5845-4409				AMELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, V2; Baernstein HD, 1934, J BIOL CHEM, V106, P451; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1250, DOI 10.1021/bi00574a021; FIRST EA, 1998, COMPREHENSIVE BIOL C, V1, P573; GAO WW, 1994, BIOCHEMISTRY-US, V33, P11528, DOI 10.1021/bi00204a015; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; JAKUBOWSKI H, 1993, FEBS LETT, V317, P237, DOI 10.1016/0014-5793(93)81283-6; Jakubowski H, 1996, BIOCHEMISTRY-US, V35, P8252, DOI 10.1021/bi960344v; Jakubowski H, 1996, NUCLEIC ACIDS RES, V24, P2505, DOI 10.1093/nar/24.13.2505; Jakubowski H, 2000, CIRC RES, V87, P45, DOI 10.1161/01.RES.87.1.45; Jakubowski H, 1997, J BIOL CHEM, V272, P1935; Jakubowski H, 1999, BIOCHEMISTRY-US, V38, P8088, DOI 10.1021/bi990629i; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1995, J BIOL CHEM, V270, P17672, DOI 10.1074/jbc.270.30.17672; JAKUBOWSKI H, 1991, EMBO J, V10, P593, DOI 10.1002/j.1460-2075.1991.tb07986.x; JAKUBOWSKI H, 1990, P NATL ACAD SCI USA, V87, P4504, DOI 10.1073/pnas.87.12.4504; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; Jakubowski H, 1999, FASEB J, V13, P2277, DOI 10.1096/fasebj.13.15.2277; Jakubowski H, 2000, J NUTR, V130, p377S, DOI 10.1093/jn/130.2.377S; JAKUBOWSKI H, 2000, HOMOCYSTEINE HLTH DI; JAKUBOWSKI H, 2000, ENCY LIFE SCI; KIM HY, 1993, P NATL ACAD SCI USA, V90, P11553, DOI 10.1073/pnas.90.24.11553; *PROM, 1998, PROM TECHN B, V127; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; van Hest JCM, 1998, FEBS LETT, V428, P68, DOI 10.1016/S0014-5793(98)00489-X	29	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21813	21816		10.1074/jbc.C000280200	http://dx.doi.org/10.1074/jbc.C000280200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10829011	hybrid			2022-12-25	WOS:000088363800010
J	Yamit-Hezi, E; Nir, S; Wolstein, O; Dikstein, R				Yamit-Hezi, E; Nir, S; Wolstein, O; Dikstein, R			Interaction of TAF(II)105 with selected p65/RelA dimers is associated with activation of subset of NF-kappa B genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ZINC-FINGER PROTEIN; TRANSCRIPTIONAL ACTIVATION; CELL-DEATH; INDUCED APOPTOSIS; FACTOR-ALPHA; A20; PROMOTER; TNF; INHIBITOR	TAF(II)105, a substoichiometric coactivator subunit of TFIID, is important for activation of anti-apoptotic genes by NF-kappa B in response to the cytokine tumor necrosis factor (TNF)-alpha In the present study we have analyzed the mechanism of TAF(II)105 function with respect to its regulation of p65/RelA, a component of NF-kappa B. We found two independent p65/RelA-binding domains within the N terminus of TAF(II)105. One of these domains appears to be crucial for TAF(II)105-mediated anti-apoptotic gene activation in response to TNF-alpha, Analysis of the interaction between TAF(II)105 and different NF-kappa B complexes has revealed substantial differences in the affinity of TAF(II)105 toward different p65/RelA-containing dimers. We hare identified the TNF-alpha induced anti-apoptotic A20 gene as a target gene of TAF(II)105. A20 has a differential protective effect on cell death induced by TNF-alpha in the presence of either the dominant negative mutant of TAF(II)105 (TAF(II)105 Delta C) or the superdominant I kappa B alpha. The results suggest that the inhibitory effect of TAF(II)105 Delta C on NF-K kappa-dependent genes is restricted to a subset of anti-apoptotic genes while the effect of I kappa B alpha is more general. Thus, an interaction between NF-kappa B and a specific coactivator is important for specifying target gene activation.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Dikstein, R (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	hcrivka@wiccmail.weizmann.ac.il						Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Foo SY, 1999, TRENDS GENET, V15, P229; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Jaattela M, 1996, J IMMUNOL, V156, P1166; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Oelgeschlager T, 1998, MOL CELL, V1, P925, DOI 10.1016/S1097-2765(00)80092-1; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Song HY, 1996, P NATL ACAD SCI USA, V93, P6721, DOI 10.1073/pnas.93.13.6721; TEWARI M, 1995, J IMMUNOL, V154, P1699; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Wissing D, 1998, FREE RADICAL BIO MED, V25, P57, DOI 10.1016/S0891-5849(98)00043-4; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161	38	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18180	18187		10.1074/jbc.275.24.18180	http://dx.doi.org/10.1074/jbc.275.24.18180			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849440	hybrid			2022-12-25	WOS:000087659400038
J	Guha, M; Bai, W; Nadler, JL; Natarajan, R				Guha, M; Bai, W; Nadler, JL; Natarajan, R			Molecular mechanisms of tumor necrosis factor alpha gene expression in monocytic cells via hyperglycemia-induced oxidant stress-dependent and -independent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE-C; SMOOTH-MUSCLE CELLS; INDUCED ACTIVATION; DIABETES-MELLITUS; OXIDATIVE STRESS; PROMOTER REGION; BINDING-SITES; GLUCOSE; SUPEROXIDE	Increased oxidative stress has been reported in vivo in the diabetic state via the production of reactive oxygen species (ROS), Such stress is bound to play a key role on activation of circulating monocytes, leading to the accelerated atherosclerosis observed in diabetics. However the exact molecular mechanisms of monocyte activation by high glucose is currently unclear. Here, we demonstrate that chronic high glucose (CHG) causes a dramatic increase in the release of the inflammatory cytokine tumor necrosis factor alpha (TNF alpha), at least in part through enhanced TNF alpha mRNA transcription, mediated by ROS via activation of transcription factors nuclear factor kappa B (NF-kappa B) and activating protein-1 (AP-1), TNF alpha accumulation in the conditioned media was increased 10-fold and mRNA levels were increased 11.5-fold by CHG, The following observations supported that both NF-kappa B and AP-1 mediated enhanced TNF alpha transcription by CHG: 1) A 295-base pair fragment of the proximal TNF alpha promoter containing NF-kappa B and AP-1 sites reproduced the effects of CHG on TNF alpha transcription in a luciferase reporter assay, 2) mutational analyses of both NF-kappa B and the AP-1 sites abrogated 90% of the luciferase activity, 3) gel-shift analysis using the binding sites showed activation of NF-kappa B and AP-1 in CHG nuclear extracts, and 4) Western blot analyses demonstrated elevated nuclear levels of p65 and p50 and decreased cytosolic levels of I kappa B alpha in CHG-treated monocytes, That ROS acted as a key intermediate in the CHG pathway was supported by the following evidence: 1) increased superoxide levels similar to those observed with PMA or TNF alpha, 2) increased phosphorylation of stress-responsive mitogen-activated protein kinases p38 and JNK-1, 3) counteraction of the effects of CHG on TNF alpha production, the 295TNFluc reporter activity, activation of NF kappa B, and repression of I kappa B alpha by antioxidants and p38 mitogen-activated protein kinase inhibitors. The study suggests that ROS function as key components in the regulatory pathway progressing from elevated glucose to monocyte activation.	City Hope Natl Med Ctr, Grad Sch Biol Sci, Dept Diabet & Endocrinol, Duarte, CA 91010 USA; Genet Inst, Pasadena, CA 91105 USA; Univ Virginia, Dept Internal Med, Charlottesville, VA 22908 USA	City of Hope; University of Virginia	Natarajan, R (corresponding author), City Hope Natl Med Ctr, Grad Sch Biol Sci, Dept Diabet & Endocrinol, 1500 E Duarte Rd, Duarte, CA 91010 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL055798] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065073] Funding Source: NIH RePORTER; NHLBI NIH HHS [P0I HL55798] Funding Source: Medline; NIDDK NIH HHS [R01 DK065073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aepfelbacher M, 1996, J IMMUNOL, V157, P5070; Baynes JW, 1999, DIABETES, V48, P1, DOI 10.2337/diabetes.48.1.1; Brehm M, 1996, TOXICOL LETT, V87, P131, DOI 10.1016/0378-4274(96)03768-X; Carpentier I, 1998, FEBS LETT, V425, P195, DOI 10.1016/S0014-5793(98)00226-9; Ceolotto G, 1999, DIABETES, V48, P1316, DOI 10.2337/diabetes.48.6.1316; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; Cosentino F, 1997, CIRCULATION, V96, P25; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Desfaits AC, 1998, DIABETES CARE, V21, P487, DOI 10.2337/diacare.21.4.487; ECONOMOU JS, 1989, J EXP MED, V170, P321, DOI 10.1084/jem.170.1.321; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; FAN ST, 1995, J IMMUNOL, V154, P3266; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Hill JR, 1998, J BIOL CHEM, V273, P3308, DOI 10.1074/jbc.273.6.3308; HORMANN MA, 1999, CELL, V97, P889; IDO Y, 1997, DIABETOLOGIA, V40, P115; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Ishii H, 1998, J MOL MED, V76, P21, DOI 10.1007/s109-1998-8101-y; JOVIAGE S, 1996, ARTERIOSCLER THROMB, P1573; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kashiwagi A., 1996, DIABETES, V45, P84; Klann E, 1998, J BIOL CHEM, V273, P4516, DOI 10.1074/jbc.273.8.4516; Kuprash DV, 1999, J IMMUNOL, V162, P4045; Lee C, 1998, J BIOL CHEM, V273, P25272, DOI 10.1074/jbc.273.39.25272; LEITMAN DC, 1992, MOL CELL BIOL, V12, P1352, DOI 10.1128/MCB.12.3.1352; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Natarajan R, 1999, HYPERTENSION, V33, P378, DOI 10.1161/01.HYP.33.1.378; Ogura M, 1998, J IMMUNOL, V161, P3569; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; Patel NA, 1999, FASEB J, V13, P103, DOI 10.1096/fasebj.13.1.103; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sartippour MR, 1998, DIABETES, V47, P431, DOI 10.2337/diabetes.47.3.431; SATO H, 1993, ONCOGENE, V8, P395; SATRIANO JA, 1993, J CLIN INVEST, V92, P1564, DOI 10.1172/JCI116737; TESFAMARIAM B, 1992, AM J PHYSIOL, V263, P321; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Wilmer WA, 1999, DIABETES, V48, pA36; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A; Yamakawa T, 1999, ENDOCRINOLOGY, V140, P3562, DOI 10.1210/en.140.8.3562; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; YIM HS, 1995, J BIOL CHEM, V270, P28228; Zagariya A, 1998, MOL CELL BIOL, V18, P2815, DOI 10.1128/MCB.18.5.2815	47	249	263	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17728	17739		10.1074/jbc.275.23.17728	http://dx.doi.org/10.1074/jbc.275.23.17728			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837498	hybrid			2022-12-25	WOS:000087485000073
J	Geymayer, S; Doppler, W				Geymayer, S; Doppler, W			Activation of NF-kappa B p50/p65 is regulated in the developing mammary gland and inhibits STAT5-mediated beta-casein gene expression	FASEB JOURNAL			English	Article						TNF-alpha; prolactin; milk protein gene transcription; tyrosine phosphorylation	TUMOR-NECROSIS-FACTOR; GLUCOCORTICOID RECEPTOR; SYNERGISTIC ACTIVATION; ALPHA DEGRADATION; EPITHELIAL-CELLS; IMMUNE-RESPONSES; BREAST-CANCER; PROLACTIN; STAT5; MICE	The NF-kappa B family of transcription factors regulates diverse cellular functions such as immune response and cell growth and development, and has been reported to be constitutively active in a variety of mammary carcinoma cell lines. However, its role in normal mammary gland development has not been addressed. In our study, we detected developmentally regulated NF-kappa B activity in the mammary gland of mice. During pregnancy, DNA binding activity of NF-kappa B p50/p65 increased until day 16 postcoitum and decreased with the onset of lactation, most likely due to reduced p50 and p65 protein levels in the nucleus. Cotransfection experiments performed with 293 cells revealed an inhibition of the prolactin receptor/JAK2/STAT5 pathway by NF-kappa B. In HC11 cells, NF-kappa B p50/p65 activity was inversely correlated with prolactin-induced STAT5 tyrosine phosphorylation, expression of endogenous beta-casein gene, and of a transfected beta-casein gene promoter reporter construct. This indicates a negative cross talk between NF-kappa B and the prolactin receptor/JAK2/STAT5 activation pathway, which occurs at the level of STAT5 tyrosine phosphorylation. Our results provide evidence for a role of NF-kappa B in normal mammary gland development, and indicate its function as a negative regulator of beta-casein gene expression during pregnancy by interfering with STATS tyrosine phosphorylation.-Geymayer, S., Doppler, W. Activation of NF-kappa B p50/p65 is regulated in the developing mammary gland and inhibits STATS-mediated beta-casein gene expression.	Univ Innsbruck, Inst Med Chem & Biochem, A-6020 Innsbruck, Austria	University of Innsbruck	Doppler, W (corresponding author), Univ Innsbruck, Inst Med Chem & Biochem, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	Wolfgang.Doppler@uibk.ac.at.osupersub						BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baichwal V. R., 1997, CURR BIOL, V7, P94; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BASOLO F, 1993, INT J CANCER, V55, P926, DOI 10.1002/ijc.2910550609; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; Delfino F, 1998, MOL ENDOCRINOL, V12, P1696, DOI 10.1210/me.12.11.1696; Dumont A, 1998, TRENDS BIOCHEM SCI, V23, P233, DOI 10.1016/S0968-0004(98)01212-2; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; Lechner J, 1997, J BIOL CHEM, V272, P20954, DOI 10.1074/jbc.272.33.20954; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; Mayr S, 1998, EUR J BIOCHEM, V258, P784, DOI 10.1046/j.1432-1327.1998.2580784.x; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NAUMANN M, 1999, IN PRESS ONCOGENE; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Storz P, 1998, FEBS LETT, V440, P41, DOI 10.1016/S0014-5793(98)01421-5; STREULI CH, 1995, J BIOL CHEM, V270, P21639, DOI 10.1074/jbc.270.37.21639; Sun L, 1998, ONCOGENE, V16, P2095, DOI 10.1038/sj.onc.1201731; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Varela LM, 1996, ENDOCRINOLOGY, V137, P4915, DOI 10.1210/en.137.11.4915; Weih F, 1997, J EXP MED, V185, P1359, DOI 10.1084/jem.185.7.1359; WELTE T, 1994, EUR J BIOCHEM, V223, P997, DOI 10.1111/j.1432-1033.1994.tb19078.x; WELTE T, 1994, MOL ENDOCRINOL, V8, P1091, DOI 10.1210/me.8.8.1091; Winklehner-Jennewein P, 1998, GENE, V217, P127, DOI 10.1016/S0378-1119(98)00380-1	34	64	66	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1159	1170		10.1096/fasebj.14.9.1159	http://dx.doi.org/10.1096/fasebj.14.9.1159			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834938				2022-12-25	WOS:000087427300013
J	Maacke, H; Jost, K; Opitz, S; Miska, S; Yuan, Y; Hasselbach, L; Luttges, J; Kalthoff, H; Sturzbecher, HW				Maacke, H; Jost, K; Opitz, S; Miska, S; Yuan, Y; Hasselbach, L; Luttges, J; Kalthoff, H; Sturzbecher, HW			DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma	ONCOGENE			English	Article						carcinogenesis; drug resistance; p53; genetic instability; SOS-repair	HOMOLOGOUS RECOMBINATION; BREAK REPAIR; PROTEIN; CELLS; RESISTANCE; RADIATION; SPHEROIDS; GENES; P53	Molecular processes that could contribute to differences in chemo- and radioresistance include variations in DNA repair mechanisms. In mammalian cells, the product of the rad51 gene mediates DNA repair via homologous recombination. We describe that in contrast to conventional monolayer cell systems Rad51 protein accumulates to high-levels in three-dimensional cell culture models as well as in orthotopic xeno-transplants of human pancreatic cancer cells. Strikingly, over-expression of wild-type Rad51 was also found in 66% of human pancreatic adenocarcinoma tissue specimens. Functional analysis revealed that Rad51 over-expression enhances survival of cells after induction of DNA double strand breaks. These data suggest that perturbations of Rad51 expression contribute to the malignant phenotype of pancreatic cancer.	Med Univ Lubeck, Univ Clin Lubeck, Inst Human Genet, D-23538 Lubeck, Germany; Univ Kiel, Inst Pathol, Clin Gen & Thorac Surg, D-24105 Kiel, Germany	University of Lubeck; University of Kiel	Sturzbecher, HW (corresponding author), Med Univ Lubeck, Univ Clin Lubeck, Inst Human Genet, Ratzeburger Allee 160, D-23538 Lubeck, Germany.		Kalthoff, Holger/B-1618-2010					Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Buchhop S, 1996, HYBRIDOMA, V15, P205, DOI 10.1089/hyb.1996.15.205; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; Desoize B, 1998, ANTICANCER RES, V18, P4147; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Israel L, 1996, J THEOR BIOL, V178, P375, DOI 10.1006/jtbi.1996.0033; KALTHOFF H, 1993, ONCOGENE, V8, P289; Kloppel GES, 1996, HISTOLOGICAL TYPING; Loeb LA, 1998, ADV CANCER RES, V72, P25, DOI 10.1016/S0065-230X(08)60699-5; MuellerKlieser W, 1997, AM J PHYSIOL-CELL PH, V273, pC1109, DOI 10.1152/ajpcell.1997.273.4.C1109; Ohnishi T, 1998, BIOCHEM BIOPH RES CO, V245, P319, DOI 10.1006/bbrc.1998.8440; OLIVE PL, 1994, CANCER METAST REV, V13, P121, DOI 10.1007/BF00689632; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Strauss BS, 1998, GENETICS, V148, P1619; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Yanagisawa T, 1998, ORAL ONCOL, V34, P524, DOI 10.1016/S1368-8375(98)00045-1	20	167	175	0	12	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 25	2000	19	23					2791	2795		10.1038/sj.onc.1203578	http://dx.doi.org/10.1038/sj.onc.1203578			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851081				2022-12-25	WOS:000087318500009
J	Osheroff, WP; Beard, WA; Yin, S; Wilson, SH; Kunkel, TA				Osheroff, WP; Beard, WA; Yin, S; Wilson, SH; Kunkel, TA			Minor groove interactions at the DNA polymerase beta active site modulate single-base deletion error rates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; DIFFERENT SEQUENCE CONTEXTS; ESCHERICHIA-COLI; TEMPLATE-PRIMER; NUCLEOTIDE INCORPORATION; MUTATIONAL SPECIFICITY; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURES; III HOLOENZYME; FIDELITY	The structures of open and closed conformations of DNA polymerase beta (pol beta) suggests that the rate of single-nucleotide deletions during synthesis may be modulated by interactions in the DNA minor groove that align the templating base with the incoming dNTP. To test this hypothesis, we measured the single-base deletion error rates of wild-type pol beta and lysine and alanine mutants of Arg(283), whose side chain interacts with the minor groove edge of the templating nucleotide at the active site. The error rates of both mutant enzymes are increased > 100-fold relative to wild-type pol beta, Template engineering experiments performed to distinguish among three possible models for deletion formation suggest that most deletions in repetitive sequences by pol beta initiate by strand slippage. However, pol beta also generates deletions by a different mechanism that is strongly enhanced by the substitutions at Arg283. Analysis of error specificity suggests that this mechanism involves nucleotide misinsertion followed by primer relocation, creating a misaligned intermediate. The structure of pol beta bound to non-gapped DNA also indicates that the templating nucleotide and its downstream neighbor are out of register in the open conformation and this could facilitate misalignment (dNTP or primer terminus) with the next template base.	NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kunkel, TA (corresponding author), NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.	kunkel@niehs.nih.gov	Wilson, Samuel H/E-6644-2019; Kunkel, Thomas A./D-5088-2019	Wilson, Samuel H/0000-0002-1702-5293; Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES050158, Z01ES050158] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Ahn JW, 1998, BIOCHEM J, V331, P79, DOI 10.1042/bj3310079; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; BEBENEK K, 1993, REVERSE TRANSCRIPTAS, V23, P85; Bloom LB, 1997, J BIOL CHEM, V272, P27919, DOI 10.1074/jbc.272.44.27919; CAI H, 1993, J BIOL CHEM, V268, P23567; Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; Efrati E, 1997, J BIOL CHEM, V272, P2559; Fujii S, 1999, J MOL BIOL, V289, P835, DOI 10.1006/jmbi.1999.2802; Hashim MF, 1997, J BIOL CHEM, V272, P20205, DOI 10.1074/jbc.272.32.20205; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kroutil LC, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P699; Kroutil LC, 1999, NUCLEIC ACIDS RES, V27, P3481, DOI 10.1093/nar/27.17.3481; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; Kroutil LC, 1998, J MOL BIOL, V278, P135, DOI 10.1006/jmbi.1998.1676; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; KUNKEL TA, 2000, IN PRESS ANN REV BIO, V69; Li SX, 1999, BIOCHEMISTRY-US, V38, P4800, DOI 10.1021/bi9827058; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; Opresko PL, 1998, BIOCHEMISTRY-US, V37, P2111, DOI 10.1021/bi9722711; Osheroff WP, 1999, J BIOL CHEM, V274, P20749, DOI 10.1074/jbc.274.30.20749; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; Pham PT, 1999, J BIOL CHEM, V274, P3705, DOI 10.1074/jbc.274.6.3705; Roberts J.D., 1996, DNA REPLICATION EUKA, P217; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202	44	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28033	28038						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10851238				2022-12-25	WOS:000089197100068
J	Burtelow, MA; Kaufmann, SH; Karnitz, LM				Burtelow, MA; Kaufmann, SH; Karnitz, LM			Retention of the human Rad9 checkpoint complex in extraction-resistant nuclear complexes after DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE RAD1(+); FISSION YEAST; HUMAN HOMOLOG; ATAXIA-TELANGIECTASIA; STRUCTURAL HOMOLOG; CDC25 PHOSPHATASE; PROTEIN-KINASE; CONTROL GENE; ATM; PATHWAYS	Studies in yeasts and mammals have identified many genes important for DNA damage-induced checkpoint activation, including Rad9, Hus1, and Rad1; however, the functions of these gene products are unknown. In this study we show by immunolocalization that human Rad9 (hRad9) is localized exclusively in the nucleus. However, hRad9 was readily released from the nucleus into the soluble extract upon biochemical fractionation of un-irradiated cells. In contrast, DNA damage promptly converted hRad9 to an extraction-resistant form that was retained at discrete sites within the nucleus. Conversion of hRad9 to the extraction-resistant nuclear form occurred in response to diverse DNA damaging agents and the replication inhibitor hydroxyurea but not other cytotoxic stimuli. Additionally, extraction-resistant hRad9 interacted with its binding partners, hHus1 and an inducibly phosphorylated form of hRad1. Thus, these studies demonstrate that hRad9 is a nuclear protein that becomes more firmly anchored to nuclear components after DNA damage, consistent with a proximal function in DNA damage-activated checkpoint signaling pathways.	Mayo Clin & Mayo Fdn, Div Radiat Oncol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Div Dev Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Karnitz, LM (corresponding author), Mayo Clin & Mayo Fdn, Div Radiat Oncol, Guggenheim 13, Rochester, MN 55905 USA.	karnitz.larry@mayo.edu		Kaufmann, Scott/0000-0002-4900-7145				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Bao SD, 1999, CANCER RES, V59, P2023; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Bluyssen HAR, 1998, GENOMICS, V54, P331, DOI 10.1006/geno.1998.5582; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Caspari T, 1999, BIOCHIMIE, V81, P173, DOI 10.1016/S0300-9084(99)80050-9; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Dean FB, 1998, GENOMICS, V54, P424, DOI 10.1006/geno.1998.5587; FIELDS AP, 1986, EXP CELL RES, V164, P139, DOI 10.1016/0014-4827(86)90461-1; Freire R, 1998, GENE DEV, V12, P2560, DOI 10.1101/gad.12.16.2560; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; Li L, 1999, ONCOGENE, V18, P1689, DOI 10.1038/sj.onc.1202469; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; LONG KE, 1994, GENE, V148, P155, DOI 10.1016/0378-1119(94)90250-X; Longhese MP, 1998, EMBO J, V17, P5525, DOI 10.1093/emboj/17.19.5525; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Marathi UK, 1998, GENOMICS, V54, P344, DOI 10.1006/geno.1998.5589; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Parker AE, 1998, J BIOL CHEM, V273, P18340, DOI 10.1074/jbc.273.29.18340; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zeng Y, 1999, MOL CELL BIOL, V19, P7410	43	95	95	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26343	26348		10.1074/jbc.M001244200	http://dx.doi.org/10.1074/jbc.M001244200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852904	hybrid			2022-12-25	WOS:000088999700064
J	Bell, LM; Leong, MLL; Kim, B; Wang, E; Park, J; Hemmings, BA; Firestone, GL				Bell, LM; Leong, MLL; Kim, B; Wang, E; Park, J; Hemmings, BA; Firestone, GL			Hyperosmotic stress stimulates promoter activity and regulates cellular utilization of the serum- and glucocorticoid-inducible protein kinase (Sgk) by a p38 MAPK-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; RESPONSE ELEMENT; OSMOTIC-STRESS; TRANSCRIPTIONAL REGULATION; INFLAMMATORY CYTOKINES; GLUT4 TRANSLOCATION; MAMMALIAN-CELLS	We have established that the serum- and glucocorticold-inducible protein kinase (Sgk) is a new component of the hyperosmotic stress response. Treatment of NMuMg mammary epithelial cells with the organic osmolyte, sorbitol, caused the stable accumulation of Sgk transcripts and protein after an approximately 4-h lag. Transient transfection of a series of sgk-CAT reporter plasmids containing either 5' deletions or continuous 6-base pair substitutions identified a hyperosmotic stress-regulated element that is GC-rich and is necessary for the sorbitol stimulation of sgk gene promoter activity. Gel shift analysis identified four major DNA-protein complexes in the hyperosmotic stress-regulated element that, by competition with excess consensus wild type and mutant oligonucleotides and by antibody supershifts, contains the Spl transcription factor. Several lines of evidence suggest that the p38 MAPK signaling pathway mediates the hyperosmotic stress stimulation of sgk: gene expression. Treatment with pharmacological inhibitors of p38 MAPK or with a dominant negative form of MKK3, an upstream regulator of p38 MAPK, significantly reduced or ablated the sorbitol induction of sgk promoter activity or protein production. Using an in vitro peptide transphosphorylation assay, sorbitol treatment activates either endogenous or exogenous Sgk that is localized to the cytoplasmic compartment. Thus, we propose that the stimulated expression of enzymatically active Sgk after sorbitol treatment is a newly defined component of the p38 MAPK-mediated response to hyperosmotic stress.	Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA; Friedrich Miescher Inst, CH-4056 Basel, Switzerland	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Friedrich Miescher Institute for Biomedical Research	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Cell & Mol Biol, 591 LSA, Berkeley, CA 94720 USA.		Park, Jongsun/E-7465-2010	Park, Jongsun/0000-0002-4690-1854	NATIONAL CANCER INSTITUTE [R01CA071514] Funding Source: NIH RePORTER; NCI NIH HHS [CA-71514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Alliston TN, 1997, MOL ENDOCRINOL, V11, P1934, DOI 10.1210/me.11.13.1934; AMMENDOLA R, 1994, EUR J BIOCHEM, V225, P483, DOI 10.1111/j.1432-1033.1994.t01-1-00483.x; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buse P, 1999, J BIOL CHEM, V274, P7253, DOI 10.1074/jbc.274.11.7253; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chen D, 1999, MOL CELL BIOL, V19, P4684; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delmolino LM, 1997, J CELL PHYSIOL, V173, P371; Denkert C, 1998, ARCH BIOCHEM BIOPHYS, V354, P172, DOI 10.1006/abbi.1998.0661; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; IMAIZUMI K, 1994, MOL BRAIN RES, V26, P189, DOI 10.1016/0169-328X(94)90090-6; Inoue Y, 1998, J BIOL CHEM, V273, P2977, DOI 10.1074/jbc.273.5.2977; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kumar JM, 1999, J AM SOC NEPHROL, V10, P2488; Kurowski TG, 1999, DIABETES, V48, P658, DOI 10.2337/diabetes.48.3.658; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lavoie L, 1999, J BIOL CHEM, V274, P28279, DOI 10.1074/jbc.274.40.28279; Lin MC, 1997, J CLIN INVEST, V99, P737, DOI 10.1172/JCI119219; Lotem J, 1999, P NATL ACAD SCI USA, V96, P12016, DOI 10.1073/pnas.96.21.12016; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; Maiyar AC, 1996, J BIOL CHEM, V271, P12414, DOI 10.1074/jbc.271.21.12414; Maiyar AC, 1997, MOL ENDOCRINOL, V11, P312, DOI 10.1210/me.11.3.312; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; OWENS RB, 1974, J NATL CANCER I, V52, P1375, DOI 10.1093/jnci/52.4.1375; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Posas F, 1998, CURR OPIN MICROBIOL, V1, P175, DOI 10.1016/S1369-5274(98)80008-8; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Waldegger S, 1999, GASTROENTEROLOGY, V116, P1081, DOI 10.1016/S0016-5085(99)70011-9; Waldegger S, 1997, P NATL ACAD SCI USA, V94, P4440, DOI 10.1073/pnas.94.9.4440; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Watts BA, 1998, AM J PHYSIOL-RENAL, V275, pF478, DOI 10.1152/ajprenal.1998.275.4.F478; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; WEBSTER MK, 1993, J BIOL CHEM, V268, P11482; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876	78	136	137	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25262	25272		10.1074/jbc.M002076200	http://dx.doi.org/10.1074/jbc.M002076200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10842172	hybrid			2022-12-25	WOS:000088849400031
J	Cockman, ME; Masson, N; Mole, DR; Jaakkola, P; Chang, GW; Clifford, SC; Maher, ER; Pugh, CW; Ratcliffe, PJ; Maxwell, PH				Cockman, ME; Masson, N; Mole, DR; Jaakkola, P; Chang, GW; Clifford, SC; Maher, ER; Pugh, CW; Ratcliffe, PJ; Maxwell, PH			Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 1-ALPHA HIF-1-ALPHA; IRON-REGULATORY PROTEIN-2; DEPENDENT PROTEOLYSIS; UBIQUITIN LIGASE; GENE-PRODUCT; ELONGIN-B; DEGRADATION; ACTIVATION; COMPLEX; FACTOR-1-ALPHA	The von Hippel-Lindau tumor suppressor protein (pVHL) has emerged as a key factor in cellular responses to oxygen availability, being required for the oxygen-dependent proteolysis of alpha subunits of hypoxia inducible factor-1 (HIF), Mutations in VHL cause a hereditary cancer syndrome associated with dysregulated angiogenesis, and up-regulation of hypoxia inducible genes, Here we investigate the mechanisms underlying these processes and show that extracts from VHL-deficient renal carcinoma cells have a defect in HIF-alpha ubiquitylation activity which is complemented by exogenous pVHL, This defect was specific for HIF-alpha among a range of substrates tested. Furthermore, HIF-alpha subunits were the only pVHL-associated proteasomal substrates identified by comparison of metabolically labeled anti-pVHL immunoprecipitates from proteosomally inhibited cells and normal cells. Analysis of pVHL/HIF-alpha interactions defined short sequences of conserved residues within the internal transactivation domains of HIF-alpha molecules sufficient for recognition by pVHL, In contrast, while full-length pVHL and the p19 variant interact with HIF-alpha, the association was abrogated by further N-terminal and C-terminal truncations. The interaction was also disrupted by tumor-associated mutations in the beta-domain of pVHL and loss of interaction was associated with defective HIF-alpha ubiquitylation and regulation, defining a mechanism by which these mutations generate a constitutively hypoxic pattern of gene expression promoting angiogenesis, The findings indicate that pVHL regulates HIF-alpha proteolysis by acting as the recognition component of a ubiquitin ligase complex, and support a model in which its beta domain interacts with short recognition sequences in HIF-alpha subunits.	Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Birmingham, Dept Paediat & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England	University of Oxford; Wellcome Centre for Human Genetics; University of Birmingham	Ratcliffe, PJ (corresponding author), Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.		Jaakkola, Panu M/B-4355-2012; MAHER, EAMONN R/A-9507-2008; Maxwell, Patrick H/C-5557-2008; Cockman, Matthew/V-9619-2019	MAHER, EAMONN R/0000-0002-6226-6918; Maxwell, Patrick H/0000-0002-0338-2679; Cockman, Matthew/0000-0002-3310-4821; Mole, David/0000-0002-0984-300X; Pugh, Chris/0000-0002-5170-1662; Jaakkola, Panu/0000-0002-2365-4985; Clifford, Steve/0000-0003-4893-2184; Ratcliffe, Peter/0000-0002-2853-806X				Beroud C, 1998, NUCLEIC ACIDS RES, V26, P256, DOI 10.1093/nar/26.1.256; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Hanson ES, 1999, J BIOL CHEM, V274, P5047, DOI 10.1074/jbc.274.8.5047; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Ohh M, 1999, J CLIN INVEST, V104, P1583, DOI 10.1172/JCI8161; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268	33	853	894	0	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25733	25741		10.1074/jbc.M002740200	http://dx.doi.org/10.1074/jbc.M002740200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10823831	hybrid			2022-12-25	WOS:000088849400089
J	Esperet, C; Sabatier, S; Deville, MA; Ouazana, R; Bouhassira, EE; Godet, J; Morle, F; Bernet, A				Esperet, C; Sabatier, S; Deville, MA; Ouazana, R; Bouhassira, EE; Godet, J; Morle, F; Bernet, A			Non-erythroid genes inserted on either side of human HS-40 impair the activation of its natural alpha-globin gene targets without being themselves preferentially activated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; REGULATORY ELEMENT HS-40; MEDIATED CASSETTE EXCHANGE; ZETA-GLOBIN; IN-VIVO; HOMOLOGOUS RECOMBINATION; TRANSGENIC MICE; FAR UPSTREAM; THALASSEMIA; EXPRESSION	The human cu-globin gene complex includes three functional globin genes (5'-zeta 2-alpha 2-alpha 1-3') regulated by a common positive regulatory element named HS-40 displaying strong erythroid-specific enhancer activity. How this enhancer activity can be shared between different promoters present at different positions in the same complex is poorly understood. To address this question, we used homologous recombination to target the insertion of marker genes driven by cytomegalovirus or long terminal repeat promoters in both possible orientations either upstream or downstream from the HS-40 region into the single human alpha-globin gene locus present in hybrid mouse erythroleukemia cells. We also used CRE recombinase-mediated cassette exchange to target the insertion of a tagged alpha-globin gene at the same position downstream from HS-40. All these insertions led to a similar decrease in the HS-40-dependent transcription of downstream human alpha-globin genes in differentiated cells. Interestingly, this decrease is associated with the strong activation of the proximal newly inserted alpha-globin gene, whereas in marked contrast, the transcription of the non-erythroid marker genes remains insensitive to HS-40. Taken together, these results indicate that the enhancer activity of HS-40 can be trapped by non-erythroid promoters in both upstream and downstream directions without necessarily leading to their own activation.	Univ Lyon 1, CNRS, Ctr Genet Mol & Cellulaire, UMR 5534, F-69622 Villeurbanne, France; Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Yeshiva University; Albert Einstein College of Medicine	Bernet, A (corresponding author), Univ Lyon 1, CNRS, Ctr Genet Mol & Cellulaire, UMR 5534, Bat 741,43 Blvd 11 Novembre 1918, F-69622 Villeurbanne, France.	bernet@biomserv.univ-lyon1.fr	Bouhassira, Eric/AAZ-4184-2021					Baron MH, 1996, GENE EXPRESSION, V6, P129; BERNET A, 1995, BLOOD, V86, P1202; BERNETGRANDAUDI A, 1994, CR ACAD SCI III-VIE, V314, P1; Bouhassira EE, 1997, BLOOD, V90, P3332, DOI 10.1182/blood.V90.9.3332; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Chen HL, 1997, NUCLEIC ACIDS RES, V25, P2917, DOI 10.1093/nar/25.14.2917; CRADDOCK CF, 1995, EMBO J, V14, P1718, DOI 10.1002/j.1460-2075.1995.tb07161.x; Dillon N, 1997, MOL CELL, V1, P131, DOI 10.1016/S1097-2765(00)80014-3; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; Feng YQ, 1999, J MOL BIOL, V292, P779, DOI 10.1006/jmbi.1999.3113; Fiering S, 1999, METHOD ENZYMOL, V306, P42; FIERING S, 1993, P NATL ACAD SCI USA, V90, P8469, DOI 10.1073/pnas.90.18.8469; FISCHELGHODSIAN N, 1987, NUCLEIC ACIDS RES, V15, P9215, DOI 10.1093/nar/15.22.9215; GOURDON G, 1994, NUCLEIC ACIDS RES, V22, P4139, DOI 10.1093/nar/22.20.4139; Gribnau J, 1998, EMBO J, V17, P6020, DOI 10.1093/emboj/17.20.6020; Grosveld F, 1999, CURR OPIN GENET DEV, V9, P152, DOI 10.1016/S0959-437X(99)80023-9; GROSVELD F, 1993, BAILLIERE CLIN HAEM, V6, P31, DOI 10.1016/S0950-3536(05)80065-4; HATTON CSR, 1990, BLOOD, V76, P221; HIGGS DR, 1993, BAILLIERE CLIN HAEM, V6, P117, DOI 10.1016/S0950-3536(05)80068-X; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; Huang BL, 1998, P NATL ACAD SCI USA, V95, P14669, DOI 10.1073/pnas.95.25.14669; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; KROWZYNSKI A, 1985, J MOL BIOL, V18, P231; Leder A, 1997, BLOOD, V90, P1275, DOI 10.1182/blood.V90.3.1275.1275_1275_1282; LIEBHABER SA, 1990, P NATL ACAD SCI USA, V87, P9431, DOI 10.1073/pnas.87.23.9431; MANSOUR SL, 1988, CELL, V44, P319; MORLE F, 1986, NUCLEIC ACIDS RES, V14, P3279, DOI 10.1093/nar/14.8.3279; MORLE F, 1985, EMBO J, V4, P1245, DOI 10.1002/j.1460-2075.1985.tb03767.x; NANDI AK, 1988, P NATL ACAD SCI USA, V85, P3845, DOI 10.1073/pnas.85.11.3845; PONDEL MD, 1992, NUCLEIC ACIDS RES, V20, P237, DOI 10.1093/nar/20.2.237; REN SC, 1993, BLOOD, V81, P1058; ROBERTSON G, 1995, P NATL ACAD SCI USA, V92, P5371, DOI 10.1073/pnas.92.12.5371; ROMAO L, 1991, BLOOD, V78, P1589; ROMBEL I, 1995, P NATL ACAD SCI USA, V92, P6454, DOI 10.1073/pnas.92.14.6454; SHARPE JA, 1992, EMBO J, V11, P4565, DOI 10.1002/j.1460-2075.1992.tb05558.x; Smith ZE, 1999, HUM MOL GENET, V8, P1373, DOI 10.1093/hmg/8.8.1373; Tanimoto K, 1999, NATURE, V398, P344, DOI 10.1038/18698; Trimborn T, 1999, GENE DEV, V13, P112, DOI 10.1101/gad.13.1.112; VICKERS MA, 1993, P NATL ACAD SCI USA, V90, P3437, DOI 10.1073/pnas.90.8.3437; VYAS P, 1995, GENOMICS, V29, P679, DOI 10.1006/geno.1995.9951; Wen SC, 2000, MOL CELL BIOL, V20, P1993, DOI 10.1128/MCB.20.6.1993-2003.2000; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; ZHANG QY, 1995, J BIOL CHEM, V270, P8501, DOI 10.1074/jbc.270.15.8501	45	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25831	25839		10.1074/jbc.M001757200	http://dx.doi.org/10.1074/jbc.M001757200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827181	hybrid			2022-12-25	WOS:000088849400101
J	Gotthardt, M; Trommsdorff, M; Nevitt, MF; Shelton, J; Richardson, JA; Stockinger, W; Nimpf, J; Herz, J				Gotthardt, M; Trommsdorff, M; Nevitt, MF; Shelton, J; Richardson, JA; Stockinger, W; Nimpf, J; Herz, J			Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; PDZ DOMAIN; CYTOPLASMIC DOMAIN; MEMBRANE-PROTEIN; APOLIPOPROTEIN-E; VLDL RECEPTOR; MICE LACKING; INTEGRIN; BINDING; REELIN	The members of the low density lipoprotein (LDL) receptor gene family bind a broad spectrum of extracellular ligands, Traditionally, they had been regarded as mere cargo receptors that promote the endocytosis and lysosomal delivery of these ligands, However, recent genetic experiments in mice have revealed critical functions for two LDL receptor family members, the very low density lipoprotein receptor and the apoE receptor-a, in the transmission of extracellular signals and the activation of intracellular tyrosine kinases, This process regulates neuronal migration and is crucial for brain development. Signaling through these receptors requires the interaction of their cytoplasmic tails with the intracellular adaptor protein Disabled-1 (DAB1), Here, we identify an extended set of cytoplasmic proteins that might also participate in signal transmission by the LDL receptor gene family. Most of these novel proteins are adaptor or scaffold proteins that contain PID or PDZ domains and function in the regulation of mitogen-activated protein kinases, cell adhesion, vesicle trafficking, or neurotransmission, We show that binding of DAB1 interferes with receptor internalization suggesting a mechanism by which signaling through this class of receptors might be regulated. Taken together, these findings imply much broader physiological functions for the LDL receptor family than had previously been appreciated. They form the basis for the elucidation of the molecular pathways by which cells respond to the diversity of ligands that bind to these multifunctional receptors on the cell surface.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Bioctr, Dept Mol Genet, Inst Med Biochem, A-1030 Vienna, Austria; Univ Vienna, A-1030 Vienna, Austria	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Vienna	Herz, J (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Gotthardt, Michael/ABE-8274-2021	Gotthardt, Michael/0000-0003-1788-3172; Nimpf, Johannes/0000-0002-9273-3492	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063762, R37HL063762, P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63762, HL20948, R37 HL063762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; Cremona O, 1999, CELL, V99, P179, DOI 10.1016/S0092-8674(00)81649-9; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; De Vries L, 1998, P NATL ACAD SCI USA, V95, P12340, DOI 10.1073/pnas.95.21.12340; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; McLoughlin DM, 1999, EUR J NEUROSCI, V11, P1988, DOI 10.1046/j.1460-9568.1999.00610.x; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Nemoto Y, 1999, EMBO J, V18, P2991, DOI 10.1093/emboj/18.11.2991; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Sheng M, 1999, ANN NY ACAD SCI, V868, P483, DOI 10.1111/j.1749-6632.1999.tb11317.x; Sipes JM, 1999, J BIOL CHEM, V274, P22755, DOI 10.1074/jbc.274.32.22755; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Stockinger W, 1998, J BIOL CHEM, V273, P32213, DOI 10.1074/jbc.273.48.32213; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; VANDRIEL IR, 1987, J BIOL CHEM, V262, P17443; Wang LH, 1999, J BIOL CHEM, V274, P14137, DOI 10.1074/jbc.274.20.14137; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; Willnow TE, 1996, P NATL ACAD SCI USA, V93, P8460, DOI 10.1073/pnas.93.16.8460; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhang XA, 1999, J BIOL CHEM, V274, P11, DOI 10.1074/jbc.274.1.11; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	38	387	415	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25616	25624		10.1074/jbc.M000955200	http://dx.doi.org/10.1074/jbc.M000955200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827173	hybrid			2022-12-25	WOS:000088849400076
J	Mullin, JL; Gorkun, OV; Binnie, CG; Lord, ST				Mullin, JL; Gorkun, OV; Binnie, CG; Lord, ST			Recombinant fibrinogen studies reveal that thrombin specificity dictates order of fibrinopeptide release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; LATERAL AGGREGATION; TERMINAL DOMAIN; ALPHA-THROMBIN; POLYMERIZATION; HIRUDIN; CONVERSION; INHIBITORS; TURBIDITY; FRAGMENTS	During cleavage of fibrinogen by thrombin, fibrinopeptide A (FpA) release precedes fibrinopeptide B (FpB) release. To examine the basis for this ordered release, we synthesized A'beta fibrinogen, replacing FpB with a fibrinopeptide A-like peptide, FpA' (G14V). Analyses of fibrinopeptide release from A'beta fibrinogen showed that FpA release and FpA' release were similar; the release of either peptide followed simple first-order kinetics. Specificity constants for FpA and FpA' were similar, demonstrating that these peptides are equally competitive substrates for thrombin. In the presence of Gly-Pro-Arg-Pro, an inhibitor of fibrin polymerization, the rate of FEB release from normal fibrinogen was reduced 3-fold, consistent with previous data; in contrast, the rate of FpA' release from A'beta fibrinogen was unaffected. Thus, with A'beta fibrinogen, fibrinopeptide release from the beta chain is similar to fibrinopeptide release from the alpha chain. We conclude that the ordered release of fibrinopeptides is dictated by the specificity of thrombin for its substrates. We analyzed polymerization, following changes in turbidity, and found that polymerization of A'beta fibrinogen was similar to that of normal fibrinogen. We analyzed clot structure by scanning electron microscopy and found that clots from A'beta fibrinogen were similar to clots from normal fibrinogen. We conclude that premature release of the fibrinopeptide from the N terminus of the beta chain does not affect polymerization of fibrinogen.	Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Lord, ST (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, CB 7525,605 Brinkhous Bullitt Bldg, Chapel Hill, NC 27599 USA.		Ariel, Pablo/AGJ-4118-2022		NHLBI NIH HHS [R01-HL31048] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031048] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BINNIE CG, 1993, BIOCHEMISTRY-US, V32, P107, DOI 10.1021/bi00052a015; BINNIE CG, 1993, BLOOD, V81, P3186; CARR ME, 1978, MACROMOLECULES, V11, P46, DOI 10.1021/ma60061a009; CORNISHBOWDEN A, 1979, FUNDAMENTALS ENZYME, P208; DECRISTOFARO R, 1993, BIOCHEM J, V289, P475, DOI 10.1042/bj2890475; DENNIS S, 1990, EUR J BIOCHEM, V188, P61, DOI 10.1111/j.1432-1033.1990.tb15371.x; ECKHARDT T, 1981, J CLIN INVEST, V67, P809, DOI 10.1172/JCI110098; Everse SJ, 1999, BIOCHEMISTRY-US, V38, P2941, DOI 10.1021/bi982626w; FERRY JD, 1947, J AM CHEM SOC, V69, P388, DOI 10.1021/ja01194a066; Gorkun OV, 1997, BLOOD, V89, P4407, DOI 10.1182/blood.V89.12.4407; HANNA LS, 1984, BIOCHEMISTRY-US, V23, P4681, DOI 10.1021/bi00315a025; HANTGAN RR, 1979, J BIOL CHEM, V254, P1272; HENSCHEN A, 1983, ANN NY ACAD SCI, V408, P28, DOI 10.1111/j.1749-6632.1983.tb23232.x; HenschenEdman AH, 1997, CELL MOL LIFE SCI, V53, P29, DOI 10.1007/PL00000577; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; HOGG DH, 1978, THROMB RES, V12, P953, DOI 10.1016/0049-3848(78)90051-8; HORTIN GL, 1991, J BIOL CHEM, V266, P6866; HURLETJENSEN A, 1982, THROMB RES, V27, P419, DOI 10.1016/0049-3848(82)90059-7; KAMINSKI M, 1983, J BIOL CHEM, V258, P530; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER BG, 1988, J BIOL CHEM, V263, P15056; LAUDANO AP, 1978, P NATL ACAD SCI USA, V75, P3085, DOI 10.1073/pnas.75.7.3085; LEWIS SD, 1985, J BIOL CHEM, V260, P192; LIU LW, 1991, J BIOL CHEM, V266, P16977; LORD ST, 1990, J BIOL CHEM, V265, P838; Lord ST, 1996, BIOCHEMISTRY-US, V35, P2342, DOI 10.1021/bi952353u; MARTINELLI RA, 1980, BIOCHEMISTRY-US, V19, P2343, DOI 10.1021/bi00552a010; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NG AS, 1993, METHOD ENZYMOL, V222, P341; RUF W, 1988, BIOCHIM BIOPHYS ACTA, V965, P169, DOI 10.1016/0304-4165(88)90053-0; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; TAKEBE M, 1995, THROMB HAEMOSTASIS, V73, P662; VANDERDRIFT ACM, 1983, FIBRINOGEN STRUCTURE, P3; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577; WEISEL JW, 1993, J MOL BIOL, V232, P285, DOI 10.1006/jmbi.1993.1382; WEISEL JW, 1992, BIOPHYS J, V63, P111, DOI 10.1016/S0006-3495(92)81594-1	36	31	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25239	25246		10.1074/jbc.M004142200	http://dx.doi.org/10.1074/jbc.M004142200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837485	hybrid, Green Published			2022-12-25	WOS:000088849400028
J	Petropoulos, H; Skesjanc, IS				Petropoulos, H; Skesjanc, IS			Analysis of the inhibition of MyoD activity by ITF-2B and full-length E12/E47	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX TRANSCRIPTION FACTOR; MUSCLE DIFFERENTIATION PROGRAM; CREATINE-KINASE ENHANCER; DNA-BINDING; CARDIAC-MUSCLE; REGULATORY ELEMENTS; MAMMALIAN-CELLS; E-BOX; GENE-EXPRESSION; TRANSGENIC MICE	MyoD heterodimerizes with E type factors (E12/E47 and ITF-2A/ITF-2B) and binds E box sequences within promoters of muscle-specific genes. In transient transfection assays, MyoD activates transcription in the presence of ITF-2A but not ITF-28, which contains a 182-amino acid N-terminal extension. The first 83 amino acids of the inhibitory N terminus of ITF-2B show high sequence homology to the N terminus of full-length E12/E47. Previous studies that showed activation of MyoD by E12 used an artificially N-terminally truncated form. Here we show that the full-length form of E12 inhibits MyoD function. A conserved cu-helix motif, capable of interacting with the transcriptional machinery, was not essential for inhibition, Furthermore, the fusion of N-terminal ITF-2B sequences or non-inhibiting ITF-2A sequences to truncated E12 was sufficient in converting the activator into an inhibitor. Overexpression of ITF-2B did not inhibit C2C12 myogenesis or affect levels of endogenous muscle gene expression, consistent with the finding that inhibitory E type proteins are present in muscle. Furthermore, we found that MyoD co-transfected with either ITF-2B or ITF-2A converted fibroblasts into myoblasts with the same frequency. Our findings suggest that the ability of E type proteins to inhibit MyoD activity is dependent on the context of the E box.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Skesjanc, IS (corresponding author), Univ Western Ontario, Dept Biochem, Med Sci Bldg, London, ON N6A 5C1, Canada.							ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Bailey P, 1999, MOL ENDOCRINOL, V13, P1155, DOI 10.1210/me.13.7.1155; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BURRIDGE K, 1975, J MOL BIOL, V99, P1, DOI 10.1016/S0022-2836(75)80154-9; Cash DE, 1997, J CELL BIOL, V136, P445, DOI 10.1083/jcb.136.2.445; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; Chen BB, 1997, J BIOL CHEM, V272, P2459, DOI 10.1074/jbc.272.4.2459; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CORNELIUSSEN B, 1991, J VIROL, V65, P6084, DOI 10.1128/JVI.65.11.6084-6093.1991; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DENARDI C, 1993, J CELL BIOL, V123, P823, DOI 10.1083/jcb.123.4.823; Donoviel DB, 1996, MOL CELL BIOL, V16, P1649; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Filvaroff EH, 1996, DEV BIOL, V178, P459, DOI 10.1006/dbio.1996.0231; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; FUJISAWASEHARA A, 1992, J BIOL CHEM, V267, P10031; Hamamori Y, 1997, MOL CELL BIOL, V17, P6563, DOI 10.1128/MCB.17.11.6563; Hebrok M, 1997, EXP CELL RES, V232, P295, DOI 10.1006/excr.1997.3541; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; HENTHORN P, 1990, NUCLEIC ACIDS RES, V18, P677, DOI 10.1093/nar/18.3.677; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JAVAUX F, 1991, NUCLEIC ACIDS RES, V19, P1121, DOI 10.1093/nar/19.5.1121; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lemercier C, 1998, EMBO J, V17, P1412, DOI 10.1093/emboj/17.5.1412; Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Massari ME, 1996, MOL CELL BIOL, V16, P121; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Narumi O, 2000, J BIOL CHEM, V275, P3510, DOI 10.1074/jbc.275.5.3510; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Ridgeway AG, 2000, J BIOL CHEM, V275, P41, DOI 10.1074/jbc.275.1.41; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J., 2002, MOL CLONING LAB MANU; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Shield MA, 1996, MOL CELL BIOL, V16, P5058; Skerjanc IS, 1996, J BIOL CHEM, V271, P3555, DOI 10.1074/jbc.271.7.3555; SKERJANC IS, 1994, DEV BIOL, V163, P125, DOI 10.1006/dbio.1994.1128; SKERJANC IS, 1994, MOL CELL BIOL, V1464, P8451; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898; Zhuang YA, 1998, MOL CELL BIOL, V18, P3340, DOI 10.1128/MCB.18.6.3340	65	14	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25095	25101		10.1074/jbc.M004251200	http://dx.doi.org/10.1074/jbc.M004251200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833525	hybrid			2022-12-25	WOS:000088849400009
J	Shapiro, MJ; Weiss, EJ; Faruqi, TR; Coughlin, SR				Shapiro, MJ; Weiss, EJ; Faruqi, TR; Coughlin, SR			Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLED RECEPTOR; PROTEOLYTIC MECHANISM; ENDOTHELIAL-CELLS; INTERNALIZATION; DESENSITIZATION; TRAFFICKING; CLONING; RESENSITIZATION; DETERMINANTS; SPECIFICITY	Protease-activated receptors 1 and 4 (PAR1 and PAR4) mediate thrombin signaling in human platelets. Whether these receptors are redundant, interact, or serve only partially overlapping functions is unknown. We report that PAR1 and PAR4 signal with distinct tempos, In transfected fibroblasts, PARA triggered substantially more phosphoinositide hydrolysis per activated receptor than PAR1 and was shut off more slowly than PAR1, Shutoff and internalization of PAR1 depends upon phosphorylation of its carboxyl tail upon receptor activation. In contrast to PAR1, phosphorylation of PARA was undetectable, and activation-dependent internalization of PAR4 was much slower than that seen for PAR1. Mutation of potential phosphorylation sites in the carboxyl tail of PAR1 enhanced PAR1 signaling, whereas analogous mutations in PAR4 had no effect. Thus PAR4 signaling is shut off less rapidly than PAR1, probably due to differences in receptor phosphorylation, PAR1 and PARA also signaled with distinct tempos in platelets. PAR1 triggered a rapid and transient increase in intracellular calcium, whereas PAR4 triggered a more prolonged response. Together, the tempo of these responses accounted for that triggered by thrombin, Thus differences in the rates at which PAR1 and PAR4 are shut off allow thrombin to trigger intracellular signaling with distinct temporal characteristics.	Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Univ Calif San Francisco, Daiichi Res Ctr, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Coughlin, SR (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, HSE-1300,505 Parnassus Ave, San Francisco, CA 94143 USA.				NHLBI NIH HHS [HL44907] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERNDT MC, 1981, PLATELETS BIOL PATHO, P43; BRASS LF, 1994, J BIOL CHEM, V269, P2943; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; DAVEY MG, 1967, NATURE, V216, P857, DOI 10.1038/216857a0; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; Ferguson SSG, 1998, LIFE SCI, V62, P1561, DOI 10.1016/S0024-3205(98)00107-6; Hammes SR, 1999, BIOCHEMISTRY-US, V38, P2486, DOI 10.1021/bi982527i; HEIN L, 1994, J BIOL CHEM, V269, P27719; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; Ishihara H, 1998, BLOOD, V91, P4152, DOI 10.1182/blood.V91.11.4152.411k22_4152_4157; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; ISHII K, 1995, J BIOL CHEM, V270, P16435, DOI 10.1074/jbc.270.27.16435; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; NELKEN NA, 1992, J CLIN INVEST, V90, P1614, DOI 10.1172/JCI116031; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SAGE SO, 1996, USE FLUORESCENT INDI, P67; Sambrano GR, 2000, J BIOL CHEM, V275, P6819, DOI 10.1074/jbc.275.10.6819; Shapiro MJ, 1998, J BIOL CHEM, V273, P29009, DOI 10.1074/jbc.273.44.29009; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P4813, DOI 10.1074/jbc.270.9.4813; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P8367, DOI 10.1074/jbc.270.14.8367; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	35	186	193	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25216	25221		10.1074/jbc.M004589200	http://dx.doi.org/10.1074/jbc.M004589200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837487	hybrid			2022-12-25	WOS:000088849400025
J	Feldman, DH; Harvey, WR; Stevens, BR				Feldman, DH; Harvey, WR; Stevens, BR			A novel electrogenic amino acid transporter is activated by K+ or Na+, is alkaline pH-dependent, and is Cl--independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ENERGIZATION; L-PROLINE TRANSPORTER; GATED ION-CHANNEL; SEROTONIN TRANSPORTERS; XENOPUS-OOCYTES; GABA TRANSPORTER; V-ATPASES; CLONING; EXPRESSION; COTRANSPORTER	A new eukaryotic nutrient amino acid transporter has been cloned from an epithelium that is exposed to high voltages and alkaline pH. The full-length cDNA encoding this novel CAATCH1 (cation-anion-activated Amino acid transporter/channel) was isolated using a polymerase chain reaction-based strategy, and its expression product in Xenopus oocytes displayed a combination of several unique, unanticipated functional properties. CAATCH1 electrophysiological properties resembled those of Na+,Cl--coupled neurotransmitter amine transporters, although CAATCH1 was cloned from a gut absorptive epithelium rather than from an excitable tissue. Amino acids such as L-proline, L-threonine, and L-methionine elicited complex current-voltage relationships in alkaline pH-dependent CAATCH1 that were reminiscent of the behavior of the dopamine, serotonin, and norepinephrine transporters (DAT, SERT, NET) in the presence of their substrates and pharmacological inhibitors such as cocaine or antidepressants, These I-V relationships indicated a combination of substrate-associated carrier current plus an independent CAATCH1-associated leakage current that could be blocked by certain amino acids. However, unlike all structurally related proteins, CAATCH1 activity is absolutely independent of Cl-. Unlike related KAAT1, CAATCH1 possesses a methionine-inhibitable constitutive leakage current and is able to switch its narrow substrate selectivity, preferring threonine in the presence of K+ but preferring proline in the presence of Na+.	Univ Florida, Coll Med, Dept Physiol, Gainesville, FL 32652 USA; Univ Florida, Whitney Lab, St Augustine, FL 32086 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Stevens, BR (corresponding author), Univ Florida, Coll Med, Dept Physiol, 1600 SW Archer Rd,Box 100274, Gainesville, FL 32652 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030464] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI30464] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amara S G, 1998, Adv Pharmacol, V42, P164; AMARAVADI L, 1994, BIOTECHNIQUES, V16, P98; ARGOS P, 1982, EUR J BIOCHEM, V128, P565; Beckman ML, 1998, J MEMBRANE BIOL, V164, P1; Bossi E, 1999, PFLUG ARCH EUR J PHY, V438, P788, DOI 10.1007/s004240051108; Bossi E, 1999, J PHYSIOL-LONDON, V515, P729, DOI 10.1111/j.1469-7793.1999.729ab.x; Broer A, 2000, BIOCHEM J, V346, P705, DOI 10.1042/0264-6021:3460705; Cao YW, 1997, J NEUROSCI, V17, P2257; Cao YW, 1998, J NEUROSCI, V18, P7739; Castagna M, 1998, P NATL ACAD SCI USA, V95, P5395, DOI 10.1073/pnas.95.9.5395; Colville C, 1994, MEMBRANE PROTEIN EXP, P243; COREY JL, 1994, P NATL ACAD SCI USA, V91, P1188, DOI 10.1073/pnas.91.3.1188; DeFelice L J, 1998, Adv Pharmacol, V42, P186; DEMCHYSHYN LL, 1994, P NATL ACAD SCI USA, V91, P5158, DOI 10.1073/pnas.91.11.5158; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Fairman WA, 1999, AM J PHYSIOL-RENAL, V277, pF481, DOI 10.1152/ajprenal.1999.277.4.F481; Feldman DH, 1999, BIOPHYS J, V76, pA249; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; Galli A, 1999, J NEUROSCI, V19, P6290; Galli A, 1997, J NEUROSCI, V17, P3401; Galli A, 1998, P NATL ACAD SCI USA, V95, P13260, DOI 10.1073/pnas.95.22.13260; GERENCSER GA, 1994, J EXP BIOL, V196, P59; GRAF R, 1992, FEBS LETT, V300, P119, DOI 10.1016/0014-5793(92)80177-I; GRIFFITH JK, 1998, TRANSPORTER FACTS BO; HAGER K, 1995, J MEMBRANE BIOL, V143, P103; Harvey WR, 1997, J EXP BIOL, V200, P203; Harvey WR, 1998, AM ZOOL, V38, P426; Hecker KH, 1996, BIOTECHNIQUES, V20, P478; Hilgemann DW, 1999, J GEN PHYSIOL, V114, P459, DOI 10.1085/jgp.114.3.459; Hille B., 1992, IONIC CHANNELS EXCIT; Hirayama BA, 1997, J BIOL CHEM, V272, P2110; Kanai Y, 1997, CURR OPIN CELL BIOL, V9, P565, DOI 10.1016/S0955-0674(97)80035-X; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Loo DDF, 1999, J PHYSIOL-LONDON, V518, P195, DOI 10.1111/j.1469-7793.1999.0195r.x; MACKENZIE B, 1994, PFLUG ARCH EUR J PHY, V426, P121, DOI 10.1007/BF00374679; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MBUNGU D, 1995, ARCH BIOCHEM BIOPHYS, V318, P489, DOI 10.1006/abbi.1995.1258; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Seal RP, 1999, ANNU REV PHARMACOL, V39, P431, DOI 10.1146/annurev.pharmtox.39.1.431; Sonders MS, 1997, J NEUROSCI, V17, P960; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; STEVENS BR, 1987, J BIOL CHEM, V262, P6546; STEVENS BR, 1992, MAMMALIAN AMINO ACID TRANSPORT, P149; Su A, 1996, BIOPHYS J, V70, P762, DOI 10.1016/S0006-3495(96)79616-9; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; Zerangue N, 1996, J BIOL CHEM, V271, P27991, DOI 10.1074/jbc.271.45.27991	48	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24518	24526		10.1074/jbc.M907582199	http://dx.doi.org/10.1074/jbc.M907582199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10829035	hybrid			2022-12-25	WOS:000088683300039
J	Muller, B; Link, J; Smythe, C				Muller, B; Link, J; Smythe, C			Assembly of U7 small nuclear ribonucleoprotein particle and histone RNA 3 ' processing in Xenopus egg extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; HAIRPIN BINDING-PROTEIN; COILED BODIES; CELL-CYCLE; STEM-LOOP; GERMINAL VESICLE; END FORMATION; INVITRO; 3'-END; SNRNA	In animals, replication-dependent histone genes are expressed in dividing somatic cells during S phase to maintain chromatin condensation. Histone mRNA 3'-end formation is an essential regulatory step producing an mRNA with a hairpin structure at the 3'-end. This requires the interaction of the U7 small nuclear ribonucleoprotein particle (snRNP) with a purine-rich spacer element and of the hairpin-binding protein with the hairpin element, respectively, in the 3'-untranslated region of histone RNA. Here, we demonstrate that bona fide histone RNA 3' processing takes place in Xenopus egg extracts in a reaction dependent on the addition of synthetic U7 RNA that is assembled into a ribonucleoprotein particle by protein components available in the extract. In addition to reconstituted U7 snRNP, Xenopus hairpin-binding protein SLBP1 is necessary for efficient processing. Histone RNA 3' processing is not affected by addition of non-destructible cyclin B, which drives the egg extract into M phase, but SLBP1 is phosphorylated in this extract. SPH-1, the Xenopus homologue of human p80-coilin found in coiled bodies, is associated with U7 snRNPs. However, this does not depend on the U7 RNA being able to process histone RNA and also occurs with U1 snRNPs; therefore, association of SPH1 cannot be considered as a hallmark of a functional U7 snRNP.	Univ Bern, Inst Zool, Abt Entwicklungsbiol, CH-3012 Bern, Switzerland; Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland; Univ Dundee, Inst Med Sci, Dept Biochem, Prot Phosphorylat Unit,MRC, Dundee DD1 4HN, Scotland	University of Bern; University of Aberdeen; University of Dundee	Muller, B (corresponding author), Univ Bern, Inst Zool, Abt Entwicklungsbiol, Baltzerstr 4, CH-3012 Bern, Switzerland.			Muller, Berndt/0000-0003-1279-5421				Abbott J, 1999, MOL BIOL CELL, V10, P487, DOI 10.1091/mbc.10.2.487; ADAMSON ED, 1974, J MOL BIOL, V88, P263, DOI 10.1016/0022-2836(74)90481-1; BAUER DW, 1994, MOL BIOL CELL, V5, P633, DOI 10.1091/mbc.5.6.633; Bauer DW, 1997, MOL BIOL CELL, V8, P73, DOI 10.1091/mbc.8.1.73; Bellini M, 1998, MOL BIOL CELL, V9, P2987, DOI 10.1091/mbc.9.10.2987; BIRCHMEIER C, 1984, P NATL ACAD SCI-BIOL, V81, P1057, DOI 10.1073/pnas.81.4.1057; BIRCHMEIER C, 1983, CELL, V35, P433, DOI 10.1016/0092-8674(83)90176-9; BIRCHMEIER C, 1982, CELL, V26, P739; BOND UM, 1991, GENE DEV, V5, P1709, DOI 10.1101/gad.5.9.1709; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COTTEN M, 1988, EMBO J, V7, P801, DOI 10.1002/j.1460-2075.1988.tb02878.x; Dominski Z, 1999, GENE, V239, P1, DOI 10.1016/S0378-1119(99)00367-4; Dominski Z, 1999, MOL CELL BIOL, V19, P3561; FERREIRA JA, 1994, J CELL BIOL, V126, P11, DOI 10.1083/jcb.126.1.11; Furger A, 1998, RNA, V4, P246; GALL JG, 1995, DEV GENET, V16, P25, DOI 10.1002/dvg.1020160107; Gall JG, 1999, MOL BIOL CELL, V10, P4385, DOI 10.1091/mbc.10.12.4385; GALLI G, 1983, CELL, V34, P823, DOI 10.1016/0092-8674(83)90539-1; GEORGIEV O, 1984, NUCLEIC ACIDS RES, V12, P8539, DOI 10.1093/nar/12.22.8539; GICK O, 1987, P NATL ACAD SCI USA, V84, P8937, DOI 10.1073/pnas.84.24.8937; GRAVES RA, 1985, J MOL BIOL, V183, P179, DOI 10.1016/0022-2836(85)90211-6; GRIMM C, 1993, EMBO J, V12, P1229, DOI 10.1002/j.1460-2075.1993.tb05764.x; GRUBER A, 1990, GENE, V95, P303, DOI 10.1016/0378-1119(90)90377-4; Harlow E., 1988, ANTIBODIES LAB MANUA; HARRIS ME, 1991, MOL CELL BIOL, V11, P2416, DOI 10.1128/MCB.11.5.2416; HARTL P, 1993, J CELL BIOL, V120, P613, DOI 10.1083/jcb.120.3.613; LERNER EA, 1981, P NATL ACAD SCI-BIOL, V78, P2737, DOI 10.1073/pnas.78.5.2737; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; LUSCHER B, 1987, EMBO J, V6, P1721, DOI 10.1002/j.1460-2075.1987.tb02423.x; Martin F, 1997, EMBO J, V16, P769, DOI 10.1093/emboj/16.4.769; Marzluff William F., 1992, Gene Expression, V2, P93; MELIN L, 1992, EMBO J, V11, P691, DOI 10.1002/j.1460-2075.1992.tb05101.x; MOWRY KL, 1987, MOL CELL BIOL, V7, P1663, DOI 10.1128/MCB.7.5.1663; MOWRY KL, 1987, SCIENCE, V238, P1682, DOI 10.1126/science.2825355; MOWRY KL, 1989, MOL CELL BIOL, V9, P3105, DOI 10.1128/MCB.9.7.3105; Muller B, 1997, SEMIN CELL DEV BIOL, V8, P567, DOI 10.1006/scdb.1997.0182; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; PANDEY NB, 1994, MOL CELL BIOL, V14, P1709, DOI 10.1128/MCB.14.3.1709; PFALLER R, 1991, CELL, V65, P209, DOI 10.1016/0092-8674(91)90155-R; Schaller A, 1997, J BIOL CHEM, V272, P10435; SCHAUFELE F, 1986, NATURE, V323, P777, DOI 10.1038/323777a0; SCHUMPERLI D, 1988, TRENDS GENET, V4, P187, DOI 10.1016/0168-9525(88)90074-1; SMITH HO, 1991, P NATL ACAD SCI USA, V88, P9784, DOI 10.1073/pnas.88.21.9784; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SMYTHE C, 1991, FUNCTIONAL ORG NUCL, P449; SOLDATI D, 1988, MOL CELL BIOL, V8, P1518, DOI 10.1128/MCB.8.4.1518; SPYCHER C, 1994, NUCLEIC ACIDS RES, V22, P4023, DOI 10.1093/nar/22.20.4023; STAUBER C, 1990, METHOD ENZYMOL, V181, P74; STEFANOVIC B, 1995, NUCLEIC ACIDS RES, V23, P3141, DOI 10.1093/nar/23.16.3141; STREIT A, 1993, NUCLEIC ACIDS RES, V21, P1569, DOI 10.1093/nar/21.7.1569; STRUB K, 1984, EMBO J, V3, P2801, DOI 10.1002/j.1460-2075.1984.tb02212.x; STRUB K, 1986, EMBO J, V5, P1675, DOI 10.1002/j.1460-2075.1986.tb04411.x; Tuma RS, 1999, CHROMOSOMA, V108, P337, DOI 10.1007/s004120050385; TUMA RS, 1993, J CELL BIOL, V122, P767, DOI 10.1083/jcb.122.4.767; VANDONGEN W, 1981, DEV BIOL, V86, P303, DOI 10.1016/0012-1606(81)90188-3; VASSEROT AP, 1989, P NATL ACAD SCI USA, V86, P4345, DOI 10.1073/pnas.86.12.4345; Wang ZF, 1996, GENE DEV, V10, P3028, DOI 10.1101/gad.10.23.3028; Wang ZF, 1999, MOL CELL BIOL, V19, P835; WOODLAND HR, 1980, FEBS LETT, V121, P1, DOI 10.1016/0014-5793(80)81252-X; Wu CHH, 1996, RNA, V2, P811; WU CHH, 1993, P NATL ACAD SCI USA, V90, P6257, DOI 10.1073/pnas.90.13.6257; ZELLER R, 1984, EMBO J, V3, P1075, DOI 10.1002/j.1460-2075.1984.tb01931.x	62	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24284	24293		10.1074/jbc.M003253200	http://dx.doi.org/10.1074/jbc.M003253200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827192	hybrid			2022-12-25	WOS:000088683300009
J	Witherow, DS; Wang, Q; Levay, K; Cabrera, JL; Chen, J; Willars, GB; Slepak, VZ				Witherow, DS; Wang, Q; Levay, K; Cabrera, JL; Chen, J; Willars, GB; Slepak, VZ			Complexes of the G protein subunit G beta(5) with the regulators of G protein signaling RGS7 and RGS9 - Characterization in native tissues and in transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; HETEROTRIMERIC G-PROTEINS; MUSCARINIC ACETYLCHOLINE-RECEPTORS; BETA-GAMMA-DIMERS; ADULT-RAT BRAIN; ALPHA-SUBUNIT; TRANSITION-STATE; PHOSPHOLIPASE-C; IN-VITRO; TRANSDUCIN	A novel protein class, termed regulators of G protein signaling (RGS), negatively regulates G protein pathways through a direct interaction with G alpha subunits and stimulation of GTP hydrolysis. An RGS subfamily including RGS6, -7, -9, and -11, which contain a characteristic G gamma-like domain, also has the unique ability to interact with the G protein beta subunit G beta(5). Here, we examined the behavior of G beta(5), RGS7, RGS9, and G alpha in tissue extracts using immunoprecipitation and conventional chromatography. Native G beta(5) and RGS7 from brain, as well as photoreceptor-specific G beta(5)L and RGS9, always co-purified as tightly associated dimers, and neither RGS-free G beta(5) nor G beta(5)-free RGS could be detected, Co-expression in COS-7 cells of G beta(5), dramatically increased the protein level of RGS7 and vice versa, indicating that cells maintain G beta(5) : RGS stoichiometry in a manner similar to G beta gamma complexes. This mechanism is non-transcriptional and is based on increased protein stability upon dimerization. Thus, analysis of native G beta(5)-RGS and their coupled expression argue that in vivo, G beta(5) and G gamma-like domain-containing RGSs only exist as heterodimers. Native G beta(5)-RGS7 did not co-precipitate or co-purify with G alpha(o) or G alpha(q); nor did G beta(5)-L-RGS9 with G alpha(t). However, in transfected cells, RGS7 and G beta(5)-RGS7 inhibited G alpha(q)-mediated Ca2+ response to muscarinic M3 receptor activation. Thus, G beta(5)-RGS dimers differ from other RGS proteins in that they do not bind to G alpha with high affinity, but they can still inhibit G protein signaling.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Sch Med, Program Neurosci, Miami, FL 33136 USA; Univ So Calif, Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA; Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Miami; University of Miami; University of Southern California; University of Leicester	Slepak, VZ (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, R-189,1600 NW 10th Ave, Miami, FL 33136 USA.	vslepak@newssun.med.miami.edu		Witherow, D. Scott/0000-0002-7344-1574	NEI NIH HHS [EY12155, EY12703] Funding Source: Medline; NIGMS NIH HHS [R01 GM60019] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012703, R01EY012155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060019] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Bayewitch ML, 1998, FASEB J, V12, P1019, DOI 10.1096/fasebj.12.11.1019; Benzing T, 1999, NAT MED, V5, P913, DOI 10.1038/11354; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Betty M, 1998, NEUROSCIENCE, V85, P475, DOI 10.1016/S0306-4522(97)00623-4; BIGAY J, 1994, METHOD ENZYMOL, V237, P139; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; EULER T, 1995, J COMP NEUROL, V361, P461, DOI 10.1002/cne.903610310; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; Gold SJ, 1997, J NEUROSCI, V17, P8024; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Hirschman JE, 1997, J BIOL CHEM, V272, P240; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Jones MB, 1999, ANAL BIOCHEM, V268, P126, DOI 10.1006/abio.1998.3064; Khawaja XZ, 1999, J NEUROCHEM, V72, P174, DOI 10.1046/j.1471-4159.1999.0720174.x; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Kovoor A, 2000, J BIOL CHEM, V275, P3397, DOI 10.1074/jbc.275.5.3397; Lan KL, 1998, J BIOL CHEM, V273, P12794, DOI 10.1074/jbc.273.21.12794; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Liang JJ, 2000, J NEUROSCI RES, V60, P58, DOI 10.1002/(SICI)1097-4547(20000401)60:1<58::AID-JNR6>3.0.CO;2-L; Liang JJ, 1998, J NEUROCHEM, V71, P345; Maier U, 2000, J BIOL CHEM, V275, P13746, DOI 10.1074/jbc.275.18.13746; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; Nahorski SR, 1997, LIFE SCI, V60, P1039, DOI 10.1016/S0024-3205(97)00045-3; Natochin M, 1997, FEBS LETT, V411, P179, DOI 10.1016/S0014-5793(97)00687-X; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; Pham K, 1998, BIOTECHNIQUES, V25, P198, DOI 10.2144/98252bm04; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; PRONIN AN, 1993, FEBS LETT, V328, P89, DOI 10.1016/0014-5793(93)80971-V; Saitoh O, 1999, J BIOL CHEM, V274, P9899, DOI 10.1074/jbc.274.14.9899; SCHMIDT CJ, 1991, J BIOL CHEM, V266, P4538; Scholich K, 1999, SCIENCE, V283, P1328, DOI 10.1126/science.283.5406.1328; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Sullivan E, 1999, METH MOL B, V114, P125; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Wang Q, 1999, J BIOL CHEM, V274, P17365, DOI 10.1074/jbc.274.24.17365; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WESS J, 1995, LIFE SCI, V56, P915, DOI 10.1016/0024-3205(95)00028-5; Wieland T, 1997, J BIOL CHEM, V272, P8853; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zhang JH, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0004.2000; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	62	128	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24872	24880		10.1074/jbc.M001535200	http://dx.doi.org/10.1074/jbc.M001535200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10840031	hybrid			2022-12-25	WOS:000088683300085
J	MacGillivray, MK; Cruz, TF; McCulloch, CAG				MacGillivray, MK; Cruz, TF; McCulloch, CAG			The recruitment of the interleukin-1 (IL-1) receptor-associated kinase (IRAK) into focal adhesion complexes is required for IL-1 beta-induced ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; PROTEIN-KINASE; ACCESSORY PROTEIN; RHEUMATOID-ARTHRITIS; PERIODONTAL-DISEASE; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; TERMINAL KINASES; MESANGIAL CELLS	The interleukin-1 (IL-1) receptor colocalizes with focal adhesion complexes (FACs), actin enriched structures involved in cell adhesion and signaling in fibroblasts and chondrocytes, The colocalization of FACs and IL-1 receptors has been implicated in the restriction of IL-1 signaling transduction to ERK; however, the mechanism of this restriction and the requirement of IL-1 receptor-associated proteins have not been characterized. We determined if the association kinetics of the interleukin-1 receptor-associated kinase (IRAK) colocalizes with FACs and the requirement for IRAK in IL-1-dependent ERK activation. Human gingival fibroblasts were incubated with collagen-coated beads to induce the assembly of FACs at sites of cell-bead contact. Immunoblot analysis of bead-isolated FACs showed a time-dependent assembly of the focal adhesion proteins beta-actin, vinculin, and talin, which was blocked by the actin monomer sequestering toxin latrunculin B, Although no IRAK was isolated with FACs from unstimulated cells, phosphorylated IRAK was transiently associated with FACs isolated from IL-1 beta-stimulated fibroblasts, Fibroblasts plated on tissue culture plastic (which permitted the formation of focal adhesions) showed phosphorylation of ERK, JNK, and p38, Cells plated on poly-L-lysine (to prevent the formation of focal adhesions) showed activation only of JNK and p38. ERR activation was partially restored by incubating cells plated on poly-L-lysine with collagen-coated beads before IL-1 stimulation, Cells treated with latrunculin B or swinholide A, which caused a progressive depolymerization of actin filaments, showed a reduction or elimination of IL-1-induced ERK activation, respectively. Fibroblasts electroinjected with a mouse monoclonal anti-IRAK antibody to block the recruitment of IRAK into FACs failed to activate ERK after IL-1 treatment, indicating that FAG-associated IRAK is required for the activation of ERK. These data indicate that the integrity of actin filament arrays and the recruitment of IRAK into focal adhesions are involved in the restriction of IL-1 signaling to ERK.	Univ Toronto, Fac Dent, MRC, Periodontal Physiol Grp, Toronto, ON M5S 3E2, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	MacGillivray, MK (corresponding author), Univ Toronto, Fac Dent, MRC, Periodontal Physiol Grp, Rm 243 Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.							ARORA PD, 1995, J BIOL CHEM, V270, P6042, DOI 10.1074/jbc.270.11.6042; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; CRUZ TF, 1990, BIOCHEM J, V269, P717, DOI 10.1042/bj2690717; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1988, FASEB J, V2, P108, DOI 10.1096/fasebj.2.2.3277884; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DOWER SK, 1990, J INVEST DERMATOL, V94, P68; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; GLOGAUER M, 1992, EXP CELL RES, V200, P227, DOI 10.1016/0014-4827(92)90168-8; Greene C, 1999, BBA-MOL CELL RES, V1451, P109, DOI 10.1016/S0167-4889(99)00079-8; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13737; Gronewold TMA, 1999, CELL TISSUE RES, V295, P121, DOI 10.1007/s004410051218; HANAZAWA S, 1985, INFECT IMMUN, V50, P262, DOI 10.1128/IAI.50.1.262-270.1985; HAYWARD M, 1987, AGENTS ACTIONS, V22, P251, DOI 10.1007/BF02009053; HONIG J, 1989, J PERIODONTAL RES, V24, P362, DOI 10.1111/j.1600-0765.1989.tb00883.x; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; KRACHT M, 1994, J EXP MED, V180, P2017, DOI 10.1084/jem.180.6.2017; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117; Lo YYC, 1998, J BIOL CHEM, V273, P7059, DOI 10.1074/jbc.273.12.7059; Luo L, 1997, BIOCHEM J, V324, P653, DOI 10.1042/bj3240653; Matthews JS, 1999, CYTOKINE, V11, P643, DOI 10.1006/cyto.1998.0478; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; NG SB, 1994, J BIOL CHEM, V269, P19021; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; QWARNSTROM EE, 1991, P NATL ACAD SCI USA, V88, P1232, DOI 10.1073/pnas.88.4.1232; RICHARDS D, 1988, ARCH ORAL BIOL, V33, P237, DOI 10.1016/0003-9969(88)90184-7; Ridyard MS, 1999, ANAT EMBRYOL, V199, P1, DOI 10.1007/s004290050203; ROZENGURT E, 1995, CANCER SURV, V24, P81; Saklatvala J, 1996, PHILOS T ROY SOC B, V351, P151, DOI 10.1098/rstb.1996.0011; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1994, CLIN IMMUNOL IMMUNOP, V72, P8; Singh R, 1999, J CLIN INVEST, V103, P1561, DOI 10.1172/JCI5754; SIRUM KL, 1989, BIOCHEMISTRY-US, V28, P8691, DOI 10.1021/bi00448a004; Spector I, 1999, MICROSC RES TECHNIQ, V47, P18, DOI 10.1002/(SICI)1097-0029(19991001)47:1<18::AID-JEMT3>3.0.CO;2-E; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; TATAKIS DN, 1993, J PERIODONTOL, V64, P416; Thomas JA, 1999, J IMMUNOL, V163, P978; Uciechowski P, 1996, FEBS LETT, V394, P273, DOI 10.1016/0014-5793(96)00967-2; van den Berg WB, 1999, Z RHEUMATOL, V58, P136, DOI 10.1007/s003930050163; Volpe F, 1997, FEBS LETT, V419, P41, DOI 10.1016/S0014-5793(97)01426-9; Weisberg E, 1997, CRIT REV ONCOGENESIS, V8, P343, DOI 10.1615/CritRevOncog.v8.i4.40; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Wesche H, 1998, FEBS LETT, V429, P303, DOI 10.1016/S0014-5793(98)00468-2; Wilmer WA, 1997, J BIOL CHEM, V272, P10877; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Zhu P, 1998, BIOCHEM J, V330, P975, DOI 10.1042/bj3300975	63	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23509	23515		10.1074/jbc.M003186200	http://dx.doi.org/10.1074/jbc.M003186200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10823834	hybrid			2022-12-25	WOS:000088564200016
J	Jorgensen, R; Sogaard, TMM; Rossing, AB; Martensen, PM; Justesen, J				Jorgensen, R; Sogaard, TMM; Rossing, AB; Martensen, PM; Justesen, J			Identification and characterization of human mitochondrial tryptophanyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; INTERFERON-GAMMA; NADH DEHYDROGENASE; BACILLUS-SUBTILIS; HUMAN-FIBROBLASTS; OUTER-MEMBRANE; PROTEINS; EXPRESSION; CELLS; SEQUENCE	A full-length cDNA clone encoding the human mitochondrial tryptophanyl-tRNA synthetase (h(mt)TrpRS) has been identified. The deduced amino acid sequence shows high homology to both the mitochondrial tryptophanyl-tRNA synthetase ((mt)TrpRS) from Saccharomyces cerevisiae and to different eubacterial forms of tryptophanyl-tRNA synthetase (TrpRS). Using the baculovirus expression system, we have expressed and purified the protein with a carboxyl-terminal histidine tag. The purified His-tagged h(mt)TrpRS catalyzes Trp-dependent exchange of PPi in the PPi-ATP exchange assay. Expression of h(mt)TrpRS in both human and insect cells leads to high levels of h(mt)TrpRS localizing to the mitochondria, and in insect cells the first 18 amino acids constitute the mitochondrial localization signal sequence, Until now the human cytoplasmic tryptophanyl-tRNA synthetase (hTrpRS) was thought to function as the h(mt)TrpRS, possibly in the form of a splice variant. However, no mitochondrial localization signal sequence was ever detected and the present identification of a different (mt)TrpRS almost certainly rules out that possibility. The h(mt)TrpRS shows kinetic properties similar to human mitochondrial phenylalanyl-tRNA synthetase (h(mt)-PheRS), and h(mt)TrpRS is not induced by interferon-gamma as is hTrpRS.	Aarhus Univ, Dept Biol Mol & Struct, DK-8000 Aarhus C, Denmark	Aarhus University	Justesen, J (corresponding author), Aarhus Univ, Dept Biol Mol & Struct, CF Moellers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.		Jørgensen, René/P-5619-2014; Martensen, Pia/I-3996-2012	Jørgensen, René/0000-0003-0672-466X; Martensen, Pia Moller/0000-0002-1259-0226; Sogaard, Teit Max Moscote/0000-0001-6224-4818				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BERESTEN SF, 1989, EUR J BIOCHEM, V184, P575, DOI 10.1111/j.1432-1033.1989.tb15052.x; Borglum AD, 1996, CYTOGENET CELL GENET, V73, P99, DOI 10.1159/000134317; Bullard JN, 1999, J MOL BIOL, V288, P567, DOI 10.1006/jmbi.1999.2708; CELIS JE, 1987, LEUKEMIA, V1, P800; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; CHOMYN A, 1985, NATURE, V314, P592, DOI 10.1038/314592a0; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; ELDRIDGE MG, 1992, PROTEIN SCI, V1, P271; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FLECKNER J, 1995, CYTOKINE, V7, P70, DOI 10.1006/cyto.1995.1009; FLECKNER J, 1991, P NATL ACAD SCI USA, V88, P11520, DOI 10.1073/pnas.88.24.11520; FROHMAN MA, 1994, PCR METH APPL, V4, pS40; FROLOVA LY, 1991, GENE, V109, P291, DOI 10.1016/0378-1119(91)90624-K; Hogue CWV, 1996, J MOL BIOL, V260, P446, DOI 10.1006/jmbi.1996.0413; KISSELEV L, 1993, TRENDS BIOCHEM SCI, V18, P263, DOI 10.1016/0968-0004(93)90178-P; Kisselev L L, 1979, Methods Enzymol, V59, P234; KISSELEV LL, 1993, BIOCHIMIE, V75, P1027, DOI 10.1016/0300-9084(93)90002-A; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; Martinez-Dominguez MT, 1998, CYTOGENET CELL GENET, V83, P249, DOI 10.1159/000015196; MYERS AM, 1985, J BIOL CHEM, V260, P5371; NATSOULIS G, 1986, CELL, V46, P235, DOI 10.1016/0092-8674(86)90740-3; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Okamoto K, 1998, J CELL BIOL, V142, P613, DOI 10.1083/jcb.142.3.613; PENNEYS NS, 1974, BIOCHEMISTRY-US, V13, P560, DOI 10.1021/bi00700a024; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; PETERSON ET, 1992, BIOCHEMISTRY-US, V31, P10380, DOI 10.1021/bi00157a028; PFEFFERKORN ER, 1984, P NATL ACAD SCI-BIOL, V81, P908, DOI 10.1073/pnas.81.3.908; POPENKO VI, 1993, EUR J CELL BIOL, V62, P248; Possee RD., 1992, BACULOVIRUS EXPRESSI; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUBIN BY, 1991, J BIOL CHEM, V266, P24245; Sever S, 1996, BIOCHEMISTRY-US, V35, P32, DOI 10.1021/bi952103d; Shaw AC, 1999, ELECTROPHORESIS, V20, P984, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<984::AID-ELPS984>3.0.CO;2-R; STUBBS L, 1992, MAMM GENOME, V3, P127, DOI 10.1007/BF00352457; TAKAGI Y, 1992, BIOCHEM BIOPH RES CO, V184, P471, DOI 10.1016/0006-291X(92)91218-F; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; TOLSTRUP AB, 1995, J BIOL CHEM, V270, P397, DOI 10.1074/jbc.270.1.397; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wright G, 1997, EXP CELL RES, V234, P78, DOI 10.1006/excr.1997.3579; XU ZJ, 1989, J BIOL CHEM, V264, P4304; Zhang YL, 1998, BBA-GENE STRUCT EXPR, V1443, P245, DOI 10.1016/S0167-4781(98)00223-1	45	40	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16820	16826		10.1074/jbc.275.22.16820	http://dx.doi.org/10.1074/jbc.275.22.16820			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828066	hybrid			2022-12-25	WOS:000087392200060
J	Vairapandi, M; Azam, N; Balliet, AG; Hoffman, B; Liebermann, DA				Vairapandi, M; Azam, N; Balliet, AG; Hoffman, B; Liebermann, DA			Characterization of MyD118, Gadd45, and proliferating cell nuclear antigen (PCNA) interacting domains - PCNA impedes MyD118 and Gadd45-mediated negative growth control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-REGULATED PROTEIN GADD45; CYCLIN-DEPENDENT KINASES; DNA-REPLICATION; POLYMERASE-DELTA; REPAIR; GENES; TRANSCRIPTION; P21(WAF1/CIP1); ACTIVATION; INHIBITORS	MyD118 and Gadd45 are related genes encoding for proteins that play important roles in negative growth control, including growth suppression and apoptosis. MyD118 and Gadd45 are related proteins that previously were shown to interact with proliferating cell nuclear antigen (PCNA), implicated in DNA replication, DNA repair, and cell cycle progression. To establish the role of MyD118 and Gadd45 interactions with PCNA, in this work we sought to identify the interacting domains and analyze the significance of this interaction in negative growth control. Using complementary in vivo and in vitro interaction assays the N-terminal (1-46) and middle (100-127) regions of PCNA were identified as harboring MyD118- and Gadd45 interacting domains, whereas PCNA interacting domains within MyD118 and Gadd45 were localized to the C termini of these proteins (amino acids 114-156 and 131-165, respectively). These findings provide first evidence that similar domains within MyD118 and Gadd45 mediate interactions with PCNA. Importantly, ectopic expression of MyD118 or Gadd45 N-terminal peptides, lacking the PCNA interacting domain, was found to suppress colony formation or induce apoptosis more efficiently than the full-length proteins. These findings suggest that interaction of MyD118 or Gadd45 with PCNA, in essence, serves to impede negative growth control.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	lieberma@unix.temple.edu			NCI NIH HHS [1RO1CA43618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Carrier F, 1999, MOL CELL BIOL, V19, P1673; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CHEN IT, 1995, ONCOGENE, V11, P1931; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; GRANA X, 1995, ONCOGENE, V11, P211; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HALL PA, 1995, ONCOGENE, V10, P2427; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; Heuer KH, 1996, BIOCHEMISTRY-US, V35, P9069, DOI 10.1021/bi952817o; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Nigg EA, 1996, CURR OPIN CELL BIOL, V8, P312, DOI 10.1016/S0955-0674(96)80003-2; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Vairapandi M, 1996, ONCOGENE, V12, P2579; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885	44	110	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16810	16819		10.1074/jbc.275.22.16810	http://dx.doi.org/10.1074/jbc.275.22.16810			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828065	hybrid			2022-12-25	WOS:000087392200059
J	Cuzzocrea, S; Misko, TP; Costantino, G; Mazzon, E; Micali, A; Caputi, AP; MacArthur, H; Salvemini, D				Cuzzocrea, S; Misko, TP; Costantino, G; Mazzon, E; Micali, A; Caputi, AP; MacArthur, H; Salvemini, D			Beneficial effects of peroxynitrite decomposition catalyst in a rat model of splanchnic artery occlusion and reperfusion	FASEB JOURNAL			English	Article						SAO; polymorphonuclear leukocyte; cytokine; nitrate	ADHESION MOLECULE-1 ICAM-1; NITRIC-OXIDE PRODUCTION; ADP-RIBOSE SYNTHETASE; TIME-COURSE; MYOCARDIAL-ISCHEMIA; ENDOTHELIAL DYSFUNCTION; INTESTINAL ISCHEMIA; ENDOTOXIC-SHOCK; INJURY; INFLAMMATION	The aim of the present study was to investigate the protective effect of the peroxynitrite decomposition catalyst 5,10,15,20-tetrakis(2,4,6-trimethyl-3,5-disulfonatophenyl)-porphyrinato iron (III) (FeTMPS) in a model of splanchnic artery occlusion shock (SAO). SAO shock was induced in rats by clamping both the superior mesenteric artery and the celiac trunk for 45 min, followed by release of the clamp (reperfusion). At 60 min after reperfusion, animals were killed for histological examination and biochemical studies. There was a marked increase in the oxidation of dihydrorhodamine 123 to rhodamine (a marker of peroxynitrite-induced oxidative processes) in the plasma of the SAO-shocked rats after reperfusion, but not during ischemia alone. Immunohistochemica1 examination demonstrated a marked increase in the immunoreactivity to nitrotyrosine, an index of nitrogen species such as peroxynitrite, in the necrotic ileum in shocked rats. SAG-shocked rats developed a significant increase of tissue myeloperoxidase and malonaldehyde activity, and marked histological injury to the distal ileum. SAO shock was also associated with a significant mortality (0% survival at 2 h after reperfusion). Reperfused ileum tissue sections from SAG-shocked rats showed positive staining for P-selectin localized mainly in the vascular endothelial cells. Ileum tissue sections obtained from SAO-shocked rats and stained with antibody to ICAM-1 showed a diffuse staining. Administration of FeTMPS significantly reduced ischemia/reperfusion injury in the bowel, and reduced lipid and the production of peroxynitrite during reperfusion. Treatment with PN catalyst also markedly reduced the intensity and degree of P-selectin and ICAM-1 staining in tissue sections from SAG-shocked rats and improved survival. Our results clearly demonstrate that peroxynitrite decomposition catalysts exert a protective effect in SAO and that this effect may be due to inhibition of the expression of adhesion molecules and the tissue damage associated with peroxynitrite-related pathways.-Cuzzocrea S., Misko, T. P., Costantino, C., Mazzon, E., Micali, A., Caputi, A. P., Macarthur, H., Salvemini, D. Beneficial effects of peroxynitrite decomposition catalyst in a rat model of splanchnic artery occlusion and reperfusion.	Univ Messina, Inst Pharmacol, I-98100 Messina, Italy; Univ Messina, Sch Med, Dept Biomorphol, I-98100 Messina, Italy; Discovery Pharmacol, St Louis, MO 63167 USA; St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; Metaphore Pharmaceut, St Louis, MO 63110 USA	University of Messina; University of Messina; Saint Louis University	Cuzzocrea, S (corresponding author), Univ Messina Policlin, Sch Med, Inst Pharmacol, Via C Valeria Gazzi, I-98100 Messina, Italy.	salvator@www.unime.it	Mazzon, Emanuela/AAL-4334-2020	mazzon, emanuela/0000-0002-5073-717X; Micali, Antonio/0000-0003-0826-1910				Adams DH, 1997, BRIT J CANCER, V75, P1421, DOI 10.1038/bjc.1997.245; ALTURA BM, 1985, MICROCIRC ENDOTH LYM, V2, P3; AzMa T, 1996, BRIT J PHARMACOL, V119, P455, DOI 10.1111/j.1476-5381.1996.tb15694.x; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BITTERMAN H, 1988, P SOC EXP BIOL MED, V188, P265; BOYD AW, 1988, P NATL ACAD SCI USA, V85, P3095, DOI 10.1073/pnas.85.9.3095; BRONER CW, 1988, CRIT CARE MED, V16, P848, DOI 10.1097/00003246-198809000-00006; BUTCHER EC, 1992, ADV EXP MED BIOL, V323, P181; BUTCHER EC, 1993, RES IMMUNOL, V144, P695, DOI 10.1016/S0923-2494(93)80053-2; CAPUTI AP, 1980, J PHARMACOL EXP THER, V215, P309; CAREY C, 1992, CIRC SHOCK, V38, P209; CAZEVIEILLE C, 1993, FREE RADICAL BIO MED, V14, P389, DOI 10.1016/0891-5849(93)90088-C; Clark WM, 1995, MOL CHEM NEUROPATHOL, V26, P213, DOI 10.1007/BF02815139; Crow J P, 1995, Curr Top Microbiol Immunol, V196, P57; Cuzzocrea S, 1998, FREE RADICAL BIO MED, V24, P450, DOI 10.1016/S0891-5849(97)00280-3; Cuzzocrea S, 1998, LIFE SCI, V63, P789, DOI 10.1016/S0024-3205(98)00334-8; Cuzzocrea S, 1997, BRIT J PHARMACOL, V121, P1065, DOI 10.1038/sj.bjp.0701234; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DOUGHERTY GJ, 1988, EUR J IMMUNOL, V18, P35, DOI 10.1002/eji.1830180107; DREYER WJ, 1991, CIRCULATION, V84, P400, DOI 10.1161/01.CIR.84.1.400; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; FARHOOD A, 1995, J LEUKOCYTE BIOL, V57, P368, DOI 10.1002/jlb.57.3.368; Fukuyama N, 1997, FREE RADICAL BIO MED, V22, P771, DOI 10.1016/S0891-5849(96)00401-7; GAUTHIER TW, 1994, AM J PHYSIOL-GASTR L, V267, pG562, DOI 10.1152/ajpgi.1994.267.4.G562; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GRANGER DN, 1981, GASTROENTEROLOGY, V81, P22; Granger DN, 1997, AM J PHYSIOL-GASTR L, V273, pG982, DOI 10.1152/ajpgi.1997.273.5.G982; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; Johnson K J, 1992, Immunol Ser, V57, P1; KANWAR S, 1994, CIRC SHOCK, V42, P135; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEFER AM, 1993, ANNU REV PHARMACOL, V33, P71, DOI 10.1146/annurev.pa.33.040193.000443; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; MA TT, 1995, GASTROENTEROLOGY, V108, P463, DOI 10.1016/0016-5085(95)90075-6; MA XL, 1993, CIRC RES, V72, P403, DOI 10.1161/01.RES.72.2.403; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Misko TP, 1998, J BIOL CHEM, V273, P15646, DOI 10.1074/jbc.273.25.15646; MULLANE KM, 1988, ANN NY ACAD SCI, V524, P103, DOI 10.1111/j.1749-6632.1988.tb38534.x; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; RATYCH RE, 1987, SURGERY, V102, P122; Salvemini D, 1999, BRIT J PHARMACOL, V127, P685, DOI 10.1038/sj.bjp.0702604; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829, DOI 10.1111/j.1476-5381.1996.tb15475.x; Salvemini D, 1998, P NATL ACAD SCI USA, V95, P2659, DOI 10.1073/pnas.95.5.2659; Salvemini D, 1998, DRUG NEWS PERSPECT, V11, P204; SALVEMINI D, 1995, J CLIN INVEST, V96, P301, DOI 10.1172/JCI118035; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; SHREENIWAS R, 1992, J CLIN INVEST, V90, P2333, DOI 10.1172/JCI116122; Stern MK, 1996, J AM CHEM SOC, V118, P8735, DOI 10.1021/ja961279f; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; TSAO PS, 1990, CIRCULATION, V82, P1402, DOI 10.1161/01.CIR.82.4.1402; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; YU L, 1994, P NATL ACAD SCI USA, V91, P1691, DOI 10.1073/pnas.91.5.1691; ZIMMERMANN BJ, 1993, PATHOPHYSIOLOGY SHOC, P322; Zingarelli B, 1997, CARDIOVASC RES, V36, P205, DOI 10.1016/S0008-6363(97)00137-5; Zingarelli B, 1997, BRIT J PHARMACOL, V120, P259, DOI 10.1038/sj.bjp.0700872; ZINGARELLI B, 1992, EUR J PHARMACOL, V222, P13, DOI 10.1016/0014-2999(92)90456-E	61	91	92	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1061	1072		10.1096/fasebj.14.9.1061	http://dx.doi.org/10.1096/fasebj.14.9.1061			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834927				2022-12-25	WOS:000087427300002
J	Tonini, R; Ferroni, A; Valenzuela, SM; Warton, K; Campbell, TJ; Breit, SN; Mazzanti, M				Tonini, R; Ferroni, A; Valenzuela, SM; Warton, K; Campbell, TJ; Breit, SN; Mazzanti, M			Functional characterization of the NCC27 nuclear protein in stable transfected CHO-K1 cells	FASEB JOURNAL			English	Article						single-channel currents; NCC27; ion channel	MOLECULAR-CLONING; CHLORIDE CHANNEL; ION CHANNELS; P64	NCC27 belongs to a family of small, highly conserved, organellar ion channel proteins. It is constitutively expressed by native CHO-K1 and dominantly localized to the nucleus and nuclear membrane. When CHO-K1 cells are transfected with NCC27-expressing constructs, synthesized proteins spill over into the cytoplasm and ion channel activity can then be detected on the plasma as well as nuclear membrane. This provided a unique opportunity to directly compare electrophysiological characteristics of the one cloned channel, both on the nuclear and cytoplasmic membranes. At the same time, as NCC27 is unusually small for an ion channel protein, we wished to directly determine whether it is a membrane-resident channel in its own right. In CHO-K1 cells transfected with epitope-tagged NCC27 constructs, we have demonstrated that the NCC27 conductance is chloride dependent and that the electrophysiological characteristics of the channels are essentially identical whether expressed on plasma or nuclear membranes. In addition, we show that a monoclonal antibody directed at an epitope tag added to NCC27 rapidly inhibits the ability of the expressed protein to conduct chloride, but only when the antibody has access to the tag epitope. By selectively tagging either the amino or carboxyl terminus of NCC27 and varying the side of the membrane from which we record channel activity, we have demonstrated conclusively that NCC27 is a transmembrane protein that directly forms part of the ion channel and, further, that the amino terminus projects outward and the carboxyl terminus inward. We conclude that despite its relatively small size, NCC27 must form an integral part of an ion channel complex.-Tonini, R., Ferroni, A., Valenzuela, S. M., Warton, K., Campbell, T. J., Breit, S. N., Mazzanti, M. Functional characterization of the NCC27 nuclear protein in stable transfected CHO-K1 cells.	Univ Rome La Sapienza, Dipartimento Biol Cellulare & Sviluppo, I-00185 Rome, Italy; Univ Milan 1, Dipartimento Fisiol & Biochim Gen, I-20133 Milan, Italy; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; Univ New S Wales, Dept Med, Sydney, NSW 2010, Australia; Univ New S Wales, Victor Chang Cardiac Res Inst, Sydney, NSW 2010, Australia	Sapienza University Rome; St Vincents Hospital Sydney; University of New South Wales Sydney; University of New South Wales Sydney; Victor Chang Cardiac Research Institute	Mazzanti, M (corresponding author), Univ Rome La Sapienza, Dipartimento Biol Cellulare & Sviluppo, Piazzale Aldo Moro 5, I-00185 Rome, Italy.		Mazzanti, Michele/A-8941-2011; Valenzuela, Stella/R-6387-2019; Tonini, Raffaella/J-2960-2012	Valenzuela, Stella/0000-0001-5934-6047; Campbell, Terry/0000-0003-0055-4137; Mazzanti, Michele/0000-0002-1819-3811; TONINI, Raffaella/0000-0003-1652-4709				BUSTAMANTE JO, 1992, PFLUG ARCH EUR J PHY, V421, P473, DOI 10.1007/BF00370259; BUSTAMANTE JO, 1995, J MEMBRANE BIOL, V146, P239; INNOCENTI B, 1993, J MEMBRANE BIOL, V131, P137, DOI 10.1007/BF02791322; LANDRY D, 1993, J BIOL CHEM, V268, P14948; MAK DOD, 1994, J BIOL CHEM, V269, P29375; MATZKE AJM, 1990, FEBS LETT, V271, P161, DOI 10.1016/0014-5793(90)80397-2; MAZZANTI M, 1990, NATURE, V343, P764, DOI 10.1038/343764a0; Nilius B, 1996, GEN PHARMACOL-VASC S, V27, P1131, DOI 10.1016/S0306-3623(96)00061-4; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; Rousseau E, 1996, BIOPHYS J, V70, P703, DOI 10.1016/S0006-3495(96)79610-8; Szewczyk A, 1998, MOL MEMBR BIOL, V15, P49, DOI 10.3109/09687689809027518; TONINI R, 1999, FASEB J, V14; Tulk BM, 1998, AM J PHYSIOL-RENAL, V274, pF1140, DOI 10.1152/ajprenal.1998.274.6.F1140; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575	14	92	95	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1171	1178		10.1096/fasebj.14.9.1171	http://dx.doi.org/10.1096/fasebj.14.9.1171			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834939				2022-12-25	WOS:000087427300014
J	Gunnewijk, MGW; Poolman, B				Gunnewijk, MGW; Poolman, B			Phosphorylation state of HPr determines the level of expression and the extent of phosphorylation of the lactose transport protein of Streptococcus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; GRAM-POSITIVE BACTERIA; KINASE-CATALYZED PHOSPHORYLATION; PHOSPHOCARRIER PROTEIN; CATABOLITE REPRESSION; BACILLUS-SUBTILIS; SERYL RESIDUE; PHOSPHOENOLPYRUVATE; PHOSPHATE; RECONSTITUTION	The lactose transport protein (LacS) of Streptococcus thermophilus is composed of a translocator domain and a regulatory domain that is phosphorylated by HPr(His-P), the general energy coupling protein of the phosphoenolpyruvate:carbohydrate phosphotransferase system (PTS). Lactose transport is affected by the phosphorylation state of HPr through changes in the activity of the LacS protein as well as expression of the lacS gene. To address whether or not CcpA-HPr(Ser-P)mediated catabolite control is involved, the levels of LacS were determined under conditions in which the cellular phosphorylation state of HPr greatly differed. It appears that HPr(Ser-P) is mainly present in the exponential phase of growth, whereas HPr(His similar toP) dominates in the stationary phase. The transition from HPr(Ser-P) to HPr(His similar toP) parallels an increase in LacS level, a drop in lactose and an increase in galactose concentration in the growth medium. Because the K-m(out) for lactose is higher than that for galactose, the lactose transport capacity decreases as lactose concentration decreases and galactose accumulates in the medium. Our data indicate that S. thermophilus compensates for the diminished transport capacity by synthesizing more LacS and phosphorylating the protein, which results in increased transport activity. The link between transport capacity and lacS expression levels and LacS phosphorylation are discussed.	Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen; University of Groningen	Poolman, B (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Poolman, Bert/D-1882-2012					Brochu D, 1999, J BACTERIOL, V181, P709, DOI 10.1128/JB.181.3.709-717.1999; DEUTSCHER J, 1983, P NATL ACAD SCI-BIOL, V80, P6790, DOI 10.1073/pnas.80.22.6790; DEUTSCHER J, 1985, J BACTERIOL, V163, P1203, DOI 10.1128/JB.163.3.1203-1209.1985; DEUTSCHER J, 1984, FEMS MICROBIOL LETT, V23, P57; DUINE JA, 1982, ARCH MICROBIOL, V131, P27, DOI 10.1007/BF00451494; FOUCAUD C, 1992, J BIOL CHEM, V267, P22087; Galinier A, 1997, P NATL ACAD SCI USA, V94, P8439, DOI 10.1073/pnas.94.16.8439; Gunnewijk MGW, 2000, J BIOL CHEM, V275, P34080, DOI 10.1074/jbc.M003513200; Gunnewijk MGW, 1999, J BACTERIOL, V181, P632, DOI 10.1128/JB.181.2.632-641.1999; GUNNEWIJK MGW, 1997, MOL MECH SIGNALING M, V101, P319; Heuberger EHML, 2000, EUR J BIOCHEM, V267, P228, DOI 10.1046/j.1432-1327.2000.00993.x; HUECK CJ, 1995, MOL MICROBIOL, V15, P395, DOI 10.1111/j.1365-2958.1995.tb02252.x; Knol J, 1996, J BIOL CHEM, V271, P15358, DOI 10.1074/jbc.271.26.15358; KONINGS WN, 1989, CRC CR REV MICROBIOL, V16, P419, DOI 10.3109/10408418909104474; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASON PW, 1981, J BIOL CHEM, V256, P1861; MATTOO RL, 1984, ANAL BIOCHEM, V139, P1, DOI 10.1016/0003-2697(84)90383-X; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; POOLMAN B, 1989, J BACTERIOL, V171, P244, DOI 10.1128/jb.171.1.244-253.1989; POOLMAN B, 1995, P NATL ACAD SCI USA, V92, P778, DOI 10.1073/pnas.92.3.778; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; REIZER J, 1989, BIOCHIMIE, V71, P989, DOI 10.1016/0300-9084(89)90102-8; REIZER J, 1988, P NATL ACAD SCI USA, V85, P2041, DOI 10.1073/pnas.85.7.2041; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; Saier MH, 1996, MICROBIOL-UK, V142, P217, DOI 10.1099/13500872-142-2-217; Sambrook J., 2002, MOL CLONING LAB MANU; THEVENOT T, 1995, J BACTERIOL, V177, P2751, DOI 10.1128/jb.177.10.2751-2759.1995; THOMPSON J, 1984, J BACTERIOL, V158, P791, DOI 10.1128/JB.158.3.791-800.1984; VADEBONCOEUR C, 1991, ANAL BIOCHEM, V196, P24, DOI 10.1016/0003-2697(91)90112-7; Veenhoff LM, 1999, J BIOL CHEM, V274, P33244, DOI 10.1074/jbc.274.47.33244; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; WEIGEL N, 1982, J BIOL CHEM, V257, P4499	32	33	36	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 3	2000	275	44					34073	34079		10.1074/jbc.M003512200	http://dx.doi.org/10.1074/jbc.M003512200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	369YL	10842177	hybrid, Green Published			2022-12-25	WOS:000165095300013
J	Chopin, V; Salzet, M; Baert, JL; Vandenbulcke, F; Sautiere, PE; Kerckaert, JP; Malecha, J				Chopin, V; Salzet, M; Baert, JL; Vandenbulcke, F; Sautiere, PE; Kerckaert, JP; Malecha, J			Therostasin, a novel clotting factor Xa inhibitor from the rhynchobdellid leech, Theromyzon tessulatum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-XA; AMINO-ACID-SEQUENCE; BLOOD-COAGULATION; PROTEASE INHIBITOR; HIRUDO-MEDICINALIS; ANTISTASIN; ANTICOAGULANT; PROTEINS; SARAFOTOXINS; ENDOTHELINS	Therostasin is a potent naturally occurring tight-binding inhibitor of mammalian Factor Xa (K-i, 34 pM), isolated from the rhynchobdellid leech Theromyzon tessulatum, Therostasin is a cysteine-rich protein (8991 Dal consisting of 82 amino acid residues with 16 cysteine residues. Its amino acid sequence has been determined by a combination of techniques, including Edman degradation, enzymatic cleavage, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) on the native and s-beta -pyridylethylated compound. Sequence analysis reveals that it shares no significant homology with other Factor Xa inhibitors except for the putative reactive site. Moreover, it contains a signature pattern for proteins of the endothelin family, potent vasoconstrictors isolated in mammal and snake venom. Therostasin cDNA (825 bp) codes for a polypeptide of 82 amino acid residues preceded by 19 residues, representing a signal peptide sequence. As for the other known inhibitors of Factor Xa, therostasin is expressed and stored in the cells of the leech salivary glands.	CNRS, UMR 8526, Inst Biol Lille, F-59019 Lille, France; INSERM, U524, Lab Oncohematol, F-59045 Lille, France; Univ Sci & Technol Lille, CNRS, UPRESA 8017, Lab Endocrinol Annelides,SN 3, F-59655 Villeneuve Dascq, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille		michel.salzet@univ-lille1.fr	Salzet, Michel/A-7675-2011	Salzet, Michel/0000-0003-4318-0817; SAUTIERE, Pierre-Eric/0000-0003-4974-7116; Vandenbulcke, Franck/0000-0002-9735-1784				BIETH JG, 1980, CLIN RES PROC, V16, P183; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANKAMP RG, 1990, J LAB CLIN MED, V115, P89; CAPPELLO M, 1995, P NATL ACAD SCI USA, V92, P6152, DOI 10.1073/pnas.92.13.6152; Chopin V, 1998, EUR J BIOCHEM, V258, P662, DOI 10.1046/j.1432-1327.1998.2580662.x; HAN JH, 1989, GENE, V75, P47, DOI 10.1016/0378-1119(89)90382-X; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HOLSTEIN TW, 1992, FEBS LETT, V309, P288, DOI 10.1016/0014-5793(92)80791-E; JUNG HI, 1995, J BIOL CHEM, V270, P13879, DOI 10.1074/jbc.270.23.13879; Kim DR, 1998, EUR J BIOCHEM, V254, P692, DOI 10.1046/j.1432-1327.1998.2540692.x; KLOOG Y, 1989, TRENDS PHARMACOL SCI, V10, P212, DOI 10.1016/0165-6147(89)90261-7; KREZEL AM, 1994, SCIENCE, V264, P1944, DOI 10.1126/science.8009227; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lapatto R, 1997, EMBO J, V16, P5151, DOI 10.1093/emboj/16.17.5151; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; MALECHA J, 1989, CAN J ZOOL, V67, P636, DOI 10.1139/z89-091; MANIATIS T, 1989, MOL CLONIN LAB MANUA, V1; MARKWARDT F, 1957, H-S Z PHYSIOL CHEM, V308, P147, DOI 10.1515/bchm2.1957.308.1.147; NUTT E, 1988, J BIOL CHEM, V263, P10162; OHTA N, 1994, THROMB HAEMOSTASIS, V72, P825; ROTERS FJ, 1992, J COMP PHYSIOL B, V162, P85, DOI 10.1007/BF00257940; Salzet M, 2000, J BIOL CHEM, V275, P30774, DOI 10.1074/jbc.M000787200; Salzet M, 2000, EUR J BIOCHEM, V267, P4917, DOI 10.1046/j.1432-1327.2000.01550.x; SALZET M, 2000, IN PRESS PARASITOL T; Sawyer R. T, 1986, LEECH BIOL BEHAV, V1; SEYMOUR JL, 1994, BIOCHEMISTRY-US, V33, P3949, DOI 10.1021/bi00179a022; SEYMOUR JL, 1990, J BIOL CHEM, V265, P10143; SOKOLOVSKY M, 1991, TRENDS BIOCHEM SCI, V16, P261, DOI 10.1016/0968-0004(91)90100-A; SOLLNER C, 1994, EUR J BIOCHEM, V219, P937, DOI 10.1111/j.1432-1033.1994.tb18575.x; Stefano GB, 1999, INT REV CYTOL, V187, P261, DOI 10.1016/S0074-7696(08)62420-1; THEUNISSEN HJM, 1994, THROMB RES, V75, P41, DOI 10.1016/0049-3848(94)90138-4; TUSZYNSKI GP, 1987, J BIOL CHEM, V262, P9718; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; Whitlow M, 1999, ACTA CRYSTALLOGR D, V55, P1395, DOI 10.1107/S0907444999007350	34	45	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 20	2000	275	42					32701	32707		10.1074/jbc.M909217199	http://dx.doi.org/10.1074/jbc.M909217199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	366KD	10852926	hybrid			2022-12-25	WOS:000090003800046
J	Versteeg, HH; Hoedemaeker, I; Diks, SH; Stam, JC; Spaargaren, M; Henegouwen, PMPVE; van Deventer, SJH; Peppelenbosch, MP				Versteeg, HH; Hoedemaeker, I; Diks, SH; Stam, JC; Spaargaren, M; Henegouwen, PMPVE; van Deventer, SJH; Peppelenbosch, MP			Factor VIIa/tissue factor-induced signaling via activation of Src-like kinases, phosphatidylinositol 3-kinase, and Rac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASES; CANINE KIDNEY-CELLS; HUMAN TISSUE FACTOR; FACTOR VIIA; ACTIN CYTOSKELETON; ESCHERICHIA-COLI; HUMAN MONOCYTES; IN-VITRO	Tissue factor (TF), apart from activating the extrinsic pathway of the blood coagulation, is a principal regulator of embryonic angiogenesis and oncogenic neoangiogenesis, but also influences inflammation, leukocyte diapedesis and tumor progression. The intracellular domain of TF lacks homology to other classes of receptors and hence the signaling mechanism is poorly understood. Here we demonstrate that factor VIIa (the natural ligand for TF) induces the activation of the Src family members c-Src, Lyn, and Yes, and subsequently phosphatidylinositol 3-kinase (PI3K), followed by stimulation of c-Akt/protein kinase B as well as the small GTPases Rac and Cdc42. In turn Rac mediates p38 mitogen-activated protein (MAP) kinase activation and cytoskeletal reorganization, whereas factor VIIa-induced p42/p44 MAP kinase stimulation required PI3R enzymatic activity but was not inhibited by dominant negative Rac proteins. We propose that this Src family member/PI3K/Rac-dependent signaling pathway is a major mediator of factor VIIa/TF effects in pathophysiology.	Acad Med Ctr, Lab Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands; Univ Utrecht, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands; Dept Pathol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University	Peppelenbosch, MP (corresponding author), Acad Med Ctr, Lab Expt Internal Med, G2-130,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Spaargaren, Marcel/AAU-1298-2021; Versteeg, Henri/G-1783-2018; van Bergen en Henegouwen, Paul/B-8870-2011	Spaargaren, Marcel/0000-0002-3135-5109; Versteeg, Henri/0000-0003-4294-175X; van Bergen en Henegouwen, Paul/0000-0001-6050-9042; Peppelenbosch, Maikel/0000-0001-9112-6028				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BACH RR, 1988, CRC CR REV BIOCH MOL, V23, P339, DOI 10.3109/10409238809082548; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P6258, DOI 10.1073/pnas.93.13.6258; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Camerer E, 1996, J BIOL CHEM, V271, P29034, DOI 10.1074/jbc.271.46.29034; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Fuhrer DK, 1996, EXP HEMATOL, V24, P195; FUKUI Y, 1991, ONCOGENE, V6, P407; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARLOS K, 1994, NATURE, V370, P662, DOI 10.1038/370662a0; Haussinger D, 1999, GASTROENTEROLOGY, V116, P921, DOI 10.1016/S0016-5085(99)70076-4; HerreraVelit P, 1996, J IMMUNOL, V156, P1157; Ibitayo AI, 1998, AM J PHYSIOL-GASTR L, V275, pG705, DOI 10.1152/ajpgi.1998.275.4.G705; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; JUCKER M, 1995, J BIOL CHEM, V270, P27817; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; Masuda M, 1996, EUR J IMMUNOL, V26, P2529, DOI 10.1002/eji.1830261037; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Min W, 1997, J IMMUNOL, V159, P3508; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ott I, 1998, J CELL BIOL, V140, P1241, DOI 10.1083/jcb.140.5.1241; Pendurthi UR, 1997, P NATL ACAD SCI USA, V94, P12598, DOI 10.1073/pnas.94.23.12598; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Randolph GJ, 1998, BLOOD, V92, P4167, DOI 10.1182/blood.V92.11.4167.423k35_4167_4177; Ridley AJ, 1999, BIOCHEM SOC SYMP, V65, P111; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; Sorensen BB, 1999, J BIOL CHEM, V274, P21349, DOI 10.1074/jbc.274.30.21349; Stephens L, 1996, PHILOS T R SOC B, V351, P211, DOI 10.1098/rstb.1996.0018; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; SYMONS M, 1995, CURR OPIN BIOTECH, V6, P668, DOI 10.1016/0958-1669(95)80110-3; Taylor FB, 1998, BLOOD, V91, P1609, DOI 10.1182/blood.V91.5.1609.1609_1609_1615; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Toomey JR, 1997, P NATL ACAD SCI USA, V94, P6922, DOI 10.1073/pnas.94.13.6922; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451	59	91	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28750	28756		10.1074/jbc.M907635199	http://dx.doi.org/10.1074/jbc.M907635199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10844001	Green Published, hybrid			2022-12-25	WOS:000089330700056
J	Elisseeva, EL; Slupsky, CM; Crump, MP; Clark-Lewis, I; Sykes, BD				Elisseeva, EL; Slupsky, CM; Crump, MP; Clark-Lewis, I; Sykes, BD			NMR studies of active N-terminal peptides of stromal cell-derived factor-1 - Structural basis for receptor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR; LYMPHOCYTE CHEMOATTRACTANT; PROTEIN STRUCTURES; CHEMICAL-SHIFTS; CC-CHEMOKINE; HIV-1 ENTRY; FACTOR-I; INTERLEUKIN-8; IDENTIFICATION; SDF-1	Stromal cell-derived factor 1 (SDF-1), a member of the CXC chemokine family, is the only chemokine to bind to the receptor CXCR4 This receptor is also a co-receptor for syncytia-inducing forms of HIV in CD4(+) cells. In addition, SDF-1. is responsible for attracting mature lymphocytes to the bone marrow and can therefore contribute to host versus graft rejection in bone marrow transplantation, Clearly, by manipulating SDF-1 activity, we could find a possible anti-viral AIDS treatment and aid in bone marrow transplantation. SDF-1 binds to CXCR4 primarily via the N terminus, which appears flexible in the recently determined three-dimensional structure of SDF-1. Strikingly, short N-terminal SDF-1 peptides have been shown to have significant SDF-1 activity, By using NMR, we have determined the major conformation of the N terminus of SDF-1 in a 17-mer (residues 1-17 of SDF-1) and a g-mer dimer (residues 1-9 of SDF-1 linked by a disulfide bond at residue 9). Residues 5-8 and 11-14 form similar structures that can be characterized as a beta-turn of the beta-alpha R type. These structural motifs are likely to be interconverting with other states, but the major conformation may be important for recognition in receptor binding. These results suggest for the first time that there may be a link between structuring of short N-terminal chemokine peptides and their ability to activate their receptor. These studies will act as a starting point for synthesizing non-peptide analogs that act as CXCR4 antagonists.	Univ Alberta, Prot Engn Network Ctr Excellence, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Heritage Med Res Ctr 713, Dept Biochem, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Sykes, BD (corresponding author), Univ Alberta, Prot Engn Network Ctr Excellence, Edmonton, AB T6G 2S2, Canada.			Crump, Matthew/0000-0002-7868-5818				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Andersen NH, 1997, J AM CHEM SOC, V119, P8547, DOI 10.1021/ja963250h; Bacon KB, 1996, INT ARCH ALLERGY IMM, V109, P97, DOI 10.1159/000237207; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; BRUNGER AT, X PLOR VERSION 3 1 Y; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Hesselgesser J, 1998, J BIOL CHEM, V273, P15687, DOI 10.1074/jbc.273.25.15687; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; Kelley LA, 1996, PROTEIN ENG, V9, P1063, DOI 10.1093/protein/9.11.1063; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Loetscher P, 1998, J BIOL CHEM, V273, P22279, DOI 10.1074/jbc.273.35.22279; Maghazachi AA, 1998, FASEB J, V12, P913, DOI 10.1096/fasebj.12.11.913; MERTUKA G, 1995, J BIOMOL NMR, V5, P14; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MOSER B, 1993, J BIOL CHEM, V268, P7125; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SCHRAUFSTATTER IU, 1995, J BIOL CHEM, V270, P10428, DOI 10.1074/jbc.270.18.10428; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Tamamura H, 1998, BIOCHEM BIOPH RES CO, V253, P877, DOI 10.1006/bbrc.1998.9871; TORDA AE, 1990, J MOL BIOL, V214, P223, DOI 10.1016/0022-2836(90)90157-H; Williams G, 1996, J BIOL CHEM, V271, P9579, DOI 10.1074/jbc.271.16.9579; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wuthrich K., 1986, NMR PROTEINS NUCL AC; Xin XM, 1999, FEBS LETT, V457, P219, DOI 10.1016/S0014-5793(99)01035-2	39	37	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26799	26805						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10846182				2022-12-25	WOS:000089144800020
J	Janez, A; Worrall, DS; Imamura, T; Sharma, PM; Olefsky, JM				Janez, A; Worrall, DS; Imamura, T; Sharma, PM; Olefsky, JM			The osmotic shock-induced glucose transport pathway in 3T3-L1 adipocytes is mediated by Gab-1 and requires Gab-1 associated phosphatidylinositol 3-kinase activity for full activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 TRANSLOCATION; GROWTH-FACTOR; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); SIGNALING PATHWAY; DOCKING PROTEIN; SKELETAL-MUSCLE; BINDING-SITE; INSULIN; RECEPTOR; KINASE	Osmotic shock treatment of 3T3-L1 adipocytes causes an increase in glucose transport activity and translocation of GLUT4 protein similar to that elicited by insulin treatment. Insulin stimulation of GLUT4 translocation and glucose transport activity was completely inhibited by wortmannin, however, activation by osmotic shock was only partially blocked. Additionally, we have found that the newly identified insulin receptor substrate Gab-l (Grb2-associated binder-1) is tyrosine-phosphorylated following sorbitol stimulation. Treatment of cells with the tyrosine kinase inhibitor genistein inhibited osmotic shock-stimulated Gab-l phosphorylation as well as shock-induced glucose transport. Furthermore, pretreatment with the selective Src family kinase inhibitor PP2 completely inhibited the ability of sorbitol treatment to cause tyrosine phosphorylation of Gab-1. We have also shown that microinjection of anti-Gab-1 antibody inhibits osmotic shock-induced GLUT4 translocation. Furthermore, phosphorylated Gab-l binds and activates phosphatidylinositol 3-kinase (PI3K) in response to osmotic shock. The PI3K activity associated with Gab-1 was 82% of that associated with anti-phosphotyrosine antibodies, indicating that Gab-l is the major site for PI3K recruitment following osmotic shock stimulation, Although wortmannin only causes a partial block of osmotic shock-stimulated glucose uptake, wortmannin completely abolishes Gab-l associated PI3K activity. This suggests that other tyrosine kinase-dependent pathways, in addition to the Gab-1-PI3K pathway, contribute to osmotic shock-mediated glucose transport. To date, Gab-l is the first protein identified as a member of the osmotic shock signal transduction pathway.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jolefsky@ucsd.edu			NIDDK NIH HHS [DK-33651, DK09595] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, F32DK009595, R37DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; Elmendorf JS, 1998, J BIOL CHEM, V273, P13289, DOI 10.1074/jbc.273.21.13289; Haruta T, 1998, ENDOCRINOLOGY, V139, P358, DOI 10.1210/en.139.1.358; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; Imamura T, 1999, MOL CELL BIOL, V19, P6765; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; OKADA T, 1994, J BIOL CHEM, V269, P3568; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; Rocchi S, 1998, MOL ENDOCRINOL, V12, P914, DOI 10.1210/me.12.7.914; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V91, P9931; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Shepherd PR, 1997, BIOCHEM SOC T, V25, P978, DOI 10.1042/bst0250978; SHEPHERD PR, 1998, BIOCHEM J, V25, P471; Vollenweider P, 1997, ENDOCRINOLOGY, V138, P4941, DOI 10.1210/en.138.11.4941; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wojtaszewski JFP, 1998, BBA-GEN SUBJECTS, V1380, P396, DOI 10.1016/S0304-4165(98)00011-7; Wu-Wong JSR, 1999, J BIOL CHEM, V274, P8103, DOI 10.1074/jbc.274.12.8103; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	31	31	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26870	26876						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842168				2022-12-25	WOS:000089144800029
J	Abramovich, C; Shen, WF; Pineault, N; Imren, S; Montpetit, B; Largman, C; Humphries, RK				Abramovich, C; Shen, WF; Pineault, N; Imren, S; Montpetit, B; Largman, C; Humphries, RK			Functional cloning and characterization of a novel nonhomeodomain protein that inhibits the binding of PBX1-HOX complexes to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOX HOMEODOMAIN PROTEINS; I INTERFERON RECEPTOR; BONE-MARROW CELLS; HOMEOBOX GENES; PBX PROTEINS; EXPORT SIGNALS; PRE-B; TRANSCRIPTIONAL ACTIVATOR; COOPERATIVE INTERACTIONS; NUCLEAR-LOCALIZATION	PBX1 is a homeodomain protein that functions in complexes with other homeodomain-containing proteins to regulate gene expression during developmental and/or differentiation processes. A yeast two hybrid screen of a fetal liver-hematopoietic cDNA library using PBX1a as bait led to the discovery of a novel non-homeodomain-containing protein that interacts with PBX1 as well as PBX2 and PBX3. RNA analysis revealed it to be expressed in CD34(+) hematopoietic cell populations enriched in primitive progenitors, as is PBX1; search of the expressed sequence tag data base indicated that it is also expressed in other early embryonic as well as adult tissues. The full-length cDNA encodes a 731-amino acid protein that has no significant homology to known proteins. This protein that we have termed hematopoietic PBX-interacting protein (HPIP) is mainly localized in the cytosol and in small amounts in the nucleus. The region of PBX that interacts with HPIP includes both the homeodomain and immediate N-terminal flanking sequences. Strikingly, electrophoretic mobility shift assays revealed that HPIP inhibits the ability of PBX-HOX heterodimers to bind to target sequences. Moreover, HPIP strongly inhibits the transactivation activity of ESA-PBX. Together these findings suggest that HPIP is a new regulator of PBX function.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Vet Affairs Med Ctr, Dept Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94121 USA; Univ British Columbia, Dept Med, Vancouver, BC V6T 2B5, Canada	British Columbia Cancer Agency; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of British Columbia	Humphries, RK (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.		Montpetit, Ben/L-6456-2019	Montpetit, Ben/0000-0002-8317-983X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048642] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48642] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Bischof LJ, 1998, J BIOL CHEM, V273, P7941, DOI 10.1074/jbc.273.14.7941; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; Davis LG, 1994, BASIC METHODS MOL BI; EPPLEN C, 1994, HUM GENET, V93, P35; Ferretti E, 1999, MECH DEVELOP, V83, P53, DOI 10.1016/S0925-4773(99)00031-3; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Georgiev O, 1996, GENE, V168, P165, DOI 10.1016/0378-1119(95)00764-4; GONZALEZCRESPO S, 1995, DEVELOPMENT, V121, P2117; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; Green NC, 1998, J BIOL CHEM, V273, P13273, DOI 10.1074/jbc.273.21.13273; HAWLEY RG, 1994, GENE THER, V1, P136; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; LeBrun DP, 1997, ONCOGENE, V15, P2059, DOI 10.1038/sj.onc.1201367; LEBRUN DP, 1994, ONCOGENE, V9, P1641; Lu Q, 1996, P NATL ACAD SCI USA, V93, P470, DOI 10.1073/pnas.93.1.470; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; Lu Q, 1996, MOL CELL BIOL, V16, P1632; LU QA, 1995, MOL CELL BIOL, V15, P3786; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Passner JM, 1999, NATURE, V397, P714, DOI 10.1038/17833; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; Pinsonneault J, 1997, EMBO J, V16, P2032, DOI 10.1093/emboj/16.8.2032; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; RAUSKOLB C, 1995, DEVELOPMENT, V121, P3663; Ryoo HD, 1999, GENE DEV, V13, P1704, DOI 10.1101/gad.13.13.1704; Sambrook J., 2002, MOL CLONING LAB MANU; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Shen WF, 1996, NUCLEIC ACIDS RES, V24, P898, DOI 10.1093/nar/24.5.898; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; Shimamoto T, 1998, INT J HEMATOL, V67, P339; Smith KS, 1997, ONCOGENE, V14, P2917, DOI 10.1038/sj.onc.1201249; Thorsteinsdottir U, 1999, MOL CELL BIOL, V19, P6355; Thorsteinsdottir U, 1997, HEMATOL ONCOL CLIN N, V11, P1221, DOI 10.1016/S0889-8588(05)70491-3; VANDIJK MA, 1993, P NATL ACAD SCI USA, V90, P6061, DOI 10.1073/pnas.90.13.6061	52	47	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26172	26177		10.1074/jbc.M001323200	http://dx.doi.org/10.1074/jbc.M001323200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10825160	hybrid			2022-12-25	WOS:000088999700041
J	Chang, P; Marians, KJ				Chang, P; Marians, KJ			Identification of a region of Escherichia coli DnaB required for functional interaction with DnaG at the replication fork	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; COORDINATED LEADING-STRAND; OKAZAKI FRAGMENT SIZE; N-TERMINAL DOMAIN; PHI-X174-TYPE PRIMOSOME; CRYSTAL-STRUCTURE; HELICASE-PRIMASE; ATP HYDROLYSIS; PROTEINS; COMPLEX	The fundamental activities of the replicative primosomes of Escherichia coli are provided by DnaB, the replication fork DNA helicase, and DnaG, the Okazaki fragment primase. As we have demonstrated previously, DnaG is recruited to the replication fork via a transient protein-protein interaction with DnaB. Here, using site-directed amino acid mutagenesis, we have defined the region on DnaB required for this protein-protein interaction. Mutations in this region of DnaB affect the DnaB-DnaG; interaction during both general priming-directed and phi X174 complementary strand DNA synthesis, as well as at replication forks reconstituted in rolling circle DNA replication reactions. The behavior of the purified mutant DnaB proteins in the Various replication systems suggests that access to the DnaG binding pocket on DnaB may be restricted at the replication fork.	Cornell Univ, Weill Grad Sch Med Sci, Mol Biol Grad Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Chang, P (corresponding author), Cornell Univ, Weill Grad Sch Med Sci, Mol Biol Grad Program, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM034557, GM34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bird LE, 2000, BIOCHEMISTRY-US, V39, P171, DOI 10.1021/bi9918801; Biswas EE, 1999, BIOCHEMISTRY-US, V38, P10919, DOI 10.1021/bi990048t; BISWAS SB, 1994, BIOCHEMISTRY-US, V33, P11307, DOI 10.1021/bi00203a028; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Fass D, 1999, STRUCTURE, V7, P691, DOI 10.1016/S0969-2126(99)80090-2; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; Kim DR, 1996, J BIOL CHEM, V271, P20681, DOI 10.1074/jbc.271.34.20681; Kim S, 1996, J BIOL CHEM, V271, P4315; Learn BA, 1997, P NATL ACAD SCI USA, V94, P1154, DOI 10.1073/pnas.94.4.1154; Liu J, 1996, J BIOL CHEM, V271, P15656, DOI 10.1074/jbc.271.26.15656; LIU J, 1996, J BIOL CHEM, V271, P15649; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MODEL P, 1974, J MOL BIOL, V83, P231, DOI 10.1016/0022-2836(74)90389-1; MOK M, 1987, J BIOL CHEM, V262, P16644; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Stordal L, 1996, J BACTERIOL, V178, P4620, DOI 10.1128/jb.178.15.4620-4627.1996; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; Tougu K, 1996, J BIOL CHEM, V271, P21391, DOI 10.1074/jbc.271.35.21391; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WEINER JH, 1976, P NATL ACAD SCI USA, V73, P752, DOI 10.1073/pnas.73.3.752; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; WICKNER S, 1978, SINGLE STRANDED DNA, P255; WICKNER S, 1977, P NATL ACAD SCI USA, V72, P2815; WU CA, 1992, J BIOL CHEM, V267, P4030; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	40	35	37	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26187	26195		10.1074/jbc.M001800200	http://dx.doi.org/10.1074/jbc.M001800200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10833513	hybrid			2022-12-25	WOS:000088999700043
J	Hermand, P; Huet, M; Callebaut, I; Gane, P; Ihanus, E; Gahmberg, CG; Cartron, JP; Bailly, P				Hermand, P; Huet, M; Callebaut, I; Gane, P; Ihanus, E; Gahmberg, CG; Cartron, JP; Bailly, P			Binding sites of leukocyte beta(2) integrins (LFA-1, Mac-1) on the human ICAM-4/LW blood group protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-3; FUNCTION-ASSOCIATED ANTIGEN-1; HUMAN-ERYTHROCYTE-MEMBRANE; MONOCLONAL-ANTIBODIES; NEURONAL GLYCOPROTEIN; LIGAND; TELENCEPHALIN; RHINOVIRUS; EXPRESSION; SURFACE	The red cell ICAM-4/LW blood group glycoprotein, which belongs to the family of intercellular adhesion molecules (ICAMs), has been reported to interact with CD11a/CD18 (LFA-1) and CD11b/CD18 (Mac-1) beta(2) integrins. To better define the basis of the ICAM-4/beta(2) integrin interaction, we have generated wild-type, domain-deleted and mutated recombinant chimeric ICAM-4-Fc proteins and analyzed their interaction in a cellular adhesion assay with LFA-1 and Mac-1 L-cell stable transfectants. We found that monoclonal antibodies against CD11a, CD11b, CD18, or LWab block adhesion of transfectant L-cells to immobilized ICAM-4-Fc protein and that the ICAM-4/beta(2) integrin interaction was highly sensitive to the presence of the divalent cations Ca2+ and Mg2+. Deletion of individual Ig-domains D1 or D2 of the extracellular part of ICAM-8 showed that LFA-1 binds to the first Ig-like domain, whereas the Mac-1 binding site encompassed both the first and the second Ig-like domains. Based on the crystal structure of ICAM-8, we propose a model for the Ig-like domains D1 and D2 of ICAM-4. Accordingly, by site-directed mutagenesis of 22 amino acid positions spread out on all faces of the ICAM-4 molecule, we identified four exposed residues, Leu(80), Trp(93), and Arg(97) On the CFG face and Trp(77) On the E-F loop of domain D1 that may contact LFA-1 as part of the binding site. However, the single and double mutants R52E and T91Q on the CFG face of domain D1, which correspond to the key residues Glu(34) and Gln(73) for ICAM-1 binding to LFA-1, had no effect on LFA-1 binding. In contrast, all mutants on the CFG face of domain D1 and residues Glu(151) and Thr(154) in the C'-E loop of the domain D2 seem to play a dominant role in Mac-1 binding. These data suggest that the binding site for LFA-1 on ICAM-4 overlaps but is distinct from the Mac-1 binding site.	Inst Natl Transfus Sanguine, INSERM, U76, F-75015 Paris, France; Univ Paris 06, LMCP, CNRS UMR 7590, F-75252 Paris, France; Univ Paris 07, LMCP, CNRS UMR 7590, F-75252 Paris, France; Univ Helsinki, Dept Biosci, Div Biochem, FIN-00014 Helsinki, Finland	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); Universite Paris Cite; University of Helsinki	Cartron, JP (corresponding author), Inst Natl Transfus Sanguine, INSERM, U76, 6 Rue Alexandre Cabanel, F-75015 Paris, France.		Gahmberg, Carl/AAE-1876-2019	Gahmberg, Carl/0000-0001-9892-9296; HERMAND, Patricia/0000-0003-0628-9733				BAILLY P, 1994, P NATL ACAD SCI USA, V91, P5306, DOI 10.1073/pnas.91.12.5306; Bailly P, 1995, EUR J IMMUNOL, V25, P3316, DOI 10.1002/eji.1830251217; Bell ED, 1998, J IMMUNOL, V161, P1363; Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BLOY C, 1990, J BIOL CHEM, V265, P21482; BOSSY D, 1994, GENOMICS, V23, P712, DOI 10.1006/geno.1994.1565; CARTRON JP, 1994, BLOOD REV, V8, P199, DOI 10.1016/0268-960X(94)90108-2; Casasnovas JM, 1997, NATURE, V387, P312, DOI 10.1038/387312a0; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DIACOVO TG, 1994, J CLIN INVEST, V94, P1243, DOI 10.1172/JCI117442; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; Gahmberg CG, 1997, EUR J BIOCHEM, V245, P215, DOI 10.1111/j.1432-1033.1997.00215.x; HERMAND P, 1995, BLOOD, V86, P1590, DOI 10.1182/blood.V86.4.1590.bloodjournal8641590; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; Kishimoto T K, 1994, Adv Pharmacol, V25, P117, DOI 10.1016/S1054-3589(08)60431-7; Klickstein LB, 1996, J BIOL CHEM, V271, P23920, DOI 10.1074/jbc.271.39.23920; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI R, 1993, J BIOL CHEM, V268, P17513; MALLINSON G, 1986, BIOCHEM J, V234, P649, DOI 10.1042/bj2340649; Mizuno T, 1997, J BIOL CHEM, V272, P1156, DOI 10.1074/jbc.272.2.1156; NORTAMO P, 1988, SCAND J IMMUNOL, V28, P537, DOI 10.1111/j.1365-3083.1988.tb01485.x; NORTAMO P, 1991, EUR J IMMUNOL, V21, P2629, DOI 10.1002/eji.1830211049; OCKENHOUSE CF, 1992, CELL, V68, P63, DOI 10.1016/0092-8674(92)90206-R; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SANSOM D, 1991, GENOMICS, V11, P462, DOI 10.1016/0888-7543(91)90157-A; SONNEBORN HH, 1984, DEV BIOLOGICALS, V57, P61; SONNEBORN HH, 1994, VOX SANGUINIS S2, V67, P114; Spring FA, 1998, BLOOD, V92, p589A; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Stanley P, 1998, J BIOL CHEM, V273, P3358, DOI 10.1074/jbc.273.6.3358; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Tian L, 1997, J IMMUNOL, V158, P928; TRASK B, 1993, GENOMICS, V15, P133, DOI 10.1006/geno.1993.1021; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; Wang JH, 1998, IMMUNOL REV, V163, P197, DOI 10.1111/j.1600-065X.1998.tb01198.x; YOSHIHARA Y, 1994, NEURON, V12, P541, DOI 10.1016/0896-6273(94)90211-9; [No title captured]	41	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26002	26010		10.1074/jbc.M002823200	http://dx.doi.org/10.1074/jbc.M002823200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10846180	hybrid			2022-12-25	WOS:000088999700018
J	Luong, A; Hannah, VC; Brown, MS; Goldstein, JL				Luong, A; Hannah, VC; Brown, MS; Goldstein, JL			Molecular characterization of human acetyl-CoA synthetase, an enzyme regulated by sterol regulatory element-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; LOW-DENSITY-LIPOPROTEIN; COENZYME-A SYNTHETASE; TRANSGENIC MICE; SACCHAROMYCES-CEREVISIAE; CULTURED-CELLS; BLOOD ACETATE; MESSENGER-RNA; CHOLESTEROL; GENE	Through suppressive subtractive hybridization, we identified a new gene whose transcription is induced by sterol regulatory element-binding proteins (SREBPs). The gene encodes acetyl-CoA synthetase (ACS), the cytosolic enzyme that activates acetate so that it can be used for lipid synthesis or for energy generation. ACS genes were isolated previously from yeast, but not from animal cells. Recombinant human ACS was produced by expressing the cloned cDNA transiently in human cells. After purification by nickel chromatography, the 701-amino acid cytosolic enzyme was shown to function as a monomer. The recombinant enzyme produced acetyl-CoA from acetate in a reaction that required ATP. As expected for a gene controlled by SREBPs, ACS mRNA was induced when cultured cells were deprived of sterols and repressed by sterol addition. The pattern of regulation resembled the regulation of enzymes of fatty acid synthesis. ACS mRNA was also elevated in livers of transgenic mice that express dominant-positive versions of all three isoforms of SREBP. We conclude that ACS mRNA, and hence the ability of cells to activate acetate, is regulated by SREBPs in parallel with fatty acid synthesis in animal cells.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brown, MS (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd,Rm L5-238, Dallas, TX 75390 USA.	mbrow1@mednet.swmed.edu; jgolds@mednet.swmed.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014, GM08203] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AssimacopoulosJeannet F, 1997, J BIOL CHEM, V272, P1659, DOI 10.1074/jbc.272.3.1659; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; BARTH C, 1972, BIOCHIM BIOPHYS ACTA, V260, P1, DOI 10.1016/0005-2760(72)90067-7; BERG P, 1956, J BIOL CHEM, V222, P991; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BUCKLEY BM, 1977, BIOCHEM J, V166, P539, DOI 10.1042/bj1660539; Carroll PT, 1997, BRAIN RES, V753, P47, DOI 10.1016/S0006-8993(96)01485-0; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; Conti E, 1996, STRUCTURE, V4, P287, DOI 10.1016/S0969-2126(96)00033-0; CRABTREE B, 1989, BIOCHEM J, V257, P673, DOI 10.1042/bj2570673; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DEVIRGILIO C, 1992, YEAST, V8, P1043, DOI 10.1002/yea.320081207; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Espenshade PJ, 1999, J BIOL CHEM, V274, P22795, DOI 10.1074/jbc.274.32.22795; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Hiesinger M, 1997, FEBS LETT, V415, P16, DOI 10.1016/S0014-5793(97)01085-5; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HOWARD BV, 1974, J BIOL CHEM, V249, P7912; HUANG KP, 1970, ANAL BIOCHEM, V37, P98, DOI 10.1016/0003-2697(70)90263-0; IMESCH E, 1984, INT J BIOCHEM, V16, P875, DOI 10.1016/0020-711X(84)90146-0; Korn BS, 1998, J CLIN INVEST, V102, P2050, DOI 10.1172/JCI5341; KORNBERG HL, 1966, BIOCHEM J, V99, P1; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Rawson RB, 1997, MOL CELL, V1, P47, DOI 10.1016/S1097-2765(00)80006-4; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; SCHEPPACH W, 1991, CLIN SCI, V80, P177, DOI 10.1042/cs0800177; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; VANDENBERG MA, 1995, EUR J BIOCHEM, V231, P704; vandenBerg MA, 1996, J BIOL CHEM, V271, P28953, DOI 10.1074/jbc.271.46.28953; WEBSTER LT, 1963, J BIOL CHEM, V238, P4010; WOLCZUNOWICZ M, 1977, LIFE SCI, V20, P1347, DOI 10.1016/0024-3205(77)90360-5; WOODNUTT G, 1986, COMP BIOCHEM PHYS B, V85, P487, DOI 10.1016/0305-0491(86)90033-7; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	43	185	196	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26458	26466		10.1074/jbc.M004160200	http://dx.doi.org/10.1074/jbc.M004160200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10843999	hybrid			2022-12-25	WOS:000088999700080
J	Nika, J; Yang, WM; Pavitt, GD; Hinnebusch, AG; Hannig, EM				Nika, J; Yang, WM; Pavitt, GD; Hinnebusch, AG; Hannig, EM			Purification and kinetic analysis of eIF2B from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; INITIATION FACTOR-II; POLYPEPTIDE-CHAIN INITIATION; TRANSLATION INITIATION; PROTEIN-SYNTHESIS; EUKARYOTIC INITIATION-FACTOR-2; ALPHA-SUBUNIT; GAMMA-SUBUNIT; DROSOPHILA-MELANOGASTER; RABBIT RETICULOCYTES	Eukaryotic translation initiation factor 2B (eIF2B) is the heteropentameric guanine nucleotide exchange factor for translation initiation factor 2 (eIF2). Recent studies in the yeast Saccharomyces cerevisiae have served to characterize genetically the exchange factor. However, enzyme kinetic studies of the yeast enzyme have been hindered by the lack of sufficient quantities of protein suitable for biochemical analysis. We have purified yeast eIF2B and characterized its catalytic properties in vitro. Values for K-m and V-max were determined to be 12.2 nM and 250.7 fmol/min, respectively, at 0 degrees C. The calculated turnover number (K-cat) of 43.2 pmol of GDP released per min/pmol of eIF2B at 30 degrees C is approximately 1 order of magnitude lower than values previously reported for the mammalian factor. Reciprocal plots at varying fixed concentrations of the second substrate were linear and intersected to the left of the gamma axis. This is consistent with a sequential catalytic mechanism and argues against a ping-pong mechanism similar to that proposed for EF-Tu/EF-Ts. In support of this model, our yeast eIF2B preparations bind guanine nucleotides, with an apparent dissociation constant for GTP in the low micromolar range.	Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75083 USA; NICHHD, Lab Eukaryot Gene Regulat, NIH, Bethesda, MD 20892 USA	University of Texas System; University of Texas Dallas; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Hannig, EM (corresponding author), Univ Texas, Dept Mol & Cell Biol, Mail Stn FO 3-1,POB 8306888, Richardson, TX 75083 USA.	hannig@utdallas.edu	Pavitt, Graham D/A-1363-2010	Pavitt, Graham D/0000-0002-8593-2418; Hannig, Ernest/0000-0002-2260-3342	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001004] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001004] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHMAD MF, 1985, J BIOL CHEM, V260, P6960; AKKARAJU GR, 1991, J BIOL CHEM, V266, P24451; BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSHMAN JL, 1993, MOL CELL BIOL, V13, P4618, DOI 10.1128/MCB.13.8.4618; BUSHMAN JL, 1993, MOL CELL BIOL, V13, P1920, DOI 10.1128/MCB.13.3.1920; CIGAN AM, 1991, MOL CELL BIOL, V11, P3217, DOI 10.1128/MCB.11.6.3217; CIGAN AM, 1993, P NATL ACAD SCI USA, V90, P5350, DOI 10.1073/pnas.90.11.5350; DEALDANA CRV, 1994, MOL CELL BIOL, V14, P3208, DOI 10.1128/MCB.14.5.3208; DEVER TE, 1995, MOL CELL BIOL, V15, P6351; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P546; DHOLAKIA JN, 1989, J BIOL CHEM, V264, P20638; DHOLAKIA JN, 1988, P NATL ACAD SCI USA, V85, P51, DOI 10.1073/pnas.85.1.51; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; Erickson FL, 1996, EMBO J, V15, P6311, DOI 10.1002/j.1460-2075.1996.tb01021.x; Fabian JR, 1997, J BIOL CHEM, V272, P12359, DOI 10.1074/jbc.272.19.12359; HANNIG EM, 1990, GENETICS, V126, P549; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; HANNIG EM, 1988, MOL CELL BIOL, V8, P4808, DOI 10.1128/MCB.8.11.4808; HERSHEY JWB, 1990, ENZYME, V44, P17, DOI 10.1159/000468744; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HWANG YW, 1985, J BIOL CHEM, V260, P1498; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KIMBALL SR, 1991, J BIOL CHEM, V266, P1969; KIMBALL SR, 1994, BIOCHIMIE, V76, P729, DOI 10.1016/0300-9084(94)90077-9; Kleijn M, 1998, J BIOL CHEM, V273, P5536, DOI 10.1074/jbc.273.10.5536; KOONIN EV, 1995, PROTEIN SCI, V4, P1608, DOI 10.1002/pro.5560040819; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Manchester KL, 1997, BIOCHEM BIOPH RES CO, V239, P223, DOI 10.1006/bbrc.1997.7462; MATTS RL, 1983, P NATL ACAD SCI-BIOL, V80, P2559, DOI 10.1073/pnas.80.9.2559; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Olsen DS, 1998, GENETICS, V149, P1495; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PANNIERS R, 1988, J BIOL CHEM, V263, P5519; PANNIERS R, 1994, BIOCHIMIE, V76, P737, DOI 10.1016/0300-9084(94)90078-7; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; PETRYSHYN R, 1983, METHOD ENZYMOL, V99, P346; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; Price NT, 1996, BIOCHEM J, V318, P631, DOI 10.1042/bj3180631; Price NT, 1996, BIOCHEM J, V318, P637, DOI 10.1042/bj3180637; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; ROWLANDS AG, 1988, EUR J BIOCHEM, V175, P93, DOI 10.1111/j.1432-1033.1988.tb14170.x; Santoyo J, 1997, J BIOL CHEM, V272, P12544, DOI 10.1074/jbc.272.19.12544; Sherman F., 1986, METHODS YEAST GENETI, P163; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; SIEKIERKA J, 1984, P NATL ACAD SCI-BIOL, V81, P352, DOI 10.1073/pnas.81.2.352; SIKORSKI RS, 1989, GENETICS, V122, P19; Singh L P, 1996, SAAS Bull Biochem Biotechnol, V9, P1; SINGH LP, 1994, BIOCHEMISTRY-US, V33, P9152, DOI 10.1021/bi00197a018; Sood R, 2000, BIOCHEM J, V346, P281, DOI 10.1042/0264-6021:3460281; Sood R, 2000, GENETICS, V154, P787; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; TRACHSEL H, 1978, P NATL ACAD SCI USA, V75, P3654, DOI 10.1073/pnas.75.8.3654; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Yang WM, 1996, MOL CELL BIOL, V16, P6603	65	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26011	26017		10.1074/jbc.M003718200	http://dx.doi.org/10.1074/jbc.M003718200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852917	hybrid			2022-12-25	WOS:000088999700019
J	Fukamizo, T; Juffer, AH; Vogel, HJ; Honda, Y; Tremblay, H; Boucher, I; Neugebauer, WA; Brzezinski, R				Fukamizo, T; Juffer, AH; Vogel, HJ; Honda, Y; Tremblay, H; Boucher, I; Neugebauer, WA; Brzezinski, R			Theoretical calculation of pk(a) reveals an important role of Arg(205) in the activity and stability of Streptomyces sp N174 chitosanase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTINUUM ELECTROSTATIC MODEL; ACID-DISSOCIATION CONSTANTS; HORDEUM-VULGARE L; GLYCOSYL HYDROLASES; CRYSTAL-STRUCTURE; IONIZABLE GROUPS; AMINO-ACIDS; PROTEINS; CATALYSIS; MECHANISM	Based on the crystal structure of chitosanase from Streptomyces sp, N174, we have calculated theoretical pK(alpha) values of the ionizable groups of this protein using a combination of the boundary element method and continuum electrostatics. The pK(alpha) value obtained for Arg(205), which is located in the catalytic cleft, was abnormally high (>20.0), indicating that the guanidyl group may interact strongly with nearby charges. Chitosanases possessing mutations in this position (R205A, R205H, and R205Y), produced by Streptomyces lividans expression system, were found to have less than 0.3% of the activity of the wild type enzyme and to possess thermal stabilities 4-5 kcal/mol lower than that of the wild type protein. In the crystal structure, the Arg205 Side chain is in close proximity to the Asp(145) Side chain (theoretical pK(alpha), -1.6), which is in turn close to the Arg(190) side chain (theoretical pK(alpha), 17,7), These theoretical pK(alpha) values are abnormal, suggesting that both of these residues may participate in the Arg(205) interaction network. Activity and stability experiments using Asp(145)- and Arg(190)-mutated chitosanases (D145A and R190A) provide experimental data supporting the hypothesis derived from the theoretical pK(alpha) data and prompt the conclusion that Arg(205) forms a strong interaction network with Asp(145) and Arg(190) that stabilizes the catalytic cleft.	Kinki Univ, Fac Agr, Biophys Chem Lab, Nara 6318505, Japan; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Sherbrooke, Dept Biol, Fac Sci, Grp Rech Biol Actinoycetes, Sherbrooke, PQ J1K 2R1, Canada; Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1K 5N4, Canada; Univ Oulu, Bioctr, FIN-90014 Oulu, Finland; Univ Oulu, Dept Biochem, FIN-90014 Oulu, Finland	Kindai University (Kinki University); University of Calgary; University of Sherbrooke; University of Sherbrooke; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	Fukamizo, T (corresponding author), Kinki Univ, Fac Agr, Biophys Chem Lab, 3327-204 Nakamachi, Nara 6318505, Japan.	fukamizo@nara.kindai.ac.jp	Brzezinski, Ryszard/A-3192-2008; Fukamizo, Tamo/AAY-7251-2020	Juffer, Andre/0000-0003-3533-0520; Brzezinski, Ryszard/0000-0002-9090-5051				Andersen MD, 1997, BIOCHEM J, V322, P815, DOI 10.1042/bj3220815; BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; Beroza P, 1996, J COMPUT CHEM, V17, P1229, DOI 10.1002/(SICI)1096-987X(19960730)17:10<1229::AID-JCC4>3.0.CO;2-Q; Boucher I, 1995, J BIOL CHEM, V270, P31077, DOI 10.1074/jbc.270.52.31077; BOUCHER I, 1992, APPL MICROBIOL BIOT, V38, P188, DOI 10.1007/BF00174466; Brameld KA, 1998, P NATL ACAD SCI USA, V95, P4276, DOI 10.1073/pnas.95.8.4276; CHEN L, 1995, J BIOL CHEM, V270, P8093, DOI 10.1074/jbc.270.14.8093; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Demchuk E, 1996, J PHYS CHEM-US, V100, P17373, DOI 10.1021/jp960111d; DENIS F, 1992, GENE, V111, P115, DOI 10.1016/0378-1119(92)90611-R; FUKAMIZO T, 1995, BIOCHEM J, V311, P377, DOI 10.1042/bj3110377; Fukamizo T, 1997, BIOCHEM CELL BIOL, V75, P687, DOI 10.1139/bcb-75-6-687; HART PJ, 1995, J MOL BIOL, V248, P402, DOI 10.1006/jmbi.1995.0230; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; Honda Y, 1997, FEBS LETT, V411, P346, DOI 10.1016/S0014-5793(97)00726-6; Honda Y, 1999, BBA-PROTEIN STRUCT M, V1429, P365, DOI 10.1016/S0167-4838(98)00243-X; Imoto T., 1972, ENZYMES, V7, P665; INOUE M, 1992, BIOCHEMISTRY-US, V31, P5545, DOI 10.1021/bi00139a017; Juffer AH, 1998, J COMPUT AID MOL DES, V12, P289, DOI 10.1023/A:1016089901704; Juffer AH, 1998, BIOCHEM CELL BIOL, V76, P198, DOI 10.1139/bcb-76-2-3-198; Juffer AH, 1997, J PHYS CHEM B, V101, P7664, DOI 10.1021/jp9715944; JUFFER AH, 1991, J COMPUT PHYS, V97, P144, DOI 10.1016/0021-9991(91)90043-K; LEVER M, 1972, ANAL BIOCHEM, V47, P273, DOI 10.1016/0003-2697(72)90301-6; Marcotte EM, 1996, NAT STRUCT BIOL, V3, P155, DOI 10.1038/nsb0296-155; MASSON JY, 1993, CHITIN ENZYMOLOGY, P283; MATTHEWS BW, 1974, P NATL ACAD SCI USA, V71, P4178, DOI 10.1073/pnas.71.10.4178; Monzingo AF, 1996, NAT STRUCT BIOL, V3, P133, DOI 10.1038/nsb0296-133; OBEROI H, 1993, BIOPHYS J, V65, P48, DOI 10.1016/S0006-3495(93)81032-4; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; Saito J, 1999, J BIOL CHEM, V274, P30818, DOI 10.1074/jbc.274.43.30818; SEKI K, 1997, ADV CHITIN SCI, V2, P284; TAKAHASHI T, 1992, BIOPOLYMERS, V32, P897, DOI 10.1002/bip.360320802; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; VANDERSPOEL D, 1996, GROMACS USER MANUAL; WANG QP, 1994, J AM CHEM SOC, V116, P11594, DOI 10.1021/ja00104a060; WATANABE T, 1993, J BIOL CHEM, V268, P18567	37	33	34	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25633	25640		10.1074/jbc.M002574200	http://dx.doi.org/10.1074/jbc.M002574200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829022	hybrid			2022-12-25	WOS:000088849400078
J	Ishida, N; Kitagawa, M; Hatakeyama, S; Nakayama, K				Ishida, N; Kitagawa, M; Hatakeyama, S; Nakayama, K			Phosphorylation at serine 10, a major phosphorylation site of p27(Kip1), increases its protein stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT-KINASE INHIBITOR; KAPPA-B-ALPHA; UBIQUITIN-MEDIATED DEGRADATION; ACUTE LYMPHOBLASTIC-LEUKEMIA; CELL-CYCLE PROGRESSION; F-BOX PROTEIN; BREAST-CANCER; MUTATIONAL ANALYSIS; MOLECULAR ANALYSIS; BUTYROLACTONE-I	The association of the p27(Kip1) protein with cyclin and cyclin-dependent kinase complexes inhibits their kinase activities and contributes to the control of cell proliferation. The p27(Kip1) protein has now been shown to be phosphorylated in vivo, and this phosphorylation reduces the electrophoretic mobility of the protein. Substitution of Ser(10) with Ala (S10A) markedly reduced the extent of p27(Kip1) phosphorylation and prevented the shift in electrophoretic mobility. Phosphopeptide mapping and phosphoamino acid analysis revealed that phosphorylation at Ser(10) accounted for similar to 70% of the total phosphorylation of p27(Kip1), and the extent of phosphorylation at this site was similar to 25- and 75-fold greater than that at Ser(178) and Thr(187), respectively. The phosphorylation of p27(Kip1) was markedly reduced when the positions of Ser(10) and Pro(11) were reversed, suggesting that a proline-directed kinase is responsible for the phosphorylation of Ser(10) The extent of Ser(10) phosphorylation was markedly increased in cells in the G(0)-G(1) phase of the cell cycle compared with that apparent for cells in S or M phase. The p27(Kip1) protein phosphorylated at Ser(10) was significantly more stable than the unphosphorylated form. Furthermore, a mutant p27(Kip1) in which Ser(10) was replaced with glutamic acid in order to mimic the effect of Ser(10) phosphorylation exhibited a marked increase in stability both in vivo and in vitro compared with the wild-type or S10A mutant proteins. These results suggest that Ser(10) is the major site of phosphorylation of p27(Kip1) and that phosphorylation at this site, like that at Thr(187), contributes to regulation of p27(Kip1) stability.	Kyushu Univ, Dept Mol & Cell Biol, Med Inst Bioregulat, Higashi Ku, Fukuoka 8128582, Japan; CREST, Japan Sci & Technol Corp, Kawaguchi 3320012, Japan	Kyushu University; Japan Science & Technology Agency (JST)	Nakayama, K (corresponding author), Kyushu Univ, Dept Mol & Cell Biol, Med Inst Bioregulat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	nakayak1@bioreg.kyushu-u.ac.jp	Hatakeyama, Shigetsugu/C-8333-2012	Hatakeyama, Shigetsugu/0000-0002-2150-9979				BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Ellis M, 1999, EMBO J, V18, P644, DOI 10.1093/emboj/18.3.644; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Ferrando AA, 1996, HUM GENET, V97, P91; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Hattori K, 1999, J BIOL CHEM, V274, P29641, DOI 10.1074/jbc.274.42.29641; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kawamata N, 1996, CANCER, V77, P570; KAWAMATA N, 1995, CANCER RES, V55, P2266; Kawana H, 1998, AM J PATHOL, V153, P505, DOI 10.1016/S0002-9440(10)65593-9; KITAGAWA M, 1994, ONCOGENE, V9, P2549; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KITAGAWA M, 1993, ONCOGENE, V8, P2425; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; MACIEJEWSKI PM, 1995, J BIOL CHEM, V270, P27661, DOI 10.1074/jbc.270.46.27661; Mann DJ, 1999, EMBO J, V18, P654, DOI 10.1093/emboj/18.3.654; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; MOROSETTI R, 1995, BLOOD, V86, P1924, DOI 10.1182/blood.V86.5.1924.bloodjournal8651924; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PIETENPOL JA, 1995, CANCER RES, V55, P1206; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Seriu T, 1996, LEUKEMIA, V10, P345; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spirin KS, 1996, CANCER RES, V56, P2400; Stegmaier K, 1996, CANCER RES, V56, P1413; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tan P, 1997, CANCER RES, V57, P1259; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	66	183	189	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25146	25154		10.1074/jbc.M001144200	http://dx.doi.org/10.1074/jbc.M001144200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10831586	hybrid			2022-12-25	WOS:000088849400016
J	Wada, H; Hasegawa, K; Morimoto, T; Kakita, T; Yanazume, T; Sasayama, S				Wada, H; Hasegawa, K; Morimoto, T; Kakita, T; Yanazume, T; Sasayama, S			A p300 protein as a coactivator of GATA-6 in the transcription of the smooth muscle-myosin heavy chain gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTES; CDNA CLONING; CELLS; EXPRESSION; DIFFERENTIATION; ISOFORM; IDENTIFICATION; PROLIFERATION; GATA-4/5/6; ADAPTER	The mechanisms that regulate smooth muscle development and differentiation are poorly understood. Although recent studies have suggested the possible role of a zinc finger transcription factor, GATA-6, in the differentiation of vascular smooth muscle cells (VSMCs), the downstream gene targeted by GATA-6 is unknown, The expression of smooth muscle-myosin heavy chain (Sm-MHC) provides a highly specific marker for the differentiated phenotype of VSMCs as well. as the smooth muscle cell lineage. Here, we show that GATA-6 bound to a GATA-like motif (-810/-805) within the rat Sm-MHC promoter in a sequence-specific manner and activated this promoter through this site, In addition, we show that the transcriptional coactivator p300 associated with GATA-6 during the transcription of the Sm-MHC gene. A p300/GATA-6 complex in VSMCs was up-regulated by induction of the quiescent phenotype. A wildtype E1A, which interferes with endogenous p300, but not a mutant E1A defective for p300 binding, markedly down-regulated the expression of endogenous Sm-MHC in quiescent-phenotype VSMCs, These studies provide the first identification of a functionally important GATA-6 binding site within a smooth muscle-specific promoter and suggest a role for p300 in the maintenance of the differentiated phenotype in VSMCs as a coactivator of GATA-6.	Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Hasegawa, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, 54 Kawara Cho, Kyoto 6068507, Japan.			Wada, Hiromichi/0000-0002-8980-224X				ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BABIJ P, 1993, NUCLEIC ACIDS RES, V21, P1467, DOI 10.1093/nar/21.6.1467; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; Jiang YM, 1996, DEV BIOL, V174, P258, DOI 10.1006/dbio.1996.0071; Kakita T, 1999, J BIOL CHEM, V274, P34096, DOI 10.1074/jbc.274.48.34096; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KELLEY CA, 1994, CAN J PHYSIOL PHARM, V72, P1351, DOI 10.1139/y94-195; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KOCHER O, 1991, LAB INVEST, V65, P459; KUROO M, 1991, J BIOL CHEM, V266, P3768; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Morimoto T, 1999, J BIOL CHEM, V274, P12811, DOI 10.1074/jbc.274.18.12811; Morrisey EE, 1996, DEV BIOL, V177, P309, DOI 10.1006/dbio.1996.0165; Morrisey EE, 1997, DEV BIOL, V183, P21, DOI 10.1006/dbio.1996.8485; NAGAI R, 1989, J BIOL CHEM, V264, P9734; Narita N, 1996, GENOMICS, V36, P345, DOI 10.1006/geno.1996.0472; OWENS GK, 1995, PHYSIOL REV, V75, P487; Perlman H, 1998, J BIOL CHEM, V273, P13713, DOI 10.1074/jbc.273.22.13713; REIDY MA, 1992, ARCH PATHOL LAB MED, V116, P1276; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SIMON MC, 1995, NAT GENET, V11, P9, DOI 10.1038/ng0995-9; Suzuki E, 1996, GENOMICS, V38, P283, DOI 10.1006/geno.1996.0630; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	34	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25330	25335		10.1074/jbc.M000828200	http://dx.doi.org/10.1074/jbc.M000828200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10851229	hybrid			2022-12-25	WOS:000088849400039
J	Naik, RS; Davidson, EA; Gowda, DC				Naik, RS; Davidson, EA; Gowda, DC			Developmental stage-specific biosynthesis of glycosylphosphatidylinositol anchors in intraerythrocytic Plasmodium falciparum and its inhibition in a novel manner by mannosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-LINKED OLIGOSACCHARIDES; ERYTHROCYTIC STAGES; STRUCTURAL-ANALYSIS; MEMBRANE ANCHOR; MAMMALIAN-CELLS; GPI; PROTEINS; INTERMEDIATE; METABOLISM; PRECURSORS	Glycosylphosphatidylinositols (GPIs) are the major glycoconjugates in intraerythrocytic stage Plasmodium falciparum. Several functional proteins including merozoite surface protein 1 are anchored to the cell surface by GPI modification, and GPIs are vital to the parasite. Here, we studied the developmental stage-specific biosynthesis of GPIs by intraerythrocytic P. falciparum. Tie parasite synthesizes GPIs exclusively during the maturation of early trophozoites to late trophozoites but not during the development of rings to early trophozoites or late trophozoites to schizonts and merozoites, Mannosamine, an inhibitor of GPI biosynthesis, inhibits the growth of the parasite specifically at the trophozoite stage, preventing further development to schizonts and causing death. Mannosamine has no effect on the development of either rings to early trophozoites or late trophozoites to schizonts and merozoites. The analysis of GPIs and proteins synthesized by the parasite in the presence of mannosamine demonstrates that the effect is because of the inhibition of GPI biosynthesis, The data also show that mannosamine inhibits GPI biosynthesis by interfering with the addition of mannose to an inositol-acylated GlcN-phosphatidylinositol (PI) intermediate, which is distinctively different from the pattern seen in other organisms. In other systems, mannosamine inhibits GPI biosynthesis by interfering with either the transfer of a mannose residue to the Man alpha 1-6Man alpha 1-4GlcN-PI intermediate or the formation of ManN-Man-GlcN-PI, an aberrant GPI intermediate, which cannot be a substrate for further addition of mannose. Thus, the parasite GPI biosynthetic pathway could be a specific target for antimalarial drug development.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Georgetown University	Gowda, DC (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	gowda@bc.georgetown.edu		Gowda, Channe/0000-0002-6860-5108	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041139] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41139] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRETON CB, 1990, RES IMMUNOL, V141, P743, DOI 10.1016/0923-2494(90)90005-J; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FERGUSON MAJ, 1991, CELL BIOL INT REP, V15, P991, DOI 10.1016/0309-1651(91)90052-K; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; FERGUSON MAJ, 1994, PARASITOL TODAY, V10, P48, DOI 10.1016/0169-4758(94)90392-1; FIELD MC, 1993, J BIOL CHEM, V268, P9570; Field MC, 1997, GLYCOBIOLOGY, V7, P161, DOI 10.1093/glycob/7.2.161-d; Gerold P, 1999, BIOCHEM J, V344, P731, DOI 10.1042/0264-6021:3440731; GEROLD P, 1994, J BIOL CHEM, V269, P2597; Gerold P, 1996, MOL BIOCHEM PARASIT, V75, P131, DOI 10.1016/0166-6851(95)02518-9; Gowda DC, 1997, J BIOL CHEM, V272, P6428, DOI 10.1074/jbc.272.10.6428; Gowda DC, 1999, PARASITOL TODAY, V15, P147, DOI 10.1016/S0169-4758(99)01412-X; Kinoshita T, 1997, J BIOCHEM-TOKYO, V122, P251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LISANTI MP, 1991, EMBO J, V10, P1969, DOI 10.1002/j.1460-2075.1991.tb07726.x; Marshall VM, 1997, INFECT IMMUN, V65, P4460, DOI 10.1128/IAI.65.11.4460-4467.1997; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MENON AK, 1994, METHOD ENZYMOL, V230, P418; Milne KG, 1999, J BIOL CHEM, V274, P1465, DOI 10.1074/jbc.274.3.1465; PAN YT, 1992, J BIOL CHEM, V267, P8991; PAN YT, 1992, J BIOL CHEM, V267, P21250; PAN YT, 1985, ARCH BIOCHEM BIOPHYS, V242, P447, DOI 10.1016/0003-9861(85)90229-2; RALTON JE, 1993, J BIOL CHEM, V268, P24183; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SEVLEVER D, 1993, J BIOL CHEM, V268, P10938; Trigg P. I., 1998, MALARIA PARASITE BIO, P11; UDEINYA IJ, 1980, B WORLD HEALTH ORGAN, V58, P445	29	35	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24506	24511		10.1074/jbc.M002151200	http://dx.doi.org/10.1074/jbc.M002151200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10833517	hybrid			2022-12-25	WOS:000088683300037
J	Sattler, M; Verma, S; Shrikhande, G; Byrne, CH; Pride, YB; Winkler, T; Greenfield, EA; Salgia, R; Griffin, JD				Sattler, M; Verma, S; Shrikhande, G; Byrne, CH; Pride, YB; Winkler, T; Greenfield, EA; Salgia, R; Griffin, JD			The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; HYDROGEN-PEROXIDE; DNA-DAMAGE; GROWTH-FACTORS; CIGARETTE TAR; PHOSPHORYLATION; TRANSFORMATION; APOPTOSIS; COMPLEX; PHOSPHATASES	The BCR/ABL oncogene causes chronic myelogenous leukemia, a myeloproliferative disorder characterized by clonal expansion of hematopoietic progenitor cells and myeloid cells, It is shown here that transformation of the hematopoietic cell lines Ba/F3, 32Dcl3, and M07e with BCR/ABL results in an increase in reactive oxygen species (ROS) compared with quiescent, untransformed cells. The increase in ROS was directly due to BCR/ABL because it was blocked by the ABL-specific tyrosine kinase inhibitor STI571, Oxidative stress through ROS is believed to have many biochemical effects, including the potential ability to inhibit protein-tyrosine phosphatases (PTPases), To understand the significance of increased production of ROS, a model system was established in which hydrogen peroxide (H2O2) was added to untransformed cells to mimic the increase in ROS induced constitutively by BCR/ABL. H2O2 substantially reduced total cellular PTPase activity to a degree approximately equivalent to that of pervanadate, a well known PTPase inhibitor. Further, stimulation of untransformed cells with H2O2 or pervanadate increased tyrosine phosphorylation of each of the most prominent known substrates of BCR/ABL, including c-ABL, c-CBL, SHC, and SHP-2. Treatment of the BCR/ABL-expressing cell line MO7/p210 with the reducing agents pyrrolidine dithiocarbamate or N-acetylcysteine reduced the accumulation of ROS and also decreased tyrosine phosphorylation of cellular proteins. Further, treatment of M07e cells with H2O2 or pervanadate increased the tyrosine kinase activity of c-ABL, Drugs that alter ROS metabolism or reactivate PTPases may antagonize BCR/ABL transformation.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Sattler, M (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.		Winkler, Thomas/S-3787-2017	Winkler, Thomas/0000-0002-8072-0168; Pride, Yuri/0000-0002-5884-0964	NATIONAL CANCER INSTITUTE [R29CA075348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER; NCI NIH HHS [CA75348-03] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beckmann K. B., 1997, OXIDATIVE STRESS MOL, P201; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CHANCE B, 1963, J BIOL CHEM, V238, P418; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Dreher D, 1996, EUR J CANCER, V32A, P30, DOI 10.1016/0959-8049(95)00531-5; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; Huang RP, 1996, J CELL BIOL, V133, P211, DOI 10.1083/jcb.133.1.211; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; LaMontagne KR, 1998, MOL CELL BIOL, V18, P2965, DOI 10.1128/MCB.18.5.2965; LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; Lotem J, 1996, P NATL ACAD SCI USA, V93, P9166, DOI 10.1073/pnas.93.17.9166; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; Niu TQ, 1999, J CELL BIOCHEM, V72, P145, DOI 10.1002/(SICI)1097-4644(19990101)72:1<145::AID-JCB15>3.0.CO;2-G; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PEDERSEN B, 1982, BRIT J HAEMATOL, V51, P339, DOI 10.1111/j.1365-2141.1982.tb02789.x; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pryor WA, 1998, CHEM RES TOXICOL, V11, P441, DOI 10.1021/tx970159y; RAMBALDI A, 1989, BLOOD, V73, P1113; Rao GN, 1996, ONCOGENE, V13, P713; Sattler M, 1999, BLOOD, V93, P2928; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; SATTLER M, 1995, EXP HEMATOL, V23, P1040; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Sonoda Y, 1997, BIOCHEM BIOPH RES CO, V241, P769, DOI 10.1006/bbrc.1997.7895; SPARKS JW, 1985, J BIOL CHEM, V260, P2042; SPENCER JPE, 1995, FEBS LETT, V375, P179, DOI 10.1016/0014-5793(95)01199-O; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Taub J, 1999, NATURE, V399, P162, DOI 10.1038/20208; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Tauchi T, 1997, INT J ONCOL, V11, P471; Yeh LH, 1999, AM J PHYSIOL-CELL PH, V276, pC838, DOI 10.1152/ajpcell.1999.276.4.C838; Yoshie Y, 1997, CARCINOGENESIS, V18, P1359, DOI 10.1093/carcin/18.7.1359; Yurchak LK, 1996, J BIOL CHEM, V271, P12549, DOI 10.1074/jbc.271.21.12549	39	250	258	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24273	24278		10.1074/jbc.M002094200	http://dx.doi.org/10.1074/jbc.M002094200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10833515	hybrid			2022-12-25	WOS:000088683300007
J	Vesa, J; Kruttgen, A; Shooter, EM				Vesa, J; Kruttgen, A; Shooter, EM			p75 reduces TrkB tyrosine autophosphorylation in response to brain-derived neurotrophic factor and neurotrophin 4/5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; AFFINITY NGF RECEPTOR; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; SYMPATHETIC NEURONS; MOLECULAR-CLONING; FACTOR-BINDING; FACTOR FAMILY; FUNCTIONAL INTERACTIONS; PROTOONCOGENE PRODUCT	Neurotrophins mediate their signals through two different receptors: the family of receptor tyrosine kinases, Trks, and the low affinity pan-neurotrophin receptor p75. Trk receptors show more restricted ligand specificity, whereas all neurotrophins are able to bind to p?5, One important function of p75 is the enhancement of nerve growth factor signaling via TrkA by increasing TrKA tyrosine autophosphorylation. Here, we have examined the importance of p75 on TrkB- and TrkC-mediated neurotrophin signaling in an MG87 fibroblast cell line stably transfected with either p75 and TrkB or p75 and TrkC, as well as in PC12 cells stably transfected with TrkB. In contrast to TrkA signaling, p75 had a negative effect on TrkB tyrosine autophosphorylation in response to its cognate neurotrophins, brain-derived neurotrophic factor and neurotrophin 4/5. On the other hand, p75 had no effect on TrkB or TrkC activation in neurotrophin 3 treatment. p75 did not effect extracellular signal-regulated kinase 2 tyrosine phosphorylation in response to brain-derived neurotrophic factor, neurotrophin 3, or neurotrophin 4/5. These results suggest that the observed reduction in TrkB tyrosine autophosphorylation caused by p75 does not influence Ras/mitogen-activated protein kinase signaling pathway in neurotrophin treatments.	Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University	Shooter, EM (corresponding author), Stanford Univ, Sch Med, Dept Neurobiol, 299 Campus Dr, Stanford, CA 94305 USA.		Kruttgen, Alexander P/E-9232-2010		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER; NINDS NIH HHS [NS04270] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; BARBACID M, 1993, ONCOGENE, V8, P2033; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BATTLEMAN DS, 1993, J NEUROSCI, V13, P941; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Canossa M, 1996, EMBO J, V15, P3369, DOI 10.1002/j.1460-2075.1996.tb00702.x; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1993, BIOCHEM SOC T, V21, P895, DOI 10.1042/bst0210895; CURTIS R, 1995, NEURON, V14, P1201, DOI 10.1016/0896-6273(95)90267-8; DECHANT G, 1994, PROG NEUROBIOL, V42, P347, DOI 10.1016/0301-0082(94)90075-2; deChaves EIP, 1997, J BIOL CHEM, V272, P3028, DOI 10.1074/jbc.272.5.3028; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; Frade JM, 1996, NATURE, V383, P166; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; Hapner SJ, 1998, DEV BIOL, V201, P90, DOI 10.1006/dbio.1998.8970; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1993, EXP NEUROL, V124, P31, DOI 10.1006/exnr.1993.1170; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAISHO Y, 1990, FEBS LETT, V266, P187, DOI 10.1016/0014-5793(90)81536-W; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; Kruttgen A, 1998, P NATL ACAD SCI USA, V95, P9614, DOI 10.1073/pnas.95.16.9614; Lachance C, 1997, NEUROSCIENCE, V81, P861, DOI 10.1016/S0306-4522(97)00237-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LEE KF, 1994, DEVELOPMENT, V120, P1027; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOEB DM, 1994, J BIOL CHEM, V269, P8901; LOMENHOERTH C, 1995, J NEUROCHEM, V64, P1780; MacPhee IJ, 1997, J BIOL CHEM, V272, P23547, DOI 10.1074/jbc.272.38.23547; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Ultsch MH, 1999, J MOL BIOL, V290, P149, DOI 10.1006/jmbi.1999.2816; VERDI JM, 1994, NEURON, V13, P1359, DOI 10.1016/0896-6273(94)90421-9; vonBartheld CS, 1996, J NEUROSCI, V16, P2995; WESKAMP G, 1991, NEURON, V6, P649, DOI 10.1016/0896-6273(91)90067-A; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9	61	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24414	24420		10.1074/jbc.M001641200	http://dx.doi.org/10.1074/jbc.M001641200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10825163	hybrid			2022-12-25	WOS:000088683300024
J	Xu, Q; Ji, YS; Schmedtje, JF				Xu, Q; Ji, YS; Schmedtje, JF			Sp1 increases expression of cyclooxygenase-2 in hypoxic vascular endothelium - Implications for the mechanisms of aortic aneurysm and heart failure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROSTAGLANDIN E-2 SYNTHESIS; NITRIC-OXIDE SYNTHASE; TRANSCRIPTION FACTORS; BINDING-SITE; MOLECULAR-CLONING; SP-FAMILY; ACTIVATION; GENE; PROTEIN	Cyclooxygenase-2 (COX-2) catalyzes prostaglandin synthesis from arachidonic acid and is expressed locally in aortic aneurysm and heart failure. Cellular hypoxia is also found in these conditions. We have previously shown that cox-2 is transcriptionally regulated by hypoxia in human umbilical vein endothelial cells (HUVEC) in culture via the transactivation factor NF-kappa B p65, leading to increased production of prostaglandin E-2, an inhibitor of vascular smooth muscle cell proliferation. Sp1 is a transactivation factor known to be important in the regulation of cytokine expression in association with NF-kappa B. We hypothesized that Sp1 is involved in the induction of cox-2 in hypoxic HUVEC, Electrophoretic mobility shift assays with hypoxic HUVEC nuclear protein showed that both Spl and the related protein Sp3 specifically bound to the cox-2 promoter. Immunoblotting demonstrated that hypoxia increased the nuclear localization of Sp1 but did not change the Sp3 content in HUVEC. Overexpression of Sp1 through transfection of HUVEC enhanced cox-2 promoter activity as measured by reporter gene expression and by the production of COX-2. The specificity of the results was confirmed by mutation of the Sp1-binding site in the cox-2 promoter construct and by reproducibility in an Sp-deficient Drosophila SL2 cell line. The regulatory role of Spl discovered in this work supports the concept that a mechanistic link exists between vascular cellular hypoxia and mediators of inflammation associated with aortic aneurysm and heart failure.	Wake Forest Univ, Sch Med, Dept Med, Cardiol Sect, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Physiol & Pharmacol, Winston Salem, NC 27157 USA; Univ Texas, Med Branch, Dept Med, Div Cardiol, Galveston, TX 77555 USA	Wake Forest University; Wake Forest University; University of Texas System; University of Texas Medical Branch Galveston	Schmedtje, JF (corresponding author), 1615 Franklin Rd SW, Roanoke, VA 24016 USA.							ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Baker CSR, 1999, ARTERIOSCL THROM VAS, V19, P646, DOI 10.1161/01.ATV.19.3.646; Bjornheden T, 1999, ARTERIOSCL THROM VAS, V19, P870, DOI 10.1161/01.ATV.19.4.870; BRINKMAN HJM, 1990, THROMB HAEMOSTASIS, V63, P291; Busija David W., 1996, Microcirculation (Philadelphia), V3, P379, DOI 10.3109/10739689609148310; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FARBER HW, 1990, EXP CELL RES, V191, P27, DOI 10.1016/0014-4827(90)90031-5; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hansen TVO, 1999, MOL CELL ENDOCRINOL, V155, P1, DOI 10.1016/S0303-7207(99)00120-3; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Holmes DR, 1997, J VASC SURG, V25, P810, DOI 10.1016/S0741-5214(97)70210-6; ISAKSON P, 1995, ADV PROSTAG THROMB L, V23, P49; Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416; Ji YS, 1998, CIRC RES, V83, P295, DOI 10.1161/01.RES.83.3.295; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kapadia Samir, 1998, Cardiology Clinics, V16, P645, DOI 10.1016/S0733-8651(05)70041-2; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; Ping DS, 2000, J BIOL CHEM, V275, P1708, DOI 10.1074/jbc.275.3.1708; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Sharma R, 2000, INT J CARDIOL, V72, P175, DOI 10.1016/S0167-5273(99)00186-2; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Sjottem E, 1997, J MOL BIOL, V267, P490, DOI 10.1006/jmbi.1997.0893; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tsukamoto Y, 1996, J CLIN INVEST, V98, P1930, DOI 10.1172/JCI118994; Walton LJ, 1999, CIRCULATION, V100, P48, DOI 10.1161/01.CIR.100.1.48; Wang SB, 1999, J BIOL CHEM, V274, P33190, DOI 10.1074/jbc.274.47.33190; Watanabe Y, 1997, CARDIOVASC RES, V35, P217, DOI 10.1016/S0008-6363(97)00085-0; Wong SCY, 1998, CIRCULATION, V98, P100, DOI 10.1161/01.CIR.98.2.100; Wu KK, 1998, CIRCULATION, V98, P95, DOI 10.1161/01.CIR.98.2.95; Wu YX, 1998, BIOCHEM J, V330, P1469, DOI 10.1042/bj3301469; Xu XM, 1997, J BIOL CHEM, V272, P6943, DOI 10.1074/jbc.272.11.6943; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463	54	101	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24583	24589		10.1074/jbc.M003894200	http://dx.doi.org/10.1074/jbc.M003894200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10825178	hybrid			2022-12-25	WOS:000088683300048
J	Brosh, RM; Li, JL; Kenny, MK; Karow, JK; Cooper, MP; Kureekattil, RP; Hickson, ID; Bohr, VA				Brosh, RM; Li, JL; Kenny, MK; Karow, JK; Cooper, MP; Kureekattil, RP; Hickson, ID; Bohr, VA			Replication protein A physically interacts with the Bloom's syndrome protein and stimulates its helicase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ROTHMUND-THOMSON-SYNDROME; WERNERS-SYNDROME GENES; ESCHERICHIA-COLI; BINDING PROTEIN; SYNDROME CELLS; MOLECULAR-CLONING; RECQ FAMILY; IN-VIVO; RECOMBINATION	Bloom's syndrome is a rare autosomal recessive disorder characterized by genomic instability and predisposition to cancer. BLM, the gene defective in Bloom's syndrome, encodes a 159-kDa protein possessing DNA-stimulated ATPase and ATP-dependent DNA helicase activities. We have examined mechanistic aspects of the catalytic functions of purified recombinant BLM protein, Through analyzing the effects of different lengths of DNA cofactor on ATPase activity, we provide evidence to suggest that BLM translocates along single-stranded DNA in a processive manner. The helicase reaction catalyzed by BLM protein was examined as a function of duplex DNA length. We show that BLM: catalyzes unwinding of short DNA duplexes (less than or equal to 71 base pairs (bp)) but is severely compromised on longer DNA duplexes (greater than or equal to 259-bp), The presence of the human single-stranded DNA-binding protein (human replication protein A (hRPA)) stimulates the BLM unwinding reaction on the 259-bp partial duplex DNA substrate. Heterologous single-stranded DNA-binding proteins fail to stimulate similarly the helicase activity of BLM protein. This is the first demonstration of a functional interaction between BLM and another protein. Consistent with a functional interaction between hRPA and the BLM helicase, we demonstrate a direct physical interaction between the two proteins mediated by the 70-kDa subunit of RPA. The interactions between BLM and hRPA suggest that the two proteins function together in vivo to unwind DNA duplexes during replication, recombination, or repair.	NIA, Mol Genet Lab, NIH, Baltimore, MD 21224 USA; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England; Montefiore Med Ctr, Dept Radiat Oncol, Bronx, NY 10467 USA; Montefiore Med Ctr, Albert Einstein Canc Ctr, Bronx, NY 10467 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Cancer Research UK; University of Oxford; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Bohr, VA (corresponding author), NIA, Mol Genet Lab, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Hickson, Ian/AAJ-7548-2020; Bohr, Vilhelm/AAP-5931-2020	Hickson, Ian/0000-0002-0583-566X	NATIONAL CANCER INSTITUTE [R29CA071612] Funding Source: NIH RePORTER; NCI NIH HHS [CA71612] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bahr A, 1998, ONCOGENE, V17, P2565, DOI 10.1038/sj.onc.1202389; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Chakraverty RK, 1999, BIOESSAYS, V21, P286; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GIANNELLI F, 1977, NATURE, V265, P466, DOI 10.1038/265466a0; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; Kitao S, 1999, NAT GENET, V22, P82, DOI 10.1038/8788; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; Lindor NM, 1996, CLIN GENET, V49, P124; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; LONN U, 1990, CANCER RES, V50, P3141; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; NAKAYAMA K, 1985, MOL GEN GENET, V200, P266, DOI 10.1007/BF00425434; Neff NF, 1999, MOL BIOL CELL, V10, P665, DOI 10.1091/mbc.10.3.665; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; SALK D, 1985, ADV EXP MED BIOL, V190, P305; SEKI M, 1994, NUCLEIC ACIDS RES, V22, P4566, DOI 10.1093/nar/22.22.4566; SEO YS, 1991, J BIOL CHEM, V266, P13161; Sibenaller ZA, 1998, BIOCHEMISTRY-US, V37, P12496, DOI 10.1021/bi981110+; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Sun H, 1998, J BIOL CHEM, V273, P27587, DOI 10.1074/jbc.273.42.27587; Walpita D, 1999, P NATL ACAD SCI USA, V96, P5622, DOI 10.1073/pnas.96.10.5622; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	39	246	252	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23500	23508		10.1074/jbc.M001557200	http://dx.doi.org/10.1074/jbc.M001557200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10825162	hybrid, Green Submitted			2022-12-25	WOS:000088564200015
J	Maeshima, Y; Colorado, PC; Kalluri, R				Maeshima, Y; Colorado, PC; Kalluri, R			Two RGD-independent alpha(v)beta(3) integrin binding sites on tumstatin regulate distinct anti-tumor properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; IV COLLAGEN; ALPHA-3(IV) CHAIN; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANES; MOLECULAR-CLONING; LAMININ RECEPTOR; MELANOMA-CELLS; ANGIOGENESIS; PROTEIN	Vascular basement membrane is an important regulator of angiogenesis and undergoes many alterations during angiogenesis and these changes are speculated to influence neovascularization. Recently, fragments of collagen molecules have been identified to possess antiangiogenic activity. Tumstatin (alpha 3(IV)NC1 domain) is one such novel molecule with distinct anti-tumor properties and possesses an N-terminal (amino acids 54-132) anti-angiogenic and a C-terminal (amino acids 185-203) anti-tumor cell activity (Maeshima, Y., et al. 2000) J. Biol. Chem. 275, 21340-21348). Previous studies have identified the 185-203 amino acid sequence as a ligand for alpha(nu)beta(3) integrin (Shahan, T. A. et al. (1999) Cancer Res. 59, 4584-4590). In the present study, we found distinct additional RGD-independent alpha(nu)beta(3) integrin binding site within 54-132 amino acids of tumstatin. This site is not essential for inhibition of tumor cell proliferation but necessary for the anti-angiogenic activity. A fragment of tumstatin containing 54-132 amino acid (tum-2) binds both endothelial cells and melanoma cells but only inhibited proliferation of endothelial cells, with no effect on tumor cell proliferation. A similar experiment with fragment of tumstatin containing the 185-203 amino acid (tum-4) demonstrates that it binds both endothelial cells and melanoma cells but only inhibits the proliferation of melanoma cells. The presence of cyclic RGD peptides did not affect the alpha(nu)beta(3) integrin-mediated activity of tumstatin, although significant inhibition of endothelial cell binding to vitronectin was observed. The two distinct RGD-independent binding sites on tumstatin suggest unique alpha(nu)beta(3) integrin-mediated mechanisms governing the two distinct anti-tumor properties of tumstatin.	Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Ctr Canc, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Kalluri, R (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, RW 563A,330 Brookline Ave, Boston, MA 02215 USA.		Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X	NIDDK NIH HHS [DK-55001, DK-51711] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051711] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Colorado PC, 2000, CANCER RES, V60, P2520; Dhanabal M, 1999, CANCER RES, V59, P189; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; Han J, 1997, J BIOL CHEM, V272, P20395, DOI 10.1074/jbc.272.33.20395; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HERLYN D, 1990, CANCER RES, V50, P2296; Hermann P, 1999, J CELL BIOL, V144, P767, DOI 10.1083/jcb.144.4.767; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; Isik FF, 1998, J CELL PHYSIOL, V175, P149, DOI 10.1002/(SICI)1097-4652(199805)175:2<149::AID-JCP4>3.0.CO;2-O; KALLURI R, 1991, J BIOL CHEM, V266, P24018; Kalluri R, 1996, J BIOL CHEM, V271, P9062, DOI 10.1074/jbc.271.15.9062; Kalluri R, 1997, J CLIN INVEST, V99, P2470, DOI 10.1172/JCI119431; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; Liu SG, 1997, CLIN BIOCHEM, V30, P455, DOI 10.1016/S0009-9120(97)00049-0; Madri JA, 1997, TRANSPL IMMUNOL, V5, P179, DOI 10.1016/S0966-3274(97)80035-4; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; Petitclerc E, 1999, CANCER RES, V59, P2724; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Senger DR, 1996, AM J PATHOL, V149, P293; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Shahan TA, 1999, CANCER RES, V59, P4584; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; Suzuma K, 1998, INVEST OPHTH VIS SCI, V39, P1028; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TURNER N, 1992, J CLIN INVEST, V89, P592, DOI 10.1172/JCI115625; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881	38	205	238	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23745	23750		10.1074/jbc.C000186200	http://dx.doi.org/10.1074/jbc.C000186200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10837460	hybrid			2022-12-25	WOS:000088564200048
J	Krehan, A; Ansuini, H; Bocher, O; Grein, S; Wirkner, U; Pyerin, W				Krehan, A; Ansuini, H; Bocher, O; Grein, S; Wirkner, U; Pyerin, W			Transcription factors Ets1, NF-kappa B, and Sp1 are major determinants of the promoter activity of the human protein kinase CK2 alpha gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; SUBUNIT-IV GENE; CASEIN KINASE; MEDIATED PHOSPHORYLATION; CELLULAR-REGULATION; INITIATOR ACTIVITY; ALPHA-GENE; II-ALPHA; BINDING; CK2	CK2 alpha is one of two isoforms of protein kinase CK2, a highly conserved, ubiquitous, and vital phosphotransferase whose expression is kept at constant cellular levels and whose dysregulated expression has been linked to malignant diseases. The upstream sequence of the gene coding for human CK2 alpha (CSNK1A1, chromosomal location 20p13) has been examined for promoter location and transcription factor interactions using reporter gene assays (luciferase; HeLa cells), site-directed mutagenesis, electrophoretic mobility shift assays, super-shifts, UV cross-linking, Western blotting, and DNA affinity chromatography. Highest promoter activity has been found in a region comprising positions -9 to 46, Factors Spl, Ets-1, and NF-kappa B have been identified as interaction partners and, by mutation of individual sites and simultaneous mutations of two or more sites, shown to cross-talk to each other. At least two of the factors (Spl; NF-kappa B) were susceptible to phosphorylation by CK2 holoenzyme, a tetramer: composed of two CK2 alpha and two regulatory CK2 beta proteins, but not by individual CK2 alpha, Because the phosphorylation decreases promoter binding and repeated immunoprecipitation reveals presence of "free" CK2 beta in cell extracts, it is tempting to speculate that the gene product CK2 alpha might readily form CK2 holoenzyme and feed back onto gene transcription. The data represent the first promoter control analysis of a mammalian CK2 alpha gene and provide a hypothesis of how the constant expression level of CK2 alpha may be achieved.	Deutsch Krebsforschungszentrum, Biochem Zellphysiol B0200, D-69120 Heidelberg, Germany; Univ Perugia, I-06100 Perugia, Italy	Helmholtz Association; German Cancer Research Center (DKFZ); University of Perugia	Pyerin, W (corresponding author), Deutsch Krebsforschungszentrum, Biochem Zellphysiol B0200, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	w.pyerin@dkfz-heidelberg.de						AHMED K, 1994, CELL MOL BIOL RES, V40, P1; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BODENBACH L, 1994, EUR J BIOCHEM, V220, P263, DOI 10.1111/j.1432-1033.1994.tb18622.x; BOHM SK, 1995, BIOCHEM J, V311, P835; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; COCHET C, 1983, J BIOL CHEM, V258, P1403; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; DUAYAO MP, 1992, CURR TOP MICROBIOL I, V182, P421; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Guesdon F, 1997, CYTOKINE, V9, P471, DOI 10.1006/cyto.1996.0190; Gumina RJ, 1997, BLOOD, V89, P1260, DOI 10.1182/blood.V89.4.1260; GUNTHER M, 1995, MOL CELL BIOL, V15, P2490; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; KOBAYASHI R, 1989, ANAL BIOCHEM, V183, P9, DOI 10.1016/0003-2697(89)90162-0; KOLLMAR R, 1994, J BIOL CHEM, V269, P2252; Krehan A, 1998, EUR J BIOCHEM, V251, P667, DOI 10.1046/j.1432-1327.1998.2510667.x; Krehan A, 1996, BIOCHEMISTRY-US, V35, P4966, DOI 10.1021/bi951989i; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; Lodie TA, 1998, J IMMUNOL, V161, P268; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; OLEMOIYOI OK, 1995, SCIENCE, V267, P834, DOI 10.1126/science.7846527; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PYERIN W, 1994, ADV ENZYME REGUL, V34, P225, DOI 10.1016/0065-2571(94)90018-3; Pyerin Walter, 1996, P117, DOI 10.1002/9783527615032.ch4; QUINN JP, 1991, FEBS LETT, V286, P225, DOI 10.1016/0014-5793(91)80979-D; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SETH A, 1993, AIDS RES HUM RETROV, V9, P1017, DOI 10.1089/aid.1993.9.1017; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Sucharov C, 1995, GENE EXPRESSION, V5, P93; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Tran K, 1997, MOL CELL BIOL, V17, P5386, DOI 10.1128/MCB.17.9.5386; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; VANDIJK MA, 1992, MOL CELL ENDOCRINOL, V88, P175, DOI 10.1016/0303-7207(92)90022-X; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Wirkner U, 1999, MOL CELL BIOCHEM, V191, P59, DOI 10.1023/A:1006848814894; Wirkner U, 1998, GENOMICS, V48, P71, DOI 10.1006/geno.1997.5136; WU RL, 1994, J BIOL CHEM, V269, P28450; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yu M, 1997, J BIOL CHEM, V272, P29060, DOI 10.1074/jbc.272.46.29060	65	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18327	18336		10.1074/jbc.M909736199	http://dx.doi.org/10.1074/jbc.M909736199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849443	hybrid			2022-12-25	WOS:000087659400058
J	Lin, S; Fagan, KA; Li, KX; Shaul, PW; Cooper, DMF; Rodman, DM				Lin, S; Fagan, KA; Li, KX; Shaul, PW; Cooper, DMF; Rodman, DM			Sustained endothelial nitric-oxide synthase activation requires capacitative Ca2+ entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-ENTRY; SUBCELLULAR-LOCALIZATION; ENDOPLASMIC-RETICULUM; NADPH-DIAPHORASE; ADENYLYL-CYCLASE; PLASMA-MEMBRANE; TUMOR PROMOTER; INTACT-CELLS; MICE LACKING; AEQUORIN	Endothelial nitric-oxide synthase (eNOS), a Ca2+/calmodulin-dependent enzyme, is critical for vascular homeostasis. While eNOS is membrane-associated through its N-myristoylation, the significance of membrane association in locating eNOS near sources of Ca2+ entry is uncertain. To assess the Ca2+ source required for eNOS activation, chimera containing the full-length eNOS cDNA and HA-tagged aequorin sequence (EHA), and MHA (myristoylation deficient EHA) were generated and transfected into COS-7 cells. The EHA chimera was primarily targeted to the plasma membrane while MHA was located intracellularly. Both constructs retained enzymatic eNOS activity and aequorin-mediated Ca2+ sensitivity. The plasma membrane-associated EHA and intracellular MHA were compared in their ability to sense changes in local Ca2+ concentration, demonstrating preferential sensitivity to Ca2+ originating from intracellular pools (MHA) or from capacitative Ca2+ entry (EHA). Measurements of eNOS activation in intact cells revealed that the eNOS enzymatic activity of EHA was more sensitive to Ca2+ influx via capacitative Ca2+ entry than intracellular release, whereas MHA eNOS activity was more responsive to intracellular Ca2+ release. When eNOS activation by CCE was compared with that generated by an equal rise in [Ca2+](i) due to the Ca2+ ionophore ionomycin, a 10-fold greater increase in NO production was found in the former condition. These results demonstrate that EHA and MHA chimera are properly targeted and retain full functions of eNOS and aequorin, and that capacitative Ca2+ influx is the principle stimulus for sustained activation of eNOS on the plasma membrane in intact cells.	Univ Colorado, Hlth Sci Ctr, CVP Res Lab, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Neurosci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Physiol & Biophys, Denver, CO 80262 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rodman, DM (corresponding author), Univ Colorado, Hlth Sci Ctr, CVP Res Lab, Div Pulm Sci & Crit Care Med, 4200 E 9th Ave,B133, Denver, CO 80262 USA.				NHLBI NIH HHS [HL14985, HL48038] Funding Source: Medline; NIGMS NIH HHS [GM 32483] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL048038, R01HL048038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032483] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLATTER LA, 1995, CIRC RES, V76, P922, DOI 10.1161/01.RES.76.5.922; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; BRINI M, 1993, EMBO J, V12, P4813, DOI 10.1002/j.1460-2075.1993.tb06170.x; BRINI M, 1994, CELL CALCIUM, V16, P259, DOI 10.1016/0143-4160(94)90089-2; BUCKLEY BJ, 1995, AM J PHYSIOL-CELL PH, V269, pC757, DOI 10.1152/ajpcell.1995.269.3.C757; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CASADEI J, 1990, P NATL ACAD SCI USA, V87, P2047, DOI 10.1073/pnas.87.6.2047; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; Demura Y, 1998, BRIT J PHARMACOL, V125, P1180, DOI 10.1038/sj.bjp.0702197; DOLOR RJ, 1992, AM J PHYSIOL, V262, P171; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HECKER M, 1994, BIOCHEM J, V299, P247, DOI 10.1042/bj2990247; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LantinHermoso RL, 1997, AM J PHYSIOL-LUNG C, V273, pL119, DOI 10.1152/ajplung.1997.273.1.L119; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Nakahashi Y, 1997, J BIOL CHEM, V272, P18093, DOI 10.1074/jbc.272.29.18093; Nakatsubo N, 1998, FEBS LETT, V427, P263, DOI 10.1016/S0014-5793(98)00440-2; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHERERSINGLER U, 1983, J NEUROSCI METH, V9, P229, DOI 10.1016/0165-0270(83)90085-7; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TANAHASHI H, 1990, GENE, V96, P249, DOI 10.1016/0378-1119(90)90260-X; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; VANDENHAZEL HB, 1993, J BIOL CHEM, V268, P18002; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Wang YP, 1996, J BIOL CHEM, V271, P5647, DOI 10.1074/jbc.271.10.5647; WRIGHT CD, 1989, BIOCHEM BIOPH RES CO, V160, P813, DOI 10.1016/0006-291X(89)92506-0	47	148	150	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17979	17985		10.1074/jbc.275.24.17979	http://dx.doi.org/10.1074/jbc.275.24.17979			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849433	hybrid			2022-12-25	WOS:000087659400012
J	Zhao, L; Gregoire, F; Sul, HS				Zhao, L; Gregoire, F; Sul, HS			Transient induction of ENC-1, a Kelch-related actin-binding protein, is required for adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; ADIPOSE CONVERSION; TRIGLYCERIDE ACCUMULATION; 3T3-L1 PREADIPOCYTES; INTERACTION MOTIF; MESSENGER-RNA; CELL-SHAPE; DOMAIN; FIBRONECTIN; COLLAGEN	In an attempt to study molecules that play a regulatory role early in adipocyte differentiation, we identified by differential display ENC-1, a Drosophila kelch-related protein. ENC-1 colocalizes with actin filaments. ENC-1 is expressed in adipose tissue, specifically in the adipose derived stroma vascular fraction. ENC-1 mRNA levels are transiently increased 8-12-fold early in in vitro adipocyte differentiation of primary cells of the adipose-derived stroma-vascular fraction and of 3T3-L1 cells. Treatment with the adipogenic inducers dexamethasone and methylisobutylxanthine causes an increase in ENC-1 mRNA levels specifically in preadipocytes, and methylisobutylxanthine is the main effector of ENC-1 expression. The induction of ENC-1 precedes expression of the transcription factors, peroxisome proliferator-activated receptor (PPAR gamma) and CCAAT/enhancer-binding protein (C/EBP alpha), and other adipocyte markers including adipocyte fatty acid-binding protein. The ENC-1 induction correlates with the subsequent differentiation of primary stroma-vascular cells into adipocytes. Furthermore, decreasing the endogenous ENC-1 levels by stable antisense transfection, thereby preventing the transient induction, effectively inhibits 3T3-L1 adipocyte differentiation. Overall, these studies indicate that ENC-1, an actin-binding protein, plays a regulatory role early in adipocyte differentiation when cytoskeletal reorganization and cell shape change from fibroblastic preadipocytes to spherical adipocytes occur.	Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Sul, HS (corresponding author), Univ Calif Berkeley, Dept Nutr Sci, Berkeley, CA 94720 USA.	hsul@nature.berkeley.edu	Han, Zaiqi/AAI-2233-2019		NIDDK NIH HHS [R01 DK 50828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; ANTRAS J, 1989, BIOL CELL, V66, P247, DOI 10.1016/0248-4900(89)90177-9; ARATANI Y, 1988, J BIOL CHEM, V263, P16163; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BENZEEV A, 1991, BIOESSAYS, V13, P207, DOI 10.1002/bies.950130502; BJORNTORP P, 1982, METABOLISM, V31, P366, DOI 10.1016/0026-0495(82)90112-3; CHEN W, 1995, MOL CELL BIOL, V15, P3424; DANI C, 1989, J BIOL CHEM, V264, P10119; FERNANDEZ JLR, 1989, DIFFERENTIATION, V42, P65, DOI 10.1111/j.1432-0436.1989.tb00608.x; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; GREGOIRE FM, 1995, INT J OBESITY, V19, P664; Hernandez MC, 1998, EXP CELL RES, V242, P470, DOI 10.1006/excr.1998.4109; Hernandez MC, 1997, J NEUROSCI, V17, P3038; Kim IF, 1999, GENE, V228, P73, DOI 10.1016/S0378-1119(99)00006-2; KIRKLAND JL, 1990, AM J PHYSIOL, V258, pC206, DOI 10.1152/ajpcell.1990.258.2.C206; KURIHARCUCH W, 1978, CELL, V14, P53, DOI 10.1016/0092-8674(78)90300-8; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; PAIRAULT J, 1987, BIOL CELL, V61, P149, DOI 10.1111/j.1768-322X.1987.tb00581.x; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; SIDHU RS, 1979, J BIOL CHEM, V254, P1111; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; SPIEGELMAN BM, 1983, CELL, V35, P657, DOI 10.1016/0092-8674(83)90098-3; SPIEGELMAN BM, 1982, CELL, V29, P53, DOI 10.1016/0092-8674(82)90089-7; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; WEINER FR, 1989, BIOCHEMISTRY-US, V28, P4094, DOI 10.1021/bi00435a070; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	30	45	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16845	16850		10.1074/jbc.275.22.16845	http://dx.doi.org/10.1074/jbc.275.22.16845			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828068	hybrid			2022-12-25	WOS:000087392200063
J	Reiss, K; Wang, JY; Romano, G; Furnari, FB; Cavenee, WK; Morrione, A; Tu, X; Baserga, R				Reiss, K; Wang, JY; Romano, G; Furnari, FB; Cavenee, WK; Morrione, A; Tu, X; Baserga, R			IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation	ONCOGENE			English	Article						insulin-like growth factor; IGF-I receptor; prostate cancer; PTEN; IRS-I	GROWTH-FACTOR-I; DOMINANT-NEGATIVE MUTANT; FOCAL ADHESION KINASE; SMOOTH-MUSCLE CELLS; INSULIN-RECEPTOR; TUMOR-GROWTH; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; TYROSINE PHOSPHORYLATION; ALPHA-V-BETA-3 INTEGRIN; BINDING-PROTEINS	LNCaP prostatic cancer cells are characterized by having a PTEN mutation, low levels of type 1 insulin-like growth factor receptor (IGF-IR) and no IRS-1, one of the major substrates of the IGF-IR, The absence of IRS-1, an activator of PI3-kinase, is compensated in these cells by the mutation in PTEN, an inhibitor of PI3-kinase, However, IGF-IR signaling in the absence of IRS-1 can cause cell differentiation and growth arrest. We hypothesized that these three characteristics may not be unrelated, specifically that, together, they may favor the metastatic spread of prostatic cancer cells without decreasing their growth potential. In support of this hypothesis, we report here that: (1) IRS-1 expression increases cell adhesion and decreases cell motility; (2) over-expression of the IGF-IR, in the absence of IRS-1, causes growth arrest and (3) a combination of TGF-IR and IRS-1 restores the transformed phenotype of LNCaP cells. These findings suggest a mechanism by which prostatic cancer cells can achieve metastatic potential without interfering with their growth potential.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Ludwig Inst Canc Res, La Jolla, CA 92093 USA	Jefferson University; Ludwig Institute for Cancer Research	Baserga, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,624 BLSB, Philadelphia, PA 19107 USA.			Furnari, Frank/0000-0003-1909-4361	NCI NIH HHS [CA 78890, CA 53484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053484, P01CA078890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGELLOZNICOUD P, 1995, ENDOCRINOLOGY, V136, P5485, DOI 10.1210/en.136.12.5485; Baserga Renato, 1999, V17, P329; Bright RK, 1997, CANCER RES, V57, P995; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; CARSON JP, 1999, CANCER RES, V59, P49; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Davies MA, 1999, CANCER RES, V59, P2551; Dunn SE, 1998, CANCER RES, V58, P3353; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; GLEAVE ME, 1992, CANCER RES, V52, P1598; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Guvakova MA, 1997, EXP CELL RES, V231, P149, DOI 10.1006/excr.1996.3457; Huynh H, 1998, CANCER RES, V58, P215; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Mantzoros CS, 1997, BRIT J CANCER, V76, P1115, DOI 10.1038/bjc.1997.520; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PIETRZKOWSKI Z, 1993, CANCER RES, V53, P1102; Plymate SR, 1997, ENDOCRINOLOGY, V138, P1728, DOI 10.1210/en.138.4.1728; Reiss K, 1999, J CELL PHYSIOL, V181, P124, DOI 10.1002/(SICI)1097-4652(199910)181:1<124::AID-JCP13>3.0.CO;2-0; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Soos G, 1997, ANTICANCER RES, V17, P4253; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; THALMANN GN, 1994, CANCER RES, V54, P2577; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; White MF, 1998, RECENT PROG HORM RES, V53, P119; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	48	76	76	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2687	2694		10.1038/sj.onc.1203587	http://dx.doi.org/10.1038/sj.onc.1203587			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851068				2022-12-25	WOS:000087193000004
J	Xia, WY; Lau, YK; Hu, MCT; Li, L; Johnston, DA; Sheng, SJ; El-Naggar, AK; Hung, MC				Xia, WY; Lau, YK; Hu, MCT; Li, L; Johnston, DA; Sheng, SJ; El-Naggar, AK; Hung, MC			High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma	ONCOGENE			English	Article						cancer; maspin; protease inhibitor; tumor suppressor	CANCER CELLS; GENE MASPIN; NECK-CANCER; HEAD; OVEREXPRESSION; SUPPRESSOR; SERPIN; P53; AMPLIFICATION; MUTATION	Maspin, a member of the serpin family of protease inhibitors, is known to have tumor-suppressor functions, However, the association between its expression level and survival has not been demonstrated in human cancer. Using the immunohistochemical technique to examine the expression levels of maspin in 44 cases of oral squamous cell carcinoma (SCC), we found that 66% of the cases expressed low to intermediate levels of maspin and 34% of the cases expressed high levels of maspin, We further examined maspin protein expression in a series of sis SCC cell lines from the head and neck, and found that all but one expressed low or no maspin protein. We also compared the clinicopathological features of the oral SCC cases with the maspin expression level, and found that high maspin expression was associated with the absence of lymph node metastasis, More importantly,,ve showed that higher maspin expression was significantly associated with better rates of overall survival, suggesting that high maspin expression may be a favorable prognostic marker for oral SCC.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Shanghai Second Med Univ, Peoples Hosp 9, Dept Oral Pathol, Shanghai, Peoples R China; Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Shanghai Jiao Tong University; Wayne State University	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Box 108, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; BERENSON JR, 1989, ONCOGENE, V4, P1111; FIELD JK, 1989, ONCOGENE, V4, P1463; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; Sager R, 1996, CURR TOP MICROBIOL, V213, P51; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; SOMERS KD, 1992, CANCER RES, V52, P5997; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Umekita Y, 1997, CANCER LETT, V113, P87, DOI 10.1016/S0304-3835(97)04600-4; WATLING DL, 1992, HEAD NECK-J SCI SPEC, V14, P437, DOI 10.1002/hed.2880140603; Xia WY, 1997, CLIN CANCER RES, V3, P3; YAMAMOTO T, 1986, CANCER RES, V46, P414; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	17	128	138	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2398	2403		10.1038/sj.onc.1203535	http://dx.doi.org/10.1038/sj.onc.1203535			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828881				2022-12-25	WOS:000087018400004
J	Salzet, M; Chopin, V; Baert, JL; Matias, I; Malecha, J				Salzet, M; Chopin, V; Baert, JL; Matias, I; Malecha, J			Theromin, a novel leech thrombin inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; NITRIC-OXIDE RELEASE; HIRUDINARIA-MANILLENSIS; BIOCHEMICAL-CHARACTERIZATION; HAEMENTERIA-GHILIANII; ANTITHROMBOTIC DRUGS; RECOMBINANT HIRUDIN; BIOLOGICAL-ACTIVITY; ELASTASE INHIBITOR; TRYPSIN-INHIBITOR	We purified the most potent thrombin inhibitor described to date from the rhynchobdellid leech Theromyzon tessulatum. Designated theromin, it was purified to apparent homogeneity by gel permeation and anion exchange chromatography followed by two reverse-phase steps of high performance liquid chromatography. The primary sequence of theromin (a homodimer of 67 amino acid residues including 16 cysteine residues) was determined by a combination of reduction and s-beta-pyridylethylation, Edman degradation, trypsin enzymatic digestion, and matrix-assisted laser desorption mass spectrometry measurement. Theromin exhibits no sequence homology with any other thrombin inhibitors. Furthermore, theromin significantly diminishes, in a dose-dependent manner, the level of human granulocyte and monocyte activation induced by lipopolysaccharides. In summary, this potent thrombin inhibitor promises to have high biomedical significance.	Univ Sci & Tech Lille Flandres Artois, CNRS, Unite Propre Rech Super Associee 8017, Lab Endocrinol Annelides, F-59655 Villeneuve Dascq, France; Inst Biol Lille, Unite Mixte Rech 8526, F-59019 Lille, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille		michel.salzet@univ-lille1.fr	Salzet, Michel/A-7675-2011; Matias, Ignacio R. R/D-7483-2016	Salzet, Michel/0000-0003-4318-0817; Matias, Ignacio R. R/0000-0002-2229-6178				Beijering RJR, 1996, ANN HEMATOL, V72, P177, DOI 10.1007/s002770050158; BIETH JG, 1980, CLIN RES PROC, V16, P183; BLANKENSHIP DT, 1990, BIOCHEM BIOPH RES CO, V166, P1384, DOI 10.1016/0006-291X(90)91020-S; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG JY, 1990, J BIOL CHEM, V265, P22159; Chopin V, 1998, EUR J BIOCHEM, V254, P565, DOI 10.1046/j.1432-1327.1998.2540565.x; Chopin V, 1998, EUR J BIOCHEM, V258, P662, DOI 10.1046/j.1432-1327.1998.2580662.x; Chopin V, 1997, EUR J BIOCHEM, V249, P733, DOI 10.1111/j.1432-1033.1997.t01-1-00733.x; CHOPIN V, 2000, IN PRESS J BIOL CHEM, V275; DEFILIPPIS V, 1995, BIOCHEMISTRY-US, V34, P9552, DOI 10.1021/bi00029a032; ELECTRICWALA A, 1991, BLOOD COAGUL FIBRIN, V2, P83, DOI 10.1097/00001721-199102000-00013; ELECTRICWALA A, 1993, J ENZYM INHIB, V6, P293, DOI 10.3109/14756369309020179; FORTKAMP E, 1986, DNA-J MOLEC CELL BIO, V5, P511, DOI 10.1089/dna.1.1986.5.511; Fritz H., 1976, Methods Enzymol, V45, P797; GASIC GJ, 1983, CANCER RES, V43, P1633; GOLDSTEIN AM, 1986, COMP BIOCHEM PHYS B, V84, P117, DOI 10.1016/0305-0491(86)90280-4; Haycraft J. B., 1884, P ROY SOC LOND B BIO, V36, P478, DOI [10.1098/rspl.1883.0135, DOI 10.1098/RSPL.1883.0135]; HEMBERGER JU, Patent No. 01404; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; JUNG HI, 1995, J BIOL CHEM, V270, P13879, DOI 10.1074/jbc.270.23.13879; Kim DR, 1996, J ENZYM INHIB, V10, P81, DOI 10.3109/14756369609020161; KREZEL AM, 1994, SCIENCE, V264, P1944, DOI 10.1126/science.8009227; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Magazine HI, 1996, J IMMUNOL, V156, P4845; MALECHA J, 1989, CR ACAD SCI III-VIE, V309, P127; MARKWARDT F, 1967, H-S Z PHYSIOL CHEM, V348, P1381, DOI 10.1515/bchm2.1967.348.1.1381; MARKWARDT F, 1967, PHARMAZIE, V22, P239; MARKWARDT F, 1994, PHARMAZIE, V49, P313; Nieto-Fernandez FE, 1999, COMP BIOCHEM PHYS B, V123, P295, DOI 10.1016/S0305-0491(99)00074-7; PRATT CW, 1987, BIOCHEMISTRY-US, V26, P2855, DOI 10.1021/bi00384a029; Prevot V, 1998, BRAIN RES, V790, P236, DOI 10.1016/S0006-8993(98)00066-3; ROSTON D, 1996, INT J CARDIOL S, V53, P11; Salzet M, 1999, IMMUNOL TODAY, V20, P541, DOI 10.1016/S0167-5699(99)01495-4; Salzet M, 1998, MOL BRAIN RES, V55, P173, DOI 10.1016/S0169-328X(97)00156-3; SALZET M, 1999, IN PRESS PRASITOL TO; SEEMULLER U, 1977, H-S Z PHYSIOL CHEM, V358, P1105, DOI 10.1515/bchm2.1977.358.2.1105; SEYMOUR JL, 1990, J BIOL CHEM, V265, P10143; Shionoya T, 1927, J EXP MED, V46, P19, DOI 10.1084/jem.46.1.19; SOLLNER C, 1994, EUR J BIOCHEM, V219, P937, DOI 10.1111/j.1432-1033.1994.tb18575.x; Stefano GB, 1997, BRAIN RES, V753, P219, DOI 10.1016/S0006-8993(96)01484-9; Stefano GB, 1996, CRIT REV IMMUNOL, V16, P109, DOI 10.1615/CritRevImmunol.v16.i2.10; STRUBE KH, 1993, J BIOL CHEM, V268, P8590; TALBOT M, 1989, SEMIN THROMB HEMOST, V15, P293, DOI 10.1055/s-2007-1002722; TOPOL EJ, 1994, CIRCULATION, V89, P1557, DOI 10.1161/01.CIR.89.4.1557; VERSTRAETE M, 1995, DRUGS, V49, P856, DOI 10.2165/00003495-199549060-00002; WALSMANN P, 1985, THROMB RES, V40, P563, DOI 10.1016/0049-3848(85)90293-2; WALSMANN P, 1981, PHARMAZIE, V36, P653	47	47	61	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30774	30780		10.1074/jbc.M000787200	http://dx.doi.org/10.1074/jbc.M000787200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10837466	hybrid			2022-12-25	WOS:000089762700007
J	Ennion, S; Hagan, S; Evans, RJ				Ennion, S; Hagan, S; Evans, RJ			The role of positively charged amino acids in ATP recognition by human P2X(1) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-2X RECEPTOR; SENSORY NEURONS; CHANNEL; BINDING; LIGAND; DESENSITIZATION; RESIDUES; SUBUNITS; ACETYLCHOLINE; PURINOCEPTORS	P2X receptors for ATP are a family of ligand-gated cation channels. There are 11 conserved positive charges in the extracellular loop of P2X receptors. We have generated point mutants of these conserved residues (either Lys --> Arg, Lys --> Ala, Arg --> Lys, or Arg --> Ale) in the human P2X(1) receptor to determine their contribution to the binding of negatively charged ATP, ATP evoked concentration-dependent (EC50 similar to 0.8 mu M) desensitizing responses at wild-type (WT) P2X(1) receptors expressed in Xenopus oocytes, Suramin produced a parallel rightward shift in the concentration response curve with an estimated pK(B) of 6.7. Substitution of amino acids at positions Lys-53, Lys-190, Lys-215, Lys-325, Arg-202, Arg-305, and Arg-314 either had no effect or only a small change in ATP potency, time course, and/or suramin sensitivity. Modest changes in ATP potency were observed for mutants at K70R and R292K/A (20- and 100-fold decrease, respectively). Mutations at residues K68A and K309A reduced the potency of ATP by >1400-fold and prolonged the time course of the P2X(1) receptor current but had no effect on suramin antagonism. Lys-68, Lys-70, Arg-292, and Lys-309 are close to the predicted transmembrane domains of the receptor and suggest that the ATP binding pocket may form close to the channel vestibule.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Evans, RJ (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, POB 138, Leicester LE1 9HN, Leics, England.							Boue-Grabot E, 2000, J BIOL CHEM, V275, P10190, DOI 10.1074/jbc.275.14.10190; Brandle U, 1997, FEBS LETT, V404, P294, DOI 10.1016/S0014-5793(97)00128-2; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; Burnstock G, 1997, NEUROPHARMACOLOGY, V36, P1127, DOI 10.1016/S0028-3908(97)00125-1; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; ERB L, 1995, J BIOL CHEM, V270, P4185, DOI 10.1074/jbc.270.9.4185; EVANS RJ, 1994, BRIT J PHARMACOL, V113, P853, DOI 10.1111/j.1476-5381.1994.tb17071.x; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; GALZI JL, 1991, P NATL ACAD SCI USA, V88, P5051, DOI 10.1073/pnas.88.11.5051; GarciaGuzman M, 1997, MOL PHARMACOL, V51, P109, DOI 10.1124/mol.51.1.109; Jiang QL, 1997, MOL PHARMACOL, V52, P499, DOI 10.1124/mol.52.3.499; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; Koshimizu T, 1998, J BIOL CHEM, V273, P12853, DOI 10.1074/jbc.273.21.12853; LEFF P, 1990, BRIT J PHARMACOL, V101, P645, DOI 10.1111/j.1476-5381.1990.tb14134.x; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; Muller M, 1996, J BIOL CHEM, V271, P1877; Mulryan K, 2000, NATURE, V403, P86, DOI 10.1038/47495; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Ralevic V, 1998, PHARMACOL REV, V50, P413; Ramjeesingh M, 1999, BIOCHEMISTRY-US, V38, P1463, DOI 10.1021/bi982243y; Rassendren F, 1997, EMBO J, V16, P3446, DOI 10.1093/emboj/16.12.3446; Reimann F, 1999, J PHYSIOL-LONDON, V520, P661, DOI 10.1111/j.1469-7793.1999.00661.x; Simon J, 1997, MOL PHARMACOL, V52, P237, DOI 10.1124/mol.52.2.237; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; Valera S, 1995, RECEPTOR CHANNEL, V3, P283; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; Yamamoto H, 1999, MOL CELL BIOCHEM, V190, P169, DOI 10.1023/A:1006947216144	34	151	152	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29361	29367		10.1074/jbc.M003637200	http://dx.doi.org/10.1074/jbc.M003637200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10827197				2022-12-25	WOS:000089439800026
J	Vorachek, WR; Steppan, CM; Lima, M; Black, H; Bhattacharya, R; Wen, P; Kajiyama, Y; Locker, J				Vorachek, WR; Steppan, CM; Lima, M; Black, H; Bhattacharya, R; Wen, P; Kajiyama, Y; Locker, J			Distant enhancers stimulate the albumin promoter through complex proximal binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FETOPROTEIN GENE; GROUP PROTEIN HMG-I(Y); CBF-DNA COMPLEX; NF-KAPPA-B; TRANSCRIPTION FACTOR; IN-VIVO; ALPHA-1-FETOPROTEIN GENE; FUNCTIONAL-ANALYSIS; HMG I(Y); RAT	The albumin-alpha-fetoprotein locus epitomizes the main features of transcriptional regulation of fetal and adult hepatocyte-specific genes: developmentally regulated promoters and strong distant enhancers. Full enhancer activity required only a proximal albumin-promoter region containing the TATA box, hepatic nuclear factor 1 (HNF1), and nuclear factor Y (NF-Y) sites. Deletion of the HNF1 site abrogated enhancer and promoter activity, whereas methylation of the site reduced all activity by about 3-fold. Deletion of the NF-Y site attenuated activity by about half, but much of the activity could be replaced by juxtaposition of an upstream region (designated distal element TV). Gel shift and competition analysis demonstrated that binding of architectural factors overlapped NF-Y binding. Moreover, a mutation that eliminated NF-Y binding but only minimally perturbed the surrounding region did not affect enhancer function. In plasmids with a second promoter, the enhancers simultaneously stimulated both albumin and Lu-fetoprotein promoters with minimal competition, but surprisingly some mutations in the albumin promoter attenuated expression from both promoters, whereas another uncoupled their expression. With single promoters, the function of the proximal promoter region was controlled by three parameters in the following hierarchy: HNF1 binding > local architecture > NF-Y binding, but integrated two-promoter function had a much greater dependence on NF-Y.	Albert Einstein Coll Med, Sch Med, Dept Pathol, Bronx, NY 10461 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	Yeshiva University; Albert Einstein College of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Locker, J (corresponding author), Albert Einstein Coll Med, Sch Med, Dept Pathol, Bronx, NY 10461 USA.				NCI NIH HHS [CA68440, CA76354] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068440, R01CA076354] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER F, 1984, J MOL BIOL, V173, P159, DOI 10.1016/0022-2836(84)90187-6; Apergis GA, 1998, J BIOL CHEM, V273, P2917, DOI 10.1074/jbc.273.5.2917; BABISS LE, 1987, GENE DEV, V1, P256, DOI 10.1101/gad.1.3.256; BELAYEW A, 1982, MOL CELL BIOL, V2, P1427, DOI 10.1128/MCB.2.11.1427; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; CHEVRETTE M, 1987, NUCLEIC ACIDS RES, V15, P1338, DOI 10.1093/nar/15.3.1338; Coustry F, 1998, BIOCHEM J, V331, P291, DOI 10.1042/bj3310291; Currie RA, 1997, J BIOL CHEM, V272, P30880, DOI 10.1074/jbc.272.49.30880; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; Gribnau J, 1998, EMBO J, V17, P6020, DOI 10.1093/emboj/17.20.6020; GROUPP ER, 1994, J BIOL CHEM, V269, P22178; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; GUERTIN M, 1988, MOL CELL BIOL, V8, P1398, DOI 10.1128/MCB.8.4.1398; HATAMOCHI A, 1986, J BIOL CHEM, V261, P1310; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HERBOMEL P, 1989, MOL CELL BIOL, V9, P4750, DOI 10.1128/MCB.9.11.4750; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; HERBST RS, 1990, MOL CELL BIOL, V10, P3896, DOI 10.1128/MCB.10.8.3896; HU IM, 1992, CELL GROWTH DIFFER, V3, P577; INGRAM RS, 1981, P NATL ACAD SCI-BIOL, V78, P4694, DOI 10.1073/pnas.78.8.4694; IZBAN MG, 1989, J BIOL CHEM, V264, P9171; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; JIN JR, 1995, DNA CELL BIOL, V14, P267, DOI 10.1089/dna.1995.14.267; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LEVAN G, 1991, GENOMICS, V10, P699, DOI 10.1016/0888-7543(91)90455-N; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; Liberati C, 1998, FEBS LETT, V433, P174, DOI 10.1016/S0014-5793(98)00905-3; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LOCKER J, 1996, TRANSCRIPTION FACTOR, P12; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; Maity SN, 1996, METHOD ENZYMOL, V273, P217; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; McPherson CE, 1996, NUCLEIC ACIDS RES, V24, P397, DOI 10.1093/nar/24.3.397; MILLONIG JH, 1995, MOL CELL BIOL, V15, P3848; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; MUGLIA L, 1984, NUCLEIC ACIDS RES, V12, P6751, DOI 10.1093/nar/12.17.6751; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; PEAVY DE, 1981, BIOCHEM J, V198, P289, DOI 10.1042/bj1980289; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; POWER SC, 1994, BIOCHEM BIOPH RES CO, V203, P1447, DOI 10.1006/bbrc.1994.2347; Rachubinski RA, 1999, J BIOL CHEM, V274, P18278, DOI 10.1074/jbc.274.26.18278; SARGENT TD, 1981, MOL CELL BIOL, V1, P871, DOI 10.1128/MCB.1.10.871; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Song YH, 1998, J BIOL CHEM, V273, P28408, DOI 10.1074/jbc.273.43.28408; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Trimborn T, 1999, GENE DEV, V13, P112, DOI 10.1101/gad.13.1.112; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; TRONCHE F, 1989, MOL CELL BIOL, V9, P4759, DOI 10.1128/MCB.9.11.4759; TRONCHE F, 1990, MOL BIOL MED, V7, P173; URANO Y, 1986, J BIOL CHEM, V261, P3244; URANO Y, 1984, GENE, V32, P255; VACHER J, 1992, MOL CELL BIOL, V12, P856, DOI 10.1128/MCB.12.2.856; WEN P, 1993, NUCLEIC ACIDS RES, V21, P1911, DOI 10.1093/nar/21.8.1911; WEN P, 1994, MOL CELL BIOL, V14, P6616, DOI 10.1128/MCB.14.10.6616; WEN P, 1991, DNA CELL BIOL, V10, P525, DOI 10.1089/dna.1991.10.525; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WU KJ, 1994, J BIOL CHEM, V269, P1177; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649; ZHANG DE, 1991, J BIOL CHEM, V266, P21179	67	23	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					29031	29041		10.1074/jbc.M003039200	http://dx.doi.org/10.1074/jbc.M003039200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10842175	hybrid			2022-12-25	WOS:000089330700090
J	Vihinen, H; Saarinen, J				Vihinen, H; Saarinen, J			Phosphorylation site analysis of Semliki Forest virus nonstructural protein 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN-KINASE-II; STRAND RNA-SYNTHESIS; SINDBIS VIRUS; MASS-SPECTROMETRY; MINUS-STRAND; REPLICATION COMPLEXES; GENE-EXPRESSION; P PROTEIN; C-ZETA; CELLS	Nonstructural protein 3 (Nsp3) is an essential subunit of the alphavirus RNA replication complex, although its specific function(s) has yet to be well defined. Previously, it has been shown that Semliki Forest virus Nsp3 (482 amino acids) is a phosphoprotein, and, in the present study, we have mapped its major phosphorylation sites. Mass spectrometric methods utilized included precursor ion scanning, matrix-assisted laser desorption/ionization mass spectrometry used in conjunction with on-target alkaline phosphatase digestions, and tandem mass spectrometry, Two-dimensional peptide mapping was applied to separate tryptic P-32-labeled phosphopeptides of Nsp3, Radiolabeled peptides were then subjected to Edman sequencing, and phosphoamino acid analysis. In addition, radiolabeled Nsp3 was cleaved successively with cyanogen bromide and trypsin, and microscale iron-chelate affinity chromatography was used to enrich phosphopeptides. By combining these methods, we showed that Nsp3 is phosphorylated on serine residues 320, 327, 332, 335, 356, 359, 362, and 367, and is heavily phosphorylated on peptide Gly(338)-Lys(415), which carries 7-12 phosphates distributed over its 13 potential phosphorylation sites. These analytical findings were corroborated by constructing a Nsp3 derivative devoid of phosphorylation, The results represent the first determination of phosphorylation sites of an alphavirus nonstructural protein, but the approach can be utilized in phosphoprotein analysis in general.	Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Program Cellular Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Prot Chem Lab, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Vihinen, H (corresponding author), Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Program Cellular Biotechnol, POB 56,Viikinkaari 9, FIN-00014 Helsinki, Finland.	helena.vihinen@helsinki.fi						AHOLA T, 1995, P NATL ACAD SCI USA, V92, P507, DOI 10.1073/pnas.92.2.507; Annan RS, 1997, J PROTEIN CHEM, V16, P391, DOI 10.1023/A:1026384605285; BARIK S, 1992, P NATL ACAD SCI USA, V89, P6570, DOI 10.1073/pnas.89.14.6570; BARTON DJ, 1988, J VIROL, V62, P3597, DOI 10.1128/JVI.62.10.3597-3602.1988; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; CHATTOPADHYAY D, 1987, CELL, V49, P407, DOI 10.1016/0092-8674(87)90293-5; DAS T, 1995, VIROLOGY, V211, P218, DOI 10.1006/viro.1995.1394; de Cedron MG, 1999, FEBS LETT, V448, P19, DOI 10.1016/S0014-5793(99)00321-X; Gupta AK, 2000, J VIROL, V74, P91, DOI 10.1128/JVI.74.1.91-98.2000; HARDY WR, 1989, J VIROL, V63, P4653, DOI 10.1128/JVI.63.11.4653-4664.1989; Huntley CC, 1997, J BIOL CHEM, V272, P16578, DOI 10.1074/jbc.272.26.16578; KAARIAINEN L, 1987, J CELL SCI, P231; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOONIN EV, 1993, CRIT REV BIOCHEM MOL, V28, P375, DOI 10.3109/10409239309078440; LAAKKONEN P, 1994, J VIROL, V68, P7418, DOI 10.1128/JVI.68.11.7418-7425.1994; LASTARZA MW, 1994, J VIROL, V68, P5781, DOI 10.1128/JVI.68.9.5781-5791.1994; LASTARZA MW, 1994, VIROLOGY, V202, P224, DOI 10.1006/viro.1994.1338; LEADER DP, 1988, J GEN VIROL, V69, P1441, DOI 10.1099/0022-1317-69-7-1441; LEMM JA, 1994, EMBO J, V13, P2925, DOI 10.1002/j.1460-2075.1994.tb06587.x; LI GP, 1990, VIROLOGY, V179, P416, DOI 10.1016/0042-6822(90)90310-N; Liu Z, 1997, VIROLOGY, V232, P198, DOI 10.1006/viro.1997.8548; Neubauer G, 1999, ANAL CHEM, V71, P235, DOI 10.1021/ac9804902; Nyman TA, 1998, EUR J BIOCHEM, V253, P485, DOI 10.1046/j.1432-1327.1998.2530485.x; Pehrson JR, 1998, NUCLEIC ACIDS RES, V26, P2837, DOI 10.1093/nar/26.12.2837; PERANEN J, 1988, J GEN VIROL, V69, P2165, DOI 10.1099/0022-1317-69-9-2165; PERANEN J, 1991, J GEN VIROL, V72, P195, DOI 10.1099/0022-1317-72-1-195; SHIRAKO Y, 1994, J VIROL, V68, P1874, DOI 10.1128/JVI.68.3.1874-1885.1994; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Vasiljeva L, 2000, J BIOL CHEM, V275, P17281, DOI 10.1074/jbc.M910340199; WANG YF, 1994, J VIROL, V68, P6466, DOI 10.1128/JVI.68.10.6466-6475.1994; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; WYATT LS, 1995, VIROLOGY, V210, P202, DOI 10.1006/viro.1995.1332; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m	34	54	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27775	27783						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10851234				2022-12-25	WOS:000089197100036
J	Dedier, S; Reinelt, S; Reitinger, T; Folkers, G; Rognan, D				Dedier, S; Reinelt, S; Reitinger, T; Folkers, G; Rognan, D			Thermodynamic stability of HLA-B*2705 center dot peptide complexes - Effect of peptide and major histocompatibility complex protein mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; HUMAN-LEUKOCYTE ANTIGEN; HLA CLASS-I; MHC MOLECULES; NONNATURAL PEPTIDES; BINDING-AFFINITY; ANCHOR POSITIONS; VIRAL PEPTIDES; HLA-B27; SPECIFICITY	Designing synthetic vaccines from class I major histocompatibility complex (MHC)-binding antigenic peptides requires not only knowledge of the binding affinity of the designed peptide but also predicting the stability of the formed MHC-peptide complex. In order to better investigate structure-stability relationships, we have determined by circular dichroism spectroscopy the thermal stability of a class I MHC protein, HLA-B*2705, in complex with a set of 39 singly substituted peptide analogues. The influence of two anchoring side chains (P3 and P9) was studied by peptide mutation and appropriate site directed mutagenesis of the HLA-B*2705 binding groove. The side chain at P9 is clearly the one that contributes the most to the thermal stability of the MHC-peptide complexes, as destabilization up to 25 degrees C are obtained after P9 mutation. Interestingly, structure-stability relationships do not fully mirror structure-binding relationships. ks important as the C-terminal side chain are the terminal ammonium and carboxylate groups. Removal of a single II-bond between HLA-B27 and the terminal peptide moieties results in thermal destabilization up to 10 degrees C. Depending on the bound peptide and the location of the deleted II-bond, the decrease in the thermal stability of the corresponding complex is quantitatively different. The present study suggests that any peptidic amino acid at positions 3 and 9 promotes refolding of the B27-peptide complex. Once the complex is formed, the C-terminal side chain seems to play an important role for maintaining a stable complex.	Swiss Fed Inst Technol, Dept Appl Biosci, CH-8057 Zurich, Switzerland	ETH Zurich	Rognan, D (corresponding author), Swiss Fed Inst Technol, Dept Appl Biosci, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Rognan, Didier/B-9939-2014	Folkers, Gerd/0000-0002-3620-705X				Allen RL, 1999, J IMMUNOL, V162, P5045; Batalia MA, 1997, BIOPOLYMERS, V43, P281, DOI 10.1002/(SICI)1097-0282(1997)43:4<281::AID-BIP3>3.0.CO;2-R; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; Bouvier M, 1996, P NATL ACAD SCI USA, V93, P4583, DOI 10.1073/pnas.93.10.4583; Brooks JM, 1998, J IMMUNOL, V161, P5252; Collins EJ, 1999, J IMMUNOL, V162, P331; de Castro JAL, 1998, CURR OPIN IMMUNOL, V10, P59, DOI 10.1016/S0952-7915(98)80033-2; ELVIN J, 1993, J IMMUNOL METHODS, V158, P161, DOI 10.1016/0022-1759(93)90210-X; FAHNESTOCK ML, 1994, BIOCHEMISTRY-US, V33, P8149, DOI 10.1021/bi00192a020; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; FRUCI D, 1994, HUM IMMUNOL, V41, P34, DOI 10.1016/0198-8859(94)90081-7; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P643; ISLAM SA, 1998, PREPI VERSION 0 95; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; Krebs S, 1998, J BIOL CHEM, V273, P19072, DOI 10.1074/jbc.273.30.19072; Krebs S, 1998, J PEPT SCI, V4, P378, DOI 10.1002/(SICI)1099-1387(199809)4:6<378::AID-PSC157>3.0.CO;2-B; Kuhns JJ, 1999, J BIOL CHEM, V274, P36422, DOI 10.1074/jbc.274.51.36422; Lamas JR, 1998, INT IMMUNOL, V10, P259, DOI 10.1093/intimm/10.3.259; Lamas JR, 1999, ARTHRITIS RHEUM-US, V42, P1975, DOI 10.1002/1529-0131(199909)42:9<1975::AID-ANR25>3.0.CO;2-V; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Morgan CS, 1997, PROTEIN SCI, V6, P1771, DOI 10.1002/pro.5560060819; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ottenhoff THM, 1997, J IMMUNOL METHODS, V200, P89, DOI 10.1016/S0022-1759(96)00190-1; PACE NC, 1997, PROTEIN STRUCTURE PR, P299; PARKER KC, 1994, BIOCHEMISTRY-US, V33, P7736, DOI 10.1021/bi00190a029; Poenaru S, 1999, J MED CHEM, V42, P2318, DOI 10.1021/jm981123l; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; ROGNAN D, 1995, P NATL ACAD SCI USA, V92, P753, DOI 10.1073/pnas.92.3.753; Rovero P, 1995, J Pept Sci, V1, P266, DOI 10.1002/psc.310010407; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SAPER MA, 1991, J MOL BIOL, V75, P693; SETTE A, 1994, MOL IMMUNOL, V31, P813, DOI 10.1016/0161-5890(94)90019-1; SETTE A, 1994, J IMMUNOL, V153, P5586; TANIGAKI N, 1993, HUM IMMUNOL, V36, P119, DOI 10.1016/0198-8859(93)90114-G; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; vanderBurg SH, 1996, J IMMUNOL, V156, P3308; VILLADANGOS JA, 1995, EUR J IMMUNOL, V25, P2370, DOI 10.1002/eji.1830250837; Weiss GA, 1996, P NATL ACAD SCI USA, V93, P10945, DOI 10.1073/pnas.93.20.10945; WEISS GA, 1995, CHEM BIOL, V2, P401, DOI 10.1016/1074-5521(95)90221-X; YOUNG C, 1999, POV RAY VERSION 3 1	46	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27055	27061						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10823832				2022-12-25	WOS:000089144800053
J	Inatome, R; Tsujimura, T; Hitomi, T; Mitsui, N; Hermann, P; Kuroda, S; Yamamura, H; Yanagi, S				Inatome, R; Tsujimura, T; Hitomi, T; Mitsui, N; Hermann, P; Kuroda, S; Yamamura, H; Yanagi, S			Identification of CRAM, a novel unc-33 gene family protein that associates with CRIMP3 and protein-tyrosine kinase(s) in the developing rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH CONE COLLAPSE; AXON GUIDANCE; SEMAPHORIN RECEPTOR; NEUROPILIN; CELLS; OUTGROWTH; NEURONS; P72(SYK); ULIP	Four members of collapsin response mediator proteins (CRMPs) are thought to be involved in the semaphorin-induced growth cone collapse during neural development. Here we report the identification of a novel CRMPS associated protein, designated CRAM for CRMP3-associated molecule, that belongs to the unc-33 gene family. The deduced amino acid sequence reveals that the CRAM gene encodes a protein of 563 amino acids, shows 57% identity with dihydropyrimidinase, and shows 50-51% identity with CRMPs. CRAM appears to form a large complex composed of CRMPS and other unidentified proteins in vivo. Indeed, CRAM physically associates with CRMPS when co-expressed in COS-7 cells. The expression of CRAM is brain-specific, is high in fetal and neonatal rat brain, and decreases to very low levels in adult brain. Moreover, CRAM expression is up-regulated during neuronal differentiation of embryonal carcinoma P19 and PC12 cells. Finally, immunoprecipitation analysis of rat brain extracts shows that CRAM is co-immunoprecipitated with proteins that contain protein-tyrosine kinase activity, Taken together, our results suggest that CRAM, which interacts with CRMP3 and protein-tyrosine kinase(s), is a new member of an emerging family of molecules that potentially mediate signals involved in the guidance and outgrowth of axons.	Kobe Univ, Sch Med, Dept Biochem, Chuo Ku, Kobe, Hyogo 6500017, Japan; Osaka Univ, Inst Sci & Ind Res, Dept Struct Mol Biol, Ibaraki, Osaka 5670047, Japan	Kobe University; Osaka University	Yanagi, S (corresponding author), Kobe Univ, Sch Med, Dept Biochem, Chuo Ku, Kobe, Hyogo 6500017, Japan.			Yanagi, Shigeru/0000-0002-1392-8663				Byk T, 1998, EUR J BIOCHEM, V254, P14, DOI 10.1046/j.1432-1327.1998.2540014.x; Byk T, 1996, J NEUROSCI, V16, P688; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; Fujisawa H, 1998, CURR OPIN NEUROBIOL, V8, P587, DOI 10.1016/S0959-4388(98)80085-8; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; Holder N, 1999, DEVELOPMENT, V126, P2033; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kolodkin AL, 1998, PROG BRAIN RES, V117, P115; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MINTURN JE, 1995, J NEUROSCI, V15, P6757; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Quinn CC, 1999, J NEUROBIOL, V41, P158, DOI 10.1002/(SICI)1097-4695(199910)41:1<158::AID-NEU19>3.0.CO;2-0; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; STAINES WA, 1994, NEUROSCIENCE, V58, P735, DOI 10.1016/0306-4522(94)90451-0; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wang LH, 1996, J NEUROSCI, V16, P6197; Wang LH, 1997, J NEUROCHEM, V69, P2261; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; YANAGI S, 1994, EUR J BIOCHEM, V224, P329, DOI 10.1111/j.1432-1033.1994.00329.x; YANAGI S, 1995, CELL SIGNAL, V7, P185, DOI 10.1016/0898-6568(94)00088-S; Yanagi S, 1996, J BIOL CHEM, V271, P30487, DOI 10.1074/jbc.271.48.30487; YI F, 1991, J BIOL CHEM, V266, P3900; Yoneya H, 1998, BIOCHEM BIOPH RES CO, V245, P140, DOI 10.1006/bbrc.1998.8309	34	84	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27291	27302						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10851247				2022-12-25	WOS:000089144800083
J	Caterina, JJ; Yamada, S; Caterina, NCM; Longenecker, G; Holmback, K; Shi, J; Yermovsky, AE; Engler, JA; Birkedal-Hansen, H				Caterina, JJ; Yamada, S; Caterina, NCM; Longenecker, G; Holmback, K; Shi, J; Yermovsky, AE; Engler, JA; Birkedal-Hansen, H			Inactivating mutation of the mouse tissue inhibitor of metalloproteinases-2(Timp-2) gene alters proMMP-2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASES; GELATINASE-A; 72-KDA GELATINASE; PROGELATINASE-A; TERMINAL DOMAIN; IV COLLAGENASE; TIMP-2; COMPLEX; FIBROBLASTS; EXPRESSION	To understand the biologic function of TIMP-2, a member of the tissue inhibitors of metalloproteinases family, an inactivating mutation was introduced in the mouse Timp-2 gene by homologous recombination, Outbred homozygous mutants developed and procreated indistinguishably from wild type littermates, suggesting that fertility, development, and growth are not critically dependent on TIMP-2, Lack of functional TIMP-2, however, dramatically altered the activation of proMMP-2 both in vivo and in vitro. Fully functional TIMP-2 is essential for efficient activation of proMMP-2 in vivo, No evidence of successful functional compensation was observed. The results illustrate the duality of TIMP-2 function, i.e. at low concentrations, TIMP-2 exerts a "catalytic" or enhancing effect on cell-mediated proMMP-2 activation, whereas at higher concentrations, TIMP-2 inhibits the activation and/or activity of MMP-2.	NIDCR, Matrix Metalloprot Unit, NIH, Bethesda, MD 20892 USA; NIDCR, Gene Targeting Res & Core Facil, NIH, Bethesda, MD 20892 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Alabama System; University of Alabama Birmingham	Caterina, JJ (corresponding author), 30 Convent Dr,MSC 4380, Bethesda, MD 20892 USA.				NCI NIH HHS [CA13148] Funding Source: Medline; NIDCR NIH HHS [DE10631, DE08228] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000676, R01DE010631, P50DE008228] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Blavier L, 1997, MOL BIOL CELL, V8, P1513, DOI 10.1091/mbc.8.8.1513; BODDEN MK, 1994, J BIOL CHEM, V269, P18943; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Caterina NCM, 1997, J BIOL CHEM, V272, P32141, DOI 10.1074/jbc.272.51.32141; Edwards DR, 1996, INT J OBES RELAT MET, V20, P9; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; *GEN COMP GROUP IN, 1999, WISC PACK VERS 9 0; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Havemose-Poulsen A, 1998, J PERIODONTAL RES, V33, P280, DOI 10.1111/j.1600-0765.1998.tb02201.x; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Huang W, 1997, J BIOL CHEM, V272, P22086, DOI 10.1074/jbc.272.35.22086; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Nagase H, 1997, BIOCHEM J, V325, P163, DOI 10.1042/bj3250163; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Oliver GW, 1997, ANAL BIOCHEM, V244, P161, DOI 10.1006/abio.1996.9895; Overall CM, 1999, ANN NY ACAD SCI, V878, P747, DOI 10.1111/j.1749-6632.1999.tb07780.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Sambrook J, 1989, MOL CLOINING LAB MAN; SHIMIZU S, 1992, GENE, V114, P291, DOI 10.1016/0378-1119(92)90591-C; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023	30	114	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26416	26422		10.1074/jbc.M001271200	http://dx.doi.org/10.1074/jbc.M001271200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10827176	hybrid			2022-12-25	WOS:000088999700074
J	Crompton, AM; Foley, LH; Wood, A; Roscoe, W; Stokoe, D; McCormick, F; Symons, M; Bollag, G				Crompton, AM; Foley, LH; Wood, A; Roscoe, W; Stokoe, D; McCormick, F; Symons, M; Bollag, G			Regulation of Tiam1 nucleotide exchange activity by pleckstrin domain binding ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GLUTATHIONE-S-TRANSFERASE; DBL ONCOGENE PRODUCT; L-ASCORBIC-ACID; HOMOLOGY DOMAINS; RAS TRANSFORMATION; RECOMBINANT RAS; RHO; INVASION; KINASE	Rho family GTPases play roles in cytoskeletal organization and cellular transformation. Tiam1 is a member of the Dbl family of guanine nucleotide exchange factors that activate Rho family GTPases. These exchange factors have in common a catalytic Dbl homology and adjacent pleckstrin homology domain. Previous structural studies suggest that the pleckstrin domain, a putative phosphoinositide-binding site, may serve a regulatory function. We identified ascorbyl stearate as a compound that binds to the pleckstrin domain of p120 Ras GTPase-activating protein. Furthermore, ascorbyl stearate appears to be a general pleckstrin domain ligand, perhaps by mimicking an endogenous amphiphilic ligand. Tiam1 nucleotide exchange activity was greatly stimulated by ascorbyl stearate. Certain phosphoinositides also stimulated Tiam1 activity but were less potent than ascorbyl stearate. Tiam1 contains an additional N-terminal pleckstrin domain, but only the C-terminal pleckstrin domain was required for activation. Our results suggest that the pleckstrin domains of Dbl-type proteins may not only be involved in subcellular localization but may also directly regulate the nucleotide exchange activity of an associated Dbl homology domain. In addition, this paper introduces ascorbyl stearate as a pleckstrin domain ligand that can modulate the activity of certain pleckstrin domain-containing proteins.	Onyx Pharmaceut, Richmond, CA 94806 USA; Hoffmann La Roche Inc, Dept Oncol, Nutley, NJ 07110 USA	Roche Holding	Bollag, G (corresponding author), Onyx Pharmaceut, 3031 Res Dr, Richmond, CA 94806 USA.							ANDO S, 1992, J BIOL CHEM, V267, P25709; ANDREWS GC, 1984, CARBOHYD RES, V134, P321, DOI 10.1016/0008-6215(84)85048-X; Aravind L, 1999, CURR BIOL, V9, pR195, DOI 10.1016/S0960-9822(99)80127-4; BOCK K, 1979, CARBOHYD RES, V68, P313, DOI 10.1016/S0008-6215(00)83780-5; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1995, METHOD ENZYMOL, V255, P21; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOLLAG G, 1995, METHOD ENZYMOL, V255, P161; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DePaolo D, 1996, MOL CELL BIOL, V16, P1450; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fukuda M, 1996, J BIOL CHEM, V271, P18838, DOI 10.1074/jbc.271.31.18838; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HABETS GGM, 1995, ONCOGENE, V10, P1371; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORI Y, 1991, ONCOGENE, V6, P515; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Ma AD, 1997, J CELL BIOL, V136, P1071, DOI 10.1083/jcb.136.5.1071; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NAIDU AK, 1993, ANTICANCER RES, V13, P1469; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; OHMORI M, 1983, AGR BIOL CHEM TOKYO, V47, P607, DOI 10.1080/00021369.1983.10865689; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PORFIRI E, 1995, METHOD ENZYMOL, V255, P13; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SCHAFER WR, 1992, ANNU REV GENET, V30, P209; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Sprang SR, 1998, CELL, V95, P155, DOI 10.1016/S0092-8674(00)81746-8; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	61	45	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25751	25759		10.1074/jbc.M002050200	http://dx.doi.org/10.1074/jbc.M002050200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10835422	hybrid			2022-12-25	WOS:000088849400091
J	Escolar, L; Perez-Martin, J; de Lorenzo, V				Escolar, L; Perez-Martin, J; de Lorenzo, V			Evidence of an unusually long operator for the fur repressor in the aerobactin promoter of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UPTAKE REGULATION PROTEIN; FERRIC UPTAKE REGULATOR; SALMONELLA-TYPHIMURIUM; VIRULENCE GENES; IRON REGULATION; BINDING; DNA; TRANSCRIPTION; EXPRESSION; SELECTION	Production of the siderophore aerobactin in Escherichia coli is transcriptionally metalloregulated through the iron-dependent binding of the Fur (ferric uptake regulator) to a large region (>100 base pairs) within the cognate promoter in the pColV-K30 plasmid. We show in this article that such an unusually long operator results from the specific addition of degenerate repeats 5'-NAT(APT)AT-3' and not from a fortuitous occupation of the DNA adjacent to the primary binding sites by an excess of the repressor. Furthermore, the protection pattern revealed by DNase I and hydroxyl radical footprinting reflected a side-by-side oligomerization of the protein along an extended DNA stretch. This type of DNA-protein interactions is more like those observed in some eukaryotic factors and nucleoid-associated proteins than typical of specific prokaryotic regulators.	CSIC, Ctr Nacl Biotecnol, Dept Microbial Biotechnol, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	de Lorenzo, V (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Microbial Biotechnol, Campus Cantoblanco, Madrid 28049, Spain.		Perez-Martin, Jose/K-5117-2014	Perez-Martin, Jose/0000-0001-9849-7382; de Lorenzo, Victor/0000-0002-6041-2731				Althaus EW, 1999, BIOCHEMISTRY-US, V38, P6559, DOI 10.1021/bi982788s; Azam TA, 1999, J BIOL CHEM, V274, P33105, DOI 10.1074/jbc.274.46.33105; BAGG A, 1985, J BACTERIOL, V161, P450, DOI 10.1128/JB.161.1.450-453.1985; BAGG A, 1987, MICROBIOL REV, V51, P509, DOI 10.1128/MMBR.51.4.509-518.1987; BINDEREIF A, 1985, J BACTERIOL, V162, P109; BRICKMAN TJ, 1990, J MOL BIOL, V212, P669, DOI 10.1016/0022-2836(90)90229-F; CALDERWOOD SB, 1988, J BACTERIOL, V170, P1015, DOI 10.1128/jb.170.2.1015-1017.1988; Chai SH, 1998, J BIOL CHEM, V273, P33841, DOI 10.1074/jbc.273.50.33841; DELORENZO V, 1987, J BACTERIOL, V169, P2624, DOI 10.1128/jb.169.6.2624-2630.1987; DELORENZO V, 1988, J MOL BIOL, V203, P875, DOI 10.1016/0022-2836(88)90113-1; Desai PJ, 1996, J BACTERIOL, V178, P5020, DOI 10.1128/jb.178.16.5020-5023.1996; Earhart C.F., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1075; Escolar L, 1998, J MOL BIOL, V283, P537, DOI 10.1006/jmbi.1998.2119; Escolar L, 1997, MOL MICROBIOL, V26, P799, DOI 10.1046/j.1365-2958.1997.6211987.x; Escolar L, 1999, J BACTERIOL, V181, P6223, DOI 10.1128/JB.181.20.6223-6229.1999; FRECHON D, 1994, BIOCHEM BIOPH RES CO, V201, P346, DOI 10.1006/bbrc.1994.1708; GRIGGS DW, 1989, J BACTERIOL, V171, P1048, DOI 10.1128/jb.171.2.1048-1054.1989; Hall HK, 1996, J BACTERIOL, V178, P5683, DOI 10.1128/jb.178.19.5683-5691.1996; HANTKE K, 1984, MOL GEN GENET, V197, P337, DOI 10.1007/BF00330982; HANTKE K, 1987, MOL GEN GENET, V210, P135, DOI 10.1007/BF00337769; HUNT MD, 1994, J BACTERIOL, V176, P3944, DOI 10.1128/JB.176.13.3944-3955.1994; KARJALAINEN TK, 1991, MICROB PATHOGENESIS, V11, P317, DOI 10.1016/0882-4010(91)90017-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LECAM E, 1994, P NATL ACAD SCI USA, V91, P11816, DOI 10.1073/pnas.91.25.11816; LITWIN CM, 1993, CLIN MICROBIOL REV, V6, P137, DOI 10.1128/CMR.6.2.137-149.1993; MAKEMSON JC, 1982, CURR MICROBIOL, V7, P181, DOI 10.1007/BF01568972; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCARTER L, 1989, J BACTERIOL, V171, P731, DOI 10.1128/jb.171.2.731-736.1989; Ochsner UA, 1996, P NATL ACAD SCI USA, V93, P4409, DOI 10.1073/pnas.93.9.4409; Pizzi S, 1999, J BIOL CHEM, V274, P2539, DOI 10.1074/jbc.274.4.2539; Ptashne M., 1992, A GENETIC SWITCH; SAITO T, 1991, EUR J BIOCHEM, V197, P29, DOI 10.1111/j.1432-1033.1991.tb15878.x; Sambrook J., 2002, MOL CLONING LAB MANU; STOJILJKOVIC I, 1994, J MOL BIOL, V236, P531, DOI 10.1006/jmbi.1994.1163; TARDAT B, 1993, MOL MICROBIOL, V9, P53, DOI 10.1111/j.1365-2958.1993.tb01668.x; TSOLIS RM, 1995, J BACTERIOL, V177, P4628, DOI 10.1128/jb.177.16.4628-4637.1995; Watnick PI, 1997, J BACTERIOL, V179, P243, DOI 10.1128/jb.179.1.243-247.1997; Watnick PI, 1998, GENE, V209, P65, DOI 10.1016/S0378-1119(98)00018-3; Wee S, 1988, Biol Met, V1, P62, DOI 10.1007/BF01128019; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291; Zheng M, 1999, J BACTERIOL, V181, P4639, DOI 10.1128/JB.181.15.4639-4643.1999	41	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24709	24714		10.1074/jbc.M002839200	http://dx.doi.org/10.1074/jbc.M002839200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10833520	hybrid			2022-12-25	WOS:000088683300065
J	Sendra, R; Tse, C; Hansen, JC				Sendra, R; Tse, C; Hansen, JC			The yeast histone acetyltransferase A2 complex, but not free Gcn5p, binds stably to nucleosomal arrays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADA-COMPLEX; IN-VIVO; SACCHAROMYCES-CEREVISIAE; NATIVE COMPLEXES; GENE ACTIVATION; N-TERMINI; ACETYLATION; TRANSCRIPTION; PROTEINS; SAGA	We have investigated the structural basis for the differential catalytic function of the yeast Gcn5p-containing histone acetyltransferase (HAT) A2 complex and free recombinant yeast Gcn5p (rGcn5p), HAT A2 is shown to be a unique complex that contains Gcn5p, Ada2p, and Ada3p, but not proteins specific to other related HAT A complexes, e,g, ADA, SAGA. Nevertheless, HAT A2 produces the same unique polyacetylation pattern of nucleosomal substrates reported previously for ADA and SAGA, demonstrating that proteins specific to the ADA and SAGA complexes do not influence the enzymatic activity of Gcn5p within the HAT A2 complex. To investigate the role of substrate interactions in the differential behavior of free and complexed Gcn5p, sucrose density gradient centrifugation was used to characterize the binding of HAT A2 and free rGcn5p to intact and trypsinized nucleosomal arrays, H3/H4 tetramer arrays, and nucleosome core particles. We find that HAT A2 forms stable complexes with all nucleosomal substrates tested. In distinct contrast, rGcn5p does not interact stably with nucleosomal arrays, despite being able to specifically monoacetylate the H3 N terminus of nucleosomal substrates, Our data suggest that the ability of the KAT A2 complex to bind stably to nucleosomal arrays is functionally related to both local and global acetylation by the complexed and free forms of Gcn5p.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA; Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Valencia, Spain	University of Texas System; University of Texas Health San Antonio; University of Valencia	Hansen, JC (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.	hansen@bioc02.uthscsa.edu	Sendra, Ramón/K-3549-2014	Sendra, Ramón/0000-0002-5519-4362	NIGMS NIH HHS [GM45916] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045916, R01GM045916] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Candau R, 1996, J BIOL CHEM, V271, P5237; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; DAVIE JR, 1994, J CELL BIOCHEM, V55, P98, DOI 10.1002/jcb.240550112; Davie JR, 1999, J CELL BIOCHEM, P141; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Grant PA, 1999, SEMIN CELL DEV BIOL, V10, P169, DOI 10.1006/scdb.1999.0298; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HANSEN JC, 1993, J BIOL CHEM, V268, P5840; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Harlow E., 1988, ANTIBODIES LAB MANUA; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; Johns E W, 1977, Methods Cell Biol, V16, P183; Kegeles G, 1978, Methods Enzymol, V48, P248; Keohane AM, 1998, DEV GENET, V22, P65, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;65::AID-DVG7&gt;3.0.CO;2-5; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Pollard KJ, 1999, EMBO J, V18, P5622, DOI 10.1093/emboj/18.20.5622; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Roberts SM, 1997, GENETICS, V147, P451; Ruiz-Garcia AB, 1998, J BIOL CHEM, V273, P12599, DOI 10.1074/jbc.273.20.12599; RuizGarcia AB, 1997, FEBS LETT, V403, P186, DOI 10.1016/S0014-5793(97)00049-5; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Syntichaki P, 1998, J BIOL CHEM, V273, P24414, DOI 10.1074/jbc.273.38.24414; Tse C, 1997, BIOCHEMISTRY-US, V36, P11381, DOI 10.1021/bi970801n; Tse C, 1998, P NATL ACAD SCI USA, V95, P12169, DOI 10.1073/pnas.95.21.12169; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Tse C, 1998, J BIOL CHEM, V273, P32388, DOI 10.1074/jbc.273.49.32388; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; YAGER TD, 1984, J BIOL CHEM, V259, P4212	47	36	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24928	24934		10.1074/jbc.M003783200	http://dx.doi.org/10.1074/jbc.M003783200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10825174	hybrid			2022-12-25	WOS:000088683300093
J	Stegman, MA; Vallance, JE; Elangovan, G; Sosinski, J; Cheng, Y; Robbins, DJ				Stegman, MA; Vallance, JE; Elangovan, G; Sosinski, J; Cheng, Y; Robbins, DJ			Accelerated publication - Identification of a tetrameric hedgehog signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; CUBITUS-INTERRUPTUS PROTEIN; KINESIN-RELATED PROTEIN; TARGET GENE-EXPRESSION; SEGMENT POLARITY GENE; DROSOPHILA-MELANOGASTER; PATTERN DUPLICATIONS; SMOOTHENED GENE; IMAGINAL DISCS; GLI FAMILY	Hedgehog (Hh) signal transduction requires a large cytoplasmic multi-protein complex that binds microtubules in an Hh-dependent manner. Here, we show that three members of this complex, Costal2 (Cosa), Fused (Fu), and Cubitus interruptus (Ci), bind each other directly to form a trimeric complex. We demonstrate that this trimeric signaling complex exists in Drosophila lacking Suppressor of Fused (Su(fu)), an extragenic suppressor of fu, indicating that Su(fu) is not required for the formation, or apparently function, of the Hh signaling complex. However, we subsequently show that Su(fu), although not a requisite component of this complex, does form a tetrameric complex with Fu, Cos2, and Ci. This additional Su(fu)-containing Hh signaling complex does not appear to be enriched on microtubules, Additionally, we demonstrate that in response to Hh Ci accumulates in the nucleus without its various cytoplasmic binding partners, including Su(fu), We discuss a model in which Su(fu) and Cosa each bind to Fu and Ci to exert some redundant effect on Ci such as cytoplasmic retention. This model is consistent with genetic data demonstrating that Su(fu) is not required for Hh signal transduction proper and with the elaborate genetic interactions observed among Su(fu), fu, cos2, and ci.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Calif San Francisco, George Williams Hooper Fdn, San Francisco, CA 94143 USA	University System of Ohio; University of Cincinnati; University of California System; University of California San Francisco	Robbins, DJ (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Bethesda Ave, Cincinnati, OH 45267 USA.			Vallance, Jefferson/0000-0001-6473-3623	NATIONAL CANCER INSTITUTE [R01CA082628] Funding Source: NIH RePORTER; NCI NIH HHS [CA82628-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Altaba ARI, 1997, CELL, V90, P193, DOI 10.1016/S0092-8674(00)80325-6; Alves G, 1998, MECH DEVELOP, V78, P17, DOI 10.1016/S0925-4773(98)00130-0; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BUMCROT DA, 1995, CURR BIOL, V5, P612, DOI 10.1016/S0960-9822(95)00123-0; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Crowley MT, 1996, J BIOL CHEM, V271, P1145, DOI 10.1074/jbc.271.2.1145; EATON S, 1990, GENE DEV, V4, P1068, DOI 10.1101/gad.4.6.1068; FORBES AJ, 1993, DEVELOPMENT, P115; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; LEPAGE T, 1995, NATURE, V373, P711, DOI 10.1038/373711a0; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; Ohlmeyer JT, 1997, GENE DEV, V11, P2250, DOI 10.1101/gad.11.17.2250; PAN DJ, 1995, CELL, V80, P543, DOI 10.1016/0092-8674(95)90508-1; Pearse RV, 1999, DEV BIOL, V212, P323, DOI 10.1006/dbio.1999.9335; PHAM A, 1995, GENETICS, V140, P587; PREAT T, 1992, GENETICS, V132, P725; PREAT T, 1993, GENETICS, V135, P1047; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; Quirk J, 1997, COLD SPRING HARB SYM, V62, P217; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; SanchezHerrero E, 1996, MECH DEVELOP, V55, P159, DOI 10.1016/0925-4773(96)00498-4; SIMPSON P, 1987, DEV BIOL, V122, P201, DOI 10.1016/0012-1606(87)90345-9; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Stone DM, 1999, J CELL SCI, V112, P4437; Therond PP, 1996, P NATL ACAD SCI USA, V93, P4224, DOI 10.1073/pnas.93.9.4224; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	38	91	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					21809	21812		10.1074/jbc.C000043200	http://dx.doi.org/10.1074/jbc.C000043200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10825151	hybrid			2022-12-25	WOS:000088363800009
J	Poland, BW; Xu, MQ; Quiocho, FA				Poland, BW; Xu, MQ; Quiocho, FA			Structural insights into the protein splicing mechanism of PI-SceI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; INTEIN; MODULATION; CLEAVAGE; LIGATION; ELEMENTS; SYSTEM	PI-SceI is a member of a class of proteins (inteins) that excise themselves from a precursor protein and in the process ligate the flanking protein sequences (exteins). We report here the 2.1-Angstrom resolution crystal structure of a PI-SceZ miniprecursor (VMA29) containing 10 N-terminal extein residues and 4 C-terminal extein residues. Mutations at the N- and C-terminal splicing junctions, blocking in vivo protein splicing, allowed the mini-precursor to be purified and crystallized. The structure reveals both the N- and C-terminal scissile peptide bonds to be in distorted trans conformations (tau approximate to 100 degrees). Modeling of the wild-type PI-SceI based on the VMA29 structure indicates a large conformational change (movement of >9 Angstrom) must occur 60 allow transesterification to be completed. A zinc atom was discovered at the C-terminal splicing junction. Residues Cys(455), His(453) and Glu(80) along with a water molecule (Wat(53)) chelate the zinc atom. The crystal structure of VMA29 has captured the intein in its pre-spliced state.	Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; New England Biolabs Inc, Beverly, MA 01915 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	Quiocho, FA (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, 1 Baylor Plaza, Houston, TX 77030 USA.		Wood, David W/B-2992-2012					Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Evans TC, 1999, J BIOL CHEM, V274, P3923, DOI 10.1074/jbc.274.7.3923; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; HIRATA R, 1992, BIOCHEM BIOPH RES CO, V188, P40, DOI 10.1016/0006-291X(92)92347-Z; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; Kawasaki M, 1996, BIOCHEM BIOPH RES CO, V222, P827, DOI 10.1006/bbrc.1996.0826; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; Mathys S, 1999, GENE, V231, P1, DOI 10.1016/S0378-1119(99)00103-1; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paulus H, 1998, CHEM SOC REV, V27, P375, DOI 10.1039/a827375z; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 1997, NUCLEIC ACIDS RES, V25, P1087, DOI 10.1093/nar/25.6.1087; Pietrokovski S, 1998, PROTEIN SCI, V7, P64, DOI 10.1002/pro.5560070106; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; Southworth MW, 1999, BIOTECHNIQUES, V27, P110, DOI 10.2144/99271st04; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x; Xu QA, 1999, CELL, V98, P651, DOI 10.1016/S0092-8674(00)80052-5	25	123	136	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16408	16413		10.1074/jbc.275.22.16408	http://dx.doi.org/10.1074/jbc.275.22.16408			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828056	hybrid			2022-12-25	WOS:000087392200003
J	Bae, SS; Perry, DK; Oh, YS; Choi, JH; Galadari, SH; Ghayur, T; Ryu, SH; Hannun, YA; Suh, PG				Bae, SS; Perry, DK; Oh, YS; Choi, JH; Galadari, SH; Ghayur, T; Ryu, SH; Hannun, YA; Suh, PG			Proteolytic cleavage of phospholipase C-gamma 1 during apoptosis in Molt-4 cells	FASEB JOURNAL			English	Article						PLC-gamma 1; proteolysis; tyrosine phosphorylation	CYTOCHROME-C; FOCAL ADHESION; CASPASE FAMILY; SH3 DOMAIN; DEATH; PROTEIN; ACTIVATION; PHOSPHORYLATION; BCL-2; ELEGANS	Apoptosis is a cell suicide mechanism that requires the activation of cellular death proteases for its induction. We examined whether the progress of apoptosis involves cleavage of phospholipase C-gamma 1 (PLC-gamma 1), which plays a pivotal role in mitogenic signaling pathway. Pretreatment of T leukemic Molt-4 cells with PLC inhibitors such as U-73122 or ET-18-OCH3 potentiated etoposide-induced apoptosis in these cells. PLC-gamma 1 was fragmented when Molt-4 cells were treated with several apoptotic stimuli such as etoposide, ceramides, and tumor necrosis factor alpha. Cleavage of PLC-gamma 1 was blocked by overexpression of Bcl-2 and by specific inhibitors of caspases such as Z-DEVD-CH2F and YVAD-cmk. Purified caspase-3 and caspase-7, group II caspases, cleaved PLC-gamma 1 in vitro and generated a cleavage product of the same size as that observed in vivo, suggesting that PLC-gamma 1 is cleaved by group II caspases in vivo. From point mutagenesis studies, Ala-Glu-Pro-Asp(770) was identified to be a cleavage site within PLC-gamma 1. Epidermal growth factor receptor (EGFR) -induced tyrosine phosphorylation of PLC-gamma 1 resulted in resistance to cleavage by caspase-3 in vitro. Furthermore, cleaved PLC-gamma 1 could not be tyrosine-phosphorylated by EGFR in vitro. In addition, tyrosine-phosphorylated PLC-gamma 1 was not significantly cleaved during etoposide-induced apoptosis in Molt-4 cells. This suggests that the growth factor-induced tyrosine phosphorylation may suppress apoptosis-induced fragmentation of PLC-gamma 1. We provide evidence for the biochemical relationship between PLC-gamma 1-mediated signal pathway and apoptotic signal pathway, indicating that the defect of PLC-gamma 1-mediated signaling pathway can facilitate an apoptotic progression.-Bae, S. S., Ferry, D. K., Oh, Y. S., Choi, J. H., Galadari, S. H., Ghayur, T., Ryu, S. H., Hannun, Y. A., Suh, P.-G. Proteolytic cleavage of phospholipase C-gamma 1 during apoptosis in Molt-4 cells.	Pohang Univ Sci & Technol, Div Mol & Life Sci, Dept Signal Transduct, Nam Gu, Pohang 790784, South Korea; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; United Arab Emirates Univ, Fac Med & Hlth Sci, Dept Biochem, Al Ain, U Arab Emirates; BASF Biores Corp, Worcester, MA 01605 USA	Pohang University of Science & Technology (POSTECH); Medical University of South Carolina; United Arab Emirates University; BASF	Suh, PG (corresponding author), Pohang Univ Sci & Technol, Div Mol & Life Sci, Dept Signal Transduct, Nam Gu, San 31 Hyoja Dong, Pohang 790784, South Korea.		Suh, Pann-Ghill/F-3610-2010; Galadari, Sehamuddin/AAK-6039-2020; Choi, Jang Hyun/B-3055-2012	Ryu, Sung Ho/0000-0003-0913-3048; Oh, Yong-Seok/0000-0002-9039-2014				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Chang JS, 1997, CANCER RES, V57, P5465; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DIETRICH A, 1992, FEBS LETT, V313, P220, DOI 10.1016/0014-5793(92)81195-R; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FERNALD AW, 1994, BIOCHEM J, V302, P503, DOI 10.1042/bj3020503; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG PS, 1995, FEBS LETT, V358, P287, DOI 10.1016/0014-5793(94)01453-8; Jarpe MB, 1998, ONCOGENE, V17, P1475, DOI 10.1038/sj.onc.1202183; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Oh WK, 1997, BIOCHEM BIOPH RES CO, V235, P794, DOI 10.1006/bbrc.1997.6875; Perry DK, 1997, CELL DEATH DIFFER, V4, P29, DOI 10.1038/sj.cdd.4400200; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUH PG, 1988, J BIOL CHEM, V263, P14497; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YANG LJ, 1994, J BIOL CHEM, V269, P7156; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	47	64	66	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1083	1092		10.1096/fasebj.14.9.1083	http://dx.doi.org/10.1096/fasebj.14.9.1083			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834929				2022-12-25	WOS:000087427300004
J	Bernardi, R; Liebermann, DA; Hoffman, B				Bernardi, R; Liebermann, DA; Hoffman, B			Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation	ONCOGENE			English	Article						cdc25A; cell cycle; differentiation; myc; proteasome; protein degradation; ubiquitin	MYELOBLASTIC-LEUKEMIA CELLS; C-MYC; PROTEIN-DEGRADATION; G(1)/S TRANSITION; DEPENDENT KINASES; S-PHASE; PHOSPHATASE; PROTEOLYSIS; ACTIVATION; DEPHOSPHORYLATION	Members of the cdc25 family are protein phosphatases that play pivotal roles in cell cycle progression. Cdc25A has been shown to be a critical regulator of the G1/S transition of mammalian cells and to be a myc-target gene with oncongenic properties. We investigated the regulation of cdc25A during terminal differentiation using myeloblastic leukemia M1 cells, that can be induced to undergo differentiation into macrophages by interleukin-6 (IL-6) treatment. In this report it is shown that cdc25A protein is degraded by the ubiquitin-proteasome machinery in both terminally differentiating and cycling cells. Cdc25A was found to have two major peaks of accumulation during cell cycle progression, one in G1 and the other in S/G2, Evidence was obtained that degradation of cdc25A by the ubiquitin-proteasome machinery in terminally differentiating myeloid cells is accelerated compared to cycling cells, Moreover, deregulated expression of c-myc in M1 cells, which had been previously shown to block terminal differentiation, was also found to block IL-6 induced degradation of cdc25A.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		bernardi, rosa/B-1650-2013	bernardi, rosa/0000-0002-3607-6336	NCI NIH HHS [1RO1CA51168, 1RO1CA4316] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Dick LR, 1997, J BIOL CHEM, V272, P182; Dixon D, 1998, EXP CELL RES, V240, P236, DOI 10.1006/excr.1998.3940; Draetta G, 1997, BBA-REV CANCER, V1332, pM53, DOI 10.1016/S0304-419X(96)00049-2; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Hershko A, 1997, CURR OPIN CELL BIOL, V9, P788, DOI 10.1016/S0955-0674(97)80079-8; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; Hoyt MA, 1997, CELL, V91, P149, DOI 10.1016/S0092-8674(00)80396-7; Iavarone A, 1997, NATURE, V387, P417; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; Lammer C, 1998, J CELL SCI, V111, P2445; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAGATA A, 1991, NEW BIOL, V3, P959; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Parsons Ramon, 1998, Current Opinion in Oncology, V10, P88, DOI 10.1097/00001622-199801000-00014; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Vigo E, 1999, MOL CELL BIOL, V19, P6379	42	61	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2447	2454		10.1038/sj.onc.1203564	http://dx.doi.org/10.1038/sj.onc.1203564			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828887				2022-12-25	WOS:000087018400010
J	Yue, JB; Mulder, KM				Yue, JB; Mulder, KM			Requirement of Ras/MAPK pathway activation by transforming growth factor ss for transforming growth factor ss(1) production in a Smad-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; FACTOR-BETA; TGF-BETA; EPITHELIAL-CELLS; SIGNAL-TRANSDUCTION; FACTOR-BETA-1 GENE; FIBROBLAST GROWTH; PROMOTER ACTIVITY; DOMAIN PROTEIN; DORSAL CLOSURE	Our previous results have shown that transforming growth factor beta (TGF beta) rapidly activates Ras, as well as both ERKs and SAPKs, In order to address the biological significance of the activation of these pathways by TGF beta, here we examined the role of the Ras/MAPK pathways and the Smads in TGF beta(3) induction of TGF beta(1) expression in untransformed lung and intestinal epithelial cells. Expression of either a dominant-negative mutant of Ras (RasN17) or a dominant-negative mutant of MKK4 (DN MKK4), or addition of the MEK1 inhibitor PD98059, inhibited the ability of TGF beta(3) to induce AP-1 complex formation at the TGF beta(1) promoter, and the subsequent induction of TGF beta(1) mRNA, The primary components present in this TGF beta(3)-inducible AP-1 complex at the TGF beta(1) promoter were JunD and Fra-2, although c-Jun and FosB were also involved. Furthermore, deletion of the AP-1 site in the TGF beta(1) promoter or addition of PD98059 inhibited the ability of TGF beta(3) to stimulate TGF beta(1) promoter activity. Collectively, our data demonstrate that TGF beta(3) induction of TGF beta(1) is mediated through a signaling cascade consisting of Ras, the MAPKKs MKK4 and MEK1, the MAPKs SAPKs and ERKs, and the specific AP-1 proteins Fra-2 and JunD. Although Smads and Smad4 were not detectable in TGF beta(3)-inducible AP-1 complexes at the TGF beta(1) promoter, stable expression of dominant-negative Smad3 could significantly inhibit the ability of TGF beta(3) to stimulate TGF beta(1) promoter activity. Transient expression of dominant-negative Smad4 also inhibited the ability of TGF beta(3) to transactivate the TGF beta(1) promoter. Thus, although the Ras/MAPK pathways are essential for TGF beta(3) induction of TGF beta(1), Smads may only contribute to this biological response in an indirect manner.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pharmacol H078, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Mulder, KM (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pharmacol H078, 500 Univ Dr, Hershey, PA 17033 USA.		Yue, Jianbo/AAC-4588-2019; Yue, Jianbo/C-4463-2009; Yue, Jianbo/K-8002-2015	Yue, Jianbo/0000-0001-6384-5447	NATIONAL CANCER INSTITUTE [R01CA068444, R01CA054816] Funding Source: NIH RePORTER; NCI NIH HHS [CA68444, CA51424, CA54816] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17; Frey RS, 1997, CANCER LETT, V117, P41, DOI 10.1016/S0304-3835(97)00211-5; Frey RS, 1997, CANCER RES, V57, P628; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; KIM SJ, 1989, J BIOL CHEM, V264, P7041; KIM SJ, 1989, J BIOL CHEM, V264, P402; Kivinen L, 1999, CELL GROWTH DIFFER, V10, P621; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MATSUI M, 1990, ONCOGENE, V5, P249; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Newfeld SJ, 1996, DEVELOPMENT, V122, P2099; Newfeld SJ, 1997, DEVELOPMENT, V124, P3167; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; RiesgoEscovar JR, 1997, SCIENCE, V278, P669, DOI 10.1126/science.278.5338.669; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Sluss HK, 1997, J CELL BIOCHEM, V67, P1; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Virolle T, 1998, J BIOL CHEM, V273, P17318, DOI 10.1074/jbc.273.28.17318; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Yue JB, 1999, ONCOGENE, V18, P2033, DOI 10.1038/sj.onc.1202521; Yue JB, 1998, ONCOGENE, V17, P47, DOI 10.1038/sj.onc.1201903; Yue JB, 1999, J CELL PHYSIOL, V178, P387; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zeitlinger J, 1997, EMBO J, V16, P7393, DOI 10.1093/emboj/16.24.7393; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zimmerman CM, 1998, J BIOL CHEM, V273, P677, DOI 10.1074/jbc.273.2.677	62	122	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					30765	30773		10.1074/jbc.M000039200	http://dx.doi.org/10.1074/jbc.M000039200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10843986	hybrid			2022-12-25	WOS:000089762700006
J	Miarons, PB; Fresno, M				Miarons, PB; Fresno, M			Lectins from tropical sponges - Purification and characterization of lectins from genus Aplysina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCANASE-RELEASED OLIGOSACCHARIDES; RICINUS-COMMUNIS AGGLUTININ; GEODIA-CYDONIUM LECTIN; FUNCTIONAL-CHARACTERIZATION; ADHESION RECEPTORS; AGGREGATION FACTOR; GOLGI MEMBRANES; COMBINING SITES; ANIMAL LECTINS; CELL-ADHESION	Only a few animal phyla have been screened for the presence and distribution of lectins, Probably the most intensively studied group is the mollusk. In this investigation, 22 species from 12 families of tropical sponges collected in Los Rogues National Park (Venezuela) were screened for the presence of lectins. Nine saline extracts exhibited strong hemagglutinating activity against pronase-treated hamster red blood cells; five of these reacted against rabbit red blood cells, four with trypsin-treated bovine red blood cells, and five with human red blood cells regardless of the blood group type. Extracts from the three species studied from genus Aplysina (archeri, lawnosa, and cauliformis) were highly reactive and panagglutinating against the panel of red blood cells tested. The lectins from A. archeri and A. lawnosa were purified to homogeneity by ammonium sulfate fractionation, affinity chromatography on p-aminobenzyl-beta-1-thiogalactopyranoside-agarose, and gel filtration chromatography. Both lectins exhibited a native molecular mass of 63 kDa and by SDS-polyacrylamide gel electrophoresis under reducing conditions have an apparent molecular mass of 16 kDa, thus suggesting they occur as homotetramers. The purified lectins contain 3-4 mol of divalent cation per molecule, which are essential for their biological activity. Hapten inhibition of hemagglutination was carried out to define the sugar binding specificity of the purified A. archeri lectin. The results indicate a preference of the lectin for nonreducing beta-linked D-Gal residues being the best inhibitors of red blood cells binding methyl-beta-D-Gal and thiodigalactoside (Gal beta 1-4-thiogalactopyranoside). The behavior of several glycans on immobilized lectin affinity chromatography confirmed and extended the specificity data obtained by hapten inhibition.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Miarons, PB (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	Pbonay@cbm.uam.es		Fresno Escudero, Manuel/0000-0002-9223-5477				ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; ATTA AM, 1989, BRAZ J MED BIOL RES, V22, P379; ATTA AM, 1990, BRAZ J MED BIOL RES, V23, P191; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BRETTING H, 1981, J IMMUNOL, V127, P1652; BRETTING H, 1976, BIOCHEMISTRY-US, V15, P5029, DOI 10.1021/bi00668a013; BRETTING H, 1976, BIOCHEMISTRY-US, V15, P3228, DOI 10.1021/bi00660a011; CARVER JP, 1984, BIOL CARBOHYDRATES, V2, P289; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; DEBRAY H, 1986, CARBOHYD RES, V151, P359, DOI 10.1016/S0008-6215(00)90355-0; DIEHLSEIFERT B, 1985, EUR J BIOCHEM, V147, P517; DODD RY, 1968, VOX SANG, V15, P386, DOI 10.1111/j.1423-0410.1968.tb04079.x; DRAKE DK, 1982, J CELL BIOL, V93, P383, DOI 10.1083/jcb.93.2.383; GAMULIN V, 1994, BIOL CHEM H-S, V375, P583; GREEN ED, 1987, J BIOL CHEM, V262, P12018; GREEN ED, 1987, J BIOL CHEM, V262, P12030; Hanisch FG, 1996, GLYCOBIOLOGY, V6, P321, DOI 10.1093/glycob/6.3.321; HENKART P, 1973, BIOCHEMISTRY-US, V12, P3045, DOI 10.1021/bi00740a016; HIRABAYASHI J, 1993, GLYCOBIOLOGY, V3, P297, DOI 10.1093/glycob/3.4.297; Hughes RC, 1997, BIOCHEM SOC T, V25, P1194, DOI 10.1042/bst0251194; KAMIYA H, 1990, NIPPON SUISAN GAKK, V56, P1159, DOI 10.2331/suisan.56.1159; KAMIYA H, 1986, B JPN SOC SCI FISH, V52, P2205; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; KAWAGISHI H, 1994, J BIOL CHEM, V269, P1375; KHUNS WJ, 1974, ANN NY ACAD SCI, V234, P58; Kruse M, 1998, J MOL EVOL, V46, P721, DOI 10.1007/PL00006353; MIZUOCHI T, 1979, J BIOL CHEM, V254, P6419; Morel JL, 1997, MOL PHARMACOL, V51, P1042, DOI 10.1124/mol.51.6.1042; MULLER WEG, 1994, BRAZ J MED BIOL RES, V27, P2083; Muller WEG, 1997, CELL TISSUE RES, V289, P383, DOI 10.1007/s004410050885; Muller WEG, 1998, NATURWISSENSCHAFTEN, V85, P11, DOI 10.1007/s001140050444; MULLER WEG, 1983, EUR J BIOCHEM, V133, P263, DOI 10.1111/j.1432-1033.1983.tb07457.x; MULLER WEG, 1981, EUR J CELL BIOL, V24, P28; NAMBIAR MP, 1995, EXP CELL RES, V219, P671, DOI 10.1006/excr.1995.1278; OKeefe BR, 1997, EUR J BIOCHEM, V245, P47, DOI 10.1111/j.1432-1033.1997.t01-1-00047.x; Pahler S, 1998, P ROY SOC B-BIOL SCI, V265, P421, DOI 10.1098/rspb.1998.0311; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; PFEIFER K, 1993, GLYCOBIOLOGY, V3, P179, DOI 10.1093/glycob/3.2.179; Rabinovich GA, 1999, BRAZ J MED BIOL RES, V32, P383, DOI 10.1590/S0100-879X1999000400002; SATO S, 1991, J BIOL CHEM, V266, P11485; Schutze J, 1999, P ROY SOC B-BIOL SCI, V266, P63, DOI 10.1098/rspb.1999.0605; SPIK G, 1975, FEBS LETT, V50, P296, DOI 10.1016/0014-5793(75)90053-8; TAKASAKI S, 1986, BIOCHEMISTRY-US, V25, P5706; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; TURNER RS, 1973, NATURE, V244, P509, DOI 10.1038/244509a0; WagnerHulsmann C, 1996, GLYCOBIOLOGY, V6, P785, DOI 10.1093/glycob/6.8.785-d; Wu JH, 1998, FEBS LETT, V427, P134, DOI 10.1016/S0014-5793(98)00411-6; YAMAMOTO K, 1981, BIOCHEM J, V195, P701, DOI 10.1042/bj1950701; YAMASHITA K, 1987, J BIOL CHEM, V262, P1602; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	52	28	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29283	29289		10.1074/jbc.M001366200	http://dx.doi.org/10.1074/jbc.M001366200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10852905	hybrid			2022-12-25	WOS:000089439800016
J	O'Farrell, TJ; Pourmotabbed, T				O'Farrell, TJ; Pourmotabbed, T			Identification of structural elements important for matrix metalloproteinase type V collagenolytic activity as revealed by chimeric enzymes - Role of fibronectin-like domain and active site of gelatinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL COLLAGENASE; C-TERMINAL DOMAIN; HUMAN FIBROBLAST COLLAGENASE; BASEMENT-MEMBRANE COLLAGEN; RAT EMBRYO CELLS; CATALYTIC DOMAIN; SUBSTRATE-SPECIFICITY; TISSUE INHIBITOR; CYSTEINE SWITCH; IV COLLAGENASE	Digestion of type V collagen by the gelatinases is an important step in tumor cell metastasis because this collagen maintains the integrity of the extracellular matrix that must be breached during this pathological profess. However, the structural elements that provide the gelatinases with this unique proteolytic activity among matrix metalloproteinases had not been thoroughly defined. To identify these elements, we examined the substrate specificity of chimeric enzymes containing domains of gelatinase B and fibroblast collagenase. We have found that the addition of the fibronectin-like domain of gelatinase B to fibroblast collagenase is sufficient to endow the enzyme with the ability to cleave type V collagen. In addition, the substitution of the catalytic zinc-binding active site region of fibroblast collagenase with that of gelatinase B increased the catalytic efficiency of the enzyme 3- to 4-fold. This observation led to the identification of amino acid residues, Leu(397), Ala(406) Asp(410), and pro(415), in this region of gelatinase B that are important for its efficient catalysis as determined by substituting these amino acids with the corresponding residues from fibroblast collagenase. Leu(397) and Ala(406) are important for the general proteolytic activity of the enzyme, whereas Asp(410) and pro(415) specifically enhance its ability to cleave type V collagen and gelatin, respectively, These data provide fundamental information about the structural elements that distinguish the gelatinases from other matrix metalloproteinases in terms of substrate specificity and catalytic efficiency.	Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Pourmotabbed, T (corresponding author), Univ Tennessee, Dept Biochem, 858 Madison Ave,Suite G01, Memphis, TN 38163 USA.				NIAMS NIH HHS [AR-41843] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041843, R29AR041843] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bafetti LM, 1998, J BIOL CHEM, V273, P143, DOI 10.1074/jbc.273.1.143; Banyai L, 1996, J BIOL CHEM, V271, P12003, DOI 10.1074/jbc.271.20.12003; BANYAI L, 1994, BIOCHEM J, V298, P403, DOI 10.1042/bj2980403; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; Bu CH, 1996, J BIOL CHEM, V271, P14308, DOI 10.1074/jbc.271.24.14308; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; GOOLEY PR, 1994, NAT STRUCT BIOL, V1, P111, DOI 10.1038/nsb0294-111; HARRIS ED, 1972, BIOCHIM BIOPHYS ACTA, V258, P566, DOI 10.1016/0005-2744(72)90249-5; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HAYAKAWA T, 1991, BIOMED RES-TOKYO, V12, P169, DOI 10.2220/biomedres.12.169; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; HIROSE T, 1992, J RHEUMATOL, V19, P593; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LIOTTA LA, 1979, P NATL ACAD SCI USA, V76, P2268, DOI 10.1073/pnas.76.5.2268; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MODESTI A, 1984, EUR J CELL BIOL, V35, P246; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; MURPHY G, 1982, BIOCHEM J, V203, P209, DOI 10.1042/bj2030209; MURPHY G, 1994, J BIOL CHEM, V269, P6632; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1992, J BIOL CHEM, V267, P9612; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NAGASE H, 1991, BIOCHEM SOC T, V19, P715, DOI 10.1042/bst0190715; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; NIYIBIZI C, 1994, BIOCHEM BIOPH RES CO, V202, P328, DOI 10.1006/bbrc.1994.1931; O'Farrell TJ, 1998, ARCH BIOCHEM BIOPHYS, V354, P24, DOI 10.1006/abbi.1998.0662; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; OVERALL CM, 1991, INFECT IMMUN, V59, P4687, DOI 10.1128/IAI.59.12.4687-4692.1991; PAGE RC, 1991, J PERIODONTAL RES, V26, P230, DOI 10.1111/j.1600-0765.1991.tb01649.x; PARK AJ, 1991, J BIOL CHEM, V266, P1584; POURMOTABBED T, 1994, BBA-PROTEIN STRUCT M, V1204, P97, DOI 10.1016/0167-4838(94)90038-8; SANCHEZLOPEZ R, 1993, J BIOL CHEM, V268, P7238; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHNIERER S, 1993, BIOCHEM BIOPH RES CO, V191, P319, DOI 10.1006/bbrc.1993.1220; SELLERS A, 1978, BIOCHEM J, V171, P493, DOI 10.1042/bj1710493; Shipley JM, 1996, J BIOL CHEM, V271, P4335; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STAMS T, 1994, NAT STRUCT BIOL, V1, P119, DOI 10.1038/nsb0294-119; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; WINDSOR LJ, 1994, J BIOL CHEM, V269, P26201; WOLF C, 1992, J INVEST DERMATOL, V99, P870, DOI 10.1111/1523-1747.ep12614846; WU JJ, 1991, J BIOL CHEM, V266, P5625; WYSOCKI AB, 1993, J INVEST DERMATOL, V101, P64, DOI 10.1111/1523-1747.ep12359590; YE QZ, 1995, BIOCHEMISTRY-US, V34, P4702, DOI 10.1021/bi00014a026; YE QZ, 1992, BIOCHEMISTRY-US, V31, P11231, DOI 10.1021/bi00160a038; YU LP, 1990, ARTHRITIS RHEUM, V33, P1626, DOI 10.1002/art.1780331104	55	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27964	27972						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10823838				2022-12-25	WOS:000089197100060
J	Adams, A; Thorn, JM; Yamabhai, M; Kay, BK; O'Bryan, JP				Adams, A; Thorn, JM; Yamabhai, M; Kay, BK; O'Bryan, JP			Intersectin, an adaptor protein involved in clathrin-mediated endocytosis, activates mitogenic signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; GROWTH-FACTOR RECEPTOR; XENOPUS OOCYTES; EH-DOMAIN; MEIOTIC MATURATION; ONCOGENE PRODUCT; EPS15 HOMOLOGY; RAS PROTEINS; TRANSFORMATION; COMPONENTS	Intersectin is a member of a growing family of adaptor proteins that possess conserved Eps15 homology (EH) domains as well as additional protein recognition motifs. In general, EH domain-containing proteins play an integral role in clathrin-mediated endocytosis. Indeed, intersectin functions in the intermediate stages of clathrin-coated vesicle assembly. However, recent evidence suggests that components of the endocytic machinery also regulate mitogenic signaling pathways. In this report, we provide several lines of evidence that intersectin has the capacity to activate mitogenic signaling pathways. First, intersectin overexpression activated the Elk-l transcription factor in an MAPK-independent manner, This ability resides within the EH domains, as expression of the tandem EH domains was sufficient to activate Elk-l. Second, intersectin cooperated with epidermal growth factor to potentiate Elk-l activation; however, a similar level of Elk-l activation was obtained by expression of the tandem EH domains suggesting that the coiled-coil region and SH3 domains act to regulate the EH domains. Third, intersectin expression was sufficient to induce oncogenic transformation of rodent fibroblasts. And finally, intersectin cooperated with progesterone to accelerate maturation of Xenopus laevis oocytes. Together, these data suggest that intersectin links endocytosis with regulation of pathways important for cell growth and differentiation.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Wisconsin System; University of Wisconsin Madison	O'Bryan, JP (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233,Bldg 101,Rm F336,MD F3-06, Res Triangle Pk, NC 27709 USA.			O'Bryan, John/0000-0001-5386-1080	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090091] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; BERNARD OA, 1994, ONCOGENE, V9, P1039; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Cupers P, 1997, J BIOL CHEM, V272, P33430, DOI 10.1074/jbc.272.52.33430; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; Guipponi M, 1998, GENOMICS, V53, P369, DOI 10.1006/geno.1998.5521; Hussain NK, 1999, J BIOL CHEM, V274, P15671, DOI 10.1074/jbc.274.22.15671; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; O'Bryan JP, 1998, J BIOL CHEM, V273, P20431, DOI 10.1074/jbc.273.32.20431; Okamoto M, 1999, J BIOL CHEM, V274, P18446, DOI 10.1074/jbc.274.26.18446; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Roos J, 1998, J BIOL CHEM, V273, P19108, DOI 10.1074/jbc.273.30.19108; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Tong XK, 2000, EMBO J, V19, P1263, DOI 10.1093/emboj/19.6.1263; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401	39	68	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27414	27420						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10851244				2022-12-25	WOS:000089144800100
J	Cabiscol, E; Piulats, E; Echave, P; Herrero, E; Ros, J				Cabiscol, E; Piulats, E; Echave, P; Herrero, E; Ros, J			Oxidative stress promotes specific protein damage in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-CELLS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; PYRUVATE-DEHYDROGENASE; HYDROGEN-PEROXIDE; YEAST; SUPEROXIDE; RESPONSES; IDENTIFICATION; BIOCHEMISTRY; INACTIVATION	We have analyzed the proteins that are oxidatively damaged when Saccharomyces cerevisiae cells are exposed to stressing; conditions. Carbonyl groups generated by hydrogen peroxide or menadione on proteins of aerobically respiring cells were detected by Western blotting, purified, and identified. Mitochondrial proteins such as E2 subunits of both pyruvate dehydrogenase and cr-ketoglutarate dehydrogenase, aconitase, heat-shock protein 60, and the cytosolic fatty acid synthase (cu subunit) and glyceraldehyde-3-phosphate dehydrogenase were the major targets. In addition we also report the in, vivo modification of lipoamide present in the above-mentioned E2 subunits under the stressing conditions tested and that this also occurs with the homologous enzymes present in Escherichia coli cells that were used for comparative analysis. Under fermentative conditions, the main protein targets in S. cerevisiae cells treated with hydrogen peroxide or menadione were pyruvate decarboxylase, enolase, fatty acid synthase, and glyceraldehyde-3-phosphate dehydrogenase. Under the stress conditions tested, fermenting cells exhibit a lower viability than aerobically respiring cells and, consistently, increased peroxide generation as well as higher content of protein carbonyls and lipid peroxides, Our results strongly suggest that the oxidative stress in prokaryotic and eukaryotic cells shares common features.	Univ Lleida, Fac Med, Dept Ciencies Med Basiques, E-25198 Lleida, Spain	Universitat de Lleida	Ros, J (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Avinguda Rovira Roure 44, E-25198 Lleida, Spain.	joaquim.ros@cmb.udl.ed	Cabiscol, Elisa/A-4584-2009; ROS, Joaquim/ABG-7487-2020; Herrero, Enrique/B-5592-2009; Ros, Joaquim/A-7507-2010	Cabiscol, Elisa/0000-0003-2795-7999; ROS, Joaquim/0000-0003-0901-8648; Herrero, Enrique/0000-0002-6763-111X; 				Ayala A, 1996, J BIOL CHEM, V271, P23105, DOI 10.1074/jbc.271.38.23105; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Brown RK, 1996, FREE RADICALS PRACTI, P119; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; COLLINSON LP, 1992, J GEN MICROBIOL, V138, P329, DOI 10.1099/00221287-138-2-329; Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC, P4; Davidson JF, 1996, P NATL ACAD SCI USA, V93, P5116, DOI 10.1073/pnas.93.10.5116; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; Demple B., 1996, REGULATION GENE EXPR, P433; Dukan S, 1999, J BIOL CHEM, V274, P26027, DOI 10.1074/jbc.274.37.26027; Dukan S, 1998, GENE DEV, V12, P3431, DOI 10.1101/gad.12.21.3431; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; Fansler B., 1969, METHODS ENZYMOL, V13, P26; FARR SB, 1991, MICROBIOL REV, V55, P561, DOI 10.1128/MMBR.55.4.561-585.1991; Flikweert MT, 1996, YEAST, V12, P247, DOI 10.1002/(SICI)1097-0061(19960315)12:3<247::AID-YEA911>3.0.CO;2-I; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; HASSAN HM, 1979, ARCH BIOCHEM BIOPHYS, V196, P385, DOI 10.1016/0003-9861(79)90289-3; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; JAMIESON DJ, 1994, MICROBIOL-UK, V140, P3277, DOI 10.1099/13500872-140-12-3277; JAMIESON DJ, 1992, J BACTERIOL, V174, P6678, DOI 10.1128/JB.174.20.6678-6681.1992; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; KOBAYASHI N, 1993, MOL CELL BIOL, V13, P248, DOI 10.1128/MCB.13.1.248; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; KRESZE GB, 1981, EUR J BIOCHEM, V119, P573, DOI 10.1111/j.1432-1033.1981.tb05646.x; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LYNEN F, 1969, METHOD ENZYMOL, V14, P17; MAITRA PK, 1971, J BIOL CHEM, V246, P475; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MCALISTER L, 1985, J BIOL CHEM, V260, P5019; MoradasFerreira P, 1996, MOL MICROBIOL, V19, P651, DOI 10.1046/j.1365-2958.1996.403940.x; MUNDAY R, 1989, FREE RADICAL BIO MED, V7, P659, DOI 10.1016/0891-5849(89)90147-0; Rivera-Nieves J, 1999, J BIOL CHEM, V274, P19525, DOI 10.1074/jbc.274.28.19525; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Schweizer M., 1997, OXIDATIVE STRESS MOL, P169; SHACTER E, 1994, FREE RADICAL BIO MED, V17, P429, DOI 10.1016/0891-5849(94)90169-4; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1991, J BIOL CHEM, V266, P17201; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; Tamarit J, 1998, J BIOL CHEM, V273, P3027, DOI 10.1074/jbc.273.5.3027; TANGERAS A, 1980, BIOCHIM BIOPHYS ACTA, V589, P162, DOI 10.1016/0005-2728(80)90035-3; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168	48	351	360	1	57	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27393	27398						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10852912				2022-12-25	WOS:000089144800097
J	Padre, RC; Stull, JT				Padre, RC; Stull, JT			Functional assembly of fragments from bisected smooth muscle myosin light chain kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL RETRACTION; STRUCTURAL BASIS; PSEUDOSUBSTRATE SEQUENCE; INTRASTERIC REGULATION; CALMODULIN BINDING; NEUTRON-SCATTERING; PROTEIN-KINASES; PHOSPHORYLATION; ACTIVATION; AUTOINHIBITION	The C-terminal regulatory segment of smooth muscle myosin light chain kinase folds back on its catalytic core to inhibit kinase activity. This regulatory segment consists of autoinhibitory residues linking the catalytic core to the calmodulin-binding sequence and perhaps additional C-terminal residues including an immunoglobulin-like motif. However, mutational and biochemical analyses showed no specific involvement of residues C-terminal to the calmodulin binding sequence. To obtain additional insights on the proposed mechanisms for autoinhibition and Ca2+/calmodulin activation of the kinase, the polypeptide backbone chain of myosin light chain kinase was cleaved by genetic means to produce N- and C-terminal protein fragments. The N-terminal fragment containing the catalytic core was catalytically inactive when expressed alone. Go-expression of the N-terminal fragment with the C-terminal fragment containing the regulatory segment restored kinase activity. Deletion of the autoinhibitory linker residues without or with the calmodulin-binding sequence prevented restoration of kinase activity. In the presence or absence of Ca2+/calmodulin, regulatory segment binding occurred through the linker region connecting the catalytic core to the calmodulin-binding sequence. Collectively, these results indicate that residues C-terminal to the calmodulin-binding sequence (including the immunoglobulin-like motif) are not functional components of the regulatory segment. Furthermore, the principal autoinhibitory motif is contained in the sequence linking the catalytic core of myosin light chain kinase to the calmodulin-binding sequence.	Univ Texas, SW Med Ctr, Dept Physiol M 9040, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Stull, JT (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol M 9040, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	jstull@mednet.swmed.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL029043] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06296, HL29043] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Barth A, 1998, J BIOL CHEM, V273, P2174, DOI 10.1074/jbc.273.4.2174; BERTOLAET BL, 1995, BIOCHEMISTRY-US, V34, P5736, DOI 10.1021/bi00017a005; BOWMAN BF, 1992, J BIOL CHEM, V267, P5346; Chin D, 1999, BIOCHEMISTRY-US, V38, P15061, DOI 10.1021/bi990883a; CHOI OH, 1994, J BIOL CHEM, V269, P536; CREIGHTON TE, 1983, BIOPOLYMERS, V22, P49, DOI 10.1002/bip.360220110; FAUX MC, 1993, J BIOL CHEM, V268, P12484; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; GALLAGHER PJ, 1993, J BIOL CHEM, V268, P26578; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23936; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; Garnier J, 1996, METHOD ENZYMOL, V266, P540; GAY GD, 1994, BIOCHEMISTRY-US, V33, P7957, DOI 10.1021/bi00191a024; GOECKELER ZM, 1995, J CELL BIOL, V130, P613, DOI 10.1083/jcb.130.3.613; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; Graf R, 1996, P NATL ACAD SCI USA, V93, P11591, DOI 10.1073/pnas.93.21.11591; GUERRIERO V, 1986, BIOCHEMISTRY-US, V25, P8372, DOI 10.1021/bi00374a007; HASHIMOTO Y, 1994, BBA-MOL CELL RES, V1223, P163, DOI 10.1016/0167-4889(94)90222-4; HATHAWAY DR, 1983, ANAL BIOCHEM, V135, P37, DOI 10.1016/0003-2697(83)90726-1; HERRING BP, 1991, J BIOL CHEM, V266, P11838; HOLZAPFEL G, 1983, EXP CELL RES, V148, P117, DOI 10.1016/0014-4827(83)90192-1; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; IKEBE M, 1994, J BIOL CHEM, V269, P28165; IKEBE M, 1989, J BIOL CHEM, V264, P6967; ITO M, 1991, BIOCHEMISTRY-US, V30, P3498, DOI 10.1021/bi00228a021; Jian XY, 1996, J NEUROBIOL, V31, P379, DOI 10.1002/(SICI)1097-4695(199611)31:3<379::AID-NEU10>3.0.CO;2-B; KAMM KE, 1989, J BIOL CHEM, V264, P21223; KERRICK WGL, 1984, P NATL ACAD SCI-BIOL, V81, P165, DOI 10.1073/pnas.81.1.165; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; Kobe B, 1996, EMBO J, V15, P6810, DOI 10.1002/j.1460-2075.1996.tb01072.x; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; KRUEGER JK, 1995, J BIOL CHEM, V270, P16848, DOI 10.1074/jbc.270.28.16848; Krueger JK, 1998, BIOCHEMISTRY-US, V37, P13997, DOI 10.1021/bi981311d; Krueger JK, 1997, BIOCHEMISTRY-US, V36, P6017, DOI 10.1021/bi9702703; Ladurner AG, 1997, J MOL BIOL, V273, P317, DOI 10.1006/jmbi.1997.1303; Lin PJ, 1997, J BIOL CHEM, V272, P7412, DOI 10.1074/jbc.272.11.7412; MAMIYA S, 1989, J BIOL CHEM, V264, P8575; Mayans O, 1998, NATURE, V395, P863, DOI 10.1038/27603; MILLER JR, 1983, MOL PHARMACOL, V24, P235; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; Ostermeier M, 1999, P NATL ACAD SCI USA, V96, P3562, DOI 10.1073/pnas.96.7.3562; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; Persechini A, 1996, J BIOL CHEM, V271, P19279, DOI 10.1074/jbc.271.32.19279; POTTER JD, 1975, J BIOL CHEM, V250, P4628; SANCHO J, 1992, J MOL BIOL, V224, P741, DOI 10.1016/0022-2836(92)90558-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBA K, 1992, P NATL ACAD SCI USA, V89, P1880, DOI 10.1073/pnas.89.5.1880; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SHRODE LD, 1995, AM J PHYSIOL-CELL PH, V269, pC257, DOI 10.1152/ajpcell.1995.269.1.C257; STULL JT, 1990, J BIOL CHEM, V265, P16683; STULL JT, 1996, BIOCH SMOOTH MUSCLE, P119; STULL JT, 1986, ENZYMES, P113; SWEENEY JL, 1993, AM J PHYSIOL, V264, pC1085; TANAKA M, 1995, EMBO J, V14, P2839, DOI 10.1002/j.1460-2075.1995.tb07283.x; TASAYCO ML, 1992, SCIENCE, V255, P594, DOI 10.1126/science.1736361; ULLMANN A, 1967, J MOL BIOL, V24, P339, DOI 10.1016/0022-2836(67)90341-5; WYSOLMERSKI RB, 1991, AM J PHYSIOL, V261, pC32, DOI 10.1152/ajpcell.1991.261.1.C32; WYSOLMERSKI RB, 1990, P NATL ACAD SCI USA, V87, P16, DOI 10.1073/pnas.87.1.16; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002; Zhi G, 1998, J BIOL CHEM, V273, P8951, DOI 10.1074/jbc.273.15.8951	61	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26665	26673						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842170				2022-12-25	WOS:000089144800002
J	Fagan, KA; Smith, KE; Cooper, DMF				Fagan, KA; Smith, KE; Cooper, DMF			Regulation of the Ca2+-inhibitable adenylyl cyclase type VI by capacitative Ca2+ entry requires localization in cholesterol-rich domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; C6-2B GLIOMA-CELLS; RECEPTOR-LIKE PROTEIN; PLASMA-MEMBRANE; INOSITOL 1,4,5-TRISPHOSPHATE; SIGNAL-TRANSDUCTION; CAVEOLAE MEMBRANE; POLARIZED EPITHELIA; CALCIUM; INHIBITION	The endogenous Ca2+-inhibitable adenylyl cyclase type VI of C6-2B glioma cells is regulated only by capacitative Ca2+ entry and not by a substantial elevation of [Ca2+](i) from either intracellular stores or via ionophore-mediated Ca2+ entry (Chiono, M., Mahey, R,, Tate, G,, and Cooper, D. M, F. (1995) J. Biol. Chem. 270, 1149-1155; Fagan, K, A., Mons, N., and Cooper, D, M. F, (1998) J, Biol. Chem, 273, 9297-9305), The present studies explored the role of cholesterol-rich domains in maintaining this functional association. The cholesterol-binding agent, filipin, profoundly inhibited adenylyl cyclase activity, Depletion of plasma membrane cholesterol with methyl-beta-cyclodextrin did not affect forskolin-stimulated adenylyl cyclase activity and did not affect capacitative Ca2+ entry, However, cholesterol depletion completely ablated the regulation of adenylyl cyclase by capacitative Ca2+ entry. Repletion of cholesterol restored the sensitivity of adenylyl cyclase to capacitative Ca2+ entry. Adenylyl cyclase catalytic activity and immunoreactivity were extracted into buoyant caveolar fractions with Triton X-100, The presence of adenylyl cyclase in such structures was eliminated by depletion of plasma membrane cholesterol, Altogether, these data lead us to conclude that adenylyl cyclase must occur in cholesterol-rich domains to be susceptible to regulation by capacitative Ca2+ entry. These findings are the first indication of regulatory significance for the localization of adenylyl cyclase in caveolae.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cooper, DMF (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Box C-236,4200 E 9th Ave, Denver, CO 80262 USA.				NIGMS NIH HHS [GM32483] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032483] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BOYAJIAN CL, 1991, J BIOL CHEM, V266, P4995; Burnay MM, 1998, BIOCHEM J, V330, P21, DOI 10.1042/bj3300021; Cali JJ, 1996, J BIOL CHEM, V271, P1089, DOI 10.1074/jbc.271.2.1089; CHANG YC, 1992, ANAL BIOCHEM, V205, P22, DOI 10.1016/0003-2697(92)90573-P; CHIONO M, 1995, J BIOL CHEM, V270, P1149, DOI 10.1074/jbc.270.3.1149; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DEBERNARDI MA, 1993, BIOCHEM J, V293, P325, DOI 10.1042/bj2930325; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; EVANS T, 1984, MOL PHARMACOL, V26, P395; Fagan KA, 1999, J BIOL CHEM, V274, P12445, DOI 10.1074/jbc.274.18.12445; Fagan KA, 1998, J BIOL CHEM, V273, P9297, DOI 10.1074/jbc.273.15.9297; Fagan KA, 1996, J BIOL CHEM, V271, P12438, DOI 10.1074/jbc.271.21.12438; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; FIELDING CJ, 1995, BIOCHEMISTRY-US, V34, P14237, DOI 10.1021/bi00043a031; FUJIMOTO T, 1995, J CELL SCI, V108, P7; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Haasemann M, 1998, J CELL SCI, V111, P917; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Isshiki M, 1999, CELL CALCIUM, V26, P201, DOI 10.1054/ceca.1999.0073; Isshiki M, 1998, P NATL ACAD SCI USA, V95, P5009, DOI 10.1073/pnas.95.9.5009; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; Lasley RD, 2000, J BIOL CHEM, V275, P4417, DOI 10.1074/jbc.275.6.4417; LENCER WI, 1995, J CELL BIOL, V131, P951, DOI 10.1083/jcb.131.4.951; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Mineo C, 1998, J CELL BIOL, V141, P601, DOI 10.1083/jcb.141.3.601; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Neher E, 1998, NEURON, V20, P389, DOI 10.1016/S0896-6273(00)80983-6; Ohvo H, 1996, BIOCHEMISTRY-US, V35, P8018, DOI 10.1021/bi9528816; PALADE GE, 1953, J APPL PHYS, V24, P1424; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Razani B, 1999, J BIOL CHEM, V274, P26353, DOI 10.1074/jbc.274.37.26353; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Sandhoff R, 1999, J LIPID RES, V40, P126; Schlegel A, 1998, CELL SIGNAL, V10, P457, DOI 10.1016/S0898-6568(98)00007-2; Schwencke C, 1999, MOL ENDOCRINOL, V13, P1061, DOI 10.1210/me.13.7.1061; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shuttleworth TJ, 1999, J BIOL CHEM, V274, P31174, DOI 10.1074/jbc.274.44.31174; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SOLOMON Y, 1974, ANAL BIOCHEM, V58, P541; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Toya Y, 1998, ENDOCRINOLOGY, V139, P2025, DOI 10.1210/en.139.4.2025; Watson EL, 1998, AM J PHYSIOL-CELL PH, V274, pC557, DOI 10.1152/ajpcell.1998.274.3.C557	55	111	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26530	26537		10.1074/jbc.M001369200	http://dx.doi.org/10.1074/jbc.M001369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10843990	hybrid			2022-12-25	WOS:000088999700089
J	Lopez-Ongil, S; Senchak, V; Saura, M; Zaragoza, C; Ames, M; Ballermann, B; Rodriguez-Puyol, M; Rodriguez-Puyol, D; Lowenstein, CJ				Lopez-Ongil, S; Senchak, V; Saura, M; Zaragoza, C; Ames, M; Ballermann, B; Rodriguez-Puyol, M; Rodriguez-Puyol, D; Lowenstein, CJ			Superoxide regulation of endothelin-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; OXYGEN RADICALS; ANGIOTENSIN-II; NADPH OXIDASE; POLYMORPHONUCLEAR LEUKOCYTES; CARDIOVASCULAR-SYSTEM; LATENT COLLAGENASE; PHAGOCYTIC-CELLS; OXIDATIVE STRESS; SMOOTH-MUSCLE	Reactive oxygen species (ROS) act as signaling molecules in the cardiovascular system, regulating cellular proliferation and migration. However, an excess of ROS can damage cells and alter endothelial cell function. We hypothesized that endogenous mechanisms protect the vasculature from excess levels of ROS. We now shaw that superoxide can inhibit endothelin-converting enzyme activity (ECE) and decrease endothelin-l synthesis. Superoxide inhibits ECE but hydrogen peroxide and nitric oxide do not. Superoxide inhibits ECE by ejecting zinc from the enzyme, and the addition of exogenous zinc restores enzymatic activity. Superoxide may inhibit other zinc metalloproteinases by a similar mechanism and may thus play an important role in regulating the biology of blood vessels.	Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21205 USA; Univ Alcala de Henares, Dept Physiol, Res Unit, Madrid 28871, Spain; IRSIN, Madrid 28871, Spain; MIT, Ctr Environm Hlth Sci, Nucl Reactor Lab, Cambridge, MA 02138 USA	Johns Hopkins University; Johns Hopkins University; Universidad de Alcala; Massachusetts Institute of Technology (MIT)	Lowenstein, CJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, 720 Rutland Ave, Baltimore, MD 21205 USA.	clowenst@jhmi.edu	Ballermann, Barbara J/G-5349-2016; Zaragoza, Carlos/AAH-9275-2019; Zaragoza Sanchez, Carlos/G-8718-2011; Puyol, Diego Rodriguez/AAG-9752-2020	Ballermann, Barbara J/0000-0002-8220-6381; Puyol, Diego Rodriguez/0000-0002-9125-9311; Lowenstein, Charles/0000-0003-0485-7514; Lopez-Ongil, Susana/0000-0003-0045-1680; Zaragoza, Carlos/0000-0002-1706-8592	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063706, P50HL052315] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aubin P, 1997, CLIN CHEM, V43, P64; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; BURKHARDT H, 1986, ENZYME, V36, P221, DOI 10.1159/000469298; BURKHARDT H, 1986, ARTHRITIS RHEUM, V29, P379, DOI 10.1002/art.1780290311; Finkel T, 1999, J LEUKOCYTE BIOL, V65, P337, DOI 10.1002/jlb.65.3.337; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Galis ZS, 1998, CIRCULATION, V97, P2445, DOI 10.1161/01.CIR.97.24.2445; Gardner PR, 1997, BIOSCIENCE REP, V17, P33, DOI 10.1023/A:1027383100936; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; Goldschmidt-Clermont PJ, 1999, GENE EXPRESSION, V7, P255; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 1999, CIRC RES, V85, P562, DOI 10.1161/01.RES.85.6.562; Griendling KK, 1997, CIRCULATION, V96, P3264; Griendling KK, 1996, FASEB J, V10, P283, DOI 10.1096/fasebj.10.2.8641561; Harrison DG, 1997, CLIN CARDIOL, V20, P11; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; INOUE A, 1989, J BIOL CHEM, V264, P14954; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jewett SL, 1999, FREE RADICAL BIO MED, V26, P905, DOI 10.1016/S0891-5849(98)00274-3; JONES OTG, 1994, METHOD ENZYMOL, V233, P222; KUNDU GC, 1992, LIFE SCI, V50, P965, DOI 10.1016/0024-3205(92)90175-O; KUNDU GC, 1993, INT J PEPT PROT RES, V42, P64; LopezOngil S, 1996, AM J PHYSIOL-HEART C, V271, pH1072, DOI 10.1152/ajpheart.1996.271.3.H1072; MARSDEN PA, 1990, AM J PHYSIOL, V258, pF1295, DOI 10.1152/ajprenal.1990.258.5.F1295; MAYO LA, 1990, METHOD ENZYMOL, V186, P567; Miyauchi T, 1999, ANNU REV PHYSIOL, V61, P391, DOI 10.1146/annurev.physiol.61.1.391; Munzel T, 1999, ANN NY ACAD SCI, V874, P386, DOI 10.1111/j.1749-6632.1999.tb09253.x; OHNAKA K, 1990, BIOCHEM BIOPH RES CO, V168, P1128, DOI 10.1016/0006-291X(90)91146-J; Orzechowski HD, 1997, J MOL MED-JMM, V75, P512, DOI 10.1007/s001090050136; Owens MW, 1997, AM J PHYSIOL-LUNG C, V273, pL445, DOI 10.1152/ajplung.1997.273.2.L445; PAGANO PJ, 1993, AM J PHYSIOL, V265, pH707, DOI 10.1152/ajpheart.1993.265.2.H707; Pagano PJ, 1997, P NATL ACAD SCI USA, V94, P14483, DOI 10.1073/pnas.94.26.14483; Parks WC, 1998, BIOL EXTRAC, P263; PHAN SH, 1989, AM J PATHOL, V134, P1201; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Rajagopalan S, 1996, J CLIN INVEST, V98, P2572, DOI 10.1172/JCI119076; Retsky KL, 1999, FREE RADICAL BIO MED, V26, P90, DOI 10.1016/S0891-5849(98)00151-8; Schweizer A, 1997, BIOCHEM J, V328, P871, DOI 10.1042/bj3280871; Shimada K, 1996, BIOCHEM J, V315, P863, DOI 10.1042/bj3150863; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; SHIMADA K, 1995, FEBS LETT, V371, P140, DOI 10.1016/0014-5793(95)00886-E; SHINGU M, 1994, RHEUMATOL INT, V14, P77, DOI 10.1007/BF00300251; SHINGU M, 1994, INFLAMMATION, V18, P613, DOI 10.1007/BF01535259; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SUZUKI H, 1995, HYPERTENSION, V25, P1083, DOI 10.1161/01.HYP.25.5.1083; Suzuki YJ, 1999, J MOL CELL CARDIOL, V31, P345, DOI 10.1006/jmcc.1998.0872; TAKAHASHI M, 1993, J BIOL CHEM, V268, P21394; TAKAHASHI M, 1995, BIOCHEM J, V311, P657, DOI 10.1042/bj3110657; UCHIDA K, 1994, J BIOL CHEM, V269, P2405; UCHIDA K, 1993, FEBS LETT, V332, P208, DOI 10.1016/0014-5793(93)80632-5; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046	54	41	42	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26423	26427		10.1074/jbc.M000767200	http://dx.doi.org/10.1074/jbc.M000767200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10833511	hybrid			2022-12-25	WOS:000088999700075
J	Ragolia, L; Zuo, Q; Begum, N				Ragolia, L; Zuo, Q; Begum, N			Inhibition of myogenesis by depletion of the glycogen-associated regulatory subunit of protein phosphatase-1 in rat skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; DNA-BINDING; PHOSPHATIDYLINOSITOL 3-KINASE; RETINOBLASTOMA PROTEIN; INSULIN; DIFFERENTIATION; PHOSPHORYLATION; MECHANISM; MITOSIS; TYPE-1	In this study, we examined the role of the glycogen-associated regulatory subunit of protein phosphatase-l (PP-1(G)) in L6 rat skeletal muscle cell myogenesis. The level of PP-1(G) was depleted by transfection with an inducible antisense oriented PP-1(G) gene. Western blot analysis of the PP-1(G)-depleted cell line revealed a >90% depletion of PP-1(G) protein and a 45% reduction in cellular PP-1 activity and abolished the ability of L6 myoblasts to differentiate into multinucleated myotubes. PP-1(G)-depleted cells also exhibited a marked reduction in the expression of the differentiation marker myogenin as well as creatine kinase. After 7 days in culture, PP-1(G)-depleted cells sustained myoblast levels of inhibitor of differentiation-a, whereas control L6 cells had a severely lower inhibitor of differentiation-a level and progressed into myotubes. Myoblasts were unable to exit the cell cycle, as measured by the impaired induction of p27 cyclin-dependent kinase inhibitor, a >2-fold increase in DNA synthesis, and elevated levels of phosphorylated retinoblastoma protein (pRb). Replacement of the PP-1(G) gene restored PP-1(G) protein expression, PP-1 enzymatic activity, and the ability to differentiate into myotubes. We conclude that PP-1(G) plays a definite role in L6 myogenesis via its regulation of PP-1 catalytic activity.	Winthrop Univ Hosp, Diabet Res Lab, Mineola, NY 11501 USA; SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA	Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Ragolia, L (corresponding author), Winthrop Univ Hosp, Diabet Res Lab, 222 Stn Plaza N,Suite 511-B, Mineola, NY 11501 USA.	lragolia@winthrop.org	Ragolia, Louis/AAW-2383-2021					Begum N, 1998, J BIOL CHEM, V273, P25164, DOI 10.1074/jbc.273.39.25164; BEGUM N, 1998, AM J PHYSIOL, V275, pC422; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BUCKINGHAM M, 1994, CELL, V78, P15, DOI 10.1016/0092-8674(94)90568-1; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; HUBBARD MJ, 1991, METHOD ENZYMOL, V201, P414; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KIM SJ, 1992, J BIOL CHEM, V267, P15140; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Nelson DA, 1997, J BIOL CHEM, V272, P4528, DOI 10.1074/jbc.272.7.4528; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Puntoni F, 1997, BIOCHEM BIOPH RES CO, V235, P704, DOI 10.1006/bbrc.1997.6886; Ragolia L, 1997, ENDOCRINOLOGY, V138, P2398, DOI 10.1210/en.138.6.2398; Ragolia L, 1999, MOL ENDOCRINOL, V13, P1773, DOI 10.1210/me.13.10.1773; Rubin Ethel, 1998, Frontiers in Bioscience, V3, pD1209; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SRINIVASAN M, 1994, J BIOL CHEM, V269, P12514; STONE EM, 1993, CURR BIOL, V3, P13, DOI 10.1016/0960-9822(93)90140-J; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603	30	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26102	26108		10.1074/jbc.M001955200	http://dx.doi.org/10.1074/jbc.M001955200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852907	hybrid			2022-12-25	WOS:000088999700031
J	Rosenkilde, MM; Kledal, TN; Holst, PJ; Schwartz, TW				Rosenkilde, MM; Kledal, TN; Holst, PJ; Schwartz, TW			Selective elimination of high constitutive activity or chemokine binding in the human herpesvirus 8 encoded seven transmembrane oncogene ORF74	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; ALPHA(1B)-ADRENERGIC RECEPTOR; MURINE CYTOMEGALOVIRUS; EXTRACELLULAR DOMAIN; MCP-1 RECEPTOR; ACTIVATION; RESIDUES; IDENTIFICATION	Open reading frame 74 (ORF74) encoded by human herpesvirus 8 is a highly constitutively active seven transmembrane (7TM) receptor stimulated by angiogenic chemokines, e.g, growth-related oncogene-cv, and inhibited by angiostatic chemokines e.g, interferon-gamma-inducible protein. Transgenic mice expressing ORF74 under control of the CD2 promoter develop highly vascularized Kaposi's sarcoma-like tumors. Through targeted mutagenesis we here create three distinct phenotypes of ORF74: a receptor with normal, high constitutive signaling through the phospholipase C pathway but deprived of binding and action of chemokines obtained through deletion of 22 amino acids from the N-terminal extension; an ORF74 with high constitutive activity but with selective elimination of stimulatory regulation by angiogenic chemokines obtained through substitution of basic residues at the extracellular ends of TRI-V or TM-VI; and an ORF74 lacking constitutive activity but with preserved ability to be stimulated by agonist chemokines obtained through introduction of an Asp residue on the hydrophobic, presumed membrane-exposed face of TM-II, It is concluded that careful molecular dissection can selectively eliminate either agonist or inverse agonist modulation as well as high constitutive activity of the virally encoded oncogene ORF74 and that these mutant forms presumably can be used in transgenic animals to identify the molecular mechanism of its transforming activity.	Univ Copenhagen, Panum Inst 18 6 12, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark	University of Copenhagen	Schwartz, TW (corresponding author), Univ Copenhagen, Panum Inst 18 6 12, Dept Pharmacol, Mol Pharmacol Lab, Blegdamsvej 3, DK-2200 Copenhagen, Denmark.	schwartz@molpharm.dk		Rosenkilde, Mette Marie/0000-0001-9600-3254; Schwartz, Thue W./0000-0002-0261-6904; Holst, Peter Johannes/0000-0002-1279-304X				AHUJA SK, 1993, J BIOL CHEM, V268, P20691; AHUJA SK, 1999, CHEMOKINES DIS; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Balmforth AJ, 1997, J BIOL CHEM, V272, P4245, DOI 10.1074/jbc.272.7.4245; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Blanpain C, 1999, J BIOL CHEM, V274, P34719, DOI 10.1074/jbc.274.49.34719; Burger M, 1999, J IMMUNOL, V163, P2017; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; Dairaghi DJ, 1998, SEMIN VIROL, V8, P377, DOI 10.1006/smvy.1997.0146; Damon I, 1998, P NATL ACAD SCI USA, V95, P6403, DOI 10.1073/pnas.95.11.6403; DavisPoynter NJ, 1997, J VIROL, V71, P1521, DOI 10.1128/JVI.71.2.1521-1529.1997; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; FIELD BN, 1995, FIELDS VIROLOGY; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; Hjorth SA, 1998, MOL ENDOCRINOL, V12, P78, DOI 10.1210/mend.12.1.0045; Ho HH, 1999, J BIOL CHEM, V274, P31327, DOI 10.1074/jbc.274.44.31327; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Horuk R, 1998, NATURE, V393, P524, DOI 10.1038/31116; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Lalani AS, 1999, CYTOKINE GROWTH F R, V10, P219, DOI 10.1016/S1359-6101(99)00018-0; LEONG SR, 1994, J BIOL CHEM, V269, P19343; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; MacDonald MR, 1997, J VIROL, V71, P1671, DOI 10.1128/JVI.71.2.1671-1678.1997; Marie J, 1999, MOL PHARMACOL, V55, P92, DOI 10.1124/mol.55.1.92; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Moore BB, 1998, TRENDS CARDIOVAS MED, V8, P51, DOI 10.1016/S1050-1738(97)00128-X; Penfold MET, 1999, P NATL ACAD SCI USA, V96, P9839, DOI 10.1073/pnas.96.17.9839; ROSENKILDE MM, 1994, J BIOL CHEM, V269, P28160; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Sozzani S, 1998, BLOOD, V92, P4036, DOI 10.1182/blood.V92.11.4036.423k17_4036_4039; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; TELFORD EAR, 1995, J MOL BIOL, V249, P520, DOI 10.1006/jmbi.1995.0314; Wells TNC, 1997, CURR OPIN BIOTECH, V8, P741, DOI 10.1016/S0958-1669(97)80129-2; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445	44	54	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26309	26315		10.1074/jbc.M003800200	http://dx.doi.org/10.1074/jbc.M003800200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10842179	hybrid			2022-12-25	WOS:000088999700059
J	van de Water, B; Tijdens, IB; Verbrugge, A; Huigsloot, M; Dihal, AA; Stevens, JL; Jaken, S; Mulder, GJ				van de Water, B; Tijdens, IB; Verbrugge, A; Huigsloot, M; Dihal, AA; Stevens, JL; Jaken, S; Mulder, GJ			Cleavage of the actin-capping protein alpha-adducin at Asp-Asp-Ser-Asp(633)-Ala by caspase-3 is preceded by its phosphorylation on serine 726 in cisplatin-induced apoptosis of renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROXIMAL TUBULAR CELLS; MARCKS-RELATED DOMAIN; ERYTHROCYTE ADDUCIN; RAT-KIDNEY; RHO-KINASE; C-MYC; SPECTRIN; DEATH; MATRIX	Decreased phosphorylation of focal adhesion kinase and paxillin is associated with loss of focal adhesions and stress fibers and precedes the onset of apoptosis (van de Water, B,, Nagelkerke, J, F., and Stevens, J, L, (1999) J, Biol. Chem. 274, 13328-13337), The cortical actin cytoskeletal network is also lost during apoptosis, yet little is known about the temporal relationship between altered phosphorylation of proteins that are critical in the regulation of this network and their potential cleavage by caspases during apoptosis. Adducins are central in the cortical actin network organization. Cisplatin caused apoptosis of renal proximal tubular epithelial cells, which was associated with the cleavage of alpha-adducin into a 74-kDa fragment; this was blocked by a general caspase inhibitor benzyloxycarbonyl-val-Ala-Asp-fluoromethyl ketone (z-VAD-fmk). Hemagglutinin-tagged human alpha-adducin was cleaved into a similar 74-kDa fragment by caspase-3 in vitro but not by caspase-6 or -7, Asp-Arg-Val-Asp(29)-Glu, Asp-Ile-Val-Asp(208)-Arg, and Asp-Asp-Ser-Asp(635)-Ala were identified as the principal caspase-3 cleavage sites; Asp-Asp-Ser-Asp(633)-Ala was key in the formation of the 74-kDa fragment. Cisplatin also caused an increased phosphorylation of alpha-adducin and gamma-adducin in the MARCKS domain that preceded alpha-adducin cleavage and was associated with loss of adducins from adherens junctions; this was not affected by z-VAD-fmk. In conclusion, the data support a model in which increased phosphorylation of alpha-adducin due to cisplatin leads to dissociation from the cytoskeleton, a situation rendered irreversible by caspase-3-mediated cleavage of alpha-adducin at Asp-Asp-Ser-Asp(633)-Ala.	Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Toxicol, NL-2300 RA Leiden, Netherlands; Univ Vermont, Sch Med, Dept Pathol, Burlington, VT 05405 USA	Leiden University; Leiden University - Excl LUMC; University of Vermont	van de Water, B (corresponding author), Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Toxicol, POB 9503, NL-2300 RA Leiden, Netherlands.				NCI NIH HHS [CA71607] Funding Source: Medline; NIDDK NIH HHS [DK47267] Funding Source: Medline; NIEHS NIH HHS [ES07847] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071607] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007847] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BOOGAARD PJ, 1989, TOXICOL APPL PHARM, V101, P135, DOI 10.1016/0041-008X(89)90219-6; Brady H.R., 1996, KIDNEY, P1200; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DONG LQ, 1995, J BIOL CHEM, V270, P25534, DOI 10.1074/jbc.270.43.25534; Fowler L, 1998, CELL GROWTH DIFFER, V9, P177; Fowler L, 1998, CELL GROWTH DIFFER, V9, P405; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; GOLDSTEIN RS, 1996, TOXICOLOGY, P417; GOLIGORSKY MS, 1993, AM J PHYSIOL, V264, pF1, DOI 10.1152/ajprenal.1993.264.1.F1; HARTWIG JH, 1995, PROTEIN PROFILE, V2, P703; HATZINGER PB, 1989, IN VITRO CELL DEV B, V25, P205; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; HUGHES CA, 1995, J BIOL CHEM, V270, P18990, DOI 10.1074/jbc.270.32.18990; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; JOSHI R, 1990, J BIOL CHEM, V265, P13130; JOSHI R, 1991, J CELL BIOL, V115, P665, DOI 10.1083/jcb.115.3.665; Kamada S, 1998, P NATL ACAD SCI USA, V95, P8532, DOI 10.1073/pnas.95.15.8532; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kruidering M, 1998, CELL DEATH DIFFER, V5, P601, DOI 10.1038/sj.cdd.4400392; Kuhlman PA, 1996, J BIOL CHEM, V271, P7986, DOI 10.1074/jbc.271.14.7986; Li XL, 1998, J BIOL CHEM, V273, P19329, DOI 10.1074/jbc.273.30.19329; Li XL, 1996, J BIOL CHEM, V271, P15695, DOI 10.1074/jbc.271.26.15695; Lieberthal W, 1998, SEMIN NEPHROL, V18, P505; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; Matsuoka Y, 1996, J BIOL CHEM, V271, P25157, DOI 10.1074/jbc.271.41.25157; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; OSBORNE BA, 1995, SEMIN CANCER BIOL, V6, P27, DOI 10.1006/scbi.1995.0004; RACUSEN LC, 1991, LAB INVEST, V64, P546; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Sanders EJ, 1995, INT REV CYTOL, V163, P105, DOI 10.1016/S0074-7696(08)62210-X; Shimizu T, 1998, J BIOL CHEM, V273, P8669, DOI 10.1074/jbc.273.15.8669; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van de Water B, 1999, J BIOL CHEM, V274, P13328, DOI 10.1074/jbc.274.19.13328; VANDEWATER B, 1994, AM J PHYSIOL-RENAL, V267, pF888, DOI 10.1152/ajprenal.1994.267.5.F888; VANDEWATER B, 1994, J BIOL CHEM, V269, P14546; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Zhan Y, 1997, MOL CELL BIOL, V17, P6755, DOI 10.1128/MCB.17.11.6755	59	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25805	25813		10.1074/jbc.M001680200	http://dx.doi.org/10.1074/jbc.M001680200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10823823	hybrid, Green Published			2022-12-25	WOS:000088849400098
J	Yamashita, S; Mochizuki, N; Ohba, Y; Tobiume, M; Okada, Y; Sawa, H; Nagashima, K; Matsuda, M				Yamashita, S; Mochizuki, N; Ohba, Y; Tobiume, M; Okada, Y; Sawa, H; Nagashima, K; Matsuda, M			CalDAG-GEFIII activation of Ras, R-Ras, and Rap1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; DEPENDENT ACTIVATION; SIGNAL-TRANSDUCTION; BINDING PROTEINS; CELL-ADHESION; EXPRESSION; CRK; C3G; TRANSFORMATION; KINASE	We characterized a novel guanine nucleotide exchange factor (GEF) for Ras family G proteins that is highly homologous to CalDAG-GEFI, a GEF for Rap1 and R-Ras, and to RasGRP/CalDAG-GEFII, a GEF for Res and R-Ras. This novel GEF, referred to as CalDAG-GEFIII, increased the GTP/GDP ratio of Ha-Ras, R-Ras, and Rap1 in 293T cells. CalDAG-GEFIII promoted the guanine nucleotide exchange of Ha-Ras, R-Ras, and Rap1 in vitro also, indicating that CalDAG-GEFIII exhibited the widest substrate specificity among the known GEFs for Res family G proteins. Expression of CalDAG-GEFIII was detected in the glial cells of the brain and the glomerular mesangial cells of the kidney by in. situ hybridization. CalDAG-GEFIII activated ERW MAPK most efficiently, followed by CalDAG-GEFII and CalDAG-GEFI in 293T cells. JNK activation was most prominent in cells expressing CalDAG-GEFII, followed by CalDAG-GEFIII and CaLDAG-GEFI. Expression of CalDAG-GEFIII induced neuronal differentiation of PC12 cells and anchorage-independent growth of Rat1A cells less efficiently than did CalDAG-GEFII. Thus, coactivation of Rap1 by CalDAG-GEFIII apparently attenuated Ras-MAPK-dependent neuronal differentiation and cellular transformation. Altogether, CalDAG-GEFIII activated a broad range of Res family Gr proteins and exhibited a biological activity different from that of either CalDAG-GEFI or CalDAG-GEFII.	Int Med Ctr Japan, Res Inst, Dept Pathol, Shinjuku Ku, Tokyo 1628655, Japan; Hokkaido Univ, Sch Med, Lab Mol & Cellular Pathol, Sapporo, Hokkaido 0608638, Japan	National Center for Global Health & Medicine - Japan; Hokkaido University	Matsuda, M (corresponding author), Int Med Ctr Japan, Res Inst, Dept Pathol, Shinjuku Ku, 1-12-1 Toyama, Tokyo 1628655, Japan.		Sawa, Hirofumi/AAW-8816-2021; Ohba, Yusuke/E-7944-2011; Sawa, Hirofumi/F-6954-2012	Sawa, Hirofumi/0000-0003-2569-2755; Matsuda, Michiyuki/0000-0002-5876-9969				BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COX AD, 1994, ONCOGENE, V9, P3281; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; FEIG LA, 1994, NATURE, V370, P508, DOI 10.1038/370508a0; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Graham SM, 1996, MOL CELL BIOL, V16, P6132; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Ichiba T, 1999, FEBS LETT, V457, P85, DOI 10.1016/S0014-5793(99)01012-1; Ichiba T, 1997, J BIOL CHEM, V272, P22215, DOI 10.1074/jbc.272.35.22215; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Movilla N, 1999, ONCOGENE, V18, P5860, DOI 10.1038/sj.onc.1202968; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohtsuka T, 1999, BIOCHEM BIOPH RES CO, V265, P38, DOI 10.1006/bbrc.1999.1619; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; Tanaka M, 1997, P NATL ACAD SCI USA, V94, P4493, DOI 10.1073/pnas.94.9.4493; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695	42	121	126	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25488	25493		10.1074/jbc.M003414200	http://dx.doi.org/10.1074/jbc.M003414200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10835426	hybrid			2022-12-25	WOS:000088849400059
J	Ariyoshi, K; Nosaka, T; Yamada, K; Onishi, M; Oka, Y; Miyajima, A; Kitamura, T				Ariyoshi, K; Nosaka, T; Yamada, K; Onishi, M; Oka, Y; Miyajima, A; Kitamura, T			Constitutive activation of STAT5 by a point mutation in the SH2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PHOSPHOTYROSYL PEPTIDE; PERIPHERAL-BLOOD CELLS; MEDIATED GENE-TRANSFER; SRC HOMOLOGY-2 DOMAIN; BCL-X-L; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; ABL ONCOGENE	We previously identified a constitutively active form of STAT (signal transducer and activator of transcription) 5A by polymerase chain reaction-driven random mutagenesis followed by retrovirus-mediated expression screening, which had two point mutations in the DNA-binding and transcriptional activation domains, and was designated STAT5A1*6, STAT5A1*6 showed markedly elevated DNA binding and transactivation activities with stable tyrosine phosphorylation and nuclear accumulation, and conferred autonomous cell growth on interleukin 3-dependent Ba/F3 cells. We now report another constitutively active mutant, STAT5A-N642H which has a single point mutation (N642H) in its SH2 domain, identified using the same strategy as that used to identify STAT5A1*G, STAT5A-N642H showed identical properties to those of STAT5A1*6 both biochemically and biologically. Interestingly the mutation in STAT5A-N642H resulted in restoration of the conserved critical histidine which is involved in the binding of phosphotyrosine in the majority of SH2-containing proteins. Introduction of an additional mutation (Y694F) to STAT5A-N642H, which disrupted critical tyrosine 694 required for dimerization of STATE, abolished all the activities manifested by the mutant STAT5A-N642H, which indicates that dimerization is required for the activity of STAT5A-N642H as was the case for the wild-type STAT5A The present findings also show that different mutations rendered STAT5A constitutively active, through a common mechanism, which is similar to that of physiological activation.	Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Tokyo 1088639, Japan; Univ Tokyo, Dept Internal Med 3, Tokyo 1138655, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Yamaguchi Univ, Sch Med, Dept Internal Med 3, Yamaguchi 7558505, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Yamaguchi University	Kitamura, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Hematopoiet Factors, Tokyo 1088639, Japan.	kitamura@ims.u-tokyo.ac.jp	Kitamura, Toshio/AAA-2071-2021					BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chai SK, 1997, J IMMUNOL, V159, P4720; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Futterer K, 1998, J MOL BIOL, V281, P523, DOI 10.1006/jmbi.1998.1964; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GouilleuxGruart V, 1996, BLOOD, V87, P1692; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Kamogawa Y, 1998, J IMMUNOL, V161, P1074; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Lilly M, 1997, CANCER RES, V57, P5348; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Onishi M, 1996, EXP HEMATOL, V24, P324; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Shuai K, 1996, ONCOGENE, V13, P247; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thomas J, 1998, ONCOGENE, V16, P1399, DOI 10.1038/sj.onc.1201672; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WeberNordt RM, 1996, BLOOD, V88, P809; Wellbrock C, 1998, ONCOGENE, V16, P3047, DOI 10.1038/sj.onc.1201844; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	59	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24407	24413		10.1074/jbc.M909771199	http://dx.doi.org/10.1074/jbc.M909771199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10823841	hybrid			2022-12-25	WOS:000088683300023
J	Li, YH; Salter-Cid, L; Vitiello, A; Preckel, T; Lee, JD; Angulo, A; Cai, ZL; Peterson, PA; Yang, Y				Li, YH; Salter-Cid, L; Vitiello, A; Preckel, T; Lee, JD; Angulo, A; Cai, ZL; Peterson, PA; Yang, Y			Regulation of transporter associated with antigen processing by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; HISTOCOMPATIBILITY COMPLEX-MOLECULES; DROSOPHILA-MELANOGASTER CELLS; HUMAN CYTOMEGALOVIRUS; INTRACELLULAR-TRANSPORT; PEPTIDE-TRANSPORT; GENE-PRODUCT; TAP; PROTEASOMES; BINDING	The ATP-binding cassette transporter associated with antigen processing (TAP) is required for transport of antigenic peptides, generated by proteasome complexes in the cytoplasm, into the lumen of the endoplasmic reticulum where assembly with major histocompatibility complex class I molecules takes place. The TAP transporter is a heterodimer of TAP1 and TAPS, Here we show that both TAP1 and TAPS are phosphorylated under physiological conditions. Phosphorylation induces formation of high molecular weight TAP complexes that contain TAP1, TAPS, tapasin, and class I heterodimers, In addition, a 43-kDa phosphoprotein, which appears to be a kinase, is contained in the phosphorylated TAP-containing complexes. Phosphorylated TAP complexes are able to bind peptides and ATP, however, they are not capable of transporting peptides. After de-phosphorylation, TAP complexes regain the ability to transport peptides, Interestingly, phosphorylation levels of TAP complexes induced by viral infection inversely correlates with a significant reduction in TAP-dependent peptide transport activity. Enhanced TAP phosphorylation appears to be one of several strategies that viruses have exploited to better escape from host immune surveillance. These results demonstrate that major histocompatibility complex class I antigen processing and presentation is modulated by reversible TAP phosphorylation, and implicate the importance of TAP phosphorylation in the regulation of cytotoxic immune response.	RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; Scripps Res Inst, Res Inst, La Jolla, CA 92037 USA	Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute	Yang, Y (corresponding author), RW Johnson Pharmaceut Res Inst, 3210 Merryfield Row, San Diego, CA 92121 USA.	yyang@prius.jnj.com		Angulo, Ana/0000-0002-5792-1164				Ahn K, 1996, J BIOL CHEM, V271, P18237, DOI 10.1074/jbc.271.30.18237; Ahn K, 1997, IMMUNITY, V6, P613, DOI 10.1016/S1074-7613(00)80349-0; Ahn KS, 1996, P NATL ACAD SCI USA, V93, P10990, DOI 10.1073/pnas.93.20.10990; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; Armandola EA, 1996, EUR J IMMUNOL, V26, P1748, DOI 10.1002/eji.1830260813; Blevitt JM, 1999, J BIOMOL SCREEN, V4, P87, DOI 10.1177/108705719900400208; Bose S, 1999, MOL BIOL REP, V26, P11, DOI 10.1023/A:1006969517958; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Deverson EV, 1998, J IMMUNOL, V160, P2767; Elliott T, 1997, ADV IMMUNOL, V65, P47, DOI 10.1016/S0065-2776(08)60741-5; Fourie AM, 1998, CURR TOP MICROBIOL, V232, P49; FRUH K, 1995, NATURE, V375, P415, DOI 10.1038/375415a0; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; Gallina A, 1999, J VIROL, V73, P1468, DOI 10.1128/JVI.73.2.1468-1478.1999; Germann UA, 1998, CYTOTECHNOLOGY, V27, P31, DOI 10.1023/A:1008023629269; Gilbert MJ, 1996, NATURE, V383, P720, DOI 10.1038/383720a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; Keicho N, 1999, TISSUE ANTIGENS, V53, P366, DOI 10.1034/j.1399-0039.1999.530407.x; LEE CH, 1994, MOL CELLS, V4, P481; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; Lobigs M, 1999, IMMUNOGENETICS, V49, P931, DOI 10.1007/s002510050576; McNicholas CM, 1996, P NATL ACAD SCI USA, V93, P8083, DOI 10.1073/pnas.93.15.8083; Ofosu MH, 1998, IMMUNOL INVEST, V27, P281, DOI 10.3109/08820139809070901; Ohta Y, 1999, IMMUNOGENETICS, V49, P171, DOI 10.1007/s002510050478; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Powis SJ, 1996, IMMUNITY, V4, P159, DOI 10.1016/S1074-7613(00)80680-9; Quadri SA, 1998, IMMUNOL LETT, V61, P25, DOI 10.1016/S0165-2478(97)00157-0; Reits EAJ, 2000, NATURE, V404, P774, DOI 10.1038/35008103; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Schoenhals GJ, 1999, EMBO J, V18, P743, DOI 10.1093/emboj/18.3.743; Sheppard DN, 1999, PHYSIOL REV, V79, P23; SONG ES, 1994, J BIOL CHEM, V269, P7024; TECTOR M, 1994, J BIOL CHEM, V269, P25816; van Endert PM, 1999, CURR OPIN IMMUNOL, V11, P82, DOI 10.1016/S0952-7915(99)80015-6; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; Vanoye CG, 1999, AM J PHYSIOL-CELL PH, V276, pC370, DOI 10.1152/ajpcell.1999.276.2.C370; WANG K, 1994, FEBS LETT, V350, P337, DOI 10.1016/0014-5793(94)00806-X; Wehren A, 1996, BIOL CHEM, V377, P497; Wolf DG, 1998, ARCH VIROL, V143, P1223, DOI 10.1007/s007050050370; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; Yang Y, 1996, IMMUNOL RES, V15, P208, DOI 10.1007/BF02918250; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; YANG Y, 1992, J BIOL CHEM, V267, P11669; Zhu H, 1998, P NATL ACAD SCI USA, V95, P14470, DOI 10.1073/pnas.95.24.14470	47	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					24130	24135		10.1074/jbc.M003617200	http://dx.doi.org/10.1074/jbc.M003617200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10823836	hybrid			2022-12-25	WOS:000088564200098
J	Miller, AF; Harvey, SAK; Thies, RS; Olson, MS				Miller, AF; Harvey, SAK; Thies, RS; Olson, MS			Bone morphogenetic protein-9 - An autocrine/paracrine cytokine in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MESSENGER-RNA EXPRESSION; OSTEOGENIC PROTEIN-1; SIGNAL-TRANSDUCTION; RAT-KIDNEY; TGF-BETA; RECEPTOR; CELLS; INTERNALIZATION; SKELETAL	Bone morphogenetic proteins (BMPs) occupy important roles during development serving to direct cells through specific differentiation programs. While several BMPs are essential for embryonic viability, their significance in mediating intercellular communication in the context of adult organ systems remains largely unknown, In the adult rat we characterized the tissue-and cell-specific transcription and translation of BMP-9, Utilizing a ribonuclease protection assay, we determined that in the adult animal, BMP-9 expression occurs predominantly in the liver. Furthermore, we determined that the non-parenchymal cells of the liver, i.e, endothelial, Kupffer, and stellate cells, are the major sources of this message, Western analyses corroborate the ribonuclease protection assay results, confirming that LEC and KC contain an abundance of immunoreactive BMP-9, Using [I-125]BMP-9, a receptor with specific binding affinity for BRBP-9 was characterized in primary cultures of hepatic endothelial cells and Kupffer cells. BMP-9 binding to these cell types was observed to be fully reversible and highly specific for this ligand, Additionally, we demonstrate that BMPP-9 is specifically internalized upon binding to its receptor. This may represent a novel BMP receptor and is the first to be characterized in primary cultures of mature liver nonparenchymal cells. Our results depict BMP-9 as a potential autocrine/paracrine mediator in the hepatic reticuloendothelial system.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA; Genet Inst Inc, Cambridge, MA 02140 USA	University of Texas System; University of Texas Health San Antonio	Olson, MS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.	olson@biochem.uthscsa.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019473] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bergeron JJM, 1995, BIOSCIENCE REP, V15, P411, DOI 10.1007/BF01204345; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Blessing M, 1996, J CELL BIOL, V135, P227, DOI 10.1083/jcb.135.1.227; CUNNINGHAM NS, 1992, P NATL ACAD SCI USA, V89, P11740, DOI 10.1073/pnas.89.24.11740; Eakes AT, 1998, AM J PHYSIOL-GASTR L, V274, pG1068, DOI 10.1152/ajpgi.1998.274.6.G1068; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GANDHI CR, 1993, ARCH BIOCHEM BIOPHYS, V305, P38, DOI 10.1006/abbi.1993.1390; GANDHI CR, 1992, BIOCHEM J, V281, P485, DOI 10.1042/bj2810485; GRESSNER AM, 1994, ANN BIOL CLIN-PARIS, V52, P205; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; Heck DA, 1998, LIFE SCI, V62, P1467, DOI 10.1016/S0024-3205(98)00091-5; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; IWASAKI S, 1995, J BIOL CHEM, V270, P5476, DOI 10.1074/jbc.270.10.5476; JAKOWLEW SB, 1991, CELL REGUL, V2, P535, DOI 10.1091/mbc.2.7.535; Jortikka L, 1997, CELL SIGNAL, V9, P47, DOI 10.1016/S0898-6568(96)00094-0; KING JA, 1994, DEV BIOL, V166, P112, DOI 10.1006/dbio.1994.1300; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; Knittel T, 1997, EXP CELL RES, V232, P263, DOI 10.1006/excr.1997.3504; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; Kossman T, 1992, GROWTH FACTORS, V7, P73, DOI 10.3109/08977199209023939; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; LUYTEN FP, 1994, EXP CELL RES, V210, P224, DOI 10.1006/excr.1994.1033; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1986, J CELL PHYSIOL, V128, P216, DOI 10.1002/jcp.1041280212; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Natsume T, 1997, J BIOL CHEM, V272, P11535; OZKAYNAK E, 1992, J BIOL CHEM, V267, P25220; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; ROCKEY DC, 1994, J INVEST MED, V42, P660; ROSEN V, 1994, J BONE MINER RES, V9, P1759; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Simon N, 1999, AM J PHYSIOL-RENAL, V276, pF382, DOI 10.1152/ajprenal.1999.276.3.F382; SONG JJ, 1995, ENDOCRINOLOGY, V136, P4293, DOI 10.1210/en.136.10.4293; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; THIES RS, 1992, ENDOCRINOLOGY, V130, P1318, DOI 10.1210/en.130.3.1318; Vukicevic S, 1998, J CLIN INVEST, V102, P202, DOI 10.1172/JCI2237; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAMAJI N, 1994, BIOCHEM BIOPH RES CO, V205, P1944, DOI 10.1006/bbrc.1994.2898; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1; Zhang HB, 1996, DEVELOPMENT, V122, P2977; Zhao GQ, 1998, DEVELOPMENT, V125, P1103	45	114	126	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					17937	17945		10.1074/jbc.275.24.17937	http://dx.doi.org/10.1074/jbc.275.24.17937			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849432	hybrid			2022-12-25	WOS:000087659400006
J	Price-Schiavi, SA; Zhu, XY; Aquinin, R; Carraway, KL				Price-Schiavi, SA; Zhu, XY; Aquinin, R; Carraway, KL			Sialomucin complex (rat Muc4) is regulated by transforming growth factor beta in mammary gland by a novel post-translational mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PARTICLE; ADENOCARCINOMA CELLS; MOLECULAR-CLONING; EPITHELIAL-CELLS; EXTRACELLULAR-MATRIX; GLYCOPROTEIN COMPLEX; EXPRESSION; PROTEIN; GROWTH-FACTOR-BETA-1; RECEPTOR	Sialomucin complex (SMC, rat Muc4) is a heterodimeric glycoprotein complex consisting of a mucin subunit ASGP-1 (for ascites sialoglycoprotein-1) and a transmembrane subunit ASGP-2, produced from a single gene and precursor. SMC expression is tightly regulated in mammary gland; the level in lactating mammary gland is about 100-fold that in virgin gland. In rat mammary epithelial cells, SMC is post-transcriptionally regulated by Matrigel by inhibition of SMC precursor synthesis. SMC is also posttranscriptionally regulated by transforming growth factor-beta (TGF beta), The repression of SMC expression by TGF beta is rapid, is independent of TGF beta-induced cell cycle arrest, and does not require new protein synthesis. Unlike Matrigel, TGF beta does not reduce SMC protein synthesis, as SMC precursor accumulation is equivalent in TGF beta-treated and untreated cells. Instead, SMC precursor in TGF beta-treated cells is more persistent and does not become processed as rapidly into mature ASGP-1 and ASGP-2, indicating that TGF beta disrupts processing of SMC precursor. These results indicate that SMC, a product of normal mammary gland and milk, is regulated by TGF beta by a novel post-translational mechanism. Thus, SMC is regulated by multiple posttranscriptional mechanisms, which serve to repress potential deleterious effects of overexpression.	Univ Miami, Sch Med, Dept Cell Biol & Anat R124, Miami, FL 33101 USA; Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33101 USA	University of Miami; University of Miami	Carraway, KL (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat R124, POB 016960, Miami, FL 33101 USA.				NATIONAL CANCER INSTITUTE [R01CA052498] Funding Source: NIH RePORTER; NCI NIH HHS [CA 52498] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Carraway CAC, 1999, J BIOL CHEM, V274, P25659, DOI 10.1074/jbc.274.36.25659; CARRAWAY K L, 1991, Glycobiology, V1, P131, DOI 10.1093/glycob/1.2.131; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARRAWAY KL, 1992, J CELL SCI, V103, P299; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARRAWAY KL, 1979, J CELL BIOL, V83, P529, DOI 10.1083/jcb.83.3.529; Chen TP, 1998, CANCER RES, V58, P4805; Close MJ, 1997, J CELL SCI, V110, P2861; DANIEL CW, 1989, DEV BIOL, V135, P20, DOI 10.1016/0012-1606(89)90154-1; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; ELBEIN AD, 1984, CRC CR REV BIOCH MOL, V16, P21, DOI 10.3109/10409238409102805; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; Gacheru SN, 1997, J CELL BIOCHEM, V65, P395, DOI 10.1002/(SICI)1097-4644(19970601)65:3<395::AID-JCB9>3.0.CO;2-N; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; HOWARD SC, 1982, JNCI-J NATL CANCER I, V69, P33; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; Juang SH, 1996, ONCOGENE, V12, P1033; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 1999, CANCER RES, V59, P2229; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCNEER RR, 1997, FRONT BIOSCI, V2, P449; MERCIER JC, 1993, J DAIRY SCI, V76, P3079, DOI 10.3168/jds.S0022-0302(93)77647-X; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; Nollet S, 1998, BIOCHEM J, V332, P739, DOI 10.1042/bj3320739; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; ROBINSON SD, 1991, DEVELOPMENT, V113, P867; ROBINSON SD, 1993, J CELL BIOL, V120, P245, DOI 10.1083/jcb.120.1.245; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; Rydziel S, 1997, J CELL PHYSIOL, V170, P145, DOI 10.1002/(SICI)1097-4652(199702)170:2<145::AID-JCP6>3.0.CO;2-O; Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; STAMPFER MR, 1993, J CELL PHYSIOL, V155, P210, DOI 10.1002/jcp.1041550127; STAMPFER MR, 1988, BREAST CANCER CELLUL, P1; SUDLOW AW, 1994, BIOCHEM J, V304, P333, DOI 10.1042/bj3040333; VALVERIUS EM, 1989, CANCER RES, V49, P6269; WU K, 1994, J BIOL CHEM, V269, P11950; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	43	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17800	17807		10.1074/jbc.275.23.17800	http://dx.doi.org/10.1074/jbc.275.23.17800			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837499	hybrid			2022-12-25	WOS:000087485000082
J	Taylor, LM; Khachigian, LM				Taylor, LM; Khachigian, LM			Induction of platelet-derived growth factor B-chain expression by transforming growth factor-beta involves transactivation by Smads	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; HUMAN ATHEROSCLEROTIC LESIONS; COLLAGEN GENE-EXPRESSION; FLUID SHEAR-STRESS; TGF-BETA; FACTOR-A; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; RECEPTOR EXPRESSION; REGULATORY ELEMENTS	Transforming growth factor-beta (TGF-beta) regulates a diverse array of biological processes, such as proliferation, differentiation, extracellular matrix production, and apoptosis. In cultured vascular endothelial cells, TGF-beta induces the expression of platelet-derived growth factor (PDGF) B-chain, a mitogen and chemoattractant, at the level of transcription. The molecular mechanism(s) underlying this process are not presently understood. In this study, we performed serial 5' deletion and transient transfection analysis to define a region in the PDGF-B promoter mediating inducible responsiveness to TGF-beta. This region contains an atypical nucleotide recognition element for the Smad family of transcriptional regulators. Electrophoretic mobility shift analysis revealed that nuclear proteins bound to this site in a transient and specific manner. Supershift studies demonstrated the physical association of Smad4 with the promoter. Overexpression of Smad4 activated the PDGF-B promoter and superinduced PDGF-B promoter-dependent expression in cells exposed to TGF-beta. Moreover, simultaneous cotransfection of Smad3 and Smad4 activated the PDGF-B promoter. This effect was attenuated when Smad4 was substituted with its dominant negative counterpart. Mutation of the (-81)CAGA(-78) motif in the PDGF-B promoter abrogated Smad-inducible promoter-dependent expression. Overexpression of Smad2 and Smad3 transactivated the PDGF-B promoter in a synergistic manner. These findings demonstrate the existence of a novel, functional binding element in the proximal region of the PDGF-B promoter mediating responsiveness to TGF-beta.	Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia; Prince Wales Hosp, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Khachigian, LM (corresponding author), Univ New S Wales, Sch Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia.		Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				BARRETT TB, 1987, P NATL ACAD SCI USA, V84, P1099, DOI 10.1073/pnas.84.4.1099; BARTRAM CR, 1984, BLOOD, V63, P223; Bobik A, 1999, CIRCULATION, V99, P2883, DOI 10.1161/01.CIR.99.22.2883; DANIEL TO, 1987, J BIOL CHEM, V262, P11893; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DIRKS RPH, 1995, NUCLEIC ACIDS RES, V23, P1119, DOI 10.1093/nar/23.7.1119; Evanko SP, 1998, AM J PATHOL, V152, P533; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; HANCOCK WW, 1994, AM J PATHOL, V145, P1008; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JIN HM, 1994, J BIOL CHEM, V269, P28648; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KANZAKI T, 1995, ARTERIOSCL THROM VAS, V15, P1951, DOI 10.1161/01.ATV.15.11.1951; KAVANAUGH WM, 1988, J BIOL CHEM, V263, P8470; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; KIM SK, 1995, CIRCULATION, V92, P88, DOI 10.1161/01.CIR.92.1.88; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; LINDNER V, 1995, AM J PATHOL, V146, P1488; LINDNER V, 1995, CIRC RES, V76, P951, DOI 10.1161/01.RES.76.6.951; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Nikol S, 1998, ATHEROSCLEROSIS, V139, P31, DOI 10.1016/S0021-9150(98)00050-1; OBrien ER, 1996, ARTERIOSCL THROM VAS, V16, P576, DOI 10.1161/01.ATV.16.4.576; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; POMPILI VJ, 1995, ARTERIOSCL THROM VAS, V15, P2254, DOI 10.1161/01.ATV.15.12.2254; RAO CD, 1986, P NATL ACAD SCI USA, V83, P2392, DOI 10.1073/pnas.83.8.2392; REKHTER MD, 1994, CIRC RES, V75, P410, DOI 10.1161/01.RES.75.3.410; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; Song CZ, 1998, J BIOL CHEM, V273, P29287, DOI 10.1074/jbc.273.45.29287; STARKSEN NF, 1987, J BIOL CHEM, V262, P14381; SWAN DC, 1982, P NATL ACAD SCI-BIOL, V79, P4691, DOI 10.1073/pnas.79.15.4691; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Trejo SR, 1996, J BIOL CHEM, V271, P14584, DOI 10.1074/jbc.271.24.14584; Ueda M, 1996, AM J PATHOL, V149, P831; vanEps RGS, 1997, J VASC SURG, V25, P1044, DOI 10.1016/S0741-5214(97)70128-9; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143; Wong C, 1999, MOL CELL BIOL, V19, P1821; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	54	86	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16709	16716		10.1074/jbc.275.22.16709	http://dx.doi.org/10.1074/jbc.275.22.16709			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828062	hybrid			2022-12-25	WOS:000087392200045
J	Sano, M; Fukuda, K; Kodama, H; Pan, J; Saito, M; Matsuzaki, J; Takahashi, T; Makino, S; Kato, T; Ogawa, S				Sano, M; Fukuda, K; Kodama, H; Pan, J; Saito, M; Matsuzaki, J; Takahashi, T; Makino, S; Kato, T; Ogawa, S			Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; MUSCLE CELL HYPERTROPHY; MYOCYTES IN-VITRO; GENE-EXPRESSION; VENTRICULAR MYOCYTES; GROWTH-FACTOR; RAT; FIBROBLASTS; RELEASE; GP130	This study was designed to investigate whether angiotensin II induces the interleukin (IL)-6 family of cytokines in cardiac fibroblasts and, if so, whether these cytokines can augment cardiac hypertrophy. Angiotensin II increased IL-6, leukemia inhibitory factor (LIF) and cardiotrophin-1 mRNA by 6.5-, 10.2-, and 2.0-fold, respectively, but did not affect IL-11, ciliary neurotrophic factor, or oncostatin M in cardiac fibroblasts, Enzyme-linked immunosorbent assay revealed that angiotensin II-stimulated conditioned medium from cardiac fibroblasts contained 9.3 ng/ml IL-6 at 24 h, which was 24-fold higher than the control. It phosphorylated gp130 and STAT3 in cardiomyocytes, which was reduced with RX435 (anti-gp130 blocking antibody). It increased [H-3]phenylalanine uptake and cell area by 44% and 86% in cardiomyocytes compared with mock medium. RX435 suppressed these increases by 26% and 38%, while TAK044 (endothelin-A/B-R blocker) suppressed them by 52% and 52%, respectively. Antisense oligonucleotides against LIF and cardiotrophin-1 blocked their up-regulation, and attenuated the conditioned medium-induced increase in [H-3]phenylalanine uptake by 21% and 13%, respectively. The combination of antisense oligonucleotides to LIF and cardiotrophin-1 decreased their uptake by 33%, These results indicated that angiotensin II induced IL-6, LIF, and cardiotrophin-1 in cardiac fibroblasts, and that these cytokines, particularly LIF and cardiotrophin-1, activated gp130-linked signaling and contributed to angiotensin II-induced cardiomyocyte hypertrophy.	Keio Univ, Dept Internal Med, Cardiopulm Div, Shinjuku Ku, Tokyo 1608582, Japan; Chugai Pharmaceut Co Ltd, Shizuoka 4128513, Japan	Keio University; Chugai Pharmaceutical Co., Ltd.; Roche Holding	Fukuda, K (corresponding author), Keio Univ, Dept Internal Med, Cardiopulm Div, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.		Sano, Motoaki/L-3405-2013; Fukuda, Keiichi/L-3777-2013					BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BAKER KM, 1990, AM J PHYSIOL, V259, P324; CRABOS M, 1994, J CLIN INVEST, V93, P2372, DOI 10.1172/JCI117243; DELAFONTAINE P, 1993, J BIOL CHEM, V268, P16866; EID H, 1994, J CARDIOVASC PHARM, V24, P715, DOI 10.1097/00005344-199424050-00005; FISHER SA, 1995, AM J PHYSIOL-CELL PH, V268, pC910; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Fukuda K, 1998, J MOL CELL CARDIOL, V30, P2069, DOI 10.1006/jmcc.1998.0770; Funakoshi Y, 1999, HYPERTENSION, V34, P118, DOI 10.1161/01.HYP.34.1.118; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; Gray MO, 1998, CARDIOVASC RES, V40, P352, DOI 10.1016/S0008-6363(98)00121-7; Harada M, 1997, CIRCULATION, V96, P3737; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; IKEDA S, 1994, J PHARMACOL EXP THER, V270, P728; ITO H, 1993, J CLIN INVEST, V92, P395; JUDD AM, 1992, ENDOCRINOLOGY, V130, P1245, DOI 10.1210/en.130.3.1245; KIM NN, 1995, AM J PHYSIOL-ENDOC M, V269, pE426, DOI 10.1152/ajpendo.1995.269.3.E426; Kodama H, 1997, CIRC RES, V81, P656; Kunisada K, 1996, CIRCULATION, V94, P2626, DOI 10.1161/01.CIR.94.10.2626; Kuwahara K, 1999, CIRCULATION, V100, P1116, DOI 10.1161/01.CIR.100.10.1116; LEE AA, 1995, J MOL CELL CARDIOL, V27, P2347, DOI 10.1016/S0022-2828(95)91983-X; LINDPAINTNER K, 1991, CIRC RES, V68, P905, DOI 10.1161/01.RES.68.4.905; LONG CS, 1993, J MOL CELL CARDIOL, V25, P915, DOI 10.1006/jmcc.1993.1104; LONG CS, 1991, CELL REGUL, V2, P1081, DOI 10.1091/mbc.2.12.1081; MORIYAMA T, 1995, J AM SOC NEPHROL, V6, P95; NISHIDA M, 1993, J CLIN INVEST, V91, P1934, DOI 10.1172/JCI116412; Pan J, 1998, HEART VESSELS, V13, P199, DOI 10.1007/BF01745045; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; PFEFFER JM, 1982, P NATL ACAD SCI-BIOL, V79, P3310, DOI 10.1073/pnas.79.10.3310; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; VILLARREAL FJ, 1993, CIRCULATION, V88, P2849, DOI 10.1161/01.CIR.88.6.2849; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258	37	189	205	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29717	29723		10.1074/jbc.M003128200	http://dx.doi.org/10.1074/jbc.M003128200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10843995	hybrid, Green Submitted			2022-12-25	WOS:000089439800072
J	Chen, J; Wang, YP; Wang, Y; Nakajima, T; Iwasawa, K; Hikiji, H; Sunamoto, M; Choi, DK; Yoshida, Y; Sakaki, Y; Toyo-oka, T				Chen, J; Wang, YP; Wang, Y; Nakajima, T; Iwasawa, K; Hikiji, H; Sunamoto, M; Choi, DK; Yoshida, Y; Sakaki, Y; Toyo-oka, T			Autocrine action and its underlying mechanism of nitric oxide on intracellular Ca2+ homeostasis in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CULTURED RAT ASTROCYTES; NA+/CA2+ EXCHANGE; HUMAN PLATELETS; RELAXING FACTOR; EXTRUSION MECHANISMS; PANCREATIC ACINAR; CALCIUM INFLUX; CYTOSOLIC CA2+	The rise in cytosolic Ca2+ concentration (Ca-i(2+)) in vascular endothelial cells (ECs) activates the production and release of nitric oxide (NO). NO modifies Ca-i(2+) homeostasis in many types of nonendothelial cells. However, its effect on endothelial Ca-i(2+) homeostasis at basal and excited states remains unclear. In the present study, to elucidate the effect of NO on basal Ca-i(2+) inositol 1,4,5-trisphosphate-induced Ca-i(2+) release (IICR) was blocked by expressing an antisense against type-1 inositol 1,1,B-trisphosphate receptors or by microinjecting heparin to individual ECs, and the effects of NO that was released by and diffused from adjacent IICR-intact ECs were recorded. After ATP or bradykinin stimulation, IICR-inhibited ECs showed a marked reduction of basal Ca-i(2+), which was abolished by NG-monomethyl-L-arginine monoacetate pretreatment. The reduction disappeared in sparsely seeded ECs. Exogenous NO gas mimicked the effect of ATP or bradykinin to reduce basal Ca-i(2+). Blocking plasma membrane Ca2+-ATPase Ca2+-ATPase (PMCA), but not Na+-Ca2+ exchange or sarcoplasmic/ endoplasmic reticulum Ca2+-ATPase, suppressed the reduction, indicating that the reduction resulted from a NO-dependent potentiation of PMCA. To elucidate the effect of NO on elevated Ca-i(2+), ATP-, bradykinin-, or thapsigargin-evoked Ca-i(2+) response in the presence and absence of NO production was compared in adjacent BOB-intact ECs. NO was found to potentiate PMCA, which, in turn, greatly attenuated agonist-evoked Ca2+ elevation. NO also potentiated Ca2+ influx, which markedly increased the sustained phase of Ca2+, elevation and possibly NO production. NO did not affect other Ca-i(2+)-elevating and Ca-i(2+)-sequestrating components. Thus, NO-dependent potentiation of PMCA is crucial for Ca-i(2+) homeostasis over a wide Ca-i(2+) range.	Univ Tokyo, Dept Internal Med 2, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Dept Oral & Maxillofacial Surg, Tokyo 1130033, Japan; Univ Tokyo, Ctr Human Genome, Inst Med Sci, Tokyo 1130033, Japan; Takeda Chem Ind Ltd, Mol Chem Lab, Osaka 5320024, Japan; Niigata Univ, Dept Pharmacol, Niigata 9518122, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Takeda Chemical Industries; Niigata University	Wang, YP (corresponding author), Univ Tokyo, Dept Internal Med 2, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.			Choi, Dong-Kug/0000-0001-7041-1524				ASANO S, 1995, J NEUROCHEM, V64, P2437; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Bian XP, 1996, CELL CALCIUM, V19, P351, DOI 10.1016/S0143-4160(96)90075-5; BISCHOF G, 1995, CELL CALCIUM, V17, P250, DOI 10.1016/0143-4160(95)90071-3; Bischof G, 1997, CELL CALCIUM, V21, P135, DOI 10.1016/S0143-4160(97)90037-3; BUCKLEY BJ, 1995, AM J PHYSIOL-CELL PH, V269, pC757, DOI 10.1152/ajpcell.1995.269.3.C757; Cavallini L, 1996, J BIOL CHEM, V271, P5545, DOI 10.1074/jbc.271.10.5545; Clementi E, 1997, TRENDS PHARMACOL SCI, V18, P266; Clementi E, 1998, BIOCHEM PHARMACOL, V55, P713, DOI 10.1016/S0006-2952(97)00375-4; CLEMENTI E, 1995, MOL PHARMACOL, V47, P517; Cohen RA, 1999, CIRC RES, V84, P210, DOI 10.1161/01.RES.84.2.210; DIPOLO R, 1982, BIOCHIM BIOPHYS ACTA, V688, P237, DOI 10.1016/0005-2736(82)90599-5; DIPOLO R, 1978, NATURE, V274, P390, DOI 10.1038/274390a0; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; FURUKAWA KI, 1991, J BIOL CHEM, V266, P12337; Goto Y, 1996, EUR J PHARMACOL, V314, P185, DOI 10.1016/S0014-2999(96)00532-8; GUKOVSKAYA A, 1994, AM J PHYSIOL, V266, pG350, DOI 10.1152/ajpgi.1994.266.3.G350; HANSEN BA, 1991, ANN NY ACAD SCI, V639, P566, DOI 10.1111/j.1749-6632.1991.tb17352.x; Herscher CJ, 1997, ANN NY ACAD SCI, V834, P407, DOI 10.1111/j.1749-6632.1997.tb52284.x; HIRATA M, 1990, J BIOL CHEM, V265, P1268; JOHANSSON JS, 1992, BIOCHIM BIOPHYS ACTA, V1105, P40, DOI 10.1016/0005-2736(92)90160-N; Kawaguchi H, 1997, CIRCULATION, V95, P2441, DOI 10.1161/01.CIR.95.10.2441; Klishin A, 1998, AM J PHYSIOL-CELL PH, V274, pC1117, DOI 10.1152/ajpcell.1998.274.4.C1117; KRATJE RB, 1985, BIOCHIM BIOPHYS ACTA, V816, P365, DOI 10.1016/0005-2736(85)90504-8; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LASKEY RE, 1990, J BIOL CHEM, V265, P2613; LUCKHOFF A, 1988, BRIT J PHARMACOL, V95, P189; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; Morgan AJ, 1998, J PHYSIOL-LONDON, V513, P83, DOI 10.1111/j.1469-7793.1998.083by.x; Mountian I, 1999, CELL CALCIUM, V25, P371, DOI 10.1054/ceca.1999.0034; NGUYEN BL, 1991, AM J PHYSIOL, V261, pH1043, DOI 10.1152/ajpheart.1991.261.4.H1043; Sang KHL, 1996, BRIT J PHARMACOL, V119, P1361, DOI 10.1111/j.1476-5381.1996.tb16047.x; SARKADI B, 1978, FEBS LETT, V89, P78, DOI 10.1016/0014-5793(78)80526-2; SCHILLING WP, 1988, AM J PHYSIOL, V255, pH219, DOI 10.1152/ajpheart.1988.255.2.H219; Sedova M, 1999, CELL CALCIUM, V25, P333, DOI 10.1054/ceca.1999.0036; SHIKANO K, 1988, J PHARMACOL EXP THER, V247, P873; Shimizu H, 1997, CELL CALCIUM, V21, P31, DOI 10.1016/S0143-4160(97)90094-4; SHIN WS, 1992, J BIOL CHEM, V267, P20377; Snitsarev VA, 1999, CELL CALCIUM, V25, P409, DOI 10.1054/ceca.1999.0041; Strobaek D, 1996, BRIT J PHARMACOL, V118, P1645, DOI 10.1111/j.1476-5381.1996.tb15587.x; Takuma K, 1996, J NEUROCHEM, V67, P1840; Trepakova ES, 1999, CIRC RES, V84, P201, DOI 10.1161/01.RES.84.2.201; UNEYAMA H, 1994, BRIT J PHARMACOL, V111, P245, DOI 10.1111/j.1476-5381.1994.tb14051.x; VANE JR, 1990, NEW ENGL J MED, V323, P27; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; Volk T, 1997, J CELL PHYSIOL, V172, P296, DOI 10.1002/(SICI)1097-4652(199709)172:3<296::AID-JCP3>3.0.CO;2-J; WAKABAYASHI S, 1987, J BIOL CHEM, V262, P9121; Wang YP, 1996, J BIOL CHEM, V271, P5647, DOI 10.1074/jbc.271.10.5647; WANG YP, 1996, CIRCULATION, V94, P713; XU X, 1994, J BIOL CHEM, V269, P12645; Xu X, 1997, CELL CALCIUM, V22, P217, DOI 10.1016/S0143-4160(97)90015-4; Xu X, 1996, J BIOL CHEM, V271, P11737, DOI 10.1074/jbc.271.20.11737; YUI Y, 1991, J BIOL CHEM, V266, P3369	57	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28739	28749		10.1074/jbc.M000910200	http://dx.doi.org/10.1074/jbc.M000910200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10852903	hybrid			2022-12-25	WOS:000089330700055
J	Pan, M; Liang, J; Fisher, EA; Ginsberg, HN				Pan, M; Liang, J; Fisher, EA; Ginsberg, HN			Inhibition of translocation of nascent apolipoprotein B across the endoplasmic reticulum membrane is associated with selective inhibition of the synthesis of apolipoprotein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; LOW-DENSITY-LIPOPROTEIN; HEP G2 CELLS; UBIQUITIN-PROTEASOME PATHWAY; APO-B; INTRACELLULAR DEGRADATION; MESSENGER-RNA; SECRETION; B100; TRANSLATION	In HepG2 cells, inhibition of apolipoprotein B100 (apoB) translocation across the endoplasmic reticulum by an microsomal triglyceride transfer protein (MTP) inhibitor (CP-10447) in the presence of N-acetyl-leucinyl-norleucinal, a proteasomal inhibitor, results in accumulation of newly synthesized apoB in the translocation channel. Here we demonstrated that such accumulation led to a specific reduction of apoB synthesis. ApoB mRNA levels remained unchanged, but we observed reduced rates of elongation of nascent apoB in puromycin-synchronized cells pretreated with MTP inhibitor. This observation was consistent with a longer half-ribosome transit time for the synthesis of apoB in MTP-inhibited cells. Initiation of translation of apoB mRNA was not impaired by MTP inhibition. Overall, these findings suggest that translocation arrest of apoB in the endoplasmic reticulum channel can exert a selective and negative effect on the synthesis of apoB at the stage of elongation.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; CUNY Mt Sinai Sch Med, Cardiovasc Inst, Lab Lipoprot Res, New York, NY 10029 USA	Columbia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Ginsberg, HN (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168 St, New York, NY 10032 USA.			Fisher, Edward/0000-0001-9802-143X	NHLBI NIH HHS [HL58541, HL55638, T32 HL07343] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007343, R01HL055638, R01HL058541] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAD Y, 1990, J LIPID RES, V31, P567; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BOREN J, 1990, J BIOL CHEM, V265, P10556; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; BRETT DJ, 1995, BIOCHEM J, V310, P11, DOI 10.1042/bj3100011; CHEN XL, 1993, J BIOL CHEM, V268, P21007; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1991, J BIOL CHEM, V266, P5080; ESKRIDGE EM, 1983, J BIOL CHEM, V258, P1487; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; Haghpassand M, 1996, J LIPID RES, V37, P1468; HALL MN, 1982, ANN INST PASTEUR MIC, VA133, P123; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hovland R, 1999, FEBS LETT, V444, P97, DOI 10.1016/S0014-5793(99)00039-3; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; JAMIL H, 1996, P NATL ACAD SCI USA, V93, P1191; JANUS ED, 1980, EUR J CLIN INVEST, V10, P161, DOI 10.1111/j.1365-2362.1980.tb02076.x; Jeong JK, 1997, J BIOL CHEM, V272, P7511, DOI 10.1074/jbc.272.11.7511; KIM JM, 1991, J BIOL CHEM, V266, P14931; Linnik KM, 1998, J BIOL CHEM, V273, P21368, DOI 10.1074/jbc.273.33.21368; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; PULLINGER CR, 1989, J LIPID RES, V30, P1065; Rustaeus S, 1998, J BIOL CHEM, V273, P5196, DOI 10.1074/jbc.273.9.5196; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P53; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; WALDEN WE, 1986, BIOCHEMISTRY-US, V25, P2033, DOI 10.1021/bi00356a030; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; WETTERAU JR, 1992, SCIENCE, V258, P999; WU XJ, 1994, J BIOL CHEM, V269, P12375; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	41	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27399	27405						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10846173				2022-12-25	WOS:000089144800098
J	Abril, AM; Salas, M; Hermoso, JM				Abril, AM; Salas, M; Hermoso, JM			Identification of residues within two regions involved in self-association of viral histone-like protein p6 from phage O29	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHI-29 DNA-REPLICATION; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; H-NS; INVITRO TRANSCRIPTION; NUCLEOPROTEIN COMPLEX; NUCLEOTIDE-SEQUENCES; HOST FACTOR; EARLY GENES; BINDING	Protein p6 of Bacillus subtilis phage phi 29 is involved in the initiation of viral DNA replication and transcription by forming a multimeric nucleoprotein complex with the phage DNA. Based on this, together with its abundance and its capacity to bind to the whole viral genome, it has been proposed to be a viral histone-like protein. Protein p6 is in a monomer-dimer-oligomer equilibrium association. we have identified protein p6 mutants deficient in self-association by testing random mutants obtained by degenerated polymerase chain reaction in an in vivo assay for dimer formation. The mutations were mainly clustered in two regions located at the N terminus, and the central part of the protein. Site-directed single mutants, corresponding to those found in vivo, have been constructed and purified. Mutant p6A44V, located at the central part of the protein, showed an impaired dimer formation ability, and a reduced capacity to bind DNA and to activate the initiation of phi 29 DNA replication. Mutant p6I8T has at least 10-fold reduced self-association capacity, does not bind DNA nor activate phi 29 DNA initiation of replication. C-terminal deletion mutants showed an enhanced dimer formation capacity. The highly acidic tail, removed in these mutants, is proposed to modulate the protein p6 self-association.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Salas, Margarita/J-9873-2014	Salas, Margarita/0000-0001-5939-3441	NIGMS NIH HHS [5RO1 GM27242-20] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abril AM, 1997, BIOCHEMISTRY-US, V36, P11901, DOI 10.1021/bi970994e; Abril AM, 1999, J MOL BIOL, V292, P581, DOI 10.1006/jmbi.1999.3078; ARCANGIOLI B, 1994, NUCLEIC ACIDS RES, V22, P2930, DOI 10.1093/nar/22.15.2930; Azam TA, 1999, J BACTERIOL, V181, P6361, DOI 10.1128/JB.181.20.6361-6370.1999; BAILONE A, 1978, VIROLOGY, V84, P547, DOI 10.1016/0042-6822(78)90273-8; BALZER D, 1992, NUCLEIC ACIDS RES, V20, P1851, DOI 10.1093/nar/20.8.1851; BARTHELEMY I, 1989, J VIROL, V63, P460, DOI 10.1128/JVI.63.1.460-462.1989; BLANCO L, 1986, NUCLEIC ACIDS RES, V14, P4923, DOI 10.1093/nar/14.12.4923; BRAVO A, 1994, MOL GEN GENET, V245, P529, DOI 10.1007/BF00282215; CARRASCOSA JL, 1976, EUR J BIOCHEM, V66, P229, DOI 10.1111/j.1432-1033.1976.tb10512.x; Ceschini S, 2000, J BIOL CHEM, V275, P729, DOI 10.1074/jbc.275.2.729; Claret L, 1997, J MOL BIOL, V273, P93, DOI 10.1006/jmbi.1997.1310; Elias-Arnanz M, 1999, GENE DEV, V13, P2502, DOI 10.1101/gad.13.19.2502; FLAMM EL, 1985, J MOL BIOL, V183, P117, DOI 10.1016/0022-2836(85)90206-2; FREIRE R, 1994, EMBO J, V13, P4353, DOI 10.1002/j.1460-2075.1994.tb06755.x; GUTIERREZ C, 1994, EMBO J, V13, P269, DOI 10.1002/j.1460-2075.1994.tb06257.x; JOHNSON RC, 1988, P NATL ACAD SCI USA, V85, P3484, DOI 10.1073/pnas.85.10.3484; KOCH C, 1988, P NATL ACAD SCI USA, V85, P4237, DOI 10.1073/pnas.85.12.4237; Leung DW, 1989, TECHNIQUE, V1, P11; MILLER HI, 1984, COLD SPRING HARB SYM, V43, P1121; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; MURRAY CL, 1982, J BIOL CHEM, V257, P1053; OTERO MJ, 1989, NUCLEIC ACIDS RES, V17, P4567, DOI 10.1093/nar/17.12.4567; OTERO MJ, 1990, GENE, V95, P25, DOI 10.1016/0378-1119(90)90409-K; PASTRANA R, 1985, NUCLEIC ACIDS RES, V13, P3083, DOI 10.1093/nar/13.9.3083; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; PRIETO I, 1988, P NATL ACAD SCI USA, V85, P314, DOI 10.1073/pnas.85.2.314; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; ROUVIEREYANIV J, 1979, FEBS LETT, V106, P297, DOI 10.1016/0014-5793(79)80518-9; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SERRANO M, 1993, J MOL BIOL, V230, P248, DOI 10.1006/jmbi.1993.1140; SERRANO M, 1990, SCIENCE, V248, P1012, DOI 10.1126/science.2111580; SERRANO M, 1989, EMBO J, V8, P1879, DOI 10.1002/j.1460-2075.1989.tb03584.x; Spurio R, 1997, EMBO J, V16, P1795, DOI 10.1093/emboj/16.7.1795; TALAVERA A, 1972, EUR J BIOCHEM, V31, P367, DOI 10.1111/j.1432-1033.1972.tb02542.x; Ueguchi C, 1997, J MOL BIOL, V274, P145, DOI 10.1006/jmbi.1997.1381; WHITELEY HR, 1986, VIROLOGY, V155, P392, DOI 10.1016/0042-6822(86)90202-3; Williams RM, 1996, J BACTERIOL, V178, P4335, DOI 10.1128/jb.178.15.4335-4343.1996; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	39	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26404	26410		10.1074/jbc.M002739200	http://dx.doi.org/10.1074/jbc.M002739200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10829023	hybrid			2022-12-25	WOS:000088999700072
J	Xie, ZY; Turk, E; Wright, EM				Xie, ZY; Turk, E; Wright, EM			Characterization of the Vibrio parahaemolyticus Na+/glucose cotransporter - A bacterial member of the sodium/glucose transporter (SGLT) family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-GALACTOSE MALABSORPTION; POLYTOPIC MEMBRANE-PROTEINS; THYROID NA+/I SYMPORTER; ESCHERICHIA-COLI; NA+/PROLINE TRANSPORTER; SCANNING MUTAGENESIS; TRAFFICKING DEFECTS; MISSENSE MUTATIONS; CYSTEINE; PERMEASE	The Vibrio parahaemolyticus sodium/glucose transporter (vSGLT) is a bacterial member of the SGLT gene family. Wild-type and mutant vSGLT proteins were expressed in Escherichia coli, and transport activity was measured in intact cells and plasma membrane vesicles. Two cysteine less vSGLT proteins exhibited sugar transport rates comparable with that of the wild-type protein. Six residues in two regions of vSGLT known to be of functional importance in SGLT1 were replaced individually with cysteine in the cysteine-less protein. Characterization of these single cysteine-substituted vSGLTs showed that two residues (Gly-151 and Gln-428) are essential for transport function, whereas the other four residues (Leu-147, Leu-149, Ala-423, and Gln-425) are not, 2-Aminoethylmethanethiosulfonate (MTSEA) blocked Na+/glucose transport by only the transporter bearing a cysteine at position 425 (Q425C), MTSEA inhibition was reversed by dithiothreitol and blocked by the presence of both Na+ and D-glucose, indicating that conformational changes of the vSGLT protein are involved in Na+/glucose transport. A split version of vSGLT was generated by co-expression of the N-terminal (N-7) and C-terminal (C-7) halves of the transporter. The split vSGLT maintained Naf-dependent glucose transport activity. Chemical cross-linking of split vSGLT, with a cysteine in each N-7 and C-7 fragment, suggested that hydrophilic loops between helices 4 and 5 and between helices 10 and 11 are within 8 Angstrom of each other. We conclude that the mechanism of Na+/glucose transport by vSGLT is similar to mammalian SGLTs and that further studies on vSGLT will provide novel insight to the structure and function of this class of cotransporters.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Wright, EM (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.	ewright@mednet.ucla.edu			NIDDK NIH HHS [DK 19567, DK 44602] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044602, R01DK019567] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Bibi E, 1998, TRENDS BIOCHEM SCI, V23, P51, DOI 10.1016/S0968-0004(97)01134-1; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; HAGER K, 1995, J MEMBRANE BIOL, V143, P103; HENDERSON PJF, 1977, BIOCHEM J, V162, P309, DOI 10.1042/bj1620309; HIRAYAMA BA, 1992, BIOCHIM BIOPHYS ACTA, V1103, P37, DOI 10.1016/0005-2736(92)90054-P; Hirayama BA, 1996, AM J PHYSIOL-GASTR L, V270, pG919, DOI 10.1152/ajpgi.1996.270.6.G919; HIRAYAMA BA, 1991, AM J PHYSIOL, V261, pC296, DOI 10.1152/ajpcell.1991.261.2.C296; Jung H, 1998, J BIOL CHEM, V273, P26400, DOI 10.1074/jbc.273.41.26400; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Lam JT, 1999, BBA-MOL BASIS DIS, V1453, P297, DOI 10.1016/S0925-4439(98)00109-4; Levy O, 1998, J BIOL CHEM, V273, P22657, DOI 10.1074/jbc.273.35.22657; Lo B, 1998, J BIOL CHEM, V273, P903, DOI 10.1074/jbc.273.2.903; Lo B, 1998, J BIOL CHEM, V273, P29341, DOI 10.1074/jbc.273.45.29341; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; Lostao MP, 1995, FEBS LETT, V377, P181, DOI 10.1016/0014-5793(95)01339-3; LOSTAO MP, 1994, J MEMBRANE BIOL, V142, P161; Martin MG, 1997, GASTROENTEROLOGY, V112, P1206, DOI 10.1016/S0016-5085(97)70132-X; Martin MG, 1996, NAT GENET, V12, P216, DOI 10.1038/ng0296-216; Quick M, 1998, BIOCHEMISTRY-US, V37, P13800, DOI 10.1021/bi980562j; Quick M, 1996, EUR J BIOCHEM, V239, P732, DOI 10.1111/j.1432-1033.1996.0732u.x; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; Sarker RI, 1997, J BACTERIOL, V179, P1805, DOI 10.1128/jb.179.5.1805-1808.1997; Sarker RI, 1996, BBA-BIOMEMBRANES, V1279, P149, DOI 10.1016/0005-2736(95)00252-9; SARKER RI, 1994, J BACTERIOL, V176, P7378, DOI 10.1128/JB.176.23.7378-7382.1994; Sarker RI, 1996, BBA-BIOMEMBRANES, V1281, P1, DOI 10.1016/0005-2736(96)00025-9; SHORT SA, 1975, J BIOL CHEM, V250, P4291; TANAKA S, 1967, J BACTERIOL, V93, P642, DOI 10.1128/JB.93.2.642-648.1967; TSUCHIYA T, 1978, MEMBRANE BIOCHEM, V2, P63, DOI 10.3109/09687687809063858; Turk E, 2000, J BIOL CHEM, V275, P25711, DOI 10.1074/jbc.M003127200; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; Wright EM, 1998, ACTA PHYSIOL SCAND, V163, P257; Wu JH, 1996, P NATL ACAD SCI USA, V93, P14498, DOI 10.1073/pnas.93.25.14498; ZEN KH, 1994, BIOCHEMISTRY-US, V33, P8198, DOI 10.1021/bi00193a005	39	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25959	25964		10.1074/jbc.M002687200	http://dx.doi.org/10.1074/jbc.M002687200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852908	hybrid			2022-12-25	WOS:000088999700012
J	Caruthers, JM; Kang, I; Rynkiewicz, MJ; Cane, DE; Christianson, DW				Caruthers, JM; Kang, I; Rynkiewicz, MJ; Cane, DE; Christianson, DW			Crystal structure determination of aristolochene synthase from the blue cheese mold, Penicillium roqueforti	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SESQUITERPENE CYCLASE; FARNESYL PYROPHOSPHATE; ENZYMATIC CYCLIZATION; BACTERIAL EXPRESSION; TERPENOID CYCLASE; ESCHERICHIA-COLI; BIOSYNTHESIS; PROGRAM; SYSTEM; GENE	The 2.5-Angstrom resolution crystal structure of recombinant aristolochene synthase from the blue cheese mold, Penicillium roqueforti, is the first of a fungal terpenoid cyclase, The structure of the enzyme reveals active site features that participate in the cyclization of the universal sesquiterpene cyclase substrate, farnesyl diphosphate, to form the bicyclic hydrocarbon aristolochene. Metal-triggered carbocation formation initiates the cyclization cascade, which proceeds through multiple complex intermediates to yield one exclusive structural and stereochemical isomer of aristolochene, Structural homology of this fungal cyclase with plant and bacterial terpenoid cyclases, despite minimal amino acid sequence identity, suggests divergence from a common, primordial ancestor in the evolution of terpene biosynthesis.	Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA; Brown Univ, Dept Chem, Providence, RI 02912 USA	University of Pennsylvania; Brown University	Christianson, DW (corresponding author), Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA.			Rynkiewicz, Michael/0000-0002-4717-5700	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056838, R01GM030301, R37GM030301] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56838, GM30301] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BACK K, 1995, J BIOL CHEM, V270, P7375, DOI 10.1074/jbc.270.13.7375; BACK KW, 1994, ARCH BIOCHEM BIOPHYS, V315, P527, DOI 10.1006/abbi.1994.1533; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cane D.E., 1999, COMPR NAT PROD CHEM, V2, P155, DOI [10.1016/B978-0-08-091283-7.00039-4, DOI 10.1016/B978-0-08-091283-7.00039-4]; CANE DE, 1990, CHEM REV, V90, P1089, DOI 10.1021/cr00105a002; Cane DE, 1996, J AM CHEM SOC, V118, P10037, DOI 10.1021/ja961981b; CANE DE, 1985, ACCOUNTS CHEM RES, V18, P220, DOI 10.1021/ar00115a005; Cane DE, 1996, BIOCHEMISTRY-US, V35, P12369, DOI 10.1021/bi961344y; CANE DE, 1994, J AM CHEM SOC, V116, P12063, DOI 10.1021/ja00105a061; CANE DE, 1990, J AM CHEM SOC, V112, P3209, DOI 10.1021/ja00164a051; CANE DE, 1993, ARCH BIOCHEM BIOPHYS, V304, P415, DOI 10.1006/abbi.1993.1369; CANE DE, 1987, J ANTIBIOT, V40, P1331, DOI 10.7164/antibiotics.40.1331; CANE DE, 1989, J AM CHEM SOC, V111, P8914, DOI 10.1021/ja00206a022; CARUTHERS JM, 2000, THESIS U PENNSYLVANI; CROTEAU R, 1985, METHOD ENZYMOL, V110, P383; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GOVINDACHARI TR, 1970, TETRAHEDRON, V26, P615, DOI 10.1016/S0040-4020(01)97854-8; HOHN TM, 1989, ARCH BIOCHEM BIOPHYS, V272, P137, DOI 10.1016/0003-9861(89)90204-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWRENCE BM, 1973, PHYTOCHEMISTRY, V12, P2995, DOI 10.1016/0031-9422(73)80522-9; Lesburg CA, 1998, CURR OPIN STRUC BIOL, V8, P695, DOI 10.1016/S0959-440X(98)80088-2; Lesburg CA, 1997, SCIENCE, V277, P1820, DOI 10.1126/science.277.5333.1820; LESLIE AGW, 1990, CRYSTALLOGRAPHIC COM, V5; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miklis PC, 1998, J AM CHEM SOC, V120, P10482, DOI 10.1021/ja980505d; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; NEEDHAM JV, 1993, BIOCHEMISTRY-US, V32, P3363, DOI 10.1021/bi00064a020; PROCTOR RH, 1993, J BIOL CHEM, V268, P4543; REARDON D, 1995, FASEB J, V9, P497, DOI 10.1096/fasebj.9.7.7737457; Rising KA, 2000, J AM CHEM SOC, V122, P1861, DOI 10.1021/ja993584h; Starks CM, 1997, SCIENCE, V277, P1815, DOI 10.1126/science.277.5333.1815; TARSHIS LC, 1994, BIOCHEMISTRY-US, V33, P10871, DOI 10.1021/bi00202a004; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; VOGELI U, 1988, PLANT PHYSIOL, V88, P1291, DOI 10.1104/pp.88.4.1291; WHITEHEAD IM, 1990, PHYTOCHEMISTRY, V29, P479, DOI 10.1016/0031-9422(90)85100-T; WHITEHEAD IM, 1989, PHYTOCHEMISTRY, V28, P775, DOI 10.1016/0031-9422(89)80114-1; Wise M. L., 1999, COMPREHENSIVE NATURA, P97, DOI DOI 10.1016/B978-0-08-091283-7.00038-2	43	138	142	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25533	25539		10.1074/jbc.M000433200	http://dx.doi.org/10.1074/jbc.M000433200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10825154	hybrid			2022-12-25	WOS:000088849400065
J	Rosenfeld, SS; Xing, J; Whitaker, M; Cheung, HC; Brown, F; Wells, A; Milligan, RA; Sweeney, HL				Rosenfeld, SS; Xing, J; Whitaker, M; Cheung, HC; Brown, F; Wells, A; Milligan, RA; Sweeney, HL			Kinetic and spectroscopic evidence for three actomyosin : ADP states in smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN MOTOR DOMAIN; ACTIN-BASED MOTOR; X-RAY STRUCTURES; DICTYOSTELIUM-DISCOIDEUM; LIGHT-CHAIN; RELEASE; SUBFRAGMENT-1; SKELETAL; COMPLEX; DISSOCIATION	Smooth muscle myosin II undergoes an additional movement of the regulatory domain with ADP release that is not seen with fast skeletal muscle myosin II. In this study, we have examined the interactions of smooth muscle myosin subfragment 1 with ADP to see if this additional movement corresponds to an identifiable state change. These studies indicate that for this myosin:ADP, both the catalytic site and the actin-binding site can each assume one of two conformations. Relatively loose coupling between these two binding sites leads to three discrete actin-associated ADP states, Following an initial, weakly bound state, binding of myosin: ADP to actin shifts the equilibrium toward a mixture of two states that each bind actin strongly but differ in the conformation of their catalytic sites. By contrast, fast myosins, including Dictyostelium myosin II, have reciprocal coupling between the actin- and ADP-binding sites, so that either actin or nucleotide, but not both, can be tightly bound. This uncoupling, which generates a second strongly bound actomyosin ADP state in smooth muscle, would prolong the fraction of the ATPase cycle time that this actomyosin spends in a force-generating conformation and may be central to explaining the physiologic differences between this and other myosins.	Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Penn, Dept Physiol, Philadelphia, PA 19104 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Scripps Research Institute; University of Pennsylvania	Rosenfeld, SS (corresponding author), Univ Alabama, Dept Neurol, UAb Stn, Birmingham, AL 35294 USA.		Sweeney, H Lee/F-1862-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL015835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR031239] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034856] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL15835-27] Funding Source: Medline; NIAMS NIH HHS [AR31239] Funding Source: Medline; NINDS NIH HHS [NS34856] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Corrie JET, 1999, NATURE, V400, P425, DOI 10.1038/22704; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; Dantzig JA, 1999, BIOPHYS J, V77, P386, DOI 10.1016/S0006-3495(99)76897-9; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gollub J, 1996, NAT STRUCT BIOL, V3, P796, DOI 10.1038/nsb0996-796; Guilford WH, 1997, BIOPHYS J, V72, P1006, DOI 10.1016/S0006-3495(97)78753-8; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; IKEBE M, 1986, BIOCHEMISTRY-US, V25, P6177, DOI 10.1021/bi00368a052; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; Jontes JD, 1997, P NATL ACAD SCI USA, V94, P14332, DOI 10.1073/pnas.94.26.14332; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEPNIEKS JJ, 1979, J BIOL CHEM, V254, P1677; LIN SH, 1991, BIOCHEMISTRY-US, V30, P4317, DOI 10.1021/bi00231a030; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; PERSECHINI A, 1983, BIOCHEMISTRY-US, V22, P470, DOI 10.1021/bi00271a033; POOLE KIV, 1997, J MUSCLE RES CELL M, V18, P179; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; ROSENFELD SS, 1987, J BIOL CHEM, V262, P9994; Rosenfeld SS, 1996, J BIOL CHEM, V271, P30212, DOI 10.1074/jbc.271.47.30212; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1908; Ruppel KM, 1996, ANNU REV CELL DEV BI, V12, P543, DOI 10.1146/annurev.cellbio.12.1.543; SLEEP JA, 1980, BIOCHEMISTRY-US, V19, P1276, DOI 10.1021/bi00548a002; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SUMMERS MD, 1987, TEX AGR EXP STN B, P1555; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; VanBuren P., 1995, Biophysical Journal, V68, P256; Wells AL, 1999, NATURE, V401, P505, DOI 10.1038/46835; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0	36	50	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25418	25426		10.1074/jbc.M002685200	http://dx.doi.org/10.1074/jbc.M002685200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827085	hybrid			2022-12-25	WOS:000088849400050
J	Turk, E; Kim, O; le Coutre, J; Whitelegge, JP; Eskandari, S; Lam, JT; Kreman, M; Zampighi, G; Faull, KF; Wright, EM				Turk, E; Kim, O; le Coutre, J; Whitelegge, JP; Eskandari, S; Lam, JT; Kreman, M; Zampighi, G; Faull, KF; Wright, EM			Molecular characterization of Vibrio parahaemolyticus vSGLT - A model for sodium-coupled sugar cotransporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-GALACTOSE MALABSORPTION; ESCHERICHIA-COLI; NA+/GLUCOSE COTRANSPORTER; NA+/PROLINE TRANSPORTER; FUNCTIONAL EXPRESSION; TRAFFICKING DEFECTS; MISSENSE MUTATIONS; MASS-SPECTROMETRY; MEMBRANE TOPOLOGY; CLONING	The Na+/galactose cotransporter (vSGLT) of Vibrio parahaemolyticus, tagged with C-terminal hexahistidine, has been purified to apparent homogeneity by Ni2+ affinity chromatography and gel filtration. Resequencing the vSGLT gene identified an important correction: the N terminus constitutes an additional 13 functionally essential residues. The mass of His-tagged vSGLT expressed under its native promoter, as determined by electrospray ionization-mass spectrometry (ESI-MS), verifies these 13 residues in wild-type vSGLT. A fusion protein of vSGLT and green fluorescent protein, comprising a mass of over 90 kDa, was also successfully analyzed by ESI-MS. Reconstitution of purified vSGLT yields proteoliposomes active in Na+-dependent galactose uptake, with sugar preferences (galactose > glucose > fucose) reflecting those of wild-type vSGLT in vivo. Substrates are transported with apparent 1:1 stoichiometry and apparent K-m values of 129 mM (Na+) and 158 mu M (galactose). Freeze-fracture electron microscopy of functional proteoliposomes shows intramembrane particles of a size consistent with vSGLT existing as a monomer. We conclude that vSGLT is a suitable model for the study of sugar cotransporter mechanisms and structure, with potential applicability to the larger SGLT family of important sodium:solute cotransporters, It is further demonstrated that ESI-MS is a powerful tool for the study of proteomics of membrane transporters.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Pasarow Mass Spectrometry Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Neuropsychiat, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Turk, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, CHS Box 951751, Los Angeles, CA 90095 USA.	eturk@mednet.ucla.edu			NIDDK NIH HHS [DK-44602, DK5-1131, DK-44582] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044602, R01DK051131, R01DK044582] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; ASHTON DS, 1994, FEBS LETT, V342, P1, DOI 10.1016/0014-5793(94)80572-5; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; DeGrip WJ, 1998, BIOCHEM J, V330, P667; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HENDERSON PJF, 1977, BIOCHEM J, V162, P309, DOI 10.1042/bj1620309; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; Hill RA, 1997, PROTEIN EXPRES PURIF, V10, P162, DOI 10.1006/prep.1997.0732; HIRSCHHORN N, 1991, SCI AM, V264, P50, DOI 10.1038/scientificamerican0591-50; JACKOWSKI S, 1990, J BACTERIOL, V172, P3842, DOI 10.1128/jb.172.7.3842-3848.1990; Jung H, 1998, J BIOL CHEM, V273, P26400, DOI 10.1074/jbc.273.41.26400; Jung H, 1998, BIOCHEMISTRY-US, V37, P11083, DOI 10.1021/bi980684b; Konig N, 1997, J MOL BIOL, V265, P590, DOI 10.1006/jmbi.1996.0763; KWON HM, 1992, J BIOL CHEM, V267, P6297; Lam JT, 1999, BBA-MOL BASIS DIS, V1453, P297, DOI 10.1016/S0925-4439(98)00109-4; le Coutre J, 2000, BIOCHEMISTRY-US, V39, P4237, DOI 10.1021/bi000150m; Levy O, 1998, J BIOL CHEM, V273, P22657, DOI 10.1074/jbc.273.35.22657; Loo DDF, 1998, P NATL ACAD SCI USA, V95, P7789, DOI 10.1073/pnas.95.13.7789; Martin MG, 1997, GASTROENTEROLOGY, V112, P1206, DOI 10.1016/S0016-5085(97)70132-X; Martin MG, 1996, NAT GENET, V12, P216, DOI 10.1038/ng0296-216; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; Panayotova-Heiermann M, 1998, BIOCHEMISTRY-US, V37, P10522, DOI 10.1021/bi9800395; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; Prasad PD, 1998, J BIOL CHEM, V273, P7501, DOI 10.1074/jbc.273.13.7501; Sarker RI, 1997, J BACTERIOL, V179, P1805, DOI 10.1128/jb.179.5.1805-1808.1997; Sarker RI, 1996, BBA-BIOMEMBRANES, V1279, P149, DOI 10.1016/0005-2736(95)00252-9; Sarker RI, 1996, BBA-BIOMEMBRANES, V1281, P1, DOI 10.1016/0005-2736(96)00025-9; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TURK E, 1994, J BIOL CHEM, V269, P15204; Turk E, 1997, J MEMBRANE BIOL, V159, P1, DOI 10.1007/s002329900264; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WELLS RG, 1992, AM J PHYSIOL, V263, pF459, DOI 10.1152/ajprenal.1992.263.3.F459; Whitelegge JP, 1999, P NATL ACAD SCI USA, V96, P10695, DOI 10.1073/pnas.96.19.10695; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6; Wright EM, 1998, ACTA PHYSIOL SCAND, V163, P257; ZAMPIGHI GA, 1985, P NATL ACAD SCI USA, V82, P8468, DOI 10.1073/pnas.82.24.8468	44	79	80	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25711	25716		10.1074/jbc.M003127200	http://dx.doi.org/10.1074/jbc.M003127200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10835424	hybrid			2022-12-25	WOS:000088849400086
J	Brandt, PC; Vanaman, TC				Brandt, PC; Vanaman, TC			Elevated glucocorticoid receptor transactivation and down-regulation of alpha(1) integrin are associated with loss of plasma membrane Ca2+-ATPase isoform 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA CELLS; MOLECULAR-CLONING; NEURITE OUTGROWTH; MESSENGER-RNA; PC12 CELLS; CA-2+-TRANSPORTING ATPASE; ALPHA-1-BETA-1 INTEGRIN; SKELETAL-MUSCLE; RAT-BRAIN	We have previously shown that inhibition of expression of the plasma membrane Ca2+-ATPase isoform I in PC6 cells leads to loss of nerve growth factor-mediated neurite extension (Brandt, P, C,, Sisken, J, E,, Neve, R, L,, and Vanaman, T, C, (1996) Proc. Natl, Acad, Sci, U.S.A. 93, 13843-13848). Cells lacking plasma membrane Ca2+-ATPase 1 did not attach to collagen-coated plates as tightly as controls, suggesting that a defect in adhesion might be underlying the inability to extend neurites, We report here that cell lines lacking plasma membrane Ca2+-ATPase 1 do not produce alpha(1) integrin, which is required for both collagen adherence and neurite extension. Because alpha(1) integrin gene transcription can be down-regulated by glucocorticoids, the response of cells to glucocorticoids was investigated. Cortisol-dependent transactivation from the mouse mammary tumor virus promoter in cells lacking plasma membrane Ca2+-ATPase 1 was stimulated 145-216-fold over untreated cells compared with 15-26-fold for controls. This increase was not due to increased binding affinity of the receptor for cortisol, an increased number of cortisol-binding sites, or increased translocation of the receptor to the nucleus, Expression of additional glucocorticoid receptor-dependent genes required for neurite extension must also be altered in cells missing the plasma membrane Ca2+-ATPase 1 because constitutive expression of alpha(1) integrin did not restore their nerve growth factor-mediated neurite extension capability. The impact of plasma membrane Ca2+-ATPase isoform 1 on other signaling systems and the resultant profound yet subtle effects on PC6 cells strongly suggests that it plays an important role in modulating signal transduction pathways downstream of Ca2+-mediated signals.	Texas A&M Syst Hlth Sci Ctr, Dept Med Pharmacol & Toxicol, College Stn, TX 77843 USA; Univ Kentucky, Med Ctr, Dept Biochem, Lexington, KY 40536 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Kentucky	Brandt, PC (corresponding author), Texas A&M Syst Hlth Sci Ctr, Dept Med Pharmacol & Toxicol, College Stn, TX 77843 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021868] Funding Source: NIH RePORTER; NINDS NIH HHS [NS21868] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; Bach LA, 1997, J ENDOCRINOL, V155, P225, DOI 10.1677/joe.0.1550225; BRANDT P, 1992, GENOMICS, V14, P484, DOI 10.1016/S0888-7543(05)80246-0; BRANDT P, 1992, J NEUROCHEM, V59, P1566, DOI 10.1111/j.1471-4159.1992.tb08476.x; BRANDT P, 1994, J NEUROCHEM, V62, P799; BRANDT P, 1992, J BIOL CHEM, V267, P4376; Brandt PC, 1998, CALMODULIN AND SIGNAL TRANSDUCTION, P397; Brandt PC, 1996, P NATL ACAD SCI USA, V93, P13843, DOI 10.1073/pnas.93.24.13843; BURK SE, 1992, J BIOL CHEM, V267, P19683; EAKIN TJ, 1995, MOL BRAIN RES, V29, P71, DOI 10.1016/0169-328X(94)00231-3; FREEMAN TC, 1995, AM J PHYSIOL-GASTR L, V269, pG126, DOI 10.1152/ajpgi.1995.269.1.G126; FUJITA K, 1989, ENVIRON HEALTH PERSP, V80, P127, DOI 10.2307/3430738; Grant NJ, 1996, J NEUROCHEM, V66, P1400; GREEB J, 1989, J BIOL CHEM, V264, P18569; HAMMES A, 1994, FASEB J, V8, P428, DOI 10.1096/fasebj.8.6.8168693; IGNATIUS MJ, 1990, J CELL BIOL, V111, P709, DOI 10.1083/jcb.111.2.709; KEETON TP, 1995, BIOCHEM J, V306, P779, DOI 10.1042/bj3060779; KEETON TP, 1993, J BIOL CHEM, V268, P2740; Krstic MD, 1997, MOL CELL BIOL, V17, P3947, DOI 10.1128/MCB.17.7.3947; Morris TA, 1998, EXP CELL RES, V240, P218, DOI 10.1006/excr.1997.3925; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STAHL WL, 1994, NEUROSCI LETT, V178, P267, DOI 10.1016/0304-3940(94)90775-7; Stewart HJS, 1997, J NEUROBIOL, V33, P914, DOI 10.1002/(SICI)1097-4695(199712)33:7<914::AID-NEU4>3.0.CO;2-B; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; TAWIL NJ, 1990, BIOCHEMISTRY-US, V29, P6540, DOI 10.1021/bi00479a028; TURNER DC, 1987, DEV BIOL, V121, P510, DOI 10.1016/0012-1606(87)90187-4; TURNER DC, 1989, J NEUROSCI, V9, P3287; WERB Z, 1978, J EXP MED, V147, P1684, DOI 10.1084/jem.147.6.1684; ZHANG ZY, 1993, J BIOL CHEM, V268, P5557; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	33	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24534	24539		10.1074/jbc.M003388200	http://dx.doi.org/10.1074/jbc.M003388200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827194	hybrid			2022-12-25	WOS:000088683300041
J	Wajant, H; Haas, E; Schwenzer, R; Muhlenbeck, F; Kreuz, S; Schubert, G; Grell, M; Smith, C; Scheurich, P				Wajant, H; Haas, E; Schwenzer, R; Muhlenbeck, F; Kreuz, S; Schubert, G; Grell, M; Smith, C; Scheurich, P			Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; INDUCED CELL-DEATH; TNF RECEPTOR; DEPENDENT APOPTOSIS; TERMINAL KINASE; ACTIVATION; PATHWAY; SIGNAL; INTERACTS	In HeLa cells, induction of apoptosis and nuclear factor kappa B (NF-kappa B) activation initiated by TRAIL/Apo2L or the agonistic Apol/Fas-specific monoclonal antibody anti-APO-1 require the presence of cycloheximide (CHX). Inhibition of caspases prevented TRAIL/anti-APO-1-induced apoptosis, but not NF-kappa B activation, indicating that both pathways bifurcate upstream of the receptor-proximal caspase-8, Under these conditions, TRAIL and anti-APO-1 up-regulated the expression of the known MF-kappa B targets interleukin-8, cellular inhibitor of apoptosis 2 (cIAP2), and TRAF1 (TRAF, tumor necrosis factor receptor-associate factor). In the presence of CHX, the stable overexpression of a deletion mutant of the Fas-associated death domain molecule FALL comprising solely the death domain of the molecule but lacking its death effector domain (FADD-(80-208)) led to the same response pattern as TRAIL or anti-APO-1 treatment. Moreover, the ability of death receptors to induce NF-kappa B activation was drastically reduced in a FADD-deficient Jurkat cell line. TRAIL-, anti-APO-1-, and FADD-(80 -208)-initiated gene induction was blocked by a dominant-negative mutant of TRAF2 or the p38 kinase inhibitor SB203580, similar to tumor necrosis factor receptor-1-induced NF-kappa B activation. CHX treatment rapidly down-regulated endogenous cFLIP protein levels, and overexpression of cellular FLICE inhibitory protein (cFLIP) inhibited death receptor-induced NF-kappa B activation. Thus, a novel functional role of cFLIP as a negative regulator of gene induction by death receptors became apparent.	Univ Stuttgart, Inst Cell Biol & Immunol, D-70569 Stuttgart, Germany; Immunex Res & Dev Corp, Seattle, WA 98101 USA	University of Stuttgart	Wajant, H (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Allmandring 31, D-70569 Stuttgart, Germany.		Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chan SL, 1999, J BIOL CHEM, V274, P32461, DOI 10.1074/jbc.274.45.32461; Chang HY, 1999, P NATL ACAD SCI USA, V96, P1252, DOI 10.1073/pnas.96.4.1252; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Costanzo A, 1999, J BIOL CHEM, V274, P20127, DOI 10.1074/jbc.274.29.20127; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Griffith TS, 1998, J IMMUNOL, V161, P2833; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Irmler M, 2000, FEBS LETT, V468, P129, DOI 10.1016/S0014-5793(00)01206-0; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Leverkus M, 2000, CANCER RES, V60, P553; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Pan GH, 1998, FEBS LETT, V431, P351, DOI 10.1016/S0014-5793(98)00791-1; Ponton A, 1996, J BIOL CHEM, V271, P8991, DOI 10.1074/jbc.271.15.8991; RENSINGEHL A, 1995, J INFLAMM, V45, P161; Reuther JY, 1999, J BIOL CHEM, V274, P20664, DOI 10.1074/jbc.274.29.20664; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	48	155	160	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24357	24366		10.1074/jbc.M000811200	http://dx.doi.org/10.1074/jbc.M000811200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10823821	hybrid			2022-12-25	WOS:000088683300017
J	Nieswandt, B; Bergmeier, W; Schulte, V; Rackebrandt, K; Gessner, JE; Zirngibl, H				Nieswandt, B; Bergmeier, W; Schulte, V; Rackebrandt, K; Gessner, JE; Zirngibl, H			Expression and function of the mouse collagen receptor glycoprotein VI is strictly dependent on its association with the FcR gamma chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PLATELETS; ACTIVATION; AGGREGATION; ADHESION; INTEGRIN; PATIENT; CELLS	Platelet glycoprotein (GP) VI has been proposed as the major collagen receptor for activation of human platelets. Human GPVI belongs to the immunoglobulin superfamily and is noncovalently associated with the FcR gamma chain that is involved in signaling through the receptor. In mice, similar mechanisms seem to exist as platelets from FcR gamma chain-deficient mice do not aggregate in response to collagen. However, the activating collagen receptor on mouse platelets has not been definitively identified. In the current study we examined the function and in vivo expression of GPVI in control and FcR gamma chain-deficient mice with the first monoclonal antibody against GPVI (JAQ1). On wild type platelets, JAQ1 inhibited platelet aggregation induced by collagen but not PMA or thrombin. Cross-linking of bound JAQ1, on the other hand, induced aggregation of wild type but not FcR gamma chain-deficient platelets. JAQ1 stained platelets and megakaryocytes from wild type but not FcR gamma chain-deficient mice. Furthermore, JAQ1 recognized GPVI (approximately 60 kDa) in immunoprecipitation and Western blot experiments with wild type but not FcR gamma chain deficient platelets. These results strongly suggest that GPVI is the collagen receptor responsible for platelet activation in mice and demonstrate that the association with the FcR gamma chain is critical for its expression and function.	Univ Witten Herdecke, Dept Mol Oncol, D-42283 Wuppertal, Germany; Hannover Med Sch, Dept Clin Immunol, D-30625 Hannover, Germany	Witten Herdecke University; Hannover Medical School	Nieswandt, B (corresponding author), Univ Witten Herdecke, Klinikum Wuppertal, IMMI, Heusnerstr 40, D-42283 Wuppertal, Germany.							Arase N, 1997, J EXP MED, V186, P1957, DOI 10.1084/jem.186.12.1957; Bergmeier W, 2000, BLOOD, V95, P886, DOI 10.1182/blood.V95.3.886.003k45_886_893; Chiang TM, 1997, J CLIN INVEST, V100, P514, DOI 10.1172/JCI119560; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; CLEMETSON KJ, 1982, J CLIN INVEST, V70, P304, DOI 10.1172/JCI110618; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Kehrel B, 1998, BLOOD, V91, P491; Kubagawa H, 1999, J EXP MED, V189, P309, DOI 10.1084/jem.189.2.309; Matsuno K, 1996, BRIT J HAEMATOL, V92, P960, DOI 10.1046/j.1365-2141.1996.422962.x; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON HC, 1995, J BIOL CHEM, V270, P29781; Nieswandt B, 1999, BLOOD, V94, P684, DOI 10.1182/blood.V94.2.684; Ono M, 1999, J BIOL CHEM, V274, P30288, DOI 10.1074/jbc.274.42.30288; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; REHLI M, 1995, J BIOL CHEM, V270, P15644, DOI 10.1074/jbc.270.26.15644; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; SUGIYAMA T, 1987, BLOOD, V69, P1712; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; VANZANTEN GH, 1994, J CLIN INVEST, V93, P615, DOI 10.1172/JCI117014	22	189	197	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23998	24002		10.1074/jbc.M003803200	http://dx.doi.org/10.1074/jbc.M003803200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10825177	hybrid			2022-12-25	WOS:000088564200082
J	Zhou, DP; Henion, TR; Jungalwala, FB; Berger, EG; Hennet, T				Zhou, DP; Henion, TR; Jungalwala, FB; Berger, EG; Hennet, T			The beta 1,3-galactosyltransferase beta 3GalT-V is a stage-specific embryonic antigen-3 (SSEA-3) synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TERATOCARCINOMA CELLS; UDP-GALACTOSE; MONOCLONAL-ANTIBODY; CARCINOMA-CELLS; CLONING; EXPRESSION; GALACTOSYLTRANSFERASE; TUMORS; GENE	We have previously reported the molecular cloning of beta 1,3-galactosyltransferase-V (P3GalT-V), which catalyzes the transfer of Gal to GlcNAc-based accepters with a preference for the core3 O-linked glycan GlcNAc(beta 1,3)-GalNAc structure. Further characterization indicated that the recombinant beta 3GalT-V enzyme expressed in Sf9 insect cells also utilized the glycolipid Lc3Cer as an efficient acceptor. Surprisingly, we also found that beta 3GalT-V catalyzes the transfer of Gal to the terminal GalNAc unit of the globoside Gb4, thereby synthesizing the glycolipid Gb5, also known as the stage-specific embryonic antigen-3 (SSEA-3). The SSEA-3 synthase activity of beta 3GalT-V was confirmed in vivo by stable expression of the human beta 3GalT-V gene in F9 mouse teratocarcinoma cells, as detected with the monoclonal antibody MC-631 by flow cytometry analysis and immunostaining of extracted glycolipids. The biological relation between SSEA-3 formation and beta 3GalT-V was further documented by showing that F9 cells treated with the differentiation-inducing agent retinoic acid induced the expression of both the SSEA-3 epitope and the endogenous mouse beta 3GalT-V gene. This study represents the first example of a glycosyltransferase, which utilizes two kinds of sugar acceptor substrates without requiring any additional modifier molecule.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Eunice Kennedy Shriver Ctr Mental Retardat Inc, Waltham, MA 02452 USA	University of Zurich	Hennet, T (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		zhou, dapeng/GXG-9715-2022; Zhou, Dapeng/A-6446-2019	Zhou, Dapeng/0000-0003-1347-3811	NICHD NIH HHS [P01-HD05505] Funding Source: Medline; NINDS NIH HHS [R01-NS24405] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024405] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Andrews PW, 1996, INT J CANCER, V66, P806, DOI 10.1002/(SICI)1097-0215(19960611)66:6<806::AID-IJC17>3.0.CO;2-0; Blixt O, 1999, GLYCOBIOLOGY, V9, P1061, DOI 10.1093/glycob/9.10.1061; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; BRODBECK U, 1967, J BIOL CHEM, V242, P1391; CHEN C, 1989, BIOCHEMISTRY-US, V28, P2229, DOI 10.1021/bi00431a039; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Hennet T, 1998, J BIOL CHEM, V273, P58, DOI 10.1074/jbc.273.1.58; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; KANNAGI R, 1983, J BIOL CHEM, V258, P8934; KANNAGI R, 1983, EMBO J, V2, P2355, DOI 10.1002/j.1460-2075.1983.tb01746.x; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; KOUL O, 1990, J LIPID RES, V31, P2227; KRUPNICK JG, 1994, INT J CANCER, V59, P692, DOI 10.1002/ijc.2910590518; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; WENK J, 1994, INT J CANCER, V58, P108, DOI 10.1002/ijc.2910580118; Zhou DP, 1999, EUR J BIOCHEM, V263, P571, DOI 10.1046/j.1432-1327.1999.00541.x; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	20	45	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22631	22634		10.1074/jbc.C000263200	http://dx.doi.org/10.1074/jbc.C000263200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10837462	hybrid			2022-12-25	WOS:000088419400007
J	Mietus-Snyder, M; Gowri, MS; Pitas, RE				Mietus-Snyder, M; Gowri, MS; Pitas, RE			Class A scavenger receptor up-regulation in smooth muscle cells by oxidized low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; CHOLESTEROL OXIDATION-PRODUCTS; FACTOR-KAPPA-B; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; PHOSPHOLIPASE A(2); GENE-EXPRESSION; SARCOPLASMIC-RETICULUM; EPITHELIAL-CELLS; LIPID PEROXIDES	Oxidative stress caused by phorbol esters or reactive oxygen up-regulates the class A scavenger receptor (SR-A) in human smooth muscle cells (SMC), which normally do not express this receptor. The increase in SR-A expression correlates with activation of the redox-sensitive transcription factors activating protein-1 c-Jun and CCAAT enhancer-binding protein beta. Here we show that coincubation of SMC with macrophages or oxidized low density lipoproteins (LDL) from macrophage-conditioned medium activates these game regulatory pathways and stimulates SR-A expression. The increased SR-A gene transcription induced by cell-oxidized LDL up-regulated SR-A mRNA and increased by 30-fold the uptake of acetyl LDL, a ligand for the SR-A. Copper-oxidized LDL also increased SR-A receptor expression. Oxidized LDL with a lipid peroxide level of 80-100 nmol/mg of LDL protein and an electrophoretic mobility similar to 1.5 times that of native LDL exhibited the greatest bioactivity. Inhibition of calcium flux suppressed SR-A induction by oxidized LDL. Conversely, calcium ionophore greatly enhanced SR-A up-regulation by oxidized LDL or other treatments that promote intracellular oxidative stress. This enhancement was dependent upon concurrent up-regulation of SMC cyclooxygenase-2 expression and activity and was blocked by the cyclooxygenase-2 inhibitors NS-398 and Resveratrol. In THP-I cells, oxidized LDL induced monocyte-to-macrophage differentiation and increased SR-A expression. These findings support a role for mildly oxidized LDL in the redox regulation of macrophage differentiation and SR-A expression and suggest that increased vascular oxidative stress may contribute to the formation of both SMC and macrophage foam cells.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Pitas, RE (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.			Mietus-Snyder, Michele/0000-0003-2791-9896	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARES MPS, 1995, ARTERIOSCL THROM VAS, V15, P1584, DOI 10.1161/01.ATV.15.10.1584; AZULA FJ, 1993, AM J PHYSIOL, V265, pC1681, DOI 10.1152/ajpcell.1993.265.6.C1681; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bjorkerud B, 1996, ARTERIOSCL THROM VAS, V16, P416, DOI 10.1161/01.ATV.16.3.416; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHAKRABORTI S, 1989, AM J PHYSIOL, V257, P430; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DEJAGER S, 1993, ARTERIOSCLER THROMB, V13, P371, DOI 10.1161/01.ATV.13.3.371; DOAN TN, 1994, BIOCHEM J, V297, P209, DOI 10.1042/bj2970209; DRAKE TA, 1991, AM J PATHOL, V138, P601; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; ELSAADANI M, 1989, J LIPID RES, V30, P627; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; GONG QQ, 1995, J BIOL CHEM, V270, P21672, DOI 10.1074/jbc.270.37.21672; GROVER AK, 1988, AM J PHYSIOL, V255, pC297, DOI 10.1152/ajpcell.1988.255.3.C297; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hall AJ, 1999, J BIOL CHEM, V274, P376, DOI 10.1074/jbc.274.1.376; Hamilton LC, 1999, FASEB J, V13, P245, DOI 10.1096/fasebj.13.2.245; Hong YH, 1997, J IMMUNOL, V159, P2418; INABA T, 1992, J BIOL CHEM, V267, P13107; Ivandic B, 1999, ARTERIOSCL THROM VAS, V19, P1284, DOI 10.1161/01.ATV.19.5.1284; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pharmtox.35.1.655; Leitinger N, 1999, ARTERIOSCL THROM VAS, V19, P1291, DOI 10.1161/01.ATV.19.5.1291; LI HM, 1995, J CLIN INVEST, V95, P122, DOI 10.1172/JCI117628; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; Martin T, 1997, EUR J IMMUNOL, V27, P1091, DOI 10.1002/eji.1830270508; Maziere C, 1999, FEBS LETT, V448, P49, DOI 10.1016/S0014-5793(99)00324-5; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Mietus-Snyder M, 1998, ARTERIOSCL THROM VAS, V18, P1440, DOI 10.1161/01.ATV.18.9.1440; MietusSnyder M, 1997, ARTERIOSCL THROM VAS, V17, P969, DOI 10.1161/01.ATV.17.5.969; MORISAKI N, 1994, BIOCHEM J, V303, P247, DOI 10.1042/bj3030247; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NEGRESALVAYRE A, 1992, BIOCHIM BIOPHYS ACTA, V1123, P207, DOI 10.1016/0005-2760(92)90113-A; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Ogita T, 1997, AM J PHYSIOL-HEART C, V272, pH17, DOI 10.1152/ajpheart.1997.272.1.H17; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PITAS RE, 1992, ARTERIOSCLER THROMB, V12, P1235, DOI 10.1161/01.ATV.12.11.1235; PITAS RE, 1990, J BIOL CHEM, V265, P12722; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; Ray BK, 1999, DNA CELL BIOL, V18, P65, DOI 10.1089/104454999315637; RIMARACHIN JA, 1994, ARTERIOSCLER THROMB, V14, P1021, DOI 10.1161/01.ATV.14.7.1021; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SALGO MG, 1993, ARCH BIOCHEM BIOPHYS, V304, P123, DOI 10.1006/abbi.1993.1330; SEVANIAN A, 1995, J LIPID RES, V36, P1971; SMITH WL, 1986, ANNU REV PHYSIOL, V48, P251; Speir E, 1998, CIRC RES, V83, P210, DOI 10.1161/01.RES.83.2.210; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinbrecher UP, 1999, BBA-MOL CELL BIOL L, V1436, P279, DOI 10.1016/S0005-2760(98)00127-1; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; SUZUKI YJ, 1992, AM J PHYSIOL, V262, pH114, DOI 10.1152/ajpheart.1992.262.1.H114; SUZUKI YJ, 1991, AM J PHYSIOL, V261, pH568, DOI 10.1152/ajpheart.1991.261.2.H568; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Verhagen JCD, 1996, J LIPID RES, V37, P1488; Vogel RA, 1997, CLIN CARDIOL, V20, P426, DOI 10.1002/clc.4960200505; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Yoshida H, 1998, ARTERIOSCL THROM VAS, V18, P794, DOI 10.1161/01.ATV.18.5.794; Zhou YF, 1996, J CLIN INVEST, V98, P2129, DOI 10.1172/JCI119019	69	75	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17661	17670		10.1074/jbc.275.23.17661	http://dx.doi.org/10.1074/jbc.275.23.17661			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837497	hybrid			2022-12-25	WOS:000087485000065
J	Mitsuhashi, N; Miki, T; Senbongi, H; Yokoi, N; Yano, H; Miyazaki, M; Nakajima, N; Iwanaga, T; Yokoyama, Y; Shibata, T; Seino, S				Mitsuhashi, N; Miki, T; Senbongi, H; Yokoi, N; Yano, H; Miyazaki, M; Nakajima, N; Iwanaga, T; Yokoyama, Y; Shibata, T; Seino, S			MTABC3, a novel mitochondrial ATP-binding cassette protein involved in iron homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED SIDEROBLASTIC ANEMIA; ABC TRANSPORTER; SULFONYLUREA RECEPTOR; MEMBRANE-PROTEIN; YEAST; GENE; DNA; IDENTIFICATION; ATM1P; CELLS	Atm1p, a mitochondrial half-type ATP-binding cassette (ABC) protein in Saccharomyces cerevisiae, transports a precursor of the iron-sulfur (Fe/S) cluster from mitochondria to the cytosol, We have identified a novel half-type human ABC protein, designating it MTABC3 (mammalian mitochondrial ABC protein 3). MTABC3 mRNA is ubiquitously expressed in all of the rat and human tissues examined. MTABC3 protein is shown to be present in the mitochondria, as assessed by immunoblot analysis and confocal microscopic analysis of subcellular fractions of Chinese hamster ovary cells stably expressing MTABC3. Accumulation of iron in the mitochondria, mitochondrial DNA damage, and respiratory dysfunction in the yeast ATM1 mutant strain (atm1-1 mutant cells) were almost fully reversed by expressing MTABC3 in these mutant cells. These results indicate that MTABC3 is a novel ortholog of the yeast and suggest an important role in mitochondrial function, Interestingly, the human MTABC3 gene has been mapped to chromosome 2q36, a region within the candidate locus for lethal neonatal metabolic: syndrome, a disorder of the mitochondrial function associated with iron metabolism, indicating that MTABC3 is a candidate gene for this disorder.	Chiba Univ, Grad Sch Med, Dept Mol Med, Chuo Ku, Chiba 2608670, Japan; RIKEN, Cellular & Mol Biol Lab, Wako, Saitama 3510198, Japan; Chiba Univ, Grad Sch Med, Dept Surg Organ Pathophysiol, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Sch Med, Novo Nordisk Pharma, Dept Med Genet,Chuo Ku, Chiba 2608670, Japan; Hokkaido Univ, Grad Sch Vet Med, Lab Anat, Sapporo, Hokkaido 0600818, Japan; Okayama Univ, Sch Med, Dept Pediat, Okayama 7008558, Japan	Chiba University; RIKEN; Chiba University; Chiba University; Novo Nordisk; Hokkaido University; Okayama University	Mitsuhashi, N (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	seino@molmed.m.chiba-u.ac.jp	MIKI, Takashi/ABD-3995-2020	MIKI, Takashi/0000-0001-5741-1626				Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; Chen Q, 1997, J BIOL CHEM, V272, P15247, DOI 10.1074/jbc.272.24.15247; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Csere P, 1998, FEBS LETT, V441, P266, DOI 10.1016/S0014-5793(98)01560-9; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEAN M, 1995, CURR OPIN GENET DEV, V5, P779, DOI 10.1016/0959-437X(95)80011-S; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DELMAESTRO RF, 1980, ACTA PHYSIOL SCAND, P153; Fellman V, 1998, LANCET, V351, P490, DOI 10.1016/S0140-6736(97)09272-6; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hogue DL, 1999, J MOL BIOL, V285, P379, DOI 10.1006/jmbi.1998.2259; HUDSPETH MES, 1980, BIOCHIM BIOPHYS ACTA, V610, P221, DOI 10.1016/0005-2787(80)90003-9; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; LEIGHTON J, 1995, EMBO J, V14, P188, DOI 10.1002/j.1460-2075.1995.tb06989.x; Linton KJ, 1998, MOL MICROBIOL, V28, P5, DOI 10.1046/j.1365-2958.1998.00764.x; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; RIORDAN JR, 1989, SCIENCE, V245, P1066; Savary S, 1997, GENOMICS, V41, P275, DOI 10.1006/geno.1997.4658; Senbongi H, 1999, MOL GEN GENET, V262, P426; Shimada Y, 1998, J HUM GENET, V43, P115, DOI 10.1007/s100380050051; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; TAKAHASHI E, 1990, HUM GENET, V86, P14; TANGERAS A, 1980, BIOCHIM BIOPHYS ACTA, V589, P162, DOI 10.1016/0005-2728(80)90035-3; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Visapaa I, 1998, AM J HUM GENET, V63, P1396, DOI 10.1086/302123; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WENDLAND B, 1994, MOL ENDOCRINOL, V8, P1070, DOI 10.1210/me.8.8.1070	43	107	112	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17536	17540		10.1074/jbc.275.23.17536	http://dx.doi.org/10.1074/jbc.275.23.17536			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837493	hybrid			2022-12-25	WOS:000087485000046
J	Ribbe, MW; Bursey, EH; Burgess, BK				Ribbe, MW; Bursey, EH; Burgess, BK			Identification of an Fe protein residue (Glu(146)) of Azotobacter vinelandii nitrogenase that is specifically involved in FeMo cofactor insertion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; DEFICIENT MOFE PROTEIN; IN-VITRO BIOSYNTHESIS; KLEBSIELLA-PNEUMONIAE; DINITROGENASE REDUCTASE; SWISS-MODEL; APODINITROGENASE; PURIFICATION; MATURATION; CLUSTER	The Fe protein of nitrogenase has three separate functions. Much is known about the regions of the protein that are critical to its function as an electron donor to the MoFe protein, but almost nothing is known about the regions of the protein that are critical to its functions in either FeMo cofactor biosynthesis or FeMo cofactor insertion. Using computer modeling and information obtained from Fe protein mutants that were made decades ago by chemical mutagenesis, we targeted a surface residue GlU(146) as potentially being involved in FeMo cofactor biosynthesis and/or insertion, The Azotobacter vinelandii strain expressing an E146D Fe protein variant grows at similar to 50% of the wild type rate. The purified E146D Fe protein is fully functional as an electron donor to the MoFe protein, but the MoFe protein synthesized by that strain is partially (similar to 56%) FeMo cofactor-deficient, The E146D Fe protein is fully functional in an in vitro FeMo cofactor biosynthesis assay, and the strain expressing this protein accumulates "free" FeMo cofactor. Assays that compared the ability of wild type and E146D Fe proteins to participate in FeMo cofactor insertion demonstrate, however, that the mutant is severely altered in this last reaction. This is the first known mutation that only influences the insertion reaction.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Burgess, BK (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	bburgess@uci.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043144] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-43144] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; Angove HC, 1998, J BIOL CHEM, V273, P26330, DOI 10.1074/jbc.273.41.26330; Angove HC, 1997, J AM CHEM SOC, V119, P8730, DOI 10.1021/ja9712837; BAGIUNOW MC, 1993, NEW HORIZONS NITROGE, P131; Blanchard CZ, 1996, BIOCHEMISTRY-US, V35, P472, DOI 10.1021/bi951429j; BURGESS BK, 1993, ACS SYM SER, V535, P144; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; Bursey EH, 1998, J BIOL CHEM, V273, P16927, DOI 10.1074/jbc.273.27.16927; Bursey EH, 1998, J BIOL CHEM, V273, P29678, DOI 10.1074/jbc.273.45.29678; CHANG CL, 1988, J BACTERIOL, V170, P4015, DOI 10.1128/jb.170.9.4015-4022.1988; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; CLARK LJ, 1955, ANAL CHEM, V27, P2000, DOI 10.1021/ac60108a046; CORBIN JL, 1984, APPL ENVIRON MICROB, V47, P1027, DOI 10.1128/AEM.47.5.1027-1030.1984; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; DEITS TL, 1989, J BIOL CHEM, V264, P6619; Erickson JA, 1999, BIOCHEMISTRY-US, V38, P14279, DOI 10.1021/bi991389+; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GAVINI N, 1994, BIOCHEMISTRY-US, V33, P11842, DOI 10.1021/bi00205a021; GREENER T, 1993, NEW HORIZONS NITROGE, P123; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAWKES TR, 1983, BIOCHEM J, V209, P43, DOI 10.1042/bj2090043; HOMER MJ, 1993, J BACTERIOL, V175, P4907, DOI 10.1128/JB.175.15.4907-4910.1993; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER T R, 1988, Biofactors, V1, P199; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LOWERY RG, 1989, BIOCHEMISTRY-US, V28, P1206, DOI 10.1021/bi00429a038; MADDEN MS, 1991, J BACTERIOL, V173, P5403, DOI 10.1128/jb.173.17.5403-5405.1991; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Newton WE, 1992, BIOL NITROGEN FIXATI, P877; PAGE WJ, 1979, J BACTERIOL, V139, P1058, DOI 10.1128/JB.139.3.1058-1061.1979; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PETERS JW, 1995, ANNU REV MICROBIOL, V49, P335, DOI 10.1146/annurev.mi.49.100195.002003; Pulakat L, 1996, J BIOL CHEM, V271, P1884, DOI 10.1074/jbc.271.4.1884; Rangaraj P, 1999, J BIOL CHEM, V274, P19778, DOI 10.1074/jbc.274.28.19778; Rangaraj P, 1997, P NATL ACAD SCI USA, V94, P11250, DOI 10.1073/pnas.94.21.11250; ROBINSON AC, 1986, J BACTERIOL, V166, P180, DOI 10.1128/jb.166.1.180-186.1986; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Schlessman JL, 1998, J MOL BIOL, V280, P669, DOI 10.1006/jmbi.1998.1898; Seefeldt LC, 1997, ACCOUNTS CHEM RES, V30, P260, DOI 10.1021/ar960260e; Shah VK, 1999, J BACTERIOL, V181, P2797, DOI 10.1128/JB.181.9.2797-2801.1999; SHAH VK, 1985, J BIOL CHEM, V260, P3891; SHAH VK, 1997, BIOL NITROGEN FIXATI, P51; SHEN BH, 1993, J BIOL CHEM, V268, P25928; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; TAL S, 1991, J BIOL CHEM, V266, P10654; Thorneley RNF, 1996, J BIOL INORG CHEM, V1, P576, DOI 10.1007/s007750050095; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; VANDEBOGART M, 1967, ANAL BIOCHEM, V20, P325, DOI 10.1016/0003-2697(67)90038-3; WALKER GA, 1974, BIOCHEMISTRY-US, V13, P2382, DOI 10.1021/bi00708a023; WATT GD, 1994, J INORG BIOCHEM, V53, P281, DOI 10.1016/0162-0134(94)85115-8; WHITE TC, 1992, J BIOL CHEM, V267, P24007; WOLLE D, 1992, J BIOL CHEM, V267, P3667; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643	62	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17631	17638		10.1074/jbc.275.23.17631	http://dx.doi.org/10.1074/jbc.275.23.17631			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837496	hybrid			2022-12-25	WOS:000087485000061
J	Broome, MA; Courtneidge, SA				Broome, MA; Courtneidge, SA			No requirement for Src family kinases for PDGF signaling in fibroblasts expressing SV40 large T antigen	ONCOGENE			English	Article						p53; PDGF; mitogenesis; Src	EPIDERMAL GROWTH-FACTOR; DNA-SYNTHESIS; SH3 DOMAIN; CELLS; TRANSDUCTION; GENE; P53	A growing body of literature suggests that the ubiquitously expressed Src family kinases (Src, Fyn and Yes) are required for agents such as platelet-derived growth factor (PDGF) to stimulate DNA synthesis. Yet Klinghoffer and colleagues recently presented evidence that fibroblasts derived from mice null for Src, Fyn and Yes responded normally to PDGF (Klinghoffer et al,, 1999, EMBO J,, 18: 2459-2471), What is the reason for this discrepancy? We noted that Klinghoffer ef al, (1999) used SV40 large T antigen (largeT) to facilitate derivation of cell lines from the embryos. We therefore tested the effect of largeT on PDGF receptor signaling, We found that expression of largeT overcame the inhibitory effects of interfering forms of both Ras (N17Ras) and Src (SrcK-). Furthermore, injection of SrcK- or the cst.1 antibody (which inhibits Src, Fyn and Yes) failed to inhibit PDGF-stimulated DNA synthesis in NIH3T3 cells expressing dominant negative p53, and fibroblasts derived from p53 null embryos. These data suggest firstly that caution should be used in interpretation of experiments conducted in cell lines expressing largeT, and secondly that the role of Src family kinases in growth factor signaling may be to oppose the effects of negative growth regulators such as p53.	SUGEN Inc, San Francisco, CA 94080 USA	Pfizer	Courtneidge, SA (corresponding author), SUGEN Inc, 230 E Grand Ave, San Francisco, CA 94080 USA.							BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DICKMANNS A, 1994, J VIROL, V68, P5496, DOI 10.1128/JVI.68.9.5496-5508.1994; Dilworth S M, 1990, Semin Cancer Biol, V1, P407; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Prives C, 1999, J PATHOL, V187, P112; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991	15	42	43	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2000	19	24					2867	2869		10.1038/sj.onc.1203608	http://dx.doi.org/10.1038/sj.onc.1203608			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851090				2022-12-25	WOS:000087403600008
J	Honda, K; Mihara, H; Kato, Y; Yamaguchi, A; Tanaka, H; Yasuda, H; Furukawa, K; Urano, T				Honda, K; Mihara, H; Kato, Y; Yamaguchi, A; Tanaka, H; Yasuda, H; Furukawa, K; Urano, T			Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway	ONCOGENE			English	Article						Aurora2; degradation; anaphase-promoting complex; ubiquitin-proteasome pathway	CHROMOSOME SEGREGATION; CELL-CYCLE; IN-VIVO; YEAST; PROTEOLYSIS; EXPRESSION; BINDING; IPL1; TRANSFORMATION; LOCALIZATION	Human Aurora2 was originally identified by its close homology to yeast IPL1 and fly aurora, which are key regulators of chromosome segregation and a family of serine/threonine kinases, Here we demonstrate that the Aurora2 protein is degraded rapidly after G2/M phase release in mammalian cells. Aurora2 protein has a rapid turnover rate with a half-life of approximately 2 h, Tn eukaryotic cells, the ubiquitin-proteasome pathway is the major mechanism for the targeted degradation of unstable proteins, The treatment of mammalian cells with proteasome inhibitors blocks Aurora2 degradation. Furthermore, Aurora2 is polyubiquitinated in vivo and in vitro using anaphase-promoting complex (APC), These results demonstrate that Aurora2 protein is turned over through the APC-ubiquitin-proteasome pathway.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Fukui Med Sch, Dept Surg 1, Fukui 9101193, Japan; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan	Nagoya University; University of Fukui; Tokyo University of Pharmacy & Life Sciences	Urano, T (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai-machi, Nagoya, Aichi 4660065, Japan.			Urano, Takeshi/0000-0003-3383-3554				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Maki CG, 1996, CANCER RES, V56, P2649; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Shindo M, 1998, BIOCHEM BIOPH RES CO, V244, P285, DOI 10.1006/bbrc.1998.8250; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; URANO T, 1993, ONCOGENE, V8, P1371; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; YANAI A, 1997, ONCOGENE, V14, P2493; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	30	126	130	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2000	19	24					2812	2819		10.1038/sj.onc.1203609	http://dx.doi.org/10.1038/sj.onc.1203609			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851084				2022-12-25	WOS:000087403600002
J	Leroy, A; Lauwaet, T; De Bruyne, G; Cornelissen, M; Mareel, M				Leroy, A; Lauwaet, T; De Bruyne, G; Cornelissen, M; Mareel, M			Entamoeba histolytica disturbs the tight junction complex in human enteric T84 cell layers	FASEB JOURNAL			English	Article						invasion; transepithelial electrical resistance; paracellular permeability; ZO proteins; amebiasis	ZONULA OCCLUDENS TOXIN; EPITHELIAL-CELLS; TYROSINE PHOSPHORYLATION; PERIPHERAL COMPONENT; POSSIBLE INVOLVEMENT; IN-VITRO; PROTEIN; PERMEABILITY; LECTIN; ZO-1	Entamoeba (E.) histolytica trophozoites initiate amebiasis through invasion into the enteric mucosa. It was our aim to understand the molecular interactions between amebic trophozoites and enterocytes during the early steps of invasion. Trophozoites of E. histolytica strain HM1:IMSS were seeded on the apical side of enteric T84 cell layers, which were established on filters in two-compartment culture chambers. Cocultures were analyzed for paracellular permeability by measurement of transepithelial electrical resistance (TER) and for the tight junction proteins ZO-1, ZO-2, occludin, and cingulin by immunocytochemistry and immunoprecipitation, On direct contact with the apical side of the enteric cells, trophozoites caused an increase in paracellular permeability as evidenced by a decrease of TER associated with all increase in [H-3]mannitol flux. Immunoprecipitation of cocultures revealed dephosphorylation of ZO-2, loss of ZO-1 from ZO-2, and degradation of ZO-1 but less so of ZO-2 and none of occludin or E-cadherin. In conclusion, trophozoite-associated increase in paracellular permeability of enteric cell layers is ascribed to disturbance of the molecular organization of tight junction proteins.-Leroy, A., Lauwaet, T., De Bruyne, G., Cornelissen, M., Marcel, M. Entamoeba histolytica disturbs the tight junction complex in human enteric T84 cell layers.	State Univ Ghent Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; State Univ Ghent, Dept Anat Histol & Embryol, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University	Mareel, M (corresponding author), State Univ Ghent Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, De Pintelaan 185, B-9000 Ghent, Belgium.							CITI S, 1995, J CELL SCI, V108, P2917; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; DIAMOND LS, 1978, T ROY SOC TROP MED H, V72, P431, DOI 10.1016/0035-9203(78)90144-X; Fasano A, 1997, GASTROENTEROLOGY, V112, P839, DOI 10.1053/gast.1997.v112.pm9041245; FASANO A, 1995, J CLIN INVEST, V96, P710, DOI 10.1172/JCI118114; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GRIFFITHS JK, 1994, INFECT IMMUN, V62, P4506, DOI 10.1128/IAI.62.10.4506-4514.1994; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; HECHT G, 1992, GASTROENTEROLOGY, V102, P416, DOI 10.1016/0016-5085(92)90085-D; HECHT G, 1994, AM J PHYSIOL, V266, pG214, DOI 10.1152/ajpgi.1994.266.2.G214; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; Leippe M, 1997, PARASITOL TODAY, V13, P178, DOI 10.1016/S0169-4758(97)01038-7; LEROY A, 1995, INFECT IMMUN, V63, P4253, DOI 10.1128/IAI.63.11.4253-4260.1995; LEROY A, 1994, INVAS METAST, V14, P177; Leroy A, 1997, BIOCHEM SOC T, V25, P228, DOI 10.1042/bst0250228; Leroy Ancy, 1997, Invasion and Metastasis, V17, P138; LI E, 1994, INFECT IMMUN, V62, P5112, DOI 10.1128/IAI.62.11.5112-5119.1994; MADARA JL, 1986, J CELL BIOL, V102, P2125, DOI 10.1083/jcb.102.6.2125; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; MADARA JL, 1987, J MEMBRANE BIOL, V100, P149, DOI 10.1007/BF02209147; MARTINEZPALOMO A, 1985, J PROTOZOOL, V32, P166, DOI 10.1111/j.1550-7408.1985.tb03033.x; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Moll T, 1998, J CELL BIOL, V140, P403, DOI 10.1083/jcb.140.2.403; PETRI WA, 1987, J CLIN INVEST, V80, P1238, DOI 10.1172/JCI113198; PETRI WA, 1991, ASM NEWS, V57, P299; Petri William A. Jr, 1993, Seminars in Cell Biology, V4, P305, DOI 10.1006/scel.1993.1037; Que X, 1997, PARASITOL TODAY, V13, P190, DOI 10.1016/S0169-4758(97)01043-0; RAVDIN JI, 1989, INFECT IMMUN, V57, P2179, DOI 10.1128/IAI.57.7.2179-2186.1989; SAFFER LD, 1991, INFECT IMMUN, V59, P4681, DOI 10.1128/IAI.59.12.4681-4683.1991; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STADDON JM, 1995, J CELL SCI, V108, P609; Tsukamoto T, 1999, AM J PHYSIOL-RENAL, V276, pF737, DOI 10.1152/ajprenal.1999.276.5.F737; vanHengel J, 1997, J CELL BIOL, V137, P1103, DOI 10.1083/jcb.137.5.1103; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	42	65	66	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1139	1146		10.1096/fasebj.14.9.1139	http://dx.doi.org/10.1096/fasebj.14.9.1139			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834936				2022-12-25	WOS:000087427300011
J	Toulouse, A; Loubeau, M; Morin, J; Pappas, JJ; Wu, JP; Bradley, WEC				Toulouse, A; Loubeau, M; Morin, J; Pappas, JJ; Wu, JP; Bradley, WEC			RAR beta involvement in enhancement of lung tumor cell immunogenicity revealed by array analysis	FASEB JOURNAL			English	Article						lung cancer; retinoic acid receptor beta; tumor suppression; cDNA array	ACID-RECEPTOR-BETA; BREAST-CANCER CELLS; RETINOIC-ACID; CARCINOMA-CELLS; EXPRESSION; RNA; CHEMOPREVENTION; TRANSGENE; RAPAMYCIN; INDUCTION	The retinoid receptors (RARs and RXRs) ape mediators of the multiple effects of retinoic acid. Of these, the retinoic acid receptor beta 2 (RAR beta 2) has frequently been shown to be the principal mediator of the growth and tumor suppressive effects of retinoic acid; this gene is inactivated in many epithelial tumors and their derived cell lines. We have searched for genes that are regulated by this isoform and are potentially involved in tumor suppression. Using the Atlas human cDNA array I, we identified 27 genes (not counting RAR beta itself) that are regulated, directly or indirectly, by RAR beta 2 when it is transfected into Calu-1, a lung tumor-derived line that does not normally express RAR beta. Several of the affected genes code for proteins whose functions would augment the process of apoptosis and/or the host's immune response. The latter group included ICAM-1 and MHC class I heavy chain, whose protein products play particularly important roles in the mounting of an effective antitumor response. We then confirmed by flow cytometry that the observed increases in message levels were reflected in increased cell surface protein levels for ICAM-1 and MHC class I in RAR beta 2 transfectants of two RAR beta-deficient lines, Calu-1 and the epidermoid lung cancer-derived line SKMES. Finally, we showed that RAR beta 2 transfection of Calu-1 cells enhanced the heterologous CTL response in both the induction and the effector phases by up to threefold. These results support the hypothesis that down-regulation of these genes (and possibly others) in RAR beta-deficient tumor cells contributes to immune system evasion, and suggest a novel therapeutic approach for this disease.-Toulouse, A., Loubeau, M., Morin, Pappas, J. J., Wu, J., Bradley W. E. C. RAR beta involvement in enhancement of lung tumor cell immunogenicity revealed by array analysis.	CHUM, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; CHUM, Ctr Rech, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Surg, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University; McGill University	Toulouse, A (corresponding author), Montreal Gen Hosp, Res Inst, Rm L12-132,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	mbem@musica.mcgill.ca	Toulouse, Andre/A-3159-2009	Loubeau, Martine/0000-0003-4629-7850; Toulouse, Andre/0000-0002-4045-8265				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Ayoub J, 1999, J CLIN ONCOL, V17, P3546, DOI 10.1200/JCO.1999.17.11.3546; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; BERARD J, 1994, EMBO J, V13, P5570, DOI 10.1002/j.1460-2075.1994.tb06894.x; Bookman MA, 1998, SEMIN ONCOL, V25, P381; BOUILLON M, 1991, BIOCHIM BIOPHYS ACTA, V1097, P95, DOI 10.1016/0925-4439(91)90091-M; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN HF, 1994, J IMMUNOL, V152, P3107; Coligan JKA, 1991, CURRENT PROTOCOLS IM; Garrido F, 1995, ADV CANCER RES, V67, P155, DOI 10.1016/S0065-230X(08)60713-7; GEBERT JF, 1991, ONCOGENE, V6, P1859; GRAHAM S, 1984, JNCI-J NATL CANCER I, V73, P1423; Herman JG, 1996, CANCER RES, V56, P722; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; JARROUS N, 1994, J BIOL CHEM, V269, P23141; Jen Y, 1996, DEV DYNAM, V207, P235; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LUO H, 1993, CLIN EXP IMMUNOL, V94, P371; Norton JD, 1998, MOL CELL BIOL, V18, P2371, DOI 10.1128/MCB.18.4.2371; REARICK JI, 1989, ENVIRON HEALTH PERSP, V80, P229, DOI 10.2307/3430748; Rishi AK, 1999, NUCLEIC ACIDS RES, V27, P3111, DOI 10.1093/nar/27.15.3111; ROMAN SD, 1992, CANCER RES, V52, P2236; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; Shang YF, 1999, J BIOL CHEM, V274, P18005, DOI 10.1074/jbc.274.25.18005; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P33; Toulouse A, 1998, RESP PHARM & PHARMAC, P193; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965; Widschwendter M, 1997, CANCER RES, V57, P4158; Xu XC, 1999, J NATL CANCER I, V91, P1317, DOI 10.1093/jnci/91.15.1317; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Xu XC, 1997, CANCER RES, V57, P4992	34	24	27	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1224	1232		10.1096/fasebj.14.9.1224	http://dx.doi.org/10.1096/fasebj.14.9.1224			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834944				2022-12-25	WOS:000087427300019
J	Sathyanarayanan, PV; Cremo, CR; Poovaiah, BW				Sathyanarayanan, PV; Cremo, CR; Poovaiah, BW			Plant chimeric Ca2+/calmodulin-dependent protein kinase - Role of the neural visinin-like domain in regulating autophosphorylation and calmodulin affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CALMODULIN; BINDING; HOMOLOG; GENE	Chimeric Ca2+/calmodulin-dependent protein kinase (CCaMK) is characterized by a serine-threonine kinase domain, an autoinhibitory domain, a calmodulin-binding domain and a neural visinin-like domain with three EF-hands. The neural visinin-like Ca2+-binding domain at the C-terminal end of the CaM-binding domain makes CCaMK unique among all the known calmodulin-dependent kinases. Biological functions of the plant visinin-like proteins or visinin-like domains in plant proteins are not well known. Using EF-hand deletions in the visinin-like domain, we found that the visinin-like domain regulated Ca2+-stimulated autophosphorylation of CCaMK. To investigate the effects of Ca2+-stimulated autophosphorylation on the interaction with calmodulin, the equilibrium binding constants of CCaMK were measured by fluorescence emission anisotropy using dansylated calmodulin. Binding was 8-fold tighter after Ca2+-stimulated autophosphorylation. This shift in affinity did not occur in CCaMK deletion mutants lacking Ca2+-stimulated autophosphorylation. A variable calmodulin affinity regulated by Ca2+-stimulated autophosphorylation mediated through the visinin-like domain is a new regulatory mechanism for CCaMK activation and calmodulin-dependent protein kinases. Our experiments demonstrate the existence of two functional molecular switches in a protein kinase regulating the kinase activity, namely a visinin-like domain acting as a Ca2+-triggered switch and a CaM-binding domain acting as an autophosphorylation-triggered molecular switch.	Washington State Univ, Dept Hort, Lab Plant Mol Biol & Physiol, Pullman, WA 99164 USA; Univ Nevada, Sch Med, Dept Biochem, Reno, NV 89557 USA; Univ Nevada, Sch Agr, Reno, NV 89557 USA	Washington State University; Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno	Poovaiah, BW (corresponding author), Washington State Univ, Dept Hort, Lab Plant Mol Biol & Physiol, Pullman, WA 99164 USA.	poovaiah@wsu.edu						Berridge M, 1999, CURR BIOL, V9, pR157, DOI 10.1016/S0960-9822(99)80101-8; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; Bevington P. R., 1969, DATA REDUCTION ERROR, P56; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; HARPER JF, 1991, SCIENCE, V252, P951, DOI 10.1126/science.1852075; Kobayashi M, 1998, Tanpakushitsu Kakusan Koso, V43, P1681; Lu YT, 1996, PLANTA, V199, P18; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; PATIL S, 1995, P NATL ACAD SCI USA, V92, P4897, DOI 10.1073/pnas.92.11.4897; Poovaiah BW, 1999, PLANTA, V209, P161, DOI 10.1007/s004250050618; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; Putney JW, 1998, SCIENCE, V279, P191, DOI 10.1126/science.279.5348.191; Ramachandiran S, 1997, J BIOCHEM-TOKYO, V121, P984; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; SODERLING TR, 1995, ADV SEC MESS PHOSPH, V30, P175; Takezawa D, 1996, J BIOL CHEM, V271, P8126, DOI 10.1074/jbc.271.14.8126; Wang WY, 1999, J BIOL CHEM, V274, P12001, DOI 10.1074/jbc.274.17.12001; WATILLON B, 1993, PLANT PHYSIOL, V101, P1381, DOI 10.1104/pp.101.4.1381; Yang EY, 1999, J BIOL CHEM, V274, P26199, DOI 10.1074/jbc.274.37.26199; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851	26	54	56	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30417	30422		10.1074/jbc.M000771200	http://dx.doi.org/10.1074/jbc.M000771200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10840028	hybrid			2022-12-25	WOS:000089577900068
J	Albrecht, C; von der Kammer, H; Mayhaus, M; Klaudiny, J; Schweizer, M; Nitsch, RM				Albrecht, C; von der Kammer, H; Mayhaus, M; Klaudiny, J; Schweizer, M; Nitsch, RM			Muscarinic acetylcholine receptors induce the expression of the immediate early growth regulatory gene CYR61	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PROTEIN-COUPLED RECEPTORS; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; CHOLINERGIC INNERVATION; EXTRACELLULAR-MATRIX; INTEGRIN ALPHA(V)BETA(3); DIFFERENTIAL EXPRESSION; TRANSCRIPTION FACTORS; DEPENDENT ACTIVATION	In brain, muscarinic acetylcholine receptors (mAChRs) modulate neuronal functions including long term potentiation and synaptic plasticity in neuronal circuits that are involved in learning and memory formation. To identify mAChR-inducible genes, we used a differential display approach and found that mAChRs rapidly induced transcription of the immediate early gene CYR61 in HEK 293 cells with a maximum expression after 1 h of receptor stimulation. CYR61 is a member of the emerging CCN gene family that includes CYR61/CEF10, CTGF/FISP-12, and NOV; these encode secretory growth regulatory proteins with distinct functions in cell proliferation, migration, adhesion, and survival. We found that CYR61, CTGF, and NOV were expressed throughout the human central nervous system. Stimulation of mAChRs induced CYR61 expression in primary neurons and rat brain where CYR61 mRNA was detected in cortical layers V and VI and in thalamic nuclei. In contrast, CTGF and NOV expression was not altered by mAChRs neither in neuronal tissue culture nor rat brain. Receptor subtype analyses demonstrated that mi and m3 mAChR subtypes strongly induced CYR61 expression, whereas m2 and m4 mAChRs had only subtle effects. Increased CYR61 expression was coupled to mAChRs by both protein kinase C and elevations of intracellular Ca2+. Our results establish that CYR61 expression in mammalian brain is under the control of cholinergic neurotransmission; it may thus be involved in cholinergic regulation of synaptic plasticity.	Univ Zurich, Dept Psychiat Res, CH-8008 Zurich, Switzerland; Slovak Acad Sci, Inst Chem, Bratislava 84238, Slovakia; Univ Hamburg, Ctr Mol Neurobiol Hamburg, D-20246 Hamburg, Germany	University of Zurich; Slovak Academy of Sciences; University of Hamburg	Nitsch, RM (corresponding author), Univ Zurich, Dept Psychiat Res, August Forel Str 1, CH-8008 Zurich, Switzerland.	nitsch@bli.unizh.ch	Klaudiny, Jaroslav/AAZ-8814-2021	Klaudiny, Jaroslav/0000-0003-0482-1212				ANDREASSON K, 1995, NEUROSCIENCE, V69, P781, DOI 10.1016/0306-4522(95)00245-E; ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; Baxter MG, 1999, CURR OPIN NEUROBIOL, V9, P178, DOI 10.1016/S0959-4388(99)80024-5; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRANN MR, 1993, PROG BRAIN RES, V98, P121; Brown DA, 1997, LIFE SCI, V60, P1137, DOI 10.1016/S0024-3205(97)00058-1; Chevalier G, 1998, AM J PATHOL, V152, P1563; Chung KC, 1998, NEUROSCI LETT, V255, P155, DOI 10.1016/S0304-3940(98)00733-2; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; Coso OA, 1996, J BIOL CHEM, V271, P3963; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DEFREITAS MF, 1995, NEURON, V15, P333, DOI 10.1016/0896-6273(95)90038-1; Ding WQ, 1998, J NEUROCHEM, V70, P1722; Dragunow M, 1996, BEHAV GENET, V26, P293, DOI 10.1007/BF02359385; FELDER CC, 1989, J BIOL CHEM, V264, P20356; FELDER CC, 1995, FASEB J, V9, P619, DOI 10.1096/fasebj.9.8.7768353; FIBIGER HC, 1991, TRENDS NEUROSCI, V14, P220, DOI 10.1016/0166-2236(91)90117-D; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Guillery RW, 1995, J ANAT, V187, P583; HARTMANN D, 1995, DEV NEUROSCI-BASEL, V17, P246, DOI 10.1159/000111293; Hertel M, 2000, EUR J NEUROSCI, V12, P376, DOI 10.1046/j.1460-9568.2000.00930.x; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; HUGHES P, 1994, MOL BRAIN RES, V24, P166, DOI 10.1016/0169-328X(94)90129-5; Igarashi A, 1996, J INVEST DERMATOL, V106, P729, DOI 10.1111/1523-1747.ep12345771; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Jay P, 1997, ONCOGENE, V14, P1753, DOI 10.1038/sj.onc.1200986; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; Kondo Y, 1999, BRAIN RES, V834, P146, DOI 10.1016/S0006-8993(99)01517-6; KRNJEVIC K, 1993, PROG BRAIN RES, V98, P285; Lanahan A, 1998, NEUROBIOL LEARN MEM, V70, P37, DOI 10.1006/nlme.1998.3836; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; LEHRACH H., 1990, GENOME ANAL, P39; LETOURNEAU PC, 1994, J NEUROSCI, V14, P915, DOI 10.1523/JNEUROSCI.14-03-00915.1994; LEVEY AI, 1991, J NEUROSCI, V11, P3218; Levey AI, 1996, P NATL ACAD SCI USA, V93, P13541, DOI 10.1073/pnas.93.24.13541; LEVEY AI, 1995, J NEUROSCI, V15, P4077; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LYNFORD G, 1995, NEURON, V14, P433; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MESULAM MM, 1983, J COMP NEUROL, V214, P170, DOI 10.1002/cne.902140206; Naeve GS, 1997, P NATL ACAD SCI USA, V94, P2648, DOI 10.1073/pnas.94.6.2648; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; OIAN Z, 1993, NATURE, V361, P453; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; Perry E, 1999, TRENDS NEUROSCI, V22, P273, DOI 10.1016/S0166-2236(98)01361-7; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; Roche KW, 1999, J BIOL CHEM, V274, P25953, DOI 10.1074/jbc.274.36.25953; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; Scholz G, 1996, MOL CELL BIOL, V16, P481; SEGAL M, 1992, J PHYSIOL-LONDON, V448, P655, DOI 10.1113/jphysiol.1992.sp019063; SEMBA K, 1989, PROG BRAIN RES, V79, P37; Staubli U, 1998, J NEUROSCI, V18, P3460; Su BY, 1998, CR ACAD SCI III-VIE, V321, P883, DOI 10.1016/S0764-4469(99)80002-X; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; von der Kammer H, 1999, NUCLEIC ACIDS RES, V27, P2211, DOI 10.1093/nar/27.10.2211; von der Kammer H, 1998, J BIOL CHEM, V273, P14538, DOI 10.1074/jbc.273.23.14538; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; Winkler J, 1998, J MOL MED-JMM, V76, P555, DOI 10.1007/s001090050250; Xin LW, 1996, J CLIN PATHOL-CL MOL, V49, pM91; Yamagata K, 1999, J BIOL CHEM, V274, P19473, DOI 10.1074/jbc.274.27.19473; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351	78	56	61	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28929	28936		10.1074/jbc.M003053200	http://dx.doi.org/10.1074/jbc.M003053200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10852911	hybrid			2022-12-25	WOS:000089330700078
J	Cheesman, EJ; Sharp, RJ; Zlot, CH; Liu, CYY; Taylor, S; Marcovina, SM; Young, SG; McCormick, SPA				Cheesman, EJ; Sharp, RJ; Zlot, CH; Liu, CYY; Taylor, S; Marcovina, SM; Young, SG; McCormick, SPA			An analysis of the interaction between mouse apolipoprotein B100 and apolipoprotein(a)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSING HUMAN APOLIPOPROTEIN(A); LOW-DENSITY-LIPOPROTEIN; TRANSGENIC MICE; B GENE; BINDING; CONSERVATION; MUTAGENESIS; SEQUENCES; DOMAINS; CLONING	The assembly of lipoprotein(a) (Lp(a)) involves an initial noncovalent interaction between apolipoprotein (apo) B100 and apo(a), followed by the formation of a disulfide bond between apoB100 cysteine 4326 and apo(a) cysteine 4057, The structural features of apoB100 that are required for its noncovalent interaction with apo(a) have not been fully defined. To analyze that initial interaction, me tested whether apo(a) could bind noncovalently to two apoB proteins that lack cysteine 4326: mouse apoB100 and human apoB100-C4326G. Our experiments demonstrated that both mouse apoB and the human apoB100-C4326G bind noncovalently to apo(a), We next sought to gain insights into the apoB amino acid sequences required for the interaction between apoB100 and apo(a). Previous studies of truncated human apoB proteins indicated that the carboxyl terminus of human apoB100 (amino acids 4330-4397) is important for Lp(a) assembly. To determine whether the carboxyl terminus of mouse apoB100 can interact with apo(a), transgenic mice were produced with a mutant human apoB gene construct in which human apoB100 amino acids 4279-4536 were replaced with the corresponding mouse apoB100 sequences and tyrosine 4326 was changed to a cysteine. The mutant apoB100 bound to apo(a) and formed bona fide disulfide-linked Lp(a), but Lp(a) assembly was less efficient than with wildtype human apoB100, The fact that Lp(a) assembly was less efficient with the mouse apoB sequences provides additional support for the notion that sequences in the carboxyl terminus of apoB100 are important for Lp(a) assembly.	Univ Otago, Dept Biochem, Dunedin 9001, New Zealand; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Washington, Dept Med, NW Lipid Res Labs, Seattle, WA 98103 USA	University of Otago; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle	McCormick, SPA (corresponding author), Univ Otago, Dept Biochem, POB 56, Dunedin 9001, New Zealand.	sally.mccormick@stonebow.otago.ac.nz		McCormick, Sally/0000-0001-9857-0703; Young, Stephen/0000-0001-7270-3176	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CALLOW MJ, 1995, J BIOL CHEM, V270, P23914, DOI 10.1074/jbc.270.41.23914; Chauhan V, 1998, BIOCHEMISTRY-US, V37, P3735, DOI 10.1021/bi9718853; CHIESA G, 1992, J BIOL CHEM, V267, P24369; ERNST A, 1995, J BIOL CHEM, V270, P6227, DOI 10.1074/jbc.270.11.6227; Frank S, 1996, EUR J CLIN INVEST, V26, P109, DOI 10.1046/j.1365-2362.1996.112255.x; Gabel BR, 1998, ARTERIOSCL THROM VAS, V18, P1738, DOI 10.1161/01.ATV.18.11.1738; Gabel BR, 1996, ARTERIOSCL THROM VAS, V16, P1559, DOI 10.1161/01.ATV.16.12.1559; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; LAPLAUD PM, 1988, J LIPID RES, V29, P1157; LAWN RM, 1995, J BIOL CHEM, V270, P24004, DOI 10.1074/jbc.270.41.24004; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; MAKINO K, 1989, ATHEROSCLEROSIS, V78, P81, DOI 10.1016/0021-9150(89)90161-5; MANCINI FP, 1995, ATHEROSCLEROSIS, V10, P884; MARCOVINA SM, 1995, CLIN CHEM, V41, P246; McCormick SPA, 1997, J BIOL CHEM, V272, P23616, DOI 10.1074/jbc.272.38.23616; McCormick SPA, 1996, J BIOL CHEM, V271, P11963, DOI 10.1074/jbc.271.20.11963; MCCORMICK SPA, 1995, P NATL ACAD SCI USA, V92, P10147, DOI 10.1073/pnas.92.22.10147; MCCORMICK SPA, 1994, J BIOL CHEM, V269, P24284; Nielsen LB, 1997, J BIOL CHEM, V272, P29752, DOI 10.1074/jbc.272.47.29752; PEASE RJ, 1990, J BIOL CHEM, V265, P553; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P7593, DOI 10.1073/pnas.90.16.7593; Segrest JP, 1998, J LIPID RES, V39, P85; Sharp RJ, 1999, CIRCULATION, V100, P109; TRIEU VN, 1995, BIOCHEM J, V307, P17, DOI 10.1042/bj3070017; TRIEU VN, 1995, BIOCHEM J, V309, P899, DOI 10.1042/bj3090899; TRIEU VN, 1995, J BIOL CHEM, V270, P15471, DOI 10.1074/jbc.270.26.15471; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; YOUNG SG, 1986, ARTERIOSCLEROSIS, V6, P178, DOI 10.1161/01.ATV.6.2.178; YOUNG SG, 1987, J CLIN INVEST, V79, P1831, DOI 10.1172/JCI113025	32	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28195	28200						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10837476				2022-12-25	WOS:000089197100088
J	Allard, B; Couble, ML; Magloire, H; Bleicher, F				Allard, B; Couble, ML; Magloire, H; Bleicher, F			Characterization and gene expression of high conductance calcium-activated potassium channels displaying mechanosensitivity in human odontoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; RAT; PULP; PHARMACOLOGY; ISOFORMS; CLONING; NERVES; TEETH; GERM; CAT	Odontoblasts form a layer of cells responsible for the dentin formation and possibly mediate early stages of sensory processing in teeth. Several classes of ion channels have previously been identified in the odontoblast or pulp cell membrane, and it is suspected that these channels assist in these events. This study was carried out to characterize the K-Ca channels on odontoblasts fully differentiated in vitro using the patch clamp technique and to investigate the HSLO gene expression encoding the alpha-subunit of these channels on odontoblasts in vivo. In inside-out patches, K-Ca channels were identified on the basis of their K+ selectivity, conductance, voltage, and Ca2+ dependence. In cell-attached patches, these channels were found to be activated by application of a negative pressure as well as an osmotic shock, By reverse transcription-polymerase chain reaction, a probe complementary to K-Ca alpha-subunit mRNA was constructed and used for in situ hybridization on human dental pulp samples. Transcripts were expressed in the odontoblast layer. The use of antibodies showed that the K-Ca channels were preferentially detected at the apical pole of the odontoblasts. These channels could be involved in mineralization processes. Their mechanosensitivity suggests that the fluid displacement within dentinal tubules could be transduced into electrical cell signals.	Fac Odontol, Lab Dev Tissus Dentaires, F-69372 Lyon 08, France; Univ Lyon 1, UMR CNRS 5578, Lab Physiol Elements Excitables, F-69622 Villeurbanne, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Magloire, H (corresponding author), Fac Odontol, Lab Dev Tissus Dentaires, Rue G Paradin,EA 1892, F-69372 Lyon 08, France.	magloire@laennec.univ-lyon1.fr						ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; BLATZ AL, 1987, TRENDS NEUROSCI, V10, P463, DOI 10.1016/0166-2236(87)90101-9; Bleicher F, 1999, MATRIX BIOL, V18, P133, DOI 10.1016/S0945-053X(99)00007-4; BYERS MR, 1984, INT REV NEUROBIOL, V25, P39, DOI 10.1016/S0074-7742(08)60677-7; Couble ML, 2000, CALCIFIED TISSUE INT, V66, P129, DOI 10.1007/PL00005833; DAVIDSON RM, 1994, ARCH ORAL BIOL, V39, P613, DOI 10.1016/0003-9969(94)90137-6; DAVIDSON RM, 1990, PFLUG ARCH EUR J PHY, V416, P646, DOI 10.1007/BF00370609; DONG WK, 1985, BRAIN RES, V334, P389, DOI 10.1016/0006-8993(85)90239-2; DWORETZKY SI, 1994, MOL BRAIN RES, V27, P189, DOI 10.1016/0169-328X(94)90203-8; Gribkoff V K, 1997, Adv Pharmacol, V37, P319; Guo L, 1999, J BONE MINER RES, V14, P1357, DOI 10.1359/jbmr.1999.14.8.1357; Guo L, 1998, J DENT RES, V77, P341, DOI 10.1177/00220345980770020201; HILDEBRAND C, 1995, PROG NEUROBIOL, V45, P165, DOI 10.1016/0301-0082(94)00045-J; Ibuki T, 1996, J DENT RES, V75, P1963, DOI 10.1177/00220345960750120801; JYVASJARVI E, 1989, J PHYSIOL-LONDON, V411, P663, DOI 10.1113/jphysiol.1989.sp017597; Kaczorowski GJ, 1996, J BIOENERG BIOMEMBR, V28, P255, DOI 10.1007/BF02110699; KIRBER MT, 1992, FEBS LETT, V297, P24, DOI 10.1016/0014-5793(92)80319-C; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; LUMSDEN AGS, 1988, DEVELOPMENT, V103, P155; Mallouk N, 2000, AM J PHYSIOL-CELL PH, V278, pC473, DOI 10.1152/ajpcell.2000.278.3.C473; MARKOWITZ K, 1991, ARCH ORAL BIOL, V36, P1, DOI 10.1016/0003-9969(91)90047-X; MCMANUS OB, 1991, J BIOENERG BIOMEMBR, V23, P537, DOI 10.1007/BF00785810; Mienville JM, 1996, J MEMBRANE BIOL, V153, P211, DOI 10.1007/s002329900124; PACHA J, 1991, AM J PHYSIOL, V261, pF696, DOI 10.1152/ajprenal.1991.261.4.F696; Rosenblatt KP, 1997, NEURON, V19, P1061, DOI 10.1016/S0896-6273(00)80397-9; SEUX D, 1994, ARCH ORAL BIOL, V39, P167, DOI 10.1016/0003-9969(94)90113-9; Shibukawa Yoshiyuki, 1997, Bulletin of Tokyo Dental College, V38, P177; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Vergara C, 1998, CURR OPIN NEUROBIOL, V8, P321, DOI 10.1016/S0959-4388(98)80056-1; Wallner M, 1995, RECEPTOR CHANNEL, V3, P185	30	69	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25556	25561		10.1074/jbc.M002327200	http://dx.doi.org/10.1074/jbc.M002327200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10840032	hybrid			2022-12-25	WOS:000088849400068
J	Bittner, MA; Holz, RW				Bittner, MA; Holz, RW			Latrotoxin stimulates secretion in permeabilized cells by regulating an intracellular Ca2+- and ATP-dependent event - A role for protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; WIDOW SPIDER VENOM; FROG NEUROMUSCULAR-JUNCTION; CALCIUM-INDEPENDENT RECEPTOR; ALPHA-LATROTOXIN; QUANTAL SECRETION; COUPLED RECEPTOR; BINDING-PROTEIN; EXOCYTOSIS; TOXIN	alpha-latrotoxin, a component of black widow spider venom, stimulates transmitter release from nerve terminals and intact chromaffin cells and enhances secretion from permeabilized chromaffin cells already maximally stimulated by Ca2+. In this study we demonstrate that chromaffin cells contain a protein antigenically similar to the cloned Ca2+-independent receptor for alpha-latrotoxin. Although this receptor has homology to the secretin family of G-protein-linked receptors, pertussis toxin has no effect on the ability of alpha-latrotoxin to enhance secretion, suggesting that neither G(i) nor G(o) is involved in the response. Furthermore, in the absence of Ca2+, alpha-latrotoxin does not stimulate polyphosphoinositide-specific phospholipase C. alpha-Latrotoxin specifically enhances ATP-dependent secretion in permeabilized cells. An in situ assay for protein kinase C reveals that alpha-latrotoxin augments the activation of protein kinase C by Ca2+, and use of protein kinase inhibitors demonstrates that this activation is important for the toxin's enhancing effect. This enhancement of secretion requires Ca2+ concentrations above 3 mu M and is not supported by Ba2+ or nonhydrolyzable guanine nucleotides, which do not stimulate protein kinase C, We conclude that cu-latrotoxin stimulates secretion in permeabilized cells by regulating a Ca2+- and ATP-dependent event involving protein kinase C.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Bittner, MA (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, M 1301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027959] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK27959] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barnett DW, 1996, PFLUG ARCH EUR J PHY, V432, P1039, DOI 10.1007/s004240050232; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BITTNER MA, 1993, CELL MOL NEUROBIOL, V13, P649, DOI 10.1007/BF00711564; BITTNER MA, 1986, J BIOL CHEM, V261, P182; BITTNER MA, 1990, J NEUROCHEM, V54, P205, DOI 10.1111/j.1471-4159.1990.tb13302.x; Bittner MA, 1998, J NEUROSCI, V18, P2914; Capogna M, 1996, J NEUROPHYSIOL, V76, P3149, DOI 10.1152/jn.1996.76.5.3149; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; EBERHARD DA, 1988, TRENDS NEUROSCI, V11, P517, DOI 10.1016/0166-2236(88)90174-9; EBERHARD DA, 1987, J NEUROCHEM, V49, P1634, DOI 10.1111/j.1471-4159.1987.tb01037.x; FESCE R, 1986, J GEN PHYSIOL, V88, P59, DOI 10.1085/jgp.88.1.59; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Hlubek MD, 2000, MOL PHARMACOL, V57, P519, DOI 10.1124/mol.57.3.519; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; Ichtchenko K, 1998, EMBO J, V17, P6188, DOI 10.1093/emboj/17.21.6188; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Krasnoperov VG, 1996, BIOCHEM BIOPH RES CO, V227, P868, DOI 10.1006/bbrc.1996.1598; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lang JC, 1998, EMBO J, V17, P648, DOI 10.1093/emboj/17.3.648; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Liu J, 1998, J NEUROSCI, V18, P6113; LONGENEC.HE, 1970, NATURE, V225, P701, DOI 10.1038/225701a0; MELDOLESI J, 1983, NEUROSCIENCE, V10, P997, DOI 10.1016/0306-4522(83)90238-5; PETRENKO AG, 1993, J BIOL CHEM, V268, P1860; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; PUMPLIN DW, 1977, J PHYSIOL-LONDON, V273, P443, DOI 10.1113/jphysiol.1977.sp012103; ROSENTHAL L, 1990, MOL PHARMACOL, V38, P917; Smith C, 1998, NEURON, V20, P1243, DOI 10.1016/S0896-6273(00)80504-8; Sugita S, 1999, NEURON, V22, P489, DOI 10.1016/S0896-6273(00)80704-7; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; SURKOVA I, 1994, ANN NY ACAD SCI, V710, P48, DOI 10.1111/j.1749-6632.1994.tb26613.x; TERBUSH DR, 1990, J BIOL CHEM, V265, P21179; TERBUSH DR, 1992, J NEUROCHEM, V58, P680, DOI 10.1111/j.1471-4159.1992.tb09771.x; TERBUSH DR, 1988, J BIOL CHEM, V263, P18873; TZENG MC, 1979, J NEUROCHEM, V33, P263, DOI 10.1111/j.1471-4159.1979.tb11728.x; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094	37	11	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25351	25357		10.1074/jbc.M004884200	http://dx.doi.org/10.1074/jbc.M004884200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10851245	hybrid			2022-12-25	WOS:000088849400042
J	Feng, LX; Ravindranath, N; Dym, M				Feng, LX; Ravindranath, N; Dym, M			Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-KIT; PHOSPHATIDYLINOSITOL 3-KINASE; A SPERMATOGONIA; D1 EXPRESSION; GROWTH-FACTOR; GERM-CELLS; MOUSE; ACTIVATION; RECEPTOR; TESTIS	Stem cell factor (SCF)/c-kit plays an important role in the regulation of hematopoiesis, melanogenesis, and spermatogenesis, In the testis, the SCF/c-kit system is believed to regulate germ cell proliferation, meiosis, and apoptosis, Studies with type A spermatogonia in vivo and in vitro have indicated that SCF induces DNA synthesis and proliferation. However, the signaling pathway for this function of SCF/c-kit has not been elucidated. We now demonstrate that SCF activates phosphoinositide 3-kinase (P13-K) and p70 S6 kinase (p70S6K) and that rapamycin, a FRAP/mammalian target of rapamycin-dependent inhibitor of p70S6K, completely inhibited bromodeoxyuridine incorporation induced by SCF in primary cultures of spermatogonia, SCF induced cyclin D3 expression and phosphorylation of the retinoblastoma protein through a pathway that is sensitive to both wortmannin and rapamycin, Furthermore, AKT, but not protein kinase C-zeta is used by SCF/c-kit/P13-K to activate p70S6K, Dominant negative AKT-K179M: completely abolished p70S6K phosphorylation induced by the constitutively active P13-K catalytic subunit p110, Constitutively active v-AKT highly phosphorylated p70S6K, which was totally inhibited by rapamycin, Thus, SCF/c-kit uses a rapamycin-sensitive P13-K/AKT/p70S6K/cyclin D3 pathway to promote spermatogonial cell proliferation.	Georgetown Univ, Med Ctr, Dept Cell Biol, Washington, DC 20007 USA	Georgetown University	Dym, M (corresponding author), Georgetown Univ, Med Ctr, Dept Cell Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.	dymm@gunet.georgetown.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033728] Funding Source: NIH RePORTER; NICHD NIH HHS [HD33728] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Blume-Jensen P, 2000, NAT GENET, V24, P157, DOI 10.1038/72814; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; DIRAMI G, 1996, ERNST SCHERING RES F, P141; DYM M, 1995, BIOL REPROD, V52, P8, DOI 10.1095/biolreprod52.1.8; DYM M, 1994, P NATL ACAD SCI USA, V91, P11287, DOI 10.1073/pnas.91.24.11287; DYM M, 1983, HISTOLOGY CELL TISSU; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Grewe M, 1999, CANCER RES, V59, P3581; Kissel H, 2000, EMBO J, V19, P1312, DOI 10.1093/emboj/19.6.1312; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Li H, 1997, ENDOCRINOLOGY, V138, P1289, DOI 10.1210/en.138.3.1289; Loveland KL, 1997, J ENDOCRINOL, V153, P337, DOI 10.1677/joe.0.1530337; Mauduit C, 1999, HUM REPROD UPDATE, V5, P535, DOI 10.1093/humupd/5.5.535; Orth JM, 1997, BIOL REPROD, V57, P676, DOI 10.1095/biolreprod57.3.676; PACKER AI, 1995, MOL REPROD DEV, V42, P303, DOI 10.1002/mrd.1080420307; RASSOULZADEGAN M, 1993, CELL, V75, P997, DOI 10.1016/0092-8674(93)90543-Y; ROSSI P, 1993, DEV BIOL, V155, P68, DOI 10.1006/dbio.1993.1007; TAJIMA Y, 1991, J REPROD FERTIL, V91, P441, DOI 10.1530/jrf.0.0910441; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Vincent S, 1998, DEVELOPMENT, V125, P4585; WENG QP, 1995, MOL CELL BIOL, V15, P2333; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689; Zhang Q, 1999, ENDOCRINOLOGY, V140, P2790, DOI 10.1210/en.140.6.2790	27	189	216	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25572	25576		10.1074/jbc.M002218200	http://dx.doi.org/10.1074/jbc.M002218200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10849422	hybrid			2022-12-25	WOS:000088849400070
J	Rogalski, SL; Appleyard, SM; Pattillo, A; Terman, GW; Chavkin, C				Rogalski, SL; Appleyard, SM; Pattillo, A; Terman, GW; Chavkin, C			TrkB activation by brain-derived neurotrophic factor inhibits the G protein-gated inward rectifier Kir3 by tyrosine phosphorylation of the channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC TRANSMISSION; POTASSIUM CHANNEL; XENOPUS OOCYTES; K+-CHANNEL; HIPPOCAMPAL-NEURONS; OPIOID RECEPTORS; KINASE; CURRENTS; SUPPRESSION; CLONING	protein-activated inwardly rectifying potassium channels (Kir3) are widely expressed throughout the brain, and regulation of their activity modifies neuronal excitability and synaptic transmission. In this study, we show that the neurotrophin brain-derived neurotrophic factor (BDNF), through activation of TrkB receptors, strongly inhibited the basal activity of Kir3, This inhibition was subunit dependent as functional homomeric channels of either Kir3.1 or Kir3.4 were significantly inhibited, whereas homomeric channels composed of Kir3.2 were insensitive. The general tyrosine kinase inhibitors genistein, GS 6976, and K252a but not the serine/threonine kinase inhibitor staurosporine blocked the BDNF-induced inhibition of the channel. BDNF was also found to directly stimulate channel phosphorylation because Kir3.1 immunoprecipitated from BDNF-stimulated cells showed enhanced labeling by anti-phosphotyrosine-specific antibodies. The BDNF effect required specific tyrosine residues in the amino terminus of Kir3.1 and Kir3.4 channels. Mutations of either Tyr-12, Tyr-67, or both in Kir3.1 or mutation of either Tyr-32, Tyr-53, or both of Kir3.4 channels to phenylalanine significantly blocked the BDNF-induced inhibition. The insensitive Kir3.2 was made sensitive to BDNF by adding a tyrosine (D41Y) and a lysine (P32R) upstream to generate a phosphorylation site motif analogous to that present in Kir3.4, These results suggest that neurotrophin activation of TrkB receptors may physiologically control neuronal excitability by direct tyrosine phosphorylation of the Kir3.1 and Kir3.4 subunits of G protein-gated inwardly rectifying potassium channels.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Chavkin, C (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.		Chavkin, Charles/G-2797-2010		NIDA NIH HHS [R37 DA011672, R01 DA011672, DA11672] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R37DA011672, R01DA011672] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; Bausch SB, 1995, RECEPTOR CHANNEL, V3, P221; Behrens MM, 1999, J NEUROCHEM, V72, P919, DOI 10.1046/j.1471-4159.1999.0720919.x; Berninger B, 1996, CURR OPIN NEUROBIOL, V6, P324, DOI 10.1016/S0959-4388(96)80115-2; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Chauhan-Patel R, 1998, J PHYSIOL-LONDON, V512, P109, DOI 10.1111/j.1469-7793.1998.109bf.x; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Desai NS, 1999, LEARN MEMORY, V6, P284; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; HENRY DJ, 1995, MOL PHARMACOL, V47, P551; Hilborn MD, 1998, J NEUROSCI, V18, P590; Holmes TC, 1996, J NEUROSCI, V16, P1581; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; Iwasaki Y, 1998, J NEUROCHEM, V71, P106; Jonas EA, 1996, J NEUROSCI, V16, P1645; Jonas EA, 1996, CURR OPIN NEUROBIOL, V6, P318, DOI 10.1016/S0959-4388(96)80114-0; Kafitz KW, 1999, NATURE, V401, P918, DOI 10.1038/44847; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Kerr BJ, 1999, J NEUROSCI, V19, P5138; LESSMANN V, 1994, NEUROREPORT, V6, P21; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Rogalski SL, 1999, J NEUROCHEM, V72, P1409, DOI 10.1046/j.1471-4159.1999.721409.x; Sadick MD, 1997, EXP CELL RES, V234, P354, DOI 10.1006/excr.1997.3614; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; SHARMA N, 1993, J CELL BIOL, V123, P1835, DOI 10.1083/jcb.123.6.1835; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; SNUTCH TP, 1988, TRENDS NEUROSCI, V11, P250, DOI 10.1016/0166-2236(88)90102-6; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; TIMPE LC, 1994, J NEUROSCI, V14, P1195, DOI 10.1523/JNEUROSCI.14-03-01195.1994; UEDA H, 1994, NEUROREPORT, V5, P1985, DOI 10.1097/00001756-199410000-00037; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; WILSON GF, 1993, NATURE, V366, P433, DOI 10.1038/366433a0; Wischmeyer E, 1998, J BIOL CHEM, V273, P34063, DOI 10.1074/jbc.273.51.34063; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103	43	56	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25082	25088		10.1074/jbc.M000183200	http://dx.doi.org/10.1074/jbc.M000183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833508	Green Accepted, hybrid			2022-12-25	WOS:000088849400007
J	de Vries, CJM; van Achterberg, TAE; Horrevoets, AJG; ten Cate, JW; Pannekoek, H				de Vries, CJM; van Achterberg, TAE; Horrevoets, AJG; ten Cate, JW; Pannekoek, H			Differential display identification of 40 genes with altered expression in activated human smooth muscle cells - Local expression in atherosclerotic lesions of smags, smooth muscle activation-specific genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; TUMOR-NECROSIS-FACTOR; FACTOR-KAPPA-B; MESSENGER-RNA; APOPTOSIS PROTEIN-1; GM-CSF; INTERLEUKIN-8; CLONING; INDUCTION; INHIBITOR	Detailed knowledge on the molecular and cellular mechanisms that control (re)-differentiation of vascular smooth muscle cells (SMCs) is critical to understanding the pathological processes underlying atherogenesis. We identified by differential display/reverse transcriptase-polymerase chain reaction 40 genes with altered expression in cultured SMCs upon stimulation with the conditioned medium of activated macrophages, This set of genes comprises 10 known genes and 30 novel genes, which we call "smags" (for smooth muscle activation-specific genes). To determine the in vivo significance of these (novel) genes in atherogenesis, we performed in situ hybridization experiments on vascular tissue, Specifically, FLICE (Fas-associated death domain-like interleukin-1 beta-converting enzyme)-like inhibitory protein (FLIP) is expressed in neointimal SMCs as well as in lesion macrophages and endothelial cells, whereas the expression of the novel genes smag-63, smag-64, and smag-84 is restricted to neointimal SMCs. Characterization of full-length smag-64 cDNA revealed that it encodes a novel protein of 66 amino acids. smag-82 cDNA comprises the complete, unknown, 3'-untranslated region of fibroblast growth factor-5, Collectively, our results illustrate the complex changes of SMC gene expression that occur in response to stimulation with cytokines and growth factors secreted by activated macrophages, Moreover, we identified interesting candidate genes that may play a role in the differentiation of SMCs during atherogenesis.	Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	de Vries, CJM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Biochem, K1-163,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	c.j.devries@amc.uva.nl						ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; Boot RG, 1999, ARTERIOSCL THROM VAS, V19, P687, DOI 10.1161/01.ATV.19.3.687; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; CALNAN BJ, 1995, IMMUNITY, V3, P273; CHANG C, 1989, J STEROID BIOCHEM, V34, P391; CLEM RJ, 1997, TRENDS BIOCHEM SCI, V23, P159; COUFFINHAL T, 1994, CIRC RES, V74, P225, DOI 10.1161/01.RES.74.2.225; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Erl W, 1999, CIRC RES, V84, P668, DOI 10.1161/01.RES.84.6.668; FILONZI EL, 1993, ATHEROSCLEROSIS, V99, P241, DOI 10.1016/0021-9150(93)90026-Q; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HEDVAT CV, 1995, MOL ENDOCRINOL, V9, P1692, DOI 10.1210/me.9.12.1692; Horrevoets AJG, 1999, BLOOD, V93, P3418, DOI 10.1182/blood.V93.10.3418.410k23_3418_3431; KOCH AE, 1993, AM J PATHOL, V142, P1423; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; OWENS GK, 1995, PHYSIOL REV, V75, P487; Ozawa K, 1998, J BIOL CHEM, V273, P29262, DOI 10.1074/jbc.273.44.29262; POSTON RN, 1992, AM J PATHOL, V140, P665; PRINTSEVA OY, 1992, AM J PATHOL, V140, P889; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; vanderLoop FTL, 1996, J CELL BIOL, V134, P401, DOI 10.1083/jcb.134.2.401; WANG J, 1994, EXP MOL PATHOL, V61, P109, DOI 10.1006/exmp.1994.1030; WANG JM, 1991, ARTERIOSCLER THROMB, V11, P1166, DOI 10.1161/01.ATV.11.5.1166; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YUE TL, 1994, CIRC RES, V75, P1, DOI 10.1161/01.RES.75.1.1	39	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23939	23947		10.1074/jbc.M910099199	http://dx.doi.org/10.1074/jbc.M910099199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10823842	hybrid			2022-12-25	WOS:000088564200074
J	Illerhaus, J; Altschmied, L; Reichert, J; Zak, E; Herrmann, RG; Haehnel, W				Illerhaus, J; Altschmied, L; Reichert, J; Zak, E; Herrmann, RG; Haehnel, W			Dynamic interaction of plastocyanin with the cytochrome bf complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; PHOTOSYSTEM-I; SPINACH PLASTOCYANIN; CRYSTAL-STRUCTURE; CROSS-LINKING; BC(1) COMPLEX; BINDING; DOMAIN; SITE; IDENTIFICATION	The interaction between plastocyanin and the intact cytochrome bf complex, both from spinach, has been studied by stopped-flow kinetics with mutant plastocyanin to elucidate the site of electron transfer and the docking regions of the molecule. Mutation of Tyr-83 to Arg or Leu provides no evidence for a second electron transfer path via Tyr-83 of plastocyanin, which has been proposed to be the site of electron transfer from cytochrome f, The data found with mutations of acidic residues indicate that both conserved negative patches are essential for the binding of plastocyanin to the intact cytochrome bf complex. Replacing Ala-90 and Gly-10 at the flat hydrophobic surface of plastocyanin by larger residues slowed down and accelerated, respectively, the rate of electron transfer as compared with wild-type plastocyanin, These opposing effects reveal that the hydrophobic region around the electron transfer site at His-87 is divided up into two regions, of which only that with Ala-90 contributes to the attachment to the cytochrome bf complex. These binding sites of plastocyanin are substantially different from those interacting with photosystem I. It appears that each of the two binding regions of plastocyanin is split into halves, which are used in different combinations in the molecular recognition at the two membrane complexes.	Univ Freiburg, Inst Biol Biochem 2, D-79104 Freiburg, Germany; Univ Munich, Inst Bot, D-80638 Munich, Germany	University of Freiburg; University of Munich	Haehnel, W (corresponding author), Univ Freiburg, Inst Biol Biochem 2, Schanzlestr 1, D-79104 Freiburg, Germany.	haehnel@uni-freiburg.de	Reichert, Jan/AAE-6609-2019	Reichert, Jan/0000-0002-6020-6049; Altschmied, Lothar/0000-0002-7692-2971				ANDERSON GP, 1987, BIOCHIM BIOPHYS ACTA, V894, P386, DOI 10.1016/0005-2728(87)90117-4; BAYMANN F, 1991, ANAL BIOCHEM, V199, P269, DOI 10.1016/0003-2697(91)90100-8; Beissinger M, 1998, EMBO J, V17, P27, DOI 10.1093/emboj/17.1.27; BENDALL DS, 1999, PHOTOTROPHIC PROKARY, P315; BENGIS C, 1977, J BIOL CHEM, V252, P4564; BLACK MT, 1987, ARCH BIOCHEM BIOPHYS, V252, P655, DOI 10.1016/0003-9861(87)90071-3; Carrell CJ, 1997, STRUCTURE, V5, P1613, DOI 10.1016/S0969-2126(97)00309-2; CHRISTENSEN HEM, 1992, BIOCHIM BIOPHYS ACTA, V1099, P35, DOI 10.1016/0304-4173(92)90005-Y; Comolli LR, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P1589; Drepper F, 1996, BIOCHEMISTRY-US, V35, P1282, DOI 10.1021/bi951471e; DUTTON PL, 1974, BIOCHIM BIOPHYS ACTA, V346, P165, DOI 10.1016/0304-4173(74)90008-1; FARVER O, 1981, P NATL ACAD SCI-BIOL, V78, P4190, DOI 10.1073/pnas.78.7.4190; FRAZAO C, 1995, STRUCTURE, V3, P1159, DOI 10.1016/S0969-2126(01)00252-0; GROSS EL, 1991, BIOCHIM BIOPHYS ACTA, V1056, P166, DOI 10.1016/S0005-2728(05)80283-X; GUSS JM, 1983, J MOL BIOL, V169, P521; HAEHNEL W, 1994, EMBO J, V13, P1028, DOI 10.1002/j.1460-2075.1994.tb06351.x; HE S, 1991, EMBO J, V10, P4011, DOI 10.1002/j.1460-2075.1991.tb04976.x; Hibino T, 1996, J BIOCHEM-TOKYO, V120, P556; HIPPLER M, 1989, FEBS LETT, V250, P280, DOI 10.1016/0014-5793(89)80738-0; Hippler M, 1998, P NATL ACAD SCI USA, V95, P7339, DOI 10.1073/pnas.95.13.7339; Hippler M, 1996, EMBO J, V15, P6374, DOI 10.1002/j.1460-2075.1996.tb01028.x; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; HURT E, 1981, EUR J BIOCHEM, V117, P591; ILLERHAUS J, 1998, THESIS U FREIBURG FR; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Kannt A, 1996, BBA-BIOENERGETICS, V1277, P115, DOI 10.1016/S0005-2728(96)00090-4; KATOH S, 1962, J BIOCHEM-TOKYO, V51, P32, DOI 10.1093/oxfordjournals.jbchem.a127497; LEE BH, 1995, J BIOCHEM, V117, P1209; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MARTINEZ SE, 1994, STRUCTURE, V2, P95, DOI 10.1016/S0969-2126(00)00012-5; Metzger SU, 1997, BBA-BIOENERGETICS, V1319, P233, DOI 10.1016/S0005-2728(96)00164-8; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P4552, DOI 10.1021/bi00068a010; MODI S, 1992, BIOCHIM BIOPHYS ACTA, V1102, P85, DOI 10.1016/0005-2728(92)90068-D; MODI S, 1992, BIOCHIM BIOPHYS ACTA, V1101, P64, DOI 10.1016/0167-4838(92)90467-R; MOSS DA, 1990, EUR J BIOCHEM, V117, P591; NORDLING M, 1991, FEBS LETT, V291, P327, DOI 10.1016/0014-5793(91)81313-W; Pearson DC, 1996, BIOPHYS J, V71, P64, DOI 10.1016/S0006-3495(96)79236-6; PENFIELD KW, 1985, J AM CHEM SOC, V107, P4519, DOI 10.1021/ja00301a024; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; RATAJCZAK R, 1988, BIOCHIM BIOPHYS ACTA, V933, P306, DOI 10.1016/0005-2728(88)90038-2; Reichert J, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P693; SANDERSON DG, 1986, BIOCHIM BIOPHYS ACTA, V852, P269, DOI 10.1016/0005-2728(86)90232-X; Soriano GM, 1996, BIOCHEMISTRY-US, V35, P14590, DOI 10.1021/bi9616211; Soriano GM, 1998, BIOCHEMISTRY-US, V37, P15120, DOI 10.1021/bi9807714; TAKENAKA K, 1984, J BIOCHEM-TOKYO, V96, P1813, DOI 10.1093/oxfordjournals.jbchem.a135015; Ubbink M, 1998, STRUCTURE, V6, P323, DOI 10.1016/S0969-2126(98)00035-5; WYNN RM, 1988, BIOCHEMISTRY-US, V27, P5863, DOI 10.1021/bi00416a007; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Yu CA, 1998, BBA-BIOENERGETICS, V1365, P151, DOI 10.1016/S0005-2728(98)00055-3; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	50	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17590	17595		10.1074/jbc.275.23.17590	http://dx.doi.org/10.1074/jbc.275.23.17590			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837495	hybrid			2022-12-25	WOS:000087485000055
J	Nevrivy, DJ; Peterson, VJ; Avram, D; Ishmael, JE; Hansen, SG; Dowell, P; Hruby, DE; Dawson, MI; Leid, M				Nevrivy, DJ; Peterson, VJ; Avram, D; Ishmael, JE; Hansen, SG; Dowell, P; Hruby, DE; Dawson, MI; Leid, M			Interaction of GRASP, a protein encoded by a novel retinoic acid-induced gene, with members of the cytohesin family of guanine nucleotide exchange factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; ADP-RIBOSYLATION FACTOR; ACTIVATED RECEPTOR-ALPHA; GROWTH-FACTOR-BETA; MESSENGER-RNA; PLASMA-MEMBRANE; NEURONAL DIFFERENTIATION; FACTOR ARNO; C-FOS; PHOSPHATIDYLINOSITOL 3-KINASE	A novel, retinoic acid-induced gene, <(GR)under bar>P1-associated (s) under bar caffold (p) under bar rotein (GRASP), was isolated from P19 embryonal carcinoma cells using a subtractive screening strategy. GRASP was found to be highly expressed in brain and exhibited lower levels of expression in lung, heart, embryo, kidney, and ovary. The predicted amino acid sequence of GRASP is characterized by several putative protein-protein interaction motifs, suggesting that GRASP may be a component of a larger protein complex in the cell. Although GRASP does not harbor a predicted membrane spanning domain(s), the protein was observed to be associated with the plasma membrane of transiently transfected mammalian cells. Yeast two-hybrid screening revealed that GRASP interacted strongly with the (G) under bar eneral (R) under bar eceptor for (P) under bar hosphoinositides (1) under bar (GRP1), a brefeldin A-insensitive guanine nucleotide exchange factor for the ADP-ribosylation factor family of proteins, GRASP.GrRP1 interactions were also demonstrated in vitro and in mammalian cells in which GRASP was shown to enhance GRP1 association with the plasma membrane. Furthermore, GRASP colocalized with endogenous ADP-ribosylation factors at the plasma membrane in transfected cells, suggesting that GRASP may modulate signaling by this family of small GTPases.	Oregon State Univ, Coll Pharm, Mol Pharmacol Lab, Corvallis, OR 97331 USA; Oregon State Univ, Coll Pharm, Mol & Cellular Biol Program, Corvallis, OR 97331 USA; Oregon State Univ, Coll Pharm, Toxicol Program, Corvallis, OR 97331 USA; Oregon State Univ, Ctr Environm Hlth Sci, Corvallis, OR 97331 USA; Oregon State Univ, Dept Microbiol, Corvallis, OR 97331 USA; Mol Med Res Inst, Mountain View, CA 94043 USA	Oregon State University; Oregon State University; Oregon State University; Oregon State University; Oregon State University	Leid, M (corresponding author), Oregon State Univ, Coll Pharm, Mol Pharmacol Lab, Corvallis, OR 97331 USA.	mark.leid@orst.edu			NCI NIH HHS [CA51993] Funding Source: Medline; NIEHS NIH HHS [ES002010, ES07060] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA051993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007060] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Avram D, 1999, J BIOL CHEM, V274, P14331, DOI 10.1074/jbc.274.20.14331; BERG RW, 1990, DEV BIOL, V138, P123, DOI 10.1016/0012-1606(90)90182-I; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; BOUILLET P, 1995, DEV DYNAM, V204, P372, DOI 10.1002/aja.1002040404; Bouillet P, 1996, MECH DEVELOP, V58, P141, DOI 10.1016/S0925-4773(96)00569-2; BOUILLET P, 1995, DEV BIOL, V170, P420, DOI 10.1006/dbio.1995.1226; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Clodi M, 1998, ENDOCRINOLOGY, V139, P4984, DOI 10.1210/en.139.12.4984; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; DEDHAR S, 1991, J BIOL CHEM, V266, P21846; DIXON B, 1993, BIOCHIM BIOPHYS ACTA, V1216, P321, DOI 10.1016/0167-4781(93)90165-A; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Dowell P, 1999, J BIOL CHEM, V274, P15901, DOI 10.1074/jbc.274.22.15901; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; ELIAS MCQB, 1994, BRAZ J MED BIOL RES, V27, P2181; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Frank SR, 1998, MOL BIOL CELL, V9, P3133, DOI 10.1091/mbc.9.11.3133; GAETANO C, 1994, CLIN EXP METASTAS, V12, P63, DOI 10.1007/BF01784335; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Gudas L J, 1986, Prog Clin Biol Res, V226, P181; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; Katagiri K, 1996, BLOOD, V87, P4276, DOI 10.1182/blood.V87.10.4276.bloodjournal87104276; KENNEDY MB, 1995, TRENDS BIOCHEM SCI, V20, P350, DOI 10.1016/S0968-0004(00)89074-X; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; Klarlund JK, 1998, J BIOL CHEM, V273, P1859, DOI 10.1074/jbc.273.4.1859; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; KOBAYASHI M, 1994, FEBS LETT, V356, P60, DOI 10.1016/0014-5793(94)01238-5; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KONDO T, 1992, NUCLEIC ACIDS RES, V20, P5729, DOI 10.1093/nar/20.21.5729; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; Langille SE, 1999, J BIOL CHEM, V274, P27099, DOI 10.1074/jbc.274.38.27099; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LEID M, 1994, J BIOL CHEM, V269, P14175; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; LOESER RF, 1994, EXP CELL RES, V211, P17, DOI 10.1006/excr.1994.1053; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Monier S, 1998, J CELL SCI, V111, P3427; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Nagel W, 1998, J BIOL CHEM, V273, P14853, DOI 10.1074/jbc.273.24.14853; Nagel WG, 1998, MOL BIOL CELL, V9, P1981, DOI 10.1091/mbc.9.8.1981; Neeb A, 1999, EUR J CELL BIOL, V78, P533, DOI 10.1016/S0171-9335(99)80018-1; Niethammer M, 1996, J NEUROSCI, V16, P2157; OBRIG TG, 1971, J BIOL CHEM, V246, P174; Oulad-Abdelghani M, 1998, INT J DEV BIOL, V42, P23; OuladAbdelghani M, 1997, DEV DYNAM, V210, P173, DOI 10.1002/(SICI)1097-0177(199710)210:2<173::AID-AJA9>3.0.CO;2-D; Pacheco-Rodriguez G, 1998, J BIOL CHEM, V273, P26543, DOI 10.1074/jbc.273.41.26543; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROGUSKA MA, 1985, J BIOL CHEM, V260, P3893; ROSS SA, 1994, J CELL PHYSIOL, V159, P263, DOI 10.1002/jcp.1041590210; ROSSINO P, 1991, CELL REGUL, V2, P1021, DOI 10.1091/mbc.2.12.1021; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SMOLICH BD, 1994, DEV BIOL, V166, P300, DOI 10.1006/dbio.1994.1316; Snow BE, 1997, BIOCHEM BIOPH RES CO, V233, P770, DOI 10.1006/bbrc.1997.6537; SONG S, 1989, FEBS LETT, V256, P51, DOI 10.1016/0014-5793(89)81716-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; Venkateswarlu K, 1998, BIOCHEM J, V335, P139, DOI 10.1042/bj3350139; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZWARTKRUIS F, 1993, EXP CELL RES, V205, P422, DOI 10.1006/excr.1993.1108	89	69	75	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16827	16836		10.1074/jbc.275.22.16827	http://dx.doi.org/10.1074/jbc.275.22.16827			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828067	hybrid			2022-12-25	WOS:000087392200061
J	Wolstein, O; Silkov, A; Revach, M; Dikstein, R				Wolstein, O; Silkov, A; Revach, M; Dikstein, R			Specific interaction of TAF(II)105 with OCA-B is involved in activation of octamer-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CELL-SPECIFIC COACTIVATOR; TATA-BINDING PROTEIN; IN-VIVO; FUNCTIONAL-CHARACTERIZATION; PROMOTER SELECTIVITY; GENE-TRANSCRIPTION; LACKING TAF(II)S; YEAST; COMPLEX	TAF(II)105 is a TFIID-associated factor highly expressed in B lymphocytes. This subunit is found in a small portion of TFIID complexes and is homologous to human TAF(II)130 and Drosophila TAF(II)110. In the present study we show that TAF(II)105 is involved in transcription activation directed by the B cell-specific octamer element found in many B cell-specific genes. B cells overexpressing TAF(II)105 display higher octamer-dependent transcription, whereas expression of a C-terminal truncated form of TAF(II)105 inhibits octamer transcription in a dominant negative manner. In addition, antibodies directed against TAF(II)105 specifically inhibit octamer-dependent transcription. Reporter gene analysis revealed that TAF(II)105 elevates octamer transcription in the presence of OCA-B, a cofactor subunit of Oct1 and Oct2 proteins. In vitro binding assays and functional studies established that the effect of TAF(II)105 on octamer activity involves interaction of TAF(II)105 with octamer-binding complexes via the C-terminal activation domain of OCA-B. These findings link TAF(II)105 coactivator function to B cell-specific transcription.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Dikstein, R (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.							Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; Henderson A, 1998, ANNU REV IMMUNOL, V16, P163, DOI 10.1146/annurev.immunol.16.1.163; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; Luo Y, 1998, MOL CELL BIOL, V18, P3803, DOI 10.1128/MCB.18.7.3803; LUO Y, 1995, MOL CELL BIOL, V15, P4115; Malik S, 1998, P NATL ACAD SCI USA, V95, P2192, DOI 10.1073/pnas.95.5.2192; Matthias P, 1998, SEMIN IMMUNOL, V10, P155, DOI 10.1006/smim.1998.0117; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; Oelgeschlager T, 1998, MOL CELL, V1, P925, DOI 10.1016/S1097-2765(00)80092-1; PFISTERER P, 1995, J BIOL CHEM, V270, P29870, DOI 10.1074/jbc.270.50.29870; POON D, 1993, J BIOL CHEM, V268, P15325; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WIRTH T, 1995, IMMUNOBIOLOGY, V193, P161, DOI 10.1016/S0171-2985(11)80540-1; Wu SY, 1998, J BIOL CHEM, V273, P12492, DOI 10.1074/jbc.273.20.12492; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; Zhou JM, 1998, P NATL ACAD SCI USA, V95, P13483, DOI 10.1073/pnas.95.23.13483; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	44	18	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16459	16465		10.1074/jbc.275.22.16459	http://dx.doi.org/10.1074/jbc.275.22.16459			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828057	hybrid			2022-12-25	WOS:000087392200010
J	Thullberg, M; Bartek, J; Lukas, J				Thullberg, M; Bartek, J; Lukas, J			Ubiquitin/proteasome-mediated degradation of p19(INK4d) determines its periodic expression during the cell cycle	ONCOGENE			English	Article						INK4 family; p19(INK4d); cyclin D; CDK4; ubiquitin/proteasome-dependent degradation; retinoblastoma protein	DEPENDENT KINASES CDK4; TUMOR-SUPPRESSOR; RETINOBLASTOMA-PROTEIN; GROWTH SUPPRESSION; INHIBITOR P27; LUNG-CANCER; INK4 FAMILY; TGF-BETA; S-PHASE; P16(INK4A)	Assembly and activity of the proto-oncogenic cyclin D/ CDK4(6) complexes, the major driving force of G1 phase progression, is negatively regulated by a family of INK4 CDK inhibitors p16(INK4a), p15(INK4b), p18(INK4c), and p19(INK4d). Expression of the INK4 family members is controlled at the transcriptional level, through differential response to environmental and intracellular signals such as cytokines, oncogenic overload, or cellular senescence. Here we show that the periodic oscillation of the p19(INK4d) protein during the cell cycle is determined by the ubiquitin/proteasome-dependent mechanism, allowing the protein abundance to follow the changes in its mRNA expression. Within the INK4 family, this regulatory mode appears restricted to p19(INK4d) whose ubiquitination was dependent on the integrity of lysine 62, and binding to CDK4. These results highlight unexpected differences among the INK4 inhibitors, and suggest how p19(INK4d) may help regulate the rate of cyclin D/CDK4(6) complex formation, and thereby timely progression through the mammalian cell division cycle.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen O, Denmark	Danish Cancer Society	Lukas, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen O, Denmark.		Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Amati B, 1999, NAT CELL BIOL, V1, pE91, DOI 10.1038/12087; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bartkova J, 1996, CANCER RES, V56, P5475; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Esposito V, 1997, CANCER RES, V57, P3381; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Haas K, 1997, ONCOGENE, V15, P179, DOI 10.1038/sj.onc.1201171; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lukas C, 1999, HYBRIDOMA, V18, P225, DOI 10.1089/027245799315871; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1995, ONCOGENE, V10, P2125; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Pavey S, 1999, CANCER RES, V59, P4185; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHAPIRO GI, 1995, CANCER RES, V55, P6200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Thullberg M, 2000, HYBRIDOMA, V19, P63, DOI 10.1089/027245700315806; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Welcker M, 1996, ONCOGENE, V13, P419; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wolff B, 1999, ONCOGENE, V18, P2663, DOI 10.1038/sj.onc.1202617; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	47	48	49	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2000	19	24					2870	2876		10.1038/sj.onc.1203579	http://dx.doi.org/10.1038/sj.onc.1203579			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851091				2022-12-25	WOS:000087403600009
J	Perez-Losada, J; Pintado, B; Gutierrez-Adan, A; Flores, T; Banares-Gonzalez, B; del Campo, JC; Martin-Martin, JF; Battaner, E; Sanchez-Garcia, I				Perez-Losada, J; Pintado, B; Gutierrez-Adan, A; Flores, T; Banares-Gonzalez, B; del Campo, JC; Martin-Martin, JF; Battaner, E; Sanchez-Garcia, I			The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice	ONCOGENE			English	Article						chromosomal abnormality; malignant solid tumors; adipose tissue; cancer development	ENHANCER-BINDING-PROTEIN; HUMAN MYELOID-LEUKEMIA; ADIPOCYTE DIFFERENTIATION; CHROMOSOMAL TRANSLOCATION; MYXOID LIPOSARCOMA; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC TRANSFORMATION; RETINOIC ACID; C/EBP-ALPHA; GENE	The characteristic t(12;16)(q13;p11) chromosomal translocation, which leads to gene fusion that encodes the FUS-CHOP chimeric protein, is associated with human Liposarcomas. The altered expression of FUS-CHOP has been implicated in a characteristic subgroup of human liposarcomas. We have introduced the FUS-CHOP transgene into the mouse genome in which the expression of the transgene is successfully driven by the elongation factor 1 alpha (EF1 alpha) promoter to all tissues, The consequent overexpression of FUS-CHOP results in most of the symptoms of human liposarcomas, including the presence of lipoblasts with round nuclei, accumulation of intracellular lipid, induction of adipocyte-specific genes and a concordant block in the differentiation program, We have demonstrated that liposarcomas in the FUS-CHOP transgenic mice express high Levels of the adipocyte regulatory protein PPAR gamma, whereas it is not expressed in embryonic fibroblasts from these animals following induction to differentiation toward the adipocyte lineage, indicating that the in vitro system does not really reflect the in vivo situation and the developmental defect is downstream of PPAR gamma expression. No tumors of other tissues were found in these transgenic mice despite widespread activity of the EF1 alpha promoter. This establishes FUS-CHOP overexpression as a key determinant of human liposarcomas and provide the first in vivo evidence for a link between a fusion gene created by a chromosomal translocation and a solid tumor.	Univ Salamanca, CSIC, Inst Microbiol Bioquim, Dept Proliferac & Diferenciac Celular, Salamanca 37007, Spain; Ctr Invest & Tecnol, Area Reprod Anim, Madrid 28040, Spain; Univ Salamanca, Serv Anat Patol, E-37008 Salamanca, Spain; Univ Salamanca, Serv Radiodiagnost, E-37008 Salamanca, Spain; Univ Salamanca, Dept Bioquim & Biol Mol, E-37008 Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca; University of Salamanca; University of Salamanca; University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, CSIC, Inst Microbiol Bioquim, Dept Proliferac & Diferenciac Celular, Edificio Dept,Avda Campo Charro S-N, Salamanca 37007, Spain.		SANCHEZ-GARCIA, ISIDRO/A-5631-2019; Pérez-Losada, Jesús/A-5883-2019; Pintado, Belen/N-3233-2014; Gutierrez-Adan, Alfonso/A-1485-2014	Pérez-Losada, Jesús/0000-0003-2400-624X; Pintado, Belen/0000-0002-8485-2520; Gutierrez-Adan, Alfonso/0000-0001-9893-9179; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905	NCI NIH HHS [1R01CA79955-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079955] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adelmant G, 1998, J BIOL CHEM, V273, P15574, DOI 10.1074/jbc.273.25.15574; AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; Altabef M, 1996, EMBO J, V15, P2707, DOI 10.1002/j.1460-2075.1996.tb00631.x; Aman P, 1996, GENOMICS, V37, P1, DOI 10.1006/geno.1996.0513; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; BENNETT JH, 1995, J CLIN PATHOL, V48, P950, DOI 10.1136/jcp.48.10.950; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; CHANG HR, 1989, CANCER, V64, P1514, DOI 10.1002/1097-0142(19891001)64:7<1514::AID-CNCR2820640726>3.0.CO;2-2; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; ICHIKAWA H, 1994, CANCER RES, V54, P2865; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KNIGHT JC, 1995, CANCER RES, V55, P24; Kuroda M, 1997, AM J PATHOL, V151, P735; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MACK TM, 1995, CANCER-AM CANCER SOC, V75, P211, DOI 10.1002/1097-0142(19950101)75:1+<211::AID-CNCR2820751309>3.0.CO;2-X; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PANAGOPOULOS I, 1995, ONCOGENE, V11, P1133; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PRASAD DDK, 1994, ONCOGENE, V9, P3717; PRICE BD, 1992, CANCER RES, V52, P3814; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Takada T, 1997, NAT BIOTECHNOL, V15, P458, DOI 10.1038/nbt0597-458; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	44	104	108	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2000	19	20					2413	2422		10.1038/sj.onc.1203572	http://dx.doi.org/10.1038/sj.onc.1203572			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828883				2022-12-25	WOS:000087018400006
J	Renne, T; Dedio, J; David, G; Muller-Ester, W				Renne, T; Dedio, J; David, G; Muller-Ester, W			High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-LUNG FIBROBLASTS; BINDING-PROTEIN; UROKINASE RECEPTOR; GROWTH-FACTOR; LIGHT-CHAIN; PLASMA-MEMBRANE; ALPHA-SUBUNIT; HEAVY-CHAIN; SURFACE; DOMAIN	Kininogens, the high molecular weight precursor of vasoactive kinins, bind to a wide variety of cells in a specific, reversible, and saturable manner. The cell docking sites have been mapped to domains D3 and D5(H) of kininogens; however, the corresponding cellular acceptor sites are not fully established. To characterize the major cell binding sites for kininogens exposed by the endothelial cell line EA.hy926, we digested intact cells with trypsin and other proteases and found a time- and concentration-dependent loss of I-125-labeled high molecular weight kininogen (H-kininogen) binding capacity (up to 82%), indicating that proteins are crucially involved in kininogen cell attachment. Cell surface digestion with heparinases similarly reduced kininogen binding capacity (up to 78%), and the combined action of heparinases and trypsin almost eliminated kininogen binding (up to 85%), suggesting that proteoglycans of the heparan sulfate type are intimately involved. Consistently, inhibitors such as p-nitrophenyl-beta -D-xylopyranoside and chlorate interfering with heparan sulfate proteoglycan biosynthesis reduced the total number of kininogen binding sites in a time- and concentration-dependent manner (up to 67%). In vitro binding studies demonstrated that biotinylated H-kininogen binds to heparan sulfate glycosaminoglycans via domains D3 and D5(H) and that the presence of Zn2+ promotes this association. Cloning and over-expression of the major endothelial heparan sulfate-type proteoglycans syndecan-1, syndecan-2, syndecan-4, and glypican in HEK293t cells significantly increased total heparan sulfate at the cell surface and thus the number of kininogen binding sites (up to 3.3-fold). This gain in kininogen binding capacity was completely abolished by treating transfected cells with heparinases. We conclude that heparan sulfate proteoglycans on the surface of endothelial cells provide a platform for the local accumulation of kininogens on the vascular lining. This accumulation may allow the circumscribed release of short-lived kinins from their precursor molecules in close proximity to their sites of action.	Goethe Univ Frankfurt, Inst Biochem 2, D-60590 Frankfurt, Germany; Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, Ctr Human Genet, B-3000 Louvain, Belgium	Goethe University Frankfurt; KU Leuven	Muller-Ester, W (corresponding author), Goethe Univ Frankfurt, Inst Biochem 2, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	wme@biochem2.de		Renne, Thomas/0000-0003-4594-5975				ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BJORK I, 1989, BIOCHEMISTRY-US, V28, P1213; Borza DB, 1998, J BIOL CHEM, V273, P5493, DOI 10.1074/jbc.273.10.5493; Carey DJ, 1997, BIOCHEM J, V327, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; CRUZ MA, 1993, J BIOL CHEM, V268, P21238; DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961; David G, 1998, MATRIX BIOL, V17, P461, DOI 10.1016/S0945-053X(98)90092-0; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1992, J CELL BIOL, V118, P961, DOI 10.1083/jcb.118.4.961; Dedio J, 1998, J IMMUNOL, V160, P3534; DeLa Cadena RA, 1998, THROMB HAEMOSTASIS, V79, P186; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Goletz S, 1997, J CELL SCI, V110, P1585; GORODETSKY R, 1993, AM J HEMATOL, V42, P278, DOI 10.1002/ajh.2830420307; GREENGARD JS, 1992, METHOD ENZYMOL, V215, P369; HASAN AAK, 1994, J BIOL CHEM, V269, P31822; HASAN AAK, 1995, J BIOL CHEM, V270, P19256, DOI 10.1074/jbc.270.33.19256; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; HENDERSON LM, 1994, BLOOD, V84, P474; HERWALD H, 1995, J BIOL CHEM, V270, P14634; Herwald H, 1998, NAT MED, V4, P298, DOI 10.1038/nm0398-298; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; HOJIMA Y, 1984, BLOOD, V63, P1453; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; JASPARD E, 1993, J BIOL CHEM, V268, P9496; Joseph K, 1999, MOL MED, V5, P555, DOI 10.1007/BF03401982; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; KITAMURA N, 1983, NATURE, V305, P545, DOI 10.1038/305545a0; Kojima T, 1996, J BIOL CHEM, V271, P5914, DOI 10.1074/jbc.271.10.5914; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; MELONI FJ, 1992, BLOOD, V79, P1233; MILTON SG, 1993, J CELL PHYSIOL, V157, P333, DOI 10.1002/jcp.1041570217; MOLLER LB, 1993, J BIOL CHEM, V268, P11152; Moshfegh K, 1998, BIOCHEM BIOPH RES CO, V249, P903, DOI 10.1006/bbrc.1998.9125; Renne T, 1999, J BIOL CHEM, V274, P25777, DOI 10.1074/jbc.274.36.25777; Rosenberg RD, 1997, J CLIN INVEST, V100, pS67; SASTRE L, 1986, J IMMUNOL, V137, P1060; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; Song Q, 1996, AM J PHYSIOL-RENAL, V270, pF919, DOI 10.1152/ajprenal.1996.270.6.F919; THOMPSON RE, 1979, P NATL ACAD SCI USA, V76, P4862, DOI 10.1073/pnas.76.10.4862; vandenBerg RH, 1997, J IMMUNOL, V158, P3909; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; WACHTFOGEL YT, 1994, J BIOL CHEM, V269, P19307; Wells MJ, 1997, J BIOL CHEM, V272, P28574, DOI 10.1074/jbc.272.45.28574; Xiao YF, 1998, P NATL ACAD SCI USA, V95, P2680, DOI 10.1073/pnas.95.5.2680; YABKOWITZ R, 1989, J BIOL CHEM, V264, P10888; Zimmermann P, 1999, FASEB J, V13, pS91	53	102	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	2000	275	43					33688	33696		10.1074/jbc.M000313200	http://dx.doi.org/10.1074/jbc.M000313200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	368EK	10843988	hybrid			2022-12-25	WOS:000090104600071
J	De Wolf, MJS				De Wolf, MJS			A dipeptide metalloendoprotease substrate completely blocks the response of cells in culture to cholera toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-LABILE ENTEROTOXIN; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; BREFELDIN-A; GOLGI-APPARATUS; CRYSTAL-STRUCTURE; EPITHELIAL-CELLS; MEMBRANE; PROTEIN; INHIBITION	Prior exposure (15 min at 37 degrees C) of several cell types (Vero, SH-SY5Y neuroblastoma, human intestinal epithelial T84) to 3 mM N-benzoyloxycarbonyl-Gly-Phe-amide (Cbz-Gly-Phe-NH2), a competitive substrate for metalloendoproteases, completely suppressed cholera toxin (CT)-induced intracellular cAMP accumulation. The specificity of the inhibitory effect was demonstrated by the complete lack of effect of the dipeptide Cbz-Gly-Gly-NH2, an inactive analogue of Cbz-Gly-Phe-NH2. The effect was reversible and dose- (IC50 as low as 0.2 mM depending on the cell type) and time-dependent. Adding Cbz-Gly-Phe-NH2 during the lag phase caused a diminution of its inhibitory effect similar to that observed with brefeldin A (BFA). Whereas the dipeptide completely suppressed the CT-induced adenylate cyclase (AC) activity, a direct effect on AC is unlikely since the elevation of intracellular cAMP by forskolin was only slightly reduced. The A(1) peptide of CT and NAD(+) activated the AC to the same extent in membranes from control and Cbz-Gly-Phe-NH2-treated cells or when Cbz-Gly-Phe-NH2 was added directly to the assay. The inhibitory effects of suboptimal amounts of Cbz-Gay-Phe-NH2 and BFA were not additive pointing to a similar mode of action of the two substances. However, Madin-Darby canine kidney cells of which the Golgi structure is BFA-resistant were not resistant to the inhibitory action of Cbz-Gly-Phe-NH2 on CT cytotoxicity, Several lines of evidence indicate that a perturbation of intracellular Ca2+ homeostasis by Cbz-Gly-Phe-NH2 is not responsible for the inhibitory effect of the dipeptide. The dipeptide had also no effect on the binding of I-125-CT to cells and even increased its intracellular internalization. In contrast with BFA, Cbz-Gly-Phe-NH2 did not completely suppress the formation of the catalytically active A(1) fragment from bound CT. The data are compatible with a role of metalloendoprotease activity in the intracellular trafficking and processing of CT, although other mechanisms of action of Cbz-Gly-Phe-NH2 cannot be excluded.	Univ Antwerp, RUCA, Lab Human Biochem, B-2020 Antwerp, Belgium	University of Antwerp	De Wolf, MJS (corresponding author), Univ Antwerp, RUCA, Lab Human Biochem, Groenenborgerlaan 171, B-2020 Antwerp, Belgium.	mjdewolf@ruca.ua.ac.be						BROSTROM MA, 1991, J BIOL CHEM, V266, P7037; BROSTROM MA, 1981, MOL PHARMACOL, V20, P59; BROSTROM MA, 1994, BIOCHEM J, V304, P499, DOI 10.1042/bj3040499; CIEPLAK W, 1995, MOL MICROBIOL, V16, P789, DOI 10.1111/j.1365-2958.1995.tb02440.x; CUATRECASAS P, 1973, BIOCHEMISTRY-US, V12, P3547, DOI 10.1021/bi00742a031; DEWOLF M, 1985, BIOCHIM BIOPHYS ACTA, V832, P165, DOI 10.1016/0167-4838(85)90328-0; DEWOLF MJS, 1987, BIOCHEMISTRY-US, V26, P3799, DOI 10.1021/bi00387a010; DEWOLF MJS, 1981, J BIOL CHEM, V256, P5481; FINKELSTEIN RA, 1988, HDB NATURAL TOXINS, V4, P1; FISHMAN PH, 1982, J CELL BIOL, V93, P860, DOI 10.1083/jcb.93.3.860; Hazes B, 1997, BIOCHEMISTRY-US, V36, P11051, DOI 10.1021/bi971383p; HUNZIKER W, 1991, CELL, V67, P617, DOI 10.1016/0092-8674(91)90535-7; IVESSA NE, 1995, J BIOL CHEM, V270, P25960, DOI 10.1074/jbc.270.43.25960; JANICOT M, 1987, EUR J BIOCHEM, V163, P433, DOI 10.1111/j.1432-1033.1987.tb10816.x; KASSIS S, 1982, J BIOL CHEM, V257, P2148; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; LENCER WI, 1993, J CLIN INVEST, V92, P2941, DOI 10.1172/JCI116917; LENCER WI, 1995, J CELL BIOL, V131, P951, DOI 10.1083/jcb.131.4.951; Lencer WI, 1997, J BIOL CHEM, V272, P15562, DOI 10.1074/jbc.272.24.15562; LENNARZ WJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P149, DOI 10.1016/0304-4157(91)90022-O; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5855; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAMBIAR MP, 1993, J CELL PHYSIOL, V154, P222, DOI 10.1002/jcp.1041540203; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; ORLANDI PA, 1993, J BIOL CHEM, V268, P12010; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PITT A, 1991, EUR J CELL BIOL, V55, P328; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; Sandvig K, 1996, P NATL ACAD SCI USA, V93, P12339, DOI 10.1073/pnas.93.22.12339; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SPANGLER BD, 1992, MICROBIOL REV, V56, P622, DOI 10.1128/MMBR.56.4.622-647.1992; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; TUSZYNSKI GP, 1980, ANAL BIOCHEM, V106, P118, DOI 10.1016/0003-2697(80)90126-8; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wolf AA, 1998, J CELL BIOL, V141, P917, DOI 10.1083/jcb.141.4.917; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; ZHANG RG, 1995, J MOL BIOL, V251, P563, DOI 10.1006/jmbi.1995.0456	41	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30240	30247		10.1074/jbc.M004434200	http://dx.doi.org/10.1074/jbc.M004434200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10831601	hybrid			2022-12-25	WOS:000089577900046
J	Heise, CE; O'Dowd, BF; Figueroa, DJ; Sawyer, N; Nguyen, T; Im, DS; Stocco, R; Bellefeuille, JN; Abramovitz, M; Cheng, R; Williams, DL; Zeng, ZZ; Liu, QY; Ma, L; Clements, MK; Coulombe, N; Liu, Y; Austin, CP; George, SR; O'Neill, GP; Metters, KM; Lynch, KR; Evans, JF				Heise, CE; O'Dowd, BF; Figueroa, DJ; Sawyer, N; Nguyen, T; Im, DS; Stocco, R; Bellefeuille, JN; Abramovitz, M; Cheng, R; Williams, DL; Zeng, ZZ; Liu, QY; Ma, L; Clements, MK; Coulombe, N; Liu, Y; Austin, CP; George, SR; O'Neill, GP; Metters, KM; Lynch, KR; Evans, JF			Characterization of the human cysteinyl leukotriene 2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; DOUBLE-BLIND; HUMAN LUNG; ASTHMA; ANTAGONIST; GENES; EXPRESSION; CLONING; CELLS; D4	The contractile and inflammatory actions of the cysteinyl leukotrienes (CysLTs), LTC4, LTD4, and LTE4, are thought to be mediated through at least two distinct but related CysLT G protein-coupled receptors. The human CysLT(1) receptor has been recently cloned and characterized. We describe here the cloning and characterization of the second cysteinyl leukotriene receptor, CysLT(2), a 346-amino acid protein with 38% amino acid identity to the CysLT(1) receptor. The recombinant human CysLT(2) receptor was expressed in Xenopus oocytes and HEK293T cells and shown to couple to elevation of intracellular calcium when activated by LTC4, LTD4, or LTE4. Analyses of radiolabeled LTD4 binding to the recombinant CysLT(2) receptor demonstrated high affinity binding and a rank order of potency for competition of LTC4 = LTD4 >> LTE4. In contrast to the dual CysLT(1)/ CysLT(2) antagonist, BAY u9773, the CysLT(1) receptor-selective antagonists MK-571, montelukast (Singulair(TM)), zafirlukast (Accolate(TM)), and pranlukast (Onon(TM)) exhibited low potency in competition for LTD4 binding and as antagonists of CysLT(2) receptor signaling. CysLT(2) receptor mRNA was detected in lung macrophages and airway smooth muscle, cardiac Purkinje cells, adrenal medulla cells, peripheral blood leukocytes, and brain, and the receptor gene was mapped to chromosome 13q14, a region linked to atopic asthma.	Merck & Co Inc, Dept Pharmacol, West Point, PA 19486 USA; Merck & Co Inc, Dept Bioinformat, West Point, PA 19486 USA; Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Ctr Addict & Mental Hlth, Toronto, ON M5S 2S1, Canada; Merck Frosst Canada & Co, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada	Merck & Company; Merck & Company; University of Virginia; University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Merck & Company	Evans, JF (corresponding author), Merck & Co Inc, Dept Pharmacol, 770 Sumneytown Pike,POB 4, West Point, PA 19486 USA.	jilly_evans@merck.com	George, Susan R/P-9669-2018; George, Susan/W-7494-2019	IM, DONG-SOON/0000-0001-8054-8946	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052722, T32GM007055] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM07055, R01 GM52722] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN SP, 1992, BRIT J CLIN PHARMACO, V34, P409; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLEMAN RA, 1995, ADV PROSTAG THROMB L, V23, P283; Cookson W, 1999, NATURE, V402, pB5, DOI 10.1038/35037002; DURIEUX ME, 1993, AM J PHYSIOL, V264, pC1360, DOI 10.1152/ajpcell.1993.264.5.C1360; Folco G, 2000, AM J RESP CRIT CARE, V161, pS112, DOI 10.1164/ajrccm.161.supplement_1.ltta-22; FREY EA, 1993, EUR J PHARM-MOLEC PH, V244, P239, DOI 10.1016/0922-4106(93)90149-4; Grossman J, 1997, J ASTHMA, V34, P321, DOI 10.3109/02770909709067222; Hooks SB, 1998, MOL PHARMACOL, V53, P188, DOI 10.1124/mol.53.2.188; HULTING AL, 1985, P NATL ACAD SCI USA, V82, P3834, DOI 10.1073/pnas.82.11.3834; Kimura K, 1999, HUM MOL GENET, V8, P1487, DOI 10.1093/hmg/8.8.1487; LABAT C, 1992, J PHARMACOL EXP THER, V263, P800; LINDGREN JA, 1984, P NATL ACAD SCI-BIOL, V81, P6212, DOI 10.1073/pnas.81.19.6212; Lynch KR, 1999, NATURE, V399, P789; MARCHESE A, 1994, GENOMICS, V23, P609, DOI 10.1006/geno.1994.1549; METTERS KM, 1995, J LIPID MEDIAT CELL, V12, P413, DOI 10.1016/0929-7855(95)00027-N; ODowd BF, 1996, FEBS LETT, V394, P325, DOI 10.1016/0014-5793(96)00901-5; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Retief JD, 1999, GENOME RES, V9, P373; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Suissa S, 1997, ANN INTERN MED, V126, P177, DOI 10.7326/0003-4819-126-3-199702010-00001; TUDHOPE SR, 1994, EUR J PHARMACOL, V264, P317, DOI 10.1016/0014-2999(94)00485-4; Ungrin MD, 1999, ANAL BIOCHEM, V272, P34, DOI 10.1006/abio.1999.4145; Vigorito C, 1997, INT J CLIN LAB RES, V27, P178, DOI 10.1007/BF02912454; Walch L, 1999, J PHYSIOL PHARMACOL, V50, P567; Winking M, 1998, CEREBROVASC DIS, V8, P318, DOI 10.1159/000015874; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	28	533	564	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 29	2000	275	39					30531	30536		10.1074/jbc.M003490200	http://dx.doi.org/10.1074/jbc.M003490200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	358VM	10851239	hybrid			2022-12-25	WOS:000089577900084
J	Cai, RL; Yan-Neale, Y; Cueto, MA; Xu, H; Cohen, D				Cai, RL; Yan-Neale, Y; Cueto, MA; Xu, H; Cohen, D			HDAC1, a histone deacetylase, forms a complex with Hus1 and Rad9, two G(2)/M checkpoint Rad proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; TRANSCRIPTIONAL REPRESSION; SACCHAROMYCES-CEREVISIAE; PROMYELOCYTIC LEUKEMIA; ATAXIA-TELANGIECTASIA; HUMAN HOMOLOGS; CDNA CLONING; CONTROL GENE; FAMILY; INHIBITION	HDAC1 is a member of the histone deacetylase family, which plays an important role in modulating the eukaryotic chromatin structure. Numerous studies have demonstrated its involvement in transcription and in tumorigenesis. To better understand the functions and regulation of HDAC1, a yeast two-hybrid screening approach was chosen to identify novel interactions involving HDAC1. Human HDAC1 was found to interact specifically in yeast, mammalian cells, and irt vitro with the human Hus1 gene product, whose Schizosaccharomyces pombe homolog has been implicated in G(2)/M checkpoint control. Both HDAC1 and Hus1 proteins localize to the nuclei. Furthermore, HDAC1 and Hus1 were found to exist in a complex with Rad9, a known Hus1-interacting factor. In addition, bioinformatics analysis of the protein sequences of Hus1, Rad1, and Rad9, three checkpoint Rad proteins that form a complex, revealed that they all contain a putative proliferating cell nuclear antigen (PCNA) fold, raising the possibility that these factors may bind to DNA in a PCNA-like ring structure. The results reported in this study strongly suggest a novel pathway involving HDAC1 in G(2)/M checkpoint control through the interaction with a functional Rad complex that may utilize a PCNA-like structure. Therefore, physically and functionally similar apparatus may function during G(2)/M checkpoint and DNA replication.	Novartis Pharmaceut Corp, Funct Genom Area, Summit, NJ 07901 USA; Novartis Pharmaceut Corp, Biomol Struct & Comp, Core Technol Area, Summit, NJ 07901 USA	Novartis; Novartis	Cohen, D (corresponding author), Novartis Pharmaceut Corp, Funct Genom Area, 556 Morris Ave,LSB 1237, Summit, NJ 07901 USA.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bailey TL, 1997, J COMPUT BIOL, V4, P45, DOI 10.1089/cmb.1997.4.45; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Dean FB, 1998, GENOMICS, V54, P424, DOI 10.1006/geno.1998.5587; DUNCAN MK, 1995, MAMM GENOME, V6, P697, DOI 10.1007/BF00354290; DUNCAN MK, 1993, J COMP PATHOL, V109, P13, DOI 10.1016/S0021-9975(08)80236-8; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HENIKOFF S, 1995, GENE, V163, P17; HIGGINS DG, 1996, METHOD ENZYMOL, V266, P388; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kim GD, 1999, J BIOL CHEM, V274, P31127, DOI 10.1074/jbc.274.44.31127; Kostrub CF, 1997, MOL GEN GENET, V254, P389, DOI 10.1007/PL00008606; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KRISHNA TSR, 1994, J MOL BIOL, V241, P265, DOI 10.1006/jmbi.1994.1495; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Matsuda T, 1997, ONCOGENE, V15, P2773, DOI 10.1038/sj.onc.1201461; MEGEE PC, 1995, GENE DEV, V9, P1716, DOI 10.1101/gad.9.14.1716; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; PEJOVIC T, 1995, ANN MED, V27, P73, DOI 10.3109/07853899509031940; PELLAS TC, 1991, P NATL ACAD SCI USA, V88, P8787, DOI 10.1073/pnas.88.19.8787; Roy WJ, 1997, ONCOGENE, V15, P2031, DOI 10.1038/sj.onc.1201372; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; THELEN MP, 1994, J BIOL CHEM, V269, P747; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; WATSON TA, 1997, ONCOGENE, V17, P207; Weiss RS, 1999, GENOMICS, V59, P32, DOI 10.1006/geno.1999.5865; Xiao HY, 1997, BIOCHEM BIOPH RES CO, V237, P457, DOI 10.1006/bbrc.1997.7158; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	65	56	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27909	27916						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10846170				2022-12-25	WOS:000089197100053
J	Mavaddat, N; Mason, DW; Atkinson, PD; Evans, EJ; Gilbert, RJC; Stuart, DI; Fennelly, JA; Barclay, AN; Davis, SJ; Brown, MH				Mavaddat, N; Mason, DW; Atkinson, PD; Evans, EJ; Gilbert, RJC; Stuart, DI; Fennelly, JA; Barclay, AN; Davis, SJ; Brown, MH			Signaling lymphocytic activation molecule (CDw150) is homophilic but self-associates with very low affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; HUMAN B-LYMPHOCYTES; CRYSTAL-STRUCTURE; IMMUNOGLOBULIN SUPERFAMILY; PROTEIN INTERACTIONS; HEMOPHILIC ADHESION; LIGAND INTERACTIONS; ENCODING GENE; CD58 LFA-3; CD2	Signaling lymphocytic activating molecule ((SLAM) CDw150) is a glycoprotein that belongs to the CD2 subset of the immunoglobulin superfamily and is expressed on the surface of activated T- and B-cells, It has been proposed that SLAM is homophilic and required for bidirectional signaling during T- and B-cell activation. Previous work has suggested that the affinity of SLAM self-association might be unusually high, undermining the concept that protein interactions mediating transient cell-cell contacts, such as those involving leukocytes, have to be weak in order that such contacts are readily reversible. Using surface plasmon resonance-based methods and analytical ultracentrifugation (AUC), we confirm that SLAM is homophilic. However, we also establish a new theoretical treatment of surface plasmon resonance-derived homophilic binding data, which indicates that SLAM-SLAM interactions (solution K-d similar to 200 mu M) are in fact considerably weaker than most other well characterized protein-protein interactions at the cell surface (solution hi, similar to 0.4-20 mu M), a conclusion that is supported by the AUC analysis. Whereas further analysis of the AUC data imply that SLAM could form "head to head'' dimers spanning adjacent cells, the very low affinity raises important questions regarding the physiological role and/or properties of such interactions.	Univ Oxford, Nuffield Dept Clin Med, Mol Sci Div, Oxford OX3 9DU, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England; Univ Oxford, Oxford Ctr Mol Sci, Oxford OX1 3QU, England	University of Oxford; University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	Davis, SJ (corresponding author), Univ Oxford, Nuffield Dept Clin Med, Mol Sci Div, Oxford OX3 9DU, England.			Stuart, David/0000-0002-3426-4210; Gilbert, Robert/0000-0001-9336-5604; Mavaddat, Nasim/0000-0003-0307-055X; Atkinson, Paul/0000-0001-8205-9388				ASHFORD DA, 1993, J BIOL CHEM, V268, P3260; Atkins AR, 1999, FEBS LETT, V451, P162, DOI 10.1016/S0014-5793(99)00554-2; Aversa G, 1997, IMMUNOL CELL BIOL, V75, P202, DOI 10.1038/icb.1997.30; Aversa G, 1997, J IMMUNOL, V158, P4036; Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BROWN MH, 1994, PROTEIN ENG, V7, P515, DOI 10.1093/protein/7.4.515; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Byron O, 1997, BIOPHYS J, V72, P408, DOI 10.1016/S0006-3495(97)78681-8; CANN JR, 1974, BIOCHEMISTRY-US, V13, P1868, DOI 10.1021/bi00706a015; Carrasco B, 1999, BIOPHYS J, V77, P2902, DOI 10.1016/S0006-3495(99)77123-7; Castro AG, 1999, J IMMUNOL, V163, P5860; CLARK SJ, 1987, P NATL ACAD SCI USA, V84, P1649, DOI 10.1073/pnas.84.6.1649; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; COELFEN H, 1995, PROGR COLLOID POLYM, V99, P167; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; De Angelis E, 1999, EMBO J, V18, P4744, DOI 10.1093/emboj/18.17.4744; de la Torre JG, 1999, EUR BIOPHYS J BIOPHY, V28, P119, DOI 10.1007/s002490050191; delaFuente MA, 1997, BLOOD, V90, P2398; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Dustin ML, 1996, J CELL BIOL, V132, P465, DOI 10.1083/jcb.132.3.465; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; ESNOUF RM, 1997, J MOL GRAPH MODEL, V15, P112; Ikemizu S, 1999, P NATL ACAD SCI USA, V96, P4289, DOI 10.1073/pnas.96.8.4289; Ikemizu S, 2000, IMMUNITY, V12, P51, DOI 10.1016/S1074-7613(00)80158-2; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; KILLEEN N, 1988, EMBO J, V7, P3087, DOI 10.1002/j.1460-2075.1988.tb03174.x; KRAULIS PJ, 1991, SCIENCE, V254, P581, DOI 10.1126/science.1658931; LAUE TM, 1992, 835 DS SPINC BUS UN; Li SC, 1999, CURR BIOL, V9, P1355, DOI 10.1016/S0960-9822(00)80080-9; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mikhalap SV, 1999, J IMMUNOL, V162, P5719; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; O'Callaghan CA, 1999, ANAL BIOCHEM, V266, P9, DOI 10.1006/abio.1998.2930; Pfuhl M, 1999, J BIOMOL NMR, V14, P307, DOI 10.1023/A:1008319917267; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; Punnonen J, 1997, J EXP MED, V185, P993, DOI 10.1084/jem.185.6.993; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schachman H.K., 1959, ULTRACENTRIFUGATION; SCHACHMAN HK, 1951, J AM CHEM SOC, V73, P4808, DOI 10.1021/ja01154a099; SCHATZ PJ, 1993, BIO-TECHNOL, V11, P1138, DOI 10.1038/nbt1093-1138; Sewell AK, 1999, NAT MED, V5, P399, DOI 10.1038/7398; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; SIDORENKO SP, 1993, J IMMUNOL, V151, P4614; SQUIRE PG, 1979, ARCH BIOCHEM BIOPHYS, V196, P165, DOI 10.1016/0003-9861(79)90563-0; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Su XD, 1998, SCIENCE, V281, P991, DOI 10.1126/science.281.5379.991; Sun J, 1996, J BIOL CHEM, V271, P18561, DOI 10.1074/jbc.271.31.18561; Sun QH, 1996, J BIOL CHEM, V271, P11090, DOI 10.1074/jbc.271.19.11090; Tangye SG, 1999, J IMMUNOL, V162, P6981; van der Merwe PA, 1999, J EXP MED, V190, P1371, DOI 10.1084/jem.190.10.1371; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; Wang J, 1999, CELL, V97, P791, DOI 10.1016/S0092-8674(00)80790-4; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WONG YW, 1990, J EXP MED, V171, P2115, DOI 10.1084/jem.171.6.2115; Wyer JR, 1999, IMMUNITY, V10, P219, DOI 10.1016/S1074-7613(00)80022-9	61	125	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28100	28109						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10831600				2022-12-25	WOS:000089197100076
J	Sawamura, N; Morishima-Kawashima, M; Waki, H; Kobayashi, K; Kuramochi, T; Frosch, MP; Ding, K; Ito, M; Kim, TW; Tanzi, RE; Oyama, F; Tabira, T; Ando, S; Ihara, Y				Sawamura, N; Morishima-Kawashima, M; Waki, H; Kobayashi, K; Kuramochi, T; Frosch, MP; Ding, K; Ito, M; Kim, TW; Tanzi, RE; Oyama, F; Tabira, T; Ando, S; Ihara, Y			Mutant presenilin 2 transgenic mice - A large increase in the levels of A beta 42 id presumably associated with the low density membrane domain that contains decreased levels of glycerophospholipids and sphingomyelin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID-BETA-PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; A-BETA; IN-VIVO; MISSENSE MUTATIONS; ANCHORED PROTEINS; TRANSFECTED CELLS; PRECURSOR PROTEIN; SENILE PLAQUES; BRAIN	The N141I mutation in presenilin (PS) 2 is tightly linked with a form of autosomal dominant familial Alzheimer's disease in the Volga German families. We previously reported that mouse brains harboring mutant PS2 contained increased levels of amyloid beta protein (A beta) 42 in the Tris-saline-soluble fraction (Oyama, F., Sawamura, N., Kobayashi, K., Morishima-Kawashima, M., Kuramochi, T., Ito, M., Tomita, T., Maruyama, K., Saido, T. C., Iwatsubo, T., Capell, A., Waiter, J., Grunberg, J., Ueyama, Y., Haass, C. and Ihara, Y. (1998) J. Neurochem. 71, 313-322). Here, using a new extraction protocol, we quantitated the A beta 40 and A beta 42 levels in the Tris-saline-insoluble fraction. The insoluble A beta levels were found to be higher than the soluble A beta levels, and the insoluble A beta 42 levels were markedly increased in mutant PS2 transgenic mice. To investigate the origin of the insoluble A beta 42, we prepared the detergent-insoluble, low density membrane fraction. This fraction from two independent lines of mutant PS2 transgenic mice contained remarkably increased levels of A beta 42 and significantly low levels of glycerophospholipids and sphingomyelin. This unexpected finding suggests that a large increase in the levels of A beta 42 in mutant PS2 mice is presumably induced through alterations of the lipid composition in the low density membrane domain in the brain.	Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Metropolitan Inst Gerontol, Dept Membrane Biochem, Itabashi Ku, Tokyo 1730015, Japan; Cent Inst Expt Anim, Miyamae Ku, Kawasaki, Kanagawa 2160001, Japan; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol,Div Neuropathol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Natl Inst Neurosci, Natl Ctr Neurol & Psychiat, Dept Demyelinating Dis & Aging, Tokyo 1878502, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi 3320012, Japan	University of Tokyo; Tokyo Metropolitan Institute of Gerontology; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital; National Center for Neurology & Psychiatry - Japan; Japan Science & Technology Agency (JST)	Ihara, Y (corresponding author), Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	yihara@m.u-tokyo.ac.jp	Sawamura, Naoya/K-1663-2018; Tanzi, Rudolph/AAE-9622-2019; Frosch, Matthew P/ABD-7456-2021; Oyama, Fumitaka/P-6186-2016	Sawamura, Naoya/0000-0003-4753-1119; Tanzi, Rudolph/0000-0002-7032-1454; Frosch, Matthew P/0000-0002-3940-9861; Oyama, Fumitaka/0000-0002-1095-8306				Ando S, 1987, CHROMATOGRAPHY LIPID, P266; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BLUSZTAJN JK, 1990, BRAIN RES, V536, P240, DOI 10.1016/0006-8993(90)90030-F; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Cook DG, 1996, P NATL ACAD SCI USA, V93, P9223, DOI 10.1073/pnas.93.17.9223; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Hamano T, 1997, J NEUROPATH EXP NEUR, V56, P922, DOI 10.1097/00005072-199708000-00010; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; ITOH YH, 1986, ANAL BIOCHEM, V154, P200, DOI 10.1016/0003-2697(86)90515-4; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kang DE, 1999, J NEUROSCI, V19, P4229; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim TW, 1997, J BIOL CHEM, V272, P11006; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Kramer EM, 1997, J BIOL CHEM, V272, P8937; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LEVYLAHAD E, 1995, SCIENCE, V269, P970, DOI 10.1126/science.7638621; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MASON RP, 1992, NEUROBIOL AGING, V13, P413, DOI 10.1016/0197-4580(92)90116-F; MIETTINEN T, 1959, ACTA CHEM SCAND, V13, P856, DOI 10.3891/acta.chem.scand.13-0856; Mizuno T, 1999, J BIOL CHEM, V274, P15110, DOI 10.1074/jbc.274.21.15110; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; Nakabayashi J, 1998, J NEUROPATH EXP NEUR, V57, P343, DOI 10.1097/00005072-199804000-00007; NITSCH RM, 1992, P NATL ACAD SCI USA, V89, P1671, DOI 10.1073/pnas.89.5.1671; OLIVE S, 1995, J NEUROCHEM, V65, P2307; Oyama F, 1998, J NEUROCHEM, V71, P313; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheek S, 1997, P NATL ACAD SCI USA, V94, P11179, DOI 10.1073/pnas.94.21.11179; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shinkai Y, 1997, ANN NEUROL, V42, P899, DOI 10.1002/ana.410420612; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SINGH H, 1971, J LIPID RES, V12, P473; SODERBERG M, 1992, J NEUROCHEM, V59, P1646; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; SUZUKI N, 1994, AM J PATHOL, V145, P452; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; WAKI H, 1994, ANAL BIOCHEM, V222, P156, DOI 10.1006/abio.1994.1467; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xu GY, 1996, MICROCHEM J, V53, P29, DOI 10.1006/mchj.1996.0005; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; YOO AS, 2000, IN PRESS NEURON	62	77	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27901	27908						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10846187				2022-12-25	WOS:000089197100052
J	Koszelak, ME; Huggins, CF; Fay, PJ				Koszelak, ME; Huggins, CF; Fay, PJ			Sites in the A2 subunit involved in the interfactor VIIIa interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; MILD HEMOPHILIA-A; CATALYZED PROTEOLYSIS; PROCOAGULANT ACTIVITY; ANTIHEMOPHILIC-FACTOR; A1/A3-C1-C2 DIMER; FACTOR-IXA; THROMBIN; INACTIVATION; A2-SUBUNIT	Factor Villa is a trimer of the Al, A2, and A3-C1-C2 subunits, Regions in the A2 subunit that interact with the A1/A3-C1-C2 dimer were localized using synthetic peptides derived from A2 sequences showing high probability of being surface exposed. Peptides were restricted to residues 373-562 of A2 based on the earlier observation that this region of A2 reacts with Al using a zero length cross-linker, Peptides were assessed for their capacity to inhibit the reconstitution of factor Villa from the isolated A1/A3-C1-C2 dimer and A2 subunit. Reconstitution was monitored using both regeneration of factor Villa activity and fluorescence quenching of an acrylodan-labeled A2 (Ac-A2) by fluorescein-labeled A1/A3-C1-C2. The activity assay identified four peptides as inhibitors, residues 373-395 (IC50 = 65 mu M), 418-428 (IC50 = 25 mu M), 482-493 (IC50 = 325 mu M), and 518-533 (IC50 = 585 mu M). The 373-395 and 518-533 peptides eliminated the fluorescence quenching of Ac-A2, whereas the 418-428 peptide reduced but did not eliminate Ac-A2 quenching, Peptide 482-493 had no effect on the fluorescence quenching of Ac-A2 suggesting that the peptide did not directly affect reassociation of the factor Villa subunits. These results identify three regions in the A2 subunit (373-395, 418-428, and 518-533) that interact with the A1/A3-C1-C2 dimer, Furthermore, comparison of results obtained using the two assays distinguish inhibition of the intersubunit interactions from intermolecular interactions.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Fay, PJ (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Sch Med, POB 610,601 Elmwood Ave, Rochester, NY 14642 USA.	Philip_Fay@urmc.rochester.edu		Huggins, Christine/0000-0002-5873-1194	NHLBI NIH HHS [HL 30616, HL 38199] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038199, P01HL030616] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASILLAS G, 1971, COAGULATION, V4, P107; Celie PHN, 1999, BRIT J HAEMATOL, V106, P792, DOI 10.1046/j.1365-2141.1999.01590.x; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1993, J BIOL CHEM, V268, P17861; Fay PJ, 1999, J BIOL CHEM, V274, P29826, DOI 10.1074/jbc.274.42.29826; FAY PJ, 1994, J BIOL CHEM, V269, P20522; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; HEALEY JF, 1995, J BIOL CHEM, V270, P14505, DOI 10.1074/jbc.270.24.14505; HULTIN MB, 1981, BLOOD, V57, P476; KRISHNASWAMY S, 1989, J BIOL CHEM, V264, P3160; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Lapan KA, 1997, J BIOL CHEM, V272, P2082; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MANN KG, 1990, BLOOD, V76, P1; MCMULLEN BA, 1995, PROTEIN SCI, V4, P740; MIMS MP, 1993, BIOCHEMISTRY-US, V32, P9215, DOI 10.1021/bi00086a029; MOSESSON MW, 1990, J CLIN INVEST, V85, P1983, DOI 10.1172/JCI114662; OBrien LM, 1997, BLOOD, V90, P3943, DOI 10.1182/blood.V90.10.3943; PAN Y, 1995, NAT STRUCT BIOL, V2, P740, DOI 10.1038/nsb0995-740; Pemberton S, 1997, BLOOD, V89, P2413, DOI 10.1182/blood.V89.7.2413; PERSSON E, 1995, BIOCHEMISTRY-US, V34, P12775, DOI 10.1021/bi00039a038; Pipe SW, 1999, BLOOD, V93, P176, DOI 10.1182/blood.V93.1.176.401k07_176_183; PITTMAN DD, 1992, BLOOD, V79, P389; Sudhakar K, 1996, J BIOL CHEM, V271, P23015, DOI 10.1074/jbc.271.38.23015; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	36	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27137	27144						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10831590				2022-12-25	WOS:000089144800064
J	Elshourbagy, NA; Ames, RS; Fitzgerald, LR; Foley, JJ; Chambers, JK; Szekeres, PG; Evans, NA; Schmidt, DB; Buckley, PT; Dytko, GM; Murdock, PR; Milligan, G; Groarke, DA; Tan, KB; Shabon, U; Nuthulaganti, P; Wang, DY; Wilson, S; Bergsma, DJ; Sarau, HM				Elshourbagy, NA; Ames, RS; Fitzgerald, LR; Foley, JJ; Chambers, JK; Szekeres, PG; Evans, NA; Schmidt, DB; Buckley, PT; Dytko, GM; Murdock, PR; Milligan, G; Groarke, DA; Tan, KB; Shabon, U; Nuthulaganti, P; Wang, DY; Wilson, S; Bergsma, DJ; Sarau, HM			Receptor for the pain modulatory neuropeptides FF and AF is an orphan G protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL-CORD; RAT; MORPHINE; FMRFAMIDE; PEPTIDES; BRAIN; NPFF; MEMBRANES; ANTISERUM; ANALGESIA	Opiate tolerance and dependence are major clinical and social problems. The anti-opiate neuropeptides FF and AF (NPFF and NPAF) have been implicated in pain modulation as well as in opioid tolerance and may play a critical role in this process, although their mechanism of action has remained unknown. Here we describe a cDNA encoding a novel neuropeptide Y-like human orphan G protein-coupled receptor (GPCR), referred to as HLWAR77 for which NPAF and NPFF have high affinity. Cells transiently or stably expressing HLWAR77 bind and respond in a concentration-dependent manner to NPAF and NPFF and are also weakly activated by FMRF-amide (Phe-Met-Arg-Phe-amide) and a variety of related peptides. The high affinity and potency of human NPFF and human NPAF for HLWAR77 strongly suggest that these are the cognate ligands for this receptor. Expression of HLWAR77 was demonstrated in brain regions associated with opiate activity, consistent with the pain-modulating activity of these peptides, whereas the expression in adipose tissue suggests other physiological and pathophysiological activities for FMRF-amide neuropeptides. The discovery that the anti-opiate neuropeptides are the endogenous ligands for HLWAR77 will aid in defining the physiological role(s) of these ligands and facilitate the identification of receptor agonists and antagonists.	SmithKline Beecham Pharmaceut, Dept Biol Mol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Renal Pharmacol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Pulm Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Vasc Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; Univ Glasgow, Mol Pharmacol Grp, Div Biochem & Mol Biol, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; University of Glasgow	Ames, RS (corresponding author), SmithKline Beecham Pharmaceut, Dept Biol Mol, 709 Swedeland Rd, King Of Prussia, PA 19406 USA.		Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519				ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; Chambers JK, 2000, J BIOL CHEM, V275, P10767, DOI 10.1074/jbc.275.15.10767; Cikos S, 1999, BIOCHEM BIOPH RES CO, V256, P352, DOI 10.1006/bbrc.1999.0332; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Coward P, 1999, ANAL BIOCHEM, V270, P242, DOI 10.1006/abio.1999.4061; DEVILLERS JP, 1994, NEUROPHARMACOLOGY, V33, P661, DOI 10.1016/0028-3908(94)90172-4; Fitzgerald LR, 1999, ANAL BIOCHEM, V275, P54, DOI 10.1006/abio.1999.4295; GOUARDERES C, 1993, EUR J PHARMACOL, V237, P73, DOI 10.1016/0014-2999(93)90095-Y; KAVALIERS M, 1991, PEPTIDES, V12, P235, DOI 10.1016/0196-9781(91)90005-A; KIVIPELTO L, 1989, J COMP NEUROL, V286, P269, DOI 10.1002/cne.902860211; KONTINEN VK, 1995, PEPTIDES, V16, P973, DOI 10.1016/0196-9781(95)00068-U; LAKE JR, 1991, NEUROSCI LETT, V132, P29, DOI 10.1016/0304-3940(91)90425-S; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; MAJANE EA, 1993, ENDOCRINOLOGY, V133, P1578, DOI 10.1210/en.133.4.1578; MALIN DH, 1990, PEPTIDES, V11, P277, DOI 10.1016/0196-9781(90)90082-G; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Panula P, 1996, PROG NEUROBIOL, V48, P461, DOI 10.1016/0301-0082(96)00001-9; PAYZA K, 1993, J NEUROCHEM, V60, P1894, DOI 10.1111/j.1471-4159.1993.tb13417.x; Perry SJ, 1997, FEBS LETT, V409, P426, DOI 10.1016/S0014-5793(97)00557-7; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; Roumy M, 1998, EUR J PHARMACOL, V345, P1, DOI 10.1016/S0014-2999(97)01604-X; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Seifert R, 1999, TRENDS PHARMACOL SCI, V20, P383, DOI 10.1016/S0165-6147(99)01368-1; Sol JC, 1999, PEPTIDES, V20, P1219, DOI 10.1016/S0196-9781(99)00126-6; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; STINUS L, 1995, PEPTIDES, V16, P1235, DOI 10.1016/0196-9781(95)02019-S; Vilim FS, 1999, MOL PHARMACOL, V55, P804; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757	30	225	235	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25965	25971		10.1074/jbc.M004515200	http://dx.doi.org/10.1074/jbc.M004515200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851242	hybrid			2022-12-25	WOS:000088999700013
J	Sagami, I; Sato, Y; Daff, S; Shimizu, T				Sagami, I; Sato, Y; Daff, S; Shimizu, T			Aromatic residues and neighboring Arg(414) in the (6R)-5,6,7,8-tetrahydro-L-biopterin binding site of full-length neuronal nitric-oxide synthase are crucial in catalysis and heme reduction with NADPH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRIC CYTOCHROME P-450-CAM; TETRAHYDROBIOPTERIN-BINDING; MOLECULAR-CLONING; ELECTRON-TRANSFER; NO SYNTHASE; ESCHERICHIA-COLI; PTERIN COFACTOR; LIGAND TRANS; L-ARGININE; DOMAIN	Nitric-oxide synthase (NOS) requires the cofactor, (6R)-5,6,7,8-tetrahydrobiopterin (H4B), for catalytic activity. The crystal structures of NOSs indicate that H4B is surrounded by aromatic residues. We have mutated the conserved aromatic acids, Trp(676) Trp(678), Phe(691) His(692), and Tyr(706), together with the neighboring Ar-414 residue within the H4B binding region of full-length neuronal NOS. The W676L, W678L, and F691L mutants had no NO formation activity and had very low heme reduction rates (<0.02 min(-1)) with NADPH, Thus, it appears that Trp(676), Trp(678), and Phe(691) are important to retain the appropriate active site conformation for H4B/L-Arg binding and/or electron transfer to the heme from NADPH, The mutation of Tyr(706) to Leu and Phe decreased the activity down to 13 and 29%, respectively, of that of the wild type together with a dramatically increased EC50 value for H4B (30-40-fold of wild type). The Tyr706 phenol group interacts with the heme propionate and Arg(414) amine via hydrogen bonds. The mutation of Ar-414 to Leu and Glu resulted in the total loss of NO formation activity and of the heme reduction with NADPH, Thus, hydrogen bond networks consisting of the heme carboxylate, Tyr(706), and Arg(414) are crucial in stabilizing the appropriate conformation(s) of the heme active site for H4B/L-Arg binding and/or efficient electron transfer to occur.	Tohoku Univ, Inst Chem React Sci, Aoba Ku, Sendai, Miyagi 9808577, Japan	Tohoku University	Sagami, I (corresponding author), Tohoku Univ, Inst Chem React Sci, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.							ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Bommel HM, 1998, J BIOL CHEM, V273, P33142, DOI 10.1074/jbc.273.50.33142; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHO HJ, 1995, P NATL ACAD SCI USA, V92, P11514, DOI 10.1073/pnas.92.25.11514; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; Feelisch M., 1996, METHODS NITRIC OXIDE; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; Ghosh S, 1999, J BIOL CHEM, V274, P24100, DOI 10.1074/jbc.274.34.24100; Gorren ACF, 1998, BIOCHEM J, V331, P801, DOI 10.1042/bj3310801; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Huang LX, 1999, BIOCHEMISTRY-US, V38, P1912, DOI 10.1021/bi981954t; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; IGNARRO L, 1996, NITRIC OXIDE BIOCH M; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; Maines MD., 1996, NITRIC OXIDE SYNTHAS; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; Mayer B, 1997, BIOCHEMISTRY-US, V36, P8422, DOI 10.1021/bi970144z; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Miller RT, 1997, BIOCHEMISTRY-US, V36, P15277, DOI 10.1021/bi972022c; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; Reif A, 1999, J BIOL CHEM, V274, P24921, DOI 10.1074/jbc.274.35.24921; Riethmuller C, 1999, J BIOL CHEM, V274, P16047, DOI 10.1074/jbc.274.23.16047; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Sagami I, 1998, J BIOL CHEM, V273, P2105, DOI 10.1074/jbc.273.4.2105; SHETA EA, 1994, J BIOL CHEM, V269, P15147; Shimanuki T, 1999, J BIOL CHEM, V274, P26956, DOI 10.1074/jbc.274.38.26956; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; SONO M, 1982, J BIOL CHEM, V257, P5496; Stuehr DJ, 1997, ANNU REV PHARMACOL, V37, P339, DOI 10.1146/annurev.pharmtox.37.1.339; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; WHITE RE, 1982, J BIOL CHEM, V257, P3073; Witteveen CFB, 1999, J BIOL CHEM, V274, P29755, DOI 10.1074/jbc.274.42.29755; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	52	26	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26150	26157		10.1074/jbc.M000534200	http://dx.doi.org/10.1074/jbc.M000534200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10846172	hybrid			2022-12-25	WOS:000088999700038
J	Liu, Z; Chen, Y; Mo, R; Hui, CC; Cheng, JF; Mohandas, N; Huang, CH				Liu, Z; Chen, Y; Mo, R; Hui, CC; Cheng, JF; Mohandas, N; Huang, CH			Characterization of human RhCG and mouse Rhcg as novel nonerythroid Rh glycoprotein homologues predominantly expressed in kidney and testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTE-MEMBRANE; BLOOD-GROUP POLYPEPTIDES; GROUP ANTIGEN EXPRESSION; INSITU HYBRIDIZATION; GENE STRUCTURE; NULL DISEASE; PROTEIN; SEQUENCE; ORGANIZATION; TRANSPORT	In mammals, the Rh family includes the variable Rh polypeptides and invariant RhAG glycoprotein. These polytopic proteins are confined to the erythroid lineage and are assembled into a multisubunit complex essential for Rfi antigen expression and plasma membrane integrity. Here, we report the characterization of RhCG and Rhcg, a pair of novel Rh homologues present in human and mouse nonerythroid tissues. Despite sharing a notable similarity to the erythroid forms, including the 12-transmembrane topological fold, the RHCG/Rhcg pair is distinct in chromosome location, genomic organization, promoter structure, and tissue-specific expression. RHCG and Rhcg map at 15q25 of human chromosome 15 and the long arm of mouse chromosome 7, respectively, each having 11 exons and a CpG-rich promoter. Northern blots detected kidney and testis as the major organs of RHCG or Rhcg expression. In situ hybridization revealed strong expression of Rhcg in the kidney collecting tubules and testis seminiferous tubules. Confocal imaging of transiently expressed green fluorescence protein fusion proteins localized RhCG exclusively to the plasma membrane, a distribution confirmed by cellular fractionation and Western blot analysis. In vitro translation and ex vivo expression showed that RhCG carries a complex N-glycan, probably at the (NLS50)-N-48 sequon of exoloop 1. These results pinpoint RhCG and Rhcg as novel polytopic membrane glycoproteins that may function as epithelial transporters maintaining normal homeostatic conditions in kidney and testis.	New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Biochem & Mol Genet, New York, NY 10021 USA; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1X8, Canada; Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	New York Blood Center; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Huang, CH (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Biochem & Mol Genet, 310 E 67th St, New York, NY 10021 USA.			Cheng, Jan-Fang/0000-0001-7315-7613	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054459] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54459] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGRE P, 1991, BLOOD, V78, P551, DOI 10.1182/blood.V78.3.551.bloodjournal783551; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Blancher A., 1997, MOL BIOL EVOLUTION B, P147; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Carritt B, 1997, HUM MOL GENET, V6, P843, DOI 10.1093/hmg/6.6.843; CHERIFZAHAR B, 1994, GENOMICS, V19, P68, DOI 10.1006/geno.1994.1014; CHERIFZAHAR B, 1991, HUM GENET, V86, P398, DOI 10.1007/BF00201843; CherifZahar B, 1996, NAT GENET, V12, P168, DOI 10.1038/ng0296-168; CHUMAKOV IM, 1995, NATURE, V377, P175; CONNOR J, 1988, BIOCHEMISTRY-US, V27, P848, DOI 10.1021/bi00403a002; Fawcett D., 1994, TXB HISTOLOGY; FONG AD, 1990, BIOCHIM BIOPHYS ACTA, V1022, P325, DOI 10.1016/0005-2736(90)90281-R; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Harlow E., 1988, ANTIBODIES LAB MANUA; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; Huang CH, 1999, AM J HEMATOL, V62, P25, DOI 10.1002/(SICI)1096-8652(199909)62:1<25::AID-AJH5>3.0.CO;2-K; Huang CH, 1998, BLOOD, V92, P1776, DOI 10.1182/blood.V92.5.1776.417k25_1776_1784; Huang CH, 2000, SEMIN HEMATOL, V37, P150, DOI 10.1016/S0037-1963(00)90040-4; Huang CH, 1998, J BIOL CHEM, V273, P2207, DOI 10.1074/jbc.273.4.2207; Huang CH, 1996, BLOOD, V88, P2326, DOI 10.1182/blood.V88.6.2326.bloodjournal8862326; Huang CH, 1997, BLOOD, V90, P391; HUANG CH, 2000, IN PRESS J MOL EVOL; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Iwamoto S, 1998, BIOCHEM BIOPH RES CO, V243, P233, DOI 10.1006/bbrc.1997.8023; Kaiser BN, 1998, SCIENCE, V281, P1202, DOI 10.1126/science.281.5380.1202; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu Z, 1999, BIOCHEM GENET, V37, P119, DOI 10.1023/A:1018726303397; Marini AM, 1997, TRENDS BIOCHEM SCI, V22, P460, DOI 10.1016/S0968-0004(97)01132-8; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; Matassi G, 1998, GENOMICS, V47, P286, DOI 10.1006/geno.1997.5112; MCKUSICK VA, 1999, HUMAN GENOME DATABAS; MOLLISON PL, 1997, BLOOD TRANSFUSION CL; MOORE S, 1982, NATURE, V295, P529, DOI 10.1038/295529a0; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; RIDGWELL K, 1994, J BIOL CHEM, V269, P6410; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; Sambrook J., 2002, MOL CLONING LAB MANU; SCHROIT AJ, 1990, BIOCHEMISTRY-US, V29, P10303, DOI 10.1021/bi00497a003; Seack J, 1997, IMMUNOGENETICS, V46, P493, DOI 10.1007/s002510050310; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SMITH RE, 1990, BLOOD, V76, P1021; TOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	47	120	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25641	25651		10.1074/jbc.M003353200	http://dx.doi.org/10.1074/jbc.M003353200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10852913	hybrid			2022-12-25	WOS:000088849400079
J	Schmitt, JM; Stork, PJS				Schmitt, JM; Stork, PJS			beta(2)-adrenergic receptor activates extracellular signal-regulated kinases (ERKs) via the small G protein Rap1 and the serine/threonine kinase B-Raf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; BETA-ADRENERGIC RECEPTORS; COUPLED RECEPTORS; MAP KINASE; DEPENDENT ACTIVATION; TYROSINE KINASE; CYCLIC-AMP; ADENYLYL CYCLASE; ONCOGENIC RAS; 3T3 CELLS	G protein-coupled receptors can induce cellular proliferation by stimulating the mitogen-activated protein (MAP) kinase cascade. Heterotrimeric G proteins are composed of both alpha and beta gamma subunits that can signal independently to diverse intracellular signaling pathways including those that activate MAP kinases. In this study, we examined the ability of isoproterenol, an agonist of the beta(2)-adrenergic receptor (beta(2)AR), to stimulate extracellular signal-regulated kinases (ERKs). Using HEK293 cells, which express endogenous beta(2)AR, we show that isoproterenol stimulates ERKs via beta(2)AR. This action of isoproterenol requires cAMP-dependent protein kinase and is insensitive to pertussis toxin, suggesting that G alpha(s) activation of cAMP-dependent protein kinase is required. Interestingly, beta(2)AR activates both the small G proteins Rap1 and Res, but only Rap1 is capable of coupling to Raf isoforms. beta(2)AR inhibits the Ras-dependent activation of both Raf isoforms Raf-1 and B-Raf, whereas Rap1 activation by isoproterenol recruits and activates B-Raf. beta(2)AR activation of ERKs is not blocked by expression of RasN17, an interfering mutant of Ras, but is blocked by expression of either RapN17 or Rap1GAP1, both of which interfere with Rap1 signaling. We propose that isoproterenol can activate ERKs via Rap1 and B-Raf in these cells.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Dev & Cell Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Stork, PJS (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, L474,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	stork@ohsu.edu						Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Beavo J A, 1975, Adv Cyclic Nucleotide Res, V5, P241; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Butcher R W, 1968, Adv Enzyme Regul, V6, P357, DOI 10.1016/0065-2571(68)90023-X; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; Chen TS, 1999, CANCER RES, V59, P213; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P4086, DOI 10.1073/pnas.94.8.4086; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Franke B, 2000, MOL CELL BIOL, V20, P779, DOI 10.1128/MCB.20.3.779-785.2000; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hu CD, 1999, J BIOL CHEM, V274, P48, DOI 10.1074/jbc.274.1.48; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; IISMAA T P, 1992, Current Opinion in Cell Biology, V4, P195, DOI 10.1016/0955-0674(92)90033-9; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MacNicol MC, 1999, J BIOL CHEM, V274, P13193, DOI 10.1074/jbc.274.19.13193; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; Mineo C, 1997, J BIOL CHEM, V272, P10345; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; MOROZOV A, 1999, NEUR M OCT 23 29 MIA; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Okada T, 1999, MOL CELL BIOL, V19, P6057; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Pieroni J P, 1993, Curr Opin Neurobiol, V3, P345, DOI 10.1016/0959-4388(93)90127-K; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Tang H, 1999, J BIOL CHEM, V274, P12401, DOI 10.1074/jbc.274.18.12401; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Winder DG, 1999, NEURON, V24, P715, DOI 10.1016/S0896-6273(00)81124-1; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760	76	148	153	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25342	25350		10.1074/jbc.M003213200	http://dx.doi.org/10.1074/jbc.M003213200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10840035	Green Submitted, hybrid			2022-12-25	WOS:000088849400041
J	Graff, JR; Konicek, BW; McNulty, AM; Wang, ZJ; Houck, K; Allen, S; Paul, JD; Hbaiu, A; Goode, RG; Sandusky, GE; Vessella, RL; Neubauer, BL				Graff, JR; Konicek, BW; McNulty, AM; Wang, ZJ; Houck, K; Allen, S; Paul, JD; Hbaiu, A; Goode, RG; Sandusky, GE; Vessella, RL; Neubauer, BL			Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27(Kip1) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; FORKHEAD TRANSCRIPTION FACTOR; INITIATION-FACTOR 4E; INHIBITOR P27(KIP1); NEGATIVE REGULATION; ANDROGEN RECEPTOR; CELL-SURVIVAL; MESSENGER-RNA; PHOSPHORYLATION; PATHWAY	The PTEN tumor suppressor gene is frequently inactivated in human prostate cancers, particularly in more advanced cancers, suggesting that the AKT/protein kinase B (PKB) kinase, which is negatively regulated by PTEN, may be involved in human prostate cancer progression. me now show that ART activation and activity are markedly increased in androgen-independent, prostate-specific antigen-positive prostate cancer cells (LNAI cells) established from xenograft tumors of the androgen-dependent LNCaP cell line. These LNAI cells show increased expression of integrin-linked kinase, which is putatively responsible for AKT activation/Ser-473 phosphorylation, as well as for increased phosphorylation of the AKT target protein, BAD. Furthermore, expression of the p27(Kip1) cell cycle regulator was diminished in LNAI cells, consistent with the notion that AKT directly inhibits AFX/Forkhead-mediated transcription of p27(Kip1). To assess directly the impact of increased AKT activity on prostate cancer progression, an activated hAKT1 mutant was overexpressed in LNCaP cells, resulting in a B-fold increase in xenograft tumor growth. Like LNAI cells, these transfectants showed dramatically reduced p271(Kip1) expression. Together, these data implicate increased AKT activity in prostate tumor progression and androgen independence and suggest that diminished p27(Kip1) expression, which has been repeatedly associated with prostate cancer progression, may be a consequence of increased AKT activity.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA; Univ Washington, Dept Urol, Seattle, WA 98195 USA; Div Eli Lilly & Co, Sphinx Pharmaceut, Durham, NC 27707 USA	Eli Lilly; University of Washington; University of Washington Seattle; Eli Lilly	Graff, JR (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, DC 0546, Indianapolis, IN 46285 USA.		Houck, Keith/G-8654-2014	Houck, Keith/0000-0002-0055-2249				Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; ATTIA MAM, 1966, CANCER RES, V26, P1787; Berges RR, 1995, CLIN CANCER RES, V1, P473; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Coffer PJ, 1998, BIOCHEM J, V335, P1; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; Craft N, 1998, CANCER METAST REV, V17, P421, DOI 10.1023/A:1006141806801; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Culig Z, 1996, PROSTATE, V28, P392, DOI 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; De Marzo AM, 1998, AM J PATHOL, V153, P911, DOI 10.1016/S0002-9440(10)65632-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; delPeso L, 1997, SCIENCE, V278, P687; Denmeade SR, 1996, PROSTATE, V28, P251; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Gioeli D, 1999, CANCER RES, V59, P279; GRAFF JR, 1995, INT J CANCER, V60, P255; Graff JR, 1997, BIOCHEM BIOPH RES CO, V240, P15, DOI 10.1006/bbrc.1997.7592; Guo YP, 1997, CLIN CANCER RES, V3, P2269; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Ittmann MM, 1998, ONCOL REP, V5, P1329; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Macri E, 1998, CANCER METAST REV, V17, P337, DOI 10.1023/A:1006133620914; McConkey DJ, 1996, CANCER RES, V56, P5594; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Russell PJ, 1998, CLIN CHEM, V44, P705; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Takaishi H, 1999, P NATL ACAD SCI USA, V96, P11836, DOI 10.1073/pnas.96.21.11836; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tsihlias J, 1998, CANCER RES, V58, P542; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Webber MM, 1997, PROSTATE, V30, P58; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yang RM, 1998, J UROLOGY, V159, P941, DOI 10.1016/S0022-5347(01)63776-5; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458	46	328	348	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24500	24505		10.1074/jbc.M003145200	http://dx.doi.org/10.1074/jbc.M003145200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827191	hybrid			2022-12-25	WOS:000088683300036
J	Luschen, S; Ussat, S; Scherer, G; Kabelitz, D; Adam-Klages, S				Luschen, S; Ussat, S; Scherer, G; Kabelitz, D; Adam-Klages, S			Sensitization to death receptor cytotoxicity by inhibition of Fas-associated death domain protein (FADD)/caspase signaling - Requirement of cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; MEDIATED APOPTOSIS; ADAPTER MOLECULE; TNF; ACTIVATION; PROLIFERATION; FADD; CD95; LYMPHOCYTES	Upon binding of their ligands, death receptors belonging to the tumor necrosis factor (TNF) receptor family initiate a signaling pathway leading to the activation of caspases and ultimately apoptosis, TNF, however, in parallel elicits survival signals, protecting many cell types from cell death that can only be induced by combined treatment with TNF and inhibitors of protein synthesis. Here, we report that in NIH3T3 cells, apoptosis in response TNF and cycloheximide is not inhibited by the broad spectrum caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone (zVAD.fmk). Moreover, treatment with zVAD.fmk sensitizes the cells to the cytotoxic action of TNF, Sensitization was also achieved by overexpression of a dominant-negative mutant of Fas-associated death domain protein and, to a lesser-extent, by specific inhibition of caspase-8. A similar, but weaker sensitization of zVAD.fmk to treatment with the TNF-related apoptosis-inducing Ligand (TRAIL) or anti-CD95 antibody was demonstrated. The unexpected cell death in response to TNF and caspase inhibition occurs despite the activation of nuclear factor kappa B and c-Jun N-terminal kinases. The mode of cell death shows several signs of apoptosis including DNA fragmentation, although activation of caspase-3 was excluded. TNF/zVAD.fmk-induced cell death is preceded by an accumulation of cells in the G(2)/M phase of the cell cycle, indicating an important role of cell cycle progression. This hypothesis is further strengthened by the observation that arresting the cells in the G(1) phase of the cell cycle inhibited TNF/zVAD.fmk-induced cell death, whereas blocking them in the G(2)/M phase augmented it.	Univ Kiel, Inst Immunol, D-24105 Kiel, Germany	University of Kiel	Adam-Klages, S (corresponding author), Univ Kiel, Inst Immunol, Michaelisstr 5, D-24105 Kiel, Germany.	sadam@email.uni-kiel.de	Adam-Klages, Sabine/E-9761-2010; Kabelitz, Dieter/A-2757-2010; Kabelitz, Dieter/AAB-4199-2021					AGGARWAL BB, 1995, FEBS LETT, V364, P5, DOI 10.1016/0014-5793(95)00339-B; Ahmad M, 1997, CANCER RES, V57, P615; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BENITO M, 1993, GROWTH REGULAT, V3, P172; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; BOSTOCK CJ, 1971, EXP CELL RES, V68, P163, DOI 10.1016/0014-4827(71)90599-4; BREKKE OL, 1994, LIPIDS, V29, P91, DOI 10.1007/BF02537148; Drenou B, 1999, J IMMUNOL, V163, P4115; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Fan WM, 1999, BIOCHEM PHARMACOL, V57, P1215; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Gravestein LA, 1998, SEMIN IMMUNOL, V10, P423, DOI 10.1006/smim.1998.0144; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hwang A, 1998, RADIAT RES, V150, pS52, DOI 10.2307/3579808; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; KONDO S, 1995, J RADIAT RES, V36, P56, DOI 10.1269/jrr.36.56; Kumar S, 1999, CLIN EXP PHARMACOL P, V26, P295, DOI 10.1046/j.1440-1681.1999.03031.x; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; MACKAY F, 1994, J IMMUNOL, V153, P5274; Magnusson C, 1999, IMMUNOL CELL BIOL, V77, P41, DOI 10.1046/j.1440-1711.1999.00800.x; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OConnor PM, 1997, CANCER SURV, V29, P151; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitz I, 1999, CELL DEATH DIFFER, V6, P821, DOI 10.1038/sj.cdd.4400569; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Singh A, 1998, J INTERF CYTOK RES, V18, P439, DOI 10.1089/jir.1998.18.439; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wyllie AH, 1997, BRIT MED BULL, V53, P451; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	53	73	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24670	24678		10.1074/jbc.M003280200	http://dx.doi.org/10.1074/jbc.M003280200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827087	hybrid			2022-12-25	WOS:000088683300060
J	Yu, M; Haslam, RHA; Haslam, DB				Yu, M; Haslam, RHA; Haslam, DB			HEDJ, an Hsp40 co-chaperone localized to the endoplasmic reticulum of human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONES; PROTEIN TRANSLOCATION; SECRETORY PROTEINS; QUALITY-CONTROL; NUCLEAR-FUSION; HSP70 PROTEINS; DNAJ HOMOLOG; YEAST; BIP	Hsp40 co-chaperones, characterized by the presence of a highly conserved J domain, are involved in nearly all aspects of protein synthesis, folding, and secretion. Within the lumen of the endoplasmic reticulum, these chaperones are also involved in reverse translocation and degradation of misfolded proteins. We describe here the cloning and characterization of a novel Hsp40 chaperone, which we named HEDJ. Epitope-tagged HEDJ was demonstrated by confocal microscopy to be localized to the endoplasmic reticulum. Protease susceptibility, glycosidase treatment, and detergent solubility assays demonstrated that the molecule was luminally oriented and membrane-associated. In vitro experiments demonstrated that the J domain interacted with the endoplasmic reticulum-associated Hsp70, Bip, in an ATP-dependent manner and was capable of stimulating its ATPase activity. HEDJ mRNA expression was detected in all human tissues examined. Highly homologous sequences were found in mouse, Drosophila, and Caenorhabditis elegans data bases. These results suggest potential roles for HEDJ in protein import, folding, or translocation within the endoplasmic reticulum.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)	Haslam, DB (corresponding author), Washington Univ, Sch Med, Dept Pediat, Box 8116,1 Childrens Pl, St Louis, MO 63110 USA.		Haslam, David/G-3825-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD033688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047900, R29AI042817] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI047900, AI42817] Funding Source: Medline; NICHD NIH HHS [HD33688] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bies C, 1999, BIOL CHEM, V380, P1175, DOI 10.1515/BC.1999.149; Brizzio V, 1999, MOL BIOL CELL, V10, P609, DOI 10.1091/mbc.10.3.609; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; Cannon KS, 1999, J BIOL CHEM, V274, P7537, DOI 10.1074/jbc.274.11.7537; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Corsi AK, 1997, J CELL BIOL, V137, P1483, DOI 10.1083/jcb.137.7.1483; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Haslam DB, 1996, P NATL ACAD SCI USA, V93, P10697, DOI 10.1073/pnas.93.20.10697; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LYMAN SK, 1995, J CELL BIOL, V131, P1163, DOI 10.1083/jcb.131.5.1163; Matlack KES, 1997, SCIENCE, V277, P938, DOI 10.1126/science.277.5328.938; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; Nishikawa S, 1998, BIOCHEM BIOPH RES CO, V244, P785, DOI 10.1006/bbrc.1998.8342; Pilon M, 1998, MOL BIOL CELL, V9, P3455, DOI 10.1091/mbc.9.12.3455; Russell R, 1999, BIOCHEMISTRY-US, V38, P4165, DOI 10.1021/bi9824036; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; Schmitz A, 2000, J CELL BIOL, V148, P1203, DOI 10.1083/jcb.148.6.1203; Silberstein S, 1998, J CELL BIOL, V143, P921, DOI 10.1083/jcb.143.4.921; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; Wesche J, 1999, J BIOL CHEM, V274, P34443, DOI 10.1074/jbc.274.48.34443; Xiong XM, 1999, J BIOL CHEM, V274, P2616, DOI 10.1074/jbc.274.5.2616; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943	35	87	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24984	24992		10.1074/jbc.M000739200	http://dx.doi.org/10.1074/jbc.M000739200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827079	hybrid			2022-12-25	WOS:000088683300100
J	Yang, Y; Sowden, MP; Smith, HC				Yang, Y; Sowden, MP; Smith, HC			Induction of cytidine to uridine editing on cytoplasmic apolipoprotein B mRNA by overexpressing APOBEC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MOORING SEQUENCE; SECONDARY STRUCTURE; BINDING PROTEINS; IN-VITRO; COMPLEX; TISSUE; RAT; CLONING; LIVER	post-transcriptional editing of apolipoprotein B (apoB) mRNA is regulated in hepatic cells to achieve a steady state proportion of edited and unedited RNA molecules. This activity is catalyzed by APOBEC-1 apoB mRNA editing catalytic subunit 1) in what has been widely accepted as nuclear event occurring during or after mRNA splicing. Introns impair the efficiency of editing within an adjacent exon in a distance-dependent manner in reporter RNAs. We show here that this inhibition can be overcome by overexpressing APOBEC-1 and that the enhanced editing efficiency on these reporter RNAs occurred after splicing on cytoplasmic transcripts. Given the absolute requirement of auxiliary proteins in apoB mRNA editing, the data suggested that auxiliary proteins were distributed with APOBEC-1 in both the nucleus and cytoplasm of McArdle cells. In fact, immunolocalization of one such auxiliary protein, APOBEC-1 complementation factor (ACP) demonstrated a nuclear and cytoplasmic distribution. We also demonstrate that in the absence of alterations in APOBEC-1 expression, changes in edited apoB RNA induced by ethanol arise through the stimulation of nuclear editing activity. The finding that apoB mRNA editing can occur in the cytoplasm but normally does not suggests that under biological conditions, restricting editing activity to the nucleus must be an important step in regulating the proportion of the edited apoB mRNAs.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Ctr Environm Hlth Sci, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Smith, HC (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA.	harold_smith@urmc.rochester.edu		Smith, Harold/0000-0001-6257-6791	NIDDK NIH HHS [DK43739] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043739] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANT S, 1997, NUCL ACIDS S SER, V36, P115; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1217, P65; BACKUS JW, 1992, NUCLEIC ACIDS RES, V20, P6007, DOI 10.1093/nar/20.22.6007; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1219, P1, DOI 10.1016/0167-4781(94)90240-2; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; Chen L, 1996, J THEOR BIOL, V183, P391, DOI 10.1006/jtbi.1996.0230; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DAVIDSON NO, 1993, ANN MED, V25, P539; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; Greeve J, 1998, BIOL CHEM, V379, P1063, DOI 10.1515/bchm.1998.379.8-9.1063; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; Hersberger M, 1999, J BIOL CHEM, V274, P34590, DOI 10.1074/jbc.274.49.34590; INUI Y, 1994, J LIPID RES, V35, P1477; LAU PP, 1995, J LIPID RES, V36, P2069; LAU PP, 1991, J BIOL CHEM, V266, P20550; Lau PP, 1997, J BIOL CHEM, V272, P1452, DOI 10.1074/jbc.272.3.1452; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; Mehta A, 1998, MOL CELL BIOL, V18, P4426, DOI 10.1128/MCB.18.8.4426; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506; Oka K, 1997, J BIOL CHEM, V272, P1456, DOI 10.1074/jbc.272.39.24387; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Richardson N, 1998, J BIOL CHEM, V273, P31707, DOI 10.1074/jbc.273.48.31707; Schock D, 1996, P NATL ACAD SCI USA, V93, P1097, DOI 10.1073/pnas.93.3.1097; SHAH RR, 1991, J BIOL CHEM, V266, P16301; Siddiqui JFM, 1999, EXP CELL RES, V252, P154, DOI 10.1006/excr.1999.4598; Smith H C, 1993, Semin Cell Biol, V4, P267, DOI 10.1006/scel.1993.1032; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; Smith HC, 1997, RNA, V3, P1105; Sowden M, 1996, J BIOL CHEM, V271, P3011, DOI 10.1074/jbc.271.6.3011; Sowden M, 1996, RNA, V2, P274; Sowden MP, 1998, NUCLEIC ACIDS RES, V26, P1644, DOI 10.1093/nar/26.7.1644; Steinburg MF, 1999, BIOCHEM BIOPH RES CO, V263, P81, DOI 10.1006/bbrc.1999.1329; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Van Mater D, 1998, BIOCHEM BIOPH RES CO, V252, P334, DOI 10.1006/bbrc.1998.9647; Yamanaka S, 1996, J BIOL CHEM, V271, P11506, DOI 10.1074/jbc.271.19.11506; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; Yang Y, 1997, J BIOL CHEM, V272, P27700, DOI 10.1074/jbc.272.44.27700; Yang Y, 1997, P NATL ACAD SCI USA, V94, P13075, DOI 10.1073/pnas.94.24.13075; Yang Y, 1996, BIOCHEM BIOPH RES CO, V218, P797, DOI 10.1006/bbrc.1996.0142	42	43	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					22663	22669		10.1074/jbc.M910406199	http://dx.doi.org/10.1074/jbc.M910406199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10833526	hybrid			2022-12-25	WOS:000088419400012
J	Block, K; Kardana, A; Igarashi, P; Taylor, HS				Block, K; Kardana, A; Igarashi, P; Taylor, HS			In utero diethylstilbestrol (DES) exposure alters Hox gene expression in the developing mullerian system	FASEB JOURNAL			English	Article						genes; homeobox; teratogens; fetal development; estrogens	NUCLEAR RECEPTOR COACTIVATORS; RETINOIC ACID; ESTROGEN-RECEPTOR; SEX STEROIDS; MICE; ENDOMETRIUM; MECHANISMS; TAMOXIFEN; MUTATION; MOUSE	Diethylstilbestrol (DES) was widely used to treat pregnant women through 1971, The reproductive tracts of their female offspring exposed to DES in utero are characterized by anatomic abnormalities, Here we show that DES administered to mice in utero produces changes in the expression pattern of several Hox genes that are involved in patterning of the reproductive tract. DES produces posterior shifts in Hox gene expression and homeotic anterior transformations of the reproductive tract. In human uterine or cervical cell cultures, DES induces HOXA9 or HOXA10 gene expression, respectively, to levels approximately twofold that induced by estradiol, The DES-induced expression is not inhibited by cyclohexamide, Estrogens are novel morphogens that directly regulate the expression pattern of posterior Hox genes in a manner analogous to retinoic acid regulation of anterior Hox genes. Alterations in HOX gene expression are a molecular mechanism by which DES affects reproductive tract development. Changes in Hox gene expression are a potential marker for the effects of in utero drug use that may become apparent only at late stages of development.-Block, K., Kardana, A., Igarashi, P., Taylor, H. S. In utero diethylstilbestrol (DES) exposure alters Hox gene expression in the developing mullerian system.	Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Yale University; Yale University	Taylor, HS (corresponding author), Yale Univ, Sch Med, Dept Obstet & Gynecol, 333 Cedar St, New Haven, CT 06520 USA.			Igarashi, Peter/0000-0001-8698-1185				BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Benson GV, 1996, DEVELOPMENT, V122, P2687; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; DECHERNEY AH, 1981, FERTIL STERIL, V36, P741; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; Gendron RL, 1997, BIOL REPROD, V56, P1097, DOI 10.1095/biolreprod56.5.1097; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gradishar WJ, 1997, J CLIN ONCOL, V15, P840, DOI 10.1200/JCO.1997.15.2.840; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HSIEHLI HM, 1995, DEVELOPMENT, V121, P1373; Jordan VC, 1998, J NATL CANCER I, V90, P967, DOI 10.1093/jnci/90.13.967; KALDAS RS, 1989, REPROD TOXICOL, V3, P81, DOI 10.1016/0890-6238(89)90042-7; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; MABLY TA, 1992, TOXICOL APPL PHARM, V114, P118, DOI 10.1016/0041-008X(92)90103-Y; Manzanares M, 1997, NATURE, V387, P191, DOI 10.1038/387191a0; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MCLACHLAN JA, 1980, CANCER RES, V40, P3988; Mortlock DP, 1997, NAT GENET, V15, P179, DOI 10.1038/ng0297-179; NOLLER KL, 1974, MED CLIN N AM, V58, P739; NOMURA T, 1977, CANCER RES, V37, P1099; SATOKATA I, 1995, NATURE, V374, P46; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; Tanenbaum DM, 1998, P NATL ACAD SCI USA, V95, P5998, DOI 10.1073/pnas.95.11.5998; Taylor HS, 1998, J CLIN INVEST, V101, P1379, DOI 10.1172/JCI1057; Taylor HS, 1999, J CLIN ENDOCR METAB, V84, P1129, DOI 10.1210/jc.84.3.1129; Taylor HS, 1997, BIOL REPROD, V57, P1338, DOI 10.1095/biolreprod57.6.1338; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WALTERS LM, 1993, REPROD TOXICOL, V7, P599, DOI 10.1016/0890-6238(93)90036-7; Warot X, 1997, DEVELOPMENT, V124, P4781	34	193	203	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1101	1108		10.1096/fasebj.14.9.1101	http://dx.doi.org/10.1096/fasebj.14.9.1101			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834931				2022-12-25	WOS:000087427300006
J	Offer, T; Russo, A; Samuni, A				Offer, T; Russo, A; Samuni, A			The pro-oxidative activity of SOD and nitroxide SOD mimics	FASEB JOURNAL			English	Article						papain; hydrogen peroxide; superoxide; oxidative damage; thiol	SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; LIPID-PEROXIDATION; CU,ZN-SUPEROXIDE DISMUTASE; RADICAL PRODUCTION; TOXICITY; CELLS; H2O2; INACTIVATION; MECHANISM	Native Cu,Zn-SOD and synthetic SOD mimics sometimes demonstrate an apparently anomalous bell-shaped dose-response relationship when protecting various biological systems from oxidative stress. Several mechanisms have been proposed to account for such an effect, including: overproduction of H2O2, peroxidative activity of SOD, and opposing roles played by O-2(.-) in both initiation and termination of radical chain reactions. In the present study, ferrocyanide and thiols, which are susceptible to one-electron and two-electron oxidation, respectively, were subjected to a flux of superoxide in the presence and absence of SOD or SOD mimics. The results show that 1) either O-2(.-)/HO2. or H2O2 alone partially inactivates papain, whereas when combined they act synergistically; 2) nitroxide SOD mimics, but not SOD, exhibit a bell-shaped dose-response relationship in protecting papain from inactivation; 3) SOD, which at low dose inhibits superoxide-induced oxidation of ferrocyanide, loses its antioxidative effect as its concentration increases, These findings offer an additional explanation for the pro-oxidative activity of SOD and SOD mimics without invoking any dual activity of O-2(.-) or a combined effect of SOD and H2O2. The most significant outcome of an increase in SOD level is a decrease of [O-2(.-)](steady state), rather than any notable elevation of [H2O2](steady state). As a result, the reaction kinetics of the high oxidation state of each catalyst is altered. In the presence of ultra-low [O-2(.-)](steady state), the oxidized form of SOD [Cu(II),Zn-SOD] or SOD mimic (oxoammonium cation) does not react with O-2(.-) but rather oxidizes the target molecule that it was supposed to have protected. Consequently, these catalysts exert an anti- or pro-oxidative effect depending on their concentration.-Offer, T., Russo, A., Samuni, A. The pro-oxidative activity of SOD and nitroxide SOD mimics.	Hebrew Univ Jerusalem, Hadassah Med Sch, Fac Med, IL-91120 Jerusalem, Israel; NCI, Radiat Biol Branch, NIH, Bethesda, MD 20892 USA	Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Offer, T (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Fac Med, IL-91120 Jerusalem, Israel.							ARMSTRONG DA, 1978, PHOTOCHEM PHOTOBIOL, V28, P743, DOI 10.1111/j.1751-1097.1978.tb07011.x; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BERNIER M, 1989, AM J PHYSIOL, V256, pH1344, DOI 10.1152/ajpheart.1989.256.5.H1344; BEYER WF, 1991, ARCH BIOCHEM BIOPHYS, V285, P60, DOI 10.1016/0003-9861(91)90328-G; BLOUGH NV, 1988, ENVIRON SCI TECHNOL, V22, P77, DOI 10.1021/es00166a008; DEGRAFF WG, 1992, ENVIRON MOL MUTAGEN, V19, P21, DOI 10.1002/em.2850190105; ELROYSTEIN O, 1986, EMBO J, V5, P615, DOI 10.1002/j.1460-2075.1986.tb04255.x; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; GALLEZ B, 1992, TOXICOL LETT, V63, P35, DOI 10.1016/0378-4274(92)90105-S; Gariboldi MB, 1998, FREE RADICAL BIO MED, V24, P913, DOI 10.1016/S0891-5849(97)00372-9; Goss SPA, 1999, J BIOL CHEM, V274, P28233, DOI 10.1074/jbc.274.40.28233; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; ISHII T, 1991, FREE RADICAL RES COM, V14, P187, DOI 10.3109/10715769109088948; Jewett SL, 1999, FREE RADICAL BIO MED, V26, P905, DOI 10.1016/S0891-5849(98)00274-3; KEDZIORA J, 1988, FREE RADICAL BIO MED, V4, P317, DOI 10.1016/0891-5849(88)90052-4; KRISHNA MC, 1992, P NATL ACAD SCI USA, V89, P5537, DOI 10.1073/pnas.89.12.5537; Krishna MC, 1996, J BIOL CHEM, V271, P26018, DOI 10.1074/jbc.271.42.26018; LIN WS, 1975, RADIAT RES, V62, P438, DOI 10.2307/3574138; Liochev SI, 1997, ARCH BIOCHEM BIOPHYS, V346, P263, DOI 10.1006/abbi.1997.0298; LIOCHEV SI, 1992, ARCH BIOCHEM BIOPHYS, V294, P138, DOI 10.1016/0003-9861(92)90147-O; MAO GD, 1993, J BIOL CHEM, V268, P416; MCCORD JM, 1995, P SOC EXP BIOL MED, V209, P112; MCCORD JM, 1998, OXIDAT STRESS DIS, V1, P1; Meara JP, 1996, J MED CHEM, V39, P3357, DOI 10.1021/jm950445b; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; MIURA Y, 1995, FREE RADICAL RES, V22, P209, DOI 10.3109/10715769509147540; Monti E, 1996, FREE RADICAL BIO MED, V21, P463, DOI 10.1016/0891-5849(96)00124-4; Muller A, 1997, EXP EYE RES, V64, P637, DOI 10.1006/exer.1996.0277; NELSON SK, 1994, FREE RADICAL BIO MED, V16, P195, DOI 10.1016/0891-5849(94)90143-0; NILSSON UA, 1989, J BIOL CHEM, V264, P11131; NORRIS KH, 1990, MUTAT RES, V237, P95, DOI 10.1016/0921-8734(90)90015-J; Offer T, 1998, FREE RADICAL BIO MED, V25, P832, DOI 10.1016/S0891-5849(98)00162-2; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P465, DOI 10.1016/0891-5849(90)90123-Z; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P473, DOI 10.1016/0891-5849(90)90124-2; RACHMILEWITZ D, 1994, GUT, V35, P1181, DOI 10.1136/gut.35.9.1181; ROTILIO G, 1973, BIOCHIM BIOPHYS ACTA, V302, P229, DOI 10.1016/0005-2744(73)90151-4; SAMUNI A, 1991, BIOCHEMISTRY-US, V30, P555, DOI 10.1021/bi00216a033; SAMUNI A, 1988, J BIOL CHEM, V263, P17921; SAMUNI A, 1991, J CLIN INVEST, V87, P1526, DOI 10.1172/JCI115163; Sankarapandi S, 1999, J BIOL CHEM, V274, P34576, DOI 10.1074/jbc.274.49.34576; SCOTT MD, 1989, J BIOL CHEM, V264, P2498; SCOTT MD, 1987, J BIOL CHEM, V262, P3640; SEIS H, 1986, ARCH BIOCHEM BIOPHYS, V251, P393; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; SLEDZINSKI Z, 1995, INT J PANCREATOL, V18, P153; Subramainam R, 1996, BIOCHEM ARCH, V12, P105; VAIDYANATHAN VV, 1993, MOL CELL BIOCHEM, V129, P57, DOI 10.1007/BF00926576; VOEST EE, 1992, BIOCHIM BIOPHYS ACTA, V1136, P113, DOI 10.1016/0167-4889(92)90245-7; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006	50	95	101	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2000	14	9					1215	1223		10.1096/fasebj.14.9.1215	http://dx.doi.org/10.1096/fasebj.14.9.1215			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834943				2022-12-25	WOS:000087427300018
J	Behrens, A; Jochum, W; Sibilia, M; Wagner, EF				Behrens, A; Jochum, W; Sibilia, M; Wagner, EF			Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation	ONCOGENE			English	Article						C-Jun N-terminal phosphorylation; tumorigenesis; Ras; Fos; Src	CELL-CYCLE PROGRESSION; NUCLEOTIDE EXCHANGE FACTOR; EMBRYONAL CARCINOMA-CELLS; TRANSGENIC MICE; HA-RAS; ACTIVATION DOMAIN; PROTEIN; MOUSE; AP-1; EXPRESSION	The nuclear phosphoprotein c-Jun is a major component of the AP-1 transcription factor, whose activity is augmented by many oncogenes, An important mechanism to stimulate AP-1 function is N-terminal phosphorylation of c-Jun at the serine residues 63 and 73 by the c-Jun N-terminal kinases (JNKs), Mice and cells harboring a mutant allele of c-jun, which has the JNK phosphoacceptor serines changed to alanines (junAA), were used to determine the function of c-Jun N-terminal phosphorylation (JNP) during oncogenic transformation in vitro and ill ripe. JunAA immortalized fibroblasts expressing v-ras and v-fos showed reduced tumorigenicity in nude mice, but the efficiency of v-src transformation was unaffected by the lack of JNP. To assess the significance of JNP in tumour development in vivo, two transgenic mouse tumour models were employed. Skin tumour development caused by constitutive activation of the ras pathway by KS-SOS-P expression and c-fos-induced osteosarcoma formation were impaired in mice lacking JNP. Inhibition of JNP may, therefore, be a novel therapeutic strategy to inhibit tumour growth in vivo.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Wagner, EF (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.			Sibilia, Maria/0000-0001-6129-5613; Behrens, Axel/0000-0002-1557-1143; Wagner, Erwin F/0000-0001-7872-0196				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Bannister AJ, 1995, ONCOGENE, V11, P2509; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOULTER CA, 1988, ONCOGENE, V2, P207; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Pompetti F, 1996, J CELL BIOCHEM, V63, P37; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; REDMOND SMS, 1988, ONCOGENE, V2, P259; Rutberg SE, 1996, ONCOGENE, V13, P167; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SIBILIA M, 2000, UNPUB; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TODARO GJ, 1965, J CELL COMPAR PHYSL, V66, P325, DOI 10.1002/jcp.1030660310; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VOGT PK, 1992, CANCER, V69, P2610, DOI 10.1002/1097-0142(19920515)69:10<2610::AID-CNCR2820691035>3.0.CO;2-J; WAGNER EF, 1985, EMBO J, V4, P663, DOI 10.1002/j.1460-2075.1985.tb03680.x; WANG ZQ, 1995, CANCER RES, V55, P6244; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	40	167	173	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 18	2000	19	22					2657	2663		10.1038/sj.onc.1203603	http://dx.doi.org/10.1038/sj.onc.1203603			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	316XH	10851065				2022-12-25	WOS:000087193000001
J	Jensen, AA; Spalding, TA; Burstein, ES; Sheppard, PO; O'Hara, PJ; Brann, MR; Krogsgaard-Larsen, P; Brauner-Osborne, H				Jensen, AA; Spalding, TA; Burstein, ES; Sheppard, PO; O'Hara, PJ; Brann, MR; Krogsgaard-Larsen, P; Brauner-Osborne, H			Functional importance of the Ala(116)-Pro(136) region in the calcium-sensing receptor - Constitutive activity and inverse agonism in a family C G-protein-coupled receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; RANDOM SATURATION MUTAGENESIS; HUMAN CA2+ RECEPTOR; CA2+-SENSING RECEPTOR; MUSCARINIC RECEPTOR; EXTRACELLULAR DOMAIN; TERMINAL DOMAIN; LIGAND-BINDING; SPORADIC HYPOPARATHYROIDISM; ACTIVATING MUTATIONS	The calcium-sensing receptor (CaR) belongs to family C of the G-protein-coupled receptor superfamily. To date 14 activating mutations in Call showing increased sensitivity to Ca2+ have been identified in humans with autosomal dominant hypocalcemia. Four of these activating mutations are found in the Ala(116)-Pro(136) region of CaR, indicating that this part of the receptor is particularly sensitive to mutation-induced activation. This region was subjected to random saturation mutagenesis, and 219 mutant receptor clones were isolated and screened pharmacologically in a high throughput screening assay. Selected mutants were characterized further in an inositol phosphate assay. The vast majority of the mutants tested displayed an increased affinity for Ca2+. Furthermore, 21 of the mutants showed increased basal activity in the absence of agonist. This constitutive activity was not diminished when the mutations were transferred to a chimeric receptor Ca/la consisting of the amino-terminal domain of the CaR and the 7 transmembrane and intracellular domains of the metabotropic glutamate receptor mGluR1a. CPCCOEt, a noncompetitive antagonist acting at the 7 transmembrane domain of mGluR1a, suppressed the elevated basal response of the constitutively activated Calla mutants demonstrating inverse agonist activity of CPCCOEt Taken together, our results demonstrate that the Ala(116)-Pro(136) region is of key importance for the maintenance of the inactive conformation of CaR.	Royal Danish Sch Pharm, Dept Med Chem, NauroSci PharmaBiotec Res Ctr, DK-2100 Copenhagen, Denmark; ACADIA Pharmaceut Inc, San Diego, CA 92121 USA; ZymoGenet Inc, Seattle, WA 98102 USA	Royal Danish School of Pharmacy; Zymogenet Inc.	Brauner-Osborne, H (corresponding author), Royal Danish Sch Pharm, Dept Med Chem, NauroSci PharmaBiotec Res Ctr, 2 Univ Pk, DK-2100 Copenhagen, Denmark.	hbo@dfh.dk	Jensen, Anders/AAJ-3335-2020; Bräuner-Osborne, Hans/D-7260-2011	Jensen, Anders/0000-0002-7927-5052; Bräuner-Osborne, Hans/0000-0001-9495-7388				Annoura H, 1996, BIOORG MED CHEM LETT, V6, P763, DOI 10.1016/0960-894X(96)00104-7; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Baron J, 1996, HUM MOL GENET, V5, P601, DOI 10.1093/hmg/5.5.601; BRAESTRUP C, 1982, SCIENCE, V216, P1241, DOI 10.1126/science.6281892; Brauner-Osborne H, 1996, EUR J PHARMACOL, V295, P93, DOI 10.1016/0014-2999(95)00639-7; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; Brauner-Osborne H, 1999, NEUROREPORT, V10, P3923; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1999, AM J MED, V106, P238, DOI 10.1016/S0002-9343(98)00418-5; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; CHAHINE M, 1994, PFLUG ARCH EUR J PHY, V427, P136, DOI 10.1007/BF00585952; Chikatsu N, 1999, CLIN ENDOCRINOL, V50, P537, DOI 10.1046/j.1365-2265.1999.00729.x; Collins MT, 1998, J CLIN ENDOCR METAB, V83, P1083, DOI 10.1210/jc.83.4.1083; DeLuca F, 1997, J CLIN ENDOCR METAB, V82, P2710, DOI 10.1210/jc.82.8.2710; Fan GF, 1998, FEBS LETT, V436, P353, DOI 10.1016/S0014-5793(98)01165-X; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Gama L, 1998, J BIOL CHEM, V273, P29712, DOI 10.1074/jbc.273.45.29712; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; Hammerland LG, 1998, MOL PHARMACOL, V53, P1083; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Kobayashi M, 1997, J CLIN ENDOCR METAB, V82, P2716, DOI 10.1210/jc.82.8.2716; Kolczewski S, 1999, BIOORG MED CHEM LETT, V9, P2173, DOI 10.1016/S0960-894X(99)00346-7; LIM K, 1989, BIOTECHNIQUES, V7, P576; Litschig S, 1999, MOL PHARMACOL, V55, P453; Malitschek B, 1999, MOL PHARMACOL, V56, P448, DOI 10.1124/mol.56.2.448; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Mohler H, 1999, Trends Pharmacol Sci, V20, P87, DOI 10.1016/S0165-6147(99)01323-1; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Okzaki R, 1999, J CLIN ENDOCR METAB, V84, P363; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505; Pin JP, 1999, EUR J PHARMACOL, V375, P277, DOI 10.1016/S0014-2999(99)00258-7; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Silverberg SJ, 1997, NEW ENGL J MED, V337, P1506, DOI 10.1056/NEJM199711203372104; Spalding TA, 1997, BIOCHEMISTRY-US, V36, P10109, DOI 10.1021/bi970565g; Spalding TA, 1998, J BIOL CHEM, V273, P21563, DOI 10.1074/jbc.273.34.21563; Spalding TA, 1995, J PHARMACOL EXP THER, V275, P1274; Tirindelli R, 1998, TRENDS NEUROSCI, V21, P482, DOI 10.1016/S0166-2236(98)01274-0; Varney MA, 1999, J PHARMACOL EXP THER, V290, P170; Ward BK, 1997, HUM MUTAT, V10, P233; Watanabe T, 1998, J CLIN ENDOCR METAB, V83, P2497, DOI 10.1210/jc.83.7.2497; Wichmann J, 1999, BIOORG MED CHEM LETT, V9, P1573, DOI 10.1016/S0960-894X(99)00227-9; Zhao XM, 1999, FEBS LETT, V448, P180, DOI 10.1016/S0014-5793(99)00368-3	53	55	59	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29547	29555		10.1074/jbc.M910023199	http://dx.doi.org/10.1074/jbc.M910023199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10835431	Green Submitted, hybrid			2022-12-25	WOS:000089439800050
J	Mattatall, NR; Jazairi, J; Hill, BC				Mattatall, NR; Jazairi, J; Hill, BC			Characterization of ypmQ, an accessory protein required for the expression of cytochrome c oxidase in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; COPPER TRANSPORT; SUPEROXIDE-DISMUTASE; TERMINAL OXIDASES; PLASMA-MEMBRANES; QUINOL OXIDASE; YEAST; GENE; CLONING; CHAPERONE	A search of the Bacillus subtilis genome identifies a potential homolog, ypmQ, of the inner mitochondrial membrane protein Sco1 from yeast, Sco1 has been found to aid the delivery of copper to cytochrome c oxidase, B. subtilis expresses two members of the cytochrome oxidase family, a cytochrome c oxidase that has two copper centers, Cu-A and Cu-B, and a menaquinol oxidase that has only Cu-B. Deletion of ypmQ in B. subtilis depresses expression of cytochrome c oxidase but not menaquinol oxidase, Level of cytochrome c oxidase recover when copper is added to the growth medium of the Delta ypmQ strain or when ypmQ is expressed from a plasmid, Neither treatment affects the amount or activity of menaquinol oxidase. YpmQ in which two conserved cysteines are replaced by serines and a conserved histidine is replaced by alanine do not complement the deletion of ypmQ even though these mutant forms are found in the membrane extract at a level similar to the wild type protein. Fire propose that the two cysteines and the histidine are critical for the function of YpmQ and suggest they are involved in copper exchange between YpmQ and the Cu-A site of cytochrome c oxidase.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Hill, BC (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; BLACKBURN NJ, 1994, BIOCHEMISTRY-US, V33, P10401, DOI 10.1021/bi00200a022; BOLIVAR F, 1977, GENE, V2, P75, DOI 10.1016/0378-1119(77)90074-9; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DAVID PS, 1998, THESIS QUEENS U KING; GENNIS RB, 1993, BIOCHEM SOC T, V21, P992, DOI 10.1042/bst0210992; GLASER P, 1993, MOL MICROBIOL, V10, P371, DOI 10.1111/j.1365-2958.1993.tb01963.x; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; HAIMA P, 1987, MOL GEN GENET, V209, P335, DOI 10.1007/BF00329663; HENNING W, 1995, BIOCHEM J, V309, P279, DOI 10.1042/bj3090279; HILL BC, 1993, ARCH BIOCHEM BIOPHYS, V301, P129, DOI 10.1006/abbi.1993.1124; Hill BC, 1996, BIOCHEMISTRY-US, V35, P6136, DOI 10.1021/bi952486f; HILL BC, 1993, J BIOENERG BIOMEMBR, V25, P115, DOI 10.1007/BF00762853; HILL BC, 1991, J BIOL CHEM, V266, P2219; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; Hunter DJB, 1997, FEBS LETT, V412, P43, DOI 10.1016/S0014-5793(97)00735-7; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; LAURAEUS M, 1991, EUR J BIOCHEM, V197, P699, DOI 10.1111/j.1432-1033.1991.tb15961.x; Michel H, 1998, ANNU REV BIOPH BIOM, V27, P329, DOI 10.1146/annurev.biophys.27.1.329; MILLETT F, 1983, BIOCHEMISTRY-US, V22, P546, DOI 10.1021/bi00272a004; MUELLER JP, 1989, J BACTERIOL, V171, P4967, DOI 10.1128/jb.171.9.4967-4978.1989; Papadopoulou LC, 1999, NAT GENET, V23, P333; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; Roberts VA, 1999, J BIOL CHEM, V274, P38051, DOI 10.1074/jbc.274.53.38051; ROBINSON NC, 1980, BIOCHEMISTRY-US, V19, P3656, DOI 10.1021/bi00557a003; SANTANA M, 1992, J BIOL CHEM, V267, P10225; Schmidt PJ, 1999, J BIOL CHEM, V274, P36952, DOI 10.1074/jbc.274.52.36952; SCHULZE M, 1988, MOL GEN GENET, V211, P492, DOI 10.1007/BF00425706; Siegal ML, 1996, BIOTECHNIQUES, V21, P614; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; STEINMETZ M, 1994, GENE, V142, P79, DOI 10.1016/0378-1119(94)90358-1; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; TAHA TSM, 1992, BIOCHEMISTRY-US, V31, P9090, DOI 10.1021/bi00152a053; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; VILLANI G, 1995, BBA-BIOENERGETICS, V1232, P67, DOI 10.1016/0005-2728(95)00112-5; Wang LH, 1999, J BIOL CHEM, V274, P19246, DOI 10.1074/jbc.274.27.19246; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; Zhen YJ, 1999, J BIOL CHEM, V274, P38032, DOI 10.1074/jbc.274.53.38032	48	83	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28802	28809		10.1074/jbc.M002741200	http://dx.doi.org/10.1074/jbc.M002741200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10837475	hybrid			2022-12-25	WOS:000089330700062
J	Evans, RL; Park, K; Turner, RJ; Watson, GE; Nguyen, HV; Dennett, MR; Hand, AR; Flagella, M; Shull, GE; Melvin, JE				Evans, RL; Park, K; Turner, RJ; Watson, GE; Nguyen, HV; Dennett, MR; Hand, AR; Flagella, M; Shull, GE; Melvin, JE			Severe impairment of salivation in Na+/K+/2Cl(-) cotransporter (NKCC1)-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; NHE3 NA+/H+ EXCHANGER; NA+-K+-2CL(-) COTRANSPORTER; FLUID SECRETION; UP-REGULATION; MUSCARINIC STIMULATION; MOLECULAR-CLONING; CHROMOSOMAL LOCALIZATION; TARGETED DISRUPTION; CL COTRANSPORTER	The salivary fluid secretory mechanism is thought to require Na+/K+/2Cl(-) cotransporter-mediated Cl- uptake. To directly test this possibility we studied the in vivo and in vitro functioning of acinar cells from the parotid glands of mice with targeted disruption of Na+/R+/2Cl(-) cotransporter isoform 1 (Nkcc1), the gene encoding the salivary Na+/K+/2Cl(-) cotransporter. In wildtype mice NKCC1 was localized to the basolateral membranes of parotid acinar cells, whereas expression was not detected in duct cells. The lack of functional NKCC1 resulted in a dramatic reduction (>60%) in the volume of saliva secreted in response to a muscarinic agonist, the primary in situ salivation signal, Consistent with defective Cl- uptake, a loss of bumetanide-sensitive Cl- influx was observed in parotid acinar cells from mice lacking NKCC1. Cl-/HCO3- exchanger activity was increased in parotid acinar cells isolated from knockout mice suggesting that the residual saliva secreted by mice lacking NKCC1 is associated with anion exchanger-dependent Cl- uptake. Indeed, expression of the Cl-/HCO3- exchanger AE2 was enhanced suggesting that this transporter compensates for the loss of functional Na+/K+/2Cl(-) cotransporter. Furthermore, the ability of the parotid gland to conserve NaCl was abolished in NKCC1-deficient mice. This deficit was not associated with changes in the morphology of the ducts, but transcript levels for the alpha-, beta-, and gamma-subunits of the epithelial Na+ channel were reduced. These data directly demonstrate that NKCC1 is the major Cl- uptake mechanism across the basolateral membrane of acinar cells and is critical for driving saliva secretion in vivo.	Univ Rochester, Med Ctr, Ctr Oral Biol, Aab Inst Biomed Sci, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Eastman Dept Dent, Rochester, NY 14642 USA; NIDCR, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA; Univ Connecticut, Dept Pediat Dent, Farmington, CT 06030 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University of Rochester; University of Rochester; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Connecticut; University System of Ohio; University of Cincinnati	Melvin, JE (corresponding author), Univ Rochester, Med Ctr, Ctr Oral Biol, Aab Inst Biomed Sci, Box 611,601 Elmwood Ave, Rochester, NY 14642 USA.			Watson, Gene/0000-0002-3397-1116	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008921, Z01DE000415, ZIADE000415, P01DE013539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK050594, R01DK050594] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE08921, DE13539] Funding Source: Medline; NIDDK NIH HHS [DK50594] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARREOLA J, 1996, J GEN PHYSIOL, V108, P1; Bell SM, 1999, AM J PHYSIOL-CELL PH, V276, pC788, DOI 10.1152/ajpcell.1999.276.4.C788; CASE RM, 1984, J PHYSIOL-LONDON, V349, P619, DOI 10.1113/jphysiol.1984.sp015177; Cook D. I., 1994, P1061; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; Delpire E, 1999, NAT GENET, V22, P192, DOI 10.1038/9713; DINUDOM A, 1993, PFLUG ARCH EUR J PHY, V423, P164, DOI 10.1007/BF00374977; Evans RL, 1999, J BIOL CHEM, V274, P29025, DOI 10.1074/jbc.274.41.29025; Evans RL, 1997, J PHYSIOL-LONDON, V499, P351, DOI 10.1113/jphysiol.1997.sp021932; Field EA, 1997, BRIT J ORAL MAX SURG, V35, P96, DOI 10.1016/S0266-4356(97)90683-5; Flagella M, 1999, J BIOL CHEM, V274, P26946, DOI 10.1074/jbc.274.38.26946; FOSKETT JK, 1990, AM J PHYSIOL, V259, pC998; FOX PC, 1985, J AM DENT ASSOC, V110, P519, DOI 10.14219/jada.archive.1985.0384; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Haas M, 1998, J BIOENERG BIOMEMBR, V30, P161, DOI 10.1023/A:1020521308985; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Hayashi T, 1996, J MEMBRANE BIOL, V152, P253, DOI 10.1007/s002329900103; He XJ, 1997, PFLUG ARCH EUR J PHY, V433, P260; Kurihara K, 1999, AM J PHYSIOL-CELL PH, V277, pC1184, DOI 10.1152/ajpcell.1999.277.6.C1184; LAU KR, 1989, AM J PHYSIOL, V256, pC288, DOI 10.1152/ajpcell.1989.256.2.C288; LAU KR, 1990, J PHYSIOL-LONDON, V425, P407, DOI 10.1113/jphysiol.1990.sp018111; Lee MG, 1998, J PHYSIOL-LONDON, V513, P341, DOI 10.1111/j.1469-7793.1998.341bb.x; Lee MG, 1999, J BIOL CHEM, V274, P14670, DOI 10.1074/jbc.274.21.14670; Longman L P, 1995, Gerodontology, V12, P67, DOI 10.1111/j.1741-2358.1995.tb00133.x; MANDEL ID, 1989, J AM DENT ASSOC, V119, P298, DOI 10.14219/jada.archive.1989.0211; MANGANEL M, 1990, J BIOL CHEM, V265, P4284; Mastroianni N, 1996, GENOMICS, V35, P486, DOI 10.1006/geno.1996.0388; MELVIN JE, 1988, J BIOL CHEM, V263, P19564; Melvin JE, 1999, J BIOL CHEM, V274, P22855, DOI 10.1074/jbc.274.32.22855; MELVIN JE, 1992, AM J PHYSIOL, V262, pG393, DOI 10.1152/ajpgi.1992.262.3.G393; MELVIN JE, 1987, BIOCHEM BIOPH RES CO, V145, P754, DOI 10.1016/0006-291X(87)91029-1; Moore-Hoon ML, 1998, BBA-BIOMEMBRANES, V1373, P261, DOI 10.1016/S0005-2736(98)00112-6; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Mount DB, 1998, J EXP BIOL, V201, P2091; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; NAUNTOFTE B, 1986, AM J PHYSIOL, V251, pC175, DOI 10.1152/ajpcell.1986.251.2.C175; NOVAK I, 1986, PFLUG ARCH EUR J PHY, V407, P649, DOI 10.1007/BF00582647; Park K, 1999, AM J PHYSIOL-GASTR L, V276, pG470, DOI 10.1152/ajpgi.1999.276.2.G470; PAULAIS M, 1994, AM J PHYSIOL, V266, pC1594, DOI 10.1152/ajpcell.1994.266.6.C1594; PAULAIS M, 1992, J CLIN INVEST, V89, P1142, DOI 10.1172/JCI115695; Paulais M, 1996, AM J PHYSIOL-GASTR L, V270, pG213, DOI 10.1152/ajpgi.1996.270.1.G213; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; Schultheis PJ, 1998, J BIOL CHEM, V273, P29150, DOI 10.1074/jbc.273.44.29150; TABAK LA, 1982, J ORAL PATHOL MED, V11, P1, DOI 10.1111/j.1600-0714.1982.tb00138.x; ZHANG GH, 1992, J MEMBRANE BIOL, V129, P311; ZHAO H, 1995, J BIOL CHEM, V270, P19599, DOI 10.1074/jbc.270.33.19599	48	141	146	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26720	26726						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10831596				2022-12-25	WOS:000089144800009
J	Barok, Z; Li, X; Fernandes, VFJ; Zhou, B; Ann, DK; Crandall, ED				Barok, Z; Li, X; Fernandes, VFJ; Zhou, B; Ann, DK; Crandall, ED			Differential regulation of rat aquaporin-5 promoter/enhancer activities in lung and salivary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-I; SURFACTANT PROTEIN-C; GENE-EXPRESSION; ALTERNATIVE PROMOTERS; MONOCLONAL-ANTIBODIES; WATER CHANNELS; CLONING; T1-ALPHA; CULTURE; TISSUES	Aquaporin-5 (AQP5) is a water channel protein that is selectively expressed in respiratory, salivary, and lacrimal tissues. In order to establish the tissue-specific transcriptional programs that underlie its lung and salivary-specific expression, a 4,5-kilobase pair DNA fragment encompassing the 5'-flanking region of the rat AQP5 gene has been characterized in detail. A major transcription start site utilized in lung and salivary glands has been localized downstream of a TATAA-like motif, Transient transfection assays of -4,3- and -1.7-AQP5-luciferase constructs in AQP5-expressing lung (MLE-15) and salivary (Pa-4) cells and nonexpressing fibroblast (NIH3T3) and epithelial (HeLa) cells demonstrate preferential transcriptional enhancement of reporter activities in MLE-15 and Pa-4 cells. Transient transfection assays of a series of 5' -> 3' deletion constructs of -4.3-AQP5-luciferase suggest that a common salivary and lung enhancer is located between nucleotides -274 and -139, and a lung-specific enhancer is located between nucleotides -894 and -710. There is one putative lung-specific repressor located in the region of nucleotides -1003/-894 and a common lung and salivary repressor located at nucleotides -503/-385, Moreover, 3' -> 5' deletions up to -171 and -127 base pairs almost abolish transcriptional activation in salivary and lung cells, respectively. Together, our findings indicate that the combination of enhancer/repressor elements within the proximal 5'-flankinng region of rat AQP5 gene dictates its restricted expression in both lung and salivary cells.	Univ So Calif, Div Pulm & Crit Care Med, Dept Med, Los Angeles, CA 90033 USA; Univ So Calif, Dept Mol Pharmacol & Toxicol, Will Rogers Inst Pulm Res Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Los Angeles, CA 90033 USA; Univ So Calif, Sch Pharm, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California	Barok, Z (corresponding author), Univ So Calif, Div Pulm & Crit Care Med, Dept Med, GNH 11-900,2025 Zonal Ave, Los Angeles, CA 90033 USA.	zborok@hsc.usc.edu	CRANDALL, EDWARD/AAD-8382-2020	Borok, Zea/0000-0001-8673-8177	NHLBI NIH HHS [HL38621, HL38578] Funding Source: Medline; NIDCR NIH HHS [DE 10742] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL038578, R01HL038621, R01HL038578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADAMSON IYR, 1974, LAB INVEST, V30, P35; Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; Bachurski CJ, 1997, J BIOL CHEM, V272, P32759, DOI 10.1074/jbc.272.52.32759; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Borok Z, 1998, AM J RESP CELL MOL, V18, P554, DOI 10.1165/ajrcmb.18.4.2838; Borok Z, 1998, AM J PHYSIOL-LUNG C, V275, pL155, DOI 10.1152/ajplung.1998.275.1.L155; BOROK Z, 1994, IN VITRO CELL DEV-AN, V30A, P99; BROWN D, 1995, HISTOCHEM CELL BIOL, V104, P1, DOI 10.1007/BF01464780; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CHEEK JM, 1989, EXP CELL RES, V184, P375, DOI 10.1016/0014-4827(89)90337-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANTO SI, 1992, AM J RESP CELL MOL, V6, P296, DOI 10.1165/ajrcmb/6.3.296; DANTO SI, 1995, AM J RESP CELL MOL, V12, P497, DOI 10.1165/ajrcmb.12.5.7742013; DIGLIO CA, 1977, LAB INVEST, V37, P622; DOBBS LG, 1988, BIOCHIM BIOPHYS ACTA, V970, P146, DOI 10.1016/0167-4889(88)90173-5; Dobbs LG, 1998, P NATL ACAD SCI USA, V95, P2991, DOI 10.1073/pnas.95.6.2991; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; EVANS MJ, 1975, EXP MOL PATHOL, V22, P142, DOI 10.1016/0014-4800(75)90059-3; Funaki H, 1998, AM J PHYSIOL-CELL PH, V275, pC1151, DOI 10.1152/ajpcell.1998.275.4.C1151; HAMMAN S, 1998, AM J PHYSIOL, V274, pC1332; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; HUANG TH, 1994, AM J RESP CELL MOL, V10, P192, DOI 10.1165/ajrcmb.10.2.7509163; INASE N, 1995, J BIOL CHEM, V270, P17913, DOI 10.1074/jbc.270.30.17913; KALINA M, 1992, AM J RESP CELL MOL, V6, P594, DOI 10.1165/ajrcmb/6.6.594; KIKKAWA Y, 1975, LAB INVEST, V32, P295; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.ph.58.030196.003155; King LS, 1997, AM J PHYSIOL-CELL PH, V273, pC1541, DOI 10.1152/ajpcell.1997.273.5.C1541; Koyama N, 1999, AM J RESP CRIT CARE, V159, pA293; Krane CM, 1999, MAMM GENOME, V10, P498, DOI 10.1007/s003359901030; Lee MD, 1996, J BIOL CHEM, V271, P8599, DOI 10.1074/jbc.271.15.8599; MASON RJ, 1985, AM REV RESPIR DIS, V131, P786; MASON RJ, 1997, LUNG SCI FDN, P543; Matsuzaki T, 1999, CELL TISSUE RES, V295, P513, DOI 10.1007/s004410051257; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rai T, 1997, AM J PHYSIOL-RENAL, V273, pF264, DOI 10.1152/ajprenal.1997.273.2.F264; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; Ramirez MI, 1997, J BIOL CHEM, V272, P26285, DOI 10.1074/jbc.272.42.26285; Ramirez MI, 1999, DEV DYNAM, V215, P319, DOI 10.1002/(SICI)1097-0177(199908)215:4<319::AID-AJA4>3.0.CO;2-B; REYNOLDS GA, 1985, J BIOL CHEM, V260, P369; RISHI AK, 1995, DEV BIOL, V167, P294, DOI 10.1006/dbio.1995.1024; Schneeberger EE., 1997, LUNG SCI FDN, V2, P535; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHANNON JM, 1992, AM J PHYSIOL, V262, pL427, DOI 10.1152/ajplung.1992.262.4.L427; Smith JK, 1999, J INTERF CYTOK RES, V19, P929, DOI 10.1089/107999099313479; Toonen RFG, 1996, BIOCHEM J, V316, P467, DOI 10.1042/bj3160467; Umenishi F, 1996, DNA CELL BIOL, V15, P475, DOI 10.1089/dna.1996.15.475; Umenishi F, 1998, GENOMICS, V47, P341, DOI 10.1006/geno.1997.5125; Umenishi F, 1996, AM J RESP CELL MOL, V15, P673, DOI 10.1165/ajrcmb.15.5.8918374; Umenishi F, 1998, GENOMICS, V50, P373, DOI 10.1006/geno.1998.5337; Vanderbilt JN, 1998, AM J RESP CELL MOL, V19, P662, DOI 10.1165/ajrcmb.19.4.3121; Verkman AS, 1998, AM J MED SCI, V316, P310, DOI 10.1097/00000441-199811000-00004; Whitsett JA, 1998, BBA-MOL BASIS DIS, V1408, P303, DOI 10.1016/S0925-4439(98)00076-3	54	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26507	26514		10.1074/jbc.M910007199	http://dx.doi.org/10.1074/jbc.M910007199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10849430	hybrid			2022-12-25	WOS:000088999700086
J	Smolenski, A; Poller, W; Walter, U; Lohmann, SM				Smolenski, A; Poller, W; Walter, U; Lohmann, SM			Regulation of human endothelial cell focal adhesion sites and migration by cGMP-dependent protein kinase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; VASCULAR SMOOTH-MUSCLE; ACTIN-BASED MOTILITY; TRANSMEMBRANE CONDUCTANCE REGULATOR; LIGHT-CHAIN PHOSPHATASE; INTACT HUMAN PLATELETS; LISTERIA-MONOCYTOGENES; CYCLIC-AMP; ELEVATING VASODILATORS; MYOSIN PHOSPHATASE	cGMP-dependent protein kinase type I (cGK I), a major constituent of the atrial natriuretic peptide (ANP)/nitric oxide/cGMP signal transduction pathway, phosphorylates the vasodilator-stimulated phosphoprotein (VASP), a member of the Ena/VASP family of proteins involved in regulation of the actin cytoskeleton. Here we demonstrate that stimulation of human umbilical vein endothelial cells (HUVECs) by both ANP and 8-(4-chlorophenylthio)guanosine 3':5'-monophosphate (8-pCPT-cGMP) activates transfected cGK I and causes detachment of VASP and its known binding partner (zyxin) from focal adhesions in >60% of cells after 30 min. The ANP effects, but not the 8-pCPT-cGMP effects, reversed after 3 h of treatment. In contrast, a catalytically inactive cGK I beta mutant (cGK I beta-K405A) was incapable of mediating these effects. VASP mutated (Ser/Thr to Ala) at all three of its established phosphorylation sites (vesicular stomatitis virus-tagged VASP-AAA mutant) was not phosphorylated by cGK I and was resistant to detaching from HUVEC focal adhesions in response to 8-pCPT-cGMP. Furthermore, activation of cGK I, but not of mutant cGK I beta-K405A, caused a 1.5-2-fold inhibition of HUVEC migration, a dynamic process highly dependent on focal adhesion formation and disassembly. These results indicate that cGK I phosphorylation of VASP results in loss of VASP and zyxin from focal adhesions, a response that could contribute to cGK alteration of cytoskeleton-regulated processes such as cell migration.	Univ Wurzburg, Med Klin, Inst Klin Biochem & Pathobiochem, D-97080 Wurzburg, Germany	University of Wurzburg	Lohmann, SM (corresponding author), Univ Wurzburg, Med Klin, Inst Klin Biochem & Pathobiochem, Josef Schneider Str 2, D-97080 Wurzburg, Germany.	slohmann@klin-biochem.uni-wuerzburg.de	Walter, ulrich/W-2478-2017; Poller, Wolfgang/AAB-2185-2021	Walter, ulrich/0000-0001-6784-2307; Poller, Wolfgang/0000-0002-2805-6634; Smolenski, Albert/0000-0001-9210-9406				Abel Kathrin, 1996, European Journal of Cell Biology, V69, P39; Ahern-Djamali SM, 1998, MOL BIOL CELL, V9, P2157, DOI 10.1091/mbc.9.8.2157; Aszodi A, 1999, EMBO J, V18, P37, DOI 10.1093/emboj/18.1.37; Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Boerth NJ, 1997, J VASC RES, V34, P245, DOI 10.1159/000159231; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; BUTT E, 1994, J BIOL CHEM, V269, P14509; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; Chen LH, 1998, CIRC RES, V82, P862; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; Comer AR, 1998, MOL CELL BIOL, V18, P152, DOI 10.1128/MCB.18.1.152; DRAIJER R, 1995, CIRC RES, V76, P199, DOI 10.1161/01.RES.76.2.199; DRAIJER R, 1995, CIRC RES, V77, P897, DOI 10.1161/01.RES.77.5.897; EIGENTHALER M, 1993, J BIOL CHEM, V268, P13526; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GLUCK U, 1994, J CELL SCI, V107, P1773; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; HALBRUGGE M, 1990, J BIOL CHEM, V265, P3088; Han JD, 1996, J BIOL CHEM, V271, P29211, DOI 10.1074/jbc.271.46.29211; Hauser W, 1999, P NATL ACAD SCI USA, V96, P8120, DOI 10.1073/pnas.96.14.8120; HORSTRUP K, 1994, EUR J BIOCHEM, V225, P21, DOI 10.1111/j.1432-1033.1994.00021.x; Huttelmaier S, 1999, FEBS LETT, V451, P68, DOI 10.1016/S0014-5793(99)00546-3; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; Huttenlocher A, 1996, J CELL BIOL, V134, P1551, DOI 10.1083/jcb.134.6.1551; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; IKEDA M, 1995, HYPERTENSION, V26, P401, DOI 10.1161/01.HYP.26.3.401; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; Loisel TP, 1999, NATURE, V401, P613, DOI 10.1038/44183; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Massberg S, 1999, J EXP MED, V189, P1255, DOI 10.1084/jem.189.8.1255; MASSIA SP, 1992, J BIOL CHEM, V267, P14019; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; MurphyUllrich JE, 1996, J CELL SCI, V109, P2499; Nakamura M, 1999, CELL SIGNAL, V11, P671, DOI 10.1016/S0898-6568(99)00036-4; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; NISHIKAWA M, 1984, J BIOL CHEM, V259, P8429; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; NOLTE C, 1991, J BIOL CHEM, V266, P14808; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; PISTOR S, 1995, CURR BIOL, V5, P517, DOI 10.1016/S0960-9822(95)00104-7; POLLARD TD, 1995, CURR BIOL, V5, P837, DOI 10.1016/S0960-9822(95)00167-9; Poller W, 1996, GENE THER, V3, P521; QWARNSTROM EE, 1991, P NATL ACAD SCI USA, V88, P1232, DOI 10.1073/pnas.88.4.1232; Reinhard M, 1996, FEBS LETT, V399, P103, DOI 10.1016/S0014-5793(96)01295-1; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; REINHARD M, 1999, GUIDEBOOK CYTOSKELET, P168; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; SOUTHWICK FS, 1994, P NATL ACAD SCI USA, V91, P5168, DOI 10.1073/pnas.91.11.5168; Suehiro K, 1997, J BIOL CHEM, V272, P5360, DOI 10.1074/jbc.272.8.5360; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; TAYLOR SS, 1988, FASEB J, V2, P2677, DOI 10.1096/fasebj.2.11.3294077; TURNER CE, 1989, J BIOL CHEM, V264, P11938; Vaandrager AB, 1997, J BIOL CHEM, V272, P4195, DOI 10.1074/jbc.272.7.4195; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; WALDMANN R, 1989, EUR J PHARMACOL, V159, P317, DOI 10.1016/0014-2999(89)90165-9; WALTER U, 1980, J BIOL CHEM, V255, P3757; WOLFE L, 1989, J BIOL CHEM, V264, P4157	71	110	119	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25723	25732		10.1074/jbc.M909632199	http://dx.doi.org/10.1074/jbc.M909632199			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10851246	hybrid			2022-12-25	WOS:000088849400088
J	Valentine, JE; Kalkhoven, E; White, R; Hoare, S; Parker, MG				Valentine, JE; Kalkhoven, E; White, R; Hoare, S; Parker, MG			Mutations in the estrogen receptor ligand binding domain discriminate between hormone-dependent transactivation and transrepression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLUCOCORTICOID-MEDIATED REPRESSION; INTERLEUKIN-6 GENE-EXPRESSION; NEGATIVE CROSS-TALK; NUCLEAR RECEPTORS; DNA-BINDING; ANDROGEN RECEPTOR; RETINOIC ACID; AP-1 ACTIVITY; TRANSCRIPTIONAL COACTIVATORS	The estrogen receptor (ER) suppresses transcriptional activity of the Re1A subunit of nuclear factor-KB in a hormone-dependent manner by a mechanism involving both the receptor DNA binding domain and ligand binding domain (LBD). In this study we examine the role of the ER LED in mediating ligand-dependent RelA transrepression. Both ER alpha and ER beta inhibit RelA in response to 17 beta-estradiol but not in the presence of antihormones. We have identified residues within the ER alpha LED that are responsible for receptor dimerization and show that dimerization is necessary for transactivation and transrepression. Moreover we have generated mutant receptors that have lost their ability to inhibit RelA but retain their capacity to stimulate transcription and conversely mutants that are transcriptionally defective but capable of antagonizing Re1A Overexpression of p160 and cAMP-response element-binding protein-binding protein/p300 co-activators failed to relieve repression of RelA, which is consistent with the demonstration that RelA inhibition can occur independently of these co-activators. These findings suggest it is unlikely that sequestration of these cofactors required for ER transcriptional activation can account for hormone-dependent antagonism of Re1A The identification of ER mutants that discriminate between transactivation and transrepression implies that distinct surfaces within the LED are involved in mediating these two receptor functions.	Imperial Canc Res Fund, Mol Endocrinol Lab, London WC2A 3PX, England	Cancer Research UK; University of London; Queen Mary University London	Parker, MG (corresponding author), Imperial Canc Res Fund, Mol Endocrinol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.							Aarnisalo P, 1999, ENDOCRINOLOGY, V140, P3097, DOI 10.1210/en.140.7.3097; Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bevan C, 1999, EXP CELL RES, V253, P349, DOI 10.1006/excr.1999.4719; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Cerillo G, 1998, J STEROID BIOCHEM, V67, P79, DOI 10.1016/S0960-0760(98)00078-8; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Glass CK, 2000, GENE DEV, V14, P121; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; HECK S, 1997, EMBO J, V16, P4689; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Iafrati MD, 1997, NAT MED, V3, P545, DOI 10.1038/nm0597-545; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; LAHOOTI H, 1994, MOL ENDOCRINOL, V8, P182, DOI 10.1210/me.8.2.182; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; Mak HY, 1999, MOL CELL BIOL, V19, P3895; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; ONATE SA, 1995, SCIENCE, V270, P1354; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; POTTRATZ ST, 1994, J CLIN INVEST, V93, P944, DOI 10.1172/JCI117100; RAY A, 1994, J BIOL CHEM, V269, P12940; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Ray P, 1997, FEBS LETT, V409, P79, DOI 10.1016/S0014-5793(97)00487-0; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Saatcioglu F, 1997, MOL CELL BIOL, V17, P4687, DOI 10.1128/MCB.17.8.4687; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VANDESTOLPE A, 1994, J BIOL CHEM, V269, P6185; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VOGEL JJ, 1996, EMBO J, V15, P101; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	74	77	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25322	25329		10.1074/jbc.M002497200	http://dx.doi.org/10.1074/jbc.M002497200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10840033	hybrid			2022-12-25	WOS:000088849400038
J	Hingorani, K; Szebeni, A; Olson, MOJ				Hingorani, K; Szebeni, A; Olson, MOJ			Mapping the functional domains of nucleolar protein B23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-LIKE ACTIVITY; LOCALIZATION SIGNALS; PHOSPHOPROTEIN B23; IDENTIFICATION; NUCLEAR; OLIGOMERIZATION; TRANSLOCATION; POLYPEPTIDES; PURIFICATION; PARTICLES	Protein B23 is a multifunctional nucleolar protein whose cellular location and characteristics strongly suggest that it is a ribosome assembly factor. The protein has nucleic acid binding, ribonuclease, and molecular chaperone activities. To determine the contributions of unique polypeptide segments enriched in certain classes of amino acid residues to the respective activities, several constructs that produced N- and C-terminal deletion mutant proteins were prepared. The C-terminal quarter of the protein was shown to be necessary and sufficient for nucleic acid binding. Basic and aromatic segments at the N- and C-terminal ends, respectively, of the nucleic acid binding region were required for activity, The molecular chaperone activity was contained in the N-terminal half of the molecule, with important contributions from both nonpolar and acidic regions. The chaperone activity also correlated with the ability of the protein to form oligomers. The central portion of the molecule was required for ribonuclease activity and possibly contains the catalytic site; this region overlapped with the chaperone-containing segment of the molecule. The C-terminal, nucleic acid-binding region enhanced the ribonuclease activity but was not essential for it. These data suggest that the three activities reside in mainly separate but partially overlapping segments of the polypeptide chain.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center	Olson, MOJ (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, 2500 N State St, Jackson, MS 39216 USA.							BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; BUCHNER J., 1998, MOL CHAPERONES LIFE, P553; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; EICHLER DC, 1982, J BIOL CHEM, V257, P4384; FANKHAUSER C, 1991, MOL CELL BIOL, V11, P2567, DOI 10.1128/MCB.11.5.2567; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; Gerlt J. A., 1993, NUCLEASES, P1; GIBBONS DL, 1995, J BIOL CHEM, V270, P7335, DOI 10.1074/jbc.270.13.7335; Guha S, 1998, J BIOL CHEM, V273, P30077, DOI 10.1074/jbc.273.46.30077; HADJIOLOV AA, 1985, NUCLEOLUS RIBOSOME B, P87; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Herrera JE, 1996, BIOCHEMISTRY-US, V35, P2668, DOI 10.1021/bi9523320; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; MARIDOR G, 1990, NUCLEIC ACIDS RES, V18, P1286, DOI 10.1093/nar/18.5.1286; MAXWELL ES, 1995, ANNU REV BIOCHEM, V64, P897, DOI 10.1146/annurev.bi.64.070195.004341; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Nakajima H, 2000, EUR J BIOCHEM, V267, P295, DOI 10.1046/j.1432-1327.2000.00931.x; OLSON MOJ, 1986, BIOCHEMISTRY-US, V25, P484, DOI 10.1021/bi00350a031; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SZEBENI A, 1995, BIOCHEMISTRY-US, V34, P8037, DOI 10.1021/bi00025a009; Szebeni A, 1999, PROTEIN SCI, V8, P905; UMEKAWA H, 1993, CELL MOL BIOL RES, V39, P635; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; WANG DR, 1994, J BIOL CHEM, V269, P30994; Warner AK, 1999, CELL MOTIL CYTOSKEL, V44, P68; Ye XJ, 1997, J BIOL CHEM, V272, P3606, DOI 10.1074/jbc.272.6.3606; Yonehara M, 1996, J BIOL CHEM, V271, P2641, DOI 10.1074/jbc.271.5.2641; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8; YUNG BYM, 1985, BIOCHEM PHARMACOL, V34, P4059, DOI 10.1016/0006-2952(85)90387-9; Zirwes RF, 1997, MOL BIOL CELL, V8, P231, DOI 10.1091/mbc.8.2.231	42	204	218	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24451	24457		10.1074/jbc.M003278200	http://dx.doi.org/10.1074/jbc.M003278200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10829026	hybrid			2022-12-25	WOS:000088683300029
J	Chabot, DJ; Broder, CC				Chabot, DJ; Broder, CC			Substitutions in a homologous region of extracellular loop 2 of CXCR4 and CCR5 alter coreceptor activities for HIV-1 membrane fusion and virus entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LINES; INFECTIOUS MOLECULAR CLONE; CHEMOKINE RECEPTOR; TYPE-1 ENTRY; VACCINIA VIRUS; IMMUNODEFICIENCY VIRUSES; MONONUCLEAR PHAGOCYTES; ENVELOPE GLYCOPROTEINS; MONOCLONAL-ANTIBODY; PRIMARY MACROPHAGES	CXCR4 and CCR5 are the principal coreceptors for human immunodeficiency virus type-1 (HIV-1) infection. Previously, mutagenesis of CXCR4 identified single amino acid changes that either impaired CXCR4's coreceptor activity for CXCR4-dependent (X4) isolate envelope glycoproteins (Env) or expanded its activity, allowing it to serve as a functional coreceptor for CCR5-dependent (R5) isolates. The most potent of these point mutations was an alanine substitution for the aspartic acid residue at position 187 in extracellular loop 2 (ecl-2), and here we show that this mutation also permits a variety of primary R5 isolate Envs, including those of other subtypes (clades), to employ it as a coreceptor. We also examined the corresponding region of CCR5 and demonstrate that the substitution of the serine residue in the homologous ecl-2 position with aspartic acid impairs CCR5 coreceptor activity for isolates across several clades. These results highlight a homologous and critical element in ecl-2, of both the CXCR4 and CCR5 molecules, for their respective coreceptor activities. Charge elimination expands CXCR4 coreceptor activity, while a similar charge introduction can destroy the coreceptor function of CCR5. These findings provide further evidence that there are conserved elements in both CXCR4 and CCR5 involved in coreceptor function.	Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Microbiol & Immunol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Broder, CC (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.		Broder, Christopher/E-1169-2013	Chabot, Donald/0000-0003-4925-5779	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043885] Funding Source: NIH RePORTER; NIAID NIH HHS [R01AI43885] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALEXANDER WA, 1992, J VIROL, V66, P2934, DOI 10.1128/JVI.66.5.2934-2942.1992; Alkhatib G, 1996, J VIROL, V70, P5487, DOI 10.1128/JVI.70.8.5487-5494.1996; Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; BERGER EA, 1995, HIV PRACTICAL APPROA, V2, P123; Berson JF, 1998, SEMIN IMMUNOL, V10, P237, DOI 10.1006/smim.1998.0130; Bieniasz Paul D., 1998, Frontiers in Bioscience, V3, pD44; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Blanpain C, 1999, J BIOL CHEM, V274, P18902, DOI 10.1074/jbc.274.27.18902; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Brelot A, 1999, J VIROL, V73, P2576, DOI 10.1128/JVI.73.4.2576-2586.1999; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; BRODER CC, 1999, THEORETICAL BIOL BIO, V3, P20; Chabot DJ, 1999, J VIROL, V73, P6598, DOI 10.1128/JVI.73.8.6598-6609.1999; Chabot DJ, 2000, J VIROL, V74, P4404, DOI 10.1128/JVI.74.9.4404-4413.2000; Chakrabarti S, 1997, BIOTECHNIQUES, V23, P1094, DOI 10.2144/97236st07; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Clapham PR, 1999, MOL MEMBR BIOL, V16, P49, DOI 10.1080/096876899294751; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; DEJONG JJ, 1992, J VIROL, V66, P6777, DOI 10.1128/JVI.66.11.6777-6780.1992; Dimitrov DS, 1998, J MEMBRANE BIOL, V166, P75, DOI 10.1007/s002329900450; DIMITROV DS, 1997, HIV MEMBRANE RECEPTO; Doms RW, 1997, VIROLOGY, V235, P179, DOI 10.1006/viro.1997.8703; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Doranz BJ, 1997, J VIROL, V71, P6305, DOI 10.1128/JVI.71.9.6305-6314.1997; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Edinger AL, 1997, P NATL ACAD SCI USA, V94, P4005, DOI 10.1073/pnas.94.8.4005; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; Genoud S, 1999, J VIROL, V73, P1645, DOI 10.1128/JVI.73.2.1645-1648.1999; HARRINGTON RD, 1993, J VIROL, V67, P5939, DOI 10.1128/JVI.67.10.5939-5947.1993; Hesselgesser J, 1998, J IMMUNOL, V160, P877; Hill CM, 1998, VIROLOGY, V248, P357, DOI 10.1006/viro.1998.9283; Hoffman TL, 1999, MOL MEMBR BIOL, V16, P57, DOI 10.1080/096876899294760; Hoxie JA, 1998, J REPROD IMMUNOL, V41, P197, DOI 10.1016/S0165-0378(98)00059-X; Kolchinsky P, 1999, J VIROL, V73, P8120, DOI 10.1128/JVI.73.10.8120-8126.1999; LaCasse RA, 1999, SCIENCE, V283, P357, DOI 10.1126/science.283.5400.357; Lapham CK, 1999, NAT MED, V5, P303, DOI 10.1038/6523; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Lu ZH, 1997, P NATL ACAD SCI USA, V94, P6426, DOI 10.1073/pnas.94.12.6426; McKnight A, 1997, J VIROL, V71, P1692, DOI 10.1128/JVI.71.2.1692-1696.1997; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; Olson WC, 1999, J VIROL, V73, P4145, DOI 10.1128/JVI.73.5.4145-4155.1999; Picard L, 1997, VIROLOGY, V231, P105, DOI 10.1006/viro.1997.8506; Picard L, 1997, J VIROL, V71, P5003, DOI 10.1128/JVI.71.7.5003-5011.1997; Quinnan GV, 1998, AIDS RES HUM RETROV, V14, P939, DOI 10.1089/aid.1998.14.939; Rabut GEE, 1998, J VIROL, V72, P3464, DOI 10.1128/JVI.72.4.3464-3468.1998; Reeves JD, 1998, J GEN VIROL, V79, P1793, DOI 10.1099/0022-1317-79-7-1793; Ross TM, 1998, J VIROL, V72, P1918, DOI 10.1128/JVI.72.3.1918-1924.1998; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; Siciliano SJ, 1999, J BIOL CHEM, V274, P1905, DOI 10.1074/jbc.274.4.1905; Strizki JM, 1997, J VIROL, V71, P5678, DOI 10.1128/JVI.71.7.5678-5683.1997; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Wang ZX, 1998, J BIOL CHEM, V273, P15007, DOI 10.1074/jbc.273.24.15007; Wang ZX, 1999, J BIOL CHEM, V274, P28413, DOI 10.1074/jbc.274.40.28413; Willett BJ, 1997, J VIROL, V71, P6407, DOI 10.1128/JVI.71.9.6407-6415.1997; Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496	71	37	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 4	2000	275	31					23774	23782		10.1074/jbc.M003438200	http://dx.doi.org/10.1074/jbc.M003438200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	340YL	10827088	hybrid			2022-12-25	WOS:000088564200052
J	Youn, HD; Grozinger, CM; Liu, JO				Youn, HD; Grozinger, CM; Liu, JO			Calcium regulates transcriptional repression of myocyte enhancer factor 2 by histone deacetylase 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN STEROID-RECEPTOR; FACTOR MEF2; COREPRESSOR; ACTIVATION; APOPTOSIS; COMPLEX; FAMILY; NUR77; CALCINEURIN; PROTEINS	The myocyte enhancer factor 2 (MEF2) consists of a family of transcription factors that play important roles in a number of physiological processes from muscle cell differentiation to neuronal survival and T cell apoptosis. MEF2 has been reported to be associated with several distinct repressors including Cabin1(cain), MEF2-interacting transcriptional repressor (MITR), and HDAC4. It has been previously shown that Cabin1 is associated with MEF2 in a calcium-sensitive manner; activated calmodulin binds to Cabin1 and releases it from MEF2. However, it was not known whether the binding of HDAC4 and MITR to MEF2 is also regulated by calcium. We report that HDAC4 and MITR contain calmodulin-binding domains that overlap with their MEF2-binding domains. Binding of calmodulin to HDAC4 leads to its dissociation from MEF2, relieving MEF2 from the transcriptional repression by HDAC4. Together, HDAC4, MITE, and Cabin1 constitute a family of calcium-sensitive transcriptional repressors of MEF2.	MIT, Dept Chem & Biol, Canc Res Ctr, Cambridge, MA 02139 USA; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Massachusetts Institute of Technology (MIT); Harvard University	Liu, JO (corresponding author), MIT, Dept Chem & Biol, Canc Res Ctr, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Youn, Hong-Duk/J-2774-2012		NIGMS NIH HHS [GM55783, GM38627] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038627, R01GM038627, R01GM055783] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; Hansen JC, 1998, BIOCHEMISTRY-US, V37, P17637, DOI 10.1021/bi982409v; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hassig CA, 1997, CURR OPIN CHEM BIOL, V1, P300, DOI 10.1016/S1367-5931(97)80066-X; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kao HY, 2000, GENE DEV, V14, P55; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mao ZX, 1999, SCIENCE, V286, P785, DOI 10.1126/science.286.5440.785; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Winoto A, 1997, CURR OPIN IMMUNOL, V9, P365, DOI 10.1016/S0952-7915(97)80083-0; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	40	130	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 21	2000	275	29					22563	22567		10.1074/jbc.C000304200	http://dx.doi.org/10.1074/jbc.C000304200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	337LY	10825153	hybrid			2022-12-25	WOS:000088363800109
J	Behncken, SN; Billestrup, N; Brown, R; Amstrup, J; Conway-Campbell, B; Waters, MJ				Behncken, SN; Billestrup, N; Brown, R; Amstrup, J; Conway-Campbell, B; Waters, MJ			Growth hormone (GH)-independent dimerization of GH receptor by a leucine zipper results in constitutive activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROPOIETIN EPO RECEPTOR; EXTRACELLULAR DOMAIN; CRYSTAL-STRUCTURE; TYROSINE KINASE; COMPLEX; IDENTIFICATION; TRANSCRIPTION; ANTIBODIES; RESIDUES; AFFINITY	Growth hormone initiates signaling by inducing homodimerization of two GH receptors. Here, we have sought to determine whether constitutively active receptor can be created in the absence of the extracellular domain by substituting it with high affinity leucine zippers to create dimers of the growth hormone receptor (GHR) signaling domain. The entire extracellular domain of the GHR was replaced by the hemagglutinin-tagged zipper sequence of either the c-Fos or c-Jun transcription factor (termed Fos-GHR and Jun-GHR, respectively). Transient transfection of Fos-GHR or Jun-GHR resulted in activation of the serine protease inhibitor 2.1 promoter in Chinese hamster ovary-K1 cells to a level equal to that achieved by fully activated wild type GHR. Furthermore, stable expression of Jun-GHR alone or Fos-GHR and Jun-GHR together in the interleukin 3-dependent BaF-B03 cell line resulted in cell proliferation after interleukin 3 withdrawal at a rate equal to maximally stimulated wild type GHR-expressing cells. Activation of STAT 5b was also observed in Fos-Jun-GHR-expressing cells at a level equal to that in chronically GH-treated GHR-expressing cells. Thus, forced dimerization of the transmembrane and cytoplasmic domains of the GHR in the absence of the extracellular domain can lead to the constitutive activation of known GH signaling end points, supporting the view that proximity of Janus kinase 2 (JAK2) kinases is the essential element in signaling. Such constitutively active GH receptors may have particular utility for transgenic live-stock applications.	Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia; Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia; Hagedorn Res Inst, DK-2820 Gentofte, Denmark	University of Queensland; University of Queensland; Novo Nordisk; Hagedorn Research Institute	Waters, MJ (corresponding author), Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia.		waters, michael j/C-9582-2014; Conway-Campbell, Becky/B-8571-2009	Billestrup, Nils/0000-0002-4968-8067				Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; Behncken SN, 1997, J BIOL CHEM, V272, P27077, DOI 10.1074/jbc.272.43.27077; BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; Chen CM, 1997, J BIOL CHEM, V272, P5133, DOI 10.1074/jbc.272.8.5133; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; CLARKSON RWE, 1995, MOL ENDOCRINOL, V9, P108, DOI 10.1210/me.9.1.108; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Elliott S, 1996, J BIOL CHEM, V271, P24691, DOI 10.1074/jbc.271.40.24691; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Livnah O, 1999, SCIENCE, V283, P987, DOI 10.1126/science.283.5404.987; LOBIE PE, 1994, J BIOL CHEM, V269, P31735; Mellado M, 1997, J BIOL CHEM, V272, P9189; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; Patel N, 1996, J BIOL CHEM, V271, P30386, DOI 10.1074/jbc.271.48.30386; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Rowlinson SW, 1998, J BIOL CHEM, V273, P5307, DOI 10.1074/jbc.273.9.5307; ROWLINSON SW, 1995, J BIOL CHEM, V270, P16833, DOI 10.1074/jbc.270.28.16833; Sundstrom M, 1996, J BIOL CHEM, V271, P32197, DOI 10.1074/jbc.271.50.32197; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Waters MJ., 1999, HDB PHYSL, P397	31	23	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					17000	17007		10.1074/jbc.275.22.17000	http://dx.doi.org/10.1074/jbc.275.22.17000			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828073	hybrid			2022-12-25	WOS:000087392200085
J	Orpiszewski, J; Schormann, N; Kluve-Beckerman, B; Liepnieks, JJ; Benson, MD				Orpiszewski, J; Schormann, N; Kluve-Beckerman, B; Liepnieks, JJ; Benson, MD			Protein aging hypothesis of Alzheimer disease	FASEB JOURNAL			English	Article						amyloid; beta-protein; succinimide; isoaspartate; amyloidosis	AMYLOID-BETA-PEPTIDE; L-ISOASPARTYL METHYLTRANSFERASE; IN-VITRO; AMINOSUCCINYL PEPTIDES; SUCCINIMIDE FORMATION; BOND ISOMERIZATION; HAIRPIN FORMATION; TRANSGENIC MICE; MAMMALIAN BRAIN; NEUROTOXICITY	Alzheimer disease (AD), the most common form of aging-related neurodegenerative disorders, is associated with formation of fibrillar deposits of amyloid beta-protein (A beta), While the direct involvement of A beta in AD has been well documented, the relations between AP production, amyloid formation, and neurodegeneration remain unknown. We propose that AD is initiated by a protein aging-related structural transformation in soluble A beta. We hypothesize that spontaneous chemical modification of aspartyl residues in A beta to transient succinimide induces a non-native conformation in a fraction of soluble A beta, rendering it amyloidogenic and neurotoxic, Conformationally altered A beta is characterized by increased stability in solution and the presence of a nonnative p-turn that determines folding of A beta in solution and the structure of A beta subunits incorporated into amyloid fibrils, While the soluble 'non-native' A beta is both the factor triggering the neurodegenerative cascade and the precursor of amyloid plaques, these two events result from interaction of A beta with different sets of cellular components and need not coincide in space and time. Extensive literature data and experimental evidence are provided in support of this hypothesis.-Orpiszewski, J., Schormann, N., Kluve-Beckerman, B., Liepnieks, J. J., Benson, M. D. Protein aging hypothesis of Alzheimer disease.	Aprot Corp, Carmel, IN 46082 USA; Indiana Univ, Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; Richard L Roudebush Vet Affairs Med Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	Orpiszewski, J (corresponding author), Aprot Corp, POB 3813, Carmel, IN 46082 USA.	aprot@excite.com						Aswad DW, 1995, CRC SERIES ANAL BIOT; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P77, DOI 10.1016/S0968-0004(98)01345-0; Blanco F, 1998, CURR OPIN STRUC BIOL, V8, P107, DOI 10.1016/S0959-440X(98)80017-1; Brovia V, 1996, J NEUROCHEM, V67, P382; CAPASSO S, 1992, ACTA CRYSTALLOGR B, V48, P285, DOI 10.1107/S010876819101368X; Capasso S, 1995, CHIRALITY, V7, P605, DOI 10.1002/chir.530070808; CAPASSO S, 1984, ACTA CRYSTALLOGR C, V43, P1607; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; CLARKE S, 1987, INT J PEPT PROT RES, V30, P808, DOI 10.1111/j.1399-3011.1987.tb03390.x; Coles M, 1998, BIOCHEMISTRY-US, V37, P11064, DOI 10.1021/bi972979f; David CL, 1998, J BIOL CHEM, V273, P32063, DOI 10.1074/jbc.273.48.32063; DEALBA E, 1996, FOLDING DESIGN, V26, P133; DYSON HJ, 1995, FASEB J, V9, P37, DOI 10.1096/fasebj.9.1.7821757; FABIAN H, 1994, EUR J BIOCHEM, V221, P959, DOI 10.1111/j.1432-1033.1994.tb18811.x; Fersht AR, 1997, CURR OPIN STRUC BIOL, V7, P3, DOI 10.1016/S0959-440X(97)80002-4; Fonseca MI, 1999, EXP NEUROL, V157, P277, DOI 10.1006/exnr.1999.7058; Fukuda H, 1999, BIOORG MED CHEM LETT, V9, P953, DOI 10.1016/S0960-894X(99)00121-3; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Ghetti B, 1996, BRAIN PATHOL, V6, P127, DOI 10.1111/j.1750-3639.1996.tb00796.x; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Haque TS, 1997, J AM CHEM SOC, V119, P2303, DOI 10.1021/ja963653h; HAQUE TS, 1994, J AM CHEM SOC, V116, P4105, DOI 10.1021/ja00088a067; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hui JO, 1998, ARCH BIOCHEM BIOPHYS, V358, P377, DOI 10.1006/abbi.1998.0884; JOHNSON BA, 1991, NEUROBIOL AGING, V12, P19, DOI 10.1016/0197-4580(91)90034-H; JOHNSON BA, 1985, J NEUROCHEM, V45, P1119, DOI 10.1111/j.1471-4159.1985.tb05531.x; Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132; Kortemme T, 1998, SCIENCE, V281, P253, DOI 10.1126/science.281.5374.253; Kuo YM, 1998, BBA-MOL BASIS DIS, V1406, P291, DOI 10.1016/S0925-4439(98)00014-3; Kuo YM, 1996, J BIOL CHEM, V271, P4077; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LOWENSON JD, 1994, TRENDS CARDIOVAS MED, V4, P3, DOI 10.1016/1050-1738(94)90019-1; MAY PC, 1997, ALZHEIMERS DIS REV, V2, P15; Moechars D, 1999, NEUROSCIENCE, V91, P819, DOI 10.1016/S0306-4522(98)00599-5; MORI H, 1994, TOHOKU J EXP MED, V174, P251, DOI 10.1620/tjem.174.251; Munoz V, 1997, NATURE, V390, P196, DOI 10.1038/36626; Najbauer J, 1996, BIOCHEMISTRY-US, V35, P5183, DOI 10.1021/bi953063g; Neira JL, 1996, FOLD DES, V1, P231, DOI 10.1016/S1359-0278(96)00034-X; Neve RL, 1998, TRENDS NEUROSCI, V21, P15, DOI 10.1016/S0166-2236(97)01168-5; Noguchi S, 1998, J MOL BIOL, V278, P231, DOI 10.1006/jmbi.1998.1674; Orpiszewski J, 1999, J MOL BIOL, V289, P413, DOI 10.1006/jmbi.1999.2768; Orpiszewski J, 1996, J BIOL CHEM, V271, P22965, DOI 10.1074/jbc.271.38.22965; PARANANDI MV, 1995, BIOCHEM BIOPH RES CO, V212, P442, DOI 10.1006/bbrc.1995.1989; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; POTTER SM, 1993, PROTEIN SCI, V2, P1648, DOI 10.1002/pro.5560021011; RamirezAlvarado M, 1996, NAT STRUCT BIOL, V3, P604, DOI 10.1038/nsb0796-604; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SHAPIRA R, 1988, J NEUROCHEM, V50, P69, DOI 10.1111/j.1471-4159.1988.tb13231.x; Sharman GJ, 1997, CHEM COMMUN, P1955; SIBANDA BL, 1985, NATURE, V316, P170, DOI 10.1038/316170a0; Small DH, 1998, NEUROCHEM RES, V23, P795, DOI 10.1023/A:1022471729291; Solomon B, 1997, P NATL ACAD SCI USA, V94, P4109, DOI 10.1073/pnas.94.8.4109; SZENDREI GI, 1994, EUR J BIOCHEM, V226, P917, DOI 10.1111/j.1432-1033.1994.t01-1-00917.x; Szendrei GI, 1996, INT J PEPT PROT RES, V47, P289; TAM J P, 1988, Peptide Research, V1, P6; TOMIYAMA T, 1994, J BIOL CHEM, V269, P10205; Valazquez P, 1997, NAT MED, V3, P77, DOI 10.1038/nm0197-77; Valle, 1995, METABOLIC BASIS INHE, P4159; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; Yan SD, 1997, NATURE, V389, P689; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yang AS, 1996, J MOL BIOL, V259, P873, DOI 10.1006/jmbi.1996.0364; Zhou HXX, 1996, NAT STRUCT BIOL, V3, P446, DOI 10.1038/nsb0596-446	69	46	50	2	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1255	1263		10.1096/fasebj.14.9.1255	http://dx.doi.org/10.1096/fasebj.14.9.1255			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834947				2022-12-25	WOS:000087427300022
J	Zemel, MB; Shi, H; Greer, B; Dirienzo, D; Zemel, PC				Zemel, MB; Shi, H; Greer, B; Dirienzo, D; Zemel, PC			Regulation of adiposity by dietary calcium	FASEB JOURNAL			English	Article						human adipocytes; lipolysis; agouti; PTH	CYTOSOLIC-FREE CALCIUM; INSULIN-RESISTANCE; HUMAN ADIPOCYTES; RAT ADIPOCYTES; AGOUTI GENE; HYPERTENSION; OBESITY; MECHANISMS	Recent data from this laboratory demonstrate that increasing adipocyte intracellular Ca2+ results in a coordinated stimulation of lipogenesis and inhibition of lipolysis. We have also noted that increasing dietary calcium of obese patients for 1 year resulted in a 4.9 kg loss of body fat (P<0.01). Accordingly, we tested the possibility that calcitrophic hormones may act on adipocytes to increase Ca2+ and lipid metabolism by measuring the effects of 1,25(OH)(2)-D in primary cultures of human adipocytes, and found significant, sustained increases in intracellular Ca2+ and a corresponding marked inhibition of lipolysis (EC50 similar to 50 pM; P<0.001), suggesting that dietary calcium could reduce adipocyte mass by suppressing 1,25-(OH)(2)-D. To test this hypothesis, we placed transgenic mice expressing the agouti gene specifically in adipocytes on a low (0.4%) Ca/high fat/high sucrose diet either unsupplemented or with 25 or 50% of the protein replaced by non-fat dry milk or supplemented to 1.2% Ca with CaCO3 for 6 wk. Weight gain and fat pad mass were reduced by 26-39% by the three high calcium diets (P<0.001). The high calcium diets exerted a corresponding 51% inhibition of adipocyte fatty acid synthase expression and activity (P<0.002) and stimulation of lipolysis by 3.4- to 5.2-fold (P<0.015). This concept of calcium modulation of adiposity was further evaluated epidemiologically in the NHANES III data set. After controlling for energy intake, relative risk of being in the highest quartile of body fat was set to 1.00 for the lowest quartile of Ca intake and was reduced to 0.75, 0.40, and 0.16 for the second, third, and fourth quartiles, respectively, of calcium intake for women (n=380;P<0.0009); a similar inverse relationship was also noted in men (n=7114; P<0.0006). Thus, increasing dietary calcium suppresses adipocyte intracellular Ca2+ and thereby modulates energy metabolism and attenuates obesity risk.	Univ Tennessee, Dept Nutr, Knoxville, TN 37996 USA; Natl Dairy Council, Rosemont, IL 60018 USA	University of Tennessee System; University of Tennessee Knoxville	Zemel, MB (corresponding author), Univ Tennessee, Dept Nutr, 1215 W Cumberland Ave,Room 229, Knoxville, TN 37996 USA.	mzemel@utk.edu		Zemel, Michael/0000-0003-4104-5750				Barbagallo M, 1997, J CLIN ENDOCR METAB, V82, P1761, DOI 10.1210/jc.82.6.1761; BOOBIS LH, 1983, CLIN CHIM ACTA, V132, P173, DOI 10.1016/0009-8981(83)90245-0; BYYNY RL, 1992, AM J HYPERTENS, V5, P459, DOI 10.1093/ajh/5.7.459; DRAZNIN B, 1988, J CLIN INVEST, V82, P1848, DOI 10.1172/JCI113801; DRAZNIN B, 1987, J BIOL CHEM, V262, P14385; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Jones BH, 1996, AM J PHYSIOL-ENDOC M, V270, pE192, DOI 10.1152/ajpendo.1996.270.1.E192; Kim JH, 1997, AM J PHYSIOL-ENDOC M, V272, pE379, DOI 10.1152/ajpendo.1997.272.3.E379; Kim JH, 1996, FASEB J, V10, P1646, DOI 10.1096/fasebj.10.14.9002558; MANNE J, 1995, P NATL ACAD SCI USA, V92, P4721, DOI 10.1073/pnas.92.11.4721; Moustaid N, 1996, J NUTR, V126, P865, DOI 10.1093/jn/126.4.865; Mynatt RL, 1997, P NATL ACAD SCI USA, V94, P919, DOI 10.1073/pnas.94.3.919; National Center for Health Statistics, 1994, PLAN OP 3 NAT HLTH N; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Resnick L, 1999, PROG CARDIOVASC DIS, V42, P1, DOI 10.1016/S0033-0620(99)70006-X; RESNICK LM, 1991, HYPERTENSION, V17, P951, DOI 10.1161/01.HYP.17.6.951; SEGAL KR, 1988, AM J CLIN NUTR, V47, P7, DOI 10.1093/ajcn/47.1.7; Shah BV, 1996, SUDAAN USERS MANUAL; SHAN J, 1993, AM J HYPERTENS, V6, P983, DOI 10.1093/ajh/6.12.983; SHI H, 1999, IN PRESS FASEB J; Summerbell CD, 1998, BRIT MED J, V317, P1487, DOI 10.1136/bmj.317.7171.1487; Tebar F, 1996, ENDOCRINOLOGY, V137, P4181, DOI 10.1210/en.137.10.4181; WILLARD DH, 1995, BIOCHEMISTRY-US, V34, P12341, DOI 10.1021/bi00038a030; Xue BZ, 1998, FASEB J, V12, P1391, DOI 10.1096/fasebj.12.13.1391; ZEMEL MB, 1995, P NATL ACAD SCI USA, V92, P4733, DOI 10.1073/pnas.92.11.4733; ZEMEL MB, 1999, FASEB J, V13; ZEMEL MB, 1995, OBES RES, V3, pS338	27	703	758	1	50	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1132	1138		10.1096/fasebj.14.9.1132	http://dx.doi.org/10.1096/fasebj.14.9.1132			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834935				2022-12-25	WOS:000087427300010
J	Liu, JS; Prolla, G; Rostagno, A; Chiarle, R; Feiner, H; Inghirami, G				Liu, JS; Prolla, G; Rostagno, A; Chiarle, R; Feiner, H; Inghirami, G			Initiation of translation from a downstream in-frame AUG codon on BRCA1 can generate the novel isoform protein Delta BRCA1(17aa)	ONCOGENE			English	Article						BRCA1; translational regulation	SPORADIC BREAST-CANCER; MAMMARY EPITHELIAL-CELLS; DNA-DAMAGE RESPONSE; OVARIAN-CANCER; TRANSCRIPTIONAL ACTIVATION; NUCLEAR PHOSPHOPROTEIN; PROMOTER REGION; SPLICE VARIANTS; FAMILIAL BREAST; TUMOR-FORMATION	Expression of the breast and ovarian cancer gene BRCA1 is regulated at both the transcriptional and post-transcriptional levels. We found that the expression of the BRCA1 protein may also be regulated at the translational level. In addition to an AUG start codon at position 1, BRCA1 mRNA has a second in-frame AUG (+17) that acts as an alternative start codon to generate a novel BRCA1 protein that lacks the first 17 amino acids (Delta BRCA1(17aa)). We fused cDNAs encoding the second exon of BRCA1 of the wild-type BRCA1 gene (wt-BRCA1) and a mutated BRCA1 gene (mt-BRCA1), in which the first initiation site and its Kozak consensus sequence were abolished, with the nucleophosmin (NPM) reporter gene and used them for in vitro and in vivo translation assays, In both systems, the wt-BRCA1-NPM constructs produced two distinct proteins (18 and 16 kD) begun from the first and second AUGs, The mt-BRCA1-NPM constructs produced only the shorter 16-kD protein lacking the first 17 amino acids of the BRCA1 gene. Next, we analysed the N-terminal protein sequence of purified BRCA1 protein from normal thymocytes and found two different BRCA1 proteins, derived from translation of the first and second in-frame AUGs, Thus, BRCA1 protein expression can be regulated at the translation level in normal cells, Characterization of Delta BRCA1(17aa) may shed light on the function and regulation of BRCA1 in normal cells as well as the pathogenesis of breast and ovarian cancers.	NYU Med Ctr, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Inghirami, G (corresponding author), NYU Med Ctr, Sch Med, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.		PROLLA, GABRIEL/T-3669-2018; Prolla, Gabriel/AAH-6332-2019; Rostagno, Agueda/A-5801-2008	CHIARLE, Roberto/0000-0003-1564-8531; Rostagno, Agueda/0000-0002-6817-2074	NATIONAL CANCER INSTITUTE [T32CA009454, R21CA066229] Funding Source: NIH RePORTER; NCI NIH HHS [R21-CA66229, CA-2T32CA09454] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brown MA, 1996, ONCOGENE, V12, P2507; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; COLIZAN JE, CURR PROTOCOLS PRO S; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Cui JQ, 1998, ONCOL REP, V5, P591; Dobrovic A, 1997, CANCER RES, V57, P3347; EASTON DF, 1993, AM J HUM GENET, V52, P678; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; INGHIRAMI G, 1994, BLOOD, V83, P3581; Irminger-Finger I, 1999, BIOL CHEM, V380, P117, DOI 10.1515/BC.1999.019; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Lee WY, 1999, HISTOPATHOLOGY, V34, P106; Lu ML, 1996, CANCER RES, V56, P4578; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	53	20	21	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 25	2000	19	23					2767	2773		10.1038/sj.onc.1203599	http://dx.doi.org/10.1038/sj.onc.1203599			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851077				2022-12-25	WOS:000087318500005
J	Ahern, GP; Hsu, SF; Klyachko, VA; Jackson, MB				Ahern, GP; Hsu, SF; Klyachko, VA; Jackson, MB			Induction of persistent sodium current by exogenous and endogenous nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY NERVE-TERMINALS; VASCULAR SMOOTH-MUSCLE; HIPPOCAMPAL-NEURONS; CELLS; CHANNELS; NA+; PROTEINS; ISCHEMIA	Most voltage-gated Na+ channels inactivate almost completely at depolarized membrane potentials, but in some cells a residual Na+ current is seen that is resistant to inactivation. This persistent Na+ current can have a profound impact on the electrical behavior of excitable cells, and the regulation of this property could have important biological consequences, However, the biological signaling mechanisms that regulate the persistence of Na+ channels are not well understood. This study showed that in nerve terminals and ventricular myocytes nitric oxide (NO) reduced the inactivation of Na+ current. This effect was independent of cGMP, was blocked by N-ethylmaleimide, and could be elicited in cell-free outside-out patches. Thus, a reactive nitrogen species acts directly on the channel or closely associated protein. Persistent Na+ current could also be induced by endogenous NO generated enzymatically by NO synthase (NOS). Application of ionomycin to raise the intracellular Ca2+ concentration in myocytes activated NOS. The NO produced in response to ionomycin was detected with an NO-sensitive fluorescent dye. Persistent Na+ current was enhanced by the same treatment, and NOS inhibitors abolished both the elevation of NO and the induction of persistent Na+ current. These experiments show that NO is a potential endogenous regulator of persistent Na+ current under physiological and pathophysiological conditions.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Univ Wisconsin, Biophys Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ahern, GP (corresponding author), Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA.		Klyachko, Vitaly/E-9431-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030016, R37NS030016] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30016] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahern GP, 1999, J PHYSIOL-LONDON, V520, P165, DOI 10.1111/j.1469-7793.1999.00165.x; AHERN GP, 1998, SOC NEUR ABSTR, V24; ALONSO A, 1989, NATURE, V342, P175, DOI 10.1038/342175a0; Augustine G J, 1992, Curr Opin Neurobiol, V2, P302, DOI 10.1016/0959-4388(92)90119-6; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; Broillet MC, 1996, NEURON, V16, P377, DOI 10.1016/S0896-6273(00)80055-0; Crill WE, 1996, ANNU REV PHYSIOL, V58, P349, DOI 10.1146/annurev.physiol.58.1.349; FRENCH CR, 1990, J GEN PHYSIOL, V95, P1139, DOI 10.1085/jgp.95.6.1139; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Gee SH, 1998, J NEUROSCI, V18, P128; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hammarstrom AKM, 1999, J PHYSIOL-LONDON, V520, P451, DOI 10.1111/j.1469-7793.1999.t01-1-00451.x; Hammarstrom AKM, 1998, J PHYSIOL-LONDON, V510, P735, DOI 10.1111/j.1469-7793.1998.735bj.x; Huang XP, 1997, J CELL SCI, V110, P1625; Iadecola C, 1997, ANN NY ACAD SCI, V835, P203, DOI 10.1111/j.1749-6632.1997.tb48631.x; JACKSON MB, 1991, P NATL ACAD SCI USA, V88, P380, DOI 10.1073/pnas.88.2.380; JACKSON MB, 1995, J PHYSIOL-LONDON, V483, P597, DOI 10.1113/jphysiol.1995.sp020609; Ju YK, 1996, J PHYSIOL-LONDON, V497, P337, DOI 10.1113/jphysiol.1996.sp021772; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; LLINAS R, 1980, J PHYSIOL-LONDON, V305, P171, DOI 10.1113/jphysiol.1980.sp013357; Ohoi I, 1996, EUR J PHARMACOL, V306, P123, DOI 10.1016/0014-2999(96)00231-2; Raman IM, 1997, J NEUROSCI, V17, P4517, DOI 10.1523/jneurosci.17-12-04517.1997; Ravens U, 1999, PHARMACOL RES, V39, P167, DOI 10.1006/phrs.1998.0416; Segal MM, 1997, J NEUROPHYSIOL, V77, P3021, DOI 10.1152/jn.1997.77.6.3021; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STYS PK, 1993, P NATL ACAD SCI USA, V90, P6976, DOI 10.1073/pnas.90.15.6976; Theroux P, 1999, AM J CARDIOL, V83, p3G; Wang YP, 1996, J BIOL CHEM, V271, P5647, DOI 10.1074/jbc.271.10.5647; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234	30	116	121	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28810	28815		10.1074/jbc.M003090200	http://dx.doi.org/10.1074/jbc.M003090200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10833522	hybrid			2022-12-25	WOS:000089330700063
J	Babinski, K; Catarsi, S; Biagini, G; Seguela, P				Babinski, K; Catarsi, S; Biagini, G; Seguela, P			Mammalian ASIC2a and ASIC3 subunits co-assemble into heteromeric proton-gated channels sensitive to Gd3+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSING ION CHANNELS; NA+ CHANNEL; CATION CHANNEL; CAENORHABDITIS-ELEGANS; FUNCTIONAL EXPRESSION; CAPSAICIN RECEPTOR; MOLECULAR-CLONING; DEGENERIN MDEG; SODIUM-CHANNEL; NEURONS	Proton receptors of the acid-sensing ion channel (ASIC) family are expressed in sensory neurons and thus could play a critical role in the detection of noxious acidosis. To investigate the subunit composition of native ASICs in peripheral and central neurons, we coinjected human as well as rodent ASIC2a and ASIC3 subunits in Xenopus oocytes, The amplitudes of acid-induced biphasic responses mediated by co-expressed ASIC2a and ASIC3 subunits were much larger (as much as 20-fold) than the currents mediated by the respective homomers, clearly indicating functional association. The reversal potential of the ASIC2a+3 current (greater than or equal to+20 mV) reflected a cationic current mainly selective for sodium, The sensitivity to pH or amiloride of single versus co-expressed ASIC subunits was not significantly different; however, gadolinium ions inhibited ASICS and ASIC2a+3 responses with much higher potency (IC50 similar to 40 mu M) than the ASIC2a response (IC50 greater than or equal to 1 mM). Biochemical interaction between ASIC2a and ASIC3 subunits was demonstrated by co-purification from transfected human embryonic kidney (HEK293) cells and Xenopus oocytes. Our in situ hybridization data showed that rat ASIC2a and ASIC3 transcripts are colocalized centrally, whereas reverse transcription-polymerase chain reaction data led us to detect co-expression of human ASIC2a and ASIC3 subunits in trigeminal sensory ganglia, brain, and testis where they might coassemble into a novel subtype of proton-gated channels sensitive to gadolinium.	McGill Univ, Montreal Neurol Inst, Cell Biol Excitable Tissue Grp, Montreal, PQ H3A 2B4, Canada; Antalium Inc, Montreal, PQ H3A 1X6, Canada; Univ Modena, Dept Biomed Sci, Physiol Sect, I-41100 Modena, Italy	McGill University; Universita di Modena e Reggio Emilia	Seguela, P (corresponding author), McGill Univ, Montreal Neurol Inst, Cell Biol Excitable Tissue Grp, 3801 Univ St,Rm 778, Montreal, PQ H3A 2B4, Canada.		Biagini, Giuseppe/F-7668-2013; Biagini, Giuseppe/I-3227-2013	Biagini, Giuseppe/0000-0002-7130-2511; Biagini, Giuseppe/0000-0002-7130-2511				Adams CM, 1998, J CELL BIOL, V140, P143, DOI 10.1083/jcb.140.1.143; AKAIKE N, 1994, PROG NEUROBIOL, V43, P73, DOI 10.1016/0301-0082(94)90016-7; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Coscoy S, 1999, J BIOL CHEM, V274, P10129, DOI 10.1074/jbc.274.15.10129; CUNNINGHAM JT, 1995, J NEUROPHYSIOL, V73, P2094, DOI 10.1152/jn.1995.73.5.2094; Darboux I, 1998, BIOCHEM BIOPH RES CO, V246, P210, DOI 10.1006/bbrc.1998.8183; Darboux I, 1998, J BIOL CHEM, V273, P9424, DOI 10.1074/jbc.273.16.9424; de Weille JR, 1998, FEBS LETT, V433, P257, DOI 10.1016/S0014-5793(98)00916-8; Eccles JC, 1967, CEREBELLUM NEURONAL; Garcia-Anoveros J, 1998, NEURON, V20, P1231, DOI 10.1016/S0896-6273(00)80503-6; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Hamill OP, 1996, PHARMACOL REV, V48, P231; Horisberger JD, 1998, CURR OPIN CELL BIOL, V10, P443, DOI 10.1016/S0955-0674(98)80056-2; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; Lai CC, 1996, J CELL BIOL, V133, P1071, DOI 10.1083/jcb.133.5.1071; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; Liu JD, 1996, SCIENCE, V273, P361, DOI 10.1126/science.273.5273.361; Mano I, 1999, BIOESSAYS, V21, P568, DOI 10.1002/(SICI)1521-1878(199907)21:7&lt;568::AID-BIES5&gt;3.0.CO;2-L; Marcinkiewicz M, 1997, NEUROSCIENCE, V76, P425, DOI 10.1016/S0306-4522(96)00318-1; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Sakai H, 1999, J PHYSIOL-LONDON, V519, P323, DOI 10.1111/j.1469-7793.1999.0323m.x; Schaefer L, 2000, FEBS LETT, V471, P205, DOI 10.1016/S0014-5793(00)01403-4; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6	31	139	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28519	28525		10.1074/jbc.M004114200	http://dx.doi.org/10.1074/jbc.M004114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10842183	hybrid			2022-12-25	WOS:000089330700026
J	Bardos, JI; Saurin, AJ; Tissot, C; Duprez, E; Freemont, PS				Bardos, JI; Saurin, AJ; Tissot, C; Duprez, E; Freemont, PS			HPC3 is a new human polycomb orthologue that interacts and associates with RING1 and Bmi1 and Has transcriptional repression properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYC TRANSGENIC MICE; DROSOPHILA-MELANOGASTER; GENE-EXPRESSION; GROUP PROTEINS; MONOCLONAL-ANTIBODIES; CELL-PROLIFERATION; CHROMO DOMAIN; ZINC FINGER; C-MYC; COMPLEXES	Polycomb group (PcG) proteins were first described in Drosophila as factors responsible for maintaining the transcriptionally repressed state of Hox/homeotic genes in a stable and heritable manner throughout development. A growing number of vertebrate genes related to the Drosophila PcG proteins have recently been identified, including two Polycomb orthologues, Pc2 and M33. PcG proteins form multiprotein complexes, termed PcG bodies, that are thought to repress transcription by altering chromatin structure. Here we report the identification and characterization of HPC3 (human Polycomb 3), a novel PcG protein isolated in a yeast two-hybrid screen using human RING1 as bait. HPC3 shows strong sequence similarity to Drosophila Pc and also to vertebrate Pc2 and M33, particularly within the chromodomain and C-box, Previous studies indicate that M33 and human Pc2 (HPC2) can interact with RING1, and we show here that HPC3 also binds to RING1. This interaction is dependent upon the HPC3 C-box but, only partially on the RING finger of RING1, In contrast to HPC2, HPC3 interactions with RING1 are only observed in vivo with covalently modified forms of RING1. HPC3 also colocalizes with other PcG proteins in human PcG bodies. Consistent with its role as a PcG member, HPC3 is able to act as a long range transcriptional silencer when targeted to a reporter gene by a heterologous DNA-binding domain. Taken together, these data suggest that HPC3 is part of a large multiprotein complex that also contains other PcG proteins and is involved in repression of transcriptional activity.	Imperial Canc Res Fund, Mol Struct & Funct Lab, London WC2A 3PX, England	Cancer Research UK	Freemont, PS (corresponding author), Imperial Canc Res Fund, Mol Struct & Funct Lab, POB 123, London WC2A 3PX, England.	freemont@icrf.icnet.uk	duprez, estelle a/R-2357-2016	Freemont, Paul/0000-0002-5658-8486; Duprez, Estelle/0000-0003-3810-5740; Saurin, Andrew/0000-0001-5162-003X				Alkema MJ, 1997, J MOL BIOL, V273, P993, DOI 10.1006/jmbi.1997.1372; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Assier E, 1999, GENE, V230, P145, DOI 10.1016/S0378-1119(99)00066-9; BARTON GJ, 1990, J MOL BIOL, V212, P389, DOI 10.1016/0022-2836(90)90133-7; Bel S, 1998, DEVELOPMENT, V125, P3543; BIENZ L, 1995, BIOESSAYS, V17, P775, DOI 10.1002/bies.950170907; Breiling A, 1999, MOL CELL BIOL, V19, P8451; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; CASTELLIGAIR JE, 1990, EMBO J, V9, P4267, DOI 10.1002/j.1460-2075.1990.tb07875.x; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRANKE A, 1995, CHROMOSOME RES, V3, P351, DOI 10.1007/BF00710016; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; Hashimoto N, 1998, BIOCHEM BIOPH RES CO, V245, P356, DOI 10.1006/bbrc.1998.8438; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hemenway CS, 1998, ONCOGENE, V16, P2541, DOI 10.1038/sj.onc.1202042; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, SEMIN CELL DEV BIOL, V10, P227, DOI 10.1006/scdb.1999.0304; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; James P, 1996, GENETICS, V144, P1425; JURGENS G, 1985, NATURE, V316, P153, DOI 10.1038/316153a0; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; KOONIN EV, 1995, NUCLEIC ACIDS RES, V23, P4229, DOI 10.1093/nar/23.21.4229; KRIEF P, 1994, ONCOGENE, V9, P3449; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LANDECKER HL, 1994, DEV GENET, V15, P425, DOI 10.1002/dvg.1020150505; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; LEVISTRAUSS M, 1988, SCIENCE, V240, P201, DOI 10.1126/science.3353717; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; MORATA G, 1993, CURR OPIN GENET DEV, V3, P606, DOI 10.1016/0959-437X(93)90096-8; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; MULLER J, 1995, DEVELOPMENT, V121, P2847; NAGAFUCHI S, 1994, NAT GENET, V8, P177, DOI 10.1038/ng1094-177; ORLANDO V, 1995, CURR OPIN GENET DEV, V5, P174, DOI 10.1016/0959-437X(95)80005-0; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; PARO R, 1995, TRENDS GENET, V11, P295, DOI 10.1016/S0168-9525(00)89081-2; PIRROTTA V, 1995, CURR OPIN GENET DEV, V5, P466, DOI 10.1016/0959-437X(95)90050-Q; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Satijn DPE, 1999, BBA-GENE STRUCT EXPR, V1447, P1, DOI 10.1016/S0167-4781(99)00130-X; Satijn DPE, 1999, MOL CELL BIOL, V19, P57; Satijn DPE, 1997, MOL CELL BIOL, V17, P6076, DOI 10.1128/MCB.17.10.6076; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887; Schoorlemmer J, 1997, EMBO J, V16, P5930, DOI 10.1093/emboj/16.19.5930; Schumacher A, 1997, TRENDS GENET, V13, P167, DOI 10.1016/S0168-9525(97)01133-5; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10373, DOI 10.1093/nar/15.24.10373; Stroumbakis ND, 1996, MOL CELL BIOL, V16, P192; TAMKUN JW, 1995, CURR OPIN GENET DEV, V5, P473, DOI 10.1016/0959-437X(95)90051-H; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1998, CELL MOL LIFE SCI, V54, P71, DOI 10.1007/s000180050126; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; vanderLugt NMT, 1996, MECH DEVELOP, V58, P153, DOI 10.1016/S0925-4773(96)00570-9; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0	68	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	2000	275	37					28785	28792		10.1074/jbc.M001835200	http://dx.doi.org/10.1074/jbc.M001835200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	354KY	10825164	hybrid			2022-12-25	WOS:000089330700060
J	Stofega, MR; Argetsinger, LS; Wang, HY; Ullrich, A; Carter-Su, C				Stofega, MR; Argetsinger, LS; Wang, HY; Ullrich, A; Carter-Su, C			Negative regulation of growth hormone receptor/JAK2 signaling by signal regulatory protein alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; PROMOTED TYROSYL PHOSPHORYLATION; INHIBITORY RECEPTORS; PHOSPHATASE SH-PTP2; KINASE; ACTIVATION; SHP-2; JAK2; BINDING; FAMILY	Signal regulatory proteins (SIRPs) are receptor-like transmembrane proteins, the majority of which contain a cytoplasmic proline-rich region and four cytoplasmic tyrosines that, when phosphorylated, bind SH2 domain-containing protein tyrosine phosphatases (SHP). We demonstrated previously that growth hormone (GH) induces tyrosyl phosphorylation of SIRP alpha and association of SIRP alpha with SHP-2. The GH-activated tyrosine kinase JAK2 associates with and tyrosyl-phosphorylates SIRP alpha 1. Here we show that JAK2-SIRP alpha 1 association does not require phosphotyrosines in SIRP alpha 1 or JAK2 or the proline-rich region of SIRP alpha 1. However, when the C-terminal 30 amino acids of SIRP alpha 1 containing the proline-rich region and tyrosine 495 are deleted, tyrosyl phosphorylation of SIRP alpha 1 by JAK2 and association of SHP-2 with SIRP alpha 1 are reduced. GH-dependent tyrosyl phosphorylation of JAK2 is reduced when wild-type SIRP alpha 1 compared with SIRP alpha 1 lacking the four cytoplasmic tyrosines (SIRP 4YF) is expressed in cells, suggesting that SIRP alpha 1 negatively regulates GHR/JAK2 signaling. Consistent with reduced JAK2 activity, overexpression of wild-type SIRP alpha 1 but not SIRP 4YF reduces GH-induced phosphorylation of ERKs 1 and 2, STAT3, and STAT5B. These results suggest that SIRP alpha 1 is a negative regulator of GH signaling and that the ability of SIRP alpha 1 mutants to negatively regulate GHR-JAK2 signaling correlates with their ability to bind SHP-2.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Max Planck Society	Carter-Su, C (corresponding author), Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA.	cartersu@umich.edu	Wang, Hongyang/B-1340-2010		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048283, R01DK034171, P60DK020572, R37DK034171] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK034171, DK 34171, P60-DK20572, DK48283] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Cambier JC, 1997, P NATL ACAD SCI USA, V94, P5993, DOI 10.1073/pnas.94.12.5993; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; COOPER D, 1995, P NATL ACAD SCI USA, V92, P3978, DOI 10.1073/pnas.92.9.3978; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; HARDING PA, 1994, MOL CELL ENDOCRINOL, V106, P171, DOI 10.1016/0303-7207(94)90200-3; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; SMIT LS, 1999, HDB PHYSL, V5, P445; Stofega MR, 1998, J BIOL CHEM, V273, P7112, DOI 10.1074/jbc.273.12.7112; SZECOWKA J, 1990, ENDOCRINOLOGY, V126, P1834, DOI 10.1210/endo-126-4-1834; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Takeda H, 1998, ONCOGENE, V16, P3019, DOI 10.1038/sj.onc.1201839; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; Vivier E, 1997, IMMUNOL TODAY, V18, P286, DOI 10.1016/S0167-5699(97)80025-4; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; Yokoyama WM, 1997, J EXP MED, V186, P1803, DOI 10.1084/jem.186.11.1803; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	37	50	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					28222	28229						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10842184				2022-12-25	WOS:000089197100092
J	Akiyama, TE; Ward, JM; Gonzalez, FJ				Akiyama, TE; Ward, JM; Gonzalez, FJ			Regulation of the liver fatty acid-binding protein gene by hepatocyte nuclear factor 1 alpha (HNF1 alpha) - Alterations in fatty acid homeostasis in HNF1 alpha-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; ACYL-COA OXIDASE; BETA-OXIDATION; RAT-LIVER; PEROXISOME PROLIFERATORS; LIPOPROTEIN-LIPASE; DIABETIC RAT; EXPRESSION; SEQUENCE; MOUSE	Hepatocyte nuclear factor 1 alpha (HNF1 alpha)-null mice have enlarged fatty livers and alterations in the expression of genes encoding enzymes involved in the synthesis, catabolism, and transport of fatty acids. Elevations in the expression of genes encoding fatty acid synthetic enzymes (fatty acid synthase and acyl-CoA carboxylase) and peroxisomal B-oxidation enzymes (CYP4A3, bifunctional enzyme, and thiolase) were observed in the livers of HNF1 alpha-null mice, whereas hepatic mitochondrial p-oxidation gene (medium and short chain acyl-CoA dehydrogenase) expression levels remain unchanged relative to HNF1 alpha-heterozygous controls. An elevation in the levels of fatty acid transporter gene expression was also observed. In contrast, there was a marked reduction of liver fatty acid-binding protein (L-FABP) gene expression in the livers of HNF1 alpha-null mice. Isolation and sequence analysis of the 5'-flanking region of the mouse L-FABP gene revealed the presence of two HNF1 alpha regulatory elements. The results of transient transfection studies indicate that HNF1 alpha is required to transactivate the expression of the L-FABP promoter. Taken together, these data define a critical role for HNF1 alpha in the pathogenesis of a phenotype marked by fatty infiltration of the liver and in the regulation of the L-FABP gene, the expression of which may have a direct impact on the maintenance of fatty acid homeostasis.	NIH, Lab Metab, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, Off Lab Anim Sci, Vet & Tumor Pathol Sect,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Gonzalez, FJ (corresponding author), NIH, Lab Metab, 9000 Rockville Pike, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [Z01BC005561, ZIABC005561] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asayama K, 1999, MOL CELL BIOCHEM, V194, P227, DOI 10.1023/A:1006930513476; BASS NM, 1985, J BIOL CHEM, V260, P1432; BAUMHUETER S, 1989, ANN NY ACAD SCI, V557, P272; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BERRY SA, 1993, J AM COLL NUTR, V12, P638; BESNARD P, 1993, FEBS LETT, V327, P219, DOI 10.1016/0014-5793(93)80173-R; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; Djouadi F, 1998, J CLIN INVEST, V102, P1083, DOI 10.1172/JCI3949; Engels W, 1999, MOL CELL BIOCHEM, V192, P53, DOI 10.1023/A:1006855214237; Fielding BA, 1998, BRIT J NUTR, V80, P495, DOI 10.1017/S0007114598001585; GORDON JI, 1985, J BIOL CHEM, V260, P1995; GORDON JI, 1982, BIOCHEMISTRY-US, V21, P5424, DOI 10.1021/bi00265a007; Hashimoto T, 1999, J BIOL CHEM, V274, P19228, DOI 10.1074/jbc.274.27.19228; KAIKAUS RM, 1993, J BIOL CHEM, V268, P9593; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; MANNAERTS GP, 1992, CELL BIOCHEM FUNCT, V10, P141, DOI 10.1002/cbf.290100303; Memon RA, 1999, DIABETES, V48, P121, DOI 10.2337/diabetes.48.1.121; MENDEL DB, 1991, J BIOL CHEM, V266, P677; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; RIFAI N, 1986, ARCH PATHOL LAB MED, V110, P694; Schroeder F, 1998, CHEM PHYS LIPIDS, V92, P1, DOI 10.1016/S0009-3084(98)00003-6; SIMON TC, 1993, J BIOL CHEM, V268, P18345; SWEETSER DA, 1986, J BIOL CHEM, V261, P5553; TAKAHASHI K, 1983, EUR J BIOCHEM, V136, P589, DOI 10.1111/j.1432-1033.1983.tb07781.x; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VANDENHEUVEL JP, 1993, BIOCHIM BIOPHYS ACTA, V1177, P183, DOI 10.1016/0167-4889(93)90039-R	30	85	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27117	27122						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10852923				2022-12-25	WOS:000089144800061
J	Papanikolaou, NA; Sabban, EL				Papanikolaou, NA; Sabban, EL			Ability of Egr1 to activate tyrosine hydroxylase transcription in PC12 cells - Cross-talk with AP-1 factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; N-METHYLTRANSFERASE GENE; IMMOBILIZATION STRESS; CYCLIC-AMP; C-FOS; REGULATORY ELEMENTS; PARKINSONS-DISEASE; RESPONSE ELEMENT; EXPRESSION; COMPLEX	We have recently identified an Egr1 motif that overlaps with the Spl element in the tyrosine hydroxylase (TI-I) promoter. Here we examine whether this motif has a functional role in the regulation of TH transcription in PC12 cells. In nuclear extracts from control PC12 cells, an oligonucleotide containing the TH Sp1/Egr1 motif binds Spl-containing complexes, Treatment of PC12 cells with phorbol ester (2 mu M 12-O-tetradecanoylphorbol-13-acetate (TPA)) gives rise to a new Egr1-containing complex. TPA treatment reduces the steady-state levels of the Spl protein and leads to the appearance of immunoreactive Egr1 protein within 30-60 min, Expression of the Egr1 protein in PC12 cells stimulates the chloramphenicol acetyltransferase reporter gene placed under the control of the first 272 nucleotides of the rat TH promoter. Site-directed mutagenesis of either the Sp1/Egr1 motif or of an upstream AP-1 motif or both abolishes the Egr1 mediated induction of chloramphenicol acetyltransferase activity. An oligonucleotide encompassing the AP-1/E-box sequence of the rat TH promoter competes in electrophoretic mobility shift assays for binding of nuclear extracts from control and TPA-treated cells to an oligonucleotide containing the Sp1/Egr1 element, indicating that; these two enhancers may interact. The results show that Egr1 can activate TH transcription and reveals cross-talk between Sp1/Egr1 and AP-1 factors.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Sabban, EL (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	sabban@nymc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028869] Funding Source: NIH RePORTER; NINDS NIH HHS [NS28869] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CAO XM, 1993, J BIOL CHEM, V268, P16949; Corti O, 1999, P NATL ACAD SCI USA, V96, P12120, DOI 10.1073/pnas.96.21.12120; DEFRANCO C, 1993, BIOCHEM BIOPH RES CO, V194, P425, DOI 10.1006/bbrc.1993.1837; DEFRANCO C, 1993, MOL ENDOCRINOL, V7, P365, DOI 10.1210/me.7.3.365; EBERT SN, 1994, J BIOL CHEM, V269, P20885; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; FAUCONBIGUET N, 1986, EMBO J, V5, P287; FOSSOM LH, 1992, MOL PHARMACOL, V42, P898; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GIZANGGINSBERG E, 1994, MOL ENDOCRINOL, V8, P249, DOI 10.1210/me.8.2.249; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; HASS R, 1992, BIOCHEM PHARMACOL, V44, P1569, DOI 10.1016/0006-2952(92)90474-W; HIREMAGALUR B, 1993, J BIOL CHEM, V268, P23704; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; Imaoka T, 1998, HUM GENE THER, V9, P1093, DOI 10.1089/hum.1998.9.7-1093; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; KIM KS, 1994, J NEUROCHEM, V63, P834; KIM KS, 1993, J BIOL CHEM, V268, P15689; Kumer SC, 1996, J NEUROCHEM, V67, P443; Kvetnansky R, 1998, ANN NY ACAD SCI, V851, P342, DOI 10.1111/j.1749-6632.1998.tb09008.x; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; Mallet J, 1996, TRENDS NEUROSCI, V19, P191, DOI 10.1016/S0166-2236(96)10029-1; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; Menezes A, 1996, J NEUROCHEM, V67, P2316; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORGAN DG, 1988, ANN NY ACAD SCI, V515, P145, DOI 10.1111/j.1749-6632.1988.tb32978.x; MORITA K, 1995, J BIOL CHEM, V270, P11161, DOI 10.1074/jbc.270.19.11161; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; NANKOVA B, 1993, J NEUROCHEM, V61, P776; NANKOVA B, 1994, P NATL ACAD SCI USA, V91, P5937, DOI 10.1073/pnas.91.13.5937; Noti JD, 1996, MOL CELL BIOL, V16, P2940; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Osaka H, 1997, MOL BRAIN RES, V49, P222, DOI 10.1016/S0169-328X(97)00148-4; OSAKA H, 1994, SOC NEUROSCI, V20, P125; Papanikolaou NA, 1999, J NEUROCHEM, V73, P433, DOI 10.1046/j.1471-4159.1999.0730433.x; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Ryu SJ, 1999, P NATL ACAD SCI USA, V96, P7137, DOI 10.1073/pnas.96.13.7137; Sabban EL, 1997, SEMIN CELL DEV BIOL, V8, P101, DOI 10.1006/scdb.1996.0129; Sharma P, 1998, HYPERTENSION, V32, P676, DOI 10.1161/01.HYP.32.4.676; VISKUPIC E, 1994, J NEUROCHEM, V63, P808; Wei J, 1997, LIFE SCI, V61, P1341, DOI 10.1016/S0024-3205(97)00679-6; WESSEL TC, 1992, MOL BRAIN RES, V15, P349, DOI 10.1016/0169-328X(92)90128-X; WONG DL, 1999, FUND CLIN PHARMACOL, V13; Yang CY, 1998, J NEUROCHEM, V71, P1358; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8	47	54	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26683	26689						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842166				2022-12-25	WOS:000089144800004
J	Kessler, SP; Rowe, TM; Gomos, JB; Kessler, PM; Sen, GC				Kessler, SP; Rowe, TM; Gomos, JB; Kessler, PM; Sen, GC			Physiological non-equivalence of the two isoforms of angiotensin-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTICULAR ISOZYME; BLOOD-PRESSURE; MESSENGER-RNAS; MALE-FERTILITY; CELL-SURFACE; SOMATIC ACE; GENE; MICE; TRANSCRIPTION; EXPRESSION	The structurally related somatic and germinal isoforms of angiotensin-converting enzyme (ACE) contain the same catalytic active center and are encoded by the same gene, whose disruption causes renal atrophy, hypotension, and male sterility. The reason for the evolutionary conservation of both isozymes is an enigma, because, in vitro, they have very similar enzymatic properties. Despite the common enzymatic properties, discrete expression of both isoforms is maintained in alternate cell types. We have previously shown that sperm-specific expression of transgenic germinal ACE in Ace -/- male mice restores fertility without curing their other abnormalities (Ramaraj, P., Kessler, S. P., Colmenares, C. & Sen, G. C. (1998) J. Clin. Invest. 102, 371-378). In this report we tested the biological equivalence of somatic ACE and germinal ACE utilizing an in vivo isozymic substitution approach. Here we report that restoration of male fertility was not achieved by the transgenic expression of enzymatically active, somatic ACE in the sperm of Ace -/- mice. Therefore, the requisite physiological functions of the two tissue-specific isozymes of ACE are not interchangeable.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Sen, GC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	seng@ccf.org			NHLBI NIH HHS [HL 48258] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048258] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BELDENT V, 1995, J BIOL CHEM, V270, P28962, DOI 10.1074/jbc.270.48.28962; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P7118, DOI 10.1021/bi00243a012; Ertoy D, 2000, V CH MO CAR, V1, P205; Esther CR, 1997, J CLIN INVEST, V99, P2375, DOI 10.1172/JCI119419; FRIEDLAND J, 1978, BIOCHEM BIOPH RES CO, V83, P843, DOI 10.1016/0006-291X(78)91471-7; Hagaman JR, 1998, P NATL ACAD SCI USA, V95, P2552, DOI 10.1073/pnas.95.5.2552; Houard X, 1998, EUR J BIOCHEM, V257, P599, DOI 10.1046/j.1432-1327.1998.2570599.x; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; Isaac RE, 1999, ANN NY ACAD SCI, V897, P342, DOI 10.1111/j.1749-6632.1999.tb07904.x; Isaac RE, 1997, BIOCHEM J, V328, P587, DOI 10.1042/bj3280587; Kessler SP, 1996, GENE EXPRESSION, V6, P73; Kessler SP, 1998, J BIOL CHEM, V273, P9971, DOI 10.1074/jbc.273.16.9971; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; Krebs LT, 2000, J PHARMACOL EXP THER, V293, P260; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; KUMAR RS, 1991, J BIOL CHEM, V266, P3854; LANGFORD KG, 1993, BIOL REPROD, V48, P1210, DOI 10.1095/biolreprod48.6.1210; OPPONG SY, 1993, BIOCHEM J, V292, P597, DOI 10.1042/bj2920597; PERICH RB, 1992, MOL PHARMACOL, V42, P286; Ramaraj P, 1998, J CLIN INVEST, V102, P371, DOI 10.1172/JCI3545; ROUSSEAU A, 1995, J BIOL CHEM, V270, P3656, DOI 10.1074/jbc.270.8.3656; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; SEN I, 1991, J BIOL CHEM, V266, P21985; Strawn WB, 1999, HYPERTENSION, V33, P207, DOI 10.1161/01.HYP.33.1.207; STRITTMATTER SM, 1987, NEUROSCIENCE, V21, P407, DOI 10.1016/0306-4522(87)90131-X; TATEI K, 1995, MECH DEVELOP, V51, P157, DOI 10.1016/0925-4773(95)00349-5; THEKKUMKARA TJ, 1992, NUCLEIC ACIDS RES, V20, P683, DOI 10.1093/nar/20.4.683; Tian BH, 1997, HYPERTENSION, V30, P128, DOI 10.1161/01.HYP.30.1.128; WILLIAMS TA, 1992, BIOCHEM J, V288, P875, DOI 10.1042/bj2880875	30	70	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26259	26264		10.1074/jbc.M004006200	http://dx.doi.org/10.1074/jbc.M004006200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10831599	hybrid			2022-12-25	WOS:000088999700053
J	Doostzadeh-Cizeron, J; Yin, S; Goodrich, DW				Doostzadeh-Cizeron, J; Yin, S; Goodrich, DW			Apoptosis induced by the nuclear death domain protein p84N5 is associated with caspase-6 and NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 HOMOLOG BAK; CELL-DEATH; RECOMBINANT ADENOVIRUS; CYTOCHROME-C; P53; GENE; EXPRESSION; FAMILY; PHOSPHORYLATION; LYMPHOCYTES	Although the mechanisms involved in responses to extracellular or mitochondrial apoptotic signals have received considerable attention, the mechanisms utilized within the nucleus to transduce apoptotic signals are not well understood. We have characterized apoptosis induced by the nuclear death domain-containing protein p84N5, Adenovirus-mediated N5 gene transfer or transfection of p84N5 expression vectors induces apoptosis in tumor cell lines with nearly 10096 efficiency as indicated by cellular morphology, DNA fragmentation, and annexin V staining, Using peptide substrates and Western blotting, we have determined that NB-induced apoptosis is initially accompanied by activation of caspase-6. Activation of caspases-3 and -9 does not peak until 3 days after the peak of caspase-8 activity. Expression of p84N5 also leads to activation of NF-KB as indicated by nuclear translocation of p65RelA and transcriptional activation of a NF-kappa B-dependent reporter promoter. Changes in the relative expression level of Bcl-2 family proteins, including Bak and Bcl-Xs, are also observed during p84N5-induced apoptosis, Finally, we demonstrate that p84N5-induced apoptosis does not require p53 and is not inhibited by p53 coexpression. We propose that p84N5 is involved in an apoptotic pathway distinct from those triggered by death domain-containing receptors or by p53.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Goodrich, DW (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd,Box 108, Houston, TX 77030 USA.	goodrich@odin.mdacc.tmc.edu			NATIONAL CANCER INSTITUTE [P30CA016672, R01CA070292] Funding Source: NIH RePORTER; NCI NIH HHS [CA-70292, CA-16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; CHEN YM, 1991, ONCOGENE, V6, P1799; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Cregan SP, 1999, J NEUROSCI, V19, P7860; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Doostzadeh-Cizeron J, 1999, MOL BIOL CELL, V10, P3251, DOI 10.1091/mbc.10.10.3251; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Haimovitz-Friedman A, 1998, RADIAT RES, V150, pS102, DOI 10.2307/3579812; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; HUYGHE BG, 1995, HUM GENE THER, V6, P1403, DOI 10.1089/hum.1995.6.11-1403; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; MIYASHITA T, 1995, CELL, V80, P293; Orth R, 1997, J BIOL CHEM, V272, P8841; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; SINGER W, 1990, CONCEPTS NEUROSCI, V1, P1; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Song QZ, 1999, EMBO J, V18, P167, DOI 10.1093/emboj/18.1.167; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YIN S, 2000, IN PRESS CANC GENE T, P32; Yu YJ, 1998, CANCER RES, V58, P4277; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	49	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25336	25341		10.1074/jbc.M000793200	http://dx.doi.org/10.1074/jbc.M000793200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10840029	hybrid			2022-12-25	WOS:000088849400040
J	Skalski, V; Brown, KR; Choi, BY; Lin, ZY; Chen, S				Skalski, V; Brown, KR; Choi, BY; Lin, ZY; Chen, S			A 3 '-5 ' exonuclease in human leukemia cellsn - Implications for resistance to 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5 '-monophosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOBLASTIC-LEUKEMIA; CYTOSINE-ARABINOSIDE; SYNDROME PROTEIN; DNA-POLYMERASES; CELLULAR DNA; FLUDARABINE; 3'->5'-EXONUCLEASE; IDENTIFICATION; TRIPHOSPHATE	A 3'-5' exonuclease that excises the nucleotide analogs 1-beta-D-arabinofuranosylcytosine monophosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate incorporated at 3' ends of DNA was purified from the nuclei of: 1) primary human chronic lymphocytic leukemia cells, 2) primary and established human acute myeloblastic leukemia cells, and 3) lymphocytes obtained from healthy individuals. The activity of this nuclear exonuclease (exoN) is elevated approximately 6-fold in 1-beta-D-arabinofuranosylcytosine-resistant leukemia cells as compared with drug-sensitive cells, and it differs between two healthy individuals and among three leukemia patients. exoN is a 46-kDa monomer, requires 50 mM KCl and 1 mM magnesium for optimal activity, and shows a preference for single-stranded over duplex DNA. Its physical and enzymatic properties indicate that exoN is a previously uncharacterized enzyme whose activity may confer resistance to clinical nucleoside analogs in leukemia cells.	Princess Margaret Hosp, Ontario Canc Inst, Div Expt Therapeut, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Skalski, V (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Div Expt Therapeut, 620 Univ Ave, Toronto, ON M5G 2M9, Canada.			Brown, Kevin/0000-0002-5514-2538				BELYAKOVA NV, 1993, EUR J BIOCHEM, V217, P493, DOI 10.1111/j.1432-1033.1993.tb18269.x; Bennett JM, 1997, CANCER, V80, P2205; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; FREI E, 1969, CANCER RES, V29, P1325; HARRINGTON JA, 1993, ANTIMICROB AGENTS CH, V37, P18; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; HU ZB, 1995, LEUKEMIA, V9, P789; HUANG P, 1992, J BIOL CHEM, V267, P2817; HUANG P, 1991, CANCER RES, V51, P6110; HUANG P, 1995, CANCER CHEMOTH PHARM, V36, P181, DOI 10.1007/BF00685844; HUANG P, 1990, J BIOL CHEM, V265, P16617; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; JULIUSSON G, 1992, NEW ENGL J MED, V327, P1056, DOI 10.1056/NEJM199210083271504; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kamiya K, 1996, J BIOL CHEM, V271, P19428, DOI 10.1074/jbc.271.32.19428; KEATING MJ, 1989, BLOOD, V74, P19; KOISTINEN P, 1991, LEUKEMIA, V5, P704; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NICKEL W, 1992, J BIOL CHEM, V267, P848; PANASCI L, 1988, CANCER RES, V48, P1972; PERRINO FW, 1994, J BIOL CHEM, V269, P16357; RICHEL DJ, 1990, CANCER RES, V50, P6515; RUSTUM YM, 1979, CANCER RES, V39, P42; SKALSKI V, 1995, BIOCHEM PHARMACOL, V50, P815, DOI 10.1016/0006-2952(95)00205-E; SKALSKI V, 1993, J BIOL CHEM, V268, P23234; SPRIGGS D, 1986, BIOCHEM PHARMACOL, V35, P247, DOI 10.1016/0006-2952(86)90521-6; STELLWAGEN E, 1990, METHOD ENZYMOL, V182, P318; STEUART CD, 1971, NATURE-NEW BIOL, V233, P109, DOI 10.1038/newbio233109a0; VAZQUEZPADUA MA, 1990, CANCER COMMUN, V2, P55, DOI 10.3727/095535490820874740; Vincent B R, 1979, Somatic Cell Genet, V5, P67; WILEY JS, 1982, J CLIN INVEST, V69, P479, DOI 10.1172/JCI110472; Zhu L, 1999, BIOCHEM BIOPH RES CO, V259, P262, DOI 10.1006/bbrc.1999.0774	34	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25814	25819		10.1074/jbc.M001460200	http://dx.doi.org/10.1074/jbc.M001460200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833512	hybrid			2022-12-25	WOS:000088849400099
J	Yengo, CM; Chrin, LR; Rovner, AS; Berger, CL				Yengo, CM; Chrin, LR; Rovner, AS; Berger, CL			Tryptophan 512 is sensitive to conformational changes in the rigid relay loop of smooth muscle myosin during the MgATPase cycles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICTYOSTELIUM-DISCOIDEUM MYOSIN; X-RAY STRUCTURE; MOTOR DOMAIN; LIGHT-CHAIN; CRYSTAL-STRUCTURE; ADP RELEASE; ACTIVE-SITE; LEVER ARM; HEAD; FLUORESCENCE	To examine the structural basis of the intrinsic fluorescence changes that occur during the MgATPase cycle of myosin, we generated three mutants of smooth muscle myosin motor domain essential light chain (MDE) containing a single conserved tryptophan residue located at Trp-441 (W441-MDE), Trp-512 (W512-MDE), or Trp-597 (W597-MDE), Although W441- and W597-MDE were insensitive to nucleotide binding, the fluorescence intensity of W512-MDE increased in the presence of MgADP-berellium fluoride (BeFX) (31%), MgADP-AIF(4)(-) (31%), MgATP (36%), and MgADP (30%) compared with the nucleotide-free environment (rigor), which was similar to the results of wild type-RIDE. Thus, Trp-512 may be the sole ATP-sensitive tryptophan residue in myosin, In addition, acrylamide quenching indicated that Trp-512 was more protected from solvent in the presence of MgATP or MgADP-AIF(4)(-) than in the presence of MgADP-BeFX MgADP, or in rigor. Furthermore, the degree of energy transfer from Trp-512 to 2'(3')-O-(N-methylanthraniloyl)-labeled nucleotides was greater in the presence of MgADP-BeFX MgATP, or MgADP-AIF(4)(-) than MgADP, We conclude that the conformation of the rigid relay loop containing Trp-512 is altered upon MgATP hydrolysis and during the transition from weak to strong actin binding, establishing a communication pathway from the active site to the actin-binding and converter/lever arm regions of myosin during muscle contraction.	Univ Vermont, Coll Med, Dept Physiol & Mol Biophys, Burlington, VT 05405 USA	University of Vermont	Berger, CL (corresponding author), Univ Vermont, Coll Med, Dept Physiol & Mol Biophys, Burlington, VT 05405 USA.				NHLBI NIH HHS [HL38113, HL63798] Funding Source: Medline; NIAMS NIH HHS [AR44219] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063798, R01HL038113, R29HL038113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044219] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; Baker JE, 1998, P NATL ACAD SCI USA, V95, P2944, DOI 10.1073/pnas.95.6.2944; Batra R, 1999, BIOL CHEM, V380, P1017, DOI 10.1515/BC.1999.126; Bauer CB, 1997, J MOL BIOL, V274, P394, DOI 10.1006/jmbi.1997.1325; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Fairclough R H, 1978, Methods Enzymol, V48, P347; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Franks-Skiba K., 1995, Biophysical Journal, V68, P142; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; Gulick AM, 1997, BIOESSAYS, V19, P561, DOI 10.1002/bies.950190707; Highsmith S, 1999, BIOCHEMISTRY-US, V38, P9791, DOI 10.1021/bi9907633; HIRATSUKA T, 1992, J BIOL CHEM, V267, P14949; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; JOHNSON KA, 1978, BIOCHEMISTRY-US, V17, P3432, DOI 10.1021/bi00610a002; JOHNSON WC, 1991, P NATL ACAD SCI USA, V88, P9748, DOI 10.1073/pnas.88.21.9748; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; Kurzawa SE, 1997, BIOCHEMISTRY-US, V36, P317, DOI 10.1021/bi962166b; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J. R., 1983, PRINCIPLES FLUORESCE, P305; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; Park S, 1996, BBA-PROTEIN STRUCT M, V1296, P1, DOI 10.1016/0167-4838(96)00086-6; PARKER CA, 1960, ANALYST, V85, P587, DOI 10.1039/an9608500587; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Rayment I, 1996, ANNU REV PHYSIOL, V58, P671; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RICHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1908; SMITH CA, 1995, BIOCHEMISTRY-US, V34, P8973, DOI 10.1021/bi00028a005; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; WERBER MM, 1972, BIOCHEMISTRY-US, V11, P2872, DOI 10.1021/bi00765a021; WERBER MM, 1992, BIOCHEMISTRY-US, V31, P7190, DOI 10.1021/bi00146a023; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; WOLEDGE R, 1985, ENERGETIC ASPECTS MU, P155; Woodward SKA, 1995, BIOCHEMISTRY-US, V34, P16056, DOI 10.1021/bi00049a020; Xiao M, 1998, P NATL ACAD SCI USA, V95, P15309, DOI 10.1073/pnas.95.26.15309; Yengo CM, 1998, P NATL ACAD SCI USA, V95, P12944, DOI 10.1073/pnas.95.22.12944	44	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25481	25487		10.1074/jbc.M002910200	http://dx.doi.org/10.1074/jbc.M002910200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827189	hybrid			2022-12-25	WOS:000088849400058
J	Cabral, CM; Choudhury, P; Liu, Y; Sifers, RN				Cabral, CM; Choudhury, P; Liu, Y; Sifers, RN			Processing by endoplasmic reticulum mannosidases partitions a secretion-impaired glycoprotein into distinct disposal pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT ALPHA-MANNOSIDASE; QUALITY-CONTROL; INTRACELLULAR DEGRADATION; LINKED OLIGOSACCHARIDES; HUMAN ALPHA(1)-ANTITRYPSIN; APOLIPOPROTEIN-B; HUMAN-DISEASE; PROTEIN; PROTEASOME; CALNEXIN	In the early secretory pathway, a distinct set of processing enzymes and family of lectins facilitate the folding and quality control of newly synthesized glycoproteins, In this regard, we recently identified a mechanism in which processing by endoplasmic reticulum mannosidase I, which attenuates the removal of glucose from asparagine-linked oligosaccharides, sorts terminally misfolded alpha(1)-antitrypsin for proteasome-mediated degradation in response to its abrogated physical dissociation from calnexin (Liu, Y,, Choudhury, P., Cabral, C,, and Sifers, R, N. (1999) J. Biol, Chem. 274, 5861-5867), In the present study, we examined the quality control of genetic variant PI Z, which undergoes inappropriate polymerization following biosynthesis. Here we show that in stably transfected hepatoma cells the additional processing of asparagine-linked oligosaccharides by endoplasmic reticulum mannosidase II partitions variant PI Z away from the conventional disposal mechanism in response to an arrested posttranslational interaction with calnexin. Intracellular disposal is accomplished by a nonproteasomal system that functions independently of cytosolic components but is sensitive to tyrosine phosphatase inhibition. The functional role of ER mannosidase II in glycoprotein quality control is discussed.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Grad Program, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Sifers, RN (corresponding author), Baylor Coll Med, Dept Pathol, 1 Baylor Plaza, Houston, TX 77030 USA.	rsifers@bcm.tmc.edu	Sifers, Richard Norman/AGQ-7262-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062553] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL/DK62553] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELI K, 1994, J BIOL CHEM, V269, P9166; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRANTLY M, 1988, AM J MED, V84, P13; CARLSON JA, 1988, J CLIN INVEST, V82, P26, DOI 10.1172/JCI113580; Cavallo D, 1999, J BIOL CHEM, V274, P23135, DOI 10.1074/jbc.274.33.23135; Choudhury P, 1997, J BIOL CHEM, V272, P13446, DOI 10.1074/jbc.272.20.13446; Choudhury P, 1997, NEWS PHYSIOL SCI, V12, P162; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fernandez F, 1998, EMBO J, V17, P5877, DOI 10.1093/emboj/17.20.5877; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LE A, 1990, J BIOL CHEM, V265, P14001; LE AQ, 1992, J BIOL CHEM, V267, P1072; LE AQ, 1994, J BIOL CHEM, V269, P7514; Liao W, 2000, J BIOL CHEM, V275, P3950, DOI 10.1074/jbc.275.6.3950; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Liu Y, 1997, J BIOL CHEM, V272, P7946, DOI 10.1074/jbc.272.12.7946; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; McCracken AA, 1996, GENETICS, V144, P1355; Miller SC, 1998, J BIOL CHEM, V273, P32618, DOI 10.1074/jbc.273.49.32618; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; Novoradovskaya N, 1998, J CLIN INVEST, V101, P2693, DOI 10.1172/JCI549; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SIDHAR SK, 1995, J BIOL CHEM, V270, P8393, DOI 10.1074/jbc.270.15.8393; SIFERS RN, 1995, NAT STRUCT BIOL, V2, P355, DOI 10.1038/nsb0595-355; SIFERS RN, 1989, MOL BIOL MED, V6, P127; SIFERS RN, 1992, SEMIN LIVER DIS, V12, P301, DOI 10.1055/s-2008-1040399; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; Weng SA, 1996, ARCH BIOCHEM BIOPHYS, V325, P113, DOI 10.1006/abbi.1996.0014; WENG SA, 1993, J BIOL CHEM, V268, P25656; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363; Zapun A, 1997, CELL, V88, P29, DOI 10.1016/S0092-8674(00)81855-3	55	100	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					25015	25022		10.1074/jbc.M910172199	http://dx.doi.org/10.1074/jbc.M910172199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827201	hybrid			2022-12-25	WOS:000088683300104
J	Flury, I; Benachour, A; Conzelmann, A				Flury, I; Benachour, A; Conzelmann, A			YLL031c belongs to a novel family of membrane proteins involved in the transfer of ethanolaminephosphate onto the core structure of glycosylphosphatidylinositol anchors in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL PROTEINS; SACCHAROMYCES-CEREVISIAE; GPI ANCHOR; ENDOPLASMIC-RETICULUM; MAMMALIAN-CELLS; GENE DISRUPTIONS; BIOSYNTHESIS; IDENTIFICATION; PCR; PHOSPHOETHANOLAMINE	MCD4 and GP17 are important for the addition of glycosylphosphatidylinositol (GPI) anchors to proteins in the yeast Saccharomyces cerevisiae, Mutations in these genes lead to a reduction of GPI anchoring and cell wall fragility. Gpi7 mutants accumulate a GPI lipid intermediate of the structure Man alpha 1-2[NH2-(CH2)(2)-PO4-->]Man-alpha 1-2Man alpha 1- 6[NH2-(CH2)(2)-PO4-->]Man alpha 1- 4GlcN alpha 1-6 [acyl-->] linositol-PO4-lipid, which, in comparison with the complete GPI precursor lipid CP2, lacks an HF-sensitive side chain on the alpha 1-6-linked mannose, In contrast, mcd4-174 accumulates only minor amounts of abnormal GPI intermediates. Here we investigate whether YLL031c, an open reading frame predicting a further homologue of GP17 and MCD4, plays any rob in GPI anchoring. YLL031c is an essential gene. Its depletion results in a reduction of GPI anchor addition to GPI proteins as well as to cell wall fragility. YLL031c-depleted cells accumulate GPI intermediates with the structures Man alpha 1-2Man alpha 1-2Man alpha 1-6[NH2-(CH2)(2)PO4-->]Man alpha 1- 4GlcN alpha 1-6[acyl-->]inositol-PO4-lipid and Man alpha 1-2Man alpha 1-2Man alpha 1-6Man alpha 1-4GlcN alpha 1-6[acyl-->] inositol-PO4-lipid. Subcellular localization studies of a tagged version of YLL031c suggest that this protein is mainly in the ER, in contrast to Gpi7p, which is found at the cell. surface, The data are compatible with the idea that YLL031c transfers the ethanolaminephosphate to the inner alpha 1-2-linked mannose, ie. the group that links the GPI lipid anchor to proteins, whereas Mcd4p and Gpi7p transfer ethanolaminephosphate onto the alpha 1-4- and alpha 1-6-linked mannoses of the GPI anchor, respectively.	Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland	University of Fribourg	Conzelmann, A (corresponding author), Univ Fribourg, Inst Biochem, Chemin Musee 5, CH-1700 Fribourg, Switzerland.	andreas.conzelmann@unifr.ch						Benachour A, 1999, J BIOL CHEM, V274, P15251, DOI 10.1074/jbc.274.21.15251; BENGHEZAL M, 1995, J CELL BIOL, V130, P1333, DOI 10.1083/jcb.130.6.1333; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; BREWIS IA, 1995, J BIOL CHEM, V270, P22946, DOI 10.1074/jbc.270.39.22946; Canivenc-Gansel E, 1998, GLYCOBIOLOGY, V8, P761, DOI 10.1093/glycob/8.8.761; Caro LHP, 1997, YEAST, V13, P1477, DOI 10.1002/(SICI)1097-0061(199712)13:15<1477::AID-YEA184>3.0.CO;2-L; Doering TL, 1996, EMBO J, V15, P182, DOI 10.1002/j.1460-2075.1996.tb00346.x; ESMON B, 1981, CELL, V25, P451, DOI 10.1016/0092-8674(81)90063-5; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; Gaynor EC, 1999, MOL BIOL CELL, V10, P627, DOI 10.1091/mbc.10.3.627; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; Hamada K, 1998, MOL GEN GENET, V258, P53, DOI 10.1007/s004380050706; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; HIROSE S, 1992, J BIOL CHEM, V267, P16968; Hong YJ, 1999, J BIOL CHEM, V274, P35099, DOI 10.1074/jbc.274.49.35099; HUXLEY C, 1990, TRENDS GENET, V6, P236, DOI 10.1016/0168-9525(90)90190-H; INOUE N, 1993, J BIOL CHEM, V268, P6882; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; Kapteyn JC, 1996, GLYCOBIOLOGY, V6, P337, DOI 10.1093/glycob/6.3.337; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafontaine D, 1996, NUCLEIC ACIDS RES, V24, P3469, DOI 10.1093/nar/24.17.3469; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Lussier M, 1997, GENETICS, V147, P435; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MENON AK, 1992, J BIOL CHEM, V267, P15277; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; Mondesert G, 1997, GENETICS, V147, P421; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; PUOTI A, 1993, J BIOL CHEM, V268, P7215; PUOTI A, 1992, J BIOL CHEM, V267, P22673; Ram AFJ, 1998, J BACTERIOL, V180, P1418, DOI 10.1128/JB.180.6.1418-1424.1998; Reggiori F, 1997, EMBO J, V16, P3506, DOI 10.1093/emboj/16.12.3506; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; VANDERVAART JM, 1995, J BACTERIOL, V177, P3104, DOI 10.1128/jb.177.11.3104-3110.1995; Vidugiriene J, 1999, J BIOL CHEM, V274, P15203, DOI 10.1074/jbc.274.21.15203; VOSSEN JH, 1995, BBA-GEN SUBJECTS, V1243, P549, DOI 10.1016/0304-4165(95)00002-S; Vossen JH, 1997, J BACTERIOL, V179, P2202, DOI 10.1128/jb.179.7.2202-2209.1997; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; Zhang NS, 1999, YEAST, V15, P1287, DOI 10.1002/(SICI)1097-0061(19990915)15:12<1287::AID-YEA458>3.0.CO;2-S	44	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24458	24465		10.1074/jbc.M003844200	http://dx.doi.org/10.1074/jbc.M003844200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10823837	hybrid			2022-12-25	WOS:000088683300030
J	Bellmann, K; Burkart, V; Bruckhoff, J; Kolb, H; Landry, J				Bellmann, K; Burkart, V; Bruckhoff, J; Kolb, H; Landry, J			p38-dependent enhancement of cytokine-induced nitric-oxide synthase gene expression by heat shock protein 70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; P38 MAP KINASE; STRESS-INDUCED APOPTOSIS; NONOBESE DIABETIC MICE; SIGNALING PATHWAY; IN-VITRO; SERINE PHOSPHORYLATION; MOLECULAR CHAPERONES; EPITHELIAL-CELLS; CARDIAC MYOCYTES	Heat shock protein (hsp) 70 protects cells against stress by means of its ability to chaperone denatured proteins and to modulate stress-activated signaling pathways. Because inflammatory processes are often accompanied by hsp expression and because stress and cytokines share several signaling pathways, we investigated the possibility that hsp70 might modulate the cellular response to cytokines. We found that stable cell clones overexpressing hsp70, or cells shortly after transfection with hsp70, produced 2 times more nitric oxide and inducible nitric-oxide synthase (iNOS) protein and mRNA in response to cytokines than control cells expressing undetectable amounts of hsp70. Since mitogen-activated protein kinases participate in the activation of iNOS by cytokines, we investigated whether hsp70 affected the activation of these signaling pathways. hsp70 overexpression led to a specific enhancement of the activation of the p38 pathway by cytokines, producing little or no effect on the activation of extracellular signal-regulated kinase or Jun N-terminal kinase. Blocking p38 activity with SB203580 totally abolished the enhancing effect of hsp70 on cytokine-induced endogenous iNOS mRNA accumulation or transcription of an iNOS promoter-driven luciferase gene, while having little effect on the cytokine response observed in control cells. We conclude that the p38 pathway acts as an enhancing factor in the activation of iNOS by cytokines and that, hsp70 can modulate the cellular response to cytokines by acting on signaling elements upstream of p38.	Univ Laval, Ctr Rech Cancerol, Hotel Dieun Quebec, Quebec City, PQ G1R 2J6, Canada; German Diabet Res Inst, Immunobiol Sect, D-40225 Dusseldorf, Germany	Laval University; Deutsches Diabetes-Zentrum (DDZ)	Bellmann, K (corresponding author), Univ Laval, Ctr Rech Cancerol, Hotel Dieun Quebec, 9 Rue McMahon, Quebec City, PQ G1R 2J6, Canada.							BELLMANN K, 1995, J CLIN INVEST, V95, P2840, DOI 10.1172/JCI117989; Bellmann K, 1996, FEBS LETT, V391, P185, DOI 10.1016/0014-5793(96)00730-2; Bercovich B, 1997, J BIOL CHEM, V272, P9002; BERNARD C, 1994, EUR J PHARM-ENVIRON, V270, P115, DOI 10.1016/0926-6917(94)90087-6; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Blachere NE, 1997, J EXP MED, V186, P1315, DOI 10.1084/jem.186.8.1315; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; BURSTON SG, 1995, ESSAYS BIOCHEM, V29, P125; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Caivano M, 1998, FEBS LETT, V429, P249, DOI 10.1016/S0014-5793(98)00578-X; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chan ED, 1999, J IMMUNOL, V162, P415; Chen BC, 1999, IMMUNOLOGY, V97, P124, DOI 10.1046/j.1365-2567.1999.00747.x; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; Darville MI, 1998, DIABETOLOGIA, V41, P1101, DOI 10.1007/s001250051036; DaSilva J, 1997, J BIOL CHEM, V272, P28373, DOI 10.1074/jbc.272.45.28373; Decker T, 1997, J INTERF CYTOK RES, V17, P121, DOI 10.1089/jir.1997.17.121; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; deVera ME, 1996, HEPATOLOGY, V24, P1238; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; ENSOR JE, 1994, AM J PHYSIOL, V266, pC967, DOI 10.1152/ajpcell.1994.266.4.C967; Faure V, 1999, J BIOL CHEM, V274, P4794, DOI 10.1074/jbc.274.8.4794; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; FINCATO G, 1991, BLOOD, V77, P579; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Gollob JA, 1999, J IMMUNOL, V162, P4472; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; Guan ZH, 1998, AM J PHYSIOL-RENAL, V274, pF673, DOI 10.1152/ajprenal.1998.274.4.F673; HALL TJ, 1994, EXPERIENTIA, V50, P1048, DOI 10.1007/BF01923460; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HELQVIST S, 1991, DIABETOLOGIA, V34, P150, DOI 10.1007/BF00418268; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kluger MJ, 1997, AM J PHYSIOL-REG I, V273, pR858, DOI 10.1152/ajpregu.1997.273.3.R858; Kolb H, 1998, IMMUNOL TODAY, V19, P556, DOI 10.1016/S0167-5699(98)01366-8; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; KRONCKE KD, 1991, BIOCHEM BIOPH RES CO, V175, P752, DOI 10.1016/0006-291X(91)91630-U; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LaPointe MC, 1999, HYPERTENSION, V33, P276, DOI 10.1161/01.HYP.33.1.276; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; Liu H, 1999, ONCOGENE, V18, P3461, DOI 10.1038/sj.onc.1202699; LOWFRIEDRICH I, 1992, BASIC RES CARDIOL, V87, P12, DOI 10.1007/BF00795385; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Nollen EAA, 1999, MOL CELL BIOL, V19, P2069; Ozawa Y, 1996, J AUTOIMMUN, V9, P517, DOI 10.1006/jaut.1996.0069; Pilon M, 1999, CELL, V97, P679, DOI 10.1016/S0092-8674(00)80780-1; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Rothe H, 1996, DIABETOLOGIA, V39, P119; ROTHE H, 1994, DIABETOLOGIA, V37, P1154, DOI 10.1007/BF00418380; SIMON MM, 1995, J CLIN INVEST, V95, P926, DOI 10.1172/JCI117800; Stewart S, 1999, MOL CELL BIOL, V19, P5523; TANGUAY RM, 1993, DEV GENET, V14, P112, DOI 10.1002/dvg.1020140205; Tishler M, 1996, SEMIN ARTHRITIS RHEU, V26, P558, DOI 10.1016/S0049-0172(96)80043-6; Todryk S, 1999, J IMMUNOL, V163, P1398; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wong HR, 1995, AM J PHYSIOL-LUNG C, V269, pL843, DOI 10.1152/ajplung.1995.269.6.L843; Wysk M, 1999, P NATL ACAD SCI USA, V96, P3763, DOI 10.1073/pnas.96.7.3763	77	43	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18172	18179		10.1074/jbc.M000340200	http://dx.doi.org/10.1074/jbc.M000340200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849439	hybrid			2022-12-25	WOS:000087659400037
J	Rao, GN				Rao, GN			Oxidant stress stimulates phosphorylation of eIF4E without an effect on global protein synthesis in smooth muscle cells - Lack of evidence for a role of H2O2 in angiotensin II-induced hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR 4E; RECEPTOR TYROSINE KINASE; CAP-BINDING PROTEIN; C-JUN EXPRESSION; HYDROGEN-PEROXIDE; TRANSLATION INITIATION; MESSENGER-RNA; FACTOR EIF-4E; MAP KINASE; PHAS-I	Reactive oxygen species (ROS) are implicated in the pathogenesis of several proliferative diseases, including atherosclerosis and cancer. Eukaryotic translation initiation factor 4E (eIF4E) plays an important role in cell proliferation and differentiation. To gain insight into molecular mechanisms by which ROS influence the pathogenesis of these diseases, I have studied the effect of H2O2, a ROS, on eIF4E phosphorylation. H2O2 induced eIF4E phosphorylation in a dose- and time-dependent manner in growth-arrested smooth muscle cells (SMC). H2O2-induced eIF4E phosphorylation occurred on serine residues. PD098059, a specific inhibitor of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase inhibited ERK activities but had no significant effect on eIF4E phosphorylation induced by H2O2. Similarly, SB203580, a specific inhibitor of p38 MAPK, although inhibiting H2O2-induced p38 MAPK activity, had no effect on H2O2-induced eIF4E phosphorylation. Calphostin C, a specific inhibitor of protein kinase C, also had no effect on H2O2-induced eIF4E phosphorylation. In contrast, trifluoperazine, an antagonist of calcium/calmodulin kinases, completely blocked H2O2-induced eIF4E phosphorylation. In addition, intracellular and extracellular Ca2+ chelators significantly inhibited H2O2-induced eIF4E phosphorylation. Despite its ability to induce eIF4E phosphorylation, H2O2 had no significant effect on protein levels and new protein synthesis as compared with control. In contrast, it induced the expression of c-Fos, c-Jun, and HSP70 in a time-dependent manner in SMC. Together, these results suggest that H2O2, a ROS and a cellular oxidant, induces eIF4E phosphorylation in a manner that is dependent on Ca2+' and Ca2+/calmodulin kinases and independent of ERKs, p38 MAPK, and protein kinase C. These results also suggest that enhanced eIF4E phosphorylation by H2O2 appears to be an important event in SMC in response to oxidant stress and that eIF4E phosphorylation may be associated with the translation of a small subset of mRNAs such as c-fos, c-jun, and HSP70 gene mRNAs, whose products may have a critical role in cell survival.	Univ Texas, Med Branch, Dept Anat & Neurosci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Rao, GN (corresponding author), Univ Texas, Med Branch, Dept Anat & Neurosci, 10-138 Med Res Bldg,301 Univ Blvd,Rt 1043, Galveston, TX 77555 USA.	grao@utmb.edu						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CRAWFORD D, 1988, ONCOGENE, V3, P27; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DONALDSON RW, 1991, J BIOL CHEM, V266, P3162; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1987, ARCH BIOCHEM BIOPHYS, V256, P651, DOI 10.1016/0003-9861(87)90622-9; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; Flynn A, 1996, FEBS LETT, V389, P162, DOI 10.1016/0014-5793(96)00564-9; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GIGUERE R, 1980, CLIN BIOCHEM, V13, P103, DOI 10.1016/S0009-9120(80)90723-7; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HILDEBRANDT E, 1989, ANAL BIOCHEM, V177, P407, DOI 10.1016/0003-2697(89)90075-4; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KAUFMAN RJ, 1993, J BIOL CHEM, V268, P11902; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P543, DOI 10.1042/bj3070543; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LARSSON R, 1988, J BIOL CHEM, V263, P17452; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; MORLEY SJ, 1991, J BIOL CHEM, V266, P4669; MORLEY SJ, 1990, J BIOL CHEM, V265, P10611; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; MORRIS DR, 1995, PROG NUCLEIC ACID RE, V51, P339, DOI 10.1016/S0079-6603(08)60883-1; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Rao GN, 1997, CELL SIGNAL, V9, P181, DOI 10.1016/S0898-6568(96)00139-8; RAO GN, 1994, J BIOL CHEM, V269, P7180; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; Rao GN, 1996, ONCOGENE, V13, P713; Rao GN, 1996, J BIOL CHEM, V271, P20805, DOI 10.1074/jbc.271.34.20805; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; Rousseau D, 1996, ONCOGENE, V13, P2415; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Wang XM, 1998, J BIOL CHEM, V273, P9373, DOI 10.1074/jbc.273.16.9373; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488	71	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16993	16999		10.1074/jbc.275.22.16993	http://dx.doi.org/10.1074/jbc.275.22.16993			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828072	hybrid			2022-12-25	WOS:000087392200084
J	Jagla, W; Wiede, A; Dietzmann, K; Rutkowski, K; Hoffmann, W				Jagla, W; Wiede, A; Dietzmann, K; Rutkowski, K; Hoffmann, W			Co-localization of TFF3 peptide and oxytocin in the human hypothalamus	FASEB JOURNAL			English	Article						pituitary; TFF-domain; neuropeptide; oxytocin; vasopressin; epithelial cell migration; anxiolytic	INTESTINAL TREFOIL FACTOR; PANCREATIC SPASMOLYTIC POLYPEPTIDE; PARAVENTRICULAR NUCLEUS; MAGNOCELLULAR NEURONS; PS2 GENE; IMMUNOCYTOCHEMICAL LOCALIZATION; NEUROHYPOPHYSEAL HORMONES; RECEPTOR-BINDING; MOUSE ASTROCYTES; LACTATING RATS	TFF-peptides (formerly P domain peptides, trefoil factors) are typical secretory products of many mucous epithelial cells. TFF3 is also synthesized in the hypothalamus and has anxiolytic or anxiogenic activities when injected into the rat amygdala. Here we show by immunohistochemistry that TFF3 is localized to a distinct population of neurons of the human hypothalamic paraventricular and supraoptic nuclei. Generally, TFF3-positive cells are co-localized in oxytocin-producing cells and not in vasopressin-producing cells. Relatively large amounts of TFF3-but not TFF1 and TFE2-are present in the posterior lobe of the human pituitary, where it is probably released into the bloodstream. Furthermore, TFF3 was also detectable in human postmortem cerebrospinal fluid.-Jagla, W., Wiede, A, Dietzmann, K, Rutkowski, IC, Hoffmann, W. Go-localization of TFF3 peptide and oxytocin in the human hypothalamus.	Otto Von Guericke Univ, Inst Mol Med & Med Chem, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Inst Neuropathol, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University	Hoffmann, W (corresponding author), Univ Klinikum Magdeburg, Inst Mol Biol & Med Chem, Leipziger Str 44, D-39120 Magdeburg, Germany.	Werner.Hoffmann@Medizin.Uni-Magdeburg.de	Hoffmann, Werner/AAY-9182-2020	Hoffmann, Werner/0000-0003-0031-9540				BENBARAK Y, 1985, J NEUROSCI, V5, P81; BUIJS RM, 1979, CELL TISSUE RES, V204, P355; BUIJS RM, 1978, CELL TISSUE RES, V192, P423, DOI 10.1007/bf00224932; CARTER CS, 1992, NEUROSCI BIOBEHAV R, V16, P131, DOI 10.1016/S0149-7634(05)80176-9; CHINERY R, 1993, EUR J BIOCHEM, V212, P557, DOI 10.1111/j.1432-1033.1993.tb17693.x; CHINERY R, 1995, PEPTIDES, V16, P749, DOI 10.1016/0196-9781(95)00045-L; CHINERY R, 1995, BRIT J PHARMACOL, V115, P77, DOI 10.1111/j.1476-5381.1995.tb16322.x; DICRICKX K, 1979, CELL TISSUE RES, V196, P203; Dierickx K, 1980, Int Rev Cytol, V62, P119; DIERICKX K, 1977, CELL TISSUE RES, V184, P15, DOI 10.1007/BF00220524; FODOR M, 1992, NEUROSCIENCE, V46, P891, DOI 10.1016/0306-4522(92)90192-5; Forsling ML, 1998, EXP PHYSIOL, V83, P409, DOI 10.1113/expphysiol.1998.sp004124; FRANDSEN EK, 1988, REGUL PEPTIDES, V20, P45, DOI 10.1016/0167-0115(88)90056-0; FRANDSEN EK, 1986, REGUL PEPTIDES, V16, P291, DOI 10.1016/0167-0115(86)90028-5; HIROTA M, 1994, BIOCHEM MOL BIOL INT, V33, P515; HIROTA M, 1994, NEUROSCI LETT, V171, P49, DOI 10.1016/0304-3940(94)90601-7; HIROTA M, 1995, BIOCHEM MOL BIOL INT, V35, P1079; HOFFMANN W, 1993, TRENDS BIOCHEM SCI, V18, P239, DOI 10.1016/0968-0004(93)90170-R; Ishunina TA, 1999, J CLIN ENDOCR METAB, V84, P4637, DOI 10.1210/jc.84.12.4637; Jagla W, 1998, CELL TISSUE RES, V291, P13; Jagla W, 1999, CELL TISSUE RES, V298, P161, DOI 10.1007/s004419900087; KIYAMA H, 1990, J NEUROENDOCRINOL, V2, P257, DOI 10.1111/j.1365-2826.1990.tb00401.x; KONIGSTORFER A, 1989, J BIOL CHEM, V264, P13689; Landry M, 1997, J ENDOCRINOL, V155, P467, DOI 10.1677/joe.0.1550467; Langer G, 1999, INVEST OPHTH VIS SCI, V40, P2220; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; LUDWIG M, 1995, AM J PHYSIOL-ENDOC M, V268, pE537, DOI 10.1152/ajpendo.1995.268.4.E537; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; MEZEY E, 1991, ENDOCRINOLOGY, V129, P1814, DOI 10.1210/endo-129-4-1814; MORTON A, 1969, J COMP NEUROL, V136, P143, DOI 10.1002/cne.901360203; OKADO N, 1982, ANAT RECORD, V202, P117, DOI 10.1002/ar.1092020114; Podolsky DK, 1997, J GASTROENTEROL, V32, P122, DOI 10.1007/BF01213309; Poulsen SS, 1998, GUT, V43, P240, DOI 10.1136/gut.43.2.240; POW DV, 1989, NEUROSCIENCE, V32, P435, DOI 10.1016/0306-4522(89)90091-2; PROBST JC, 1995, MOL BRAIN RES, V33, P269, DOI 10.1016/0169-328X(95)00137-H; Probst JC, 1996, FASEB J, V10, P1518, DOI 10.1096/fasebj.10.13.8940297; Purba JS, 1996, ARCH GEN PSYCHIAT, V53, P137; Russell JA, 1998, J ENDOCRINOL, V157, P343, DOI 10.1677/joe.0.1570343; Schwarzberg H, 1999, PHARMACOL BIOCHEM BE, V62, P173, DOI 10.1016/S0091-3057(98)00137-3; SILVERMAN AJ, 1983, ANNU REV NEUROSCI, V6, P357, DOI 10.1146/annurev.ne.06.030183.002041; SOFRONIEW MV, 1983, TRENDS NEUROSCI, V6, P467, DOI 10.1016/0166-2236(83)90221-7; SOFRONIEW MV, 1980, J HISTOCHEM CYTOCHEM, V28, P475, DOI 10.1177/28.5.7381192; Swaab DF, 1998, PROG BRAIN RES, V119, P577; SWAAB DF, 1995, J CLIN ENDOCR METAB, V80, P573, DOI 10.1210/jc.80.2.573; SWAAB DF, 1997, HAND CHEM N, V13, P39; Tan XD, 1999, BIOCHEM J, V338, P745, DOI 10.1042/0264-6021:3380745; Tan XD, 1997, BIOCHEM BIOPH RES CO, V237, P673, DOI 10.1006/bbrc.1997.7144; THEODOSIS DT, 1992, ANN NY ACAD SCI, V652, P303, DOI 10.1111/j.1749-6632.1992.tb34363.x; TOMASETTO C, 1990, EMBO J, V9, P407, DOI 10.1002/j.1460-2075.1990.tb08125.x; Tomasetto C, 2000, GASTROENTEROLOGY, V118, P70, DOI 10.1016/S0016-5085(00)70415-X; WANG H, 1995, NEUROSCIENCE, V68, P1179, DOI 10.1016/0306-4522(95)00186-M; Wiede A, 1999, AM J RESP CRIT CARE, V159, P1330, DOI 10.1164/ajrccm.159.4.9804149; Wong WM, 1999, GUT, V44, P890, DOI 10.1136/gut.44.6.890; Wright NA, 1997, FEBS LETT, V408, P121, DOI 10.1016/S0014-5793(97)00424-9	54	66	70	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2000	14	9					1126	1131		10.1096/fasebj.14.9.1126	http://dx.doi.org/10.1096/fasebj.14.9.1126			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	320XZ	10834934				2022-12-25	WOS:000087427300009
J	Brandvold, KA; Neiman, P; Ruddell, A				Brandvold, KA; Neiman, P; Ruddell, A			Angiogenesis is an early event in the generation of myc-induced lymphomas	ONCOGENE			English	Article						angiogenesis; lymphoma; c-myc; v-myc oncogene; avian retrovirus	NON-HODGKINS-LYMPHOMAS; C-MYC; TUMOR ANGIOGENESIS; CELL; VIRUS; FABRICIUS; BURSA; GENE; IDENTIFICATION; TRANSFORMATION	Angiogenesis was identified as an early consequence of myc gene overexpression in two models of retroviral lymphomagenesis. Avian leukosis virus (ALV) induces bursal lymphoma in chickens after proviral c-myc gene integration, while the HB-1 retrovirus carries a v-myc oncogene and also induces metastatic lymphoma. Immunohistochemical studies of the effects of increased c-myc or v-myc overexpression revealed early angiogenesis within myc-transformed bursal follicles, which persisted in lymphomas and metastases. Abnormal vessel growth was consistently detected within 13 days after transplantation of a few myc-overexpressing progenitors into ablated bursal follicles, suggesting that these angiogenic changes may support the initial expansion of tumor precursors, as well as later stage lymphomagenesis, Conditioned media from myc-overexpressing B cell lines promoted proliferation of vascular endothelium in vitro, while media from B cells expressing low myc levels showed little effect. Moreover, ectopic myc overexpression in the low myc B cell lines increased production of the endothelial growth activity, indicating that myc induces secretion of angiogenic factors from B cells. These findings demonstrate that myc overexpression in lymphocytes generates an angiogenic phenotype in vitro as well as in vivo.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Med, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Ruddell, A (corresponding author), Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.			Ruddell, Alanna/0000-0002-0195-5576	NCI NIH HHS [R01 CA20068, R01 CA68328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA020068, R01CA068328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISTER K, 1983, J VIROL, V46, P337, DOI 10.1128/JVI.46.2.337-346.1983; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Bowers WJ, 1996, J VIROL, V70, P3051, DOI 10.1128/JVI.70.5.3051-3059.1996; COOPER MD, 1968, JNCI-J NATL CANCER I, V41, P373; EWERT DL, 1989, VIROLOGY, V170, P433, DOI 10.1016/0042-6822(89)90434-0; EWERT DL, 1988, ADV VET SCI COMP MED, V32, P37; Gong M, 1998, J VIROL, V72, P5517, DOI 10.1128/JVI.72.7.5517-5525.1998; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HENRIKSSON M, 1996, ADV CANCER RES, V68, P110; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Kerbel RS, 1998, MOL MED, V4, P286, DOI 10.1007/BF03401737; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; NEIMAN P, 1985, P NATL ACAD SCI USA, V82, P222, DOI 10.1073/pnas.82.1.222; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NEIMAN PE, 1994, ADV IMMUNOL, V56, P467, DOI 10.1016/S0065-2776(08)60457-5; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; PerezAtayde AR, 1997, AM J PATHOL, V150, P815; Ribatti D, 1998, BRIT J CANCER, V77, P1900, DOI 10.1038/bjc.1998.316; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; Vacca A, 1999, BRIT J CANCER, V79, P965, DOI 10.1038/sj.bjc.6690154; Vacca A, 1998, INT J CLIN LAB RES, V28, P55, DOI 10.1007/s005990050018	26	84	87	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2000	19	23					2780	2785		10.1038/sj.onc.1203589	http://dx.doi.org/10.1038/sj.onc.1203589			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	319BE	10851079				2022-12-25	WOS:000087318500007
J	Duriez, C; Falette, N; Cortes, U; Moyret-Lalle, C; Puisieux, A				Duriez, C; Falette, N; Cortes, U; Moyret-Lalle, C; Puisieux, A			Absence of p53-dependent induction of the metastatic suppressor KAI1 gene after DNA damage	ONCOGENE			English	Article						p53; KAI1; p53-transcriptional target; DNA damage	WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; CELLULAR-RESPONSE; BINDING FUNCTION; CANCER; GROWTH; EXPRESSION; PROTEIN; IDENTIFICATION; PROGRESSION	The p53 tumor suppressor protein functions to monitor the integrity of the genome. If a damage is detected, p53 binds tightly to specific sequence elements in the DNA and induces the transactivation of genes involved in various growth regulatory processes such as cell cycle progression, DNA repair and apoptosis, A p53-binding site was recently identified in the promoter region of the metastatic suppressor KAI1 gene, suggesting that this gene was a direct transcriptional target of p53. To test the relevance of this hypothesis, we studied the endogenous KAI1 expression in a series of human cell lines with varying p53 status in response to genotoxic treatment as well as in different cellular models exhibiting an inducible p53 activity. Overall, our data indicate that KAI1 expression is not significantly modulated by p53. This observation provides a direct evidence that the presence of a p53-binding site in regulatory domains is not a sufficient criteria to define a p53-transcriptional target gene.	INSERM, U453, Dept Oncol Fondamentale & Appl, Ctr Leon Berard, F-69008 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Puisieux, A (corresponding author), INSERM, U453, Dept Oncol Fondamentale & Appl, Ctr Leon Berard, 28 Rue Laennec, F-69008 Lyon, France.		Moyret-Lalle, Caroline/G-2742-2013	Moyret-Lalle, Caroline/0000-0002-8359-2018; PUISIEUX, Alain/0000-0002-9938-3798				Adachi M, 1996, CANCER RES, V56, P1751; Bacus SS, 1996, ONCOGENE, V12, P2535; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Guillot C, 1996, CLIN CANCER RES, V2, P1439; Guo XZ, 1998, HEPATOLOGY, V28, P1481, DOI 10.1002/hep.510280606; Guo XZ, 1996, CANCER RES, V56, P4876; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	33	22	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2461	2464		10.1038/sj.onc.1203580	http://dx.doi.org/10.1038/sj.onc.1203580			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828889				2022-12-25	WOS:000087018400012
J	Pollevick, GD; Di Noia, JM; Salto, ML; Lima, C; Leguizamon, MS; de Lederkremer, RM; Frasch, ACC				Pollevick, GD; Di Noia, JM; Salto, ML; Lima, C; Leguizamon, MS; de Lederkremer, RM; Frasch, ACC			Trypanosoma cruzi surface mucins with exposed variant epitopes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVINE SUBMAXILLARY MUCIN; O-LINKED GLYCOPROTEINS; MAMMALIAN-CELLS; METACYCLIC TRYPOMASTIGOTES; PLASMODIUM-FALCIPARUM; CHAGAS-DISEASE; SIALIC-ACID; GLYCOSYLATION; ANTIGENS; GENES	The protozoan parasite Trypanosoma cruzi, the agent of Chagas disease, has a large number of mucin molecules on its surface, whose expression is regulated during the life cycle, These mucins are the main accepters of sialic acid, a monosaccharide that is required by the parasite to infect and survive in the mammalian host. A large mucin-like gene family named TcMUC containing about 500 members has been identified previously in T. cruzi, TcMUC can be divided into two subfamilies according to the presence or absence of tandem repeats in the central region of the genes. In this work, T. cruzi parasites were transfected with one tagged member of each subfamily. Only the product from the gene with repeats was highly O-glycosylated in vivo, The O-linked oligosaccharides consisted mainly of beta-D-Galp(1-->4)GlcNAc and beta-D-Galp(1-->4)[beta-D-Galp(1-->6)]-D-GlcNAc. The same glycosyl moieties were found in endogenous mucins, The mature product was anchored by glycosylphosphatidylinositol to the plasma membrane and exposed to the medium. Sera from infected mice recognized the recombinant product of one repeats-containing gene thus showing that they are expressed during the infection, TcMUC genes encode a hypervariable region at the N terminus. We now show that the hypervariable region is indeed present in the exposed mature N termini of the mucins because sera from infected hosts recognized peptides having sequences from this region. The results are discussed in comparison with the mucins from the insect stages of the parasite (Di Noia, J. M,, D'Orso, I., Sanchez, D. O., and Frasch, A. C. C. (2000) J, Biol. Chem. 275, 10218-10227) which do not have variable regions.	Univ Nacl Gen San Martin, CONICET, Inst Tecnol Chascomus, Inst Invest Biotecnol, RA-1650 San Martin, Buenos Aires, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Organ, CONICET,CIHIDECAR, Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Med, Dept Microbiol, Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Buenos Aires	Frasch, ACC (corresponding author), Univ Nacl Gen San Martin, CONICET, Inst Tecnol Chascomus, Inst Invest Biotecnol, Av Gral Paz S-N,INTI,Edificio 24, RA-1650 San Martin, Buenos Aires, Argentina.	cfrasch@iib.unsam.edu.ar	Di Noia, Javier Marcelo/D-2285-2012	Di Noia, Javier Marcelo/0000-0003-2896-0321; Frasch, Alberto Carlos/0000-0001-7532-653X				ALMEIDA IC, 1994, BIOCHEM J, V304, P793, DOI 10.1042/bj3040793; Almeida IC, 2000, EMBO J, V19, P1476, DOI 10.1093/emboj/19.7.1476; ALVES MJM, 1975, FEBS LETT, V52, P188, DOI 10.1016/0014-5793(75)80803-9; BORST P, 1994, SCIENCE, V264, P1872, DOI 10.1126/science.7516579; CAMPETELLA O, 1992, PARASITOL TODAY, V8, P378, DOI 10.1016/0169-4758(92)90175-2; CAPPA SMG, 1981, MEDICINA-BUENOS AIRE, V41, P119; CAZZULO JJ, 1985, MOL BIOCHEM PARASIT, V16, P329, DOI 10.1016/0166-6851(85)90074-X; CAZZULO JJ, 1992, FASEB J, V6, P3259, DOI 10.1096/fasebj.6.14.1426764; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; DEARRUDA MV, 1989, EUR J BIOCHEM, V182, P413, DOI 10.1111/j.1432-1033.1989.tb14847.x; DELEDERKREMER RM, 1976, BIOCHIM BIOPHYS ACTA, V444, P85, DOI 10.1016/0304-4165(76)90226-9; Di Noia JM, 2000, J BIOL CHEM, V275, P10218, DOI 10.1074/jbc.275.14.10218; Di Noia JM, 1998, J BIOL CHEM, V273, P10843, DOI 10.1074/jbc.273.18.10843; DiNoia JM, 1996, J BIOL CHEM, V271, P32078, DOI 10.1074/jbc.271.50.32078; DINOIA JM, 1995, J BIOL CHEM, V270, P24146, DOI 10.1074/jbc.270.41.24146; Evans DT, 1999, NAT MED, V5, P1270, DOI 10.1038/15224; Fernandez V, 1999, J EXP MED, V190, P1393, DOI 10.1084/jem.190.10.1393; Freitas-Junior LHG, 1998, MOL BIOCHEM PARASIT, V93, P101, DOI 10.1016/S0166-6851(98)00025-5; FUKUDA M, 1993, GLYCOBIOLOGY PRACTIC, P15; Gallo-Rodriguez C, 1997, CARBOHYD RES, V305, P163, DOI 10.1016/S0008-6215(97)00256-5; Gallo-Rodriguez C, 1999, ORG LETT, V1, P245, DOI 10.1021/ol9905811; GalloRodriguez C, 1996, J ORG CHEM, V61, P1886, DOI 10.1021/jo951934m; GERKEN TA, 1989, BIOCHEMISTRY-US, V28, P5536, DOI 10.1021/bi00439a030; HARIHARAN S, 1993, MOL BIOCHEM PARASIT, V57, P15, DOI 10.1016/0166-6851(93)90240-X; Harlow E., 1988, ANTIBODIES LAB MANUA; ISHIDA C, 1993, J CLIN MICROBIOL, V31, P936, DOI 10.1128/JCM.31.4.936-940.1993; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; Kahn SJ, 1997, J IMMUNOL, V159, P4444; Labriola Carlos, 1993, Biological Research, V26, P101; MartinezCalvillo S, 1997, GENE, V199, P71, DOI 10.1016/S0378-1119(97)00348-X; MENSAWILMOT K, 1995, METHOD ENZYMOL, V250, P641; Millar AE, 1999, J IMMUNOL, V162, P6092; MORTARA RA, 1992, INFECT IMMUN, V60, P4673, DOI 10.1128/IAI.60.11.4673-4678.1992; PASTINI AC, 1994, CLIN CHEM, V40, P1893; Pereira-Chioccola VL, 2000, J CELL SCI, V113, P1299; Plebanski M, 1999, IMMUNITY, V10, P651, DOI 10.1016/S1074-7613(00)80064-3; Previato JO, 1998, J BIOL CHEM, V273, P14982, DOI 10.1074/jbc.273.24.14982; PREVIATO JO, 1995, J BIOL CHEM, V270, P7241, DOI 10.1074/jbc.270.13.7241; PREVIATO JO, 1994, BIOCHEM J, V301, P151, DOI 10.1042/bj3010151; REYES MB, 1994, GENE, V140, P139, DOI 10.1016/0378-1119(94)90745-5; RUIZ RD, 1993, PARASITE IMMUNOL, V15, P121, DOI 10.1111/j.1365-3024.1993.tb00591.x; Salto ML, 2000, ANAL BIOCHEM, V279, P79, DOI 10.1006/abio.1999.4466; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHENKEIN H A, 1991, Critical Reviews in Oral Biology and Medicine, V2, P65; SCHENKMAN S, 1992, J EXP MED, V175, P1635, DOI 10.1084/jem.175.6.1635; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; Stockbauer KE, 1998, P NATL ACAD SCI USA, V95, P3128, DOI 10.1073/pnas.95.6.3128; Tomlinson S, 1998, PARASITOL TODAY, V14, P354, DOI 10.1016/S0169-4758(98)01295-2; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Van Klinken BJW, 1998, ANAL BIOCHEM, V265, P103; VANKLINKEN BJW, 1995, AM J PHYSIOL-GASTR L, V269, pG613, DOI 10.1152/ajpgi.1995.269.5.G613; Varki A, 1998, TRENDS CELL BIOL, V8, P34, DOI 10.1016/S0962-8924(97)01198-7; Wahlgren M, 1999, CELL, V96, P603, DOI 10.1016/S0092-8674(00)80569-3; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; ZINGALES B, 1982, FEBS LETT, V142, P238, DOI 10.1016/0014-5793(82)80143-9; Zingales B, 1997, ACTA TROP, V68, P159, DOI 10.1016/S0001-706X(97)00088-0	60	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 8	2000	275	36					27671	27680						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	352CN	10843987				2022-12-25	WOS:000089197100021
J	Carew, MA; Yang, XN; Schultz, C; Shears, SB				Carew, MA; Yang, XN; Schultz, C; Shears, SB			myo-inositol 3,4,5,6-tetrakisphosphate inhibits an apical calcium-activated chloride conductance in polarized monolayers of a cystic fibrosis cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR CELLS; MYOINOSITOL 1,3,4,5,6-PENTAKISPHOSPHATE; ACINAR-CELLS; SECRETION; AGONIST; PHOSPHATES; CHANNELS; TRANSPORT; EPITHELIA; MEMBRANE	Does inositol 3,4,5,6 tetrakisphosphate (Ins(3,4,5,6)P-4) inhibit apical Ca2+-activated Cl- conductance (CaCC)? We studied this question using human CFPAC-1 pancreatoma cells grown in polarized monolayers. Cellular Ins(3,4,5,6)P-4 levels were acutely sensitive to purinergic receptor activation, rising 3-fold within 1 min of agonist addition. Intracellular Ins(3,4,5,6)P-4, levels were therefore specifically elevated, independently of receptor activation, by incubating cells with a cell-permeant bioactivable analogue, 1,2-di-O-butyl-myo-inositol 3,4,5,6-tetrakisphosphate octakis(acetoxymethyl)ester (Bt(2)Ins (3,4,5,6)P-4/AM). The latter inhibited Ca2+-activated Cl- secretion by 60%. We next used nystatin to selectively permeabilize the basolateral membrane to monovalent anions and cations, thereby preventing this membrane from electrochemically dominating ion movements through the apical membrane. Thus, we studied autonomous regulation of apical Cl- channels in situ. The properties of Cl- flux across the apical membrane were those expected of CaCC: niflumic acid sensitivity, outward rectification, and 2-fold greater permeability of I- over Cl-. Following nystatin-treatment, we elevated intracellular levels of Ins(3,4,5,6)P-4, with either purinergic agonists or with Bt(2)Ins(3,4,5,6)P-4/AM. Both protocols inhibited Ca2+-activated Cl- secretion (up to 70%). These studies provide the first demonstration that, in a physiologically relevant context of a polarized monolayer, there is an apical, Ins(3,4,5,6)P-4-inhibited CaCC.	NIEHS, Inositide Signaling Sect, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Univ Bremen, Inst Organ Chem, UFT, D-28359 Bremen, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Bremen	Carew, MA (corresponding author), NIEHS, Inositide Signaling Sect, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		; shears, stephen/C-6335-2019	Schultz, Carsten/0000-0002-5824-2171; shears, stephen/0000-0001-7309-8916	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080046, Z01ES080046] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ACRA SA, 1991, JPEN-PARENTER ENTER, V15, pS93, DOI 10.1177/014860719101500393S; AlNakkash L, 1997, AM J PHYSIOL-GASTR L, V273, pG204, DOI 10.1152/ajpgi.1997.273.1.G204; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; Andersson L1992A, SCRIPTA BOT BELG, V1, P1; BALLA T, 1989, J BIOL CHEM, V264, P13605; BARKER CJ, 1992, BIOCHEM J, V286, P469, DOI 10.1042/bj2860469; Barrett KE, 1998, AM J PHYSIOL-CELL PH, V274, pC958, DOI 10.1152/ajpcell.1998.274.4.C958; BARRETT KE, 1993, AM J PHYSIOL, V265, pC859; Barrett KE, 1997, AM J PHYSIOL-CELL PH, V272, pC1069, DOI 10.1152/ajpcell.1997.272.4.C1069; Begenisich T, 1998, J MEMBRANE BIOL, V163, P77, DOI 10.1007/s002329900372; Bennett WD, 1996, AM J RESP CRIT CARE, V153, P1796, DOI 10.1164/ajrccm.153.6.8665037; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Chan HC, 1996, AM J PHYSIOL-CELL PH, V271, pC469, DOI 10.1152/ajpcell.1996.271.2.C469; CHAO AC, 1995, J CLIN INVEST, V96, P1794, DOI 10.1172/JCI118225; Clarke LL, 1999, AM J PHYSIOL-CELL PH, V276, pC777, DOI 10.1152/ajpcell.1999.276.4.C777; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL785, DOI 10.1152/ajplung.1996.271.5.L785; DEVOR DC, 1992, AM J PHYSIOL, V263, pC780, DOI 10.1152/ajpcell.1992.263.4.C780; Frings S, 2000, PROG NEUROBIOL, V60, P247, DOI 10.1016/S0301-0082(99)00027-1; GALIETTA LJV, 1994, PFLUG ARCH EUR J PHY, V426, P534, DOI 10.1007/BF00378531; Garrad RC, 1998, J BIOL CHEM, V273, P29437, DOI 10.1074/jbc.273.45.29437; Greger R, 2000, ANNU REV PHYSIOL, V62, P467, DOI 10.1146/annurev.physiol.62.1.467; Grubb BR, 1997, AM J PHYSIOL-GASTR L, V273, pG258, DOI 10.1152/ajpgi.1997.273.2.G258; Ho MWY, 1997, AM J PHYSIOL-CELL PH, V272, pC1160, DOI 10.1152/ajpcell.1997.272.4.C1160; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; Ismailov II, 1996, P NATL ACAD SCI USA, V93, P10505, DOI 10.1073/pnas.93.19.10505; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; KNOWLES MR, 1995, CHEST, V107, pS71, DOI 10.1378/chest.107.2_Supplement.71S; MCCONNELL FM, 1992, BIOCHEM J, V284, P447, DOI 10.1042/bj2840447; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; O'Reilly CM, 1998, BRIT J PHARMACOL, V124, P1597, DOI 10.1038/sj.bjp.0701990; PARADISO AM, 1995, NATURE, V377, P643, DOI 10.1038/377643a0; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Rudolf MT, 1998, J MED CHEM, V41, P3635, DOI 10.1021/jm970781n; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; SHEARS SB, 1997, SIGNALLING INOSITIDE, P33; STEPHENS LR, 1988, BIOCHEM J, V253, P721, DOI 10.1042/bj2530721; Tan Z, 1997, J BIOL CHEM, V272, P2285; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; VENGLARIK CJ, 1990, AM J PHYSIOL, V259, P358; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WONG NS, 1992, BIOCHEM J, V286, P459, DOI 10.1042/bj2860459; Xie WW, 1998, J PHYSIOL-LONDON, V510, P661, DOI 10.1111/j.1469-7793.1998.661bj.x; Xie WW, 1996, J BIOL CHEM, V271, P14092, DOI 10.1074/jbc.271.24.14092; Yang XN, 1999, J BIOL CHEM, V274, P18973, DOI 10.1074/jbc.274.27.18973	47	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26906	26913						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842174				2022-12-25	WOS:000089144800034
J	Hawkins, CJ; Yoo, SJ; Peterson, EP; Wang, SL; Vernooy, SY; Hay, BA				Hawkins, CJ; Yoo, SJ; Peterson, EP; Wang, SL; Vernooy, SY; Hay, BA			The Drosophila caspase DRONC cleaves following glutamate or aspartate and is regulated by DIAP1, HID, and GRIM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; INTERLEUKIN-1-BETA CONVERTING-ENZYME; ANTIAPOPTOTIC PROTEIN P35; INDUCED APOPTOSIS; COMBINATORIAL APPROACH; BACULOVIRUS INHIBITOR; CYSTEINE PROTEASE; FAMILY PROTEASES; REAPER; IDENTIFICATION	The caspase family of cysteine proteases plays important roles in bringing about apoptotic cell death. All caspases studied to date cleave substrates COOH-terminal to an aspartate, Here we show that the Drosophila caspase DRONC cleaves COOH-terminal to glutamate as well as aspartate, DRONC autoprocesses itself following a glutamate residue, but processes a second caspase, drICE, following an aspartate, DRONC prefers tetrapeptide substrates in which aliphatic amino acids are present at the P2 position, and the P1 residue can be either aspartate or glutamate, Expression of a dominant negative form of DRONC blocks cell death induced by the Drosophila cell death activators reaper, hid, and grim, and DRONC overexpression in flies promotes cell death. Furthermore, the Drosophila cell death inhibitor DIAP1 inhibits DRONC activity in yeast, and DIAP1's ability to inhibit DRONC-dependent yeast cell death is suppressed by HID and GRIM. These observations suggest that DRONC acts to promote cell death. However, DRONC activity is not suppressed by the caspase inhibitor and cell death suppressor baculovirus p35. We discuss possible models for DRONC function as a cell death inhibitor.	Div Biol, Pasadena, CA 91125 USA		Hay, BA (corresponding author), Div Biol, MC 156-29, Pasadena, CA 91125 USA.		Hawkins, Christine/B-8769-2011	Hawkins, Christine/0000-0001-8120-1071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057422] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM057422-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1997, J BIOL CHEM, V272, P1421, DOI 10.1074/jbc.272.3.1421; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Bergmann A, 1998, ONCOGENE, V17, P3215, DOI 10.1038/sj.onc.1202586; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; Dorstyn L, 1999, J BIOL CHEM, V274, P30778, DOI 10.1074/jbc.274.43.30778; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Graczyk PP, 1999, RESTOR NEUROL NEUROS, V14, P1; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hawkins CJ, 1999, P NATL ACAD SCI USA, V96, P2885, DOI 10.1073/pnas.96.6.2885; Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; HOWARD AD, 1991, J IMMUNOL, V147, P2964; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Kaiser WJ, 1998, FEBS LETT, V440, P243, DOI 10.1016/S0014-5793(98)01465-3; Kang JJ, 1999, J BIOL CHEM, V274, P3189, DOI 10.1074/jbc.274.5.3189; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; LaCount DJ, 2000, J BIOL CHEM, V275, P15657, DOI 10.1074/jbc.M000791200; Lisi S, 2000, GENETICS, V154, P669; Manji GA, 1997, J VIROL, V71, P4509, DOI 10.1128/JVI.71.6.4509-4516.1997; McCall K, 1998, SCIENCE, V279, P230, DOI 10.1126/science.279.5348.230; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Mittl PRE, 1997, J BIOL CHEM, V272, P6539, DOI 10.1074/jbc.272.10.6539; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Seshagiri S, 1997, P NATL ACAD SCI USA, V94, P13606, DOI 10.1073/pnas.94.25.13606; Shaham S, 1998, J BIOL CHEM, V273, P35109, DOI 10.1074/jbc.273.52.35109; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; Song ZW, 2000, MOL CELL BIOL, V20, P2907, DOI 10.1128/MCB.20.8.2907-2914.2000; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SPREIJ T E, 1971, Netherlands Journal of Zoology, V21, P221; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; Talanian RV, 1997, J BIOL CHEM, V272, P9677; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Vucic D, 1997, MOL CELL BIOL, V17, P667, DOI 10.1128/MCB.17.2.667; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Wing JP, 1998, CELL DEATH DIFFER, V5, P930, DOI 10.1038/sj.cdd.4400423; WOLFF T, 1991, DEVELOPMENT, V113, P825; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Zhou L, 1999, MOL CELL, V4, P745, DOI 10.1016/S1097-2765(00)80385-8; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	63	198	203	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27084	27093						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10825159				2022-12-25	WOS:000089144800057
J	Kamino, K; Inoue, K; Maruyama, T; Takamatsu, N; Harayama, S; Shizuri, Y				Kamino, K; Inoue, K; Maruyama, T; Takamatsu, N; Harayama, S; Shizuri, Y			Barnacle cement proteins - Importance of disulfide bonds in their insolubility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEGABALANUS-ROSA; ACORN BARNACLE	Barnacles produce a cement that is a proteinaceous underwater adhesive for their secure attachment to the substratum, The biochemical properties of the cement have not previously been elucidated, because the insolubility of the cement proteins hampers their purification and characterization. We developed a non-hydrolytic method to render soluble most of the cement components, thereby allowing the proteins to be analyzed. Megabalanus rosa cement could be almost completely rendered soluble by its reduction with 0.5 M dithiothreitol at 60 degrees C in a 7 M guanidine hydrochloride solution, the high concentration of dithiothreitol being indispensable to achieve this. The effectiveness of this reduction treatment was confirmed by the detachment of the barnacle from the substratum. Three proteins comprising up to 94% of the whole cement were identified as the major cement components. The cDNA clone of one of these major proteins was isolated, and the site-specific expression of the gene in the basal portion of the adult barnacle, where the cement glands are located, was demonstrated. A sequence analysis revealed this cement component to be a novel protein of 993 amino acid residues, including a signal peptide. This is the first report of the major component of the barnacle cement protein complex.	Marine Biotechnol Inst, Shimizu Labs, Shizuoka 4240037, Japan; Marine Biotechnol Inst, Kamaishi Labs, Kamaishi, Iwate 0260001, Japan; Kitasato Univ, Sch Sci, Dept Biosci, Sagamihara, Kanagawa 228, Japan	Kitasato University	Kamino, K (corresponding author), Marine Biotechnol Inst, Shimizu Labs, 1900 Sodeshi, Shizuoka 4240037, Japan.			Harayama, Shigeaki/0000-0003-2103-7796				Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; DOUGHERTY WJ, 1990, J CRUSTACEAN BIOL, V10, P469, DOI 10.2307/1548336; FYHN UEH, 1976, BIOL BULL, V150, P47, DOI 10.2307/1540588; IKEUCHI M, 1989, FEBS LETT, V242, P263, DOI 10.1016/0014-5793(89)80482-X; Kamino K, 1996, BIOL BULL, V190, P403, DOI 10.2307/1543033; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACOMBE D, 1970, BIOL BULL, V139, P164, DOI 10.2307/1540134; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURSEN RA, 1992, BIOPOLYMERS, P55; Naldrett MJ, 1997, MAR BIOL, V127, P629, DOI 10.1007/s002270050053; Rzepecki LM, 1995, MOL MAR BIOL BIOTECH, V4, P313; SAROYAN JR, 1970, BIOL BULL, V139, P333, DOI 10.2307/1540088; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SKOOG B, 1986, TRENDS ANALC HEM, V5; TAKAMATSU N, 1993, GENE, V128, P251; WAITE JH, 1987, INT J ADHES ADHES, V7, P9, DOI 10.1016/0143-7496(87)90048-0; WALKER G, 1972, J MAR BIOL ASSOC UK, V52, P429, DOI 10.1017/S0025315400018786; WALKER G, 1970, MAR BIOL, V7, P239, DOI 10.1007/BF00367494; West MW, 1999, P NATL ACAD SCI USA, V96, P11211, DOI 10.1073/pnas.96.20.11211	20	153	158	2	64	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27360	27365						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10840046				2022-12-25	WOS:000089144800093
J	Vispe, S; Satoh, MS				Vispe, S; Satoh, MS			DNA repair patch-mediated double strand DNA break formation in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; PURIFIED HUMAN PROTEINS; LIGASE-I; MAMMALIAN-CELLS; IONIZING-RADIATION; POLYMERASE-EPSILON; DEPENDENT REPAIR; URACIL RESIDUES; RAD51 PROTEIN; DAMAGED DNA	To investigate the mechanism of double strand DNA break formation in mammalian cells, an in vitro assay was established using closed circular DNA containing two uracils on opposite DNA strands (18 and 30 base pairs apart) and extracts prepared from human cells. In this assay, formation of double strand breaks was detected by the conversion of circular DNA to linear DNA. Approximately 4-fold more double strand DNA breaks were produced by extracts from cells deficient in DNA ligase I (46BR) relative to those produced by extracts from control cells (MRC5, derived from a clinically normal individual). In parallel with the amount of double strand DNA breaks, extracts from 46BR cells produced longer repair patches (up to 24 bases in length) than those from MRC5 cells (typically <5 bases long). When purified DNA ligase I was added to 46BR extracts to complement the DNA ligase deficiency, only a negligible difference was found between the amount of double strand DNA breaks or the repair patch size generated in the assay relative to MRC5 extracts. Together, our data demonstrate that double strand DNA breaks are produced through formation of DNA repair patches. We refer to this process of double strand break formation as the "DNA repair patch-mediated pathway."	Univ Laval, Fac Med, CHUQ, Med Res Ctr,Hlth & Environm Unit,DNA Repair Grp, Quebec City, PQ G1V 4G2, Canada	Laval University	Satoh, MS (corresponding author), Univ Laval, Fac Med, CHUQ, Med Res Ctr,Hlth & Environm Unit,DNA Repair Grp, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	Masahiko.Sato@crchul.ulaval.ca						AHNSTROM G, 1982, INT J RADIAT BIOL, V41, P671, DOI 10.1080/09553008214550761; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Biade S, 1998, J BIOL CHEM, V273, P898, DOI 10.1074/jbc.273.2.898; BRADLEY MO, 1987, MUTAT RES, V189, P69, DOI 10.1016/0165-1218(87)90034-6; Chaudhry MA, 1997, J BIOL CHEM, V272, P15650, DOI 10.1074/jbc.272.25.15650; CHAUDHRY MA, 1995, J MOL BIOL, V249, P914; CLEAVER JE, 1985, CANCER RES, V45, P1163; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIANOV GL, 1991, MOL GEN GENET, V225, P448, DOI 10.1007/BF00261686; DUGLE DL, 1976, P NATL ACAD SCI USA, V73, P809, DOI 10.1073/pnas.73.3.809; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Harrison L, 1999, J MOL BIOL, V290, P667, DOI 10.1006/jmbi.1999.2892; HISAMOTO N, 1994, MOL CELL BIOL, V14, P3158, DOI 10.1128/MCB.14.5.3158; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Mackenney VJ, 1997, J BIOL CHEM, V272, P11550; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; Mossi R, 1998, J BIOL CHEM, V273, P14322, DOI 10.1074/jbc.273.23.14322; NOCENTINI S, 1995, RADIAT RES, V144, P170, DOI 10.2307/3579256; Nocentini S, 1999, RADIAT RES, V151, P423, DOI 10.2307/3579829; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; SATOH MS, 1993, J BIOL CHEM, V268, P5480; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SQUIRES S, 1983, CARCINOGENESIS, V4, P565, DOI 10.1093/carcin/4.5.565; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; TEO IA, 1983, CARCINOGENESIS, V4, P559, DOI 10.1093/carcin/4.5.559; TEO IA, 1983, MUTAT RES, V107, P371, DOI 10.1016/0027-5107(83)90177-X; Vispe S, 1997, BIOCHIMIE, V79, P587, DOI 10.1016/S0300-9084(97)82007-X; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; WALKER IG, 1984, CAN J BIOCHEM CELL B, V62, P329, DOI 10.1139/o84-046; WALLACE SS, 1988, ENVIRON MOL MUTAGEN, V12, P431, DOI 10.1002/em.2860120411; Wallace SS, 1998, RADIAT RES, V150, pS60, DOI 10.2307/3579809; Ward JF, 1998, CONT CANC RES, P65; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X	44	21	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27386	27392						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10827190				2022-12-25	WOS:000089144800096
J	Chen, H; Deere, M; Hecht, JT; Lawler, J				Chen, H; Deere, M; Hecht, JT; Lawler, J			Cartilage oligomeric matrix protein is a calcium-binding protein, and a mutation in its type 3 repeats causes conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; COMP GENE; PLATELET THROMBOSPONDIN; ENDOPLASMIC-RETICULUM; PSEUDOACHONDROPLASIA; TENDON; CELLS	Mutations in residues in the type 3 calcium-binding repeats and COOH-terminal globular region of cartilage oligomeric matrix protein (COMP) lead to two skeletal dysplasias, pseudoachondroplasia and multiple epiphyseal dysplasia, It has been hypothesized that these mutations cause COMP to misfold and to be retained in the endoplasmic reticulum, However, this hypothesis is not supported by previous reports that COMP, when purified in the presence of EDTA, shows no obvious difference in electron microscopic appearance in the presence or absence of calcium ions. Since this discrepancy may be due to the removal of calcium during purification, we have expressed wild-type COMP and the most common mutant form found in pseudoachondroplasia, MUT3, using a mammalian expression system and have purified both proteins in the presence of calcium. Both proteins are expressed as pentamers, Direct calcium binding experiments demonstrate that wild-type COMP, when purified in the presence of calcium, is a calcium-binding protein, Rotary shadowing electron microscopy and Limited trypsin digestion at various calcium concentrations show that there are conformational changes associated with calcium binding to COMP, Whereas COMB exists in a more compact conformation in the presence of calcium, it shows a more extended conformation when calcium is removed. MUT3, with a single aspartic acid deletion in the type 3 repeats, binds less calcium and presents an intermediate conformation between the calcium-replete and calcium depleted forms of COMP, In conclusion, we show that a single mutation in the type 3 repeats of COMP causes the mutant protein to misfold, Our data demonstrate the importance of calcium binding to the structure of COMP and provide a plausible explanation for the observation that mutations in the type 3 repeats and COOH-terminal globular region lead to pseudoachondroplasia.	Beth Israel Deaconess Med Ctr, Dept Pathol, Div Tumor BIol & Angiogenesis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Texas, Sch Med, Dept Pediat, Houston, TX 77225 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Texas System	Lawler, J (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Div Tumor BIol & Angiogenesis, Res N,Rm 270C,99 Brookline Ave, Boston, MA 02215 USA.		Lawler, Jack/AAJ-1379-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049081] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49081] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ballo R, 1997, AM J MED GENET, V68, P396, DOI 10.1002/(SICI)1096-8628(19970211)68:4<396::AID-AJMG4>3.3.CO;2-R; Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Cohn DH, 1996, ANN NY ACAD SCI, V785, P188, DOI 10.1111/j.1749-6632.1996.tb56258.x; COOPER RR, 1973, J BONE JOINT SURG AM, VA 55, P475, DOI 10.2106/00004623-197355030-00003; Deere M, 1998, AM J MED GENET, V80, P510, DOI 10.1002/(SICI)1096-8628(19981228)80:5<510::AID-AJMG14>3.0.CO;2-F; Delot E, 1999, HUM MOL GENET, V8, P123, DOI 10.1093/hmg/8.1.123; Delot E, 1998, J BIOL CHEM, V273, P26692, DOI 10.1074/jbc.273.41.26692; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; DiCesare PE, 1997, FEBS LETT, V412, P249, DOI 10.1016/S0014-5793(97)00789-8; EFIMOV VP, 1994, FEBS LETT, V341, P54, DOI 10.1016/0014-5793(94)80239-4; HAUSER N, 1995, FEBS LETT, V368, P307, DOI 10.1016/0014-5793(95)00675-Y; Hecht JT, 1998, MATRIX BIOL, V17, P269, DOI 10.1016/S0945-053X(98)90080-4; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; Horton William A., 1993, P641; Ikegawa S, 1998, HUM GENET, V103, P633, DOI 10.1007/s004390050883; LAWLER J, 1995, J BIOL CHEM, V270, P2809, DOI 10.1074/jbc.270.6.2809; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1983, J BIOL CHEM, V258, P2098; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LODISH HF, 1992, J BIOL CHEM, V267, P12753; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; MISENHEIMER TM, 1995, J BIOL CHEM, V270, P1729, DOI 10.1074/jbc.270.4.1729; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; NEWTON G, 1994, GENOMICS, V24, P435, DOI 10.1006/geno.1994.1649; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; PEDRINIMILLE A, 1984, J BONE JOINT SURG AM, V66A, P1408, DOI 10.2106/00004623-198466090-00014; Prabakaran D, 1996, EUR J CELL BIOL, V70, P134; QABAR A, 1995, J BIOL CHEM, V270, P12725, DOI 10.1074/jbc.270.21.12725; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; Smith RKW, 1997, MATRIX BIOL, V16, P255, DOI 10.1016/S0945-053X(97)90014-7; SPEZIALE MV, 1990, J BIOL CHEM, V265, P17859; STANESCU R, 1993, AM J MED GENET, V45, P501, DOI 10.1002/ajmg.1320450420; SUN X, 1992, J CELL BIOL, V118, P693, DOI 10.1083/jcb.118.3.693; TURK JL, 1986, ARCH BIOCHEM BIOPHYS, V245, P446, DOI 10.1016/0003-9861(86)90236-5; Zaia J, 1997, J BIOL CHEM, V272, P14120, DOI 10.1074/jbc.272.22.14120	39	88	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26538	26544		10.1074/jbc.M909780199	http://dx.doi.org/10.1074/jbc.M909780199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10852928	hybrid, Green Published			2022-12-25	WOS:000088999700090
J	Cozzi, A; Corsi, B; Levi, S; Santambrogio, P; Albertini, A; Arosio, P				Cozzi, A; Corsi, B; Levi, S; Santambrogio, P; Albertini, A; Arosio, P			Overexpression of wild type and mutated human ferritin H-chain in HeLa cells - In vivo role of ferritin ferroxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERFERRITINEMIA-CATARACT SYNDROME; IRON-RESPONSIVE ELEMENT; MESSENGER-RNA; OXIDATIVE STRESS; GENE-EXPRESSION; MAMMALIAN-CELLS; MECHANISM; HETEROPOLYMERS; PROTEIN; SUBUNIT	Transfectant HeLa cells were generated that expressed human ferritin H-chain wild type and an H-chain mutant with inactivated ferroxidase activity under the control of the tetracycline-responsive promoter (Tet-off), The clones accumulated exogenous ferritins up to levels 14-16-fold over background, half of which were as H-chain homopolymers. This had no evident effect in the mutant ferritin clone, whereas it induced an iron-deficient phenotype in the H-ferritin wild type clone, manifested by similar to 5-fold increase of IRPs activity, similar to 2.5-fold increase of transferrin receptor, similar to 1.8-fold increase in iron-transferrin iron uptake, and similar to 50% reduction of labile iron pool. Overexpression of the H-ferritin, but not of the mutant ferritin, strongly reduced cell growth and increased resistance to H2O2 toxicity, effects that were reverted by prolonged incubation in iron-supplemented medium. The results show that in HeLa cells H-ferritin regulates the metabolic iron pool with a mechanism dependent on the functionality of the ferroxidase centers, and this affects, in opposite directions, cellular growth and resistance to oxidative damage. This, and the finding that also in vivo H-chain homopolymers are much less efficient than the H/L heteropolymers in taking up iron, indicate that functional activity of H-ferritin in HeLa cells is that predicted from the in vitro data.	IRCCS H San Raffaele, Dibit, Dept Biol & Technol Res, I-20132 Milan, Italy; Univ Brescia, Dept MI & Biomed Technol, I-25100 Brescia, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Brescia	Arosio, P (corresponding author), Via Olgettina 58, I-20132 Milan, Italy.		levi, sonia/A-3161-2015; arosio, paolo/E-6817-2010; Santambrogio, Paolo/AAN-3837-2020; Cozzi, Anna/AAN-3821-2020; arosio, paolo/S-3272-2019	levi, sonia/0000-0002-5092-0847; Santambrogio, Paolo/0000-0002-5481-2130; arosio, paolo/0000-0002-5343-8992; albertini, alberto/0000-0002-7989-649X				BEAUMONT C, 1995, NAT GENET, V11, P444, DOI 10.1038/ng1295-444; CAIRO G, 1985, BIOCHEM BIOPH RES CO, V133, P314, DOI 10.1016/0006-291X(85)91877-7; Cazzola M, 1997, BLOOD, V90, P814, DOI 10.1182/blood.V90.2.814.814_814_821; Corsi B, 1998, BIOCHEM J, V330, P315, DOI 10.1042/bj3300315; Corsi B, 1999, FEBS LETT, V460, P149, DOI 10.1016/S0014-5793(99)01330-7; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; COZZI A, 1989, CLIN CHIM ACTA, V184, P197, DOI 10.1016/0009-8981(89)90052-1; Epsztejn S, 1999, BLOOD, V94, P3593, DOI 10.1182/blood.V94.10.3593.422k26_3593_3603; Fan HZ, 1996, FEBS LETT, V382, P145, DOI 10.1016/0014-5793(96)00143-3; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARRISON PM, 1994, ADV EXP MED BIOL, V356, P1; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hwang J, 2000, SCIENCE, V287, P122, DOI 10.1126/science.287.5450.122; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Juan SH, 1998, ARCH BIOCHEM BIOPHYS, V355, P56, DOI 10.1006/abbi.1998.0722; Konijn AM, 1999, BLOOD, V94, P2128, DOI 10.1182/blood.V94.6.2128.418k20_2128_2134; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEVI S, 1994, J BIOL CHEM, V269, P30334; LEVI S, 1989, BIOCHEMISTRY-US, V28, P5179, DOI 10.1021/bi00438a040; Levi S, 1996, BIOCHEM J, V317, P467, DOI 10.1042/bj3170467; Levi S, 1998, BLOOD, V91, P4180, DOI 10.1182/blood.V91.11.4180.411k38_4180_4187; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; LOUACHE F, 1985, FEBS LETT, V183, P223, DOI 10.1016/0014-5793(85)80781-X; Picard V, 1996, BLOOD, V87, P2057; Picard V, 1998, J BIOL CHEM, V273, P15382, DOI 10.1074/jbc.273.25.15382; ROBERTS S, 1988, J BIOL CHEM, V263, P19181; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; SANTAMBROGIO P, 1992, J BIOL CHEM, V267, P14077; SANTAMBROGIO P, 1993, J BIOL CHEM, V268, P12744; Santambrogio P, 1996, BIOCHEM J, V314, P139, DOI 10.1042/bj3140139; Yang XK, 1999, BIOCHEM J, V338, P615, DOI 10.1042/0264-6021:3380615; Yang XK, 1998, BIOCHEMISTRY-US, V37, P9743, DOI 10.1021/bi973128a	35	199	214	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25122	25129		10.1074/jbc.M003797200	http://dx.doi.org/10.1074/jbc.M003797200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10833524	hybrid			2022-12-25	WOS:000088849400013
J	Katsumi, A; Tuley, EA; Bodo, I; Sadler, JE				Katsumi, A; Tuley, EA; Bodo, I; Sadler, JE			Localization of disulfide bonds in the cystine knot domain of human von Willebrand factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE SUBMAXILLARY MUCIN; HUMAN VONWILLEBRAND-FACTOR; NORRIE DISEASE; SELECTIVE REDUCTION; DIMERIZATION; SEQUENCE; MUTATION; LINKAGE; CHAIN; CELLS	von Willebrand factor (VWF) is a multimeric glycoprotein that is required for normal hemostasis. After translocation into the endoplasmic reticulum, proVWF subunits dimerize through disulfide bonds between their C-terminal cystine knot-like (CK) domains. CK domains are characterized by six conserved cysteines, Disulfide bonds between cysteines 2 and 5 and between cysteines 3 and 6 define a ring that is penetrated by a disulfide bond between cysteines 1 and 4. Dimerization often is mediated by additional cysteines that differ among CK domain subfamilies. When expressed in a baculovirus system, recombinant VWF CK domains (residues 1957-2050) were secreted as dimers that were converted to monomers by selective reduction and alkylation of three unconserved cysteine residues: Cys(2008), CyS2010 and Cys(2048). BY partial reduction and alkylation, chemical and proteolytic digestion, mass spectrometry, and amino acid sequencing, the remaining intrachain disulfide bonds were characterized: Cys(1961)-Cys(2011) (1-4), Cys(1987)-Cys(2041) (2-5), Cys(1991)-Cys(2045) (3-6), and Cys(1976)- Cys(2025). The mutation C2008A or C2010A prevented dimerization, whereas the mutation C2048A did not. Symmetry considerations and molecular modeling based on the structure of transforming growth factor-beta suggest that one or three of residues Cys(2008), Cys(2010), and Cys(2048) in each subunit mediate the covalent dimerization of proVWF.	Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Sadler, JE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, 660 S Euclid Ave,Box 8022, St Louis, MO 63110 USA.		Sadler, Evan/D-8556-2011	Sadler, J. Evan/0000-0001-5705-469X				Bures EJ, 1998, BIOCHEMISTRY-US, V37, P12172, DOI 10.1021/bi981082v; CHEN ZY, 1992, NAT GENET, V1, P204, DOI 10.1038/ng0692-204; CORMACK B, 1997, CURRENT PROTOCOLS MO; Daopin Sun, 1993, Proteins Structure Function and Genetics, V17, P176, DOI 10.1002/prot.340170207; Eckhardt AE, 1997, J BIOL CHEM, V272, P33204, DOI 10.1074/jbc.272.52.33204; ENAYAT MS, 1997, THROMB HAEMOST S, V82, P655; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; GRAY WR, 1993, PROTEIN SCI, V2, P1749, DOI 10.1002/pro.5560021018; Haniu M, 1996, BIOCHEMISTRY-US, V35, P16799, DOI 10.1021/bi9605550; Haniu M., 1997, CURRENT TOPICS PEPTI, V2, P115; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; Katsumi A, 1996, BLOOD, V87, P4164, DOI 10.1182/blood.V87.10.4164.bloodjournal87104164; Katsumi A, 2000, THROMB HAEMOSTASIS, V83, P239; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13665, DOI 10.1074/jbc.270.23.13665; Lu DS, 1997, J BIOL CHEM, V272, P31293, DOI 10.1074/jbc.272.50.31293; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MEITINGER T, 1993, NAT GENET, V5, P376, DOI 10.1038/ng1293-376; Montgomery RR, 1999, BLOOD, V94, p443A; NACHMAN R, 1977, J CLIN INVEST, V60, P914, DOI 10.1172/JCI108846; Perez-Vilar J, 1999, J BIOL CHEM, V274, P31751, DOI 10.1074/jbc.274.45.31751; Perez-Vilar J, 1997, J BIOL CHEM, V272, P33410, DOI 10.1074/jbc.272.52.33410; Perez-Vilar J, 1998, J BIOL CHEM, V273, P6982, DOI 10.1074/jbc.273.12.6982; RANDI AM, 1992, J BIOL CHEM, V267, P21187; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; Schneppenheim R, 1996, P NATL ACAD SCI USA, V93, P3581, DOI 10.1073/pnas.93.8.3581; Schneppenheim R, 1999, BLOOD, V94, p453A; Tamaoki H, 1998, PROTEIN ENG, V11, P649, DOI 10.1093/protein/11.8.649; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195	32	90	92	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25585	25594		10.1074/jbc.M002654200	http://dx.doi.org/10.1074/jbc.M002654200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10831592	hybrid			2022-12-25	WOS:000088849400072
J	Stockinger, W; Brandes, C; Fasching, D; Hermann, M; Gotthardt, M; Herz, J; Schneider, WJ; Nimpf, J				Stockinger, W; Brandes, C; Fasching, D; Hermann, M; Gotthardt, M; Herz, J; Schneider, WJ; Nimpf, J			The reelin receptor ApoER2 recruits JNK-interacting proteins-1 and-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E RECEPTOR-2; HUMAN ENDOTHELIAL-CELLS; CENTRAL-NERVOUS-SYSTEM; TERMINAL KINASE JNK; LIPOPROTEIN RECEPTOR; C-JUN; SIGNAL-TRANSDUCTION; BRAIN-DEVELOPMENT; ADAPTER PROTEINS; VLDL RECEPTOR	Correct positioning of neurons during embryonic development of the brain depends, among other processes, on the proper transmission of the reelin signal into the migrating cells via the interplay of its receptors with cytoplasmic signal transducers. Cellular components of this signaling pathway characterized to date are cell surface receptors for reelin like apolipoprotein E receptor 2 (ApoER2), very low density lipoprotein receptor (VLDLR), and cadherin-related neuronal receptors, and intracellular components like Disabled-1 and the nonreceptor tyrosine kinase Fyn, which bind to the intracellular domains of the ApoER2 and VLDL receptor or of cadherin-related neuronal receptors, respectively. Here we show that ApoER2, but not VLDLR, also binds the family of JNK-interacting proteins (JIPs), which act as molecular scaffolds for the JNK-signaling pathway. The ApoER2 binding domain on JIP-2 does not overlap with the binding sites for MLK3, MKK7, and JNK. These results suggest that ApoER2 is able to assemble a multiprotein complex containing Disabled-1 and JIPs, together with their binding partners, to the cell surface of neurons. This complex might participate in ApoER2-specific reelin signaling and thus would explain the different phenotype of mice lacking the ApoER2 from that of VLDLR-deficient mice.	Bioctr, Dept Mol Genet, Inst Med Biochem, A-1030 Vienna, Austria; Univ Vienna, A-1030 Vienna, Austria; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Vienna; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Nimpf, J (corresponding author), Bioctr, Dept Mol Genet, Inst Med Biochem, Dr Bohrgasse 9-2, A-1030 Vienna, Austria.		Gotthardt, Michael/ABE-8274-2021	Gotthardt, Michael/0000-0003-1788-3172; Nimpf, Johannes/0000-0002-9273-3492; Hermann, Marcela/0000-0003-2298-4269	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762] Funding Source: NIH RePORTER; NHLBI NIH HHS [R37 HL063762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Brandes C, 1997, GENOMICS, V42, P185, DOI 10.1006/geno.1997.4702; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Clatworthy AE, 1999, NEUROSCIENCE, V90, P903, DOI 10.1016/S0306-4522(98)00489-8; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Gliemann J, 1998, BIOL CHEM, V379, P951; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kim DH, 1997, J BIOL CHEM, V272, P8498, DOI 10.1074/jbc.272.13.8498; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Riddell DR, 1999, ATHEROSCLEROSIS, V144, P83, DOI 10.1016/S0021-9150(99)80317-7; Riddell DR, 1997, J BIOL CHEM, V272, P89; Robaire B., 1988, P999; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schneider WJ, 1997, CURR OPIN LIPIDOL, V8, P315, DOI 10.1097/00041433-199710000-00011; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Stockinger W, 1998, J BIOL CHEM, V273, P32213, DOI 10.1074/jbc.273.48.32213; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Wang NP, 1999, ARTERIOSCL THROM VAS, V19, P2078, DOI 10.1161/01.ATV.19.9.2078; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zerbinatti CV, 1999, BIOL REPROD, V61, P665, DOI 10.1095/biolreprod61.3.665; Zhu Y, 1999, BBA-MOL CELL BIOL L, V1436, P557, DOI 10.1016/S0005-2760(98)00167-2; Zhu Y, 1998, ARTERIOSCL THROM VAS, V18, P473, DOI 10.1161/01.ATV.18.3.473	49	190	197	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25625	25632		10.1074/jbc.M004119200	http://dx.doi.org/10.1074/jbc.M004119200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10827199	hybrid			2022-12-25	WOS:000088849400077
J	Tan, Y; Demeter, MR; Ruan, H; Comb, MJ				Tan, Y; Demeter, MR; Ruan, H; Comb, MJ			BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; STRUCTURAL BASIS; DEATH AGONIST; MAP KINASE; BH3 DOMAIN; PATHWAY; PROTEIN; AKT; ACTIVATION; APOPTOSIS	The BH3 domain of BAD mediates its death-promoting activities via heterodimerization to the Bcl-XL family of death regulators. Growth and survival factors inhibit the death-promoting activity of BAD by stimulating phosphorylation at multiple sites including Ser-112 and Ser-136, Phosphorylation at these sites promotes binding of BAD to 14-3-3 proteins, sequestering BAD away from the mitochondrial membrane where it dimerizes with Bcl-XL to exert its killing effects. We report here that the phosphorylation of BAD at Ser-155 within the BH3 domain is a second phosphorylation-dependent mechanism that inhibits the death-promoting activity of BAD, Protein kinase A, RSK1, and survival factor signaling stimulate phosphorylation of BAD at Ser-155, blocking the binding of BAD to Bcl-XL, RSK1 phosphorylates BAD at both Ser-112 and Ser-155 and rescues BAD-mediated cell death in a manner dependent upon phosphorylation at both sites.	Cell Signaling Technol, Cummings Ctr 166B, Beverly, MA 01915 USA		Comb, MJ (corresponding author), Cell Signaling Technol, Cummings Ctr 166B, Beverly, MA 01915 USA.	combm@cellsignal.com			NIDA NIH HHS [DA05706] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nebreda AR, 1999, SCIENCE, V286, P1309, DOI 10.1126/science.286.5443.1309; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	35	266	271	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25865	25869		10.1074/jbc.M004199200	http://dx.doi.org/10.1074/jbc.M004199200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10837486	hybrid			2022-12-25	WOS:000088849400105
J	Wang, HCR; Fecteau, KA				Wang, HCR; Fecteau, KA			Detection of a novel quiescence-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOBACTERIUM-VIOLACEUM NO-968; ARREST-SPECIFIC GENE; IRRADIATION-INDUCED APOPTOSIS; CASPASE-MEDIATED ACTIVATION; GROWTH ARREST; MAP KINASE; SIGNAL-TRANSDUCTION; PHOSPHORYLATION SITES; CELLS; DEPSIPEPTIDE	We have identified a cell quiescence-specific 33-kDa cytoplasmic protein kinase (p33(QIK), Quiescence-Induced Kinase) based on induction of p33(QIK)-specific kinase activity of cells growth-arrested in the quiescent phase and deactivation upon entry into the cell cycle. Blockage of macromolecular synthesis prevents p33(QIK) from deactivation, indicating a requirement of newly synthesized regulators for deactivation of p33(QIK) during G(0)/G(1) transition. Stress shock induces additional increases of p33(QIK) activity in a quiescence-dependent manner that correlates with induction of apoptosis, Using a specific antibody to Krs1/Mst2 protein, we found that p33(QIK) is related to p63(Krs1) and is distinguishable from a 36-kDa protein kinase, which is induced through proteolytic modification of activated p63(Krs1) in proliferating cells undergoing apoptosis, p33(QIK) is constantly expressed in quiescent, proliferating, and apoptotic quiescent cells, Regulation of p33(QIK) activity involves protein phosphorylation/dephosphorylation in a proteolysis-independent manner. Regulation of p33(QIK) and related p63(Krs1) and p36 appears to involve distinct pathways in quiescent and proliferating cells, respectively. Our results illustrate the relevance of p33(QIK) activity for cell quiescence that may provide a new insight into signaling pathways regulated in cells during quiescence and quiescence-related apoptosis.	Univ Tennessee, Coll Vet Med, Dept Comparat Med, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Wang, HCR (corresponding author), Univ Tennessee, Coll Vet Med, Dept Comparat Med, 2407 River Dr, Knoxville, TN 37996 USA.	hcrwang@utk.edu	Wang, Hwa-Chain/L-5646-2015	Wang, Hwa-Chain/0000-0001-5836-4120	NATIONAL CANCER INSTITUTE [R29CA069530] Funding Source: NIH RePORTER; NCI NIH HHS [1R29CA69530] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAI GE, 1988, FASEB J, V2, P3010, DOI 10.1096/fasebj.2.14.2846396; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CAMPISI J, 1984, EXP CELL RES, V152, P459, DOI 10.1016/0014-4827(84)90647-5; Chan WH, 1998, J PROTEIN CHEM, V17, P485, DOI 10.1023/A:1022578820147; Chan WH, 1999, J CELL PHYSIOL, V178, P397, DOI 10.1002/(SICI)1097-4652(199903)178:3<397::AID-JCP14>3.3.CO;2-U; CICCARELLI C, 1990, MOL CELL BIOL, V10, P1525, DOI 10.1128/MCB.10.4.1525; COCCIA EM, 1992, MOL CELL BIOL, V12, P3514, DOI 10.1128/MCB.12.8.3514; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL FLO; DENHARDT DT, 1986, BIOCHIM BIOPHYS ACTA, V865, P83, DOI 10.1016/0304-419X(86)90024-7; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Kakeya H, 1998, CANCER RES, V58, P4888; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KIM YH, 1993, J BIOL CHEM, V268, P18513; LARSSON O, 1985, J CELL SCI, V75, P259; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Lu ML, 1996, P NATL ACAD SCI USA, V93, P8977, DOI 10.1073/pnas.93.17.8977; MacKintosh C, 1996, FEBS LETT, V397, P235, DOI 10.1016/S0014-5793(96)01175-1; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MANFIOLETTI G, 1990, MOL CELL BIOL, V10, P2924, DOI 10.1128/MCB.10.6.2924; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; Rajgolikar G, 1998, BREAST CANCER RES TR, V51, P29, DOI 10.1023/A:1006091014092; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Scholz G, 1996, MOL CELL BIOL, V16, P481; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tang TK, 1998, J CELL BIOCHEM, V70, P442, DOI 10.1002/(SICI)1097-4644(19980915)70:4<442::AID-JCB2>3.3.CO;2-N; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; UEDA H, 1994, J ANTIBIOT, V47, P301; UEDA H, 1994, BIOSCI BIOTECH BIOCH, V58, P1579, DOI 10.1271/bbb.58.1579; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; Watabe M, 1999, ONCOGENE, V18, P5211, DOI 10.1038/sj.onc.1202901; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P7195, DOI 10.1073/pnas.88.16.7195; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	50	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25850	25857		10.1074/jbc.M000818200	http://dx.doi.org/10.1074/jbc.M000818200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10840030	hybrid			2022-12-25	WOS:000088849400103
J	Escalante, M; Courtney, J; Chin, WG; Teng, KK; Kim, JI; Fajardo, JE; Mayer, BJ; Hempstead, BL; Birge, RB				Escalante, M; Courtney, J; Chin, WG; Teng, KK; Kim, JI; Fajardo, JE; Mayer, BJ; Hempstead, BL; Birge, RB			Phosphorylation of c-Crk II on the negative regulatory Tyr(222) mediates nerve growth factor-induced cell spreading and morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-TYROSINE KINASE; V-CRK; ADAPTER PROTEIN; PC12 CELLS; IN-VIVO; PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; TERMINAL DOMAIN	The Crk family of adaptor proteins participate in diverse signaling pathways that regulate growth factor-induced proliferation, anchorage-dependent DNA synthesis, and cytoskeletal reorganization, important for cell adhesion and motility, Using kidney epithelial 293T cells for transient co-transfection studies and the nerve growth factor (NGF)-responsive PC12 cell line as a model system for neuronal morphogenesis, we demonstrate that the non-receptor tyrosine kinase c-Abl is an intermediary for NGF-inducible c-Crk II phosphorylation on the negative regulatory Tyr(222). Transient expression of a c-Crk II Tyr(222) point mutant (c-Crk Y222F) in 293T cells induces hyperphosphorylation of paxillin on Tyr(31) and enhances complex formation between c-Crk Y222F and paxillin as well as c-Crk Y222F and c-Abl, suggesting that c-Crk II Tye(222) phosphorylation induces both the dissociation of the Crk SH2 domain from paxillin and the Crk SH3 domain from c-Abl. Interestingly, examination of the early kinetics of NGF stimulation in PC12 cells showed that c-Crk II Tyr(222) phosphorylation preceded paxillin Tyr(31) phosphorylation, followed by a transient initial dissociation of the c-Crk II paxillin complex. PC12 cells overexpressing c-Crk Y222F manifested a defect in cellular adhesion and neuritogenesis that led to detachment of cells from the extracellular matrix, thus demonstrating the biological significance of c-Crk II tyrosine phosphorylation in NGF-dependent morphogenesis. Whereas previous studies have shown that Crk SH2 binding to paxillin is critical for cell adhesion and migration, our data show that the phosphorylation cycle of c-Crk II determines its dynamic interaction with paxillin, thereby regulating turnover of multiprotein complexes, a critical aspect of cytoskeletal plasticity and actin dynamics.	Rockefeller Univ, Mol Oncol Lab, New York, NY 10021 USA; Cornell Univ, New York Presbyterian Hosp, Weill Med Coll, Div Hematol Oncol, New York, NY 10021 USA; Harvard Univ, Howard Hughes Med Inst, Childrens Hosp, Sch Med,Dept Microbiol & Mol Genet, Boston, MA 12115 USA	Rockefeller University; Cornell University; NewYork-Presbyterian Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Birge, RB (corresponding author), New Jersey Med Sch, 185 Orange Ave,MSB,E-647,Univ Hts, Newark, NJ 07103 USA.		KIM, JONG-IL/D-1019-2011	KIM, JONG-IL/0000-0002-7240-3744; Teng, Kenneth/0000-0002-9392-2172	NIGMS NIH HHS [GM55760] Funding Source: Medline; NINDS NIH HHS [NS30687] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030687] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; AltunGultekin ZF, 1996, J NEUROSCI RES, V44, P308, DOI 10.1002/(SICI)1097-4547(19960515)44:4<308::AID-JNR2>3.0.CO;2-G; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Butler AA, 1997, J BIOL CHEM, V272, P27660, DOI 10.1074/jbc.272.44.27660; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Garton AJ, 1999, J BIOL CHEM, V274, P3811, DOI 10.1074/jbc.274.6.3811; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hoeve J.T., 1993, ONCOGENE, V8, P2469; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ILAC D, 1995, NATURE, V377, P539; Ishiki M, 1997, ENDOCRINOLOGY, V138, P4950, DOI 10.1210/en.138.11.4950; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Ling P, 1999, MOL CELL BIOL, V19, P1359; Manes S, 1999, MOL CELL BIOL, V19, P3125; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MELAMED I, 1995, J EXP MED, V181, P1071, DOI 10.1084/jem.181.3.1071; Nakashima N, 1999, J BIOL CHEM, V274, P3001, DOI 10.1074/jbc.274.5.3001; Nievers MG, 1997, J CELL SCI, V110, P389; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Sakai R, 1997, ONCOGENE, V14, P1419, DOI 10.1038/sj.onc.1200954; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Senechal K, 1998, MOL CELL BIOL, V18, P5082, DOI 10.1128/MCB.18.9.5082; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Teng KK, 1996, MOL CELL NEUROSCI, V8, P157, DOI 10.1006/mcne.1996.0054; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; TOMASELLI KJ, 1987, J CELL BIOL, V105, P2347, DOI 10.1083/jcb.105.5.2347; Torres M, 1996, ONCOGENE, V12, P77; TURNER CE, 1994, J CELL SCI, V107, P1583; Weinstein DE, 1999, DEV BRAIN RES, V116, P29, DOI 10.1016/S0165-3806(99)00072-3; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yano H, 2000, J NEUROSCI RES, V59, P356, DOI 10.1002/(SICI)1097-4547(20000201)59:3<356::AID-JNR9>3.0.CO;2-G	71	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24787	24797		10.1074/jbc.M000711200	http://dx.doi.org/10.1074/jbc.M000711200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10825157	hybrid			2022-12-25	WOS:000088683300076
J	Liu, CY; Schroder, M; Kaufman, RJ				Liu, CY; Schroder, M; Kaufman, RJ			Ligand-independent dimerization activates the stress response kinases IRE1 and PERK in the lumen of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; GLUCOSE-REGULATED PROTEINS; HAMSTER OVARY CELLS; KAR2 BIP GENE; TRANSCRIPTIONAL INDUCTION; SACCHAROMYCES-CEREVISIAE; TRANSMEMBRANE PROTEIN; SIGNAL-TRANSDUCTION; RESIDENT PROTEINS; MAMMALIAN-CELLS	IRE1 and PERK are type I transmembrane serine/threonine protein kinases that are activated by unfolded proteins in the endoplasmic reticulum (ER) to signal adaptive responses. IRE1 is present in all eukaryotic cells and signals the unfolded protein response through its kinase and endoribonuclease activities. PERK signals phosphorylation of a translation initiation factor to inhibit protein synthesis in higher eukaryotic cells but is absent in the Saccharomyces cerevisiae genome. The amino acid sequences of the amino-terminal ER luminal domains (NLDs) from IRE1 and PERK display limited homology and have diverged among species. In this study, we have demonstrated that the NLD of yeast Ire1p is required for signaling. However, the NLDs from human IRE1 alpha and murine IRE1 beta and the Caenorhabditis elegans IRE1 and PERK function as replacements for the S. cerevisiae Ire1p-NLD to signal the unfolded protein response. Replacement of the Ire1p-NLD with a functional leucine zipper dimerization motif yielded a constitutively active kinase that surprisingly was further activated by ER stress. These results demonstrate that ER stress-induced dimerization of the NLD is sufficient for IRE1 and PERK activation and is conserved through evolution. We propose that ligand-independent activation of IRE1 and PERK permits homodimerization upon accumulation of unfolded proteins in the lumen of the ER.	Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kaufman, RJ (corresponding author), Univ Michigan, Med Ctr, Howard Hughes Med Inst, 4570 MSRB II,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		Longo, Kenneth A/A-5631-2010; Liu, Andrew C/B-3548-2009	Liu, Andrew C/0000-0003-1927-0900				Argon Y, 1999, SEMIN CELL DEV BIOL, V10, P495, DOI 10.1006/scdb.1999.0320; BEH CT, 1995, P NATL ACAD SCI USA, V92, P9820, DOI 10.1073/pnas.92.21.9820; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; FARRELL RE, 1993, RNA METHODOLOGIES LA, P47; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KITABAYASHI I, 1990, NUCLEIC ACIDS RES, V18, P3400, DOI 10.1093/nar/18.11.3400; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; NG DTW, 1992, MOL BIOL CELL, V3, P143, DOI 10.1091/mbc.3.2.143; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Sakai M, 1997, ONCOGENE, V14, P745, DOI 10.1038/sj.onc.1200869; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shi YG, 1999, J BIOL CHEM, V274, P5723, DOI 10.1074/jbc.274.9.5723; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; SIKORSKI RS, 1989, GENETICS, V122, P19; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vidan S, 1997, MOL CELL BIOL, V17, P2688, DOI 10.1128/MCB.17.5.2688; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Welihinda AA, 1998, MOL CELL BIOL, V18, P1967, DOI 10.1128/MCB.18.4.1967; Welihinda AA, 1996, J BIOL CHEM, V271, P18181, DOI 10.1074/jbc.271.30.18181; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943	41	301	319	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24881	24885		10.1074/jbc.M004454200	http://dx.doi.org/10.1074/jbc.M004454200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10835430	hybrid			2022-12-25	WOS:000088683300086
J	Romero, MF; Henry, D; Nelson, S; Harte, PJ; Dillon, AK; Sciortino, CM				Romero, MF; Henry, D; Nelson, S; Harte, PJ; Dillon, AK; Sciortino, CM			Cloning and characterization of a Na+-driven anion exchanger (NDAE1) - A new bicarbonate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BASE TRANSPORT; INTRACELLULAR PH; DROSOPHILA-MELANOGASTER; CHLORIDE TRANSPORT; COTRANSPORTER; SODIUM; MOSQUITO; MIDGUT; CELLS; FIBROBLASTS	Regulation of intra- and extracellular ion activities (e,g. H+, Cl-, Na+) is key to normal function of the central nervous system, digestive tract, respiratory tract, and urinary system. With our cloning of an electrogenic Na+/HCO3- cotransporter (NBC), we found that NBC and the anion exchangers form a bicarbonate transporter superfamily, Functionally three other HCO3- transporters are known: a neutral Na+/HCO3- cotransporter, a K+/HCO3- cotransporter, and a Na+-dependent Cl--HCO3- exchanger. We report the cloning and characterization of a Na+-coupled Cl--HCO3- exchanger and a physiologically unique bicarbonate transporter superfamily member. This Drosophila cDNA encodes a 1030-amino acid membrane protein with both sequence homology and predicted topology similar to the anion exchangers and NBCs, The mRNA is expressed throughout Drosophila development and is prominent in the central nervous system. When expressed in Xenopus oocytes, this membrane protein mediates the transport of Cl-, Na+, H+, and HCO3- but does not require HCO3-. Transport is blocked by the stilbene 4,4'-diisothiocyanodihydrostilbene-2,2'-disulfonates and may not be strictly electroneutral. Our functional data suggest this Na+ driven anion exchanger (NDAE1) is responsible for the Nai-dependent Cl--HCO3- exchange activity characterized in neurons, kidney, and fibroblasts. NDAE1 may be generally important for fly development, because disruption of this gene is apparently lethal to the Drosophila larva.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Romero, MF (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, E-545,2119 Abington Rd, Cleveland, OH 44106 USA.	mfr2@po.cwru.edu			NIDDK NIH HHS [DK07678] Funding Source: Medline; NIGMS NIH HHS [GM39255] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039255] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALPER SL, 1991, ANNU REV PHYSIOL, V53, P549, DOI 10.1146/annurev.physiol.53.1.549; Butcher GA, 1996, EXP PARASITOL, V84, P371, DOI 10.1006/expr.1996.0125; BUTLER GAD, 1994, EXP EYE RES, V59, P343, DOI 10.1006/exer.1994.1116; CASSEL D, 1988, J BIOL CHEM, V263, P6122; Choi I, 1999, FASEB J, V13, pA400; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DADD RH, 1975, J INSECT PHYSIOL, V21, P1847, DOI 10.1016/0022-1910(75)90252-8; DOW JAT, 1992, J EXP BIOL, V172, P355; DUNCAN G, 1992, EXP EYE RES, V54, P941, DOI 10.1016/0014-4835(92)90158-O; Ganz MB, 1998, AM J PHYSIOL-RENAL, V274, pF550, DOI 10.1152/ajprenal.1998.274.3.F550; GANZ MB, 1994, AM J PHYSIOL, V266, pF576, DOI 10.1152/ajprenal.1994.266.4.F576; GANZ MB, 1989, NATURE, V337, P648, DOI 10.1038/337648a0; GUGGINO WB, 1983, J MEMBRANE BIOL, V71, P227, DOI 10.1007/BF01875464; Hacker JK, 1997, VIROLOGY, V235, P40, DOI 10.1006/viro.1997.8675; HOGAN EM, 1995, J GEN PHYSIOL, V106, P821, DOI 10.1085/jgp.106.5.821; Ishibashi K, 1998, BIOCHEM BIOPH RES CO, V246, P535, DOI 10.1006/bbrc.1998.8658; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; Lee AH, 1998, CANCER RES, V58, P1901; MOFFETT DF, 1994, PHYSIOL ZOOL, V67, P68, DOI 10.1086/physzool.67.1.30163835; PARDUE ML, 1994, METHOD CELL BIOL, V44, P333, DOI 10.1016/S0091-679X(08)60922-X; Pushkin A, 1999, J BIOL CHEM, V274, P16569, DOI 10.1074/jbc.274.23.16569; REITHMEIER RAF, 1993, CURR OPIN STRUC BIOL, V3, P515, DOI 10.1016/0959-440X(93)90077-X; Roch F, 1998, MOL GEN GENET, V257, P103, DOI 10.1007/PL00008620; Romero MF, 1999, ANNU REV PHYSIOL, V61, P699, DOI 10.1146/annurev.physiol.61.1.699; Romero MF, 1997, NATURE, V387, P409, DOI 10.1038/387409a0; Romero MF, 1998, AM J PHYSIOL-RENAL, V274, pF425, DOI 10.1152/ajprenal.1998.274.2.F425; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROTIN D, 1989, CANCER RES, V49, P205; RUSSELL JM, 1976, NATURE, V264, P73, DOI 10.1038/264073a0; SCHWIENING CJ, 1994, J PHYSIOL-LONDON, V475, P59, DOI 10.1113/jphysiol.1994.sp020049; Sciortino CM, 1999, AM J PHYSIOL-RENAL, V277, pF611, DOI 10.1152/ajprenal.1999.277.4.F611; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMAS RC, 1977, J PHYSIOL-LONDON, V273, P317, DOI 10.1113/jphysiol.1977.sp012096; TOROK T, 1993, GENETICS, V135, P71; Zhuang ZP, 1999, J EXP BIOL, V202, P2449	39	106	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24552	24559		10.1074/jbc.M003476200	http://dx.doi.org/10.1074/jbc.M003476200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827195	hybrid			2022-12-25	WOS:000088683300044
J	Spelbrink, JN; Toivonen, JM; Hakkaart, GAJ; Kurkela, JM; Cooper, HM; Lehtinen, SK; Lecrenier, N; Back, JW; Speijer, D; Foury, F; Jacobs, HT				Spelbrink, JN; Toivonen, JM; Hakkaart, GAJ; Kurkela, JM; Cooper, HM; Lehtinen, SK; Lecrenier, N; Back, JW; Speijer, D; Foury, F; Jacobs, HT			In vivo functional analysis of the human mitochondrial DNA polymerase POLG expressed in cultured human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASES; BINDING PROTEIN; ACCESSORY SUBUNIT; CATALYTIC SUBUNIT; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MUTATIONAL SPECTRUM; POLYACRYLAMIDE GELS; GAMMA; IDENTIFICATION	The human gene POLG encodes the catalytic subunit of mitochondrial DNA polymerase, but its precise roles in mtDNA metabolism in Dice have not hitherto been documented. By expressing POLG fusion proteins in cultured human cells, we show that the enzyme is targeted to mitochondria, where the Myc epitope-tagged POLG is catalytically active as a DNA polymerase. Long-term culture of cells expressing wild-type POLG-myc revealed no alterations in mitochondrial function. Expression of POLG-myc mutants created dominant phenotypes demonstrating important roles for the protein in mtDNA maintenance and integrity. The D198A amino acid replacement abolished detectable 3'-5' (proofreading) exonuclease activity and led to the accumulation of a significant load (1:1700) of mtDNA point mutations during 3 months of continuous culture. Further culture resulted in the selection of cells with an inactivated mutator polymerase, and a reduced mutation load in mtDNA Transient expression of POLG-myc variants D890N or D1135A inhibited endogenous mitochondrial DNA polymerase activity and caused mtDNA depletion. Deletion of the POLG CAG repeat did not affect enzymatic properties, but modestly up-regulated expression. These findings demonstrate that POLG exonuclease and polymerase functions are essential for faithful mtDNA maintenance in vivo, and indicate the importance of key residues for these activities.	Tampere Univ, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, FIN-33101 Tampere, Finland; Univ Catholique Louvain, Unite Biochim Physiol, B-1348 Louvain La Neuve, Belgium; Univ Amsterdam, EC Slater Inst, NL-1018 TV Amsterdam, Netherlands; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland	Tampere University; Tampere University; Tampere University Hospital; Universite Catholique Louvain; University of Amsterdam; University of Glasgow	Jacobs, HT (corresponding author), Tampere Univ, Inst Med Technol, POB 607, FIN-33101 Tampere, Finland.		Toivonen, Janne M./E-5691-2011; B, Jw/N-7879-2019; Speijer, Dave/AAE-4613-2019; Jacobs, Howard T/G-2434-2011; Back, JW/B-3641-2009; Spelbrink, Johannes N/L-4661-2015	Toivonen, Janne M./0000-0002-7243-1737; B, Jw/0000-0002-1310-4373; Speijer, Dave/0000-0002-2340-2753; Back, JW/0000-0002-1310-4373; Spelbrink, Johannes N/0000-0002-9756-2602; Jacobs, Howard/0000-0003-1895-6003				ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Andre P, 1997, GENOME RES, V7, P843, DOI 10.1101/gr.7.8.843; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLANCO L, 1991, NUCLEIC ACIDS RES, V19, P955, DOI 10.1093/nar/19.4.955; Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123; El Meziane A, 1998, NAT GENET, V18, P350; Fan L, 1999, P NATL ACAD SCI USA, V96, P9527, DOI 10.1073/pnas.96.17.9527; Farr CL, 1999, J BIOL CHEM, V274, P14779, DOI 10.1074/jbc.274.21.14779; FernandezSilva P, 1997, EMBO J, V16, P1066, DOI 10.1093/emboj/16.5.1066; FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x; FOURY F, 1989, J BIOL CHEM, V264, P20552; Fuenmayor J, 1998, J EUKARYOT MICROBIOL, V45, P404, DOI 10.1111/j.1550-7408.1998.tb05091.x; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; GRAY H, 1992, J BIOL CHEM, V267, P5835; HAUSWIRTH WW, 1987, MITOCHONDRIA PRACTIC, P176; HESS J, 1995, LANCET, V346, P189, DOI 10.1016/S0140-6736(95)91251-7; HU JP, 1995, GENE, V160, P105, DOI 10.1016/0378-1119(95)00215-R; ITO J, 1990, NUCLEIC ACIDS RES, V18, P6716, DOI 10.1093/nar/18.22.6716; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Larsson NG, 1997, HUM MOL GENET, V6, P185, DOI 10.1093/hmg/6.2.185; Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4; Lehtinen SK, 2000, GENETICS, V154, P363; Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; Marcelino LA, 1998, CANCER RES, V58, P2857; Mikhailov VS, 1996, J BIOL CHEM, V271, P18939, DOI 10.1074/jbc.271.31.18939; Mikhailov VS, 1996, J BIOL CHEM, V271, P30774, DOI 10.1074/jbc.271.48.30774; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Nielsen-Preiss SM, 2000, ARCH BIOCHEM BIOPHYS, V374, P229, DOI 10.1006/abbi.1999.1590; NIJTMANS LGJ, 1995, BBA-MOL CELL RES, V1265, P117, DOI 10.1016/0167-4889(94)00203-Q; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; Rovio A, 1999, EUR J HUM GENET, V7, P140, DOI 10.1038/sj.ejhg.5200244; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schultz RA, 1998, J BIOL CHEM, V273, P3447, DOI 10.1074/jbc.273.6.3447; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHOUBRIDGE EA, 1995, BIOCHEM BIOPH RES CO, V213, P189, DOI 10.1006/bbrc.1995.2115; SPELBRINK JN, 1994, HUM MOL GENET, V3, P1989, DOI 10.1093/hmg/3.11.1989; Spelbrink JN, 1997, CURR GENET, V32, P115, DOI 10.1007/s002940050255; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P350; VANDENBOGERT C, 1991, BIOCHIM BIOPHYS ACTA, V1097, P87, DOI 10.1016/0925-4439(91)90090-V; Vanderstraeten S, 1998, J BIOL CHEM, V273, P23690, DOI 10.1074/jbc.273.37.23690; Walker RL, 1997, GENOMICS, V40, P376, DOI 10.1006/geno.1996.4580; Wang YX, 1997, J BIOL CHEM, V272, P13640, DOI 10.1074/jbc.272.21.13640; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P860, DOI 10.1074/jbc.270.2.860; WILLIAMS RS, 1986, J BIOL CHEM, V261, P2390; Woriax VL, 1995, BBA-GENE STRUCT EXPR, V1264, P347, DOI 10.1016/0167-4781(95)00176-X; ZEVIANI M, 1995, BBA-MOL BASIS DIS, V1271, P153, DOI 10.1016/0925-4439(95)00022-V	57	156	160	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24818	24828		10.1074/jbc.M000559200	http://dx.doi.org/10.1074/jbc.M000559200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10827171	hybrid			2022-12-25	WOS:000088683300079
J	Lee, DS; Tomita, S; Kirino, Y; Suzuki, T				Lee, DS; Tomita, S; Kirino, Y; Suzuki, T			Regulation of X11L-dependent amyloid precursor protein metabolism by XB51, a novel X11L-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE EXOCYTOSIS; CYTOPLASMIC DOMAIN; ALZHEIMERS; IDENTIFICATION; CLEAVAGE; COMPLEX; BRAIN; CELLS; APP	We isolated a cDNA encoding a novel protein, XB51, that interacts with the amino-terminal domain of the neuron-specific X11-like protein (X11L). The protein XB51 inhibited the association of X11L with amyloid precursor protein through a non-competitive mechanism and abolished the suppression of beta-amyloid production by X11L. The majority of XB51 is localized around the nucleus and recovered in 3-[(3-cholamidopropy1)dimethylammonio]-1-propanesulfonic acid (CHAPS) buffer-insoluble fraction when XB51 is expressed in cells. Association of XB51 with X11L changed the intracellular distribution of XB51 and resulted in redistribution of XB51 into the CHAPS buffer-soluble fraction. These observations suggest that XB51, together with X11L, plays an important role in the regulatory system of amyloid precursor protein metabolism and beta-amyloid generation.	Univ Tokyo, Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Suzuki, T (corresponding author), Univ Tokyo, Sch Pharmaceut Sci, Lab Neurobiophys, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		Suzuki, Toshiharu/B-5342-2013					Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; Oishi M, 1997, MOL MED, V3, P111, DOI 10.1007/BF03401803; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Price DL, 1998, SCIENCE, V282, P1079, DOI 10.1126/science.282.5391.1079; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Tomita S, 1998, J BIOL CHEM, V273, P19304, DOI 10.1074/jbc.273.30.19304; Tomita S, 2000, J BIOL CHEM, V275, P13056, DOI 10.1074/jbc.C000019200; Tomita S, 1998, J BIOL CHEM, V273, P6277, DOI 10.1074/jbc.273.11.6277; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087	12	28	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	2000	275	30					23134	23138		10.1074/jbc.C000302200	http://dx.doi.org/10.1074/jbc.C000302200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	338KV	10833507	hybrid			2022-12-25	WOS:000088419400072
J	Walsh, MT; Foley, JF; Kinsella, BT				Walsh, MT; Foley, JF; Kinsella, BT			The alpha, but not the beta, isoform of the human thromboxane A(2) receptor is a target for prostacyclin-mediated desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; AGONIST-DEPENDENT PHOSPHORYLATION; GTP-BINDING PROTEIN; HUMAN PLATELETS; CROSS-TALK; PROSTANOID RECEPTORS; COUPLED RECEPTORS; NITRIC-OXIDE; ALPHA-1-ADRENERGIC RECEPTOR; ADENYLYL-CYCLASE	In this study, we examined the effects the prostacyclin receptor (IP) agonist cicaprost exhibited on U46619-mediated thromboxane A(2) receptor (TP) signaling in platelets and compared it to that which occurs in human embryonic kidney (HEK) 293 cells stably overexpressing the individual TF alpha or TP beta isoforms. Consistent with previous studies, cicaprost abrogated U46619-mediated platelet aggregation and mobilization of intracellular calcium ([Ca2+](i)). In HEK 293 cells, signaling by TP alpha, but not TP beta, was subject to IP-mediated desensitization in a protein kinase A-dependent, protein kinase C-independent manner. Desensitization of TP alpha signaling was independent of the nature of the IP agonist used, the level of IP expression, or the subtype of G(q) protein. Signaling by TPDelta 328, a truncated variant of TP devoid of the divergent residues of the TPs, or by TP alpha(S329A), a site-directed mutant of TP alpha, were insensitive to IP agonist activation. Whole cell phosphorylations established that TPa; but not TP beta or TP alpha(S329A), is subject to IP-mediated phosphorylation and that TP alpha phosphorylation is inhibited by H-89. Thus, we conclude that TP alpha, but not TP beta, is subject to cross-desensitization by IP mediated through direct protein kinase A phosphorylation at Ser(329) and propose that TP alpha may be the isoform physiologically relevant to TP:IP-mediated vascular hemostasis.	Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dept Biochem, Dublin 4, Ireland	University College Dublin	Kinsella, BT (corresponding author), Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dept Biochem, Merville House, Dublin 4, Ireland.			Kinsella, B. Therese/0000-0003-3072-941X				Allan CJ, 1996, J PHARMACOL EXP THER, V277, P1132; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Armstrong RA, 1996, PHARMACOL THERAPEUT, V72, P171, DOI 10.1016/S0163-7258(96)00103-9; AZUMA H, 1986, BRIT J PHARMACOL, V88, P411, DOI 10.1111/j.1476-5381.1986.tb10218.x; Becker KP, 1999, BBA-MOL CELL RES, V1450, P288, DOI 10.1016/S0167-4889(99)00068-3; Becker KP, 1998, BBA-MOL CELL RES, V1403, P109, DOI 10.1016/S0167-4889(98)00019-6; Blom N, 1998, NUCLEIC ACIDS RES, V26, P382, DOI 10.1093/nar/26.1.382; BOIE Y, 1994, J BIOL CHEM, V269, P12173; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASS LF, 1987, J CLIN INVEST, V79, P1269, DOI 10.1172/JCI112947; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BUECHLER WA, 1994, ANN NY ACAD SCI, V714, P151; Chuang TT, 1996, TRENDS PHARMACOL SCI, V17, P416, DOI 10.1016/S0165-6147(96)10048-1; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; COLEMAN RW, 1994, HEMOSTASIS THROMBASI; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; Djellas Y, 1999, J BIOL CHEM, V274, P14325, DOI 10.1074/jbc.274.20.14325; FARNDALE RW, 1992, SIGNAL TRANSDUCTION, P75; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FINDIK D, 1995, J CELL BIOCHEM, V57, P12, DOI 10.1002/jcb.240570103; FITZGERALD DJ, 1990, LANCET, V335, P751, DOI 10.1016/0140-6736(90)90869-7; GEILEN CC, 1992, FEBS LETT, V309, P381, DOI 10.1016/0014-5793(92)80811-T; GODFREY PP, 1992, SIGNAL TRANSDUCTION, P105; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Habib A, 1999, J BIOL CHEM, V274, P2645, DOI 10.1074/jbc.274.5.2645; Habib A, 1997, J BIOL CHEM, V272, P7191, DOI 10.1074/jbc.272.11.7191; Hayes JS, 1999, J BIOL CHEM, V274, P23707, DOI 10.1074/jbc.274.34.23707; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HIRATA T, 1994, J CLIN INVEST, V94, P1662, DOI 10.1172/JCI117510; Hirata T, 1996, J CLIN INVEST, V97, P949, DOI 10.1172/JCI118518; HUNT JA, 1992, BIOCHEM PHARMACOL, V43, P1747, DOI 10.1016/0006-2952(92)90705-N; HWANG KC, 1995, J BIOL CHEM, V270, P27058, DOI 10.1074/jbc.270.45.27058; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; KAHN NN, 1990, CIRC RES, V66, P932, DOI 10.1161/01.RES.66.4.932; Kinsella BT, 1997, J PHARMACOL EXP THER, V281, P957; KINSELLA BT, 1994, J BIOL CHEM, V269, P29914; KITANAKA J, 1995, BBA-MOL CELL RES, V1265, P220, DOI 10.1016/0167-4889(94)00225-4; KNEZEVIC I, 1993, J BIOL CHEM, V268, P26011; KRUMNICK JG, 1998, ANN REV PHARM TOXICO, V38, P289; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LIEBERMAN EH, 1991, CIRC RES, V68, P1722, DOI 10.1161/01.RES.68.6.1722; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MELLION BT, 1981, BLOOD, V57, P946; MENDELSOHN ME, 1990, J BIOL CHEM, V265, P19028; Miggin SM, 1998, BBA-GEN SUBJECTS, V1425, P543, DOI 10.1016/S0304-4165(98)00109-3; MOLLACE V, 1991, BRIT J PHARMACOL, V104, P633, DOI 10.1111/j.1476-5381.1991.tb12481.x; Morinelli TA, 1997, BIOCHEM PHARMACOL, V53, P1823, DOI 10.1016/S0006-2952(97)00005-1; MORRIS GM, 1991, J BIOL CHEM, V266, P2233; MUCK S, 1997, ADV EXP MED BIOL, V43, P47; MURRAY R, 1990, J BIOL CHEM, V265, P21670; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; NAMBA T, 1992, BIOCHEM BIOPH RES CO, V184, P1197, DOI 10.1016/S0006-291X(05)80009-9; NAMBA T, 1994, J BIOL CHEM, V269, P9986; NEGISHI M, 1993, PROG LIPID RES, V32, P417, DOI 10.1016/0163-7827(93)90017-Q; NUSING RM, 1993, J BIOL CHEM, V268, P25253; OATES JA, 1988, NEW ENGL J MED, V319, P689, DOI 10.1056/NEJM198809153191106; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; OGAWA Y, 1995, GENOMICS, V27, P142, DOI 10.1006/geno.1995.1016; OMAHONY DJ, 1997, PR MED BIOL A, V8, P385; Ozaki S, 1997, J BIOCHEM, V121, P440; Parent JL, 1999, J BIOL CHEM, V274, P8941, DOI 10.1074/jbc.274.13.8941; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; Penn RB, 1999, J PHARMACOL EXP THER, V288, P428; RAYCHOWDHURY MK, 1995, J BIOL CHEM, V270, P7011, DOI 10.1074/jbc.270.12.7011; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; SCHAFER AI, 1980, BLOOD, V55, P649; SCHWANER I, 1995, BBA-MOL CELL RES, V1265, P8, DOI 10.1016/0167-4889(94)00198-N; Selbie LA, 1998, TRENDS PHARMACOL SCI, V19, P87, DOI 10.1016/S0165-6147(97)01166-8; SERNERI GGN, 1984, LANCET, V2, P838; SHENKER A, 1991, J BIOL CHEM, V266, P9309; Siegel G, 1989, Eicosanoids, V2, P213; Smyth EM, 1996, J BIOL CHEM, V271, P33698, DOI 10.1074/jbc.271.52.33698; Smyth EM, 1998, J BIOL CHEM, V273, P23258, DOI 10.1074/jbc.273.36.23258; SNEDDON JM, 1988, P NATL ACAD SCI USA, V85, P2800, DOI 10.1073/pnas.85.8.2800; Spurney RF, 1998, BIOCHEM PHARMACOL, V55, P1271, DOI 10.1016/S0006-2952(97)00633-3; Spurney RF, 1998, J BIOL CHEM, V273, P28496, DOI 10.1074/jbc.273.43.28496; Spurney RF, 1997, J PHARMACOL EXP THER, V283, P207; Sulakhe PV, 1997, MOL CELL BIOCHEM, V176, P75, DOI 10.1023/A:1006874928424; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; USHIKUBI F, 1994, MOL PHARMACOL, V46, P808; vanderVuurst H, 1997, ARTERIOSCL THROM VAS, V17, P1830, DOI 10.1161/01.ATV.17.9.1830; VANWILLIGEN G, 1995, BIOCHEM BIOPH RES CO, V214, P254, DOI 10.1006/bbrc.1995.2282; Vezza R, 1999, J BIOL CHEM, V274, P12774, DOI 10.1074/jbc.274.18.12774; Walsh MT, 1998, J PHARMACOL EXP THER, V286, P1026; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; Watanabe T, 1996, BBA-LIPID LIPID MET, V1304, P161, DOI 10.1016/S0005-2760(96)00111-7; Watson S., 1994, G PROTEIN LINKED REC; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; Wise H, 1996, TRENDS PHARMACOL SCI, V17, P17, DOI 10.1016/0165-6147(96)81565-3; Yukawa M, 1997, CIRC RES, V80, P551, DOI 10.1161/01.RES.80.4.551	92	98	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 7	2000	275	27					20412	20423		10.1074/jbc.M907881199	http://dx.doi.org/10.1074/jbc.M907881199			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332QG	10827090	hybrid			2022-12-25	WOS:000088084500028
J	Kato, Y; Zhao, M; Morikawa, A; Sugiyama, T; Chakravortty, D; Koide, N; Yoshida, T; Tapping, RI; Yang, Y; Yokochi, T; Lee, JD				Kato, Y; Zhao, M; Morikawa, A; Sugiyama, T; Chakravortty, D; Koide, N; Yoshida, T; Tapping, RI; Yang, Y; Yokochi, T; Lee, JD			Big mitogen-activated kinase regulates multiple members of the MEF2 protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN PROMOTER; TRANSCRIPTION FACTOR MEF2C; SIGNAL-TRANSDUCTION PATHWAY; MAP-KINASE; PROTEIN-KINASE-1 BMK1; COUPLED RECEPTORS; P38; INDUCTION; GENE; PHOSPHORYLATION	Big mitogen-activated protein (MAP) kinase (BMK1), a member of the mammalian MAP kinase family, is activated by growth factors. The activation of BMK1 is required for growth factor-induced cell proliferation and cell cycle progression. me have previously shown that BMK1 regulates c-jun gene expression through direct phosphorylation and activation of transcription factor MEF2C. MEF2C belongs to the myocyte enhancer factor 2 (MEF2) protein family, a four-membered family of transcription factors denoted MEF2A, -2B, -2C, and -2D. Here, we demonstrate that, in addition to MEF2C, BMK1 phosphorylates and activates MEF2A and MEF2D but not MEF2B. The blocking of BMK1 signaling inhibits the epidermal growth factor-dependent activation of these three MEF2 transcription factors. The sites phosphorylated by activated BMK1 were mapped to Ser-355, Thr-312, and Thr-319 of MEF2A and Ser-179 of MEF2D both in vitro and in vivo. Site-directed mutagenesis reveals that the phosphorylation of these sites in MEF2A and MEF2D are necessary for the induction of MEF2A and 2D transactivating activity by either BMK1 or by epidermal growth factor. Taken together, these data demonstrate that, upon growth factor induction, BMK1 directly phosphorylates and activates three members of the MEF2 family of transcription factors thereby inducing MEF2-dependent gene expression.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; Aichi Med Univ, Dept Microbiol & Immunol, Nagakute, Aichi 4801195, Japan; Linking Univ, Dept Pathol 2, SE-58185 Linkoping, Sweden	Scripps Research Institute; Johnson & Johnson; Johnson & Johnson USA; Aichi Medical University	Lee, JD (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		chakravortty, dipshikha/A-9492-2009; Chakravortty, Dipshikha/AAI-4448-2020		NIGMS NIH HHS [GM53214] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053214] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Coso OA, 1997, J BIOL CHEM, V272, P20691, DOI 10.1074/jbc.272.33.20691; Coso OA, 1996, J BIOL CHEM, V271, P3963; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Lin Q, 1998, DEVELOPMENT, V125, P4565; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Yan C, 1999, J BIOL CHEM, V274, P143, DOI 10.1074/jbc.274.1.143; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; Yang SH, 1999, MOL CELL BIOL, V19, P4028; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; Zhao M, 1999, MOL CELL BIOL, V19, P21; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	37	124	132	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18534	18540		10.1074/jbc.M001573200	http://dx.doi.org/10.1074/jbc.M001573200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849446	hybrid			2022-12-25	WOS:000087659400085
J	Lionberger, JM; Wilson, MB; Smithgall, TE				Lionberger, JM; Wilson, MB; Smithgall, TE			Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; POSITIVE HUMAN LEUKEMIAS; DNA-BINDING ACTIVITY; FES TYROSINE KINASE; PHILADELPHIA-CHROMOSOME; C-ABL; FIBROBLAST TRANSFORMATION; HEMATOPOIETIC-CELLS; ADAPTER PROTEIN; ACTIVATION	Bcr-Abl is the constitutively active protein-tyrosine kinase expressed as a result of the Philadelphia translocation in chronic myelogenous leukemia. Bcr-Abl is coupled to many of the same signaling pathways normally regulated by hematopoietic cytokines. Recent work shows that Hck, a member of the Src tyrosine kinase family with myeloid-restricted expression, associates with and is activated by Bcr-Abl. Here we investigated the mechanism of Hck interaction with Bcr-Abl and the requirement for Hck activation in Bcr-Abl transformation signaling. Binding studies demonstrated that the Hck SH3 and SH2 domains are sufficient for interaction with Bcr-Abl in vitro. Hck binding localizes to the Abl SH2, SH3, and kinase domains as well as the distal portion of the C-terminal tail. To address the requirement for endogenous Src family kinase activation in Bcr-Abl signaling a kinase defective mutant of Hck was stably expressed in the cytokine-dependent myeloid leukemia cell line DAGM. Kinase-defective Hck dramatically suppressed Bcr-Abl-induced outgrowth of these cells in the absence of cytokine compared with a control cell line expressing beta-galactosidase. In contrast, kinase-defective Hck did not affect cell proliferation in response to interleukin-3, suggesting that the effect is specific for Bcr-Abl, These data show that Hck interacts with Bcr-Abl through a complex mechanism involving kinase-dependent and -independent components and that interaction with Hck or other Src family members is essential for transformation signaling by Bcr-Abl.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.				NCI NIH HHS [CA81398] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081398] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; BAHNSON AB, 1995, J VIROL METHODS, V54, P131, DOI 10.1016/0166-0934(95)00035-S; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Briggs SD, 1999, J BIOL CHEM, V274, P26579, DOI 10.1074/jbc.274.37.26579; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Cheng HY, 1999, MOL CELL BIOL, V19, P8335; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Gotoh A, 1997, Curr Opin Hematol, V4, P3; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Li JZ, 1998, J BIOL CHEM, V273, P13828, DOI 10.1074/jbc.273.22.13828; Lionberger JM, 2000, CANCER RES, V60, P1097; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nosaka Y, 1999, J BIOL CHEM, V274, P30154, DOI 10.1074/jbc.274.42.30154; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Shuai K, 1996, ONCOGENE, V13, P247; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	42	104	114	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18581	18585		10.1074/jbc.C000126200	http://dx.doi.org/10.1074/jbc.C000126200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849448	hybrid			2022-12-25	WOS:000087659400091
J	Jove, R				Jove, R			Preface: STAT signaling	ONCOGENE			English	Editorial Material						signal transducer and activator of transcription; STAT			H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Jove, R (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.								0	51	55	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2000	19	21					2466	2467		10.1038/sj.onc.1203549	http://dx.doi.org/10.1038/sj.onc.1203549			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321MN	10851044				2022-12-25	WOS:000087459400001
J	Moe, PC; Levin, G; Blount, P				Moe, PC; Levin, G; Blount, P			Correlating a protein structure with function of a bacterial mechanosensitive channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ION-CHANNEL; SINGLE RESIDUE; PATCH-CLAMP; MSCL; PRESSURE; MEMBRANE; RECONSTITUTION; ACTIVATION; STRESS	MscL, a mechanosensitive channel found in many bacteria, protects cells from hypotonic shock by reducing intracellular pressure through release of cytoplasmic osmolytes. First isolated from Escherichia coli, this protein has served as a model for how a protein senses and responds to membrane tension. Recently the structure of a functionally uncharacterized MscL homologue from Mycobacterium tuberculosis was solved by x-ray diffraction to a resolution of 3.5 Angstrom Here we demonstrate that the protein forms a functional MscL-like mechanosensitive channel in E, coli membranes and azolectin proteoliposomes Furthermore, we show that M. tuberculosis MscL crystals, when re-solubilized and reconstituted, yield wild-type channel currents in patch damp, demonstrating that the protein does not irreversibly change conformation upon crystallization. Finally, we apply functional clues acquired from the E, coli MscL to the M. tuberculosis channel and show a mechanistic correlation between these channels. However, the inability of the M. tuberculosis channel to gate at physiological membrane tensions, demonstrated by in vivo E. coli expression and in vitro reconstitution, suggests that the membrane environment or other additional factors influence the gating of this channel.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Blount, P (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	pbloun@mednet.swmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061028] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM061028] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barik S, 1997, Methods Mol Biol, V67, P173; Batiza AF, 1999, STRUCTURE, V7, pR99, DOI 10.1016/S0969-2126(99)80061-6; Berrier C, 1996, J MEMBRANE BIOL, V151, P175, DOI 10.1007/s002329900068; Blount P, 1999, Methods Enzymol, V294, P458; Blount P, 1996, BIOL CELL, V87, P1, DOI 10.1016/S0248-4900(97)89832-2; Blount P, 1999, TRENDS MICROBIOL, V7, P420, DOI 10.1016/S0966-842X(99)01594-2; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Blount P, 1996, EMBO J, V15, P4798, DOI 10.1002/j.1460-2075.1996.tb00860.x; Blount P, 1997, J BIOL CHEM, V272, P32150, DOI 10.1074/jbc.272.51.32150; Booth IR, 1999, CURR OPIN MICROBIOL, V2, P166, DOI 10.1016/S1369-5274(99)80029-0; BREHM P, 1984, J PHYSIOL-LONDON, V350, P631, DOI 10.1113/jphysiol.1984.sp015222; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Epstein W, 1970, J BACTERIOL, V101, P836, DOI 10.1128/JB.101.3.836-843.1970; Ghazi A, 1998, BIOCHIMIE, V80, P357; GUHARAY F, 1985, J PHYSIOL-LONDON, V363, P119, DOI 10.1113/jphysiol.1985.sp015699; HAMILL O, 1993, BIOPHYS J, V65, P17, DOI 10.1016/S0006-3495(93)81028-2; Hase CC, 1997, BIOCHEM BIOPH RES CO, V232, P777, DOI 10.1006/bbrc.1997.6370; HASE CC, 1995, J BIOL CHEM, V270, P18329, DOI 10.1074/jbc.270.31.18329; Hase CC, 1997, J MEMBRANE BIOL, V157, P17, DOI 10.1007/s002329900212; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; Jackson M.B., 1993, THERMODYNAMICS MEMBR, P327; Levina N, 1999, EMBO J, V18, P1730, DOI 10.1093/emboj/18.7.1730; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; Moe PC, 1998, MOL MICROBIOL, V28, P583, DOI 10.1046/j.1365-2958.1998.00821.x; Nakamaru Y, 1999, FEBS LETT, V444, P170, DOI 10.1016/S0014-5793(99)00054-X; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; SACHS F, 1991, MOL CELL BIOCHEM, V104, P57; Spencer RH, 1999, CURR OPIN STRUC BIOL, V9, P448, DOI 10.1016/S0959-440X(99)80063-3; Sukharev S, 1999, FASEB J, V13, pS55; Sukharev Sergei I., 1994, Methods (Orlando), V6, P51, DOI 10.1006/meth.1994.1007; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0; Sukharev SI, 1999, J GEN PHYSIOL, V113, P525, DOI 10.1085/jgp.113.4.525; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; SZABO I, 1992, BIOCHIM BIOPHYS ACTA, V1112, P29, DOI 10.1016/0005-2736(92)90250-P; SZABO I, 1993, J MEMBRANE BIOL, V131, P203, DOI 10.1007/BF02260109; Yoshimura K, 1999, BIOPHYS J, V77, P1960, DOI 10.1016/S0006-3495(99)77037-2	37	83	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 6	2000	275	40					31121	31127		10.1074/jbc.M002971200	http://dx.doi.org/10.1074/jbc.M002971200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	362DE	10846181	hybrid			2022-12-25	WOS:000089762700054
J	Merkel, JS; Regan, L				Merkel, JS; Regan, L			Modulating protein folding rates in vivo and in vitro by side-chain interactions between the parallel beta strands of green fluorescent protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE DISULFIDE BONDS; PHAGE-T4 LYSOZYME; PAIR CORRELATIONS; MUTATIONS; SHEETS; STABILITY; MUTANTS; THERMOSENSITIVITY; STABILIZATION; CHROMOPHORE	We have identified pairs of residues across the two parallel beta strands of green fluorescent protein that facilitate native strand register of the surface-exposed beta barrel. After constructing a suitable host environment around two guest residues, minimizing interactions of the guest residues with surrounding side-chains yet maintaining the wild-type protein structure and the chromophore environment, we introduced a library of cross-strand pairings by cassette mutagenesis. Colonies of Escherichia coli transformed with the library differ in intracellular fluorescence. Most of the fluorescent pairs have predominantly charged and polar guest site residues. The magnitude and the rate of fluorescence acquisition in vivo from transformed E. coli cells varies among the mutants despite comparable levels of protein expression. Spectroscopic measurements of purified mutants show that the native protein structure is maintained. Kinetic studies using purified protein with fully matured chromophores demonstrate that the mutants span a 10-fold range in folding rates with undetectable differences in unfolding rates. Thus, green fluorescent protein provides an ideal system for monitoring determinants of in vivo protein folding. Cross-strand pairings affect both protein stability and folding kinetics by favoring the formation of native strand register preferentially to non-native strand alignments.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	Yale University; Yale University	Regan, L (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave, New Haven, CT 06520 USA.	lynne@csb.yale.edu						Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Blasie CA, 1997, BIOCHEMISTRY-US, V36, P6218, DOI 10.1021/bi962805i; BOKMAN SH, 1981, BIOCHEM BIOPH RES CO, V101, P1372, DOI 10.1016/0006-291X(81)91599-0; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; Cootes AP, 1998, PROTEINS, V32, P175, DOI 10.1002/(SICI)1097-0134(19980801)32:2<175::AID-PROT4>3.3.CO;2-P; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Hutchinson EG, 1998, PROTEIN SCI, V7, P2287, DOI 10.1002/pro.5560071106; LIM CR, 1995, J BIOCHEM-TOKYO, V118, P13, DOI 10.1093/oxfordjournals.jbchem.a124868; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; MATSUMURA M, 1991, METHOD ENZYMOL, V202, P336; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MATTHEWS BW, 1987, P NATL ACAD SCI USA, V84, P6663, DOI 10.1073/pnas.84.19.6663; Merkel JS, 1999, STRUCT FOLD DES, V7, P1333, DOI 10.1016/S0969-2126(00)80023-4; Merkel JS, 1998, FOLD DES, V3, P449, DOI 10.1016/S1359-0278(98)00062-5; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; NICHOLSON H, 1992, BIOPOLYMERS, V32, P1431, DOI 10.1002/bip.360321103; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Palm GJ, 1997, NAT STRUCT BIOL, V4, P361, DOI 10.1038/nsb0597-361; Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Reid BG, 1997, BIOCHEMISTRY-US, V36, P6786, DOI 10.1021/bi970281w; Siemering KR, 1996, CURR BIOL, V6, P1653, DOI 10.1016/S0960-9822(02)70789-6; Smith CK, 1996, PROTEIN SCI, V5, P2009, DOI 10.1002/pro.5560051007; SMITH CK, 1995, SCIENCE, V270, P980, DOI 10.1126/science.270.5238.980; Stauber RH, 1998, BIOTECHNIQUES, V24, P462, DOI 10.2144/98243rr01; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; van Thor JJ, 1998, BIOCHEMISTRY-US, V37, P16915, DOI 10.1021/bi981170f; WARD WW, 1982, BIOCHEMISTRY-US, V21, P4535, DOI 10.1021/bi00262a003; WOUTERS MA, 1995, PROTEINS, V22, P119, DOI 10.1002/prot.340220205	36	23	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	2000	275	38					29200	29206		10.1074/jbc.M004734200	http://dx.doi.org/10.1074/jbc.M004734200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	356JH	10844000	hybrid			2022-12-25	WOS:000089439800005
J	Lenferink, AEG; van Zoelen, EJJ; van Vugt, MJH; Grothe, S; van Rotterdam, W; van de Poll, MLM; O'Connor-McCourt, MD				Lenferink, AEG; van Zoelen, EJJ; van Vugt, MJH; Grothe, S; van Rotterdam, W; van de Poll, MLM; O'Connor-McCourt, MD			Superagonistic activation of ErbB-1 by EGF-related growth factors with enhanced association and dissociation rate constants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; MITOGENIC ACTIVITY; TYROSINE KINASES; ALPHA CHIMERAS; HIGH-AFFINITY; BINDING-SITE; LIGAND; INTERNALIZATION	Epidermal growth factor (EGF) and transforming growth factor-alpha (TGF alpha) are mitogenic hormones that exert their activity primarily by binding to the EGF receptor, also known as ErbB-1, We have recently characterized a set of EGF/TGF alpha chimeric molecules with similar high affinity for ErbB-1 as EGF and TGF alpha and shown that three of these chimeras induce mitogenic cell stimulation at already a 10-fold lower concentration than their wild-type counterparts (Lenferink, A. E,, Kramer, R, H,, van Vugt, M. J., Konigswieser, M., DiFiore, P, P,, van Zoelen, E, J,, and van de Poll, M. L. (1997) Biochem. J, 327, 859-865), In the present study we show that these so-called superagonistic chimeras do not differ from EGF and TGF alpha in their ability to induce ErbB-1 tyrosine phosphorylation but are considerably more potent in activation of mitogen-activated protein kinase phosphorylation. Direct cell binding studies and analysis of ligand-receptor interaction by surface plasmon resonance measurements revealed that both the association rate constant (k(on)) and the dissociation rate constant (k(off)) of these superagonists is 3-5-fold higher in comparison with the wild-type ligands and nonsuperagonistic chimeras. These data indicate that the dynamic on and off rate constants for receptor binding may be more specific parameters for determining the mitogenic activity of peptide hormones than their constants for equilibrium receptor binding.	Catholic Univ Nijmegen, Dept Cell Biol, NL-6525 ED Nijmegen, Netherlands; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	Radboud University Nijmegen; National Research Council Canada	van Zoelen, EJJ (corresponding author), Catholic Univ Nijmegen, Dept Cell Biol, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.		van Zoelen, Everardus J./D-9192-2012					Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bergeron JJM, 1995, BIOSCIENCE REP, V15, P411, DOI 10.1007/BF01204345; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; Debanne M T, 1995, Methods Mol Biol, V39, P349; GRIMAUX M, 1989, TUMOR BIOL, V10, P215, DOI 10.1159/000217618; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Keresztes M, 1999, J CELL BIOL, V145, P421, DOI 10.1083/jcb.145.3.421; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; KOHDA D, 1993, J BIOL CHEM, V268, P1976; KRAMER RH, 1994, J BIOL CHEM, V269, P8708; Lenferink AEG, 1997, BIOCHEM J, V327, P859; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; Puddicombe SM, 1996, J BIOL CHEM, V271, P30392, DOI 10.1074/jbc.271.48.30392; Reddy CC, 1996, NAT BIOTECHNOL, V14, P1696, DOI 10.1038/nbt1296-1696; Schuck P, 1996, TRENDS BIOCHEM SCI, V21, P458, DOI 10.1016/S0968-0004(96)20025-8; van de Poll MLM, 1998, J BIOL CHEM, V273, P16075, DOI 10.1074/jbc.273.26.16075; vandePoll MLM, 1997, BIOCHEMISTRY-US, V36, P7425, DOI 10.1021/bi970227f; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; VANZOELEN EJJ, 1993, BIOCHEMISTRY-US, V32, P6275, DOI 10.1021/bi00075a022; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WALKER F, 1990, BIOCHEMISTRY-US, V29, P10635, DOI 10.1021/bi00499a009; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	28	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26748	26753						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10840042				2022-12-25	WOS:000089144800013
J	DeCamp, DL; Thompson, TM; de Sauvage, FJ; Lerner, MR				DeCamp, DL; Thompson, TM; de Sauvage, FJ; Lerner, MR			Smoothened activates G alpha(i)-mediated signaling in frog melanophores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASAL-CELL CARCINOMAS; SONIC HEDGEHOG; RECEPTOR COMPLEX; HUMAN HOMOLOG; G-PROTEINS; GENE; DROSOPHILA; ENCODES; MUTATIONS; CULTURE	The 7-pass transmembrane protein Smoothened was investigated for its ability to act as a G-protein-coupled receptor in Xenopus laevis melanophores. A plasmid containing the human Smoothened cDNA insert was transfected into immortalized frog pigment cells. Cells expressing the protein showed a phenotype of persistent pigment aggregation, a hallmark of constitutive G(alpha i) activation. Smoothened-mediated pigment aggregation was reversed by treatment with pertussis toxin or by co-expression with dominant negative G(alpha i). The ability of melanophores to express functional Smoothened was also determined by its co-expression with the twelve-pass transmembrane protein, Patched. Patched blocked Smoothened-mediated melanosome aggregation in a dose-dependent manner, consistent with its physiological role as an inhibitor of Smoothened. That the reconstituted Patched-Smoothened receptor complex functions normally in pigment cells was demonstrated by co-transfection with the activating ligand, Sonic hedgehog, as well as by direct application of the recombinant Sonic hedgehog protein. Sonic hedgehog reversed Patched-mediated inhibition of Smoothened and induced pigment aggregation. The findings demonstrate that the human Sonic hedgehog receptor complex can be functionally reconstituted in melanophores and that it is capable of transmembrane signaling by utilizing endogenous G(alpha i).	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA; Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Roche Holding; Genentech; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lerner, MR (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd,F4-100, Dallas, TX 75390 USA.		de Sauvage, Frederic/ABE-8400-2020	de Sauvage, Frederic/0000-0002-5275-2584	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041940] Funding Source: NIH RePORTER; NIAMS NIH HHS [P30 AR41940] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alcedo J, 1997, BIOL CHEM, V378, P583; Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Chen Y, 1998, DEVELOPMENT, V125, P4943; DANIOLOS A, 1990, PIGM CELL RES, V3, P38, DOI 10.1111/j.1600-0749.1990.tb00260.x; Fan HR, 1997, NAT MED, V3, P788, DOI 10.1038/nm0797-788; Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hammerschmidt M, 1998, DEV BIOL, V194, P166, DOI 10.1006/dbio.1997.8796; HOWLETT AC, 1985, MOL PHARMACOL, V27, P429; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; LIM K, 1989, BIOTECHNIQUES, V7, P576; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; POTENZA MN, 1992, PIGM CELL RES, V5, P372, DOI 10.1111/j.1600-0749.1992.tb00565.x; POTENZA MN, 1994, J NEUROSCI, V14, P1463, DOI 10.1523/JNEUROSCI.14-03-01463.1994; Potenza MN, 1999, J PHARMACOL EXP THER, V291, P482; Provencio I, 1998, P NATL ACAD SCI USA, V95, P340, DOI 10.1073/pnas.95.1.340; Sehgal A, 1998, J SURG ONCOL, V69, P239, DOI 10.1002/(SICI)1096-9098(199812)69:4<239::AID-JSO9>3.0.CO;2-U; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; SLEPAK VZ, 1995, J BIOL CHEM, V270, P4037, DOI 10.1074/jbc.270.8.4037; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	28	91	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					26322	26327		10.1074/jbc.M004055200	http://dx.doi.org/10.1074/jbc.M004055200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10835429	hybrid			2022-12-25	WOS:000088999700061
J	Sato, K; Ebihara, T; Adachi, E; Kawashima, S; Hattori, S; Irie, S				Sato, K; Ebihara, T; Adachi, E; Kawashima, S; Hattori, S; Irie, S			Possible involvement of aminotelopeptide in self-assembly and thermal stability of collagen I as revealed by its removal with proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIL FORMATION; CROSS-LINKING; INVITRO; MATRIX; EXPRESSION; SITES	The functions of aminotelopeptide and N-terminal cross-linking of collagen I were examined. Acetic acid-soluble collagen I (ASC) was purified from neonatal bovine skin and treated with three kinds of proteases, The amino acid sequencing analysis of the N terminus showed that ASC contained a full-length aminotelopeptide. Pepsin and papain cleaved the aminotelopeptide of the alpha 1 chain at the same site and the aminotelopeptide of the alpha 2 chain at different sites. Proctase-treated ASC lost the whole aminotelopeptide, and the N-terminal sequence began from the tenth residue inside the triple helical region. The rates of fibril formation of pepsin-treated ASC and proctase-treated ASC were the same and were slower than that of ASC. The denaturation temperatures, monitored by CD ellipticity at 221 nm, of ASC, pepsin-treated, or papain-treated collagens were the same at 41.8 degrees C, Proctase-treated ASC showed a lower denaturation temperature of 39.9 degrees C. We also observed the morphology of the collagen fibrils under an electron microscope. The ASC fibrils were straight and thin, whereas the fibrils of pepsin-treated ASC were slightly twisted, and the fibrils from papain- and proctase-treated ASC were highly twisted and thick. When the collagen gel strength was examined by a modified method of viscosity-measurement, ASC was the strongest, followed by pepsin-treated ASC, and papain- and proctase-treated ASCs were the weakest. These results suggest that the aminotelopeptide plays important roles in fibril formation and thermal stability. In addition, the functions of intermolecular cross-linking in aminotelopeptides may contribute to the formation of fibrils in the correct staggered pattern and to strengthening the collagen gel.	Nippi Res Inst Biomatrix, Adachi Ku, Tokyo 1208601, Japan; Japan Inst Leather Res, Dept Biomatrix Engn, Adachi Ku, Tokyo 1208601, Japan; Kitasato Univ, Grad Sch Med, Dept Mol Morphol, Sagamihara, Kanagawa 2288555, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Biol, Bunkyo Ku, Tokyo 1138613, Japan	Kitasato University; Tokyo Metropolitan Institute of Medical Science	Sato, K (corresponding author), Nippi Res Inst Biomatrix, Adachi Ku, Tokyo 1208601, Japan.							ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; Adachi E, 1997, INT REV CYTOL, V173, P73; BORNSTEIN P, 1966, BIOCHEMISTRY-US, V5, P3803, DOI 10.1021/bi00876a010; Ebihara T, 1999, CONNECT TISSUE, V31, P17; Freemont AJ, 1999, ANN RHEUM DIS, V58, P357, DOI 10.1136/ard.58.6.357; GELMAN RA, 1979, J BIOL CHEM, V254, P180; HAYASHI T, 1974, J BIOCHEM-TOKYO, V75, P651, DOI 10.1093/oxfordjournals.jbchem.a130433; HELSETH DL, 1981, J BIOL CHEM, V256, P7118; KADLER KE, 1990, BIOCHEM J, V268, P339, DOI 10.1042/bj2680339; Muraoka M, 1996, J BIOCHEM-TOKYO, V119, P167; NAGAN N, 1994, J BIOL CHEM, V269, P22366; PIEZ KA, 1968, ANNU REV BIOCHEM, V37, P547, DOI 10.1146/annurev.bi.37.070168.002555; Prockop DJ, 1998, J BIOL CHEM, V273, P15598, DOI 10.1074/jbc.273.25.15598; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; SATO K, 2000, CONNECT TISSUE, V32, P1; SELL DR, 1989, J BIOL CHEM, V264, P21597; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Stimler NP., 1976, BIOCH COLLAGEN, P137; Suzuki Y, 1999, J BIOCHEM, V126, P54, DOI 10.1093/oxfordjournals.jbchem.a022436; Uitto VJ, 1998, AM J PATHOL, V152, P1489; WOODLEY DT, 1991, J INVEST DERMATOL, V97, P580, DOI 10.1111/1523-1747.ep12481920; YAMAUCHI M, 1987, J BIOL CHEM, V262, P11428	22	105	110	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25870	25875		10.1074/jbc.M003700200	http://dx.doi.org/10.1074/jbc.M003700200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10851240	hybrid			2022-12-25	WOS:000088849400106
J	Zimmer, S; Stocker, A; Sarbolouki, MN; Spycher, SE; Sassoon, J; Azzi, A				Zimmer, S; Stocker, A; Sarbolouki, MN; Spycher, SE; Sassoon, J; Azzi, A			A novel human tocopherol-associated protein - Cloning, in vitro expression, and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-E-DEFICIENCY; RANDOMIZED CONTROLLED TRIAL; RAT OLFACTORY EPITHELIUM; ALPHA-TOCOPHEROL; BINDING-PROTEIN; IN-VIVO; CELL; SUPPLEMENTATION; IDENTIFICATION; PURIFICATION	Vitamin E (alpha-tocopherol) is an essential dietary nutrient for humans and animals. The mechanisms involved in cellular regulation as well as in the preferential cellular and tissue accumulation of alpha-tocopherol are not yet well established. We previously reported (Stocker, A., Zimmer, S., Spycher, S. E., and Azzi, A. (1999) IUBMB Life 48, 49-55) the identification of a novel 46-kDa tocopherol-associated protein (TAP) in the cytosol of bovine liver. Here, we describe the identification, the molecular cloning into Escherichia coli, and the in vitro expression of the human homologue of bovine TAP, hTAP. This protein appears to belong to a family of hydrophobic ligand binding proteins, which have the CRAL (cis-retinal binding motif) sequence in common. By using a biotinylated alpha-tocopherol derivative and the IASys resonant mirror biosensor, the purified recombinant protein was shown to bind tocopherol at a specific binding site with K-d 4.6 x 10(-7) M. Northern analyses showed that hTAP mRNA has a size of approximately 2800 base pairs and is ubiquitously expressed. The highest amounts of hTAP message are found in liver, brain, and prostate. In conclusion, hTAP has sequence homology to proteins containing the CRAL_TRIO structural motif. TAP binds to alpha-tocopherol and biotinylated tocopherol, suggesting the existence of a hydrophobic pocket, possibly analogous to that of SEC14.	Univ Bern, Inst Biochem & Mol Biol, CH-3012 Bern, Switzerland; Univ Tehran, Inst Biochem & Biophys, Tehran, Iran; Univ Bern, Inst Gen Microbiol, CH-3012 Bern, Switzerland	University of Bern; University of Tehran; University of Bern	Stocker, A (corresponding author), Univ Bern, Inst Biochem & Mol Biol, Buhlstr 28, CH-3012 Bern, Switzerland.	achim.stocker@mci.unibe.ch	Stocker, Achim/O-5217-2017	Stocker, Achim/0000-0001-6862-7887				Aratri E, 1999, FEBS LETT, V447, P91, DOI 10.1016/S0014-5793(99)00277-X; Aravind L, 1999, CURR BIOL, V9, pR195, DOI 10.1016/S0960-9822(99)80127-4; ARITA M, 1995, BIOCHEM J, V306, P437, DOI 10.1042/bj3060437; Azzi A, 1999, DIABETES RES CLIN PR, V45, P191, DOI 10.1016/S0168-8227(99)00049-2; Azzi A, 1998, Z ERNAHRUNGSWISS, V37, P21; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Brigelius-Flohe R, 1999, FASEB J, V13, P1145, DOI 10.1096/fasebj.13.10.1145; BURTON GW, 1982, LANCET, V2, P327; Cavalier L, 1998, AM J HUM GENET, V62, P301, DOI 10.1086/301699; Cockcroft S, 1998, BIOESSAYS, V20, P423, DOI 10.1002/(SICI)1521-1878(199805)20:5<423::AID-BIES9>3.3.CO;2-U; DuttaRoy AK, 1997, METHOD ENZYMOL, V282, P278; Evans HM, 1922, SCIENCE, V56, P650, DOI 10.1126/science.56.1458.650; GEORGE AJT, 1995, J IMMUNOL METHODS, V183, P51, DOI 10.1016/0022-1759(95)00031-5; Gorgani NN, 1997, BIOCHEMISTRY-US, V36, P6653, DOI 10.1021/bi962573n; Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440; Karasu C, 1997, METABOLISM, V46, P872, DOI 10.1016/S0026-0495(97)90072-X; Kolleck I, 1999, FREE RADICAL BIO MED, V27, P882, DOI 10.1016/S0891-5849(99)00139-2; KUHLENKAMP J, 1993, PROTEIN EXPRES PURIF, V4, P382, DOI 10.1006/prep.1993.1050; Labauge P, 1998, REV NEUROL-FRANCE, V154, P339; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Merkulova MI, 1999, FEBS LETT, V450, P126, DOI 10.1016/S0014-5793(99)00470-6; Meydani SN, 1997, JAMA-J AM MED ASSOC, V277, P1380, DOI 10.1001/jama.277.17.1380; NOVOSELOV VI, 1994, FEBS LETT, V353, P286, DOI 10.1016/0014-5793(94)01051-X; OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141; Ozer NK, 1998, FREE RADICAL BIO MED, V24, P226, DOI 10.1016/S0891-5849(97)00136-6; Pastori M, 1998, BIOCHEM BIOPH RES CO, V250, P582, DOI 10.1006/bbrc.1998.9351; Phillips SE, 1999, MOL CELL, V4, P187, DOI 10.1016/S1097-2765(00)80366-4; Poynter ME, 1999, CELL IMMUNOL, V195, P127, DOI 10.1006/cimm.1999.1525; Ricciarelli R, 1999, FREE RADICAL BIO MED, V27, P729, DOI 10.1016/S0891-5849(99)00007-6; Rubio I, 1997, BIOTECHNIQUES, V22, P269, DOI 10.2144/97222bm15; SAXENA P, 1992, J BACTERIOL, V174, P1956, DOI 10.1128/jb.174.6.1956-1964.1992; Sha BD, 1998, NATURE, V391, P506, DOI 10.1038/35179; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Stocker A, 1999, IUBMB LIFE, V48, P49, DOI 10.1080/152165499307413; STRAFACE E, 1995, INT J RADIAT BIOL, V68, P579, DOI 10.1080/09553009514551571; TRABER MG, 1989, AM J CLIN NUTR, V49, P517, DOI 10.1093/ajcn/49.3.517; Vatassery GT, 1998, J NUTR, V128, P152, DOI 10.1093/jn/128.2.152; Wu DY, 1999, ATHEROSCLEROSIS, V147, P297, DOI 10.1016/S0021-9150(99)00199-9; YOSHIDA H, 1992, J LIPID RES, V33, P343	39	168	179	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25672	25680		10.1074/jbc.M000851200	http://dx.doi.org/10.1074/jbc.M000851200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829015	hybrid, Green Published			2022-12-25	WOS:000088849400082
J	Zhou, XM; Liu, YM; Payne, G; Lutz, RJ; Chittenden, T				Zhou, XM; Liu, YM; Payne, G; Lutz, RJ; Chittenden, T			Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser(155)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; SIGNALING PATHWAY; APOPTOSIS; SURVIVAL; MITOCHONDRIA; BINDING; BCL-2; TRANSCRIPTION; RECOGNITION; BCL-X(L)	The Bcl-2 family protein BAD promotes apoptosis by binding through its BH3 domain to Bcl-x(L) and related cell death suppressors. When BAD is phosphorylated on either Ser(12) or Ser(136), it forms a complex with 14-3-3 in the cytosol and no longer interacts with Bcl-x(L) at the mitodhondria. Here we show that phosphorylation of a distinct site Ser(155), which is at the center of the BAD BH3 domain, directly suppressed the pro-apoptotic function of BAD by eliminating its affinity for Bcl-x(L) Protein kinase A functioned as a BAD Ser(155) kinase bath fn vitro and in cells. BAD Ser(155) was found to be a major site of phosphorylation induced following stimulation by growth factors and prevented by protein kinase A inhibitors but not by inhibitors of the phosphatidylinosital 3-kinase/Akt pathway, Growth factors inhibited BAD-induced apoptosis in both a Ser(112)/Ser(136)- and a Ser(155)-dependent fashion. Thus, growth factors engage an anti-apoptotic signaling pathway that inactivates BAD by direct modification of its BH3 cell death effector domain.	Apoptosis Technol Inc, Cambridge, MA 02139 USA		Zhou, XM (corresponding author), Apoptosis Technol Inc, 128 Sidney St, Cambridge, MA 02139 USA.							BERRIDGE MV, 1993, EXP HEMATOL, V21, P269; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Burtscher I, 1999, CANCER RES, V59, P3923; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAY RN, 1989, J BIOL CHEM, V264, P431; DEBLAQUIERE J, 1994, J BIOL CHEM, V269, P4812; Fladmark KE, 1997, BIOCHEM BIOPH RES CO, V232, P20, DOI 10.1006/bbrc.1997.6214; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LINDER ME, 1992, SCI AM, V267, P56; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; PESO LD, 1997, SCIENCE, V278, P687; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Strasser A, 1997, BBA-REV CANCER, V1333, pF151, DOI 10.1016/S0304-419X(97)00019-X; TORTORA G, 1994, INT J CANCER, V59, P712, DOI 10.1002/ijc.2910590521; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	26	196	201	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					25046	25051		10.1074/jbc.M002526200	http://dx.doi.org/10.1074/jbc.M002526200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10837473	hybrid			2022-12-25	WOS:000088683300108
J	Hartenstine, MJ; Goodman, MF; Petruska, J				Hartenstine, MJ; Goodman, MF; Petruska, J			Base stacking and even/odd behavior of hairpin loops in DNA triplet repeat slippage and expansion with DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRINUCLEOTIDE REPEAT; RAT-BRAIN; TRANSGLUTAMINASE; DISEASE; THERMODYNAMICS; TRANSCRIPTION; INSTABILITY; ATAXIN-1	Repetitions of CAG or CTG triplets in DNA can form intrastrand hairpin loops with combinations of normal and mismatched base pairs that easily rearrange. Such loops may promote primer-template slippage in DNA replication or repair to give triplet-repeat expansions like those associated with neurodegenerative diseases. Using self-priming sequences (e.g (CAG)(16)(CTG)(4)), we resolve all hairpin loops formed and measure their slippage and expansion rates with DNA polymerase at 37 degrees C. Comparing CAG/CTG loop structures with GAC/GTC structures, having similar hydrogen bonding but different base stacking, we find that GAG, CTG, and GTC triplets predominantly form even-membered loops that slip in steps of two triplets, whereas GAC triplets favor odd-numbered loops Slippage rates decline as hairpin stability increases, supporting the idea that slippage initiates more easily in less stable regions. Loop stabilities (in low salt) increase in the order GTC < CAG < GAC < CTG, while slippage rates decrease in the order GTC > CAG approximate to GAC > CTG. Loops of GTC compared with CTG melt 9 degrees C lower and slip g-fold faster. We interpret results in terms of base stacking, by relating melting temperature to standard enthalpy changes for doublets of base pairs and mispairs, considering enthalpy-entropy compensation.	Univ So Calif, Dept Biol Sci, Hedco Mol Biol Labs, Los Angeles, CA 90089 USA	University of Southern California	Goodman, MF (corresponding author), Univ So Calif, Dept Biol Sci, Hedco Mol Biol Labs, SHS Rm,172 Univ Pk, Los Angeles, CA 90089 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021422, R37GM021422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011398, P01AG017179] Funding Source: NIH RePORTER; NIA NIH HHS [AG17179, AG11398] Funding Source: Medline; NIGMS NIH HHS [GM 21422] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEHNKRAPPA A, 1994, HUM MUTAT, V3, P19, DOI 10.1002/humu.1380030104; Cooper AJL, 1997, J NEUROCHEM, V69, P431; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Davis BM, 1997, P NATL ACAD SCI USA, V94, P7388, DOI 10.1073/pnas.94.14.7388; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; GAEY AM, 1995, CELL, V81, P533; Gellibolian R, 1997, J BIOL CHEM, V272, P16793, DOI 10.1074/jbc.272.27.16793; GILAD GM, 1985, J NEUROCHEM, V45, P1522, DOI 10.1111/j.1471-4159.1985.tb07222.x; Jakupciak JP, 1999, J BIOL CHEM, V274, P23468, DOI 10.1074/jbc.274.33.23468; Kahlem P, 1996, P NATL ACAD SCI USA, V93, P14580, DOI 10.1073/pnas.93.25.14580; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; Kunkel TA, 1997, CELL, V88, P155, DOI 10.1016/S0092-8674(00)81832-2; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; OHASHI H, 1995, J BIOCHEM-TOKYO, V118, P1271, DOI 10.1093/oxfordjournals.jbchem.a125018; PEARSON CE, 1996, AM J HUM GENET, V59, P244; Petruska J, 1998, J BIOL CHEM, V273, P5204, DOI 10.1074/jbc.273.9.5204; PETRUSKA J, 1995, J BIOL CHEM, V270, P746, DOI 10.1074/jbc.270.2.746; Petruska J, 1996, NUCLEIC ACIDS RES, V24, P1992, DOI 10.1093/nar/24.11.1992; Peyret N, 1999, BIOCHEMISTRY-US, V38, P3468, DOI 10.1021/bi9825091; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; VERKERK AJMH, 1993, HUM MOL GENET, V2, P399, DOI 10.1093/hmg/2.4.399; Wells R.D., 1998, GENETIC INSTABILITIE; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875	29	61	63	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18382	18390		10.1074/jbc.275.24.18382	http://dx.doi.org/10.1074/jbc.275.24.18382			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849445	hybrid			2022-12-25	WOS:000087659400065
J	Zhong, LW; Holmgren, A				Zhong, LW; Holmgren, A			Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG ADENOCARCINOMA CELLS; ESCHERICHIA-COLI; HELA-CELLS; GLUTATHIONE-REDUCTASE; GLUTAREDOXIN SYSTEMS; REDOX REGULATION; HUMAN PLACENTA; RAT-LIVER; PURIFICATION; NADPH	Mammalian thioredoxin reductases (TrxR) are dimers homologous to glutathione reductase with a selenocysteine (SeCys) residue in the conserved C-terminal sequence -GIy-Cys-SeCys-Gly. We removed the selenocysteine insertion sequence in the rat gene, and we changed the SeCys(498) encoded by TGA to Cys or Ser by mutagenesis. The truncated protein having the C-terminal SeCys-Gly dipeptide deleted, expected in selenium deficiency, was also engineered. All three mutant enzymes were overexpressed in Escherichia coli and purified to homogeneity with 1 mol of FAD per monomeric subunit, Anaerobic titrations with NADPH rapidly generated the A(540nm) absorbance resulting from the thiolate-flavin charge transfer complex characteristic of mammalian TrxR. However, only the SeCys(498) --> Cys enzyme showed catalytic activity in reduction of thioredoxin, with a 100-fold lower k(cat) and a 10-fold lower K-m compared with the wild type rat enzyme. The pH optimum of the SeCys(498) --> Cys mutant enzyme was 9 as opposed to 7 for the wild type TrxR, strongly suggesting involvement of the low pK(a) SeCys selenol in the enzyme mechanism. Whereas H2O2 was a substrate for the wild type enzyme, all mutant enzymes lacked hydroperoxidase activity. Thus selenium is required for the catalytic activities of TrxR explaining the essential role of this trace element in cell growth.	Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden	Karolinska Institutet	Holmgren, A (corresponding author), Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.							Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; ARNER ESJ, 1995, J BIOL CHEM, V270, P3479, DOI 10.1074/jbc.270.8.3479; Arner ESJ, 1999, METHOD ENZYMOL, V300, P226; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; AXLEY MJ, 1991, P NATL ACAD SCI USA, V88, P8450, DOI 10.1073/pnas.88.19.8450; BERRY MJ, 1991, J BIOL CHEM, V266, P14155; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; BJORNSTEDT M, 1992, J BIOL CHEM, V267, P8030; Bjornstedt M, 1997, BIOMED ENVIRON SCI, V10, P271; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; CLARKE LC, 1997, JAMA-J AM MED ASSOC, V276, P1957; Combs GF, 1998, PHARMACOL THERAPEUT, V79, P179, DOI 10.1016/S0163-7258(98)00014-X; Gallegos A, 1997, CANCER RES, V57, P4965; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gorlatov SN, 1998, P NATL ACAD SCI USA, V95, P8520, DOI 10.1073/pnas.95.15.8520; Gorlatov SN, 1999, ARCH BIOCHEM BIOPHYS, V369, P133, DOI 10.1006/abbi.1999.1356; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Gromer S, 1998, BIOCHEM J, V332, P591, DOI 10.1042/bj3320591; GUILBERT LJ, 1976, NATURE, V263, P594, DOI 10.1038/263594a0; HEIDER J, 1992, EMBO J, V11, P3759, DOI 10.1002/j.1460-2075.1992.tb05461.x; Hill KE, 1997, BIOCHEM BIOPH RES CO, V234, P293, DOI 10.1006/bbrc.1997.6618; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1980, P NATL ACAD SCI-BIOL, V77, P5149, DOI 10.1073/pnas.77.9.5149; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; KARPLUS PA, 1987, J MOL BIOL, V195, P701, DOI 10.1016/0022-2836(87)90191-4; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Liu SY, 1997, P NATL ACAD SCI USA, V94, P6138, DOI 10.1073/pnas.94.12.6138; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MCKEEHAN WL, 1976, P NATL ACAD SCI USA, V73, P2023, DOI 10.1073/pnas.73.6.2023; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Nikitovic D, 1996, J BIOL CHEM, V271, P19180, DOI 10.1074/jbc.271.32.19180; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; Rigobello MP, 1998, FREE RADICAL BIO MED, V24, P370, DOI 10.1016/S0891-5849(97)00216-5; Smith AD, 1999, J NUTR, V129, P194, DOI 10.1093/jn/129.1.194; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Watabe S, 1999, EUR J BIOCHEM, V264, P74, DOI 10.1046/j.1432-1327.1999.00578.x; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; ZHONG L, 1997, PROTEIN SCI, V6, P84	48	325	342	3	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 16	2000	275	24					18121	18128		10.1074/jbc.M000690200	http://dx.doi.org/10.1074/jbc.M000690200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CU	10849437	hybrid			2022-12-25	WOS:000087659400031
J	O'Connor, DJ; Lu, X				O'Connor, DJ; Lu, X			Stress signals induce transcriptionally inactive E2F-1 independently of p53 and Rb	ONCOGENE			English	Article						E2F1; p53; transcription; DNA damage; hypoxia; stress response	RETINOBLASTOMA GENE-PRODUCT; S-PHASE ENTRY; DNA-DAMAGE; CELL-CYCLE; P53-INDEPENDENT APOPTOSIS; DEREGULATED EXPRESSION; PROTEIN; FAMILY; DEGRADATION; LEADS	One of the common features of cellular response to stress is cell cycle arrest or apoptosis, E2F is one of the key factors which controls cell cycle progression. Overexpression of E2F-1 can also induce apoptosis, In order to understand the role of E2F-1 in cellular response to stress, we studied the E2F-1 response in various cell lines to different types of stress signals including UV irradiation, cisplatin, etoposide and hypoxia, We showed here that the expression level of E2F-1 can be up regulated by the treatment of DNA damage agents as well as hypoxia, The kinetics of E2F-1 increase was dependent on the types of inducer and was similar to that of p53, However, stress signals can induce E2F-1 expression independently of p53 and Rb, Furthermore, the induced E2F-1 was transcriptionally inactive, All these results suggested that E2F-1 may play a very important role in cellular response to stress and this novel role of E2F-1 is independent of its transactivation function.	Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research	Lu, X (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.			Lu, Xin/0000-0002-6587-1152				Amellem O, 1996, EXP CELL RES, V227, P106, DOI 10.1006/excr.1996.0255; Blattner C, 1999, MOL CELL BIOL, V19, P3704; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Huang YY, 1997, CANCER RES, V57, P3640; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Krtolica A, 1998, ONCOGENE, V17, P2295, DOI 10.1038/sj.onc.1202159; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHANG YH, 1995, ONCOGENE, V10, P2085	35	65	68	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2369	2376		10.1038/sj.onc.1203540	http://dx.doi.org/10.1038/sj.onc.1203540			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828878				2022-12-25	WOS:000087018400001
J	Groth, A; Weber, JD; Willumsen, BM; Sherr, CJ; Roussel, MF				Groth, A; Weber, JD; Willumsen, BM; Sherr, CJ; Roussel, MF			Oncogenic Ras induces p19(ARF) and growth arrest in mouse embryo fibroblasts lacking p21(Cip1) and p27(Kip1) without activating cyclin D-dependent kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARF TUMOR-SUPPRESSOR; CELL-CYCLE; RETINOBLASTOMA PROTEIN; DNA-REPLICATION; S-PHASE; P53-DEPENDENT APOPTOSIS; COOPERATING ONCOGENES; INHIBITOR P27(KIP1); PROTEASOME PATHWAY; GENE-EXPRESSION	Oncogenic Res induces two products of the INK4a/ARF tumor suppressor locus (p16(INK4a) and p19(ARF)) in primary human and rodent fibroblasts, ultimately leading to a permanent state of cell cycle arrest resembling replicative senescence. Whereas p16(INK4a) antagonizes the activities of cyclin D-dependent kinases, p19(ARF) activates the p53 transcription factor. Immortalized rodent fibroblast cell lines that lack INK4a/ARP function, ARF alone, or p53 are resistant to the growth inhibitory effects of oncogenic Res and instead continue to proliferate and undergo morphological transformation. Primary mouse embryo fibroblasts lacking Cip1 and Kip1 genes encoding inhibitors of cyclin-dependent kinase-2 were used to further explore the effects of oncogenic Res on arrest of the cell division cycle. Although early passage primery fibroblast strains that lack both p21(Cip1) and p27(Kip1) fail to assemble cyclin Ii-dependent kinases, oncogenic has retained its ability to induce p19(ARF), but not p16(INK4a), protecting Cip/Kip-null cells from proliferating and undergoing transformation. Under these conditions, Res did not induce G(1) phase arrest but instead triggered DNA synthesis, abnormal nuclear divisions, failure of cytokinesis, and emergence of polyploid cells. Therefore, in the absence of p16(INK4a), p21(Cip1), and p27(Kip1), oncogenic Res affects the functions of genes required for completion of the cell cycle.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38101 USA; St Jude Childrens Res Hosp, Howard Hughes Med Inst, Memphis, TN 38105 USA; Univ Copenhagen, Dept Mol Cell Biol, DK-1353 Copenhagen K, Denmark	St Jude Children's Research Hospital; Howard Hughes Medical Institute; St Jude Children's Research Hospital; University of Copenhagen	Sherr, CJ (corresponding author), St Jude Childrens Res Hosp, Dept Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38101 USA.	sherr@stjude.org	Sherr, Charles J/N-8074-2018; Willumsen, Berthe M/H-1903-2012; Groth, Anja/AAH-5386-2019; Roussel, Martine F/F-1469-2016	Sherr, Charles J/0000-0002-5516-6206; Willumsen, Berthe M/0000-0002-2277-6999; Groth, Anja/0000-0003-0577-1771; Roussel, Martine F/0000-0002-1740-8139; Weber, Jason/0000-0002-1069-6983	NCI NIH HHS [CA-21765, CA-71907, CA-56819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056819, P01CA071907, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Hara E, 1996, MOL CELL BIOL, V16, P859; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; Reznikoff CA, 1996, CANCER RES, V56, P2886; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; Sorensen TS, 1996, MOL CELL BIOL, V16, P5888; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Winston JT, 1996, ONCOGENE, V12, P127; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	93	76	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27473	27480						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10842176				2022-12-25	WOS:000089144800106
J	Inagaki, N; Nishizawa, M; Arimura, N; Yamamoto, H; Takeuchi, Y; Miyamoto, E; Kaibuchi, K; Inagaki, M				Inagaki, N; Nishizawa, M; Arimura, N; Yamamoto, H; Takeuchi, Y; Miyamoto, E; Kaibuchi, K; Inagaki, M			Activation of Ca2+/calmodulin-dependent protein kinase II within post-synaptic dendritic spines of cultured hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; INTERMEDIATE FILAMENTS; POSTSYNAPTIC DENSITY; NUCLEAR-LOCALIZATION; CAM KINASE; PHOSPHORYLATION; CALMODULIN; EXPRESSION; RECEPTORS; CELLS	To understand the cell signaling of protein kinases, it is essential to monitor their activity in each of the subcellular compartments. Here we developed a method to visualize the activities of Ca2+/calmodulin-dependent protein kinase II (CaMKII) in the cytoplasm, plasma membrane, and nucleus, separately, by utilizing targeted phosphorylation motifs and phosphorylation-specific antibodies. This approach was used to monitor the activities of post-synaptic CaMKII in cultured hippocampal neurons. Strong stimulation of the neurons by N-methyl-D-aspartate led to global activations of CaMKII in the cell bodies and dendrites, On the other hand, weak stimulation by removal of Mg2+ block of N-methyl-D-aspartate receptors induced CaMKII signaling localized within single dendritic spines. Post-synaptic CaMKII is thought to modify synaptic efficiency. The present data for the first time demonstrate the activation of CaMKII localized within single dendritic spines and are consistent with the notion that synaptic efficiency is modified by CaMKII in single or multiple spine level depending on the strength of receptor activation.	Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan; Aichi Canc Ctr, Inst Res, Biochem Lab, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Kumamoto Univ, Sch Med, Dept Pharmacol, Kumamoto 8600811, Japan	Nara Institute of Science & Technology; Aichi Cancer Center; Kumamoto University	Inagaki, N (corresponding author), Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 6300101, Japan.		Inagaki, Masaki/B-9920-2016	Inagaki, Naoyuki/0000-0002-2664-9196				Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bayer KU, 1998, EMBO J, V17, P5598, DOI 10.1093/emboj/17.19.5598; BERNINGER B, 1993, NEUROREPORT, V4, P1303, DOI 10.1097/00001756-199309150-00004; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; Craig A. M, 1998, CULTURING NERVE CELL, P79; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3450; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Inagaki N, 1997, J BIOL CHEM, V272, P25195, DOI 10.1074/jbc.272.40.25195; INAGAKI N, 1994, TRENDS BIOCHEM SCI, V19, P448, DOI 10.1016/0968-0004(94)90128-7; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kosako H, 1999, ONCOGENE, V18, P2783, DOI 10.1038/sj.onc.1202633; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Mochly-Rosen D, 1998, FASEB J, V12, P35; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; MURPHY TH, 1994, SCIENCE, V263, P529, DOI 10.1126/science.7904774; NISHIZAWA K, 1991, J BIOL CHEM, V266, P3074; OGAWARA M, 1995, J CELL BIOL, V131, P1055, DOI 10.1083/jcb.131.4.1055; Ouyang Y, 1997, J NEUROSCI, V17, P5416; Peters A., 1991, FINE STRUCTURE NERVO; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; Shen K, 1999, SCIENCE, V284, P162, DOI 10.1126/science.284.5411.162; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Takeuchi Y, 1999, J NEUROCHEM, V72, P815, DOI 10.1046/j.1471-4159.1999.0720815.x; Yuste R, 1996, NEURON, V16, P701, DOI 10.1016/S0896-6273(00)80091-4	38	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					27165	27171						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10852918				2022-12-25	WOS:000089144800067
J	Perdiz, D; Grof, P; Mezzina, M; Nikaido, O; Moustacchi, E; Sage, E				Perdiz, D; Grof, P; Mezzina, M; Nikaido, O; Moustacchi, E; Sage, E			Distribution and repair of bipyrimidine photoproducts in solar UV-irradiated mammalian cells - Possible role of Dewar photoproducts in solar mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; ULTRAVIOLET-B RADIATION; HUMAN-SKIN FIBROBLASTS; INDUCED DNA-DAMAGE; TRANS-SYN-I; XERODERMA-PIGMENTOSUM; CIS-SYN; WAVELENGTH DEPENDENCE; SIMULATED SUNLIGHT; 6-4 PHOTOPRODUCTS	In order to better understand the relative contribution of the different UV components of sunlight to solar mutagenesis, the distribution of the bipyrimidine photolesions, cyclobutane pyrimidine dimers (CPD), (6-4) photoproducts ((6-4)PP), and their Dewar valence photoisomers (DewarPP) was examined in Chinese hamster ovary cells irradiated with WC, UVB, or UVA radiation or simulated sunlight. The absolute amount of each type of photoproduct was measured by using a calibrated and sensitive immune-dot-blot assay. As already established for UVC and UVB, we report the production of CPD by UVA radiation, at a yield in accordance with the DNA absorption spectrum. At biologically relevant doses, DewarPP were more efficiently produced by simulated solar light than by WE (ratios of DewarPP to (6-4)PP of 1:3 and 1:8, respectively), but were detected neither after UVA nor after UVC radiation, The comparative rates of formation for CPD, (6-4)PP and DewarPP are 1:0.25 for UVC, 1:0.12:0.014 for UVB, and 1:0.18:0.06 for simulated sunlight. The repair rates of these photoproducts were also studied in nucleotide excision re pair-proficient cells irradiated with UVB, UVA radiation, or simulated sunlight. Interestingly, DewarPP were eliminated slowly, inefficiently, and at the same rate as CPD, In contrast, removal of (6-4) photoproducts was rapid and completed 24 h after exposure, Altogether, our results indicate that, in addition to CPD and (6-4)PP, DewarPP may play a role in solar cytotoxicity and mutagenesis.	Inst Curie Rech, CNRS UMR 218, LRC 1, Commissariat Energie Atom, F-75248 Paris 05, France; Semmelweis Univ, Inst Biophys & Radiat Biol, H-1444 Budapest, Hungary; CNRS, Genethon 3, CNRS URA 1923, F-91002 Evry, France; Kanazawa Univ, Fac Pharmaceut Sci, Div Radiat Biol, Kanazawa, Ishikawa 9200934, Japan	CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Semmelweis University; Centre National de la Recherche Scientifique (CNRS); Kanazawa University	Sage, E (corresponding author), Inst Curie Rech, CNRS UMR 218, LRC 1, Commissariat Energie Atom, F-75248 Paris 05, France.	Evelyne.Sage@curie.u-psud.fr	Perdiz, Daniel/R-4471-2018; Grof, Pal/C-5107-2013	Grof, Pal/0000-0002-6488-893X; Perdiz, Daniel/0000-0002-6804-5980				Alapetite C, 1996, INT J RADIAT BIOL, V69, P359, DOI 10.1080/095530096145922; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; Bodak N, 1999, P NATL ACAD SCI USA, V96, P5117, DOI 10.1073/pnas.96.9.5117; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CADET J, 1992, J PHOTOCH PHOTOBIO B, V15, P277, DOI 10.1016/1011-1344(92)85135-H; CHADWICK CA, 1995, J PHOTOCH PHOTOBIO B, V28, P163, DOI 10.1016/1011-1344(94)07096-7; CLINGEN PH, 1995, CANCER RES, V55, P2245; CLINGEN PH, 1995, PHOTOCHEM PHOTOBIOL, V61, P163, DOI 10.1111/j.1751-1097.1995.tb03955.x; COLLINS AR, 1995, MUTAT RES-DNA REPAIR, V336, P69, DOI 10.1016/0921-8777(94)00043-6; DAYAGROSJEAN L, 1995, J PHOTOCH PHOTOBIO B, V28, P115, DOI 10.1016/1011-1344(95)07130-T; Douki T, 1999, PHOTOCHEM PHOTOBIOL, V70, P184, DOI 10.1111/j.1751-1097.1999.tb07988.x; DOUKI T, 1992, J PHOTOCH PHOTOBIO B, V15, P199, DOI 10.1016/1011-1344(92)85124-D; Douki T, 1997, PHOTOCHEM PHOTOBIOL, V66, P171, DOI 10.1111/j.1751-1097.1997.tb08639.x; DROBETSKY EA, 1995, P NATL ACAD SCI USA, V92, P2350, DOI 10.1073/pnas.92.6.2350; DROBETSKY EA, 1994, CARCINOGENESIS, V15, P1577, DOI 10.1093/carcin/15.8.1577; DUMAZ N, 1993, P NATL ACAD SCI USA, V90, P10529, DOI 10.1073/pnas.90.22.10529; EVENO E, 1995, CANCER RES, V55, P4325; Fekete A, 1998, PHOTOCHEM PHOTOBIOL, V68, P527, DOI 10.1562/0031-8655(1998)068<0527:AOTEOV>2.3.CO;2; FREEMAN SE, 1989, P NATL ACAD SCI USA, V86, P5605, DOI 10.1073/pnas.86.14.5605; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; HASELTINE WA, 1983, CELL, V33, P13, DOI 10.1016/0092-8674(83)90329-X; HORSFALL MJ, 1994, J MOL BIOL, V235, P465, DOI 10.1006/jmbi.1994.1006; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Hwang GS, 1996, EUR J BIOCHEM, V235, P359, DOI 10.1111/j.1432-1033.1996.00359.x; IARC (International Agency for Research on Cancer), 1992, MON EV CARC RISKS HU, V55; Jing YQ, 1998, NUCLEIC ACIDS RES, V26, P3845, DOI 10.1093/nar/26.16.3845; Kielbassa C, 1997, CARCINOGENESIS, V18, P811, DOI 10.1093/carcin/18.4.811; KOCHEVAR IE, 1990, BIOORGANIC PHOTOCHEM, P273; Kuluncsics Z, 1999, J PHOTOCH PHOTOBIO B, V49, P71, DOI 10.1016/S1011-1344(99)00034-2; LECLERC JE, 1991, P NATL ACAD SCI USA, V88, P9685, DOI 10.1073/pnas.88.21.9685; MATSUNAGA T, 1993, PHOTOCHEM PHOTOBIOL, V57, P934, DOI 10.1111/j.1751-1097.1993.tb02952.x; Mitchell DL, 1999, CANCER RES, V59, P2875; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MITCHELL DL, 1993, INT CONGR SER, V1021, P337; MITCHELL DL, 1987, PHOTOCHEM PHOTOBIOL, V45, P781, DOI 10.1111/j.1751-1097.1987.tb07882.x; MORI T, 1991, PHOTOCHEM PHOTOBIOL, V54, P225, DOI 10.1111/j.1751-1097.1991.tb02010.x; MULLAART E, 1988, J INVEST DERMATOL, V90, P346, DOI 10.1111/1523-1747.ep12456316; Nakagawa A, 1998, J INVEST DERMATOL, V110, P143, DOI 10.1046/j.1523-1747.1998.00100.x; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; PEAK MJ, 1987, PHOTOCHEM PHOTOBIOL, V45, P381, DOI 10.1111/j.1751-1097.1987.tb05390.x; REARDON JT, 1993, J BIOL CHEM, V268, P21301; REGAN JD, 1990, MUTAT RES, V235, P157, DOI 10.1016/0921-8777(90)90069-H; Robert C, 1996, J INVEST DERMATOL, V106, P721, DOI 10.1111/1523-1747.ep12345616; ROSENSTEIN BS, 1991, RADIAT RES, V126, P338, DOI 10.2307/3577923; ROSENSTEIN BS, 1987, PHOTOCHEM PHOTOBIOL, V45, P775, DOI 10.1111/j.1751-1097.1987.tb07881.x; ROZA L, 1988, PHOTOCHEM PHOTOBIOL, V48, P627, DOI 10.1111/j.1751-1097.1988.tb02873.x; Sage E, 1996, P NATL ACAD SCI USA, V93, P176, DOI 10.1073/pnas.93.1.176; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; Sage E, 1999, NATO ASI 2, V55, P115; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; SMITH CA, 1993, J BIOL CHEM, V268, P11143; Smith CA, 1996, BIOCHEMISTRY-US, V35, P4146, DOI 10.1021/bi951975c; SUTHERLAND JC, 1981, RADIAT RES, V86, P399, DOI 10.2307/3575456; SVOBODA DL, 1993, J BIOL CHEM, V268, P10694; SZYMKOWSKI DE, 1993, P NATL ACAD SCI USA, V90, P9823, DOI 10.1073/pnas.90.21.9823; TAYLOR JS, 1990, PHOTOCHEM PHOTOBIOL, V51, P161, DOI 10.1111/j.1751-1097.1990.tb01698.x; TAYLOR JS, 1988, BIOCHEMISTRY-US, V27, P7206, DOI 10.1021/bi00419a007; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; Tung BS, 1996, MUTAT RES-DNA REPAIR, V362, P65, DOI 10.1016/0921-8777(95)00034-8; TYRRELL RM, 1973, PHOTOCHEM PHOTOBIOL, V17, P69, DOI 10.1111/j.1751-1097.1973.tb06334.x; TYRRELL RM, 1990, J PHOTOCH PHOTOBIO B, V4, P349, DOI 10.1016/1011-1344(90)85014-N; VINK AA, 1994, J PHOTOCH PHOTOBIO B, V24, P25, DOI 10.1016/1011-1344(94)07005-9; VREESWIJK MPG, 1994, J BIOL CHEM, V269, P31858; WEISS RB, 1993, PHOTOCHEM PHOTOBIOL, V58, P219, DOI 10.1111/j.1751-1097.1993.tb09552.x; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; Zhang XS, 1997, PHOTOCHEM PHOTOBIOL, V65, P119, DOI 10.1111/j.1751-1097.1997.tb01886.x	67	213	217	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 1	2000	275	35					26732	26742						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	351EL	10827179				2022-12-25	WOS:000089144800011
J	Nguyen, LH; Erzberger, JP; Root, J; Wilson, DM				Nguyen, LH; Erzberger, JP; Root, J; Wilson, DM			The human homolog of Escherichia coli orn degrades small single-stranded RNA and DNA oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-I; ACTIVE-SITE; AMINO-ACID; EXONUCLEASE; PROTEIN; OLIGORIBONUCLEASE; NUCLEUS; MOTIFS; DECAY; GENE	We report here the identification of human homologues to the essential Escherichia coli Orn protein and the related yeast mitochondrial DNA-escape pathway regulatory factor Ynt20, The human proteins appear to arise from alternatively spliced transcripts, and are thus identical, except the human Ynt20 equivalent contains an NH2-terminal extension that possesses a predicted mitochondrial protease cleavage signal. In vitro analysis revealed that the smaller human protein exhibits a 3' to 5' exonuclease activity for small (primarily less than or equal to 5 nucleotides in length) single-stranded RNA and DNA oligomers, We have named this human protein Sfn for Small fragment nuclease to reflect its broad substrate range, and have termed the longer protein hSfn alpha. Sfn prefers Mn2+ as a metal cofactor and displays a temperature-resistant (to 50 degrees C) nuclease activity. Kinetic analysis indicates that Sfn exhibits a similar affinity for small RNAs and DNAs (K-m of similar to 1.5 mu M), but degrades small RNAs similar to 4-fold more efficiently than DNA, Mutation of a conserved aspartate (Asp(136)) to alanine abolishes both nuclease activities of Sfn, Northern blot analysis revealed that a l-kilobase transcript corresponding to SFN and/or SFN alpha (these mRNAs differ by only two nucleotides) is expressed at varying levels in all fetal and adult human tissues examined. Expressed tag sequence clone analysis found that the two splice variants, SFN to SFN alpha, are present at a ratio of roughly 4 to 1, respectively. The results presented within suggest a role for human Sfn in cellular nucleotide recycling.	Univ Calif Lawrence Livermore Natl Lab, Mol & Struct Biol Div, Livermore, CA 94551 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Wilson, DM (corresponding author), Univ Calif Lawrence Livermore Natl Lab, Mol & Struct Biol Div, Livermore, CA 94551 USA.		Wilson, David M/AAK-5409-2021	Wilson, David M/0000-0002-8945-0395	NCI NIH HHS [CA79056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLUTHNER M, 1992, J EXP MED, V176, P973, DOI 10.1084/jem.176.4.973; BURGESS RR, 1991, METHOD ENZYMOL, V208, P3; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DATTA AK, 1975, J BIOL CHEM, V250, P7313; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DEUTSCHER MP, 1993, J BACTERIOL, V175, P4577, DOI 10.1128/JB.175.15.4577-4583.1993; Erzberger JP, 1999, J MOL BIOL, V290, P447, DOI 10.1006/jmbi.1999.2888; GAVEL Y, 1990, PROTEIN ENG, V4, P33, DOI 10.1093/protein/4.1.33; Ghosh S, 1999, P NATL ACAD SCI USA, V96, P4372, DOI 10.1073/pnas.96.8.4372; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2521, DOI 10.1093/nar/21.10.2521; KOONIN EV, 1997, CURR BIOL, V7, P604; Lee BI, 1999, J BIOL CHEM, V274, P37763, DOI 10.1074/jbc.274.53.37763; MORRISSEY JP, 1995, TRENDS BIOCHEM SCI, V20, P78, DOI 10.1016/S0968-0004(00)88962-8; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; NIYOGI SK, 1975, J BIOL CHEM, V250, P7307; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Sambrook J., 2002, MOL CLONING LAB MANU; Shafer KS, 1999, CURR GENET, V36, P183, DOI 10.1007/s002940050489; SHAFER KS, 1999, CURR GENET, V34, P438; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Wilson DM, 1998, NUCLEIC ACIDS RES, V26, P3762, DOI 10.1093/nar/26.16.3762; Zhang XL, 1998, J BACTERIOL, V180, P2779, DOI 10.1128/JB.180.10.2779-2781.1998; ZIEMIN L, P NATL ACAD SCI US, V88, P10735	27	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	2000	275	34					25900	25906		10.1074/jbc.M002672200	http://dx.doi.org/10.1074/jbc.M002672200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	348RF	10851236	hybrid			2022-12-25	WOS:000088999700004
J	Crosas, B; Allali-Hassani, A; Martinez, SE; Martras, S; Persson, B; Jornvall, H; Pares, X; Farres, J				Crosas, B; Allali-Hassani, A; Martinez, SE; Martras, S; Persson, B; Jornvall, H; Pares, X; Farres, J			Molecular basis for differential substrate specificity in class IV alcohol dehydrogenases - A conserved function in retinoid metabolism but not in ethanol oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OMEGA-HYDROXYFATTY ACIDS; HUMAN STOMACH; EXPRESSION PATTERNS; MUTANT MICE; SEQUENCE; CDNA; ADH; AMPLIFICATION; PURIFICATION; ISOENZYMES	Mammalian class IV alcohol dehydrogenase enzymes are characteristic of epithelial tissues, exhibit moderate to high K-m values for ethanol, and are very active in retinol oxidation, The human enzyme shows a K-m value for ethanol which is 2 orders of magnitude lower than that of rat class IV. The uniquely significant difference in the substrate-binding pocket between the two enzymes appears to be at position 294, Val in the human enzyme and Ala in the rat enzyme. Moreover, a deletion at position 117 (Gly in class I) has been pointed out as probably responsible for class IV specificity toward retinoids, With the aim of establishing the role of these residues, we have studied the kinetics of the recombinant human and rat wild-type enzymes, the human G117ins and V294A mutants, and the rat A294V mutant toward aliphatic alcohols and retinoids, 9-cis-Retinol was the best retinoid substrate for both human and rat class IV, strongly supporting a role of class IV in the generation of 9-cis-retinoic acid. In contrast, 13-cis retinoids were not substrates, The G117ins mutant showed a decreased catalytic efficiency toward retinoids and toward three-carbon and longer primary aliphatic alcohols, a behavior that resembles that of the human class I enzyme, which has Gly(117). Th, K-m values for ethanol dramatically changed in the 294 mutants, where the human V294A mutant showed a 280-fold increase, and the rat A294V mutant a 50-fold decrease, compared with those of the respective wild-type enzymes. This demonstrates that the Val/Ala exchange at position 294 is mostly responsible for the kinetic differences with ethanol between the human and rat class IV. In contrast, the kinetics toward retinoids was only slightly affected by the mutations at position 294, compatible with a more conserved function of mammalian class IV alcohol dehydrogenase in retinoid metabolism.	Univ Autonoma Barcelona, Dept Biochem & Mol Biol, E-08193 Barcelona, Spain; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Autonomous University of Barcelona; Karolinska Institutet	Pares, X (corresponding author), Univ Autonoma Barcelona, Dept Biochem & Mol Biol, E-08193 Barcelona, Spain.		Farrés, Jaume/F-8648-2016; Pares, Xavier/K-8228-2017	Farrés, Jaume/0000-0001-9069-3987; Pares, Xavier/0000-0002-5071-9465				ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052; Allali-Hassani A, 1998, FEBS LETT, V426, P362, DOI 10.1016/S0014-5793(98)00374-3; AllaliHassani A, 1997, FEBS LETT, V405, P26, DOI 10.1016/S0014-5793(97)00151-8; Ang HL, 1996, ALCOHOL CLIN EXP RES, V20, P1050, DOI 10.1111/j.1530-0277.1996.tb01946.x; Ang HL, 1996, J BIOL CHEM, V271, P9526, DOI 10.1074/jbc.271.16.9526; BENSON S A, 1984, Biotechniques, V2, P126; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; BOLEDA MD, 1989, ARCH BIOCHEM BIOPHYS, V274, P74, DOI 10.1016/0003-9861(89)90416-5; Cleland W W, 1979, Methods Enzymol, V63, P103; DANIELSSON O, 1994, P NATL ACAD SCI USA, V91, P4980, DOI 10.1073/pnas.91.11.4980; Deltour L, 1999, DEV GENET, V25, P1, DOI 10.1002/(SICI)1520-6408(1999)25:1<1::AID-DVG1>3.0.CO;2-W; Deltour L, 1999, J BIOL CHEM, V274, P16796, DOI 10.1074/jbc.274.24.16796; DOWNES JE, 1995, ADV EXP MED BIOL, V372, P349; EKLUND H, 1990, EUR J BIOCHEM, V193, P303, DOI 10.1111/j.1432-1033.1990.tb19337.x; FARRES J, 1994, EUR J BIOCHEM, V224, P549, DOI 10.1111/j.1432-1033.1994.00549.x; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; Foglio MH, 1999, BBA-PROTEIN STRUCT M, V1432, P239, DOI 10.1016/S0167-4838(99)00104-1; FRIEDMAN KD, 1988, NUCLEIC ACIDS RES, V16, P8718, DOI 10.1093/nar/16.17.8718; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Han CL, 1998, EUR J BIOCHEM, V254, P25, DOI 10.1046/j.1432-1327.1998.2540025.x; HELLER J, 1973, J BIOL CHEM, V248, P6308; HURLEY TD, 1995, ADV EXP MED BIOL, V372, P321; JORNVALL H, 1995, ALCOHOL ALCOHOLISM, V30, P153; JULIA P, 1987, EUR J BIOCHEM, V162, P179, DOI 10.1111/j.1432-1033.1987.tb10559.x; KEDISHVILI NY, 1995, J BIOL CHEM, V270, P3625, DOI 10.1074/jbc.270.8.3625; Kitson KE, 1996, ALCOHOL CLIN EXP RES, V20, pA82, DOI 10.1111/j.1530-0277.1996.tb01752.x; KOIVUSALO M, 1989, FEBS LETT, V257, P105, DOI 10.1016/0014-5793(89)81797-1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; Moreno A, 1996, FEBS LETT, V395, P99, DOI 10.1016/0014-5793(96)01009-5; MORENO A, 1991, J BIOL CHEM, V266, P1128; PARES X, 1990, METHOD ENZYMOL, V189, P436; PARES X, 1994, P NATL ACAD SCI USA, V91, P1893, DOI 10.1073/pnas.91.5.1893; PARK DH, 1992, J BIOL CHEM, V267, P5527; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5467; Xie PG, 1997, J BIOL CHEM, V272, P18558, DOI 10.1074/jbc.272.30.18558; Xie PGT, 1999, PROTEIN SCI, V8, P2639; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; ZgombicKnight M, 1997, GENOMICS, V41, P105, DOI 10.1006/geno.1997.4637; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P4305, DOI 10.1074/jbc.270.9.4305; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P10868, DOI 10.1074/jbc.270.18.10868	41	32	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25180	25187		10.1074/jbc.M910040199	http://dx.doi.org/10.1074/jbc.M910040199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829036	hybrid			2022-12-25	WOS:000088849400020
J	Ho, DH; Badellino, K; Baglia, FA; Sun, MF; Zhao, MM; Gailani, D; Walsh, PN				Ho, DH; Badellino, K; Baglia, FA; Sun, MF; Zhao, MM; Gailani, D; Walsh, PN			The role of high molecular weight kininogen and prothrombin as cofactors in the binding of factor XI A3 domain to the platelet surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-XI; ACTIVATED HUMAN PLATELETS; WASHED HUMAN-PLATELETS; BLOOD-COAGULATION; PLASMA PREKALLIKREIN; APPLE-3 DOMAIN; HEAVY-CHAIN; LIGHT CHAIN; FACTOR-IX; SITE	We have reported that prothrombin (1 mu M) is able to replace high molecular weight kininogen (45 nM) as a cofactor for the specific binding of factor XI to the platelet (Baglia, F. k, and Walsh, P. N. (1998) Biochemistry 37, 2271-2281). We have also determined that prothrombin fragment 2 binds to the Apple 1 domain of factor XI at or near the site where high molecular weight kininogen binds. A region of 31 amino acids derived from high molecular weight kininogen (HK31-mer) can also bind to factor XI. (Tait, J. F., and Fujikawa, K. (1987) J. Biol Chem. 262, 11651-11656). We therefore investigated the role of prothrombin fragment 2 and HR31-mer as cofactors in the binding of factor XI to activated platelets. Our experiments demonstrated that prothrombin fragment 2 (1 mu M) or the HK31-mer (8 mu M) are able to replace high molecular weight kininogen (45 nM) or prothrombin (1 mu M) as cofactors for the binding of factor XI to the platelet. To localize the platelet binding site on factor XI, we used mutant full-length recombinant factor XI molecules in which the platelet binding site in the Apple 3 domain was altered by alanine scanning mutagenesis. The recombinant factor XI with alanine substitutions at positions Ser(248), Arg(250), Lys(255), Leu(287), Phe(260), or GLn(263) were defective in their ability to bind to activated platelets. Thus, the interaction of factor XI with platelets is mediated by the amino acid residues Ser(248), Arg(250), Lys(255), Leu(257), Phe(260), and Gln(263) within the Apple 3 domain.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Dept Med, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Dept Biochem, Philadelphia, PA 19140 USA; Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Vanderbilt University; Vanderbilt University	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Dept Med, 3400 N Broad St, Philadelphia, PA 19140 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058837, R01HL056153, R01HL046213] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58837, HL46213, HL56153] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKTULGA A, 1975, PLATELETS RECENT ADV, P185; BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; BAGLIA FA, 1990, J BIOL CHEM, V265, P4149; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; BINDER B, 1975, THROMB DIATH HAEMOST, V34, P354; BRUNNEE T, 1993, BLOOD, V81, P580; DELACADENA RA, 1992, PROTEIN SCI, V1, P151; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; GAILANI D, 1993, SEMIN THROMB HEMOST, V19, P396, DOI 10.1055/s-2007-993291; GREENGARD JS, 1984, BIOCHEMISTRY-US, V23, P6863, DOI 10.1021/bi00321a090; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; Ho DH, 1998, J BIOL CHEM, V273, P16382, DOI 10.1074/jbc.273.26.16382; HO DH, 1980, BIOCHEMISTRY-US, V34, P316; HOLMSEN H, 1994, HEMOSTASIS THROMBOSI, P530; Kaplan A P, 1981, Ann N Y Acad Sci, V370, P253, DOI 10.1111/j.1749-6632.1981.tb29738.x; Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8903, DOI 10.1021/bi9525031; Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8890, DOI 10.1021/bi9525029; SEAMAN FS, 1994, BIOCHEM J, V304, P715, DOI 10.1042/bj3040715; STEVENS WK, 1993, BIOCHEMISTRY-US, V32, P2787, DOI 10.1021/bi00062a008; Sun MF, 1999, J BIOL CHEM, V274, P36373, DOI 10.1074/jbc.274.51.36373; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; TAIT JF, 1987, J BIOL CHEM, V262, P11651; THOMPSON RE, 1979, P NATL ACAD SCI USA, V76, P4862, DOI 10.1073/pnas.76.10.4862; Tordai H, 1999, FEBS LETT, V461, P63, DOI 10.1016/S0014-5793(99)01416-7; WALSH PN, 1993, THROMB HAEMOSTASIS, V70, P75; WARNCRAMER BJ, 1985, BIOCHEM BIOPH RES CO, V133, P417, DOI 10.1016/0006-291X(85)90922-2; Zhao MM, 1998, J BIOL CHEM, V273, P31153, DOI 10.1074/jbc.273.47.31153	31	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25139	25145		10.1074/jbc.M001890200	http://dx.doi.org/10.1074/jbc.M001890200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10823824	hybrid			2022-12-25	WOS:000088849400015
J	Tanaka, N; Yonekura, H; Yamagishi, S; Fujimori, H; Yamamoto, Y; Yamamoto, H				Tanaka, N; Yonekura, H; Yamagishi, S; Fujimori, H; Yamamoto, Y; Yamamoto, H			The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear Factor-kappa B, and by 17 beta-estradiol through Sp-1 in human vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; GROWTH-FACTOR; DIABETIC-RETINOPATHY; ESTROGEN-RECEPTOR; BINDING-PROTEINS; GENE-EXPRESSION; OXIDANT STRESS; TRANSCRIPTIONAL ACTIVATION; POSSIBLE MECHANISM; SURFACE RECEPTOR	The binding of advanced glycation end products (AGE) to the receptor for AGE (RAGE) is known to deteriorate various cell functions and is implicated in the pathogenesis of diabetic vascular complications. Here we show that AGE, tumor necrosis factor-alpha (TNF-alpha), and 17 beta-estradiol (E-2) up-regulated RAGE mRNA and protein levels in human microvascular endothelial cells and ECV304 cells, with the mRNA stability being essentially invariant. Transient transfection experiments with human RAGE promoter-luciferase chimeras revealed that the region from nucleotide number -751 to -629 and the region from -239 to -89 in the RAGE 5'-flanking sequence exhibited the AGE/TNF-alpha and E-2 responsiveness, respectively. Site-directed mutation of an nuclear factor-kappa B (NF-kappa B) site at -671 or of Sp-1 sites at -189 and -172 residing in those regions resulted in an abrogation of the AGE/TNF-alpha- or E-2-mediated transcriptional activation. Electrophoretic mobility shift assays revealed that ECV304 cell nuclear extracts contained factors which retarded the NF-kappa B and Sp-1 elements, and that the DNA-protein complexes were supershifted by anti-p65/p50 NF-kappa B and anti-Sp-1/estrogen receptor or antibodies, respectively. These results suggest that AGE, TNF-alpha, and E-2 can activate the RAGE gene through NF-kappa B and Sp-1, causing enhanced AGE-RAGE interactions, which would lead to an exacerbation of diabetic microvasculopathy.	Kanazawa Univ, Sch Med, Dept Biochem, Kanazawa, Ishikawa 9208640, Japan; Kanazawa Univ, Sch Med, Dept Ophthalmol, Kanazawa, Ishikawa 9208640, Japan	Kanazawa University; Kanazawa University	Yamamoto, H (corresponding author), Kanazawa Univ, Sch Med, Dept Biochem, 13-1 Takara Machi, Kanazawa, Ishikawa 9208640, Japan.							Algarte M, 1999, MOL CELL BIOL, V19, P6140; AxerSiegel R, 1996, OPHTHALMOLOGY, V103, P1815, DOI 10.1016/S0161-6420(96)30421-1; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BRADFORD MM, 1972, ANAL BIOCHEM, V71, P248; BRETT J, 1993, AM J PATHOL, V143, P1699; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; HATAKEYAMA H, 1994, J BIOL CHEM, V269, P24316; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Kaji M, 1996, CANCER GENE THER, V3, P393; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KLEIN BEK, 1990, DIABETES CARE, V13, P34, DOI 10.2337/diacare.13.1.34; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li JF, 1997, J BIOL CHEM, V272, P16498, DOI 10.1074/jbc.272.26.16498; Li JF, 1998, J BIOL CHEM, V273, P30870, DOI 10.1074/jbc.273.47.30870; Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MOLONEY JBM, 1982, AM J OPHTHALMOL, V93, P745, DOI 10.1016/0002-9394(82)90471-8; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NOMURA M, 1995, J BIOL CHEM, V270, P28316; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Qin CH, 1999, ENDOCRINOLOGY, V140, P2501, DOI 10.1210/en.140.6.2501; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; Schmidt AM, 1999, CIRC RES, V84, P489, DOI 10.1161/01.RES.84.5.489; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Schocket LS, 1999, AM J OPHTHALMOL, V128, P477, DOI 10.1016/S0002-9394(99)00234-2; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Soulis T, 1997, DIABETOLOGIA, V40, P619, DOI 10.1007/s001250050725; SUGAYA K, 1994, GENOMICS, V23, P408, DOI 10.1006/geno.1994.1517; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; Suzuma I, 1999, INVEST OPHTH VIS SCI, V40, P2122; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; Xie W, 1999, ENDOCRINOLOGY, V140, P219, DOI 10.1210/en.140.1.219; Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723; Yamagishi S, 1998, DIABETOLOGIA, V41, P1435, DOI 10.1007/s001250051089; Yamagishi S, 1996, FEBS LETT, V384, P103, DOI 10.1016/0014-5793(96)00279-7; YAMAGISHI SI, 1995, BIOCHEM BIOPH RES CO, V213, P681, DOI 10.1006/bbrc.1995.2185; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yonekura H, 1999, J BIOL CHEM, V274, P35172, DOI 10.1074/jbc.274.49.35172	55	367	406	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	2000	275	33					25781	25790		10.1074/jbc.M001235200	http://dx.doi.org/10.1074/jbc.M001235200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	346BB	10829018	hybrid			2022-12-25	WOS:000088849400095
J	Martin, DW; Sachs, JR				Martin, DW; Sachs, JR			Ligands presumed to label high affinity and low affinity ATP binding sites do not interact in an (alpha beta)(2) diprotomer in duck nasal gland Na+,K+-ATPase, nor do the sites coexist in native enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE; FLUORESCEIN ISOTHIOCYANATE; ACTIVE-SITE; SODIUM; NA,K-ATPASE; MECHANISM; PUMP	The inter-action of ligands deemed to be ATP analogues with renal Na+,K+-ATPase suggests that two ATP binding sites coexist on each functional unit. Previous studies in which fluorescein B-isothiocyanate (FITC) was used to label the high affinity ATP site and 2'(3')O-(2,4,6-trinitrophenyl)adenosine 5'-diphosphate (TNP-ADP) was used to probe the low affinity site suggested that the two sites coexist on the same alpha beta protomer, Other studies in which FITC labeled the high affinity site and erythrosin-5-isothiocyanate (ErITC) labeled the low affinity site led to the conclusion that the high and low affinity sites exist on separate interacting protomers in a functional diprotomer, We report here that at 100% inhibition of ATPase activity by FITC, each cup protomer of duck nasal gland enzyme has a single bound FITC, Both TNP-ADP and ErITC interact with FITC-bound protomers, which unambiguously demonstrates that putative high and low affinity ATP sites coexist on the same protomer, In unlabeled nasal gland enzyme, TNP-ADP and ErITC inhibit both ATPase activity and p-nitrophenyl phosphatase activity, functions attributed to the putative high and low affinity ATP site, respectively, by interacting with a single site with characteristics of the high affinity ATP binding site. In FITC-labeled enzyme, TNP-ADP and ErITC inhibit p-nitrophenyl phosphatase activity but at much higher concentrations than with the unmodified enzyme. Low affinity sites do not exist on the unmodified enzyme but can be detected only after the high affinity site is modified by FITC.	SUNY Stony Brook, Div Hematol, Dept Med, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Martin, DW (corresponding author), SUNY Stony Brook, Div Hematol, Dept Med, HSC T15-040, Stony Brook, NY 11794 USA.	dwight.martin@sunysb.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019185] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19185] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMLER E, 1992, BIOPHYS J, V61, P553, DOI 10.1016/S0006-3495(92)81859-3; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; BUXBAUM E, 1991, SODIUM PUMP RECENT D, P405; CARILLI CT, 1982, J BIOL CHEM, V257, P5601; CZERWINSKI A, 1967, AM J PHYSIOL, V213, P786, DOI 10.1152/ajplegacy.1967.213.3.786; DAVIS RL, 1988, BIOCHIM BIOPHYS ACTA, V953, P26, DOI 10.1016/0167-4838(88)90006-4; Faller LD, 2000, BIOPHYS J, V78, p77A; GLYNN IM, 1982, MEMBRANES TRANSPORT, V1, P529; HELLEN EH, 1997, BIOPHYS CHEM, V69, P197; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; KARLISH SJD, 1980, J BIOENERG BIOMEMBR, V12, P111, DOI 10.1007/BF00744678; Linnertz H, 1998, J BIOL CHEM, V273, P28813, DOI 10.1074/jbc.273.44.28813; Martin DW, 1999, BIOCHEMISTRY-US, V38, P7485, DOI 10.1021/bi983019b; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2357; NEUFELD AH, 1969, J BIOL CHEM, V244, P6493; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POST RL, 1972, J BIOL CHEM, V247, P6530; SACHS JR, 1994, BBA-BIOMEMBRANES, V1193, P199, DOI 10.1016/0005-2736(94)90349-2; SCHEINERBOBIS G, 1993, BIOCHEMISTRY-US, V32, P9592, DOI 10.1021/bi00088a011; SCHONER W, 1994, SODIUM PUMP, P332; Stokes DL, 2000, BIOPHYS J, V78, P1765, DOI 10.1016/S0006-3495(00)76727-0; Ward DG, 1996, J BIOL CHEM, V271, P12317, DOI 10.1074/jbc.271.21.12317; XU KY, 1989, BIOCHEMISTRY-US, V28, P5764, DOI 10.1021/bi00440a010; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	24	27	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24512	24517		10.1074/jbc.M003179200	http://dx.doi.org/10.1074/jbc.M003179200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10831595	hybrid			2022-12-25	WOS:000088683300038
J	Zimmer, MA; Tiu, J; Collins, MA; Ordal, GT				Zimmer, MA; Tiu, J; Collins, MA; Ordal, GT			Selective methylation changes on the Bacillus subtilis chemotaxis receptor McpB promote adaptation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTATE RECEPTOR; ESCHERICHIA-COLI; SENSORY RECEPTOR; PROTEIN METHYLTRANSFERASE; COVALENT MODIFICATION; BACTERIAL CHEMOTAXIS; CYTOPLASMIC DOMAIN; METHYLESTERASE; ESTERIFICATION; PURIFICATION	The Bacillus subtilis McpB is a class III chemotaxis receptor, from which methanol is released in response to all stimuli. McpB has four putative methylation sites based upon the Escherichia coli consensus sequence. To explore the nature of methanol release from a class III receptor, all combinations of putative methylation sites Gln(371), Gln(595), Glu(630), and Glu(637) were Substituted with aspartate, a conservative substitution that effectively eliminates methylation. McpB ((Q371D,E630D,E637D)) in a Delta(mcpA mcpB tlpA tlpB)101::cat mcpC4::erm background failed to release methanol in response to either the addition or removal of the McpB-mediated attractant asparagine, In the same background, McpB ((E630D,E637D)) produced methanol only upon asparagine addition, whereas McpB((Q371D,E630D)) produced methanol only upon asparagine removal. Thus methanol release from McpB was selective, Mutants unable to methylate site 637 but able to methylate site 630 had high prestimulus biases and were incapable of adapting to asparagine addition. Mutants unable to methylate site 630 but able to methylate site 637 had low prestimulus biases and were impaired in adaptation to asparagine removal. We propose that selective methylation of these two sites represents a method of adaptation novel from E, coli and present a model in which a charged residue rests between them. The placement of this charge would allow for opposing electrostatic effects (and hence opposing receptor conformational changes). We propose that CheC, a protein not found in enteric systems, has a role in regulating this selective methylation.	Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Coll Liberal Arts & Sci, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Ordal, GT (corresponding author), Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA.				NIGMS NIH HHS [GM54365] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM054365, R01GM054365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLGREN JA, 1983, BIOCHEM J, V213, P759, DOI 10.1042/bj2130759; BISCHOFF DS, 1993, BIOCHEMISTRY-US, V32, P9256, DOI 10.1021/bi00086a035; BLOCK SM, 1983, J BACTERIOL, V154, P312, DOI 10.1128/JB.154.1.312-323.1983; BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BOYD A, 1980, J BACTERIOL, V143, P809, DOI 10.1128/JB.143.2.809-815.1980; BURGESSCASSLER A, 1982, J BIOL CHEM, V257, P8412; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; DANIELSON MA, 1994, BIOCHEMISTRY-US, V33, P6100, DOI 10.1021/bi00186a009; DUNTEN P, 1991, J BIOL CHEM, V266, P1491; FALKE JJ, 1988, J BIOL CHEM, V263, P14850; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; FUHRER DK, 1991, J BACTERIOL, V173, P7443, DOI 10.1128/jb.173.23.7443-7448.1991; Garrity LF, 1997, MICROBIOL-UK, V143, P2945, DOI 10.1099/00221287-143-9-2945; GOLDMAN DJ, 1984, BIOCHEMISTRY-US, V23, P675, DOI 10.1021/bi00299a014; GueroutFleury AM, 1996, GENE, V180, P57, DOI 10.1016/S0378-1119(96)00404-0; HANLON DW, 1994, J BIOL CHEM, V269, P14038; KEHRY MR, 1984, J BIOL CHEM, V259, P1828; Kim KK, 1999, NATURE, V400, P787, DOI 10.1038/23512; Kirby JR, 1997, MOL MICROBIOL, V24, P869, DOI 10.1046/j.1365-2958.1997.3941759.x; Kirby JR, 1999, J BIOL CHEM, V274, P11092, DOI 10.1074/jbc.274.16.11092; Kirby JR, 2000, MOL MICROBIOL, V35, P44, DOI 10.1046/j.1365-2958.2000.01676.x; KIRSCH ML, 1993, J BIOL CHEM, V268, P18610; KIRSCH ML, 1993, J BIOL CHEM, V268, P25350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LeMoual H, 1996, J MOL BIOL, V261, P568, DOI 10.1006/jmbi.1996.0483; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; Muller J, 1997, MICROBIOL-UK, V143, P3231, DOI 10.1099/00221287-143-10-3231; NETTLETON DO, 1991, J BACTERIOL, V171, P120; NORDMANN B, 1994, J BIOL CHEM, V269, P16449; ORDAL GW, 1977, J BACTERIOL, V129, P156, DOI 10.1128/JB.129.1.156-165.1977; ORDAL GW, 1975, SCIENCE, V189, P802, DOI 10.1126/science.808854; Rosario MML, 1996, MOL MICROBIOL, V21, P511, DOI 10.1111/j.1365-2958.1996.tb02560.x; ROSARIO MML, 1995, BIOCHEMISTRY-US, V34, P3823, DOI 10.1021/bi00011a040; SHAPIRO MJ, 1994, J BIOL CHEM, V269, P11054; SMIBERT RM, 1994, METHODS GEN MOL BACT, V1, P603; SPRINGER WR, 1977, P NATL ACAD SCI USA, V74, P533, DOI 10.1073/pnas.74.2.533; SPUDICH EN, 1989, P NATL ACAD SCI USA, V86, P7746, DOI 10.1073/pnas.86.20.7746; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; TERWILLIGER TC, 1983, J BIOL CHEM, V258, P9608; TERWILLIGER TC, 1984, J BIOL CHEM, V259, P7719; THOELKE MS, 1987, J BIOL CHEM, V262, P2811; TOEWS ML, 1979, P NATL ACAD SCI USA, V81, P5544; ULLAH AHJ, 1981, J BACTERIOL, V145, P958, DOI 10.1128/JB.145.2.958-965.1981; WONG LS, 1995, J BACTERIOL, V177, P4342, DOI 10.1128/jb.177.15.4342-4349.1995	45	45	47	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 11	2000	275	32					24264	24272		10.1074/jbc.M004001200	http://dx.doi.org/10.1074/jbc.M004001200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	343CC	10825179	Green Submitted, hybrid			2022-12-25	WOS:000088683300006
J	Kimura, K; Tsuji, T; Takada, Y; Miki, T; Narumiya, S				Kimura, K; Tsuji, T; Takada, Y; Miki, T; Narumiya, S			Accumulation of GTP-bound RhoA during cytokinesis and a critical role of ECT2 in this accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCHANGE FACTOR; CELL-ADHESION; PROTEIN-RHO; GTPASES; KINASE; CDC42; TARGET; CYCLE; G(1)	We developed a new pull-down assay for GTP-Rho and examined its level during cell cycle. HeLa cells were arrested in the S phase by thymidine and were enriched in the prometaphase, metaphase, telophase, and G(1) phase by collecting at 0, 45, 90, and 180 min after the release from the nocodazole arrest, respectively. The level of GTP-Rho did not change significantly from the S phase to the prometaphase, but increased thereafter, peaking in the telophase, and returned to the original level in the G(1) phase. The GDP-GTP exchange activity for Rho measured in cell lysates in parallel increased also during the mitosis with a peak in the metaphase. Using this system, we examined a role of ECT2, an exchanger for Rho GTPases, suggested to be involved in cytokinesis (Tatsumoto, T., Xie, X., Blumenthal, R., Okamoto, I., and Miki., T. (1999) J. Cell. Biol, 147, 921-928). Expression of the dominant negative form of ECT2 completely suppressed both the rise of GTP-Rho in the telophase and the increased GDP-GTP exchange activity in the mitotic cell extracts. These results suggest a critical role of ECT2 in Rho activation during cytokinesis.	Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan; NCI, Mol Tumor Biol Sect, Basic Res Lab, NIH, Bethesda, MD 20892 USA	Kyoto University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan.							Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Nishimura Y, 1998, FEBS LETT, V441, P121, DOI 10.1016/S0014-5793(98)01531-2; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Prokopenko SN, 1999, GENE DEV, V13, P2301, DOI 10.1101/gad.13.17.2301; Reid T, 1999, J BIOL CHEM, V274, P33587, DOI 10.1074/jbc.274.47.33587; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; Yamazaki M, 1999, J BIOL CHEM, V274, P6035, DOI 10.1074/jbc.274.10.6035	23	134	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 9	2000	275	23					17233	17236		10.1074/jbc.C000212200	http://dx.doi.org/10.1074/jbc.C000212200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	321ZJ	10837491	hybrid			2022-12-25	WOS:000087485000004
J	Simpson, CS; Morris, BJ				Simpson, CS; Morris, BJ			Regulation of neuronal cell adhesion molecule expression by NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE-II; POSTSYNAPTIC DENSITY PROTEIN; SYNAPTIC PLASTICITY; GENE-EXPRESSION; ALZHEIMERS-DISEASE; STRIATAL NEURONS; MEMORY FORMATION; RAT HIPPOCAMPUS	The neuronal cell adhesion molecule (NCAM) is a key mediator of structural plasticity in the central nervous system, but the mechanisms that control its expression are unknown. Equally, although the transcription factor NF-kappa B is present in the brain, few NF-kappa B-regulated genes relevant for central nervous system function have been identified. We have previously demonstrated that NF-kappa KB is activated in neuronal cultures treated with kainic acid or nitric oxide. We show here that kainic acid or nitric oxide also increase the levels of NCAM mRNA and protein in neurons and that this induction of NCAM expression is sensitive to dexamethasone and to antisense, but not missense, oligonucleotides designed to suppress NF-kappa B synthesis. Nitric oxide also stimulates protein binding to an NF-kappa B site in the promoter of the NCAM gene. This indicates that NF-kappa B, which has recently been implicated in synaptic plasticity and also in the etiology of neurodegenerative disease, plays a crucial role in the activity-dependent regulation of NCAM gene expression, In addition, since both NCAM and NF-kappa B are present in the post-synaptic density, this represents a route allowing direct communication between the synapse and the nucleus.	Univ Glasgow, Inst Biomed & Life Sci, Div Neurosci & Biomed Syst, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	Morris, BJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Neurosci & Biomed Syst, W Med Bldg, Glasgow G12 8QQ, Lanark, Scotland.							Arami S, 1996, BEHAV BRAIN RES, V81, P81, DOI 10.1016/S0166-4328(96)00046-0; AUTIERI MV, 1995, BIOCHEM BIOPH RES CO, V213, P827, DOI 10.1006/bbrc.1995.2204; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; Boissiere F, 1997, NEUROREPORT, V8, P2849, DOI 10.1097/00001756-199709080-00009; BOULTON CL, 1995, NEUROSCIENCE, V69, P699, DOI 10.1016/0306-4522(95)00349-N; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Buchs PA, 1996, P NATL ACAD SCI USA, V93, P8040, DOI 10.1073/pnas.93.15.8040; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Cremer H, 1998, P NATL ACAD SCI USA, V95, P13242, DOI 10.1073/pnas.95.22.13242; de Quervain DJF, 1998, NATURE, V394, P787, DOI 10.1038/29542; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; DESMOND NL, 1986, J COMP NEUROL, V253, P476, DOI 10.1002/cne.902530405; DIFIGLIA M, 1989, J NEUROSCI, V9, P4158; Doyle C, 1996, J NEUROSCI, V16, P418; Fields RD, 1996, TRENDS NEUROSCI, V19, P473, DOI 10.1016/S0166-2236(96)30013-1; GEDDES JW, 1985, SCIENCE, V230, P1179, DOI 10.1126/science.4071042; GEINISMAN Y, 1991, BRAIN RES, V566, P77, DOI 10.1016/0006-8993(91)91683-R; GERTZ HJ, 1987, NEUROSCI LETT, V76, P228, DOI 10.1016/0304-3940(87)90720-8; Glazewski S, 1996, SCIENCE, V272, P421, DOI 10.1126/science.272.5260.421; GREENSTREET EH, 1994, NEUROREPORT, V6, P109, DOI 10.1097/00001756-199412300-00029; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Guerrini L, 1997, J NEUROSCI, V17, P6057; Holst BD, 1998, P NATL ACAD SCI USA, V95, P2597, DOI 10.1073/pnas.95.5.2597; HOLST BD, 1995, MOL BIOL CELL, V6, P573; Inglis FM, 1998, J NEUROSCI, V18, P10493; JOHNSTON HM, 1995, MOL BRAIN RES, V31, P141, DOI 10.1016/0169-328X(95)00046-U; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; KHACHIGIAN LM, 1995, BIOCHEM BIOPH RES CO, V206, P462, DOI 10.1006/bbrc.1995.1065; Kirschbaum C, 1996, LIFE SCI, V58, P1475, DOI 10.1016/0024-3205(96)00118-X; Kleinert H, 1996, MOL PHARMACOL, V49, P15; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Krushel LA, 1999, J BIOL CHEM, V274, P2432, DOI 10.1074/jbc.274.4.2432; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; LUTHI A, 1994, NATURE, V372, P777, DOI 10.1038/372777a0; Maekawa K, 1999, BIOCHEM J, V337, P179, DOI 10.1042/0264-6021:3370179; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MCNEILL RB, 1995, J BIOL CHEM, V270, P10043, DOI 10.1074/jbc.270.17.10043; Meberg PJ, 1996, MOL BRAIN RES, V38, P179, DOI 10.1016/0169-328X(95)00229-L; Mikkonen M, 1999, EUR J NEUROSCI, V11, P1754, DOI 10.1046/j.1460-9568.1999.00593.x; MORRIS BJ, 1995, J BIOL CHEM, V270, P24740; Morris BJ, 1997, EUR J NEUROSCI, V9, P2334, DOI 10.1111/j.1460-9568.1997.tb01650.x; MOSER MB, 1994, P NATL ACAD SCI USA, V91, P12673, DOI 10.1073/pnas.91.26.12673; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PerezOtano I, 1996, GLIA, V16, P306, DOI 10.1002/(SICI)1098-1136(199604)16:4<306::AID-GLIA3>3.0.CO;2-Y; PERSOHN E, 1989, J COMP NEUROL, V288, P92, DOI 10.1002/cne.902880108; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Roberts LA, 1998, MOL BRAIN RES, V56, P38, DOI 10.1016/S0169-328X(98)00026-6; Roberts LA, 1996, MOL BRAIN RES, V42, P123, DOI 10.1016/S0169-328X(96)00148-9; Rodriguez JJ, 1998, EUR J NEUROSCI, V10, P2994, DOI 10.1046/j.1460-9568.1998.00316.x; ROSE SPR, 1995, BEHAV BRAIN RES, V66, P73, DOI 10.1016/0166-4328(94)00127-2; Rusakov DA, 1997, NEUROSCIENCE, V80, P69, DOI 10.1016/S0306-4522(97)00125-5; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; Schuster T, 1998, J NEUROBIOL, V37, P359, DOI 10.1002/(SICI)1097-4695(19981115)37:3<359::AID-NEU2>3.0.CO;2-4; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; Simpson CS, 1999, J NEUROCHEM, V73, P353, DOI 10.1046/j.1471-4159.1999.0730353.x; Skibo GG, 1998, NEUROSCIENCE, V82, P1; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; Strack S, 1997, J NEUROCHEM, V68, P2119; Suzuki T, 1997, NEUROREPORT, V8, P2931, DOI 10.1097/00001756-199709080-00025; THOMAS KL, 1994, NEURON, V13, P737, DOI 10.1016/0896-6273(94)90040-X; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; XIE QW, 1994, J BIOL CHEM, V269, P4705	73	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 2	2000	275	22					16879	16884		10.1074/jbc.275.22.16879	http://dx.doi.org/10.1074/jbc.275.22.16879			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	320FY	10828070	hybrid			2022-12-25	WOS:000087392200068
J	Mazumder, S; Gong, B; Almasan, A				Mazumder, S; Gong, B; Almasan, A			Cyclin E induction by genotoxic stress leads to apoptosis of hematopoietic cells	ONCOGENE			English	Article						Cyclin E; cyclin dependent kinase 2; apoptosis; ionizing radiation; caspase-3	S-PHASE ENTRY; THYMOCYTE APOPTOSIS; CDK INHIBITORS; ACTIVATION; KINASE; TRANSITION; CANCER; DEATH; P53; FIBROBLASTS	Cyclin E is essential for progression through the G1 phase of the cell cycle and initiation of DNA replication by interacting with, and activating its catalytic partner, the cyclin-dependent kinase 2 (Cdk2), We found a substantial increase in cyclin E mRNA, accompanied by increased production of cyclin E protein and cyclin E/ Cdk2 kinase activity in multiple myeloma and lymphoma cells following irradiation. Cyclin E expression increased early in a time and dose-dependent manner, with a threefold induction reached 8h following gamma-irradiation, Run-on analyses indicated a predominantly transcriptional regulation of cyclin E, Stable overexpression of cyclin E, but not cyclin D1, sensitized IM-9 cells to gamma-irradiation-induced apoptosis; in contrast, a dominant-negative Cdk2, prevented apoptosis. Irradiation of cyclin E overexpressing cells led to an enhanced caspase activation and exposure of the phosphatidylserine on the plasma membrane, two key markers of apoptosis, events which were completely abolished in cells expressing a dominant-negative Cdk2, This study identifies cyclin E as a target for activation by ionizing radiation and which plays a functional role in apoptosis of hematopoietic cells. Oncogene (2000) 19, 2828-2835.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Radiat Oncol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Almasan, A (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, NB40, Cleveland, OH 44195 USA.		Almasan, Alex/C-2715-2008	Almasan, Alex/0000-0002-8916-6650	NATIONAL CANCER INSTITUTE [R01CA081504, R01CA082858] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA82858, CA81504, R01 CA082858, R01 CA081504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Gong BD, 1999, CELL GROWTH DIFFER, V10, P491; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lawrence TS, 1996, CANCER RES, V56, P3203; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Martin JMC, 1999, CANCER RES, V59, P1134; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; MAZARS GR, 1992, ONCOGENE, V7, P1015; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Sauter ER, 1999, CANCER RES, V59, P4876; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456	38	54	59	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2000	19	24					2828	2835		10.1038/sj.onc.1203623	http://dx.doi.org/10.1038/sj.onc.1203623			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851086	Green Accepted			2022-12-25	WOS:000087403600004
